

(43) International Publication Date 1 August 2002 (01.08.2002)

#### **PCT**

#### (10) International Publication Number WO 02/059377 A2

(51) International Patent Classification7:

C12Q 1/68

(21) International Application Number: PCT/US02/02242

(22) International Filing Date: 24 January 2002 (24.01.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/263,965	24 January 2001 (24.01.2001)	US
60/265,928	2 February 2001 (02.02.2001)	US
09/829,472	9 April 2001 (09.04.2001)	US
60/282,698	9 April 2001 (09.04.2001)	US
60/288,590	4 May 2001 (04.05.2001)	US
60/294,443	29 May 2001 (29.05.2001)	US
-		

(71) Applicant: EOS BIOTECHNOLOGY, INC. [US/US]; 225A Gateway Boulevard, South San Francisco, CA 94080-7019 (US).

(72) Inventors: MACK, David, H.; 2076 Monterey Avenue, Menlo Park, CA 94025 (US). GISH, Kurt, C.; 40 Perego Terrace #2, San Francisco, CA 94131 (US). AFAR, Daniel; 435 Visitacion Avenue, Brisbane, CA 94005 (US).

(74) Agents: BASTIAN, Kevin, L. et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  $\mathsf{MX}$ ,  $\mathsf{MZ}$ ,  $\mathsf{NO}$ ,  $\mathsf{NZ}$ ,  $\mathsf{OM}$ ,  $\mathsf{PH}$ ,  $\mathsf{PL}$ ,  $\mathsf{PT}$ ,  $\mathsf{RO}$ ,  $\mathsf{RU}$ ,  $\mathsf{SD}$ ,  $\mathsf{SE}$ ,  $\mathsf{SG}$ , SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,


upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the begin-

NE, SN, TD, TG). Published: without international search report and to be republished ning of each regular issue of the PCT Gazette.

(54) Title: METHODS OF DIAGNOSIS OF BREAST CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF BREAST CANCER

(57) Abstract: Described herein are genes whose expression are up-regulated or down-regulated in breast cancer. Related methods and compositions that can be used for diagnosis and treatment of breast cancer are disclosed. Also described herein are methods that can be used to identify modulators of breast cancer.



# METHODS OF DIAGNOSIS OF BREAST CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF BREAST CANCER

5

10

## CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims priority to USSN 60/263,965, filed January 24, 2001; USSN 60/265,928, filed February 2, 2001; USSN 09/829,472 filed April 9, 2001; USSN 60/282,698, filed April 9, 2001; USSN 60/288,590, filed May 4, 2001; and USSN 60/294,443, filed May 29, 2001, all of which are incorporated herein by reference in their entirety.

#### FIELD OF THE INVENTION

The invention relates to the identification of nucleic acid and protein

expression profiles and nucleic acids, products, and antibodies thereto that are involved in breast cancer; and to the use of such expression profiles and compositions in the diagnosis, prognosis and therapy of breast cancer. The invention further relates to methods for identifying and using agents and/or targets that inhibit breast cancer.

20

25

## BACKGROUND OF THE INVENTION

Breast cancer is one of the most frequently diagnosed cancers and the second leading cause of female cancer death in North America and northern Europe, with lung cancer being the leading cause. Lifetime incidence of the disease in the United States is one-in-eight, with a 1-in-29 lifetime risk of dying from breast cancer. Early detection of breast cancer, using mammography, clinical breast examination, and self breast examination, has dramatically improved the treatment of the disease, although sensitivity is still major concern, as mammographic sensitivity has been estimated at only 60%–90%. Treatment of breast cancer consists largely of surgical lumpectomy or mastectomy, radiation therapy, anti-

WO 02/059377

hormone therapy, and/or chemotherapy. Although many breast cancer patients are effectively treated, the current therapies can all induce serious side effects which diminish quality of life. Deciding on a particular course of treatment is typically based on a variety of prognostic parameters and markers (Fitzgibbons et al., 2000, Arch. Pathol. Lab. Med. 124:966-978; Hamilton and Piccart, 2000, Ann. Oncol. 11:647-663), including genetic predispostion markers BRCA-1 and BRCA-2 (Robson, 2000, J. Clin. Oncol. 18:113sup-118sup).

5

10

15

20

25

30

Imaging of breast cancer for diagnosis has been problematic and limited. In addition, dissemination of tumor cells (metastases) to locoregional lymph nodes is an important prognostic factor; five year survival rates drop from 80 percent in patients with no lymph node metastases to 45 to 50 percent in those patients who do have lymph node metastases. A recent report showed that micrometastases can be detected from lymph nodes using reverse transcriptase-PCR methods based on the presence of mRNA for carcinoembryonic antigen, which has previously been shown to be present in the vast majority of breast cancers but not in normal tissues. Liefers et al., New England J. of Med. 339(4):223 (1998).

The identification of novel therapeutic targets and diagnostic markers is essential for improving the current treatment of breast cancer patients. Recent advances in molecular medicine have increased the interest in tumor-specific cell surface antigens that could serve as targets for various immunotherapeutic or small molecule strategies. Antigens suitable for immunotherapeutic strategies should be highly expressed in cancer tissues and ideally not expressed in normal adult tissues. Expression in tissues that are dispensable for life, however, may be tolerated. Examples of such antigens include Her2/neu and the B-cell antigen CD20. Humanized monclonal antibodies directed to Her2/neu (Herceptin®/trastuzumab) are currently in use for the treatment of metastatic breast cancer (Ross and Fletcher, 1998, Stem Cells 16:413-428). Similarly, anti-CD20 monoclonal antibodies (Rituxin®/rituximab) are used to effectively treat non-Hodgekin's lymphoma (Maloney et al., 1997, Blood 90:2188-2195; Leget and Czuczman, 1998, Curr. Opin. Oncol. 10:548-551).

Other potential immunotherapeutic targets have been identified for breast cancer. One such target is polymorphic epithelial mucin (MUC1). MUC1 is a transmembrane

protein, present at the apical surface of glandular epithelial cells. It is often overexpressed in breast cancer, and typically exhibits an altered glycosylation pattern, resulting in an antigenically distinct molecule, and is in early clinical trials as a vaccine target (Gilewski et al., 2000, Clin. Cancer Res. 6:1693-1701; Scholl et al., 2000, J. Immunother. 23:570-580). The tumor-expressed protein is often cleaved into the circulation, where it is detectable as the tumor marker, CA 15-3 (Bon et al., 1997, Clin. Chem. 43:585-593). However, many patients have tumors that express neither HER2 nor MUC-1; therefore, it is clear that other targets need to be identified to manage localized and metastatic disease. Many other genes have been reported to be overexpressed in breast cancer, such as EGFR (Sainsbury et al., 1987, Lancet 1(8547):1398-1402), c-erbB3 (Naidu et al., 1988, Br. J. Cancer 78:1385-1390), FGFR2 (Penault-Llorca et al., 1991, Int. J. Cancer 61:170-176), PKW (Preiherr et al., 2000, 10 Anticancer Res. 20:2255-2264), MTA1 (Nawa et al., 2000, J. Cell Biochem. 79:202-212), breast cancer associated gene 1 (Kurt et al., 2000, Breast Cancer Res. Treat. 59:41-48). Although monoclonal antibodies to the protein products of some of these overexpressed genes have been reported (for review, see Green et al., 2000, Cancer Treat. Rev. 26:269-286), 15 none are currently approved for breast cancer therapy in the US.

Disclosures of certain genes and ESTs described as being expressed in breast cancer are found in international patent applications WO-99/33869, WO-97/25426, WO-97/02280 and WO-00/55173, WO-98/45328 and WO-00/22130. Similarly, genes and ESTs described as being expressed in breast cancer are disclosed in US Patent Nos. 5,759,776 and 5,693,522. The utility of such genes is described in each of these publications, and their disclosures are incorporated herein in their entirety.

20

25

30

While industry and academia have identified novel sequences, there has not been an equal effort exerted to identify the function of these novel sequences. The elucidation of a role for novel proteins and compounds in disease states for identification of therapeutic targets and diagnostic markers is essential for improving the current treatment of breast cancer patients. Accordingly, provided herein are molecular targets for therapeutic intervention in breast and other cancers. Additionally, provided herein are methods that can be used in diagnosis and prognosis of breast cancer. Further provided are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer.

10

15

20

25

cancer.

## SUMMARY OF THE INVENTION

The present invention therefore provides nucleotide sequences of genes that are up- and down-regulated in breast cancer cells. Such genes are useful for diagnostic purposes, and also as targets for screening for therapeutic compounds that modulate breast cancer, such as hormones or antibodies. Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.

In one aspect, the present invention provides a method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.

In one embodiment, the present invention provides a method of determining the level of a breast cancer associated transcript in a cell from a patient.

In one embodiment, the present invention provides a method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.

In one embodiment, the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Tables 1-25.

In one embodiment, the biological sample is a tissue sample. In another embodiment, the biological sample comprises isolated nucleic acids, e.g., mRNA.

In one embodiment, the polynucleotide is labeled, e.g., with a fluorescent label.

In one embodiment, the polynucleotide is immobilized on a solid surface.

In one embodiment, the patient is undergoing a therapeutic regimen to treat breast cancer. In another embodiment, the patient is suspected of having metastatic breast

In one embodiment, the patient is a human.

In one embodiment, the breast cancer associated transcript is mRNA.

In one embodiment, the method further comprises the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.

In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of breast cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a breast cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25, thereby monitoring the efficacy of the therapy. In a further embodiment, the patient has metastatic breast cancer. In a further embodiment, the patient has a drug resistant form of breast cancer.

5

10

15

20

25

In one embodiment, the method further comprises the step of: (iii) comparing the level of the breast cancer-associated transcript to a level of the breast cancer-associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

Additionally, provided herein is a method of evaluating the effect of a candidate breast cancer drug comprising administering the drug to a patient and removing a cell sample from the patient. The expression profile of the cell is then determined. This method may further comprise comparing the expression profile to an expression profile of a healthy individual. In a preferred embodiment, said expression profile includes a gene of Tables 1-25.

In one aspect, the present invention provides an isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-25.

In one embodiment, an expression vector or cell comprises the isolated nucleic acid.

In one aspect, the present invention provides an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25.

In another aspect, the present invention provides an antibody that specifically binds to an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25.

WO 02/059377 PCT/US02/02242

In one embodiment, the antibody is conjugated to an effector component, e.g., a fluorescent label, a radioisotope or a cytotoxic chemical.

In one embodiment, the antibody is an antibody fragment. In another embodiment, the antibody is humanized.

5

10

15

20

25

30

In one aspect, the present invention provides a method of detecting a breast cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody as described herein.

In another aspect, the present invention provides a method of detecting antibodies specific to breast cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprising a sequence from Tables 1-25.

In another aspect, the present invention provides a method for identifying a compound that modulates a breast cancer-associated polypeptide, the method comprising the steps of: (i) contacting the compound with a breast cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25; and (ii) determining the functional effect of the compound upon the polypeptide.

In one embodiment, the functional effect is a physical effect, an enzymatic effect, or a chemical effect.

In one embodiment, the polypeptide is expressed in a eukaryotic host cell or cell membrane. In another embodiment, the polypeptide is recombinant.

In one embodiment, the functional effect is determined by measuring ligand binding to the polypeptide.

In another aspect, the present invention provides a method of inhibiting proliferation of a breast cancer-associated cell to treat breast cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified as described herein.

In one embodiment, the compound is an antibody.

In another aspect, the present invention provides a drug screening assay comprising the steps of: (i) administering a test compound to a mammal having breast cancer

WO 02/059377

or to a cell sample isolated therefrom; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell sample or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of breast cancer.

In one embodiment, the control is a mammal with breast cancer or a cell sample therefrom that has not been treated with the test compound. In another embodiment, the control is a normal cell or mammal.

5

10

15

20

25

30

In one embodiment, the test compound is administered in varying amounts or concentrations. In another embodiment, the test compound is administered for varying time periods. In another embodiment, the comparison can occur after addition or removal of the drug candidate.

In one embodiment, the levels of a plurality of polynucleotides that selectively hybridize to a sequence at least 80% identical to a sequence as shown in Tables 1-25 are individually compared to their respective levels in a control cell sample or mammal. In a preferred embodiment the plurality of polynucleotides is from three to ten.

In another aspect, the present invention provides a method for treating a mammal having breast cancer comprising administering a compound identified by the assay described herein.

In another aspect, the present invention provides a pharmaceutical composition for treating a mammal having breast cancer, the composition comprising a compound identified by the assay described herein and a physiologically acceptable excipient.

In one aspect, the present invention provides a method of screening drug candidates by providing a cell expressing a gene that is up- and down-regulated as in a breast cancer. In one embodiment, a gene is selected from Tables 1-25. The method further includes adding a drug candidate to the cell and determining the effect of the drug candidate on the expression of the expression profile gene.

In one embodiment, the method of screening drug candidates includes comparing the level of expression in the absence of the drug candidate to the level of

WO 02/059377

5

10

15

20

25

expression in the presence of the drug candidate, wherein the concentration of the drug candidate can vary when present, and wherein the comparison can occur after addition or removal of the drug candidate. In a preferred embodiment, the cell expresses at least two expression profile genes. The profile genes may show an increase or decrease.

Also provided is a method of evaluating the effect of a candidate breast cancer drug comprising administering the drug to a transgenic animal expressing or over-expressing the breast cancer modulatory protein, or an animal lacking the breast cancer modulatory protein, for example as a result of a gene knockout.

Moreover, provided herein is a biochip comprising one or more nucleic acid segments of Tables 1-25, wherein the biochip comprises fewer than 1000 nucleic acid probes. Preferably, at least two nucleic acid segments are included. More preferably, at least three nucleic acid segments are included.

Furthermore, a method of diagnosing a disorder associated with breast cancer is provided. The method comprises determining the expression of a gene of Tables 1-25, preferably a gene of Table 25, in a first tissue type of a first individual, and comparing the distribution to the expression of the gene from a second normal tissue type from the first individual or a second unaffected individual. A difference in the expression indicates that the first individual has a disorder associated with breast cancer.

In a further embodiment, the biochip also includes a polynucleotide sequence of a gene that is not up- and down-regulated in breast cancer.

In one embodiment a method for screening for a bioactive agent capable of interfering with the binding of a breast cancer modulating protein (breast cancer modulatory protein) or a fragment thereof and an antibody which binds to said breast cancer modulatory protein or fragment thereof. In a preferred embodiment, the method comprises combining a breast cancer modulatory protein or fragment thereof, a candidate bioactive agent and an antibody which binds to said breast cancer modulatory protein or fragment thereof. The method further includes determining the binding of said breast cancer modulatory protein or fragment thereof and said antibody. Wherein there is a change in binding, an agent is identified as an interfering agent. The interfering agent can be an agonist or an antagonist. Preferably, the agent inhibits breast cancer.

Also provided herein are methods of eliciting an immune response in an individual. In one embodiment a method provided herein comprises administering to an individual a composition comprising a breast cancer modulating protein, or a fragment thereof. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-25.

5

10

15

20

25

30

Further provided herein are compositions capable of eliciting an immune response in an individual. In one embodiment, a composition provided herein comprises a breast cancer modulating protein, preferably encoded by a nucleic acid of Tables 1-25, more preferably of Table 25, or a fragment thereof, and a pharmaceutically acceptable carrier. In another embodiment, said composition comprises a nucleic acid comprising a sequence encoding a breast cancer modulating protein, preferably selected from the nucleic acids of Tables 1-25, and a pharmaceutically acceptable carrier.

Also provided are methods of neutralizing the effect of a breast cancer protein, or a fragment thereof, comprising contacting an agent specific for said protein with said protein in an amount sufficient to effect neutralization. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-25.

In another aspect of the invention, a method of treating an individual for breast cancer is provided. In one embodiment, the method comprises administering to said individual an inhibitor of a breast cancer modulating protein. In another embodiment, the method comprises administering to a patient having breast cancer an antibody to a breast cancer modulating protein conjugated to a therapeutic moiety. Such a therapeutic moiety can be a cytotoxic agent or a radioisotope.

#### DETAILED DESCRIPTION OF THE INVENTION

In accordance with the objects outlined above, the present invention provides novel methods for diagnosis and prognosis evaluation for breast cancer (PC), including metastatic breast cancer, as well as methods for screening for compositions which modulate breast cancer. Also provided are methods for treating breast cancer.

Tables 1-24B provide unigene cluster identification numbers for the nucleotide sequence of genes that exhibit increased or decreased expression in breast cancer

samples. Tables 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 18, 19, 20, 21, and 22 list those genes that are up-regulated in breast cancer cells. Table 14 lists those genes that are highly upregulated in breast cancer cells. Table 1, 2, 3, 15, and 23 list genes that are down-regulated in breast cancer cells and Table 16, lists genes that are highly down-regulated in breast cancer genes. The Tables also provide an exemplar accession number that provides a nucleotide sequence that is part of the unigene cluster.

#### **Definitions**

5

10

.15

20

25

The term "breast cancer protein" or "breast cancer polynucleotide" or "breast cancer-associated transcript" refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologues that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater nucleotide sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleotide sequence of or associated with a gene of Tables 1-25; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-25, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid sequence, or the complement thereof of Tables 1-25 and conservatively modified variants thereof or (4) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acid, to an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-25. A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or other mammal. A "breast cancer polypeptide" and a "breast cancer polynucleotide," include both naturally occurring or recombinant forms.

WO 02/059377

5

10

15

20

25

30

A "full length" breast cancer protein or nucleic acid refers to a breast cancer polypeptide or polynucleotide sequence, or a variant thereof, that contains all of the elements normally contained in one or more naturally occurring, wild type breast cancer polynucleotide or polypeptide sequences. The "full length" may be prior to, or after, various stages of post-translation processing or splicing, including alternative splicing.

"Biological sample" as used herein is a sample of biological tissue or fluid that contains nucleic acids or polypeptides, e.g., of a breast cancer protein, polynucleotide or transcript. Such samples include, but are not limited to, tissue isolated from primates, e.g., humans, or rodents, e.g., mice, and rats. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, etc. Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.

"Providing a biological sample" means to obtain a biological sample for use in methods described in this invention. Most often, this will be done by removing a sample of cells from an animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and/or for another purpose), or by performing the methods of the invention *in vivo*. Archival tissues, having treatment or outcome history, will be particularly useful.

The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site http://www.ncbi.nlm.nih.gov/BLAST/ or the like). Such sequences are then said to

be "substantially identical." This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions, as well as naturally occurring, e.g., polymorphic or allelic variants, and man-made variants. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

5

10

15

20

25

30

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of one of the number of contiguous positions selected from the group consisting typically of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al., eds. 1995 supplement)).

Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms,

5

10

15

30

which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990). BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, e.g., for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) 20 uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands. 25

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a

PCT/US02/02242

nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. Log values may be large negative numbers, e.g., 5, 10, 20, 30, 40, 40, 70, 90, 110, 150, 170, etc.

WO 02/059377

5

10

15

20

25

30

An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.

A "host cell" is a naturally occurring cell or a transformed cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells *in vivo*, and the like. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa, and the like (see, e.g., the American Type Culture Collection catalog or web site, www.atcc.org).

The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein or nucleic acid that is the predominant species present in a preparation is substantially purified. In particular, an isolated nucleic acid is separated from some open reading frames that naturally flank the gene and encode proteins other than protein encoded by the gene. The term "purified" in some embodiments denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Preferably, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure. "Purify" or "purification" in other embodiments means

removing at least one contaminant from the composition to be purified. In this sense, purification does not require that the purified compound be homogenous, e.g., 100% pure.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.

5

10

20

25

30

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

"Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino

15

20

acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. One of skill will recognize that in certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, often silent variations of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not with respect to actual probe sequences.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid.

Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts et al., Molecular Biology of the Cell (3<sup>rd</sup> ed., 1994) and Cantor & Schimmel, Biophysical Chemistry Part I: The Conformation of Biological Macromolecules (1980). "Primary structure" refers to the amino acid sequence of a particular peptide. "Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that

WO 02/059377 PCT/US02/02242

often form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of  $\beta$ -sheet and  $\alpha$ -helices. "Tertiary structure" refers to the complete three dimensional structure of a polypeptide monomer. "Quaternary structure" refers to the three dimensional structure formed, usually by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.

5

30

"Nucleic acid" or "oligonucleotide" or "polynucleotide" or grammatical equivalents used herein means at least two nucleotides covalently linked together. Oligonucleotides are typically from about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50 or more nucleotides in length, up to about 100 nucleotides in length. Nucleic acids and 10 polynucleotides are a polymers of any length, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have alternate backbones, comprising, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages (see Eckstein, 15 Oligonucleotides and Analogues: A Practical Approach, Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Sanghui & 20 Cook, eds.. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g. to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid 25 analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

A variety of references disclose such nucleic acid analogs, including, for example, phosphoramidate (Beaucage et al., Tetrahedron 49(10):1925 (1993) and references therein; Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al, Chem. Lett. 805

WO 02/059377 PCT/US02/02242

(1984), Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 91986)), phosphorothioate (Mag et al., Nucleic Acids Res. 19:1437 (1991); and U.S. Patent No. 5,644,048), phosphorodithioate (Briu et al., J. Am. Chem. Soc. 111:2321 (1989), O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and 5 linkages (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207 (1996), all of which are incorporated by reference). Other analog nucleic acids include those with positive backbones (Denpcy et al., Proc. Natl. Acad. Sci. USA 92:6097 (1995); non-ionic backbones (U.S. Patent Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; 10 Kiedrowshi et al., Angew. Chem. Intl. Ed. English 30:423 (1991); Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); Letsinger et al., Nucleoside & Nucleotide 13:1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook; Mesmaeker et al., Bioorganic & Medicinal Chem. Lett. 4:395 (1994); Jeffs et al., J. Biomolecular NMR 34:17 (1994); Tetrahedron Lett. 15 37:743 (1996)) and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids (see Jenkins et al., Chem. Soc. Rev. (1995) pp 169-176). Several nucleic acid analogs 20 are described in Rawls, C & E News June 2, 1997 page 35. All of these references are hereby expressly incorporated by reference.

Particularly preferred are peptide nucleic acids (PNA) which includes peptide nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids. This results in two advantages. First, the PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (T<sub>m</sub>) for mismatched versus perfectly matched basepairs. DNA and RNA typically exhibit a 2-4°C drop in T<sub>m</sub> for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-9°C. Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is

25

30

relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable.

5

10

15

20

25

30

The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand also defines the sequence of the complementary strand; thus the sequences described herein also provide the complement of the sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. "Transcript" typically refers to a naturally occurring RNA, e.g., a pre-mRNA, hnRNA, or mRNA. As used herein, the term "nucleoside" includes nucleotides and nucleoside and nucleoside analogs, and modified nucleosides such as amino modified nucleosides. In addition, "nucleoside" includes non-naturally occurring analog structures. Thus, e.g. the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.

A "label" or a "detectable moiety" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include <sup>32</sup>P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide. The labels may be incorporated into the breast cancer nucleic acids, proteins and antibodies at any position. Any method known in the art for conjugating the antibody to the label may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982).

An "effector" or "effector moiety" or "effector component" is a molecule that is bound (or linked, or conjugated), either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds, to an antibody. The "effector" can be a variety of molecules including, e.g., detection moieties including

WO 02/059377

5

10

15

20

radioactive compounds, fluorescent compounds, an enzyme or substrate, tags such as epitope tags, a toxin; activatable moieties, a chemotherapeutic agent; a lipase; an antibiotic; or a radioisotope emitting "hard" e.g., beta radiation.

A "labeled nucleic acid probe or oligonucleotide" is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe. Alternatively, method using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin.

As used herein a "nucleic acid probe or oligonucleotide" is defined as a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not functionally interfere with hybridization. Thus, e.g., probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled as with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence. Diagnosis or prognosis may be based at the genomic level, or at the level of RNA or protein expression.

The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, e.g., recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed

25

10

15

20

25

30

or not expressed at all. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed *in vitro*, in general, by the manipulation of nucleic acid, e.g., using polymerases and endonucleases, in a form not normally found in nature. In this manner, operably linkage of different sequences is achieved. Thus an isolated nucleic acid, in a linear form, or an expression vector formed *in vitro* by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e., using the *in vivo* cellular machinery of the host cell rather than *in vitro* manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention. Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid as depicted above.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e.g., from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein will often refer to two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a

10

15

20

25

30



promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T<sub>m</sub>) for the specific sequence at a defined ionic strength pH. The T<sub>m</sub> is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T<sub>m</sub>, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times





background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C. For PCR, a temperature of about 36°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90°C - 95°C for 30 sec - 2 min., an annealing phase lasting 30 sec. - 2 min., and an extension phase of about 72°C for 1 - 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.).

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and Current Protocols in Molecular Biology, ed. Ausubel, et al.

25

20

15

The phrase "functional effects" in the context of assays for testing compounds that modulate activity of a breast cancer protein includes the determination of a parameter that is indirectly or directly under the influence of the breast cancer protein or nucleic acid, e.g., a functional, physical, or chemical effect, such as the ability to decrease breast cancer. It includes ligand binding activity; cell growth on soft agar; anchorage dependence; contact

inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of breast cancer cells. "Functional effects" include in vitro, in vivo, and ex vivo activities.

5

10

15

20

30

By "determining the functional effect" is meant assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of a breast cancer protein sequence, e.g., functional, enzymatic, physical and chemical effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein, measuring inducible markers or transcriptional activation of the breast cancer protein; measuring binding activity or binding assays, e.g. binding to antibodies or other ligands, and measuring cellular proliferation. Determination of the functional effect of a compound on breast cancer can also be performed using breast cancer assays known to those of skill in the art such as an in vitro assays, e.g., cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of breast cancer cells. The functional effects can be evaluated by many means known to those skilled in the art, e.g., microscopy for quantitative or qualitative measures of alterations in morphological features, measurement of changes in RNA or protein levels for breast cancer-associated sequences, measurement of RNA stability, identification of downstream or reporter gene expression (CAT, luciferase,  $\beta$ -gal, GFP and the like), e.g., via chemiluminescence, fluorescence, colorimetric reactions, antibody binding, 25 inducible markers, and ligand binding assays.

"Inhibitors", "activators", and "modulators" of breast cancer polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules or compounds identified using in vitro and in vivo assays of breast cancer polynucleotide and polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially or totally block

10

15

20

25

30

activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of breast cancer proteins, e.g., antagonists. Antisense nucleic acids may seem to inhibit expression and subsequent function of the protein. "Activators" are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate breast cancer protein activity. Inhibitors, activators, or modulators also include genetically modified versions of breast cancer proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules and the like. Such assays for inhibitors and activators include, e.g., expressing the breast cancer protein *in vitro*, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above. Activators and inhibitors of breast cancer can also be identified by incubating breast cancer cells with the test compound and determining increases or decreases in the expression of 1 or more breast cancer proteins, e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more breast cancer proteins, such as breast cancer proteins encoded by the sequences set out in Tables 1-25.

Samples or assays comprising breast cancer proteins that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a polypeptide is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation of a breast cancer polypeptide is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more preferably 200-500% (i.e., two to five fold higher relative to the control), more preferably 1000-3000% higher.

The phrase "changes in cell growth" refers to any change in cell growth and proliferation characteristics in vitro or in vivo, such as formation of foci, anchorage independence, semi-solid or soft agar growth, changes in contact inhibition and density limitation of growth, loss of growth factor or serum requirements, changes in cell morphology, gaining or losing immortalization, gaining or losing tumor specific markers, ability to form or suppress tumors when injected into suitable animal hosts, and/or

10

15

20

25

30

immortalization of the cell. See, e.g., Freshney, Culture of Animal Cells a Manual of Basic Technique pp. 231-241 (3<sup>rd</sup> ed. 1994).

"Tumor cell" refers to precancerous, cancerous, and normal cells in a tumor. "Cancer cells," "transformed" cells or "transformation" in tissue culture, refers to spontaneous or induced phenotypic changes that do not necessarily involve the uptake of new genetic material. Although transformation can arise from infection with a transforming virus and incorporation of new genomic DNA, or uptake of exogenous DNA, it can also arise spontaneously or following exposure to a carcinogen, thereby mutating an endogenous gene. Transformation is associated with phenotypic changes, such as immortalization of cells, aberrant growth control, nonmorphological changes, and/or malignancy (see, Freshney, Culture of Animal Cells a Manual of Basic Technique (3<sup>rd</sup> ed. 1994)).

"Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody or its functional equivalent will be most critical in specificity and affinity of binding. See Paul, Fundamental Immunology.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain  $(V_L)$  and variable heavy chain  $(V_H)$  refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, e.g., pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'<sub>2</sub>, a dimer of Fab which itself is a light chain joined to V<sub>H</sub>-C<sub>H</sub>1 by a disulfide bond. The F(ab)'<sub>2</sub>



may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)'<sub>2</sub> dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al., Nature 348:552-554 (1990))

For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many technique known in the art can be used (see, e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al., Immunology Today 4:72 (1983); Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988); and Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (see, e.g., McCafferty et al., Nature 348:552-554 (1990); Marks et al., Biotechnology 10:779-783 (1992)).

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

WO 02/059377

10

15

20

25

# Identification of breast cancer-associated sequences

In one aspect, the expression levels of genes are determined in different patient samples for which diagnosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a "fingerprint" of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is characteristic of the state of the cell. That is, normal tissue (e.g., normal breast or other tissue) may be distinguished from cancerous or metastatic cancerous tissue of the breast, or breast cancer tissue or metastatic breast cancerous tissue can be compared with tissue samples of breast and other tissues from surviving cancer patients. By comparing expression profiles of tissue in known different breast cancer states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained.

The identification of sequences that are differentially expressed in breast cancer versus non-breast cancer tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated: does a chemotherapeutic drug act to down-regulate breast cancer, and thus tumor growth or recurrence, in a particular patient. Similarly, diagnosis and treatment outcomes may be done or confirmed by comparing patient samples with the known expression profiles. Metastatic tissue can also be analyzed to determine the stage of breast cancer in the tissue. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a particular expression profile; e.g., screening can be done for drugs that suppress the breast cancer expression profile. This may be done by making biochips comprising sets of the important breast cancer genes, which can then be used in these screens. These methods can also be done on the protein basis; that is, protein expression levels of the breast cancer proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the breast cancer nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense nucleic acids, or the breast cancer proteins (including antibodies and other modulators thereof) administered as therapeutic drugs.

WO 02/059377

Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in breast cancer, herein termed "breast cancer sequences." As outlined below, breast cancer sequences include those that are up-regulated (i.e., expressed at a higher level) in breast cancer, as well as those that are down-regulated (i.e., expressed at a lower level). In a preferred embodiment, the breast cancer sequences are from humans; however, as will be appreciated by those in the art, breast cancer sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other breast cancer sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc.) and pets, e.g., (dogs, cats, etc.). Breast cancer sequences from other organisms may be obtained using the techniques outlined below.

5

10

15

20

25

30

Breast cancer sequences can include both nucleic acid and amino acid sequences. As will be appreciated by those in the art and is more fully outlined below, breast cancer nucleic acid sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids, as well as screening applications; e.g., biochips comprising nucleic acid probes or PCR microtiter plates with selected probes to the breast cancer sequences can be generated.

A breast cancer sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the breast cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

For identifying breast cancer-associated sequences, the breast cancer screen typically includes comparing genes identified in different tissues, e.g., normal and cancerous tissues, or tumor tissue samples from patients who have metastatic disease vs. non metastatic tissue. Other suitable tissue comparisons include comparing breast cancer samples with metastatic cancer samples from other cancers, such as lung, breast, gastrointestinal cancers, ovarian, etc. Samples of different stages of breast cancer, e.g., survivor tissue, drug resistant states, and tissue undergoing metastasis, are applied to biochips comprising nucleic acid probes. The samples are first microdissected, if applicable, and treated as is known in the art

10

15

20



for the preparation of mRNA. Suitable biochips are commercially available, e.g. from Affymetrix. Gene expression profiles as described herein are generated and the data analyzed.

In one embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, preferably normal breast, but also including, and not limited to lung, heart, brain, liver, breast, kidney, muscle, colon, small intestine, large intestine, spleen, bone and placenta. In a preferred embodiment, those genes identified during the breast cancer screen that are expressed in any significant amount in other tissues are removed from the profile, although in some embodiments, this is not necessary. That is, when screening for drugs, it is usually preferable that the target be disease specific, to minimize possible side effects.

In a preferred embodiment, breast cancer sequences are those that are up-regulated in breast cancer; that is, the expression of these genes is higher in the breast cancer tissue as compared to non-cancerous tissue. "Up-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred. All unigene cluster identification numbers and accession numbers herein are for the GenBank sequence database and the sequences of the accession numbers are hereby expressly incorporated by reference. GenBank is known in the art, see, e.g., Benson, DA, et al., Nucleic Acids Research 26:1-7 (1998) and http://www.ncbi.nlm.nih.gov/. Sequences are also available in other databases, e.g.,

European Molecular Biology Laboratory (EMBL) and DNA Database of Japan (DDBJ).

U.S. Patent Application N. 09/687,576, with the same assignee as the present application, further discloses related sequences, compositions, and methods of diagnosis and treatment of breast cancer is hereby expressly incorporated by reference.

In another preferred embodiment, breast cancer sequences are those that are down-regulated in the breast cancer; that is, the expression of these genes is lower in breast cancer tissue as compared to non-cancerous tissue (see, e.g., Tables 1,2, 3, 15, 16 etc...). "Down-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred.

25

#### Informatics

5

15

20

25

30

The ability to identify genes that are over or under expressed in breast cancer can additionally provide high-resolution, high-sensitivity datasets which can be used in the areas of diagnostics, therapeutics, drug development, pharmacogenetics, protein structure, biosensor development, and other related areas. For example, the expression profiles can be used in diagnostic or prognostic evaluation of patients with breast cancer. Or as another example, subcellular toxicological information can be generated to better direct drug structure and activity correlation (see Anderson, Pharmaceutical Proteomics: Targets, Mechanism, and Function, paper presented at the IBC Proteomics conference, Coronado, CA (June 11-12, 1998)). Subcellular toxicological information can also be utilized in a biological sensor device to predict the likely toxicological effect of chemical exposures and likely tolerable exposure thresholds (see U.S. Patent No. 5,811,231). Similar advantages accrue from datasets relevant to other biomolecules and bioactive agents (e.g., nucleic acids, saccharides, lipids, drugs, and the like).

Thus, in another embodiment, the present invention provides a database that includes at least one set of assay data. The data contained in the database is acquired, e.g., using array analysis either singly or in a library format. The database can be in substantially any form in which data can be maintained and transmitted, but is preferably an electronic database. The electronic database of the invention can be maintained on any electronic device allowing for the storage of and access to the database, such as a personal computer, but is preferably distributed on a wide area network, such as the World Wide Web.

The focus of the present section on databases that include peptide sequence data is for clarity of illustration only. It will be apparent to those of skill in the art that similar databases can be assembled for any assay data acquired using an assay of the invention.

The compositions and methods for identifying and/or quantitating the relative and/or absolute abundance of a variety of molecular and macromolecular species from a biological sample undergoing breast cancer, i.e., the identification of breast cancer-associated sequences described herein, provide an abundance of information, which can be correlated with pathological conditions, predisposition to disease, drug testing, therapeutic monitoring,

gene-disease causal linkages, identification of correlates of immunity and physiological status, among others. Although the data generated from the assays of the invention is suited for manual review and analysis, in a preferred embodiment, prior data processing using highspeed computers is utilized.

5

10

15

20

30

An array of methods for indexing and retrieving biomolecular information is known in the art. For example, U.S. Patents 6,023,659 and 5,966,712 disclose a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. U.S. Patent 5,953,727 discloses a relational database having sequence records containing information in a format that allows a collection of partial-length DNA sequences to be catalogued and searched according to association with one or more sequencing projects for obtaining full-length sequences from the collection of partial length sequences. U.S. Patent 5,706,498 discloses a gene database retrieval system for making a retrieval of a gene sequence similar to a sequence data item in a gene database based on the degree of similarity between a key sequence and a target sequence. U.S. Patent 5,538,897 discloses a method using mass spectroscopy fragmentation patterns of peptides to identify amino acid sequences in computer databases by comparison of predicted mass spectra with experimentally-derived mass spectra using a closeness-of-fit measure. U.S. Patent 5,926,818 discloses a multidimensional database comprising a functionality for multi-dimensional data analysis described as on-line analytical processing (OLAP), which entails the consolidation of projected and actual data according to more than one consolidation path or dimension. U.S. Patent 5,295,261 reports a hybrid database structure in which the fields of each database record are divided into two classes, navigational and informational data, with navigational fields stored in a hierarchical topological map which can be viewed as a tree structure or as the merger of two or more such tree structures. 25

See also Mount et al., Bioinformatics (2001); Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids (Durbin et al., eds., 1999); Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins (Baxevanis & Oeullette eds., 1998)); Rashidi & Buehler, Bioinformatics: Basic Applications in Biological Science and Medicine (1999); Introduction to Computational Molecular Biology (Setubal et

al., eds 1997); Bioinformatics: Methods and Protocols (Misener & Krawetz, eds, 2000); Bioinformatics: Sequence, Structure, and Databanks: A Practical Approach (Higgins & Taylor, eds., 2000); Brown, Bioinformatics: A Biologist's Guide to Biocomputing and the Internet (2001); Han & Kamber, Data Mining: Concepts and Techniques (2000); and Waterman, Introduction to Computational Biology: Maps, Sequences, and Genomes (1995).

5

10

15

20

25

The present invention provides a computer database comprising a computer and software for storing in computer-retrievable form assay data records cross-tabulated, e.g., with data specifying the source of the target-containing sample from which each sequence specificity record was obtained.

In an exemplary embodiment, at least one of the sources of target-containing sample is from a control tissue sample known to be free of pathological disorders. In a variation, at least one of the sources is a known pathological tissue specimen, e.g., a neoplastic lesion or another tissue specimen to be analyzed for breast cancer. In another variation, the assay records cross-tabulate one or more of the following parameters for each target species in a sample: (1) a unique identification code, which can include, e.g., a target molecular structure and/or characteristic separation coordinate (e.g., electrophoretic coordinates); (2) sample source; and (3) absolute and/or relative quantity of the target species present in the sample.

The invention also provides for the storage and retrieval of a collection of target data in a computer data storage apparatus, which can include magnetic disks, optical disks, magneto-optical disks, DRAM, SRAM, SGRAM, SDRAM, RDRAM, DDR RAM, magnetic bubble memory devices, and other data storage devices, including CPU registers and on-CPU data storage arrays. Typically, the target data records are stored as a bit pattern in an array of magnetic domains on a magnetizable medium or as an array of charge states or transistor gate states, such as an array of cells in a DRAM device (e.g., each cell comprised of a transistor and a charge storage area, which may be on the transistor). In one embodiment, the invention provides such storage devices, and computer systems built therewith, comprising a bit pattern encoding a protein expression fingerprint record comprising unique identifiers for at least 10 target data records cross-tabulated with target source.

10

15

20

25

30

When the target is a peptide or nucleic acid, the invention preferably provides a method for identifying related peptide or nucleic acid sequences, comprising performing a computerized comparison between a peptide or nucleic acid sequence assay record stored in or retrieved from a computer storage device or database and at least one other sequence. The comparison can include a sequence analysis or comparison algorithm or computer program embodiment thereof (e.g., FASTA, TFASTA, GAP, BESTFIT) and/or the comparison may be of the relative amount of a peptide or nucleic acid sequence in a pool of sequences determined from a polypeptide or nucleic acid sample of a specimen.

The invention also preferably provides a magnetic disk, such as an IBM-compatible (DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format (e.g., Linux, SunOS, Solaris, AIX, SCO Unix, VMS, MV, Macintosh, etc.) floppy diskette or hard (fixed, Winchester) disk drive, comprising a bit pattern encoding data from an assay of the invention in a file format suitable for retrieval and processing in a computerized sequence analysis, comparison, or relative quantitation method.

The invention also provides a network, comprising a plurality of computing devices linked via a data link, such as an Ethernet cable (coax or 10BaseT), telephone line, ISDN line, wireless network, optical fiber, or other suitable signal transmission medium, whereby at least one network device (e.g., computer, disk array, etc.) comprises a pattern of magnetic domains (e.g., magnetic disk) and/or charge domains (e.g., an array of DRAM cells) composing a bit pattern encoding data acquired from an assay of the invention.

The invention also provides a method for transmitting assay data that includes generating an electronic signal on an electronic communications device, such as a modem, ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the signal includes (in native or encrypted format) a bit pattern encoding data from an assay or a database comprising a plurality of assay results obtained by the method of the invention.

In a preferred embodiment, the invention provides a computer system for comparing a query target to a database containing an array of data structures, such as an assay result obtained by the method of the invention, and ranking database targets based on the degree of identity and gap weight to the target data. A central processor is preferably initialized to load and execute the computer program for alignment and/or comparison of the

assay results. Data for a query target is entered into the central processor via an I/O device. Execution of the computer program results in the central processor retrieving the assay data from the data file, which comprises a binary description of an assay result.

The target data or record and the computer program can be transferred to secondary memory, which is typically random access memory (e.g., DRAM, SRAM, SGRAM, or SDRAM). Targets are ranked according to the degree of correspondence between a selected assay characteristic (e.g., binding to a selected affinity moiety) and the same characteristic of the query target and results are output via an I/O device. For example, a central processor can be a conventional computer (e.g., Intel Pentium, PowerPC, Alpha, PA-8000, SPARC, MIPS 4400, MIPS 10000, VAX, etc.); a program can be a commercial or public domain molecular biology software package (e.g., UWGCG Sequence Analysis Software, Darwin); a data file can be an optical or magnetic disk, a data server, a memory device (e.g., DRAM, SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device can be a terminal comprising a video display and a keyboard, a modem, an ISDN terminal adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or other suitable I/O device.

The invention also preferably provides the use of a computer system, such as that described above, which comprises: (1) a computer; (2) a stored bit pattern encoding a collection of peptide sequence specificity records obtained by the methods of the invention, which may be stored in the computer; (3) a comparison target, such as a query target; and (4) a program for alignment and comparison, typically with rank-ordering of comparison results on the basis of computed similarity values.

## Characteristics of breast cancer-associated proteins

5

10

15

20

25

30

Breast cancer proteins of the present invention may be classified as secreted proteins, transmembrane proteins or intracellular proteins. In one embodiment, the breast cancer protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus. Intracellular proteins are involved in all aspects of cellular function and replication (including, e.g., signaling pathways); aberrant expression of such proteins often results in unregulated or disregulated cellular processes (see, e.g., Molecular

WO 02/059377

Biology of the Cell (Alberts, ed., 3rd ed., 1994). For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are involved in maintaining the structural integrity of organelles.

5

10

15

20

25

30

An increasingly appreciated concept in characterizing proteins is the presence in the proteins of one or more motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of primary sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate. One useful database is Pfam (protein families), which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains. Versions are available via the internet from Washington University in St. Louis, the Sanger Center in England, and the Karolinska Institute in Sweden (see, e.g., Bateman et al., Nuc. Acids Res. 28:263-266 (2000); Sonnhammer et al., Proteins 28:405-420 (1997); Bateman et al., Nuc. Acids Res. 27:260-262 (1999); and Sonnhammer et al., Nuc. Acids Res. 26:320-322-(1998)).

In another embodiment, the breast cancer sequences are transmembrane proteins. Transmembrane proteins are molecules that span a phospholipid bilayer of a cell. They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described

15

20

25

30

PCT/US02/02242

for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.

Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors such as G protein coupled receptors (GPCRs) are classified as "seven transmembrane domain" proteins, as they contain 7 membrane spanning regions. Characteristics of transmembrane domains include approximately 20 consecutive hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted (see, e.g. PSORT web site http://psort.nibb.ac.jp/). Important transmembrane protein receptors include, but are not limited to the insulin receptor, insulin-like growth factor receptor, human growth hormone receptor, glucose transporters, transferrin receptor, epidermal growth factor receptor, low density lipoprotein receptor, epidermal growth factor receptor, leptin receptor, interleukin receptors, e.g. IL-1 receptor, IL-2 receptor,

The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are found on receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include

10

15

20

25

30



cytokines, mitogenic factors, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules. In this respect, they mediate cell-cell interactions. Cellassociated ligands can be tethered to the cell, e.g., via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure.

Breast cancer proteins that are transmembrane are particularly preferred in the present invention as they are readily accessible targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities. Antibodies may be used to label such readily accessible proteins in situ. Alternatively, antibodies can also label intracellular proteins, in which case samples are typically permeablized to provide access to intracellular proteins.

It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, e.g., through recombinant methods. Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.

In another embodiment, the breast cancer proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins have a signal peptide or signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; by virtue of their circulating nature, they serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor) or an endocrine manner (acting on cells at a distance). Thus secreted molecules find use in modulating or altering numerous aspects of physiology. Breast cancer proteins that are secreted proteins are particularly preferred in the present invention as they serve as good targets for diagnostic markers, e.g., for blood, plasma, serum, or stool tests.

### Use of breast cancer nucleic acids

As described above, breast cancer sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology or linkage to the breast cancer PCT/US02/02242 WO 02/059377

sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions. Typically, linked sequences on a mRNA are found on the same molecule.

5

15

20

25

30

The breast cancer nucleic acid sequences of the invention, e.g., the sequences in Tables 1-25, can be fragments of larger genes, i.e., they are nucleic acid segments. "Genes" in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, as will be appreciated by those in the art, using the sequences provided herein, extended sequences, in either direction, of the breast cancer genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Ausubel, et al., supra. Much can be done by informatics and many sequences can be clustered to include multiple sequences corresponding to a single gene, e.g., systems such as UniGene (see, http://www.ncbi.nlm.nih.gov/UniGene/).

Once the breast cancer nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire breast cancer nucleic acid coding regions or the entire mRNA sequence. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant breast cancer nucleic acid can be further-used as a probe to identify and isolate other breast cancer nucleic acids, e.g., extended coding regions. It can also be used as a "precursor" nucleic acid to make modified or variant breast cancer nucleic acids and proteins.

The breast cancer nucleic acids of the present invention are used in several ways. In a first embodiment, nucleic acid probes to the breast cancer nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, e.g., for gene therapy, vaccine, and/or antisense applications.

Alternatively, the breast cancer nucleic acids that include coding regions of breast cancer proteins can be put into expression vectors for the expression of breast cancer proteins, again for screening purposes or for administration to a patient.

In a preferred embodiment, nucleic acid probes to breast cancer nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof) are

10

15

20

25

30

made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the breast cancer nucleic acids, *i.e.* the target sequence (either the target sequence of the sample or to other probe sequences, e.g., in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.

A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases.

In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used. That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping (i.e., have some sequence in common), or separate. In some cases, PCR primers may be used to amplify signal for higher sensitivity.

As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can typically be covalent or non-covalent. By "non-covalent binding" and grammatical equivalents herein is meant one or more of electrostatic,

PCT/US02/02242 WO 02/059377

hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.

5

10

15

20

25

In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant a material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silicabased materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluoresce. A preferred substrate is described in copending application entitled Reusable Low Fluorescent Plastic Biochip, U.S. Application Serial No. 09/270,214, filed March 15, 1999, herein incorporated by reference in its entirety.

Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, for flow-through sample analysis to minimize WO 02/059377

sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.

5

10

15

20

25

30

In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, e.g., the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, e.g. using linkers as are known in the art; e.g., homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

In this embodiment, oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside.

In another embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S. Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affimetrix GeneChip<sup>TM</sup> technology.

Often, amplification-based assays are performed to measure the expression level of breast cancer-associated sequences. These assays are typically performed in conjunction with reverse transcription. In such assays, a breast cancer-associated nucleic acid

PCT/US02/02242 WO 02/059377

sequence acts as a template in an amplification reaction (e.g., Polymerase Chain Reaction, or PCR). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the amount of breast cancer-associated RNA. Methods of quantitative amplification are well known to those of skill in the art. Detailed protocols for quantitative PCR are provided, e.g., in Innis et al., PCR Protocols, A Guide to Methods and Applications (1990).

5

10

15

20

25

30

In some embodiments, a TaqMan based assay is used to measure expression. TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5' fluorescent dye and a 3' quenching agent. The probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3' end. When the PCR product is amplified in subsequent cycles, the 5' nuclease activity of the polymerase, e.g., AmpliTaq, results in the cleavage of the TaqMan probe. This cleavage separates the 5' fluorescent dye and the 3' quenching agent, thereby resulting in an increase in fluorescence as a function of amplification (see, e.g., literature provided by Perkin-Elmer, e.g., www2.perkin-elmer.com).

Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR) (see Wu & Wallace, Genomics 4:560 (1989), Landegren et al., Science 241:1077 (1988), and Barringer et al., Gene 89:117 (1990)), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA 86:1173 (1989)), self-sustained sequence replication (Guatelli et al., Proc. Nat. Acad. Sci. USA 87:1874 (1990)), dot PCR, and linker adapter PCR, etc.

# Expression of breast cancer proteins from nucleic acids

In a preferred embodiment, breast cancer nucleic acids, e.g., encoding breast cancer proteins are used to make a variety of expression vectors to express breast cancer proteins which can then be used in screening assays, as described below. Expression vectors and recombinant DNA technology are well known to those of skill in the art (see, e.g., Ausubel, supra, and Gene Expression Systems (Fernandez & Hoeffler, eds, 1999)) and are used to express proteins. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these

10

15

20

25

expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the breast cancer protein. The term "control sequences" refers to DNA sequences used for the expression of an operably linked coding sequence in a particular host organism. Control sequences that are suitable for prokaryotes, e.g., include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.

Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is typically accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the breast cancer protein. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

In general, transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.



10

15

20

25

30



In addition, an expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, e.g. in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art (e.g., Fernandez & Hoeffler, supra).

In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

The breast cancer proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a breast cancer protein, under the appropriate conditions to induce or cause expression of the breast cancer protein. Conditions appropriate for breast cancer protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation or optimization. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are Saccharomyces cerevisiae and other yeasts, E. coli, Bacillus subtilis, Sf9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, HeLa cells, HUVEC (human umbilical vein endothelial cells), THP1 cells (a macrophage cell line) and various other human cells and cell lines.

In a preferred embodiment, the breast cancer proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include

PCT/US02/02242 WO 02/059377

retroviral and adenoviral systems. One expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by reference. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter (see, e.g., Fernandez & Hoeffler, supra). Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenlyation signals include those derived form SV40.

10

15

20

25

30

The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used.

Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

In a preferred embodiment, breast cancer proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; e.g., the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the breast cancer protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which

render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for Bacillus subtilis, E. coli, Streptococcus cremoris, and Streptococcus lividans, among others (e.g., Fernandez & Hoeffler, supra). The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

In one embodiment, breast cancer proteins are produced in insect cells.

Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

In a preferred embodiment, breast cancer protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica.

15

20

25

30

The breast cancer protein may also be made as a fusion protein, using techniques well known in the art. Thus, e.g., for the creation of monoclonal antibodies, if the desired epitope is small, the breast cancer protein may be fused to a carrier protein to form an immunogen. Alternatively, the breast cancer protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the breast cancer protein is a breast cancer peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes.

In a preferred embodiment, the breast cancer protein is purified or isolated after expression. Breast cancer proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the breast cancer protein may be purified using a standard anti-breast cancer protein antibody column. Ultrafiltration

PCT/US02/02242 WO 02/059377

and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, Protein Purification (1982). The degree of purification necessary will vary depending on the use of the breast cancer protein. In some instances no purification will be necessary.

Once expressed and purified if necessary, the breast cancer proteins and nucleic acids are useful in a number of applications. They may be used as immunoselection reagents, as vaccine reagents, as screening agents, etc.

## Variants of breast cancer proteins

5

10

15

20

25

30

In one embodiment, the breast cancer proteins are derivative or variant breast cancer proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative breast cancer peptide will often contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion or deletion may occur at any residue within the breast cancer peptide.

Also included within one embodiment of breast cancer proteins of the present invention are amino acid sequence variants. These variants typically fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the breast cancer protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant breast cancer protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the breast cancer protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to


10

15

20

25

30



optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed breast cancer variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, e.g., M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of breast cancer protein activities.

Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.

Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the breast cancer protein are desired, substitutions are generally made in accordance with the amino acid substitution relationships provided in the definition section.

The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analog, although variants also are selected to modify the characteristics of the breast cancer proteins as needed. Alternatively, the variant may be designed such that the biological activity of the breast cancer protein is altered. For example, glycosylation sites may be altered or removed.

Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those described above. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue

25

having an electropositive side chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine.

Covalent modifications of breast cancer polypeptides are included within the

scope of this invention. One type of covalent modification includes reacting targeted amino
acid residues of a breast cancer polypeptide with an organic derivatizing agent that is capable
of reacting with selected side chains or the N-or C-terminal residues of a breast cancer
polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking
breast cancer polypeptides to a water-insoluble support matrix or surface for use in the
method for purifying anti-breast cancer polypeptide antibodies or screening assays, as is more
fully described below. Commonly used crosslinking agents include, e.g., 1,1bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, e.g., esters
with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters
such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-Nmaleimido-1,8-octane and agents such as methyl-3-((p-azidophenyl)dithio)propioimidate.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl, threonyl or tyrosyl residues, methylation of the amino groups of the lysine, arginine, and histidine side chains (Creighton, *Proteins: Structure and Molecular Properties*, pp. 79-86 (1983)), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the breast cancer polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence breast cancer polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence breast cancer polypeptide. Glycosylation patterns can be altered in many ways. For example the use of different cell types to express breast cancer-associated sequences can result in different glycosylation patterns.

Addition of glycosylation sites to breast cancer polypeptides may also be accomplished by altering the amino acid sequence thereof. The alteration may be made, e.g., by the addition of, or substitution by, one or more serine or threonine residues to the native sequence breast cancer polypeptide (for O-linked glycosylation sites). The breast cancer amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the breast cancer polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

5

10

15

20

25

30

Another means of increasing the number of carbohydrate moieties on the breast cancer polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330, and in Aplin & Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the breast cancer polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of breast cancer comprises linking the breast cancer polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

Breast cancer polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising a breast cancer polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a breast cancer polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the breast cancer polypeptide. The presence of such epitope-tagged forms of a breast cancer polypeptide can be detected using

10

15

20

25

30

an antibody against the tag polypeptide. Also, provision of the epitope tag enables the breast cancer polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of a breast cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; HIS6 and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5 (Field et al., Mol. Cell. Biol. 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan et al., Molecular and Cellular Biology 5:3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky et al., Protein Engineering 3(6):547-553 (1990)). Other tag polypeptides include the Flag-peptide (Hopp et al., BioTechnology 6:1204-1210 (1988)); the KT3 epitope peptide (Martin et al., Science 255:192-194 (1992)); tubulin epitope peptide (Skinner et al., J. Biol. Chem. 266:15163-15166 (1991)); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA 87:6393-6397 (1990)).

Also included are other breast cancer proteins of the breast cancer family, and breast cancer proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related breast cancer proteins from humans or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include the unique areas of the breast cancer nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art (e.g., Innis, PCR Protocols, *supra*).

#### Antibodies to breast cancer proteins

In a preferred embodiment, when the breast cancer protein is to be used to generate antibodies, e.g., for immunotherapy or immunodiagnosis, the breast cancer protein

PCT/US02/02242 WO 02/059377

should share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is typically meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller breast cancer protein will be able to bind to the full-length protein, particularly linear epitopes. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity.

5

10

20

25

30

Methods of preparing polyclonal antibodies are known to the skilled artisan (e.g., Coligan, supra; and Harlow & Lane, supra). Polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of the figures or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler & Milstein, Nature 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Tables 1-25 or fragment thereof, or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene

PCT/US02/02242 WO 02/059377

glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (1986)). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens or that have binding specificities for two epitopes on the same antigen. In one embodiment, one of the binding specificities is for a protein encoded by a nucleic acid Tables 1-25 or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific. Alternatively, tetramer-type technology may create multivalent reagents.

In a preferred embodiment, the antibodies to breast cancer protein are capable of reducing or eliminating a biological function of a breast cancer protein, as is described below. That is, the addition of anti-breast cancer protein antibodies (either polyclonal or preferably monoclonal) to breast cancer tissue (or cells containing breast cancer) may reduce or eliminate the breast cancer. Generally, at least a 25% decrease in activity, growth, size or the like is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

In a preferred embodiment the antibodies to the breast cancer proteins are humanized antibodies (e.g., Xenerex Biosciences, Mederex, Inc., Abgenix, Inc., Protein Design Labs, Inc.) Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include

5

10

15

20

25

30

PCT/US02/02242

WO 02/059377

25

30

human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a nonhuman species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise 10 at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992)). Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., 15 Science 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-20 human species.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom & Winter, J. Mol. Biol. 227:381 (1991); Marks et al., J. Mol. Biol. 222:581 (1991)). The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, p. 77 (1985) and Boerner et al., J. Immunol. 147(1):86-95 (1991)). Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge,

10

15

20

25

30

respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, e.g., in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10:779-783 (1992); Lonberg et al., Nature 368:856-859 (1994); Morrison, Nature 368:812-13 (1994); Fishwild et al., Nature Biotechnology 14:845-51 (1996); Neuberger, Nature Biotechnology 14:826 (1996); Lonberg & Huszar, Intern. Rev. Immunol. 13:65-93 (1995).

By immunotherapy is meant treatment of breast cancer with an antibody raised against breast cancer proteins. As used herein, immunotherapy can be passive or active. Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. As appreciated by one of ordinary skill in the art, the antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen, leading to an immune response.

In a preferred embodiment the breast cancer proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted breast cancer protein.

In another preferred embodiment, the breast cancer protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment, bind the extracellular domain of the breast cancer protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane breast cancer protein. As will be appreciated by one of ordinary skill in the art, the antibody may be a competitive, non-competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the breast cancer protein. The antibody is also an antagonist of the breast cancer protein. Further, the antibody prevents activation of the transmembrane breast cancer protein. In one aspect, when the antibody prevents the binding of other molecules to the breast cancer

10

15

20

25

30

protein, the antibody prevents growth of the cell. The antibody may also be used to target or sensitize the cell to cytotoxic agents, including, but not limited to TNF-α, TNF-β, IL-1, INF-γ and IL-2, or chemotherapeutic agents including 5FU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity or antigen-dependent cytotoxicity (ADCC). Thus, breast cancer is treated by administering to a patient antibodies directed against the transmembrane breast cancer protein. Antibody-labeling may activate a co-toxin, localize a toxin payload, or otherwise provide means to locally ablate cells.

In another preferred embodiment, the antibody is conjugated to an effector moiety. The effector moiety can be any number of molecules, including labelling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the breast cancer protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the breast cancer protein. The therapeutic moiety may inhibit enzymatic activity such as protease or collagenase or protein kinase activity associated with breast cancer.

In a preferred embodiment, the therapeutic moiety can also be a cytotoxic agent. In this method, targeting the cytotoxic agent to breast cancer tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with breast cancer. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against breast cancer proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane breast cancer proteins not only serves to increase the local concentration of therapeutic moiety in the breast cancer afflicted area, but also serves to reduce deleterious side effects that may be associated with the therapeutic moiety.

In another preferred embodiment, the breast cancer protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the breast cancer protein can be targeted within a cell, i.e., the nucleus, an antibody thereto contains a signal for that target localization, i.e., a nuclear localization signal.

5

10

15

20

25

30

The breast cancer antibodies of the invention specifically bind to breast cancer proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a  $K_d$  of at least about 0.1 mM, more usually at least about 1  $\mu$ M, preferably at least about 0.1  $\mu$ M or better, and most preferably, 0.01  $\mu$ M or better. Selectivity of binding is also important.

### Detection of breast cancer sequence for diagnostic and therapeutic applications

In one aspect, the RNA expression levels of genes are determined for different cellular states in the breast cancer phenotype. Expression levels of genes in normal tissue (i.e., not undergoing breast cancer) and in breast cancer tissue (and in some cases, for varying severities of breast cancer that relate to prognosis, as outlined below) are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a "fingerprint" of the state. While two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is reflective of the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be performed or confirmed to determine whether a tissue sample has the gene expression profile of normal or cancerous tissue. This will provide for molecular diagnosis of related conditions.

"Differential expression," or grammatical equivalents as used herein, refers to qualitative or quantitative differences in the temporal and/or cellular gene expression patterns within and among cells and tissue. Thus, a differentially expressed gene can

15

20

25

qualitatively have its expression altered, including an activation or inactivation, in, e.g., normal versus breast cancer tissue. Genes may be turned on or turned off in a particular state, relative to another state thus permitting comparison of two or more states. A qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques. Some genes will be expressed in one state or cell type, but not in both. Alternatively, the difference in expression may be quantitative, e.g., in that expression is increased or decreased; i.e., gene expression is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip<sup>™</sup> expression arrays, Lockhart, *Nature Biotechnology* 14:1675-1680 (1996). hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, northern analysis and RNase protection. As outlined above, preferably the change in expression (i.e., upregulation or downregulation) is at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably at least about 200%, with from 300 to at least 1000% being especially preferred.

Evaluation may be at the gene transcript, or the protein level. The amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, e.g., with antibodies to the breast cancer protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins corresponding to breast cancer genes, i.e., those identified as being important in a breast cancer phenotype, can be evaluated in a breast cancer diagnostic test.

In a preferred embodiment, gene expression monitoring is performed simultaneously on a number of genes. Multiple protein expression monitoring can be performed as well. Similarly, these assays may be performed on an individual basis as well.

In this embodiment, the breast cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of breast cancer sequences in

15

20

25

30

a particular cell. The assays are further described below in the example. PCR techniques can be used to provide greater sensitivity.

In a preferred embodiment nucleic acids encoding the breast cancer protein are detected. Although DNA or RNA encoding the breast cancer protein may be detected, of particular interest are methods wherein an mRNA encoding a breast cancer protein is detected. Probes to detect mRNA can be a nucleotide/deoxynucleotide probe that is complementary to and hybridizes with the mRNA and includes, but is not limited to, oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding a breast cancer protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3indoyl phosphate.

In a preferred embodiment, various proteins from the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in diagnostic assays. This can be performed on an individual gene or corresponding polypeptide level. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes and/or corresponding polypeptides.

As described and defined herein, breast cancer proteins, including intracellular, transmembrane or secreted proteins, find use as markers of breast cancer.

Detection of these proteins in putative breast cancer tissue allows for detection or diagnosis

of breast cancer. In one embodiment, antibodies are used to detect breast cancer proteins. A preferred method separates proteins from a sample by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be another type of gel, including isoelectric focusing gels and the like). Following separation of proteins, the breast cancer protein is detected, e.g., by immunoblotting with antibodies raised against the breast cancer protein. Methods of immunoblotting are well known to those of ordinary skill in the art.

5

10

15

20

25

30

In another preferred method, antibodies to the breast cancer protein find use in in situ imaging techniques, e.g., in histology (e.g., Methods in Cell Biology: Antibodies in Cell Biology, volume 37 (Asai, ed. 1993)). In this method cells are contacted with from one to many antibodies to the breast cancer protein(s). Following washing to remove non-specific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the breast cancer protein(s) contains a detectable label, e.g. an enzyme marker that can act on a substrate. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of breast cancer proteins. As will be appreciated by one of ordinary skill in the art, many other histological imaging techniques are also provided by the invention.

In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.

In another preferred embodiment, antibodies find use in diagnosing breast cancer from blood, serum, plasma, stool, and other samples. Such samples, therefore, are useful as samples to be probed or tested for the presence of breast cancer proteins.

Antibodies can be used to detect a breast cancer protein by previously described immunoassay techniques including ELISA, immunoblotting (western blotting), immunoprecipitation, BIACORE technology and the like. Conversely, the presence of antibodies may indicate an immune response against an endogenous breast cancer protein.

In a preferred embodiment, *in situ* hybridization of labeled breast cancer nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including

breast cancer tissue and/or normal tissue, are made. In situ hybridization (see, e.g., Ausubel, supra) is then performed. When comparing the fingerprints between an individual and a standard, the skilled artisan can make a diagnosis, a prognosis, or a prediction based on the findings. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis and molecular profiling of the condition of the cells may lead to distinctions between responsive or refractory conditions or may be predictive of outcomes.

In a preferred embodiment, the breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in prognosis assays. As above, gene expression profiles can be generated that correlate to breast cancer, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being preferred. As above, breast cancer probes may be attached to biochips for the detection and quantification of breast cancer sequences in a tissue or patient. The assays proceed as outlined above for diagnosis. PCR method may provide more sensitive and accurate quantification.

#### Assays for therapeutic compounds

10

15

20

25

30

In a preferred embodiment members of the proteins, nucleic acids, and antibodies as described herein are used in drug screening assays. The breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in drug screening assays or by evaluating the effect of drug candidates on a "gene expression profile" or expression profile of polypeptides. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent (e.g., Zlokarnik, et al., Science 279:84-8 (1998); Heid, Genome Res 6:986-94, 1996).

In a preferred embodiment, the breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified breast cancer proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the breast cancer phenotype or an identified physiological function of a breast cancer protein. As above, this can be done on an individual gene level or

by evaluating the effect of drug candidates on a "gene expression profile". In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, *supra*.

5

10

15

20

25

Having identified the differentially expressed genes herein, a variety of assays may be executed. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene as up regulated in breast cancer, test compounds can be screened for the ability to modulate gene expression or for binding to the breast cancer protein. "Modulation" thus includes both an increase and a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing breast cancer, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in breast cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in breast cancer tissue compared to normal tissue often provides a target value of a 10-fold increase in expression to be induced by the test compound.

The amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the gene product itself can be monitored, e.g., through the use of antibodies to the breast cancer protein and standard immunoassays. Proteomics and separation techniques may also allow quantification of expression.

In a preferred embodiment, gene expression or protein monitoring of a number of entities, i.e., an expression profile, is monitored simultaneously. Such profiles will typically involve a plurality of those entities described herein..

In this embodiment, the breast cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of breast cancer sequences in a particular cell. Alternatively, PCR may be used. Thus, a series, e.g., of microtiter plate, may be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well.

Expression monitoring can be performed to identify compounds that modify the expression of one or more breast cancer-associated sequences, e.g., a polynucleotide sequence set out in Table 17. Generally, in a preferred embodiment, a test modulator is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate breast cancer, modulate breast cancer proteins, bind to a breast cancer protein, or interfere with the binding of a breast cancer protein and an antibody or other binding partner.

The term "test compound" or "drug candidate" or "modulator" or grammatical equivalents as used herein describes any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the breast cancer phenotype or the expression of a breast cancer sequence, e.g., a nucleic acid or protein sequence. In preferred embodiments, modulators alter expression profiles, or expression profile nucleic acids or proteins provided herein. In one embodiment, the modulator suppresses a breast cancer phenotype, e.g. to a normal tissue fingerprint. In another embodiment, a modulator induced a breast cancer phenotype. Generally, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

10

15

20

25

30

Drug candidates encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Preferred small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.

In one aspect, a modulator will neutralize the effect of a breast cancer protein. By "neutralize" is meant that activity of a protein is inhibited or blocked and the consequent effect on the cell.

In certain embodiments, combinatorial libraries of potential modulators will be screened for an ability to bind to a breast cancer polypeptide or to modulate activity. Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a "lead compound") with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.

5

10

15

20

25

30

In one preferred embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such "combinatorial chemical libraries" are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks (Gallop *et al.*, *J. Med. Chem.* 37(9):1233-1251 (1994)).

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent No. 5,010,175, Furka, Pept. Prot. Res. 37:487-493 (1991), Houghton et al., Nature, 354:84-88 (1991)), peptoids (PCT Publication No WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as

hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho, et al., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)). See, generally, Gordon et al., J. Med. Chem. 37:1385 (1994), nucleic acid libraries (see, e.g., Strategene, Corp.), peptide nucleic acid libraries (see, e.g., U.S. Patent 5,539,083), antibody libraries (see, e.g., Vaughn et al., Nature Biotechnology 14(3):309-314 (1996), and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., Science 274:1520-1522 (1996), and U.S. Patent No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, Baum, C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and metathiazanones, U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent No. 5,506,337; benzodiazepines, U.S. Patent No. 5,288,514; and the like).

5

10

15

20

25

Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA).

A number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art. In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis,

MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

The assays to identify modulators are amenable to high throughput screening. Preferred assays thus detect enhancement or inhibition of breast cancer gene transcription, inhibition or enhancement of polypeptide expression, and inhibition or enhancement of polypeptide activity.

High throughput assays for the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art. Similarly, binding assays and reporter gene assays are similarly well known. Thus, e.g., U.S. Patent No. 5,559,410 discloses high throughput screening methods for proteins, U.S. Patent No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (i.e., in arrays), while U.S. Patent Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.

10

15

20

25

In addition, high throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA, etc.). These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e.g., Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.

In one embodiment, modulators are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, e.g., cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially

preferred. Particularly useful test compound will be directed to the class of proteins to which the target belongs, e.g., substrates for enzymes or ligands and receptors.

In a preferred embodiment, modulators are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

5

10

15

20

25

In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, e.g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.

Modulators of breast cancer can also be nucleic acids, as defined above.

As described above generally for proteins, nucleic acid modulating agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.

In a preferred embodiment, the candidate compounds are organic chemical moieties, a wide variety of which are available in the literature.

After the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing a target sequence to be analyzed is added to the biochip. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate. For example, an *in vitro* transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.

5

10

15

20

25

30

In a preferred embodiment, the target sequence is labeled with, e.g., a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.

As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5,681,702, 5,597,909, 5,545,730, 5,594,117, 5,591,584, 5,571,670, 5,580,731, 5,571,670, 5,591,584, 5,624,802, 5,635,352, 5,594,118, 5,359,100, 5,124,246 and 5,681,697, all of which are hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.

A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to,

temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc.

These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

5

10

15

20

25

30

The reactions outlined herein may be accomplished in a variety of ways. Components of the reaction may be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal hybridization and detection, and/or reduce non-specific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target.

The assay data are analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile.

Screens are performed to identify modulators of the breast cancer phenotype. In one embodiment, screening is performed to identify modulators that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. In another embodiment, e.g., for diagnostic applications, having identified differentially expressed genes important in a particular state, screens can be performed to identify modulators that alter expression of individual genes. In an another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product.

In addition screens can be done for genes that are induced in response to a candidate agent. After identifying a modulator based upon its ability to suppress a breast cancer expression pattern leading to a normal expression pattern, or to modulate a single breast cancer gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically

modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated breast cancer tissue reveals genes that are not expressed in normal tissue or breast cancer tissue, but are expressed in agent treated tissue. These agent-specific sequences can be identified and used by methods described herein for breast cancer genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated breast cancer tissue sample.

5

10

15

20

25

30

Thus, in one embodiment, a test compound is administered to a population of breast cancer cells, that have an associated breast cancer expression profile. By "administration" or "contacting" herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (i.e., a peptide) may be put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97/01019. Regulatable gene therapy systems can also be used.

Once the test compound has been administered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.

Thus, e.g., breast cancer tissue may be screened for agents that modulate, e.g., induce or suppress the breast cancer phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on breast cancer activity. By defining such a signature for the breast cancer phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of

either the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "breast cancer proteins" or a "breast cancer modulatory protein". The breast cancer modulatory protein may be a fragment, or alternatively, be the full length protein to the fragment encoded by the nucleic acids of the Tables. Preferably, the breast cancer modulatory protein is a fragment. In a preferred embodiment, the breast cancer amino acid sequence which is used to determine sequence identity or similarity is encoded by a nucleic acid of Table 25. In another embodiment, the sequences are naturally occurring allelic variants of a protein encoded by a nucleic acid of Table 25. In another embodiment, the sequences are sequence variants as further described herein.

Preferably, the breast cancer modulatory protein is a fragment of approximately 14 to 24 amino acids long. More preferably the fragment is a soluble fragment. Preferably, the fragment includes a non-transmembrane region. In a preferred embodiment, the fragment has an N-terminal Cys to aid in solubility. In one embodiment, the C-terminus of the fragment is kept as a free acid and the N-terminus is a free amine to aid in coupling, i.e., to cysteine.

10

15

20

25

In one embodiment the breast cancer proteins are conjugated to an immunogenic agent as discussed herein. In one embodiment the breast cancer protein is conjugated to BSA.

Measurements of breast cancer polypeptide activity, or of breast cancer or the breast cancer phenotype can be performed using a variety of assays. For example, the effects of the test compounds upon the function of the breast cancer polypeptides can be measured by examining parameters described above. A suitable physiological change that affects activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of breast cancer associated with tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second

messengers such as cGMP. In the assays of the invention, mammalian breast cancer polypeptide is typically used, e.g., mouse, preferably human.

5

10

15

20

25

Assays to identify compounds with modulating activity can be performed in vitro. For example, a breast cancer polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e.g., from 0.5 to 48 hours. In one embodiment, the breast cancer polypeptide levels are determined in vitro by measuring the level of protein or mRNA. The level of protein is measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively binds to the breast cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.

Alternatively, a reporter gene system can be devised using the breast cancer protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or  $\beta$ -gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "breast cancer proteins." The breast cancer protein may be a fragment, or alternatively, be the full length protein to a fragment shown herein.

In one embodiment, screening for modulators of expression of specific genes is performed. Typically, the expression of only one or a few genes are evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate

differentially expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate structure activity relationships.

In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the breast cancer proteins can be used in the assays.

Thus, in a preferred embodiment, the methods comprise combining a breast cancer protein and a candidate compound, and determining the binding of the compound to the breast cancer protein. Preferred embodiments utilize the human breast cancer protein, although other mammalian proteins may also be used, e.g. for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative breast cancer proteins may be used.

10

15

20

25

30

Generally, in a preferred embodiment of the methods herein, the breast cancer protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g. a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflon<sup>TM</sup>, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving

areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

In a preferred embodiment, the breast cancer protein is bound to the support, and a test compound is added to the assay. Alternatively, the candidate agent is bound to the support and the breast cancer protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

The determination of the binding of the test modulating compound to the breast cancer protein may be done in a number of ways. In a preferred embodiment, the compound is labeled, and binding determined directly, e.g., by attaching all or a portion of the breast cancer protein to a solid support, adding a labeled candidate agent (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as appropriate.

10

15

20

25

30

In some embodiments, only one of the components is labeled, e.g., the proteins (or proteinaceous candidate compounds) can be labeled. Alternatively, more than one component can be labeled with different labels, e.g., <sup>125</sup>I for the proteins and a fluorophor for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful.

In one embodiment, the binding of the test compound is determined by competitive binding assay. The competitor is a binding moiety known to bind to the target molecule (i.e., a breast cancer protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding between the compound and the binding moiety, with the binding moiety displacing the compound. In one embodiment, the test compound is labeled. Either the compound, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at a temperature which facilitates optimal activity, typically between 4 and 40°C. Incubation periods are typically optimized, e.g., to facilitate rapid high throughput

screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

In a preferred embodiment, the competitor is added first, followed by the test compound. Displacement of the competitor is an indication that the test compound is binding to the breast cancer protein and thus is capable of binding to, and potentially modulating, the activity of the breast cancer protein. In this embodiment, either component can be labeled. Thus, e.g., if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement.

5

10

15

20

25

In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the test compound is bound to the breast cancer protein with a higher affinity. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the test compound is capable of binding to the breast cancer protein.

In a preferred embodiment, the methods comprise differential screening to identity agents that are capable of modulating the activity of the breast cancer proteins. In this embodiment, the methods comprise combining a breast cancer protein and a competitor in a first sample. A second sample comprises a test compound, a breast cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the breast cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the breast cancer protein.

Alternatively, differential screening is used to identify drug candidates that bind to the native breast cancer protein, but cannot bind to modified breast cancer proteins. The structure of the breast cancer protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect the activity of a

breast cancer protein are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

Positive controls and negative controls may be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in an order that provides for the requisite binding.

10

15

20

25

30

In a preferred embodiment, the invention provides methods for screening for a compound capable of modulating the activity of a breast cancer protein. The methods comprise adding a test compound, as defined above, to a cell comprising breast cancer proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes a breast cancer protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, e.g. hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e. cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process.

In this way, compounds that modulate breast cancer agents are identified.

Compounds with pharmacological activity are able to enhance or interfere with the activity of the breast cancer protein. Once identified, similar structures are evaluated to identify critical structural feature of the compound.

In one embodiment, a method of inhibiting breast cancer cell division is provided. The method comprises administration of a breast cancer inhibitor. In another embodiment, a method of inhibiting breast cancer is provided. The method comprises administration of a breast cancer inhibitor. In a further embodiment, methods of treating cells or individuals with breast cancer are provided. The method comprises administration of a breast cancer inhibitor.

In one embodiment, a breast cancer inhibitor is an antibody as discussed above. In another embodiment, the breast cancer inhibitor is an antisense molecule.

A variety of cell growth, proliferation, and metastasis assays are known to those of skill in the art, as described below.

Soft agar growth or colony formation in suspension

10

15

20

25

30

Normal cells require a solid substrate to attach and grow. When the cells are transformed, they lose this phenotype and grow detached from the substrate. For example, transformed cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected with tumor suppressor genes, regenerate normal phenotype and require a solid substrate to attach and grow. Soft agar growth or colony formation in suspension assays can be used to identify modulators of breast cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A therapeutic compound would reduce or eliminate the host cells' ability to grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft.

Techniques for soft agar growth or colony formation in suspension assays are described in Freshney, *Culture of Animal Cells a Manual of Basic Technique* (3<sup>rd</sup> ed., 1994), herein incorporated by reference. *See also*, the methods section of Garkavtsev *et al.* (1996), *supra*, herein incorporated by reference.

Contact inhibition and density limitation of growth

Normal cells typically grow in a flat and organized pattern in a petri dish until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. When cells are transformed, however, the cells are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, the transformed cells grow to a

higher saturation density than normal cells. This can be detected morphologically by the formation of a disoriented monolayer of cells or rounded cells in foci within the regular pattern of normal surrounding cells. Alternatively, labeling index with (<sup>3</sup>H)-thymidine at saturation density can be used to measure density limitation of growth. *See* Freshney (1994), *supra*. The transformed cells, when transfected with tumor suppressor genes, regenerate a normal phenotype and become contact inhibited and would grow to a lower density.

In this assay, labeling index with (<sup>3</sup>H)-thymidine at saturation density is a preferred method of measuring density limitation of growth. Transformed host cells are transfected with a breast cancer-associated sequence and are grown for 24 hours at saturation density in non-limiting medium conditions. The percentage of cells labeling with (<sup>3</sup>H)-thymidine is determined autoradiographically. *See*, Freshney (1994), *supra*.

## Growth factor or serum dependence

5

10

15

20

25

30

Transformed cells have a lower serum dependence than their normal counterparts (see, e.g., Temin, J. Natl. Cancer Insti. 37:167-175 (1966); Eagle et al., J. Exp. Med. 131:836-879 (1970)); Freshney, supra. This is in part due to release of various growth factors by the transformed cells. Growth factor or serum dependence of transformed host cells can be compared with that of control.

### Tumor specific markers levels

Tumor cells release an increased amount of certain factors (hereinafter "tumor specific markers") than their normal counterparts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e.g., Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985)). Similarly, Tumor angiogenesis factor (TAF) is released at a higher level in tumor cells than their normal counterparts. See, e.g., Folkman, Angiogenesis and Cancer, Sem Cancer Biol. (1992)).

Various techniques which measure the release of these factors are described in Freshney (1994), supra. Also, see, Unkless et al., J. Biol. Chem. 249:4295-4305 (1974); Strickland & Beers, J. Biol. Chem. 251:5694-5702 (1976); Whur et al., Br. J. Cancer 42:305-

312 (1980); Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985); Freshney Anticancer Res. 5:111-130 (1985).

### Invasiveness into Matrigel

5.

10

15

30

The degree of invasiveness into Matrigel or some other extracellular matrix constituent can be used as an assay to identify compounds that modulate breast cancer-associated sequences. Tumor cells exhibit a good correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells.

Techniques described in Freshney (1994), *supra*, can be used. Briefly, the level of invasion of host cells can be measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by prelabeling the cells with <sup>125</sup>I and counting the radioactivity on the distal side of the filter or bottom of the dish. *See, e.g.*, Freshney (1984), *supra*.

### Tumor growth in vivo

Effects of breast cancer-associated sequences on cell growth can be tested in transgenic or immune-suppressed mice. Knock-out transgenic mice can be made, in which the breast cancer gene is disrupted or in which a breast cancer gene is inserted. Knock-out transgenic mice can be made by insertion of a marker gene or other heterologous gene into the endogenous breast cancer gene site in the mouse genome via homologous recombination.

Such mice can also be made by substituting the endogenous breast cancer gene with a mutated version of the breast cancer gene, or by mutating the endogenous breast cancer gene, e.g., by exposure to carcinogens.

A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice

that possess germ cells partially derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi et al., Science 244:1288 (1989)). Chimeric targeted mice can be derived according to Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory (1988) and Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed., IRL Press, Washington, D.C., (1987).

Alternatively, various immune-suppressed or immune-deficient host animals can be used. For example, genetically athymic "nude" mouse (see, e.g., Giovanella et al., J. Natl. Cancer Inst. 52:921 (1974)), a SCID mouse, a thymectomized mouse, or an irradiated mouse (see, e.g., Bradley et al., Br. J. Cancer 38:263 (1978); Selby et al., Br. J. Cancer 41:52 (1980)) can be used as a host. Transplantable tumor cells (typically about 10<sup>6</sup> cells) injected into isogenic hosts will produce invasive tumors in a high proportions of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing a breast cancer-associated sequences are injected subcutaneously. After a suitable length of time, preferably 4-8 weeks, tumor growth is measured (e.g., by volume or by its two largest dimensions) and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student's T test) are said to have inhibited growth.

#### Polynucleotide modulators of breast cancer

10

15

20

25

30

Antisense Polynucleotides

In certain embodiments, the activity of a breast cancer-associated protein is down-regulated, or entirely inhibited, by the use of antisense polynucleotide, *i.e.*, a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e.g., a breast cancer protein mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and/or stability of the mRNA.

In the context of this invention, antisense polynucleotides can comprise naturally-occurring nucleotides, or synthetic species formed from naturally-occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other

sulfur containing species which are known for use in the art. Analogs are comprehended by this invention so long as they function effectively to hybridize with the breast cancer protein mRNA. See, e.g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA.

Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized *in vitro*. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art.

Antisense molecules as used herein include antisense or sense oligonucleotides. Sense oligonucleotides can, e.g., be employed to block transcription by binding to the anti-sense strand. The antisense and sense oligonucleotide comprise a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for breast cancer molecules. A preferred antisense molecule is for a breast cancer sequences in Tables 1-25, or for a ligand or activator thereof. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, e.g., Stein & Cohen (Cancer Res. 48:2659 (1988 and van der Krol et al. (BioTechniques 6:958 (1988)).

20 Ribozymes

5

10

15

25

30

In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of breast cancer-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P, and axhead ribozymes (see, e.g., Castanotto et al., Adv. in Pharmacology 25: 289-317 (1994) for a general review of the properties of different ribozymes).

The general features of hairpin ribozymes are described, e.g., in Hampel et al., Nucl. Acids Res. 18:299-304 (1990); European Patent Publication No. 0 360 257; U.S. Patent No. 5,254,678. Methods of preparing are well known to those of skill in the art (see, e.g.,

WO 94/26877; Ojwang et al., Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993); Yamada et al., Human Gene Therapy 1:39-45 (1994); Leavitt et al., Proc. Natl. Acad. Sci. USA 92:699-703 (1995); Leavitt et al., Human Gene Therapy 5:1151-120 (1994); and Yamada et al., Virology 205: 121-126 (1994)).

5

10

15

20

25

Polynucleotide modulators of breast cancer may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of breast cancer may be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of an polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.

Thus, in one embodiment, methods of modulating breast cancer in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-breast cancer antibody that reduces or eliminates the biological activity of an endogenous breast cancer protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding a breast cancer protein. This may be accomplished in any number of ways. In a preferred embodiment, e.g. when the breast cancer sequence is down-regulated in breast cancer, such state may be reversed by increasing the amount of breast cancer gene product in the cell. This can be accomplished, e.g., by overexpressing the endogenous breast cancer gene or administering a gene encoding the breast cancer sequence, using known gene-therapy techniques, e.g.. In a preferred embodiment, the gene therapy techniques include the incorporation of the exogenous gene using enhanced homologous recombination (EHR), e.g. as described in PCT/US93/03868, hereby incorporated by reference in its entirety. Alternatively, e.g. when the breast cancer

sequence is up-regulated in breast cancer, the activity of the endogenous breast cancer gene is decreased, e.g. by the administration of a breast cancer antisense nucleic acid.

In one embodiment, the breast cancer proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to breast cancer proteins. Similarly, the breast cancer proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify breast cancer antibodies useful for production, diagnostic, or therapeutic purposes. In a preferred embodiment, the antibodies are generated to epitopes unique to a breast cancer protein; that is, the antibodies show little or no cross-reactivity to other proteins. The breast cancer antibodies may be coupled to standard affinity chromatography columns and used to purify breast cancer proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the breast cancer protein.

### Methods of identifying variant breast cancer-associated sequences

10

15

20

25

30

Without being bound by theory, expression of various breast cancer sequences is correlated with breast cancer. Accordingly, disorders based on mutant or variant breast cancer genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant breast cancer genes, e.g., determining all or part of the sequence of at least one endogenous breast cancer genes in a cell. This may be accomplished using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the breast cancer genotype of an individual, e.g., determining all or part of the sequence of at least one breast cancer gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced breast cancer gene to a known breast cancer gene, i.e., a wild-type gene.

The sequence of all or part of the breast cancer gene can then be compared to the sequence of a known breast cancer gene to determine if any differences exist. This can be done using any number of known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the breast cancer gene of

the patient and the known breast cancer gene correlates with a disease state or a propensity for a disease state, as outlined herein.

In a preferred embodiment, the breast cancer genes are used as probes to determine the number of copies of the breast cancer gene in the genome.

In another preferred embodiment, the breast cancer genes are used as probes to determine the chromosomal localization of the breast cancer genes. Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the breast cancer gene locus.

10

15

20

25

30

5.

# Administration of pharmaceutical and vaccine compositions

In one embodiment, a therapeutically effective dose of a breast cancer protein or modulator thereof, is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (e.g., Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery; Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992), Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981; Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); and Pickar, Dosage Calculations (1999)). As is known in the art, adjustments for breast cancer degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. U.S. Patent Application N. 09/687,576, further discloses the use of compositions and methods of diagnosis and treatment in breast cancer is hereby expressly incorporated by reference.

A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, preferably a primate, and in the most preferred embodiment the patient is human.

The administration of the breast cancer proteins and modulators thereof of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, e.g., in the treatment of wounds and inflammation, the breast cancer proteins and modulators may be directly applied as a solution or spray.

5

10

15

20

25

The pharmaceutical compositions of the present invention comprise a breast cancer protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.

The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powder, tablets, pills, capsules and lozenges. It is recognized that breast cancer protein modulators (e.g., antibodies, antisense constructs, ribozymes, small organic molecules, etc.) when administered orally, should be protected from digestion. This is typically accomplished either by complexing the molecule(s) with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the molecule(s) in an appropriately resistant carrier, such as a liposome or a protection barrier. Means of protecting agents from digestion are well known in the art.

5

10

15

20

25

The compositions for administration will commonly comprise a breast cancer protein modulator dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs (e.g., Remington's Pharmaceutical Science (15th ed., 1980) and Goodman & Gillman, The Pharmacologial Basis of Therapeutics (Hardman et al., eds., 1996)).

Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art, e.g., Remington's Pharmaceutical Science and Goodman and Gillman, The Pharmacologial Basis of Therapeutics. supra.

The compositions containing modulators of breast cancer proteins can be administered for the rapeutic or prophylactic treatments. In the rapeutic applications, compositions are administered to a patient suffering from a disease (e.g., a cancer) in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the agents of this invention to effectively treat the patient. An amount of modulator that is capable of preventing or slowing the development of cancer in a mammal is referred to as a "prophylactically effective dose." The particular dose required for a prophylactic treatment will depend upon the medical condition and history of the mammal, the particular cancer being prevented, as well as other factors such as age, weight, gender, administration route, efficiency, etc. Such prophylactic treatments may be used, e.g., in a mammal who has previously had cancer to prevent a recurrence of the cancer, or in a mammal who is suspected of having a significant likelihood of developing cancer.

5

10

15

20

25

30

It will be appreciated that the present breast cancer protein-modulating compounds can be administered alone or in combination with additional breast cancer modulating compounds or with other therapeutic agent, e.g., other anti-cancer agents or treatments.

In numerous embodiments, one or more nucleic acids, e.g., polynucleotides comprising nucleic acid sequences set forth in Tables 1-25, such as antisense polynucleotides or ribozymes, will be introduced into cells, in vitro or in vivo. The present invention provides methods, reagents, vectors, and cells useful for expression of breast cancer-associated polypeptides and nucleic acids using in vitro (cell-free), ex vivo or in vivo (cell or organism-based) recombinant expression systems.

The particular procedure used to introduce the nucleic acids into a host cell for expression of a protein or nucleic acid is application specific. Many procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use

of calcium phosphate transfection, spheroplasts, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Berger & Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology volume 152 (Berger), Ausubel et al., eds., Current Protocols (supplemented through 1999), and Sambrook et al., Molecular Cloning - A Laboratory Manual (2nd ed., Vol. 1-3, 1989.

In a preferred embodiment, breast cancer proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, breast cancer genes (including both the full-length sequence, partial sequences, or regulatory sequences of the breast cancer coding regions) can be administered in a gene therapy application. These breast cancer genes can include antisense applications, either as gene therapy (i.e. for incorporation into the genome) or as antisense compositions, as will be appreciated by those in the art.

10

15

20

25

30

Breast cancer polypeptides and polynucleotides can also be administered as vaccine compositions to stimulate HTL, CTL and antibody responses.. Such vaccine compositions can include, e.g., lipidated peptides (see, e.g., Vitiello, A. et al., J. Clin. Invest. 95:341 (1995)), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, et al., Molec. Immunol. 28:287-294, (1991); Alonso et al., Vaccine 12:299-306 (1994); Jones et al., Vaccine 13:675-681 (1995)), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al., Nature 344:873-875 (1990); Hu et al., Clin Exp Immunol. 113:235-243 (1998)), multiple antigen peptide systems (MAPs) (see, e.g., Tam, Proc. Natl. Acad. Sci. U.S.A. 85:5409-5413 (1988); Tam, J. Immunol. Methods 196:17-32 (1996)), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, et al., In: Concepts in vaccine development (Kaufmann, ed., p. 379, 1996); Chakrabarti, et al., Nature 320:535 (1986); Hu et al., Nature 320:537 (1986); Kieny, et al., AIDS Bio/Technology 4:790 (1986); Top et al., J. Infect. Dis. 124:148 (1971); Chanda et al., Virology 175:535 (1990)), particles of viral or synthetic origin (see, e.g., Kofler et al., J. Immunol. Methods. 192:25 (1996); Eldridge et al., Sem. Hematol. 30:16 (1993); Falo et al., Nature Med. 7:649 (1995)), adjuvants (Warren et al., Annu. Rev. Immunol. 4:369 (1986);

Gupta et al., Vaccine 11:293 (1993)), liposomes (Reddy et al., J. Immunol. 148:1585 (1992); Rock, Immunol. Today 17:131 (1996)), or, naked or particle absorbed cDNA (Ulmer, et al., Science 259:1745 (1993); Robinson et al., Vaccine 11:957 (1993); Shiver et al., In: Concepts in vaccine development (Kaufmann, ed., p. 423, 1996); Cease & Berzofsky, Annu. Rev. Immunol. 12:923 (1994) and Eldridge et al., Sem. Hematol. 30:16 (1993)). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.

Vaccine compositions often include adjuvants. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bortadella pertussis* or *Mycobacterium tuberculosis* derived proteins. Certain adjuvants are commercially available as, e.g., Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

10

15

20

25

30

Vaccines can be administered as nucleic acid compositions wherein DNA or RNA encoding one or more of the polypeptides, or a fragment thereof, is administered to a patient. This approach is described, for instance, in Wolff et. al., Science 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720; and in more detail below. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e.g., U.S. Patent No. 5,922,687).

For therapeutic or prophylactic immunization purposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of

vaccinia virus, e.g., as a vector to express nucleotide sequences that encode breast cancer polypeptides or polypeptide fragments. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al., Nature 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization e.g. adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein (see, e.g., Shata et al., Mol Med Today 6:66-71 (2000); Shedlock et al., J Leukoc Biol 68:793-806 (2000); Hipp et al., In Vivo 14:571-85 (2000)).

10

15

20

25

30

Methods for the use of genes as DNA vaccines are well known, and include placing a breast cancer gene or portion of a breast cancer gene under the control of a regulatable promoter or a tissue-specific promoter for expression in a breast cancer patient. The breast cancer gene used for DNA vaccines can encode full-length breast cancer proteins, but more preferably encodes portions of the breast cancer proteins including peptides derived from the breast cancer protein. In one embodiment, a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a breast cancer gene. For example, breast cancer-associated genes or sequence encoding subfragments of a breast cancer protein are introduced into expression vectors and tested for their immunogenicity in the context of Class I MHC and an ability to generate cytotoxic T cell responses. This procedure provides for production of cytotoxic T cell responses against cells which present antigen, including intracellular epitopes.

In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the breast cancer polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are available.

In another preferred embodiment breast cancer genes find use in generating animal models of breast cancer. When the breast cancer gene identified is repressed or diminished in cancer tissue, gene therapy technology, e.g., wherein antisense RNA directed

to the breast cancer gene will also diminish or repress expression of the gene. Animal models of breast cancer find use in screening for modulators of a breast cancer-associated sequence or modulators of breast cancer. Similarly, transgenic animal technology including gene knockout technology, e.g. as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence or increased expression of the breast cancer protein. When desired, tissue-specific expression or knockout of the breast cancer protein may be necessary.

It is also possible that the breast cancer protein is overexpressed in breast cancer. As such, transgenic animals can be generated that overexpress the breast cancer protein. Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene. Animals generated by such methods find use as animal models of breast cancer and are additionally useful in screening for modulators to treat breast cancer.

15

20

25.

10

5

### Kits for Use in Diagnostic and/or Prognostic Applications

For use in diagnostic, research, and therapeutic applications suggested above, kits are also provided by the invention. In the diagnostic and research applications such kits may include any or all of the following: assay reagents, buffers, breast cancer-specific nucleic acids or antibodies, hybridization probes and/or primers, antisense polynucleotides, ribozymes, dominant negative breast cancer polypeptides or polynucleotides, small molecules inhibitors of breast cancer-associated sequences *etc*. A therapeutic product may include sterile saline or another pharmaceutically acceptable emulsion and suspension base.

In addition, the kits may include instructional materials containing directions (i.e., protocols) for the practice of the methods of this invention. While the instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the

like. Such media may include addresses to internet sites that provide such instructional materials.

The present invention also provides for kits for screening for modulators of breast cancer-associated sequences. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise one or more of the following materials: a breast cancer-associated polypeptide or polynucleotide, reaction tubes, and instructions for testing breast cancer-associated activity. Optionally, the kit contains biologically active breast cancer protein. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. Diagnosis would typically involve evaluation of a plurality of genes or products. The genes will be selected based on correlations with important parameters in disease which may be identified in historical or outcome data.

15 EXAMPLES

10

30

# Example 1: Tissue Preparation, Labeling Chips, and Fingerprints

# Purifying total RNA from tissue sample using TRIzol Reagent

The sample weight is first estimated. The tissue samples are homogenized in 1 ml of TRIzol per 50 mg of tissue using a homogenizer (e.g., Polytron 3100). The size of the generator/probe used depends upon the sample amount. A generator that is too large for the amount of tissue to be homogenized will cause a loss of sample and lower RNA yield. A larger generator (e.g., 20 mm) is suitable for tissue samples weighing more than 0.6 g. Fill tubes should not be overfilled. If the working volume is greater than 2 ml and no greater than 10 ml, a 15 ml polypropylene tube (Falcon 2059) is suitable for homogenization.

Tissues should be kept frozen until homogenized. The TRIzol is added directly to the frozen tissue before homogenization. Following homogenization, the insoluble material is removed from the homogenate by centrifugation at 7500 x g for 15 min. in a Sorvall superspeed or 12,000 x g for 10 min. in an Eppendorf centrifuge at 4°C. The cleared

homogenate is then transferred to a new tube(s). Samples may be frozen and stored at -60 to -70°C for at least one month or else continue with the purification.

The next process is phase separation. The homogenized samples are incubated for 5 minutes at room temperature. Then, 0.2 ml of chloroform per 1ml of TRIzol reagent is added to the homogenization mixture. The tubes are securely capped and shaken vigorously by hand (do not vortex) for 15 seconds. The samples are then incubated at room temp. for 2-3 minutes and next centrifuged at 6500 rpm in a Sorvall superspeed for 30 min. at 4oC.

The next process is RNA Precipitation. The aqueous phase is transferred to a fresh tube. The organic phase can be saved if isolation of DNA or protein is desired. Then 0.5 ml of isopropyl alcohol is added per 1ml of TRIzol reagent used in the original homogenization. Then, the tubes are securely capped and inverted to mix. The samples are then incubated at room temp. for 10 minutes an centrifuged at 6500 rpm in Sorvall for 20 min. at 4°C.

10

15

20

25

The RNA is then washed. The supernatant is poured off and the pellet washed with cold 75% ethanol. 1 ml of 75% ethanol is used per 1 ml of the TRIzol reagent used in the initial homogenization. The tubes are capped securely and inverted several times to loosen pellet without vortexing. They are next centrifuged at  $<8000\,$  rpm ( $<7500\,$ x g) for 5 minutes at  $4^{\circ}$ C.

The RNA wash is decanted. The pellet is carefully transferred to an Eppendorf tube (sliding down the tube into the new tube by use of a pipet tip to help guide it in if necessary). Tube(s) sizes for precipitating the RNA depending on the working volumes. Larger tubes may take too long to dry. Dry pellet. The RNA is then resuspended in an appropriate volume (e.g., 2 -5 ug/ul) of DEPC H<sub>2</sub>0. The absorbance is then measured.

The poly A+ mRNA may next be purified from total RNA by other methods such as Qiagen's RNeasy kit. The poly A + mRNA is purified from total RNA by adding the oligotex suspension which has been heated to 37°C and mixing prior to adding to RNA.

The Elution Buffer is incubated at 70°C. If there is precipitate in the buffer, warm up the 2 x Binding Buffer at 65°C. The the total RNA is mixed with DEPC-treated water, 2 x Binding

Buffer, and Oligotex according to Table 2 on page 16 of the Oligotex Handbook and next incubated for 3 minutes at 65°C and 10 minutes at room temperature.

The preparation is centrifuged for 2 minutes at 14,000 to 18,000 g, preferably, at a "soft setting," The supernatant is removed without disturbing Oligotex pellet. A little bit of solution can be left behind to reduce the loss of Oligotex. The supernatant is saved until satisfactory binding and elution of poly A+ mRNA has been found.

Then, the preparation is gently resuspended in Wash Buffer OW2 and pipetted onto the spin column and centrifuged at full speed (soft setting if possible) for 1 minute.

Next, the spin column is transferred to a new collection tube and gently resuspended in Wash Buffer OW2 and centrifuged as described herein.

10

15

20

25

Then, the spin column is transferred to a new tube and eluted with 20 to 100 ul of preheated (70°C) Elution Buffer. The Oligotex resin is gently resuspended by pipetting up and down. The centrifugation is repeated as above and the elution repeated with fresh elution buffer or first eluate to keep the elution volume low.

The absorbance is next read to determine the yield, using diluted Elution Buffer as the blank.

Before proceeding with cDNA synthesis, the mRNA is precipitated before proceeding with cDNA synthesis, as components leftover or in the Elution Buffer from the Oligotex purification procedure will inhibit downstream enzymatic reactions of the mRNA. 0.4 vol. of 7.5 M NH4OAc + 2.5 vol. of cold 100% ethanol is added and the preparation precipitated at -20°C 1 hour to overnight (or 20-30 min. at -70°C), and centrifuged at 14,000-16,000 x g for 30 minutes at 4°C. Next, the pellet is washed with 0.5 ml of 80% ethanol (-20°C) and then centrifuged at 14,000-16,000 x g for 5 minutes at room temperature. The 80% ethanol wash is then repeated. The last bit of ethanol from the pellet is then dried without use of a speed vacuum and the pellet is then resuspended in DEPC H<sub>2</sub>0 at 1 ug/ul concentration.

Alternatively the RNA may be purified using other methods (e.g., Qiagen's RNeasy kit).

No more than 100 ug is added to the RNeasy column. The sample volume is adjusted to 100 ul with RNase-free water. 350 ul Buffer RLT and then 250 ul ethanol (100%) are added to the sample. The preparation is then mixed by pipetting and applied to an RNeasy mini spin column for centrifugation (15 sec at >10,000 rpm). If yield is low, reapply the flowthrough to the column and centrifuge again.

Then, transfer column to a new 2 ml collection tube and add 500 ul Buffer RPE and centrifuge for 15 sec at >10,000 rpm. The flowthrough is discarded. 500 ul Buffer RPE and is then added and the preparation is centriuged for 15 sec at >10,000 rpm. The flowthrough is discarded. and the column membrane dried by centrifuging for 2 min at maximum speed. The column is transferred to a new 1.5-ml collection tube. 30-50 ul of RNase-free water is applied directly onto column membrane. The column is then centrifuged for 1 min at >10,000 rpm and the elution step repeated.

The absorbance is then read to determine yield. If necessary, the material may be ethanol precipitated with ammonium acetate and 2.5X volume 100% ethanol.

15

30

10

### First Strand cDNA Synthesis

The first strand can be make using using Gibco's "SuperScript Choice System for cDNA Synthesis" kit. The starting material is 5 ug of total RNA or 1 ug of polyA+ mRNAl. For total RNA, 2 ul of SuperScript RT is used; for polyA+ mRNA, 1 ul of

SuperScript RT is used. The final volume of first strand synthesis mix is 20 ul. The RNA should be in a volume no greater than 10 ul. The RNA is incubated with 1 ul of 100 pmol

T7-T24 oligo for 10 min at 70°C followed by addition on ice of 7 ul of: 4ul 5X 1st Strand

Buffer, 2 ul of 0.1M DTT, and 1 ul of 10mM dNTP mix. The preparation is then incubated at 37°C for 2 min before addition of the SuperScript RT followed by incubation at 37°C for 1 hour.

### Second Strand Synthesis

For the second strand synthesis, place 1st strand reactions on ice and add: 91 ul DEPC H<sub>2</sub>0; 30 ul 5X 2nd Strand Buffer; 3 ul 10mM dNTP mix; 1 ul 10 U/ul E.coli DNA Ligase; 4 ul 10 U/ul E.coli DNA Polymerase; and 1 ul 2 U/ul RNase H. Mix and incubate 2

hours at 16°C. Add 2 ul T4 DNA Polymerase. Incubate 5 min at 16°C. Add 10 ul of 0.5M EDTA.

### Cleaning up cDNA

The cDNA is purified using Phenol:Chloroform:Isoamyl Alcohol (25:24:1) and Phase-Lock gel tubes. The PLG tubes are centrifuged for 30 sec at maximum speed. The cDNA mix is then transferred to PLG tube. An equal volume of phenol:chloroform:isamyl alcohol is then added, the preparation shaken vigorously (no vortexing), and centrifuged for 5 minutes at maximum speed. The top aqueous solution is transferred to a new tube and ethanol precipitated by adding 7.5X 5M NH4OAc and 2.5X volume of 100% ethanol. Next, it is centrifuged immediately at room temperature for 20 min, maximum speed. The supernatant is removed, and the pellet washed with 2X with cold 80% ethanol. As much ethanol wash as possible should be removed before air drying the pellet; and resuspending it in 3 ul RNase-free water.

15

20

25

30

10

5

### In vitro Transcription (IVT) and labeling with biotin

In vitro Transcription (IVT) and labeling with biotin is performed as follows: Pipet 1.5 ul of cDNA into a thin-wall PCR tube. Make NTP labeling mix by combining 2 ul T7 10xATP (75 mM) (Ambion); 2 ul T7 10xGTP (75 mM) (Ambion); 1.5 ul T7 10xCTP (75 mM) (Ambion); 1.5 ul T7 10xUTP (75 mM) (Ambion); 3.75 ul 10 mM Bio-11-UTP (Boehringer-Mannheim/Roche or Enzo); 3.75 ul 10 mM Bio-16-CTP (Enzo); 2 ul 10x T7 transcription buffer (Ambion); and 2 ul 10x T7 enzyme mix (Ambion). The final volume is 20 ul. Incubate 6 hours at 37°C in a PCR machine. The RNA can be furthered cleaned. Clean-up follows the previous instructions for RNeasy columns or Qiagen's RNeasy protocol handbook. The cRNA often needs to be ethanol precipitated by resuspension in a volume compatible with the fragmentation step.

Fragmentation is performed as follows. 15 ug of labeled RNA is usually fragmented. Try to minimize the fragmentation reaction volume; a 10 ul volume is recommended but 20 ul is all right. Do not go higher than 20 ul because the magnesium in the fragmentation buffer contributes to precipitation in the hybridization buffer. Fragment

RNA by incubation at 94 C for 35 minutes in 1 x Fragmentation buffer (5 x Fragmentation buffer is 200 mM Tris-acetate, pH 8.1; 500 mM KOAc; 150 mM MgOAc). The labeled RNA transcript can be analyzed before and after fragmentation. Samples can be heated to 65°C for 15 minutes and electrophoresed on 1% agarose/TBE gels to get an approximate idea of the transcript size range

For hybridization, 200 ul (10 ug cRNA) of a hybridization mix is put on the chip. If multiple hybridizations are to be done (such as cycling through a 5 chip set), then it is recommended that an initial hybridization mix of 300 ul or more be made. The hybridization mix is: fragment labeled RNA (50 ng/ul final conc.); 50 pM 948-b control oligo; 1.5 pM BioB; 5 pM BioC; 25 pM BioD; 100 pM CRE; 0.1 mg/ml herring sperm DNA; 0.5 mg/ml acetylated BSA; and 300 ul with 1xMES hyb buffer.

The hybridization reaction is conducted with non-biotinylated IVT (purified by RNeasy columns) (see example 1 for steps from tissue to IVT): The following mixture is prepared:

15 IVT antisense RNA; 4 μg: μl

Random Hexamers (1 μg/μl): 4 μl

H<sub>2</sub>O: μl

14 μl

10

25

Incubate the above 14 µl mixture at 70°C for 10 min.; then put on ice.

The Reverse transcription procedure uses the following mixture:

0.1 M DTT: 3 μl 50X dNTP mix: 0.6 μl  $H_2O$ : 2.4 μl Cy3 or Cy5 dUTP (1mM): 3 μl SS RT II (BRL): 1 μl

The above solution is added to the hybridization reaction and incubated for 30 min.,  $42^{\circ}$ C. Then, 1  $\mu$ l SSII is added and incubated for another hour before being placed on ice.

16 µl

The 50X dNTP mix contains 25mM of cold dATP, dCTP, and dGTP, 10mM of dTTP and is made by adding 25  $\mu l$  each of 100mM dATP, dCTP, and dGTP; 10  $\mu l$  of 100mM dTTP to 15  $\mu l$  H<sub>2</sub>O. ]

RNA degradation is performed as follows. Add 86 µl H<sub>2</sub>O, 1.5 µl 1M NaOH/2 mM EDTA and incubate at 65°C, 10 min.. For U-Con 30, 500 µl TE/sample spin at 7000 g for 10 min, save flow through for purification. For Qiagen purification, suspend u-con recovered material in 500 µl buffer PB and proceed using Qiagen protocol. For DNAse digestion, add 1 ul of 1/100 dilution of DNAse/30 ul Rx and incubate at 37°C for 15 min. Incubate at 5 min 95°C to denature the DNAse.

10

15


### Sample preparation

For sample preparation, add Cot-1 DNA, 10  $\mu$ l; 50X dNTPs, 1  $\mu$ l; 20X SSC, 2.3  $\mu$ l; Na pyro phosphate, 7.5  $\mu$ l; 10 mg/ml Herring sperm DNA; 1 ul of 1/10 dilution to 21.8 final vol. Dry in speed vac. Resuspend in 15  $\mu$ l H<sub>2</sub>0. Add 0.38  $\mu$ l 10% SDS. Heat 95°C, 2 min and slow cool at room temp. for 20 min. Put on slide and hybridize overnight at 64°C. Washing after the hybridization: 3X SSC/0.03% SDS: 2 min., 37.5 ml 20X SSC+0.75ml 10% SDS in 250ml H<sub>2</sub>O; 1X SSC: 5 min., 12.5 ml 20X SSC in 250ml H<sub>2</sub>O; 0.2X SSC: 5 min., 2.5 ml 20X SSC in 250ml H<sub>2</sub>O. Dry slides and scan at appropiate PMT's and channels.

# TABLE 1: Figure 1 from BRCA 001 US

Table 1 shows genes, (incorporated in their entirety here and throughout the application where primekeys are provided), downregulated in tumor tissue compared to normal breast tissue.

10								
	Pkey: U		Unique Eos probeset identifier number					
	ExAccn:		Exemplar Accession number, Genbank accession number					
			Unigene number					
	Unigene	: Title:	Unigene gene titl	e ·				
15	R1:		Ratio of normal b	reast tissue to tumor				
				:				
	Pkey	ExAccn	Unigenei	UnigeneTitle .	R1			
20	100472	D90084	Hs.1023	pyruvate dehydrogenase (lipoamide) alpha	5			
		T51986		hemoglobin, gamma G	10			
		M55405		gb:Homo sapiens mucin (MUC-3) mRNA, part	5			
		BE14201	9 Hs.222056	Homo saplens cDNA FLJ11572 fis, clone HE	10			
		X52078		transcription factor 3 (E2A immunoglobul	5			
25	100635	BE25903		Ewing sarcoma breakpoint region 1	5			
	100645	X16841		neural cell adhesion molecule 1	5			
	100654	A03758		NM_000477*:Homo sapiens albumin (ALB), m	10			
	100702	L27065		gb:Human neurofibromatosis 2 (NF2) mRNA,	5			
	100915	M60832	Hs.249239	collagen, type VIII, alpha 2	5			
30	100971	BE37972	7 Hs.83213	fatty acid binding protein 4, adipocyte	10			
		AJ25056	2 Hs.82749	transmembrane 4 superfamily member 2	5			
		M90424	Hs.2099	lipocalin 1 (protein migrating faster th	5			
		NM_0016		activating transcription factor 3	10			
25		NM_0067		FBJ murine osteosarcoma viral oncogene h	10			
35		X03350	Hs.4	alcohol dehydrogenase 18 (class I), beta	10			
		M21305	11	gb:Human alpha satellite and satellite 3	10			
		N98569	Hs.76422	phospholipase A2, group IIA (platelets,	10			
		M27826	HS.26/319	endogenous retroviral protease	10			
40		AV65026			5			
40		M74447	Hs.502	transporter 2, ATP-binding cassette, sub	10			
		U22961 NM_0015	EA 1002E2	gb:Human mRNA clone with similarity to L G protein-coupled receptor 9	10 5			
		U48251	Hs.75871		10			
		U89337		tenascin XB	10			
45		U60115		four and a half LIM domains 1	5			
••		AA31353		gb:EST185419 Colon carcinoma (HCC) cell	. 10			
		NM_0067			10			
		AA82928		serum amyloid A1	10			
		X98085	Hs.54433	tenascin R (restrictin, janusin)	5			
50		AA08199		gb:zn26d06.r1 Stratagene neuroepithelium	10			
		AA12612		gb:zm78c07.r1 Stratagene neuroepithelium	5			
	103812	AA13710	7 Hs.326391	Homo sapiens, clone MGC:16638, mRNA, com	10			
	103851	AA32621	6 Hs.8719	hypothetical protein MGC1136	5			
	104080	AB04103	6 Hs.57771	kallikrein 11 (KLK11; TLSP; PRSS20; hipp	5			
55		R50727	Hs.336970		10			
		AA42212		gb:zv26h12.r1 Soares_NhHMPu_S1 Homo sapi	5			
		AL35395		hypothetical protein DKFZp434P0531	10			
		F06638		Homo saplens clone 24734 mRNA sequence	10			
<b>C</b> 0		AA42618		gb:zw11e09.r1 Soares_NhHMPu_S1 Homo sapl	5			
60		N73185	Hs.94285		10			
		N91071	Hs.109650		10			
		N99542	Hs.572	orosomucoid 1	5			
	104532	A1498763	ns.203013	hypothetical protein FLJ12748	10			



		AA101325	Hs.86154		10
		F01449	Hs.26954		5
		R40604 Al094674	Hs.30524	ESTs, Weakly similar to MCAT_HUMAN MITOC ring finger protein 24	10
5		H46749	Hs.31540		10 10
		W22165	Hs.22586		5
		AW294162	Hs.301062	UDP-N-acetyl-alpha-D-galactosamine:polyp	10
		H51276	Hs.13526		10
10		H52576	11- 407000	gb:yt85e08.r1 Soares_pineal_gland_N3HPG	5
10		H72639 H60593	Hs.167608 Hs.124990		5
		AL044174		patched (Drosophila) homolog	10 10
		Al753316	Hs.26034	ESTs	5
	111158	N66616		H.sapiens mRNA for subtelomeric repeat s	5
15		AI798376		gb:tr34b07.x1 NCI_CGAP_Ov23 Homo sapiens	10
		AJ224864	Hs.9688	leukocyte membrane antigen	5
		AA641636 R00144	Hs.37477	, , , , , , , , , , , , , , , , , , , ,	5
		Al168511	Hs.189771	gb:ow90h09.s1 Soares_fetal_liver_spleen_	10 10
20		R16733	Hs.20499		10
		R26065		gb:yh39d03.s1 Soares placenta Nb2HP Homo	5
		AA593731		ESTs, Moderately similar to ALU5_HUMAN A	10
		R42333	Hs.302292		10
25		AL117490		Ras-associated protein Rap1	10
23		NM_006668 R51889	Hs.25121 Hs.24990		10 5
		R31094	Hs.24378		10
		R77302		gb:yi75h08.s1 Soares placenta Nb2HP Homo	10
		BE618629	Hs.268809	ESTs	5
30		T98628	Hs.191290		5
		A1057205	Hs.14584		5
		AA581428 T16837	Hs.5021 Hs.4241	EST ESTs	10
		T51588	113.4241	gb:yb27e06.s1 Stratagene fetal spleen (9	5 10
35		T54659	Hs.301755	Homo sapiens cDNA FLJ11465 fis, clone HE	5
		AA743563	Hs.10305		5
		AW207424	Hs.332594		10
		N92359		ESTs, Moderately similar to A48752 B-cel	10
40		R16763 AA913635	Hs.268679	Homo sapiens cONA FLJ20812 fis, clone AD	5 10
		R06874		ESTs, Moderately similar to ALU1_HUMAN A	5
		Al791905		hypothetical protein	10
	113790	Al244311	Hs.26912		10
45		W07586	Hs.8045	ESTs	3
45		W86195	11 070 17	gb:zh54e05.s1 Soares_fetal_liver_spleen_	· 10
		Z39319 AB018263	Hs.27347	EST tumor necrosis factor receptor superfami	10
		AA745978	Hs.28273	ESTs	5 5
		AA020736	710.20270	gb:ze63b11.s1 Soares retina N2b4HR Homo	5
50	114484	AA034378	Hs.267319	endogenous retroviral protease	5 5
		AA065096		gb:zm50a02.s1 Stratagene fibroblast (937	5
		AA081507	11. 07000	gb:zn05b10.r1 Stratagene hNT neuron (937	5
		AA234826 AA234462	Hs.87386 Hs.87350	EST ESTs	5
55		AK000725	Hs.50579	hypothetical protein FLJ20718	· 5
50	115666	AF173081		Vertebrate LIN7 homolog 1, Tax interacti	5
		AB020649	Hs.74569	KIAA0842 protein	5
		AA398841	Hs.39850	hypothetical protein FLJ20517	10
60		AI478427	Hs.43125	esophageal cancer related gene 4 protein	10
60		AL133916 AA463902		hypothetical protein FLJ20093 ESTs, Weakly similar to 138022 hypotheti	10
		AW968703	Hs.13522 Hs.30085	hypothetical protein FLJ23186	5 5
		AW410377	Hs.41502	hypothetical protein FLJ21276	5
	116527	AW194253	Hs.68607	ESTs	10
65		BE314852		Homo saplens clone 23763 unknown mRNA, p	5
	116708	F10528 AW801806	Hs.70001	ESTs, Moderately similar to JC6169 nucle	5
	111/020	V1100 1000		gb:lL5-UM0070-110400-062-g07 UM0070 Homo	5

	117151	A1803656	Hs.42373	ESTs	5
	117226	N20468		gb:yx39b10.s1 Soares melanocyte 2NbHM Ho	10
		AI472863	Hs.43387		5
	117571	N34417	Hs.44584		3
5	117624	N26627	Hs.82364	ESTs, Weakly similar to JC4124 pregnancy	5
	117673	N40551	Hs.184043	Homo saplens Ets-1 binding protein (E1B)	10
		N49285	Hs.182391	ESTs	10
		AW263476	Hs.44268	myelin gene expression factor 2	10
10		BE222341	Hs.279472	ESTs	5
10		N53145		gb:yv55f09.s1 Soares fetal liver spleen	3
		AW955696	Hs.90960		10
		A1078236	Hs.49688		5
		N70907	Hs.230619		. 10
15		AL122040 AA993527	MS.102981	Homo sapiens mRNA; cDNA DKFZp434G1972 (f	3
13		AA993527 A1160570	HS.293907	hypothetical protein FLJ23403	5
		AF142419	Hs.15020	pregnancy specific beta-1-glycoprotein 6 homolog of mouse quaking QKI (KH domain	3 5
		AA514422	Hs.221849		5
		AK002001		v-maf musculoaponeurotic fibrosarcoma (a	10
20		T77892	110.01000	gb:yd20f04.s1 Soares fetal liver spleen	5
		T81824	Hs.90949		5
		W38051		Empirically selected from AFFX single pr	10
	119792	AL049798	Hs.80552		3
~ -		AF086332	Hs.58314	ESTs	10
25		AF088061	Hs.159690		5
		AF086429	Hs.58429		5
		AW803308	· Hs.62954		5
		U34249	Hs.337461	Human putative zinc finger protein (ZNFB	5
30		AL042725	U- 07400	gb:DKFZp434B1822_r1 434 (synonym: htes3)	10
50		AW136934 AA907743	Hs.97162		5
		AA401695	Hs.142373 Hs.97334		5
		AA405763		Homo sapiens cDNA FLJ20470 (is, clone KA	5 5
		AA421452		ESTs, Weakly similar to KIAA0926 protein	5
35		AK000229		Homo sapiens cDNA FLJ20222 fis, clone CO	10
		AA447555	Hs.99116		10
	122756	AA458945	Hs.95898	ESTs	10
	122771	AW135093	Hs.97282	ESTs, Highly similar to G100_HUMAN 110 K	5
40		AA609122	Hs.112645	Homo sapiens mRNA; cDNA DKFZp434D2472 (f	5
40		AI024595	Hs.97508	a disintegrin and metalloproteinase doma	5
		AA621529		gb:af47a02.s1 Soares_total_fetus_Nb2HF8_	10
		H62570		gb:yr44a01.r1 Soares fetal liver spleen	5
		H83465	11- 400050	gb:ys91a11.s1 Soares retina N2b5HR Homo	5
45		AK001527	HS. 103953	hypothetical protein FLJ10665	5
73		NM_014312 T98199		cortic al thymocyte receptor (X. laevis	10
		BE299567		hypothetical protein FLJ 10847 ESTs, Moderately similar to ALU8_HUMAN A	10 5
		NM_002666	Hs.103253		10
		BE256206	Hs.17775	p75NTR-associated cell death executor, o	5
50		AA485421	Hs.270503	ESTs, Weakly similar to ALU7_HUMAN ALU S	10
		NM_002250		potassium intermediate/small conductance	10
		R44214	Hs.101189		5
		C16161		hypothetical protein PRO2543	5
		AA193106		chromosome 11 open reading frame 23	10
55		H39537			10
		AW150717		STAT induced STAT inhibitor 3	10
		N62889		Homo sapiens cDNA FLJ12965 fls, clone NT	10
		AA443323 AA056483	He 304/62	BPOZ protein Human Chromosome 16 BAC clone CIT987SK-A	5
60		NM_013403	Hs.108665	zinedin	5 10
00		AL117472		SH3-domain protein 5 (ponsin)	5
		Al146494	Hs.109525	ESTs, Weakly similar to IRX2_HUMAN IROQU	3
		U40714		tyrosyl-tRNA synthetase	5
		AA530892		dual specificity phosphatase 1	5
65		BE617015	Hs.11006	ESTs, Moderately similar to T17372 plasm	10
		AF110141		WAS protein family, member 2	10
	129368	NM_003877	Hs.110776	STAT induced STAT inhibitor-2	5

	129371	X06828	Hs.110802	von Willebrand factor	5
•		AW245805		claudin 5 (transmembrane protein deleted	10
		W37944	Hs.4007	Sarcolemmal-associated protein	5
		BE061069		KIAA0467 protein	10
5		AF020038			10
,			Hs.11223		10
		BE222078	Hs.113069		
		BE622468	Hs.11924	ESTs, Weakly similar to 138022 hypotheti	. 5
		Al304966	Hs.12035	ESTs, Weakly similar to I38022 hypotheti	5
10		AK001676	Hs.12457	hypothetical protein FLJ10814	10
10		AK000956	Hs.13209	hypothetical protein FLJ10094	5 5
	129928	A1338993	Hs.134535	ESTs	5
	129973	AJ251760	Hs.273385	guanine nucleotide binding protein (G pr	5
	129977	NM_000399	Hs.1395	early growth response 2 (Krox-20 (Drosop	5
		NM_001158	Hs.143102	amine oxidase, copper containing 2 (reti	5
15		M62402		Insulin-like growth factor binding prote	10
		AA452006	Hs.333199		5
		W80711		Homo saplens mRNA for KIAA1727 protein,	5
		D88435		cyclin G associated kinase	10
		Al241084		nonselective sodium potassium/proton exc	. 5
20		AA435746	110.104000		5
20			Un 202400	gb:zt79e03.s1 Soares_testis_NHT Homo sap	10
		V00517		hemoglobin, gamma G	
		NM_001928		D component of complement (adipsin)	10
		X72308		small inducible cytokine A7 (monocyte ch	5
~ -		BE222978	Hs.15760	MYG1 protein	10
25		AW390834	Hs.75874	pregnancy-associated plasma protein A	5
	130563	BE270472	Hs.279900	HSPC015 protein	10
	130589	AL110226	Hs.16441	DKFZP434H204 protein	10
•	130606	AI652143	Hs.288382	hypothetical protein FLJ13111	5
		AI769067		ESTs, Weakly similar to T28770 hypotheti	3
30		AA993269	Hs.17872	Homo sapiens, clone IMAGE:3875012, mRNA	10
		NM_006691	Hs.17917	extracellular link domain-containing 1	10
		AA232075	Hs.18259	XPA binding protein 1; putative ATP(GTP)	5
		AF263462	Hs.18376	KIAA1319 protein	10
		N41322	Hs.18441	ESTs	5
35			Hs.1955		10
55		M81349		serum amyloid A4, constitutive	
		BE048821	Hs.20144	small inducible cytokine subfamily A (Cy	10
		AB040935	Hs.23954	cerebral cell adhesion molecule	10
		AA360419		inositol(myo)-1(or 4)-monophosphatase 1	10
40		X03350	Hs.4	alcohol dehydrogenase 18 (class I), beta	10
40		AW939251	Hs.25647	v-fos FBJ murine osteosarcoma viral onco	10
	131340	AK000393	Hs.25817	BTB (POZ) domain containing 2	5
	131341	AF110908	Hs.297660	TNF receptor-associated factor 3	5
	131406	H83294	Hs.284122	Wnt inhibitory factor-1	5
	131489	BE394648	Hs.27414	hypothetical protein	5
45	131543	AW966881	Hs.41639	programmed cell death 2	10
		BE559681	Hs.30736	KIAA0124 protein	5
		AA829286		serum amyloid A1	10
		AA443966	Hs.31595	ESTs	10
		H69342	Hs.26320	TRABID protein	10
50		AA021258	Hs.32753		5
50		BE244961		FE65-LIKE 2	5
		AJ000263		keratin, hair, basic, 6 (monilethrix)	10
		AW294659	Hs.34054	Homo sapiens cDNA: FLJ22488 fis, clone H	5
~ ~		AJ003112	Hs.34780	doublecortex; lissencephaly, X-linked (d	5
55		AK000010		hypothetical protein FLJ20003	10
	132115	H81604	Hs.178471	KIAA0798 gene product	5
	132177	X80818	Hs.178078	glutamate receptor, metabotropic 4	5
	132296	AA467752	Hs.195161	ESTs	5
		AW118072	Hs.89981	dlacylglycerol kinase, zeta (104kD)	. 10
60		S68874		prostaglandin E receptor 3 (subtype EP3)	5
		AI291496	Hs.5476	Homo sapiens, clone IMAGE:3530123, mRNA,	10
		NM_006283		transforming, acidic coiled-coil contain	10
		W28548	Hs.224829		10
		NM_004235	Hs.7934	Kruppel-like factor 4 (gut)	10
65		BE175645		LBP protein 32	5
O)		BE563966	Hs.6529	ESTs, Weakly similar to 178885 serine/th	5
		NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	10
	133120	1114_000210	113.00724	reserved the surrolled by the first	10

	133139	AF052138	Hs.6580	Homo saplens cDNA: FLJ23227 fis, clone C	5
	133163	AA668224	Hs.6634	Homo sapiens cDNA: FLJ22547 fis, done H	5
		AW956781	Hs.293937	ESTs, Weakly similar to FXD2_HUMAN FORKH	5
-		NM_002776	Hs.69423	kaliikrein 10 (KLK10) (PRSSL1) (nes1)	5
5		AA207059		gb:zq80h09.s1 Stratagene hNT neuron (937	5
		AF017987	Hs.7306	secreted trizzled-related protein 1	5
		H21497	Hs.7471	BBP-like protein 1	5
		L02321 H26904	Hs.75652 Hs.75736	glutathione S-transferase M5	5
10		N71725		apolipoprotein D hemoglobin, alpha 2	5 10
• •		T85626	Hs.76239	hypothetical protein FLJ20608	5
		AF072441	Hs.7840	calcineurin binding protein 1	10
		D86062		ES1 (zebrafish) protein, human homolog o	10
		Al372588	Hs.8022	TU3A protein	10
15		AA081846	Hs.7921	Homo sapiens mRNA; cDNA DKFZp566E183 (fr	10
		BE243319	Hs.79672	KIAA0652 gene product	5
		AW905827	Hs.81454	ketohexokinase (fructokinase)	10
		BE549343	Hs.82208	acyl-Coenzyme A dehydrogenase, very long	5
20		AF207664	Hs.8230	a disintegrin-like and metalloprotease (	5
20		L34155	Hs.83450	laminin, alpha 3 (nicein (150kD), kalini	5
		AI190413	Hs.8373	ESTs	10
		M64936 NM_002757	He 250970	gb:Homo sapiens retinoic acid-inducible mitogen-activated protein kinase kinase	10
		M26315	Hs.85258	CD8 antigen, alpha polypeptide (p32)	10 10
25		BE244323	Hs.85951	exportin, tRNA (nuclear export receptor	5
		U73394		killer cell immunoglobulin-like receptor	5
		AL008583		dynein, axonemal, light polypeptide 4	5
•	134728	D10216	Hs.89394	POU domain, class 1, transcription facto	5
••		NM_000078	Hs.89538	cholesteryl ester transfer protein, plas	10
30		T29618	Hs.89640	TEK tyrosine kinase, endothelial (venous	10
		T87521	Hs.261457		5
		NM_003394	Hs.91985	wingless-type MMTV integration site famil	10
		H22570 AA302517		hypothetical protein FLJ20093	5
35		X04430	Hs.92732 Hs.93913		5
33		AL036557	Hs.95910	Interleukin 6 (Interferon, beta 2) putative lymphocyte G0/G1 switch gene	10 10
		U76456		tissue inhibitor of metalloproteinase 4	5
		AB002361	Hs.96633	KIAA0363 protein	5
		U83171	Hs.97203		5
40	135304	AA416829	Hs.191597		5
	135337	AA905406	Hs.9905	ESTs, Weakly similar to unnamed protein	3
		X55019	Hs.99975	cholinergic receptor, nicotinic, delta p	10
		X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	5
45		H39537	Hs.75309	eukaryotic translation elongation factor	5
40		AW245805 M62402		claudin 5 (transmembrane protein deleted	5
		NM_006691	Hs.17917	insulin-like growth factor binding prote	5
		NM_003278	Hs.65424	extracellular link domain-containing 1 tetranectin (plasminogen-binding protein	10 3
		AF017987	Hs.7306	secreted frizzled-related protein 1	5
50		N71725		hemoglobin, alpha 2	5
		AF207664	Hs.8230	a disintegrin-like and metalloprotease (	5
		X04430	Hs.93913	Interleukin 6 (interferon, beta 2) -	10
		AL036557	Hs.95910	putative lymphocyte G0/G1 switch gene	5
	322580	AK001852	Hs.274151	ligatin	5
55		AW580227	Hs.47860	neurotrophic tyrosine kinase, receptor, type 2	10
		AW377752	Hs.83341	AXL receptor tyrosine kinase	5
		BE208364	Hs.29283	ESTs, Weakly similar to LKHU proteoglycan link	5
		AA563892	MS.306000	solute carrier family 4 (anion exchanger), memb	10
60	449826	RC_H15814_s	Hs.138506		5
		YEL024w/RIP1		Human apM1 mRNA for GS3109 (novel adipose specific coll EST - YEL024w/RIP1	3

### TABLE 1A

Table 1 A shows the accession numbers for those pkeys lacking unigeneID's for Table 1. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	

15

CAT number: G	nique Eos probeset identifier number ene cluster number enbank accession numbers
---------------	--

Pkey	CAT Number	Accessions

20	108446 108497	112224_1 110079_2	AA085383 AA126091 AA074174 AA075373 AA079120 AA070831 AA075978 AA075372 AA128503 AA074897 AA113914 AA064871 AA079329 AA071309 AA084710 AA129030 AA075042 AA074794 AA071453 AA078803
			AA148628 AA122204 AA074159 AA126185 AA079117 AA127089 AA070912 AA079280 AA131372 AA078833 AA071087 AA076131 AA071047 AA079401 AA083070 AA102076 AA115163 AA074198 AA134725 AA113889 AA121103 AA075041
0.5			AA065148 AA071310 AA101144 AA079659 AA078931 AA079209 AA070928 AA068994 AA069817 AA076187 AA069053 AA131489 AA071308 AA063317 AA070156 AA071430 AA076056 AA075684 AA070053 AA126283 AA126078 AA075895
25			AA079208 AA074583 AA071086 AA079623 AA070627 AA078802 AA076622 AA065051 AA079143 AA071110 AA079434 AA148748 AA079230 AA085188 AA074485 AA070580 AA076151 AA083166 AA085118 AA079450 AA085044 AA120938
			AA079200 AA100188 AA081472 AA122355 AA129031 AA085362 AA069220 AA070940 AA075968 AA074563 AA084027 AA115929
30	124215	1597154_1	H62570 H59063
<i>3</i> 0 .	117058 110455	1219924_1	AW801806 H90434 BE086530
	111168	46874_1 38585 1	H52576 AF085971 H52172 AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567
	111100	30303_1	AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384
			AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 AI267168
35			AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566
		•	C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374
			H66215 AA045564 Al694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703
	444400	444000 4	AW817659 BE081531 H59570
40	111498 104340	411008_1 46289_10	Al168511 Al022712 AA700366 R07371 R07324 AA426189 F15201
40	103747	117944_1	AA081995 AA101099
	134496	46501_1	M64936 Al025512 Al382987 BE061777 AA089966 BE169930 T41176 AW594624 BE502415 AA121893 Al269283 T40311
		AA257011	140011 0001402012 Alouzous DE001111 AA000000 DE 105000 141110 A41034024 DE3024 15 AA 121000 A1205200 140011
_			AI079277 AI241318 BE327710 AW975215 AW896268 AA884990 BE327514
45	103750	118365_1	AA126129 AA126033 AA082561
	105239	34624_1	AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627
			AW869639 BE061833 BE000620 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241
			AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904 C16859
50	120379	34624.3	AL042725 BE063316 AW975610 AA457591 BE062092 Al655202 AA714296 Al267264 Al075321 AA223286 AA071122
50	120373	34024_3	AA227849 AA216700 Al696002 AA101867 AA099426 AA135997 AL041698 T02815 T51824 AA207189 T59230 T51868
			AA663341 BE165757 AW818104 AW392886 AA584918 AA099408 AW856396 AW861859 AA053045
	114624	111686_1	AA081507 AA070071 AA070840 AA084352
	106851	322947_1	Al458623 AA639708 AA485409 R22065 AA485570
55	108392	113549_1	AA075124 AA075208
	100545	22955_11	M55405 AW752552
	100654	tigr_HT2969	A03758 A06977 A15293 D17029 D17107 D17171 L00132 L00133 M12523 M13075 M13076 M92816 U22961 V00494 V00495 X51363 X51364 X51365
	100702	tigr_HT3413	L27065
60	102208	6735_9	U22961 AA203623 AA503337 AI174733 AI192802 C06092 AA035357 AI190619 AI199244 AI828450 AA602296 AI378195
			Al209170 Al186653 Al127795 Al183846 H77389 Al589465 AA629390 H94306 Al018388 R68584 AA027196 Al745413 Al685092 Al093426 Al623873 Al074570 N50096 AA047486 N25060 AA327614 Al042512 Al383957 AA156873 Al333101
			100

N70806 Al141254 Al383191 Al401237 Al080709 Al093400 W84549 T90806 R00012 W01413 AA630557 Al378348 Al559265

AA877103 W84464 AA625146 R68379 AI133207 AI132980 AI133214 AI064826 AI061615 AI133473 AI174852 AI133404 Al133272 V00494 M12523 M12523 Al207526 Al133120 Al064802 Al174993 Al114729 Al061645 Al064716 Al064959 H77388 T85706 AF075298 Al110799 D17107 NM\_000477 AF190168 R50724 Al248416 Al207432 Al133684 Al133345 Al174710 5 Al133290 Al133304 Al174948 Al207484 Al110717 AF074624 Al114515 AF063516 Al110642 Al114559 Al114498 Al114759 Al207568 Al064980 Al174753 Al114666 R69184 R00011 Al064997 T60501 Al207701 T71735 AA385318 H73569 T60496 H94399 Al133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701 Al174748 Al114663 Al133104 Al132999 Al133100 Al064925 Al064979 Al133063 AA343347 T69091 AA233989 T39772 AI444620 T52290 D16931 T40012 T48403 T58926 T69195 AI133061 T50850 AI400677 AI091136 AA334608 T57411 Z20979 10 N56507 T87485 Al133622 AA343370 T40075 T69671 T53849 T74820 AF075316 Al110818 T40121 T57381 Al114468 AA332728 T51362 Al114589 R06691 Al110629 AF063503 Al140543 AA334661 AA332720 AA343262 T73513 T86549 Al114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 Al174786 Al132926 R09237 Al064838 Al133660 T60398 T88753 T55930 T92126 Al444602 T60996 Al114792 H93911 Al133106 R10779 Al065020 T90925 T50889 D17029 Al133703 AA333805 Al133040 Al133017 Al064857 Al110730 AF074637 Al207567 15 H71080 T73217 AA343950 AI174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 AI065049 T84512 T55918 AI207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AI114676 AI064778 AA035710 W52763 AI114786 AA005016 T60361 T69176 173356 T58795 T61233 T39955 T60612 Al114676 Al064778 AA035710 W52763 Al114786 T83564 AA341859 T81684 T55769 Al114710 T51776 AA343213 Al114714 T58102 Al110809 R28984 Al174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269 H54053 T732211 Al114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 Al203974 Al189471 AA005147 Al478102 Al207662 Al192792 Al768421 Al064737 AW051713 AA936693 Al133117 Al766232 Al913646 T83962 Al065112 Al207689 Al174684 Al207702 T81475 Al133325 Al032512 AA701169 Al936354 Al114720 Al433289 AA046980 Al823482 Al114536 AA860651 AW242644 R07469 AW300438 Al133416 AW271670 Al991363 T78943 Al823481 AA845518 AA719124 AA883454 T68850 T69115 Al935509 Al150977 T62890 T71374 T68294 Al174774 T67411 T68318 Al064689 T56624 T69010 T68982 T68302 Al332829 T72908 Al064819 Al205880 T62895 T69430 T95111 AA025050 T73330 W52657 T71984 T69118 W90584 Al114860 T52003 T63007 Al52323 T73329 H90384 T55048 T561811 F5203 Al326189 20 25 W52657 T71984 T69118 W92684 AI114860 T62093 T61797 AI522333 T73322 H92981 T56018 T61811 T57232 AI336158 T61821 T69457 T62900 T62912 T72917 T46885 AI702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 Al187111 T64308 T62071 T69427 Al114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 Al312890 30 T67751 Al174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300 T28321 T55864 123941 genbank\_AA621529 AA621529 118049 genbank\_N53145 N53145 102800 14782\_20 AA313538 U88895 U88902 AA422123\_i\_atAA422123\_i 35 104106 111738 genbank\_R26065 R26065 genbank\_T51588 113149 T51588 113958 genbank\_W86195 W86195 genbank\_AA070500 108335 AA070500 40 108351 genbank\_AA071193 genbank\_AA079079 AA071193 108441 AA079079 124276 genbank\_H83465 H83465 101447 entrez\_M21305 M21305 117226 genbank\_N20468 N20468 45 133379 genbank\_AA207059 AA207059,AA207241 119366 genbank\_T77892 T77892 119528 NOT\_FOUND\_entrez\_W38051 W38051 112588 genbank\_R77302 R77302 114449 genbank\_AA020736 AA020736 50 114576 genbank\_AA065096 AA065096 107459 W38002\_s\_at W38002\_s 130339 genbank\_AA435746 AA435746

# TABLE 2: Figure 2 from BRCA 001 US

Table 2 shows genes downregulated in tumor tissue compared to normal breast tissue. 5

Pkey: ExAccn: UnigeneID: Unigene Title: R1: Unique Eos probeset idenlifier number Exemplar Accession number, Genbank accession number Unigene number 10

Unigene gene title Ratio of normal breast tissue to tumor

15	Pkey	ExAccn	UnigenefD	Unigene Tittle	R1
	100499	T51986	Hs.283108	hemoglobin, gamma G	10
	100549	BE142019	Hs.222056	Homo sapiens cDNA FLJ11572 fis, clone HE	10
		A03758		NM_000477*:Homo sapiens albumin (ALB), m	10
20 ´		BE379727	Hs.83213	fatty acid binding protein 4, adipocyte	10
	101184	NM_001674	Hs.460	activating transcription factor 3	10
	101336	NM_006732	Hs.75678	FBJ murine osteosarcoma viral oncogene h	10
	101367	X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
	101447	M21305		gb:Human alpha satellite and satellite 3	10
25	101461	N98569	Hs.76422	phospholipase A2, group IIA (platelets,	10
		M27826	Hs.267319	endogenous retroviral protease	10
		M74447	Hs.502	transporter 2, ATP-binding cassette, sub-famil	10
		U22961		gb:Human mRNA clone with similarity to L	10
20		U48251	Hs.75871	protein kinase C binding protein 1	10
30		AA313538		gb:EST185419 Colon carcinoma (HCC) cell	10
		NM_006744	Hs.76461	refinol-binding protein 4, interstitial	10
		AA829286	Hs.332053	serum amyloid A1	10
		AA081995	11- 000004	gb:zn26d06.r1 Stratagene neuroepithelium	10
35		AA137107	Hs.326391	Homo saplens, clone MGC:16638, mRNA, com	10
33		R50727 AL353957	Hs.336970	ESTs	10
		F06638	Hs.284181 Hs.12440	hypothetical protein DKFZp434P0531	10
		N73185	Hs.94285	Homo sapiens clone 24734 mRNA sequence EST	10 10
		N91071	Hs.109650	ESTs	10
40		AI498763	Hs.203013	hypothetical protein FLJ12748	10
40		AA009764	Hs.190380	ESTs	10
		AA017245	Hs.32794	ESTs	10
		AA019300	Hs.125070	ESTs, Moderately similar to I54374 gene	10
		AJ298208	Hs.28805	ESTs	10
45		AA130390	Hs.25549	hypothetical protein FLJ20898	10
		AA221036		gb:zr03f12.r1 Stratagene NT2 neuronal pr	10
		N79885	Hs.6382	ESTs, Highly similar to T00391 hypotheti	10
	106181	Al803651	Hs.191608	ESTs	10
	106283	AI085846	Hs.25522	KIAA1808 protein	10
50	106379	AL042069	Hs.119021	DKFZP434N061 protein	10
	106451	AW235928	Hs.313182	ESTs	10
	106491	AA135688	Hs.10083	Homo sapiens, done IMAGE:4139786, mRNA.	10
	106782	AW054886	Hs.25682	Homo sapiens mRNA for KIAA1863 protein,	10
	107124	AB006532	Hs.31442	RecQ protein-like 4	10
55	107148	A1005036	Hs.334305	GS1999full	10
-		AF127026	Hs.5394	myosin IA	10
		AB020672	Hs.175411	KIAA0865 protein	10
		AI905985	Hs.111805	ESTs	10
<b>C</b> D		W28516	Hs.19210	hypothetical protein MGC11308	10
60		AL042425	Hs.283976	hypthetical protein PRO2389	10
		BE271708	Hs.95110	ESTs, Weakly similar to A55943 1-phospha	10
		AA071193	11- accr 1	gb:zf79b12.s1 Soares_pineal_gland_N3HPG	10
	109546		Hs.26954	Homo sapiens mRNA; cDNA DKFZp762G123 (fr	10
65		AW294162 AL044174	Hs.301062	UDP-N-acetyl-alpha-D-galactosamine:polyp	10
05	1 1031 0	AL044174	Hs.159526	patched (Drosophila) homolog	5
				100	

	111168 AI798376		gb:tr34b07.x1 NCI_CGAP_Ov23 Homo sapiens	10
	111651 R16733	Hs.20499	ESTs	10
	111803 AA593731	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	10
_	114484 AA034378	Hs.267319	endogenous retroviral protease	10
5	125284 NM_002666	Hs.103253	perilipin	10
	128850 AA193106	Hs.180817	chromosome 11 open reading frame 23	5
	128903 AW150717	Hs.296176	STAT induced STAT inhibitor 3	10
	129346 AF110141	Hs.288908	WAS protein family, member 2	10
10	129381 AW245805	Hs.110903	claudin 5 (transmembrane protein deleted	10
10	129516 AF020038	Hs.11223	Isocitrate dehydrogenase 1 (NADP+), solu	10
	129554 BE222078	Hs.113069	ESTs	10
	130085 M62402	Hs.274313	Insulin-like growth factor binding prote	10
	130243 D88435	Hs.153227	cyclin G associated kinase	10
	130400 V00517	Hs.283108	hemoglobin, gamma G	10
15	130436 NM_001928	Hs.155597	D component of complement (adipsin)	10
	130563 BE270472	Hs.279900	HSPC015 protein	10
	130589 AL110226	Hs.16441	DKFZP434H204 protein	10
	130683 AA993269	Hs.17872	Homo sapiens, clone IMAGE:3875012, mRNA	10
	130689 NM_006691	Hs.17917	extracellular link domain-containing 1	10
20	130689 AA046747	Hs.17917	extracellular link domain-containing 1	10
	130718 N70196	Hs.18376	KIAA1319 protein	10
	130798 M81349	Hs.1955	serum amyloid A4, constitutive	10
	130840 BE048821	Hs.20144	small inducible cytokine subfamily A (Cy	10
	131184 AB040935	Hs.23954	cerebral cell adhesion molecule	10
25	131282 X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
	131328 AW939251	Hs.25647	v-fos FBJ murine osteosarcoma viral onco	10
	131543 AW966881	Hs.41639	programmed cell death 2	10
	131753 AA829286	Hs.332053	serum amyloid A1	10
	131785 H69342	Hs.26320	TRABID protein	10
30	131828 AJ000263	Hs.278658	keratin, hair, basic, 6 (monilethrix)	10
	132426 AW118072	Hs.89981	diacylglycerol kinase, zeta (104kD)	10
	132675 Al291496	Hs.5476	Homo saplens, clone IMAGE:3530123, mRNA,	10
	132898 W28548	Hs.224829	ESTs	10
	132905 NM_004235	Hs.7934	Kruppel-like factor 4 (gut)	10
35	133120 NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	10
	133407 AF017987	Hs.7306	secreted frizzled-related protein 1	10
	133719 H26904	Hs.75736	apolipoprotein D	10
	134007 AF072441	Hs.7840	calcineurin binding protein 1	10
	134055 D86062	Hs.182423	ES1 (zebrafish) protein, human homolog o	10
40	134111 Al372588	Hs.8022	TU3A protein	5
	134117 AA081846	Hs.7921	Homo sapiens mRNA; cDNA DKFZp566E183 (fr	5
	134177 BE243319	Hs.79672	KIAA0652 gene product	10
	134369 AF207664	Hs.8230	a disIntegrin-like and metalloprotease (	10
	134496 M64936		gb:Homo sapiens retinoic acid-inducible	10
45	134510 NM_002757	Hs.250870	mitogen-activated protein kinase kinase	10
	134550 M26315	Hs.85258	CD8 antigen, alpha polypeptide (p32)	5
	134758 NM_000078	Hs.89538	cholesteryl ester transfer protein, plas	5
	134963 NM_003394	Hs.91985	wingless-type MMTV integration site fami	10
	135066 X04430	Hs.93913	Interleukin 6 (interferon, beta 2)	10
50	408790 AW580227	Hs.47860	neurotrophic tyrosine kinase, receptor, type 2	10
	446674 AA563892	Hs.306000	solute carrier family 4 (anion exchanger), memb	10

### TABLE 2A

Table 2A shows the accession numbers for those pkeys lacking unigeneID's for Table 2. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

t	(1	
L	v	

5

Unique Eos probeset identifier number

CAT number: Accession:

Gene cluster number

Genbank accession numbers

1	5	
_	_	

15	Pkey	CAT number	Accessions
	•	1	Notesiulia
20	111168	38585_1	AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 AI267168 AA157718
			AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254
2.5			AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374 H66215 AA045564 AI694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570
25	103747	117944_1	AA081995 AA101099
	134496	46501_1	M64936 Al025512 Al382987 BE061777 AA089966 BE169930 T41176 AW594624 BE502415 AA121893 Al269283 T40311 Al684569 AA257011 Al079277 Al241318 BE327710 AW975215 AW896268 AA884990 BE327514
	105239		AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627
30			AW869639 BE061833 BE000620 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241 AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904 C16859
	100654		A03758 A06977 A15293 D17029 D17107 D17171 L00132 L00133 M12523 M13075 M13076 M92816 U22961 V00494 V00495 X51363 X51364 X51365
35	102208	6735_9	U22961 AA203623 AA503337 Al174733 Al192802 C06092 AA035357 Al190619 Al199244 Al828450 AA602296 Al378195
33			A1209170 A11866S3 A1127795 A1183846 H77389 A1589465 AA629390 H94306 A1018388 R68584 AA027196 A1745413 A1685092 A1093426 A1623873 A1074570 N50096 AA047466 N25060 AA327614 A1042512 A1383957 AA156873 A13316 N70806 A1141254 A1383191 A1401237 A1080709 A1093400 W84549 T90806 R00012 W01413 AA630557 A1378348 A1559265 AA877103 W84464 AA625146 R68379 A1133207 A1132980 A1133214 A1064826 A1061615 A1133473 A1174852 A1133404
40			A1133272 V00494 M12523 M12523 A1207526 A1133120 A1064802 A174993 A1114729 A1061645 A1064716 A1064959 H77388 T85706 AF075298 A1110799 D17107 NM_000477 AF190168 R50724 A1248416 A1207432 A1133684 A1133345 A1174710
40			A1133290 A1133304 A1174948 A1207484 A1110717 AF074624 A1114515 AF063516 A1110642 A1114559 A1114498 A1114759 A1207568 A1064960 A1174753 A1114666 R69184 R00011 A1064997 T60501 A1207701 T71735 AA385318 H73569 T60496 H94399 A1133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 A1207490 A1132925 A1064701
45			Al174748 Al114663 Al133104 Al132999 Al133100 Al064925 Al064979 Al133063 AA343347 T69091 AA233989 T39772 Al444620 T52290 D16931 T40012 T48403 T58926 T69195 Al133061 T50850 Al400677 Al091136 AA334608 T57411 Z20979
45	•		N56507 T87485 Al133622 AA343370 T40075 T69671 T53849 T74820 AF075316 Al110481 T40121 T57381 Al114468 AA332728 T51362 Al114589 R06691 Al110629 AF063503 Al140543 AA334661 AA332720 AA343262 T73513 T86549 Al114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 Al174786 Al132926 R09237 Al064838 Al133660 T60398 T88753 T55930 T92126 Al444602 T60996 Al114792 H93911 Al133106
50			R10779 AI065020 T90925 T50889 D17029 AI133703 AA333805 AI133040 AI133017 AI064857 AI110730 AF074637 AI207567 H71080 T73217 AA343950 AI174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 AI065049 T84512 T55918 AI207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AI114676 AI064778 AA035710 W52763 AI114786
55			T83564 AA341859 T81684 T55769 A114710 T51776 AA343213 A1114714 T58102 A1110809 R28984 A174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269 H54053 T73211 A1114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 A1203974 A1189471 AA005147 A1478102 A1207662 A192792 A1768421 A1064737 AW051713 AA936693 A1133117 A1766232 A1913646
60			T83962 AI055112 AI207689 AI174684 AI207702 T81475 AI133325 AI032512 AA701169 AI936354 AI114720 AI433289 AA046980 AI823482 AI114536 AA860651 AW242644 R07469 AW300438 AI133416 AW271670 AI991363 T78943 AI823481 AA845518 AA719124 AA883454 T68850 T69115 AI935509 AI150977 T62890 T71374 T68294 AI174774 T67411 T68318 AI064689 T56624 T69010 T68982 T68302 AI332829 T72908 AI064819 AI205880 T62895 T69430 T95111 AA025050 T73330 W52657 T71984 T69118 W92684 AI114860 T62093 T61797 AI522333 T73322 H92981 T56018 T61811 T57232 AI336158

T61821 T69457 T62900 T62912 T72917 T46885 Al702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918
T59166 Al187111 T64308 T62071 T69427 Al114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394
Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 Al312890
T67751 Al174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300
T28321 T55864

14782\_20 AA313538 U88895 U88902
genbank\_AA071193 AA071193
entrez\_M21305 M21305

102800 108351 101447

5

## TABLE 3: Figure 3 from BRCA 001 US

Table 3 shows genes downregulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number
ExAccn: Exemplar Accession number, Genbank accession number
UnigenelD: Unigene number
Unigene Title: Unigene gene title
R1: Ratio of normal breast tissue to tumor

5

15					
	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
20	102208 102990	NM_006732 U22961 AA829286 AI798376	Hs.75678 Hs.332053	FBJ murine osteosarcoma viral oncogene h gb:Human mRNA done with similarity to L serum amyloid A1 gb:tr34b07.x1 NCI_CGAP_Ov23 Homo sapiens	10.0 10.0 10.0 10.0
25	130085 130840 131543 133120	AW966881		ESTs, Moderately similar to ALU5_HUMAN A insulin-tike growth factor binding prote small Inducible cytokine subfamily A (Cy programmed cell death 2 tetranectin (plasminogen-binding protein cholesteryl ester transfer protein, plas	10.0 10.0 10.0 10.0 10.0 10.0

### TABLE 3A

Table 3A shows the accession numbers for those pkeys lacking unigeneID's for Table 3. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	Pkey: CAT number:	Unique Eos probeset identifier number Gene duster number
	Accession:	Genbank accession numbers

5

1.5			•
15	Pkey	CAT number	Accessions
20		38585_1	AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 AI267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374 H66215 AA045564 AI694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570
25	102208	36735_9	U22961 AA203623 AA503337 Al174733 Al192802 C06092 AA035357 Al190619 Al199244 Al828450 AA602296 Al378195 Al209170 Al186653 Al127795 Al183846 H77389 Al589465 AA629390 H94306 Al018388 R68584 AA027196 Al745413 Al685092 Al093426 Al623873 Al074570 N50096 AA047486 N25060 AA327614 Al042512 Al383957 AA156873 Al333101 N70806 Al141254 Al383191 Al401237 Al080709 Al093400 W84549 T90806 R00012 W01413 AA630557 Al378348 Al559265 AA877103 W84464 AA625146 R68379 Al133207 Al132980 Al133214 Al064826 Al061615 Al133473 Al174852 Al133404 Al133272 V00494 M12523
30			M12523 Al207526 Al133120 Al064802 Al174993 Al114729 Al061645 Al064716 Al064959 H77388 T85706 AF075298 Al110799 D17107 NM_000477 AF190168 R50724 Al248416 Al207432 Al133684 Al133345 Al174710 Al133290 Al133304 Al174948 Al207484 Al110717 AF074624 Al114515 AF063516 Al110642 Al114559 Al114498 Al114759 Al207568 Al064960 Al174753 Al114666 R69184 R00011 Al064997 T60501 Al207701 T71735 AA385318 H73569 T60496 H94399 Al133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T7496 Al207490 Al132925 Al064701 Al174748 Al114663 Al133104 Al132999
35			A1133100 A1064925 A1064979 A1133063 AA343347 T69091 AA233989 T39772 A1444620 T52290 D16931 T40012 T48403 T58926 T69195 A1133061 T50850 Al400677 A1091136 AA334608 T57411 Z20979 N56507 T67485 A1133622 AA343370 T40075 T69671 T53849 T74820 AF075316 A1110818 T40121 T57381 A1114468 AA332728 T51362 A11415489 R06691 A1110629 AF065303 A1140543 AA334661 AA332720 AA343262 T73513 T86549 A1114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 A1174786 A1132926 R09237 A1064838 A113360 T60398 T88753 T55930 T92126 A1444602 T60996 A1114792 H93911 A1133106 R10779 A1065020 T90925 T50889 D17029 A1133703 AA333805
40			Al133040 Al133017 Al064857 Al110730 AF074637 Al207567 H71080 T73217 AA33950 Al174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 Al065049 T84512 T55918 Al207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 Al114676 Al064778 AA035710 W52763 Al114786 T83564 AA341859 T81684 T55769 Al114710 T51776 AA343213 Al114714 T58102 Al110809 R28984 Al174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364
45			AF075308 W86731 T82851 T48269 H54053 T73211 A1114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 Al203974 A1189471 AA005147 A1478102 Al207662 A1192792 Al768421 A1064737 AW051713 AA936693 A1133117 A1766232 A1913646 T83962 A1065112 A1207689 A1174684 A1207702 T81475 A1133325 A1032512 AA701169 A1936354 A1114720 A1433289 AA046980 A1823482 A1114536 AA860651 AW242644 R07469 AW300438 A1133416 AW271670 A1991363
50		•	T78943 AI823481 AA845518 AA719124 AA883454 T68850 T69115 AI935509 AI150977 T62890 T71374 T68294 AI174774 T67411 T68318 AI064689 T56624 T69010 T68982 T68302 AI332829 T72908 AI064819 AI205880 T62895 T69430 T95111 AA025050 T73330 W52657 T71984 T69118 W92684 AI114860 T62093 T61797 AI522333 T73322 H92981 T56018 T61811 T57232 AI336158 T61821 T69457 T62900 T62912 T72917 T46885 AI702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 AI187111 T64308 T62071 T69427 AI114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809
55			T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 Al312890 T67751 Al174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300 T28321 T55864

### TABLE 4: Figure 4 from BRCA 001 US

Table 4 shows genes upregulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset identifier number
Exacon: Exemplar Accession number, Genbank accession number
UnigenelD: Unigene number
Unigene Title: Unigene gene title
R1: Ratio of tumor to normal breast tissue

15	Pkey	ExAccn	UnigenelD	Uлigene Title	R1
•	100113	NM_00126	9Hs.84746	chromosome condensation 1	2.3
	100114	X02308	Hs.82962	thymidylate synthetase	2.9
	100131	D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodiesterase 1	1.9
20	100146	BE185499	Hs.2471	KIAA0020 gene product	1.9
	100147	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin I-like) (perlostin)	7.5
	100154	H60720	Hs.81892	KIAA0101 gene product	9.2
	100163	W44671	Hs.124	gene predicted from cDNA with a complete coding sequence	1.6
•	100220	AW015534	Hs.217493		2.0
25	100265	D38521	Hs.112396	KIAA0077 protein	1.5
	100271	BE160081	Hs.256290	S100 calcium-binding protein A11 (calgizzarin)	13.5
	100275	BE242802	Hs.154797	KIAA0090 protein	5.1
	100323	D50920	Hs.23106	KIAA0130 gene product	1.9
		AW247529	Hs.6793	platelet-activating factor acetylhydrolase, isoform lb, gamma subunit (29kD)	2.7
30	100364	NM_00434	1Hs.154868	carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase	2.0
				KIAA0175 gene product	2.6
		D84145	Hs.39913	novel RGD-containing protein	3.2
	100400	AW954324	Hs.75790	phosphatidylinositol glycan, class C	1.5
	100418	D86978	Hs.84790	KIAA0225 protein	2.0
35	100482	M65028	Hs.81361	heterogeneous nuclear ribonucleoprotein A/B	2.9
	100518	NM_00441	5Hs.74316	desmoplakin (DPI, DPII)	1.9
	100666	L05424	Hs.169610	CD44 antigen (homing function and Indian blood group system)	5.7
	100667	L05424	Hs.169610	CD44 antigen (homing function and Indian blood group system)	9.0
	100668	L05424	Hs.169610	CD44 antigen (homing function and Indian blood group system)	7.6
40	100678	AW502935	Hs.740	PTK2 protein tyrosine kinase 2	53.2
	100685	AA328229	Hs.184582	ribosomal protein L24	1.8
	100690	AA383256	Hs.1657	estrogen receptor 1	1.6
				general transcription factor IIH, polypeptide 2 (44kD subunit)	5.9
	100850	AA836472	Hs.297939	cathepsin B	1.7
45	100892	BE245294	Hs.180789	S164 protein	1.7
	100945	AF002225	Hs.180686	ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman syndrome)	1.5
			Hs.79172	solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 5	6.3
		AK000405	Hs.76480	ubiquitin-like 4	11.4
		H38765	Hs.80706	diaphorase (NADH/NADPH) (cytochrome b-5 reductase)	1.6
50	101031	J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase)	8.2
	101045	J05614		gb:Human proliferating cell nuclear antigen (PCNA) gene, promoter region.	5.0
	101077	N99692	Hs.75227	Empirically selected from AFFX single probeset	2.6
	101093	L06419	Hs.75093	procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome ty	
	101161	NM_00626	2Hs.37044	peripherin	16.9
55	101186	AA020956	Hs.179881	core-binding factor, beta subunit	2.0
	101216	AA284166	Hs.84113	cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase)	1.8
		AA333387		chaperonin containing TCP1, subunit 6A (zeta 1)	1.7
	101247	AA132666		glycogen synthase kinase 3 beta	1.9
	101249	L18964	Hs.1904	protein kinase C, lota	1.5
60	101332	J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	5.2
	101332	J04088		topoisomerase (DNA) II alpha (170kD)	3.4
		AI494299		COX17 (yeast) homolog, cytochrome c oxidase assembly protein	6.3
	101396	BE267931	Hs.78996	proliferating cell nuclear antigen	4.2
		M21259		gb:Human Alu repeats in the region 5' to the small nuclear rib	1.9
65	101470	NM_00054	6Hs.1846	tumor protein p53 (Li-Fraumeni syndrome)	1.6

	101478	NM_002890	)Hs.758	RAS p21 protein activator (GTPase activating protein) 1	2.5
	101483	M24486	Hs.76768	procoflagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide I	5.5
	101540	J04977	Hs.84981	X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoin	ing 2.1
			Hs.250758	proteasome (prosome, macropain) 26S subunit, ATPase, 3	1.6
5		NM_012151		coagulation factor VIII-associated (intronic transcript)	5.7
	101592	AF064853	Hs.91299	guanine nucleotide blinding protein (G protein), beta polypeptide 2	1.8
	101592	AF064853	Hs.91299	guanine nucleotide binding protein (G pr	5.6
		BE391804		guanylate binding protein 1, interferon-inducible, 67kD	2.4
	101702	AW504089	Hs.179574	protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha isoform	1.3
10	101734	M74099		cut (Drosophila)-like 1 (CCAAT displacement protein)	2.1
	101759	M80244	Hs.184601	solute carrier family 7 (cationic amino acid transporter, y+system), member 5	5.0
	101767	M81057	Hs.180884	carboxypeptidase B1 (tissue)	14.4
	101782	AA306495	Hs.1869	phosphoglucomutase 1	5.2
	101805	AW409747	Hs.75612	stress-induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein)	8.6
15	101806	AA586894	Hs.112408	S100 calcium-binding protein A7 (psoriasin 1)	8.9
	101810	NM_000318	3Hs.180612	peroxisomal membrane protein 3 (35kD, Zellweger syndrome)	3.2
				nuclear autoantigenic sperm protein (histone-binding)	1.6
				glycoprotein hormones, alpha polypeptide	31.3
••		AF182645	Hs.8024	IK cytokine, down-regulator of HLA II	1.8
20		U41514	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T	
		Al904232			8.4
		BE245149		protein tyrosine kinase 9	1.3
		BE250127		CDC20 (cell division cycle 20, S. cerevisiae, homolog)	2.0
0.5		T35901	Hs.75117	interleukin enhancer binding factor 2, 45kD	1.6
25		T35901	Hs.75117	interleukin enhancer binding factor 2, 4	1.3
				heat shock protein 75	1.4
		NM_001809		centromere protein A (17kD)	1.8
				death associated protein 3	4.6
20		AW950852		polymerase (DNA directed), delta 2, regulatory subunit (50kD)	4.3
30		AA829978			6.7
		U24389	Hs.65436	lysosomal	4.3
				heterochromatin-like protein 1	1.9
				karyopherin alpha 2 (RAG cohort 1, importin alpha 1)	4.4
35		AA306342		protein kinase C-like 2	2.7
23		BE298063		chromobox homolog 1 (Drosophila HP1 beta)	1.5
		BE378432		cyclin-dependent kinase 4	2.3
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member B2	2.0
		U39840		baculoviral IAP repeat-containing 2 hepatocyte nuclear factor 3, alpha	3.2 2.0
40		U33635			6.2
70				PTK7 protein tyrosine kinase 7 deoxyguanosine kinase	1.5
		U48705	Hs.75562	discoidin domain receptor family, member 1	6.9
		NM_001359		2,4-dienoyl CoA reductase 1, mitochondrial	1.8
		U50939	Hs.61828	amyloid beta precursor protein-binding protein 1, 59kD	1.5
45		AL080116		origin recognition complex, subunit 3 (yeast homolog)-like	3.3
-13		Al188137		COP9 homolog	2.1
		AF217197		siah binding protein 1; FBP interacting repressor, pyrimidine tract binding splicing	3.2
					2.8
				suppressor of Ty (S.cerevisiae) 5 homolog	5.7
50		U59423		MAD (mothers against decapentaplegic, Drosophila) homolog 1	2.3
		W81489		RAB31, member RAS oncogene family	5.3
		U60808		CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1	2.1
		AU077228		enhancer of zeste (Drosophila) homolog 2	1.6
		U61232	Hs.32675	tubulin-specific chaperone e	2.1
55				COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 5	1.8
	102618	AL037672	Hs.81071	extracellular matrix protein 1	5.8
	102627	AL021918	Hs.158174	zinc finger protein 184 (Kruppel-like)	1.3
				karyopherin (importin) bela 2	1.8
	102676	BE262989	Hs.12045	putative protein	2.3
60	102687	NM_007019		ubiquitin carrier protein E2-C	4.3
		U96132		hydroxyacyl-Coenzyme A dehydrogenase, type II	6.0
		BE540274		forkhead box M1	4.2
		AU077058		BRCA1 associated RING domain 1	1.9
		T97490	Hs.50002	small inducible cytokine subfamily A (Cys-Cys), member 19	2.3
65		AB014460		nth (E.coli endonuclease III)-like 1	1.2
		BE252241			6.4
	102812	U90549	Hs.236774	high-mobility group (nonhistone chromosomal) protein 17-like 3	1.6

	102827	BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (beta)	5.6
			Hs.80917	adaptor-related protein complex 3, sigma 1 subunit	2.0
	102844	AV653700	He 324275	WW domain-containing protein 1	
	102074	X02419			1.3
5			Hs.77274	plasminogen activator, urokinase	4.4
J		BE440142		signal recognition particle 19kD	1.9
			Hs.80506	small nuclear ribonucleoprotein polypeptide A'	2.4
	102968	AU076611	Hs.154672	methylene tetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cy	clohydrolase2.7
	102983	BE387202	Hs.118638	non-metastatic cells 1, protein (NM23A) expressed in	3.1
		U95742	Hs.2707	G1 to S phase transition 1	5.2
10	103023	AW500470	Hs.117950	multifunctional polypeptide similar to SAICAR synthetase and AIR carboxylase	1.6
	103038	AA926960	Hs.334883	CDC28 protein kinase 1	2.5
	103060	NM 00594	OHs 155324	matrix metalloproteinase 11 (MMP11; stromelysin 3)	4.5
	103080	AI IN77231	Hs.82932	cyclin D1 (PRAD1: parathyroid adenomatosis 1)	3.1
		D31152			
15		BE244377		collagen, type X, alpha 1 (Schmid metaphyseal chondrodysplasia)	2.4
13				famesyl-diphosphate famesyltransferase 1	3.5 ·
				ribosomal protein S18	9.9
			7Hs.82685		1.3
	103181	X69636	Hs.334731	Homo sapiens, clone IMAGE:3448306, mRNA, partial cds	2.0
	103185	NM_00682	5Hs.74368	transmembrane protein (63kD), endoplasmic reticulum/Golgi intermediate compartment	1.6
20		AA401039		protein phosphalase 4 (formerly X), catalytic subunit	2.5
		NM_00476		coatomer protein complex, subunit beta 2 (beta prime)	2.2
		NM_00493		DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1	6.3
		X72755	Hs.77367	monokine Induced by gamma interferon	8.8
		BE275607			3.0
25		X75962		chaperonin containing TCP1, subunit 3 (gamma)	
23				tumor necrosis factor receptor superfamily, member 4	1.8
		Al369285		death-associated protein	5.6
		NM_00154		Immature colon carcinoma transcript 1	1.9
		AI803447	Hs.77496	small nuclear ribonucleoprotein polypeptide G	2.5
••		X89059		gb:H.sapiens mRNA for unknown protein expressed in macrophage	1.6
30			Hs.323378	coated vesicle membrane protein	1.8
	103391	X94453	Hs.114366	pyrroline-5-carboxylate synthetase (glutamate gamma-semialdehyde synthetase)	2.3
		X94563		gb:H.sapiens dbi/acbp gene exon 1 & 2.	. 4.0
			Hs.20716	translocase of inner mitochondrial membrane 17 (yeast) homolog A	1.3
35				myeloid/lymphoid or mixed-lineage teukemia 3	5.6
35		AL031224		transcription factor AP-2 beta (activating enhancer-binding protein 2 beta)	5.1
				proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 7)	9.7
		NM_00621		phospholnositide-3-kinase, catalytic, alpha polypeptide	_ 2.0
		NM_00034		SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal)	1.3
40	103621	BE379766	Hs.150675	polymerase (RNA) II (DNA directed) polypeptide K (7.0kD)	2.0
40	103622	AA609685	Hs.278672	membrane component, chromosome 11, surface marker 1	2.3
	103727	AI878883	Hs.296381	growth factor receptor-bound protein 2	1.3
	103749	AL135301	Hs.8768	hypothetical protein FLJ10849	1.8
	103754	AI015709	Hs.172089	Homo sapiens mRNA; cDNA DKFZp586l2022 (from clone DKFZp586l2022)	1.3
				hypothetical 43.2 Kd protein	7.5
45		H26531	Hs.7367	Homo sapiens BTB domain protein (BDPL) mRNA, partial cds	1.2
		AA080912		gb:zn04d03.r1 Stratagene hNT neuron (937233) Homo sapiens cDNA clone 5' similar	1.5
			He 181971	CGI-120 protein	1,5
		W02363		hypothetical protein FLJ10330	1.5
50				hypothetical protein FLJ10416 similar to constitutive photomorphogenic protein 1	6.5
50			7Hs:97644	mammaglobin 2	2.9
			Hs.103238		1.4
	104174	AA478984	Hs.6451	PRO0659 protein	5.6
	104227	AB002343	Hs.98938	protocadherin alpha 9	1.6
				GCN5 (general control of amino-acid synthesis, yeast, homolog)-like 2	5.4
55				polymerase (RNA) II (DNA directed) polypeptide K (7.0kD)	6.3
			Hs.21851	Homo sapiens cONA FLJ12900 fis, clone NT2RP2004321	1.6
		R83113	Hs.1432	protein kinase C substrate 80K-H	5.2
		AB037762		myelin gene expression factor 2	1.2
<b>6</b> 0				hypothetical protein FLJ12748	2.1
60				DKFZP434F1735 protein	1.2
	104667	AI239923	Hs.30098	ESIS	1.3
	104757	AI694413	Hs.332649	olfactory receptor, family 2, subfamily 1, member 6	2.3
	104804	Al858702	Hs.31803	ESTs, Weakly similar to N-WASP [H.sapiens]	1.3
	104806	AB023175	Hs.22982	KIAA0958 protein	2.3
65		AW052006		PRP4/STK/WD splicing factor	10.9
-			Hs.32478		5,6
				3-phosphoinositide dependent protein kinase-1	12.3

	104867	AA278898	Hs.225979	hypothetical protein similar to small G proteins, especially RAP-2A	2.0
	104871	T78044	Hs.28893	Homo sapiens mRNA; cDNA DKFZp564O2364 (from clone DKFZp564O2364)	1.3
	104896	AW015318	Hs.23165	ESTs	17.7
_	104909	AW408164	Hs.249184	transcription factor 19 (SC1)	5.0
5	104916	AW958157	Hs.155489	NS1-associated protein 1	1.7
	104919	AA026880	Hs.25252	prolactin receptor	1,4
		AF043467		neurexophilin 2	2.2
		NM_01531		KIAA0942 protein	5.0
10		Y12059	Hs.278675	bromodomain-containing 4	1.4
10			Hs.50758	SMC4 (structural maintenance of chromosomes 4, yeast)-like 1	2.4
	104975	AL136877	Hs.50758	SMC4 (structural maintenance of chromoso	2.3
	104978	Al199268	Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010317E24 gene, clone IMAGE:3502019, mRNA, partial	cds 7.2
	104979	AA93/934	Hs.321062	ESTS	1.3
1.5		A1499930	Hs.334885	mitochondrial GTP binding protein	3.5
15		BE379584		dolichyl-diphosphooligosaccharide-protein glycosyltransferase	5.5
		AF098158		chromosome 20 open reading frame 1	3.3
		AI050715	Hs.2331	E2F transcription factor 5, p130-binding	2.2
		AA127818	11 60476	gb:zl12a02.s1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:501674 3'	6.8
20		AA907305		ESTs	2.5
20	100041	AB037716	HS.26204	KIAA1295 protein	2.2
	105045	BE242899	HS.129951	speckle-type POZ protein	3.8
			Hs.12677		9.5
		AA147884		Homo sapiens cDNA FLJ14388 fis, clone HEMBA1002716	5.6
25	105000	H58589 Z78407	Hs.35156		2.2
23		BE387350	Hs.27023		2.2
			Hs.36288	KIAA1160 protein	1.6
	105120	VAUVEEV8	He 201057	nudix (nucleoside diphosphate linked moiety X)-type motif 5	6.3
	105121	AA164697	He 177576	managed (alpha 4.3.) Intercentain bets 4.4.4.4. The high land of the control of t	2.1
30	105158	AW978357	He 23/5/5	mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isoenzyme A hypothetical protein NUF2R	2.7
-	105169	RF245294	He 180780	S164 protein	1.9
	105186	AA191512	Hs.28005	Homo sapiens cDNA FLJ11309 fis, clone PLACE1010076	1.7
		AA071276		KIAA0859 protein	4.8
		AA263143		RAD51-Interacting protein	1.9 2.8
35		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ domain-containing protein MCJ [H.sapiens]	1.9
-		AA700122		sentrin-specific protease	8.0
				KIAA0779 protein	1.8
	105359	NM_016015	Hs.8054	CGI-68 protein	8.2
	105366	BE264645	Hs.282093	hypothetical protein FLJ21918	5.0
40	105373	AW887701	Hs.32356	hypothetical protein FLJ20628	2.5
	105374	BE242803	Hs.262823	hypothetical protein FLJ10326	2.2
	105387	AW592146	Hs.108636	membrane protein CH1	2.3
	105393	AF167570	Hs.256583	interleukin enhancer binding factor 3, 90kD	5.4
4.5	105399	BE386877	Hs.334811	Now38-binding protein Now8P	1.6
45	105400	AF198620	Hs.65648	RNA binding motif protein 8A	1.6
	105445	AA252395		gb:zs12g10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:685026 3', mRNA sequence	. 5.0
	105507	BE268348	Hs.226318	CCR4-NOT transcription complex, subunit 7	1.6
		AA113449		hypothetical protein FLJ20364	1.3
50		AB023179		KIAA0962 protein	3.4
JU	100047	AA262640	MS.2/445	unknown	9.3
	100004	A A E 70 52 5	MS.288042	hypothetical protein FLJ14299	1.4
	105590	AA579535	MS.18490	hypothetical protein FLJ20452	10.9
	100001	AFU34204	U- 007000	splicing factor 3b, subunit 1, 155kD	2.9
55	102000	A A 2000ZU I		hypothetical protein FLJ12475	1.7
,,		AA280072 AK000892		fetal Alzheimer antigen	1.4
	105017	AM/2022	Hc 181300	glucocorficoid modulatory element binding protein 1 caseln kinase 1, gamma 2	1.7
	105658	AA985190	He 2/6875	hypothetical protein FLJ20059	5.5
	105697	AW499988	Hs 27801		9.4
50	105708	R26944	Hs.180777	Homo sapiens mRNA; cDNA DKFZp564M0264 (from clone DKFZp564M0264)	2.0
		BE246502	Hs.9598		1.7
		AW151952		hypothetical protein FLI20739	2.6 1.5
	105759	AI123118	Hs.15159	chemokine-like factor, alternatively spliced	1.3
	105771	A1267720	Hs.153221	synovial sarcoma, translocated to X chromosome	1.6
55	105820	AA741336	Hs.152108	transcriptional unit N143	2.2
	105826	AA478756	Hs.194477	E3 ubiquitin ligase SMURF2	1.3
	105856	AI262106	Hs.12653	ESTs	2.4

	105858	AF151066	Hs.281428	hypothetical protein	2.9
	105875	AK001708	Hs.32271	hypothetical protein FLJ10846	1.4
		AF016371			5.2
		AW194426			1.7
5		AW081202			2.8
	106017	AA477956	Hs.26268	ESTs	1.4
				downstream neighbor of SON	1.4
		AA130158			
					6.8
10					1.6
••				Homo sapiens, Similar to RIKEN cDNA 5430429M05 gene, done MGC:13155, mRNA, complete or	
	106288	AR037742	He 24336	KIAA1321 prolein	1.3
					3.6
		AL 043114	Uc 22/10	ESTs, Weakly similar to A54849 collagen alpha 1(VII) chain precursor [H.sapiens]	5.4
15		AK001404			5.7
13					6.3
					-
					6.5
		AW748420		Homo sapiens cDNA: FLJ21487 fis, clone COL05419	2.2
20		AF119256			2.7
20				Homo sapiens cDNA: FLJ23038 fis, clone LNG02039	2.3
		AA454036		ESTs	1.6
		AA243837			1.6
		AK000933			2.4
25		AA458882			7.9
25		NM_003595			7.7
					1.8
				ESTs, Moderately similar to S65657 alpha-1C-adrenergic receptor splice form 2 [H.sapiens]	1.3
					4.5
20					1.3
30		BE388094			1.6
					5.7
		AW959893		7,	16.2
25		BE564871			1.5
					2.2
35					1.3
		N49809		Homo sapiens, clone IMAGE:3343149, mRNA, partial cds	16.8
			Hs.9567		1.5
	106906	AAB61271	Hs.222024		2.2
40					3.3
40		AK000511			6.8
					6.6
		AL043152			4.8
		AW631480			6.0
45				hypothetical protein FLJ20727	1.3
45				myeloid/lymphoid or mixed-lineage leukemia 3	1.8
		AW385224		ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative function)	1.7
		AK000733		GTPase activating protein	2.5
		AK000512		hypothetical protein FLJ20505	1.7
		AV661958		GK001 protein	4.6
50 ·		AV661958		GK001 protein	3.3
	107146	AK001455	Hs.5198		2.0
		AW378065		ESTs	6.3
	107155	AW391927	Hs.7946	KIAA1288 protein	33.5
		BE122762	Hs.25338		5.2
55	107197	W15477	Hs.64639	glioma pathogenesis-related protein	6.1
	107221	AW888411	Hs.81915	leukemia-associated phosphoprotein p18 (stathmin)	17.4
	107243	BE219716	Hs.34727	ESTs, Moderately similar to 138759 zinc finger/leucine zipper protein [H.sapiens]	7.4
			Hs.315111	nuclear receptor co-repressor/HDAC3 complex subunit	1.8
		D60341	Hs.21198		6.6
60		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	
		N95657	Hs.6820	ESTs, Moderately similar to YOJ1_CAEEL HYPOTHETICAL 63.5 KD PROTEIN ZK353.1 IN	2.5
	107298	N95657	Hs.6820	ESTs, Moderately similar to YOJ1_CAEEL H	1.7
		BE277457	Hs.30661	hypothetical protein MGC4606	3.2
		T63174		Homo sapiens mRNA; cDNA DKFZp586l0324 (from clone DKFZp586l0324)	2.0
65		NM_006299		zinc finger protein 193	5.0
	107392	AW299900	Hs.267632	TATA element modulatory factor 1	1.2
	107481	AA307703	Hs.279766	kinesin family member 4A	1.6

	107529	BE515065	Hs.296585		3.0	
			Hs.59844		1.3	
				ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION :		
	107772	AA018587	Hs.303055	ESTS, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	2.1	
5	107859	AW732573	Hs.47584	potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3	3.4	
	107901	L42612	Hs.335952	keratin 6B	2.5	
	107901	L42612	Hs.335952	keratin 6B	1.6	
	107922	BE153855	Hs.61460	Ig superfamily receptor LNIR	2.2	
	107974	AW956103	Hs.61712		6.7	
10	108040	AL121031	Hs.159971	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1	1.5	
			Hs.59847		1.3	
					7.1	
			Hs.161623		2.5	
			Hs.339659		3.5	
15	108607	BE300380	Hs.69476		3.4	
			Hs.182685		1.6	
			Hs.69507		1.7	
					9.8	
					7.2	
20					1.3	
		AI089575			2.7	
					1.8	
			Hs.178904		1.5	
		H06720			2.1	
25			Hs.48480		5.3	
23		AK001431			4.0	
	100054	AA440764	Hr 105155		5.6	
	100533	AA161709	Un 171000	homeo box (expressed in ES cells) 1	1.6	
			Hs.23467		6.2	
30			Hs.72134	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1.7	
20			Hs.72127	· · · · · · · · · · · · · · · · · · ·	1.4	
			115.12121	gb:zo35d07.s1 Stratagene colon (937204) Homo sapiens cDNA clone 3' similar to contains Alu repe		5.3
		AA157811 AA164293	Un 79545		2.9	0.0
			Hs.52184		1.6	
35					3.2	
33				.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1.7	
				When the state of	2.6	
			Hs.59757 Hs.73625		2.9	
					2.0	
40			Hs.58169		5.3	
40			3Hs.82035	Production Production of the same production	5.7	
			Hs.189998		5.3	
		N99673	Hs.3585		1.4	
45					2.9	
45				4	1.3	
			Hs.115099		2.9	
				the real broken was a residual and a second	1.5	
		H83603	Hs.40408		2.2	
<b>CO</b>		N30531	Hs.42215	history brooks and the demand of the demand	3.0	
50			Hs.61438		1.9	
			Hs.189915		1.8	
				The state of the s	3.7	
		NM_01531			3.2	
			Hs.87134		2.0	
55		L40027		24 - 2 4	2.1	
		F02614	Hs.27319	<del></del>	1.4	
		R71264	Hs.16798		1.3	
	110039	H11938	Hs.21907	histone acetyltransferase	2.0	
	110056	AA503041	Hs.279009		2.5	
60	110085	AA603840	Hs.29956	KIAA0460 protein	1.7	
		T07353	Hs.7948		2.9	
	110129	R51853		ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	1.7	
		NM_01452	1Hs.17667	SH3-domain binding protein 4	4.2	
		A1668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOCHROME P450 4A11 PRECURSOR [H.sapiens]	4.2	
65		N41744	Hs.19978	CGI-30 protein	1.3	
	110259	H28428	Hs.32406	ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens]	2.2	
	110312	BE256986	Hs.11896	hypothetical protein FLJ12089	2.1	

	110330	AI288666	Hs.16621	DKFZP434I116 protein	6.2
	110501	H55748		gb:yq94a01.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:203400 3'	6.1
	110504	H55915	Hs.210859	hypothetical protein FLJ11016	6.1
_	110525	H57330		EST	6.3
5	110568	AK001160	Hs.5999	hypothetical protein FLJ10298	1.3
	110699	T97586	Hs.18090	ESTs	1.8
	110705	AB007902	Hs.32168	KIAA0442 protein	1.6
		AW190338		hypothetical protein MGC11256	7.6
10		AL138077		hypothetical protein FLJ12707	2.5
10	110762	BE044245	Hs.30011	hypothetical protein MGC2963	9.3
		AK000322		hypothetical protein FLJ20315	5.5
		BE000831			2.1
			Hs.323401	dpy-30-like protein	1.5
٠		T25829	Hs.24048		6.6
15		AA767373	Hs.35669		5.7
		R33261	Hs.6614	ESTs, Weakly similar to A43932 mucin 2 precursor, intestinal [H.sapiens]	3.4
		N31598	Hs.12727	hypothetical protein FLJ21610	1.7
	110844	AI740792	Hs.167531	methylcrotonoyi-Coenzyme A carboxylase 2 (beta)	1.7
•		BE612992	Hs.27931	hypothetical protein FLJ10607 similar to glucosamine-phosphate N-acetyltransferase	4.7
20		AA992380		gb:ot37g06.s1 Soares_testis_NHT Homo saplens cDNA clone 3' similar to contains element	2.3
		BE384447		hypothetical protein MGC13186	3.5
		AL117430		DKFZP434D156 protein	2.2
		BE092285		hypothetical protein FLJ13187	2.6
25		H04360	Hs.24283	ESTs, Moderately similar to reduced expression in cancer [H.sapiens]	1.9
25		NM_005864		signal transduction protein (SH3 containing)	6.7
		AK002180		DKFZP564O123 protein	2.0
		AK001980			1.3
	110984	AW613287	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T	
20		N63823	Hs.269115	ESTs, Moderately similar to Z195_HUMAN ZINC FINGER PROTEIN 195 [H.sapiens]	3.6
30		AB037807			2.1
		N46180		Homo sapiens cDNA FLJ13289 fis, clone OVARC1001170	2.3
		R67419	Hs.21851	Homo saplens cDNA FLJ12900 fis, clone NT2RP2004321	3.7
	111174	ALU50166	HS.26295	Homo saplens mRNA; cDNA DKFZp586D1122 (from clone DKFZp586D1122)	7.5
35		AK000136			7.1
33	111104	AI015466	HS.243901	Homo saplens cONA FLJ20738 fis, clone HEP08257	6.7
	111104	AI0 10400		Homo sapiens cDNA FLJ20738 fis, clone HE	3.3
		N67603		ESTs, Weakly similar to S65824 reverse transcriptase homolog [H.sapiens]	3.6
	111210	AW139408	Do 45140	KIAA1361 protein	1.5
40	111221	ADUS/ / 02	De 224020	KIAA1866 protein	2.6
70		N90956	He 47220	hypothetical protein FLJ22087	4.6
		AA778711			7.9
				eukaryotic translation initiation factor 1A KIAA1265 protein	6.9
		Al523913			5.0
45	111318		Hs.334728		3.8
73			He 263025	LIS1-interacting protein NUDE1, rat homolog	1.2
	111357	H58589	He 35156	Homo sapiens CDNA FLJ11027 fis, clone PLACE1004114	5.1 2.2
		AI478658	He 04631	brefeldin A-inhibited guanine nucleotide-exchange protein 1	2.8
		N94606	Hs 288969	HSCARG protein	2.2
50				oxidation resistance 1	2.1
•				sialyltransferase 9 (CMP-NeuActactosylceramide alpha-2,3-sialyltransferase; GM3 synthase)	5.1
	111392			Homo sapiens, done IMAGE:3659680, mRNA, partial cds	8.4
		R02354	Hs.15999		2.7
			Hs.227978		6.5
55		W90638		ESTs, Moderately similar to ZRF1_HUMAN ZUOTIN RELATED FACTOR-1 (M-PHASE	1.4
		R10720	Hs.20670	EST	1.6
		R52656	Hs.21691	ESTs	1.6
		AB037834		Homo sapiens mRNA for KIAA1413 protein, partial cds	2.4
		BE298665		Homo sapiens mRNA; cDNA DKFZp564D016 (from clone DKFZp564D016)	10.6
60		AW083791			6.6
		NM_015310		KIAA0942 protein	5.1
	112134		Hs.7413	ESTs; calsyntenin-2	2.8
		AB029000	Hs.70823	KIAA1077 protein	14.6
	112388	R46071	Hs.301693	Homo sapiens, done IMAGE:3638994 mRNA partial cds	9.0
65	112456	NM_016248	3Hs.232076	A kinase (PRKA) anchor protein 11	1.4
	112464	AW007287	Hs.28538	Homo saplens cDNA; FLJ21086 fis. clone CAS03272	1.4
	112506	A1742756	Hs.26079	ESTs	3.2

	112513	R68425	Hs.13809		2.0	
	112752	AK001635	Hs.14838		1.8	
	112884	AK000004	Hs.5013	Homo saplens mRNA for FLJ00004 protein, partial cds	6.6	
_	112923	T10258	Hs.5037	EST	1.5	
5		AW970826	Hs.6185	KIAA1557 protein	3.2	
		R61388	Hs.6724		6.0	
	112966	Z44718	Hs.102548	glucocorticoid receptor DNA binding factor 1	6.4	
	112978	AK000272	Hs.7099	hypothetical protein FLJ20265	1.2	
	112995	AA737033	Hs.7155	ESTs, Moderately similar to 2115357A TYKI protein [M.muscutus]	5.6	
10	112996	BE276112	Hs.7165	zinc finger protein 259	2.0	
	113047	Al571940	Hs.7549	ESTs	1.9	
	113049	AW965190	Hs.7560	Homo sapiens mRNA for KIAA1729 protein, partial cds	2.4	
	113089	T40707	Hs.270862	ESTs	1.3	
	113196	T57317		gb:yb51a03.s1 Stratagene fetal spleen (937205) Homo sapiens cDNA clone IMAGE:74668 3',	1.7	
15	113248	T63857			2.8	
	113254	AK002180	Hs.11449		1.3	
	113277	AW971049	Hs.11774	protein (peptidyl-protyl cis/trans isomerase) NIMA-interacting, 4 (parvulin)	3.2	
	113429	AA688021	Hs.179808		1.2	
		Al467908			5.9	
20		H59588	Hs.15233		2.0	
			Hs.142442		3.6	
					1.3	
		T97307			4.4	
			Hs.184411		1,3	
25		AW499665		SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member		
			Hs.10590		13.4	
		AL359588			1.7	
					1.3	
		W44735	Hs.9286		3.3	
30		BE207480			3.1	
50		H13325	Hs 332795		3.2	
		AW378212		hypothetical protein FLJ10826	2.3	
		T26483	Hs.6059		11.3	
		W57902	Hs.90744		2.7	
35		AL079314			6.1	
JJ		AW959486			6.6	
		AW953484			1.9	
		W87544	Hs.268828	.,,	1.2	
					5.4	
40					9.4	
40		AB029551			1.8	
					1.5	
					1.8	
		AB028968				2.3
45			Hs.14831		1.4	2.0
43		AL117518			15.8	
					1.9	
					2.4	
50					1.8 1.2	
50						
		H37908		• • • • • • • • • • • • • • • • • • • •	5.5	
					5.2	
				Homo sapiens, Similar to RIKEN cDNA 1110012M11 gene, clone IMAGE:3688605, mRNA, partial		
	114471	AA028074	HS.104613		1.8	
55	114480	BE066/78	HS.151678	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-To		
	114671	AA766268	HS.2662/3	hypothetical protein FLJ13346	1.9	
	114698	AA476966	HS.11085/		3.5	
					3.8	
<b>CO</b>					1.6	
60					3.1	
			Hs.54900		3.5	
		AL157545			4.3	
		AA236177			7.1	
		BE539101	Hs.5324		1.3	
65		AA236672		gb:zt29f02.s1 Soares ovary tumor NbHOT Homo sapiens cDNA done IMAGE:723771 3', mRNA se	•	1.5
	114930	AA237022	Hs.188717	ESIS	2.0	
	114938	AA242834	Hs.58384	£819	2.9	

	114965	A1733881	Hs.72472	BMP-R1B	2.3
			Hs.63931		1.3
				toll-like receptor 9	1.6
_	115061	AI751438	Hs.41271	Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1913076	11.8
5				LIM protein (similar to rat protein kina	1.5
		AI670847		hypothetical protein	1.5
			Hs.88155		2.8
			Hs.186572		2.5
10				hypothetical protein FLJ10116	1.5
10	115239	BE251328	Hs.73291	hypothetical protein FLJ10881	1.3
				ESTs, Moderately similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE	1.4 1.5
			Hs.293736	hypothetical protein FLJ11301	2.4
				hypothetical protein FLJ10461	6.2
15			Hs.89113		6.6
			Hs.48499		7.4
			Hs.59346		1.4
				ESTs, Moderately similar to 154374 gene NF2 protein [H.sapiens]	4.0
	115496	AW247593		eukaryotic translation initiation factor 4E binding protein 1	16.3
20		Y14443	Hs.88219	zinc finger protein 200	5.0
				transcription factor (SMIF gene)	2.5
			Hs.61082		6.1
				HSPC039 protein	2.9
25				7-60 protein	5.3 4.7
23		N36110		solute carrier family 2 (facilitated glucose transporter), member 10	10.6
				hypothetical protein FLJ23468 Ното sapiens, clone MGC:16063, mRNA, complete cds	12.7
			Hs.40507		2.0
			Hs.88143		3.0
30			Hs.44159		1.7
		AF231023		cadherin, EGF LAG seven-pass G-type receptor 3, flamingo (Drosophila) homolog	6.8
		BE395161		proteasome (prosome, macropain) subunit, beta type, 2	1.7
			Hs.40782		2.6
2.5				DKFZP434B168 protein	2.1
35			Hs.87440		2.1
			Hs.42761		1.3
				hypothetical protein MGC5370	4.4 7.2
		N55669		KIAA0867 protein mitochondrial ribosomal protein L13	1.2
40			Hs.46679		5.5
-10			Hs.62767		9.8
			Hs.66493		1.4
		AL359053		Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 2005735	2.4
			Hs.28777		1.8
45		BE243834		CGI-04 protein	1.4
	116189	N35719	Hs.44749	ESTs, Moderately similar to T00358 hypothetical protein KIAA0684 [H.sapiens]	1.2
			Hs.72402		2.1
			Hs.47144		1.7
60				baculoviral IAP repeat-containing 6	1.7
50				hypothetical protein FLJ10808	1.7
		AI955411	Hs.94109	Homo saplens cDNA FLJ13634 fis, clone PLACE1011133 deleted in cancer 1; RNA helicase HDB/DICE1	1.9 4.9
			Hs.49303		1.4
		AL133033		KIAA1025 protein	1.9
55			Hs.44033		1.5
-				nuclear factor VC (CCAAT-binding transcription factor)	1.9
	116358	AI149586	Hs.38125	interferon-induced protein 75, 52kD	1.9
		N50174	Hs.46765	ESTs	6.1
	116368	N90466	Hs.71109	KIAA1229 protein	1.6
60	116417	AW499664	Hs.12484	Human done 23826 mRNA sequence	7.4
		AA161411		chromosome 21 open reading frame 57	2.1
	116462	AF218313	Hs.236828	putative helicase RUVBL	1.5
	116470	AI272141	HS.83484	SRY (sex determining region Y)-box 4	2.1
65	1164/0	Al272141 AA312572	He 6244	SRY (sex determining region Y)-box 4 phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)	1.2 1.5
U)		AK001043		integrin-linked kinase-associated serine/threonine phosphatase 2C	2.7
				B-cell CLI //wmphoma 7A	23

	116700	A1800202	Hs.317589		1.4
	116705	AW074819	Hs.12313	hypothesical protein FLJ14566	3.4
	116732	AW152225	Hs.165909	FSTs. Weakly similar to (38022 hypothetical protein [H.sapiens]	2.9
		AW068115		biglycan	8.3
5	116926	H73608	Hs.290830		1.7
	117034	U72209	Hs.180324		3.4
	117132	Al393666	Hs.42315		5.2
	117247	N21032		gb;yx46f06.s1 Soares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE:264803 3', mRNA se	quence. 5
	117276	N71183	Hs.121806		1.5 2.0
10	117284	AK001701	Hs.183779	Holio Sapietis CONA FED 10030 its, Conte 1412 d 200 1002; modely carried to	2.0 2.0
	117367	Al041793	Hs.42502	E313	2.0 2.1
	117368	A1878942	Hs.90336	A I F data for thing, i factorital (*constant protein partie); member o	2.7
	117382	AF150275	Hs.40173	E313	1.4
		N32536		Solute Calles latiny 10 (Horiocarboxy) to dela danaperator, mentos	3.4
15			Hs.44532	Old Market	3.4
		N34895	Hs.44648	E313	3.0
				CGI-12 protess	1.9
			MS.39/3/		1.8
20	11/8/9	N54706	Un 200022	hubento Indused transcript 1	5.7
20	11/001	AF101470	HS.200022	hypothetical protein MGC5370	5.9
	117904	AL 427270	NS.JJ2JJ0	hypothetical protein FLJ13912	1.7
		Y10518		hypothetical protein FLJ20048	1.7
	117093	AT 110246		KIAA1785 protein	5.4
25		N54321	Hs.47790	FST	5.2
23	118301	AA453902	Hs.293264	FSTs	2.6
	118429	AA243332	Hs.74649	cytochrome c oxidase subunit VIc	2.5
	118472	AL157545	Hs.42179	bromodomain and PHD finger containing, 3	4.1
30	118488	AJ277275	Hs 50102	rana-2 (rana gene)	1.2
	118509	N22617	Hs.43228	Homo sapiens cDNA FLJ11835 fis, done HEMBA1006595	1.5
	118528	AI949952	Hs.49397	ESTs	7.4 2.5
	118656	A1458020	Hs.293287	ESTS	1.2
	118670	AA332845	Hs.152618	ESTs, Moderately similar to ZN91_HUMAN ZINC FINGER PROTEIN 91 [H.sapiens]	2.1
25				KIAA1287 protein gb:zq75g09.r1 Stratagene hNT neuron (937233) Homo sapiens cDNA clone IMAGE:647488 5'	5.2
35		AA199686		go:zq/ogu9.r1 Stratagene not neuron (337233) from a saperis 2012 close in to 2013 to 10 september 2012 close in to 2013 to 10 september	
	118925	N92293	HS.200032	ESTS, Moderately similar to ALOG_TOWNN ALO SOCI AMILY SX SEQUENCE CONTAMINATION	3.6
	118984	A1008/09	NS.Z4U/ZZ	bladder cancer overexpressed protein	4.8
				B KIAA1710 protein	1.7
40		W24781 AW453069		activity-dependent neuroprotective protein	2.2
40		AW45306		activity-dependent neuroprotective prote	1.6
			Hs.285363		1.4
		N57568	Hs.48028		25.1
	110208	MM 0012	41Hs 155478	3 cyclin T2	1.6
45	119338	A1417240	Hs.320836	ESTs, Weakly similar to A47582 B-cell growth factor precursor [H.sapiens]	1.3
	119349	T65004	Hs.163561	I ESTs	8.4
	119403	AL117554	Hs.119908	3 nucleolar protein NOP5/NOP58	6.7
			Hs.170042		2.4
	119486	A1796730	Hs.55513		2.1
50	119513	W37933		Empirically selected from AFFX single probeset	1.9 3.7
	119601	AK00015	5 Hs.91684	Homo sapiens mRNA; cDNA DKFZp6671103 (from clone DKFZp6671103)	3.0
	119602	2 AW67529	8 Hs.23369	4 hypothetical protein FLJ11350	1.4
			7 Hs.57787		1.2
		W61019	Hs.57811		1.8
55		AB03297		KIAA1151 protein	3.1
	119780	) NM_0166	25Hs.19138	1 hypothetical protein	9.2
	119789	BE39394	HS.50915	kallikrein 5 (KLK5; KLK-12; stratum comeum tryptic enzyme) ESTs, Weakly similar to IEFS_HUMAN TRANSFORMATION-SENSITIVE PROTEIN IEF SSP	3.6
	119803	AJZZ3010	) MS.43213	hypothetical protein FLJ11101	2.5
<i>4</i> 0	119810	3 AA13U9/	U NS.30002	Homo sapiens cDNA FLJ14206 fis, clone NT2RP3003157	2.7
60	11988	5 ANUARON	υ πა.30000 Μ He 11057	1 collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)	2.6
	11990	7 AVY443UC	9 Hs.58963	ESTs	2.7
		2 W57554		9 lymphold nuclear protein (LAF-4) mRNA	1.2
		6 H26735		Homo sapiens clone PP1498 unknown mRNA	45.7
65	12024	8 AI924294	Hs.17325	9 uncharacterized bone marrow protein BM033	1.2
33	12025	3 AA13137	6 Hs.32640	11 fibroblast growth factor 12B	38.9
	12026	9 AW1319	10 Hs.10403	0 ESTs	9.6

	120274	AA177051		gb:nc02a02.s1 NCI_CGAP_Pr3 Homo saplens cDNA clone IMAGE:194 similar to contains Alu	4.6
	120280	AA190577		gb:zp52g02.s1 Stratagene HeLa cell s3 937216 Homo saplens cDNA clone 3', mRNA sequence	2.0
	120296	AW995911	Hs.299883	hypothetical protein FLJ23399	1.8
				ESTs, Weakly similar to Z195_HUMAN ZINC FINGER PROTEIN 195 [H.saplens]	15.2
5		AA195517			5.5
	120325	AA195651	Hs.104106	ESTs .	6.4
	120327	AK000292	Hs.278732	hypothetical protein FLJ20285	16.1
		N85785		eukaryotic translation elongation factor 1 alpha 1	2.9
				hypothetical protein DKFZp434I143	5.7
10	120345	AA210722	Hs.104158	ESTs.	4.5
	120349	AW969481	Hs.55189	hypothetical protein	16.8
		R06859		ESTs, Weakly similar to 138022 hypothetical protein [H.sapiens]	5.0
				putative purinergic receptor	28.1
•		AA219305			12.4
15		AA228026			4.0
	120383	AL109963	Hs.123122	FSH primary response (LRPR1, rat) homolog 1	9.7
				hypothetical protein DKFZp434D0127	32.6
	120388	AA232874	Hs.104245	ESTs	3.1
	120389	AW967985	Hs.325572	ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	121.7
20				eukaryotic translation initiation factor 4E	12.5
				KIAA1013 protein	7.2
				Homo sapiens mRNA; cDNA DKFZp586F1323 (from clone DKFZp586F1323)	11.4
				Homo sapiens cDNA: FLJ22822 fis, clone KAIA3968	1.9
		AI950087		gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapiens cDNA clone 3', mRNA sequence	19.4
25		AA251973	Hs.269988	ESTs	5.4
		AA253170			10.4
		AA256837		gb:zr84d10.s1 Soares_NhHMPu_S1 Homo sapiens cDNA done IMAGE:682387 3', mRNA sequen	ce. 3.9
		BE047718	Hs.96545		9.4
		AA258601			2.4
30		BE350244			2.5
				Homo sapiens, done IMAGE:3613029, mRNA, partial cds	5.2
				ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	14.4
				ZNF135-like protein	10.2
				leucine-rich repeat-containing 2	2.1
35				N-acetylglucosamine-phosphate mutase	7.5
		AW965339			2.5
				M-phase phosphoprotein homolog	52.0
		AA286942		gb:zs56f05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:701505 3' similar to contains	Alu2.4
	120648	AA287095	Hs.140309	Homo sapiens, clone IMAGE:3677194, mRNA, partial cds	5.0
40	120653	AW063659	Hs.191649	ESTs	2.2
	120668	AW969638	Hs.112318	6.2 kd protein	2.2
	120669	BE536739	Hs.109909	ESTS	1.9
		AA976503		gb:oq30a04.s1 NCt_CGAP_GC4 Homo sapiens cDNA clone 3' similar to contains PTR7.t1 PTR7	46.8
	120696	Al821539	Hs.97249		2.5
45	120713	AW449855	Hs.96557	Homo sapiens cDNA FLJ12727 fis, done NT2RP2000027	5.9
	120718	AA292747	Hs.97296	ESTs	2.9
	120750	Al191410	Hs.96693	ESTs, Moderately similar to 2109260A B cell growth factor [H.sapiens]	7.0
	120774	AI608909	Hs.193985	ESTs	7.8
	120807	AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848 protein	6.8
50	120809	AA346495		gb:EST52657 Fetal heart II Homo sapiens cDNA 3' end similar to EST containing O family repeat,	4.4
	120938	AA386260	Hs.104632	EST	4.4
	120977	AA398155	Hs.97600	ESTs	4.4
	120984	BE262951	Hs.99052	ESTs	5.6
		Al219896			1.2
55		AA398360			3.1
	121026	Al439713	Hs.165295	ESTs	3.5
•	121081	AA398721	Hs.186749	ESTs, Highly similar to 137550 mismatch repair protein MSH2 [H.sapiens]	5.4
	121133	AA363307	Hs.97032	ESTs	3.7
	121176	AL121523	Hs.97774	ESTs	1.7
60	121223	AI002110	Hs.97169	ESTs, Weakly similar to dJ667H12.2.1 [H.sapiens]	2.9
		AA403008			1.9
				Homo sapiens cDNA FLJ13383 fis, clone PLACE1001024	3.5
		AA406137			6.0
	121439	AA410190	Hs.98076	ESTs, Weakly similar to A47582 B-cell growth factor precursor [H.sapiens]	7.4
65	121450	AA406430	Hs.105362	Homo sapiens, clone MGC:18257, mRNA, complete cds	6.9
		AW971063			1.8
	121455	H58306	Hs. 15165	retinolc acid induced 14	10.5

	121457	W07404	Hs.144502	hypothetical protein FLJ22055	3.4
			Hs.97900		14.4
			Hs.194417		13.1
			Hs.97887		28.0
5			Hs.181510		6.2
,			113.101310	gb:zt69b02.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:727563 3', mRNA sequence	
		AA412112	11-00440		7.4
			Hs.98142	EDI	
		AA412497		gb:zt95g12.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:730150 3' similar to contail	2 5
10			Hs.98096	EST	3.5
10		AA416568		gb:zu05c10.s1 Soares_testis_NHT Homo sapiens cDNA done 3', mRNA sequence	6.1
	121589	AD001528	Hs.89718	spermine synthase	3.9
	121594	AA626010	Hs.98247	ESTs	2.2
	121622	AA416931	Hs.126065	ESTs .	4.2
	121655	AA421537	Hs.178072	Homo sapiens mRNA; cDNA DKFZp434B1023 (from clone DKFZp434B1023)	7.8
15				Homo sapiens cDNA FLJ13558 fis, clone PLACE1007743	2.0
			Hs.110286		4.7
		U55184		hypothetical protein FLJ11585	12.7
	121700	A A A 10225	He 08260	Homo sapiens cDNA FLJ11953 fis, done HEMBB1000883	8.1
	121720	A10/0507	Hs.98325	ECT.	1.8
20	121723	A A A D A D A A	Hs.180744	ECT-	4.0
20					7.1
			Hs.97514		19.5
	121748	BE536911	Hs.234545	hypothetical protein NUF2R	
				KIAA1196 protein	7.9
			Hs.161008		1.7
25				hypothetical protein FLJ22501	6.6
	121786	A1810774	Hs.98376	ESTs	10.5
	121832	AW340797	Hs.98434	ESTs	5.8
	121836	AA328348	Hs.218289	ESTs	3.8
	121839	AA425691	Hs.191606	ESTs, Highly similar to KIAA1048 protein [H.sapiens]	5.0
30	121842	AF027406	Hs.104865	serine/threonine kinase 23	2.7
		AA446628		cartilage linking protein 1	2.3
			Hs.293044		2.9
			Hs.98459		5.0
		AA427950		gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:773499 3'	7.2
35	121311	AA420470	De 22240E	ESTs, Moderately similar to A46010 X-linked retinopathy protein [H.sapiens]	2.5
22					2.3
			Hs.98611		3.4
				hypothetical protein FLJ14904	11.4
				Homo sapiens, clone IMAGE:2822295, mRNA, partial cds	3.8
40		AA210863		nemo-like kinase	
40			Hs.98668		6.4
				Homo sapiens cDNA: FLJ20863 fis, clone ADKA01804	2.2
	122013	AA431085	Hs.98706	ESTs	6.5
	122036	W92142	Hs.271963	ESTs, Weakly similar to ALU5_HUMAN ALU SUBFAMILY SC SEQUENCE CONTAMINATION	13.1
	122050	AI453076	Hs.166109	ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2	9.1
45			Hs.98750		13.1
			Hs.104921		1.5
		AA398838		gb:zt80d01.r1 Soares_testis_NHT Homo sapiens cDNA clone 5', mRNA sequence	3.3
			Hs.98842		5.6
				HCF-binding transcription factor Zhangfei	5.1
50			Hs.98899		5.6
20	400000	AA444004	Un 404047	ECTO	5.8
	122302	AA441001	Hs.104947	buneth elicet exetein EL 199963 similar to audeor receptor binding SET demain protein 1	2.0
	122341	AW601965	HS.99010	hypothetical protein FLJ22263 similar to nuclear receptor-binding SET-domain protein 1	7.3
	122356	AA443/94	Hs.98390	E515	12.2
	122369	AA443985	Hs.303222	ESIS	
55	122371	AA868555	Hs.178222	ESTS	5.0
	122372	AA446008	Hs.336677	EST	7.6
	122378	AB032948	Hs.21356	hypothetical protein DKFZp762K2015	2.5
	122405	AA446572	Hs.303223	EST	2.8
	122412	AA446869	Hs.119316	ESTs	7.3
60	122415	AA446918	Hs.99088	EST	1.9
-	122418	AA446966	Hs.99090	ESTs, Moderately similar to similar to KIAA0766 [H.sapiens]	6.8
	122440	AW505139	Hs.9460	Homo sapiens mRNA; cDNA DKFZp547C244 (from clone DKFZp547C244)	2.6
			Hs.99123		1.8
	400440	A A A A 7 C 7 C	Hs.99127	FST	3.5
65	122440	AIDECIEN	Hs.104980	FSTs	1.5
65	122400	AUNIAGO	He 001/10	ESTs, Weakly similar to S43569 R01H10.6 protein - Caenorhabditis elegans [C.elegans]	9.7
	122400	MYY4 10100	Hs 99152	EST	4.8

		AA448349			6.1	
	122492	AA448417	Hs.104990	ESTS	5.4	
				Homo sapiens cDNA FLJ12082 fis, clone HEMBB1002492	1.3	
_		AA449232			11.2 10.1	
5				adaptor-related protein complex 1, sigma 2 subunit	2.5	
		AA779725			1.9	
		AA194055			9.5	
		AA452578			11.0	
10	122072	AA452601	MS.99207	Homo sapiens cDNA FLJ11048 fis, clone PLACE10Q4516	3.4	
10					2.0	
		AB040893 Al028173		KIAA1460 protein	1.7	
					4.4	
		AA411925		hypothetical protein FLJ23588	4.6	
15		AA411925 AA453518			61.5	
13		AA453630			10.7	
		AA453638			107.3	
				serine/threonine kinase 33	121.4	
		AA453641		gb:zx48e06.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence	31.1	
20		AA453987			5.6	
		AA456859			8.5	
		A1376875			10.4	
	122829	AW204530	Hs.99500	ESTs	81.8	
	122834	AA461492	Hs.99545	Homo sapiens cDNA FLJ10658 fis, clone NT2RP2006052	3.6	
25	122836	AA460581	Hs.290996	ESTs	4.5	
				ESTs, Weakly similar to putative p150 [H.sapiens]	2.7	
		AA460584			75.3	
	122854	AA600235	Hs.9625	NIMA (never in mitosis gene a)-related kinase 6	7.7	
	122856	AI929374	Hs.75367	Src-like-adapter	5.8	
30	122861	AA335721	Hs.119394	ESTS FSTs	1.3	
		BE539656		ESTs	4.1	
	122868	AF005216	Hs.115541	Janus kinase 2 (a protein tyrosine kinase)	5.3	
				Homo sapiens cDNA: FLJ21766 fis, done COLF7179	9.9	
0.5		AW081394			5.3	
35		AA769410		ESTs	13.9 11.5	
		AA470074		ESIS	1.7	
		AA470140		ES1	5.0	
	122981	AA478951	MS. 100029	TAT.	15.4	
40	123013	AW968324	H\$.17304	ESTS Homo sapiens cDNA FLJ11946 fis, clone HEMBB1000709 ninein (GSK3B Interacting protein) ESTS, Weakly similar to KIAA1395 protein [H.sapiens]	2.8	
40	123010	ALGENETA	H5.323231	ninein (GSK3B interacting protein)	8.7	
	123034	WEGGGGG	H5.44034	ESTs, Weakly similar to KIAA1395 protein (H.sapiens)	8.8	
		AA485360		ECTs, Weakly Smiller to Niver 1950 process [ Listopicies]	3.9	
		AI343652			3.8	
45		AA486256			7.4	
43				myomegalin	2.8	
		T52027	Hs 271795	ESTs, Weakly similar to i38022 hypothetical protein [H.saplens]	2.4	
	123132	AI061582	Hs.324179	Homo sapiens cDNA FLJ12371 fis, clone MAMMA1002434	15.6	
	123136	AW451999	Hs.194024	ESTs	5.1	
50		Al734179			23.8	
• •	123152	AW601773	Hs 270259	FSTs .	5.2	
	123258	AA490929	Hs.105274	ESTS Weakly similar to RMS1 HI IMAN REGULATOR OF MITOTIC SPINDLE ASSEMBLY 1 IH.	sapiens)	9.3
	123315	AA496369		gb:zv37d10.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone IMAGE:755827 3' similar t	04.1	
	123369	AA504757	Hs.105738		6.9	
55	123394	AA731404	Hs.105510	ESTs	3.6	
	123433	AW450922	Hs.112478	ESTs	3.7	
	123466	AA599042	Hs.112503	EST	7.4	
	123470	AW303285	Hs.303632	Human DNA sequence from clone RP11-110H4 on chromosome 5 Contains a pseudogene simila	rto 3.5	
	123471	AB021644	Hs.197219	zinc finger protein 14 (KOX 6)	5.2	
60				Homo sapiens, clone IMAGE:4098694, mRNA, partial cds	1.7	
	123482	N95059	Hs.55098	ESTs	1.6	
	123486	BE019072	Hs.334802	Homo saplens cDNA FLJ14680 fis, clone NT2RP2004242, weakly similar to	2.4	
	123508	AW380388	Hs.155546	KIAA1080 protein; Golgi-associated, gamma-adaptin ear containing, ARF-binding protein 2	2.2	
CE		AA609170		gb:af12a12.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence	7.8 2.8	
65		AA602964		gb:no97c02.s1 NCI_CGAP_P/2 Homo sapiens cDNA clone, mRNA sequence gb:zu71d09.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:743441 3' similar to contail	ne Alu	1.7
		AA609364		90-201 (003.51 508fes_testis_NT1 Florito sapiens conva done invoce 4044 1 0 similar to contail	5.7	
	1230/4	MIZ09009	NS. 100 10/	kinesin protein 9 gene	J.,	

	123735	NM 01324	iHs.95231	FH1/FH2 domain-containing protein	10.0	
		AA609891			5.2	
	123753	AA609955	Hs.234961	Huntingtin interacting protein E	30.6	
	123804	AA620464	Hs.261915	EST. Weakly similar to \$65657 alpha-1C-adrenergic receptor splice form 2 [H.sapiens]	2.1	
5		AA620586		gb:ae60g05.s1 Stratagene lung carcinoma 937218 Homo sapiens cDNA clone IMAGE:951320 3'	2.7	
-				metastasis-associated 1-like 1	6.2	
				choline dehydrogenase .	4.4	
				ralA binding protein 1	7.0	
		AI147155			8.1	
10				HIV-1 rev binding protein 2	3.7	
				topolsomerase-related function protein 4-2	1.2	
				putative G protein-coupled receptor	3.1	
	124203	AA372796	Hs.269339	ESTs, Weakly similar to AF161356 1 HSPC093 [H.sapiens]	5.7	
		AA640891			3.1	
15				KIAA0265 protein	3.5	
		A1267847		gb:aq49a10.x1 Stanley Frontal NB pool 2 Homo sapiens cDNA clone similar to contains	57.1	
		AA317338	Hs.7535	COBW-like protein	2.8	
				NY-REN-18 antigen	7.1	
		N34059		gb:yv28h09.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 3' similar to contains A	lu 3.3	
20	124428	H13540	Hs.82202	ribosomal protein L17	2.9	
	124440	AA532519	Hs.129043	Human DNA sequence from clone 989H11 on chromosome 22q13.1-13.2. Contains part of a	7.8	
		R10084		kinesin heavy chain member 2	2.6	
		N53935		gb:yv59d09.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 3', mRNA sequence	7.9	
			Hs.268997		7.8	
25		AA669097			3.3	
		N71076	Hs.102800	ESTs, Weakly similar to neuronal thread protein AD7c-NTP [H.sapiens]	4.5	
				FLVCR protein	3.2	
	124634	AI765123	Hs.143671	Homo sapiens cDNA FLJ13533 fis, clone PLACE1006371	5.8	
				hypothetical protein	9.3	
30				sorting nexin 17	3.5	
• •		N92593	Hs.313054		6.1	
		AW297702			8.3	
	124661	R48170	Hs.78436	EphB1	5.6	
	124683	AA381661	Hs.119878	ESTs, Weakly similar to M3K9_HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE	7.9	
35		R09166			5.7	
		R22952			11.3	
				Homo sapiens mRNA for KIAA1771 protein, partial cds	9.0	
		AW368528			8.1	
	124775	D/1772	He 100878	FSTe	4.9	
40	124777	R41933	Hs.140237	ESTS, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE Homo sapiens cDNA: FLJ22726 fis, clone HSi15005	2.8	
. •	124788	R43543	Hs.100912	Homo sapiens cDNA: FLJ22726 fis. clone HSI15005	5.1	
	124809	AL355722	Hs.106875	Homo sapiens EST from clone 35214, full insert	4.2	
				hypothetical protein FLJ22604	14.2	
	124812	R47948	Hs.188732		7.9	
45	124822	AA418160	Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PLACE1007743	6.6	
		AA501669			2.3	
		AW975868			2.7	
		R63652			2.3	
		R65763			23.9	
50	124863	Al382555	Hs.127950	bromodomain-containing 1	2.0	
• •	124876	AF135422	Hs.27059	GDP-mannose pyrophosphorylase A	4.4	
	124878	BE397530	Hs.288057	hypothetical protein FLJ22242	2.7	
		H37941	Hs.101883		5.7	
	124903	AW296713	Hs.221441	ESTs	32.4	
55	124930	AI076343	Hs.173939	ESTs, Weakly similar to ALUB_HUMAN !!!! ALU CLASS B WARNING ENTRY !!! [H.sapiens]	22.8	
-	124942	R99978	Hs.268892	ESTs, Moderately similar to B34087 hypothetical protein [H.sapiens]	6.1	
		A1078645	Hs.431	murine leukemia viral (bmi-1) oncogene homolog	1.9	
		T40841	Hs.98681		4.5	
		T59338	Hs.269463	ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	4.9	
60		179815	Hs.279793		5.0	
		T79956	Hs.100588		135.3	
		T81310	Hs.100592		5.4	
		A1472068	Hs.286236	KIAA1856 protein	5.6	
		T96595	Hs.302270	ESTs, Weakly similar to ALUF_HUMAN IIII ALU CLASS F WARNING ENTRY III [H.sapiens]	1.8	
65		T97341		ob:ve57e05.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:121856 3' sim	llar to	9.
		Al222382	Hs.240767	Human DNA sequence from done RP1-12G14 on chromosome 6q24.1-25.2. Contains the 5' end	of the gene	1.
		14/20150		Employeethy solocted from AFEX simple proheset	17	

		W44657	Hs.144232		10.7
	125249	AA630863	Hs.131375	ESTs, Moderately similar to ALUB_HUMAN IIII ALU CLASS B WARNING ENTRY III [H.sapiens]	1.3
	125255	AF098162	Hs.118631	timeless (Drosophila) homolog	9.4
_		AW401809		KIAA1150 protein	1.5
5			Hs.106932		8.0
	125298	AW972542	Hs.289008	Homo sapiens cDNA: FLJ21814 fis, clone HEP01068	1.5
	125660	AW292171	Hs.23978	scaffold attachment factor B	5.9
	125827	NM_00340	3Hs.97496	YY1 transcription factor	1.2
10		U29589	Hs.7138	cholinergic receptor, muscarinic 3	6.4
10	126005	AW409701	Hs.1578	baculoviral IAP repeat-containing 5 (survivin)	14.3
	126202	AA157632	Hs.272630	vacuolar proton pump delta polypeptide	2.4
	126695	AA643322	Hs.172028	a disintegrin and metalloproteinase domain 10	9.1
				CGI-89 protein	17.0
1.5				Homo sapiens cDNA FLJ12789 fis, clone NT2RP2001947	12.8
15			Hs.161623		7.3
				KIAA0276 protein	3.1
		D87466	Hs.240112	KIAA0276 protein	1.3
	128522	BE173977	Hs.10098	putative nucleolar RNA helicase	9.4
20			Hs.101047	transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47)	1.5
20		R39234	Hs.251699	ESTs, Weakly similar to IDN4-GGTR14 [H.sapiens]	2.8
		U31875		short-chain alcohol dehydrogenase family member	12.1
				Rho GTPase activating protein 8	2.3
	128604	AI879099	Hs.102397	GIOT-3 for gonadotropin inducible transcription repressor-3	1.3
25				zinc finger protein	7.1
25				hypothetical protein ASH1 .	1.3
	128629	AL096748	Hs.102708	DKFZP434A043 protein	3.2
				CGI-47 protein	2.0
				coatomer protein complex, subunit epsilon	1.4
30				coatomer protein complex, subunit epsilo	1.3
30				diptheria toxin resistance protein required for diphthamide biosynthesis (Saccharomyces)-like 2	2.4
				Homo sapiens, Similar to RIKEN cDNA 1700010L19 gene, clone MGC:16214, mRNA, complete of	
		W27939		hypothetical protein MGC5576	7.7
				nuclear receptor coactivator 3	3.8
35		Y15221 T85231		small Inducible cytokine subfamily B (Cys-X-Cys), member 11	1.6
<i>J J</i>	120714	100201 AVA04EE4	Ha 104222	tubulin, beta 5 hypothetical protein FLJ10702	7.6 5.5
					2.7
				ESTs, Moderately similar to 138022 hypothetical protein [H.sapiens] RP42 homolog	2.8
				proteasome (prosome, macropain) subunit, alpha type, 4	4.4
40				actin related protein 2/3 complex, subunit 4 (20 kD)	2.2
70				PDZ-binding kinase; T-cell originated protein kinase	2.8
				thymidine kinase 1, soluble	5.3
				small nuclear ribonucleoprotein polypeptide F	53.9
				stem cell growth factor; lymphocyte secreted C-type lectin	13.3
45				RD RNA-binding protein	2.6
15				nuclear prelamin A recognition factor	2.2
				valosin-containing protein	5.9
	128835	AK001731	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586H0924 (from clone DKFZp586H0924)	1.6
	128854	BE159181	Hs.168232	hypothetical protein FLJ 13855	2.2
50	128854	BE159181	Hs.168232	hypothetical protein FLJ13855	1.9
-	128868	AA419008	Hs.106730	chromosome 22 open reading frame 3	3.0
				chromosome 22 open reading frame 3	2.2
	128871	AF189723	Hs.106778	ATPase, Ca++ transporting, type 2C, member 1	1.5
	128891	F34856	Hs.292457	Homo sapiens, clone MGC:16362, mRNA, complete cds	13.3
55		R57988	Hs.10706	epithelial protein lost in neoplasm beta	4.7
				programmed cell death 5	1.4
		R67419		Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321	1.9
		Y13153		kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	7.2
		AA009647		a disintegrin and metalloproteinase domain 12 (meltrin alpha) (ADAM-12)	2.4
60				hypothetical protein DKFZp434N035	1.3
-				hypothetical protein FLJ11200	10.9
			Hs.107418		1.4
			Hs.165028		1.3
				NICE-5 protein	14.0
65				Homo sapiens cDNA FLJ14028 fis, clone HEMBA1003838	1.6
			Hs.107747	DKFZP566C243 protein	1.9
	129019	A1950087		gb.wq05c02.x1 NCI_CGAP_Kid12 Homo saplens cDNA clone 3', mRNA sequence	2.9

	129021	AL044675	Hs.173081	KIAA0530 protein	3.8
			Hs.173081	KIAA0530 protein	2.5
		R80088	Hs.108104	ubiquitin-conjugating enzyme E2L 3	3.4
~	129076	AW296806	Hs.326234	ESTs, Highly similar to T46422 hypothetical protein DKFZp434M2023.1 [H.sapiens]	5.0
5	129078	AI351010	Hs.102267	lysosomal	2.1
		AA744610			17.
	129095	L12350	HS.108623	thrombospondin 2	2.7
	120007	AA463189	HS.288906	WW Domain-Containing Gene	20.9
10	120000	0E243933	He 100042	zinc finger protein 22 (KOX 15) ATP-binding cassette, sub-family C (CFTR/MRP), member 5	3.0
10	120033	W93048		hypothetical protein MGC2747	5.8 5.9
				KIAA0050 gene product	6.3
				hypothetical protein PRO2577	1.8
		AA286914			2.1
15	129194	AA150797	Hs.109276	latexin protein	3.2
	129198	N57532	Hs.109315	KIAA1415 protein	5.8
	129207	AI934365	Hs.109439	osteoglycin (osteoinductive factor, mimecan)	8.0
	129228	U40714	Hs.239307	tyrosyl-tRNA synthetase	2.9
00	129229	AF013758	Hs.109643	polyadenylate binding protein-interacting protein 1	3.2
20	129254	AA252468	Hs.1098	DKFZp434J1813 protein	2.6
	129255	A1961727		H1 histone family, member X	7.3
		W26392		ESTs, Weakly similar to S13495 pregnancy zone protein [H.sapiens]	9.6
		AI051967			1.2
25		AA287239 H75334		Homo sapiens cDNA FLJ11311 fis, clone PLACE1010102	5.1 4.6
23			He 270860	F-box only protein 9 melanoma-associated antigen recognised by cytotoxic T lymphocytes	4.6 7.6
	129362	U30246		solute carrier family 12 (sodium/potassium/chloride transporters), member 2	6.7
				Homo sapiens done 23785 mRNA sequence	8.6
				SAR1 protein	1.4
30				CGI-99 protein	2.0
	129403	AF149785	Hs.111126	pituitary turnor-transforming 1 interacting protein	7.4
	129404	AI267700	Hs.317584	ESTs	5.0
		Al267700			2.5
25	129423	AA204686	Hs.234149	hypothetical protein FLJ20647	10.2
35	129449	Al096988	Hs.111554	ADP-ribosylation factor-like 7	8.0
				Lsm3 protein	3.2
		AA188185			6.7
		AA188185			3.6 7.1
40				hypothetical protein AL110115 membrane-associated nucleic acid binding protein	2.5
70				delta-tubulin	3.2
		W01296		hypothetical protein FLJ14784	7.5
	129560	AA317841	Hs.7845	hypothetical protein MGC2752	6.8
	129570	AI923097	Hs.11441	chromosome 1 open reading frame 8	2.0
45	129575	F08282		progestin induced protein	1.6
		H14718		Human done 23589 mRNA sequence	6.8
	129588	BE408300		postmeiotic segregation increased 2-like 9	1.4
		N57423	Hs.179898	HSPC055 protein	7.3
۲0	129594	AW403724	Hs.36989	coagulation factor VII (serum prothrombin conversion accelerator)	9.0
50·				REV3 (yeast homolog)-like, catalytic subunit of DNA polymerase zeta	1.6
		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)	2.2
	129020	U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	1.4
	129025	AD000092	Ue 16/00	hypothetical protein FLJ20391	3.8
55				KIAA0440 protein	3.3 13.4
55		U03749	J. 10. 17 Z 100	gb:Human chromogranin A (CHGA) gene, promoter an	14.1
		AW748482	Hs.77873	B7 homolog 3	2.6
				ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens]	7.4
	129720	AA156214	Hs.12152	APMCF1 protein	2.0
60	129721	NM_001415	5Hs.211539	eukaryotic translation initiation factor 2, subunit 3 (gamma, 52kD)	1.7
	129726	H15474	Hs.132898	fatty acid desaturase 1	8.3
		AK001676		hypothetical protein FLJ10814	1.8
		AA394090		Homo sapiens clone 23870 mRNA sequence	5.4
65		AF052112			1.7
65	129800	MDUZ3148	HS. 1/33/3	KIAA0931 protein	1.2
				hypothetical protein FLJ21657 SnRNP assembly defective 1 homolog	3.1 1.8
	125040	THE WOODS	v: 13. 14ULU	VILLAT GOOGLESV OFFICIAL FORESKE	1 8

	129861	AL049999	Hs.85963	DKFZP564M182 protein	2.2
	129864	Al393237	Hs.129914		1.7
	129869	A1222069	Hs.13015	hypothetical protein similar to mouse Dnajl1	2.7
_	129922	AF042379	Hs.13386	gamma-tubulin complex protein 2	4.5
5	129945	BE514376	Hs.165998	PAI-1 mRNA-binding protein	1.8
	129953	AA412195	Hs.13740	ESTs	2.5
	129972	AW753185	Hs.180628	dynamin 1-like	1.8
	129983	U09848			1.3
	129989	AB015856	Hs.247433	activating transcription factor 6	4.0
10	130010	AA301116	Hs.142838		1.6
	130081	AA287325	Hs.14713		4.0
	130082	S73265	Hs.1473	gastrin-releasing peptide	1.8
	130097	AL046962	Hs.14845	forkhead box O3A	2.8
	130100	AL135561	Hs.14891	hypothetical protein FLJ21047	2.3
15		X53002	Hs.149846	Integrin, beta 5	2.3
	130112	AA916785	Hs.180610		3.0
	130112	AA916785	Hs.180610	splicing factor proline/glutamine rich (	2.1
	130128				1.8
••	130135	AA311426	Hs.21635	tubulin, gamma 1	6.1
20	130211	NM_003358	Hs.23703	ESTs, Moderately similar to CEGT_HUMAN CERAMIDE GLUCOSYLTRANSFERASE [H.sapiens]	1.6
	130212	D80001	Hs.152629	KIAA0179 protein	1.3
		R85367	Hs.51957		2.0
	130241	AL035588	Hs.153203	MyoD family inhibitor	3.2
:	130242	X79201	Hs.153221	synovial sarcoma, translocated to X chromosome	5.4
25	130249	D81983	Hs.322852		4.8
	130263	NM_002497	Hs.153704	NIMA (never in mitosis gene a)-related kinase 2	1.4
	130287	AA479005	Hs.154036	tumor suppressing subtransferable candidate 3	2.6
	130310	AB011121	Hs.154248	amyotrophic lateral scierosis 2 (juvenile) chromosome region, candidate 3	6.3
	130353				6.2
30	130356	AF127577	Hs.155017		2.4
	130357	AJ224442	Hs.155020		3.4
					8.5
		AL135301			1.4
25		A1077464			3.3
35					1.8
	130399	AW374106	Hs.155356		3.4
	130407	BE385099	Hs.334727		2.3
					2.7
40					1.8
40					2.3
					3.9
					33.6
					4.6
15					2.7
45					5.0
					4.3
					1.6
					16.1
50			Hs.1584		6.1
50	130511		Hs.1584		5.3
		AW876523			2.1
	130542				7.8
		AA321238			1.5
E E					14.4
55		Al907018			4.7
		AA383092			7.9
		AA232119			3.3
		AF083208			1.2
۲۸		AB007891			5.6
60		AL042210			1.4
		AA609738			1.5
		AI354355			1.3
			Hs.1674		12.1
65			Hs.1674		2.4 15.9
UJ		AA383439 BE246961			13.9
		AL048842			1.5
	130074	ALUTUUTZ	113.137013	(ATT CAN I	4.0

	130675	AA442233	Hs.17731	hypothetical protein FLJ12892	5.4
	130692	AA652501	Hs.13561	hypothetical protein MGC4692	5.0
		R68537	Hs.17962	ESTs	2.0
~	130712	AJ271881	Hs.279762	bromodomain-containing 7	1.8
5	130714	Al348274	Hs.18212	DNA segment on chromosome X (unique) 9879 expressed sequence	2.0
			Hs.18586	KIAA0451 gene product	3.7
		H59696	Hs.18747		3.1
	130751	AF052105	Hs.18879	chromosome 12 open reading frame	1.4
10	130757	AL036067	Hs.18925	protein x 0001	5.7
10	130768	AF258627	Hs.211562	ATP-binding cassette, sub-family A (ABC1), member 1	5.1
		AK000355		sirtuin (silent mating type information regulation 2, S.cerevisiae, homolog) 5	5.2
			Hs.19822		1.5
		J05068	Hs.2012	transcobalamin I (vitamin B12 binding protein, R binder family)	15
15	130041	AL 13/400	Hs.20183	Homo sapiens cDNA FLJ20848 fis, done ADKA01732	2.8
13		U76248	Hs.20191		1.5
•				seven in absentia (Drosophila) homolog 2 putative DNA/chromatin binding motif	3.4
	130861	NM 01657	'AHs 20500	HBV pX associated protein-8	1.7
	130879	NM_00341	6Hs 2076	zinc finger protein 7 (KOX 4, clone HF.16)	1.9
20			Hs.20830		1.4
			Hs.20993		2.1 2.4
	130898	AB033078	Hs.186613	sphingosine-1-phosphate lyase 1	1.7
	130911	BE409769	Hs.21189	DnaJ (Hsp40) homolog, subfamily A, member 2	1.8
		N79110	Hs.21276	collagen, type IV, alpha 3 (Goodpasture antigen) binding protein	2.3
25	130944	BE382657	Hs.21486	signal transducer and activator of transcription 1, 91kD	5.4
	130971	N39842	Hs.301444	KIAA1673	2.2
			Hs.74316		1.8
	130993		Hs.21929	ESTs	1.6
20		AV658308		thyroid hormone receptor interactor 3	1.6
30		AI879165	Hs.2227	CCAAT/enhancer binding protein (C/EBP), gamma	1.2
	131042	A1826288	HS.1/163/	hypothetical protein MGC2628	1.6
		AA321649		small inducible cytokine subfamily 8 (Cys-X-Cys), member 10	7.4
		AA321649 H23230	Hs.22481	small inducible cytokine subfamily B (Cy	3.0
35			Hs.22564		1.7
<i></i>		AA194422		myosin VI myosin VI	5.1
	131070		Hs.22607	ESTs	2.5
		AA749230		dolichyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1 (	7. <b>1</b> 2.0
		AA749230		dolichyl-phosphate (UDP-N-acetylglucosam	1.9
40	131099	AL133353	Hs.226581	COX15 (yeast) homolog, cytochrome c oxidase assembly protein	7.0
	131174	NM_00654	0Hs.29131	nuclear receptor coactivator 2	1.9
	131185	BE280074	Hs.23960	cyclin B1	5.8
			Hs.24210		2.0
4.5			Hs.24332		7.0
45	131225		Hs.31659	thyroid hormone receptor-associated protein, 95-kD subunit	7.5
	131231		Hs.59757	zinc finger protein 281	2.9
	131233	D89053	Hs.268012	fatty-acid-Coenzyme A ligase, long-chain 3	3.5
	131243	AW383256	HS.24752	spectrin SH3 domain binding protein 1	2.8
50	131245	ALU800080	HS.24/66	Unioredoxin domain-containing	2.8
30	131247	ALU43100	HS.320190	fatty acid amlde hydrolase	5.6
	131283		Hs.25227		5.7
		AVESEN17	He 19/225	Homo saplens clone F19374 APO E-C2 gene cluster CGI-76 protein	1.3
	131300	A 4505691	Hs 145696	splicing factor (CC1.3)	5.0
55	131339	AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	1.8
,	131339	AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6 2.6
	131375	AW293165	Hs.143134	ESTs	
	131390	BE269388	Hs.182698	mitochondrial ribosomal protein L20	5.4 5.3
	131410	BE259110	Hs.279836	HSPC166 protein	2.2
50	131412	NM_012247	7Hs.124027	SELENOPHOSPHATE SYNTHETASE; Human selenium donor protein	2.0
	131429	AL046302	Hs.26750	hypothetical protein FLJ21908	1.4
		BE297567		hypothetical protein FLJ20392	1.7
		AA992841		KIAA1458 protein	2.0
c <b>c</b>		AV661958		GK001 protein	2.6
55		AV661958		GK001 protein	1.6
		AA732153		Homo sapiens cDNA: FLJ21333 fis, clone COL02535	2.0
	131020	AU076408	ms.20309	UDP-glucose dehydrogenase	16

	131533	BE268278	He 38303	hypothetical protein MGC2592	7.4
		AW966881		programmed cell death 2	2.2
	131544	AL355715	Hs.28555	programmed cell death 9 (PDCD9)	2.1
	131562	NM_003512	2Hs.28777	H2A histone family, member L	1.7
5		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PLACE1004405	5.1
•		T93500			
			Hs.28792		1.8
	131569	AL389951	Hs.271623	nucleoporin 50kD	5.0
	131618	BE393822	Hs.29645	Homo saplens mRNA; cDNA DKFZp761C029 (from clone DKFZp761C029); partial cds	1.8
		R78195	Hs.29692	Homo saplens cDNA FLJ11436 fis, clone HEMBA1001213	1.3
10					
IV		AB037791		hypothelical protein FLJ 10980	2.2
	131623	AB037791	Hs.29716	hypothetical protein FLJ10980	1.9
	131643	AW410601	Hs.30026	HSPC182 protein	2.9
	131653	AW960597	He 30164	ESTs	1.3
1.5		Al218918		KIAA0854 protein	2.8
15		X52486	Hs.3041	uracil-DNA glycosylase 2	2.8
	131692	BE559681	Hs.30736	KIAA0124 protein	5.6
	131714	AA642831	Hs 31016	putative DNA binding protein	2.9
		D13757			3.4
			Hs.311	phosphoribosyl pyrophosphate amidotransferase	
••	131/3/	AK001641	Hs.31323	inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein	3.8
20	131760	X76732	Hs.3164	nucleobindin 2	2.9
	131760	X76732	Hs.3164	nucleobindin 2	2.8
		AI878932		topoisomerase (DNA) I	3.4
				KIAA0948 protein	25.5
	131774	BE267158	Hs.169474	DKFZP586J0119 protein	5.5
25	131787	D87077	Hs 196275	KIAA0240 protein	2.4
				Homo sapiens cDNA FLJ14656 fis, clone NT2RP2002439	7.9
		BE501849		high-mobility group 208	1.4
	131798	X86098	Hs.301449	adenovirus 5 E1A binding protein	4.1
	131817	U20536	Hs.3280	caspase 6, apoptosis-related cysteine protease	4.2
30		U28838	Hs.32935	TATA box binding protein (TBP)-associated factor, RNA polymerase III, GTF3B subunit 2	3.5
-		AI251317		ESTs	5.1
		AA083764		hypothetical protein MGC3178	5.8
	131885	BE502341	Hs.3402	ESTs	13.7
	131885	BE502341	Hs.3402	ESTs .	2.4
35		W17064		SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member	
55					8.7
				Homo sapiens, done MGC:15961, mRNA, complete cds	
				Homo saplens, clone MGC:15961, mRNA, com	2.0
	131904	AF078866	Hs.284296	Homo sapiens cDNA: FLJ22993 fis, done KAT11914	5.5
		AA179298		stomatin-like 2	11.3
40				degenerative spermatocyte (homolog Drosophila; lipid desaturase)	1.7
70					
		AA025976		ESTs .	5.2
	131925	AF151048	Hs.183180	anaphase promoting complex subunit 11 (yeast APC11 homolog)	2.7
	131929	BE541211	Hs.34804	Homo sapiens cDNA FLJ11472 fis, clone HEMBA1001711	5.3
		BE252983		ubiquitin specific protease 1	2.3
45					
40		AA355113		x 001 protein	1.5
	131962	AKUUU046	Hs.267448	hypothetical protein FLJ20039	2.3
	131965	W79283	Hs.35962	ESTS	1.4
	131971	BE567100	Hs 154938	hypothetical protein MDS025	3.5
		U90441	Hs.3622	procollagen-profine, 2-oxoglutarate 4-dioxygenase (profine 4-hydroxylase), alpha polypeptide II	6.5
50					
50		AA503020		hypothetical protein FLJ22418	2.4
	131991	AF053306	Hs.36708	budding uninhibited by benzimidazoles 1 (yeast homolog), beta	2.1
	132019	H56995	Hs.37372	Homo sapiens DNA binding peptide mRNA, partial cds	3.2
		AF193844		COP9 complex subunit 7a	5.8
~ ~		BE266155		clathrin-associated protein AP47	1.5
55	132084	NM_002267	7Hs.3886	karyopherin alpha 3 (importin alpha 4)	3.7
	132103	BE171921	Hs.3991	ESTs	1.4
		AV646076		ESTs	5.8
		AW960474		ESTs .	1.7
		AA857025		kinesin-like 1	3.3
60	132180	NM_004460	0Hs.418	fibroblast activation protein, alpha	14.7
		AA206153		mitochondrial ribosomal protein L37	5.5
		R42432	Hs.4212		
	132 134	1142492 1114 00470		ESTs .	4.4
	132203	NM_00478	zHs.194714	synaptosomal-associated protein, 29kD	2.2
	132207	BE206939	Hs.42287	E2F transcription factor 6	2.2
65	132235	AV658411	Hs.42656	KIAA1681 protein	7.8
				KIAA0781 protein	1.5
				Homo sapiens CDNA: FL J21550 fis. clone COI 06258	1.3
	1.1/444	~1111111111111111111111111111111111111	113.141203	CRAIN SQUIEUS CLUMA: PLAZACIA US. CRUMA A RUM ZON	4.3

	132266	AA301228	Hs.43299	hypothetical protein FLJ12890	5.7
				DKFZP586L151 protein	4.2
				hypothetical protein FLJ13089	2.1
		N36110		solute carrier family 2 (facilitated glucose transporter), member 10	1.5
5	132294	AB023191	Hs.44131	KIAA0974 protein	10.0
_	132298	NM_015986	6Hs.7120	cytokine receptor-like molecule 9	1.9
		AW405882		corfistatin	9.2
		N37065	Hs.44856		2.0
				heterogeneous nuclear ribonucleoprotein D-like	6.5
10		AW572805		ESTs	3.8
		AF155582			1.5
		Al279892			12.5
		AA312135			28.3
		AL135094			1.9
15		AA100012			1.9
				mitochondrial ribosomal protein S14	6.1
		AB011084			1.7
		AW169847			8.6
	132470	Al224456	Hs.4934	H.sapiens polyA site DNA	5.2
20	132484	X16660	Hs.119007	RAB4, member RAS oncogene family	1.4
	132518	AW885606		ESTs	6.1
	132528	T78736	Hs.50758	SMC4 (structural maintenance of chromosomes 4, yeast)-like 1	3.3
	132530	AA306105	Hs.50785	SEC22, vesicle trafficking protein (S. cerevisiae) like 1	2.0
		AA454132		mitochondrial ribosomal protein L16	2.9
25	132534	BE388673	Hs.5086	hypothetical protein MGC10433	2.2
	132543	BE568452	Hs.5101	protein regulator of cytokinesls 1	7.3
		AW674699		suppressor of G2 allele of SKP1, S. cerevislae, homolog of	1.7
		AW631437		TH1 drosophila homolog	7.1
	132596	AK001484	Hs.5298	CGI-45 protein	2.2
30	132611	AA345547	Hs.53263	hypothetical protein FLJ13287	2.2
	132612	H12751	Hs.5327	PRO1914 protein	6.8
	132616	BE262677	Hs.283558	hypothetical protein PRO1855	14.0
	132638	A1796870	Hs.54277	DNA segment on chromosome X (unique) 9928 expressed sequence	11.4
	132648	U51127	Hs.54434		1.9
35		AB018319		KIAA0776 protein	2.6
	132692	AW191962	Hs.249239	collagen, type VIII, alpha 2	2.0
	132715	F11875	Hs.5534	Homo sapiens cDNA FLJ12961 fis, clone NT2RP2005645	1.5
	132718	NM_004600	Hs.554	Sjogren syndrome antigen A2 (60kD, ribonucleoprotein autoantigen SS-A/Ro)	3.0
		AI142265			2.4
40	132731	AI189075	Hs.301872	hypothetical protein MGC4840	12.4
		AA010233			14.6
		AA125985	Hs.56145	thymosin, beta, Identified in neuroblastoma cells	2.7
			Hs.56407		3.0
				KIAA0493 protein	2.3
45		Al142133		GDP dissociation Inhibitor 2	1.8
		AI026701		KIAA0310 gene product	3.7
				mutl. (E. coli) homolog 1 (colon cancer, nonpolyposis type 2)	1.8
		AB007944		KIAA0475 gene product	5.9
<b>50</b>		BE313625			8.7
50		AI815189			6.4
	132817	N27852	Hs.57553	tousled-like kinase 2	3.6
				CD44 antigen (homing function and Indian blood group system)	2.8
			Hs.57783		14.6
				Homo sapiens clone PP1596 unknown mRNA	1.6
55			Hs.5811	chromosome 21 open reading frame 59	2.5
				lectin, mannose-binding, 1	1.4
				RAB10, member RAS oncogene family	4.2
				ESTs, Moderately similar to AF116721 89 PRO2168 [H.sapiens]	2.8
<i>6</i> 0		AW007683		KIAA1266 protein	2.0
60		NM_004850		Rho-associated, coiled-coil containing protein kinase 2	1.6
		BE267143		U2(RNU2) small nuclear RNA auxillary factor 1 (non-standard symbol)	1.4
		AW503667		ring finger protein 15	5.4
		AI936442		hypothetical protein FLJ10808	6.1
65				Homo sapiens cDNA FLJ11095 fis, clone PLACE1005374	7.1
UJ			Hs.60257	Homo sapiens cDNA FLJ13598 fis, clone PLACE1009921	2.8
				Homo sapiens mRNA for KIAA1724 protein, partial cds tryoofhetical protein FLJ13222	6.1 10.3
	132341	MO 17 100	ris.DIZU	HYDOURGED DICKER FLJ 13222	103

	132942	AA554458	Hs.197751	KIAA0666 protein	1.8
	132952	A1658580	Hs.61426	Homo sapiens mesenchymal stem cell prolein OSC96 mRNA, partial cds	2.2
	132962	AA576635	Hs.6153	CGI-48 protein	4.9
				Homo sapiens cDNA FLJ11392 fis, clone HEMBA1000575	2.7
5			Hs.323277		5.3
•	132977	AA093322	He 301404	RNA binding motif protein 3	3.2
	132080	AA040606	Hs.62016	ESTs	1.3
				clone HQ0310 PRO0310p1	3.0
10	100012	AA847843	MS.62/11	Homo sapiens, clone IMAGE:3351295, mRNA	10.3
10	133015	AJ002744	Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GalNAc-T	
		AI439688		hypothetical protein FLJ20886	1.3
	133053	AI065016	Hs.6390	Homo sapiens done FLB3344 PRO0845 mRNA, complete cds	6.0
	133062	AW500374	Hs.64056	PRO0149 protein	5.3
	133069	BE247441	Hs.6430	protein with polyglutamine repeat; calcium (ca2+) homeostasis endoplasmic reticulum protein	4.9
15	133091	AK001628	Hs.64691	KIAAO483 protein	3.5
		AA808177		ESTs	13.1
			Hs.65648		1.3
		H94227	Hs.6592	Homo sapiens, clone IMAGE:2961368, mRNA, partial cds	2.2
		Z11695		mitogen-activated protein kinase 1	1.3
20					17.1
20				hypothetical protein MGC2745	
				ESTs, Weakly similar to S19560 proline-rich protein MP4 - mouse [M.musculus]	1.8
		X97795	Hs.66718		4.9
				hypothetical protein FLJ20671	3.1
		AI801777		ESTS	4.4
25	133226	AW954569	Hs.296287	Homo saptens, Similar to bromodomain-containing 4, clone IMAGE:3542455, mRNA, partial cds	1.7
		AI492924		golgi phosphoprotein 1	6.0
				ADP-ribosylation factor-like 1	1.5
				Homo sapiens, clone IMAGE:3544662, mRNA, partial cds	1.4
			Hs.69233		5.6
30				ESTs, Weakly similar to FXD2_HUMAN FORKHEAD BOX PROTEIN D2 [H.sapiens]	1.9
50		M76477	He 280082	GM2 ganglioside activator protein	4.7
		DE307956	Un CODE	NIDAC enlated acco	5.0
				NRAS-related gene	
		AA102670		gamma-aminobutyric acid (GABA) A receptor, pi	2.7
25		T79526		integral type I protein	9.3
35		AL390127		Kruppel-like factor 13	4.4
		BE257758		acid cluster protein 33	1.8
	133360	AI016521	Hs.71816	v-akt murine thymoma viral oncogene homolog 1	5.5
	133366	AA292811	Hs.72050	non-metastatic cells 5, protein expressed in (nucleoside-diphosphate kinase)	2.7
	133367	AF231919	Hs.18759	KIAA0539 gene product	1.7
40		AF245505		DKFZP564l1922 protein	1.8
		BE313555		KIAA1224 protein	1.7
		AI950382		phosphatidylserine receptor	1.3
		AW103364		inhibin, beta A (activin A, activin AB alpha polypeptide)	16.1
15				hypothetical protein HT023	12.2
45		AL031591		phosphotidylinositol transfer protein, beta	10.4
				protein kinase, Interferon-inducible double stranded RNA dependent	1.2
		AI659306		protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)	1.7
	133500	AW964804	Hs.74280	hypothetical protein FLJ22237	11.1
	133529	W45623	Hs.74571	ADP-ribosylation factor 1	2.8
50	133540	AL037159	Hs.74619	proteasome (prosome, macropain) 26S subunit, non-ATPase, 2	2.9
				damage-specific DNA binding protein 1 (127kD)	2.5
		AU077050		translin	1.5
		X75346	Hs.75074	milogen-activated protein kinase-activated protein kinase 2	2.1
		BE391579		Fas-activated serine/threonine kinase	1.3
55					2.2
<i>) )</i>				nuclear phosphoprotein similar to S. cerevislae PWP1	
		AA393273		transcription factor 6-like 1 (mitochondrial transcription factor 1-like)	1.5
	133599	NM_00288	5HS./5151	RAP1, GTPase activating protein 1	5.7
		NM_00489		H2A histone family, member Y	25.5
		NM_00204		glycyl-tRNA synthetase	15.8
60		NM_00040	1Hs.75334	exostoses (multiple) 2	3.3
	133649	U25849	Hs.75393	acid phosphatase 1, soluble	1.6
		AV661185		mitochondrial ribosomal protein L19	4.1
		L27841	Hs.75737	pericentriolar material 1	1.5
				matrix Gla protein	6.3
65				Homo sapiens, Similar to likely ortholog of yeast ARV1, clone IMAGE:3506392, mRNA	3.9
UJ		T52946		RAE1 (RNA export 1, S.pombe) homolog	1.7
	100707	DE074760	Un 4042F7	taminin receptor 1 (67kD, ribosomal protein SA)	
	133/60	DE2/1/00	F15.101J3/	remaini receptor i (07kD, noosomai protein SA)	1.8

	PCT/US02/02242

		M62194	HS.75929	cadhenn 11, type 2, OB-cadherin (osteoblast)	1.5
			Hs.76152		3.5
			Hs.301064	arfaptin 1	6.8
·~		M34338	Hs.76244		2.6
5	133797	AL133921	Hs.76272	retinoblastoma-binding protein 2	1.4
	133822	D50525	Hs.699	peptidylprolyl Isomerase B (cyclophilin B)	8.0
	133842	AW797468	Hs.285013	putative human HLA class II associated protein I	13.5
	133845	AA147026	Hs.76704	ESTs	2.2
		W29092		cellular retinoic acid-binding protein 1	1.8
10	133859	U86782	Hs.178761	26S proteasome-associated pad1 homolog	2.0
	133865	AB011155	Hs.170290	discs, large (Drosophila) homolog 5	2.8
	133867	AW340125	Hs.76989	KIAA0097 gene product	6.7
	133868	AB012193	Hs.183874	cullin 4A	2.5
		U30872	Hs.77204		3.0
15		U30825		splicing factor, arginine/serine-rich 9	1.4
		D86326	Hs.325948	vesicle docking protein p115	5.4
			6Hs 211602	SMC1 (structural maintenance of chromosomes 1, yeast)-like 1	4.9
	133936	L17128	Hs 77719	gamma-glutamyl carboxylase	3.7
			Hs.77770	adaptor-related protein complex 3, mu 2 subunit	12.1
20		X81789		splicing factor 3a, subunit 3, 60kD	9.7
	133976	AI908165	Hs 169946	GATA-binding protein 3 (T-cell receptor gene activator)	3.1
	133989	AL040328	Hs 78202	SWI/SNF related, matrix associated, actin dependent regulator of chromatin	1.3
	133997	AI824113	Hs 78281	regulator of G-protein signalling 12	9.7
	134010	AB016092	Hs 197114	RNA binding protein; AT-rich element binding factor	2.4
25	134015	D31764	Hs 278569	sorting nexin 17	2.5
			0Hs.78946	cullin 3	1.3
		U41060	Hs.79136	LIV-1 protein, estrogen regulated	4.2
			2Hs.79305	KIAA0255 gene product	2.2
		H86504		protein phosphatase 2, regulatory subunit B (B56), epsilon isoform	5.0
30	134200	BE559598	Hs.197803	KIAA0160 protein	3.2
•		AF107463		splicing factor 30, survival of motor neuron-related	2.5
		NM_00028		peroxisomal biogenesis factor 7	2.1
		NM_000402		glucose-6-phosphate dehydrogenase	9.1
		BE300078		Homo sapiens, clone IMAGE:3535294, mRNA, partial cds	2.8
35		AI878910		cisplatin resistance-associated overexpressed protein	1.8
-		AI906291		Immunoglobulin superfamily, member 3	2.0
		AW502505		Homo sapiens cDNA: FLJ21927 fis, clone HEP04178, highly similar to HSU90909	2.5
		U61397	Hs.81424	ubiquitin-like 1 (sentrin)	2.8
				KIAA1100 protein	10.4
40			Hs.81800	chondroitin sulfate proteoglycan 2 (versican)	1.9
		N92036	Hs.81848	RAD21 (S. pombe) homotog	2.6
		NM_004922		SEC24 (S. cerevisiae) related gene family, member C	2.3
-		AW291946		interleukin 6 signal transducer (gp130, oncostatin M receptor)	13.0
		AA339449		phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase,	8.8
45		X06560	Hs.82396	2',5'-oligoadenylate synthetase 1 (40-46 kD)	1.5
			Hs.323193	hypothetical protein MGC3222	8.1
		AI589941		Homo saplens, Similar to tumor differentially expressed 1, clone IMAGE:3639252, mRNA, par	
			Hs.82582	Integrin, beta-like 1 (with EGF-like repeat domains)	4.1
		AA456539		lysosomal	1.7
50		AA334551		sperm specific antigen 2	2.6
			Hs.82772	collagen, type XI, alpha 1	1.3
	134411	BE272095	Hs.167791	reticulocalbin 1, EF-hand calcium binding domain	3.2
	134415	AI750762	Hs.82911	protein tyrosine phosphatase type IVA, member 2	1.9
		AU077196		collagen, type V, alpha 2	10.3
55	134424		Hs.83023	peroxisomal biogenesis factor 11B	2.4
		AA112036		KIAA0252 protein	1.2
	134447		Hs.83428	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)	1.6
	134470		Hs.83758	CDC28 protein kinase 2	2.1
		NM 005000		Empirically selected from AFFX single probeset	5.3
60	134485		Hs.83942	cathepsin K (pycnodysostosis)	2.5
		AW246273		threonyl-tRNA synthetase	2.1
		AA425473		KIAA0971 protein	3.8
				hypothetical protein FLJ10709	2.4
		BE091005		activated RNA polymerase II transcription cofactor 4	6.7
65		AW411479		FK506-binding protein 4 (59kD)	2.3
	134577	BE244323	Hs.85951	exportin, tRNA (nuclear export receptor for tRNAs)	5.5
	424592	A A Q 27 1 7 7	He 86044	CGG triplet connect binding amining 4	

	134612	AW068223	Hs.171581	ubiquitin C-terminal hydrolase UCH37	2.2
		AF035119		deleted in liver cancer 1	2.0
	134632	X78520	Hs.174139	chloride channel 3	2.3
_	134654	AK001741	Hs.8739	hypothetical protein FLJ10879	1.4
5	134664	AA256106	Hs.87507	ESTs ·	72.9
		BE391929		transmembrane protein 4	8.5
		U62317	Hs.88251	arylsulfatase A	6.0
		NM_003474		a disintegrin and metalloproteinase domain 12 (meltrin alpha)	4.3
10		BE161887		anaphase-promoting complex subunit 10	2.3
10		Y14768	Hs.890	lysosomal	6.7
		AA852985		chromobox homolog 5 (Drosophila HP1 alpha)	2.3 2.9
				F-box only protein 6	2.9 6.6
				ring finger protein 22	. 2.3
15		X07871 AW630803	Hs.89476	CD2 antigen (p50), sheep red blood cell receptor	6.2
1)				lamin B1 integral membrane protein 1	1.9
		AD001528		spemine synthase	1.8
		AW451370		adaptor-related protein complex 1, gamma 2 subunit	1.4
		Al701162		hypothetical protein MGC11138	1.4
20		BE268326		5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	5.6
		D26488	Hs.90315	KIAA0007 protein	2.8
		Al879195		15 kDa selenoprotein	1.7
		AA532963		Homo sapiens cDNA FLJ13100 fis, clone NT2RP3002255	1.7
		AW885909		PRO1073 protein	2.1
25		AW401361		protein phosphatase 2 (formerly 2A), catalytic subunit, alpha Isoform	1.3
				phosphoserine aminotransferase	2.1
	134975	R50333	Hs.92186	Leman colled-coil protein	2.3
	135011	AB037835	Hs.92991	KIAA1414 protein	1.6
		NM_00040		glycerol-3-phosphate dehydrogenase 2 (mitochondrial)	3.9
30				hypothetical protein FLJ12619	6.2
		AW503733		KIAA1488 protein	2.0
		AB036063		p53-inducible ribonucleotide reductase small subunit 2 homolog	1.3
		AF027219		zinc finger protein 202	7.1
25				zinc finger protein 36 (KOX 18)	3.2
35		AI093155		JM27 protein	2.5 1.4
				px19-like protein	5.0
		AA477514		transfir-associated factor X ESTs, Highly similar to C10_HUMAN PUTATIVE C10 PROTEIN [H.sapiens]	6.1
		N26427	Hs.9634		4.6
40		T78802 BE463721	Hs.96560	hypothetical protein FLJ11656 putative G protein-coupled receptor	5.6
70			Hs.262603		3.5
		AW291023		ESTs, Weakly similar to A46010 X-linked retinopathy protein [H.sapiens]	1.2
		A1088775		geranylgeranyl diphosphate synthase 1	2.6
			Hs.112017		5.3
45		AA150320		protein kinase Nimu-R1	9.1
,,,		AI090838		ESTs	2.4
		AI743770	Hs.98368		13.3
		A1652069			2.6
				cell division cycle 2-like 1 (PITSLRE proteins)	8.3
50				Homo saplens cDNA FLJ10174 fis, clone HEMBA1003959	1.5
	135389	U05237	Hs.99872	fetal Alzheimer antigen	4.9
	135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone receptor, testicular feminization; spinal and bulbar	2.0
	134975	R50333	Hs.92186	Leman colled-coil protein	. 2.6
		AB037835		KIAA1414 protein	1.4
55		_	8Hs.93201		1.6
				hypothetical protein FLJ12619	1.4
		AW503733		KIAA1488 protein	1.8
		AB036063		p53-inducible ribonucleotide reductase s	2.5
60		AF027219		zinc finger protein 202	1.5
60				zinc finger protein 36 (KOX 18)	2.1
		Al093155		JM27 protein	4.4
		AA477514	Hs.279529		14.9
		N26427	Hs.9634	translin-associated factor X	1.3 1.7
65		T78802	Hs.96560	ESTs, Highly similar to C10_HUMAN PUTATI hypothetical protein FLJ11656	6.1
U)		BE463721		putative G protein-coupled receptor	2.7
		A1020727		FOX-	42.2

	13525/	AW291023 H	ls.97255	ESTs, Weakly similar to A46010 X-linked	7.6
	135263	AI088775 H	ls.55498	geranylgeranyl diphosphate synthase 1	1.8
	135274	AA448460 H	ls.112017	GE36 gene	4.1
		AA150320 H		protein kinase Nimu-R1	1.2
5		A1090838 H		ESTs	4.8
-		AI743770 H		ESTs, Weakly similar to KIAA0822 protein	
	135321	VICESUED II	la 00614	ribosome binding protein 1 (dog 180kD ho	5.8
	125254	AAATCASA II	15.500 14	noosane binding protein i (dog noxi) no	12.3
	125204	AAGTOASO II	15.103418	cell division cycle 2-like 1 (PITSLRE pr	5.7
10				Homo saplens cDNA FLJ10174 fis, clone HE	7.9
10				fetal Alzheimer antigen	1.9
		X78592 H	ls.99915	androgen receptor (dihydrotestosterone r	13.9
	302256	AA857131 H	ls.171595	HIV TAT specific factor 1	5.3
	302276	AW057736 H	ls.323910	HER2 receptor tyrosine kinase (c-erb-b2,	2.2
	303135	AW592789 H	ls.279474	HSPC070 protein	1.4
15	303686	AK000714 H	ls.109441	MSTP033 protein	5.2
	310085	R43191 H	ls.101248	Homo sapiens clone IMAGE:32553, mRNA seq	2.3
	315518	AA808229 H			2.8
				ZW10 Interactor	2.0
				rab3 GTPase-activating protein, non-cata	5.5
20				Golgi apparatus protein 1	1.4
				nucleosome assembly protein 1-like 1	1.3
		AE118083 H	e 20/0/	PRO1912 protein	
	322556	RE0/1/51 H	6 177507	hypothetical protein	2.9
					1.6
25	107927	MF232100 FR	5.10401J	RP42 homolog	1.8
23	407027	AL024540 U	5.40323	BUB3 (budding uninhibited by benzimidazo	1.6
	400150	ALUS4340 H	5.43027	SRY (sex determining region Y)-box 22	6.1
				RNA helicase family	5.6
		R73727 H	S.10161/	ESTs, Weakly similar to T32527 hypotheti	2.6
20	413670	AB000115 H	s./54/U	hypothetical protein, expressed in osteo	2.4
30				SFRS protein kinase 1	1.5
					4.2
		AA381133 H	s.80584	high-mobility group (nonhistone chromoso	23.6
	417378	R57256 Hs	s.82037	TATA box binding protein (TBP)-associate	5.8
25	418283				1.3
35					1.6
	420269			alpha thalassemia/mental retardation syn	2.3
	420802				1.6
	421225	AA463798 Hs	s.102696	MCT-1 protein	3.5
	421642	AF172066 Hs	s.106346	retinoic acid repressible protein	4.9
40	421828	AW891965 Hs	s.279789	histone deacetylase 3	3.1
	421983	Al252640 Hs	s.110364		1.9
		AA302744 Hs			2.4
	422055	NM 014320Hs	s.111029		4.1
		AF165883 Hs			7.0
45				·	4.9
					3.4
				T 1	2.1
	426372	BE304680 Hs	s.169531	markette militari i in	7.5
					1.7
50					2.4
		AB001636 Hs			3.8
		AK001333 Hs			
	441560				5.6
				11.14	2.0
55		AF167572 Hs			7.5
,,					2.2
		AI017574 Hs			2.8
	44///0	BE620592 Hs	5.71190	ESTs, Weakly similar to S16506 hypotheti	1.7
		NM_0036/7HS	5.22393		5.9
60	449687				5.6
60	450701	HJ9960 Hs	s.28846/		1.4
					4.7
	452461				2.9
				Homo sapiens cDNA FLJ20845 fis, clone AD	12.1
					4.7
65				Homo sapiens, clone MGC:2492, mRNA, comp	1.3
					3.2
	102481	U50360			6.2

	102827	BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b	7	7.9
		BE270465		protein kinase C, zeta	7	2.0
				cdk Inhibitor p21 binding protein	5	5.3
				hypothetical protein FLJ10697	2	2.0
5			Hs.87889	helicase-moi	5	5.7
•		M10905	Hs.287820	fibronectin 1		1.3
	119615	AL034423	Hs.75875	ubiquitin-conjugating enzyme E2 variant	7	2.9
	125006	BE065136	Hs.145696	splicing factor (CC1.3)	1	1.7
	127609	X80031	Hs.530	collagen, type IV, alpha 3 (Goodpasture	7	2.4
10	129209	R62676	Hs.17820	Rho-associated, coiled-coil containing p	<b>.</b>	5.2
	129917	M30773	Hs.278540	protein phosphatase 3 (formerly 2B), reg	4	4.5
	130182	BE267033	Hs.192853	ubiquitin-conjugating enzyme E2G 2 (homo	1	11.
	130365	W56119	Hs.155103	eukaryotic translation initiation factor		3.3
	131135	NM_016569	9Hs.267182	TBX3-iso protein	1	1.3
15	131853	Al681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU		3.2
	131881	AW361018	Hs.3383	upstream regulatory element binding prot	1	14.
	132726	N52298	Hs.55608	hypothetical protein MGC955		3.0
	135193	X95525	Hs.96103	TATA box binding protein (TBP)-associate		2.7
	409487	H19886		gb:yn57a05.r1 Soares adult brain N2b5H		2.3
20	416040	AW819158	He 289044	Homo saniens dDNA FL 112048 fis, clone HF	Ĩ	7.4

### **TABLE 4A**

Table 4A shows the accession numbers for those pkeys lacking unigeneID's for Table 4. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	sequ	ences c	omprising each cluster are listed in the "Accession" column.	
	Pkey:		nique Eos probeset identifier number	
	CAT nu		ene cluster number	
	Accessi	ion: (	enbank accession numbers	
15				
	Pkey	CAT num	er Accessions	
	123615	3068615	AA609170	
•	123619	371681_1	AA602964 AA609200	
20		16505	M21259	
		656394_1	Al267847 N27351	
		1642364_1 1657509_1	N34059 N46979 N53935 N53950	
		3128128	N53950 N53950 U50360	
25		110522	X89059	
		19346_14	AA992380 N33063 N21418 H79958 R21911 H79957	
			103797 109699_1 AA080912 AA075318 AA083403 AA076594 AA078992 AA084926 AA081881 AA113913 AA11389	2
	120200	400040 4	AA083821 AA134801 AA082953 AA070343 AA062835 AA075419 AA063293 AA071252 AA078900 AA062836 AW974305	
30		160212_1 328626_1	AA190577 AA181657 T63857 AW971220 AA493469 T63699	
50		44573_2	AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW96767	74
			AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE3285	/ I 517
			Al219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488	1964
35			AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al65	3832
33			AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970	
			BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA25187	<b>'4</b>
			AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI5642	200
			F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005	209
40	129019	44573_2	Al950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967676	71
			AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE3285	517
			AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488	964
			AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI65 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970	3832
45			BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA25187	· A
			Al819225 AW205862 Al683338 Al858509 AW276905 Al633006 AA972584 AA908741 AW072629 AW513996 AA293273	
			AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA551005 W80701 AW613456 Al373032 Al5642	269
	400000	0000 0	F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005	
50	120695	9683_3	AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301 AI740458 AI796100 AI935603 AW0	52210
50	122188	275673_1	AA970201 Al633384 AA425910 Al017004 Al241295 AA402816 AA291468 AA398838 AA435847	
		283769_1	AA416568 AA442889 AA417233 AA442223	
		305217_1	AA453641 AA454061	
E E		150431_1	AA157811 AA836869	
55		genbank_A		
		genbank_A genbank_T		
			D_entrez_W38150 W38150	
		382979_1	AA199686 N73861	
60		genbank_A		
		genbank_T		
		genbank_A		
	120033	genbank_A	286942 AA286942	

120809 genbank\_AA346495 AA346495 113702 genbank\_T97307 129680 23162\_1 U0 T97307 307 T97307
U03749 NM\_001275 J03483 J03915 Al214509 AW245744 AL046455 AA318960 Al741505 AA843875 Al829382 Al560122
Al858999 D55958 Al684005 D53170 AA854091 Al025609 D53119 D54729 D55504 D55377 D55313 AW512244 AA846441
AW043898 Al969102 AA405741 Al091983 AA788784 AA706586 AA854361 AW470949 AA843095 AA772028 Al148432
Al038109 AA782478 AA910064 Al220384 AA781296 AA843881 AA854064 AA843125 AA843419 AA319036 AA319054
Al273831 W32275 Al584185 C05724 AA789023 Al686818 D54392 Al022485 AA431410 AA854232 W39212 W15214 AA894441
Al803081 Al167381 AW245389 AA319430 AA335156 Al042646 AA327030 AA725170 T27943 AA889304 AA976699 Al687001
Al621107 Al865540 AA772107 C06286 AA319661 AA405992
4.105614 5 10 101045 entrez\_J05614 J05614 117247 genbank N21032 110501 genbank H55748 103392 entrez\_X94563X94563 105032 genbank AA1276 119513 NOT\_FOUND\_entrez AA127818 15 W37933 105445 genbank AA252395 AA412112 121514 genbank 121558 genbank AA412497 121911 genbank AA427950 20 123315 714071\_1 AA496369 AA496646 114911 genbank AA236672 409487 1134778\_1 · H19886 AW402806 T10231

# TABLE 5: Figure 5 from BRCA 001 US

Table 5 shows genes upregulated in tumor tissue compared to normal breast tissue.

5

Pkey: ExAccn:

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number

UnigeneID: Unigene Title: R1: 10

Unigene number

Unigene gene title Ratio of turnor to normal breast tissue

15	Pkey	ExAcon	UnigenelD	UnigeneTitle	R1
	100114	X02308	Hs.82962	thymidylate synthetase	2.9
	100147	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.5
	100154	H60720	Hs.81892	KIAA0101 gene product	9.2
	100335	AW247529		platelet-activating factor acetylhydrola	2.7
20	100666		Hs.169610	CD44 antigen (homing function and Indian	5.7
	100667	L05424	Hs.169610	CD44 antigen (homing function and Indian	9
	100668	L05424	Hs.169610	CD44 antigen (homing function and Indian	7.6
	100678	AW502935	Hs.740	PTK2 protein tyrosine kinase 2	53.2
	100988	AK000405	Hs.76480	ubiquitin-like 4	11.4
25	101031	J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B	8.2
	101045	J05614		gb:Human proliferating cell nuclear anti	5
	101332	J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	3.4
	101352	A1494299	Hs.16297	COX17 (yeast) homolog, cytochrome c oxid	6.3
••	101580	NM_012151	1Hs.83363	coagulation factor VIII-associated (intr	5.7
30		AF064853	Hs.91299	guanine nucleotide binding protein (	5.6
		M81057	Hs.180884	carboxypeptidase B1 (tissue)	14.4
		AA586894		S100 calcium-binding protein A7 (psorias	8.9
		NM_000318		peroxisomal membrane protein 3 (35kD, Ze	3.2
2.5		Al904232	Hs.75323	prohibitin	8.4
35		BE258602		heat shock protein 75	1.4
		BE313280		death associated protein 3	4.6
		AW950852		polymerase (DNA directed), delta 2, regu	4.3
		AA829978		JTV1 gene	6.7
40	102220		Hs.65436	lysosomal	4.3
40		AA306342		protein kinase C-like 2	2.7
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	2
		U33635	Hs.90572	PTK7 protein tyrosine kinase 7	6.2
		U48705	Hs.75562	discoidin domain receptor family, member	6.9
45		W81489	Hs.223025	RAB31, member RAS oncogene family	5.3
45		AL037672		extracellular matrix protein 1	5.8
		NM_007019		ubiquitin carrier protein E2-C	4.3
		U96132	Hs.171280	hydroxyacyi-Coenzyme A dehydrogenase, ty	6
	102704	AU077058	Hs.50002	BRCA1 associated RING domain 1	1.9
50		BE252241		small inducible cytokine subfamily A (Cy	2.3
50		BE244588		pyridoxal (pyridoxine, vitamin B6) kinas	6.4
		NM 005940		chaperonin containing TCP1, subunit 2 (b	5.6
		AU077231		matrix metalloproteinase 11 (MMP11; stro	4.5 3.1
		AA205475		cyclin D1 (PRAD1: parathyroid adenomatos ribosomal protein S18	9.9
55	103206		Hs.77367	monokine induced by gamma interferon	8.8
55		AI369285	Hs.75189	death-associated protein	5.6
		AI376722	Hs.180062	proteasome (prosome, macropain) subunit,	9.7
		BE270465		protein kinase C, zeta	7.9
		AK001278		hypothetical protein FLJ10416 similar to	6.5
60		BE379766		polymerase (RNA) II (DNA directed) polyp	6.3
		AW052006		PRP4/STK/WD splicing factor	10.9
		A1250789	Hs.32478	ESTs	5.6
	104854	AA041276	Hs.154729	3-phospholnositide dependent protein kin	12.3
	104867	AA278898	Hs.225979	hypothetical protein similar to small G	2

	104896	AW015318	Hs.23165	ESTs	17.7
	104909	AW408164	Hs.249184	transcription factor 19 (SC1)	5
		AW958157			1.7
_		AA026880		prolactin receptor	1.4
5			Hs.278675	bromodomain-containing 4	1.4
		Al199268		Homo sapiens, Similar to RIKEN cDNA 2010	
		AF098158			3.3
		AA907305			2.5
10		AA151342			9.5
10		H58589	Hs.35156		2.2 5.4
		AF167570			9.3
		AA262640 BE616694		hypothetical protein FLJ14299	5.5 1.4
		AA985190			9.4
15		AW151952		7	1.5
13		AF151066			2.9
		AF016371			5.2
		AA533491		h-h1. h1.	6.8
		AK001404			5.7
20		AW390282			6.3
		AA458882			7.9
	106624	NM_003595	Hs.26350	tyrosylprotein sulfotransferase 2	7.7
		BE614802		hypothetical protein FLJ12549	4.5
	106829	AW959893	Hs.27099	hypothetical protein FLJ23293 similar to	16.2
25		AB037744		KIAA1323 protein	2.2
		N49809	Hs.11197	Homo sapiens, clone IMAGE:3343149, mRNA	
		BE156256		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	6.6
		AF264750		myeloid/lymphoid or mixed-lineage leukem	1.8
20		W15477	Hs.64639	gliorna pathogenesis-related protein	6.1
30		AW732573		potassium voltage-galed channel, delayed	8.4 2.5
		L42612 BE153855	Hs.335952	keratin 68	2.2
		AW956103		lg superfamily receptor LNIR pyruvate dehydrogenase kinase, isoenzyme	6.7
		AF129535		F-box only protein 5	7.1
35		BE546947		homeo box C10	9.8
		AB029000		KIAA1077 protein	7.2
		AK001431		hypothetical protein FLJ10569	4
	109011	AA156542	Hs.72127	ESTs	1.4
		AA164293		ESTs	2.9
40		AA375752		Homo sapiens mRNA; cDNA DKFZp586F182	
		NM_015310		KIAA0942 protein	3.2
		Al668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTO	0.0
		AI288666	Hs.16621	DKFZP4341116 protein	6.2
45		H55748	Ha 20020	gb:yq94a01.s1 Soares fetal liver spleen	6.1 7.6
43		AW190338 BE044245		hypothetical protein MGC11256	9.3
		AA992380	113.30011	hypothetical protein MGC2963 gb:ot37g06.s1 Soares_testis_NHT Homo sap	
		NM_005864	He 24587	signal transduction protein (SH3 contain	6.7
		N63823	Hs.269115	ESTs, Moderately similar to Z195_HUMAN Z	
50		AK000136		asporin (LRR class 1)	7.1
		N90956	Hs.17230	hypothetical protein FLJ22087	7.9
		AA778711		eukaryotic translation initiation factor	6.9
	111392	W46342	Hs.325081	Homo saplens, clone IMAGE:3659680, mRNA	, 8.4
	111937	BE298665	Hs.14846	Homo sapiens mRNA; cDNA DKFZp564D016	(fr 10.6
55	112244	AB029000	Hs.70823	KIAA1077 protein	14.6
	112995		Hs.7155	ESTs, Moderately similar to 2115357A TYK	5.6
	113777	BE266947	Hs.10590	zinc finger protein 313	13.4
		A1269096	Hs.135578	chitobiase, di-N-acetyl-	1.3
60	113811	BE207480		Homo sapiens cDNA: FLJ22044 fis, done H	3.1 11.3
60	113834	T26483	Hs.6059	EGF-containing fibulin-like extracellula	
	113808	W57902 AL079314	Hs.90744 Hs.16537	proteasome (prosome, macropain) 26S subu hypothetical protein, similar to (U06944	6.1
	113070	AW953484	He 3849	hypothetical protein FLJ22041 similar to	1.9
	113923	AW515443	Hs 306117	KIAA0306 protein	15.8
65		AA236177		KIAA0887 protein	7.1
05	114965	AI733881	Hs.72472	BMP-R1B	2.3
	115061	AI751438	Hs.41271	Homo saplens mRNA full length insert cDN	11.8
				-	

	115278	AK002163	Hs.301724	hypothetical protein FLJ11301	1.5
	115291	BE545072	Hs.122579	hypothetical protein FLJ10461	6.2
		BE093589		hypothetical protein FLJ23468	10.6
_		AF231023			6.8
5		A1867451	Hs.46679	hypothetical protein FLJ20739	5.5
		AB037753		The state of the s	9.8
			Hs.57664	Homo saplens mRNA full length insert cDN	2.4 7.4
		AW499664 Al272141	Hs.83484	Human clone 23826 mRNA sequence SRY (sex determining region Y)-box 4	2.1
10		AK001043		integrin-linked kinase-associated serine	2.7
10		Al393666	Hs.42315	p10-binding protein	5.2
		AF161470		butyrate-Induced transcript 1	5.7
		AI949952	Hs.49397	ESTs	7.4
	119075	M10905	Hs.287820	fibronectin 1	5.7
15	119265	BE539706	Hs.285363	ESTs	1.4
		T65004	Hs.163561	ESTs	8.4
		AL117554		nudeolar protein NOP5/NOP58	6.7
		BE393948		kallikrein 5 (KLK5; KLK-L2; stratum com	9.2
20		H26735	Hs.91668	Homo sapiens done PP1498 unknown mRNA	
20		AA131376		fibroblast growth factor 12B	38.9
		AA191384 AA195651		ESTs, Weakly similar to Z195_HUMAN ZINC ESTs	6.4
		AK000292		hypothetical protein FLJ20285	16.1
		AW969481		hypothetical protein	16.8
25		AF000545		putative purinergic receptor	28.1
		AA219305		EST	12.4
		AL109963		FSH primary response (LRPR1, rat) homolo	9.7
	120386	AW969665	Hs.154848	hypothetical protein DKFZp434D0127	32.6
	120389	AW967985	Hs.325572	ESTs, Moderately similar to ALU7_HUMAN A	
30		AA134006		eukaryotic translation initiation factor	12.5
		AW966893	Hs.26613	Homo sapiens mRNA; cDNA DKFZp586F132	
		A1950087	11-00430	gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapi	
		AA253170		EST Months similar to A1114 CHIMAN A1114	10.4 5 14.4
35		AA280679 BE244830		ESTs, Weakly similar to ALU1_HUMAN ALU S ZNF135-like protein	10.2
23		AA282074		N-acetylglucosamine-phosphate mutase	7.5
		AW407987		M-phase phosphoprotein homolog	52
-		AA976503	110.11.0010	gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapie	
		AW449855	Hs.96557	Homo sapiens cDNA FLJ12727 fis, done NT	
40		Al191410	Hs.96693	ESTs, Moderately similar to 2109260A B c	7
	120774	A1608909	Hs.193985	ESTs	7.8
		AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848	
		AA346495		gb:EST52657 Fetal heart II Homo sapiens	4.4
4.5		BE262951		ESTs	5.6
45		AA398721		ESTs, Highly slmllar to 137550 mismatch	5.4
		AA406137		EST	6 13.1
		AA494172		ESTs ECT.	28
		AA402515 AA416653		ESTs ESTs	6.2
50		AA412477		EST	7.4
50		AA412497	110.00112	gb:zt95g12.s1 Soares_testis_NHT Homo sap	
		AA421537	Hs.178072	Homo saplens mRNA; cDNA DKFZp434B102	3 (f 7.8
		AA398784		ESTs	7.1
	121748	BE536911	Hs.234545	hypothetical protein NUF2R	19.5
55		AB033022		KIAA1196 protein	7.9
		AW340797		ESTs	5.8
		AA425691		ESTs, Highly similar to KIAA1048 protein	5
		AA426376	Hs.98459	ESTs	5
60		AA427950	Un DOCCO	gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_	
60		AA430211 AA431085		EST ESTs	6.4 6.5
		W92142	Hs.271963	ESTs, Weakly similar to ALU5_HUMAN ALU	
		AA443794		ESTS Veakly Sittlian to ALOS_HOWAY ALO	7.3
		AA868555		ESTs	5
65		AA446008		EST	7.6
		AW418788		ESTs, Weakly similar to S43569 R01H10.6	9.7
		AA448349		EST	6.1

	122492	AA448417 Hs.104990	ESTs	5.4
	122510	AA449232 Hs.99195	ESTs	11.2
	122530	AW959741 Hs.40368	adaptor-related protein complex 1, sigma	10.1
	122572	AA452601 Hs.99287	EST	11
5		AA453518 Hs.98023	ESTs	61.5
•		AA453630 Hs.99339	EST	10.7
		AA453638 Hs.161873		107.3
			ESTs	
		AA453641	gb:zx48e06.s1 Soares_testis_NHT Homo sap	
10		AA453987 Hs.144802	ESTs	5.6
10	122717	AA456859 Hs.178358	ESTs	8.5
	122829	AW204530 Hs.99500	ESTs	81.8
	122838	AA460584 Hs.334386	ESTs	75.3
		Al929374 Hs.75367	Src-like-adapter	5.8
		AF005216 Hs.115541	Janus kinase 2 (a protein tyrosine kinas	5.3
15				11.5
13		AA470074 Hs.169896	ESTs	
		AW338067 Hs.323231	Homo sapiens cDNA FLJ11946 fis, done HE	
		AL359571 Hs.44054	ninein (GSK3B interacting protein)	8.7
	123136	AW451999 Hs.194024	ESTs	5.1
	123152	AW601773 Hs.270259	ESTs	5.2
20	123394	AA731404 Hs.105510	ESTs	3.6
		AA599042 Hs.112503	EST	7.4
		BE019072 Hs.334802	Homo sapiens cDNA FLJ14680 fis, clone NT	
		AA609170	gb:af12a12.s1 Soares_testis_NHT Homo sap	
25		NM_013241Hs.95231	FH1/FH2 domain-containing protein	10
25	123753	AA609955 Hs.234961	Huntingtin Interacting protein E	30.6
	124006	Al147155 Hs.270016	ESTs	8.1
	124385	AI267847	gb:aq49a10.x1 Stanley Frontal NB pool 2	57.1
	124440	AA532519 Hs.129043	Human DNA sequence from clone 989H11 on	7.8
		AW297702 Hs.102915	ESTs	8.3
30		AA381661 Hs.119878	ESTs, Weakly similar to M3K9_HUMAN MITC	
50				11.3
		R22952 Hs.268685	ESTS	
		AA374756 Hs.93560	Homo sapiens mRNA for KIAA1771 protein,	9
		AW368528 Hs.100855	ESTS	8.1
~ -	124788	R43543 Hs.100912	Homo sapiens cDNA: FLJ22726 fis, clone H	5.1
35	124811	R46068 Hs.288912	hypothetical protein FLJ22604	14.2
	124812	R47948 Hs.188732	ESTs	7.9
	124822	AA418160 Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PL	6.6
		R65763 Hs.101477	EST	23.9
		AW296713 Hs.221441	ESTs	32.4
40		AI076343 Hs.173939	ESTs, Weakly similar to ALUB_HUMAN IIII	22.8
70				
		R99978 Hs.268892	ESTs, Moderately similar to B34087 hypot	6.1
		T79956 Hs.100588	EST	135.3
	125056	T81310 Hs.100592	ESTs	5.4
	125101	Al472068 Hs.286236	KIAA1856 protein	5.6
45	125115	T97341	gb:ye57e05.s1 Soares fetal liver spleen	9.6
		Al123705 Hs.106932	ĖSTs	8
		AW966158 Hs.58582	Homo sapiens cDNA FLJ12789 fis, clone NT	12.8
		R39234 Hs.251699	ESTs, Weakly similar to IDN4-GGTR14 [H.s	2.8
		AA975486 Hs.103441	Homo sapiens, Similar to RIKEN cDNA 1700	
50				
20		W27939 Hs.103834	hypothetical protein MGC5576	7.7 .
		BE302796 Hs.105097	thymidine kinase 1, soluble	5.3
	128781	N71826 Hs.105465	small nuclear ribonucleoprotein polypept	.53.9
	128797	NM_002975Hs.105927	stem cell growth factor; lymphocyte secr	13.3
	128868	AA419008 Hs.106730	chromosome 22 open reading frame 3	3
55	128891		Homo sapiens, done MGC:16362, mRNA, co	m 13.3
••		Y13153 Hs.107318	kynurenine 3-monooxygenase (kynurenine 3	
	120075	BE560779 Hs.284233	NICE-5 protein	14
			DKFZP566C243 protein	
		Al816224 Hs.107747		1.9
<b>~</b>		Al950087	gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sap	
60		AW296806 Hs.326234	ESTs, Highly similar to T46422 hypotheti	5
		AA744610 Hs.194431	palladin	17.1
	129096	AA463189 Hs.288906	WW Domain-Containing Gene	20.9
		N57532 Hs.109315	KIAA1415 protein	5.8
		BE614192 Hs.279869	melanoma-associated antigen recognised b	7.6
65		U30246 Hs.110736	solute carrier family 12 (sodium/polassi	6.7
00		NM_016039Hs.110803	CGI-99 protein	2
		Al267700 Hs.317584	ESTs	5
	123404	71201100 N3.311304	LUIS	J

ŧ

	129482	AA188185	Hs.289043		5.7
	129559	W01296	Hs.11360		7.5
	129587	H14718	Hs.11506	Human clone 23589 mRNA sequence	6.8
	129629	AK000398	Hs.11747	hypothetical protein FLJ20391	3.8
5	129649	AD000092	Hs.16488		3.3
	129680	U03749		gb:Human chromogranin A (CHGA) gene, pro	14.1
		AW748482	Hs.77873		2.6
		Al304966	Hs.12035		7.4
		AA156214			2
10		AA301116			1.6
		AL046962		forkhead box O3A	2.8
		AA311426			6.1
		NM_00335		ESTs, Moderately similar to CEGT_HUMAN C	1.6
		X79201	Hs.153221		5.4
15		NM_01344			8.5
		W56119	Hs.155103	eukaryotic translation initiation factor	11
		BE513202		PPAR binding protein	3.9
		D90041	Hs.155956		33.6
		AL121438			2.7
20		BE208491		KIAA0618 gene product	16.1
20		L32137	Hs.1584		6.1
		U64675	Hs.179825	RAN binding protein 2-like 1	7.8
		AF062649		pituitary tumor-transforming 1	14.4
		AI907018		Empirically selected from AFFX single pr	4.7
25		AA383092		replication protein A3 (14kD)	7,9
دے		AF083208		apoptosis antagonizing transcription fac	1.2
		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	12.1
		BE246961		Homo sapiens ubiquitin protein ligase (U	13.9
		R68537	Hs.17962	ESTs	2
30		H59696	Hs.18747	POP7 (processing of precursor, S. cerevi	3.1
30		AL036067		protein x 0001	5.7
		BE514434		kinesin-like 2	2.1
		BE382657		signal transducer and activator of trans	5.4
		AA321649		small inducible cytokine subfamily B (Cy	7.4
35		AA194422		myosin VI	5.1
22			Hs.226581	COX15 (yeast) homolog, cytochrome c oxid	7
			9Hs.267182	TBX3-Iso protein	3.3
		BE280074		cyclin B1	5.8
		H62087	Hs.31659	thyroid hormone receptor-associated prot	7.5
40		AL080080		thloredoxin domain-containing	2.8
40				Homo saplens done F19374 APO E-C2 gene	
		X80038	Hs.339713 Hs.271623	nucleoporin 50kD	5
				HSPC182 protein	2.9
		AW410601		putative DNA binding protein	2.9
45		AA642831	Hs.311	phosphoribosyl pyrophosphate amidotransf	3.4
43		D13757	нз.311 Hs.3164	nucleobindin 2	2.9
		X76732 AW966127		Homo sapiens cDNA FLJ14656 fis, clone NT	
		BE502341		ESTs	13.7
				Homo sapiens, clone MGC:15961, mRNA, ∞	
50		AA179298	Hs.231029	stomatin-like 2	11.3
JU					2.3
		BE252983		ubiquitin specific protease 1	3.5
			Hs.154938	hypothetical protein MDS025	14.7
		NM_00446		fibroblast activation protein, alpha	7.8
c			82Hs.194714	synaptosomal-associated protein, 29kD	10
55		AA227710		DKFZP586L151 protein	9.2
	0	N36110	Hs.305971	solute carrier family 2 (facilitated glu	
		AB023191		KIAA0974 protein	2
			8 Hs.170311	heterogeneous nuclear ribonucleoprotein	12.5
<b>CO</b>		AW57280		ESTs	28.3
60		AA312135		HSPCO34 protein	6.1
		AA100012		hypothetical protein FLJ12085	8.6
		5 AW16984		KIAA1634 protein	6.1
		2 AA454132		mitochondrial ribosomal protein L16	7.1
		4 AW63143		TH1 drosophila homolog	14
65			Hs.54277	DNA segment on chromosome X (unique) 99	
		8 NM_0046		Sjogren syndrome antigen A2 (60kD, ribon	3.7
	13272	6 N52298	Hs.55608	hypothetical protein MGC955	14.3

•	132731	AI189075	Hs.301872	hypothetical protein MGC4840	5.9
		AA010233			6.4
		AA459713		KIAA0493 protein	14.6
		Al026701	Hs.5716	KIAA0310 gene product	2.5
5		AB007944		KIAA0475 gene product	4.2
•		U78525	Hs.57783		6.1
		NM 016154		Homo sapiens clone PP1596 unknown mRNA	
		U09716	Hs.287912	lectin, mannose-binding, 1	6.1
		BE267143		U2(RNU2) small nuclear RNA auxiliary fac	2.7
10		Al817165	Hs.6120	hypothetical protein FLJ13222	2.1
		AA034365		Homo sapiens cDNA FLJ11392 fis, clone HE	
		AA040696		ESTs	1.3
		AA112748		clone HQ0310 PRO0310p1	17.1
		AJ439688	Hs.6289	hypothetical protein FLJ20886	4.4
15		X97795	Hs.66718		4.4
		AI801777	Hs.6774	ESTs ·	5.5
		Al567421	Hs.273330	Homo sapiens, clone IMAGE:3544662, mRNA	
		Al160873	Hs.69233	zinc finger protein	16.1
		AW956781		ESTs, Weakly similar to FXD2_HUMAN FORK	
20		M76477	Hs.289082	GM2 ganglioside activator protein	10.4
		Al950382	Hs.72660	phosphatidylserine receptor	5.7
		AW103364		inhibin, beta A (activin A, activin AB a	25.5
		AL037159		proteasome (prosome, macropain) 26S subu	1.7
		AW160781		nuclear phosphoprotein similar to S. cer	2.6
25		NM_004893		H2A histone family, member Y	13.5
		L27841	Hs.75737	pericentriolar material 1	6.7
		BE271766		laminin receptor 1 (67kD, ribosomal prot	5.4
		BE622743		arfaptin 1	12.1
	133791	M34338	Hs.76244	spermidine synthase	9.7
30		AL133921	Hs.76272	retinoblastoma-binding protein 2	1.3
		D50525	Hs.699	peptidylprolyl isomerase B (cyclophilin	9.7
	133850	W29092	Hs.7678	cellular retinoic acld-binding protein 1	4.2
		AB011155		discs, large (Drosophila) homolog 5	5
		U30872	Hs.77204	centromere protein F (350/400kD, mitosin	9.1
35		D86326	Hs.325948	vesicle docking protein p115	1.8
	133959	X81789	Hs.77897	splicing factor 3a, subunit 3, 60kD	10.4
	133989	AL040328	Hs.78202	SWI/SNF related, matrix associated, acti	2.6
	133997	A1824113	Hs.78281	regulator of G-protein signalling 12	13
	134234	BE300078	Hs.80449	Homo sapiens, clone IMAGE:3535294, mRNA	, 10.
40	134348	AW291946	Hs.82065	Interleukin 6 signal transducer (gp130,	6.7
	134376	X06560	Hs.82396	2',5'-oligoadenylate synthetase 1 (40-46	5.5
	134379	AW362124	Hs.323193	hypothetical protein MGC3222	5.8
	134405	AW067903	Hs.82772	collagen, type XI, alpha 1	72.9
	134421	AU077196	Hs.82985	collagen, type V, alpha 2	6.7
45	134480	NM_005000	OHs.83916	Empirically selected from AFFX single pr	6.2
	134516	AK001571	Hs.273357	hypothetical protein FLJ10709	1.4
		AW411479		FK506-binding protein 4 (59kD)	2.8
		AW630803		lamin 81	6.1
		BE002798		integral membrane protein 1	1.2
50		AD001528		spermine synthase	2.6
		A1701162	Hs.90207	hypothetical protein MGC11138	9.1
		D26488	Hs.90315	KIAA0007 protein	13.3
		A1097346	Hs.286049	phosphoserine aminotransferase	2
ے ہے		BE250865		px19-like protein	14.9
55		N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATI	
	1002.10	AI028767	Hs.262603	ESTS	12.2
		AW291023		ESTs, Weakly similar to A46010 X-linked	7.6
		AI743770	Hs.98368	ESTs, Weakly similar to KIAA0822 protein	5.8
<b>C</b> 0		A1652069	Hs.98614	ribosome binding protein 1 (dog 180kD ho	12.3
60		AA456454		cell division cycle 2-like 1 (PITSLRE pr	5.7 13.9
		X78592	Hs.99915	androgen receptor (dihydrotestosterone r	
		AW057736		HER2 receptor tyrosine kinase (c	5.3
		NM_007057		ZW10 Interactor	2.8
<i>C</i> <b>E</b>		AA902256		Golgi apparatus protein 1	5.5
65		BE041451		hypothetical protein	2.9
	420802	U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	2.3

	425182	AF041259	. Hs.155040	zinc finger protein 217	2.3
	446999	AA151520	Hs.334822	hypothetical protein MGC4485	7.5
		H39960	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.6
	452461	N78223	Hs.108106	transcription factor	4.7
5	453157	AF077036	Hs.31989	DKFZP586G1722 protein	12.

# **TABLE 5A**

Table 5A shows the accession numbers for those pkeys lacking unigeneID's for Table 5. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	Pkey: CAT numb Accession	oer: Gene di	Eos probeset identifier number uster number k'accession numbers
15	Pkey	CAT number	Accessions
	123615 124385	3068615 656394_1	AA609170 Al267847 N27351
20	110856 120472	19346_14 44573_2	AA992380 N33063 N21418 H79958 R21911 H79957 AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL 134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950374 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173566
25			AW150329 Al653832 Al762688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 Al819225 AW205862 Al683338 Al858509 AW276905 Al633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA551005 W80701 AW613456 Al373032 Al564269 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005
30	129019	44573_2	Al950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 Al219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al653832 Al762688 AA988777 AA488992 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512
35			AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI564269 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005
40	122618 125115 120809	305217_1 genbank_T973 genbank_AA3	120695 9683_3 AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301 AI740458 AI796100 AI935603 AW052210 AA970201 AI633384 AA425910 AI017004 AI241295 AA402816 AA291468 AA453641 AA454061 341 T97341
45	129680	23162_1	U03749 NM_001275 J03483 J03915 AI214509 AW245744 AL046455 AA318960 AI741505 AA843875 AI829382 AI560122 AI858999 D55958 AI684005 D53170 AA854091 AI025609 D53119 D54729 D55504 D55377 D55313 AW512244 AA846441 AW043898 AI969102 AA405741 AI091983 AA788784 AA706586 AA854361 AW470949 AA843095 AA772028 AI148432 AI038109 AA782478 AA910064 AI220384 AA781296 AA843881 AA854064 AA843125 AA843419 AA319036 AA319054 AI273831 W32275 AI584185 C05724 AA789023 AI686818 D54392 AI022485 AA431410 AA854232 W39212 W15214
50	404045	ontroy IOEC4	AA894441 Al803081 Al167381 AW245389 AA319430 AA335156 Al042646 AA327030 AA725170 T27943 AA889304 AA976699 Al687001 Al621107 Al865540 AA772107 C06286 AA319661 AA405992
55	101045 110501 121558 121911	entrez_J05614 genbank_H55 genbank_AA4 genbank_AA4	748 H55748 12497 AA412497

# TABLE 6: Figure 6 from BRCA 001 US

Table 6 shows genes upregulated in tumor tissue compared to normal breast tissue.

5

-		
	Pkev:	Unique Eos probeset identifier number
	ExAccn:	Exemplar Accession number, Genbank accession number
	UnigenelD:	Unigene number
10	Unigene Title:	Unigene gene title
	R1:	Ratio of tumor to normal breast tissue

1.5	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
15	400447	D40000	Un 420240	osteoblast specific factor 2 (fasciclin	7.5
	100147			PTK2 protein tyrosine kinase 2	53.2
	1000/0	AW502935	Ha 113/09	S100 calcium-binding protein A7 (psorias	8.9
			Hs.75562	discoidin domain receptor family, member	6.9
20		U48705 X72755	Hs.77367	monokine induced by gamma interferon	8.8
20		BE246502		sema domain, immunoglobulin domain (lg),	2.6
	105745	AW151952	Hs 46679	hypothetical protein FLJ20739	1.5
		AW503807		histone acetyltransferase	1.8
		A1668594	Hs.176588		4.2
25			Hs.102950	coat protein gamma-cop	3.2
23		H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	45.7
				fibroblast growth factor 12B	38.9
	120200	AA191384	Hs.104072	ESTs, Weakly similar to Z195_HUMAN ZINC	15.2
	120624	AW407987	Hs.173518	M-phase phosphoprotein homolog	52
30		AA976503	***************************************	gb:og30a04.s1 NCI_CGAP_GC4 Homo sapiens	46.8
50		AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848	6.8
		AA402515		ESTs	28
		AA453518		ESTs	61.5
			Hs.161873	ESTs	107.3
35		AA453641		gb:zx48e06.s1 Soares_testis_NHT Homo sap	31.1
		AW204530	Hs.99500	ESTs	81.8
	122838	AA460584	Hs.334386	ESTs	75.3
	123753	AA609955	Hs.234961	Huntingtin interacting protein E	30.6
		A1267847		gb:aq49a10.x1 Stanley Frontal NB pool 2	57.1
40	124860	R65763	Hs.101477	EST	23.9
	124930	A1076343		ESTs, Weakly similar to ALUB_HUMAN !!!!	22.8
	125051	T79956	Hs.100588	EST	135.3
	128781	N71826	Hs.105465	small nuclear ribonucleoprotein polypept	53.9
	129096	AA463189	Hs.288906	WW Domain-Containing Gene	20.9
45				melanoma-associated antigen recognised b	7.6
	129689	AW748482	2 Hs.77873	B7 homolog 3	2.6
				KIAA0618 gene product	16.1
		L32137	Hs.1584	cartilage oligomeric matrix protein (pse	6.1
		AA321649		small inducible cytokine subfamily B (Cy	7.4 2.9
50		AW41060		HSPC182 protein	
			Hs.183180	anaphase promoting complex subunit 11 (y	2.7 14.7
•	132180	NM_00446	OHs.418	fibroblast activation protein, alpha	28.3
	132370	AW57280	Hs.46645	ESTs	17.1
			Hs.27990	5 clone HQ0310 PRO0310p1	4.4
55		A1439688	Hs.6289	hypothetical protein FLJ20886	16.1
		Al160873	Hs.69233	zinc finger protein	25.5
		AW10336		inhibin, beta A (activin A, activin AB a r transducer of ERBB2, 1	1.2
		A1690916		glucose-6-phosphate dehydrogenase	1.9
60	134219	NM_0004	ひとにはいひとりりつ ひょうりょう	collagen, type XI, alpha 1	729
60	13440	AW06790	J 175.02112 0 Hc 0/0	FK506-binding protein 4 (59kD)	2.8
		AW41147	9 F15.040 Hs.92186	Leman colled-coil protein	2.6
		5 R50333	ns.92100 Hs.27952		14.9
			1 Hs.17750		2.9
	32255	0 0504140	1 112/11/20	117 pourceous protein	

# TABLE 6A

Table 6A shows the accession numbers for those pkeys lacking unigeneID's for Table 6. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1	n	
1	u	
•	•	

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number

Accession: Genbank accession numbers

15

20

Pkey	CAT number	Accessions
124385	656394_1	Al267847 N27351 AA976503 Al917802 AA953664 AA404613 AA428771 BE280542 AW194691 Al927301 Al740458 Al796100 Al935603
120695	9683_3	AM9/5503 AM917802 AA953604 AA404613 AA428771 BE280542 AW194091 AM927301 AM740436 AM746100 AM955003 AW052210 AA970201 AM633384 AA425910 AM017004 AM241295 AA402816 AA291468
122618	305217 1	AA453641 AA454061

# TABLE 7: Figure 7 from BRCA 001-1 US

Table 7 shows genes upregulated in tumor tissue compared to normal breast tissue. Open reading frames in the sequences have been characterized as having a signal sequence (SS), a transmembrane domain (TM) or other.

10	Pkey:	Unique Eos probeset identifier number
	ExAccn:	Exemplar Accession number, Genbank accession number
	UnigeneiD:	Unigene number
	Unigene Title:	Unigene gene title
	R1:	Ratio of tumor to normal breast tissue

ORF struct info: Structural characterization of open reading frame for the sequence of the gene

13	ORI- Str	uct into: Stru	ctural characte	nzation of open reading trame for the sequence of t	ne gene	
	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1	ORF struct info
	100113	NM_001269	Hs.84746	chromosome condensation 1	2.3	TM
20	100114	X02308	Hs.82962	fhymidylate synthetase	2.9	other
	100131	D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodi	1.9	other
	100146	BE185499	Hs.2471	KIAA0020 gene product	1.9	TM
	100147	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.6	other
	100154	H60720	Hs.81892	KIAA0101 gene product	9.2	other
25	100163	W44671	Hs.124	gene predicted from cDNA with a complete	1.6	other
	100220	AW015534	Hs.217493	annexin A2	2	other
	100265	D38521	Hs.112396	KIAA0077 protein	1.5	other
	100271	BE160081	Hs.256290	S100 calcium-binding protein A11 (calgiz	13.5	other
	100275	BE242802	Hs.154797	KIAA0090 protein	5.1	other
30	100323	D50920	Hs.23106	KIAA0130 gene product	1.9	TM
	100335	AW247529	Hs.6793	platelet-activating factor acetylhydrola	2.7	other
	100364	NM_004341	Hs.154868	carbamoyl-phosphate synthetase 2, aspart	2	other
	100372	NM_014791	Hs.184339	KIAA0175 gene product	2.6	other
	100393	D84145	Hs.39913	novel RGD-containing protein	3.2	other
35	100400	AW954324	Hs.75790	phosphatidylinositol glycan, class C	1.5	other
	100418	D86978	Hs.84790	KIAA0225 protein	2	other
		M65028	Hs.81361	heterogeneous nuclear ribonucleoprotein	2.9	other
	100518	NM_004415	Hs.74316	desmoplakin (DPI, DPII)	1.9	other
		L05424	Hs.169610	CD44 antigen (homing function and Indian	5.7	other
40		L05424	Hs.169610	CD44 antigen (homing function and Indian	9	?
		L05424	Hs.169610	CD44 antigen (homing function and Indian	7.7	other
		AW502935	Hs.740	PTK2 protein tyrosine kinase 2	53.2	other
		AF078847	Hs.191356	general transcription factor IIH, polype	6	other
		BE245294	Hs.180789	S164 protein	1.7	٠ ?
45	100945	AF002225	Hs.180686	ubiquitin protein ligase E3A (human papi	1.5	other
		AA157634	Hs.79172	solute carrier family 25 (mitochondrial	6.3	other
		AK000405	Hs.76480	ubiquitin-like 4	11.4	?
		H38765	Hs.80706	diaphorase (NADH/NADPH) (cytochrome b-5	1.6	other
~~		J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B	8.4	other
50		J05614		gb:Human proliferating cell nuclear anti	5	?
		N99692	Hs.75227	Empirically selected from AFFX single pr	2.6	other
		L06419	Hs.75093	procollagen-lysine, 2-oxoglutarate 5-dio	1.4	7
		AA020956	Hs.179881	core-binding factor, bela subunit	2	TM
		AA284166	Hs.84113	cyclin-dependent kinase inhibitor 3 (CDK	1.8	olher
55		AA333387	Hs.82916	chaperonin containing TCP1, subunit 6A (	1.7	TM
		AA132666	Hs.78802	glycogen synthase kinase 3 beta	1.9	other
		L18964	Hs.1904	protein kinase C, iota	1.5	other
		J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	5.3	other
<b>CO</b>		AI494299	Hs.16297	COX17 (yeast) homolog, cytochrome c oxid	4.2	other
60		BE267931	Hs.78996	proliferating cell nuclear antigen	1.9	TM
		M21259	11- 4040	gb:Human Alu repeats in the region 5' to	1.6	TM
		NM_000546	Hs.1846	tumor protein p53 (LI-Fraumeni syndrome)	2.5	other
	101478	NM_002890	Hs.758	RAS p21 protein activator (GTPase activa	5.5	other

	101483	M24486	Hs.76768	procollagen-proline, 2-oxoglutarate 4-di	2.1	other
	101540	J04977 .	Hs.84981	X-ray repair complementing defective rep	1.6	other
	101573	AW248421	Hs.250758	proteasome (prosome, macropain) 26\$ subu	5.7	other
		NM_012151	Hs.83363	coagulation factor VIII-associated (intr	1.8	other
5		AF064853	Hs.91299	guanine nucleotide binding protein (G pr	5.6	?
•		BE391804	Hs.62661	guanylate binding protein 1, interferon-	2.4	other
		AW504089	Hs.179574		1.3	other
				protein phosphatase 2 (formerly 2A), reg		
		M74099	Hs.147049	cut (Drosophila)-like 1 (CCAAT displacem	2.1	?
10		M80244	Hs.184601	solute carrier family 7 (cationic amino	5	TM
10		M81057	Hs.180884	carboxypeptidase B1 (tissue)	14.4	SS,
	101782	AA306495	Hs.1869	phosphoglucomutase 1	5.2	other
	101805	AW409747	Hs.75612	stress-induced-phosphoprotein 1 (Hsp70/H	8.6	other
	101806	AA586894	Hs.112408	S100 calcium-binding protein A7 (psorlas	8.9	SS,TM
	101810	NM_000318	Hs.180612	peroxisomal membrane protein 3 (35kD, Ze	3.2	TM
15		AA176374	Hs.243886	nuclear autoantigenic sperm protein (his	1.6	other
		AA441787	Hs.119689	glycoprotein hormones, alpha polypeptide	31.3	?
		AF182645	Hs.8024	IK cytokine, down-regulator of HLA II	1.8	other
		U41514	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	2.4	other
		BE245149	Hs.82643		1.3	other
20				protein tyrosine kinase 9		
20		BE250127	Hs.82906	CDC20 (cell division cycle 20, S. cerevi	2	. ?
		T35901	Hs.75117	Interleukin enhancer binding factor 2, 4	1.6	other
		BE258602	Hs.182366	heat shock protein 75	1.4	other
	102123	NM_001809	Hs.1594	centromere protein A (17kD)	1.8	other
	102165	BE313280	Hs.159627	death associated protein 3	4.6	?
25	102198	AW950852	Hs.74598	polymerase (DNA directed), delta 2, regu	4.4	?
	102217	AA829978	Hs.301613	JTV1 gene	6.7	other
	102220	U24389	Hs.65436	lysosomal	4.4	TM
		AW163390	Hs.278554	heterochromatin-like protein 1	1.9	TM
		AL039104	Hs.159557	karyopherin alpha 2 (RAG cohort 1, impor	4.4	other
30		AA306342	Hs.69171	protein klnase C-like 2	2.7	?
50		BE298063	Hs.77254	chromobox homolog 1 (Drosophila HP1 beta	1.5	other
		BE378432	Hs.95577	cyclin-dependent kinase 4	2.3	TM
		U37519	Hs.87539		2	TM ·
				aldehyde dehydrogenase 3 family, member	3.2	
25		AU077055	Hs.289107	baculoviral IAP repeat-containing 2		other
35		U39840	Hs.299867	hepatocyte nuclear factor 3, alpha	2	other
		U33635	Hs.90572	PTK7 protein tyrosine kinase 7	6.2	other
		AA296874	Hs.77494	deoxyguanosine kinase	1.5	TM
		U48705	Hs.75562	discoldin domain receptor family, member	7	other
4.0	102465	NM_001359	Hs.81548	2,4-dienoyl CoA reductase 1, mitochondri	1.8	SS,
40	102488	U50939	Hs.61828	amyloid beta precursor protein-binding p	1.5	?
	102489	AL080116	Hs.74420	origin recognition complex, subunit 3 (y	3.3	other
	102494	AI188137	Hs.75193	COP9 homolog	2.1	other
		AF217197	Hs.74562	siah binding protein 1; FBP interacting	3.2	other
		BE250944	Hs.183556	solute carrier family 1 (neutral amino a	2.8	?
45		AF040253	Hs.70186	suppressor of Ty (S.cerevisiae) 5 homolo	5.7	ż
15		U59423	Hs.79067	MAD (mothers against decapentaplegic, Dr	2.3	other
		W81489	Hs.223025	RAB31, member RAS oncogene family	5.3	other
		U60808		CDP-diacylglycerol synthase (phosphatida	2.1	other
			Hs.152981			?
50		AU077228	Hs.77256	enhancer of zeste (Drosophila) homolog 2	1.6	
50		U61232	Hs.32675	tubulin-specific chaperone e	2.1	other
		AW161453	Hs.198767	COP9 (constitutive photomorphogenic, Ara	1.8	other
	102618	AL037672	Hs.81071	extracellular matrix protein 1	5.8	other
	102627	AL021918	Hs.158174	zinc finger protein 184 (Kruppel-like)	1.3	<ul> <li>other</li> </ul>
	102663	NM_002270	Hs.168075	karyopherin (importin) beta 2	1.8	TM
55	102676	BE262989	Hs.12045	putative protein	2.3	other
	102687	NM_007019	Hs.93002	ubiquitin carrier protein E2-C	4.4	?
		U96132	Hs.171280	hydroxyacyl-Coenzyme A dehydrogenase, ty	6	?
		BE540274	Hs.239	forkhead box M1	4.2	other
		AU077058	Hs.54089	BRCA1 associated RING domain 1	1.9	other
60		T97490	Hs.50002	small inducible cytokine subfamily A (Cy	2.3	SS,TM
50		AB014460	Hs.66196	nth (E.coli endonuclease III)-like 1	1.2	TM
		BE252241	Hs.38041	pyrldoxal (pyrldoxine, vitamin B6) kinas	6.5	other
		U90549	Hs.236774	high-mobility group (nonhistone chromoso	1.6	other
		BE244588		chaperonin containing TCP1, subunit 2 (b		TM
65			Hs.6456		5.6	
65		AV653790	Hs.324275	WW domain-containing protein 1	1.3	TM
		X02419	Hs.77274	plasminogen activator, urokinase	4.4	other
	102925	BE440142	Hs.2943	signal recognition particle 19kD	1.9	other

	102935 BE561850	Hs.80506	small nuclear ribonucleoprotein polypept	2.4	?
	102968 AU076611	Hs.154672	methylene tetrahydrofolate dehydrogenase	2.7	other
	102983 BE387202	Hs.118638	non-metastatic cells 1, protein (NM23A)	3.1	other
	102985 U95742	Hs.2707	G1 to S phase transition 1	5.2	7
5	103023 AW500470	Hs.117950	multifunctional polypeptide similar to S	1.6	other
	103038 AA926960	Hs.334883	CDC28 protein kinase 1	2.5	TM
	103060 NM_00594		matrix metalloproteinase 11 (MMP11; stro	4.5	other
	103080 AU077231	Hs.82932	cyclin D1 (PRAD1: parathyroid adenomatos	3.1	other
	103089 D31152	Hs.179729	collagen, type X, alpha 1 (Schmid metaph	2.4	other
10	103177 BE244377	Hs.48876	famesyl-diphosphate famesyltransferase	3.5	other
	103178 AA205475	Hs.275865	ribosomal protein S18	9.9	?
	103179 NM_00177	7 Hs.82685	CD47 antigen (Rh-related antigen, integr	1.3	other
	103181 X69636	Hs.334731	Homo saplens, done IMAGE:3448306, mRNA,	2	other
	103185 NM_00682	5 Hs.74368	transmembrane protein (63kD), endoplasmi	1.6	other
15	103191 AA401039	Hs.2903	protein phosphatase 4 (formerty X), cata	2.5	other
	103193 NM_00476	6 Hs.75724	coatomer protein complex, subunit beta 2	2.2	TM
	103194 NM_00493	9 Hs.78580	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	6.3	TM
	103206 X72755	Hs.77367	monokine induced by gamma interferon	8.8	TM
~ ~	103223 BE275607	Hs.1708	chaperonin containing TCP1, subunit 3 (g	3	other
20	103232 X75962	Hs.129780	tumor necrosis factor receptor superfami	1.8	other
	103238 Al369285	Hs.75189	death-associated protein	5.6	TM
	103297 NM_00154	5 Hs.9078	immature colon carcinoma transcript 1	1.9	7
	103330 Al803447	Hs.77496	small nuclear ribonucleoprotein polypept	2.5	other
	103349 X89059		gb:H.sapiens mRNA for unknown protein ex	1.6	other
25	103376 AL036166	Hs.323378	coated vesicle membrane protein	1.8	other
	103391 X94453	Hs.114366	pyrroline-5-carboxylate synthetase (glut	2.3	other
	103392 X94563		gb:H.sapiens dbl/acbp gene exon 1 & 2.	4	TM
	103430 BE564090	Hs.20716	translocase of inner mitochondrial membr	1.3	other
20	103491 AF264750	Hs.288971	myeloid/lymphoid or mixed-lineage leukem	5.7	?
30	103505 AL031224	Hs.33102	transcription factor AP-2 beta (activati	5.1	other
	103547 Al376722	Hs.180062	proteasome (prosome, macropain) subunit,	9.7	?
	103588 NM_00621		phosphoinositide-3-kinase, catalytic, al	2	other
	103613 NM_00034		SRY (sex determining region Y)-box 9 (ca	1.3	?
25	103621 BE379766	Hs.150675	polymerase (RNA) II (DNA directed) polyp	2	other
35	103622 AA609685	Hs.278672	membrane component, chromosome 11, surfa	2.3	TM
	103727 Al878883	Hs.296381	growth factor receptor-bound protein 2	1.3	other
	103754 Al015709	Hs.172089	Homo sapiens mRNA; cDNA DKFZp586l2022 (f	1.3	other
	103780 AA094752	Hs.169992	hypothetical 43.2 Kd protein	7.6	?
40	103795 H26531	Hs.7367	Homo sapiens BTB domain protein (BDPL) m	1.3	SS,TM
40	103797 AA080912	Un 101271	gb:zn04d03.r1 Stratagene hNT neuron (937	1.6	other
	103813 Al042582	Hs.181271	CGI-120 protein	1.6	other
	103855 W02363 103886 AK001278	Hs.302267 Hs.105737	hypothetical protein FLJ10330	1.6 6.6	other TM
	104052 NM_00240		hypothetical protein FLJ10416 similar to	2.9	other
45	104079 AA251242	Hs.103238	mammaglobin 2 ESTs	1.4	other
43	104174 AA478984	Hs.6451	PRO0659 protein	5.6	TM
	104227 AB002343	Hs.98938	protocadherin alpha 9	1.6	other
	104275 AI751970	Hs.101067	GCN5 (general control of amino-acid synt	5.4	other
	104325 BE379766	Hs.150675	polymerase (RNA) II (DNA directed) polyp	6.4	other
50	104370 AA324597	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	1.6	other
50	104423 R83113	Hs.1432	protein kinase C substrate 80K-H	5.2	other
	104482 AB037762	Hs.44268	myelin gene expression factor 2	1.2	other
	104667 Al239923	Hs.30098	ESTs	1.4	other
	104757 Al694413	Hs.332649	olfactory receptor, family 2, subfamily	2.4	other
55	104804 AI858702	Hs.31803	ESTs, Weakly similar to N-WASP [H.sapien	1.4	other
•••	104806 AB023175	Hs.22982	KIAA0958 protein	2.4	other
	104827 AW052006	Hs.8551	PRP4/STK/WD splicing factor	10.9	other
	104846 Al250789	Hs.32478	ESTs	5.7	other
	104854 AA041276	Hs.154729	3-phosphoinositide dependent protein kin	12.3	7
60	104867 AA278898	Hs.225979	hypothetical protein similar to small G	2.1	other
	104871 178044	Hs.28893	Homo sapiens mRNA; cDNA DKFZp564O2364 (f	1.4	other
	104896 AW015318	Hs.23165	ESTs	17.7	other
	104909 AW408164	Hs.249184	transcription factor 19 (SC1)	5.1	TM
	104916 AW958157	Hs.155489	NS1-associated protein 1	1.8	other
65	104919 AA026880	Hs.25252	prolactin receptor	1.5	other
	104930 AF043467	Hs.32893	neurexophilin 2	2.3	other
	104973 NM_01531	0 Hs.6763	KIAA0942 protein	5.1	other

	104974	Y12059	Hs.278675	bromodomain-containing 4	1.5	other
	104975	AL136877	Hs.50758	SMC4 (structural maintenance of chromoso	2.4	other
	104978	AI199268	Hs.19322	Homo saplens, Similar to RIKEN cDNA 2010	7.3	other
	104979	AA937934	Hs.321062	ESTs	1.3	other
5	104994	A1499930	Hs.334885	mitochondrial GTP binding protein	3.6	7
	105009	BE379584	Hs.34789	dolichyl-diphosphooligosaccharide-protei	5.6	other
	105012	AF098158	Hs.9329	chromosome 20 open reading frame 1	3.4	other
	105028	AI050715	Hs.2331	E2F transcription factor 5, p130-binding	2.2	other
	105041	AB037716	Hs.26204	KIAA1295 protein	2.2	other
10	105045	BE242899	Hs.129951	speckle-type POZ protein	3.9	?
	105079	AA151342	Hs.12677	CGI-147 protein	9.5	TM
		AA147884	Hs.9812	Homo saplens cDNA FLJ14388 fis, clone HE	5.7	other
	105088	H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	2.2 .	other
		Z78407	Hs.27023	vesicle transport-related protein	2.2	other
15		BE387350	Hs.33122	KIAA1160 protein	1.6	other
		AW975433	Hs.36288	ESTs	6.4	?
		AA045648	Hs.301957	nudix (nucleoside diphosphate linked moi	2.2	other
		AA164687	Hs.177576	mannosyl (alpha-1,3-)-glycoprotein beta-	2.8	other
		AW976357	Hs.234545	hypothetical protein NUF2R	2	other
20		BE245294	Hs.180789	S164 protein	1.7	other
		AA191512	Hs.28005	Homo sapiens cDNA FLJ11309 fis, clone PL	4.9	SS,TM
		AA071276	Hs.19469	KIAA0859 protein	2	TM
		AA263143	Hs.24596	RAD51-interacting protein	2.9	7
		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ	1.9	TM
25		AA700122	Hs.3355	sentrin-specific protease	8.2	7
		AW270037	Hs.179507	KIAA0779 protein	1.8	SS,
		NM 016015	Hs.8054	CGI-68 protein	8.4	other
		BE264645	Hs.282093	hypothetical protein FLJ21918	5.1	other
		AW887701	Hs.32356	hypothetical protein FLJ20628	2.6	other
30		BE242803	Hs.262823	hypothetical protein FLJ10326	2.2	TM
		AW592146	Hs.108636	membrane protein CH1	2.3	SS,TM
		AF167570	Hs.256583	interleukin enhancer binding factor 3, 9	5.5	SS,
		BE386877	Hs.334811	Npw38-blnding protein NpwBP	1.6	other
		AF198620	Hs.65648	RNA binding motif protein 8A	1.6	other
35		AA252395		gb:zs12g10.s1 NCI_CGAP_GCB1 Homo sapiens	5.1	?
	105507	BE268348	Hs.226318	CCR4-NOT transcription complex, subunit	1.6	other
	105529	AA113449	Hs.32471	hypothetical protein FLJ20364	1.3	other
		AB023179	Hs.9059	KIAA0962 protein	3.5	other
		AA262640	Hs.27445	unknown	9.3	other
40		BE616694	Hs.288042	hypothetical protein FLJ14299	1.4	other
		AA579535	Hs.18490	hypothetical protein FLJ20452	10.9	TM
		AF054284	Hs.334826	splicing factor 3b, subunit 1, 155kD	2.9	TM
		AI808201	Hs.287863	hypothetical protein FLJ12475	1.7	?
		AA280072	Hs.99872	fetal Alzheimer antigen	1.4	other
45		AK000892	Hs.4069	glucocorticold modulatory element bindin	1.7	TM
		AW302245	Hs.181390	casein kinase 1, gamma 2	5.6	other
		AA985190	Hs.246875	hypothetical protein FLJ20059	9.4	other
		AW499988	Hs.27801	zinc finger protein 278	2	TM
		R26944	Hs.180777	Homo sapiens mRNA; cDNA DKFZp564M0264 (f	1.7	other
50		BE246502	Hs.9598	sema domain, immunoglobulin domain (ig),	2.7	other
		AW151952	Hs.46679	hypothetical protein FLJ20739	1.5	?
		Al123118	Hs.15159	chemokine-like factor, alternatively spl	1.3	other
		AI267720	Hs.153221	synovial sarcoma, translocated to X chro	1.6	other
		AA741336	Hs.152108	transcriptional unit N143	2.2	other
55		AA478756	Hs.194477	E3 ubiquitin ligase SMURF2	1.3	other
		Al262106	Hs.12653	ESTs	2.4	other
		AF151066	Hs.281428	hypothetical protein	2.9	other
		AK001708	Hs.32271	hypothetical protein FLJ10846	1.4	other
		AF016371	Hs.9880	peptidyl prolyl isomerase H (cyclophilin	5.3	other
60		AW194426	Hs.20726	ESTs	1.7	other
30		AW081202	Hs.12284	Homo sapiens, clone IMAGE:2989556, mRNA,	2.8	other
		AA477956	Hs.26268	ESTs	1.4	other
		AL157441	Hs.17834	downstream neighbor of SON	1.4	other
		AA130158	Hs.19977	ESTs, Moderately similar to ALU8_HUMAN A	1.6	?
65		AA533491	Hs.23317	hypothetical protein FLJ14681	6.9	other
		AB006624	Hs.14912	KIAA0286 protein	1.6	other
		AA251393	Hs.289052	Homo sapiens, Similar to RIKEN cDNA 5430	10.8	?

		AB037742	Hs.24336	KIAA1321 protein	1.3	other
		Y10043	Hs.19114	high-mobility group (nonhistone chromoso	3.7	other
		AL043114	Hs.22410	ESTs, Weakly similar to A54849 collagen	5.5	SS,
5		AK001404	Hs.194698	cyclin B2	5.8	other
,		AW390282 AB040916	Hs.31130	transmembrane 7 superfamily member 2	6.4	other
		AW748420	Hs.24106	KIAA1483 protein	6.6	other
		AF119256	Hs.6236 Hs.27801	Homo sapiens cDNA: FLJ21487 fis, clone C	2.2	TM
		D63078	Hs.186180	zinc finger protein 278 Homo saplens cDNA: FLJ23038 fis, clone L	2.7 2.3	other
10		AA243837	Hs.57787	ESTs	1.6	other other
		AK000933	Hs.28661	Homo sapiens cDNA FLJ10071 fis, clone HE	2.4	?
		AA458882	Hs.79732	fibulin 1	8	ss,
		NM_003595	Hs.26350	tyrosylprotein sulfotransferase 2	7.8	other
	106650	AL049951	Hs.22370	Homo sapiens mRNA; cDNA DKFZp56400122 (f	1.8	other
15		AV657117	Hs.184164	ESTs, Moderately similar to S65657 alpha	1.3	TM
		BE614802	Hs.184352	hypothetical protein FLJ12549	4.6	other
		AA600357	Hs.239489	TIA1 cytotoxic granule-associated RNA-bi	1.3	other
		BE388094	Hs.21857	ESTs	1.6	SS,
20		AF174487	Hs.293753	Bcl-2-related ovarian killer protein-lik	5.7	other
20		AW959893	Hs.27099	hypothetical protein FLJ23293 similar to	16.2	TM
		BE564871	Hs.29463	centrin, EF-hand protein, 3 (CDC31 yeast	1.5	other
		AB037744	Hs.34892	KIAA1323 protein	2.2	other
		AF151031 N49809	Hs.300631	hypothetical protein	1.3	other
25		W79171	Hs.11197 Hs.9567	Homo sapiens, clone IMAGE:3343149, mRNA, GL002 protein	16.8	other
		AA861271	Hs.222024	transcription factor BMAL2	1.5 2.2	TM other
		AK001838	Hs.296323	serum/glucocorticold regulated kinase	3.4	other
		AK000511	Hs.6294	hypothetical protein DKFZp434L1435 simil	6.8	?
		BE156256	Hs.11923	hypothetical protein	6.7	other
30		AW631480	Hs.8688	ESTs	6.1	SS,
	107004	AA146872	Hs.300700	hypothetical protein FLJ20727	1.3	other
	107029	AF264750	Hs.288971	myeloid/lymphold or mixed-lineage leukem	1.8	other
		AW385224	Hs.35198	ectonucleotide pyrophosphatase/phosphodi	1.7	other
25		AK000733	Hs.23900	GTPase activating protein	2.5	other
35		AK000512	Hs.69388	hypothetical protein FLJ20505	1.7	other
		AV661958	Hs.8207	GK001 protein	4.7	other
		AK001455	Hs.5198	Down syndrome critical region gene 2	2	other
		AW378065	Hs.8687	ESTS	6.4	TM
40		AW391927 BE122762	Hs.7946	KIAA1288 protein	33.5	other
40		W15477	Hs.25338 Hs.64639	ESTS	5.2	?
		AW888411	Hs.81915	glioma pathogenesis-related protein	6.1	other
		BE219716	Hs.34727	leukemia-associated phosphoprotein p18 ( ESTs, Moderately similar to 138759 zinc	17.4 7.4	other ?
		AW263124	Hs.315111	nudear receptor co-repressor/HDAC3 comp	1.8	other
45	107263		Hs.21198	translocase of outer mitochondrial membr	6.7	other
		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	2.5	other
		BE277457	Hs.30661	hypothetical protein MGC4606	3.2	TM
	107316	T63174	Hs.193700	Homo sapiens mRNA; cDNA DKFZp586I0324 (f	2	TM
~ ~	107354	NM_006299	Hs.96448	zinc finger protein 193	5	?
50		AW299900	Hs.267632	TATA element modulatory factor 1	1.2	other
		AA307703	Hs.279766	kinesin family member 4A	1.6	other
		BE515065	Hs.296585	nucleolar protein (KKE/D repeat)	3	TM
		AA001386	Hs.59844	ESTs	1.4	other
55		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	2.3	SS,TM
33		AA018587	Hs.303055	ESTs, Weakly similar to ALU1_HUMAN ALU S	2.2	?
	107901	AW732573	Hs.47584	potassium voltage-gated channel, delayed keratin 6B	8.4	TM
		BE153855	Hs.335952 Hs.61460	lg superfamily receptor LNIR	2.5	other
		AW956103	Hs.61712	pyruvate dehydrogenase kinase, isoenzyme	2.3 6.8	other other
60		AL121031	Hs.159971	SWI/SNF related, matrix associated, acti	1.6	other
		AA054224	Hs.59847	ESTs	1.3	other
		AF129535	Hs.272027	F-box only protein 5	7.2	?
	108296		Hs.161623	ESTs	2.6	other
		AA083069	Hs.339659	ESTs	3.6	olher
65		BE300380	Hs.69476	Homo sapiens cDNA FLJ12758 fis, clone NT	3.5	other
		AA101809	Hs.182685	ESTs	1.7	other
	108634	AW022410	Hs.69507	ESTs	1.8	SS,TM

	108647	BE546947	Hs.44276	homeo box C10	9.8	other
	108695	AB029000	Hs.70823	KIAA1077 protein	7.3	other
	108740	AI089575	Hs.9071	progesterone membrane binding protein	2.8	7
_		AK001693	Hs.273344	DKFZP564O0463 protein	1.9	other
5		AL121500	Hs.178904	ESTs	1.6	TM
		H06720	Hs.111680	endosulfine alpha	2.2	other
		AI801235	Hs.48480	ESTs	5.4	other
		AK001431	Hs.5105	hypothetical protein FLJ10569	4.1	TM
10		AA149754	Hs.195155	Homo sapiens amino acid transport system	5.7	3
10		AA151708	Hs.171980	homeo box (expressed in ES cells) 1	1.7	other
		AA152178	Hs.23467	hypothetical protein FLJ10633	6.3	other
		AB028987	Hs.72134	KIAA1064 protein	1.7	other
		AA156542	Hs.72127	ESTs ·	1.5	other
15		AA157811	11- 70040	gb:zo35d07.s1 Stratagene colon (937204)	5.4	other
15		AA164293	Hs.72545	ESTS	3	other
		AW608930	Hs.52184	hypothetical protein FLJ20618	1.6	SS. TM
		AW419196	Hs.257924	hypothetical protein FLJ13782	3.3 1.7	
		AK000684 AJ132592	Hs.183887 Hs.59757	hypothetical protein FLJ22104 zinc finger protein 281	2.7	other other
20		AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	3 .	TM
20		BE566742	Hs.58169	highly expressed in cancer, rich in leuc	2.1	other
		NM_016603	Hs.82035	potential nuclear protein C5ORF5; GAP-II	5.4	other
		AW958181	Hs.189998	ESTs	5.8	other
		AU077281	Hs.170285	nucleoporin 214kD (CAIN)	5.3	other
25		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ	1.4	other
		AA375752	Hs.82719	Homo sapiens mRNA; cDNA DKFZp586F1822 (f	3	other
		AF153201	Hs.86276	C2H2 (Kruppel-type) zinc finger protein	1.3	other
		AA213506	Hs.115099	EST	3	7
		AL096858	Hs.184245	KIAA0929 protein Msx2 Interacting nuclea	1.5	other
30		H83603	Hs.40408	homeo box C9	2.2	SS,
-	109426	N30531	Hs.42215	protein phosphatase 1, regulatory subuni	3.1	TM
	109429	A1160029	Hs.61438	ESTs	2	?
	109445	AA232103	Hs.189915	ESTs	1.8	other
	109450	AB032969	Hs.173042	KIAA1143 protein	3.8	other
35	109468	NM_015310	Hs.6763	KIAA0942 protein	3.3	other
		AW074143	Hs.87134	ESTs	2	TM
		L40027	Hs.118890	glycogen synthase kinase 3 alpha	2.1	other
		F02614	Hs.27319	ESTs	1.4	other
40		R71264	Hs.16798	ESTs	1.3	other
40		H11938	Hs.21907	histone acetyltransferase	2	other
		AA503041	Hs.279009	matrix Gla protein	2.5	other
		AA603840	Hs.29956	KIAA0460 protein	1.7	other
		T07353	Hs.7948 Hs.226429	ESTS	2.9 1.7	other
45		R51853	Hs.17667	ESTs, Wealdy similar to ALU1_HUMAN ALU S	4.3	SS, other
73		NM_014521 Al668594	Hs.176588	SH3-domain binding protein 4 ESTs, Weakly similar to CP4Y_HUMAN CYTOC	4.3	?
		N41744	Hs.19978	CGI-30 protein	1.3	other
		H28428	Hs.32406	ESTs, Weakly similar to 138022 hypotheti	2.2	other
		BE256986	Hs.11896	hypothetical protein FLJ12089	2.1	other
50		H55748	110.11000	gb:yq94a01.s1 Soares fetal liver spleen	6.1	?
-		H55915	Hs.210859	hypothetical prolein FLJ11016	6.1	TM
		H57330	Hs.37430	EST	6.4	other
		AK001160	Hs.5999	hypothetical protein FLJ10298	1.3	7
		T97586	Hs.18090	ESTs	1.8	other
55		AB007902	Hs.32168	KIAA0442 protein	1.6	TM
		AW190338	Hs.28029	hypothelical protein MGC11256	7.8	other
		AL138077	Hs.16157	hypothetical protein FLJ12707	2.5	other
	110762	BE044245	Hs.30011	hypothetical protein MGC2963	9.3	7
		AK000322	Hs.18457	hypothetical protein FLJ20315	5.5	SS,
60		BE000831	Hs.23837	Homo saplens cDNA FLJ11812 fis, clone HE	2.1	TM
		AI089660	Hs.323401	dpy-30-like protein	1.5	TM
		T25829	Hs.24048	FK506 binding protein precursor	6.7	TM
		AA767373	Hs.35669	ESTs, Moderately similar to ALU1_HUMAN A	5.7	other
CF		R33261	Hs.6614	ESTs, Weakly similar to A43932 much 2 p	3.4	other
65		N31598	Hs.12727	hypothetical protein FLJ21610	1.7	TM
		AI740792	Hs.167531	methylcrotonoyl-Coenzyme A carboxylase 2	1.7	other
	PCOUL I	BE612992	Hs.27931	hypothetical protein FLJ10607 similar to	4.7	other

	110856 AA992380		gb:ot37g06.s1 Soares_testis_NHT Homo sap	2.3	other
	110885 BE384447	Hs.16034	hypothetical protein MGC13186	3.5	7
	110897 AL117430	Hs.6880	DKFZP434D156 protein	2.2	?
5	110915 BE092285 110918 H04360	Hs.29724	hypothetical protein FLJ13187	2.6	SS,
,	110958 NM_005864	Hs.24283 Hs.24587	ESTs, Moderately similar to reduced expr	1.9	TM
	110963 AK002180	Hs.11449	signal transduction protein (SH3 contain	6.7	other
	110981 AK001980	Hs.24284	DKFZP564O123 protein	2 1.3	other
	110984 AW613287	Hs.80120	ADP-ribosyltransferase (NAD+; poly(ADP-r UDP-N-acetyl-alpha-D-galactosamine:polyp	1.8	other ?
10	111125 N63823	Hs.269115	ESTs, Moderately similar to Z195_HUMAN Z	3.7	other
	111132 AB037807	Hs.83293	hypothetical protein	2.1	TM
	111164 N46180	Hs.122489	Homo sapiens cDNA FLJ13289 fis, clone OV	2.3	other
	111172 R67419	Hs.21851	Homo saplens cDNA FLJ12900 fis, clone NT	3.7	other
1.0	111174 AL050166	Hs.26295	Homo sapiens mRNA; cDNA DKFZp586D1122 (f	7.5	other
15	111179 AK000136	Hs.10760	asporin (LRR class 1)	7.1	other
	111184 AI815486	Hs.243901	Homo sapiens cDNA FLJ20738 fis, clone HE	6.8	other
	111189 N67603	Hs.272130	ESTs, Weakly similar to S65824 reverse t	3.6	SS,
	111216 AW139408	Hs.152940	ESTs	1.5	other
20	111221 AB037782 111223 AA852773	Hs.15119	KIAA1361 protein	2.6	other
20	111239 N90956	Hs.334838 Hs.17230	KIAA1866 protein	4.7	other
	111285 AA778711	Hs.4310	hypothetical protein FLJ22087 eukaryotic translation initiation factor	7.9 7	? other
	111299 AB033091	Hs.74313	KIAA1265 protein	5	other
	111312 Al523913	Hs.34504	ESTs	3.8	other
25	111318 T99755	Hs.334728	ESTs	1.2	TM
	111337 AA837396	Hs.263925	LIS1-interacting protein NUDE1, rat homo	5.1	other
	111352 H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	2.2	other
	111370 Al478658	Hs.94631	brefeldin A-Inhibited guanine nucleotide	2.8	?
30	111384 N94606	Hs.288969	HSCARG protein	2.2	other
30	111389 AK000987	Hs.169111	oxidation resistance 1	2.1	other
	111452 R02354 111486 Al051194	Hs.15999 Hs.227978	ESTs	2.7	TM
	111549 W90638	Hs.20321	EST Moderately similar to 7051 UNIMAN 7	6.6 1.4	other
	111585 R10720	Hs.20670	ESTs, Moderately similar to ZRF1_HUMAN Z EST	1.6	other ?
35	111627 R52656	Hs.21691	ESTs	1.6	other
• •	111870 AB037834	Hs.18685	Homo sapiens mRNA for KIAA1413 protein,	2.4	other
	111937 BE298665	Hs.14846	Homo sapiens mRNA; cDNA DKFZp564D016 (fr	10.6	other
	111944 AW083791	Hs.21263	suppressor of potassium transport defect	6.6	TM
40	111987 NM_015310	Hs.6763	KIAA0942 protein	5.1	other
40	112134 R41823	Hs.7413	ESTs; calsyntenin-2	2.8	other
	112244 AB029000	Hs.70823	KIAA1077 protein	14.6	other
	112388 R46071	Hs.301693	Homo saplens, clone IMAGE:3638994, mRNA,	9	other
	112456 NM_016248 112464 AW007287	Hs.232076	A kinase (PRKA) anchor protein 11	1.4	other
45	112506 AI742756	Hs.28538 Hs.26079	Homo sapiens cDNA: FLJ21086 fis, clone C ESTs	1.4	TM
15	112513 R68425	Hs.13809	hypothetical protein FLJ10648	3.2 2	other TM
	112752 AK001635	Hs.14838	hypothetical protein FLJ10773	1.8	other
	112884 AK000004	Hs.5013	Homo sapiens mRNA for FLJ00004 protein,	6.6	other
	112923 T10258	Hs.5037	EST	1.5	?
50	112936 AW970826	Hs.6185	KIAA1557 protein	3.2	other
	112958 R61388	Hs.6724	ESTs	6.1	other
	112966 Z44718	Hs.102548	glucocorticoid receptor DNA binding fact	6.5	other
	112978 AK000272	Hs.7099	hypothetical protein FLJ20265	1.2	other
55	112995 AA737033	Hs.7155	ESTs, Moderately similar to 2115357A TYK	5.6	other
55	112996 BE276112	Hs.7165 -	zInc finger protein 259 ESTs	2	other
	113047 Al571940 113049 AW965190	Hs.7549 Hs.7560	Homo sapiens mRNA for KIAA1729 protein,	1.9 2.4	other TM
	113089 T40707	Hs.270862	ESTs	1.3	SS,
	113196 T57317		gb:yb51a03.s1 Stratagene fetal spleen (9	1.7	other
60	113248 T63857		gb:yc16e01.s1 Stratagene lung (937210) H	2.8	other
	113254 AK002180	Hs.11449	DKFZP564O123 protein	1.3	other
	113277 AW971049	Hs.11774	protein (peptidyl-prolyl cis/trans isome	3.2	other
	113429 AA688021	Hs.179808	ESTs	1.2	other
65	113499 Al467908	Hs.8882	ESTs	6	other
65	113547 H59588	Hs.15233	ESTS	2	SS,
	113647 AA813887 113702 T97307	Hs.188173	Homo sapiens cDNA FLJ12187 fis, clone MA gb:ye53h05.s1 Soares fetal liver spleen	1.3	SS,
	113102 13/30/		go.jcconoo.s i ouares retai liver speen	4.4	other
			157		

		AW499665	Hs.9456	SWI/SNF related, matrix associated, acti	1.2	other	
	113777	BE266947	Hs.10590	zinc finger protein 313	13.4	other	
	113783	AL359588	Hs.7041	hypothetical protein DKFZp762B226	1.7	other	
	113791	A1269096	Hs.135578	chitobiase, di-N-acetyl-	1.3	other	
5	113808	W44735	Hs.9286	Homo saplens cDNA: FLJ21278 fis, clone C	3.3	other	
		BE207480	Hs.6994	Homo sapiens cDNA: FLJ22044 fis, clone H	3.1	other	
		H13325	Hs.332795	hypothetical protein DKFZp761O17121	3.2	other	
		AW378212	Hs.24809	hypothetical protein FLJ10826	2.3	?	
		T26483	Hs.6059	EGF-containing fibulin-like extracellula	11.3	TM	
10		W57902	Hs.90744	proteasome (prosome, macropain) 26S subu	2.7	other	
10							
		AL079314	Hs.16537	hypothetical protein, similar to (U06944	6.1	other	
		AW959486	Hs.21732	ESTs	6.6	other	
		AW953484	Hs.3849	hypothetical protein FLJ22041 similar to	1.9	?	
1.5		W87544	Hs.268828	ESTs	1.2	other	
15		Al539519	Hs.120969	Homo saplens cDNA FLI11562 fis, clone HE	5.4	other	
		Al825386	Hs.164478	hypothetical protein FLJ21939 similar to	9.4	other	
		AB029551	Hs.7910	RING1 and YY1 binding protein	1.8	other	
	114196	AF017445	Hs.150926	fucose-1-phosphate guanylyltransferase	1.5	other	
	114226	AB028968	Hs.7989	KIAA1045 protein	1.8	other	
20	114253	BE149866	Hs.14831	Homo sapiens, Similar to zinc finger pro	2.3	other	
		AL117518	Hs.3686	KIAA0978 protein	1.4	TM	
		AW515443.co		Hs.306117		6 protein 15.8 ·	other
		Al815395	Hs.184641	fatty acid desaturase 2	1.9	TM	
		AA332453	Hs.20824	CGI-85 protein	2.4	other	
25		AA249590	Hs.100748	ESTs, Weakly similar to A28996 proline-r	1.9	other	
43		BE539976	Hs.103305		1.3	TM	
				Homo sapiens mRNA; cDNA DKFZp434B0425 (f			
		H37908	Hs.271616	ESTs, Weakly similar to ALU8_HUMAN ALU S	5.6	other	
		AL120247	Hs.40109	KIAA0872 protein	5.3	TM	
20		AI091713	Hs.106597	Homo sapiens, Similar to RIKEN cDNA 1110	1.3	other	
30		AA028074	Hs.104613	RP42 homolog	1.9	?	
		BE066778	Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:polyp	13.4	other	
		AA766268	Hs.266273	hypothetical protein FLJ13346	2	other	
	114698	AA476966	Hs.110857	polymerase (RNA) III (DNA directed) poly	3.6	other	
	114730	Al373544	Hs.331328	intermediate filament protein syncollin	3.9	other	
35	114767	Al859865	Hs.154443	minichromosome maintenance deficient (S.	1.7	other	
	114774	AV656017	Hs.184325	CGI-76 protein	3.2	other	
	114798	AA159181	Hs.54900	serologically defined colon cancer antig	3.6	other	
		AL157545	Hs.42179	bromodomain and PHD finger containing, 3	4.4	other	
		AA236177	Hs.76591	KIAA0887 protein	7.2	other	
40		BE539101	Hs.5324	hypothetical protein	1.3	other	
••		AA236672	110.006-7	gb:zt29f02.s1 Soares ovary tumor NbHOT H	1.5	other	
		AA237022	Hs.188717	ESTs	2	SS,	
					2.9	other	
		AA242834	Hs.58384	ESTS PAR		7	
15		AI733881	Hs.72472	BMP-R1B	2.3		
45		AF102546	Hs.63931	dachshund (Drosophila) homolog	1.3	other	
		AA252360	Hs.87968	toll-like receptor 9	1.6	other	
		Al751438	Hs.41271	Homo sapiens mRNA full length insert cDN	11.8	other	
	115117	A1670847	Hs.5324	hypothetical protein	1.5	other	
	115206	AW183695	Hs.186572	ESTs	2.5	other	
50	115221	AW365434	Hs.79741	hypothetical protein FLJ10116	1.5	other	
	115239	BE251328	Hs.73291	hypothetical protein FLJ10881	1.3	TM	
		AI368236	Hs.283732	ESTs, Moderately similar to ALU1_HUMAN A	1.4	other	
		AK002163	Hs.301724	hypothetical protein FLJ11301	1.5	other	
		AW972872	Hs.293736	ESTs	2.4	other	
55		BE545072	Hs.122579	hypothetical protein FLJ10461	6.3	SS,	
55		AI215069	Hs.89113	FOT-	6.7	7	
			Hs.48499	tumor antigen SLP-8p	7.5	7	
		AA314349		hypothetical protein FLJ10514	1.4	TM	
		AK001376	Hs.59346				
<b>CO</b>		AW301608	Hs.278188	ESTs, Moderately similar to 154374 gene	4.1	TM	
60		AW247593	Hs.71819	eukaryotic translation initiation factor	16.3	other	
		Y14443	Hs.88219	zinc finger protein 200	5	other	
		AJ275986	Hs.71414	transcription factor (SMIF gene)	2.5	other	
		A1540842	Hs.61082	ESTs	6.2	other	
	115587	BE081342	Hs.283037	HSPC039 protein	2.9	other	
65	115590	AA399477	Hs.67896	7-60 protein	5.3	TM	
		N36110	Hs.305971	solute carrier family 2 (facilitated glu	4.8	?	
		BE093589	Hs.38178	hypothetical protein FL123468	10.6	other	

	115655	AL048269	Hs.288544	Homo sapiens, done MGC:16063, mRNA, com	12.7	TM
		Al138785	Hs.40507	ESTs	2	other
		AA953006	Hs.88143	ESTs	3.1	other
5		AA625132	Hs.44159	hypothetical protein FLJ21615	1.7	TM
,		AF231023 BE395161	Hs.55173	cadherin, EGF LAG seven-pass G-type rece	6.9	other
		AI950339	Hs.1390 Hs.40782	proteasome (prosome, macropain) subunit, ESTs	1.7 2.7	other TM
		NM_015434	Hs.48604	DKFZP434B168 protein	2.1	other
		AI732742	Hs.87440	ESTs	2.1	other
10		AI675217	Hs.42761	ESTs	1.3	other
	115844	AI373062	Hs.332938	hypothetical protein MGC5370	4.4	other
	115866	AW062629	Hs.52081	KIAA0867 protein	7.3	other
		N55669	Hs.333823	mitochondrial ribosomal protein L13	1.2	other
16		Al867451	Hs.46679	hypothetical protein FLJ20739	5.5	other
15		AB037753	Hs.62767	KIAA1332 protein	9.8	other
		BE275469	Hs.66493	Down syndrome critical region gene 5	1.4	other
		AL359053 AA770688	Hs.57664 Hs.28777	Homo saplens mRNA full length insert cDN	2.4	other
		BE243834	Hs.50441	H2A histone family, member L CGI-04 protein	1.8 1.4	other other
20		N35719	Hs.44749	ESTs, Moderately similar to T00358 hypot	1.2	other
		AW821113	Hs.72402	ESTs	2.1	other
		AV660717	Hs.47144	DKFZP586N0819 protein	1.7	other
	116246	AF265555	Hs.250646	baculoviral IAP repeat-containing 6	1.7	other
~ ~		Al936442	Hs.59838	hypothetical protein FLJ10808	1.8	?
25		Al955411	Hs.94109	Homo saplens cDNA FLJ13634 fis, clone PL	1.9	other
		AF097645	Hs.58570	deleted in cancer 1; RNA helicase HDB/DI	5	SS,
		AI472106	Hs.49303	Homo sapiens cDNA FLJ11663 fis, clone HE	1.4	SS,
		AL133033 AK000290	Hs.4084 Hs.44033	KIAA1025 protein	1.9	?
30		AA497129	Hs.184771	dipeptidyl peptidase 8 nuclear factor I/C (CCAAT-binding transc	1.5 1.9	other
50		AI149586	Hs.38125	interferon-induced protein 75, 52kD	1.9	7
		N50174	Hs.46765	ESTs	6.1	other
		N90466	Hs.71109	KIAA1229 protein	1.6	?
	116417	AW499664	Hs.12484	Human clone 23826 mRNA sequence	7.4	other
35		AA161411	Hs.58668	chromosome 21 open reading frame 57	2.1	other
		AF218313	Hs.236828	putative helicase RUVBL	1.5	TM
		A1272141	Hs.83484	SRY (sex determining region Y)-box 4	2.1	TM
		AA312572 AK001043	Hs.6241 Hs.92033	phosphoinositide-3-kinase, regulatory su	1.5	other
40		X89984	Hs.211563	integrin-linked kinase-associated serine B-cell CLL/lymphoma 7A	2.7 2.3	other other
		A1800202	Hs.317589	hypothetical protein MGC10765	1.4	other
		AW074819	Hs. 12313	hypothetical protein FLJ14566	3.4	other
		AW152225	Hs.165909	ESTs, Weakly similar to I38022 hypotheti	2.9	other
	116926	H73608	Hs.290830	ESTs	1.7	TM
45		U72209	Hs.180324	YY1-associated factor 2	3.4	TM
		AI393666	Hs.42315	p10-binding protein	5.2	7
		N21032	11 404000	gb:yx46f06.s1 Soares melanocyte 2NbHM Ho	5.5	TM
		N71183	Hs.121806	Homo sapiens cDNA FLJ11971 fis, clone HE	1.5	TM
50		AK001701 Al041793	Hs.183779 Hs.42502	Homo sapiens cDNA FLJ10590 fis, clone NT ESTs	2 2	other other
50		Al878942	Hs.90336	ATPase, H+ transporting, lysosomal (vacu	2.1	?
		AF150275	Hs.40173	ESTs	2.7	TM
	117412		Hs.42645	solute carrier family 16 (monocarboxylic	1.4	other
	117557	AF123050	Hs.44532	diubiquitin	3.4	TM
55		N34895	Hs.44648	ESTs	3.4	?
	117745	BE294925	Hs.46680	CGI-12 protein	3	SS,
		AA121673	Hs.59/5/	zinc tinger protein 281	1.9	other
	117879		Hs.303025	chromosome 11 open reading frame 24	1.8	other
60		BE540675 AL137379	Hs.332938 Hs.47125	hypothetical protein MGC5370 hypothetical protein FLJ13912	6 1.7	? other
00	117933		Hs.116470	hypothetical protein FLJ20048	1.7	other
		AL110246	Hs.47367	KIAA1785 protein	5.4	other
	118078		Hs.47790	EST	5.2	other
	118301	AA453902	Hs.293264	ESTs	2.6	other
65		AA243332	Hs.74649	cytochrome c oxidase subunit Vtc	2.5	TM
		AL157545	Hs.42179	bromodomain and PHD finger containing, 3	4.1	other
	118488	AJ277275	Hs.50102	rapa-2 (rapa gene)	1.2	other

	118509	N22617	Hs.43228	Homo sapiens cDNA FLJ11835 fis, clone HE	1.5	other
	118528	A1949952	Hs.49397	ESTs	7.4	?
	118656	AI458020	Hs.293287	ESTs	2.5	other
	118670	AA332845	Hs.152618	ESTs, Moderately similar to ZN91_HUMAN Z	1.2	TM
5		AB033113	Hs.50187	KIAA1287 protein	2.1	TM
•		AA199686		gb:zq75g09.r1 Stratagene hNT neuron (937	5.2	other
		N92293	Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A	1.4	other
		AI668709	Hs.240722	ESTs, Moderately similar to ALU8_HUMAN A	3.6	other
		AF148713	Hs.125830		4.9	?
10				bladder cancer overexpressed protein	1.7	TM
10		W24781	Hs.293798	KIAA1710 protein		
		AW453069	Hs.3657	activity-dependent neuroprotective prote	2.2	other
		BE539706	Hs.285363	ESTs	1.4	?
		N57568	Hs.48028	EST	25.1	other
		NM_001241	Hs.155478	cyclin T2	1.6	?
15	119338	AI417240	Hs.320836	ESTs, Weakly similar to A47582 B-cell gr	1.3	other
	119403	AL117554	Hs.119908	nucleolar protein NOP5/NOP58	6.7	TM
	119478	A1624342	Hs.170042	ESTs	2.4	other
	119486	AI796730	Hs.55513	ESTs	2.1	other
	119513	W37933		Empirically selected from AFFX single pr	1.9	other
20		AK000155	Hs.91684	Homo saplens mRNA; cDNA DKFZp667I103 (fr	3.7	TM
		AW675298	Hs.233694	hypothetical protein FLJ11350	3	other
		AA243837	Hs.57787	ESTs	1.4	other
		W61019	Hs.57811	ESTs	1.2	?
		AB032977	Hs.6298	KIAA1151 protein	1.8	тM
25					3.1	other
23		NM_016625	Hs.191381	hypothetical protein		
		BE393948	Hs.50915	kallikreln 5 (KLK5; KLK-L2; stratum com	9.2	other
		AJ223810	Hs.43213	ESTs, Weakly similar to IEFS_HUMAN TRANS	3.6	TM
		AA130970	Hs.58382	hypothetical protein FLJ11101	2.5	?
••		AA081218	Hs.58608	Homo saplens cDNA FLJ14206 fis, clone NT	2.7	TM
30	119905	AW449064	Hs.119571	collagen, type III, alpha 1 (Ehlers-Danl	2.6	other
	119966	AA703129	Hs.58963	ESTs	2.7	other
	120132	W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	1.2	other
	120206	H26735	Hs.91668	Homo sapiens done PP1498 unknown mRNA	45.7	other
	120248	A1924294	Hs.173259	uncharacterized bone marrow protein BM03	1.2	other
35		AW131940	Hs.104030	ESTs	9.6	other
		AA177051		gb:nc02a02.s1 NCI_CGAP_Pr3 Homo saplens	4.7	other
		AA190577		gb:zp52g02.s1 Stratagene HeLa cell s3 93	2.1	other
		AW995911	Hs.299883	hypothetical protein FLJ23399	1.9	TM
		AA191384	Hs.104072	ESTs, Weakly similar to Z195_HUMAN ZINC	15.2	other
40		AA195517	Hs.191643	ESTs	5.6	7
<b>+</b> 0				ESTs	6.5	other
		AA195651	Hs.104106		16.1	other
		AK000292	Hs.278732	hypothetical protein FLJ20285		
		N85785	Hs.181165	eukaryotic translation elongation factor	3	other
4.5		AW450669	Hs.45068	hypothetical protein DKFZp434I143	5.8	other
45		AA210722	Hs.104158	ESTs	4.6	SS,TM
		AW969481	Hs.55189	hypothetical protein	16.8	other
	120352	R06859	Hs.193172	ESTs, Weakly similar to 138022 hypotheti	5.1	other
	120356	AF000545	Hs.296433	putative purinergic receptor	28.1	TM
	120371	AA219305	Hs.104196	EST	12.4	?
50	120382	AA228026	Hs.38774	ESTs	4.1	TM
	120383	AL109963	Hs.123122	FSH primary response (LRPR1, rat) homolo	9.7	TM
	120386	AW969665	Hs.154848	hypothetical protein DKFZp434D0127	32.6	other
		AA232874	Hs.104245	ESTs	3.2	other
		AW967985	Hs.325572	ESTs, Moderately similar to ALU7_HUMAN A	21.7	other
55		AA134006	Hs.79306	eukaryotic translation initiation factor	12.5	other
55	120000	AB023230	Hs.96427	KIAA1013 protein	7.3	other
				Homo saplens mRNA; cDNA DKFZp586F1323 (f	11.4	other
		AW966893	Hs.26613			
		AA236453	Hs.18978	Homo sapiens cDNA: FLJ22822 fis, done K	1.9	other
60		AI950087	11.00-000	gb:wq05c02.x1 NCI_CGAP_Kld12 Homo sapien	19.4	other
60		AA251973	Hs.269988	ESTs	5.5	?
		AA253170	Hs.96473	EST	10.4	?
		AA256837		gb:zr84d10.s1 Soares_NhHMPu_S1 Homo sapi	4	?
		BE047718	Hs.96545	ESTs	9.4	other
	120520	AA258601	Hs.161731	EST	2.4	other
65	120535	BE350244	Hs.96547	ESTs	2.5	?
	120551	AA279160	Hs.111407	Homo sapiens, clone IMAGE:3613029, mRNA,	5.3	other
	120570	AA280679	Hs.271445	ESTs, Weakly similar to ALU1_HUMAN ALU S	14.4	?

	120582	BE244830	Ua 204220	711F495 Mrs	400	•
		AW372799	Hs.284228 Hs.125790	ZNF135-like protein	10.2	?
		AA282074	Hs.237323	leucine-rich repeat-containing 2 N-acetylglucosamine-phosphate mutase	2.2	?
		AW965339	Hs.111471	ESTs	7.6 2.5	other
5		AW407987	Hs.173518	M-phase phosphoprotein homolog	52 52	other other
•		AA286942	113.110010	gb:zs56f05.s1 NCL_CGAP_GCB1 Homo sapiens	2.4	other
		AA287095	Hs.140309	Homo sapiens, clone IMAGE:3677194, mRNA,	5	other
		AW063659	Hs.191649	ESTs	2,2	other
		AW969638	Hs.112318	6.2 kd protein	2.2	TM
10		BE536739	Hs.109909	ESTs	1.9	TM
		AA976503		gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens	46.8	TM
	120696	AJ821539	Hs.97249	ESTs	2.5	other
	120713	AW449855	Hs.96557	Homo sapiens cDNA FLJ12727 fis, clone NT	6	other
	120718	AA292747	Hs.97296	ESTs	2.9	other
15		Al191410	Hs.96693	ESTs, Moderately similar to 2109260A B c	7.1	SS,
		Al608909	Hs.193985	ESTs	7.9	other
		AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848	7	TM
		AA346495		gb:EST52657 Fetal heart II Homo sapiens	4.5	other
20		AA386260	Hs.104632	EST	4.5	?
20		AA398155	Hs.97600	ESTs	4.5	other
		BE262951	Hs.99052	ESTs	5.6	other
		Al219896	Hs.97592	ESTs	1.3	other
		AA398360	Hs.97608	EST	3.2	other
25		AI439713	Hs.165295	ESTs	3.6	other
23		AA398721 AA363307	Hs.186749	ESTs, Highly similar to 137550 mismatch	5.5	other
		AL121523	Hs.97032 Hs.97774	ESTs ESTs	3.8	other
		AI002110	Hs.97169		1.7	TM
		AA403008	Hs.301927	ESTs, Weakly similar to dJ667H12.2.1 [H. c6.1A	2.9 1.9	other other
30		AW956981	Hs.97910	Homo saplens cDNA FLJ13383 fis, clone PL	3.5	other
-		AA406137	Hs.98019	EST	6.1	?
		AA410190	Hs.98076	ESTs, Weakly similar to A47582 B-cell gr	7.5	other
		AA406430	Hs.105362	Homo sapiens, clone MGC:18257, mRNA, com	7.1	other
		AW971063	Hs.292882	ESTs	1.8	other
35	121455		Hs.15165	retinoic acid induced 14	10.5	other
	121457	W07404	Hs.144502	hypothetical protein FLJ22055	3.5	TM
	121496	AA442224	Hs.97900	ESTs	14.4	other
	121505	AA494172	Hs.194417	ESTs	13.1	other
40	121508	AA402515	Hs.97887	ESTs	28	other
40		AA416653	Hs.181510	ESTs	6.3	other
		AA412112		gb:zt69b02.s1 Soares_testis_NHT Homo sap	2.7	SS,
		AA412477	Hs.98142	EST	7.5	?
		AA412497		gb:zt95g12.s1 Soares_testis_NHT Homo sap	2.8	other
15		AA411970	Hs.98096	EST	3.5	3
45		AA416568	11 00740	gb:zu05c10.s1 Soares_testis_NHT Homo sap	6.2	TM
		AD001528	Hs.89718	spermine synthase	4	other
		AA626010	Hs.98247	ESTs	2.2	other
		AA416931 AA421537	Hs.126065	ESTS	4.3	TM
50		AA418160	Hs.178072 Hs.86043	Homo sapiens mRNA; cDNA DKFZp434B1023 (f Homo sapiens cDNA FLJ13558 fis, clone PL	7.9	other
50		AV660305	Hs.110286	ESTs .	2 4.7	other
	121706		Hs.154145	hypothetical protein FLJ11585	12.7	other
		AA419225	Hs.98269	Homo sapiens cDNA FLJ11953 fis, clone HE	8.3	?
		Al949597	Hs.98325	ESTs	1.8	TM
55		AA421041	Hs.180744	ESTs	4.1	TM
	121744	AA398784	Hs.97514	ESTs	7.1	SS,
	121748	BE536911	Hs.234545	hypothetical protein NUF2R	19.5	other
		AB033022	Hs.158654	KIAA1196 protein	8	other
	121775	AA421773	Hs.161008	ESTs	1.7	other
60		AA292579	Hs.125133	hypothetical protein FLJ22501	6.7-	other
		AI810774	Hs.98376	ESTs	10.5	other
		AW340797	Hs.98434	ESTs	5.9	other
		AA328348	Hs.218289	ESTs	3.9	other
65		AA425691	Hs.191606	ESTs, Highly similar to KIAA1048 protein	5	other
65		AF027406	Hs.104865	serine/threonine kinase 23	2.7	?
		AA446628	Hs.2799	cartilage linking protein 1	2.3	other
	1218/1	AW972668	Hs.293044	ESTs	2.9	TM

	121882 AA426376	Hs.98459	ESTs	5	. other
	121911 AA427950		gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_	7.3	TM
	121915 AA428179	Hs.223405	ESTs, Moderately similar to A46010 X-lin	2.5	other
_	121935 AA428647	Hs.98611	EST	2.3	other ·
5	121983 AA298760	Hs.180191	hypothetical protein FLJ14904	3.4	other
	121985 Al862570	Hs.299214	Homo sapiens, clone IMAGE:2822295, mRNA,	11.4	other
	121995 AA210863	Hs.3532	nemo-like kinase	3.8	?
	121999 AA430211	Hs.98668	EST	6.5	other
10	122009 AW292763	Hs.160822	Homo sapiens cDNA: FLJ20863 fis, clone A	2.2	other
ΙŪ	122013 AA431085	Hs.98706	ESTS .	6.6	other
	122036 W92142	Hs.271963	ESTs, Weakly similar to ALUS_HUMAN ALU S	13.1	other
	122050 AI453076	Hs.166109	ELAV (embryonic lethal, abnormal vision,	9.1	other
	122060 AA431738 122114 AW161023	Hs.98750	EST	13.1	?
15		Hs.104921	ESTS	1.5 3.4	other
13	122188 AA398838 122204 AA435936	Hs.98842	gb:zt80d01.r1 Soares_testis_NHT Homo sap	5.6	other other
	122246 AA329550		EST HCF-binding transcription factor Zhangfe	5.2	other
	122257 AA436819	Hs.29417 Hs.98899	ESTs	5.6	other
	122302 AA441801	Hs.104947	ESTs .	5.8	other
20	122341 AW601969	Hs.99010	hypothetical protein FLJ22263 similar to	2	other
40	122356 AA443794	Hs.98390	ESTs	7.4	SS,TM
	122369 AA443985	Hs.303222	ESTs	12.2	?
	122371 AA868555	Hs.178222	ESTs	5	7
	122372 AA446008	Hs.336677	EST	7.8	?
25	122378 AB032948	Hs.21356	hypothetical protein DKFZp762K2015	2.5	7
25	122405 AA446572	Hs.303223	EST	2.8	TM
	122412 AA446869	Hs.119316	ESTs	7.4	other
	122415 AA446918	Hs.99088	EST	1.9	other
	122418 AA446966	Hs.99090	ESTs, Moderately similar to similar to K	6.9	?
30	122440 AW505139	Hs.9460	Homo sapiens mRNA; cDNA DKFZp547C244 (fr	2.6	other
•	122446 AA447603	Hs.99123	EST	1.8	TM
	122448 AA447626	Hs.99127	EST	3.5	other
	122458 Al266159	Hs.104980	ESTs	1.5	other
	122460 AW418788	Hs.99148	ESTs, Weakly similar to S43569 R01H10.6	9.7	other
35	122464 AA448158	Hs.99152	EST	4.9	other
	122490 AA448349	Hs.238151	EST	6.2	?
	122492 AA448417	Hs.104990	ESTs	5.5	other
	122502 AA204969	Hs.234863	Homo sapiens cDNA FLJ12082 fis, clone HE	1.3	other
40	122510 AA449232	Hs.99195	ESTs	11.2	?
40	122530 AW959741	Hs.40368	adaptor-related protein complex 1, sigma	10.1	other
	122547 AA779725	Hs.164589	ESTs	2.5	SS.
	122555 AA194055	Hs.293858	ESTs	1.9	other
	122570 AA452578	Hs.262907	ESTs	9.5	other
4.5	122572 AA452601	Hs.99287	EST	11	?
45	122586 AK001910	Hs.99303	Homo sapiens cDNA FLJ11048 fis, clone PL	3.4	other
	122587 AB040893	Hs.6968	KIAA 1460 protein	2	other
	122598 AI028173	Hs.99329	ESTs	1.7	?
•	122599 AL355841	Hs.99330	hypothetical protein FLJ23588	4.4	? other
50	122602 AA411925	Hs.301960	ESTs	4.7	•
50	122607 AA453518	Hs.98023	ESTs	61.5 10.7	other ?
	122614 AA453630	Hs.99339 Hs.161873	EST	107.3	່າ
	122616 AA453638		ESTs	121.4	other
	122617 Al681535 122618 AA453641	Hs.148135	serine/threonine kinase 33 qb:zx48e06.s1 Soares_testis_NHT Homo sap	31.1	SS,
55	122618 AA453041 122622 AA453987	Hs.144802	ESTs	5.6	other
55		Hs.178358		8.5	^^
	122717 AA456859 122762 Al376875	Hs.105119	ESTS	10.4	SS, other
	122829 AW204530	Hs.99500	ESTs	81.8	7
	122834 AA461492	Hs.99545	Homo saplens cDNA FLJ10658 fis, clone NT	3.7	ż
60	122836 AA460581	Hs.290996	ESTs	4.6	other
00	122837 AA461509	Hs.293565	ESTs, Weakly similar to putative p150 (H	2.7	TM
	122838 AA460584	Hs.334386	ESTs	75.3	other
	122854 AA600235	Hs.9625	NIMA (never in mitosis gene a)-related k	7.8	other
	122856 Al929374	Hs.75367	Src-like-adapter	5.8	other
65	122861 AA335721	Hs.119394	ESTs	1.3	other
	122866 BE539656	Hs.283705	ESTs	4.2	other
	122868 AF005216	Hs.115541	Janus kinase 2 (a protein tyrosine kinas	5.3	other

	122870 AW576312	Hs.318722	Homo sapiens cDNA: FLJ21766 fis, clone C	9.9	?
	122872 AW081394	Hs.97103	ESTs	5.3	other
	122879 AA769410	Hs.128654	ESTs	13.9	other
_	122907 AA470074	Hs.169896	ESTs	11.5	other
5	122916 AA470140	Hs.229170	EST	1.7	TM
	122981 AA478951	Hs.105629	ESTs	5	other
	123013 AW968324	Hs.17384	ESTs	15.4	other
	123016 AW338067	Hs.323231	Homo sapiens cDNA FLJ11946 fis, clone HE	2.8	other
10	123034 AL359571	Hs.44054	ninein (GSK3B interacting protein)	8.7	other
10	123072 Al382600	Hs.104308	ESTs, Weakly similar to KIAA 1395 protein	8.8	other
	123082 AA485360	Hs.105661	ESTs	4	?
	123088 Al343652	Hs.105667	ESTs	3.8	other
	123110 AA486256	Hs.193510	EST	7.4	other
1.5	123114 BE304942	Hs.265848	myomegalin	2.8	?
15	123131 T52027	Hs.271795	ESTs, Wealdy similar to 138022 hypotheti	2.4	other
	123132 Al061582	Hs.324179	Homo sapiens cDNA FLJ12371 fis, clone MA	15.6	TM
	123136 AW451999	Hs.194024	ESTs	5.2	other
	123149 AI734179	Hs.105676	ESTs	23.8	TM
20	123152 AW601773	Hs.270259	ESTs	5.2	other
20	123258 AA490929	Hs.105274	ESTs, Weakly similar to RMS1_HUMAN REGUL	9.3	?
	123315 AA496369		gb:zv37d10.s1 Soares ovary tumor NbHOT H	4.2	TM
	123369 AA504757	Hs.105738	ESTs	7	other
	123394 AA731404	Hs.105510	ESTs	3.7	other
25	123433 AW450922	Hs.112478	ESTs	3.8	other
25	123466 AA599042	Hs.112503	EST	7.4	other
	123470 AW303285	Hs.303632	Human DNA sequence from clone RP11-110H4	3.5	other
	123471 AB021644	Hs.197219	zinc finger protein 14 (KOX 6)	5.2	?
	123475 BE439553	Hs.250528	Homo sapiens, clone IMAGE:4098694, mRNA,	1.7	other
20	123482 N95059	Hs.55098	ESTs	1.6	other
30	123486 BE019072	Hs.334802	Homo sapiens cDNA FLJ14680 fis, clone NT	2.4	other
	123508 AW380388	Hs.155546	KIAA1080 protein; Golgi-associated, gamm	2.2	TM
	123615 AA609170		gb:af12a12.s1 Soares_testis_NHT Homo sap	7.9	other
	123619 AA602964		gb:no97c02.s1 NCI_CGAP_Pr2 Homo saplens	2.8	other
25	123658 AA609364		gb:zu71d09.s1 Soares_testis_NHT Homo sap	1.7	?
35	123674 AI269609	Hs.105187	kinesin protein 9 gene	5.7	7
	123735 NM_013241	Hs.95231	FH1/FH2 domain-containing protein	10	other
	123738 AA609891	Hs.112777	EST	5.2	other
	123753 AA609955	Hs.234961	Huntingtin interacting protein E	30.6	TM
40	123804 AA620464	Hs.261915	EST, Weakly similar to S65657 alpha-1C-a	2.1	other
40	123811 AA620586	11- 470040	gb:ae60g05.s1 Stratagene lung carcinoma	2.7	other
	123951 AB012922	Hs.173043	metastasis-associated 1-like 1	6.3	?
	123983 AJ272267	Hs.146178	choline dehydrogenase	4.4	other
	124001 L42542	Hs.75447	ralA binding protein 1	7.1	?
45	124006 Al147155	Hs.270016	ESTs	8.3	SS,
43	124070 Al950314	Hs.154762	HIV-1 rev binding protein 2	3.8	other
	124074 H05635	Hs.294030	topoisomerase-related function protein 4	1.2	SS,
	124178 BE463721	Hs.97101	putative G protein-coupled receptor	3.2	?
	124203 AA372796	Hs.269339	ESTs, Weakly similar to AF161356 1 HSPC0	5.7	other
50	124352 AA640891	Hs.102406	ESTs	3.1	TM
50	124375 D87454 124385 AI267847	Hs.192966	KIAA0265 protein	3.5	other
	124390 AA317338	Un 7535	gb:aq49a10.x1 Stanley Frontal NB pool 2	57.1	?
	124391 AF155099	Hs.7535 Hs.279780	COBW-like protein	2.8	other
	124391 AF133099 124417 N34059	H3.2/9/00		7.1	other
55		He gagna	gb:yv28h09.s1 Soares fetal liver spleen	3.3	other
55	124428 H13540 124440 AA532519	Hs.82202 Hs.129043	ribosomal protein L17	2.9	other
			Human DNA sequence from clone 989H11 on	7.9	other
	124466 R10084	Hs.113319	kinesin heavy chain member 2	2.6	TM
	124482 N53935 124498 H79433	Hs.268997	gb:yv59d09.s1 Soares fetal liver spleen	7.9	TM
60			ESTS	7.8	other
UU	124515 AA669097 124608 N71076	Hs.109370 Hs.102800	ESTs Woolds similar to noumnal throad	3.3	other
	124631 NM_014053	Hs.270594	ESTs, Weakly similar to neuronal thread FLVCR protein	4.6	?
	124634 AI765123	Hs.143671		3.2	other
	124637 AA160474	Hs.75798	Homo sapiens cDNA FLJ13533 fis, clone PL	5.8	other
65	124642 AW968856	Hs.278569	hypothetical protein sorting nexin 17	9.3	other
55	124649 N92593	Hs.313054	ESTs	3.5 6.1	other TM
	124661 R48170	Hs.78436	EphB1	5.6	other
	,_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		polyment :	J.U	OUICI

	124683 AA381661	Hs.119878	ESTs, Weakly similar to M3K9_HUMAN MITOG	7.9	TM
	124712 R09166	Hs.191148	ESTs	5.7	other
	124735 R22952	Hs.268685	ESTs	11.3	?
			Homo sapiens mRNA for KIAA 1771 protein,	9	other
5	124761 AA374756	Hs.93560			other
)	124768 AW368528	Hs.100855	ESTs	8.3	
	124775 R41772	Hs.100878	ESTs	4.9	other
	124777 R41933	Hs.140237	ESTs, Weakly similar to ALU1_HUMAN ALU S	2.8	other
	124788 R43543	Hs.100912	Homo sapiens cDNA: FLJ22726 fis, clone H	5.1	other
	124809 AL355722	Hs. 106875	Homo sapiens EST from done 35214, full	4.2	other
10	124811 R46068	Hs.288912	hypothetical protein FLJ22604	14.2	other
10				7.9	other
	124812 R47948	Hs.188732	ESTs		
	124822 AA418160	Hs.86043	Homo saplens cDNA FLJ13558 fis, clone PL	6.6	other
	124825 AA501669	Hs.336693	ESTs	2.3	SS,TM
	124833 AW975868	Hs.294100	ESTs	2.7	SS,TM
15	124857 R63652	Hs.137190	ESTs	2.3	other
1.5	124860 R65763	Hs.101477	EST	23.9	7
				2	other
	124863 Al382555	Hs.127950	bromodomain-containing 1		
	124876 AF135422	Hs.27059	GDP-mannose pyrophosphorylase A	4.4	SS,
	124878 BE397530	Hs.288057	hypothetical protein FLJ22242	2.7	other
20	124902 H37941	Hs.101883	ESTs	5.7	other
	124903 AW296713	Hs.221441	ESTs	32.4	other
	124930 AI076343	Hs.173939	ESTs, Weakly similar to ALUB_HUMAN !!!!	22.8	other
				6.1	other
	124942 R99978	Hs.268892	ESTs, Moderately similar to B34087 hypot		
~ ~	124958 Al078645	Hs.431	murine leukemia viral (bml-1) oncogene h	1.9	other
25	124980 T40841	Hs.98681	ESTs	4.5	?
	125002 T59338	Hs.269463	ESTs, Weakly similar to ALU1_HUMAN ALU S	4.9	other
	125047 T79815	Hs.279793	ESTs	5	?
	125051 T79956	Hs.100588	EST	135.3	?
			ESTs	5.4	other
20	125056 T81310	Hs.100592			
30	125101 Al472068	Hs.286236	KIAA1856 protein	5.6	other
	125113 T96595	Hs.302270	ESTs, Weakly similar to ALUF_HUMAN IIII	1.8	other
	125115 T97341	•	gb:ye57e05.s1 Soares fetal liver spleen	9.6	?
	125125 Al222382	Hs.240767	Human DNA sequence from clone RP1-12G14	1.5	TM
	125147 W38150		Empirically selected from AFFX single pr	1.7	?
35	125161 W44657	Hs.144232	EST	10.7	?
33			ESTs, Moderately similar to ALUB_HUMAN I	1.3	other
	125249 AA630863	Hs.131375			
	125255 AF098162	Hs.118631	timeless (Drosophila) homolog	9.4	other
	125279 AW401809	Hs.4779	KIAA1150 protein	1.5	?
	125280 Al123705	Hs.106932	ESTs	8.1	?
40	125298 AW972542	Hs.289008	Homo sapiens cDNA: FLJ21814 fis, clone H	1.5	other
	125660 AW292171	Hs.23978	scaffold attachment factor B	5.9	other
			YY1 transcription factor	1.2	?
	125827 NM_003403	Hs.97496			7
	125891 U29589	Hs.7138	cholinergic receptor, muscarinic 3	6.5	
	126005 AW409701	Hs.1578	baculoviral IAP repeat-containing 5 (sur	14.3	?
45	126202 AA157632	Hs.272630	vacuolar proton pump delta polypeptide	2.5	SS,
	126695 AA643322	Hs.172028	a disintegrin and metalloprotelnase doma	9.1	SS,TM
	127050 AW411066	Hs.274351	CGI-89 protein	17	other
	127274 AW966158		Homo sapiens cDNA FLJ12789 fis, clone NT	12.8	other
		Hs.58582			
~ ^	128355 AW293012	Hs.161623	ESTs	7.4	SS,
50	128493 D87466	Hs.240112	KIAA0276 protein	3.1	TM
	128522 BE173977	Hs.10098	putative nucleolar RNA helicase	9.4	other
	128527 AA504583	Hs.101047	transcription factor 3 (E2A immunoglobul	1.5	other
	128528 R39234	Hs.251699	ESTs, Weakly similar to IDN4-GGTR14 [H.s	2.8	other
	128595 U31875	Hs.272499	short-chain alcohol dehydrogenase family	12.1	TM
<i>E E</i>				2.4	7
55	128599 NM_015366	Hs.102336	Rho GTPase activating protein 8		
	128604 Al879099	Hs.102397	GIOT-3 for gonadotropin inducible transc	1.3	other
	128608 BE267994	Hs.102419	zinc finger protein	7.2	other
	128625 AB037841	Hs.102652	hypothetical protein ASH1	1.3	other
	128629 AL096748	Hs.102708	DKFZP434A043 protein	3.2	other
60	128639 AW582962	Hs.102897	CGI-47 protein	2	TM
UU			coatomer protein complex, subunit epsilo	1.4	other
	128656 AA458542	Hs.10326	district protein complex, automic epond		
	128658 BE397354	Hs.324830	diptheria toxin resistance protein requi	2.5	other
	128670 AA975486	Hs.103441	Homo sapiens, Similar to RIKEN cDNA 1700	7.1	?
	128691 W27939	Hs.103834	hypothetical protein MGC5576	7.8	?
65	128696 BE081143	Hs.225977	nuclear receptor coactivator 3	3.8	other
	128700 Y15221	Hs.103982	small inducible cytokine subfamily B (Cy	1.6	other
	128714 T85231	Hs.179661	tubulin, beta 5	7.8	other
	1201 17 103231	113.173001	would form o		50151

128717 AX001564   hs. 104505     128737 AF292100   hs. 1046513     128746 AJ870161   hs. 104558     128746 AJ870163   hs. 255531     128746 AJ870163   hs. 255531     128747 BAD27296   hs. 105073     128772 BE302796   hs. 105073     128787 NM. 002975   hs. 105937     128787 NM. 002975   hs. 105937     128787 NM. 002975   hs. 105937     12884 AW24431   hs. 105061     128854 BE199181   hs. 109357     128854 BE199181   hs. 109371     128854 BE199181   hs. 109371     128956 AW30942   hs. 109078     128957 AV2220 AA622037   hs. 105978     128958 AW30948   hs. 109778     128958 AW30948   hs. 10978     128958 AW30948   hs. 10978     128958 AW30948   hs. 10978     128958 AW30948   hs. 10978     128959 AW30948   hs. 10978     128958 AW30948   hs. 10978     128959 AW309597   hs. 109378     128959 AW309597   hs. 109378     128959 AW31924   hs. 10938     128959 AW31924   hs. 10938     128959 AW31924   hs. 10938     128959 AW31924   hs. 10938     128959 AW319397   hs. 10938     128959 AW31924   hs. 10939     12905 AW32958   hs. 10939     12905 AW319597   hs. 10939     12905 AW31959   hs. 10939     12905 AW31959   hs. 10939     12905 AW3195   hs. 10939		400747					
18737 A7292100   18,104613   RP42 homolog   28 TM   1874 A307211   18,251531   roleszome (prosome, macropain) subunit, 4,5				Hs.104222	hypothetical protein FLJ10702	5.5	other
188742 AA307211							
12874 AJ07279							
18874   AB027249   Hs. 104741   PDZ-binding kinases; T-cell originated pr   2.8   other the programment of	_			Hs.251531			
128772   EE302796   Hs. 105907   Hs. 10590	)	128746	Al470163	Hs.323342	actin related protein 2/3 complex, subun	2.2	other
128781 N71826		128747	AB027249	Hs.104741	PDZ-binding kinase; T-cell originated pr	2.8	other
10		128772	BE302796	Hs.105097	thymidine kinase 1, soluble	5.4	other
128814 AW248431   Hs.106357		128781	N71826	Hs. 105465	small nuclear ribonucleoprotein polypept	53.9	TM
128814 AW248431	_	128797	NM_002975	Hs.105927	stem cell growth factor, lymphocyte secr	13.3	other
128830   BE291470   Hs. 106357   Hs. 106357   Hs. 106357   Hs. 106390   Horno sapiens mRN4; cDNA DKFZp588H0924 (f 1.6   SS, other 12891   AF189723   Hs. 106778   Hs. 107318   Hs. 107418   ESTs   Hs. 107418   Hs. 107418   Hs. 107419   Hs.	10	128806	AW630942	Hs.106061	RD RNA-binding protein	2.6	other
128830   BE291770   Hs.106357   valosin-containing potein   6   other   128813   AK001731   Hs.106390   Homo sapiens mRNA; cDNA DKFZp588H0924 (f 16   S. 7   128976   R57988   Hs.106778   Hs.106781   Hs.10738   Hs.107318   Hs.107318		128814	AW248431	Hs.256526	nuclear prelamin A recognition factor	2.2	other
128854 BE159181		128830	BE281170	Hs.106357		6	other
128971   AF189723   Hs. 106778   AF1928c, Carl-transporting, type 2C, nemb   1.5   7   128905   AA622037   Hs. 10706   128925   R67419   Hs. 10768   Hs. 10768   128925   R67419   Hs. 10768   Hs. 10768   128929   AA003647   Hs. 107381   Hs. 107381   128995   AA003647   Hs. 107381   128995   AA590127   Hs. 107381   128995   AA590127   Hs. 107381   128995   AA590127   Hs. 107381   128995   AA9271217   Hs. 281434   Hs. 107381   128995   A8181224   Hs. 107747   128995   A8181224   Hs. 107747   129019   A4950087   Hs. 10824   Hs. 107747   129019   A4950087   Hs. 10824   Hs. 10824		128835	AK001731	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586H0924 (f	1.6	SS,
128971   AF189722   Hs. 106778   Hs. 10766   128920   AA622037   Hs. 165468   Hs. 10766   128925   R67419   Hs. 165468   Hs. 10766   128925   R67419   Hs. 165468   Hs. 10766   128925   AA622037   Hs. 165468   Hs. 10761   128949   AA005647   Hs. 107418   ESTs   128959   AI590177   Hs. 107341   ESTs   128959   AI590177   Hs. 107341   ESTs   1.3 other hypothetical protein FLJ11200   1.3 other hypothetical protein FLJ114028 fts, clone HE   1.6 other hypothetical protein FLJ114784   1.5 other hypothetical protein FLJ114784		128854	BE159181	Hs.168232	hypothetical protein FLJ13855	2.3	other
128906 R5798B	15					1.5	?
128920   AA622037   Hs. 166468   programmed cell death 5   1.4   other   128925   R67419   Hs. 21851   Homo sapiens cDNA FLJ12900 fis, clone NT   1.9   other   128946   Y13153   Hs. 107318   ks. 108316   ks. 108318   ks. 108319   ks. 108318   ks. 108318   ks. 108319   ks. 108318   ks. 108319   ks. 108318   ks. 108319   ks. 108318   ks. 108318   ks. 108319   ks. 108318   ks. 108						4.8	other
128925   R67419							
128946   Y13153							
28949   AA009547   Hs. 8850   Hs. 107381   Hs. 108580   Hs. 108581   Hs. 108580   Hs. 108581							
128959   Al550127	20						
128965 AW150697							
128975   Al375672							
128975   BE560779   Hs.284233   NICE-5 protein   14   Other   128995   Al816224   Hs.107747   DKF2P566C243 protein   1.9   Other   129013   Al950087   Hs.173081   Hs.108104   Utiquitin-conjugating enzyme E2L 3   3.4   Other   12908   AAV4610   Hs.19431   Ps.326234   Hs.10267   129098   AA4610   Hs.19431   Ps.326234   Hs.108623   129095   Al863189   Hs.288906   Hs.108662   129097   BE243933   Hs.108623   Hs.108624   129097   BE243933   Hs.108625   129097   BE243933   Hs.108624   129097   BE243933   Hs.108625   129097   BE243933   Hs.108624   Hs.108660   129097   Hs.108276   I29097   Hs.108276   I29097   Hs.108276   I29097   Hs.108276   I29097   Hs.108276   I29097   Hs.108276   I29097   I2909							
128979 AW271217							
128995 AB166224   Hs.107747   DKFZP566C243 protein   1.9   other   129012   AlD44675   Hs.173081   KIAA0630 protein   129032 R80088   Hs.108104   Wiquitin-conjugating enzyme E2L 3   3.4   other   129078   Al351010   Hs.102267   ysosomal   2.1   other   129088   AA744610   Hs.108263   Hs.288905   Hs.288905   Hs.288904   Hs.288905   Hs.29330   Hs.288905   Hs.288905   Hs.29330   Hs.288905   Hs.29330   Hs.288905   Hs.29330   Hs.288905   Hs.29307   Hs.203007	25						
129019 AJ950087	23						
129021 AL044675				115.10//4/			
129032 R80088				Ha 472004			
129076							
129078 AJ351010	20						
129088	30						
129095 L12350							
129096 AA463189							
12999   BE243933   Hs.108642   zinc finger protein 22 (KOX 15)   3   other 129099   AF146074   Hs.108660   ATP-binding cassette, sub-family C (CFTR   5.8   TM   129149   AA3565620   Hs.108947   KIAA0050 gene product   6.4   TM   129172   AW162916   Hs.241576   hypothetical protein MGC2747   1.8   TM   129192   AA286914   Hs.183299   ESTs   2.1   7   129194   AA150797   Hs.109276   latexin protein   129207   AI934365   Hs.109315   KIAA1415 protein   5.9   other   129207   AI934365   Hs.109439   osteoglycin (osteoinductive factor, mime   129228   U40714   Hs.239307   tyrosyl-IRNA synthetase   2.9   other   129228   AF013758   Hs.109643   polyadenylate binding protein-interactin   3.3   ?   129254   AA252468   Hs.1098   DKFZp434J1813 protein   2.6   SS,TM   129255   AI961727   Hs.109804   H1 histone family, member X   7.4   other   129238   W26392   Hs.110080   ESTs, Weakly similar to S13495 pregnancy   9.6   other   129340   H75334   Hs.11050   F-box only protein   9   4.7   SS,   12936   BE220806   Hs.10736   Solute carrier family 12 (sodium/potass)   6.7   TM   129372   NM_016039   Hs.110796   SAR1 protein   2.0   other   129403   AF149785   Hs.110803   Hs.10803   CGI-99 protein   FLJ20647   10.2   other   129403   AF149785   Hs.11126   pituitary tumor-transforming 1 interacti   7.5   other   129404   AI267700   Hs.317584   ESTS   STS   5.1   other   129404   AI267700   Hs.317584   ESTS   STS   5.1   other   129404   AI267700   Hs.317584   Hs.20447   hypothetical protein   FLJ20647   10.2   other   129573   AV8943633   Hs.306163   Hs.20447   hypothetical protein   FLJ20647   10.2   other   129573   AV769221   Hs.270847   delta-tubulin   4014141   hs.7045   cother   129570   AI923097   Hs.11041   hs.7045   chromosome 1 open reading frame 8   2.1   other   129570   AI9230							
129099 AF146074	26						
129136 W93048	33						
129149   A356620   Hs. 108947   KIAA0050 gene product   129172   AW162916   Hs. 241576   hypothetical protein PRO2577   1.8   TM   129192   A2686914   Hs. 183299   ESTs   2.1   ?   129194   AA150797   Hs. 109276   latexin protein   3.3   SS,TM   129198   N57532   Hs. 109315   KIAA1415 protein   5.9   other   129207   Al934365   Hs. 109439   osteoglycin (osteoinductive factor, mime   8.1   other   129229   AF013758   Hs. 109439   osteoglycin (osteoinductive factor, mime   8.1   other   129229   AF013758   Hs. 109643   pohyadenylate binding protein-interactin   3.3   ?   129254   AA252468   Hs. 1098   DKFZp434J1813 protein   2.6   SS,TM   129258   Al961727   Hs. 109804   H1 histone family, member X   7.4   other   129288   W26392   Hs. 110080   ESTs, Weakly similar to S13495 pregnancy   9.6   other   129286   Al051967   Hs. 110122   ESTs   1.2   other   129340   H75334   Hs. 11050   ESTs, Weakly similar to S13495 pregnancy   9.6   other   129362   U30246   Hs. 110736   solute carrier family 12 (sodium/potass)   6.7   TM   129362   U30246   Hs. 110736   solute carrier family 12 (sodium/potass)   6.7   TM   129372   NM, 016039   Hs. 110796   SAR1 protein   1.4   TM   129372   NM, 016039   Hs. 110803   GGl-99 protein   2   other   129404   Al267700   Hs. 317584   ESTs   5.1   other   129404   Al267700   Hs. 317584   ESTs   5.1   other   129404   Al267700   Hs. 317584   ESTs   5.1   other   129579   AA769221   Hs. 270447   hs. 2							
129172 AW162916							
129192 AA286914							
129194 AA150797	40						
129198 N57532	40						
129207 Al934365							
129228 U40714							
45         129229 AF013758 129254         Hs. 109643 Polyadenylate binding protein-Interactin         3.3         ?           129254 AA252468 Hs. 10980 129255 Al961727 Hs. 109804 Price							
129254 AA252468							
129255 Al961727	45						
129288 W26392							
12926 Al051967				Hs.109804			
50         129323         AA287239         Hs.5518         Homo saplens cDNA FLJ11311 fis, clone PL         5.2         other           129340         H75334         Hs.11050         F-box only protein 9         4.7         SS,           129347         BE614192         Hs.279869         melanoma-associated antigen recognised b         7.7         TM           129362         U30246         Hs.110736         solute carrier family 12 (sodium/potassl         6.7         TM           129368         BE220806         Hs.184697         Homo saplens done 23785 mRNA sequence         8.6         SS,           129372         NM_016039         Hs.110796         SAR1 protein         1.4         TM           129372         NM_016039         Hs.110803         CGI-99 protein         2         other           129404         Al267700         Hs.317584         ESTs         5.1         other           129423         AA204686         Hs.234149         hypothetical protein FLJ20647         10.2         other           129513         AW843633         Hs.306163         hypothetical protein AL110115         7.1         SS,           129515         AA76927         Hs.270847         delta-tubulin         3.2         other           129559 <td></td> <td></td> <td></td> <td>Hs.110080</td> <td>ESTs, Weakly similar to S13495 pregnancy</td> <td></td> <td></td>				Hs.110080	ESTs, Weakly similar to S13495 pregnancy		
129340 H75334		129296	AI051967	Hs.110122	ESTs		
129347   BE614192	50	129323	AA287239	Hs.5518			
129362 U30246		129340	H75334	Hs.11050			
12936   BE220806		129347	BE614192	Hs.279869	melanoma-associated antigen recognised b		
55         129370         Al686379         Hs.110796         SAR1 protein         1.4         TM           129372         NM_016039         Hs.110803         CGI-99 protein         2         other           129403         AF149785         Hs.11126         pituitary tumor-transforming 1 interacti         7.5         other           129404         Al267700         Hs.317584         ESTs         5.1         other           129423         AA204686         Hs.234149         hypothetical protein FLJ20647         10.2         other           129513         AW843633         Hs.306163         hypothetical protein AL110115         7.1         SS,           129515         AF255303         Hs.112227         membrane-associated nucleic acid binding         2.5         other           129559         W01296         Hs.11360         hypothetical protein FLJ14784         7.5         other           65         129560         AA317841         Hs.7845         hypothetical protein MGC2752         6.8         other           129570         Al923097         Hs.11441         chromosome 1 open reading frame 8         2.1         other		129362	U30246	Hs.110736		6.7	TM
129372 NM_016039		129366	BE220806	Hs.184697	Homo saplens done 23785 mRNA sequence	8.6	SS,
129403 AF149785	55			Hs.110796		1.4	TM
129403 AF149785		129372	NM_016039	Hs.110803	CGI-99 protein		other
129404 Al267700		129403	AF149785	Hs.111126	pituitary tumor-transforming 1 interacti	7.5	other
60 129402 AA188185 Hs. 289043 spindlin 6.8 other 129513 AW843633 Hs. 306163 hypothetical protein AL110115 7.1 SS, rembrane-associated nucleic acid binding 2.5 other 129557 AA769221 Hs. 270847 delta-tubulin 3.2 other 129559 W01296 Hs. 11360 hypothetical protein FLJ14784 7.5 other 129560 AA317841 Hs. 7845 hypothetical protein MGC2752 6.8 other 129570 Al923097 Hs. 11441 chromosome 1 open reading frame 8 2.1 other		129404	A1267700	Hs.317584			other
129513 AW843633 Hs.306163 hypothetical protein AL110115 7.1 SS, 129515 AF255303 Hs.112227 membrane-associated nucleic acid binding 2.5 other 129559 W01296 Hs.11360 hypothetical protein FLJ14784 7.5 other 129550 Al923097 Hs.11441 chromosome 1 open reading frame 8 2.1 other		129423	AA204686	Hs.234149	hypothetical protein FLJ20647	10.2	other
129515 AF255303	60			Hs.289043	spindlin	6.8	other
129515 AF255303				Hs.306163			
129527 AA769221				Hs.112227	membrane-associated nucleic acid binding		
65 129560 AA317841 Hs.7845 hypothetical protein MGC2752 6.8 other 129570 Al923097 Hs.11441 chromosome 1 open reading frame 8 2.1 other		129527	AA769221	Hs.270847			
129570 Al923097 Hs.11441 chromosome 1 open reading frame 8 2.1 other				Hs.11360			
129570 Al923097 Hs.11441 chromosome 1 open reading frame 8 2.1 other	65			Hs.7845			
129575 F08282 Hs.278428 progestin Induced protein 1.6 other							
		129575	F08282	Hs.278428	progestin Induced protein	1.6	other

		H14718	Hs.11506	Human clone 23589 mRNA sequence	6.8	other
		BE408300	Hs.301862	postmeiotic segregation Increased 2-like	1.4	TM
		N57423	Hs.179898	HSPC055 protein	7.4	other
~		AW403724	Hs.36989	coagulation factor VII (serum prothrombi	9	?
5		AF035537	Hs.115521	REV3 (yeast homolog)-like, catalytic sub	1.6	other
		U38945	Hs.1174	cyclin-dependent kinase Inhibitor 2A (me	2.2	other
		AD000092	Hs.16488	calreticulin	3.3	other
		NM_015556	Hs.172180	KIAA0440 protein	13.4	other
	129680	U03749		gb:Human chromogranin A (CHGA) gene, pro	14.1	?
10	129689	AW748482	Hs.77873	B7 homolog 3	2.6	other
		A1304966	Hs.12035	ESTs, Weakly similar to 138022 hypotheti	7.5	TM
	129720	AA156214	Hs.12152	APMCF1 protein	2.	other
		NM_001415	Hs.211539	eukaryotic translation initiation factor	1.7	TM
			Hs.12457	hypothetical protein FLJ10814	1.8	other
15	129779	AA394090	Hs.12460	Homo sapiens clone 23870 mRNA sequence	5.5	TM
		AF052112	Hs.12540	lysosomal	1.7	7
	129806	AB023148	Hs.173373	KIAA0931 protein	1.2	other
	129815	BE565817	Hs.26498	hypothetical protein FLJ21657	3.1	other
	129840	NM_006590	Hs.12820	SnRNP assembly defective 1 homolog	1.8	other
20	129861	AL049999	Hs.85963	DKFZP564M182 protein .	2.3	other
	129864	Al393237	Hs.129914	runt-related transcription factor 1 (acu	1.7	SS,
		Al222069	Hs.13015	hypothetical protein similar to mouse Dn	2.8	TM
	129945	BE514376	Hs.165998	PAI-1 mRNA-binding protein	1.8	other
	129953	AA412195	Hs.13740	ESTs	2.5	other
25	129972	AW753185	Hs.180628	dynamin 1-like	1.8	?
		U09848	Hs.132390	zinc finger protein 36 (KOX 18)	1.3	other
		AA301116	Hs.142838	πucleolar phosphoprotein Nopp34	1.6	other
		AA287325	Hs.14713	ESTs	4.1	other
20		S73265	Hs.1473	gastrin-releasing peptide	1.9	other
30		AL046962	Hs.14845	forkhead box O3A	2.8	other
		AL135561	Hs.14891	hypothetical protein FLJ21047	2.3	other
		X53002	Hs.149846	Integrin, beta 5	2.3	other
		AA916785	Hs.180610	splicing factor proline/glutamine rich (	3	other
35		L76937.	Hs.150477	Werner syndrome	1.8	other
23		AA311426	Hs.21635	tubulin, gamma 1	6.1	other
		NM_003358 D80001	Hs.23703 Hs.152629	ESTs, Moderately similar to CEGT_HUMAN C	1.6 1.3	other other
		R85367	Hs.51957	KIAA0179 protein splicing factor, arginine/serine-rich 2,	2	other
		AL035588	Hs.153203	MyoD family Inhibitor	3.2	other
40		X79201	Hs.153221	synovial sarcoma, translocated to X chro	5.4	?
10		D81983	Hs.322852	GAS2-related on chromosome 22	4.9	other
		NM_092497	Hs.153704	NIMA (never in mitosis gene a)-related k	1.4	other
		AA479005	Hs.154036	tumor suppressing subtransferable candid	2.6	other
		AB011121	Hs.154248	amyotrophic tateral sclerosis 2 (juvenil	6.3	other
45		Z19084	Hs.172210	MUF1 protein	6.2	other
,,,		AF127577	Hs.155017	nuclear receptor Interacting protein 1	2.4	other
		AJ224442	Hs.155020	putative methyltransferase	3.5	TM
	130359	NM_013449	Hs.277401	bromodomain adjacent to zinc finger doma	8.5	other
	130367	AL135301	Hs.8768	hypothetical protein FLJ10849	1.4	other
50	130372	AI077464	Hs.5011	RNA binding motif protein 9	3.3	?
	130393	N89487	Hs.155291	KIAA0005 gene product	1.8	other
	130399	AW374106	Hs.155356	hypothetical protein MGC2840 similar to	3.4	other
	130407	BE385099	Hs.334727	hypothetical protein MGC3017	2.3	other
	130409	NM_001197	Hs.155419	BCL2-Interacting killer (apoptosis-induc	2.7	TM
55		AF037448	Hs.155489	NS1-associated protein 1	1.8	other
	130441	U63630	Hs.155637	protein kinase, DNA-activated, catalytic	2.3	other
		BE513202	Hs.15589	PPAR binding protein	4	TM
		D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	33.6	?
<b>~</b> i		BE245851	Hs.180779	H2B histone family, member B	5	other
60		U49844	Hs.77613	ataxla telanglectasia and Rad3 related	4.4	other
		L38951	Hs.180446	karyopherin (importin) beta 1	1.6	SS,TM
		BE208491	Hs.295112	KIAA0618 gene product	16.1	other
		L32137	Hs.1584	cartilage oligomeric matrix protein (pse	6.1	other
65		AW876523 AA321238	Hs.15929 He.4310	hypothetical protein FLJ12910	2,1	other
ÛĴ		AF062649	Hs.4310 Hs.252587	eukaryotic translation initiation factor pituitary tumor-transforming 1	1.5 14.4	other ?
		Al907018	Hs.15977	Empirically selected from AFFX single pr	4.8	other
	100000		, 10, 10011	Enquirous conocide invites i A single pr	1.0	Value

	130567 AA383092	Hs.1608	replication protein A3 (14kD)	8	other
	130568 AA232119	Hs.16085	nutative G-protein coupled receptor	3.4	other
	130574 AF083208	Hs.16178	apoptosis antagonizing transcription fac	1.2	other
	130598 AL042210	Hs.16493	hypothetical protein DKFZp762N2316; KIAA	1.4	other TM
5	130601 AA609738	Hs.16525	ESTs	1.5 1,3	other
	130614 AI354355	Hs.16697	down-regulator of transcription 1, TBP-b glutamine-tructose-6-phosphate transamin	12.1	TM
	130617 M90516	Hs.1674 Hs.16758	Spir-1 protein	15.9	other
	130618 AA383439 130667 BE246961	Hs.17639	Homo sapiens ubiquitin protein ligase (U	13.9	other
10	130674 AL048842	Hs.194019	attractin	1.5	other
10	130675 AA442233	Hs.17731	hypothetical protein FLJ12892	5.4	other
	130692 AA652501	Hs.13561	hypothetical protein MGC4692	5	other
	130693 R68537	Hs.17962	ESTs	2 1.8	other TM
	130712 AJ271881	Hs.279762	bromodomain-containing 7	2	TM
15	130714 Al348274	Hs.18212	DNA segment on chromosome X (unique) 987 KIAA0451 gene product	3.8	?
	130730 AB007920	Hs.18586	POP7 (processing of precursor, S. cerevi	3.2	?
	130744 H59696	Hs.18747 Hs.18879	chromosome 12 open reading frame	1.4	other
	130751 AF052105 130757 AL036067	Hs.18925	protein x 0001	5.7	other
20	130768 AF258627	Hs.211562	ATP-binding cassette, sub-family A (ABC1	5.2	?
20	130789 AK000355	Hs.8899	sirtuin (silent mating type information	1.6	other
	130836 J05068	Hs.2012	transcobalamin I (vitamin B12 binding pr	15.7	SS, other
	130841 AL157468	Hs.325825	Homo sapiens dDNA FLJ20848 fis, done AD	2.8 1.5	other
05	130843 AA447492	Hs.20183	ESTs, Weakly similar to AF164793 1 prote seven in absentia (Drosophila) homolog 2	3.5	other
25	130844 U76248	Hs.20191 Hs.143323	putative DNA/chromatin binding motif	1.7	other
	130855 AJ243706 130861 NM_016578	Hs.20509	HBV nX associated protein-8	1.9	other
	130879 NM_003416	Hs.2076	zinc finger protein 7 (KOX 4, clone HF.1	1.4	other
	130880 BE514434	Hs.20830	kinesin-like 2	2.1	TM
30	130892 AL120837	Hs.20993	high-glucose-regulated protein 8	2.5	other other
	130898 AB033078	Hs.186613	sphingosine-1-phosphate lyase 1	1.7 1.8	other
	130911 BE409769	Hs.21189	DnaJ (Hsp40) homolog, subfamily A, membe	2.3	TM
	130919 N79110	Hs.21276	collagen, type IV, alpha 3 (Goodpasture signal transducer and activator of trans	5.4	other
25	130944 BE382657	Hs.21486 Hs.301444	KIAA1673	2.2	SS,
35	130971 N39842 130993 T97401	Hs.21929	ESTs	1.6	other
	131005 AV658308	Hs.2210	thyroid hormone receptor interactor 3	1.6	?
	131028 Al879165	Hs.2227	CCAAT/enhancer binding protein (C/EBP).	1.2 1.6	other other
	131042 Al826288	Hs.171637	hypothetical protein MGC2628	7.4	?
40	131046 AA321649	Hs.2248	small inducible cytokine subfamily B (Cy	5.1	other
	131060 AA194422	Hs.22564 Hs.22607	myosin VI ESTs	7.1	other
	131070 N53344 131076 AA749230	Hs.26433	dolichyl-phosphate (UDP-N-acetylglucosam	2.1	TM
	131099 AL133353	Hs.226581	COX15 (yeast) homolog, cytochrome c oxid	7.1	other
45	131174 NM_006540		nuclear receptor coactivator 2	1.9	?
	131185 BE280074	Hs.23960	cyclin B1	5.8	? other
	131206 AW138839	Hs.24210	ESTS	2 7.1	TM
	131213 AA885699	Hs.24332	CGI-26 protein thyroid hormone receptor-associated prot	7.6	?
50	131225 H62087	Hs.31659 Hs.59757	zinc finger protein 281	2.9	other
50	131231 N47468 131233 D89053	Hs.268012	fatty-acid-Coenzyme A ligase, long-chain	3.5	other
	131243 AW383256	Hs.24752	spectrin SH3 domain binding protein 1	2.8	?
	131245 AL080080	Hs.24766	thioredoxin domain-containing	2.8	SS,TM other
	131247 AL043100	Hs.326190	fatty acid amide hydrolase	5.6 5.8	other
55	131281 AA251716	Hs.25227	ESTs Homo sapiens done F19374 APO E-C2 gene	1.3	other
	131283 X80038	Hs.339713	CGI-76 protein	5	7
	131305 AV656017 131320 AA505691	Hs.184325 Hs.145696	solicing factor (CC1.3)	1.8	TM
	131339 AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6	other
60	131375 AW293165	Hs.143134	ESTs	5.4	other
00	131390 BE269388	Hs.182698	mitochondrial ribosomal protein L20	5.3	other
	131410 BE259110	Hs.279836		2.2	other 2
	131412 NM_01224		SELENOPHOSPHATE SYNTHETASE; Human hypothetical protein FLJ21908	1.4	other
ċ	131429 AL046302	Hs.26750	hypothetical protein FLJ20392	1.7	other
65	131458 BE297567 131475 AA992841	Hs.27047 Hs.27263	KIAA1458 protein	2	other
	131501 AV661958	Hs.8207	GK001 protein	2.6	other
	10.00		167		

	131511	AA732153	Hs.27865	Homo sapiens cDNA: FLJ21333 fis, clone C	2	other
	131528	AU076408	Hs.28309	UDP-glucose dehydrogenase	1.6	TM
		BE268278	Hs.28393	hypothelical protein MGC2592	7.4	other
-		AW966881	Hs.41639	programmed cell death 2	2.2	other
5		AL355715	Hs.28555	programmed cell death 9 (PDCD9)	2.1	other
		NM_003512	Hs.28777	H2A histone family, member L	1.7	other
		T93500	Hs.28792	Homo saplens cDNA FLJ11041 fis, clone PL	5.2	other
		AL389951	Hs.271623	nucleoporin 50kD	5	other
10		BE393822	Hs.29645	Homo sapiens mRNA; cDNA DKFZp761C029 (fr	1.8	other
10		R78195 AB037791	Hs.29692	Homo sapiens cDNA FLJ11436 fis, clone HE	1.3	other
		AW410601	Hs.29716 Hs.30026	hypothetical protein FLJ10980 HSPC182 protein	2.2 3	TM other
		AW960597	Hs.30164	ESTs	1.3	other
		Al218918	Hs.30209	KIAA0854 protein	2.8	other
15		X52486	Hs.3041	uracil-DNA glycosylase 2	2.8	other
		BE559681	Hs.30736	KIAA0124 protein	5.6	?
		AA642831	Hs.31016	putative DNA binding protein	2.9	?
	131722	D13757	Hs.311	phosphoribosyl pyrophosphate amidotransf	3.4	other
••	131737	AK001641	Hs.31323	Inhibitor of kappa light polypeptide gen	3.9	?
20	131763	A1878932	Hs.317	topoisomerase (DNA) I	3.4	other
		AA382590	Hs.170980	KIAA0948 protein	25.5	other
		D87077	Hs.196275	KIAA0240 protein	2.4	SS,
		AW966127	Hs.32246	Homo sapiens cDNA FLJ14656 fis, clone NT	8	TM
25		BE501849	Hs.32317	high-mobility group 20B	1.5	other
25		X86098	Hs.301449	adenovirus 5 E1A binding protein	4.2	other
		U20536 U28838	Hs.3280	caspase 6, apoptosis-related cysteine pr	4.3	other
		Al251317	Hs.32935 Hs.33184	TATA box binding protein (TBP)-associate ESTs	3.5 5.2	other TM
		AA083764	Hs.6101	hypothetical protein MGC3178	5.9	other
30		BE502341	Hs.3402	ESTs	13.7	other
		AA099014	Hs.231029	Homo sapiens, clone MGC:15961, mRNA, com	8.7	other
		AF078866	Hs.284296	Homo sapiens cDNA: FLJ22993 fis, done K	5.5	other
	131905	AA179298	Hs.3439	stomatin-like 2	11.3	other
0.7		AW207440	Hs.185973	degenerative spermatocyte (homolog Droso	1.7	SS,
35		AA025976	Hs.34569	ESTs	5.2	TM
		AF151048	Hs.183180	anaphase promoting complex subunit 11 (y	2.8	<ul> <li>other</li> </ul>
		BE541211	Hs.34804	Homo sapiens cDNA FLJ11472 fis, clone HE	5.4	TM
		BE252983	Hs.35086	ubiquitin specific protease 1	2.4	other
40		AA355113 AK000046	Hs.35380 Hs.267448	x 001 protein	1.5 2.3	?
70		W79283	Hs.35962	hypothetical protein FLJ20039 ESTs	1.4	other other
		BE567100	Hs.154938	hypothetical protein MDS025	3.5	other
		U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-di	6.6	TM
		AA503020	Hs.36563	hypothetical protein FLJ22418	2.4	?
45		AF053306	Hs.36708	budding uninhibited by benzimidazoles 1	2.2	SS,TM
	132019	H56995	Hs.37372	Homo saplens DNA binding peptide mRNA, p	3.3	TM
		BE266155	Hs.3832	clathrin-associated protein AP47	1.5	other
		NM_002267	Hs.3886	karyopherin alpha 3 (importin alpha 4)	3.7	other
50		BE171921	Hs.3991	ESTs	1.5	other
50		AV646076	Hs.39959	ESTs	5.8	TM
		AW960474	Hs.40289	ESTs	1.7	other
		AA857025	Hs.8878	kinesin-like 1	3.4	other
		NM_004460 R42432	Hs.418 Hs.4212	fibroblast activation protein, alpha ESTs	14.7	SS,
55		BE206939	Hs.42287	E2F transcription factor 6	2,2 1.5	other
55		AV658411	Hs.42656	KIAA1681 protein	5.7	other other
		AI566004	Hs.141269	Homo saplens cDNA: FLJ21550 fis, done C	2.1	other
		AA301228	Hs.43299	hypothetical protein FLJ12890	1.5	other
		AA227710	Hs.43658	DKFZP586L151 protein	10	other
60		AA653507	Hs.285711	hypothetical protein FLJ13089	2	other
		N36110	Hs.305971	solute carrier family 2 (facilitated glu	9.2	other
		AB023191	Hs.44131	KIAA0974 protein	2	other
		NM_015986	Hs.7120	cytokine receptor-like molecule 9	6.6	SS,
<i>(</i>		AW405882	Hs.44205	cortistatin	3.8	other
65		N37065	Hs.44856	hypothetical protein FLJ12116	1.5	other
		AW572805	Hs.46645	ESTS	28.3	?
	1323/4	AF155582	Hs.46744	core1 UDP-galactose:N-acetylgalactosamin	1.9	other

	132376 Al27	9892	Hs.46801	sorting nextn 14	2	?
	132384 AA3	12135	Hs.46967	HSPCO34 protein	6.1	?
	132393 AL1:		Hs.47334	hypothetical protein FLJ14495	1.7	other
	132450 AA1	00012	Hs.48827	hypothetical protein FLJ12085	8.6	other
5	132452 AWS	73521	Hs.247324	mitochondrial ribosomal protein S14	5.3	other
	132456 AB0	11084	Hs.48924	KIAA0512 gene product; ALEX2	1.5	other
	132470 Al22	4456	Hs.4934	H.sapiens polyA site DNA	2	other
	132484 X16	660	Hs.119007	RAB4, member RAS oncogene family	2.9	SS,
	132518 AW8	385606	Hs.5064	ESTs	2.2	other
10	132530 AA3	06105	Hs.50785	SEC22, vesicle trafficking protein (S. c	1.7	other
	132532 AA4	54132	Hs.5080	mitochondrial ribosomal protein L16	7.2	TM
	132534 BE3	88673	Hs.5086	hypothetical protein MGC10433	2.2	SS,
	132543 BE5	68452	Hs.5101	protein regulator of cytokinesis 1	2.2	other
	132574 AW6	631437	Hs.5184	TH1 drosophila homolog	14	?
15	132596 AKO	01484	Hs.5298	CGI-45 protein	1.9	other
	132611 AA3	45547	Hs.53263	hypothetical protein FLJ13287	2.6	TM
	132612 H12	751	Hs.5327	PRO1914 protein	2	other
	132616 BE2		Hs.283558	hypothetical protein PRO1855	3.1	other
	132638 AI79	96870	Hs.54277	DNA segment on chromosome X (unique) 992	12.4	TM
20	132668 AB0		Hs.5460	KIAA0776 protein	2.8	SS,
	132692 AW	191962	Hs.249239	collagen, type VIII, alpha 2	3	other
	132715 F11	875	Hs.5534	Homo sapiens cDNA FLJ12961 fis, done NT	1.8	other
	132718 NM	_004600	Hs.554	Sjogren syndrome antigen A2 (60kD, ribon	3.7	other
	132724 Al14	42265	Hs.55498	geranylgeranyl diphosphate synthase 1	1.8	TM
25	132731 Al18	89075	Hs.301872	hypothetical protein MGC4840	5.9	other
	132744 AA0		Hs.55921	glutamyl-prolyl-tRNA synthetase	8.7	other
	132760 AA1		Hs.56145	thymosin, beta, identified in neuroblast	3.6	other
	132771 Y10		Hs.56407	phosphoserine phosphatase	2.8	TM
	132773 AA4		Hs.295901	KIAA0493 protein	14.6	other
30	132784 Al14		Hs.56845	GDP dissociation inhibitor 2	1.7	other
	132798 AIO		Hs.5716	KIAA0310 gene product	2.5	other
	132807 U07		Hs.57301	mutL (E. coli) homolog 1 (colon cancer,	1.4	other
	132810 ABC		Hs.5737	KIAA0475 gene product	4.3	SS,
	132813 BE3		Hs.57435	solute carrier family 11 (proton-coupled	2.8	other
35	132815 Al8		Hs.57475	sex comb on midleg homolog 1	1.6	other
	132817 N27		Hs.57553	tousled-like kinase 2	1.4	other other
	132821 AJ2		Hs.169610	CD44 antigen (homing function and Indian	5.4	?
	132833 U78		Hs.57783	eukaryotic translation initiation factor	6.1 7.2	r other
40	132842 NM		Hs.279771	Homo sapiens clone PP1596 unknown mRNA	2.9	other
40	132844 F12		Hs.5811	chromosome 21 open reading frame 59	6.1	other
	132851 U09		Hs.287912	lectin, mannose-binding, 1	1.8	other
	132869 AW		Hs.203961	ESTs, Moderately similar to AF116721 89	2.2	other
	132873 AW		Hs.58598	KIAA1266 protein	5	TM
15	132875 NM		Hs.58617	Rho-associated, coiled-coil containing p	2.7	?
45	132891 BE:		Hs.59271	U2(RNU2) small nuclear RNA auxillary fac	5.4	ż
	132897 AW		Hs.59545	ring finger protein 15 hypothetical protein FLJ10808	3.2	other
	132902 Al9		Hs.59838	Homo sapiens cDNA FLJ11095 fis, clone PL	1.4	other
	132912 AW		Hs.167578	Homo sapiens CDNA FLJ13598 fis, clone PL	3	other
50	132913 W7		Hs.60257 Hs.127243	Homo sapiens mRNA for KIAA1724 protein,	10.3	other
50	132940 T79		Hs.197751	KIAA0666 protein	2.1	SS,
	132942 AA 132952 AI6		Hs.61426	Homo saplens mesenchymal stem cell prote	1.3	other
	132952 AIO		Hs.6153	CGI-48 protein	4.9	other
	132902 AA		Hs.288924	Homo sapiens cDNA FLJ11392 fis, clone HE	3.6	TM
55	132973 AA		Hs.323277	ESTs	13.1	other
33			Hs.301404	RNA binding motif protein 3	1.3	other
	132977 AA 132980 AA		Hs.62016	ESTs	2.3	?
	132994 AA		Hs.279905	clone HQ0310 PRO0310p1	17.1	other
	133012 AA		Hs.62711	Homo saplens, done IMAGE:3351295, mRNA	1.9	other
60	133015 AJ		Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polyp	5	TM
UU	133062 AV		Hs.64056	PRO0149 protein	6.1	other
	133069 BE		Hs.6430	protein with polyglutamine repeat; calci	1.5	TM
	133091 AK		Hs.64691	KIAA0483 protein	1.4	other
	133110 AA		Hs.65228	ESTs	5.6	other
65	133134 AF		Hs.65648	RNA binding motif protein 8A	1.9	other
00	133145 H9		Hs.6592	Homo sapiens, done IMAGE:2961368, mRNA,	4.8	?
	133152 Z1		Hs.324473	mitogen-activated protein kinase 1	5	other
				-		

							•	
		AA431620	Hs.324178	hypothetical protein MGC2745	2.7	other		
	133175	AW955632	Hs.66666	ESTs, Weakly similar to S19560 proline-r	9.3	other		
	133177	X97795	Hs.66718	RAD54 (S.cerevisiae)-like	4.5	TM		
	133208	AI801777	Hs.6774	ESTs	5.5	TM		
5		AW954569	Hs.296287	Homo sapiens, Similar to bromodomain-con	2.7	other		
-		AI492924	Hs.6831	golgi phosphoprotein 1	1.7	?		
		AI567421	Hs.273330	Homo sapiens, clone IMAGE:3544662, mRNA,	1.3	other		
		AW956781						
			Hs.293937	ESTs, Weakly similar to FXD2_HUMAN FORKH	12.2	other		
10		BE297855	Hs.69855	NRAS-related gene	1.2	other		
10		AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto	1.7	TM		
		T79526	Hs.179516	integral type I protein	11.1	?		
	133327	AL390127	Hs.7104	Kruppel-like factor 13	2.9	other		
	133347	BE257758	Hs.71475	acid cluster protein 33	2.5	?		
	133360	AI016521	Hs.71816	v-akt murine thymoma viral oncogene homo	1.5	other		
15	133366	AA292811	Hs.72050	non-metastatic cells 5, protein expresse	2.1	other		
		AF231919	Hs.18759	KIAA0539 gene product	1.3	other		
		AF245505	Hs.72157	DKFZP564I1922 protein	2.2	other		
		AI950382	Hs.72660	phosphatidylserine receptor	5.7	TM		
		AW103364			25.5			
20			H\$.727	inhibin, beta A (activin A, activin AB a		other		
20		AA305127	Hs.237225	hypothetical protein HT023	3.3	other		
		AL031591	Hs.7370	phosphotidylinositol transfer protein, b	1.6	other		
		NM_002759	Hs.274382	protein kinase, interferon Inducible dou	4.1	other		
		A1659306	Hs.73826	protein tyrosine phosphatase, non-recept	1.5	other		
0.5		AW964804	Hs.74280	hypothetical protein FLJ22237	6.3	TM		
25	133529	W45623	Hs.74571	ADP-ribosylation factor 1	4	? .		
	133543	AU077073	Hs.108327	damage-specific DNA binding protein 1 (1	1.8	?		
	133578	AU077050	Hs.75066	translin	1.5	other		
	133579	X75346	Hs.75074	mitogen-activated protein kinase-activat	3.5	TM		
	133582	BE391579	Hs.75087	Fas-activated serine/threonine kinase	6.8	TM		
30		AW160781	Hs.172589	nuclear phosphoprotein similar to S. cer	2.6	TM		
		AA393273	Hs.75133	transcription factor 6-like 1 (mitochond	1.4	other		
		NM_002885	Hs.75151	RAP1, GTPase activating protein 1	8.1	other		
		NM_004893	Hs.75258	H2A histone family, member Y	13.5	other		
		NM_002047	Hs.75280	glycyl-tRNA synthetase	2.2	other		
35		NM_000401	Hs.75334	exostoses (multiple) 2	1.8	other		
55		U25849	Hs.75393	acid phosphatase 1, soluble	2	other		
		AV661185	Hs.75574		2.8	other		
				mitochondrial ribosomal protein L19				
	133720		Hs.75737	pericentriolar material 1	6.8	other		
40		AW969976	Hs.279009	matrix Gla protein	2.5	other	2.4	***
40		AW402048.co	.*.	Hs.334787		piens, Similar to likely ortholog	3.1	TM
		T52946	Hs.196209	RAE1 (RNA export 1, S.pombe) homolog	1.4	?		
		BE271766	Hs.181357	taminin receptor 1 (67kD, ribosomal prot	5.4	other		
	133765	M62194	Hs.75929	cadherin 11, type 2, OB-cadherin (osteob	5	other		
	133780	AA557660	Hs.76152	decorin	3.8	other		
45	133797	AL133921	Hs.76272	retinoblastoma-binding protein 2	3.1	?		
	133822	D50525	Hs.699	peptidylprolyl isomerase B (cyclophilin	9.7	?		
	133842	AW797468	Hs.285013	putative human HLA class II associated p	2.4	other		
	133845	AA147026	Hs.76704	ESTs	2.5	other		
		AB011155	Hs.170290	discs, large (Drosophila) homolog 5	5	other		
50		AW340125	Hs.76989	KIAA0097 gene product	2.5	?		
••		AB012193	Hs. 183874	culin 4A	2.1	other		
		U30825	Hs.77608	splicing factor, arginine/serine-rich 9	2.8	TM		
		D86326	Hs.325948	vesicle docking protein p115		SS,		
		NM_006306	Hs.211602	SMC1 (structural maintenance of chromoso	2	?		
55								
22	133936		Hs.77719	gamma-glutamyl carboxylase	2.6	other		
		BE244332	Hs.77770	adaptor-related protein complex 3, mu 2	2.9	other		
		X81789	Hs.77897	splicing factor 3a, subunit 3, 60kD	10.4	other		
		AI908165	Hs.169946	GATA-binding protein 3 (T-cell receptor	1.9	other		
		AL040328	Hs.78202	SWI/SNF related, matrix associated, acti	2.6	SS,		
60		Al824113	Hs.78281	regulator of G-protein signalling 12	13	other		
		AB016092	Hs.197114	RNA binding protein; AT-rich element bin	8.8	other		
	134015	D31764	Hs.278569	sorting nexin 17	1.5	SS,		
	134070	NM_003590	Hs.78946	cullin 3	8.3	other		
	134110	U41060	Hs.79136	LIV-1 protein, estrogen regulated	2.7	other		
65		NM_014742	Hs.79305	KIAA0255 gene product	4.2	other		
	134134	H86504	Hs.173328	protein phosphatase 2, regulatory subuni	1.7	other		
		BE559598	Hs.197803	KIAA0160 protein	2.6	other		

	134206 AF107463	Hs.79968	splicing factor 30, survival of motor ne	1.3	other
	134219 NM_000402	Hs.80206	glucose-6-phosphate dehydrogenase	1.9	other
	134234 BE300078	Hs.80449	Homo sapiens, clone IMAGE:3535294, mRNA,	10.3	SS,
~	134275 AJ878910	Hs.3688	cisplatin resistance-associated overexpr	2.5	other
5	134292 Al906291	Hs.81234	Immunoglobulin superfamily, member 3	1.3 1.6	TM TM
	134301 AW502505	Hs.81360	Homo sapiens cDNA: FLJ21927 fis, clone H	2.1	TM
	134305 U61397	Hs.81424	ubiquitin-like 1 (sentrin) KIAA1100 protein	5.3	?
	134324 AB029023 134326 AW903838	Hs.179946 Hs.81800	chondroitin sulfate proteoglycan 2 (vers	2.5	TM
10	134329 N92036	Hs.81848	RAD21 (S. pombe) homotog	3.9	?
10	134337 NM_004922	Hs.81964	SEC24 (S. cerevisiae) related gene famil	2.4	TM
	134348 AW291946	Hs.82065	interleukin 6 signal transducer (gp130,	6.8	TM
	134367 AA339449	Hs.82285	phosphoribosylglycinamide formyltransfer	2.3	TM
	134376 X06560	Hs.82396	2',5'-ofigoadenylate synthetase 1 (40-46	5.5	other
15	134379 AW362124	Hs.323193	hypothetical protein MGC3222	5.9	TM
	134384 Al589941	Hs.8254	Homo sapiens, Similar to tumor different	2.2	other
	134391 AA417383	Hs.82582	integrin, beta-like 1 (with EGF-like rep	2.1	other
	134395 AA456539	Hs.8262	lysosomal	2.3	other other
20	134405 AW067903	Hs.82772	collagen, type XI, alpha 1	72.9 4.4	other
20	134411 BE272095	Hs.167791	reticulocalbin 1, EF-hand calcium bindin	2.3	other
	134415 AI750762	Hs.82911	protein tyrosine phosphatase type IVA, m collagen, type V, alpha 2	6.8	7
	134421 AU077196	Hs.82985 Hs.83023	peroxisomal biogenesis factor 11B	2.4	other
	134424 Z44190 134446 AA112036	Hs.83419	KIAA0252 protein	2.9	other
25	134447 M58603	Hs.83428	nuclear factor of kappa light polypeptid	6.7	other
23	134470 X54942	Hs.83758	CDC28 protein kinase 2	2.4	other
	134480 NM_005000	Hs.83916	Empirically selected from AFFX single pr	6.3	?
	134485 X82153	Hs.83942	cathepsin K (pycnodysostosis)	1.9	other
	134498 AW246273	Hs.84131	threonyl-tRNA synthetase	1.8	other
30	134513 AA425473	Hs.84429	KIAA0971 protein	1.4	other
	134516 AK001571	Hs.273357	hypothetical protein FLJ10709	1.4	other
	134520 BE091005	Hs.74861	activated RNA polymerase II transcriptio	5.6	other ?
	134529 AW411479	Hs.848	FK506-binding protein 4 (59kD)	2.8 1.7	other
25	134577 BE244323	Hs.85951	exportin, IRNA (nuclear export receptor	1.7	TM
35	134582 AA927177	Hs.86041 Hs.171581	CGG triplet repeat binding protein 1 ubiquitin C-terminal hydrolase UCH37	2.1	other
	134612 AW068223 134624 AF035119	Hs.8700	deleted in liver cancer 1	1.3	other
	134632 X78520	Hs.174139	chloride channel 3	2.1	?
	134654 AK001741	Hs.8739	hypothetical protein FLJ10879	2.3	other
40	134666 BE391929	Hs.8752	transmembrane protein 4	4	other
	134687 U62317	Hs.88251	arylsulfatase A	6.2	other
	134692 NM_003474	Hs.8850	a disintegrin and metalloproteinase doma	2	other
	134705 BE161887	Hs.88799	anaphase-promoting complex subunit 10	1.3	SS,
	134714 Y14768	Hs.890	lysosomal	7.2	?
45	134719 AA852985	Hs.89232	chromobox homolog 5 (Drosophila HP1 alph	3.2	other other
	134722 AF129536	Hs.284226	F-box only protein 6	2.5 5	other
	134746 X07871	Hs.89476	CD2 antigen (p50), sheep red blood cell	6.1	other
	134751 AW630803	Hs.89497 Hs.287850	tamin B1 integral membrane protein 1	5.6	TM
50	134790 BE002798 134834 AW451370	Hs.8991	adaptor-related protein complex 1, gamma	5.3	other
50	134850 AI701162	Hs.90207	hypothetical protein MGC11138	9.1	other
	134853 BE268326	Hs.90280	5-aminoimidazole-4-carboxamide ribonude	2.4	other
	134880 Al879195	Hs.90606	15 kDa selenoprotein	2.7	other
	134925 AW885909	Hs.6975	PRO1073 protein	1.5	other
55	134955 AW401361	Hs.91773	protein phosphatase 2 (formerly 2A), cat	4.9	other
	134971 Al097346	Hs.286049	phosphoserine aminotransferase ·	2	other
	134975 R50333	Hs.92186	Leman coiled-coil protein	2.6	TM
	135011 AB037835	Hs.92991	KIAA1414 protein	1.4 1.6	?
<b>~</b> 0	135022 NM_000408		glycerol-3-phosphate dehydrogenase 2 (ml	1.4	other
60	135032 AW301984	Hs.173685	hypothetical protein FLJ12619 KIAA1488 protein	1.8	other
	135077 AW503733	Hs.9414 Hs.94262	p53-inducible ribonucleotide reductase s	2.5	other
	135083 AB036063 135095 AF027219	Hs.9443	zinc finger protein 202	1.5	TM
	135095 AF027219 135096 AA081258	Hs. 132390	zinc finger protein 36 (KOX 18)	2.1	other
65	135153 Al093155	Hs.95420	JM27 protein	4.4	?
00	135181 BE250865	Hs.279529	px19-like protein	14.9	?
	135199 AA477514	Hs.96247	translin-associated factor X	1.3	other

	10000				
	135207 N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATI	1.7	other
	135214 T78802	Hs.96560	hypothetical protein FLJ11656	6.2	other
	135243 BE463721	Hs.97101	putative G protein-coupled receptor	2.8	TM
_	135245 Al028767	Hs.262603	ESTs	12.2	TM
5	135257 AW291023	Hs.97255	ESTs, Weakly similar to A46010 X-linked	7.7	TM
	135263 Al088775	Hs.55498	geranylgeranyl diphosphate synthase 1	1.8	other
	135274 AA448460	Hs.112017	GE36 gene	4.2	SS,
	135294 AA150320	Hs.9800	protein kinase Nimu-R1	1.2	other
	135295 Al090838	Hs.98006	ESTs	4.9	other
10	135307 AI743770	Hs.98368	ESTs, Weakly similar to KIAA0822 protein	5.9	?
	135321 Al652069	Hs.98614	ribosome blinding protein 1 (dog 180kD ho	12.3	TM
	135354 AA456454	Hs.183418	cell division cycle 2-like 1 (PITSLRE pr	5.8	?
	135361 AA373452	Hs.167700	Homo sapiens cDNA FLJ10174 fis, clone HE	8.1	other
	135389 U05237	Hs.99872	fetal Alzheimer antigen	1.9	other
15	135400 X78592	Hs.99915	androgen receptor (dihydrotestosterone r	13.9	TM
	302256 AA857131	Hs.171595	HIV TAT specific factor 1	1.6	. other
	302276 AW057736	Hs.323910	HER2 receptor tyrosine kinase (c-erb-b2,	5.3	other
	303135 AW592789	Hs.279474	HSPC070 protein	2.2	TM
	303686 AK000714	Hs.109441	MSTP033 protein	1.4	SS.
20	310085 R43191	Hs.101248	Homo saplens clone IMAGE:32553, mRNA seq	5.2	other
20	315518 AA808229	Hs.167771	ESTs	2.3	?
	317781 NM_007057	Hs.42650	ZW10 interactor	2.9	7
	320836 Al268997	Hs.197289		2.9	other
	321114 AA902256	Hs.78979	rab3 GTPase-activating protein, non-cata	5.6	
25			Golgl apparatus protein 1		SS,
23	322221 N24236	Hs.179662	nucleosome assembly protein 1-like 1	1.4	?
	322474 AF118083	Hs.29494	PRO1912 protein	1.3	other
	322556 BE041451	Hs.177507	hypothetical protein	2.9	SS,
	323541 AF292100	Hs.104613	RP42 homolog	1.6	-other
20	407827 BE278431	Hs.40323	BUB3 (budding uninhibited by benzimidazo	1.8 .	other
30	408196 AL034548	Hs.43627	SRY (sex determining region Y)-box 22	1.6	other
	408813 Al580090	Hs.48295	RNA helicase family	6.2	other
	409176 R73727	Hs.101617	ESTs, Weakly similar to T32527 hypotheti	5.7	other
	409487 H19886		gb:yn57a05.r1 Soares adult brain N2b5HB5	2.7	other
25	413670 AB000115	Hs.75470	hypothetical protein, expressed in osteo	2.6	?
35	414108 Al267592	Hs.75761	SFRS protein kinase 1	2.4	TM
	414846 AW304454	Hs.77495	UBX domain-containing 1	2.4	other
	416040 AW819158	Hs.289044	Homo sapiens cDNA FLJ12048 fis, clone	2.3	other
	416980 AA381133	Hs.80684	high-mobility group (nonhistone chromoso	4.2	TM
40	417378 R57256	Hs.82037	TATA box binding protein (TBP)-associate	23.6	other
40	418283 S79895	Hs.83942	calhepsin K (pycnodysostosis)	5.8	other
	418467 NM_006910	Hs.85273	retinoblastoma-binding protein 6	1.3	other
	420269 U72937	Hs.96264	alpha thalassemia/mental retardation syn	1.6	?
	420802 U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen -	2.3	?
	421225 AA463798	Hs.102696	MCT-1 protein	1.6	?
45	421642 AF172066	Hs.106346	retinoic acid repressible protein	3.5	other
	421828 AW891965	Hs.279789	histone deacetylase 3	5	other
	421983 AI252640	Hs.110364	peptidylprolyl isomerase C (cyclophilin	3.1	TM
	422052 AA302744	Hs.104518	ESTs	1.9	TM
	422055 NM_014320	Hs.111029	putative heme-binding protein	2.4	other
50	423750 AF165883	Hs.298229	prefoldin 2	4.2	?
	424001 W67883	Hs.137476	paternally expressed 10 (PEG10; KIAA105	7.1	?
	425182 AF041259	Hs.155040	zinc finger protein 217	2.3	other
	425284 AF155568	Hs.155489	NS1-associated protein 1	3.5	other
	426372 BE304680	Hs.169531	DEAD/H (Asp-Glu-Ala-Asp/Hls) box polypep	1.9	?
55	428049 AW183765	Hs.182238	GW128 protein	7.6	?
	428477 AW500533	Hs.11482	splicing factor, arginine/serine-rich 11	1.7	other
	437562 AB001636	Hs.5683	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	2.4	other
	438449 AK001333	Hs.6216	Homo sapiens hepatocellular carcinoma-as	3.8	other
	441560 F13386	Hs.7888	Homo sapiens clone 23736 mRNA sequence	5.6	other
60	445580 AF167572	Hs.12912	skb1 (S. pombe) homolog	2	TM
	446999 AA151520	Hs.334822	hypothetical protein MGC4485	7.6	other
	447111 Al017574	Hs.17409	cysteine-rich protein 1 (intestinal)	2.2	other
	447778 BE620592	Hs.71190	ESTs, Weakly similar to \$16506 hypotheti	2.9	other
	448873 NM 003677	Hs.22393	density-regulated protein	1.8	other
65	449687 W68520	Hs.331328	intermediate filament protein syncoilin	5.9	other
	450701 H39960	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.7	other
	450703 AA011202	Hs.184771	nuclear factor VC (CCAAT-binding transc	1.4	other

	450404	r=20000	11- 400400	to an della feeta	4.0	•
		N78223	Hs.108106	transcription factor	4.8 2.9	? other
		BE408178 AF077036	Hs.285165 Hs.31989	Homo sapiens cDNA FLJ20845 fis, clone AD DKFZP586G1722 protein	12.1	SS,TM
		BE541906	Hs.87819	Homo sapiens, clone MGC:2492, mRNA, comp	4.8	other
5		AA328229	Hs.184582	ribosomal protein L24	1.8	TM
-		AA383256	Hs.1657	estrogen receptor 1	1.6	other
	100833	AF135168	Hs.108802	N-ethylmalelmide-sensitive factor	1.3	other
	100850	AA836472	Hs.297939	cathepsin B	1.7	7
10		NM_006262	Hs.37044	peripherin	16.9	other
10		U50360		gb:Human calcium, calmodulin-dependent p	3.2	other
		AA262170	Hs.80917	adaptor-related protein complex 3, sigma	2	?
•		BE270465	Hs.78793	protein kinase C, zeta	8 1.8	other other
		AL135301 AB040450	Hs.8768 Hs.279862	hypothetical protein FLJ 10849 cdk Inhibitor p21 binding protein	2	?
15		AI498763	Hs.203013	hypothetical protein FLJ12748	2.1	other
10		AL117403	Hs.306189	DKFZP434F1735 protein	1.2	other
		AA127818	110.000100	gb:zl12a02.s1 Soares_pregnant_uterus_NbH	7	?
		AA907305	Hs.36475	ESTs	2.6	7
	106531	AA454036	Hs.8832	ESTs	1.6	other
20		AL043152	Hs.50421	KIAA0203 gene product	4.9	other
		N95657	Hs.6820	ESTs, Moderately similar to YOJ1_CAEEL H	2.5	TM
		AA122393	Hs.70811	hypothetical protein FLJ20516	1.3	other
		AW579842	Hs.104557	hypothetical protein FLJ10697	5.3 6.3	TM other
25		Al288666 NM_003896	Hs.16621 Hs.225939	DKFZP434I116 protein slalyttransferase 9 (CMP-NeuAc:lactosylc	5.1	SS,
23		W46342	Hs.325081	Homo sapiens, clone IMAGE:3659680, mRNA,	8.4	other
		AW503990	Hs.142442	HP1-BP74	3.7	TM
		AV653556	Hs.184411	albumin	1.3	other
		AK001827	Hs.87889	helicase-moi	2	other
30	115062	AA253314	Hs.154103	LIM protein (similar to rat protein kina	1.5	other
		Al634549	Hs.88155	ESTs	2.8	other
		AF161470	Hs.260622	butyrate-induced transcript 1	5.8	TM
		M10905	Hs.287820	fibronectin 1	5.7 1.3	other other
35		AL034423 AA131376	Hs.75875 Hs.326401	ubiquitin-conjugating enzyme E2 variant fibroblast growth factor 12B	38.9	other
55		BE065136	Hs.145696	splicing factor (CC1.3)	2.9	?
		X80031	Hs.530	collagen, type IV, alpha 3 (Goodpasture	1.8	other
		AA419008	Hs.106730	chromosome 22 open reading frame 3	3	other
		F34856	Hs.292457	Homo sapiens, clone MGC:16362, mRNA, com	13.3	other
40	128959	Al580127	Hs.107381	hypothetical protein FLJ11200	10.9	other
		R62676	Hs.17820	Rho-associated, coiled-coil containing p	2.4	other
		A1096988	Hs.111554	ADP-ribosylation factor-like 7	8.2	TM
		AW974265	Hs.111632	Lsm3 protein	3.3	? other
15		AK000398	Hs.11747	hypothetical protein FLJ20391	3.9 5.3	other TM
45		M30773 AF042379	Hs.278540 Hs.13386	protein phosphatase 3 (formerly 2B), reg gamma-tubulin complex protein 2	4.6	other
		AB015856	Hs.247433	activating transcription factor 6	4	SS.
		BE267033	Hs.192853	ubiquitin-conjugating enzyme E2G 2 (homo	4.6	other
		W56119	Hs.155103	eukaryotic translation initiation factor	11	other
50	130471	AL121438	Hs.183706	adducin 1 (alpha)	2.7	other
	130542	U64675	Hs.179825	RAN binding protein 2-like 1	7.9	other
		AB007891	Hs.16349	KIAA0431 protein	5.6	TM
		AF258627	Hs.211562	ATP-binding cassette, sub-family A (ABC1	5.2	other
55		BE398091	Hs.74316	desmoplakin (DPI, DPII) ESTs, Moderately similar to A46010 X-lin	1.8 1.7	TM ?
55	131047	H23230 NM_016569	Hs.22481	TBX3-iso protein	3.3	TM
	131133	AF058696	Hs.267182 Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6	other
		X76732	Hs.3164	nucleobindin 2	2.9	TM
		BE267158	Hs.169474	DKFZP586J0119 protein	5.6	other
60	131853	Al681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU	1.3	other
		AW361018	Hs.3383	upstream regulatory element binding prot	3.2	TM
		W17064	Hs.332848	SWI/SNF related, matrix associated, acti	3.2	other
		AF193844	Hs.3758	COP9 complex subunit 7a mitochondrial ribosomal protein L37	5.9 2.2	? TM
65		AA206153 NM_004782	Hs.4209 Hs.194714	synaptosomal-associated protein, 29kD	7.9	?
UJ		AB018324	Hs.42676	KIAA0781 protein	4.3	other
•		AW067708	Hs.170311	heterogeneous nuclear ribonucleoprotein	12.5	other

	132528 T78736	Hs.50758	SMC4 (structural maintenance of chromoso	7.4	7	
	132571 AW674699	Hs.5169	suppressor of G2 allele of SKP1, S. cere	6.9	other	
	132726 N52298	Hs.55608	hypothetical protein MGC955	14.3	7	
_	132863 BE268048	Hs.236494	RAB10, member RAS oncogene family	10.3	other	
5	133016 Al439688	Hs.6289	hypothetical protein FLJ20886	4.4	other	
	133053 Al065016	Hs.6390	Homo sapiens clone FLB3344 PRO0845 mRNA,	1.8	SS,TM	
	133197 Al275243	Hs.180201	hypothetical protein FLJ20671	1.8	other	
	133240 AK001489	Hs.242894	ADP-ribosylation factor-like 1	1.8	other	
	133266 Al160873	Hs.69233	zinc finger protein	16.1	other	
10	133285 M76477	Hs.289082	GM2 ganglioside activator protein	10.4	SS,	
	133383 BE313555	Hs.7252	KIAA1224 protein	1.5	7	
	133540 AL037159	Hs.74619	proteasome (prosome, macropain) 26S subu	1.7	other	
	133784 BE622743	Hs.301064	arfaptin 1	12.1	other	
	133791 M34338	Hs.76244	spermidine synthase	9.7	other	
15	133850 W29092	Hs.7678	cellular retinoic acid-binding protein 1	4.2	SS,	
	133859 U86782	Hs.178761	26S proteasome-associated pad1 homolog	2.2	other	
	133881 U30872	Hs.77204	centromere protein F (350/400kD, mitosin	9.1	other	
	134208 NM_000288	Hs.79993	peroxisomal biogenesis factor 7	3.2	other	
	134403 AA334551	Hs.82767	sperm specific antigen 2	1.4	other	
20	134724 AF045239	Hs.321576	ring finger protein 22	1.4	other	
	134806 AD001528	Hs.89718	spermine synthase	2.6	other	
	134859 D26488	Hs.90315	KIAA0007 protein	13.3	other	
	135193 X95525	Hs.96103	TATA box binding protein (TBP)-associate	3.1	other	
	AA243007		ESTs	1.6	?	
25	T70541		ESTs	2.5	SS,	
	X57766		Human stromelysin-3 mRNA	4.5	other	
	. S66431		Homo sapiens clone 23592 mRNA sequence	3.1	other	
	AA453483		ESTs	4.6	TM	
	R63925		ESTs	1.4	other	
30	AA173417		ESTs	1.9	other	
	AA280588		ESTs	2.2	other	
	AA504223		ESTs Highly similar to CHROMOSOME	2.4	other	
	AA609996		ESTs Highly similar to Surf-4 protein [M.musculus]		7	
	F02907	•	ESTs	2.3	TM	
35	AA480103		ESTs Weakly similar to IIII ALU SUBFAMILY J	2.8	TM	
	AA024664		Human NADH:ubiquinone oxidoreductase subunit	6.2	other	
	AA251776		ESTs	2.3	other	
	AA399047		ESTs	2.4	other	
	N34059		EST - RC_N34059	3.3	other	
40	U95367		Human GABA-A receptor pi subunit mRNA complet		1.7	TM
	AA490899		ESTs	3.3	other	••••
	T54762		ESTs	2.9	?	
	Z41963		Homo saplens HP protein (HP) mRNA complete cd		7	
	AA521186		ESTs	1.6	TM	
45	AA400195		ESTs	1.3	other	
	AA045083		VITAMIN K-DEPENDENT GAMMA-CARBOXYLAS	E	2.5	other
	AA099589		Homo sapiens mRNA for GDP dissociation inhibitor		1.6	TM
	W85712		ESTs Weakly similar to PROCOLLAGEN ALPHA 2		2.6	TM
	W45728		ESTs Highly similar to HETEROGENEOUS	3.7	other	
50	U61232		Human tubulin-folding cofactor E mRNA complete of		2.1	other
	AA425154		ESTs	5.3	other	
	T39176		ESTs Weakly similar to ZK1058.4 [C.elegans]	2.6	SS.TM	
	AA496000		ESTs	1.9	SS,	
•	W38150		EST - RC_W38150	1.7	?	
55	T96595		EST - RC_T96595	1.8	TM	
55	AA227463		ESTs Weakly similar to No definition line found [C.e		1.9	7
	R46025		ESTs	2.8	SS,	•
	AA233177		ESTs	2	other	
	AA338760		ESTs	1.3	?	
60	AA412106		ESTs	6.2	other	
00	L47276		EST - L47276	3.4	other	
	D82307		ESTs Weakly similar to TH1 protein [D.melanogasti		11.4	other
	AA293568		ESTs	1.5	other	34.00
	R37778		ESTs	2.4	other	
65	AA250843		Interferon regulatory factor 5	14.6	?	
03	W49521		Human prolyl 4-hydroxylase alpha (ii) subunit	6.5	į	
	D80000		Human mRNA for KIAA0178 gene partial cds	2	other	
	50000		The state of the state of the particular	-		

R99978	ESTs Weakly similar to line-1 protein ORF2 [H.sapiens]	6.1	?
AA195036	Human Ro/SSA ribonucleoprotein homolog (RoRet 5.3	?	
Z38501	ESTs Weakly similar to PROBABLE E5 1.4	other	
U37547	Human IAP homolog B (MIHB) mRNA complete cds 3.2	other	
AA479961	ESTs 1.7	other	
X57579	Inhibin beta A (activin A activin AB alpha polypeptide)	15.8	?
AA449071	ESTs 1.3	TM	
N51855	ESTs Moderately similar to NAD(+) ADP- 1.3	other	
AA421213		other	
AA355201		SS.TM	
N78717	H.sapiens mRNA for translin 1.5		
N73808	ESTs 5	?	
U86782	Human 26S proteasome-associated pad1 2.2	other	
AA234817		other	
D13666	Homo sapiens mRNA for osteoblast specific 7.5	SS,	
AA236177	ESTs 7.1	?	
U50648	Protein kinase interferon-inducible double 4.1	?	
M28211	Homo sapiens GTP-binding protein (RAB4) 2.9	other	
AA446949	ESTs 2.2	other	
W03007	ESTs 1.2	other	
W61011	ESTs 1.2	other	
W87544	ESTs 1.2	other	
X02751	Neuroblastoma RAS viral (v-ras) oncogene homolog 1.2	?	
Z14077	YY1 transcription factor 1.2	other	
Z38839	ESTs 1.2	?	
AA410894	ESTs 1.7	other	
AA504499	ESTs Highly similar to probable chloride channel 3 [H.sa	p 1.3	other
	AA195036 Z38501 U37547 AA479961 X57579 AA449071 N51855 AA421213 AA355201 N78717 N73808 U86782 AA234817 D13666 AA236177 U50648 M28211 AA446949 W03007 W61011 W87544 X02751 Z14077 Z38839 AA410894	AA195036 Human Ro/SSA ribonucleoprotein homolog (RoRet 5.3 Z38501 ESTs Weakly similar to PROBABLE E5 1.4 U37547 Human IAP homolog B (MIHB) mRNA complete cds 3.2 AA479961 ESTs 1.7 X57579 Inhibito beta A (activin A activin AB alpha polypeptide) AA449071 ESTs 1.3 N51855 ESTs Moderately similar to NAD(+) ADP- 1.3 AA42113 ESTs Weakly similar to F28F8.3 (C.elegans) 3.2 AA355201 ESTs Weakly similar to F28F8.3 (C.elegans) 1.2 N78717 Haspiens mRNA for branslin 1.5 N73808 ESTs 5 U86782 Human 26S proteasome-associated pad1 2.2 AA234817 ESTs 1.3 D13666 Homo sapiens mRNA for osteoblast specific 7.5 AA236177 ESTs 7.1 U50648 Protein kinase interferon-inductible double 4.1 M28211 Homo sapiens GTP-binding protein (RAB4) 2.9 AA446949 ESTs 1.2 W03007 ESTs 1.2 W61011 ESTs 1.2 W87544 ESTs 1.2 X02751 Neuroblastoma RAS viral (v-ras) oncogene homolog 1.2 Z14077 YY1 transcription factor 1.2 AA410894 ESTs 1.7	AA195036 Human Ro/SSA ribonucleoprotein homolog (RoRet 5.3 7 238501 ESTs Weakly similar to PROBABLE E5 1.4 other U37547 Human IAP homolog B (MIHB) mRNA complete cds 3.2 other AA479961 ESTs 1.7 other Inhibin beta A (activin A activin AB alpha polypeptide) 15.8 AA449071 ESTs 1.3 TM N51855 ESTs Moderately similar to NAD(+) ADP- 1.3 other AA421213 ESTs Weakly similar to F28F8.3 [C.elegans] 3.2 other AA355201 ESTs 1.2 SS, TM N78717 H.sapiens mRNA for translin 1.5 ? N73808 ESTs 1.5 N046782 Human 26S proteasome-associated pad1 2.2 other AA234817 ESTs 1.3 other AA234817 ESTs 1.3 other D13666 Homo sapiens mRNA for osteoblast specific 7.5 SS, AA236177 ESTs 7.1 ? U50648 Protein kinase interferon-inducible double 4.1 ? M28211 Homo sapiens GTP-binding protein (RAB4) 2.9 other AA446949 ESTs 1.2 other W61011 ESTs 1.2 other W87544 ESTs 1.2 other W87544 ESTs 1.2 other X02751 Nauroblastoma RAS viral (v-ras) oncogene homolog 1.2 ? Z14077 YY1 transcription factor 1.2 other Z38839 ESTs 1.2 other

# TABLE 7A

Table 7 A shows the accession numbers for those pkeys lacking unigeneID's for Table 7. 5 For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Pkey: CAT number:

Unique Eos probeset identifier number

Gene cluster number

Accession:

Genbank accession numbers

15

20

Pkey CAT number

Accession

102481 31281\_-28

U50360

105032 genbank\_AA127818 409487 1134778\_1

AA127818

H19886 AW402806 T10231

# TABLE 8: Figure 8 from BRCA 001-1 US

5 Table 8 shows genes upregulated in tumor tissue compared to normal breast tissue.

Specifically, one column shows the ratio of expression of the indicated gene in breast tumor tissue compared to other body tissues, and another column shows the ratio of expression of the indicated gene in breast tumor tissue compared to normal breast tissue.

10						
	Pkey:	U	nique Eos prob	eset identifier number		
	ExAcon			sion number, Genbank accession number		
	Unigene		nigene number			
	Unigene		nigene gene tit			
15	R1:					
15				normal body tissue		
	R2:		Ratio of tur	nor to normal breast tissue		
	01					
	Pkey	ExAccn .	Unigeneil	Unigene Title	R1	R2
20	400070	4 F4 C0000	11 001100			
20		AF152333	HS.284160	protocadherin gamma subfamily B, 4	1	3.8
		AV652249		polymerase (DNA directed), beta	1.7	5.3
		D38500	Hs.278468	postmelotic segregation increased 2-like	8.0	4.8
		BE160081	Hs.256290	S100 calcium-binding protein A11 (calgiz	3.2	2.3
~-		A1907114	Hs.71465	squalene epoxidase	3.3	1.4
25	100522	X51501	Hs.99949	prolactin-induced protein	11.9	0.4
	100552	AA019521	Hs.301946	lysosomal	3.8	1.2
	100599	X77343	Hs.334334	transcription factor AP-2 alpha (activat	9.4	9.4
	100676	X02761	Hs.287820	fibronectin 1	3	7.8
	100690	AA383256	Hs.1657	estrogen receptor 1	4.4	4.4
30	100895	U01351	Hs.75772	nuclear receptor subfamily 3, group C, m	1	3.9
-		K01160		NM_002122:Homo sapiens major histocom	-	4
		AA382524	Hs.250959		0.8	4.1
		NM_00292		regulator of G-protein signalling 2, 24k	1.2	
	101161	NM_006262	2 Hs.37044	peripherin		12
35		L22524	Hs.2256	•	3.1	1.1
23				matrix metalloproteinase 7 (MMP7; uterin	4.4	0.6
		Al186220	Hs.83164	collagen, type XV, alpha 1	3.1	3.4
		AW468397	HS.100000	S100 calcium-binding protein A8 (calgran	0.9	4.2
		M21305		gb:Human alpha satellite and satellite 3	29.9	0.3
40		AA310162		cytochrome c	0.8	4.9
40		M33552	Hs.56729	lysosomal	1	5.9
		BE561617	Hs.119192	H2A histone family, member Z	2.8	4
		M55998		gb:Human alpha-1 collagen type I gene, 3	3.1	1.7
	101674	NM_002291	1 Hs.82124	laminin, beta 1	1.5	4.1
	101861	AA350659	Hs.83347	anglo-associated, migratory cell protein	3.1	1.4
45	101977	AF112213	Hs.184062	putative Rab5-interacting protein	1.3	6.9
	102193	AL036335	Hs.313	secreted phosphoprotein 1 (osteopontin,	1.9	4.9
	102199	AA334592	Hs.79914	lumican	2.2	3.8
		AF015224	Hs.46452	mammaglobin 1	4.2	0.7
		NM_003480		Microfibril-associated glycoprotein-2	1.1	4.2
50		NM_001394	Hs.2359	dual specificity phosphatase 4	4.5	0.5
-	102534			von Hippel-Lindau binding protein 1		
		Al379954	Hs.79025		1.4	4.2
		BE244588	Hs.6456	KIAA0096 protein	0.9	3.9
	102962			chaperonin containing TCP1, subunit 2 (b	1.5	10.9
55			rus. 159263	collagen, type VI, alpha 2	2.2	6.2
55		AW293542	Hs.75309	eukaryotic translation elongation factor	5.6	5.7
	103119		Hs.2877	cadherin 3, type 1, P-cadherin (placenta	3.7	0.5
	103175			myomesin (M-protein) 2 (165kD)	1.3	4
	103286			phosphorylase kinase, alpha 2 (liver)	1.3	3.8
<i>c</i> 0	103319			tumor necrosis factor receptor superfami	8.0	4.6
60		BE536700	Hs.4888	seryl-tRNA synthetase	0.9	8
•	103419			Sec23 (S. cerevislae) homolog A	1.1	5.1
	103471			protein tyrosine phosphalase, receptor t	3.7	1.2
	103546	Z14244	Hs.75752	cytochrome c oxidase subunit VIIb	0.9	4.4
				100		


10

		NM_000088	Hs.172928	collagen, type I, alpha 1	3.2	3	
		AA084874		gb:zn13e04.r1 Stratagene hNT neuron (937	0.9	10	
		H24185	Hs.92918	hypothetical protein	1.9	15.9	
•		AA095971		Homo saplens cDNA: FLJ22463 fis, clone H	1.2	3.9	
5		BE439604	Hs.24322		1.4	3.9	
		AW130242		hypothetical protein FKSG44	1.6	4.1	
		AK001913	Hs.7100	hypothetical protein	1.5	4.3	
		AF183810	Hs.26102		7	7	
10		AB040927		KIAA1494 protein	2	4.6	
10		AB002347	Hs.15303	KIAA0349 protein N-terminal acetyltransferase complex ard	0.7 3.3	4.5 3.3	
		AW583693 AW365522		hypothetical protein PRO2219	2.3	4.2	
		AW804296	Hs.9950	Sec61 gamma		7	
		AF283775	Hs.35380	x 001 protein	3.1 .	1.3	
15		X51501	Hs.99949	prolactin-induced protein	3.8	0.6	
13		AW966728	Hs.54642	methonine adenosyltransferase II, beta	0.8	6.7	
		AK001731		Homo saplens mRNA; cDNA DKFZp586H092		1.7	4.8
		W94824	Hs.11565		2	7.5	1.0
		AW630488		protease, serine, 23	1.9	7.4	
20		AF123303	Hs.24713	hypothetical protein	1.1	6.3	
		R82252		protein kinase (cAMP-dependent, catalyti	1.2	4	
		AW270555		hypothetical protein	1.4	3.9	
		AA960961		zinc finger protein 83 (HPF1)	1.5	4.2	
		AA305351		uncharacterized hypothalamus protein HAR	1.1	4.1	
25		Al279065		ribosomal protein S6	1.3	4.6	
		AL133035	Hs.8728	hypothetical protein DKFZp434G171	1.2	3.6	
	104852	W70164	Hs.20107	ESTs	0.8	4.2	
	104861	AA058630	Hs.29759	RNA POLYMERASE I AND TRANSCRIPT RE	LEASE	1.7	5.1
	104873	W03831	Hs.20597	host cell factor homolog	0.8	5.4	
30	104891	W44626	Hs.30627	ESTs	0.7	6.8	
		AW955089		Novel human gene mapping to chomosome 2		1 3.9	
		BE298808	Hs.33363	DKFZP434N093 protein	3.3	3.3	
		AW076098	Hs.74316	desmoplakin (DPI, DPII)	1.2	3.7	
25		AB029020		KIAA1097 protein	1.1	5.5	
35		Al392640		amino acid transporter system A1	3.2	1.4	
		BE613061		Homo sapiens, Similar to RIKEN cDNA 0610		11.4	
		N39760	Hs.8859	Homo sapiens, Similar to RIKEN cDNA 5830		7.2	
		BE410438	Hs.9006	VAMP (vesicle-associated membrane protei	1.1	3.5	
40		AF146277	Hs.21941	CD2-associated protein	1.2 3.6	10 8.3	
40		AA313825 BE407961	Hs.18271	AD036 protein golgi phosphoprotein 3	1.7	6.8	
		AI554929		ATPase, H+ transporting, tysosomal (vacu	1.1	3.7	
		BE243327		chromosome 22 open reading frame 5	1.5	4	
		AI015709		Homo sapiens mRNA; cDNA DKFZp586l2022		1.5	14
45		W20027	Hs.23439	ESTs	4.3	2.9	•
		W03516	Hs.76698	stress-associated endoplasmic reticulum	1.5	5	
		AA252372	Hs.12144	KIAA1033 protein	1.2	3.6	
		AL137257	Hs.23458	Homo sapiens cDNA: FLJ23015 fis, clone L	1.7	15.8	
	105492	AI805717	Hs.289112	CGI-43 protein	2	4.8	
50	105495	AL037715	Hs.28785	microfibrillar-associated protein 3	1.3	3.9	
	105539	AB040884	Hs.109694	KIAA1451 protein	2.7	11.4	
	105594	AB024334	Hs.25001	tyrosine 3-monooxygenase/tryptophan 5-mo	1.3	6.1	
	105623	BE504200	Hs.30127	hypothetical protein	1.7	4.5	
	105807	AA788946	Hs.16869	ESTs, Moderately similar to CA1C RAT COL		24.6	
55	105812	BE614149	Hs.20814	CGI-27 protein	1.8	3.6	
	105823	AI559444	Hs.293960		1.9	6.6	
		AA329449		twisted gastrulation	1.5	4.3	
		A1827976	Hs.24391	hypothetical protein FLJ13612	3.8	1.9	
<b>CO</b>		BE392914	Hs.30503	Homo saplens cDNA FLJ11344 fis, clone PL	1.7	4	
60		AW028485	Hs.26136	hypothetical protein MGC14156	1.7	7.4	2.0
		AL137728	Hs.12258	Homo sapiens mRNA; cDNA DKFZp434B092		1.2	3.8
		AB033075	Hs.10669	development and differentiation enhancin	1.3	4.6 5.9	
		AB030656	Hs.17377	coronin, actin-binding protein, 1C	1.1	5.9 4.6	
65		AI690586	Hs.29403 Hs.8895	hypothetical protein FLJ22060 ESTs	2 4.1	1.2	
05		AI240665 NM_001329		C-terminal binding protein 2	2.6	7	
		T74445	Hs.5957	Homo sapiens clone 24416 mRNA sequence		10.7	
	100010	11773		The supraise stories and to the story deduction	***		

	106083	3 H62087	Hs.31659	thyroid hormone receptor-associated prot	1.5	3.6	
		AA425414	Hs.33287	nuclear factor I/B	5.4	1.2	
		5 BE613206	Hs.279607	calpastatin	1.8	4	
_		BE568205	Hs.28827	mitogen-activated protein kinase kinase	5.1	6.1	
5		3 AK000274	Hs.278635	HDCMA18P protein	1.2	5.9	
		AW051564	Hs.28285		1.8	5.4	
		BE044325	Hs.227280	U6 snRNA-associated Sm-like protein	2.3	11.2	
		N88604	Hs.30212		1.2	3.6	
10		H09548	Hs.5367	ESTs, Weakly similar to 138022 hypotheti	0.9	4.4	
10		AA459480	Hs.23956	hypothetical protein FLJ20502	1.3	3.6	
		BE387614	Hs.25797	splicing factor 3b, subunit 4, 49kD	1.6	7.3	
		AA741038	Hs.6670	ESTs	1.7	6.1	
		AA206079	Hs.6693	hypothetical protein FLJ20420	1	5.4	
15		AA487416 BE185536	NS.200231	Homo saplens cDNA: FLJ23111 fis, clone L	1.6	5.4	
15		BE503373	UP 331335	molecule possessing ankyrin repeats indu	3.3	1.2	
		T85594	He 220000	hypothetical protein FLJ13576	1.4	6.3	
		AF216751	Hs.26813	hypothetical protein FLJ10120	3.3	1.8	
		BE391904	Hs.12482	CDA14 glyceronephosphate O-acyttransferase	3	3	
20		BE147611	Hs.6354	stromal cell derived factor receptor 1	1.7	7.6	
		AI289507		hypothetical protein FLJ23399	1.2 1.8	4.3 6.5	
		BE172058	Hs.82689	tumor rejection antigen (gp96) 1	1.2	6.9	
		BE267795	Hs.22595		1.4	3.5	
		AA186629	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	2.6	4.3	
25	107679	AA011510	Hs.60512	ESTs	1.8	4	
	107914	AA027229	Hs.61329		1.3	3.5	
		AF109219	Hs.108787	phosphatidylinositol glycan, class N	1.6	3.5	
		AW368993	Hs.323748	Homo sapiens clone CDABP0086 mRNA seq	uen	1.8	8.1
20		AA291440	Hs.73149	paired box gene 8	1.1	3.5	
30		AA093668	Hs.28578	musdeblind (Drosophila)-like	0.7	5.6	
		Al283611	Hs.263479	ESTs, Weakly similar to HMG1_HUMAN HIG	H	1.2	5.6
		AW068579	Hs.7780	Homo sapiens mRNA; cDNA DKFZp564A072		3.1	6.9
		AI879238		collapsin response mediator protein-5; C	1.5	4.6	
35		AA333660 AW151340	Hs.71331		1.5	4	
<i>J J</i>		AA074374	Hs.51615 Hs.67639	ESTs, Weakly similar to ALU7_HUMAN ALU		6.3	4.7
		AF086070	Hs.237519	ESTS ECT	1.3	3.8	
		AA079487	110.201010	gb:zm97f08.s1 Stratagene colon HT29 (937	1 1.5	3.6	
		AA079500		gb:zm96h10.s1 Stratagene colon HT29 (937	1.1	3.6 4.3	
40		M23114	Hs.1526	ATPase, Ca++ transporting, cardiac muscl	2	4.9	
	108641	AA112059	Hs.429	ATP synthase, H+ transporting, mitochond	1.1	3.5	
	108668	AA058522	Hs.185751		1.2	3.6	
	108694	AA036725	Hs.61847	ESTs	1.4	3.6	
	108824	AK001332	Hs.44672	hypothetical protein FLJ10470	1.4	3.5	
45		AA133456	Hs.102548	glucocorticold receptor DNA binding fact	1.2	4	
		BE276891		retinoic acid induced 3	1.3	3.6	
		AA152312	Hs.72047	ESTs	1.1	4.1	
		Al732585	Hs.22394	hypothetical protein FLJ10893	1.2	3.5	
50		AA167512		gb:zp10f12.s1 Stratagene fetal retina 93	1.3	5	
<b>5</b> 0		BE220601		hypothetical protein FLJ13033	4	6.1	
		BE179030		Human DNA sequence from clone RP5-1174N		1.7	7.4
		AA878923 AA366263		hypothetical protein FLJ21016	3.8	7.7	
		AA173942	Hs.72531	hypothetical protein FLJ11838 Homo sapiens mRNA; cDNA DKFZp564H191	1.9	4	4.0
55		BE075297		ESTs, Weakly similar to A43932 mucin 2 p		3.7	1.3
		AW151660		ESTs	4.6 1.2	7.4 3.5	
		AW001579	Hs.9645		3.7	3.3	
		NM_014899	Hs.188006	KIAA0878 protein	2.8	3.7	
		N21207	Hs.182999		1.6	3.5	
50		BE242691	Hs.14947		3.1	1.2	
	110935	A1753230		hypothetical protein DKFZp564K142	1.9	7.5	
		Al681293	Hs.12186	hypothetical protein FLJ22558	2	4	
		AK001566		hypothetical protein FLJ10704	1.1	3.8	
< 5		BE301871		mannosyl (alpha-1,3-)-glycoprotein beta-	1	8.2	
55		BE314949	Hs.87128	hypothetical protein FLJ23309	3.3	6.1	
	111770	R27975 AF131784	DS.209401	ESTs, Moderately similar to S65657 alpha	1.2	5.4	
	111500	AC 131/04	113.23310	Homo saniens clone 25194 mRNA seguence	37	0.8	

	111903	NM_014906	Hs.166351	KIAA1072 protein	1	5.4
	111951	NM_014927	Hs.100527	KIAA0902 protein	1	3.8
	112141	AW137198	Hs.278682	Phosphatidylglycerophosphate Synthase	1.4	3.5
_	.112193	R49499	Hs.138238	ESTs	1.5	3.6
5	112197	NM_003655	Hs.5637	ESTs	4.6	2
	112610	AW500106	Hs.23643	serine/threonine protein kinase MASK	3.3	10.5
	112971	Z42387	Hs.83883	transmembrane, prostate androgen induced	3.2	3
	112984	T16971	Hs.289014	ESTs, Weakly similar to A43932 mucin 2 p	3.7	10.8
	113056	AF019226	Hs.8036	glioblastoma overexpressed	4.5	3.7
10	113449	AW160683	Hs.158006	hypothetical protein	1.2	4.4
	113497	AF143321	Hs.15572	hypothetical protein IMAGE 109914	0.9	3.6
	113508	AL042936	Hs.211571	holocytochrome c synthase (cytochrome c	1.1	3.5
	113531	AK001898	Hs.16740	hypothetical protein FLJ11036	1.2	3.9
	113604	Al075407	Hs.296083	ESTs, Moderately similar to 154374 gene	1.7	5.3
15	113674	NM_014214	Hs.5753	Inositol(myo)-1(or 4)-monophosphatase 2	0.8	6.1
	113841	W30681	Hs.146233	Homo sapiens cDNA: FLJ22130 fis, clone H	1.7	6.2
	113857	AW243158	Hs.5297	DKFZP564A2416 protein	1.2	4.6
	113931	BE255499	Hs.3496	hypothetical protein MGC15749	1.5	4
	113936	W17056	Hs.83623	nuclear receptor subfamily 1, group I, m	3.8	1
20	113987	AA345519	Hs.9641	complement component 1, q subcomponent,	1.2	4.7
	114132	A1342493	Hs.24192	Homo sapiens cDNA FLJ20767 fls, clone CO	0.3	4.3
	114156	BE179882	Hs.336920	glutathione peroxidase 3 (plasma)	1.1	4.3
	114213	N58309	Hs.19575	CGI-11 protein	1.6	9.2
	114636	AA075488		gb:zm88d01.s1 Stratagene ovarian cancer	1.6	3.7
25	114760	A1929382	Hs.252692	hypothetical protein FLJ20343	1.4	4
	114781	T10446	Hs.95388	ESTs	1	4.3
	114795	AB037858	Hs.173484	hypothetical protein FLJ10337	1.6	9.2
	114901	AV660012		hypothetical protein FLJ10788	1.4	5.2
	115096	AI683069	Hs.175319		3.7	1
30	115518	BE541042	Hs.23240	Homo sapiens cDNA: FLJ21848 fis, clone H	3.2	4.2
	115646	N36110	Hs.305971	solute carrier family 2 (facilitated glu	1.5	3.9
	115764	AW582256	Hs.91011	anterior gradient 2 (Xenepus laevis) hom	1.3	5.9
	115802	AW410233	Hs.206521	YME1 (S.cerevisiae)-like 1	1.7	6.6
	115994	AB037836		KIAA1415 protein	1.5	9.1
35	116032	BE383668	Hs.42484	hypothetical protein FLJ10618	0.9	4.3
	116046	BE395293	Hs.94491	hypothetical protein FLJ20297	1.6	5.5
	116274	AI129767	Hs.182874	guanine nucleotide binding protein (G pr	3.2	2.4
	116310	Z24854	Hs.42299	ESTs	0.8	4.7
	116356	Al371223	Hs.288671	Homo sapiens cDNA FLJ11997 fis, clone HE	2.4	3.9
40	116429	AF191018	Hs.279923	putative nucleotide binding protein, est	5.5	5.5
•	116461	AA313607	Hs.58633	Homo sapiens cDNA; FLJ22145 fis, clone H	5	1.3
	116470	Al272141	Hs.83484	SRY (sex determining region Y)-box 4	8.7	4.5
	116578	D21262	Hs.75337	nucleolar and coiled-body phosphprotein	3.2	6.9
	116579	AW888411	Hs.81915	leukemia-associated phosphoprotein p18 (	3.2	3
45	116589	AI557212	Hs.17132	ESTs, Moderately similar to 154374 gene	3.1	8.3
	116786	H25836	Hs.301527	ESTs, Moderately similar to unknown [H.s	3.2	4.5
	117170	N25929	Hs.42500	ADP-ribosylation factor-like 5	7	5.5
	117215	N20066		PTPRF Interacting protein, binding prote	1.2	6.2
••	117280	M18217		Homo sapiens cDNA: FLJ21409 fis, clone C	4.5	2.4
50	117576	Al383467	Hs.44597	ESTs	1.4	4.2
	117667	U59305	Hs.44708	Ser-Thr protein kinase related to the my	4.3	0.5
	117881	AF161470	Hs.260622	butyrate-induced transcript 1	2.1	5.7
	118336	BE327311	Hs.47166	HT021 ·	3.6	7.7
		N66845		gb:za46c11.s1 Soares fetal liver spleen	4.2	0.5
55		AL353944	Hs.50115	Homo sapiens mRNA; cDNA DKFZp761J1113		3.5
		N67343		gb:yz50b07.s1 Morton Fetal Cochlea Homo	2.1	3.8
	119159	AF142419	Hs.15020	homolog of mouse quaking QKI (KH domain	3.7	1.5
		BE048061	Hs.37054	ephrin-A3	3	1.1
<b>~</b> 0		BE218319	Hs.5807	GTPase Rab14	1.1	5.6
60		BE041667		Homo sapiens cervical cancer suppressor-	1.4	4.3
		A1905687	Hs.2533	EST	3.2	1
		AL050097		DKFZP586B0319 protein-	4.3	0.7
		BE565849	Hs.14158	copine III	3.5	1.9
CE	120407	AA235207 ·		hypothetical protein DKFZp762F2011	1.5	3.7
65		AW968080		Homo sapiens clone 24630 mRNA sequence		1.4
		AF150208		damage-specific DNA binding protein 1 (1	1.6	6.8
	120867	AA350781	Hs.96967	ESTs	1.1	3.6

3.3



	128452	X02761	Un 207020	fibranadia 4	4.0	4.2	
		T16206		fibronectin 1 ESTs, Highly similar to LDHH_HUMAN L-LAC	1.2	4.3	
		H08379		hypothetical protein DKFZp434N1429	0.6	44.4 13.1	
		NM_005904		MAD (mothers against decapentaplegic, Dr		4	
5		NM_003478	Hs.101299		1.5	5.1	
-		Al185977		ubiquitin specific protease 18	0.8	4	
		NM_014721	Hs.102471		1.3	3.7	
		AA432202	Hs.103147		1.4	3.9	
		D87432	Hs.10315	solute carrier family 7 (cation)c amino	1.2	3.6	
10		Al246669	Hs.324275			4.1	
		BE246444	Hs.283685	www.domain-containing protein 1 hypothetical protein FLJ20396 hypothetical protein FLJ10702 CD81 antigen (target of antiprotiferativ secreted frizzled-related protein 4	3	1.6	
		AK001564	Hs.104222	hypothetical protein FLJ10702	2.8	4.8	
		AA476220	Hs.54457	CD81 antigen (target of antiproliferativ	1.1	10.6	
		AF026692	Hs.105700	secreted frizzled-related protein 4	1	3.8	
15	128805	AA194554			5.3	5.3	
	128827	Al638184		Homo sapiens done 23836 mRNA sequence		5.3	
						4.5	
	128869	AA768242	Hs.80618	kSTs hypothetical protein DKFZP566D193 protein CocoaCrtsp hypothetical protein programmed cell death 5 hypothetical protein FLJ20585 MDS023 protein hypothetical protein RAB31, member RAS oncogene family	0.8	3.6	
	128889	D60985	Hs.106909	DKFZP566D193 protein	4.6	3.7	
20	128890	Al222020	Hs.182364	CocoaCrisp	3	1.5	
	128915	AK000140	Hs.107139	hypothetical protein	0.2	3.9	
	128920	AA622037	Hs.166468	programmed cell death 5	2.5	15.2	
	128926	AF155096	Hs.107213	hypothetical protein FLJ20585	4	4	
	128930	AA298958	Hs.10724	MDS023 protein	1.2	4.5	
25	128942	AW247536	Hs.10729	hypothetical protein	1.4	5	
					2.3	5.6	
		AB020716			0.9	3.9	
		AW271217		Homo sapiens cDNA FLJ14028 fis, clone HE		3.6	
20		AA258924	Hs.10758	NM_002495*:Homo sapiens NADH dehydroge		0.8	3.8
30		A1770025			1.2	5.7	
		C15105		Homo sapiens cDNA FLJ14368 fis, clone HE		9.9	
		AA371156			2.4	3.8	
		A1634522			1.2	3.8	
35		AW504486			1.2	5.5	
))		BE543205 AB002450			0.5 1	3.7	
		AW881089		Homo sapiens mRNA; cDNA DKFZp566M094		5.2 1.5	7
	129151					9.7	′
		AA335362				8.6 -	
40		M18916			1.1	3.5	
		BE542214	Hs.109697			12.8	
		W57656			3.2	5.1	
		AI878857			1.9	5.7	
		BE169531				6.6	
45	129247				1.5	3.5	
	129250	AA344367			1	5.4	
	129258	AA250970			1.3	4.1	
	129260	AF077200	Hs.279813	hypothetical protein	1.6	3.9	
	129270	AA357185	Hs.109918	ras homolog gene family, member H	1.8	4.2	
50		AB007896	Hs.110	putative L-type neutral amino acid trans	1.1	6.1	
		AA318224	Hs.296141		2.5	4.8	
		W94197	Hs.110165	ribosomal protein L26 homolog	1.6	5.1	
		AF189062	Hs.285976	tumor metastasis-suppressor	1.8	6.5	
EE					0.9	4	
55	129362					9.2	
		BE278964				4.8	
		AA318271			1	4.1	
		AA016188	MS.111244	hypothetical protein	1.8	10.7	
60		AI498631			1.1	4.8	
00	129470	AL050260			1.8 · 1	9.3 5	
		NM_004477			1.1	5 4.2	
		AA449789			1.9	4.2 6.8	
		AI631811			1,1	9.7	
65		AA769221			1.1	4.3	
	129545				1	4.2	
		AW517695			2.3	3.5	

		AW968941	Hs.166254	hypothetical protein DKFZp566I133	2.4	4.4
		AA209534	Hs.284243	tetraspan NET-6 protein	3.2	13
		D79338	Hs.239720	CCR4-NOT transcription complex, subunit	1.6	4.6
_		AL110212	Hs.301005	purine-rich element binding protein B	1.1	5.7
5		AB020335	Hs.181300	sel-1 (suppressor of lin-12, C.elegans)-	0.9	4.3
		Al207406	Hs.11866	translocase of inner mitochondrial membr	1.9	4.8
•		AW889132	Hs.11916	ribokinase	0.9	4.1
		U53209	Hs.24937	transformer-2 alpha (htra-2 alpha)	1.3	4.7
	129691	M26939	Hs.119571	collagen, type III, alpha 1 (Ehlers-Dani	4.7	3.7
10		U46386	Hs.12102	sorting nextin 3	1.2	3.6
	129747	AL050272	Hs.12305	DKFZP566B183 protein	1	8.9
		BE397454	Hs.124969	Homo saplens clone 24707 mRNA sequence	1.4	3.6
	129796	BE218319	Hs.5807	GTPase Rab14	2.9	5.1
		M62839	Hs.1252	apolipoprotein H (beta-2-glycoprotein I)	0.3	5.1
15		AF052112	Hs.12540		1.6	8.8
	129834	AL080084	Hs.296155	CGI-100 protein	0.9	5.3
	129836	AW410233	Hs.206521	YME1 (S.cerevisiae)-like 1	1.8	9.9
	129843	NM_014840		KIAA0537 gene product	0.9	3.6
•	129874	AA626937	Hs.181551	hypothetical protein MGC2594	1.4	9.5
20	129878	Z43161		30 kDa protein	1.1	6.3
	129904	AL119499	Hs.13285	neuronal potassium channel alpha subunit	1	3.5
	129917	M30773	Hs.278540	protein phosphatase 3 (formerly 2B), reg	2	5.1
	129976	X14008		lysosomal	0.9	4.9
	129982	Z14221		gb:H.sapiens germline transcript of lg h	1.2	3.6
25	130007	R15917	Hs.142570	Homo sapiens clone 24629 mRNA sequence	4.3	1.3
		BE277024		RNA binding motif protein, X chromosome	1.6	3.8
	130064	X57815.comp		Empirically selected from AFFX single pr	1.2	8.2
	130068	M93143	Hs.262869	plasminogen-like	1.4	7.9
20	130090	H97878	Hs.132390	zinc finger protein 36 (KOX 18)	1.4	12.3
30		AK001635	Hs.14838		0.2	4.6
		W61005	Hs.14896		1.	4.1
		AA916785		splicing factor proline/glutamine rich (	1.2	5.3
		T47294		X-box binding protein 1	3.8	0.8
35		NM_005095 BE094848		zinc finger protein 262	1	4.2
55		R42678	HS. 10113	homogentisate 1,2-dioxygenase (homogenti	0.5	4
		M23115	Hs.1526	KIAA0564 protein	1	3.7
		BE278370	Hs.15265	ATPase, Ca++ transporting, cardiac muscl heterogeneous nuclear ribonucleoprotein	0.4 1.7	4.4 7.5
		BE301883		glioblastoma amplified sequence	1.7	5.6
40		U29463		gb:Human cytochrome b561 gen	1.2	4.2
_		U92014	Hs.153527	Homo sapiens pTM5 mariner-like transposo	1.3	3.6
		W78907	Hs.15395	similar to arginyl-tRNA synthetase (argi	1.5	4.4
	130343	AB040914	Hs.278628	KIAA1481 protein	2.9	7.5
	130385	AW067800		stanniocalcin 2	3.2	0.2
45	130414	AW842182	Hs.241392	small inducible cytokine A5 (RANTES)	1.4	10.6
	130417	AW163518	Hs.155485	huntingtin interacting protein 2	1.7	11.7
		AA852868	Hs.132853	KIAA0171 gene product	1.1	5
		NM_006245		protein phosphatase 2, regulatory subuni	1.4	4.3
50		AW362955	Hs.15641	Homo sapiens cONA FLJ14415 fis, clone HE	1.6	7.6
50	130479		Hs.12457		0.9	4.1
		AB007915		KIAA0446 gene product	1	3.8
		AI598022		TAR DNA binding protein	1.3	4.7
		AA232119		putative G-protein coupled receptor	1.2	9.4
55		A1652143		hypothetical protein FLJ13111	1	4.1
<b>J</b> J		BE242873		WD repeat domain 15	1.1	3.6
		AL049963	HS.284205	up-regulated by BCG-CWS	0.6	3.8
		AL045128 AL042896	Hs.1691	glucan (1,4-alpha-), branching enzyme 1	0.9	6.6
		AW073971	Hs.1697		0.9	3.9
60		AI557212	Hs.17132		0.9	6.9
50		AF158555			2.6 1.2	3.9 13.8
		AI861791	Hs.278479	<u></u>	1.3	4
		Al831962	Hs.17409		1.5 2.5	4
		AL117508			2.3 1.3	6.2
65	130669	A1928985			1.4	3.9
	130693				3.2	0.8
	130694	NM_014827	Hs.17969		1.1	4.8

	130696	AA325308	Hs.18016	Homo sapiens mRNA; cDNA DKFZp586H032	4 (f	1.8
	130701	Z98883	Hs.18079	phosphatidylinositol glycan, class Q	1.1	6.7
	130707	AW190925	Hs.203559	hypothetical protein FLJ12701	1.2	4.1
	130731	Al932971	Hs.18593	Homo sapiens cDNA: FLJ21449 fis, clone C	1.4	6.9
5	130787	AF072813	Hs.252831		1.2	11.2
-		AA088809	Hs.19525	hypothetical protein FLJ22794	1.8	6.8
		NM_001761	Hs.1973	cyclin F	1.3	4.1
		Y10805	Hs.20521	HMT1 (hnRNP methyltransferase, S. cerevi		5.9
		AB037750	Hs.21061	KIAA1329 protein	1	3.8
10		AW195747	Hs.21122	hypothetical protein FLJ11830 similar to	1.3	7.9
10		BE409769	Hs.21189	DnaJ (Hsp40) homolog, subfamily A, membe		3.7
		BE390905	Hs.21198		1.9	4
				translocase of outer mitochondrial membr		10.3
		H96115	Hs.21293	UDP-N-acteylglucosamine pyrophosphorylas		
15		AB023182		KIAA0965 protein	1.5	6.8
13		AA393071		leucine aminopeptidase	1.4	5.5
		AA099923		PEST-containing nuclear protein	1.3	3.8
		BE243101	Hs.22391	chromosome 20open reading frame 3	1.9	4.1
		D87436	Hs.166318	•	1.6	3.5
		AA194422	Hs.22564	myosin VI	4.5	5
20		AL137682	Hs.22937	I-kappa-B-interacting Ras-like protein 2	2	3.7
	131101	BE387561	Hs.22981	DKFZP586M1523 protein	1.6 ·	4.5
	131104	W27770	Hs.301756	ESTs, Wealdy similar to T31475 hypotheti	0.9	3.5
	131107	BE620886	Hs.75354	GCN1 (general control of amino-acid synt	2.1	4.5
	131109	BE564123	Hs.23060	DKFZP564F0522 protein	1.1	4.6
25	131136	AB033099	Hs.23413	KIAA1273 protein	1.2	4.2
	131148	AW953575	Hs.303125	p53-induced protein PIGPC1	4.5	13.5
	131150	X77753	Hs.23582	tumor-associated calcium signal transduc	3.4	0.4
		A1472209	Hs.323117		0.8	4.9
		AW013807	Hs.182265		3.3	2.4
30		H25094	Hs.293663	ESTs, Moderately similar to 138022 hypot	0.6	4
-		AW864222	Hs.24083	KIAA0997 protein	1.4	3.8
		AW979155		amino acid transporter 2	1.2	8.5
		AL050107	Hs.24341	transcriptional co-activator with PDZ-bi	0.7	4.7
		AI815486		Homo sapiens cDNA FLJ20738 fis, clone HE		8.2
35		D89053		fatty-acid-Coenzyme A ligase, long-chain	1.7	3.5
55		AW956868	Hs.24608	DKFZP564D177 protein	1.3	5.4
		AU077158	Hs.24930	tubulin-specific chaperone a	1.6	4.8
		AU077002	Hs.24950		1.4	4.4
				regulator of G-protein signalling 5 nuclear factor I/A	3.3	2.2
40		AI750575			1.6	3.9
40		AW293399		nuclear receptor co-repressor 1		
		NM_006052	Hs.26146	Down syndrome critical region gene 3	1	11.1
		NM_014810	Hs.92200	KIAA0480 gene product	5	2
		AI452601		nuclear receptor subfamily 2, group F, m	0.9	3.5
15		AW960146		hypothetical protein FLJ12888	1	3.5
45		BE270734	Hs.2795	lactate dehydrogenase A	2	6.5
		AB040927		KIAA1494 protein	1.5	10.7
		AU076408	Hs.28309	UDP-glucose dehydrogenase	1.3	4.7
		AF157326		TBP-interacting protein	1.3	4.9
	131555	T47364		Interferon, alpha-inducible protein 27	1.5	8
50		AA936296		DKFZP586G011 protein	1.8	3.5
	131589	C18825	Hs.29191	epithelial membrane protein 2	1.3	8.2
		D83032	Hs.169984	nuclear protein	2.8	3.9
	131626	BE514605	Hs.289092	Homo sapiens cDNA: FLJ22380 fis, clone H	1.3	11.2
	131670	H03514	Hs.10130	ESTs	1.3	4.8
55	131697	C19034	Hs.288613	Homo sapiens cDNA FLJ14175 fis, clone NT	3.2	9.7
	131701	AF103798	Hs.30819	hypothetical protein	1.3	5.2
	131703	AW160865	Hs.30888	cytochrome c oxidase subunit VIIa polype	1.3	7.8
	131739	AF017986	Hs.31386	secreted frizzled-related protein 2	10.6	14.7
		A1805664	Hs.31731	peroxiredoxin 5	1.1	3.6
60		AF077036	Hs.31989	DKFZP586G1722 protein	1.6	3.7
		X62111		gb:H.sapiens VII-5 gene for immunoglobul	1.1	3.5
		Al681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU		1.2
		NM_014874	Hs.3363	KIAA0214 gene product	0.6	4.2
		NM_004642	Hs.3436	deleted in oral cancer (mouse, homolog)	2.4	4.9
65		AW207440	Hs. 185973		2.4	6
		AA772603	Hs.69476	Homo sapiens cDNA FLJ12758 fis, clone NT		9.2
		BE252983	Hs.35086	ubiquitin specific protease 1	0.5	5.2
						- /-

	40404					
		7 Al123939	Hs.182997		0.7	4.1
		AA129782	Hs.3576	Homo sapiens mRNA full length insert cDN	0.9	4.8
		AW381148 AF208856		2,3-bisphosphoglycerate mutase	1.1	6.1
5		AF119665		hypothetical protein pyrophosphatase (Inorganic)	1.3	3.9
•		AF229181		CS box-containing WD protein	3.3	6.9
		AW162336	Hs.3709	low molecular mass ubiquinone-binding pr	0.9 1.2	5.2 3.6
		BE277910	Hs.3833	3'-phosphoadenosine 5'-phosphosuliate sy	3.2	1.8
		BE379335		proteasome (prosome, macropain) 26S subu	12	3.6
10	132071	AF217798	Hs.3850	LIS1-interacting protein NUDEL; endoolig	0.7	5.2
		AI701457	Hs.38694	ESTs	2	5.3
		NM_016045	Hs.3945	CGI-107 protein	1.2	4.3
		AW960474	Hs.40289	ESTs	3.1	3.1
15		AI752235	Hs.41270	procollagen-lysine, 2-oxoglutarate 5-dio	1.8	3.7
15		AW961231	Hs.16773	Homo sapiens clone TCCCIA00427 mRNA se		1.2
		AL031709		hypothetical protein CAB56184	1.4	4.2
		AA306325 BE177330	Hs.4311	SUMO-1 activating enzyme subunit 2	2	10.3
		U28831	Hs.323093	Homo sapiens cDNA: FLJ21210 fis, clone C	1.2	4.1
20		NM_003542	Hs.44566 Hs.46423	KIAA1641 protein H4 histone family, member G	5.9	1.6
	132384	AA312135	Hs.46967	HSPCO34 protein	5.8 2.1	1.5
		AA021160	Hs.4750	hypothetical protein DKFZp564K0822	1.3	9.3 4.6
		AW361383		metalloprotease 1 (pitrilysin family)	2	4.9
	132442	AW970859	Hs.313503		1.2	5
25	132534	BE388673	Hs.5086	hypothetical protein MGC10433	2	3.9
		BE396290	Hs.5097	synaptogyrin 2	1.4	5.1
		AF065391	Hs.194718	zinc finger protein 265	1.2	4
		AV660538	Hs.284162	60S ribosomal protein L30 isolog	3	1.7
30		AF029750		TAP binding protein (tapasin)	1.8	4.7
30		AW606927	Hs.5306	hypothetical protein DKFZp586F1122 simil	1.6	4.9
		AA353044 NM_004600	Hs.5321	ARP3 (actin-related protein 3, yeast) ho	1.8	8.1
		Al264357	Hs.554 Hs.55405	Sjogren syndrome antigen A2 (60kD, ribon	4.2	2
		AK000868	Hs.5570	hypothetical protein MGC16212 hypothetical protein FLJ10006	1.1	5.3
35		BE222975	Hs.56205	insulin induced gene 1	1.4 1.1	5.2 5.8
		F07424		zinc finger protein 222	1.3	3.7
	132793	AB020713	Hs.56966	KIAA0906 protein	2.3	6.3
	132805	AW975748	Hs.5724	sclerostin	0.7	7.7
40	132863	BE268048	Hs.236494	RAB10, member RAS oncogene family	1.8	6.2
40		D63209	Hs.5944	solute carrier family 11 (proton-coupled	1.5	20.8
		AA579258	Hs.6083	Homo sapiens cDNA: FLJ21028 fis, clone C	1	3.8
		AW118826	Hs.6093		0.7	5.4
		BE263252	Hs.6101	hypothetical protein MGC3178	1.6	4.1
45		Al248173		hypothetical protein MGC12936	1	4.2
40		BE539199 X77343	Hs.62112	zinc finger protein 207	1.5	4.4
		Y00062	HS.334334	transcription factor AP-2 alpha (activat	13.9	0.8
		AW499985	Hs.42915		0.6	4.6
		NM_006379			1.5 3.5	11.1
50		AA847843	Hs.62711	Homo sapiens, clone IMAGE:3351295, mRNA	J.U 1	1 4.5
		AW502761	Hs.30909		0.9	5.5
	133056	H12028			1.7	5.3
	133063	Al654133			0.6	4.9
		AK000708	Hs.169764		1.2	3.5
55		AF089816	Hs.6454		1.2	17.5
		AA808177		ESTs	0.9	5.1
		AV655783	Hs.661	Empirically selected from AFFX single pr	1.1	4.5
		AW955632	Hs.66666	ESTs, Weakly similar to S19560 proline-r	1.5	4.8
60		AF231981 AA464362	Hs.250175	homolog of yeast long chain polyunsatura	5.5	5.9
00		AB037773	Hs.6748	hypothetical protein PP1665	1.2	3.7
		W32474	Hs.6762 Hs 301746	hypothetical protein	1.6	8.6
		AL137480	Hs.6834		2.4	4.8
		AW796524			1 1.3	4.2 3.9
65		BE617892	Hs.6895		1.4	5.4
	133271		Hs.283742	H.sapiens mRNA for retrotransposon :	3.1	0.7
	133273	N27672	Hs.69469		2.5	6.5
				•		

	122207	414/707427	Lt- 00774	D factor according	4.3		
		AW797437 BE297855	Hs.69771	B-factor, properdin	1.3	4	
		AA304961	Hs.69855	NRAS-related gene	1.4 2.2	5	
		AJ001388	Hs.699 Hs.69997	peptidylprolyl isomerase 8 (cyclophilin zinc finger protein 238	1.5	6.8 4.3	
5		AF116666	Hs.70333	hypothetical protein MGC10753	1.4	6.3	
•		X04898		apolipoprotein A-II	0.2	3.6	
		U56979		H factor 1 (complement)	0.6	5	
		BE257758	Hs.71475		1.2	4.2	
		AF245505	Hs.72157		3.7	5.8	
10	133404	AB007916 .	Hs.214646	KIAA0447 gene product	1.4	5.1	
	133408	AI738719	Hs.198427	hexokinase 2	0.9	6.3	
		AB033061	Hs.73287	KIAA1235 protein	1.2	3.7	
		AL137663	Hs.7378	Homo sapiens mRNA; cDNA DKFZp434G227		0.7	4.8
15		M27749		immunoglobulin lambda-like polypeptide 1	1.1	4.3	
15		AF038962	Hs.7381	voltage-dependent anion channel 3	0.7	4.2	
		A1962602	Hs.74284	hypothetical protein MGC2714	3.1	5.9	
		NM_004415	Hs.74316		4.3	11.5	
		BE562958 D87452	Hs.74346	hypothetical protein MGC14353	1.8 1.2	19.7	
20		H97991	Hs.74579	KIAA0263 gene product Empirically selected from AFFX single pr	1.4	5.4 3.9	
20		Al929645	Hs.225936		0.8	4.9	
	133589		Hs.75104	RNA-binding protein S1, serine-rich doma	2	10.8	
		AI423369	Hs.75111	protease, serine, 11 (IGF binding)	2.1	4.5	
		U10564	Hs.75188		3.3	1.1	
25		BE244334	Hs.75249	ADP-ribosylation factor-like 6 interacti	2.3	5.6	
	133651	Al301740		dihydropyrimidinase-like 2	0.8	13.5	
		H14843	Hs.303154	popeye protein 3	1 '	9.1	
		AJ006239	Hs.75438	quinold dihydropteridine reductase	0.5	5.8	
20	133668			mitogen-activated protein kinase 6	1.1	6.9	
30		AW503116		zinc finger protein 146	1.8	3.8	
		AI352558	Hs.75544	tyrosine 3-monooxygenase/tryptophan 5-mo	1.5	11.1	
				heterogeneous nuclear ribonucleoprotein	2	3.9	
			Hs.75667 Hs.75824	synaptophysin KIAA0174 gene product	0.6 1.2	3.5 7.2	
35			Hs.75847	CREBBP/EP300 inhibitory protein 1	1.5	5	
33			Hs.75873	zyxin	1.2	4.8	
			Hs.75929		3.2	4.1	
					2.1	3.8	
			Hs.76285	DKFZP564B167 protein	1.9	12.6	
40	133800	AF075337	Hs.76293	thymosin, beta 10	2.6	6.6	
	133802	AW239400	Hs.76297	G protein-coupled receptor kinase 6	1	4.9	
	133806		Hs.76325		0.5	3.8	
			Hs.7644	H1 histone family, member 2	1.5	4.5	
45			Hs.76550	Homo saplens mRNA; cDNA DKFZp564B1264		3.7	5.6
43			Hs.76688	, , ,	0.3	4.4	
			Hs.76704		5.5 0.6	2.9	
	133887		Hs.76930 Hs.77271		0.0 1	4.8 10.2	
			Hs.301497	protein kinase, cAMP-dependent, catalyti arginyltransferase 1	0.9	4.8	
50			Hs.7753		2.8	10.5	
50					1.8	5.6	
			Hs.7756	proteasome (prosome, macropain) 26S subu		6.6	
	133947		Hs.77810		1.5	3.8	
	133986	M54968	Hs.184050		0.9	4.3	
55	133987	L15409	Hs.174007	von Hippel-Lindau syndrome	2.3	4.3	
	133989	AL040328	Hs.78202		3.3	3.4	
	133990		Hs.7822	Homo saplens mRNA; cDNA DKFZp564C1216		1.3	5.7
				hypothetical protein hCLA-Iso	1	6.5	
<b>CO</b>			Hs.78683		1.7	3.6	
60			Hs.7869	lysosomal	1	7.5	
			Hs.78825		1.2	4	
			Hs.79069 Hs.79086		2.7 3.3	4.8	
	134207				3.3 1.3	2.1 3.5	
65			Hs.80019		1.7	6.9	
55	134218		Hs.80205		0.8	5.3	
	134270		Hs.80919		1.4	11.4	

	134277	NM_004369	Hs.80988	collagen, type VI, alpha 3	2.6	3.5
		NM_000712	Hs.81029	biliverdin reductase A	1.8	5.8
		Al022650	Hs.8117	erbb2-interacting protein ERBIN	1.1	3.6
5		R00603	Hs.8128	phosphatidylserine decarboxylase	1.1	5.9
3		NM_001430	Hs.8136	endothelial PAS domain protein 1	0.5	4.8
		AL037800 D50683	Hs.8148	selenoprotein T	1.7	7.9
		X76534	Hs.82028 Hs.82226	transforming growth factor, beta recepto	0.8	7.6
		N22687	Hs.8236	glycoprotein (transmembrane) nmb ESTs	2.2	3.6
10		AL035786	Hs.82425	actin related protein 2/3 complex, subun	1.9 1.5	3.6
		BE512856	Hs.109051		1.1	8.3 3.6
		Al750762	Hs.82911	protein tyrosine phosphatase type IVA, m	1.9	4.6
	134417	NM_006416	Hs.82921	solute carrier family 35 (CMP-sialic aci	1.2	7.5
	134421	AU077196	Hs.82985	collagen, type V, alpha 2	6.6	8.7
15	134439	Z23024	Hs.138860	Rho GTPase activating protein 1	2	3.9
		NM_013230		CD24 antigen (small cell lung carcinoma	3.5	1.1
		D86981	Hs.84084	amyloid beta precursor protein (cytoplas	1.5	4.4
		W84869	Hs.211568	eukaryotic translation initiation factor	1.2	5.7
20		AW960673 BE091005		ATP synthase, H+ transporting, mitochond	1.3	3.9
20		M23161	Hs.74861 Hs.84775	activated RNA polymerase II transcriptio	1.8	4.3
		AI902899	Hs.85155	Human transposon-like element mRNA	0.8	5.6
		Al203545		butyrate response factor 1 (EGF-response S-phase response (cyclin-related)	1.4 0.8	5 3.9
		NM_016142		steroid dehydrogenase homolog	1.3	5.7
25		AB033017	Hs.8594	KIAA1191 protein	0.9	3.7
		BE244323	Hs.85951	exportin, tRNA (nuclear export receptor	4	6.8
	134579	AW936928	Hs.85963	DKFZP564M182 protein	2.2	4.3
	134582	AA927177	Hs.86041	CGG triplet repeat binding protein 1	1.6	3.6
20		AF078859	Hs.86347	hypothetical protein	2.1	3.5
30		AF265208		SWI/SNF related, matrix associated, acti	1.7	4.2
		AK000606	Hs.8868	golgi SNAP receptor complex member 1	4.4	0.9
		D17530	Hs.89434	drebrin 1	3.1	1.6
		T51986		hemoglobin, gamma G	0.5	4.6
35		AA428520 J03464	Hs.90061	progesterone binding protein	1.3	3.7
55		AA587775	Hs.66295	collagen, type I, alpha 2 multi-PDZ-domain-containing protein	8.7	17.3
		AB020689	Hs.90419	KIAA0882 protein	1.7 3.4	4 0.9
		AI803761	Hs.90458	serine palmitoyltransferase, long chain	1.3	6.9
	134885	AJ002030	Hs.9071	progesterone membrane binding protein	1.4	9.6
40	134891	R51083	Hs.90787	ESTs	1	10.1
		BE089782	Hs.9877	hypothetical protein	1.9	3.9
		AF005043	Hs.91390	poly (ADP-ribose) glycohydrolase	1	4.3
		BE560779		NICE-5 protein	1.4	10.4
45		AK002085	Hs.92308	Homo sapiens cDNA FLJ11223 fls, clone PL	1.6	4.1
43		AB037835	Hs.92991	KIAA1414 protein	1.2	5.6
		AW301984 AL034344	MS.173685	hypothetical protein FLJ12619	1.7	7.6
		Al272141	Hs.83484	forkhead box C1	3.2	.0.6
		AK001887		SRY (sex determining region Y)-box 4 protein kinase, AMP-activated, gamma 2 n	4.2 1.3	4.1
50		AK000967	Hs.93872	KIAA1682 protein	2	4.8 3.7
		AW503733	Hs.9414	KIAA1488 protein	2.8	3.7
	135082	AB017363	Hs.94234	frizzled (Drosophila) homolog 1	2.4	4.8
	135107	T97257		ESTs, Moderately similar to 138022 hypot	1.4	5.8
~~		AA132813		KIAA1096 protein	1.8	8.5
55 :		BE563088	Hs.9552	binder of Arl Two	1.2	6.8
		AB028956	Hs.12144	KIAA1033 protein	3.1	1.4
		BE250865	MS.279529	px19-like protein	1.3	7.5
		AA534009 AL038812		interferon stimulated gene (20kD)	1.3	3.8
60		AW372569		ESTs, Moderately similar to ALU7_HUMAN A		3.9
00		AA331901		hypothetical protein MGC10924 similar to hypothetical protein FLJ10097	0.9	8.4
	135291			ESTs	1 1.2	3.8
		AA114212		serine (or cysteine) proteinase inhibito	2.6	3.5 8.9
_	135357	Al565004		cathepsin D (tysosomal aspartyl protease	2.5	5.4
65	135398	M16029		ret proto-oncogene (multiple endocrine n	0.4	7.9
		W79431	Hs.326249	ribosomal protein L22	1.5	4.5
	135400	x/8592	Hs.99915	androgen receptor (dihydrotestosterone r	3.2	1.8

		R99693		Homo sapiens cDNA FLJ12843 fls, clone NT		3.6			
		AW176909	Hs.42346	calcineurin-binding protein calsardn-1	3.3	1.6			
		AW673106		mitochondrial ribosomal protein L43	0.9	4.2			
5		AW081061		DC2 protein	3	17.3			
J		AA887146	Hs.8217	stromal antigen 2	6.2	4			
		AA147979 AA233808		mitochondrial import receptor Tom22 protein kinase, cAMP-dependent, regulato	1.2 1	6.6 3.5			
		BE616412		junctional adhesion molecule 1	1.5	4.7			
		AA054761		karyopherin alpha 1 (importin alpha 5)		5.6			
10		AA412048		CGI-39 protein; cell death-regulatory pr	1.3	3.5			
		AW239226	Hs.65450	reticulon 4	1.2	13.9			
		AF279145	Hs.8966	hypothetical protein FLJ21776	2	5.1			
		BE539367		ESTs, Weakly similar to AF220049 1 uncha	1.3	3.9			
	420186	NM_015925	Hs.95697		1.5	6.2			
15	422055	NM_014320	Hs.111029	putative heme-binding protein	2	11.3		•	
		R94023	Hs.337531	ESTs, Moderately similar to 138022 hypot	1.7	3.6			
		AF119043			3.3	2.8			
		Al929685		calmodulin 1 (phosphorylase kinase, delt	1.3	4.7			
20		AA523543	Hs.7678	cellular retinoic acid-binding protein 1	1.1	3.7			
20		AA361562		26S proteasome-associated pad1 homolog	3.2	2.5			
		Al355260		histone deacetylase 3	2.8	22	<i>-</i> 0		
		AW601325		Homo sapiens mRNA; cDNA DKFZp566M063		1.1	5.2		
		X99209		HMT1 (hnRNP methyltransferase, S. cerevi	1.8	8.8			
25		R23553 BE395875		hypothetical protein mitochondrial carrier homolog 2	1.1 1.5	5.6 6.1			
23		BE407127	Hs.8997	heat shock 70kD protein 1A	1.3	7.6			
		AB001636	Hs.5683	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	1.6	6.5			
		BE616412		junctional adhesion molecule 1	1.3	3.5			
		R60366	Hs.5822	Homo sapiens cDNA: FLJ22120 fis, clone H	2	5.7			
30		BE513940	Hs.6101	hypothetical protein MGC3178	1.1	6.2			
		AL042986	Hs.7857	erythrocyte membrane protein band	0.5	3.7			
		BE281316	Hs.47334	hypothetical protein FLJ14495	2.5	4.9			
	449404	H51066	Hs.23581	leptin receptor gene-related protein	1.1	3.6			
	449964	AW001741	Hs.273193	hypothetical protein FLJ10706	1.4	3.5			
35	451389	N73222		matrix Gla protein	4	11.2			
	452685	Al634651	Hs.30250	v-maf musculoaponeurotic fibrosarcoma (a	0.8	5.6			
		RC_H15847_s	,	peptidytprolyl Isomerase B (cyclophilin B)	1.8	4.8			
		RC_W84712	,	calumenin	3.5	4.6			
40		X14008_ma1_		lysozyme (renal amyloidosis)	0.9	4.5			
40		RC_H86543_f		ESTS	1.8	6.6 3.9			
		H07011		ESTs: Weakly similar to SAS [H.sapiens]	1.8 ESTs	6.2	0.8		
		RC_AA164586 RC_AA070485		Homo sapiens clone 23967	3.4	2.6	0.0		
		RC_H98714_s		ESTs	1.6	3.5.			
45		RC_AA406145		Lois	ESTs	4.6	3		
		AA458584		SRY (sex determining region Y)-box 4	3.4	0.4	<u>*</u>		
		AA031548		cell division cycle 42 (GTP-binding protein; 25		3.1	3.9		
		X02761		fibronectin 1	3.6	15.2			
		RC_AA487193	}	secreted frizzled-related protein 4	4.7	4			
50		R25326		Homo sapiens mRNA for putative vacuolar	0.9	5			
		RC_AA393805	5	ESTs; Weakly similar to (defline not	1.1	8.4			
		RC_AA449333	} .	ESTs	2.9	4.6			
•		RC_AA287681			ESTs	1.3	4		
		RC_AA490864		ESTs; Highly similar to heat shock factor	1.4	5			
55		RC_C14243_f		ESTs; Highly similar to heat shock factor	1.7	5			
		R21443		ESTs	1.6	3.7			
		RC_AA251902	<u> </u>	Homo saplens lysophospholipase (LPL1)	2.2	3.8			
		M21121_s		small inducible cytokine A5 (RANTES)	0.9	9.9 4.8			
60		C00038_s Y00503		ESTs keratin 19	2.8 3.1	1.1			
00		RC R27006_f		ESTs	1.6	3.7			
		RC_AA416886	_	ESTs; Weakly similar to predicted using	3.1	3.1			
		RC_AA460450		fibroblast growth factor receptor 2 (bacteria-	1.5	3.7			
		RC_AA488433		ESTs; Weakly similar to deduced amino acid		4			
65		RC_AA278400				ens HRIHFB21	15 mRNA; partial ods	1.5	3.6
		U28831		Human protein immuno-reactive with anti-PTI	14.4	0.6			
		RC_AA199588	3	Homo saplens actin-related protein Arp3 (ARF	23)	1.8	4.7		

	AF006082	Homo sapiens actin-related protein Arp2 (A	RP2)	1.6	10.9
	RC_H90899	desmoplakin (DPI; DPII)	5.4	5.5	
	RC_W95070 ·	desmoplakin (DPI; DPII)	5	2.6	
_	RC_T90946_f	Human mRNA for KIAA263 gene; complete	cds	1.1	3.9
5	D87258	protease; serine; 11 (IGF binding)	2.4	3.5	
	AA313414_s	ESTs; Weakly similar to cDNA EST EMBL:	T1157	1.5	5.3
	RC_H73484_s	ESTs; Weakly similar to similar to Yeast	1.3	6.3	
	AFFX-HUMISGF3A/M979	35_3		2.3	13.5
	AFFX-HUMRGE/M10098	_5	1.1	7.9	
10	AFFX-M27830_5			0.5	7.4
	AFFX-M27830_5			0.6	5.4
	RC_AA063431_f		ESTs	8.0	4.1
	RC_T63769_f	ferritin; light polypeptide	1.1	3.7	

#### TABLE 8A

Table 8A shows the accession numbers for those pkeys lacking unigeneID's for Table 8. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

5

Pkey: CAT number: Unique Eos probeset identifier number Gene cluster number Genbank accession numbers Accession:

15

#### CAT number Accessions

101624 entrez\_M55998

131791 221\_260

60

M55998

		····
20		7 AA128547 AA128291 AA079587 AA079600 1 T88817 AA253263
		B AA129081 AA074851 AA082852 AA074732 AA084908 AA084751 AA076042 AA131172 AA085374 AA079519
		D AA113824 AA102437 AA070833 AA070143 AA084693 AA084389 AA076373 AA075492 AA062834 AA084335
		9 AA079344 AA069916 AA079275 AA070914 AA654069 AA081976 AA080957 AA083115 AA070942 AA085296
	123526 genbank_AA608657	AA608657
25	123533 genbank_AA608751	AA608751
	125090 genbank_T91518	T91518
	125154 genbank_W38419	W38419
	118475 genbank_N66845	N66845
• •	118505 genbank_N67343	N67343
30	101046 entrez_K01160K01160	
	129982 221_267 Z14221 A	W381862 M97920 AW401444 Z66542 M29470 AW406502 X61011 M34024 AA327072 Z14166 Z14167 Z14165
		6 Z14200 AA383972 Z14205 Z14201 M18513 Z14202 AW403684 X14584 AF062221 U43760 X65892 X65883 X62107
		65885 X65893 AF062142 X65891 X17675 Z47274 Z47277 Z47276 X65888 Z47275 X62109 AF062140 L01278
2.5		AF062139 X81723 Z80340 X81733 X81743 X81744 X81732 Z80843 AW402942 AW403516 X65919 AF062190
35		7 AF062222 AF062115 Z47240 AF062263 AF062261 AF062223 AF062211 Z47238 AW401714 AW404008 AW404991
		) M99595 Z47214 Z47232 Z47218 M26995 AF062184 X65895 L38433 X81731 Z11946 Z47226 AF062205 AF174012
		F062168 AF062136 X81755 X81748 AF174019 AF062285 L06924 L11699 AW402665 L09070 L28049 L08090
		3 Z14171 AW402944 L08083 AW405627 L33035 L26907 M17750 L28052 M17751 AJ239360 U19885 L14821 X56526
40		1 L12087 L12098 U68231 L12184 AF062242 AF022000 U64499 U00570 Al268604 Y15773 X64239 X62969 U00506
40		99360 U00577 D83677 AB021539 AF035796 Z33899 U00588 AJ239353 AF174062 Z33901 X98899 AF174058 X63080
		B021529 Z18318 U00488 L01412 X81746 U21262 U21272 U00560 AF174060 U00547 U00561 Z18321 S73957
		F115130 AF115117 Z92896 U21254 Z92895 AF115112 AF062290 T28938 Y09386 AF174067 U27189 Y09384
		F174057 M17749 X69692 AF174038 U64478 U64486 AF174098 X99365 AF174077 AF174083 AF174089 AF015133 PAJ006171 U00510 U58144 AF004323 AF115109 AF004324 AF015130 AF090414 AF090418 AB021536 AB021519
45		F021986 Z92898 Z96956 L34164 AF062251 AF052524 U00549 U00541 D83687 AF052522 AF087420 AF052520
73		I 43085 U00536 L19915 L43083 AF090420 AB021530 AB021534 Z96955 Z96954 Z33903 X62964 AF103282 U00509
		B AF062289 AF062307 AW408326 L33037 L04337 L04328 X81742 L04336 L03385 AF032360 S56184 AF062191
		2 A1906954 AF103184 L04343 AW364860 AF001424 AF103163 Z98717 AF103143 AJ008250 L04323 AF103321
		1 L04342 L03818 L03817 AW404978 AW403690 U86801 AF103150 AJ010334 AF035027 AJ007327 AF103115
50	AF017458	3 AJ008207 AJ008183 AJ008196 AJ008241 AJ008208 AF103210 AF068668 AF068670 AF068671 AF068664
		AF068666 AF068665 AF068672 AW371244 AW403670 AW408074 AW404575 AW362153 AW403803 AW406702
		4 D78345 T29140 J00231 NM_002179 AW405146 AA301091 X04646 H64660 AW402990 AW406534 T93007
		AW368899 AI905833 AW406586 AA482084 AI872299 AA715266 AW404328 AI831674 AI709348 AA603112
		4 AA485775 H64492 AW404789 AA487630 AA715498 AA295885 T27613 T98113
55	108470 genbank_AA079500	AA079500
	101447 entrez_M21305	M21305
	124447 genbank_N48000	N48000
		. ALCEDOD

X62111 S67984 AJ131056 Z47243 Z47235 AF062268 Z47237 AJ131058 AF062130 AF062282 X62108 AA385989 AA464794 X69861 AW402964 M90808 Z98735 Z98734 AF035018 X79161 U00545 AF174046 AF174071 U00552 U96288 AF021989 AF062255 AF174061 S73953 AF062135 AF062155 X64147 U00555 AF174070 AF129754 U86789 Z98714 Z98738 AF021989 AF062255 AF174061 S73953 AF062135 AF062155 X64147 U00555 AF174070 AF129754 U86789 Z98714 Z98738 AF02136 AF02136 AF02136 AF02137 JA3270 JA32

S75886 AJ008175 AJ008186 AJ008188 Y08403 H15753 H22208 AA327241 AW405737 H42300 H39677 H26239 H26903

H45128 R86072 AA327565 AI660584 AW361537 AW383759 S71043 H15014 H45570 H42819 H45523 H45134 R72043 H24543 H27636 H27610 T28147 H25496 AW364071 AW364072 H45561 H45556 H42605 AI735017 T47421 R48719 H27570 H44599 AI459598 H42347 H41938 H24993 AA345888 H22339 AI538691 AJ012264 AA664201 AI880450 AA327310 AI991250 AI833028 AW001210 AI956075 H30467 AA326915 H41943 AI749266 AI744441 AA327377 AW512326 AI735170 H01634 AI587047 AI571623 AA327486 AA327103 AA327195 AA326973 T28143 5 124842 217726\_1 F 103758 AA084874\_f\_at R56485 R37248 R59992 AA084874\_f X57815 L29157 AA367448 AW328098 AW404536 L29156 L29163 H27683 R83195 AA295096 AW327822 H25458 AW404692 130064 221\_264 X57819 X57823 AW405604 AW404447 Z34914 AW406542 AA427726 AA604389 AW405606 AW405918 AW405117 10 AW407182 L03632 AW405058 L03627 AW407470 R72738 L21959 AW375738 X87888 AF124166 AF054638 AJ241406 U09902 AW405284 M12025 AA360219 L03631 L03629 AW327727 AF194810 AF058076 AF194686 AF063774 AF063737 AF063755 AF063740 AF063739 AF063738 S73129 L43088 AF063775 L33026 AF060138 AF194813 AF194812 AF194811 AF194809 AF194814 AF194808 AF064505 AF064503 AF063765 AF063757 AF063752 AF063716 AF063736 AF194806 AF058077 AF063747 AF063772 AF063781 AF060137 AF194805 AF060134 AF060132 AF058074 AF063754 AF063704 15 U38589 Z18332 AF060122 AF194807 AF060135 AF064506 AF064504 AF063773 L26540 AF058072 AF060131 AF064500 AF060136 AF064513 AF194683 AF194711 AF058075 AF063717 Z19546 AF194581 X72746 U96393 U09890 X98897 AF194592 M80916 AJ241405 AF194632 AJ388659 AF194625 Z74694 AF194588 AF194601 U09901 U09911 U09892 AJ010336 AJ006162 AJ249377 AJ241414 AA327392 U97248 X72747 Z46850 X95739 AW406701 AJ243109 AF194609 S80758 AF194595 AF194596 L22483 Z70262 D84141 AW405758 AF001788 AF194580 D84143 U76684 AF194593 L03630 20 X87892 X91134 U21249 Z46346 AJ132426 AF103659 AJ233718 AF021038 AJ233727 H24657 U09882 S75627 AA573599 AF047231 AF047232 AF103616 AW404484 Z46848 S76132 AF103663 AF103713 Y17940 AF047216 AF103595 Y17956 AF052799 AF052797 AF052802 AF052798 AF052801 AF052794 AF052796 AF047218 AF052800 AF047217 AF052795 AF032351 AF103701 AF103708 AF103710 AF103706 S62232 AF103645 AF103632 AF103647 AF103644 AF103640 AF103692 AF093581 AF103620 AW405934 Al445389 AW383753 AA360256 AF099676 H21654 H39501 Al820828 H53689 25 W26785 AW384496 AW407708 AA541663 AA911602 AI821461 AA588300 AA327050 H42717 AI951280 AA421322 AI923193 AA864302 H25133 D87023 J03011 M61771 D87017 AA526865 AA253450 U29463 U06715 W24970 AA584303 T39581 AA155603 AA305043 AA429426 W05664 AA102382 AA482044 W24487 AA319060 130232 18831\_2 T88946 F10106 AA232161 AA243117 AA158937 AA100864 109097 genbank\_AA167512 AA167512

# TABLE 9: Figure 9 from BRCA 001-2 US

Table 9 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	Pkey: ExAccn:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number
	UnigenelD: Unigene Title:	Unigene number Unigene gene title

				•
15	Pkey	ExAccn	UnigeneID	UnigeneTitle
		AA383256		estrogen receptor 1
		BE314524		putative transmembrane protein
00		BE270266		5T4 oncofetal trophoblast glycoprotein
20		AF183810		opposite strand to trichorhinophalangeal syndrome I
		AW503733		KIAA1488 protein
	105500	AW602166	Hs.222399	CEGP1 protein
		A1690586	Hs.29403	hypothetical protein FLJ22060
	106155	AA425414	Hs.33287	nuclear factor VB
25		AW503807		histone acetyltransferase
	106414	BE568205	Hs.28827	mitogen-activated protein kinase kinase 2
	110009	BE075297	Hs.6614	ESTs, Weakly similar to A43932 much 2 precursor, intestinal
		AF131784	Hs.25318	Homo sapiens clone 25194 mRNA sequence
	114540	Al904232	Hs.75323	prohibitin
30	116470	Al272141	Hs.83484	SRY (sex determining region Y)-box 4
	117280	M18217	Hs.172129	Homo sapiens cDNA: FLJ21409 fis, clone COL03924
	119771	A1905687	Hs.2533	EST
	121723	AA243499	Hs.104800	hypothetical protein FLJ10134
~ ~	124059	BE387335	Hs.283713	ESTs, Weakly similar to S64054 hypothetical protein YGL050w
35	131148	AW953575	Hs.303125	p53-induced protein PIGPC1
	132371	AA235448	Hs.46677	PRO2000 protein
	134169	Al690916	Hs.178137	transducer of ERBB2, 1
	302235	AL049987	Hs.166361	Homo sapiens mRNA; cDNA DKFZp564F112
	452410	AL133619	Hs.29383	Homo sapiens mRNA; cDNA DKFZp434
				•

# TABLE 10: Figure 10 from BRCA 001-3 PCT

5 Table 10 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10 15	Pkey: ExAccn: Unigene Unigene R1: R2: R3:	ID: ( Title: (	Exemplar Access Unigene number Unigene gene titl Ratio of tumor to Ratio of 90 Ratio of 75	e normal body tissue Percentile tumor to body Percentile body to tumor				
	R4:		Ratio of tu	mor to normal breast tissue				
20	Pkey	ExAccn	UnigenelD	Unigene Title	R1	R2	R3	R4
	100103 100131		Hs.5085 Hs.11951	proteasome (prosome, macropain) 26S subu dolichyl-phosphate mannosyltransferase p ectonucleotide pyrophosphatase/phosphodi	4.2 9.8 13.2	152 123 244	36 13 19	12.2 5 9.9
25	100147 100154 100157 100169	H60720	Hs.136348 Hs.81892 Hs.119 Hs.82043	osteoblast specific factor 2 (fasciclin KIAA0101 gene product Wilms' turnour 1-associating protein D123 gene product	15.7 4.1 4.7 5.1	1030 320 119 106	66 78 26 21	5 10.6 3 9.2
30	100203 100210	BE242284 D26361	Hs.172199 Hs.3104 Hs.118110	adenylate cyclase 7 KIAA0042 gene product bone marrow stromai cell antigen 2	4.7 4.7 3.8	47 47 47 350	1 4 93	4.3 0.7 1.9
		NM_01519 NM_00620	Hs.3085 56Hs.78398 07Hs.170040 Hs.322478	KIAA0054 gene product; Helicase KIAA0071 protein platelet-derived growth factor receptor- KIAA0117 protein	4.1 3.4 4.5 5.9	64 77 45 59	16 23 4	3 5.9 4 2.6
35	100279 100286 100294	D42084 BE247550	Hs.82007 Hs.86859 Hs.75454	KIAA0094 protein growth factor receptor-bound protein 7 peroxiredoxin 3	3.5 3.1 12.8	96 306 128	28 98 1	1.3 1.5 11.7
40		A1878927 D80004 D86957	Hs.79284 Hs.75909 Hs.80712 Hs.79299	platelet-activating factor acetythydrota mesoderm specific transcript (mouse) hom KIAA0182 protein KIAA0202 protein lipoma HMGIC fusion partner-like 2	4.2 4.5 3.5 10.2 4	187 129 78 102 40	44 29 23 1	5.4 3.1 4.8 4.8 3.8
45	100414 100418 100438 100439	NM_01473 D86978 AA013051 AA347720	35Hs.82292 Hs.84790 Hs.91417 Hs.122669	KIAA0215 gene product KIAA0225 protein topoisomerase (DNA) II binding protein KIAA0264 protein	3.2 3.6 5.6 3.5	32 36 76 35	2 7 14 9	2.9 3.2 2 3.1
50	100449 100522 100552	D87470 X51501 AA019521	Hs.57652 Hs.75400 Hs.99949 Hs.301946	cadherin, EGF LAG seven-pass G-type rece KIAA0280 protein prolactin-induced protein tysosomal	5.5 3.4 22.7 14.4	145 34 760 144	27 1 34 9	2.2 1.2 1.4 4.7
	100661 100666 100667	L05424 L05424	Hs.132748 Hs.169610 Hs.169610	plastin 3 (T isoform) Homo sapiens ribosomal protein L39 mRNA, CD44 antigen (homing function and Indian CD44 antigen (homing function and Indian	4.1 3.3 8.5 3	259 116 85 594	63 36 1 201	1.9 2.2 3.2 2.3
55	100774 100783 100821	J05581 AF078847 M26460	Hs.144630 Hs.89603 Hs.191356	nuclear receptor subfamily 2, group F, m mucin 1, transmembrane general transcription factor IIH, polype gb:Horno sapiens (clone 104) retinoblasto	5 3.5 9.7 3.3	82 37 97 33	17 11 10 1	0.9 2.8 7.2 0.8
60	100877 100892 101038	X80821 BE245294 BE297139	Hs.74861 Hs.27973 Hs.180789 Hs.79411	activated RNA polymerase II transcripto KIAA0874 protein S164 protein replication protein A2 (32kD)	3.7 6.3 4.7 3.8	477 63 47 115	130 4 1 30	3.1 5.7 4.2 7.1
	101046 101079		Hs.250502	NM_002122:Homo saplens major histocompat carbonic anhydrase VIII	3.9 3.9	390 39	100 8	11.1 3.6

	101084	AW409934	Hs.75528	nucleolar GTPase	4.1	53	13	4
	101104	AW862258	Hs.169266	neuropeptide Y receptor Y1	15.3	153	1	14.1
	101185	NM_00162	1Hs.170087	aryl hydrocarbon receptor	11.3	113	8	3.9
	101188	L20320	Hs.184298	cyclin-dependent kinase 7 (homolog of Xe	3.1	118	38	2
5	101201	L22524	Hs.2256	matrix metalloproteinase 7 (MMP7; uterin	8.2	396	48	0.9
			Hs.242894	ADP-ribosylation factor-like 1	4	110	28	10.7
		BE545277		Ts translation elongation factor, mitoch	4.2	50	12	4.4
		BE535511		transmembrane trafficking protein		135		
		BE267931			6.6		21	13.1
10			113.10330	proliferating cell nuclear antigen	6.4	249	39	22.4
10		M21305	411- 405050	gb:Human alpha satellite and satellite 3	6.5	878	135	0.8
			4Hs.195850	keratin 5 (epidermolysis bullosa simplex	4.8	622	130	0.7
		NM_00054		tumor protein p53 (Li-Fraumeni syndrome)	5.1	97	19	9.3
		NM_00289		RAS p21 protein activator (GTPase activa	9.6	96	1	8.5
4		AA053486	Hs.20315	Interferon-induced protein with tetratri	11.2	112	8	5.9
15	101507	X16896	Hs.82112	interleukin 1 receptor, type I	3.9	39	2	3.5
	101621	BE391804	Hs.62661	guanylate binding protein 1, interferon-	3.6	36	1	2.6
	101624	M55998		gb:Human alpha-1 collagen type I gene, 3	3.1	2898	923	2.2
	101664	AA436989	Hs.121017	H2A histone family, member A	6.9	103	15	8.4
		M63256	Hs.75124	cerebellar degeneration-related protein	6.4	64	2	4.9
20		L11690	Hs.620	bullous pemphigoid antigen 1 (230/240kD)	9.4	94	1	0.3
		S70114	Hs.239489	TIA1 cytotoxic granule-associated RNA-bi	8.9	89	5	
		M81057	Hs.180884					8
		M83822		carboxypeptidase B1 (tissue)	3.6	824	227	1.4
			Hs.62354	cell division cycle 4-like	9	144	16	13
25		M84605	Hs.957	putative opioid receptor, neuromedin K (	3.3	36	11	2.4
25		AW024390		pre-B-cell leukemla transcription factor	5.4	180	34	15.9
		M86849	Hs.323733	gap junction protein, beta 2, 26kD (conn	12	120	8	9
		AA446644		GA733-2 antigen; epithelial glycoprotein	3.1	353	116	2.8
		AL049610		transcription elongation factor A (SII)-	7.3	73	1	5.3
••	101960	AL036287	Hs.194662	calponin 3, acidic	3.8	399	105	3.3
30	102009	BE245149	Hs.82643	protein tyrosine kinase 9	4.6	148	32	11.3
	102095	U11313	Hs.75760	sterol carrier protein 2	9.5	95	4	8.8
	102123	NM_00180	9Hs.1594	centromere protein A (17kD)	4.2	42	7	3.4
	102125	NM 00645	6Hs.288215	slalyltransferase	9.3	93	4	3
		NM_00441		dual specificity phosphatase 5	5.4	137	26	2.5
35		AA450274		CDC16 (cell division cycle 16, S. cerevi	4.6	151	33	2.0
00		BE313280		death associated protein 3	9.3	93	5	8
		AL036335						39.7
				secreted phosphoprotein 1 (osteopontin,	45.7	457	1	
		BE314524		putative transmembrane protein	3.9	442	114	1.3
40		NM_00676		LIM domain only 4	4.9	49	1	3.6
40		U27185	Hs.82547	retinoic acid receptor responder (tazaro	3.1	31	1	1.3
		NM_00154		Inhibitor of DNA binding 4, dominant neg	3.8	163	43	0.5
		AA306342		protein kinase C-like 2	4.5	45	1	3.6
		AF015224	Hs.46452	mammaglobin 1	8.5	2058	243	1.4
	102348	U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	6.4	428	67	2.3
45	102369	U39840	Hs.299867	hepatocyte nuclear factor 3, alpha	6.7	67	9	6.3
	102407	AW602154	Hs.82143	E74-like factor 2 (ets domain transcript	5.3	53	1	4.8
		BE300330		selenophosphate synthetase 2	3.3	111	34	7.5
		NM_001394		dual specificity phosphatase 4	20.2	202	5	1.3
		NM_00393		kynureninase (L-kynurenine hydrolase)	3.8	38	1	1.5
50	102567		Hs.146847				i	
50	102580		Hs.152981	TRAF family member-associated NFKB activ	8.2	82		6.8
				CDP-diacylglycerol synthase (phosphatida	4.1	41	1	3.3
		AL037672		extracellular matrix protein 1	10.2	628	62	17.2
	102638		Hs.9216	caspase 7, apoptosis-related cysteine pr	5	66	13	5.3
e e		NM_002270		karyopherin (importin) beta 2	6.1	126	21	2.4
55	102669	U71207	Hs.29279	eyes absent (Drosophila) homolog 2	4.5	45	1	2.8
		U79293	Hs.159264	Human clone 23948 mRNA sequence	4.1	41	1	2.4
	102784	U85658	Hs.61796	transcription factor AP-2 gamma (activat	4.4	255	58	1.6
	102805	U90304	Hs.25351	iroquois homeobox protein 5	3.6	142	39	1.6
	102813	BE242035		embryonic ectoderm development	3.5	35	1	2.7
60	102823		Hs.5057	carboxypeptidase D	5.6	56	i	5.3
••		BE262386		clones 23667 and 23775 zinc finger prote	4.2	42	7	3.7
		AI815559	Hs.75730	signal recognition particle receptor ('d	3.2	58	18	5.1
		NM_002275		keratin 15				0.4
				• • • • • • • • • • • • • • • • • • • •	5.8	753	131	
65		BE512730		keratin 18	3.1	815	266	1.7
05		AL119505		activating transcription factor 2	3.2	32	4	2.6
		AU076611		methylene tetrahydrofolate dehydrogenase	5.7	251	44	6.6
	103003	AI910275	ris.1406	trefoil factor 1 (pS2)	5.6	1346	239	5.4

	103023 AW500470	Hs.117950	multifunctional polypeptide similar to S	5.8	218	38	13
	103024 NM_00234		lactotransferrin	3.7	1421	388	1.9
	103036 M13509	Hs.83169	matrix metalloproteinase 1 (MMP1; inters	3.1	94	30	5.8
	103038 AA926960		CDC28 protein kinase 1	3.5	332	94	3.1
5	103119 X63629	Hs.2877	cadherin 3, type 1, P-cadherin (placenta	4.8	312	65	30.9
	103134 X65724	Hs.2839	Norrie disease (pseudoglioma)	5.2	331	64	1.5
	103134 X65724	Hs.2839	Norrie disease (pseudoglioma)	4.9	49	5	3.8
	103171 AW583058		serine (or cystelne) proteinase inhibito	3.3	1497	458	2.1
	103206 X72755	Hs.77367	monokine induced by gamma interferon	3.5	796	228	3.2
10	103208 AW411340		retinoblastoma-binding protein 7	5.6	191	34	3.5
	103226 X75042	Hs.44313	v-rel avian reticuloendotheliosis viral	4.1	53	13	4.9
	103333 AA206186		monocyte to macrophage differentiation-a	3.4	34		
	103346 X87613	Hs.5464	thyroid hormone receptor coactivating pr		43	8	2.3
	103352 H09366	Hs.78853	uracii-DNA glycosylase	3.9		11	1
15	103375 NM_00598			9.3	93	8	8.2
	103376 AL036166		sine oculis homeobox (Drosophila) homolo coated vesicle membrane protein	9.7	97	1	9.3
	103391 X94453	Hs.114366	pyrroline-5-carboxylate synthetase (glut	6.3	98	16	9.1
	103438 AW175781		M-phase phosphoprotein 6	4.3	77	18	7.2
	103453 AI878922			4.9	153	31	2.4
20	103431 Y00815		SMT3 (suppressor of mif two 3, yeast) ho	4.9	261	53	3.7
20		Hs.75216	protein tyrosine phosphatase, receptor t	3.5	564	162	1.7
	103500 AW408009		alkylglycerone phosphate synthase	3.9	49	13	2.5
	103557 AL133415		vimentin	7.5	136	18	3.4
	103587 BE270266		5T4 oncofetal trophoblast glycoprotein	7.9	79	2	6.9
25	103605 BE409838		cadherin 1, type 1, E-cadherin (epitheli	3.3	745	229	1.8
23	103606 AW403814		BCL2-associated athanogene	3.2	41	13	2.8
	103613 NM_000346		SRY (sex determining region Y)-box 9 (ca	7.3	73	1	5.2
	103658 NM_000088		collagen, type I, alpha 1	3.8	1612	429	3.1
	103666 NM_003528		H2B histone family, member Q	3.2	32	5	2.8
20	103988 AA314389		ADP-ribosylation factor-like 5	3.2	32	9	2.7
30	103990 AB033112		bromodomain and PHD finger containing, 3	4.9	49	1	4.2
	104052 NM_002407		mammaglobin 2	7.2	498	69	9.3
	104115 AF183810		opposite strand to trichorhinophalangeal	29	290	1	26.8
	104129 H63349	Hs.98806	hypothetical protein	3.7	37	7	2.1
2.5	104146 AW880614		RNA binding motif protein, X chromosome	5.2	52	1	4.3
35	104147 BE081342	Hs.283037	HSPC039 protein	8	84	11	6.3
	104209 AB012113	Hs.16530	small inducible cytokine subfamily A (Cy	5.8	58	1	3.2
	104239 AB002367	Hs.21355	doublecortin and CaM kinase-like 1	6.4	64	8	3
	104278 AW583693	Hs.109253	N-terminal acetyltransferase complex ard	4.7	229	49	7.9
	104309 Al337300	Hs.284123	hypothetical protein MGC4604	3.2	32	7	2.4
40	104394 AA129551	Hs.172129	Homo sapiens cDNA: FLJ21409 fis, clone C	5.3	144	27	13.1
	104432 X51501	Hs.99949	prolactin-induced protein	6.9	1494	218	1.3
	104558 R56678	Hs.88959	hypothetical protein MGC4816	7.7	77	8	6.9
	104567 AA040620	Hs.5672	hypothetical protein AF140225	3.7	37	5	2.5
	104590 AW373062	Hs.83623	nuclear receptor subfamily 1, group I, m	6.1	493	81	0.7
45	104602 H47610		gb:yp75f03.s1 Soares fetal liver spleen	3.8	38	4	1.2
	104613 AF123303	Hs.24713	hypothetical protein	4.8	231	49	7.3
	104633 H00820	Hs.30977	ESTs, Weakly similar to B34087 hypotheti	3.4	154	46	3
	104636 R82252	Hs.106106	protein kinase (cAMP-dependent, catalyti	5	468	94	4.7
	104660 BE298665	Hs.14846	Homo sapiens mRNA; cDNA DKFZp564D016 (fr		82	22	3.1
50	104667 Al239923	Hs.30098	ESTs	14.9	149	1	6.4
	104766 BE244072	Hs.20815	macrophage erythroblast attacher	6.3	165	26	3.2
	104787 AA027317		gb:ze97d11.s1 Soares_fetat_heart_NbHH19W	3.8	40	11	3.8
		Hs.31803	ESTs, Weakly similar to N-WASP [H.sapien	7.7	77	i'	5.1
		Hs.125790	leucine-rich repeat-containing 2	7	70	i	6.5
55		Hs.32478	ESTs	4.7	201	43	4.5
	104896 AW015318		ESTs	7.4	74	1	6
	104919 AA026880		prolactin receptor	3.9	280		3.3
	104926 BE298808		DKFZP434N093 protein			72	
	104943 AF072873	He 11/218	frizzled (Drosophila) homolog 6	4.2	135	32	4
60	104968 AI249502	He 20660	ESTs	16.2	162	1	4.2
00 .		Hs.23003	amino acid transporter system A1	3.8	38	1	2.4
	104997 AA121686	Hs.18272	ESTs	3.2	522	165	1.9
		ns. 10592 Hs.13268	ESTs	3.2	32	4	2.9
	105038 AW503733		KIAA1488 protein	3.7		43	3.6
65	105041 AB037716		KIAA1295 protein	5.5	55 .	1	5.2
	105086 AA148710		lumican	10.3		1	3.9
		Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	6.6	66	1	5.4
	.00000 1100000	111111	HORIO SOPIEIO CUINA FLUTTUZZ IIS, CIONE PL	3.1	31	1	2.5

	105091	AA148859	Hs.179909	hypothetical protein FLJ22995	3.2	32	1	3
		AI368836		ESTs, Weakly similar to I38022 hypotheti	7.3	73	1	3.8
		AA307279		methyl-CpG binding domain protein 4	4.2	90	22	2.8
5		AL133033		KIAA1025 protein	6	60	6	4.6
,		AW612147 AA313825		Homo sapiens C1orf19 mRNA, partial cds AD036 protein	3.8	38	2	3.2
		AA975096		hypothetical protein PRO2849	9.3 5.7	436 57	47 8	5.8 5.3
		AA328102		cytoskeleton associated protein 2	4.5	45	1	3.6
		AW952479		tropomodulin 3 (ubiquitous)	4.3	43	i	3.9
10	105252	AB039670	Hs.9728	ALEX1 protein	8	80	6	7.3
	105253	AW997484	Hs.5003	KIAA0456 protein	3.9	39	6	3.2
		AA894638		ESTs	3.5	35	7	2.7
		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ	4.5	45	10	0.5
15		AK000796		hypothetical protein	3.8	93	25	7.5
13		AA234561 AF151073		ESTs	2.8	131	47	3.9
		AW994032		hypothetical protein hypothetical protein FLJ10849	3.9 5.1	79 181	20 36	6.5 15.8
		AW500718		Homo sapiens, clone MGC:16169, mRNA, com	4.1	41	2	3.3
		AF198620		RNA binding motif protein 8A	6.2	62	6	5.6
20		W20027	Hs.23439	ESTs	3.3	206	63	2.2
	105483	AL137257	Hs.23458	Homo sapiens cDNA: FLJ23015 fis, clone L	3.2	466	146	8.4
		AL117441		hypothetical protein FLJ13033	16.6	166	8	12.7
		AW602166		CEGP1 protein	25.4	508	20	3
25		AA173942		Homo saplens mRNA; cDNA DKFZp564H1916 (		117	13	10.6
23		AB037829 AK001269		regulator of nonsense transcripts 2; DKF	3.2	32	6	1.5
		AB040884		hypothetical protein FLJ10407 KIAA1451 protein	8.3	83	3	1.8
		BE616694		hypothetical protein FLJ14299	3.5 5.8	73 336	21 58	1.6 2
		AA280072		fetal Alzheimer antigen	3.2	32	1	1
30		R35343	Hs.24968	Human DNA sequence from clone RP1-233G16		79	17	5.2
	105627	AA281279		hypothetical protein FLJ14681	4	75	19	1.7
	105640	AA001021	Hs.6685	thyroid hormone receptor Interactor 8	4.5	45	1	3.7
		AW294631		ESTs	3.6	36	1	0.1
25		Al609530	Hs.279789	histone deacetylase 3	6.4	64	8	6
35		NM_014517		upstream binding protein 1 (LBP-1a)	4.7	152	33	5.3
		A1680737	Hs.289068	Homo sapiens cDNA FLJ11918 fis, clone HE	5.7	57	8	4.1
		AW377314 AAB34664		DKFZP5641052 protein nuclear receptor coactivator 2	6.9 3.4	69 34	1	4.4 3.1
		BE246502		sema domain, immunoglobulin domain (ig),	3.4	30	10	0.9
40			Hs.15159	chemokine-like factor, alternatively spl	5.4	54	1	4.4
		H57111	Hs.221132	ESTs	5.3	67	13	5.3
	105774	AW369278	Hs.23412	hypothetical protein FLJ20160	4.9	49	1	4.5
		W84446	Hs.226434	hypothetical protein MGC4643	3.3	98	30	4.7
A.E		AA878183		Homo sapiens cDNA FLJ13618 fis, clone PL	3.2	143	46	3.6
45		AF206019		REV1 (yeast homolog)- like	4	40	3	3.2
		AA788946 Al559444	Hs.16869 Hs.293960	ESTs, Moderately similar to CA1C RAT COL	4.7	747	158	5.7
		AW802282		ESTs pyruvate dehydrogenase phosphatase	3.9	371	94	4.6
		AA601518		secreted modular calcium-binding protein	3.6 4.8	68 134	19 28	6 3.2
50		Al827976	Hs.24391	hypothetical protein FLJ13612	4.3	772	179	1.7
٠,			Hs.28332	Homo sapiens cDNA: FLJ21560 fis, done C	4.3	43	1	3.7
	105870	AW021691	Hs.101067	GCN5 (general control of amino-acid synt	3.6	36	7	3.1
		AK001708		hypothetical protein FLJ10846	3.4	34	8	2.9
e e		AK001735		UDP-glucose:glycoprotein glucosyltransfe	3.6	45	13	1.3
55	105906		Hs.22380	ESTs	3.4	34	1	1.5
			Hs.8895	ESTs	21.2	212	6	17.4
		AA043039 AL122072		hypothetical protein	3.9	47	12	4.4
		AW952005		heterogeneous nuclear ribonucleoprotein hypothetical protein FLJ12903	4.4 4.7	174 47	40 1	1.6 4
60		AA382267		ESTs	4. <i>t</i> 3.4	47	15	4.4
••		AA417034		gb:zu04f10.s1 Soares_testis_NHT Homo sap	3.5	53	15	1.2
		BE614474	Hs.289074	F-box only protein 22	3.4	116	35	2.2
		NM_001329		C-terminal binding protein 2	3.6	444	125	4.6
<i></i>	106070		Hs.5957	Homo sapiens done 24416 mRNA sequence	3.6	365	103	6.9
65		AF115402		E74-like factor 5 (ets domain transcript	26.3	356	14	1
		AW379378		protein tyrosine phosphatase, receptor t	3.2	267	83	2.3
	100120	AA576953	113.22312	hypothetical protein FLJ13352	3.8	38	1	3.3

	106155	AA425414	Hs.33287	nuclear factor I/B	9.9	483	49	1.8
	106157	W37943	Hs.34892	KIAA1323 protein	6.7	94	14	8
		A1244563						
				Homo sapiens clone 015h12 My015 protein	3.3	95	29	4.4
_		AB040896		KIAA1463 protein	3.8	83	22	7.5
5	106286	AI765107	Hs.274422	hypothetical protein FLJ20550	3.3	97	30	6.4
	106290	AW961393	Hs.16364	hypothetical protein FLJ10955	4.5	116	26	4.5
		R98185	Hs.17240	ESTs	7		3	
						70		1.3
		AB007866		KIAA0406 gene product	3.2	37	12	2.6
	106330	AW977397	Hs.35580	ESTs	3.8	38	1	1.9
10	106383	AA447453	Hs.27860	Homo sapiens mRNA; cDNA DKFZp586M0723	f16	255	16	6.6
		AW748420		Homo sapiens cDNA: FLJ21487 fls, clone C	4.9		70	2.7
						337		
		Z42993	Hs.25320	Homo sapiens clone 25142 mRNA sequence	3.1	72	23	5
	106432	AK000310	Hs.17138	hypothetical protein FLJ20303	3.1	165	54	1.6
	106459	AA789081	Hs.4029	glioma-amplified sequence-41	3.1	31	1	2.6
15		AB033042		cofactor required for Sp1 transcriptiona	5.5	147	27	4.4
10								
		A1205785		ESTs	4.4	222	51	1.8
	106565	NM_01489	2Hs.227602	KIAA1116 protein	7.4	74	3	1.7
	106586	AA243837	Hs.57787	ESTs	15.2	152	1	12.6
		AK000933		Homo sapiens cDNA FLJ10071 fis, clone HE	3.8	263	69	3.9
20								
20		AA452379		ESTs, Moderately similar to ALU7_HUMAN A	4.9	49	1	4.1
	106611	R49131	Hs.26267	ATP-dependant interferon response protei	5.8	58	5	3.1
	106628	AW188205	Hs.12311	Homo sapiens clone 23570 mRNA sequence	5.3	166	32	14.9
		AL049951				75	14	
				Homo sapiens mRNA; cDNA DKFZp564O0122 (				0.8
25		BE296396		OIPB protein	3.6	210	58	4.7
25	106698	N28524	Hs.29403	hypothetical protein FLJ22060	5.7	57	10	4.8
	106710	N38902	Hs.334437	hypothetical protein MGC4248	4.4	371	84	3.2
		AA600357			4.3	101	24	
				TIA1 cytotoxic granule-associated RNA-bi				1.6
		NM_00711		triple functional domain (PTPRF Interact	4.6	46	1	4.
		AL044182		KIAA0753 gene product	3.5	58	17	1.6
30	106846	AB037744	Hs.34892	KIAA1323 protein	5.4	192	36	4.4
		BE185536		molecule possessing ankyrin repeats indu	3.3	696	214	1.8
		AA149537		hypothetical protein FLJ20477	3.8	38	1	1.6
		AA835868		mannosidase, alpha, class 1A, member 1	4.3	43	10	2.2
	106895	AK001826	Hs.25245	hypothetical protein FLJ11269	3.6	36	1	1.2
35	106897	AF039023	Hs 167496	RAN binding protein 6	4.5	45	1	3.8
-		AA134329						
				Homo sapiens, clone IMAGE:3685398, mRNA,	5.7	94	17	7.3
		A1868648	Hs.22315	ESTs	3.5	180	52	2.3
	106968	AF216751	Hs.26813	CDA14	5.5	130	24	12.5
		AA280722		ESTs, Weakly similar to 138022 hypotheti	3.2	266	83	1.8
40								
70		AL157479	N3.23/40	KIAA1598 protein	5.1	298	59	4.4
		AA598820		gb:ae36h12.s1 Gessler Wilms turnor Homo s	3.3	228	69	2.8
	107032	AV650537	Hs.247309	succinate-CoA ligase, GDP-forming, beta	3.1	55	18	3.8
		AW401864		programmed cell death 8 (apoptosis-induc	3.1	75	24	2.2
AE		AW385224		ectonucleotide pyrophosphatase/phosphodi	3.1	367	119	2.3
45	107080	AL122043	Hs.19221	hypothetical protein DKFZp566G1424	3.9	98	25	8.6
	107102	AB037765	Hs.30652	KIAA1344 protein	6.3	63	1	5.4
	107109	AA249096	Hs 32793	ESTs	4.6	71	16	3.6
		AV661958						
				GK001 protein	2.5	392	155	4.3
		AW378065		ESTs	15.6	156	7	10.8
50	107217	AL080235	Hs.35861	DKFZP586E1621 protein	4.8	48	8	3.1
	107222	BE172058	Hs.82689	tumor rejection antigen (gp96) 1	3.4	251	74	23.7
		AI290284	Hs.159872				_	
				ESTs	3.6	36	6	0.5
		AW263124		nuclear receptor co-repressor/HDAC3 comp	5.4	483	90	4
_	107295	AA186629	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	199	44	19.2
55	107299	BE277457	Hs 30661	hypothetical protein MGC4606	12.5	156	13	2.9
		T63174	Hs.193700					9.6
		• • • •		Homo sapiens mRNA; cDNA DKFZp58610324 (f		110	35	
	107318		Hs.5957	Homo sapiens clone 24416 mRNA sequence	3.5	35	1	2.6
	107485	AL042613	Hs.262476	S-adenosylmethionine decarboxylase 1	5.8	151	26	11.4
		A1498986	Hs.60090	Homo sapiens cDNA FLJ13595 fis, clone PL	3.2	32	5	2.1
60		Al580492						
JU			Hs.42743	hypothetical protein	4.4	73	17	6.2
		AA149707		ublquitin-like 3	3.5	282	80	3.7
	107859	AW732573	Hs.47584	potassium voltage-gated channel, delayed	5.7	85	15	7.8
		AW372451		CGI-79 protein	3.5	35	1	1
		AA054949		ESTs			10	2.7
65					4.3	43		
65		AA025782		ESTs	3.1	31	9	2.2
	107908	AF087999	Hs.42826	ESTs	4.7	47	4	4.3
	107922	BE153855	Hs.61460	lg superfamily receptor LNIR	9	90	1	5.5
				·	•		*	

	107994	AA036811	Hs.48469	LIM domains containing 1	4.5	45	1	3.8
			Hs.159971	SWI/SNF related, matrix associated, acti	6.5	65	ż	6
			Hs.334483	hypothetical protein FLJ23571	7.4	74	8	6
		BE548479						
5		AW151340		hypothetical protein FLJ10773	3.4	34	1	2.3
-		Al478658		ESTs, Weakly similar to ALU7_HUMAN ALU S	18.7	187	1	17
				brefeldin A-inhibited guanine nucleotide	3.8	38	1	3.2
		AA084677		hypothetical protein FLJ22222	5.7	57	1	4.9
		AW022410		ESTs	3.2	32	5 .	1.7
10		BE546947		homeo box C10	8.7	247	29	5.7
10		AB029000		KIAA1077 protein	3.7	625	168	3.8
		AF133123		general transcription factor IIIC, polyp	3.7	37	1	3.2
		AF070578		Homo saplens clone 24674 mRNA sequence	3.4	34	1	2.8
	108807	Al652236	Hs.49376	hypothetical protein FLJ20644	3.5	35	1	3.2
	108810	AW295647	' Hs.71331	hypothetical protein MGC5350	5.3	53	1	2.8
15	108846	AL117452	Hs.44155	DKFZP586G1517 protein	4.8	96	20	6.5
		AK001468		anillin (Drosophila Scraps homolog), act	5.4	54	, 1	4
			Hs.194691	retinoic acid induced 3	3.1	529	170	4.1
		Al380268		ESTs, Weakly similar to Zinc-finger prot	3.3	33	5	1.7
		NM_00724		dual specificity phosphatase 12	3.4	34	1	2.6
20			Hs.241551					
20		AW608930		chloride channel, calcium activated, fam	3.1	31	8	2
				hypothetical protein FLJ20618	3.4	71	21	2.4
			Hs.257924	hypothetical protein FLJ13782	4.1	334	82	3.4
		AK000684		hypothetical protein FLJ22104	3.3	33	1	2.9
25		H89083	Hs.181915	ESTs	4	40	7	1.1
25		BE220601		hypothetical protein FLJ13033	3.8	233	62	3.8
		AA219691		RAB6 interacting, kinesIn-like (rabkines	8.8	199	23	16.1
		AA179962		EST	3.2	32	1	2.2
	109178	AW976516	Hs.283707	Homo sapiens cDNA: FLJ21354 fis, clone C	3.2	32	10	2.9
	109235	Al381800	Hs.300684	calcitonin gene-related peptide-receptor	4.9	121	25	10.4
30	109273	AA375752	Hs.82719	Homo saplens mRNA; cDNA DKFZp586F1822 (i	f 2.9	114	39	9.9
	109292	AW975746	Hs.188662	KIAA1702 protein	7.1	71	1	6.5
		AL096858		KIAA0929 protein Msx2 interacting nuclea	6.9	69	5	6.2
		R98881	Hs.109655	sex comb on midleg (Drosophila)-like 1	3.3	39	12	1.5
		BE543313		hypothetical protein FLJ10520	4.2	56	14	2.2
35		U80736	Hs.110826	trinucleotide repeat containing 9	12.3	123	1	11.3
55		AA878923						
		Al631874	Hs.155140	hypothetical protein FLJ21016	3.2	286	91	5.7
		AA989362		casein kinase 2, alpha 1 polypeptide	8.3	83	8	1.9
				ESTs	5.9	59	10	4.2
40		F10024	Hs.268740	ESTs	3.2	41	13	3.3
40		AA173942		Homo sapiens mRNA; cDNA DKFZp564H1916 (	_	208	36	1.8
		AW965076		hypothetical protein 669	5	50	5	4.1
		R68827	Hs.95011	syntrophin, beta 1 (dystrophin-associate	3.7	37	4	2
		AW390822	Hs.301528	L-kynurenine/alpha-aminoadipate aminotra	14.2	142	·1	9.5
		AI084066	Hs.20072	myosin regulatory light chain interactin	4.1	41	7	1.7
45	109958	AA001266	Hs.133521	ESTs	4.2	58	14	0.8
	109984	Al796320	Hs.10299	Homo sapiens cDNA FLJ13545 fis, clone PL	3.2	136	43	3.6
	110009	BE075297		ESTs, Weakly similar to A43932 much 2 p	6.3	693	110	7.2
		AI668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOC		913	199	2.9
		AK000768		hypothetical protein FLJ20761	3.8	38	7	2.8
50		AI610702	Hs.28212	ESTs, Weakly similar to TRHY_HUMAN TRICH		78	12	3
-		H11236	Hs.31034	peroxisomal biogenesis factor 11A	3.7	37	1	2.1
		AF075089						
		H61560	113.30023	ESTs	3.6	36	10	2.5
			11- 40400	gb:yr22g03.s1 Soares fetal liver spleen	3.3	33	1	1.8
55		AA071276		KIAA0859 protein	3.5	35	8	1.9
55		AB007902		KIAA0442 protein	3.6	282	79	1.7
			Hs.31319	ESTS	4.4	103	24	3.8
		NM_01489		KIAA0878 protein	3.3	138	42	3.6
		BE000831	Hs.23837	Homo sapiens cDNA FLJ11812 fis, clone HE	13.5	135	1	5.1
		N22414		gb:yw39a07.s1 Welzmann Olfactory Epithel	5.4	54	1	3.7
60		AA831267	Hs.12244	hypothetical protein FLJ20097	4.7	47	4	4.2
		AI089660	Hs.323401	dpy-30-like protein	5	50	i	4.3
	110818	AL157503		Homo sapiens mRNA; cDNA DKFZp586N2424 (1		31	i	2.7
		AF153330		solute carrier family 19 (thiamine trans	8.4	84	i	5.3
		AI740792	Hs. 167531	methylcrotonoyl-Coenzyme A carboxylase 2	10.5	105	4	7.1
65		BE612992		hypothetical protein FLJ10607 similar to	7.9	79	i	6.2
50		AW963705		molecule possessing ankyrin repeats indu	3.9			1.2
		Al433165		ESTs	3.1	353 31	90	
	, ,0000			2013	U. I	31	1	1.3

	110915 BE092285 Hs.29724	hypothetical protein FLJ13187	20.9	209	1	19.5
	110930 BE242691 Hs.14947	ESTs	3.4	115	34	2.4
	110970 Y19062 Hs.96870 111084 H44186 Hs.15456	staufen (Drosophila, RNA-binding protein	3.5	35	9	3.2
5	111084 H44186 Hs.15456 111125 N63823 Hs.269115	PDZ domain containing 1	4.3	43	1	2
•	111132 AB037807 Hs.83293	ESTs, Moderately similar to Z195_HUMAN Z hypothetical protein	5.4 7.2	54 72	1 10	4.3 6.1
	111164 N46180 Hs.122489	Homo sapiens cDNA FLJ13289 fis, clone OV	7.7	77	1	5
	111179 AK000136 Hs.10760	asporin (LRR class 1)	25.1	288	12	6.7
10	111184 AI815486 Hs.243901	Homo sapiens cDNA FLJ20738 fis, clone HE	3.9	146	37	9.8
10	111190 AK002055 Hs.151046	hypothetical protein FLJ11193	6.3	63	1	5.8
	111221 AB037782 Hs.15119	KIAA1361 protein	3.7	119	33	6.7
	111223 AA852773 Hs.334838	KIAA1866 protein	3.6	402	112	4.9
	111229 AW389845 Hs.110855 111234 AA902656 Hs.21943	ESTs	4.3	43	1	1
15	111241 AA345644 Hs.288880	NIF3 (Ngg1 interacting factor 3, S.pombe PAN2 protein	3.3	33	1	1.1
10	111345 AW263155 Hs.14559	hypothetical protein FLJ10540	4.8 4.3	61 43	13 5	5.6
	111353 W20090 Hs.6616	ESTs	4.1	41	1	2.2 2.6
	111357 BE314949 Hs.87128	hypothetical protein FLJ23309	3.8	425	111	4
	111378 AW160993 Hs.326292	hypothetical gene DKFZp434A1114	4.3	65	15	5.7
20	111389 AK000987 Hs.169111	oxidation resistance 1	3.4	314	91	2.4
•	111540 U82670 Hs.9786	zinc finger protein 275	3.5	35	1	2.1
	111806 BE071382 Hs.279008	hypothetical protein FLJ20170	3.5	105	30	9.6
	111884 AW502285 Hs.127236 111923 BE383234 Hs.25925	hypothetical protein FLJ12879	3.2	37	12	3.5
25	111929 AF027208 Hs.112360	Homo saplens, clone MGC:15393, mRNA, com prominin (mouse)-like 1		62	2	5.9
2.5	111942 R40576 Hs.21590	hypothetical protein DKFZp56400523	8.1 4.2	328 125	41 30	1.7
	111987 NM_015310Hs.6763	KIAA0942 protein	6.5	65	10	7.4 1.5
•	112092 R44538	gb:yg29c02.s1 Soares infant brain 1NIB H	3.3	33	10	2.3
•	112134 R41823 Hs.7413	ESTs; calsyntenin-2	6.1	185	31	6.6
30	112197 NM_003655Hs.5637	ESTs	3.5	507	145	3.3
	112198 Al432672 Hs.288539	hypothetical protein FLJ22191	3.5	40	12	2.5
	112244 AB029000 Hs.70823	KIAA1077 protein	5.7	567	100	6.7
	112253 R51818 112269 R53734 Hs.25978	gb:yg77h12.s1 Soares infant brain 1NIB H	4	70	18	6.8
35	112275 AW972635 Hs.301904	ESTs, Weakly similar to 2109260A B cell hypothelical protein FLJ12671	3.7 4.3	37 45	1	3
50	112280 AA863360 Hs.26040	ESTs, Weakly similar to fatty acid omega	2.8	751	11 270	4.4 1.3
	112305 AK000914 Hs.26244	hypothetical protein FLJ10052	3.5	41	12	3.7
	112483 AW969785 Hs.285885	Homo sapiens cDNA FLJ11321 fis, clone PL	4.2	42	6	3.6
4.0	112513 R68425 Hs.13809	hypothetical protein FLJ10648	4.7	54	12	4.5
40	112571 AA412205 Hs.140996	ESTs	4.8	48	2	3.4
	112971 Z42387 Hs.83883	transmembrane, prostate androgen induced	4.5	390	87	5.3
	113023 AL134324 Hs.7312	ESTs	3.2	99	31	3.1
	113047 Al571940 Hs.7549	ESTs	9.6	124	13	9
45	113073 N39342 Hs.103042 113083 AA283057 Hs.266957	microtubule-associated protein 18	9.1	91 65	6	8.3
	113287 T66847 Hs.194040	hypothetical protein FLJ14281 ESTs, Weakly similar to I38022 hypotheti	6.5 3.5	65 35	6 1	4.8 1.4
	113296 AW449560 Hs.89576	inner mitochondrial membrane peptidase 2	3.5	35	4	3.3
	113523 AJ791905 Hs.95549	hypothetical protein	7.6	76	1	4.2
50	113604 Al075407 Hs.296083	ESTs, Moderately similar to 154374 gene	3.1	453	148	7
50	113617 AJ869372 Hs.17207	Homo sapiens cDNA FLJ11922 fis, clone HE	3.6	36	4	2.6
	113702 T97307	gb:ye53h05.s1 Soares fetal liver spleen	12.3	129	11	11.7
	113783 AL359588 Hs.7041	hypothetical protein DKFZp762B226	4.6	46	4	4.3
	113791 Al269096 Hs.135578 113794 T62849 Hs.11090	chitobiase, di-N-acetyl-	3.6	36	1	1.2
55	113804 BE247683 Hs.14611	membrane-spanning 4-domains, subfamily A dual specificity phosphatase 11 (RNA/RNP	3.3 3.3	744 180	227 54	2.5
	113808 W44735 Hs.9286	Homo sapiens cDNA: FLJ21278 fis, clone C	5.1	51	5	2.1 4.5
	113847 NM_005032Hs.4114	plastin 3 (T isoform)	3.2	238	75	2.1
	113849 AA457211 Hs.8858	bromodomain adjacent to zinc finger doma	4.3	43	8	3.6
60	113867 AW002834 Hs.24095	ESTs	6.1	110	18	10.2
60	113886 W76027 Hs.23920	hypothetical protein FLJ11105	4	48	12	4
	113923 AW953484 Hs.3849	hypothetical protein FLJ22041 similar to	3.7	239	65	3.6
	113936 W17056 Hs.83623	nuclear receptor subfamily 1, group 1, m	4.3	819	191	1.2
	113950 AI267652 Hs.30504 114030 AI825386 Hs.164478	Homo sapiens mRNA; cDNA DKFZp434E082 (fr		123	12	7
65	114051 AB026436 Hs.177534	hypothetical protein FLJ21939 similar to dual specificity phosphatase 10	4.4 4.5	44 45	6 4	2.3
	114057 AF116653 Hs.34192	Homo sapiens PRO0823 mRNA, complete cds	3.5	35	6	2.6 3.2
	114082 AK001612 Hs.26962	Homo sapiens cDNA FLJ10750 fis, clone NT	3.1	31	5	1.5
						-

	114124	W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	24.2	242	10	5.6
	114138	AW384793	Hs.15740	Homo sapiens mRNA; cDNA DKFZp434E033 (fr		67	1	6.3
	114162	AF155661	Hs.22265	pyruvate dehydrogenase phosphatase	3.8	73	19	1.8
_			Hs.150926	fucose-1-phosphate guanylyltransferase	4.4	104	24	5.1
5		AL049466		ESTs	5.7	57	1	4.9
			Hs.267445	Homo sapiens mRNA; cDNA DKFZp434B231 (fr		33	1	2.4
		H15261	Hs.21948	ESTs	4.2	46	11	1.4
		AF100143		fibroblast growth factor 13	4.5	45	2	3
10		AF183810		trichorhinophalangeal syndrome I	4.4	44	1	3
10		AW970128		anterior gradient 2 (Xenepus laevis) hom	4.7	770	166	5.8
		Al521936 Al859865	Hs.107149	novel protein similar to archaeal, yeast	5.2	52	3	2.3
			Hs.154443	minichromosome maintenance deficient (S.	4.6	196	43	10
		AF212848 AV656017		ets homologous factor	13.7	137	1	8.9
15		AA159181		CGI-76 protein	3.3	168	51	7.3
13		Al648602		serologically defined colon cancer antig	7.4	137	19	1.8
•		AL157545		ESTS	4.7	57	12	4.7
		BE165762		bromodomain and PHD finger containing, 3	9.1	91	1	7.6
		BE092696		hypothetical protein from BCRA2 region ESTs	10.1 6.4	111 67	11 11	10.2 5
20		AI733881		BMP-R1B	35.9	359	10	29.7
20		AW162998		KIAA1376 protein	9.4	94	8	7.3
		AA251089	113.21004	gb:zs04f05.s1 NCI_CGAP_GCB1 Homo sapiens		115	1	6.9
		AA329340	Hs.4867	mannosyl (alpha-1,3-)-glycoprotein beta-	4.2	42	9	1.1
		AW265668		hypothetical protein FLJ12428	5.1	51	ĭ	4.2
25		AI751438		Homo sapiens mRNA full length insert cDN	4.5	290	65	3.7
		NM_01415		HSPC067 protein	4.8	48	1	4.4
		AI623693	Hs.191533	ESTs	3.2	49	16	4.2
	115188	AK000219	Hs.88367	hypothetical protein FLJ20212	3.3	33	1	3
	115206	AW183695	Hs.186572	ESTs	5.8	58	1	5
30	115221	AW365434	Hs.79741	hypothetical protein FLJ10116	5.5	343	62	2.5
		AI422867		ESTs	11.2	112	1	10.3
	115291	BE545072	Hs.122579	hypothetical protein FLJ10461	4.5	96	21	7.8
		AK001468		anillin (Drosophila Scraps homolog), act	5.9	59	1	4.2
2.5		NM_01231		leucine zipper, down-regulated in cancer	9.8	98	1	8.8
35		AA081395		Homo sapiens cDNA FLJ10366 fls, clone NT	4.6	46	2	1.8
		AI088691	Hs.208414	Homo sapiens mRNA; cDNA DKFZp564D0472 (f		44	7	1.1
		N36110	Hs.305971	solute carrier family 2 (facilitated glu	3.2	372	115	2.1
		AW992356		Homo sapiens pyruvate dehydrogenase kina	10.2	506	50	2.8
40		W87707	Hs.82065	Interleukin 6 signal transducer (gp130,	5.2	405	78	10.1
70		AW992405 AW899053		Homo sapiens, clone IMAGE:3507281, mRNA,	7.6	144	19	13.9
		AW582256		F-box only protein 8	3.1	58	19	2.5 28.5
		AW338063		anterior gradient 2 (Xenepus laevis) hom	5.7	368	65 8	2.2
		R50956	Hs.159993	zinc-finger protein ZBRK1 gycosyltransferase	3.9 4.2	39 79	19	1.9
45		BE300266		transducin-like enhancer of split 1, hom	5.8	58	1	4.4
13		AI373062		hypothetical protein MGC5370	6.2	62	1	5.4
		AA291377		ESTs	3.2	40	13	0.7
		AI745379			8.4	101	12	8.7
		AW673312			3.6	36	1	2
50		Al198719	Hs.176376	ESTs	5.1	51	i	2
		AL133916		hypothetical protein FLJ20093	3.4	34	8	ī
	116127	AF126743	Hs.279884		3.5	35	8	3.3
	116129	AF189011	Hs.49163	putative ribonuclease III	4.5	45	9	3.4
	116204	AW861622	Hs.108646	Homo sapiens cDNA FLJ14934 fis, clone PL	5.2	52	4	3.9
55		AW976438		RBP1-like protein	3.8	38	7	2.1
	116238	AV660717	Hs.47144	DKFZP586N0819 protein	5.1	198	39	17.9
		N76712	Hs.44829	ESTs, Weakly similar to I38022 hypotheti	13.3	133	8	3.2
			Hs.88201		3.3	106	33	9.8
<b>CO</b>		Al955411	Hs.94109		4.8	179	38	2.8
60		AL133033			3.2	173	55	3
		AL133623			3.7	37	1	1.8
	116365		Hs.46765		3.9	39	10	0.6
		AA448588			5.6	106	19	9
65			Hs.279923	putative nucleotide binding protein, est	3.6	256	72	3.7
65		A1654450	Hs.47274	Homo sapiens mRNA; cDNA DKFZp564B176 (fr		119	39	2
					5.5	315	58	3.1
	110470	AI272141	Hs.83484	SRY (sex determining region Y)-box 4	3.4	496	144	1.6

	116507 Al418366 Hs.68501	ESTs	3.1	24	4	10
	116579 AW888411 Hs.81915	leukemla-associated phosphoprotein p18 (	3.3	31	4	1.9
	116625 F01601 Hs.241567	RNA binding motif, single stranded Inter	3.6	931 36	279	5.6
	116674 AI768015 Hs.92127	ESTs	3.6 4.5	96	1 22	1.9
5	116680 AW902848 Hs.273829	ESTs	4.2			6.9
	116710 F10577 Hs.306088	v-crk avian sarcoma virus CT10 oncogene	7.1	42	1	2.7
	116724 AA741307 Hs.65641	hypothetical protein FLJ20073	4.3	71	9	6.9
	116786 H25836 Hs.301527	ESTs, Moderately similar to unknown [H.s	22.8	190	44	5.4
	116787 AW362955 Hs.15641	Homo saplens cDNA FLJ14415 fis, clone HE	4.9	228	9	12.
10	116790 AW161357 Hs.101174	microtubule-associated protein tau		108	22	9
	116844 H64938 Hs.337434	ESTs, Weakly similar to A46010 X-linked	4.6	163	35	7.3
	117027 AW085208 Hs.130093	ESTs	6.9 4.8	69	10	2.4
	117067 H91164 Hs.335797	ESTs		48	1	2.5
	117129 H95785 Hs.167652	ESTs, Highty similar to 1819485A CENP-E	3.3 3.1	33	1	2.3
15	117147 AW901347 Hs.38592	hypothetical protein FLJ23342	4.8	38	13	1.7
	117170 N25929 Hs.42500	ADP-ribosylation factor-like 5	3.1	48 295	1	0.9
	117209 W03011 Hs.306881	MSTP043 protein	3.6	41	96 12	27.9
	117280 M18217 Hs.172129	Homo sapiens cDNA: FLJ21409 fis, clone C	3.9	322	83	2.8 4.4
	117367 Al041793 Hs.42502	ESTs	3.5	72	21	
20	117412 N32536 Hs.42645	solute carrier family 16 (monocarboxylic	17.4	174		1.3
	117475 N30205 Hs.93740	ESTs, Weakly similar to 138022 hypotheti	3.2	35	9 11	6.9
	117634 AW341639 Hs.13323	hypothetical protein FLJ22059	5	50	1	0.7
	117667 U59305 Hs.44708	Ser-Thr protein kinase related to the my	4.5	211		4.7
	117852 AW877787 Hs.136102	KIAA0853 protein	4.6	46	, 47	5
25	117873 N49967 Hs.46624	HSPC043 protein	3.1	31	1	3.8
	117924 Al521436 Hs.38891	ESTs	4.9		1	2.7
	118138 AA374756 Hs.93560	Homo sapiens mRNA for KiAA1771 protein,	5	49	1	4.4
	118449 Al813865 Hs.164478	hypothetical protein FLJ21939 similar to	3.6	50	2	3.1
	118467 AF091434 Hs.43080	platelet derived growth factor C	3.2	89	25 117	0.9
30	118472 AL157545 Hs.42179	bromodomain and PHD finger containing, 3	3.2 14.5	378		2.8
	118475 N66845	gb:za46c11.s1 Soares fetal liver spleen	3.1	145 199	1	2.4
	118509 N22617 Hs.43228	Homo saplens cDNA FLJ11835 fis, clone HE	6		64	1
	118528 Al949952 Hs.49397	ESTs	3.3	60 81	5 25	3.7
	118828 N79496 Hs.50824	EST, Moderately similar to 154374 gene N	3.4	740		1.5
35	118836 AW134482 Hs.173001	hypothetical prolein FLJ13964	4.3	162	217 38	2.8
	118854 T58283 Hs.10450	Homo sapiens cDNA: FLJ22063 fls, clone H	3.4	118	35	12.1
	118873 Al824009 Hs.44577	ESTs	3.5	35	1	2.3
	118888 AJ191811 Hs.54629	ESTs	8.4	84	10	2.9 0.8
	118901 AW292577 Hs.94445	ESTs	7.3	73	3	5.4
40	118981 N29309 Hs.39288	ESTs	5	50	5	4.7
	118991 NM_016657Hs.250696	KDEL (Lys-Asp-Glu-Leu) endoplasmic retic	3.7	37	6	
	119023 N98488	gb:zb82h01.s1 Soares_senescent_fibroblas	3.3	36	11	0.5
	119088 R39261 Hs.90790	Homo sapiens cDNA: FLJ22930 fis, clone K	3.3	167	51	0.6 2.6
	119126 R45175 Hs.117183	ESTs	5.3	53		
45	119128 H09334 Hs.92482	ESTs	3.7	37	6 4	2.3
	119271 Al061118 Hs.65328	Fanconi anemia, complementation group F	8.2	82	1	3 6.4
	119298 NM_001241Hs.155478	cyclin T2	4	40	4	1.2
	119307 BE048061 Hs.37054	ephrin-A3	3.3	571	171	2
	119367 T78324 Hs.250895	ribosomal protein L34	3.4	34	3.	2.4
50	119427 AW474547 Hs.53565	Homo sapiens PIG-M mRNA for mannosyltran	4.6	60	13	4.8
	119580 AL079310 Hs.92260	high-mobility group protein 2-like 1	8.1	94	12	6.5
	119586 AF088033 Hs.159225	ESTs	3.3	33	8	0.9
	119638 NM 016122Hs.56148	NY-REN-58 antigen	3.3	33	10	0.5
	119676 AA243837 Hs.57787	ESTs	5.4	54	1	4.1
55	119717 AA918317 Hs.57987	B-cell CLL/lymphoma 11B (zinc finger pro	4.6	46	7	
	119771 AI905687 Hs.2533	EST	3.5	2073	595	0.8 2.1
	119780 NM_016625Hs.191381	hypothetical protein	4.4	44	1	3.1
	119786 AL133396 Hs.121281	prion protein 2 (dublet)	3.4	34	1	
	119805 AJ223810 Hs.43213	ESTs, Weakly similar to IEFS_HUMAN TRANS	3.6	36	i	2.5
60	119859 AW245741 Hs.58461	ESTs, Weakly similar to A35659 krueppel-	5.2	52	6	2.9
	119899 AI057404 Hs.58698	ESTs	3.7	37		1.8
	119940 AL050097 Hs.272531	DKFZP586B0319 protein	6.9	162	4 24	1.9
	119943 BE565849 Hs.14158	copine III	3.7	590	24 159	2.6
	120132 W57554 Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	6.9	319	47	3.8 2.1
65	120150 BE005771 Hs.153746	hypothetical protein FLJ22490	5.3	53	5	0.9
	120215 AF109219 Hs.108787	phosphatidylinositol glycan, dass N	3.2	106	34	
	120260 AK000061 Hs.101590	hypothetical protein	3.4	34	1	3.3 1.7
		St	<b>.</b>	•	1	1.7

	120296	AW995911	Hs.299883	hypothetical protein FLJ23399	4.2	124	30	1.8
	120352	R06859	Hs.193172	ESTs, Weakly similar to 138022 hypotheti	7.5	112	15	2.5
	120378	AA223249	Hs.285728	abl-interactor 12 (SH3-containing protel	3.3	33	10	2.8
_	120418	AW966893	Hs.26613	Homo sapiens mRNA; cDNA DKFZp586F1323 (f	4.8	48	1	0.5
5	120473	AA251973	Hs.269988	ESTs	3.4	34	4	0.1
	120493	AW968080	Hs.152939	Homo saplens done 24630 mRNA sequence	3.9	161	42	2
	120524	AA261852	Hs.192905	ESTs	6.8	68	1	0.2
	120554	AA284447	Hs.271887	ESTs	3.2	32	5	0.6
	120562	BE244580	Hs.302267	hypothetical protein FLJ10330	8.5	127	15	1.6
10		AB037744		KIAA1323 protein	3.7	37	1	0.5
		H39599	Hs.294008	ESTs ·	3.6	36	8	0.2
		AA703226		Homo sapiens mRNA; cDNA DKFZp586B211 (fr		101	18	1.6
		AA687322		leucine zipper protein FKSG14	5.4	54	10	2.5
		A1952639	Hs.98267	ESTs	3.2	32	8	3
15		AW449855		Homo sapiens cONA FLJ12727 fis, clone NT	5.3	58	11	3.3
		Y19062	Hs.96870	staufen (Drosophila, RNA-binding protein	3.3	33	3	0.2
			Hs.238040	EST, Weakly similar to B34087 hypothetic	3.8	38	7	0.2
		AL135556		ESTs .	3.5	37	11	0.1
		AA481003		ESTs	3.1	31		
20		AA398155		ESTs			1	0.4
20		A1972375			7.9	79	1	2.7
			Hs.29626	hypothetical brain protein my038	5.1	51	1	2.4
		AL042981 AL121523		KIAA1201 protein	3.7	37	10	1
				ESTS	7	70	1	0.9
25		AA970946		ESTs	3.9	39	1	0.2
23		AA406293		ESTs	3.4	34	1	8.0
		AF044197		B-cell attracting chemokine 1 (CXCL13;	3.5	35	1	2.6
		AK000282		hypothetical protein FLJ20275	10.3	103	1	9.3
		Al002968	Hs.235402	ESTs, Weakly similar to T26525 hypotheti	3.5	143	41	2.6
20		AA412488		TATA box binding protein (TBP)-associate	4.6	46	3	0.8
30		AA412494	Hs.98152	EST	4.2	77	19	1,4
		AA416568		gb:zu05c10.s1 Soares_testis_NHT Homo sap	3.2	32	1	8.0
		Al338247	Hs.98314	Homo sapiens mRNA; cDNA DKFZp586L0120 (f		34	10	0.7
			Hs.104800		2.9	214	74	3.7
20		AA449644		Homo sapiens cDNA FLJ14201 fis, done NT	3.9	39	1	0.2
35		AA425887		hypothetical protein FLJ14303	4.4	48	11	0.9
		AV650929			3.6	.150	42	3.2
		Al249368	Hs.98558	ESTs; protease inhibitor 15 (PI15)	2.7	864	321	0.6
		AW117207		ESTs	3.5	35	3	2.3
40		AI810721	Hs.95424	ESTs	4.9	49	7	3.7
40		AW794215		KIAA1085 protein	3.2	88	28	1.2
		AF169797		adaptor protein containing pH domain, PT	12.6	126	7	7.5
		AA436475	Hs.112227	membrane-associated nucleic acid binding	4.1	43	11	1.6
	122273	AI298368	Hs.150926	fucose-1-phosphate guanylyltransferase	3.1	31	1	1
	122383	AA446189	Hs.99051	ESTs	3.3	53	16	4
45	122507	BE567620	Hs.99210	ESTs	3.2	291	91	4
	122524	AA449453	Hs.192915	ESTs, Weakly similar to ALU1_HUMAN ALU S	3.1	31	6	8.0
	122636	AW651706	Hs.99519	hypothetical protein FLJ14007	3.5	35	1	3
	122637	AA454149	Hs.99357	EST	3.2	32	10	3.1
	122798	AW366286	Hs.145696	splicing factor (CC1,3)	3.2	36	11	2.5
50	122861	AA335721	Hs.119394	ESTs	5.6	108	20	1.8
	122873	AA749382	Hs.118797	ubiquitin-conjugating enzyme E2D 3 (homo	3.6	36	1	3.4
	122946	Al718702	Hs.308026	major histocompatibility complex, class	3.7	162	44	12.4
	122963	AA478446	Hs.69559	KIAA1096 protein	7.2	72	1	5.7
	122974	AA447871	Hs.194215	ESTs, Weakly similar to I38022 hypotheti	4.7	59	13	4.7
55	123016	AW338067	Hs.323231	Homo sapiens cDNA FLJ11946 fis, clone HE	3.3	207	63	3.5
	123090	AL135185	Hs.48778	niban protein	3.8	207	55	5.5
	123137	Al073913	Hs.100686	ESTs, Weakly similar to JE0350 Anterior	9.9	351	36	13.9
	123255	AA830335	Hs.105273	ESTs	4.1	72	18	1.5
	123284	AA488988	Hs.293796	ESTs	3.7	41	11	1.6
60	123442	AA299652	Hs.111496	Homo saplens cDNA FLJ11643 fis, clone HE	6.7	67	2	2.1
		AL049325		Homo sapiens mRNA; cDNA DKFZp564D036 (fr		34	1	2.6
		BE439553			9.7	102	11	6
			Hs.112110	mitochondrial ribosomal protein L42	4.2	42	7	2.9
		AW975051			3.9	39	1	3.2
65			Hs.173933		4.3	43	i	3.5
		AL035414		hypothetical protein	5.8	58	1	4.9
		AA608588		gb:ae54e06.s1 Stratagene lung carcinoma	3.1	927	295	2.1

	123527 AF150208 Hs.108327	damage-specific DNA binding protein 1 (1	5	121	25	5.9
	123570 AA608955 Hs.109653	ESTs	6.8	68	10	6.1
	123619 AA602964	gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens		85	1	4.3
5	123673 BE550112 Hs.158549	ESTs, Weakly similar to T2D3_HUMAN TRANS	S 3.9	39	5	3.7
3	123709 AA706910 Hs.112742	ESTs	3.9	60	16	4.8
	123926 AA425769 Hs.227933	Alg5, S. cerevisiae, homolog of	3.4	80	24	3.8
	123960 AW082862 Hs.287733	hypothetical protein FLJ23189	4.5	45	2	3.6
	124006 Al147155 Hs.270016 124059 BE387335 Hs.283713	ESTs	5.8	321	55	17
10		ESTs, Weakly similar to S64054 hypotheti	10.4	880	85	5.3
•	124287 H88296 Hs.5123 124292 H11341 Hs.13366	inorganic pyrophosphatase	3.1	41	14	2.7
	124308 AA249027 Hs.241507	Homo saplens cDNA: FLJ23567 fis, clone L ribosomal protein S6	3.2	32	1	1.5
	124315 NM_005402Hs.288757	v-ral simian leukemia viral oncogene hom	10.5	105	1	9.9
	124461 AF283776 Hs.80285	Homo saplens mRNA; cDNA DKFZp586C1723	12.8	141	11	12.2
15	124483 Al821780 Hs.179864	ESTs	3.3	31 33	1	1.8
	124677 R01073	gb:ye84c03.s1 Soares fetal liver spleen	4.2	42	7	1.7 3
	124777 R41933 Hs.140237	ESTs, Weakly similar to ALU1_HUMAN ALU S	3.4	210	63	3.3
	124940 AF068846 Hs.103804	heterogeneous nuclear ribonucleoprotein	6.5	162	25	14.7
20	125079 T90298 Hs.271396	ESTs	3.1	31	6	2.4
20	125091 T91518	gb:ye20f05.s1 Stratagene lung (937210) H	3.4	985	286	2.8
	125103 AA570056 Hs.122730	ESTs, Moderately similar to KIAA1215 pro	3.6	224	63	4
	125144 AB037742 Hs.24336	KIAA1321 protein	6.3	63	6	5
	125150 W38240 125156 W93048 Hs.250723	Empirically selected from AFFX single pr	3.6	38	11	2.6
25	125226 AA782536 Hs.122647	hypothetical protein MGC2747	3.1	31	1	2.8
	125279 AW401809 Hs.4779	N-myristoyttransferase 2 KIAA1150 protein	3.2	37	12	3.6
	125299 T32982 Hs.102720	ESTs	13.1	131	1	5.1
	125303 AA173319 Hs.288193	hypothetical protein MGC12217	7.7 14.3	81	11	7.6
	125377 W72949 Hs.77495	UBX domain-containing 1	3.3	143 34	9 11	13.1 3.2
30	125390 AL038165 Hs.75187	translocase of outer mitochondrial membr	8.2	124	15	3.2 11.5
	125471 AA421691 Hs.152601	UDP-glucose ceramide glucosyltransferase	3.7	224	61	21
	125617 AA287921 Hs.164950	ESTs	6.7	67	1	6
	125621 T62641 Hs.278544	acetyl-Coenzyme A acetyltransferase 2 (a	5.5	55	10	4.2
35	125628 AA418069 Hs.241493	natural killer-tumor recognition sequenc	5.5	63	12	1
33	125660 AW292171 Hs.23978	scaffold attachment factor B	4.3	68	16	2.8
	125698 AF078847 Hs.191356 125745 Al858032 Hs.75722	general transcription factor IIH, polype	4.8	48	5	4.1
	125770 AA143045 Hs.81665	ribophorin (	6.8	223	33	2.8
	125827 NM_003403Hs.97496	v-kit Hardy-Zuckerman 4 feline sarcoma v YY1 transcription factor	8.3	87	11	0.4
40	125852 AW630088 Hs.76550	Homo sapiens mRNA; cDNA DKFZp564B1264 (	11.3	124	11	9.7
	126349 T30968 Hs.13531	hypothetical protein FLJ10971	4.9	306 68	4	26.5
	126384 AW090198 Hs.4779	KIAA1150 protein	6.4	74	14 12	1.4
	126590 W78968 Hs.181307	H3 histone, family 3A	5	264	53	6.6 3.4
4.5	126645 AA316181 Hs.61635	six transmembrane epithelial antigen of	3.8	38	1	2.7
45	126663 AW518478 Hs.181297	ESTs	3.6	36	6	2.9
	126695 AA643322 Hs.172028	a disintegrin and metalloproteinase doma	3.1	31	1	2.5
	126764 AA036755 Hs.102178	syntaxin 16	4.4	76	18	1
	126801 AW663887 Hs.7337	hypothetical protein FLJ10936	3.8	38	1	3
50	126813 AW163483 Hs.48320 126838 AL043489 Hs.279609	double ring-finger protein, Dorfin	6.7	155	23	1.4
20	126855 AA129640 Hs.128065	mitochondrial carrier homolog 2 ESTs	8.8	110	13	10.5
	126971 T26989 Hs.283664		3.6	36	10	1.9
	127167 AA625690 Hs.190272	aspartate beta-hydroxylase ESTs	5.5	79	15	4.4
	127251 AA936428 Hs.128638	ESTs	3.1	33	11	2.3
55	127349 AA412108 Hs.269350	ESTs	3.5 4.8	35 106	1 22	3.1
	127439 D60237 Hs.14368	SH3 domain binding glutamic acid-rich pr	7.5	75	1	1
	127537 Al926047 Hs.162859	ESTs	3.8	38	7	6.5 3.4
	127542 AA703684 Hs.245474	ESTs, Moderately similar to ALU5_HUMAN A	3.3	33	ġ	0.9
60	127677 AF175265 Hs.264190	vacuolar protein sorting 35 (yeast homol	4.3	152	35	12.5
60	127774 AA313639 Hs.119488	cystein-rich hydrophobic domain 2	5.4	73	14	6.8
	127999 AW978827 Hs.69851	nucleolar protein family A, member 1 (H/	5.2	81	16	1.1
	128218 AA186733 Hs.292154	stromal cell protein	3.9	220	57	2.5
	128305 Al954968 Hs.279009	matrix Gla protein	9.4	94	3	5.3
65	128470 AL049974 Hs.100261	Homo saplens mRNA; cDNA DKFZp564B222 (fr		46	8	3.9
05	128482 Al694143 Hs.296251 128501 AL133572 Hs.199009	programmed cell death 4	7.2	72	1	5.8
	128517 AW994403 Hs.100861		3.8	38	1	0.9
	120011 /11001100 110.100001	in posicular protein PLJ 14000	5.6	73	13	6.1

	128530 Al932995 Hs.18347	5 Homo saplens clone 25061 mRNA sequence	4.2	104	25	7.8
	128579 N25956 Hs.10181			172	55	3.1
			3.1			
	128595 U31875 Hs.27249		3.3	105	32	3
_	128610 N48373 Hs.10247		7.3	106	15	5
5	128653 D87432 Hs.10315	solute carrier family 7 (cationic amino	3.1	31	1	2.2
	128742 AA307211 Hs.25153	proteasome (prosome, macropain) subunit,	3.6	130	36	3.5
	128773 NM_004131Hs.1051	granzyme B (granzyme 2, cytotoxic T-lymp	3.9	43	11	1.8
	128790 AF026692 Hs.10570		17.4	409	24	7.8
	128793 AB011125 Hs.10574		3.1	34	11	2.7
10						
10	128794 NM_014720Hs.10575		3.6	36	5	1.5
	128835 AK001731 Hs.10639	<ol> <li>Homo sapiens mRNA; cDNA DKFZp586H0924</li> </ol>	l (f 3.3	288	87	7.9
	128906 R57988 Hs.10708	epithelial protein lost in neoplasm beta	11.3	113	8	2.5
	128925 R67419 Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	7.1	392	56	3.6
	128949 AA009647 Hs.8850	a disintegrin and metalloproteinase doma	4.6	132	29	9.7
15	129017 AA115333 Hs.10796		8.2	82	1	7.4
13						
	129075 BE250162 Hs.83765		5	50	1	3.3
	129095 L12350 Hs.10862		3.2	814	257	2.4
	129151 N23018 Hs.17139	1 C-terminal binding protein 2	4.4	44	1	3.8
	129168 Al132988 Hs.10905	2 chromosome 14 open reading frame 2	14.2	142	6	9.4
20	129229 AF013758 Hs.10964	3 polyadenylate blinding protein-interactin	7.1	71	1	6.2
	129243 BE169531 Hs.10972		5	64	13	6.3
	129259 AF220050 Hs.18138		5.2	75	15	6.4
	129278 NM_015344Hs.11000		3.7	39	11	3.2
0.5	129337 NM_014918Hs.11048		9.5	95	1	8.5
25	129351 AL049538 Hs.62349	ras association (RalGDS/AF-6) domain con	7.6	92	12	1.4
	129366 BE220806 Hs.18469	7 Homo sapiens done 23785 mRNA sequence	7.1	150	21	14.5
	129393 BE219987 Hs.16698	2 phosphatidylinositol glycan, class F	3.9	54	14	5.1
	129457 X61959 Hs.20777		3.6	36	1	2.7
	129486 NM_005754Hs.22068	, , , ,	4	40	4	3.2
20						
30	129586 AW964541 Hs.11500		4.6	199	44	2.3
	129598 N30436 Hs.11556	Homo sapiens cDNA FLJ12566 fls, clone NT	4.2	42	1	3.8
	129691 M26939 Hs.11957	1 collagen, type III, alpha 1 (Ehlers-Dani	6.4	1111	175	5
	129698 BE242144 Hs.12013	ATP-binding cassette, sub-family E (OABP	4.8	48	8	3.8
	129721 NM 001415Hs.21153	9 eukaryotic translation Initiation factor	5.8	171	30	2.9
35	129740 BE165866 Hs.83623		4.5	45	1	2.4
55	129755 R42216 Hs.12342		5.3	53	9	3.6
					2	
	129801 R39246 Hs.23966		3.1	31		2.5
	129821 AB028945 Hs.12696		11.4	114	1	10
40	129869 Al222069 Hs.13015	hypothetical protein similar to mouse Dn	4.7	556	119	4.5
40	129965 T71333 Hs.13854	ESTs · · · ·	3.1	31	3	3
	129977 NM_000399Hs.1395	early growth response 2 (Krox-20 (Drosop	3.2	32	1	0.2
	130036 BE061916 Hs.12584		6.7	67	1	5.7
	130057 AF027153 Hs.32478		1	1	i	1
			14.6	219	15	7.6
15	130095 AK001635 Hs.14838					
45	130115 T47294 Hs.14992		3.1	1336	434	1.4
	130170 AW977534 Hs.15146	9 calcium/calmodulin-dependent serine prot	5.3	53	9	3.2
	130173 U38847 Hs.15151	8 TAR (HIV) RNA-binding protein 1	4.2	46	11	1.1
	130343 AB040914 Hs.27862	8 KIAA1481 protein	13.2	331	25	12.4
	130356 AF127577 Hs.15501		3.3	354	108	4
50	130367 AL135301 Hs.8768	hypothetical protein FLJ10849	8.1	81	9	5.5
50				722	1	
	130385 AW067800 Hs.15522		72.2			1.9
	130407 BE385099 Hs.33472		6.5	65	4	5.3
	130417 AW163518 Hs.15548	5 huntingtin interacting protein 2	3.5	79	23	2.5
	130441 U63630 Hs.15563	7 protein kinase, DNA-activated, catalytic	6.1	61	1	5.7
55	130455 D90041 Hs.15595	6 N-acetyltransferase 1 (arylamine N-acety	10.8	706	66	9.2
	130466 W19744 Hs.18005	9 Homo sapiens cDNA FLJ20653 fis, clone KA	3.9	39	1	1.9
	130526 AW876523 Hs.15929	hypothetical protein FLJ12910	3.9	39	i	2.6
	130567 AA383092 Hs.1608	replication protein A3 (14kD)	4.4	44	1	4.1
<b>C</b> 0	130604 AA383256 Hs.1657	estrogen receptor 1	32.2	322	1	4.7
60	130614 Al354355 Hs.16697		5.2	251	48	21
	130617 M90516 Hs.1674	glutamine-fructose-6-phosphate transamin	10	100	1	7.6
	130619 Al963376 Hs.12532	chromosome 1 open reading frame 21	3.9	39	1	3.4
	.130625 AF176012 Hs.26072		10.5	105	1	9
	130677 AL161961 Hs.17767		6.8	129	19	12.1
65			4.1		1	
UJ				41		3.6
	130693 R68537 Hs.17962		9.2	234	26	16.8
	130712 AJ271881 Hs.27976	2 bromodomain-containing 7	17.5	175	2	12.8

	130723 BE247676 Hs.18442	E-1 enzyme	8.1	81	3	2.8
	130751 AF052105 Hs.18879	chromosome 12 open reading frame	4.9	49	1	4.3
	130780 AA197226 Hs.19347 130863 Y10805 Hs.20521	hypothetical protein MGC11321	3.6	100	28	6.6
5	130863 Y10805 Hs.20521 130871 AF080158 Hs.226573	HMT1 (hnRNP methyltransferase, S. cerevi	3.4	525	154	5.3
•	130888 AL044315 Hs.173094	inhibitor of kappa light polypeptide gen Homo saplens mRNA for KIAA1750 protein,	10.5	121	12	1.6
	130974 NM_003528Hs.2178	H2B histone family, member Q	6 7.1	202 100	34 14	3.7 7.5
	130979 NM_012446Hs.169833	single-stranded-DNA-binding protein	3.2	87	27	1.7
	130987 BE613269 Hs.21893	hypothetical protein DKFZp761N0624	3.5	124	35	6.5
10	130993 T97401 Hs.21929	ESTs -	4.5	45	1	2.5
	131076 AA749230 Hs.26433	dolichyl-phosphate (UDP-N-acetylglucosam	3.2	210	66	3.8
	131085 BE207357 Hs.3454	KIAA1821 protein	3.8	42	11	0.6
	131126 NM_016156Hs.181326	KIAA1073 protein	6.7	67	6	1.9
1.5	131129 BE541042 Hs.23240	Homo sapiens cDNA: FLJ21848 fis, clone H	5.8	115	20	2.5
15	131148 AW953575 Hs.303125	p53-induced protein PIGPC1	3.8	585	153	3.7
	131164 AW013807 Hs.182265	keratin 19	5.2	1320	256	3.2
	131176 AA465113 Hs.23853	ESTs, Weakly similar to A34615 profilagg	3.8	38	1	3.3
	131200 BE540516 Hs.293732 131216 Al815486 Hs.243901	hypothetical protein MGC3195	4.8	48	1	4.1
20	131245 AL080080 Hs.24766	Homo sapiens cDNA FLJ20738 fis, clone HE	6.1	343	56	16.4
20	131248 Al038989 Hs.332633	thloredoxin domain-containing Bardet-Bledl syndrome 2	8 4	100 -95	13 24	2.9
	131273 AW206008 Hs.283378	Homo sapiens cDNA: FLJ21778 fis, clone H	4.6	239	53	1.1 3.5
	131319 NM_003155Hs.25590	stanniocalcin 1	3.5	402	114	2.1
	131367 Al750575 Hs.173933	nuclear factor I/A	3.3	775	233	2.4
25	131375 AW293165 Hs.143134	ESTs	3.8	38	1	3
	131379 AK001123 Hs.26176	hypothetical protein FLJ10261	3.9	116	30	0.5
	131388 NM_014810Hs.92200	KIAA0480 gene product	7.6	76	1	5
	131475 AA992841 Hs.27263	KIAA1458 protein	5.1	113	22	6.1
20	131492 Al452601 Hs.288869	nuclear receptor subfamily 2, group F, m	8.4	169	20	4.6
30	131501 AV661958 Hs.8207	GK001 protein	3.1	197	63	18.7
	131535 N22120 Hs.75277	hypothetical protein FLJ13910	5.9	59	1	4.4
	131544 AL355715 Hs.28555 131546 AA093668 Hs.28578	programmed cell death 9 (PDCD9)	5.1	51	1	3.9
	131562 NM_003512Hs.28777	muscleblind (Drosophila)-like	3.8	79 250	21	6.9
35	131564 T93500 Hs.28792	H2A histone family, member L Homo sapiens cDNA FLJ11041 fis, clone PL	4 4.7	350 381	88	3
55	131604 AA306477 Hs.29379	hypothetical protein FLJ 10687	4.7	301 46	81 7	6.4 3.8
	131684 NM_002104Hs.3066	granzyme K (serine protease, granzyme 3;	3.2	82	26	6.6
	131687 BE297635 Hs.3069	heat shock 70kD protein 9B (mortalin-2)	6.7	93	14	8.4
	131689 AB012124 Hs.30696	transcription factor-like 5 (basic helix	3.8	51	14	1.7
40	131693 AW963776 Hs.110796	SAR1 protein	7.2	72	4	5.7
	131739 AF017986 Hs.31386	secreted frizzled-related protein 2	2.1	1561	757	1.7
	131742 AA961420 Hs.31433	ESTs	11.7	117	1	10.1
	131775 AB014548 Hs.31921	KIAA0648 protein	4.8	48	1	4.6
45	131787 D87077 Hs.196275	KIAA0240 protein	3.2	207	64	5.5
43	131798 X86098 Hs.301449	adenovirus 5 E1A binding protein	3.4	115	34	9.1
	131836 W00712 Hs.32990 131853 Al681917 Hs.3321	DKFZP566F084 protein	5.8	91	16	1.4
	131877 J04088 Hs.156346	ESTs, Highly similar to IRX1_HUMAN IROQU	4.9	632	129	1.7
	131881 AW361018 Hs.3383	topoisomerase (DNA) II alpha (170kD) upstream regulatory element binding prot	6.8 4	68	1	5.6
50	131885 BE502341 Hs.3402	ESTs	5.7	140 57	35	1.8
•	131904 AF078866 Hs.284296	Homo sapiens cDNA: FLJ22993 fis, clone K	5.5	90	1 17	4.5 2.9
	131919 T15803 Hs.272458	protein phosphatase 3 (formerly 2B), cat	5.6	95	17	9.1
	131941 BE252983 Hs.35086	ublquitin specific protease 1	7.4	103	14	6.5
	131945 NM_002916Hs.35120	replication factor C (activator 1) 4 (37	3.7	37	1	3.4
55	131949 AK000010 Hs.258798	hypothetical protein FLJ20003	3.5	35	i	2.5
	131965 W79283 Hs.35962	ESTs	5.5	168	31	4.4
	131977 U90441 Hs.3622	procollagen-proline, 2-oxoglutarate 4-di	3.7	37	9	2.8
	131985 AA503020 Hs.36563	hypothetical protein FLJ22418	40.2	402	1	4
60	131993 Al878910 Hs.3688	cisplatin resistance-associated overexpr	7.3	73	1	1.2
oo	132064 AA121098 Hs.3838	serum-Inducible kinase	22,6	226	10	0.9
	132094 NM_016045Hs.3945 132109 AW190902 Hs.40098	CGI-107 protein	3.1	227	·73	16.8
	132109 AVV190902 HS.40098 132116 AW960474 Hs.40289	cysteine knot superfamily 1, BMP antagon ESTs	3.5	73	21	6.3
	132143 D52059 Hs.7972	KIAA0871 protein	3.6 4.9	141	39	12.6
65	132160 W26406 Hs.295923	seven in absentia (Drosophila) homolog 1	4.9 4.4	49 53	1	4.1
~-	132164 AI752235 Hs.41270	procollagen-lysine, 2-oxoglutarate 5-dio	5	225	12 45	2.1 9.1
	132180 NM_004460Hs.418	fibroblast activation protein, alpha	10.7	433	45 41	7.2
			- •		• •	

							4=	
		AI699482		ESTs	3.4	58	17	4
		AI078645	Hs.431	murine leukemia viral (bmi-1) oncogene h	4.2	42	1	2.2
		NM_01598		cytokine receptor-like molecule 9	3.4	34	2	3
5		U28831	Hs.44566	KIAA1641 protein	18.6 5.5	186 323	10	1.5 10.5
5		N37065	Hs.44856	hypothetical protein FLJ12116		979	59 298	2.2
		NM_00354		H4 histone family, member G	3.3 3.6	36	1	3.1
		AA312135 W32624	Hs.278626	HSPCO34 protein	5.9	186	32	3.7
		AL135094		Arg/AbHinteracting protein ArgBP2 hypothetical protein FLJ 14495	4.2	159	38	7.1
10		BE613126		B aggressive lymphoma gene	4.6	46	1	4.3
10		N87549	Hs.125287	zinc finger protein ZNF140-like protein	3.6	146	41	1.1
		AB020699		KIAA0892 protein	3.3	33	4	2.9
		AW169847		KIAA1634 protein	8.3	145	18	3.7
		AB023164		KIAA0947 protein	4.6	46	1	4.4
15		T78736	Hs.50758	SMC4 (structural maintenance of chromoso	9.3	93	i	8.4
~~		AA306105		SEC22, vesicle trafficking protein (S. c	4.9	49	i	4.4
		BE568452		protein regulator of cytokinesis 1	11.8	201	17	19.1
		Al929659		signal recognition particle 72kD	3.8	38	1	3
		AW803564		Homo sapiens cDNA: FLJ22528 fis, clone H	4.8	93	20	3.1
20		AW606927		hypothetical protein DKFZp586F1122 simil	6.1	61	2	5.9
		BE262677		hypothetical protein PRO1855	3.4	193	58	12.3
		AF037335		carbonic anhydrase XII	14.2	390	28	22.5
		AL050025		hypothetical protein FLJ20151	3.3	909	274	3.2
	132632	AU076916	Hs.5398	guanine monphosphate synthetase	5	50	1	4.1
25	132668	AB018319	Hs.5460	KIAA0776 protein	4.2	171	41	12.6
	132742	AA025480	Hs.292812	ESTs, Weakly similar to T33468 hypotheti	6.5	65	1	5.6
	132790	AW242243	Hs.168670	peroxisomal famesylated protein	3.7	37	1	2.2
	132811	U25435	Hs.57419	CCCTC-binding factor (zinc finger protei	7	115	17	5.4
	132852	AL120050	Hs.58220	Homo sapiens cDNA: FLJ23005 fis, clone L	3.3	61	19	5.1
30	132856	NM_00144	8Hs.58367	glypican 4	4.8	48	1	3.6
	132880	BE077155	Hs.177537	hypothetical protein DKFZp761B1514	12.6	126	8	9.9
		A1936442		hypothetical protein FLJ10808	11	187	17	10.4
		BE613337		geminin	3.3	106	33	2.6
25		AL047045		Homo sapiens clone 122482 unknown mRNA	3.5	110	32	2.1
35		AF234532		myosin X	4.1	62	15	4.9
		AA093322		RNA binding motif protein 3	22.1	221	9	17.8
		X77343	Hs.334334	transcription factor AP-2 alpha (activat	12.7	311	25	2.4
		AA112748		clone HQ0310 PRO0310p1	3	380	127	5.5
40		NM_00637		sema domain, immunoglobulin domain (lg),	7.3	271 427	37 93	2.3 10.4
40		AJ002744		UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	36	1	3.1
		U92649	Hs.64311	a disintegrin and metalloproteinase doma	3.6 5.2	117	23	5.1
		AK001628 AA218564		KIAA0483 protein vacuolar protein sorting 26 (yeast homol	3.1	359	118	2.5
		AI275243		hypothetical protein FLJ20671	5.1	58	12	5.7
45		AF231981		homolog of yeast long chain polyunsatura	3	816	275	3.9
73		W32474	Hs.301746	RAP2A, member of RAS oncogene family	3.1	234	76	8.6
		AK001489		ADP-ribosylation factor-like 1	8.1	81	1	4.6
		Z48633	Hs.283742	H.sapiens mRNA for retrotransposon	12.4	124	6	10.8
		BE297855		NRAS-related gene	3.3	33	1	2.9
50		AJ001388		zinc finger protein 238	7.9	234	30	18.9
-		Al499220		hypothetical protein FLJ10074	4.6	46	5	3.5
		AK001519		CGI-74 protein	5	110	22	9.7
		AF245505		DKFZP564I1922 protein	3.2	725	227	3.2
		AF017987		secreted frizzled-related protein 1	4.1	374	91	1.1
55		AB033061		KIAA1235 protein	4.3	43	1	3.9
	133435	Al929357	Hs.323966	Homo sapiens clone H63 unknown mRNA	5.5	186	34	16.5
		W01556	Hs.238797	ESTs, Moderately similar to 138022 hypot	3.5	35	7	2.1
	133493	AW998046	Hs.194369	arginine-glutamic acid dipeptide (RE) re	3.6	39	11	0.4
	133504	NM_00441	5Hs.74316	desmoplakin (DPI, DPII)	4.1	640	158	3
60		NM_00016	5Hs.74471	gap junction protein, alpha 1, 43kD (con	3.2	351	111	5.2
		W25797	Hs.177486	amyloid beta (A4) precursor protein (pro	3.2	226	71	2.8
		AU077050		translin	3.4	178	53	8.8
		D21262	Hs.75337	nucleolar and colled-body phosphprotein	4.7	47	1 '	4
		AW246428		ubiquitin-conjugating enzyme E2N (homolo	8.5	85	1	7.2
65		NM_00692		splicing factor, arginine/serine-rich 5	3.6	36	1	0.4
		Al352558		tyrosine 3-monooxygenase/tryptophan 5-mo	3.4	234	68	10.7
	133746	AW410035	HS./5862	MAD (mothers against decapentaplegic, Dr	9.3	93	1	7.8

	133765	M62194	Hs.75929	cadherin 11, type 2, OB-cadherin (osteob	3.2	560	174	2.6
		AA557660		decorin	5.4	144	27	13.3
			Hs.301064	arfaptin 1	4.7	47	ī	4.1
-		NM_00246		myxovirus (influenza) resistance 1, homo	3.3	380	114	4.9
5		AW630088		Homo sapiens mRNA; cDNA DKFZp564B1264 (	f 6.7	304	46	7.8
		AA147026		ESTs	6.2	600	97	4.1
		AU076964		calumenin	3.3	889	267	5
			Hs.232068	transcription factor 8 (represses interf	3.7	91	25	2.6
10		R48316	Hs.7822	Homo saplens mRNA; cDNA DKFZp564C1216	f 3.4	91	27	8.5
10		AA535244		RAB2, member RAS oncogene family	7.8	78	1	5.6
		NM_00502		serine (or cysteine) proteinase inhibito	5.9	59	1	3.3
		AF091622		KIAA0244 protein	5.8	58	1	4.9
		U51166	Hs.173824	thymine-DNA glycosylase	6.4	100	16	4.4
15		R51273	Hs.79029	ESTs	5.1	51	9	3.8
13		NM_00435		cyclin G2	5	50	1	3.2
		BE513171 U41060		mitochondrial ribosomal protein L3	4.8	246	51	3.9
		NM_01478	Hs.79136	LIV-1 protein, estrogen regulated	4.5	1472	330	2.1
		D28459	Hs.80612	KIAA0203 gene product	4.6	69	15	5.8
20		C05768	Hs.8078	ubiquitin-conjugating enzyme E2A (RAD6 h	7	97	14	7.5
20		X76040	Hs.278614	Homo sapiens clone FBD3 Cri-du-chat crit	3.4	34	5	2.6
		R45621	Hs.81057	protease, serine, 15 hypothetical protein MGC2718	3.6	36	1	2.8
		AI022650			6.7	67	9	5.7
		BE538082		erbb2-interacting protein ERBIN ESTs, Moderately similar to A46010 X-lin	4.5 5.2	137	31	12
25		AW903838		chondroitin sulfate proteoglycan 2 (vers	5.2 8.6	52 568	1 66	4.9
20		AW959281		ESTs	4.8		11	22.4
		AW291946		interleukin 6 signal transducer (gp130.	7.1	53 71	4	3.7 6.4
			2Hs.199067	v-erb-b2 avian erythroblastic leukemia v	3	68	23	2.8
		AA339449		phosphoribosylglycinamide formyltransfer	4.4	44	1	4.1
30		N22687	Hs.8236	ESTs	13.3	445	34	6
		AU077143		minichromosome maintenance deficient (S.	4.5	45	2	3.4
		AA456539		lysosomal	6	60	5	5.9
		Al916662		kinectin 1 (kinesin receptor)	4.1	301	73	6.1
		AW067903		collagen, type XI, alpha 1	4.6	1216	267	4.4
35	134415	AI750762	Hs.82911	protein tyrosine phosphatase type IVA, m	4.9	163	34	15.1
	134417	NM_006416	6Hs.82921	solute carrier family 35 (CMP-sialic aci	4.9	49	3	3.8
	134419	W95642	Hs.82961	trefoil factor 3 (intestinal)	3.2	1872	592	3.3
	134421	AU077196	Hs.82985	collagen, type V, alpha 2	6.3	1075	171	3.8
4.0	134436	U29344	Hs.83190	fatty acid synthase	3.3	710	217	2
40	134485		Hs.83942	cathepsin K (pycnodysostosis)	34.3	411	12	5.1
		AF061739	Hs.83954	protein associated with PRK1	4.8	153	32	4.3
			Hs.84087	KIAA0143 protein	3.1	147	48	12.7
		BE091005		activated RNA polymerase II transcriptio	3.3	33	1	2
4.5		M14156	Hs.85112	insulin-like growth factor 1 (somatomedi	4.2	42	5	2.6
45	134570		Hs. 172280	SWI/SNF related, matrix associated, acti	3.9	39	1	2.5
		AW903849		HUEL (C4orf1)-interacting protein	3.7	41	11	0.6
		NM_002884		RAP1A, member of RAS oncogene family	5.2	52	1	3
		AW068223		ubiquitin C-terminal hydrolase UCH37	4.9	49	1	3.7
50		AW299723		bone morphogenetic protein receptor, typ	5.2	52	5	3.5
30		AK001741		hypothetical protein FLJ10879	6.4	64	1	5.1
			Hs.87409	thrombospondin 1	12.6	126	1	10.8
		AF271212 AK000606		disrupter of silencing 10	5.4	81	15	2.6
	134711		Hs.88974	golgi SNAP receptor complex member 1	3.4	179	52	1.5
55		AF129536		cytochrome b-245, beta polypeptide (chro F-box only protein 6	3.2	143	45	13.9
55		BE281128		TONDU	7	70	6	6
			Hs.90606	15 kDa selenoprotein	3.1	31	1	2.3
	134917		Hs.166994	FAT tumor suppressor (Drosophila) homolo	5.7 3.2	57 452		5 4.7
			Hs.125511	Homo sapiens mRNA; cDNA DKFZp434P1530 (f		153 452	48	
60		AK002085		Homo sapiens cDNA FLJ11223 fis, done PL	5.1	150	114 30	2 7.2
-		AW968058		nudix (nucleoside diphosphate linked moi	8.2	114	14	9.9
	135029		Hs. 187579	hydroxysteroid (17-beta) dehydrogenase 7	11.5	115	1	10
		AL034344		forkhead box C1	5.4	259	48	1.4
			Hs.83484	SRY (sex determining region Y)-box 4	3.3	1296	394	2.2
65		AK000967		KIAA1682 protein	3.8	240	64	3.2
	135073		Hs.94030	Homo saplens mRNA; cDNA DKFZp586E1624 (f		101	13	7.9
		AW274526		ovarian carcinoma antigen CA125	3.3	33	ĭ	2.6

		_							
·		W52493	Hs.94694	Homo sapiens cDNA FLJ10561 fis, clone NT	5.3	53	1	4.1	
-		NM_01625		Autosomal Highly Conserved Protein	7.4	74	5	2.4	
	135154	AK001835	Hs.267812	sorting nexin 4	6.6	69	11	6.3	
٠ ــ		Al207958	Hs.166556	Homo sapiens, Similar to TEA domain fami	6.1	61	1	5.1	
5		AB028956	Hs.12144	KIAA1033 protein	3.4	88	26	1.4	
	135242	AI583187	Hs.9700	cyclin E1	3.1	31	1	2.3	
	135243	BE463721	Hs.97101	putative G protein-coupled receptor	3.4	169	50	9.1	
	135269	NM_00340		YY1 transcription factor	3.4	475	142	2.5	
	135356	BE312948	Hs.18104	hypothetical protein FLJ11274	3.1	31	10	1.7	
10	135357	Al565004	Hs.79572	cathepsin D (lysosomal aspartyl protease	4.7	710	151	2.5	
	135389		Hs.99872	fetal Alzheimer antigen	20.6	206	4	19.1	
		L14922	Hs.166563	replication factor C (activator 1) 1 (14	3.2	32	i	2.4	
	-135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	3.2	117	37	9.4	
		AH71525	Hs.247486	ESTs	3.8	58	16	5.5	
15		X70683	Hs.93668	ESTs	1.8	1047	596	1.6	
		L14922	Hs.82128	5T4 oncofetal trophoblast glycoprotein	5	285	58	1.2	
		M23263	Hs.904	amylo-1;6-glucosidase; 4-alpha-glucanotransfera	IS	3.1	31	1	2.6
		Al267886	Hs.148027	polymerase (RNA) II (DNA directed) polypeptide		7.8	137	18	11.9
		AA044840	Hs.241676	stromal cell-derived factor 1	4.7	114	25	0.9	
20		N90960	Hs.227459	ESTs; Moderately similar to !!!! ALU SUBFAMILY	,	4.7	151	32	9.3
		AA873285	Hs.137947	ESTs	4.7	47	3	4.4	
		T56679	Hs.865	RAP1A; member of RAS oncogene family	4	40	1	3.4	
. *		AA305536		"EST176522 Colon carcinoma (Caco-2) cell line	li	3.6	121	34	11.8
0.5		Al369384		arylsulfatase D	3.5	113	33	1.7	
25		AA219081	Hs.242396	ESTs; Moderately similar to !!!! ALU SUBFAMILY	7	3.4	107	32	9.9

### TABLE 10A

Table 10 A shows the accession numbers for those pkeys lacking unigeneID's for Table 10.

For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number
Accession:	Genbank accession numbers

15

	Pkey	CAT number	Accession
20	123619		AA602964 AA609200
20		524482_2	H47610 R86920
	121581		AA416568 AA442889 AA417233 AA442223
		genbank_AA608588	AA608588
	100821	-3	M26460 U09116
26	125091		
25		NOT_FOUND_entre	
	118475	genbank_N66845	N66845
	104787	genbank_AA027317	AA027317
	106055	genbank_AA417034	AA417034
2.0		genbank_T97307	T97307
30	101046	entrez_K01160	K01160 ·
	101447	entrez_M21305	M21305
	101624	entrez_M55998	M55998
	124677	genbank_R01073	R01073
	110581	genbank_H61560	H61560
35	119023	genbank_N98488	N98488
	110775	genbank_N22414	N22414
	112092	genbank_R44538	R44538
		genbank_R51818	R51818
		genbank_AA598820	AA598820
40		genbank_AA251089	

# TABLE 11: Figure 11 from BRCA 001-3 PCT

5 Table 11 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	Pkey: ExAcon Unigend Unigend R1:	eID:	Exen Unig Unig	nplar Access ene number ene gene titk	eset Identifier number ion number, Genbank accession number e normal body tissue				
15 .	R2: R3: R4:		Ratio Ratio	of 90th perc of 75th perc	entile turnor to normal body entile normal body to turnor normal breast tissue				
20	Pkey	ExAc	cn	UnigeneID	Unigene Title	R1	R2	R3	R4
	100131 100147			Hs.11951 Hs.136348	ectonucleotide pyrophosphalase/phosphodi osteoblast specific factor 2 (fasciclin	13.2 15.7	244 1030	19 66	9.9 5
	100522	X515	01	Hs.99949	prolactin-induced protein	22.7	760	34	1.4
	100666	L0542	24	Hs.169610	CD44 antigen (homing function and Indian	8.5	85	1	3.2
25	101104	AW86	2258	Hs.169266	neuropeptide Y receptor Y1	15.3	153	1	14.1
	101478	NM_0	0289	OHs.758	RAS p21 protein activator (GTPase activa	9.6	96	1	8.5
	101724			Hs.620	bullous pemphigoid antigen 1 (230/240kD)	9.4	94	1	0.3
	101754			Hs.239489	TIA1 cytotoxic granule-associated RNA-bi	8.9	89	5	8
20				Hs.95243	transcription elongation factor A (SII)-	7.3	73	1	5.3
30	102165	BE31	3280	Hs.159627	death associated protein 3	9.3	93	5	8
				Hs.46452	mammaglobin 1	8.5	2058		1.4
	102348			Hs.87539	aldehyde dehydrogenase 3 family, member	6.4	428	67	2.3
				4Hs.2359	dual specificity phosphatase 4	20.2	202	5	1.3
25	102567				TRAF family member-associated NFKB activ	8.2	82	1	6.8
35	102823			Hs.5057	carboxypeptidase D	5.6	56	1	5.3
				Hs.297753		7.5	136	18	3.4
				Hs.2316	SRY (sex determining region Y)-box 9 (ca	7.3	73	1	5.2
				Hs.26102	opposite strand to trichorhinophalangeal	29	290	1	26.8
40	104667			Hs.30098	ESTs	14.9	149	1	6.4
40	104804 104807			Hs.31803	ESTs, Weakly similar to N-WASP [H.sapien	7.7	77	1	5.1
				Hs.23165	leucine-rich repeat-containing 2	7	70	1	6.5
					ESTs frizzled (Drosophila) homolog 6	7.4 16.2	74 162	1	6 4.2
	105038	AWSO	3733	Hs.9414	KIAA1488 protein	5.5		1	
45				Hs.22862	ESTs	2.8	55 131	47	5.2 3.9
.5					CEGP1 protein	25.4		20	3.9
				Hs.30738	hypothetical prolein FLJ10407	8.3	83	3	1.8
				Hs.5364	DKFZP5641052 protein	6.9	69	1	4.4
	106012			Hs.8895	ESTs	21.2		6	17.4
				Hs.11713	E74-like factor 5 (ets domain transcript	26.3		14	1
				Hs.33287	nuclear factor I/B	9.9		49	1.8
				Hs.30652	KIAA1344 protein	6.3	63	1	5.4
				Hs.8207	GK001 protein	2.5		155	4.3
				Hs.8687	ESTs	15.6		7	10.8
55	107922	BE153	855	Hs.61460	Ig superfamily receptor LNIR	9		i	5.5
	108339	AW15	1340-	Hs.51615	ESTs, Weakly similar to ALU7_HUMAN ALU S	18.7		1	17
	109112	AW41	9196	Hs.257924		4.1	334	82	3.4
	109292	AW97	5746	Hs.188662	KIAA1702 protein	7.1		1	6.5
	109415	U8073	6	Hs.110826	trinucleotide repeat containing 9	12.3		1	11.3
60	109912	AW39	0822	Hs.301528	L-kynurenine/alpha-aminoadipate aminotra	14.2	142	1	9.5
	110009	BE075	297	Hs.6614	ESTs, Weakly similar to A43932 much 2 p	6.3	693	110	7.2
	110915	BE092		Hs.29724	hypothetical protein FLJ13187	20.9	209	1	19.5
	111164	N4618	0	Hs.122489	Homo sapiens cDNA FLJ13289 fis, clone OV	7.7	77	1	5

	444470							
		AK000136		asporin (LRR class 1)	25.1	288	12	6.7
	111190	AK002055	Hs.151046	hypothetical protein FLJ11193	6.3	63	1	5.8
	111223	AA852773	Hs 334838	KIAA1866 protein	3.6	402		
	111357	BE314949	Lia 07420				112	4.9
5				hypothetical protein FLJ23309	3.8	425	111	4
,		AB029000		KIAA1077 protein	5.7	567	100	6.7
	113047	Al571940	Hs.7549	ESTs	9.6	124	13	9
	113702	T97307		gb:ye53h05.s1 Soares fetal liver spleen	12.3	129	11	11.7
		W57554	He 125010	lymphoid nuclear protein (LAF-4) mRNA				
			113.123013	lymphoto nuclear protein (LAP-4) micros	24.2	242	10	5.6
10	114130	AW384793	HS.15/40	Homo sapiens mRNA; cDNA DKFZp434E033 (fr	6.7	67	1	6.3
10	114768	AF212848	Hs.182339	ets homologous factor	13.7	137	1	8.9
	114860	AL157545	Hs.42179	bromodomain and PHD finger containing, 3	9.1	91	i	7.6
		AI733881	Hs.72472	BMP-R1B				
			113.1 241 2		35.9	359	10	29.7
		AA251089		gb:zs04f05.s1 NCI_CGAP_GCB1 Homo sapiens	11.5	115	1	6.9
1.5	115206	AW183695	Hs.186572	ESTs	5.8	58	1	5
15	115719	AW992405	Hs.59622	Homo sapiens, clone IMAGE:3507281, mRNA,	7.6	144	19	13.9
	115844	Al373062	He 332938	hypothetical protein MGC5370	6.2 ·		-	
		AI272141				62	1	5.4
			Hs.83484	SRY (sex determining region Y)-box 4	1.8	1047	596	1.6
		H25836	Hs.301527	ESTs, Moderately similar to unknown [H.s	22.8	228	9	12.4
	117280	M18217	Hs.172129	Homo sapiens cDNA: FLJ21409 fis, clone C	3.9	322	83	4.4
20	117412	N32536	Hs.42645	solute carrier family 16 (monocarboxylic	17.4	174		
-0		AL157545					9	6.9
				bromodomain and PHD finger containing, 3	14.5	145	1	2.4
	1,192/1	AI061118	Hs.65328	Fanconi anemia, complementation group F	8.2	82	1	6.4
	119771	A1905687	Hs.2533	EST	3.5	2073	595	2.1
	120562	BE244580	Hs 302267	hypothetical protein FLJ10330	8.5	127	15	1.6
25	121/63	VKUUU383	He 220004	hypothetical protein FLJ20275				
25	101700	A1000202	115.235001	hypothetical protein FLJ202/5	10.3	103	1	9.3
	121/23	AA243499	Hs.104800	hypothetical protein FLJ10134	2.9	214	74	3.7
	122963	AA478446	Hs.69559	KIAA1096 protein	7.2	72	1	5.7
	123137	AI073913	Hs.100686	ESTs, Weakly similar to JE0350 Anterior	9.9	351	36	13.9
		AA602964		gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens				
30			11- 440740		8.5	85	1	4.3
50			Hs.112742		3.9	60	16	4.8
		Al147155	Hs.270016		5.8	321	55	17
	124059	BE387335	Hs.283713	ESTs, Weakly similar to S64054 hypotheti	10.4	880	85	5.3
	124308	AA249027	He 241507	ribosomal protein S6				
	125070	ANNADADO	113.271301		10.5	105	1	9.9
25		AW401809		KIAA1150 protein	13.1	131	1	5.1
35	125517	AA287921	Hs.164950	ESTs	6.7	67	1	6
	127439	D60237	Hs.14368	SH3 domain blinding glutamic acid-rich pr	30.6	306	4	26.5
	128305	AI954968	Hs 279009		7.5	75	i	
		Al694143	Un 200254	araggament self death 4				6.5
			113.230231		7.2	72	1	5.8
40		AF026692		secreted frizzled-related protein 4	17.4	409	24	7.8
40	128925	R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	7.1	392	56	3.6
	129017	AA115333	Hs.107968		8.2	82	1	7.4
	120223	AND 10100	110.100040		7.1	71	1	6.2
	129337	NW_U14910	MS. 1 10488	KIAA0990 protein	9.5	95	1	8.5
4 -	129366	BE220806	Hs.184697	Homo sapiens clone 23785 mRNA sequence	7.1	150	21	14.5
45	129821	AB028945	Hs.12696	cortactin SH3 domain-binding protein	11.4	114	1	10
	130036	RF061916	Hs.125849		6.7	67	i	
			Hs.324787					5.7
					1	1	1	1
	130095	AK001635	HS. 14838	hypothetical protein FLJ10773	14.6	219	15	7.6
	130343	AB040914	Hs.278628	KIAA1481 protein	13.2	331	25	12.4
50	130385	AW067800	Hs.155223		72.2		1	1.9
		BE385099	Hs 334727					
		110203033	11- 455527	hypothetical protesti MGC3017	6.5		4	5.3
	130441		HS. 10003/	protein kinase, DNA-activated, catalytic	6.1	61	1	5.7
	130455	D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	10.8	706	66	9.2
	130604	AA383256	Hs.1657		32.2	322	1	4.7
55	130617		Hs.1674		10		i	
• •								7.6
	1007 12	MJ21 1001	115.275702	bromodomain-containing 7	17.5		2	12.8
	131148	AW953575	HS.303125	p53-induced protein PIGPC1	3.8	585	153	3.7
	131388	NM_014810	Hs.92200		7.6	76	1	5
	131564		Hs.28792		4.7		81	
60		AA961420	He 31/32					6.4
50					11.7		1	10.1
	131877	304000	ris. 156346	topoisomerase (DNA) II alpha (170kD)	6.8	68	1	5.6
	131985	AA503020	Hs.36563		40.2	402	1	4
	132316		Hs.44566		18.6		10	1.5
	132528		Hs.50758					
65					9.3		1	8.4
00			110.252012	ESTs, Weakly similar to T33468 hypotheti	6.5		1	5.6
	132990	X//343	Hs.334334	transcription factor AP-2 alpha (activat	12.7	311	25	2.4
	133015	AJ002744	Hs.246315		4.6		93	10.4
				4 4 G			- •	

				homolog of yeast long chain polyunsatura	3	816	275	3.9
	133240	AK001489	Hs.242894	ADP-ribosylation factor-like 1	8.1	81	1	4.6
	133271	Z48633	Hs.283742	H.saplens mRNA for retrotransposon	12.4	124	6	10.8
_	133640	AW246428	Hs.75355	ublquitin-conjugating enzyme E2N (homolo	8.5	85	1	7.2
5	133746	AW410035	Hs.75862	MAD (mothers against decapentaplegic, Dr	9.3	93	1	7.8
	133999	AA535244	Hs.78305	RAB2, member RAS oncogene family	7.8	78	1	5.6
	134110	U41060	Hs.79136	LIV-1 protein, estrogen regulated	4.5	1472	330	2.1
	134485	X82153	Hs.83942	cathepsin K (pycnodysostosis)	34.3	411	12	5.1
	134654	AK001741	Hs.8739	hypothetical protein FLJ10879	6.4	64	1	5.1
10	134880	AI879195	Hs.90606	15 kDa selenoprotein	5.7	57	1	5
	135029	H58818	Hs.187579	hydroxysteroid (17-beta) dehydrogenase 7	11.5	115	1	10
	135389	U05237	Hs.99872	fetal Alzheimer antigen	20.6	206	4	19.1
	128305	A1954968	Hs 279009	matrix Gla protein	9.4	94	3	53

#### TABLE 11A

Table 11A shows the accession numbers for those pkeys lacking unigeneID's for Table 11. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: CAT number: Accession: Unique Eos probeset identifier number

Gene cluster number Genbank accession numbers

15

Pkey CAT number Accession

20 123619 371681\_1 AA602964 AA609200 113702 genbank\_T97307 T97307 114988 genbank\_AA251089 AA251089

# TABLE 12: Figure 12 from BRCA 001-3 PCT

5 Table 12 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	Pkey: ExAccn: UnigenelD: Unigene Title:		Jnique Eos probeset identifier number Exemplar Accession number, Genbank accession number Jnigene number Jnigene gene title					
R1:			Ratio of tumor to normal body tissue					
	R2:			90th percentile tumor to body				
15	R3:			75th percentile body to tumor				
	R4:		Ratio of	tumor to normal breast tissue				
	Pkey	ExAccn	UnigeneiD	Unigene Title	R1	R2	R3	R4
20	100131	D12485	Hs.11951	phosphodiesterase I (PC-1)	13.2	244	19	9.9
	105500	AW602168	Hs.222399		25.4	508	20	3
	112244	AB029000	Hs.70823	KIAA1077 protein	5.7	567	100	6.7
	114124	W57554	Hs.125019	ESTs	24.2	242	10	5.6
	119771	A1905687	Hs.2533	ESTs	3.5	2073	595	2.1
25	121723	AA243499	Hs.104800	ESTs	2.9	214	74	3.7
	128790	AF026692	Hs.105700	secreted frizzled-related protein 4	17.4	409	24	7.8
	131148	AW953575	5 Hs.303125	ESTs	3.8	585	153	3.7
	131985	AA503020	Hs.36563	ESTs	40.2	402	1	4
	133199	AF231981	Hs.250175	Homo sapiens clone 23904 mRNA sequence	3	816	275	3.9


### TABLE 13: Table 1 from BRCA 001-5 US

Table 13 depicts a preferred group of genes upregulated in breast cancer cells. 5

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title · Ratio of tumor to normal body tissue Pkey: ExAccn: UnigeneID: Unigene Title: R1: 10


1.5					
15					
	Pkey	ExAccn	UniGene ID	Unigene Title	R1
	100020	M97935		control	16.7
		M97935			6.3
20		M97935		control	8.3
20		M97935		control control	6.5 14.8
		AB003103	U- 400E		
			Hs.111783	proteasome (prosome; macropain) 26S sub	7.5 4.9
		AF006084		Lsm1 protein	4.5
25				actin related protein 2/3 complex; subunit	13.4
23		AF007875		dolichyl-phosphate mannosyltransferase p	15.4
		D00596	Hs.82962	thymidylate synthetase	4.6
		D10495 D10523	Hs.155342	protein kinase C; delta	7.5
		D10023	Hs.168669	oxoglutarate dehydrogenase (lipoamide)	4.4
30		D11094	Hs.61153	proteasome (prosome; macropain) 26S sub	8.7
50		D12403 D13627	Hs.11951 Hs.15071	phosphodiesterase l/nucleotide pyrophosp	9.5
		D13643	Hs.75616	chaperonin containing TCP1; subunit 8 (t Human mRNA for KIAA0018 gene; comp	5.5 6
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin l-like	8.5
		D13666 D14657	Hs.81892		10.5
35		D14637	Hs.173714	KIAA0101 gene product MORF-related gene X	4.6
55		D14878	Hs.82043	D123 gene product	7.9
		D21090	Hs.178658	RAD23 (S. cerevisiae) homolog B	5.6
		D25538	Hs.172199	adenylate cyclase 7	9.9
		D26308	Hs.76289	biliverdin reductase B (flavin reductase (N	4.9
40		D26598	Hs.82793	proteasome (prosome; macropain) subunit	14,2
70		D26599	Hs.1390	proteasome (prosome; macropain) subunit	11.3
		D28137	Hs.118110	bone marrow stromal cell antigen 2	5.7
		D28915	Hs.82316	Interferon-induced; hepatitis C-associated	5.7
		D31888	Hs.78398	KIAA0071 protein	7.4
45		D43950	Hs.1600	chaperonin containing TCP1; subunit 5 (e	5.6
13		D49396	Hs.75454	antioxidant protein 1	12.9
		D50525	Hs.699	hypothetical protein	8.4
		D63391	Hs.6793	platelet-activating factor acetylhydrolase;	6.8
		D63487	Hs.82563	KIAA0153 protein	4.4
50		D78129	Hs.71465	Homo sapiens mRNA for squalene epoxid	12.6
		D78514	Hs.78563	ubiquitin-conjugating enzyme E2G 1 (hom	4.6
		D79987	Hs.153479	extra spindle poles; S. cerevislae; homolo	6.5
		D79997	Hs.184339	KIAA0175 gene product	8.4
		D80004	Hs.75909	KIAA0182 protein	4.5
55		D82060	Hs.278721	Ke4 gene; mouse; human homolog of	8.1
		D83777	Hs.75137	KIAA0193 gene product	10.7
		D84145	Hs.39913	novel RGD-containing protein	7.2
		D84557	Hs.155462	minichromosome maintenance deficient (m	7.2
		D86425	Hs.82733	nidogen 2	5.4
60		D86479	Hs.118397	AE-binding protein 1	4.3
- •		D86957	Hs.80712	KIAA0202 protein	11.9
		D86985	Hs.79276	Human mRNA for KIAA0232 gene; comp	9.7
		D87464	Hs.10037	KIAA0274 gene product	6.4
		D87465	Hs.74583	KIAA0275 gene product	10
65		D87469	Hs.57652	EGF-like-domain; multiple 2	6.2

	100467 D89052	Hs.7476	ATPase; H+ transporting; lysosomal (vacu	7.5
	100468 D89289	Hs.118722	fucosyltransferase 8 (alpha (1;6) fucosyltr	5
	100486 HT1112	Hs.10842	Ras-Like Protein Tc4	16.9
5	100497 HT1400 100618 HT2710	Hs.79137	Carboxyl Methyltransferase, Aspartate, A	5.6
3	100661 HT3018	Hs.114599 Hs.132748	Collagen, Type Viil, Alpha 1 Ribosomal Protein L39 Homolog	7.5 4.4
	100667 HT3127	Hs.169610	Epican, Alt. Splice 11	4.6
	100668 HT3938	Hs.169610	Epican, Alt. Splice 12	4.4
	100676 HT3742	Hs.287820	Fibronectin, All. Splice 1	9
10	100775 HT26388	Hs.89603	Mucin 1, Epithelial, Alt. Splice 9	4.7
	100783 HT4018	Hs.191356	Basic Transcription Factor, 44 Kda Subun	13.7
	100829 HT4343	Hs.278544	Cytosolic Acetoacetyl-Coenzyme A Thio	10.6
	100830 HT4344	Hs.4756	Rad2	5.5
1.5	100840 HT4392	Hs.183418	Protein Kinase Pitshe, Alpha, Alt. Splice	4.1
15	100850 HT417	Hs.297939	Cathepsin B	4
	100866 HT4582	Hs.75113	Transcription Factor Ilia	4.9
	100906 HT5158	Hs.5398	Guanosine 5'-Monophosphate Synthase	8.7
	100914 HT511	Hs.324178	Ras Inhibitor Inf	7.2 5.9
20	100916 HT544 100945 HT884	Hs.73946 Hs.180686	Endothelial Cell Growth Factor 1 Oncogene E6-Ap, Papillomavirus	4.6
20	100975 J02923	Hs.76506	lymphocyte cytosolic protein 1 (L-plastin	30.1
	100988 J03589	Hs.76480	ubiquitin-like 4	8.3
	100996 J03909	Hs.14623	Interferon; gamma-inducible protein 30	6.9
	100999 J03934	Hs.80706	diaphorase (NADH/NADPH) (cytochrom	4.3
25	101011 J04430	Hs.1211	acid phosphatase 5; tartrate resistant	5.9
	101017 J04599	Hs.821	biglycan	5.1
	101031 J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B;	37.2
	.101038 J05249	Hs.79411	replication protein A2 (32kD)	6.1
20	101054 K02405	Hs.73931	Human MHC class II HLA-DQ-beta mRN	4.3
30	101061 K03515	Hs.180532	glucose phosphate isomerase	4.3
	101091 L06132	Hs.149155	voltage-dependent anion channel 1	7.4 4.6
	101097 L06797 101104 L07615	Hs.89414 Hs.169266	chemokine (C-X-C motif); receptor 4 (fus Human neuropeptide Y receptor Y1 (NPY	4.0 18.3
	101143 L12723	Hs.90093	heat shock 70kD protein 4	17.4
35	101152 L13800	Hs.9884	Homo sapiens liver expressed protein gen	7.6
55	101183 L19779	Hs.795	H2A histone family; member O	10.9
	101216 L25876	Hs.84113	cyclin-dependent kinase Inhibitor 3 (CDK	7.4
	101233 L29008	Hs.878	sorbitol dehydrogenase	14.6
	101247 L33801	Hs.78802	glycogen synthase kinase 3 beta	7.5
40	101282 L38810	Hs.79387	proteasome (prosome; macropain) 26S sub	4.4
	101326 L42572	Hs.78504	inner membrane protein; mitochondrial (m	5.8
	101332 L47276	Hs.156346	Homo sapiens (cell line HL-6) alpha topo	18.9
	101348 L77213	Hs.30954	phosphomevalonate kinase	7.5
15	101352 L77701	Hs.16297	COX17 (yeast) homolog; cytochrome c ox	9.3
45	101378 M13755	Hs.833	interferon-stimulated protein; 15 kDa	18.
	101396 M15796 101404 M16342	Hs.78996 Hs.182447	proliferating cell nuclear antigen heterogeneous nuclear ribonucleoprotein C	8.6 4.5
	101439 M20902	Hs.268571	apolipoprotein C-I	6.1
	101464 M22538	Hs.51299	NADH dehydrogenase (ubiquinone) flavo	8.7
50	101469 M22877	Hs.169248	Human somatic cytochrome c (HCS) gene	4.2
	101472 M22960	Hs.118126	protective protein for beta-galactosidase (	6.5
	101478 M23379	Hs.758	RAS p21 protein activator (GTPase activa	. 14
	101484 M24594	Hs.20315	Interferon-induced protein 56	9.2
	101539 M30818	Hs.926	myxovirus (influenza) resistance 2; homol	5.1
55	101540 M30938	Hs.84981	X-ray repair complementing defective rep	4.7
	101544 M31169		Human propionyl-CoA carboxylase beta-s	5.5
	101552 M31642	Hs.82314	hypoxanthine phosphoribosyltransferase 1	8.5
	101580 M34677	Hs.83363	DNA segment on chromosome X (unique)	4.5
60	101600 M37583	Hs.119192	H2A histone family; member Z	5.7
vv	101663 M60750	Hs.2178	H2B histone family; member A	5.8 13.
	101664 M60752 101667 M60858	Hs.121017 Hs.79110	H2A histone family; member A nucleolin	4
	101684 M63256	Hs.75124	cerebellar degeneration-related protein (62	7.6
	101702 M64929	Hs.179574	protein phosphatase 2 (formerly 2A); regu	4.2
65	101754 M77142	Hs.239489	TIA1 cytotoxic granule-associated RNA-b	4.5
·	101758 M77836	Hs.79217	pyrroline-5-carboxylate reductase 1	5.7
	101767 M81057	Hs.180884	carboxypeptidase B1 (tissue)	21.



	102705 U77180	Hs.50002	small inducible cytokine subfamily A (Cy	11.8
	102721 U79241 .		Human clone 23759 mRNA; partial cds	15
	102729 U79254	Hs.181311	asparaginyl-tRNA synthetase	5
	102739 U79282	Hs.155572	Human clone 23801 mRNA sequence	6
5	102742 U79293	Hs.159264	Human done 23948 mRNA sequence	13.1
	102761 U82130	Hs.118910	tumor susceptibility gene 101	7
	102788 U86602	Hs.74407	nucleolar protein p40	4.1
	102790 U87269	Hs.154196	E4F transcription factor 1	7.1
	102801 U89606	Hs.38041	pyridoxal (pyridoxine; vitamin B6) kinase	4.7
10	102808 U90426	Hs.179606	nuclear RNA helicase; DECD variant of D	7.5
	102817 U90904	Hs.83724	Human clone 23773 mRNA sequence	15.2
	102823 U90914	Hs.5057	carboxypeptidase D	6.6
	102827 U91327	Hs.6456	chaperonin containing TCP1; subunit 2 (b	6
	102838 U94592	Hs.80658	Human uncoupling protein homolog (UCP	6.1
15	102841 U95006	Hs.37616	Human D9 splice variant B mRNA; comp	4.2
	102844 U96113	Hs.324275	Homo sapiens Nedd-4-like ubiquitin-prot	6.8
	102868 X02419	Hs.77274	plasminogen activator, urokinase	4
	102907 X06985	Hs.202833	heme oxygenase (decycling) 1	22.7
•	102919 X12447		aldolase A; fructose-bisphosphate	9.9
20	102929 X13238	Hs.74649	cytochrome c oxidase subunit VIc	5.4
	102973 X16663	Hs.14601	hematopoietic cell-specific Lyn substrate	4.8
	102983 X17620	Hs.118638	non-metastatic cells 1; protein (NM23A)	4.6
	102985 X17644	Hs.2707	G1 to S phase transition 1	20.6
~ -	103003 X52003	Hs.1406	trefoil factor 1 (breast cancer; estrogen-ind	10.7
25	103018 X53296	Hs.81134	Interleukin 1 receptor antagonist	5.8
	103023 X53793	Hs.117950	multifunctional polypeptide similar to SA	4
	103036 X54925	Hs.83169	matrix metalloproteinase 1 (interstitial col	7.3
	103060 X57766	Hs.155324	matrix metalloproteinase 11 (stromelysin	17.8
20	103073 X59417	Hs.74077	proteasome (prosome; macropain) subunit	5.6
30	103075 X59543	Hs.2934	ribonucleotide reductase M1 polypeptide	4.2
	103080 X59798	Hs.82932	cyclin D1 (PRAD1: parathyrold adenomat	6.7
	103094 X60787	Hs.296281	interleukin enhancer binding factor 1	5.7
	103105 X61970	Hs.76913	proteasome (prosome; macropain) subunit	5.8
25	103121 X63679	Hs.4147	translocating chain-associating membrane	4.2
35	103149 X66363	Hs.171834	PCTAIRE protein kinase 1	12
	103180 X69433	Hs.5337	Isocitrate dehydrogenase 2 (NADP+); mit	18.9
	103182 X69819	Hs.99995	intercellular adhesion molecule 3	10.7
	103188 X70040	Hs.2942	macrophage stimulating 1 receptor (c-met	4.1
40	103191 X70218	Hs.2903	protein phosphatase 4 (formerly X); cataly	10.7
40	103193 X70476	Hs.75724	coatomer protein complex; subunit beta 2	8.2
	103194 X70649	Hs.78580	DEAD/H (Asp-Glu-Ala-Asp/His) box pol	13.7
	103195 X70940	Hs.2642	eukaryotic translation elongation factor 1	13.4
	103206 X72755	Hs.77367	monokine induced by gamma interferon	15.1
45	103207 X72790	11. 04044	Human endogenous retrovirus mRNA for	5.3
43	103208 X72841	Hs.31314	retinoblastoma-binding protein 7	12.3
	103216 X74262	Hs.16003	retinoblastoma-binding protein 4	4.1
	103226 X75042	Hs.44313	v-rel avian reticuloendotheliosis viral onco	6.9
	103230 X75861	Hs.74637	testis enhanced gene transcript	7.9
50	103262 X78565	Hs.289114	hexabrachion (tenascin C; cytotactin)	5
20	103278 X79882	Hs.80680	lung resistance-related protein	5.7
	103297 X81788	Hs.9078	Immature colon carcinoma transcript 1	4.6
	103302 X82103	Hs.3059	coatomer protein complex; subunit beta	4.5
	103316 X83301	Hs.324728	SMA5	7.1
55	103330 X85373	Hs.77496	small nuclear ribonucleoprotein polypepti	4
23	103349 X89059	U. 70052	serine/threonine kinase 9	4.7
	103352 X89398	Hs.78853	uracil-DNA glycosylase	5.3
	103364 X90872	Hs.279929	SULT1C sulfotransferase	4
	103374 X91788	Hs.84974	chloride channel; nucleotide-sensitive; 1A	4.2
60	103380 X92396	Hs.24167	synaptobrevin-like 1	13.6
UU	103395 X94754 103402 X95404	Hs.279946	methionine-tRNA synthetase	14.2
	103402 X95404 103410 X96506	Hs.180370 Hs.295362	cofilin 1 (non-muscle)	4.6
			DR1-associated protein 1 (negative cofact	8.3
	103420 X97065 103421 X97074	Hs.173497	Sec23 (S. cerevisiae) homolog B	4.9
65	103427 X97303	Hs.119591 Hs.250655	adaptor-related protein complex 2; sigma	5 7
05	103430 X97544	Hs.20716	H.sapiens mRNA for Ptg-12 protein translocase of inner mitochondrial membr	
	103438 X98263	Hs.152720	M-phase phosphoprotein 6	4.5
	100700 730200	113.132120	in-bistae hiioahiiohioesii o	. 4.5

WO 02/059377



	105012 AA116036		chromosome 20 open reading frame 1	10.7
	105019 AA121879		proteasome (prosome; macropain) subunit	5.7
	105029 AA126855		ESTs	4.4
5	105033 AA127964 105035 AA128486		TP53 target gene 1 ESTs	6.3 6.5
_	105039 AA130349		ESTs	4
	105062 AA134968		ESTs	4.3
	105076 AA142858		ESTs	6.4
	105087 AA147884		ESTs	9.2
10	105091 AA148859	Hs.179909	ESTs; Weakly similar to IIII ALU SUBFA	5.7
	105093 AA149051	Hs.32405	ESTs	6.3
	105107 AA152302		DKFZP566G223 protein	6.2
	105127 AA158132		ESTs; Weakly similar to contains similarl	5.7
1.5	105132 AA159501		HBV associated factor	4.2
15	105143 AA165333		ESTs	4.7
	105154 AA171736		methyl-CpG binding domain protein 4	9
	105162 AA176690		KIAA1025 protein	9.1
	105186 AA191512 105209 AA205072		Homo sapiens mRNA; cDNA DKFZp564	19.3 7.4
20	105223 AA211388		KIAA0980 protein ESTs	5.1
20	105252 AA227428		ESTs; Weakly similar to KIAA0512 prote	11.1
	105253 AA227448		KIAA0456 protein	6.4
	105261 AA227871		MEK pariner 1	9.1
	105263 AA227926		ESTs	6.7
25	105274 AA228122		ATPase; H+ transporting; lysosomal (vacu	5.3
	105297 AA233451		transcriptional intermediary factor 1	8.7
	105309 AA233790		ESTs; Weakly similar to cONA EST yk38	7.4
	105312 AA233854		S-phase kinase-associated protein 2 (p45)	5.8
20	105342 AA235286		ESTs	4.5
30	105376 AA236559		ESTs; Weakly similar to IIII ALU SUBFA	5.8
	105386 AA236950		ESTs	5.5
	105397 AA242868 105399 AA243007		ESTs; Weakly similar to house-keeping p	7.7
	105399 AA243007 105400 AA243052		ESTs; Highly similar to SH3 domain-bind	5.6
35	105404 AA243303		RNA binding motif protein 8 ESTs	5.8 9.1
55	105409 AA243562		ESTs	4.4
	105436 AA252172		ESTs; Moderately similar to cAMP induc	5.1
	105483 AA255874		ESTs	4.9
	105493 AA256268		ESTs	6
40	105495 AA256317	Hs.28785	Homo sapiens mRNA; cDNA DKFZp586	5.2
	105496 AA256323	Hs.301997	DKFZP434N126 protein	8.7
	105500 AA256485		CGI-96 protein	9.5
	105507 AA256678		ESTs; Moderately similar to CCR4-associ	4.1
15	105538 AA258860		ring finger protein (C3H2C3 type) 6	4.1
45	105544 AA261954		ESTs	8
	105546 AA262032		ESTs; Weakly similar to 62D9.a [D.melan	8.1
	105549 AA262417		ESTs	4.6
	105551 AA262477 105560 AA262783		ribonuclease HI; large subunit ESTs	9.1 4.5
50	105565 AA278302		ESTs; Weakly similar to partial CDS [C.e	4.2
50	105566 AA278323		Homo sapiens done 24606 mRNA sequen	11.9
	105575 AA278717		ESTs	5.9
	105584 AA279012		ESTs; Weakly similar to KIAA0665 prote	4.4
	105596 AA279418		ESTs	4
55	105604 AA279787	Hs.15467	ESTs; Moderately similar to putative pho	5.6
	105610 AA279991	Hs.99872	ESTs; Weakly similar to trithorax homolo	5.3
	105621 AA280865		Homo sapiens mRNA; cDNA DKFZp564	4.8
	105627 AA281245		ESTs	7.5
<b>CO</b>	105638 AA281599		Homo saplens mRNA for for histone H2B	5.9
60	105645 AA282138		ESTs	6.4
	105650 AA282347		ESTs; Highly similar to HSPC003 [H.sap	11.3
	105666 AA283930		ESTs CDM/52 antigon (CAMPATH-1 antigen)	4.7
	105674 AA284755 105687 AA286809		CDW52 antigen (CAMPATH-1 antigen) ESTs	8
65	105700 AA287643		ESTs; Weakly similar to hypothetical pro	7.1
00	105705 AA290767		Homo sapiens mRNA; cDNA DKFZp434	4.9 8
	105709 AA291268		DKFZP586L0724 protein	6.8
	,		, p,	0.0

### WO 02/059377

			6.4
	105731 AA292711 Hs.29		6.4 7
	105753 AA299789 Hs.11		7.1
	105774 AA348014 Hs.23 105784 AA350771 Hs.17		13.4
5	105791 AA358038 Hs.14		4.3
,	105807 AA393803 Hs.16		5.3
	105808 AA393808 Hs.28		4.1
	105812 AA394126 Hs.20		14.6
	105813 AA394140 Hs.18		4.9
10	105819 AA397920 Hs.28	1783 Homo saplens mRNA; cONA DKFZp564	4.9
	105870 AA399623 Hs.10	01067 ESTs	4.8
	105874 AA400074 Hs.17		4
	105896 AA400999 Hs.78		4.8
10	105934 AA404248 Hs.16		5.2
15	105935 AA404277 Hs.26		4 8.3
	105966 AA406105 Hs.53		4.6
	105974 AA406321 Hs.62		4.5
	105990 AA410336 Hs.29		4.9
20	105995 AA410510 Hs.53 106000 AA410972 Hs.20		5.8
20	106007 AA411462 Hs.11		6.9
	106016 AA411819 Hs.81		5
	106034 AA412473 Hs.14		6.6
	106042 AA412700 Hs.16		4.6
25	106057 AA417067 Hs.28	39074 ESTs	4.5
	106065 AA417558 Hs.25		12.3
	106070 AA417761 Hs.59	357 Homo sapiens clone 24416 mRNA sequen	5
	106103 AA421104 Hs.12		15.4
	106126 AA424006 Hs.22		6.4
30	106154 AA425304 Hs.69		5.1
	106157 AA425367 Hs.34		11.1 19.3
	106166 AA425872 Hs.19		4,7
	106204 AA428024 Hs.21		5.7
35	106210 AA428239 Hs.10 106220 AA428582 Hs.33		7.7
22	106236 AA429951 Hs.2		8
	106240 AA430074 Hs.18		4.4
	106263 AA431462 Hs.20		4.9
	106288 AA435536 Hs.24		8.8
40	106293 AA435591 Hs.30		8.7
• -	106310 AA436244 Hs.17		4.5
	106317 AA436568 Hs.16	D8124 ESTs	4
	106328 AA436705 Hs.28		4.4
	106341 AA441798 Hs.5	243 ESTs; Moderately similar to pIL2 hypoth	23.7
45	106348 AA442253 Hs.10		4.7
	106350 AA442763 Hs.1		6.1
	106371 AA443923 Hs.1		6.8 4.7
	106389 AA446949 Hs.6		4.4
50	106394 AA447223 Hs.2		4.5
50	106426 AA448282 Hs.1 106459 AA449741 Hs.4		4.8
	106462 AA449912 Hs.3		5.2
	106468 AA450047 Hs.1		6.8
	106479 AA450351 Hs.7		12.4
55	106494 AA452108 Hs.1		4.5
	106503 AA452411 Hs.2	The state of the s	5.1
	106507 AA452584 Hs.2		4.9
	106533 AA453786 Hs.1		8.3
	106568 AA455970 Hs.2		7.6
60	106586 AA456598 Hs.5		8.2
	106589 AA456646 Hs.2		4.8
	106606 AA457730 Hs.2		4.4
	106611 AA458904 Hs.2		7 4.5
65	106614 AA458934 Hs.2		4.5 6.5
UJ	106628 AA459657 Hs.1 106637 AA459961 Hs.2		5.5
	106644 AA460239 Hs.1		4.4
		6710	

		AA460969		mitogen-activated protein kinase kinase ki	8.4
	106698	AA463745	Hs.29403	ESTs; Weakly similar to PROBABLE AT	5.3
	106719	AA465171	Hs.236844	ESTs	5.6
_	106726	AA465339	Hs.3886	ESTs	10.1
5	106747	AA476473	Hs.171957	triple functional domain (PTPRF interacti	10.4
	106759	AA477263	Hs.25584	ESTs	4.2
	106765	AA477717	Hs.306117	interleukin 13 receptor; alpha 1	6.9
	106784	AA478558	Hs.227913	API5-like 1	5.1
	106831	AA482014	Hs.29463	centrin; EF-hand protein; 3 (CDC31 yeast	5.1
10			Hs.238707	ESTs	4.8
		AA482548		ESTs	10.3
			Hs.285123	ESTs; Weakly similar to similar to oxyste	6.2
		AA487228		ESTs	4.5
		AA488872		Homo sapiens mRNA; cDNA DKFZp586	7.9
15		AA489101		oxysterol binding protein	6.4
10		AA489665		ESTs	4.6
			Hs.250747	SUMO-1 activating enzyme subunit 1	4.2
		AA490885		ESTs	12.3
			Hs.296323	ESTs	6.2
20			Hs.237971	ESTs	4
20		AA496347			4.8
		AA496788		retinoblastoma-blnding protein 7	4.0
				KIAA0532 protein	
		AA504631		ESTs; Weakly similar to hypothetical 43.2	4.4
25		AA505141		Human DNA sequence from clone 167A1	5.4
23		AA521121		bromodomain adjacent to zinc finger dom	4.1
		AA521157		ESTs	5.7
			Hs.195464	insulin-like growth factor binding protein	18.7
		AA598710		ESTs	6.2
20		AA599214		ESTs	4.1
30			Hs.247309	succinate-CoA ligase; GDP-forming; beta	5.3
		AA600134		glyceronephosphate O-acyltransferase	4.8
		AA600147		ESTs; Weakly similar to NADH-cytochro	5.8
		AA600310		programmed cell death 8 (apoptosis-induc	4.9
25		AA609210		ESTs	8.4
35		AA609723		ESTs	8
		AA609943		ESTs	9.5
		AA620553		flap structure-specific endonuclease 1	4.9
		AA620598		ESTs	5.3
40		AA620795		ESTs .	4
40			Hs.170088	ESTs	6.7
	107151	AA621169	Hs.8687	ESTs	19
	107159	AA621340	Hs.10600	ESTs; Weakly similar to ORF YKR081c [	8.1
	107174	AA621714	Hs.25338	ESTs	8.5
	107217	D51095	Hs.35861	DKFZP586E1621 protein	7.2
45	107252	D59971	Hs.25925	ESTs	7.9
	107295	T34527	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:po	5.6
	107299	T40327	Hs.30661	lung resistance-related protein	8.4
	107324	T81665	Hs.278422	DKFZP586G1122 protein	7.5
	107372	U85625	Hs.8297	ribonuclease 6 precursor	4.7
50	107373	U85773	Hs.154695	phosphomannomutase 2	4.8
	107481	W58247	Hs.279766	Homo sapiens kinesin superfamily motor	6.3
	107531	Y13936	Hs.17883	protein phosphatase 1G (formerly 2C); ma	8.3
		AA024835		potassium voltage-gated channel; delayed	7.3
	107890	AA026030	Hs.61311	ESTs; Weakly similar to CALPAIN 2; LA	7.3
55		AA026894		ESTs	4.9
		AA041341		ESTs	5.4
			Hs.159971	ESTs	8.4
		AA046424		ESTs; Weakly similar to HYPOTHETICA	6.6
		AA058686		ESTs	7.7
60			Hs.172608	ESTs	4
		AA071514		ESTs	4
		AA100694		Human DNA sequence from BAC 15E1 o	5.5
		AA112396		ESTs; Moderately similar to HOMEOBO	14.3
			Hs.274417	Homo sapiens mRNA; cDNA DKFZp564	5.2
65		AA120785		ESTs	5.6
00		AA121315		KIAA1077 protein	10.5
		AA126422		zn84f1.s1 Stratagene lung carcinoma 9372	4.4
					7.7

	40000		74040	FOT 11 desired in last OF 1 CROW	4.6
		AA128125		ESTs; Moderately similar to CELL GROW	4.0 5.5
			Hs.273344 Hs.111680	DKFZP564O0463 protein ESTs	7.2
			Hs.293591	ESTs	11.3
5			Hs.194691	retinoic acid induced 3	8.9
•		AA156360		ESTs	14.7
		AA156460		dual specificity phosphatase 12	4.9
		AA156542		ESTs	4.6
	109042	AA159525	Hs.71779	Homo sapiens DNA from chromosome 19	7.2
10			Hs.270737	tumor necrosis factor (ligand) superfamily	4
		AA167006		ESTs	5.9
		AA167708		ESTs	4.2 4
			Hs.257924	ESTs	4
15			Hs.301997	DKFZP434N126 protein	13.6
13		AA179845	Hs.283707	RAB6 interacting; kinesin-like (rabkinesin ESTs	11.8
			Hs.192789	ESTs; Weakly similar to !!!! ALU SUBFA	5.4
		AA195255		ESTs	6.7
		AA195515		ESTs; Weakly similar to alternatively spli	4.9
20		AA196332		ESTs	5.4
		AA206800		ESTs; Moderately similar to zinc finger p	5.5
	109415	AA227219	Hs.110826	trinucleotide repeat containing 9	20.1
			Hs.295232	ESTs	4.7
		AA232904		ESTs	6.8
25			Hs.289069	ESTs; Weakly similar to WD40 protein C	10.6
		AA233892		ESTs; Weakly similar to IIII ALU SUBFA	8 8.2
			Hs.262346	ESTs; Weakly similar to ORF2: function	4.8
	109572		Hs.171937 Hs.235873	ESTs ESTs; Weakly similar to K11C4.2 [C.eleg	5.2
30	109632	F04477	Hs.291531	ESTS; Moderately similar to GLYCERAL	6.6
50		F09684	Hs.24792	ESTs; Weakly similar to ORF YOR283w	7.1
	109726		Hs.9196	ESTs	5
		F10161	Hs.22969	ESTs	4.7
	109799		Hs.180378	Homo sapiens clone 669 unknown mRNA	4.5
35	109814	F10979	Hs.153106	Homo sapiens clone 23728 mRNA sequen	8.7
	110189	H20543	Hs.6278	DKFZP586B1621 protein	16.6
		H25577	Hs.176588	ESTs; Weakly similar to CYTOCHROME	6.2
		H29285	Hs.32468	ESTs	4.5
40		H56965	Hs.4082	yr09f06.s1 Soares fetal liver spleen 1NFL	5.7 19.5
40		H59617	Hs.5199	ESTs; Weakly similar to UBIQUITIN-CO	6.2
		H95079	Hs.15617	ESTs; Weakly similar to IIII ALU SUBFA ESTs	30.2
		H98714	Hs.24131 Hs.131705	ESTs	5.8
		N22262 N23174	Hs.22891	solute carrier family 7 (cationic amino aci	8.2
45		N24716	Hs.12244	ESTs; Weakly similar to C44B9.1 [C.eleg	6.7
73		N25262	Hs.27931	ESTs	5.9
		N26101	Hs.323401	Human ring zinc-finger protein (ZNF127-	. 4
		N29454	Hs.27552	ESTs; Weakly similar to putative p150 [H	4.3
		N30856	Hs.30246	solute carrier family 19 (thiamine transpo	12.8
50		N31952	Hs.167531	Homo sapiens mRNA full length Insert cD	10.1
		N32919	Hs.27931	ESTs	4.7
		N33063		ESTs; Weakly similar to S164 [H.saplens	4.2 12.5
		N33438	Hs.170065	ESTs	4
55		N39148	Hs.6880	DKFZP434D156 protein	23.2
55		N46252	Hs.29724	ESTs protease inhibitor 1 (anti-elastase); alpha-	4.8
		N48787	Hs.305979 Hs.96870	Homo sapiens mRNA full length insert cD	5.4
		N51374 N53375	Hs.166146	Homer, neuronal immediate early gene; 3	4.7
		N53388	Hs.7222	ESTs	13.3
60		N54067	Hs.3628	mitogen-activated protein kinase kinase ki	5.7
-0		N59543	Hs.15456	PDZ domain containing 1	8.3
		N62522	Hs.20450	ESTs	14.3
		N63823	Hs.269115	ESTs	7.9
<b>.</b>		N64378	Hs.83293	ESTs; Highly similar to unknown function	4.4
65		N64683	Hs.290943	ESTs	6
	111164	N66857	Hs.14808	ESTs; Weakly similar to !!!! ALU CLASS	4.1 5.5
	111172	N67102	Hs.21851	Homo sapiens mRNA; cDNA DKFZp586	0.0

	111178 N67227	Hs.24633	ESTs		5.7
	111179 N67239	Hs.10760	ESTs		37
	111181 N67278	Hs.171802	ESTs; Weakly similar to hypothetical pro		5.6
	111184 N67437	Hs.243901	Homo sapiens mRNA; cDNA DKFZp564		8.7
5	111221 N68869	Hs.15119	ESTs		7.3
•	111223 N68921	Hs.297939	ESTs; Weakly similar to neogenin (H.sap		9
	111229 N69113	Hs.110855	ESTs		8.9
	111241 N69514	Hs.288880	ESTs; Weakly similar to CGI-82 protein [		6.9
	111268 N70481	Hs.26118		•	4.5
10	111295 N73275		Homo sapiens clone 24766 mRNA sequen		
10		Hs.21275	ESTs; Weakly similar to ubiquitin-conjug		5.6
	111299 N73808	Hs.24936	ESTs		8.5
	111336 N79565	Hs.29894	ESTs		6.7
	111357 N91023	Hs.87128	ESTs		15
1.5	111370 N92915	Hs.94631	brefeldin A-inhibited guanine nucleotide-e		5.2
15	111806 R33468	Hs.279008	ESTs		10
•	111825 R35885	Hs.286148	stromal antigen 1		4.5
	111836 R36228	Hs.25119	ESTs		7.2
	111890 R38678	Hs.12365	ESTs		17.3
	111923 R39995	Hs.25925	Homo sapiens clone 23860 mRNA sequen		7.3
20	111942 R40576	Hs.21590	ESTs		9.2
	111987 R42036	Hs.6763	KIAA0942 protein		10.6
	112101 R44793	Hs.296341	adenylyl cyclase-associated protein 2		5.3
•	112134 R46025	Hs.7413	ESTs		17.4
	112197 R49482	Hs.5637	ESTs		4.4
25	112244 R51309	Hs.70823			11
23		115.70023	KIAA1077 protein		9.3
	112253 R51818	U- 00044	Homo sapiens mRNA; cDNA DKFZp566		
	112305 R54822	Hs.26244	ESTs		4.4
	112449 R63802	Hs.124186	ring finger protein 2		6.3
20	112483 R66534	Hs.285885	ESTs		4.9
30	112519 R68631	Hs.11861	ESTs		14.3
	112610 R79392	Hs.23643	ESTs		5.2
	112693 R88741	Hs.91065	ESTs; Moderately similar to proliferation		4.6
	112751 R93507	Hs.8207	ESTs		5.6
	112801 R97486	Hs.157160	protein kinase; DNA-activated; catalytic p		8.7
35	112869 T03313	Hs.4747	dyskeratosis congenita 1; dyskerin		5.9
	112871 T03352	Hs.12285	ESTs		5.8
	112908 T10065	Hs.3530	TLS-associated serine-arginine protein		4.1
	112966 T17119	Hs.102548	glucocorticoid receptor DNA binding fact		5.7
	112971 T17185	Hs.83883	ESTs		6.4
40	112995 T23528	Hs.7155	ESTs; Weakly similar to TYKi protein [M		9.1
-10	113047 T25867	Hs.7549	ESTs		5.4
		Hs.6986			5.7
	113075 T34660		ESTs; Weakly similar to IIII ALU SUBFA		
	113117 T47819	Hs.159153	ESTs		5.8
15	113206 T58044	Hs.241471	ESTs; Moderately similar to IIII ALU SU		6.4
45	113248 T63857		yc16e1.s1 Stratagene lung (#93721) Homo		4.6
	113260 T64896	Hs.287420	ESTs		6.9
	113277 T65797	Hs.11774	protein (peptidyl-prolyl cis/trans isomeras		5.6
	113278 T65802	Hs.11135	yc11h10.s1 Stratagene lung (#937210) Ho		4.5
	113440 T86121	Hs.191445	ESTs		6.4
50	113523 T90037	Hs.95549	ESTs		6.4
	113604 T92735	Hs.296083	ESTs		8.7
	113702 T97307		ESTs; Moderately similar to !!!! ALU SU		9.5
	113783 W19222	Hs.7041	ESTs; Weakly similar to IIII ALU SUBFA		5.2
	113794 W37382	Hs.11090	ESTs		11.9
55	113808 W44735	Hs.9286	ESTs		16.7
00	113811 W44928	Hs.6994	ESTs		4
	113822 W47350	Hs.17466	retinoic acid receptor responder (tazaroten		4.8
	113823 W47388	Hs.55099	rab6 GTPase activating protein (GAP and		4
60	113836 W56792	Hs.12040	ESTs; Weakly similar to KIAA0881 prote		4.1
60	113857 W65477	Hs.5297	Homo sapiens mRNA; cDNA DKFZp564		4.3
	113886 W72471	Hs.23920	ESTs		4.6
	113895 W73738	Hs.12921	ESTs		7.1
	113923 W80763	Hs.3849	ESTs; Weakly similar to FK506-binding p		6.8
	113931 W81205	Hs.3496	ESTs		6.1
65	113950 W85765	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434		14
	113970 W86748	Hs.8109	ESTs .		15
	114051 W94942	Hs.177534	dual specificity phosphatase 10		5.4
			• • •		

	444007 11/00000	11. 04400	507-	4.0
	114057 W96222	Hs.34192	ESTs	4.8
	114086 Z38266	Hs.288649	Homo saplens PAC clone DJ0777023 fro	5.1
	114098 Z38347	Hs.118338	ESTs; Weakly similar to similar to S. cere	6.2
5	114109 Z38435 114124 Z38595	Hs.184108	ribosomal protein L21	4.6 22
,	114138 Z38763	Hs.125019 Hs.15740	ESTs; Highly similar to KIAA0886 prote amyloid beta (A4) precursor protein-bindi	8.8
	114149 Z38814	Hs.27196	ESTs	4
	114162 Z38909	Hs.22265	ESTs	7.2
	114177 Z39062	Hs.23740	ESTs	5.3
10	114196 Z39211	Hs.150926	fucose-1-phosphate guanylyltransferase	4.4
	114208 Z39301	Hs.7859	ESTs	5.1
	114250 Z39897	Hs.13297	ESTs	7.2
	114251 Z39898	Hs.21948	ESTs	14.7
	114292 Z40715	Hs.184641	delta-6 fatty acid desaturase	19.4
15	114297 Z40758	Hs.173091	DKFZP434K151 protein	8.9
	114334 Z41342	Hs.22941	ESTs	13.7
	114460 AA024604	Hs.26102	ESTs .	10.1
	114471 AA028074	Hs.104613	ESTs	5.7
	114480 AA032243	Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:po	7.3
20	114518 AA046407		suppressor of var1 (S.cerevisiae) 3-like 1	4.3
	114542 AA055768		ESTs	11.7
	114549 AA056484		ESTs	7.3
	114652 AA101416		ESTs: Weakly similar to PTB-ASSOCIAT	6.1
26	114673 AA113303		transmembrane 4 superfamily member (te	4.3
25	114698 AA126951		ESTs; Highly similar to putative DNA-dir	7.1
	114767 AA148885		minichromosome maintenance deficient (S	5.3
	114799 AA159323 114804 AA160363		ESTs	4.2 4.8
	114811 AA161161		ESTs multiple inositol polyphosphate phosphata	7.1
30	114821 AA165313		ESTs	4.4
50	114852 AA235035		ESTs; Moderately similar to ubiquitin spe	5
	114901 AA236276		ESTs; Weakly similar to R26660_1; parti	16.9
	114902 AA236359		ESTs	5.1
	114940 AA243012		ESTs	8.5
35	114965 AA250737		ESTs	35.1
	115047 AA252627		homeo box B5	5.7
	115054 AA252863		ESTs	6.2
	115061 AA253217		ESTs	13
	115082 AA255557	Hs.198269	NADH dehydrogenase (ubiquinone) 1 alp	28.2
40	115116 AA256486		ESTs	8.8
	115140 AA258030		ESTs; Weakly similar to supported by GE	4.1
	115205 AA262470		ESTs	8.3
	115206 AA262491		ESTs	5.1
15	115239 AA278650		ESTs; Weakly similar to similar to the bet	4.6
45	115242 AA278755		ESTs	8.3
	115249 AA278961		ESTs	10.1
	115259 AA279071		splicing factor 3b; subunit 1; 155kD	9.5 5.8
	115285 AA279799 115291 AA279943		ESTs ESTs	5.1
50	115357 AA281793		ESTs	5
50	115377 AA282247		ESTs	6.1
	115400 AA283198		ESTs	4.9
	115439 AA284561		ESTs	5.8
	115471 AA287138		ESTs; Weakly similar to ASPARTYL-TR	11.7
55	115506 AA292537		Human DNA sequence from clone 620E1	6.8
	115522 AA331393		ESTs	5.8
	115572 AA398392		ESTs; Weakly similar to F33G12.3 gene p	9.7
	115587 AA399264	Hs.283037	ESTs; Highly similar to HSPC039 protein	8.7
	115600 AA400247		ESTs	4
60	115612 AA400948		ESTs; Weakly similar to zinc finger prote	8.4
	115646 AA404352		ESTs	5.3
	115652 AA405098		ESTs	16.1
	115657 AA405620		ESTs; Weakly similar to weak similarity t	4.7
65	115658 AA405625		Human DNA sequence from clone 34B21	5.1
65	115675 AA406546		Homo sapiens mRNA; cDNA DKFZp564	20.5 4.8
	115721 AA417102 115763 AA421560		ESTs ESTs	4.8 7
	113703 AM42130L	•	C013	•

	115764 AA42156		anterior gradient 2 (Xenepus laevis) homo	41.6
	115835 AA42857 115844 AA43012		ESTs . ESTs	4.2
	115875 AA43394		ESTs; Weakly similar to Weak similarity	11.9 33.5
5	115888 AA43583		KIAA0887 protein	7.2
	115922 AA44191		ESTs; Weakly similar to KIAA0926 prote	5.1
	115941 AA44360		ESTs	4.8
	115947 AA44379		ESTs	8.3
10	115948 AA44379 115951 AA44391		poly(A)-specific ribonuclease (deadenylat cofilin 1 (non-muscle)	13.5
10	115967 AA44688		ESTs	7.5 . 8.8
	115984 AA44768		ESTs	13.1
	116009 AA44944		ESTs	5.5
	116024 AA45174	8 Hs.83883	Human DNA sequence from clone 718J7	7.5
15	116028 AA45211		thloredoxin-like	12.7
	116050 AA45365		ESTs	7.2
	116097 AA45609		ESTs	11.8
	116108 AA45756 116121 AA45925		ESTs ESTs	4.5
20	116127 AA45970		v-myc avian myelocytomalosis viral onco	4.5 4.3
	116129 AA45995		ESTs; Highly similar to putative ribonucle	7.6
	116142 AA46064		ESTs	4.8
	116204 AA46570	1 Hs.108646	ESTs	6.8
0.5	116221 AA47839		ESTs	4.9
25	116222 AA47841		ESTs	4
	116238 AA47936		DKFZP586N0819 protein	4.6
	116246 AA47996 116249 AA48088		ESTs; Highly similar to ubiquitin-conjuga	4
	116250 AA48097		ESTs ESTs	18.5
30	116254 AA48114		ESTs; Weakly similar to OXYSTEROL-B	10.8 9.1
-	116256 AA48125		ESTs; Weakly similar to lysophospholipa	8.4
	116264 AA48259		Homo sapiens mRNA; cDNA DKFZp586	7.2
	116265 AA48259	5 Hs.55189	ESTs; Weakly similar to F25B5.3 [C.eleg	11.1
25	116282 AA48655		ESTs; Weakly similar to Wiskott-Aldrich	6.2
-35	116298 AA48904		ESTs	4.9
	116300 AA48919		ESTs; Weakly similar to snRNP protein B	4.6
•	116327 AA49095 116334 AA49145		Homo sapiens mRNA; cDNA DKFZp564 ESTs	5.8 4.3
	116337 AA49612		ESTs	4.3 8.4
40	116351 AA50411		Homo sapiens mRNA; cDNA DKFZp434	5.3
	116357 AA50480	6 Hs.90797	Homo sapiens clone 23620 mRNA sequen	5.2
	116415 AA60920		KIAA0874 protein	6.6
	116443 AA62031		ESTs; Weakly similar to KERATIN; TYP	4.5
45	116470 C13992	Hs.83484	ESTs	4.5
43	116480 C14088	U- 75007	glyceraldehyde-3-phosphate dehydrogena	5.6
	116578 D51272 116579 D51276	Hs.75337 Hs.81915	nucleolar phosphoprotein p130	4.1
	116626 F02028	Hs.81907	leukemia-associated phosphoprotein p18 ESTs	5.8 4.9
	116647 F03069	Hs.15395	ESTs; Weakly similar to ARGINYL-TRN	6.1
50	116674 F04816	Hs.92127	ESTs	10.6
	116680 F08813	Hs.273829	LINE retrotransposable element 1	4.2
	116700 F09983	Hs.317589	ESTs	13
	116724 F13665	Hs.65641	ESTs	8.5
55	116726 F13681	Hs.53913	ESTs	5.6
33	116732 F13779 116734 F13789	Hs.165909 Hs.93796	ESTs DKFZP586D2223 protein	11.6
	116760 H11054	Hs.155342	protein kinase C; delta	5.4 4.3
	116780 H22566	Hs.30098	ESTs	4.3 5.7
	116786 H25836	Hs.301527	tumor necrosis factor (figand) superfamily	3.7 8.8
60	116787 H28581	Hs.15641	ESTs	8.6
	116790 H29532	Hs.101174	microtubule-associated protein tau	22.2
	116803 H47357	Hs.109701	ESTs; Moderately similar to weak similar	6.7
	116877 H68116	Hs.168732	ESTs	6.5
65	116921 H72948 117216 N20083	Hs.821	biglycan ESTs	20.7
O)	117232 N200579	Hs.42792 Hs.61153	ESTs ESTs	4.4
	117284 N22162	Hs.183779	ESTs; Weakly similar to cDNA EST yk33	7.4 4.1
			TO THE PROPERTY OF THE PARTY OF	4.1

	117344 N		Hs.210706	ESTs	7.4
	117367 N		Hs.42502	ESTS	10.5
	117392 N 117394 N		Hs.93405 Hs.39871	ESTs KIAAA727 protein	5.8
5	117412 N		Hs.42645	KIAA0727 protein ESTs	8.4 18.1
-	117498 N		Hs.44268	ESTs; Highly similar to myelln gene expr	5.8
	117557 N		Hs.44532	diubiquitin	12.3
	117634 N		Hs.13323	ESTs; Weakly similar to SODIUM- AND	4.4
10	117639 N		Hs.44833	ESTs	6
10	117754 N		Hs.59757	ESTs	7.6
	117852 N		Hs.136102	KIAA0853 protein	5.9
	117879 N 117924 N		Hs.303025 Hs.38891	ESTs; Weakly similar to keratin; 67K typ ESTs	7.9
	117950 N		Hs.75478	KIAA0956 protein	7.9 5
15	117992 N		Hs.172089	Homo sapiens mRNA; cDNA DKFZp586	7
	118138 N	157773	Hs.93560	ESTs; Weakly similar to trg [R.norvegicu	4.8
	118215 N		Hs.77910	3-hydroxy-3-methylglutaryl-Coenzyme A	13.4
	118229 N		Hs.166254	heat shock 90kD protein 1; alpha	5.4
20	118265 N		Hs.48645	EST	4.2
20	118336 N 118363 N		Hs.47166	ESTS	7.2
	118429 N		Hs.48938 Hs.74649	ESTs ESTs	6
	118470 N		Hs.291033	ESTs	4.1 5.4
	118472 N		Hs.42179	ESTs	10.8
25	118475 N			ESTs; Weakly similar to IIII ALU CLASS	4.5
	118493 N	67149	Hs.50115	ESTs	5.3
	118528 N		Hs.49397	ESTs	10.4
	118542 N		Hs.49427	ESTs	7.9
30	118600 N		U- 50004	ESTs	9.2
50	118695 N 118698 N		Hs.50081 Hs.50187	Homo sapiens mRNA full length insert cD ESTs	9.8
	118901 N		Hs.94445	ESTs	4.3 8.1
	118952 N			ESTs; Highly similar to CGI-90 protein [H	12.5
	118976 N	93629	Hs.93391	ESTs	5
35	118986 N		Hs.125830	ESTs	7.3
	118989 N		Hs.45105	ESTs	8.2
	119027 N		Hs.114611	ESTS	5
	119042 RG 119075 RS		Hs.5472 Hs.287820	ESTs Shannadin 1	4
40	119260 T1		Hs.102950	fibronectin 1 ESTs; Highly similar to coat protein gamm	6 4.1
. •	119271 T1		Hs.65328	ESTs	12.1
	119298 T2		Hs.155478	cyclin T2	5.6
	119302 T2	25725		ESTs	14.3
4.5	119341 Te		Hs.146388	microtubule-associated protein 7	4
45	119495 W		Hs.55533	ESTs	5.3
	119580 W		Hs.92260	high-mobility group protein 2-like 1	5.6
	119620 W		Hs.233694 Hs.56009	ESTs; Weakly similar to ZK1058.5 [C.ele 2'-5'oligoadenylate synthetase 3	6.5
	119676 W		Hs.57787	ESTs	8.1 5.5
50	119717 W		Hs.57987	ESTs	4.6
	119729 W		Hs.94806	KIAA1062 protein	4
	119805 W	73788	Hs.43213	ESTs	4
	119859 W		Hs.58461	ESTs	4.8
55	119867 W		Hs.250696	KDEL (Lys-Asp-Glu-Leu) endoplasmic re	4.2
25	119873 W		Hs.44865	Homo sapiens mRNA; cDNA DKFZp586	4.8
	119899 W		Hs.58698 Hs.272531	ESTs DKFZP586B0319 protein	5.9
	119943 W		Hs.14158	copine III	9
	119970 W		Hs.93581	Homo sapiens mRNA: cDNA DKFZn586	4.8 4
60	120131 Z3		Hs.75887	coatomer protein complex; subunit alpha	4.2
	120150 Z3		Hs.153746	ESTs	11
	120206 Z4		Hs.91668	ESTs	8.2
	120241 Z4		Hs.65946	ESTs	15.6
65	120255 AA		Hs.56/2 Hs.221040	ESTs; Weakly similar to Similarily to Yea KIAA1038 protein	4.2
JJ			Hs.104106	ESTs .	6.8
			Hs.193172	ESTs	15.2 6.8
	/-				٠.٠

	400400 ++00000		144.4.400	
	120428 AA236822		KIAA1097 protein	5.6
	120524 AA261852		ESTs	5.6
	120528 AA262107		ESTS	4.5
5	120571 AA280738		ESTs	4.9
,	120649 AA287115 120655 AA287347		ESTs	4.5
	120668 AA287833		ESTs ESTs	6.7 8.3
	120712 AA292654		eukaryotic translation initiation factor 2 al	4.6
	120713 AA292655		ESTs	10.6
10	120724 AA293470		ESTS	5.4
- 0	120873 AA358015		EST	7.1
	120885 AA365515		ESTs; Moderately similar to IIII ALU SU	4.6
	120919 AA381125		ESTs	8.2
	120948 AA397822	Hs.104650	ESTs; Highly similar to similar to mago n	8.6
15	120969 AA398116		casein kinase 1; gamma 3	10.5
	120977 AA398155	Hs.97600	ESTs	10.9
	121103 AA398936	Hs.97697	EST	7.4
	121291 AA401753	Hs.8186	lung cancer candidate	5.3
20	121320 AA403008		T-cell receptor; alpha (V;D;J;C)	13.5
20	121463 AA411745		ESTs; Weakly similar to KIAA0554 prote	8.9
	121596 AA416740		ESTs	22.6
	121723 AA419622		ESTs; Weakly similar to Mouse 19.5 mRN	8
	121748 AA421171		ESTs	5.6
25	122125 AA434411		ESTS	5.3
25	122522 AA449444		ESTs ESTs	4
	122655 AA454756 122704 AA456326		ESTS	4 6.2
	122782 AA459894		ESTs	5.3
	122856 AA463740		Src-like-adapter	13.1
30	122882 AA465381		ESTs; Weakly similar to B0041.5 [C.eleg	5.5
	122928 AA476578		ESTs	6.3
	122974 AA478625		ESTs	6
	122997 AA479295		Kelch motif containing protein	12.5
	123016 AA480103	Hs.323231	ESTs; Weakly similar to alternatively spli	4.4
35	123107 AA486071	Hs.104207	ESTs	8.3
	123111 AA486273	Hs.191721	ESTs	4.2
	123114 AA486407		ESTs; Moderately similar to KIAA0454 p	5.2
	123136 AA487449		ESTs .	4.2
40	123137 AA487468		ESTs; Weakly similar to secreted cement	14.6
40	123169 AA488892		ESTs; Weakly similar to Gag-Pol polypro	4.5
	123176 AA489020		ESTs .	5.2
	123338 AA504249		ESTs	4
	123436 AA598714 123442 AA598803		protease; serine; 15	7.3
45	123449 AA598899		ESTS Home conions mBNM: cDNM DVE7cESA	5,9 4.1
43	123494 AA599786		Homo sapiens mRNA; cDNA DKFZp564 ESTs	4.1
	123503 AA600121		ESTs	12.8
	123533 AA608751	113.250100	ESTs; Weakly similar to IIII ALU SUBFA	7.9
	123619 AA609200		ESTs	23.1
50	123673 AA609471		ESTs	6.6
	123729 AA609778	Hs.278672	membrane component; chromosome 11; s	4.7
	123819 AA620636	Hs.112264	ESTs	4
	123960 AA621785	Hs.287733	methylmalonate-semialdehyde dehydroge	7.6
~ ~	124000 D57317	Hs.74861	activated RNA polymerase II transcription	4.4
55	124006 D60302	Hs.270016	ESTs	20.6
	124012 D80240	Hs.241471	HUM5G11A Human fetal brain (TFujiwa	6.7
	124021 F02859	Hs.13974	ESTs	4.7
	124049 F10523	Hs.74519	primase; polypeptide 2A (58kD)	4.7
60	124059 F13673 124243 H66710	Hs.283713 Hs.133525	ESTs ESTs	7.7 5.5
<b>5</b> 0	124243 H00710 124308 H93575	Hs.133525 Hs.241507	Homo sapiens mRNA; cDNA DKFZp564	5.5
	124314 H94877 .	Hs.215766	GTP-binding protein	11.4 13.7
	124315 H94892	Hs.288757	v-ral simian leukemia viral oncogene hom	14
	124350 N21359	Hs.101282	Homo sapiens mRNA; cDNA DKFZp434	8.6
65	124352 N21626	Hs.102406	ESTs	7.2
	124357 N22401		yw37g07.s1 Morton Fetal Cochlea Homo	5.2
	124390 N29325	Hs.7535	ESTs; Highly similar to COBW-like place	7.9

		N40188	Hs.11090	ESTs	9.5
		N48000		Homo sapiens mRNA; cDNA DKFZp586	4.8
		N50114	Hs.266175	ESTs	6.1
5		N63172 N74604	Hs.146409 Hs.11090	cell division cycle 42 (GTP-binding prote	5.6
,		N79515	Hs.306117	ESTs interleukin 13 receptor; alpha 1	12.8
		N91279	Hs.109654	ESTs; Moderately similar to outer membr	6.4 8.3
		R01037	Hs.181013	phosphoglycerate mutase 1 (brain)	12.3
	124677	R01073		ESTs; Weakly similar to IIII ALU CLASS	5.4
10	124724	R12405	Hs.112423	Homo sapiens mRNA; cDNA DKFZp586	6.6
		R40923	Hs.106604	ESTs	4.9
		R41933		ESTs	7.2
		R44357	Hs.48712	ESTs; Weakly similar to cDNA EST EMB	8.6
15		R63652 R88992	Hs.137190	ESTs	4.9
13		T10598	Hs.180612 Hs.324841	ESTs	4.7
		T11134	Hs.431	ESTs; Weakly similar to IIII ALU SUBFA murine leukemia viral (bmi-1) oncogene h	4.4
		T78089	Hs.270134	ESTs	12.6 4.1
		T92544	Hs.137548	CD84 antigen (leukocyte antigen)	14.8
20	125132	W15495	Hs.129781	chromosome 21 open reading frame 5	6.7
	125144	W37999	Hs.24336	ESTs	4.8
		W38419		ESTs	5.3
		W86423	Hs.105413	ESTs	6.6
25		W93640	Hs.4779	ESTs; Moderately similar to similar to AD	5.8
23		Z39436	Hs.102720	ESTs	12.2
		Z39821 Z39833	Hs.288193 Hs.124940	ESTs	10.2
		AA151216		GTP-binding protein tyrosine 3-monooxygenase/tryptophan 5-m	6.8 8
			Hs.288967	ESTs	5.4
30			Hs.267812	sorting nexin 4	4.1
		AA507383		cytochrome c oxidase subunit VIc	11.5
		Al432621	Hs.82685	CD47 antigen (Rh-related antigen; integri	4
			Hs.191356	general transcription factor IIH; polypepti	9.4
25		Al283493		ribophorin II	6.2
35		H09290	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564	25.9
		AA434562 N90960		ESTS	4.1
		N99638	Hs.265398 Hs.124084	ESTs; Weakly similar to transformation-r tumor necrosis factor receptor superfamily	16.4
		A1066486		similar to S. cerevisiae RER1	9.5 5.6
40		U46278	Hs.122489	ESTs	7.5
	126537	W40262	Hs.146310	ESTs; Weakly similar to putative p150 [H	4.1
	126590	W78968	Hs.181307	H3 histone; family 3A	4.5
		AA205862	Hs.7942	ESTs	5.2
4.5		172569	Hs.125359	Thy-1 cell surface antigen	4.4
45		AI334393		ESTs	4.6
		AI203334		ESTS	11.7
		AI052047	Hs.279607 Hs.26102	ESTS	4
		R31652	Hs.821	ESTs biglycan	7 5.6
50			Hs.179729	collagen; type X; alpha 1 (Schmid metaph	14.3
			Hs.204214	ESTs	4.5
		W07286	Hs.10340	ESTs; Weakly similar to weak similarity t	5.1
	127677	AA916752	Hs.264190	ESTs; Highly similar to MEM3 [M.muscu	17.3
			Hs.136713	ESTs; Weakly similar to V4-1 (H.sapiens	4.1
55	127997	Al281549	Hs.311054	ESTs	5.5
			Hs.166229	ESTs	5.8
		H02682	Hs.292154	ESTs; Moderately similar to recombinatio	5.8
		D59653 U83908	Hs.241471 Hs.296251	EST	7.4
60		AA280617		programmed cell death 4 ESTs; Weakly similar to p60 katanin [H.s	5.8 g 3
-			Hs.183475	Homo sapiens clone 25061 mRNA sequen	8.3 6.6
			Hs.101448	metastasis associated 1	5.2
		AA412048		keratin 8	5.1
	128595		Hs.152677	short-chain alcohol dehydrogenase family	27.1
65	128610		Hs.10247	activated leucocyte cell adhesion molecule	13.2
			Hs.102708	DKFZP434A043 protein	6.7
	128649	AA142853	Hs.103106	Homo sapiens mRNA for G7b protein (G	4.5

			Hs.103135	ESTs	6.1
	128653	R48943	Hs.10315	solute carrier family 7 (cationic amino aci	4.4
	128656	AA458542	Hs.10326	coatomer protein complex; subunit epsilon	14.3
_	128717	T30617	Hs.104222	Homo saplens mRNA; cDNA DKFZp566	24.5
5	128727	M64174	Hs.50651	Janus kinase 1 (a protein tyrosine kinase)	7.3
	128764	N49308	Hs.104938	ESTs; Weakly similar to alpha 1(XVIII) c	9.2
	128781	X85372	Hs.105465	small nuclear ribonucleoprotein polypepti	5.4
	128793	W93562	Hs.105749	KIAA0553 protein	4.6
	128835	W15528	Hs.106390	Homo saplens mRNA; cDNA DKFZp586	4
10	128845	AA455658		basement membrane-induced gene	6.9
		AA400271		Homo sapiens mRNA for putative Ca2+4	4.5
		AA252023		ESTs; Weakly similar to HRIHFB2157 [H	6.4
		D61676	Hs.21851	Homo sapiens mRNA; cDNA DKFZp586	6.4
			Hs.107260	ESTs	7
15		N29353	Hs.107318	kynurenine 3-monooxygenase (kynurenin	5.2
		AA485655		proteasome (prosome; macropain) subunit	13.1
		F10290	Hs.185807	Homo sapiens clone 24758 mRNA sequen	5.8
		AA460049		ESTs; Weakly similar to SODIUM- AND	12.6
		AA131421		ESTs	9.8
20		H13108	Hs.107968	ESTs	13.9
		X62466	Hs.276770	CDW52 antigen (CAMPATH-1 antigen)	10.7
		AA129465		ESTs	4.7
		L12350	Hs.108623	thrombospondin 2	4.4
		AA234530		N-ethylmaleimide-sensitive factor	20.7
25		AA131252		ESTs	5.9
		AA282183		ESTs	5.8
		R40556	Hs.318401	ESTs; Highly similar to HSPC039 protein	7.6
		X89109	Hs.109606	coronin; actin-binding protein; 1A	
		AA211941			12
30		W24360		polyadenylate binding protein-interacting	7.9
50		AA435665	Hs.237868	Interleukin 7 receptor	5.3
				ESTs; Moderately similar to HN1 (M.mus	8.4
		H88033	Hs.109727	KIAA0733 protein	7.8
		AA151574		pilin-like transcription factor ESTs	6.4
35		AA090695			6.2
55		Z35227	Hs.109918	ras homolog gene family; member H	5.4
		AA026318		glucose regulated protein; 58kD	4.4
		C20976	Hs.110165	ESTs; Highly similar to ribosomal protein	5.7
		N93155	Hs.285976	calmodulin 1 (phosphorylase kinase; delta	7.7
40		AA037467		ESTs	6
+0		AA167268		Human ras inhibitor mRNA; 3' end	9.3
		H18027	Hs.184697	plexin C1	18.2
		W92984	Hs.288224	ESTs	5.9
		AA151621		ESTs	4.1
A E		T80814	Hs.11101	discs; large (Drosophila) homolog 3 (neur	10.9
45		AA172056		ESTs	5.3
		N23707	Hs.111138	KIAA0712 gene product	4
		AA412087		EST; Highly similar to protein inhibitor o	8
		AA421213		Lsm3 protein	5.5
50		C00225	Hs.306163	ESTs; Weakly similar to fos39554_1 [H.s	5.5
50		AA298786		ESTs	6.8
		R21443	Hs.166254	heat shock 90kD protein 1; alpha	5
		AA278243		ESTs	6.8
		AA447410		ESTs; Weakly similar to !!!! ALU SUBFA	5.1
c		AA258308		Homo sapiens mRNA; cDNA DKFZp564	5.3
55		U26727	Hs.1174	cyclin-dependent kinase inhibitor 2A (mel	8.2
	129642	R50008	Hs.11806	7-dehydrocholesterol reductase	4.3
		AA442768		translocase of inner mitochondrial membr	4.4
		M88458	Hs.118778	KDEL (Lys-Asp-Glu-Leu) endoplasmic re	4
		X06700	Hs.119571	collagen; type III; alpha 1 (Ehlers-Danlos	6
60		AA454618		associated molecule with the SH3 domain	6.4
		AA252436		lysophospholipase I	7.7
	129836	AA452161	Hs.206521	YME1 (S.cerevisiae)-like 1	5
		N20593	Hs.288932	GDP dissociation inhibitor 2	6.9
		AA102520		ESTs; Weakly similar to heat shock prote	5
55	129896	AA043021	Hs.13225	UDP-Gal:betaGlcNAc beta 1:4- galactosy	6.6
	129982	M87789		immunoglobulin gamma 3 (Gm marker)	4
	129985	AA450045	Hs.140452	cargo selection protein (mannose 6 phosp	5.8

	130029 AA236412 Hs.236510	ESTs; Moderately similar to PFT27 (M.m	5.6
	130033 M90696 Hs.181301	cathepsin S	5.4
	130036 AA195260 Hs.125849 130069 AA055896 Hs.146428	ESTs; Moderately similar to IIII ALU SU	7.4
5	130077 T24055 Hs.91379	collagen; type V; alpha 1	7.6
•	130080 X14850 Hs.147097	ribosomal protein L26 H2A histone family; member X	4
	130096 AA223874 Hs.197955	KIAA0704 protein	12.
	130114 AA234717 Hs.14992	ESTs	5 7.8
	130125 M36803 Hs.1504	hemopexin	7.2
10	130135 M61764 Hs.21635	tubulin; gamma 1	5.6
	130170 AA610070 Hs.151469	calcium/calmodulin-dependent serine pro	7.5
	130189 D43947 Hs.151761	KIAA0100 gene product	6.4
	130208 AA620556 Hs.15250	peroxisomal D3;D2-enoyl-CoA isomerase	6.4
15	130211 D50840 Hs.23703 130235 X14046 Hs.153053	UDP-glucose ceramide glucosyltransferas	4.5
13	130235 X14046 Hs.153053 130276 S75295 Hs.169149	CD37 antigen	9.1
	130280 L13738 Hs.153937	karyopherin alpha 1 (importin alpha 5) activated p21cdc42Hs klnase	8.6
	130313 AA620323 Hs.154320	ubiquitin-activating enzyme E1C (homolo	5 6.1
	130314 D85967 Hs.154332	KIAA0212 gene product	10
20	130328 AA135673 Hs.154668	KIAA0391 gene product	6.1
	130356 X84373 Hs.155017	nuclear receptor interacting protein 1	10.6
	130367 Z38501 Hs.8768	ESTs; Weakly similar to IIII ALU SUBFA	8.3
	130378 T47333 Hs.155188	TATA box binding protein (TBP)-associa	7.1
25	130384 X66364 Hs.166071	cyclin-dependent kinase 5	5.6
25	130393 D13630 Hs.155291	KIAA0005 gene product	4.1
	130399 AA449417 Hs.155356 130407 N29888 Hs.155410	Homo sapiens mRNA for pulative glucosy	4.6
	130407 N29888 Hs.155410 130414 M21121 Hs.241392	ESTs	7
	130417 U58522 Hs.155485	small inducible cytokine A5 (RANTES) huntingtin-interacting protein 2	4.1
30	130421 D21260 Hs.178710	clathrin; heavy polypeptide-like 2	7.9 4
	130441 U35835 Hs.155637	protein kinase; DNA-activated; catalytic p	6.8
	130455 X17059 Hs.155956	N-acetyltransferase 1 (arylamine N-acetyl	26.4
	130498 L38951 Hs:180446	karyopherin (importin) beta 1	4.8
2.5	130499 AA416723 Hs.158286	Homo sapiens mRNA for KIAA0446 prot	6.1
35	130511 L32137 Hs.1584	cartilage ofigomeric matrix protein (pseud	8.3
	130553 AA430032 Hs.252587	pitultary tumor-transforming 1	7.5
	130558 H96654 Hs.15984	ESTs; Weakly similar to gene pp21 protei	5.6
	130568 AA232535 Hs.16085 130583 W24957 Hs.293907	ESTs; Highly similar to CGI-13 protein [H	4
40	130585 H66211 Hs.16331	ESTs; Moderately similar to similar to C.e ESTs	13.3
, ,	130604 X03635 Hs.1657	estrogen receptor 1	10.1 39.9
	130614 AA132007 Hs.16697	ESTs	5.1
	130619 AA477739 Hs.12532	ESTs	5.9
4.5	130622 AA235247 Hs.16846	ESTs; Weakly similar to cytochrome P45	4.1
45	130625 F03969 Hs.260720	malrix metalloproteinase 2 (gelatinase A;	8.3
	130627 L23808 Hs.1695	matrix metalloproteinase 12 (macrophage	10.3
	130629 M60346 Hs.1697	ATPase; H+ transporting; tysosomal (vacu	7
	130635 M87503 Hs.1706	interferon-stimulated transcription factor	5.5
50	130639 D59711 Hs.17132 130677 H17861 Hs.17767	ESTs ESTs	7.2
50	130681 D82808 Hs.17820		13.5
	130693 AA487202 Hs.17962	Rho-associated; coiled-coil containing pro ESTs	6
	130703 N63295 Hs.18103	ESTs	6.1
	130706 AA488843 Hs.201673	comichon-like	4.3 4
55	130712 AA292066 Hs.279762	adenylate cyclase 7	5.1
	130714 X92896 Hs.18212	DNA segment on chromosome X (unique)	8.4
	130715 T98227 Hs.171952	occludin	5.7
	130744 AA203527 Hs.18747	POP7 (processing of precursor, S. cerevis	6.2
60	130747 AA471293 Hs.6879	ESTs	8.2
ou	130751 AA435633 Hs.18879 130796 R39390 Hs.19525	Homo sapiens clone 23965 mRNA sequen	8.3
	130800 AA223386 Hs.19574	ESTs	4.5
	130855 AA425439 Hs.143323	ESTs; Weakly similar to katarin p80 subu putative DNA/chromatin blnding motif	7.7
	130859 AA287327 Hs.20478	ceroid-lipofuscinosis; neuronal 2; late infa	4.3
65	130866 M58028 Hs.2055	ubiquitin-activating enzyme E1 (A1S9T a	9.8 4.3
	130880 D14678 Hs.20830	kinesin-like 2	4.5 4.5
	130891 D31891 Hs.20991	SET domain; bifurcated; 1	4
			•

	130905	AA056489	Hs 129998	ESTs	8.7
		W03592	Hs.21198	translocase of outer mitochondrial membr	20.9
					9
		AA291710 AA074596		collagen; type IV; alpha 3 (Goodpasture a	5.3
5				bromodomain adjacent to zinc finger dom	
,		M97935	Hs.21486	signal transducer and activator of transcrip	18.8
		X57985	Hs.2178	H2B histone family; member Q	13.4
		R45698	Hs.21893	ESTs; Weakly similar to cAMP inducible	8.5
		N48963	Hs.21992	KIAA0689 protein	7.2
10		AA435748		ESTs; Weakly similar to phosphatidic acid	5.2
10		X02530	Hs.2248	small inducible cytokine subfamily B (Cy	10.1
		T35341	Hs.22880	ESTs; Highly similar to dipeptidyl peptid	6.3
	131153	H11760	Hs.23606	ESTs	7.3
	131185	M25753	Hs.23960	cyclin B1	6.2
	131200	AA609427	Hs.293732	ESTs; Moderately similar to !!!! ALU SU	4.3
15	131206	AA044078	Hs.24210	ESTs	5.5
	131210	AA430047	Hs.95549	ESTs	7.1
	131227	AA429472	Hs.236522	DKFZP434P106 protein	5.6
		D38076	Hs.24763	RAN binding protein 1	5.5
	131245	AA620599		DKFZP564E1962 protein	6.7
20		AA256042		ESTs	5.8
		U25997	Hs.25590	stannlocalcin	8.9
		'AA463450		Nijmegen breakage syndrome 1 (nibrin)	6.5
		R34531	Hs.92200	KIAA0480 gene product	9.2
		H84658	Hs.279836	ESTs	12.1
25		AA608962		calcyclin binding protein	18.1
23		Z39053	Hs.27263	ESTs	7.5
		AA121127		H3 histone; family 3A	5.5
		X02152	Hs.2795	lactate dehydrogenase A	5.1
20		N39152	Hs.301804	ESTs	4.3
30		D60856	Hs.28309	UDP-glucose dehydrogenase	8.4
		N33236	Hs.28555	ESTs; Weakly similar to B0511.8 [C.eleg	5.6
		D30946	Hs.28707	signal sequence receptor, gamma (transloc	8.7
		U90551	Hs.28777	H2A histone family; member L	18.8
0.5		AA491465		ESTs	11.8
35		AA235385		ESTs; Moderately similar to alternatively	4.7
		M15182	Hs.183868	glucuronidase; beta	5.2
	131589	U52100	Hs.29191	epithelial membrane protein 2	4.4
	131615	D14533	Hs.192803	xeroderma pigmentosum; complementatio	4.6
	131664	AA136126	Hs.30327	mitogen-activated protein kinase-activated	4.3
40	131679	AA136660	Hs.30579	ESTs	9.4
	131684	U26174	Hs.3066	granzyme K (serine protease; granzyme 3	9.7
	131687	L11066	Hs.3069	heat shock 70kD protein 9B (mortalin-2)	6.2
	131689	AA599653	Hs.30696	transcription factor-like 5 (basic helix-too	8.3
		W60913	Hs.110796	ESTs; Weakly similar to cONA EST yk45	9
45		AA233225		MRS1 protein	5.2
		D49738	Hs.31053	cytoskeleton-associated protein 1	6.6
		D31352	Hs.31433	ESTs	11
		H46831	Hs.107767	ESTs; Moderately similar to CaM-KII inh	4.9
		AA460450		DKFZP586G1722 protein	9.2
50		N32724	Hs.32317	Sox-like transcriptional factor	4.5
50		L76517	Hs.3260	presenilin 1 (Alzheimer disease 3)	5.4
		AA437226		interleukin 10 receptor; alpha	4
			Hs.180628	dynamin-like protein	6.7
		J04088			5
55			Hs.156346	topoisomerase (DNA) II alpha (170kD)	11.1
55		AA044095		ESTS	
		AA158258		heterogeneous nuclear protein similar to r	5.6
			Hs.183180	ESTs; Weakly similar to RING finger pro	4.5
		AA205460		ESTs	14.3
<b>CO</b>		D62657	Hs.35086	ubiquilin-specific protease 1	6.2
60		W90146	Hs.35962	ESTs	6.3
		D86960	Hs.3610	KIAA0205 gene product	4.2
		R70167	Hs.154938	ESTs	4.3
			Hs.268122	Homo saplens mRNA; cDNA DKFZp586	4.6
		F09788	Hs.3622	procollagen-proline; 2-oxoglutarate 4-diox	6.4
65			Hs.279882	Human DNA sequence from clone 703H1	12
		D82399	Hs.136644	Homo sapiens clone 23714 mRNA sequen	10
	132017	W67251	Hs.267659	Homo saplens vav 3 oncogene (VAV3) m	4.7

	400004			
	132021 T68246 132065 D82226		chaperonin containing TCP1; subunit 5 (e	5.2
	132085 D44466		proteasome (prosome; macropain) 26S sub	8.5
	132089 AA1319		proteasome (prosome; macropain) 26S sub ESTs	13.5 4.8
5	132109 AA5998	01 Hs.40098	ESTs	4.6 6.2
	132143 AA2570	56 Hs.7972	KIAA0871 protein	14.6
	132149 T10822		ESTs	5.3
	132153 N90141		ESTs; Moderately similar to ELONGATI	9.2
10	132160 AA2817		seven in absentia (Drosophila) homolog 1	5.5
10	132164 U84573 132180 AA4055	Hs.41270	procollagen-lysine; 2-oxoglutarate 5-dioxy	8.1
	132183 L19183	Hs.199695	fibroblast activation protein; alpha; sepras hypothetical protein	15.4 12.2
	132225 AA1289		ESTs	5.6
	132227 AA4126		ESTs	6.7
15	132235 F09058	Hs.42656	ESTs	6.2
	132256 AA6088		murine leukemla viral (bmi-1) oncogene h	6
	132298 N41849	Hs.7120	Homo sapiens cytokine receptor related p	5.6
	132314 AA2852 132325 N37065	Hs.44856	small EDRK-rich factor 2 ESTs	6.8
20	132384 AA4799		Human DNA sequence from clone 167A1	4.7
	132387 R70914	Hs.281434	heat shock 70kD protein 1	4.2 9.1
	132393 W85888		ESTs; Moderately similar to IIII ALU SU	4
	132406 F09979	Hs.4774	ESTs	15
25	132407 AA4314		ESTs	8
23	132413 AA13290 132446 AA4262		KIAA1104 protein	4
	132465 AA04789		ESTs ESTs	5.3
	132482 AA42947		ESTs; Highly similar to CGI-49 protein [H	15.4 9
	132492 T03749	Hs.4990	KIAA1089 protein	8.5
30	132528 AA28300		chromosome-associated polypeptide C	4.3
	132540 AA48898		synaptogyrin 2	9.8
	132543 AA41715		protein regulator of cytokinesis 1	10.1
	132580 L37042 132586 AA41245	Hs.283738	casein kinase 1; alpha 1	5.9
35	132608 AA19958		DKFZP434N024 protein ARP3 (actin-related protein 3; yeast) hom	4.2
55	132616 AA38626		isocitrate dehydrogenase 2 (NADP+); mit	4.2 5.2
	132617 AA17191		carbonic anhydrase XII	10.1
	·132618 AA25333		adaptor-related protein complex 1; gamma	4.8
40	132640 U33821	Hs.5437	Tax1 (human T-cell leukemia virus type I	5.7
40	132668 AA45361		KIAA0776 protein	4.4
	132694 M60830 132700 N47109	Hs.5509	ecotropic viral integration site 2B	15.6
	132724 AA41796	Hs.5521	ESTs geranylgeranyl diphosphate synthase 1	7
	132738 W42674	Hs.264636	ESTs; Moderately similar to neuronal thre	5.6 4.9
45	132742 AA49086		ESTs; Weakly similar to C43H8.1 [C.eleg	7.9
	132744 X54326	Hs.55921	glutamyl-protyl-tRNA synthetase	4.1
	132795 H99152	Hs.57079	ESTs	8
	132807 AA33177		mutL (E. coli) homolog 1 (colon cancer; n	8
50	132811 U25435 132817 AB00488	Hs.57419	transcriptional repressor	4 '
50	132840 N23817	Hs.5807	tousled-like kinase 2 Homo sapians clone 23675 mRNA sequen	6.5
	132845 D62588	Hs.5813	ESTs	5.6 12.4
	132847 T48195	Hs.58189	eukaryotic translation initiation factor 3; s	7
	132856 W79865	Hs.58367	glypican 4	6.2
55	132869 N26855	Hs.203961	ESTs	6.5
	132874 AA425770		ESTs	5.6
	132880 AA444369		ESTs	7.2
	132894 D82422 132900 N56451	Hs.5944 Hs.5978	ESTs	7.5
60	132903 AA235404		LIM domain only 7 Homo sapiens clone 25186 mRNA sequen	4.4
- 5	132904 X83618	Hs.59889	3-hydroxy-3-methylglutaryl-Coenzyme A	9.1 10.7
	132906 AA142857		ESTs; Highly similar to geminin [H.sapie	10.2
	132914 AA496037		ESTs	4.7
ce	132918 AA25260		KIAA0616 protein	7.1
65	132936 AB002305		KIAA0307 gene product	8.3
	132951 U04209	Hs.61418	microfibrillar-associated protein 1	4.3
	132957 AA23479	rt5.01469	Human gene from PAC 753P9; chromoso	13.2

	132959	AA028103	Hs.61472	ESTs; Weakly similar to unknown [S.cere	18.9
	132968	N77151	Hs.61638	myosin X	5.8
	132984	H80409	Hs.62112	zinc finger protein 207	4.3
	132990	AA458761	Hs.18387	transcription factor AP-2 alpha (activating	4.2
5	132994	AA505133	Hs.279905	solute carrier family 2 (facilitated glucose	26.4
	132998	Y00062	Hs.170121	protein tyrosine phosphatase; receptor typ	4.4
		AF006082		ARP2 (actin-related protein 2; yeast) hom	4.7
		C21400	Hs.278605	KIAA0970 protein	6.6
			Hs.246315	ESTs	7.9
10		W81298	Hs.6289		5.2
10		X62055		growth factor receptor-bound protein 2	-
			Hs.63489	protein tyrosine phosphatase; non-recepto	4
		S67325	Hs.63788	propionyl Coenzyma A carboxylase; beta	5.2
		AA071387		jumping translocation breakpoint	5
1.5		R33663	Hs.64056	ESTs	5.4
15		N70633	Hs.6456	chaperonin containing TCP1; subunit 2 (b	6
		AA122147		KIAA0483 protein	5
			Hs.285996	ESTs ·	5.6
	133124	AA156049	Hs.267923	ESTs	4.1
	133126	D16469	Hs.6551	ATPase; H+ transporting; lysosomal (vacu	6.2
20	133196	R37367	Hs.6727	Ras-GTPase activating protein SH3 doma	5.1
		Y10659	Hs.285115	Interleukin 13 receptor, alpha 1	6.2
		241415	Hs.6823	ESTs; Weakly similar to intrinsic factor-B	8.3
		N90029	Hs.6831	Homo saplens clone 1400 unknown prote	4.7
			Hs.179882	Homo sapiens done 24655 mRNA sequen	5.5
25		D31161	Hs.242894	ESTs	9
20		AF006086		actin related protein 2/3 complex; subunit	7.7
		W72187	Hs.69192	ESTs; Weakly similar to cDNA EST yk37	6.7
		AA48886			
				ESTs	4.2
20		AA421079		ESTs; Weakly similar to Sox-like transcri	4.9
30		AA410507		ESTs	4.3
		L15702	Hs.69771	B-factor; properdin	9.3
		R79723	Hs.69997	zinc finger protein 238	30.4
		AA600057		KIAA0905 protein	10.4
0.5			Hs.152316	ESTs	8.5
35		H06195	Hs.7194	ESTs; Highly similar to CGI-59 protein [H	14
	133370	AA156897	Hs.72157	DKFZP564I1922 protein	5
	133391	X57579	Hs.727	Inhibin; beta A (activin A; activin AB alp	13.9
	133395	AA491296	Hs.72805	ESTs	4.3
	133422	N79516	Hs.73287	ESTs; Weakly similar to eyelid [D.melano	4.5
40	133431	AA255438	Hs.7358	Homo saplens mRNA; cDNA DKFZp566	8
		T23983	Hs.323966	ESTs	5
		AA094989		voltage-dependent anion channel 3	8.7
		X03068	Hs.73931	major histocompatibility complex; class II	5
		X78710	Hs.211581	metal-regulatory transcription factor 1	5.3
45		AA316868			6.8
43				ESTs; Weakly similar to 140G11.h [D.me	
		X52947	Hs.74471	gap junction protein; alpha 1; 43kD (conn	5.7
		D63480	Hs.278634	KIAA0146 protein	4.8
			Hs.172772	transcription elongation factor B (SIII); po	9.5 .
50		W94333	Hs.279915	translocase of inner mitochondrial membr	5
50		F03717	Hs.75063	human immunodeficiency virus type I enh	7.4
		L37368	Hs.75104	RNA-binding protein S1; serine-rich dom	5
		D13315	Hs.75207	glyoxalase I	4.2
	133617	AA148318	Hs.75249	KIAA0069 protein	4.5
	133627	U09587	Hs.75280	glycyl-tRNA synthetase	10
55		D21262	Hs.75337	nucleolar phosphoprotein p130	4.5
	133634	U24166	Hs.234279	microtubule-associated protein; RP/EB fa	15.2
	133640	D83004	Hs.75355	ubiquitin-conjugating enzyme E2N (homo	9.1
		D89077	Hs.75367	Src-like-adapter	6.4
		AA479139		acid phosphatase 1; soluble	4.8
60		AA287383		ESTs	4.2
		AA458946		ESTs	4.3
		K01396	Hs.297681	protease inhibitor 1 (anti-elastase); alpha-	
		N21648			8.3
			Hs.75659	MpV17 transgene; murine homolog; glom	4.6
65		Y00282	Hs.75722	ribophorin II	7.5
65		L27841	Hs.75737	pericentriolar material 1	9.4
		U49278	Hs.75875	ubiquitin-conjugating enzyme E2 variant	4.5
	133/65	D21255	Hs.75929	cadherin 11 (OB-cadherin; osteoblast)	6.4

WO 02/059377

		W73693	Hs.76038	isopentenyl-diphosphate della isomerase	7.9
		Z23090	Hs.76067	heat shock 27kD protein 1	4.1
		J03473	Hs.177766	ADP-ribosyltransferase (NAD+; poly (AD	13
5		M33882	Hs.301064 Hs.76391	ESTs	5.2
J			Hs.76550	myxovirus (influenza) resistance 1; homol Homo sapiens mRNA; cDNA DKFZp564	11.7 9.4
			Hs.288660	serine protease; umbilical endothelium	4.8
		M59815	Hs.170250	complement component 4A	6.7
	133842	U73477	Hs.285013	putative human HLA class II associated p	7.1
10		T68510	Hs.76704	ESTs	6.3
		U86782	Hs.178761	26S proteasome-associated pad1 homolog	13.7
		D43948	Hs.76989	KIAA0097 gene product	4.1
		U58090	Hs.183874 Hs.182793	cullin 4A	4
15		X01060	Hs.77356	ESTs transferrin receptor (p90; CD71)	4.7
		N32811	Hs.77542	ESTs	8.3 5
		W72783	Hs.58382	ESTs; Weakly similar to C13F10.5 [C.ele	4.5
		AA045870		Homo saplens mRNA; cDNA DKFZp564	6.3
			Hs.173878	4-nitrophenylphosphatase domain and non	6.4
20	133963	L34587	Hs.184693	transcription elongation factor B (SIII); po	6.3
		D00760	Hs.250811	proteasome (prosome; macropain) subunit	11.9
		C02374	Hs.7822	Homo sapiens mRNA; cDNA DKFZp564	8.2
		M28213	Hs.78305	RAB2; member RAS oncogene family	5.2
25		J03077	Hs.78575	prosaposin (variant Gaucher disease and v	4.6
23		Z81326 S82470	Hs.78589 Hs.78768	protease inhibitor 12 (neuroserpin)	6.5
		D28473	Hs.172801	BB1 isoleucine-tRNA synthetase	11.9
		D87685	Hs.78893	KIAA0244 protein	5.2 7.3
		H98621	Hs.78946	cullin 3	4.7
30		U51166	Hs.173824	thymine-DNA glycosylase	7
		M22382	Hs.79037	heat shock 60kD protein 1 (chaperonin)	4.5
		X06323	Hs.79086	ribosomal protein; mitochondrial; L3	9.4
		U41060	Hs.79136	LIV-1 protein; estrogen regulated	4.4
35		U32519	Hs.220689 Hs.181634	Ras-GTPase-activating protein SH3-doma	6.6
33		M63138	Hs.79572	Human Chromosome 16 BAC clone CIT9	8.6
		U88871	Hs.79993	cathepsin D (lysosomal aspartyl protease) peroxisomal biogenesis factor 7	9.3
		L28010	Hs.808	heterogeneous nuclear ribonucleoprotein F	6.3 4.3
9.0		AA430008		ESTs	6.9
40	134310	AA313414	Hs.8148	Homo sapiens clone 24856 mRNA sequen	7.4
		U16306	Hs.81800	chondroitin sulfate proteoglycan 2 (versic	6.1
		D38551	Hs.81848	RAD21 (S. pombe) homolog	8.6
		AA452020		ESTs: Weakly similar to CGI-128 protein	6.1
45		R82074	Hs.82109	syndecan 1	4.4
73		L43575 M37033	Hs.82171 Hs.82212	Human clone 19187 placenta expressed m CD53 antigen	6.6
		X54199	Hs.82285	phosphoribosylglycinamide formyltransfe	5.3 4.8
		D62633	Hs.8236	ESTs	15.2
		AA412720		ESTs; Highly similar to CGI-118 protein	7.2
50	134376	X02874	Hs.82396	2';5'-oligoadenylate synthetase 1	6.4
	134381		Hs.184270	capping protein (actin filament) muscle Z-	4
		M15841	Hs.82575	small nuclear ribonucleoprotein polypepti	5.7
	134395		Hs.8262	lysosomal-associated membrane protein 2	6.9
55	134399		Hs.82689	tumor rejection antigen (gp96) 1	4.5
55		J04177	Hs.211577 Hs.82772	kinectin 1 (kinesin receptor)	11.2
		AA329274		collagen; type XI; alpha 1 protein tyrosine phosphatase type IVA; m	15.3
	134417		Hs.82921	solute carrier family 35 (CMP-sialic acid t	4.1 4.2
	134419		Hs.82961	trefoil factor 3 (intestinal)	5.9
60	134421	AA122386		collagen; type V; alpha 2	5.8
		W96151	Hs.83006	ESTs; Highly similar to CGI-139 protein	4.4
		AA449984		ESTs; Highly similar to proteine kinase JN	7
	134446		Hs.83419	KIAA0252 protein	4.6
65	134453 134470		Hs.83484 Hs.83758	SRY (sex determining region Y)-box 4 CDC28 protein kinase 2	5.1
33	134487		Hs.83954	Homo sapiens unknown mRNA	20.3
	134495		Hs.84087	KIAA0143 protein	5
				· ··· · · · · · · · · · · · · · · · ·	16.1

		M63180 U45328	Hs.84131 Hs.84285	threonyl-IRNA synthetase	6.1
		H24460	Hs.848	ubiquitin-conjugating enzyme E2I (homol FK506-binding protein 4 (59kD)	. 4.6 6.2
_		U66615	Hs.172280	SWI/SNF related; matrix associated; actin	4.8
5		AA234966		CGG triplet repeat binding protein 1	4.7
		R68884	Hs.86347	ESTs; Weakly similar to predicted using G	5.8
		X74496 W23625	Hs.86978 Hs.8739	prolyl endopeptidase	4.5
			Hs.123090	ESTs; Weakly similar to ORF YGR200c [ ESTs	13.7 5.8
10	134675	AA250745		protein kinase; cAMP-dependent; catalyti	8.9
		X04011	Hs.88974	cytochrome b-245; beta polypeptide (chro	6.8
		U89922	Hs.890	lymphotoxin beta (TNF superfamily; mem	35.7
		W47183 J05582	Hs.284226	ESTs; Weakly similar to neural F box pro	8.1
15		Z49099	Hs.89603 Hs.89718	mucin 1; transmembrane spermine synthase	. 6.2 4.2
		M27394	Hs.89751	membrane-spanning 4-domains; subfamily	7
		U51477	Hs.89981	diacylglycerol kinase; zeta (104kD)	4.1
		H60595	Hs.90061	progesterone binding protein	4.7
20		D82348 U84011	Hs.90280	5-aminolmidazole-4-carboxamide ribonuc	10.2
20		Z39762	Hs.904 Hs.90419	amylo-1;6-glucosidase; 4-alpha-glucanotr KIAA0882 protein	12.1
		N27670	Hs.9071	progesterone membrane binding protein	6 5
		N46086	Hs.92308	ESTs	4.1
25		AA236324		Homo saplens mRNA; chromosome 1 spe	16.8
25		H05625	Hs.5831	ESTs	4
		D59675	Hs.301005 Hs.92927	purine-rich element binding protein B	4.4
		U54999	Hs.278338	ESTs LGN protein	7 4.8
		AA224180		ESTs; Moderately similar to 17-beta-hydr	13.6
30	135032	AA243497	Hs.173685	Human DNA sequence from clone 30M3	4
		U77948	Hs.278589	general transcription factor II; i	8
		AA598449		Homo sapiens clone 24483 unknown mRN	5.4
		L08069 AA495950	Hs.94	heat shock protein; DNAJ-like 2 ESTs	9.3
35		W52493	Hs.94694	Homo sapiens clone 24837 mRNA sequen	6.7 10.2
		AA044842		Homo saplens mRNA; cDNA DKFZp586	6.6
			Hs.267812	sorting nextn 4	7.4
		D31157	Hs.324277	ESTs; Weakly similar to growth factor-res	6.2
40		AA454930 AA215333		ESTs	19.5
70		H20989	Hs. 198281	pulative G protein-coupled receptor pyruvate kinase; muscle	8.8
		D83174	Hs.9930	collagen-binding protein 2 (colligen 2)	12.4 5.5
	135367	AA480109		TYRO protein tyrosine kinase binding pro	5.4
4 ~		U05237	Hs.99872	fetal Alzheimer antigen	7.8
45		M23263	Hs.99915	androgen receptor (dihydrotestosterone re	9.1
		L10333 M97935	Hs.99947	reticulon 1	5.3
•		M97935		AFFX control: STAT1 AFFX control: STAT1	8.3 7
		M97935		AFFX control: STAT1	14
50		Al199738	Hs.208275	ESTs; Weakly similar to IIII ALU CLASS	9.1
	300107	AI694585	Hs.270464	ESTs; Weakly similar to !!!! ALU CLASS	7.4
	300254	AW079607	Hs.188417	ESTs; Weakly similar to ZnT-3 [H.sapien	30.1
		AW015860 AA699328		ESTs ESTs	11.9
55		Al492179	Hs.166244	ESTs; Weakly similar to cONA EST yk40	5.5 11
		AW293224	Hs.232165	ESTs	ii
	301124	T79326	Hs.298262	ESTs; Wealdy similar to dJ88J8.1 [H.sapi	8.8
		N85789	Hs.150186	ESTs; Weakly similar to PTERIN-4-ALP	6
60		A1682905	Hs.270431	ESTs; Weakly similar to IIII ALU SUBFA	4.7
00		AA373124 AA526313		ESTs; Weakly similar to C17G10.1 [C.ele	8
	301782		Hs.143046	ESTs EST cluster (not in UniGene) with exon h	4.2 18
		AA312082		GDNF family receptor alpha 1	20.7
c =	301936	NM_004694	Hs.114924	EST cluster (not in UniGene) with exon h	11.6
65		AF013956		chromobox homolog 4 (Drosophila Pc da	9.2
		NM_001992		EST cluster (not in UniGene) with exon h	4.3
	302067	いいつひせる	Hs.222399	ESTs; Weakly similar to protein-tyrosine	7.8

	302145 NM_003613Hs.151407	EST cluster (not in UniGene) with exon h	15.
	302236 Al128606 Hs.6557	zinc linger protein 161	25.
	302276 NM_004448Hs.323910	EST cluster (not in UniGene) with exon h	21.
5	302290 AL117607 Hs.175563	Homo sapiens mRNA; cDNA DKFZp564	41.
,	302326 NM_004271Hs.184018	EST duster (not in UniGene) with exon h	8.9
	302342 AB023141 Hs.190386 302372 AL117406 Hs.200102	KIAA0924 protein	5.4
	302422 AB021227 Hs.3743	Homo sapiens mRNA; cDNA DKFZp434	8.9
	302431 AF129530 Hs.226434	matrix metalloproteinase 24 (membrane-in	5.2
10	302501 AF022726 Hs.251446	EST cluster (not in UniGene) with exon h EST cluster (not in UniGene) with exon h	5.3
	302505 AL049650 Hs.247874	multiple UniGene matches	9.9
	302533 L36149 Hs.248116	chemokine (C motif) XC receptor 1	4.3 4.9
	302638 AA463798 Hs.102696	ESTs; Weakly similar to C11D2.4 [C.eleg	. 5.3
	302656 AW293005 Hs.70704	ESTs	8.4
15	302792 AA343696 Hs.46821	ESTs; Weakly similar to putative [H.sapie	4.5
	302820 X04588 Hs.85844	EST duster (not in UniGene) with exon h	6.8
	302838 U66049 Hs.82171	EST duster (not in UniGene) with exon h	8.4
	302892 N58545 Hs.42346	histone deacetylase 3	22.
20	302977 AW263124 Hs.315111	EST duster (not in UniGene) with exon h	6.8
20	302989 N46406 Hs.84700	EST cluster (not in UniGene) with exon h	8.9
	303007 AA478876 Hs.317714	pallid (mouse) homolog; pallidin	10.1
	303052 AF140242 Hs.279926	EST cluster (not in UniGene) with exon h	24.4
	303131 AW081061 Hs.103180 303132 AI929819 Hs.4055	actin-like 6	6.3
25	303132 Al929819 Hs.4055 303153 U09759 Hs.246857	ESTs	17.7
	303387 AA908797 Hs.180799	mltogen-activated protein kinase 9 ESTs	11.4
	303499 Al815990 Hs.293515	ESTs	15.8 7.2
	303502 AA488528	EST duster (not in UniGene) with exon h	5.3
	303576 T07216 Hs.301226	EST cluster (not in UniGene) with exon h	16.2
30	303620 AA397546 Hs.119151	ESTs	8.9
	303634 Al953377 Hs.28444	ESTs; Weakly similar to predicted using G	12
	303642 AW299459 Hs.111977	EST cluster (not in UniGene) with exon h	4.2
	303654 AA436942 Hs.288529	ESTs	8.4
35	303733 AW502498 Hs.15220	ESTs; Weakly similar to zinc finger prote	5.2
33	303780 Al424014 Hs.18995	ESTs; Moderately similar to KIAA0456 p	28.4
	303792 C75094 Hs.199839 303842 Al337304 Hs.126268	ESTs; Highly similar to NG22 [H.sapiens	4.4
	303842 Al337304 Hs.126268 303951 AW475081 Hs.172928	ESTs; Weakly similar to similar to PDZ d	8.1
	304465 AA421948	collagen; type I; alpha 1	7.5
40	304507 AA456426	EST singleton (not in UniGene) with exon EST	6.5
. •	304591 AA505702	EST singleton (not in UniGene) with exon	5.4
	304601 AA507875	EST singleton (not in UniGene) with exon	9.8 7.5
	304659 AA533185	EST singleton (not in UniGene) with exon	7.5
	305040 AA630582 Hs.169476	glyceraldehyde-3-phosphate dehydrogena	12.4
45	305134 AA653159 Hs.179661	EST singleton (not in UniGene) with exon	8.7
	305415 AA725116 Hs.78465	EST singleton (not in UniGene) with exon	5.3
	305453 AA738110	EST singleton (not in UniGene) with exon	4.1
	305898 AA872838	keratin 8	7.7
50	305913 AA876109	EST singleton (not in UniGene) with exon	6.3
50	305950 AA884479	EST singleton (not in UniGene) with exon	5.6
	306004 AA889992 Hs.2186	EST singleton (not in UniGene) with exon	13.2
	306009 AA894560 Hs.283370	EST singleton (not in UniGene) with exon	4.4
	306060 AA906161 Hs.76277 306398 AA970548 Hs.297681	EST singleton (not in UniGene) with exon	4.6
55	306505 AA987722 Hs.172928	EST singleton (not in UniGene) with exon	7.6
33	306576 AA995761 Hs.276092	EST singleton (not in UniGene) with exon	19.7
	307117 AJ184111 Hs.76067	EST singleton (not in UniGene) with exon heat shock 27kD protein 1	5.5
	307138 Al185516 Hs.172928	collagen; type I; alpha 1	7.7
	307187 Al190870 Hs.276417	EST singleton (not in UniGene) with exon	8.8 4.1
60	307542 Al280859 Hs.62954	EST singleton (not in UniGene) with exon	
	307554 Al281603 Hs.172928	EST singleton (not in UniGene) with exon	6 10.8
	307806 Al351739 Hs.276726	EST singleton (not in UniGene) with exon	4.7
	308079 Al472733 Hs.270208	ESTs	4.2
cr	308307 Al581398 Hs.172928	collagen; type I; alpha 1	5.4
65	308511 Al687580 Hs.169476	EST singleton (not in UniGene) with exon	10.1
	308615 AI738593 Hs.101774	EST singleton (not in UniGene) with exon	15.1
	308677 Al761173	EST singleton (not in UniGene) with exon	4.6

	308852 Al829848 Hs.182937	peptidylprotyl isomerase A (cyclophilin A	5.9
		immunoglobulin gamma 3 (Gm marker)	4.5
	308981 AI873242	EST singleton (not in UniGene) with exon	7.6
-	308995 Al880172	EST singleton (not in UniGene) with exon	6.6
5	309177 Al951118	EST singleton (not in UniGene) with exon	24.3
	309186 Al952723 Hs.90207	EST singleton (not in UniGene) with exon	6.1
	309198 Al955915	major histocompatibility complex; class I;	5.6
	309226 Al969897	EST singleton (not in UniGene) with exon	6.2
	309279 Al990102		
10		EST singleton (not in UniGene) with exon	7.9
10	309583 AW170035	EST	64.5
	309624 AW191929 Hs.252989	EST	5.3
	309629 AW192764 Hs.172928	collagen; type I; alpha 1	6.9
	309641 AW194230 Hs.253100	EST	11.4
	309698 AW238461 Hs.73742	ribosomal protein; large; P0	4.3
15	309700 AW241170 Hs.179661	Homo sapiens clone 24703 beta-tubulin m	11.9
13	310073 Al335004 Hs.148558	•	
		ESTs	4.2
	310094 AW450967 Hs.235240	ESTs	5.7
	310373 AW080778 Hs.145582	ESTs	4.8
	310438 AW022192 Hs.200197	ESTs	39,1
20	310470 Al281848 Hs.194691	ESTs	4.9
-	310583 AW205632 Hs.211198	ESTs	7
	310877 T47784 Hs.188955	ESTs	
			4.1
	311067 Al587332 Hs.209115	ESTs	11.2
0.5	311166 Al821294 Hs.118599	ESTs	24.1
25	311199 T57896 Hs.191095	EST cluster (not in UniGene)	5.7
	311465 AI758660 Hs.206132	ESTs	15.7
	311587 Al828254 Hs.271019	ESTs	6.4
	311774 AA700870 Hs.14304	ESTs	6.2
	311785 Al056769 Hs.133512	ESTs	5
30			
50		ESTs	5.9
	311935 AA216387	EST cluster (not in UniGene)	5.5
	311972 N51511 Hs.188449	EST8	5.2
	· 312014 Al435650 Hs.128778	ESTs	4.3
	312047 AA588275 Hs.180669	ESTs	14.7
35	312147 T89855 Hs.195648	EST cluster (not In UniGene)	9.8
	312153 AA759250 Hs.153028	cytochrome b-561	27.1
	312168 T92251 Hs.198882	ESTs	
			4.2
	312172 Al222168 Hs.191168	ESTs	6.1
40	312226 Al796815 Hs.199993	ESTs; Weakly similar to ubiquitous TPR	5.5
40	312292 AW451893 Hs.151124	ESTs	18.4
	312312 Al080505 Hs.134529	ESTs ·	11.9
	312369 AA582039 Hs.173884	Homo sapiens mRNA; chromosome 1 spe	4
	312407 R46180 Hs.153485	ESTs	13.6
	312430 AW139117 Hs.117494	ESTs	4.1
45			
77	312470 AW451347 Hs.175862	ESTs	4.6
	312483 Al417526 Hs.7753	ESTs	15.3
	312521 AA033609 Hs.319093	ESTs	12.5
	312544 Al498371 Hs.183526	ESTs	14.6
	312638 AW439195 Hs.256880	ESTs	5.3
50	312754 R99834 Hs.250383	ESTs	8.4
	312772 H63791	EST duster (not in UniGene)	4.3
	312821 AA699325 Hs.269880		
		ESTs .	8.3
	312837 AW292286 Hs.255058	ESTs	7.1
	312849 AA846353 Hs.194054	ESTs	5.9
55	312854 AA828713 Hs.321058	EST cluster (not in UniGene)	4.1
	312992 AA088446 Hs.170298	ESTs	7.3
	313096 Al422367 Hs.163533	ESTs .	6.1
	313112 AA732534 Hs.269099	ESTs	4.2
	313126 AA720887 Hs.283313	EST cluster (not in UniGene)	
60		'	18.1
00	313136 N59284 Hs.288010	ESTS	17
	313197 Al738851 Hs.222487	ESTs	12.9
	313219 N74924 Hs.182099	ESTs	7.1
	313258 AW068358 Hs.183918	ESTs	13.7
	313328 AW449211 Hs.105445	ESTs	27.9
65	313352 AW292127 Hs.144758	ESTs	9.8
	313417 AA741151 Hs.137323	ESTs	8.2
		ESTs	
	313455 AW081702 Hs.98571	E019	6.9

	313590 AA804410 Hs.291677	EST duster (not in UniGene)	5.3
	313663 Al953261 Hs.169813	ESTs	7.6
	313667 U69201 Hs.13684	ESTs; Weakly similar to choline kinase is	12.5
_	313749 AW450376 Hs.119004	ESTs	5.5
5	313832 AW271022 Hs.133294	ESTs	4.3
	313881 AA535580 Hs.16331	ESTs	7.7
	313915 Al969390 Hs.163443	ESTs	27.1
	313955 AI858884 Hs.270647	ESTs	5.7
	313974 Al310151 Hs.173524	ESTs	4.3
10	314097 AA648744 Hs.269493	ESTs	14.5
	314129 AA228366 Hs.115122	ESTs	9.5
	314359 AA205569 Hs.194193	ESTs	
	314384 AA535840 Hs.162203		5.4
		ESTs; Weakly similar to alternatively spli	5.3
15	314394 Al380563 Hs.130816	ESTs	13.2
IJ	314462 AA347951 Hs.326413	ESTs	6.2
	314465 AA602917 Hs.156974	ESTs	18.1
	314470 Al934422 Hs.30661	ESTs:	4.2
	314488 AA358265 Hs.182890	ESTs	6.1
20	314506 AA833655 Hs.206868	ESTs	27.8
20	314510 Al204418 Hs.190080	ESTs	9.5
	314558 Al873274 Hs.190721	ESTs	22.5
	314661 AA436432 Hs.324239	EST duster (not in UniGene)	13.3
	314691 AW207206 Hs.136319	ESTs	21.4
	314754 AW026761 Hs.134374	ESTs	4.4
25	314775 AI149880 Hs.188809	ESTs	4.4
	314943 Al476797 Hs.184572	cell division cycle 2; G1 to S and G2 to M	18.4
	314961 AW008061 Hs.231994	ESTs	10.2
	314963 Al689617 Hs.200934	ESTs	5.3
	315006 Al538613 Hs.298241	ESTs	20.7
30	315010 AA531082 Hs.240049	ESTs	5
20	315019 AA532807 Hs.105822	ESTs	
	315033 Al493046 Hs.146133	ESTs	6.1
			12
	315036 AA534953 Hs.163297	ESTs	8.3
35	315037 AW205863 Hs.133988	ESTs; Weakly similar to gene MAC25 pr	6.1
33	315051 AW292425 Hs.163484	EST	12.7
	315054 AI968598 Hs.78768	ESTs	7.6
	315073 AW452948 Hs.257631	ESTs	13.9
	315080 AA744550 Hs.136345	ESTs	4.4
40	315083 Al221325 Hs.205442	ESTs	5.1
40	315088 AA557351 Hs.152448	ESTs; Moderately similar to MULTIFUN	4.7
	315175 Al025842 Hs.152530	ESTs	11.9
	315195 AA972756 Hs.44898	ESTs	28.8
	315296 AA876905 Hs.125286	ESTs	16.1
	315303 AW194364 Hs.128022	ESTs; Weakly similar to FIG-1 PROTEIN	25.7
45	315352 AA604799 Hs.136528	ESTs; Moderately similar to !!!! ALU SU	12.3
	315364 AA643602 Hs.155485	ESTs; Highly similar to serine protease [H	4.6
	315368 AW291563 Hs.104696	ESTs	4.8
	315390 Al801565 Hs.200113	ESTs; Weakly similar to alternatively spli	4.4
	315408 AW273261 Hs.216292	ESTs	5
50	315458 AA872000 Hs.116104	ESTs	7.6
•	315472 AA828850 Hs.165469	ESTs	4.9
	315478 AA665612 Hs.120874	ESTs	5.2
	315498 AA628539 Hs.116252	ESTs; Moderately similar to IIII ALU SU	
			4.8
55	315527 Al791138 Hs.116768	ESTs	4.4
55	315530 Al200852 Hs.127780	ESTs .	22.4
	315562 AA737415 Hs.152826	ESTs	5.9
	315634 AA837085 Hs.220585	ESTs	8.8
	315647 AA648983 Hs.212911	ESTs	15
60	315652 Al521489 Hs.3053	ESTs	6.3
60	315676 AW002565 Hs.124660	ESTs	9.2
	315680 AA814309 Hs.123583	ESTs	8.1
	315735 AI831760 Hs.155111	ESTs	13.4
	315741 AA812168 Hs.122559	ESTs	5.4
	315769 AA744875 Hs.189413	ESTs	4.4
65	315978 AA830893 Hs.119769	ESTs	10.4
	315984 Al015862 Hs.131793	ESTs	5
	316042 AW297979 Hs.170698	ESTs .	14.7

		•	
	316136 AA830808 Hs.124366	ESTs	4
	316177 Al908272 Hs.293102	EST cluster (not in UniGene)	32.6
	316313 AA741300 Hs.202599	ESTs	4.8
5	316405 AA757900 Hs.270823 316480 AI749921 Hs.205377	ESTs ESTs	4.8
,	316564 AI743571 Hs.168799	ESTs; Weakly similar to IIII ALU SUBFA	12.9 8.1
	316714 AA809792 Hs.123307	ESTs	5
	316715 Al440266 Hs.170673	ESTs	4.2
	316828 AA828116 Hs.173076	ESTs	5.2
10	316869 Al954880 Hs.134604	ESTs	13.3
	316905 AW138241 Hs.210846	ESTs	6.2
	316943 AW014875 Hs.137007	ESTs	5.3
	316949 AA856749 Hs.124620	ESTs	7.2
15	317008 AW051597 Hs.143707 317028 AA962623 Hs.189144	ESTs Worldwain-Rocks DENAL CODILL	4.1
13	317067 Al805392 Hs.325335	ESTs; Weakly similar to RENAL SODIU ESTs	4.2
	317069 Al732892 Hs.190489	ESTs	4.5 6.4
	317210 AA490718	EST cluster (not in UniGene)	4.4
	317298 Al922374 Hs.158549	ESTs	5.9
20	317658 AW139077 Hs.202217	ESTs	4.6
	317674 AW294909 Hs.132208	ESTs	5.2
	317685 Al798630 Hs.149997	ESTs	4.3
	317836 AA983913 Hs.128929	ESTs	12.4
25	317881 Al827248 Hs.224398	ESTs	12.1
25	317902 Al828602 Hs.211265	ESTs	8.8
	317916 Al565071 Hs.159983 318042 AW294522 Hs.149991	ESTS	12.6
	318053 Al074465 Hs.133469	ESTs ESTs	5.6 4
	318064 AW296888 Hs.170939	ESTs	5.2
30	318070 Al024594 Hs.248942	ESTs	4.7
	318073 AW167087 Hs.131562	ESTs	15.7
•	318146 AI040125 Hs.150521	ESTs	5.9
	318186 AW016773 Hs.3709	ESTs	5.3
35	318481 Al291584 Hs.145921	ESTs; Weakly similar to HYPOTHETICA	7.6
33	318566 Al335361 Hs.226376	ESTs	5.8
	318617 AW247252 Hs.75514 318662 Al285898 Hs.294014	nucleoside phosphorylase	11.1
	318691 AW192139 Hs.181307	ESTs H3 histone; family 3A	16.3 4
	318740 NM_002543Hs.77729	EST duster (not in UniGene)	21.3
40	318744 AI793124 Hs.144479	ESTs	35
	318948 AA317274 Hs.13996	ESTs	11.7
	319163 F15257 Hs.27	glycine dehydrogenase (decarboxylating;	7
	319478 R06841 Hs.270307	EST cluster (not in UniGene)	8.9
A.E	319545 R83716 Hs.14355	ESTs	8.2
45	319668 NM_002731Hs.87773	EST cluster (not in UniGene)	25.4
	319763 AA460775 Hs.6295	ESTs	7
	319913 AA179304 Hs.271586 319936 W22152 Hs.282929	ESTs; Moderately similar to !!!! ALU SU EST cluster (not in UniGene)	8.7
	319951 AA307665 Hs.14559	ESTs	5.6 4.9
50	319962 H06350 Hs.135056	ESTs	9.2
	319977 AA632632	EST cluster (not in UniGene)	4.6
	320074 AA321166 Hs.278233	EST cluster (not in UniGene)	16.7
	320092 AF022799 Hs.113292	calpain 9 (nCL-4)	5.4
	320107 AA836461 Hs.291712	EST duster (not in UniGene)	5.3
55	320133 D63271	EST duster (not in UniGene)	5.5
	320167 AA984373 Hs.90790	EST cluster (not in UniGene)	15
	320187 T99949 Hs.303428 320211 AL039402 Hs.125783	EST duster (not in UniGene)	6.7
	320401 U90449 Hs.152717	DEME-6 protein nucleoside diphosphate kinase type 6 (inh	24.3
60	320458 Al884396 Hs.24131	ESTs	10 5.4
	320488 R31386 Hs.191791	EST duster (not in UniGene)	4.9
	320521 N31464 Hs.24743	ESTs	9.5
	320661 AA864846 Hs.115175	EST cluster (not in UniGene)	6.6
<i>~</i> =	320691 R61576 Hs.313951	hypothetical protein	5.9
65	320699 R63161 Hs.118249	EST duster (not in UniGene)	4
	320727 U96044 Hs.181125	EST cluster (not in UniGene)	45.3
	320993 AL050145 Hs.225986	Homo sapiens mRNA; cDNA DKFZp586	7.2

	321012 AA737314 Hs.194324	EST cluster (not in UniGene)	6.4
	321050 AW393497	EST duster (not in UniGene)	6.1 5
	321051 AF134149 Hs.240395	EST cluster (not in UniGene)	11.
•	321171 AI769410 Hs.221461	ESTs	
5	321192 AA295304 Hs.297939	ESTs; Weakly similar to neogenin [H.sap	7.7 5.5
	321354 AA078493	EST duster (not in UniGene)	
	321387 H68014 Hs.141278	ESTs; Weakly similar to IIII ALU SUBFA	16.
	321412 AW366305 Hs.22891	EST cluster (not in UniGene)	4.2
	321489 AW392474 Hs.172759	ESTs; Moderately similar to IIII ALU SU	6.3 9
10	321539 N98619 Hs.42915	ARP2 (actin-related protein 2; yeast) hom	
	321593 H84762 Hs.253197	ESTs	11.
	321666 D28390 Hs.272897	EST cluster (not in UniGene)	10.4
	321891 AW157424 Hs.165954	ESTs	19.
	321910 H67065 Hs.271530	ESTs; Weakly similar to IIII ALU SUBFA	5.6
15	321953 AW068268 Hs.292833	ESTs; Weakly similar to !!!! ALU CLASS	5.4
	321978 N77342 Hs.21851	EST cluster (not in UniGene)	6.5
	322017 AA310039 Hs.9192	ESTs	10.3
	322026 AA233527 Hs.283675	low density lipoprotein receptor (familial	9.8
	322035 AL137517 Hs.306201	EST cluster (not in UniGene)	27.1
20	322171 AF085968 Hs.48474	EST cluster (not in UniGene)	40.2
	322175 AF085975	EST duster (not in UniGene)	5.7
	322236 AL134970 Hs.104222	follistatin-like 1	7.7
	322303 W07459 Hs.157601	EST cluster (not in UniGene)	14.4
	322735 AA086123 Hs.297856	EST duster (not in UniGene)	13.4
25	322777 AA679082 Hs.269947	ESTs	7.6
	322818 AW043782 Hs.293616	ESTs	4.4
	322882 AW248508 Hs.279727	DiGeorge syndrome critical region gene 2	21
	322975 C16391	EST cluster (not in UniGene)	15.3
	322991 C18965 Hs.159473	ESTs	21.3
30	323011 AA580288	EST cluster (not in UniGene)	11.7
	323091 AW014094 Hs.210761	ESTs	8.9
	323107 Al301107 Hs.150790	ESTs	10.8
	323136 AL120351 Hs.30177	EST duster (not in UniGene)	6.5
	323168 AL120862 Hs.124165	ESTs	5.5
35	323195 Al064982 Hs.117950	multifunctional polypeptide similar to SA	17.9
	323201 AL049370 Hs.13350	Homo sapiens mRNA; cDNA DKFZp586	5.8
	323203 AA203135 Hs.130186	ESTs	11.6
	323243 W44372 Hs.110771	EST cluster (not in UniGene)	6.4
	323244 T70731 Hs.193620	EST cluster (not in UniGene)	7.3
40	323328 AA228078 Hs.255096	EST cluster (not in UniGene)	15.8
	323332 Al829520 Hs.227513	ESTs	4.8
	323333 AA228883 Hs.208558	EST cluster (not in UniGene)	20.2
	323570 AL038623 Hs.208752	ESTs; Weakly similar to IIII ALU SUBFA	8.8
	323604 Al751438 Hs.41271	ESTs; Weakly similar to IIII ALU SUBFA	5
45	323685 AA344205 Hs.289088	EST cluster (not in UniGene)	6.5
	323753 AA327102 Hs.70266	EST duster (not in UniGene)	7.1
	323817 AA410943	EST cluster (not in UniGene)	6.1
	323845 Al684674 Hs.41127	ESTs; Weakly similar to waclaw [D.melan	16.8
	323930 AA570698 Hs.8173	ESTs Weakly similar to wactaw (Different	10.1
50	323997 AA844907 Hs.274454	EST cluster (not in UniGene)	6.4
	324047 AA378201 Hs.271340		8
	324261 AL044891 Hs.269350	EST duster (not in UniGene)	6.3
	324302 AA543008 Hs.292471	EST duster (not in UniGene)	50.1
	324338 AL138357 Hs.145078	ESTs; Weakly similar to IIII ALU SUBFA ESTs	5.7
55	324344 AW502000 Hs.46677	EST duster (not in UniGene)	9.5
	324432 AA464510 Hs.152812	EST duster (not in UniGene)	4.4
	324495 AW501411 Hs.122489	ESTs; Weakly similar to IIII ALU CLASS	16.7
	324497 AW152624 Hs.136340	ESTs .	5.5
	324598 AA502659 Hs.163986	ESTS	5.4
60	324603 AW016378 Hs.292934	ESTS	8.8
	324620 AA448021 Hs.94109	EST duster (not in UniGene)	23.1
	324727 Al610425 Hs.19597	ESTs	21.2
	324774 Al031771 Hs.132586	ESTS	5
	324783 AA640770 Hs.200994	EST duster (not in UniGene)	5
65	324824 Al826999 Hs.224624	ESTs Cluster (not in Unicene)	4.1
	324826 AA704806 Hs.143842	ESTS	6.3
	324902 D31323 Hs.271492	ESTs	11.7
	100011132		4.8

	324961 AA613792		EST duster (not in UniGene)	13.3
	324987 T06882	Hs.172634	ESTs	19.6
	324988 T06997 325146 Al064690	Hs.121028	EST cluster (not in UniGene)	24.5
5	325622		ESTs . CH.14_hs gij5867000	4.6 5.2
٥.	326213	,	CH.17_hs gij5867224	8.1
	326474		CH.19_hs gij5867405	12.7
	326816		CH.20_hs gi[6552458	9.4
	326817		CH.20_hs gij6552458	11.7
10	327110		CH.21_hs gij6117842	14.7
	327196		CH.01_hs gi 5867446	5.1
	327283		CH.01_hs gi 5867478	4.3
	327313		CH.01_hs gi 5867501	4.8
1.5	327450		CH.02_hs gij5867766	4.1
15	328059		CH.06_hs gi 6117819	6.2
	328304 328492		CH.07_hs gi 6004478	5.4 7
	328857		CH.07_hs gi 5868455 CH.07_hs gi 6381927	5.2
	329367		CH.X_hs gi[5868842	7.6
20	329373		CH.X_hs gi 6682537	12
	329655		CH.14_p2 gij6448516	4
	329899		CH.15_p2 gi 6563505	4
	329960		CH.16_p2 gi 5091594	7.6
	330084		CH.19_p2 gi 6015302	4
25	330384 M23263		androgen receptor (dihydrotestosterone re	5.8
	330385 AA449749	)	ESTs; Highly similar to secreted apoptosi	10.2
	330387 H14624		ESTs, Highly similar to secreted apoptosi	4.4
	330388 X03363	11-20004	HER2 receptor tyrosine kinase (c-erbB-2;	17.7
30	330409 D50692	Hs.78221	c-myc binding protein	10.1 Endotholial Call Courth Easter 1 . 6.6
30	330460 TIGR:HT5 330486 M13755	Hs.833	Hs.73946 interferon-stimulated protein; 15 kDa	Endothelial Cell Growth Factor 1 5.5 67
	330494 M29696	Hs.237868	interleukin 7 receptor	6
	330500 M34423	Hs.79222	galactosidase; beta 1	13.1
	330510 M75099	Hs.227729	FK506-binding protein 2 (13kD)	29
35	330513 M81057	Hs.180884	carboxypeptidase B1 (tissue)	38,5
	330541 U22970	Hs.265827	multiple UniGene matches	7.4
	330542 U23942	Hs.226213	cytochrome P450; 51 (lanosterol 14-alpha	15
	330547 U32989	Hs.183671	tryptophan 2;3-dioxygenase	11
40	330551 U39840	Hs.299867	hepatocyte nuclear factor 3; alpha	6.5
40	330562 U49082	Hs.76460	transporter protein	7.7
	330573 U62800	Hs.83393	cystatin E/M	4
	330673 D57823	Hs.321403	Sec23 (S. cerevisiae) homolog A	10.5
	330711 AA164687 330814 AA015730		mannosyl (alpha-1;3-)-glycoprotein beta-1 ESTs; Weakly similar to transformation-r	24.3 44.1
45	330850 AA075298		ESTs. Weakly strike to transformation	4.4
	330874 AA127474		ESTs; Weakly similar to IIII ALU SUBFA	8.1
	330884 AA133457		ESTs	5.2
	330912 AA195936		general transcription factor IIA; 1 (37kD a	5
	330924 AA232136	Hs.159737	Homo sapiens mRNA; cDNA DKFZp434	9.1
50	330997 H55762	Hs.9302	ESTs	7.6
	331014 H98597	Hs.30340	ESTs	13.5
	331024 N32919	Hs.27931	ESTs	9.1
	331046 N66563	Hs.191358	ESTs	10.5
55	331135 R61398 331145 R72427	Hs.4197 Hs.129873	ESTs ESTs; Weakly similar to CYTOCHROME	7.4 41.9
55	331148 R73816	Hs.17385	ESTs Veakly similar to CT TOCHNOME	4.7
	331222 T98531-	Hs.173904	ESTs	4.1
	331230 W69807	Hs.16537	hypothetical protein; similar to (U06944)	4.9
	331306 AA252079		dachshund (Drosophila) homolog	15.1
60	331327 AA281076		ESTs	4.8
	331337 AA287662		ESTs	7.6
	331341 AA30312		ESTs; Weakly similar to IIII ALU SUBFA	13
	331344 AA357927		ESTs	12.4
	331362 AA417956		ESTs	6.5
65	331363 AA421563		anterior gradient 2 (Xenepus laevis) homo	28.2
	331376 AA44380		ESTs; Weakly similar to cDNA EST yk47	15.1 7.9
	331384 AA45600	I FIS.3304/	ESTs	7.9

WO 02/059377

		N26608	Hs.40639	ESTs	7
		N49967	Hs.46624	ESTs	19.8
		N51517 W85712	Hs.47282	ESTs	6.5
5		W88502	Hs.119571	collagen; type III; alpha 1 (Ehlers-Danios	13.8
-			Hs.182258 Hs.111471	ESTs ESTs	9.9
	331751	AA284840	Hs.143818	ESTs	5.6
			Hs.154434	ESTs; Weakly similar to unknown [H.sap	5.8
		AA312861		ESTs	7.4 7.8
10			Hs.292882	ESTs	15.2
		AA432166		succinate dehydrogenase complex; subuni	24.3
	331952	AA454756	Hs.97837	ESTs	5
	332015	AA487910	Hs.208800	ESTs; Weakly similar to !!!! ALU CLASS	10.5
1.5			Hs.125056	ESTs	11.4
15			Hs.191402	ESTs	13.6
			Hs.205293	ESTs	9.1
			Hs.112592	ESTs	8.8
			Hs.112879	EST	9
20		N22508	Hs.139315	ESTs	7.1
20		N33213	Hs.100425	ESTs	12.2
		N57927 N58172	Hs.120777	ESTs; Weakly similar to RNA POLYME	15.6
		N70088	Hs.109370 Hs.138467	ESTs ESTs	16.9
		N91279	Hs.109654	ESTs; Moderately similar to outer membr	4
25		T96130	Hs.137551	ESTs	8.2 7.7
		W15495	Hs.129781	chromosome 21 open reading frame 5	14.1
		W60326	Hs.288684	ESTs	4.4
	332362	W93640	Hs.4779	ESTs; Moderately similar to similar to AD	16.9
	332467	AA489630	Hs.119004	KIAA0665 gene product	4.8
30		M12036	Hs.323910	Human tyrosine kinase-type receptor (HE	10.4
			Hs.154424	deiodinase; lodothyronine; type II	5.8
		AA281753		Inositol 1;4;5-triphosphate receptor, type	19
	332532		Hs.1892	EST; Highly similar to PHENYLETHAN	15.3
35	332607	AA234896		E1A binding protein p300	12.3
55		AA417152	Hs.36566	CIIVI GOLINGII MINOSE I	31.1
		AA262768		protein regulator of cytokinesis 1 KIAA1067 protein	18.2 15.2
	332702		Hs.75725	transgelin 2	4.7
	332705		Hs.76293	thymosin; beta 10	5.5
40	332749	AA479968		arylsulfatase A	9.8
	332927			CH22_FGENES.38_1	17.7
	332929			CH22_FGENES.38_3	4.7
	332930			CH22_FGENES.38_4	7.4
15	332955			CH22_FGENES.48_12	5.4
45	332958			CH22_FGENES.48_15	17.8
	332961	•		CH22_FGENES.48_18	10.6
	332983			CH22_FGENES.54_5	4.3
	333009			CH22_FGENES.61_1	5.2
50	333010 333013			CH22_FGENES.61_2	8.1
50	333108			CH22_FGENES.61_5 CH22_FGENES.79_14	8.5
	333139			CH22_FGENES.83_16	5.6
	333254			CH22_FGENES.118_2	6.3
	333305			CH22_FGENES.137_2	6.8 11.4
55	333343			CH22_FGENES.139_12	5.1
	333388			CH22_FGENES.144_3	12.7
	333456			CH22_FGENES.157_5	4.2
	333459			CH22_FGENES.157_8	7.6
60	333517			CH22_FGENES.173_2	8.2
60	333585			CH22_FGENES.203_4	5
	333679			CH22_FGENES.247_6	4.3
	333743			CH22_FGENES.264_1	13.4
	333758			CH22_FGENES.268_1	4
65	333767 333768			CH22_FGENES.271_6 CH22_FGENES.271_7	5.6
JJ	333769			CH22_FGENES.271_8	12.2 48.3
	333795			CH22_FGENES.275_1	6.1
					0.1

	333796	CH22_FGENES.275_3	6.8
	333892	CH22_FGENES.292_14	4.4
	333904	CH22_FGENES.294_2	6.5
	333905	CH22_FGENES.294_3	9.3
5	333921	CH22_FGENES.296_12	9.6
	333968	CH22_FGENES.307_4	15.9
	334102	CH22_FGENES.327_60	7.1
	334222	CH22 FGENES.360 3	6.7
	334223	CH22_FGENES.360_4	33.5
10	334264	CH22_FGENES.367_15	18.5
	334343	CH22_FGENES.375_25	6.1
	334360	CH22_FGENES.378_5	
	334784	CH22_FGENES.432_9	6.1
	334789	CH22 FGENES.432 14	4.8 5.1
15	334794	CH22_FGENES.434_2	7
	334889	CH22_FGENES.452_3	12.4
	335004	CH22_FGENES.472_8	7.9
	335115	CH22_FGENES.496_2	18.8
	335287	CH22_FGENES.526_11	4.5
20	335342	CH22_FGENES.536_1	5.3
	335491	CH22_FGENES.570_23	24
	335495	CH22_FGENES.570_28	
	335498	CH22_FGENES.571_7	7
	335544	CH22_FGENES.576_5	12.2
25	335610	CH22_FGENES.583_4	8.4
40	335653	CH22_FGENES.590_4	12.9
	335682	CH22_FGENES.595_2	6.7
	335687	CH22_FGENES.596_2	12.1
	335755	CH22_FGENES.604_4	13.9
30	335782	CH22_FGENES.609_4	11.5
50	335791	CH22_FGENES.611_7	17.9
	335809	CH22_FGENES.617_6	27.3
	335822	CH22_FGENES.619_7	19.2
	335823	CH22_FGENES.619_8	19.1
35	335824	CH22_FGENES.619_11	4.5 40.2
-	335825	CH22_FGENES.619_12	34.3
	335895	CH22_FGENES.635_3	10.2
	335917	CH22_FGENES.636_13	6
	335920	CH22_FGENES.636_16	8.8
40	336035	CH22_FGENES.678_6	5.9
	336042	CH22_FGENES.679_4	5.8
	336093	CH22_FGENES.691_2	11.6
	336096	CH22_FGENES.691_5	7.6
	336150	CH22_FGENES.706_6	6.3
45	336152	CH22_FGENES.706_9	10.5
٠.٠	336416	CH22_FGENES.823_38	5
	336444	CH22_FGENES.827_10	4.8
	336449	CH22_FGENES.829_6	
	336471	CH22_FGENES.829_30	13.6
50	336512	CH22_FGENES.834_7	6.9
-	336558	CH22_FGENES.842_3	21.4
	336560	CH22_FGENES.842_5	8.2
	336676	CH22 FGENES.43-4	9
	336959	CH22_FGENES.367-13	9,4
55	337968	CH22_EM:AC005500.GENSCAN.103-2	19
-	338008		13.4
	338057	CH22_EM:AC005500.GENSCAN.127-9	15.2
	338410	CH22_EM:AC005500.GENSCAN.160-1 CH22_EM:AC005500.GENSCAN.341-6	13.9
	338451		8
60	338588	CH22_EM:AC005500.GENSCAN.359-3	11.6
JV	338665	CH22_EM:AC005500.GENSCAN.432-1	10.3
	338689	CH22_EM:AC005500.GENSCAN.464-2	4.8
	338832	CH22_EM:AC005500.GENSCAN.475-3 CH22_DJ246D7.GENSCAN.6-9	6.7
	338980	CH22_DJ240D7.GENSCAN.0-9 CH22_DA59H18.GENSCAN.2-4	4.8
65	339352	CH22_DA39H18.GENSCAN.2-4 CH22_BA354I12.GENSCAN.29-7	5.1
55	339373	CH22_BA334112.GENSCAN.29-7 CH22_BA232E17.GENSCAN.1-29	6.9
	303013	CHEC_BACACE IT IDENJOAN, 1-23	4.3

#### TABLE 13A

Table 13 A shows the accession numbers for those pkeys lacking unigeneID's for Table 13. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: Unique Eos probeset identifier number
CAT number: Gene cluster number
Accession: Genbank accession numbers

5

10

45

50

55

60

15 Accessio		on: Gen	bank accession numbers			
	Pkey	CAT number	r Accession			
20	103207 103349	371681_1 306354 110522 19346_14	AA602964 X72790 X89059 AA992380	AA609200 N33063 N21418 H79958 R21911 H79957		
25	113248	328626_1 44573_2	T63857 AV Al950087 I AA908598 Al219788 A	971220 AA493469 T63699 I70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967671 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 A884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586 AW150329 Al653832		
30			AI762688 / BE612881 AI819225 / AA969759	A988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW629970 AW276997 AW513601 AW612843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 WW205862 Al683338 Al858509 AW276905 Al633006 AA972584 AA908741 AW072629 AW513996 AA293273 AV5628 NZ2388 H84729 H60052 T92487 Al022058 AA780419 AA551005 W80701 AW613456 Al373032 Al564269 3488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW955981 T63226 F04005		
35	116480 132225 125154 118475	genbank_AA6 genbank_C14 genbank_AA1 genbank_W36 genbank_N66 25180 2	508751 1088 128980 8419 5845	A608751 C14088 A4128980 W38419 ,		
40	102313	23100_2	AA323294	035748 AA021266 AA323126 AA180515 Al613029 D28356 NM_000034 M11560 AW401425 AW248248 AA012956 ND4965 H38759 AA206622 AA580747 Al54172 AA381075 AA354229 AW402335 AW405575 AW404021 AW406207 AW476068 AA387229 AH56848 T30244 BB7046 A20659 AA26543 AA384229 AW405357 AW404021 AW406207 AW476068 AA387429 AW46540 AA387429 AW40540 AA387440 AA38740 AA387440 AA387440 AA387440 AA387440 AA387440 AA387440 AA38		

M21191 AL035748 AA021266 AA323126 AA180515 AI613029 D28356 NM\_000034 M11560 AW401425 AW248248 AA012956 AA323294 W04965 H38759 AA206522 AA580747 AI541172 AA381075 AA354229 AW402353 AW405575 AW404021 AW406207 AA075752 AW176066 AA287222 AA195818 T20243 R87945 AA295539 AA402533 AA2324319 AA224515 AW401583 AA331367 AW402140 AW249079 R31488 AA075757 X05236 AW239490 AA338036 AW239495 AA357262 AA431005 AA306726 R33804 AA216544 AW275288 AA227044 AL038124 AA243300 C03242 AA315615 AL035840 R64336 AA313917 AA018963 AA001385 AA054395 H30840 AW498825 AA086141 AI557324 AA121576 H39128 R77161 AA019688 AA380987 AA348140 AA348257 AW176086 AA362432 AA171389 AA362416 AA299338 AA313093 AA337972 C04921 AA345696 R89640 AA085425 AA481708 AA313637 AL039229 H84490 H86153 F00656 AA36668 AA347304 R65890 H41949 AA339309 AW4020002 AW404854 AA192582 AA112802 H09248 N83165 H38367 AA356339 AA455763 R66853 AA294935 H65911 AA310414 H934A5 N87014 AA001186 H83640 AA411328 AA317929 C04192 AW406288 U46335 AA323179 AA427649 A1366131 H14328 AA197161 AA379497 AA311816 AA017206 AA01137 AA017420 AA012990 AW163775 AA021397 AA295513 AA355248 AA374921 AW380419 AA345864 AA318058 AA371711 AA363255 AA057094 R88057 AA394045 AW362741 AA479579 AW362789 AW362775 AA223624 AW362809 AW362746 AW362753 AW380419 AA345864 R83920 F01120 AA495740 AA355251 AL039209 AA093339 AA333961 N86416 C03325 C03831 AA194750 AA359270 AA359460 AW245492 AA339400 AA330784 AI908970 N89223 AW361938 AI940063 AA134323 AA371741 F01267 AW372970 AA341973 AA346098 AW362746 AW362753 AW380412 AA057104 AA29571 N6652 AW362771 X12447 R59553 R87925 AA292864 R83920 F01120 AA495740 AA352551 AL039209 AA093339 AA375949 AA313744 AA374372 AA346098 AW374374 AW3723940 AA359374 AA359374 AA359374 AA374373 AA346098 AW374374 AW374387 AA353658 F01041 C02843 AA3759448 AW374414 AA213946 AI525039 H13744 R31007 AA112044 AA13404 H47935 AW177018 AA429768 AA336873 AA112875 H46393 AA191267 D59131 AW406037 AA055244 AA341880 AA179024 AA308537 AW406985 AW374374 AA357494 AW375299 A219190 AA410818 AA229768 AA336874 AA357434 AW37

	C03986 Al318091 Al860172 AA582179 Al633388 AA557193 R68075 F24105 AW518239 W56622 Al625219 Al925243
	AW468046 AI921828 AA339164 AI144391 AA643334 AA459631 AA873247 AW373432 AA604384 H27600 AI680458 AA159956
	AA610836 AA364298 AW373435 AA604225 W73754 AW087924 AA599776 N89227 AI630871 AI633128 AW514329 AA010455
5	AA563928 Al571596 Al128394 W73707 Al423575 AA583809 AA657988 Al950837 AA169782 AA6600009 Al885540 AA771884
3	A1978829 AA505408 AA533937 AA481469 AA610869 AA775241 AW273870 AW070909 A1905695 AA480115 AA574051
	AI889185 AA773167 AA331375 AA001437 AA194324 AA194300 AA558632 AI038538 AA411329 AA781570 AI833176 AA935520 AW074197 AA583063 AW073099 AW001198 AA948025 AA587857 AA191540 AI460085 AA193244 AI538037
	AA515572 AA758587 A1149311 AA508610 AA206409 AA534004 AA994600 AA827543 Al916349 AW245129 AW517804 D25663
	AA781985 AA284536 AI819422 H16040 H27531 AA456564 AA845555 AI423596 AA012908 AA889439 AA716311 AA968868
10	AA320508 AA725731 AA834202 AA935997 AA724815 AA769353 AA594803 F00827 AI342442 AI003519 AI002503 AI347597
	A1040946 AA197162 AA987883 AA292865 AW001944 A1640711 AW244044 AA456784 F30588 AA290829 H24754 A1978683
	AA483686 AA583939 AA121382 AA833831 AA477102 AA977322 AA666379 F35456 AA993537 A1749610 AA226934 AA716204
	AW513025 AA628543 AA583705 F25702 Al368748 Al124097 Al880086 AA477513 Al758834 Al690753 AA477746 F37761 AA642243 AA159957 AA250844 AA459406 AA427566 F25054 Al569314 AA961665 Al922050 Al759000 AA555236 AA514432
15	AAG42243 AAT35957 AA250644 AAG59406 AAG4127566 F25034 A1561315 AAG51605 A1922050 A1755600 AA5536256 AA514432 AA293474 AA001129 AA626789 AA641390 AA134405 F35585 AA477416 AW193359 A1361315 AA284988 F36340 A1361322
10	F26959 AA991922 AA021267 F26973 Al361314 F35891 Al918509 AA250964 AA190992 AA577139 AA865535 AA134324
	AW192842 Al224046 F18975 AA779626 AA856894 AW269997 AW014614 H95554 F31378 AA374868 F26343 AA654007
	A1830942 AA113195 F26432 W56652 AA464690 AA055263 AA340654 AA031448 AA976399 AA972526 AA063476 R83921
20	T16240 AA533290 N91545 H44053 AA883451 AA513761 AA086477 H09249 F20482 F26737 AA054148 AA857063 AA017259
20	AA179789 AA088908 H43704 AA194320 F35950 A1880127 F20441 F32878 AA962483 H39094 H56489 H44621 F19390 AJ302232 F25162 AA826965 AA086052 AA917410 AA454513 R59554 AA196755 AA086369 AA079530 H28106 AA243301
	AJ02252 F23102 AA020303 AA06032 AA911410 AA93413 A39334 AA199733 AA060339 AA079330 Ta0100 AA243301 AJ025737 AA101239 AA088887 AJ214910 AA974886 F16089 F26054 AA515092 F33436 F32829 M78061 AA235645 F19715
	F37529 AI811549 AA665180 AA708200 F01124 F32382 AA346220 AA627361 F30741 F30010 F28543 AA211715 F20245
	AA331222 F25634 F21996 W28215 F21911 R65793 AI192566 H20130 HB4491 AA719223 AA557435 F16967 F26989 F30353
25	AA857159 AA291918 F28234 F20840 F25176 F22437 T27904 AA480355 F19528 R87926 H14286 F27532 AW337864 F28411
	H13692 F25651 AA975454 F24229 F29657 F18024 AA464779 F17588 F34954 AA947328 F18063 AA657777 AA459644 N91455
	F27850 F29608 F27206 F18418 F31459 F18564 F33496 F16376 F29740 F29843 F29904 F29866 F19135 AW276602 T40337 F24835 F34672 F26474 AI926215 AA464185 F18217 N26193 AL043256 T41197 F33055 F00386 F29500 F34191 F33297
	A1937207 F22724 F15909 F26232 F18889 AA318627 F29085 AA872104 F17509 F23373 F15660 F17552 F17412 F16863
30	F34033 F21515 F17364 F18383 F16546 F17561 F17260 AA292000 F15723 T47438 F16798 F18046 F18319 F17978 F17566
	F34230 F33258 F20860 F17998 Al695701
	118600 genbank_N69222 N69222
	118952 genbank_N92966 N92966 120873 genbank_AA358015 AA358015
35	120873 genbank_AA358015 AA358015 113702 genbank_T97307 T97307
55	129982 221 267 Z14221 AW331862 M97920 AW401444 Z66542 M29470 AW406502 X61011 M34024 AA327072 Z14166 Z14167 Z14165
	AW403806 Z14200 AA383972 Z14205 Z14201 M18513 Z14202 AW403684 X14584 AF062221 U43760 X65892 X65883 X62107
	Z80847 X65885 X65893 AF062142 X65891 X17675 Z47274 Z47277 Z47276 X65888 Z47275 X62109 AF062140 L01278
40	AF062134 AF062139 X81723 Z80840 X81733 X81743 X81744 X81732 Z80843 AW402942 AW402516 X65919 AF062190
40	AF062177 AF062222 AF062115 Z47240 AF062263 AF062261 AF062223 AF062211 Z47238 AW401714 AW404008 AW404991 AF062280 M99595 Z47214 Z47232 Z47218 M26995 AF062184 X65895 L38433 X81731 Z11946 Z47226 AF062205 AF174012
	L01276 AF062168 AF062135 X81748 AF174019 AF062285 L06924 L11699 AW402665 L09070 L28049 L08090
	AW407843 Z14171 AW402944 L08083 AW405627 L33035 L26907 M17750 L28052 M17751 AJ239360 U19885 L14821 X56526
	AB014341 L12087 L12098 U68231 L12184 AF052242 AF022000 U64499 U00570 Al268604 Y15773 X64239 X62969 U00506
45.	X73605 X99360 U00577 D83677 AB021539 AF035796 Z33899 U00588 AJ239353 AF174062 Z33901 X98899 AF174068 X63080
	D83676 AB021529 Z18318 U00488 L01412 X81746 U21262 U21272 U00560 AF174060 U00547 U00561 Z18321 S73957 M26435 AF115130 AF115117 Z92896 U21254 Z92895 AF115112 AF062290 T28938 Y09386 AF174067 U27189 Y09384
	U77373 AF174057 M17749 X69692 AF174038 U64478 U64486 AF174098 X99365 AF174077 AF174083 AF174089 AF015133
	AF127792 AJ006171 U00510 U58144 AF004323 AF115109 AF004324 AF015130 AF090414 AF090418 AB021536 AB021519
50	Z96957 AF021986 Z92898 Z96956 L34164 AF062251 AF052524 U00549 U00541 D83687 AF052522 AF087420 AF052520
	AF022011 L43085 U00536 L19915 L43083 AF090420 AB021530 AB021534 Z96955 Z96954 Z33903 X62964 AF103282 U00509
	AF062298 AF062289 AF052307 AW408326 L33037 L04337 L04328 X81742 L04336 L03385 AF032360 S56184 AF062191
	AF191092 AI906954 AF103184 L04343 AW364860 AF001424 AF103163 Z98717 AF103143 AJ008250 L04323 AF103321 AF103335 L04342 L03818 L03817 AW404978 AW403690 U86801 AF103150 AJ010334 AF035027 AJ007327 AF103115
55	AF017458 AJ008207 AJ008183 AJ008198 AJ008241 AJ008208 AF103210 AF068668 AF068670 AF068661 AF068664
55	AF068669 AF068666 AF068665 AF068672 AW371244 AW403670 AW408074 AW404575 AW362153 AW403803 AW406702
	AW351514 D78345 T29140 J00231 NM_002179 AW405146 AA301091 X04646 H64660 AW402990 AW406534 T93007
	AI857980 AW368899 AI905833 AW406586 AA482084 AI872299 AA715266 AW404328 AI831674 AI709348 AA603112
60	AW514864 AA485775 H64492 AW404789 AA487630 AA715498 AA295885 T27613 T98113
60	115763 genbank_AA421560 AA421560 124357 genbank_N22401 N22401
	108733 504187_1 AA121022 AA126422
	101544 entrez_M31169 M31169
	124447 genbank_N48000 N48000
65	124677 genbank_R01073 R01073
	124777 genbank_R41933 R41933
	119302 genbank_T25725 T25725

```
103680 entrez_Z93784Z93784
               135029 H58818_at H58818
               112253 genbank_R51818
                                                                  R51818
              Pkey CAT numb
322175 46877_1
                           CAT number Accession
    5
                                                 AF085975 H53458 H53459
               323011 139750_1
                                                 AA580288 AA315655 AA133031 AA377748
                                                 C16391 C16413
               322975 1510563_1
                                                 AW881145 AA490718 M85637 AA304575 T06067 AA331991
               317210 211994_1
               323817 233566_1
                                                 AA410943 AW948953 AA334202 AA332882
10
               309583 1046029_-2 AW170035
               324961 376239_1
                                                 AA613792 AW182329 T05304 AW858385
               303502 325188_1
                                                 BE174240 AA488528 AL042253
               320133 447553_1
                                                 BE151746 BE336853 D63271 T94955 AA774994
               311935 174129_1
                                                 AA216387 T63548 AA228676
15
              321050 502195_1
                                                 C05928 AW393497
              319977 345248_1
                                                 AA534222 AA632632 T81234
              312772 4380_7
                                                 AW962299 AA310349 AW962294 H63791 H63751
              321354 116028_-2
                                               AA078493
               336512 CH22_3941FG_834_7_LINK_DJ
20
              336558 CH22_3992FG_842_3_LINK_DJ
              336560 CH22_3994FG_842_5_LINK_DJ
              329367 c_x_hs
              329373 c_x.lis
329373 c_x.lis
336676 CH22_4154FG_43_4_
338008 CH22_6490FG_LINK_EM:AC00
338057 CH22_6558FG_LINK_EM:AC00
25
              329655 c14_p2
336959 CH22_4764FG_367_13_
              329899 c15_p2
             329899 c15_p2
329960 c16_p2
338410 CH22_7067FG_LINK_EM:AC00
338451 CH22_7124FG_LINK_EM:AC00
338588 CH22_7331FG_LINK_EM:AC00
338665 CH22_7438FG_LINK_EM:AC00
338689 CH22_7464FG_LINK_EM:AC00
30
35
              308677 Al761173
             308677 A/761173
338832 CH22_7678FG_LINK_DJ246D7
338980 CH22_7859FG_LINK_DA59H18
333009 CH22_233FG_61_1_LINK_EM:A
333010 CH22_234FG_61_2_LINK_EM:A
333013 CH22_237FG_61_5_LINK_EM:A
308981 AI873242
40
              308995 AI880172
             303995 Al801712

333108 CH22_336FG_79_14_LINK_EM:

333139 CH22_368FG_83_16_LINK_EM:

333254 CH22_495FG_118_2_LINK_EM:

333305 CH22_550FG_137_2_LINK_EM:

333343 CH22_589FG_139_12_LINK_EM:

333388 CH22_584FG_144_3_LINK_EM:
45
50
              326213 c17_hs
              333456 CH22_706FG_157_5_LINK_EM:
333459 CH22_709FG_157_8_LINK_EM:
333517 CH22_773FG_173_2_LINK_EM:
              333585 CH22_846FG_203_4_LINK_EM: 333679 CH22_941FG_247_6_LINK_EM:
55
              326474 c19_hs
              333743 CH22_1009FG_264_1_LINK_EM
             333743 CH22_1009FG_264_1_LINK_EM
333768 CH22_1024FG_268_1_LINK_EM
333767 CH22_1034FG_271_6_LINK_EM
333769 CH22_1036FG_271_7_LINK_EM
333795 CH22_1063FG_275_1_LINK_EM
333796 CH22_1063FG_275_3_LINK_EM
335004 CH22_2326FG_472_8_LINK_EM
335004 CH22_2326FG_472_8_LINK_EM
33892 CH22_1163FG_292_14_LINK_EM
333904 CH22_2447FG_496_2_LINK_EM
60
65
```

333905 CH22\_1177FG\_294\_3\_LINK\_EM 333921 CH22\_1194FG\_296\_12\_LINK\_E 333968 CH22\_1245FG\_307\_4\_LINK\_EM 328059 c\_6\_hs 335287 CH22\_2629FG\_526\_11\_LINK\_E 5 326816 c20\_hs 326817 c20\_hs 335342 CH22\_2689FG\_536\_1\_LINK\_EM 335491 CH22\_2843FG\_570\_23\_LINK\_E 10 335495 CH22\_2847FG\_570\_28\_LINK\_E 335498 CH22\_2850FG\_571\_7\_LINK\_EM 328304 c\_7\_hs 305453 AA738110 335544 CH22\_2899FG\_576\_5\_LINK\_EM 335610 CH22\_2999FG\_576\_5 LINK\_EM 335653 CH22\_3013FG\_590\_4\_LINK\_EM 335682 CH22\_3043FG\_595\_2\_LINK\_EM 335687 CH22\_3048FG\_596\_2\_LINK\_EM 15 335887 CH22\_3048FG\_596\_2\_LINK\_EM
328492 c\_7\_hs
335755 CH22\_3122FG\_604\_4\_LINK\_EM
335782 CH22\_3151FG\_609\_4\_LINK\_EM
335791 CH22\_3160FG\_611\_7\_LINK\_EM
335809 CH22\_3181FG\_617\_6\_LINK\_EM
335822 CH22\_3195FG\_619\_7\_LINK\_EM
335823 CH22\_3195FG\_619\_11\_LINK\_EM
335824 CH22\_3197FG\_619\_11\_LINK\_EM
335825 CH22\_3197FG\_619\_11\_LINK\_E
335895 CH22\_3197FG\_619\_11\_LINK\_E
335895 CH22\_3277FG\_635\_3\_LINK\_EM
335917 CH22\_3294FG\_636\_13\_LINK\_E
335920 CH22\_3297FG\_636\_16\_LINK\_E
305898 AA872838
305913 AA876109
305950 AA884479
328857 c\_7\_hs 20 25 30 328857 c\_7\_hs 330084 c19\_p2 35 337968 CH22\_6419FG\_\_LINK\_EM:AC00 309177 Al951118 309198 Al955915 309226 Al969897 40 339352 CH22\_8317FG\_'LINK\_BA354I1 309279 Al990102 339373 CH22\_8348FG\_\_LINK\_BA232E1 325622 c14\_hs 334102 CH22\_1380FG\_327\_60\_LINK\_E 332927 CH22\_148FG\_38\_1\_LINK\_C20H 45 332929 CH22\_150FG\_38\_3\_LINK\_C20H 332930 CH22\_151FG\_38\_4\_LINK\_C20H 332955 CH22\_179FG\_48\_12\_LINK\_EM: 332958 CH22\_182FG\_48\_15\_LINK\_EM: 332961 CH22\_185FG\_48\_18\_LINK\_EM: 50 332983 CH22\_207FG\_54\_5\_LINK\_EMA 334222 CH22\_1506FG\_380\_3\_LINK\_EM 334223 CH22\_1507FG\_360\_4\_LINK\_EM 334264 CH22\_1551FG\_367\_15\_LINK\_E 327110 c21\_hs 334343 CH22\_1636FG\_375\_25\_LINK\_E 334360 CH22\_1654FG\_378\_5\_LINK\_EM 327196 c\_1\_hs 327283 c\_1\_hs 327313 c\_1\_hs 304465 AA421948 60 304507 AA456426 327450 c\_2\_hs 304591 AA505702 65 304601 AA507875 304659 AA533185 334784 CH22\_2096FG\_432\_9\_LINK\_EM

334789 CH22\_2101FG\_432\_14\_LINK\_E
334794 CH22\_2106FG\_434\_2\_LINK\_E
336035 CH22\_3420FG\_678\_6\_LINK\_DJ
336042 CH22\_3427FG\_679\_4\_LINK\_DJ
336093 CH22\_3481FG\_691\_2\_LINK\_DJ
336096 CH22\_3484FG\_691\_5\_LINK\_DJ
334889 CH22\_246FG\_452\_3\_LINK\_EM
336150 CH22\_3543FG\_706\_6\_LINK\_DA
336152 CH22\_3543FG\_706\_6\_LINK\_DA
336416 CH22\_3833FG\_823\_38\_LINK\_B
336444 CH22\_3864FG\_827\_10\_LINK\_D
336471 CH22\_3894FG\_829\_30\_LINK\_D

## **TABLE 13B**

5

Table 13B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 13B. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset  Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I, et al." refers to the publication
	Strand: Nt_position:	entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

	_			- p
15				
	Pkey	Ref	Strand	Nt_position
	332955	Dunham, I. et.al.	Plus	2508896-2508992
	332958	Dunham, I. et al.	Plus	2516164-2516310
20	332961	Dunham, I. et.al.	Plus	2521424-2521555
	333139	Dunham, I. et.al.	Plus	3369495-3369571
	333254	Dunham, I. et al.	Plus	2521424-2521555
	333305		Plus	4630388-4630645
	333388		Plus	4913749-4913805
25	333517		Plus	5570729-5570925
	333585	Dunham, I. et al.	Plus	6234778-6234894
•	333679	Dunham, I. et.al.	Plus	7068795-7068896
	333767	Dunham, I. et.al.	Plus	7694407-7694623
	333768	Dunham, I. et.al.	Plus	7695440-7695697
30	333769	Dunham, I. et al.	Plus	7696625-7696707
	333795	Dunham, I. et al.	Plus	7807688-7807795
	333796	Dunham, I. et al.	Plus	7808253-7808319
	333892	Dunham, I. et.al.	Plus	8156825-8157001
	333921	Dunham, I. et.al.	Plus	8380325-8380441
35	333968	Dunham, I. et al.	Plus	8681004-8681241
	334102	Dunham, I. et.al.	Plus	9995140-9996373
	334264	Dunham, I. et.al.	Plus	13234447-13234544
	334343	Dunham, I. et.al.	Plus	13655828-13656307
	334794	Dunham, I. et.al.	Plus	16374312-16374458
40	334889		Plus	19286024-19286515
	335287	Dunham, I. et.al.	Plus	22299047-22299299
	335491	Dunham, I. et.al.	Plus	24128651-24128827
	335495	Dunham, I. et.al.	Plus	24140688-24140872
	335498	Dunham, I. et.al.	Plus	24172082-24172161
45	335653	Dunham, I. et.al.	Plus	25329710-25329802
	335687	Dunham, 1. et.al.	Plus	25445952-25446064
	335809	Dunham, I. et.al.	Plus	26310772-26310909
	335822	Dunham, I. et.al.	Plus	26364087-26364196
~~	335823	Dunham, I. et.al.	Plus	26365925-26366004
50	335824	Dunham, I. et.al.	Plus	26376860-26376942
	335825	Dunham, I. et.al.	Plus	26378175-26378268
	336035	Dunham, I. et.al.	Plus	29016748-29017410
	336093	Dunham, I. et.al.	Plus	29556922-29557002
	336096	Dunham, I. et.al.	Plus	29578878-29579047
55	336444	Dunham, i. et.al.	Plus	34190585-34190718
	336959	Dunham, I. et.al.	Plus	13233040-13233126
	338008	Dunham, I. et al.	Plus	7697068-7697236
	338057	Dunham, I. et.al.	Plus	8526397-8526522
<b>CO</b>	338410	Dunham, I. et.al.	Plus	19292807-19292916
60	338588	Dunham, I. et.al.	Plus	22896767-22896920
	338665	Dunham, I. et.al.	Plus	24472654-24472853
	338832	Dunham, I. et.al.	Plus	27775128-27775290
	338980	Dunham, I. et.al.	Plus	29896789-29896874
	339352	Dunham, I. et.al.	Plus	33544784-33545121

	220000 m / 1		0000750 0000004
	332929 Dunham, I. et.al.	Minus	2020758-2020664
	332930 Dunham, I. et.al.	Minus	2022565-2022497
	332983 Dunham, I. et.al.	Minus	2631933-2631797
5	333009 Dunham, I. et.al.	Minus	2766043-2765856
)	333010 Dunham, I. et.al.	Minus	2766207-2766119
	333013 Dunham, I. et.al.	Minus	2772278-2772039
	333108 Dunham, I. et.al.	Minus	3240494-3240389
	333343 Dunham, I. et.al.	Minus	4692886-4692753
10	333456 Dunham, I. et.al.	Minus	2631933-2631797
10	333459 Dunham, I. et.al.	Minus	5144548-5144344
	333743 Dunham, I. et al.	Minus	7573218-7573060
	333758 Dunham, I. et.al. 333904 Dunham, I. et.al.	Minus	7666413-7666091
		Minus	8217374-8217261
15	333905 Dunham, I. et.al. 334222 Dunham, I. et.al.	Minus	8217796-8217670
13		Minus	12732417-12732289
	334223 Dunham, I. et.al. 334360 Dunham, I. et.al.	Minus Minus	12734365-12734269 13728850-13728751
			16294548-16294360
		Minus	16306095-16305996
20	334789 Dunham, I. et.al. 335004 Dunham, I. et.al.	Minus Minus	20581911-20581794
20			21388250-21388146
	335115 Dunham, I. et.al.	Minus	22597448-22597284
	335342 Dunham, I. et.al. 335544 Dunham, I. et.al.	Minus Minus	24650505-24650403
		Minus	25068943-25068841
25	335610 Dunham, I. et.al. 335682 Dunham, I. et.al.	Minus	25421215-25421093
23	335755 Dunham, I. et al.	Minus	25763806-25763747
	335782 Dunham, I. et.al.	Minus	25908578-25908440
	335791 Dunham, I. et.al.	Minus	25948563-25948411
	335895 Dunham, I. et.al.	Minus	26975307-26975239
30	335917 Dunham, I. et.al.	Minus	27028481-27028377
50	335920 Dunham, I. et.al.	Minus	27034927-27034811
	336042 Dunham, I. et.al.	Minus	29041694-29041500
	336150 Dunham, I. et.al.	Minus	30150423-30150256
	336152 Dunham, I. et.al.	Minus	30156053-30155870
35	336416 Dunham, I. et.al.	Minus	34047408-34047311
33	336449 Dunham, I. et.al.	Minus	34204707-34204577
	336471 Dunham, I. et al.	Minus	34215091-34214978
	336512 Dunham, I. et.al.	Minus	34278373-34278275
	336558 Dunham, I. et.al.	Minus	34375825-34375698
40	336560 Dunham, I. et.al.	Minus	34376814-34376596
	336676 Dunham, I. et al.	Minus	2022565-2022497
	337968 Dunham, I. et al.	Minus	7095797-7095680
	338451 Dunham, I. et.al.	Minus	20174286-20174193
	338689 Dunham, I. et.al.	Minus	24893073-24892972
45	339373 Dunham, I. et.al.	Minus	33860127-33860047
	325622 5867000	Plus	69994-70075
	329655 6448516	Minus	35565-35843
	329899 6563505	Minus	111058-111783
	329960 5091594	Minus	1031-1162
50	326213 5867224	Minus	60751-60927
	326474 5867405	Plus	16995-18101
	330084 6015302	Minus	57019-59337
	326816 6552458	Plus	198354-198436
	326817 6552458	Plus	199909-200001
55	327110 6117842	Plus	94608-94785
	327196 5867446	Plus	180921-181333
	327283 5867478	Minus	567-962
	327313 5867501	Minus	89734-89838
	327450 5867766	Minus	47928-48076
60	328059 6117819	Plus	37052-37204
	328492 5868455	Minus	46094-46241
	328304 6004478	Minus	3884-3952
	328857 6381927	Minus	80557-81051
15	329367 5868842	Minus	87201-87587
65	329373 6682537	Minus	38950-39301

### TABLE 14: Table 2 from BRCA 001-5 US

Table 14, a subset of table 13, depicts a preferred group of genes highly upregulated in breast cancer cells.

10	Pkey: ExAccn: UnigeneID: Unigene Title: R1:		Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of tumor to normal breast tissue				
15	Pkey	ExAcon	UniGene ID	Unigene Title	R1		
20	100114 100975 101031 101104 101143	M97935 D00596 J02923 J05070 L07615 L12723	Hs.82962 Hs.76506 Hs.151738 Hs.169266 Hs.90093	AFFX control: STAT1 thymidylate synthetase lymphocyte cytosolic protein 1 (L-plastin) matrix metalloproteinase 9 (gelatinase 8; 9 Human neuropeptide Y receptor Y1 (NPYY heat shock 70kD protein 4	16.7 15.9 30.1 37.2 18.3 17:4		
25	101378 101809 102618	L47276 M13755 M86849 U65932 U79241	Hs.156346 Hs.833 Hs.323733 Hs.81071 Hs.118666	Homo sapiens (cell line HL-6) alpha topois Interferon-stimulated protein; 15 kDa Homo sapiens connexin 26 (GJB2) mRNA extracellular matrix protein 1 Human clone 23759 mRNA; partial cds	18.9 18.1 22.5 23.2 15		
30	102817 102907 102985 103060	U90904 X06985 X17644 X57766 X69433	Hs.83724 Hs.202833 Hs.2707 Hs.155324	Human clone 23773 mRNA sequence heme oxygenase (decycling) 1 G1 to S phase transition 1 matrix metalloproteinase 11 (stromelysin 3	15.2 22.7 20.6 17.8		
35	103206 103821 104115 104667	X72755 AA157623 AA428090 AA007234	Hs.5337 Hs.77367 Hs.198793 Hs.26102 Hs.30098 Hs.28005	isocitrate dehydrogenase 2 (NADP+); mito monokine induced by gamma interferon KIAA0750 gene product ESTs ESTs ESTs Homo sapiens mRNA; cDNA DKFZp564G	18.9 15.1 23.3 28.7 16.6		
40	106103 107151 109415 110189	AA421104 AA621169	Hs.12094 Hs.8687 Hs.110826 Hs.6278 Hs.5199	ESTs ESTs trinucleotide repeat containing 9 DKFZP586B1621 protein ESTs; Weakly similar to UBIQUITIN-CON	19.3 15.4 19 20.1 16.6 19.5		
45	110734 110915 111179 111357	H98714 N46252 N67239 N91023 R46025	Hs.24131 Hs.29724 Hs.10760 Hs.87128 Hs.7413	ESTs ESTs ESTs ESTs	30.2 23.2 37 15 17.4		
50	113970 114124 114292 114901	W86748 Z38595 Z40715 AA236276	Hs.8109 Hs.125019 Hs.184641 Hs.196437 Hs.72472	ESTs ESTs; Highly similar to KIAA0886 protein delta-6 fatty acid desaturase ESTs; Weakly similar to R26660_1; partial ESTs	15 22 19.4 16.9 35.1		
55	115652 115875 116790 116921	AA405098 AA433943 H29532 H72948 N26722	Hs.38178 Hs.43946 Hs.101174 Hs.821 Hs.42645 Hs.65946	ESTs ESTs; Weakly similar to Weak similarity t microtubule-associated protein tau biglycan ESTs ESTs	16.1 33.5 22.2 20.7 18.1		
60	120325 121596 123619 124006 125852	AA195651	Hs.104106 Hs.174104	ESTs ESTs ESTs ESTs ESTs Homo sapiens mRNA; cDNA DKFZp564B ESTs; Weakly similar to transformation-rel	15.6 15.2 22.6 23.1 20.6 25.9 16.4		
				,	10.7		

WO 02/059377

#### PCT/US02/02242

	127677 AA916752 Hs.264190	ESTs; Highly similar to MEM3 [M.muscul	17.3
	128595 U31875 Hs.152677 128717 T30617 Hs.104222	short-chain alcohol dehydrogenase family m	27.1
	129124 AA234530 Hs.108802	Homo sapiens mRNA; cDNA DKFZp566L N-ethytmaleimide-sensitive factor	24.5
5	129366 H18027 Hs.184697	plexin C1	20.7 18.2
	130455 X17059 Hs.155956	N-acetyltransferase 1 (arylamine N-acetylt	26.4
	130604 X03635 Hs.1657	estrogen receptor 1	39.9
	130913 W03592 Hs.21198	translocase of outer mitochondrial membra	20.9
10	130944 M97935 Hs.21486	signal transducer and activator of transcript	18.8
10	131472 AA608962 Hs.27258 131562 U90551 Hs.28777	calcyclin binding protein	18.1
	132180 AA405569 Hs.418	H2A histone family; member L fibroblast activation protein; atpha; seprase	18.8
	132406 F09979 Hs.4774	ESTs	15.4 15
	132465 AA047896 Hs.49169	ESTs	15.4
15	132994 AA505133 Hs.279905	solute carrier family 2 (facilitated glucose t	26.4
	133294 R79723 Hs.69997	zinc finger protein 238	30.4
	133634 U24166 Hs.234279	microtubule-associated protein; RP/EB fam	15.2
	134374 D62633 Hs.8236 134405 J04177 Hs.82772	ESTs	15.2
20	134405 J04177 Hs.82772 134470 X54942 Hs.83758	collagen; type XI; alpha 1 CDC28 protein kinase 2	15.3
	134495 D63477 Hs.84087	KIAA0143 protein	20.3 16.1
	134714 U89922 Hs.890	lymphotoxin beta (TNF superfamily; memb	35.7
	135237 AA454930 Hs.9691	ESTs	19.5
0.5	301884 AA312082 Hs.105445	GDNF family receptor alpha 1	20.7
25	302276 NM_004448Hs.323910	EST duster (not in UniGene) with exon hit	21.6
	302290 AL117607 Hs.175563	Homo sapiens mRNA; cDNA DKFZp564N	41.4
	309177 AI951118	EST singleton (not in UniGene) with exon	24.3
	309583 AW170035 310438 AW022192 Hs.200197	EST ESTs	64.5
30	311166 AI821294 Hs.118599	ESTs	39.1 24.1
• •	312153 AA759250 Hs.153028	cytochrome b-561	27.1
	313915 Al969390 Hs.163443	ESTs	27.1
	314506 AA833655 Hs.206868	ESTs	27.8
25	314558 Al873274 Hs.190721	ESTs	22.5
35	314691 AW207206 Hs.136319	ESTs	21.4
	314943 Al476797 Hs.184572 315196 AA972756 Hs.44898	cell division cycle 2; G1 to S and G2 to M	18.4
	316177 Al908272 Hs.293102	ESTs EST cluster (not in UniGene)	28.8
	318073 AW167087 Hs.131562	ESTs	32.6 15.7
40	318662 Al285898 Hs.294014	ESTS	16.3
	318740 NM_002543Hs.77729	EST duster (not in UniGene)	21.3
	318744 AI793124 Hs.144479	ESTs	35
	319668 NM_002731Hs.87773	EST duster (not In UniGene)	25.4
45	320074 AA321166 Hs.278233	EST duster (not in UniGene)	16.7
43	320211 AL039402 Hs.125783 320727 U96044 Hs.181125	DEME-6 protein	24.3
	320727 U96044 Hs.181125 322818 AW043782 Hs.293616	EST duster (not in UniGene) ESTs	15.3
	322882 AW248508 Hs.279727	DiGeorge syndrome critical region gene 2	21
	324261 ALQ44891 Hs.269350	EST cluster (not in UniGene)	15.3 50.1
50	324432 AA464510 Hs.152812	EST duster (not in UniGene)	16.7
	324603 AW016378 Hs.292934	ESTs	23.1
	324620 AA448021 Hs.94109	EST cluster (not in UniGene)	21.2
	324988 T06997 Hs.121028	EST duster (not in UniGene)	24.5
55	330388 X03363	HER2 receptor tyrosine kinase (c-erbB-2; E	17.7
33	330486 M13755 Hs.833 330814 AA015730 Hs.265398	Interferon-stimulated protein; 15 kDa	67
	331145 R72427 Hs.129873	ESTs; Weakly similar to transformation-rel ESTs; Weakly similar to CYTOCHROME	44.1
	331306 AA252079 Hs.63931	dachshund (Drosophila) homolog	41.9
	331890 AA432166 Hs.3577	succinate dehydrogenase complex; subunit	15.1 24.3
60	332526 AA281753 Hs.77515	inositol 1;4;5-triphosphate receptor; type 3	19
	332532 N63192 Hs.1892	EST; Highly similar to PHENYLETHANO	15.3
	332694 AA262768 Hs.243901	KIAA1067 protein	15.2
	332958	CH22_FGENES.48_15	17.8
65	333769 333968	CH22_FGENES.271_8	48.3
33	334223	CH22_FGENES.307_4 CH22_FGENES.360_4	15.9
	334264	CH22_FGENES.367_15	33.5 18.5
			10.5

335791	CH22_FGENES.611_7	27.
336512	CH22_FGENES.834_7	21.
338008	CH22_EM:AC005500.GENSCAN.127-9	15.

#### **TABLE 14A**

Table 14A shows the accession numbers for those pkeys lacking unigeneID's for Table 14. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: Unique Eos probeset Identifier number CAT number: Gene cluster number Accession: Genbank accession numbers

15

13			
	Pkey	CAT number	Accession
20 25	336512 338008 333769 333968 335791 309177 332958 334223 334264	10460292 CH22_3941FG_E CH22_6490FG_ CH22_1036FG_E CH22_1245FG_E CH22_13160FG_E AI951118 CH22_182FG_48 CH22_1557FG_3 CH22_1551FG_3 371681_1	134_7_LINK_DJ LINK_EM:ACOO 171_8_LINK_EM 107_4_LINK_EM 111_7_LINK_EM _15_LINK_EM: 60_4_LINK_EM

#### TABLE 14B

Table 14B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 14. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10 Pkey: Ref: Strand: Nt_position:		Sequen er Indicate	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.			
	Pkey	Ref	Strand	Nt_position		
20	333769 333968	Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al.	Plus Plus	2516164-2516310 7696625-7696707 8681004-8681241 13234447-13234544		
25	334223 335791	Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al.	Minus Minus	7697068-7697236 12734365-12734269 25948563-25948411 34278373-34278275		




Table 15 shows genes downregulated in breast cancer cells.

5

Pkey: Unique Eos probeset identifier number
ExAcon: Exemplar Accession number, Genbank accession number
Unique Eos probeset identifier number
Exemplar Accession number, Genbank accession number
Unique Eos probeset identifier number
Exemplar Accession number, Genbank accession number
Unique Eos probeset identifier number
Exemplar Accession number, Genbank accession number
Unique Eos probeset identifier number
Exemplar Accession number, Genbank accession number
Unique Eos probeset identifier num

	Dhan	Fu A	11-10	511 to 201	
15	Pkey	ExAccn	UniGene i	DUnigene Title	R1
1.5	100115	D00632	He 170152	glutathione peroxidase 3 (plasma)	47
		TIGR:HT1428	He 283108	Globin Reta	1.7
	100502	TIGR:HT1496	Hs 169228	Adrenal-Specific Protein Pa2	1.5 2.3
		TIGR:HT4268		L-Glycerol-3-Phosphate:Nad+ Oxidoreduct	1.7
20		L10373	Hs.82749	transmembrane 4 superfamily member 2	1.5
		M12963	Hs.4	alcohol dehydrogenase 1 (class I); alpha po	2.9
		M15856		lipoprotein lipase	1.6
	101883	M98399	Hs.75613	CD36 antigen (collagen type I receptor; thr	1.6
	102227	U25138	Hs.93841	potassium large conductance calcium-activ	1.6
25	102857	X00129	Hs.76461	retinol-binding protein 4; interstitial	3
	103211	X73079	Hs.288579		1.8
	103496	Y09267	Hs.132821		1.5
	103562	Z21966	Hs.2815	POU domain; class 6; transcription factor 1	1.8
	104672	AA007629		glycerol-3-phosphate dehydrogenase 1 (sol	2.4
30		AA146619	Hs.18791	ESTs; Weakly similar to CALCIUM-BIND	1.7
		AA164519	Hs.15248	ESTs	1.5
		AA417915	Hs.25930	ESTs	1.5
		AA487576	Hs.26530	serum deprivation response (phosphatidyls	1.6
25		AA609645	Hs.211568		2.7
35		AA004901	Hs.261164		1.6
		AA037388	Hs.82223	Human DNA sequence from clone 141H5 o	1.7
		AA099820	Hs.49696	ESTs	2.4
		N64265	Hs.19515	yz44h12.s1 Morton Fetal Cochlea Homo sa	1.7
40		R36447	Hs.24453	ESTs	1.6
40		R70255	11 004000	ESTs	1.9
		R97970	Hs.281022	ESI	1.5
		T40652	HS.209100	DKFZP434C171 protein	1.9
		AA418033 AA443800	Hs.283559		1.6
45		AA446661	Hs.43125	ESTs	2
40		N20300	Hs.173233 Hs.218707		2.2
		N32174	Hs.44317		1.7
		R15436	Hs.77889	SRY (sex-determining region Y)-box 10	1.7
		R71792		Friedreich ataxia region gene X123 ESTs; Weakly similar to cell death activato	1.7
50		T71021 .	He 285681	ESTs; Weakly similar to cell death activato	2.8
50		W73386	Hs.249129	ESTS, Flightly Stitular to WS basic-neitx-100	1.9 3
		AA365784	Hs.97044	ESTs	1.6
		AA405747	Hs.97984	ESTs; Weakly similar to WASP-family pro	1.8
		AA421184	Hs.97549	ESTs	1.5
55		AA434447	Hs.106771		2.5
		AA443695	Hs.293410		2.1
	122485	AA448300		phospholemman	1.5
	123443	AA598841	Hs.167382	natriuretic peptide receptor Alguanylate cy	1.8
	123505	AA600135		ESTs; Moderately similar to !!!! ALU SUB	1.5
60	125284	W94688	Hs.103253	perilipin	1.7
	126300			HUM427D08B Human fetal brain (TFujiw	1.8
	126747	R72515	Hs.160318	phospholemman	1.6
		AA309765	Hs.116017	ESTs; Weakly similar to KIAA0795 protei	1.5
	127357	AA452788	Hs.75432	zx39g11.r1 Soares_total_fetus_Nb2HF8_9	1.7

	407000	4 4 00 4 40 5			
		AA634405	Hs.122608		1.5
		AA972780		ESTs; Weakly similar to IIII ALU SUBFA	1.5
		Al092391	Hs.134886		1.5
•		N44757	Hs.20340	ESTs ·	1.6
5		R71403	Hs.75309	eukaryotic translation elongation factor 2	1.7
		AA459944	Hs.108924	DKFZP586P1422 protein	1.5
		T62068	Hs.11006	ESTs	2.1
	129331	N93465	Hs.279772	ESTs; Highly similar to CGI-38 protein [H	1.5
	130085	M62402	Hs.274313	insulin-like growth factor binding protein 6	1.7
10	130400	M25079		hemoglobin; beta	1.7
	131267	AA211776	Hs.2504	myomesin 1 (skelemin) (185kD)	3.8
	131277	AA131466	Hs.23767	ESTs	1.9
	131282	M12272	Hs.4	alcohol dehydrogenase 3 (class I); gamma p	2.2
	131304	AA295848	Hs.25475	aquaporin 7	1.7
15	131810	D49487	Hs.194236	leptin (murine obesity homolog)	2.5
		AA045503	Hs.56874	ESTs; Weakly similar to Homo sapiens p2	1.6
		Z41452	Hs.6090	deleted in bladder cancer chromosome regi	1.5
		X64559	Hs.65424	tetranectin (plasminogen-binding protein)	2
		U95367	Hs.70725	gamma-aminobutyric acid (GABA) A recep	1.5
20		X74295	Hs.74369	integrin; alpha 7	1.7
		S95936	Hs.284176		2.3
		N56898	Hs.75652	glutathlone S-transferase M5	1.9
		N79674	Hs.8022	TU3A protein	4.6
		U56814	Hs.88646	deoxyribonuclease I-like 3	1.5
25		L10955	Hs.89485	carbonic anhydrase IV	1.6
		M72885	Hs.95910	Human G0S2 protein gene; complete cds	1.9
		AW027556	Hs.156286		1.7
		Al369956	Hs.257891		
		AA514805	Hs.293055		1.5
30		AI807692			1.8
50		AA923549	Hs.129129 Hs.224121		1.6
		N77976			2,1
				hemoglobin; alpha 1	1.8
		V00505 T04868	Hs.36977	hemoglobin; delta	1.6
35			Hs.46780	EST cluster (not in UniGene) with exon hit	1.7
33		U94362 H91086	Hs.58589	glycogenin 2	1.5
		AA516384		EST singleton (not in UniGene) with exon	1.5
		AA550994		EST singleton (not in UniGene) with exon	1.5
			U. 070570	EST singleton (not in UniGene) with exon	1.7
40		AA782347	H\$.272072	EST singleton (not in UniGene) with exon	1.5
40		AA923457		EST singleton (not in UniGene) with exon	1.5
		Al192534		EST singleton (not in UniGene) with exon	1.6
		Al222691	11-054577	EST singleton (not in UniGene) with exon	1.5
		AI452732		EST singleton (not in UniGene) with exon	1.9
45		Al612774	Hs.79372	retinoid X receptor; beta	1.5
43		AW296073	Hs.255504		1.5
		A1720978		ESTs; Moderately similar to alternatively s	1.8
		AW241947	Hs.232478		1.6
		AW238092	Hs.254759		2.1
50	312082		Hs.118180		1.9
50	312575		Hs.306814		2.3
	313076		Hs.143040		1.8
		W32480	Hs.157099		2.2
		AW328672	Hs.132760	•	1.9
55		A1754634	Hs.131987		1.7
55		AA759098	Hs.192007		1.8
		AA680055	Hs.264885		1.5
		AA948612	Hs.130414		1.6
		Al205077	Hs.294085		1.7
<b>~</b> 0		AA837079	Hs.24647		1.5
60		Al480204	Hs.177131		1.5
		AI650625	Hs.300756		1.6
		AW206520	Hs.129621		1.5
		W26902	Hs.154085		1.7
CE		H22654	Hs.6382	EST cluster (not in UniGene)	1.5
65		AA021402	Hs.11067	ESTs	1.7
	322102			EST cluster (not in UniGene)	1.5
	322814	A1824495	Hs.211038	ESIS	2.2

	322929	Al365585	Hs.146246	ESTs	2.3
	323831	AA335715	Hs.200299	ESTs	1.7
	324044	AL045752	Hs.22350		1.8
_	324675	AW014734	Hs.157969	ESTs	2.2
5	325272			CH.11_hs gij5866902	1.5
	325558			CH.12_hs gi 6056302	1.6
	325656			CH.14_hs gi 6056305	1.6
	326120			CH.17_hs gij5867194	1.5
	326139			CH.17_hs gij5867203	1.5
10	326855			CH.20_hs gi 6552460	1.5
	327438			CH.02_hs gi[6004454	1.6
	329733			CH.14_p2 gi 6065783	1.6
	330931	F01443	Hs.284256		4.6
	331591	N71677	Hs.42146	ESTs	1.9
15	332159	AA621393	Hs.112984	EST	1.5
	332364	W94688	Hs.103253	perilipin	2.1
	332502	H21819	Hs.14896	Homo sapiens clone 24590 mRNA sequenc	1.5
	334175			CH22_FGENES.349_10	1.5
	334347			CH22_FGENES.375_31	1.8
20	334737			CH22_FGENES.424_12	1.8
	335352			CH22_FGENES.539_5	1.5
	335639			CH22_FGENES.584_19	1.6
	336244			CH22_FGENES.746_2	1.5
	336336			CH22_FGENES.814_8	1.7
25	336865			CH22_FGENES.305-1	1.6
	337494			CH22_FGENES.799-12	1.6
	337764			CH22_EM:AC000097.GENSCAN.119-1	1.8
	337983			CH22_EM:AC005500.GENSCAN.110-1	2
20	338192			CH22_EM:AC005500.GENSCAN.228-1	1.5
30	339366			CH22_BA354I12.GENSCAN.34-2	1.5

#### TABLE 15A

Table 15A shows the accession numbers for those pkeys lacking unigeneID's for Table 15. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

```
Pkey:
                 Unique Eos probeset identifler number
CAT number:
                 Gene cluster number
```

336336 CH22\_3746FG\_814\_8\_LINK\_BA

```
Accession:
                       Genbank accession numbers
15
        Pkey CAT number Accession
        126300 250375_2
                            D81972 BE003132
20
        112538 504579 1
                            AA908813 R70255
        123505 genbank_AA600135
                                      AA600135
                            AA349096 Al368018 F21390 F17759 R48772 Al421485 Al300352 H43971 Al378525 F33652 R47898 Al264177 F22289 N28263
        104672 6735_7
                            Al276281 R48205 Al245302 Al190036 Al281050 AW242903 H42892 AA910870 AW473816 H25721 AW451438 F19647 F22375
                            H45809 F33447 AA774528 AA007629 H42537 C01077 F32386
25
        322102 46708_1
                            H45589 H19807 AF075038 H19808 H42437
        336865 CH22_4590FG_305_1_
        338192 CH22_6755FG__LINK_EM:AC00
        329733 c14_p2
        326120 c17_hs
30
        326139 c17_hs
        326855 c20_hs
        335352 CH22_2699FG_539_5_LINK_EM
        335639 CH22_2999FG_584_19_LINK_E
        307206 Al192534
35
        307377 Al222691
        337494 CH22_5727FG_799_12_
        337764 CH22_6115FG__LINK_EM:AC00
337983 CH22_6438FG__LINK_EM:AC00
        339366 CH22_8336FG__LINK_BA354I1
40
        325272 c11_hs
        325558 c12_hs
        325656 c14_hs
        334175 CH22_1455FG_349_10_LINK_E
        304182 H91086
45
        334347 CH22_1640FG_375_31_LINK_E
        327438 c_2_hs
        304622 AA516384
        334737 CH22_2049FG_424_12_LINK_E
        304682 AA550994
50
        336244 CH22_3642FG_746_2_LINK_DA
        306193 AA923457
```

#### TABLE 15B

Table 15B shows the genomic positioning for those pkeys lacking unigene ID's and
 accession numbers in Table 15. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

	115100	1.					
10	Ref: Sequence		ce source	r corresponding to an Eos probeset rca. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication			
	Strand: Indicates DNA st		s DNA sti	e DNA sequence of human chromosome 22.° Dunham I. et al., Nature (1999) 402:489-495.  and from which exons were predicted.  de positions of predicted exons.			
15							
	Pkey	Ref	Strand	Nt_position			
	334347	Dunham, I. et.al.	Plus	13663814-13663926			
	334737	Dunham, I. et.al.	Plus	15998517-15998685			
20	335639	Dunham, I. et.al.	Plus	25173591-25173696			
	337494	Dunham, I. et.al.	Plus	33339024-33339148			
	334175	Dunham, I. et.al.	Minus	11668659-11668597			
		Dunham, I. et.al.		22681512-22681384			
	22024	D 1 . 4 . 1	4.47	0.4.200700 0.4.400700			

Minus

199569-199692

327438 6004454

#### TABLE 16: Table 4 from BRCA 001-5 US

Table 16, a subset of table 15, depicts a preferred group of genes highly downregulated in breast cancer cells.

Pkey: Unique Eos probeset identifier number
ExAcon: Exemplar Accession number, Genbank accession number
UnigenelD: Unigene number
Unigene Title: Unigene gene title
R1: Ratio of normal breast tissue to tumor

15	Pkey	ExAccn	UniGene ID	Unigene Title	R1
	100502	TIGR:HT1496	Hs.169228	Adrenal-Specific Protein Pg2	2.3
	101367	M12963	Hs.4	alcohol dehydrogenase 1 (class I); alpha	2.9
20	102857		Hs.76461	retinol-binding protein 4; interstitial	3
20		AA007629 AA609645	U- 244500	glycerol-3-phosphate dehydrogenase 1	2.4
	108604	AA099820	Hs.211568	eukaryotic translation initiation factor 4 gam	2.7
			Hs.49696 Hs.43125	ESTs ESTs	2.4
		AA446661	Hs.173233	ESTS	2
25		R71792	Hs.301002		2.2
23	119798		Hs.249129	ESTs; Weakly similar to cell death activator ESTs	2.8 3
		AA434447	Hs.106771	ESTs	2.5
		AA443695	Hs.293410	ESTs	2.5
	129285	T62068	Hs.11006	ESTS	2.1
30		AA211776	Hs.2504	myomesin 1 (skelemin) (185kD)	3.8
50	131282		Hs.4	alcohol dehydrogenase 3 (class I); gamma	2.2
	131810	D49487	Hs.194236	leptin (murine obesity homolog)	2.5
		X64559	Hs.65424	tetranectin (plasminogen-binding protein)	2.3
	133601	S95936	Hs.284176	transferrin	2.3
35	134111	N79674	Hs.8022	TU3A protein	4.6
		AA923549	Hs.224121	ESTs	2.1
		AW238092	Hs.254759	ESTs	2.1
	312575	H25237	Hs.306814	ESTs	2.3
	313283	W32480	Hs.157099	ESTs	2.2
40	322814	AI824495	Hs.211038	ESTs	2.2
	322929	AI365585	Hs.146246	ESTs	2.3
	324675	AW014734	Hs.157969	ESTs	2.2
	330931	F01443	Hs.284256	ESTs	4.6
	332364	W94688	Hs.103253	perilipin	2.1
45	337983			CH22_EM:AC005500.GENSCAN.110-1	2

#### TABLE 16A

Table 16A shows the accession numbers for those pkeys lacking unigeneID's for Table 16. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

15

5

Pkey: CAT number: Unique Eos probeset identifier number

Gene cluster number Accession: Genbank accession numbers

Pkey CAT number Accession

AA349096 Al368018 F21390 F17759 R48772 Al421485 Al300352 H43971 Al378525 F33652 R47898 Al264177 F22289 N28263 104672 6735\_7 Al276281 R48205 Al245302 Al190036 Al281050 AW242903 H42892 AA910870 AW473816 H25721 AW451438 F19647 F22375

20 H45809 F33447 AA774528 AA007629 H42537 C01077 F32386

### TABLE 17: Table 1 from BRCA 014 P

5 Table 17 shows accession numbers representing 759 sequences of breast cancer genes or fragments thereof encoding breast cancer modulating proteins. For each overexpressed gene identified, a ratio of the relative amount of expression in breast tumors versus normal breast tissue.

10							
	Pkey:	Ur	ique Eos prob	eset Identifier number			
	ExAccn		Exemplar Accession number, Genbank accession number				
	Unigen		ligene number				
	Unigen		ligene gene titl				
15	R1:			normal breast tissue			
	Pkey	ExAccn	UnigenelD	Unigene Title	R1		
20							
20		AV654694	Hs.82316	interferon-induced, hepatitis C-associat	3		
		AW291587	Hs.82733		3.2		
		AI962060		AE-binding protein 1	3.6		
		D86983	Hs.118893	Melanoma associated gene	3.2		
25		X83300	Hs.289103		5.2		
23		J00124	Hs.117729	keratin 14 (epidermolysis bullosa simple	4.3		
		BE387036	Hs.1211	acid phosphatase 5, tartrate resistant	3		
		AA442324	Hs.795	H2A histone family, member O	3.2		
		L20971	Hs.188	phosphodiesterase 4B, cAMP-specific (dun	3		
30		U66042	Hs.82171	Homo sapiens clone 191B7 placenta expres	4.1		
30	1013/8	BE563085	Hs.833	interferon-stimulated protein, 15 kDa	5.3		
		R07566	Hs.73817	small inducible cytokine A3 (homologous	3.9		
		M25809	Hs.64173	ATPase, H+ transporting, lysosomal (vacu	4.5		
		M29874	Hs.1360	cytochrome P450, subfamily IIB (phenobar	9		
35		AA353776	Hs.901	CD48 antigen (B-cell membrane protein)	3.4		
22		NM_003528		H28 histone family, member Q	5.6		
		BE019494	Hs.79217	pyrroline-5-carboxylate reductase 1	3.6		
		M81057	Hs. 180884	carboxypeptidase B1 (tissue)	12		
		M89907	HS.152292	SWI/SNF related, matrix associated, acti	3.2		
40		BE260964	Hs.82045	midkine (neurite growth-promoting factor	4.1		
40		M97815		cellular retinoic acid-binding protein 2	6.5		
		NM_002038		interferon, alpha-inducible protein (clo	3		
		U23752	Hs.32964	SRY (sex determining region Y)-box 11	3		
		NM_001504		G protein-coupled receptor 9	3.7		
45		NM_005824		37 kDa leucine-rich repeat (LRR) protein	3.7		
45		NM_005651		tryptophan 2,3-dioxygenase	5.2		
		AL043202	Hs.90073	chromosome segregation 1 (yeast homolog)	3.5		
		U39840		hepatocyte nuclear factor 3, alpha	3.9		
		U62325	HS.324125	amyloid beta (A4) precursor protein-bind	4		
50		H16646		hypothetical protein PP591	3.5		
50		AA363025 AF080229	HS.1555/2	Human done 23801 mRNA sequence	3.2		
			11-00004	gb:Human endogenous retrovirus K done 1	3		
		NM_002318 M73779	Hs.83354	lysyl oxidase-like 2	3.2		
		X52509		retinoic acid receptor, alpha	3.3		
55				tyrosine aminotransferase	12.4		
"	103042 103117			ribosomal protein S3	4.5		
	103207		rts.290449	parvalbumin	3		
		BE390551	Un 77620	gb:Human endogenous retrovirus mRNA for	5.9		
		AI751601	Hs.77628	steroidogenic acute regulatory protein r	3.9		
60	103204		Hs.8375 Hs.72984	TNF receptor-associated factor 4 retinoblastoma-binding protein 5	3.3		
00	103323			gp25L2 protein	3.1		
		NM MOTORS		gpzacz protein elmilar to rat HDEN/107	3		

Hs.37189 similar to rat HREV107 Hs.9629 papillary renal cell carcinoma (transloc

103385 NM\_007069 103456 AA496425

10

	103498 Y09306		nteracting protein kinase 3	3.4
	103558 BE616547	ds.2785 keratin 17		3.7
	103563 L02911	4s.150402 Activin A receptor		3.2 4.5
~	103612 BE336654	Hs.70937 H3 histone family	y, member A	4
5	103825 Al571835	Hs.55468 ESTs Hs.88417 ESTs		3.8
	104073 AW779318 104103 AW021102	Hs.88417 ESTs Hs.21509 ESTs		4.3
	104115 AF183810		to trichorhinophalangeal	7.6
	.104168 AA461618	Hs.31704 ESTs, Weakly s	imilar to KIAA0227 [H.sapi	3.6
10	104173 AA084273	Hs.76561 ESTs, Weakly s	imilar to S47072 finger pr	4
	104181 AF173296	Hs.283740 DC6 protein		3
	104189 AB040927	Hs.301804 KIAA1494 prote	in	3.2
	104269 Al559444	Hs.293960 ESTs		4.3
	104307 Al929700	Hs.111680 endosulfine alph	18	3.1 3.2
15	104518 H20816		nRNA; cDNA DKFZp58611420 (f otein; KIAA1830 protein	4.4
	104556 AV650851	Hs.96900 hypothetical pro Hs.27268 Homo saplens o	DNA: FLJ21933 fis, clone H	3.2
	104658 AA360954 104748 AA015879	Hs.33536 ESTs	2101.1 2021000 101 0010 11	3.2
	104746 AA013673	Hs.9029 DKFZP434G03	2 protein	4.5
20	104825 AA035613	Hs.141883 ESTs	•	6.9
	104830 AW294092	Hs.21594 hypothetical pro	otein MGC15754	11.1
	104865 T79340	Hs.22575 B-cell CLL/lymp	noma 6, member B (zinc fi	3.5
	104906 BE298684		domains containing protei	6.5
	104961 H78517	Hs.33905 ESTs	•	3.6 4.5
25	105038 AW503733	Hs.9414 KIAA1488 prote		3.8
	105088 H58589		dDNA FLJ11027 fis, done PL	3
	105092 AA148982	Hs.29068 ESTs Hs.32405 Homo sapiens	mRNA; cDNA DKFZp586G0321 (f	4.8
	105093 AL137566 105304 AW134924	Hs.190325 ESTs		8.2
30	105397 AA814807	Hs.7395 hypothetical pro	otein FLJ23182	3.1
30	105409 AW505076	Hs.301855 DiGeorge synd	rome critical region gene 8	4.2
	105431 AA252033	Hs.242413 hypothetical pro	otein DKFZp434K1421	4.4
	105552 AA256750	Hs.28802 centaurin-alpha	a 2 protein	3.2
	105598 AA279439	Hs.279763 hypothetical pri		3.5 3.7
35	105650 W16741	Hs.25635 HSPC003 prote	ein	5.5
	105688 Al299139	Hs.17517 ESTs Hs.286131 CGI-101 protei	'n	3.5
	105808 Al133161 105809 AW973653	Hs.20104 hypothetical pr	otein FLJ00052	3.3
	105909 AA195191	Hs.5111 hypothetical pr	otein FLJ20729	3.2
40	105965 AA131657	Hs 23830 FSTs		3.3
	106135 AL117474	Hs.41181 Homo sapiens	mRNA; cDNA DKFZp727C191 (fr	3.2
	106184 W28948	Hs.10762 ESTs		3.3
	106293 N39842	Hs.301444 KIAA1673		4.1
	106400 BE397649	Hs.94109 Homo sapiens	cDNA FLJ13634 fis, done PL	3.1 3.2
45	106474 BE383668	Hs.42484 hypothetical pr	rotein FLJ10618	7.8
	106484 AA351978	Hs.4943 hepatocellular Hs.145998 ESTs	carcinoma associated prot	3
	106533 AL134708	Hs.335951 hypothetical pr	rotein AF301222	3.8
	106614 AA648459 106636 AW958037	Hs.286 ribosomal prot	ein L4	3.3
50	106661 AW499914	Hs.7579 hypothetical pr	rotein FLJ10402	3
30	106743 BE613328	Hs.21938 hypothetical pr	rotein FLJ12492	4.2
	106844 AA485055	He 158213 snem associa	ited antigen 6	3.4
	106864 Al311928		1 NCI_CGAP_Kid5 Homo sapiens	4.4
	106865 AW192535	Hs.19479 ESTs	NCC0774	3.6 4.1
55	106871 AW472981	Hs.321130 hypothetical p	rolein MGC2//1	3.6
	106942 AA995351	Hs.31314 retinoblastoma Hs.26813 CDA14	a-billottig protest /	5.3
	106968 AF216751 107105 AW963419	Hs.26813 CDA14 Hs.155223 stanniocalcin	2	3.4
	107158 N32849	Hs.31844 hypothetical p	rotein FLJ12586	3.1
60	107248 AW263124	He 315111 nuclear recent	tor co-repressor/HDAC3 comp	5.9
50	107265 BE379594	Hs.49136 ESTs, Modera	ately similar to ALU7_HUMAN A	3.9
	107630 AW961576	He 60178 FSTs		4.6
	107710 Al955040	Hs 265398 FSTs, Weakly	similar to transformation-r	3
<i>-</i> -	107890 AA025386	He 61311 FSTs Weakt	v similar to S10590 cysteine	3.1
65	107985 T40064	Hs.71968 Homo sapien	s mRNA; cDNA DKFZp564F053 (fr	4.8 3.3
	108000 Al263307	Hs.239884 H2B histone f	anny, member c	3.8
	108217 AA058686	Hs.62588 ESTs		5.0

WO 02/059377

#### PCT/US02/02242

	100425	T00407	Un 404404	Home analoge aDMA, EL 120000 E	
		T82427 AB033073	Hs. 43857	Homo sapiens cDNA: FLJ20869 fis, clone A similar to glucosamine-6-sulfatases	3 3.3
		AA121022	110.70007	gb:zn84f10.r1 Stratagene lung cardinoma	3.9
		AF068290	Hs.79741	hypothetical protein FLJ10116	6.1
5		AA011449	Hs.271627		3.6
		AA136674	Hs.118681		3.9
		AF186114		tumor necrosis factor (ligand) superfami	3.7
		AK000684		hypothetical protein FLJ22104	3.1
10		Al970536 · N23235	Hs.16603 Hs.30567	hypothetical protein FLJ13163 ESTs, Weakly similar to B34087 hypotheti	3.7
		AA196443	Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PL	4.5 3.7
		AW504732	Hs.21275	hypothetical protein FLJ11011	4.6
		AA232255		ESTs, Moderately similar to A46010 X-lin	6.4
4.5		AA234087	Hs.262346	ESTs, Weakly similar to S72482 hypotheti	4.8
15		R45584	Hs.23025	ESTs, Weakly similar to ALU5_HUMAN ALU S	3.3
		AA325138		hypothetical protein FLJ22672	3
		AW973964 F09609	MS.291531	ESTs, Highly similar to 1203217A dehydro	3
		F06838	Hs.14763	gb:HSC33H092 normalized infant brain cDN ESTs	3.2 3.2
20		R43646	Hs.12422	ESTs	3.8
		AW818436	Hs.23590	solute carrier family 16 (monocarboxylic	3.3
		AK001680	Hs.30488	DKFZP434F091 protein	3.6
		AW973152	Hs.31050	ESTs	4.2
25		AA379597	Hs.5199	HSPC150 protein similar to ublquitin-con	5.1
23		H89355 Al239832	Hs.15617	adrenergic, alpha-2A-, receptor ESTs, Weakly similar to ALU4_HUMAN ALU S	5.3
		BE092285	Hs.29724	hypothetical protein FLJ13187	3.7 3.7
•		N64683	Hs.290943		4
		N66563	Hs.191358		3.1
30		AI767435	Hs.29822	ESTs	4.5
		AI457338	Hs.29894	ESTs	5.4
		R07856	Hs.16355	ESTs	3.2
		R08440 AA602004	Hs.23260	gb:y119f09.s1 Soares fetal liver spleen	3.1
35		R35252	Hs.24944	ESTs ESTs. Weakly similar to 2109260A B cell	3.2 3.3
55		R38239		ESTs, Weakly similar to putative p150 [H	3.1
		AA421081	Hs.12388	ESTs	3.4
		AF070526	Hs.13429	Homo sapiens clone 24787 mRNA sequence	3.3
40		AW379029		ESTs, Weakly similar to unnamed protein	4.4
40		BE246743		hypothetical protein FLJ22635	7.3
		AB033064 H24334	Hs.334806 Hs.26125	KIAA1238 protein	3.2
		R54797	ns.20125	gb:yg87b07.s1 Soares infant brain 1NIB H	4.4 3.4
		R66067	Hs.28664	ESTs .	8.2
45		Al791493		ESTs, Weakly similar to A36036 cytochrom	5.5
		R82040		gb:yj06b06.s1 Soares placenta Nb2HP Homo	3.9
		R82331	Hs.164599	ESTs	5.4
		AW844878	Hs.19769	hypothetical protein MGC4174	3.2
50		Al418466	Hs.33665	ESTS	4.7
50		AA082465 AB032977	Hs.6298	choline/ethanolaminephosphotransferase	3.7
		AA828380	Hs.126733	KIAA1151 protein	3.1 3.4
		AW813731		ESTs, Moderately similar to S65657 alpha	3.4
		BE613410	Hs.31575	SEC63, endoplasmic reticulum translocon	3.2
55	113200	T57773	Hs.10263	ESTs	3.5
		BE262470	Hs.241471		6.2
		T79925		ESTs, Weakly similar to ALU1_HUMAN ALU S	3.7
		U54727 T91451	Hs.191445	ESTS	3
60		AW367788	Hs.86538 Hs.323954	postmeiotic segregation increased 2-like	3.4 3.1
50		A1702609	Hs.15713	hypothetical protein MGC2776	3.1
		NM_004585	Hs.17466	retinoic acid receptor responder (tazaro	3.9
	113835	Al912410	Hs.27475	Homo sapiens cDNA FLJ12749 fis. clone NT	3
65		W81598		gb:zd88g02.s1 Soares fetal heart NbHH19W	4.6
65		W84768	U= 0400	gb:zh53d03.s1 Soares fetal liver spieen	3.1
		W27249	Hs.8109	hypothetical protein FLJ21080 hypothetical protein MGC3077	6.9
	114000	AA378776	115.200049	hypothetical protein MGC3077	4.3

	114148 AW470411	Hs.288433	neurotrimin	4.1
	114424 AW780192	Hs.267596	ESTs	3.4
	114518 AW163267	Hs.106469	suppressor of var1 (S.cerevisiae) 3-like	3.1
	114563 Al979168	Hs.82226	glycoprotein (transmembrane) nmb	4.8
5	114965 AI733881		BMP-R18	10.1
•	114995 AA769266	Hs.193657	ESTs	3.6
	115121 Al634549		ESTs	3.2
	115134 AW968073	Hs. 194331	ESTs, Highly similar to A55713 inositol	4.2
	115167 AA749209		hypothetical protein	3
10	115253 BE149845	Hs.289038	hypothetical protein MGC4126	3.6
10	115277 AA814100		ESTs	3.9
	115327 N46436	Hs.109221		3.4
	115354 AA281636	Hs.334827		4.8
	115657 AA405620	Hs.55158	ESTs, Wealdy similar to T29520 hypotheti	3.5
15	115676 AA953006		ESTs	9.3
13	115709 AW293849	Hs.58279	ESTs, Weakly similar to ALU7_HUMAN ALU S	3.4
	115729 AA417812	Hs.38775	ESTs	4
		Hs.40479	ESTs	3.1
	115787 Al126772	Hs.86434	hypothetical protein FLJ21816	3.6
20	115830 AW970529 115835 AA521410	Hs.41371	ESTs	3.1
20		Hs.52463	KIAA0966 protein	3
	115850 NM_014937	Ha 166186	hypothetical protein FLJ13852	3.2
	115900 AK001500		Homo sapiens mRNA; cDNA DKFZp727C191 (fr	3
	115935 AA354549	Hs.41181	poly(A)-specific ribonuclease (deadenyla	3.1
25	115948 AL042465	Hs.43445 Hs.93847	NM_016931:Homo sapiens NADPH oxidase 4 (	6.7
25	116092 AB041035		WD repeat domain 10	3.6
	116115 AL042355	Hs.70202		3.1
	116184 AW450737		CGI-09 protein	3.3
	116192 AA464976	Hs.62528	ESTs, Moderately similar to A46010 X-lin	3.2
20	116208 Al219083	Hs.42532	ESTs, Moderately similar to ALU8_HUMAN A	3.6
30	116246 AF265555		baculoviral IAP repeat-containing 6	4.1
	116443 AW962196		LBP protein 32	4.1
	116470 Al272141	Hs.83484	SRY (sex determining region Y)-box 4	8.6
	116726 AK001114	Hs.53913	hypothetical protein FLJ10252	3.2
25	116845 AA649530		gb:ns44f05.s1 NCI_CGAP_Alv1 Homo sapiens ESTs, Moderately similar to ZN75_HUMAN Z	3.5
35	117026 H88256	Hs.50456		3.1
	117216 AI569804	Hs.42792	ESTs, Weakly similar to 178885 serine/th	3.2
	117296 AL133427	Hs.42506	Homo sapiens mRNA full length insert cDN	4.7
	117403 H84455	Hs.40639	ESTs	3
40	117691 AB040959	Hs.93836	DKFZP434N014 protein	3.3
40	118229 AW968941		hypothetical protein DKFZp5661133	4.3
	118363 AI183838	Hs.48938	hypothetical protein FLJ21802	3.1
	118416 N66028	Hs.49105	FKBP-associated protein	3.4
	118470 AW970584	Hs.291033	ESIS	5.2
	118502 AL157488	Hs.50150	Homo sapiens mRNA; cDNA DKFZp564B182 (fr	3.4
45	118695 AK000465	Hs.50081	KIAA1199 protein	3.3
	118925 N92293		ESTs, Moderately similar to ALU8_HUMAN A	
	119025 BE003760	Hs.55209	Homo sapiens mRNA; cDNA DKFZp434K0514 (f	19
	119036 R95872	Hs.117572	chemokine binding protein 2	3.7
	119063 R16833	Hs.53106		4.1
50	119075 M10905		) fibronectin 1	3.2
	119620 W47620	Hs.56009	2'-5'-oligoadenylate synthetase 3 (100 k	3.3
	119741 AF041853	Hs.43670	kinesin family member 3A	. 3.1
	119747 Al970797	Hs.64859	ESTs	5
	119754 AL037824	Hs.194695	ras homolog gene family, member l	3.0
55	119905 AW449064	Hs.11957	l ∞llagen, type III, alpha 1 (Ehlers-Dani	3.
	120084 W94472	Hs.59529	ESTs, Moderately similar to ALU1_HUMAN A	8.4
	120241 AA825686	Hs.321176	ESTs, Weakly similar to S65824 reverse t	3.0
	120326 AA196300	Hs.21145	hypothetical protein RG083M05.2	3.
	120742 AA225084		ab:nc21d06.r1 NCI_CGAP_Pr1 Homo sapiens	3.
60	120870 AA357172	Hs.29258	1 ESTs. Moderately similar to ALU1_HUMAN A	5.
00	120885 AA365515	Hs.30187	2 hypothetical protein MGC4840	3
	120970 AA398118	Hs.97579		3.
	121054 AW976570	Hs 97387	ESTs	5.
	121095 AA320134	Hs.19602	9 Homo sapiens mRNA for KIAA1657 protein,	4
65	121103 AA398936	Hs.97697	EST	3.
03	121121 AA399371	Hs.18909	5 similar to SALL1 (sal (Drosophila)-like	6.
	121337 AW885727	Hs.30157	0 ESTs	4.

		•			
		AW206227	Hs.287727	hypothetical protein FLJ23132	5
	121611	M31669	Hs.1735	inhibin, beta B (activin AB beta polypep	3.6
		AA640987	Hs.193767		5.6
_	121770	NM_015902	Hs.278428	progestin induced protein	3.4
5		AK000492	Hs.98806	hypothetical protein	4.1
		AA443311	Hs.98998	ESTs	3
		AA446965	Hs.112092		4.7
		AI767879	Hs.99214		3.8
10		AW973253	Hs.292689		3
10		AA323296	Hs.97837		5.6
		AA526911	Hs.82772		3.2
		AW205931	Hs.99598	hypothetical protein MGC5338	8.6
		AA487809		catenin (cadherin-associated protein), d	3
1.5		AA228776	Hs.191721		6.9
15		AA371307	Hs.125056		3.6
		AA491253		Empirically selected from AFFX single pr	7
		BE149685		KIAA1554 protein	3.1
		T66087		Homo sapiens unknown mRNA sequence	3.4
20		Al308876		hypothetical protein DKFZp761D112	3.1
20		AI675944		Homo sapiens cDNA FLJ12033 fis, clone HE	3.8
		AA580082	Hs.112264		4.7
		AA352723	Hs.241471		3.8
		H69125	Hs.133525		4.1
25		N22401	11. 100015	gb:yw37g07.s1 Morton Fetal Cochlea Homo	4.1
23		N22508		Homo saplens cDNA: FLJ21479 fis, clone C	3.6
		AW451645		Homo sapiens cDNA FLJ11973 fis, clone HE	3.1
		N34151		interferon Induced transmembrane protein	3.5
		R41396	MS.1U1//4	hypothetical protein FLJ23045	4.3
30		BE065136		splicing factor (CC1.3)	6
30		178906		ESTs, Moderately similar to ALU1_HUMAN A	8.1
		W60326 AW970536		Homo sapiens cDNA FLJ11750 fis, clone HE	4.7
			Hs.105413		3.1
		AF086534 AL359573		ESTs, Moderately similar to ALU1_HUMAN A	3.3
35			Hs.114574	GTP-binding protein	3
55		AW880562 AI422996	Hs.161378		3 3.2
		A1924630	Hs.4943	hepatocellular carcinoma associated prot	3.2
		N99638	113.4343	gb:za39g11.r1 Soares fetal liver spleen	3.2 4
		AW975814	He 326714	Homo sapiens clone IMAGE:713177, mRNA se	4
40		AA648886	Hs.151999		3.8
		AW450979	110.101000	gb:UI-H-BI3-ala-a-12-0-UI.s1 NCI_CGAP_Su	3
		AW771958	Hs 175437	ESTs, Moderately similar to PC4259 ferri	3.6
		AA961459	Hs.125644		4.1
		AW068311		Homo saplens mRNA full length Insert cDN	3.3
45		AA650274	Hs.41296	fibronectin leucine rich transmembrane p	4.6
		NM_003616		survival of motor neuron protein interac	3.9
		Y13153		kynurenine 3-monooxygenase (kynurenine 3	3.1
		AA775076		Homo sapiens, Similar to PRO0478 protein	3.9
		D56365	Hs.63525	poly(rC)-binding protein 2	3.3
50	129270	AA357185		ras homolog gene family, member H	3.1
	129301	AF182277		cytochrome P450, subfamily IIB (phenobar	3.9
	129385	AA172106		Rag C protein	6.2
	129619	AA209534		tetraspan NET-6 protein	3.4
	129629	AK000398	Hs.11747	hypothetical protein FLJ20391	3
55	129725	X56411	Hs.1219	alcohol dehydrogenase 4 (class II), pi p	3.2
	130069	AI754813	Hs.146428	collagen, type V, alpha 1	5.4
	130092	X03363	Hs.323910	v-erb-b2 avian erythroblastic leukemia v	4.4
		Al347487	Hs.132781	class I cytokine receptor	4.6
	130382	NM_003450	Hs.155204	zinc finger protein 174	5.6
60		AI582291		ESTs, Weakly similar to O4HUD1 debrisoqu	3
		R77776	Hs.18103	ESTs	3.8
		AA809875	Hs.25933	ESTs .	4.2
		AB014544	Hs.21572	KIAA0644 gene product	4.7
C =		AI399653	Hs.22917	ESTs	4.3
65		H09048	Hs.23606	ESTs	3.8
	131253		Hs.24853	ESTs	3.5
	131372	AW293399	Hs.144904	nuclear receptor co-repressor 1	3.6

WO 02/059377

#### PCT/US02/02242

	131507 A1005050	11- 07700	FOT- West of State of	
	131507 Al826268 131587 Al695549	Hs.27769	ESTs, Weakly similar to MCAT_HUMAN MITOC glucuronidase, beta	3.2
	131739 AF017986	Hs.31386	secreted frizzled-related protein 2	3.1 3.2
_	131795 BE501849	Hs.32317	high-mobility group 20B	3.2
5	131970 D86960	Hs.3610	KIAA0205 gene product	3.6
	131986 NM_002314		LIM domain kinase 1	3.2
	132093 AA400091	Hs.39421	ESTs	3.2
	132122 AA426202 132159 D76435	Hs.40403	Cbp/p300-interacting transactivator, wit	3
10	132333 AA192669	Hs.41154 Hs.45032	Zic family member 1 (odd-paired Drosophi ESTs	3.2
•	132406 AL133731	Hs.4774	Homo sapiens mRNA; cDNA DKFZp761C1712 (f	3.5 9.2
	132482 AV660345		CGI-49 protein	8.2
	132543 BE568452	Hs.5101	protein regulator of cytokinesis 1	3.4
1.5	132624 AA326108	Hs.33829	bHLH protein DEC2	3.2
15	132700 AA319233		ESTs	4.8
	132725 NM_006276		splicing factor, arginine/serine-rich 7	3.6
	132799 W73311 132847 T48195	Hs.169407 Hs.58189	SAC2 (suppressor of actin mutations 2, y	3.2
	132857 Y00272		eukaryotic translation initiation factor cell division cycle 2, G1 to S and G2 to	3.5
20	132936 AL120659	Hs.6111	aryl-hydrocarbon receptor nuclear transl	4.4 4.8
	133130 Al128606	Hs.6557	zinc finger protein 161	3.3
	133142 AW952412	Hs.65874	ESTs, Weakly similar to A40348 Elav/Sex-	3.5
	133167 AW162840	Hs.6641	kinesin family member 5C	4.5
25	133225 AW600291	Hs.6823	hypothetical protein FLJ10430	3.3
25	133274 AA085191	Hs.6949	hypothetical protein MGC11275	3
	133275 Z93241 133287 AW797437		CGI-96 protein	4.5
	133376 BE618768	Hs.69771 Hs.7232	B-factor, properdin	4.1
	133462 AW675064	Hs.73875	acetyi-Coenzyme A carboxylase alpha fumarylacetoacetate hydrolase (fumarylac	5.1 3
30	133740 AW162919		RAB2, member RAS oncogene family-like	3.4
	133831 BE274552	Hs.76578	protein Inhibitor of activated STAT3	3.9
	133976 Al908165	Hs.169946	GATA-binding protein 3 (T-cell receptor	6.2
	134666 BE391929	Hs.8752	transmembrane protein 4	3.1
35	134710 Al433797	Hs.8889	serine hydroxymethyltransferase 1 (solub	3
33	134731 D89377 134776 J05582	Hs.89404	msh (Drosophila) homeo box homolog 2	5.8
	135230 AF064804	Hs.89603 Hs.96757	mucin 1, transmembrane	4
	135303 R61253	Hs.98265	suppressor of Ty (S.cerevisiae) 3 homolo KIAA1877 protein	3.2
	135400 X78592	Hs.99915	androgen receptor (dihydrotestosterone r	3.3 4.8
40	135411 L10333	Hs.99947	reticulon 1	3.8
	300089 AJ199738	Hs.208275	ESTs, Weakly similar to ALUA_HUMAN !!!!	3.8
	300233 AW614220	Hs.189402	ESTs	4.2
	300254 AW183618	Hs.55610	solute carrier family 30 (zinc transport	9.9
45	300256 AW591433	Hs.298241	Transmembrane protease, serine 3	4.9
40	300378 Z45270 300973 AA572949	Hs.235873 Hs.207566	hypothetical protein FLJ22672	3.4
	301111 R10799	Hs.191990		3.5
	301341 AA887801		G protein-coupled receptor	3.8 13.9
	301548 AI091631	Hs.203845	two pore potassium channel KT3.3	4,4
50	301884 AA312082	Hs.105445	GDNF family receptor alpha 1	5.7
	301936 U79745	Hs.114924	solute carrier family 16 (monocarboxylic	8.6
	301976 T97905		gb:ye54c10.r1 Soares fetal liver spleen	3.9
	302001 AB020711	Hs.2/8346	KIAA0904 protein	7.7
55	302067 BE542706 302094 AW749321		CEGP1 protein	7.3
55	302099 AL049670		ESTs ribosomal protein L34 pseudogene 1	3.3
	302145 NM_003613	Hs.151407	cartilage intermediate layer protein, nu	4.2 7.9
	302235 AL049987	Hs.166361	Homo sapiens mRNA; cDNA DKFZp564F112 (fr	5.6
	302276 AW057736	Hs.323910	HER2 receptor tyrosine kinase (c-erb-b2.	5.4
60	302290 AA179949	Hs.175563	Homo sapiens mRNA: cDNA DKFZn564N0763 (f	34.1
	302372 AL117406	Hs.200102	ATP-binding cassette transporter MRP8	6.7
	302378 AL109712	Hs.296506	Homo sapiens mRNA full length Insert cDN	4
	302384 Al678059	HS.2026/6	synaptonemal complex protein 2	4.3
65	302385 AJ224172 302680 AW192334	Hs.38218 .	lipophilin B (uteroglobin family member)	13.8
JJ	302830 Al038997	Hs.132921		9.6 5
	302857 AF282265		inner centromere protein antigens (135kD	3.4

	302892	AW176909	Hs.42346	calcineurin-binding protein calsarcin-1	3.4
	302970	W05608		ESTs, Weakly similar to A49019 dynein he	5.1
		AA652687	Hs.96151	Human DNA sequence from clone RP5-1103G7	3.7
		AL121460			
5				hypothetical protein FLJ20508	4.1
J		AW006352	ms.159043	ESTs, Weakly similar to T32554 hypotheti	4.2
		AA355607		ESTs, Weakly similar to putative WHSC1 p	4.3
		AA367699	Hs.10082	potassium intermediate/small conductance	3.3
	303642	AW299459		gbxs50d08x1 NCI_CGAP_Kid11 Homo saplen	4.2
	303780	Al424014	Hs.18995	KIAA1304 protein	3.6
10	303797	AW629759		gb:hh70e05.y1 NCI_CGAP_GU1 Homo sapiens	4.9
		R53434	Hs.90207	hypothetical protein MGC11138	3.7
		AA149951	Hs.62112		
			NS.02112	zinc finger protein 207	3
		AA582081		gb:nn32h08.s1 NCI_CGAP_Gas1 Homo sapiens	4.1
10		AA876109		gb:nx24h01.s1 NCI_CGAP_GC3 Homo sapiens	3
15	305917	AA876469		gb:oe48b04.s1 NCI_CGAP_Pr25 Homo sapiens	3.1
	307010	Al140014		gb:qa68f09.x1 Soares_fetal_heart_NbHH19W .	3.5
-	307041	Al144243		gb:qb85b12.x1 Soares_fetal_heart_NbHH19W	3.9
		AI476803		gb:tj77e12x1 Soares_NSF_F8_9W_OT_PA_P_S	
		Al581398	Un 470000		4.3
20				collagen, type I, alpha 1	4.6
20		AK000142		hypothetical protein FLJ23045	4.4
		Al951118		Homo sapiens breast cancer antigen NY-BR	17.3
	309328	AW024348	Hs.233191	EST, Weakly similar to A27217 glucose tr	3.2
	309574	AW168083		gb:xg59g04.x1 NCI_CGAP_Ut4 Homo sapiens	3.1
	309583	AW170035	Hs.326736	Homo sapiens breast cancer antigen NY-BR	57.6
25		Al199712		ESTs, Weakly similar to 1917210A Pro/Arg	4.6
		Al685841	Hs.161354		
		AW022192	Hs.200197		3.6
					4.6
		Al939456	Hs.160870		3.2
20		AK000703		Homo sapiens mRNA for KIAA1551 protein,	3.6
30		AI380797	Hs.158992	ESTs	10.2
	310895	AI955121	Hs.165724	N-acetylgalactosamine-4-O-sulfotransfera	3.4
	310955	AI476732	Hs.263912	ESTs	10.9
	311117	Al671439		Homo sapiens mRNA for KIAA1657 protein,	3.1
		AI821005	Hs.118599		10.8
35		AA641098			
55				ESTs, Moderately similar to ALU1_HUMAN A	4.3
		AI758660	Hs.206132		4.4
		AI828254		ESTs, Weakly similar to A47582 B-cell gr	5.1
		AW023595	Hs.232048		5.8
4.0	311774	AA700870	Hs.14304	ESTs	3.3
40	311785	AI056769	Hs.133512	ESTs	3.9
	311872	R12375	Hs.194600	ESTs	3.3
	311889	AA767342		ESTs, Weakly similar to PSF_HUMAN PTB-AS	3
		AI358522	Hs.270188		3
		T60843	Hs.189679	•	-
45		AA216387	115.105075		5.6
73				gb:nc16b02.s1 NCI_CGAP_Pr1 Homo sapiens	5.2
		AA373630	Hs.188750		3
		AA759263	Hs.14041	ESTs	3.4
		T78968	Hs.14411	ESTs	3.5
	312090	T80177	Hs.118064	similar to rat nuclear ubiquitous casein	3.8
50	312147	Al633744		ESTs, Weakly similar to 138022 hypotheti	4.4
		BE261944		hexokinase 1	5.2
	312168		Hs.198882		
					3.3
	312182		Hs.326263		3.3
<i></i>		AA700439	Hs.188490		3.4
55		AW438602	Hs.191179	ESTs	3.9
	312219	H73505	Hs.117874	ESTs	4
		AA315703	Hs.199993	ESTs, Weakly similar to ALUB_HUMAN IIII	4.9
		AA972712	Hs.269737		5.7
		AA516420		ESTs, Weakly similar to I38022 hypotheti	
60		AW439195			6.3
JU				ESTs, Weakly similar to S65657 alpha-1C-	4.9
		AW291545	Hs.185018		4.9
		AW292286	Hs.255058		4.4
		AA497043	Hs.115685	ESTS	3.1
		Al422023	Hs.161338	ESTs	4.3
65	313079	N76497	Hs.1787	proteolipid protein 1 (Pelizaeus-Merzbac	3.3
		AF026944	Hs.293797		5.8
		AW073310		Homo sapiens cDNA FLJ14142 fis, clone MA	4.5
			50000	capiono cora i i se i i i i i i i i i i i i i i i i	7.5

	313126 AA	746503 ł	ts.283313	ESTs	10
	313166 AI8	101098 F	ls.151500	ESTs	3.5
	313197 AW		ls.222487	ESTs	3.3
-	313280 AW		ls.222830		4.7
5	313325 AI4		ls.127832	ESTs	3.4
	313328 AW			GDNF family receptor alpha 1	12
	313352 AW		ls.144758		4.1
	313385 AIO		ls.269819		3
10	313393 AI6		ls.200141		5.2
10	313417 AA7 313434 W9		ls.137323		3.5
	313569 AI2		la 425445	gb:zh48g05.r1 Soares_fetal_liver_spleen_	3.7
	313591 AA	13413 1	13. 133 140	hypothetical protein FLJ13984	3
	313615 AIS		le 301007	gb:zf12f01.s1 Soares_fetal_heart_NbHH19W hypothetical protein FLJ13033	5.6
15	313915 C18	3863 F	ls 163443	Homo sapiens cDNA FLJ11576 fis, done HE	3.2 26
	313975 AW			keratin 18	3
	313979 AI5		ls.221024		4.9
	313997 AV6			hypothetical protein MGC3077	3.9
	314043 AA8		s.291872		3.1
20	314078 AW		s.329700		8.3
	314097 AA6		s.269493		6.6
	314121 AI7:	32083 H	s.187619	ESTs	6.2
	314129 AA2		s.115122	ESTs	4
0.5	314138 AA7			gb:ny97f11.s1 NCI_CGAP_GCB1 Homo sapiens	5.9
25	314236 AA7		s.189023		3.1
	314244 ALO		s.103238		4
	314305 AI28			Homo sapiens cDNA FLJ13266 fis, clone OV	8
	314306 AI69		s.192425		3.7
30	314322 AA9		s.190060		3.3
50	314394 AWS 314401 AI66			ESTs, Moderately similar to 138022 hypot	4.2
	314465 AA6		s.234557		3.3
	314506 AA8		s.156974	Homo sapiens cDNA FLJ14056 fis, done HE	4.7
	314510 Al20		s.190080		8.5 4
	UITUIU MILL	ון טודדיג		LO13	4
35	314546 AW0	007211 H	s 16131	hypothetical protein FI 112876	2 4
35	314546 AW0 314547 AA3			hypothetical protein FLJ12876 FSTs	3.4 6.7
35	314546 AW0 314547 AA3 314558 AI87	99272 H	s.144341	ESTs	6.7
35	314547 AA3	199272 H 73274 H	s.144341 s.190721	ESTs ESTs	6.7 27.
	314547 AA3 314558 AJ87	199272 H 173274 H 125310 H	s.144341 s.190721	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr	6.7 27. 4.4
35 40	314547 AA3 314558 AI87 314627 AA4	199272 H 13274 H 125310 H 1979268	s.144341 s.190721	ESTs ESTs, ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo	6.7 27. 4.4 4.6
	314547 AA3 314558 AI87 314627 AA4 314648 AW3 314691 AW2 314729 AA4	99272 H 73274 H 125310 H 979268 207206 H 57367 H	s.144341 s.190721 s.155766 s.136319 s.191638	ESTS ESTS ESTS, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTS ESTS	6.7 27. 4.4
	314547 AA3 314558 AI87 314627 AA4 314648 AW3 314691 AW2 314729 AA4 314754 AW0	199272 H 173274 H 125310 H 1979268 207206 H 157367 H 1026761 H	s.144341 s.190721 s.155766 s.136319 s.191638 s.134374	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs	6.7 27. 4.4 4.6 20.
	314547 AA3 314558 AI87 314627 AA4 314648 AW3 314691 AW2 314729 AA4 314754 AW0 314814 BE3	199272 H 173274 H 125310 H 1979268 207206 H 157367 H 126761 H 50122 H	s.144341 s.190721 s.155766 s.136319 s.191638 s.134374 s.157367	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs ESTs, Weakly similar to 178885 serine/th	6.7 27. 4.4 4.6 20. 3.6
40	314547 AA3 314558 AI87 314627 AA4 314648 AW3 314691 AW2 314729 AA4 314754 AW0 314814 BE3 314864 AW3	199272 H 73274 H 125310 H 1979268 207206 H 157367 H 1026761 H 150122 H 1971198 H	s.144341 s.190721 s.155766 s.136319 s.191638 s.134374 s.157367 s.294068	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs ESTs, Weakly similar to I78885 serine/th ESTs	6.7 27. 4.4 4.6 20. 3.6 3.6
	314547 AA3 314558 AI87 314627 AA4 314648 AW5 314691 AW2 314754 AW2 314754 AW2 314814 BE3 314864 AW5 314881 AI09	199272 H 73274 H 125310 H 1979268 2 207206 H 57367 H 1026761 H 50122 H 1971198 H 15087 H	s.144341 s.190721 s.155766 s.136319 s.191638 s.134374 s.157367 s.294068 s.152299	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gbtEST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs ESTs, Weakly similar to 178885 serine/th ESTs, Moderately similar to S65657 alpha	6.7 27. 4.4 4.6 20. 3.6 4.9 4.3 3.7
40	314547 AA3 314558 AI87 314627 AA4 314648 AW3 314729 AA4 314754 AW0 314814 BE3 314864 AW3 314884 AW3 314882 AA8	199272 H 73274 H 125310 H 379268 207206 H 57367 H 50122 H 971198 H 95087 H 28032 H	s.144341 s.190721 s.155766 s.136319 s.191638 s.134374 s.157367 s.294068 s.152299 s.189076	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs, Weakly similar to 178885 serine/th ESTs, Moderately similar to S65657 alpha ESTs	6.7 27. 4.4 4.6 20. 3.6 4.9 4.3 3.7 3.1
40	314547 AA3 314558 AIB7 314627 AA4 314648 AW3 314691 AW3 314754 AW0 314814 BE3 314864 AW9 314882 AA8 314981 AW9	199272 H 173274 H 125310 H 1979268 207206 H 157367 H 150122 H 150122 H 1971198 H 195087 H 128032 H 1972359 H	s.144341 s.190721 s.155766 s.136319 s.191638 s.134374 s.157367 s.294068 s.152299 s.189076 s.293334	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs, Weakly similar to I78885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTS	6.7 27. 4.4 4.6 20. 3.6 4.9 4.3 3.7 3.1 3
40	314547 AA3 314558 AI87 314627 AA4 314648 AW3 314754 AW0 314754 AW0 314814 BE3 314864 AW9 314881 AI09 314881 AI09 314881 AI09 314881 AI09	199272 H73274 H73274 H73274 H732730 H757367 H757367 H757367 H757367 H757367 H757367 H757367 H757359 H75759	s.144341 s.190721 s.155766 s.136319 s.191638 s.134374 s.157367 s.294068 s.152299 s.189076 s.293334 s.298241	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs, Weakly similar to I78885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 4.9 4.3 3.7 3.1 3
40	314547 AA3 314558 AIB7 314627 AA4 314648 AW3 314729 AA4 314754 AW0 314814 BE3 314864 AW3 314881 AW9 314882 AA8 314981 AW3 315006 AIS3 315006 AIS3	199272 H 173274 H 125310 H 1979268 207206 H 157367 H 150122 H 150122 H 151198 H 15087 H 15087 H 15087 H 15087 H 15087 H 15087 H	s.144341 s.190721 s.155766 s.136319 s.191638 s.134374 s.157367 s.294068 s.152299 s.169076 s.293334 s.298241 s.312989	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs ESTs, Weakly similar to 178885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 4.9 4.3 3.7 3.1 3.1 5.3
40	314547 AA3 314558 AIB7 314627 AA4 314648 AW3 314691 AW2 314754 AW2 314864 BA3 314864 AW3 314882 AA8 314882 AA8 314981 AW5 315006 AI53 315006 AI53	199272 H 13274 H 125310 H 1979268 207206 H 57367 H 126761 H 550122 H 1971198 H 195087 H 28032 H 1972359 H 18613 H 1833447 H	s.144341 s.190721 s.155766 s.136319 s.191638 s.134374 s.157367 s.294068 s.152299 s.169076 s.293334 s.298241 s.312989 s.163484	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs, Weakly similar to 178885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTS ESTS ESTS ESTS ESTS ESTS ESTS	6.7 27. 4.4 4.6 20. 3.6 3.6 4.9 4.3 3.7 3.1 3 10.5 5.3 12.5
40	314547 AA3 314558 AIB7 314627 AA4 314648 AW5 314691 AW2 314754 AW6 314864 AW5 314864 AW5 314881 AW5 314881 AW5 315006 AIS3 315001 AAS3 315001 AW2 315000 AAS6	199272 H 173274 H 125310 H 1979268 1 157367 H 126761 H 15087 H 15087 H 15087 H 15087 H 16613 H 18613 H 18613 H 192425 H	s.144341 s.190721 s.155766 s.136319 s.191638 s.134374 s.157367 s.294068 s.152299 s.169076 s.293334 s.293334 s.293334 s.163484 s.163484	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs, Weakly similar to 178885 serine/th ESTs, Weakly similar to S65657 alpha ESTs ESTs ESTs Transmembrane protease, serine 3 ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 3.6 4.9 4.3 3.7 3.1 5.3 12.5 5.8
40	314547 AA3 314558 AI87 314627 AA4 314648 AW3 314674 AW3 314754 AW3 314874 BE3 314881 AI09 314882 AA8 314981 AW3 315006 AI53 315021 AA53 315021 AA53 315021 AA53 315021 AA53 315021 AA53	199272 H 173274 H 125310 H 1979268 207206 H 157367 H 150722 H 150122 H 15087 H 15087 H 16613 H 16613 H 16613 H 1672359 H 16613 H 16613 H 16613 H 16614 H 167248 H	s.144341 s.190721 s.155766 s.136319 s.191638 s.134374 s.157367 s.294068 s.152299 s.169076 s.293334 s.298241 s.312989 s.163484 s.189048 s.257631	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs, Weakly similar to I78885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 4.9 4.3 3.7 3.1 5.8 4.2
40	314547 AA3 314558 AIB7 314627 AA4 314674 AW2 314729 AA4 314754 AW2 314814 BE3 314881 AW3 314881 AW3 314881 AW3 315000 AA53 315001 AW2 315000 AA53 315000 AA74	199272 H 13274 H 125310 H 1979268 207206 H 57367 H 1026761 H 1971198 H 1971198 H 1971198 H 19772359 H 18613 H 18613 H 18643 H 18644 H 192425 H 152948 H 14550 H	s.144341 s.190721 s.155766 s.136319 s.191638 s.134374 s.157367 s.294068 s.152299 s.169076 s.293334 s.298241 s.312989 s.189048 s.189048 s.189048 s.189048 s.189048 s.189048	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs, Weakly similar to I78885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs Transmembrane protease, serine 3 ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 4.9 4.3 3.7 3.1 5.8 4.2 3.7
40 45 50	314547 AA3 314558 AIB7 314627 AA4 314628 AW3 314691 AW2 314729 AA4 314754 AW3 314881 AIG9 314882 AA8 314881 AW5 315051 AW2 315051 AW2 315050 AA5 315073 AW4 315073 AW4 315073 AW4	199272 H 13274 H 125310 H 1979268 207206 H 57367 H 1026761 H 550122 H 1971198 H 195087 H 28032 H 1972359 H 18613 H 192425 H 15104 H 152948 H 144550 H	s.144341 s.190721 s.155766 s.136319 s.191638 s.134374 s.157367 s.294068 s.152299 s.189076 s.298241 s.312989 s.163484 s.189048 s.257631 s.257631 s.2530	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gbtEST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs, Weakly similar to 178885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 4.9 4.3 3.7 3.1 5.3 4.2 3.7 6
40	314547 AA3 314558 AIB7 314527 AA4 314684 AW5 314691 AW7 314754 AW6 314874 AW6 314881 AI09 314882 AA8 314981 AW5 315000 AI53 315051 AW7 315060 AA53 315073 AW4 315080 AA7 315080 AA7 315080 AA7	199272 H 173274 H 125310 H 17979268 1207206 H 157367 H 126761 H 15087 H 15087 H 15087 H 15087 H 15087 H 151087 H 151088	s.144341 s.190721 s.155766 s.136319 s.191638 s.154374 s.294068 s.152299 s.189076 s.293334 s.298241 s.312989 s.163484 s.163484 s.257631 s.257631 s.257631 s.257631 s.257631 s.257631 s.257631	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gbtEST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs, Weakly similar to 178885 serine/th ESTs, Weakly similar to S65657 alpha ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 4.9 4.3 3.7 3.1 5.3 4.2 3.7 6 3.9
40 45 50	314547 AA3 314558 AIB7 314527 AA4 314648 AW5 314691 AW7 314729 AA4 314754 AW7 314814 BE3 314864 AW5 314881 AIO9 314881 AW5 315006 AIS3 315001 AAS3 315001 AW7 315080 AAS7 315073 AW4 315175 AIO2 315175 AIO2 315175 AIO2 315183 AW1 315193 AI24	199272	s.144341 s.190721 s.155766 s.136319 s.191638 s.191638 s.157367 s.294068 s.152299 s.152299 s.31298 s.31298 s.31	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs, Weakly similar to I78885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs Transmembrane protease, serine 3 ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 3.6 4.9 4.3 3.7 5.8 4.2 3.7 6 3.9 4.4
40 45 50	314547 AA3 314558 AIB7 314527 AA4 314684 AW5 314691 AW7 314754 AW6 314874 AW6 314881 AI09 314882 AA8 314981 AW5 315000 AI53 315051 AW7 315060 AA53 315073 AW4 315080 AA7 315080 AA7 315080 AA7	199272 H 13274 H 125310 H 1979268 207206 H 157367 H 1026761 H 1071198 H 105087 H 10771198 H 105087 H 10771198 H 105087 H	s.144341 s.190721 s.155766 s.136319 s.191638 s.194374 s.157367 s.294068 s.152299 s.163484 s.293241 s.312989 s.163484 s.152500 s.152500 s.152530 s.152530 s.152530 s.152530 s.152530 s.152530 s.152530 s.152530 s.152530	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs ESTs, Weakly similar to I78885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs Transmembrane protease, serine 3 ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 3.6 4.9 4.3 3.7 5.8 4.2 3.7 6 3.9 4.4 8.2
40 45 50 55	314547 AA3 314558 AIB7 314627 AA4 314628 AW3 314691 AW2 314729 AA4 314724 AW0 314881 AIO9 314882 AA8 314981 AW2 315006 AIS3 315001 AW2 315006 AA53 315001 AW2 315000 AA53 315013 AW2 315080 AA73 315175 AIO2 315183 AW2 315196 AI36	199272	s.144341 s.190721 s.155766 s.136319 s.191638 s.194374 s.157367 s.294068 s.152299 s.169076 s.298241 s.312989 s.163484 s.189048 s.257631 s.257631 s.257631 s.152530 s.22077 s.2101768 s.165900	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs, Weakly similar to I78885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs Transmembrane protease, serine 3 ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 3.6 4.9 4.3 3.7 5.3 12.9 6 3.9 4.4 8.2 3.6
40 45 50	314547 AA3 314558 AIB7 314527 AA4 314648 AW5 314674 AWC 314754 AWC 314874 AWS 314881 AIG9 314882 AA8 314981 AW5 315000 AIS3 315001 AA55 315073 AW4 315080 AA75 315175 AIG2 315175 AIG2 315193 AIG4 315196 AIG3 315198 AIG4 315196 AIG8 315	199272	s.144341 s.190721 s.155766 s.136319 s.191638 s.194374 s.157367 s.294068 s.152299 s.169076 s.298241 s.312989 s.163484 s.189048 s.257631 s.257631 s.257631 s.152530 s.22077 s.2101768 s.165900	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs ESTs, Weakly similar to 178885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27.444 4.6 20.3.6 3.6 4.9 4.3 3.7 3.1 5.3 10.5 5.8 4.2 3.7 6 3.9 4.4 8.2 3.6 3.4
40 45 50 55	314547 AA3 314558 AIB7 314627 AA4 314629 AW2 314729 AA4 314724 AW2 314881 AIO9 314882 AA8 314981 AW2 315000 AA53 315001 AW2 315000 AA53 315001 AW2 315000 AA53 315013 AW2 315193 AW2 315193 AI24 315196 AI36 315198 AI74 315198 AI74 315203 AW5 315282 AI22	199272	s.144341 s.190721 s.155766 s.136319 s.191638 s.191638 s.157367 s.294068 s.152299 s.163484 s.298241 s.312989 s.163484 s.298241 s.312989 s.163484 s.295631 s.152530 s.200277 s.131765 s.44898 s.165900 s.1672619 s.200740	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs ESTs, Weakly similar to I78885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs ESTs ESTs ESTs Transmembrane protease, serine 3 ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 3.6 4.9 4.3 3.7 5.3 12.9 6 3.9 4.4 8.2 3.6
40 45 50 55	314547 AA3 314527 AA4 314527 AA4 314627 AA4 314628 AW3 314691 AW2 314729 AA4 314754 AWC 314882 AA8 314881 AW9 314882 AA8 314981 AW2 315000 AA53 315001 AW2 315000 AA54 315013 AW2 315175 AI02 315183 AW1 315193 AI24 315260 AW5	199272	s.144341 s.190721 s.155766 s.136319 s.191638 s.191638 s.157367 s.294068 s.152299 s.169076 s.293334 s.293334 s.293241 s.312989 s.163484 s.295241 s.312989 s.163484 s.257631 s.152530 s.220277 s.144823 s.165900 s.172619 s.220740 s.172619 s.220740 s.144923 s.220740 s.125286	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs ESTs, Weakly similar to I78885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs ESTs Transmembrane protease, serine 3 ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27.44.4 4.6 20.3.6 3.6 4.9 4.3 3.7 3.1 5.3 10.5 5.8 4.2 3.7 6 3.9 4.4 8.2 3.6 3.4 3.4
40 45 50 55	314547 AA3 314527 AA4 314527 AA4 314627 AA4 314628 AW3 314691 AW2 314729 AA4 314754 AW2 314881 AW2 314882 AA8 314881 AW3 315051 AW2 315060 AA5 315073 AW4 315175 AI02 315175 AI02 315183 AW1 315193 AI24 315240 R387 315280 AW5 315280 AW8 315280 AA83 315280 AA83	199272	s.144341 s.190721 s.155766 s.136319 s.191638 s.134374 s.157367 s.294068 s.152299 s.189076 s.298241 s.312989 s.163484 s.298241 s.312989 s.163484 s.189048 s.257631 s.152530 s.220277 s.220277 s.220277 s.144898 s.165900 s.172619 s.220740 s.144923 s.144923 s.144923 s.145268 s.104696	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs ESTs, Weakly similar to 178885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 4.9 4.3 3.7 3.1 5.8 4.2 3.7 6 3.9 4.4 8.2 3.6 3.4 4.9
40 45 50 55 60	314547 AA3 314558 AIB7 314627 AA4 314684 AWS 314691 AWZ 314729 AA4 314754 AWS 314881 AIG9 314882 AA8 314981 AWS 315060 AI53 315051 AWZ 315060 AI53 315073 AW4 315193 AI24 315196 AI36 315193 AI24 315196 AI36 315263 AWS 315263 AWS 315282 AI22 315282 AI22 315282 AA22 315282 AAB3 315283 ABG3 315397 AA22	199272	s.144341 s.190721 s.155766 s.136319 s.191638 s.191638 s.157367 s.294068 s.152299 s.152299 s.152299 s.152299 s.293334 s.298241 s.312989 s.293334 s.298241 s.312989 s.257631 s.136345 s.152530 s.220277 s.131765 s.44898 s.257631 s.136345 s.220277 s.172619 s.2202740 s.172619 s.220740 s.172619 s.104698 s.104698 s.104698 s.104698 s.104698 s.104698 s.104698 s.104698 s.104698 s.104698	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs ESTs, Weakly similar to 178885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 4.9 4.3 3.7 3.1 5.8 4.2 3.7 6 3.9 4.2 3.6 4.2 3.6 4.2 3.6 4.2 3.6 4.2 3.6 4.2 3.6 4.2 3.6 4.2 3.6 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2
40 45 50 55	314547 AA3 314558 AIB7 314627 AA4 314627 AA4 314629 AW2 314729 AA4 314729 AA4 314729 AA4 314729 AA4 314881 AIO9 314881 AIO9 314882 AA8 314981 AW2 315000 AA53 315001 AA53 315001 AA53 315001 AA53 315001 AA53 315001 AW2 315000 AA54 315000 AA54 315190 AI36 315198 AI74 315198 AI74 315198 AI74 315263 AW5 315282 AI22 315296 AA88 315388 AB03 315398 AA23 315389 AA33	99272	s.144341 s.190721 s.155766 s.136319 s.191638 s.191638 s.157367 s.294068 s.152299 s.163484 s.298241 s.312989 s.163484 s.298241 s.312989 s.163484 s.295631 s.152530 s.220277 s.131765 s.44898 s.165900 s.162500 s.172619 s.220274 s.172619 s.220274 s.172619 s.220274 s.172619 s.220274 s.172619 s.17	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs ESTs, Weakly similar to I78885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs Transmembrane protease, serine 3 ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 4.9 4.3 3.7 5.8 4.2 3.6 3.4 4.9 4.7 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1
40 45 50 55 60	314547 AA3 314558 AIB7 314627 AA4 314684 AWS 314691 AWZ 314729 AA4 314754 AWS 314881 AIG9 314882 AA8 314981 AWS 315060 AI53 315051 AWZ 315060 AI53 315073 AW4 315193 AI24 315196 AI36 315193 AI24 315196 AI36 315263 AWS 315263 AWS 315282 AI22 315282 AI22 315282 AA22 315282 AAB3 315283 ABG3 315397 AA22	99272	s.144341 s.190721 s.155766 s.136319 s.191638 s.191638 s.157367 s.294068 s.152299 s.169076 s.2932341 s.2932341 s.312989 s.163484 s.2932341 s.312989 s.163484 s.295263 s.165900 s.172619 s.220740 s.172619 s.220740 s.144923 s.165900 s.172619 s.220740 s.144923 s.165900 s.172619 s.220740 s.144923 s.165900 s.172619 s.220740 s.172619 s.220740 s.144923 s.165900 s.172619 s.220740 s.144923 s.165900 s.172619 s.220740 s.144923 s.165900 s.172619 s.220740 s.220740	ESTs ESTs ESTs, Weakly similar to A47582 B-cell gr gb:EST391378 MAGE resequences, MAGP Homo ESTs ESTs ESTs ESTs ESTs, Weakly similar to I78885 serine/th ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs, Moderately similar to S65657 alpha ESTs ESTs Transmembrane protease, serine 3 ESTs ESTs ESTs ESTs ESTs ESTs ESTs ESTs	6.7 27. 4.4 4.6 20. 3.6 4.9 4.3 3.7 3.1 5.8 4.2 3.7 6 3.9 4.2 3.6 4.2 3.6 4.2 3.6 4.2 3.6 4.2 3.6 4.2 3.6 4.2 3.6 4.2 3.6 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2

				•	
	315530	AW015415	Hs.127780	ESTs	8.9
	315562	AA737415	Hs.152826	ESTs	5.5
	315634	AA837085	Hs.220585	ESTs	6.3
		AA648983	Hs.212911		3.6
5		Al418055	Hs.161160		5.1
•		AW515373			3.1
				Homo sapiens cDNA FLJ13580 fis, clone PL	
		AW270550	Hs.116957		3.8
		AA737345	Hs.294041		5
	315878	AA683336	Hs.189046	ESTs	3.1
10	315977	AW865916	Hs.151206	ESTs	4.7
	315978	AA830893	Hs.119769	ESTs	4.1
		AI217477	Hs.194591		4.1
		AA764950	Hs.119898		7
		Al469960	Hs.170698		
15					4.9
13		Al962796	Hs.136754		4.1
		AW517524		NOD2 protein	3.2
		AW975114	Hs.293273		3.8
	316100	AW203986	Hs.213003	ESTs	3.2
	316133	AI187742	Hs.125562	ESTs	3.7
20 .	316177	A1904982	Hs.293102	ESTs, Moderately similar to ALU1_HUMAN A	30.7
		AI433540		gb:ti69g05.x1 NCI_CGAP_Kld11 Homo sapien	3.1
		AI640761	Hs.224988		3.5
		AA740994	Hs.209609		3.8
25		AA741300		ESTs, Weakly similar to I38022 hypotheti	4.4
25		AA747807	Hs.149500		3.2
		AA938198		poly(A) polymerase gamma	9.4
	316697	AW293174	Hs.252627	ESTs	4.4
	316715	A1440266	Hs.170673	ESTs, Weakly similar to T24832 hypotheti	3
	316868	AI660898	Hs.195602		3.2
30		A1954880	Hs.134604		3.2
• •		AA836331	Hs.134981		4.4
		AA838114	Hs.221612		3.7
		AW014875	Hs.137007		4.6
25		AI732892	Hs.190489	=	5.9
35		AW445167	Hs.126036		4.1
		Al125252	Hs.126419		3.5
	317404	A1806867	Hs.126594	ESTs	5.1
	317452	AA972965	Hs.135568	ESTs	6.9
	317501	AI822034	Hs.137097	ESTs ·	4.6
40		AW294909	Hs.132208		4.3
		AW664964	Hs.128899		6.1
		X56348		ret proto-oncogene (multiple endocrine n	3.1
		A1681545		hypothetical prolein FLJ13117	3.4
45		A1827248		Homo sapiens cDNA FLJ11469 fls, clone HE	9.6
45	317902	AW102941	Hs.211265		4.1
	317916	AI565071	Hs.159983	ESTs	10.3
	318042	AW294522	Hs.149991	ESTs	3.1
		AI077540	Hs.134090	ESTs	3.9
		AW294013	Hs.200942		3
50		AI093930		Homo sapiens cDNA: FLJ21000 fis, done C	4.4
• •		AF107493		Homo sapiens LUCA-15 protein mRNA, splic	5.4
		AW402677		RNA binding motif protein, X chromosome	4.4
		AA526235		Homo saplens cONA FLJ11983 fis, clone HE	5.9
		T49598	Hs.156832		4
55		NM_002543	Hs.77729	oxidised low density lipoprotein (lectin	7.3
	318744	Al793124	Hs.144479	ESTs	17.8
		F11802	Hs.6818	ESTs	3
		NM_012391	Hs.79414	prostate epithelium-specific Ets transcr	3.6
		AI524124	Hs.270307		4.6
60		W88532	Hs.254562		3.3
JU			13.234302		
		AA761668	U- 4000F0	gb:nz24c08.s1 NCI_CGAP_GCB1 Homo saplens	3.2
		T79366	HS. 108258	actin binding protein; macrophin (microf	3.3
		AA071267		gb:zm61g01.r1 Stratagene fibroblast (937	6.2
65		C19035	Hs.164259		3.3
65		AA534222		gb:nj21d02.s1 NCI_CGAP_AA1 Homo sapiens	4.3
	320074	AA321166	Hs.278233	ESTs .	3.4
	320167	AA984373	Hs.90790	Homo saplens cDNA: FLJ22930 fis, clone K	4.1

	320187	T99949	Hs 303428	Homo sapiens cDNA FLJ14832 fis, clone OV	5.3
		AL039402	Ha 125703	DEME 6 amin's	
				DEME-6 protein	9.2
		AI026984	Hs.293662		3.1
_		U78082	Hs.167738	RNA polymerase II transcriptional regula	3.1
5		N50617 .	Hs.80506	small nuclear ribónucleoprotein polypept	6.1
	320654	AI160015	Hs.118112		3.5
		A1601188	Hs.120910		3
		AA214584	Hs.290167		3.7
		Al359144		= 17	
10				Homo sapiens cDNA: FLJ23031 fis, done L	3.1
10		BE144167		hypothetical protein similar to RNA-bind	3.3
		A1732643	Hs.144151	ESTs	12.3
	321171	A1769410	Hs.221461	ESTs	3.3
	321253	AA610649	Hs.333239	ESTs	3
	321318	AB033041		vang (van gogh, Drosophila)-like 2	3.9
15		AJ432199	Hs.247084		3
10		AW975944	Hs.237396		
					11.7
		A1471598	Hs.197531	- · · · · ·	3.8
		U29112	Hs.196151	ESTs	4.4
	321811	D80630		gb:HUM091D02B Human fetal brain (TFujiwa	3.2
20	321828	R59890	Hs.83623	nuclear receptor subfamily 1, group I, m	3.1
	321910	H67065		ESTs, Weakly similar to ALU7_HUMAN ALU S	4.7
		AL049351		Homo sapiens mRNA; cDNA DKFZp566C093 (fr	3.5
		N77342			
			Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	5
25		AL137517	HS.334473	hypothetical protein DKFZp564O1278	19
25		AF075083		gb:Homo sapiens full length insert cDNA	3.6
		BE265745	Hs.194359	ESTs, Weakly similar to ALUC_HUMAN !!!!	3
	322296	W76326		gb:zd60d04.r1 Soares_fetal_heart_NbHH19W	4.4
	322303	Al357412	Hs.157601		11.5
		AW963372	Hs.46677	PRO2000 protein	3
30		T55958	110110011	gb:yb35f05.r1 Stratagene fetal spleen (9	3
50		AF147347			
			11- 050450	gb:Homo sapiens full length insert cDNA	4.2
		AF155108		Homo sapiens, Similar to RIKEN cDNA 2810	4
		W92147	Hs.118394		5.4
	322675	AA017656		gb:ze39h01.r1 Soares retina N2b4HR Homo	3.1
35	322766	AW068805	Hs.288467	Homo saplens cDNA FLJ12280 fis, clone MA	5.2
	322818	AW043782	Hs.293616		7.6
		AW248508		Homo sapiens cDNA FLJ14035 fis, clone HE	5.9
		C16391	110.210121		16.5
			11-040704	gb:C16391 Clontech human aorta polyA mRN	
40		AJ902456		ESTs, Weakly similar to 138022 hypotheti	4
40		AK002088		Homo sapiens cDNA FLJ11226 fis, clone PL	3.3
	323168	AL120862	Hs.124165	programmed cell death 9 (PDCD9)	6.3
	323244	AW675572	Hs.193620	ESTs	4.6
	323262	AL133990	Hs.190642	ESTs	10.5
		A1829520		gb:wl19c06.x1 NCI_CGAP_Ut1 Homo sapiens	6.2
45		AV651680	Hs.208558		4.3
		AI655499	Hs.161712		
				- <del>-</del> · -	9.2
		AW445014	Hs.197746		3.1
		BE081058	Hs.243023		4
	323693	AA317962	Hs.249721	ESTs, Moderately similar to PC4259 femi	3
50	323782	AW961560	Hs.97600	ESTs	3.2
	323817	AA410943		BMP-R1B	8.4
		AL043683	Hs.8173	hypothetical protein FLJ10803	3.3
		AI825204	Hs.211408		4.5
		AL044949	Hs.116298		4.5
55		AI472078	Hs.303662	ESTs	8.4
		BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	49.4
	324285	AA431159	Hs.122954	ESTs	3
		AI524039	Hs.192524		3
		AA642007	Hs.116369		3.3
60		AA464510	Hs.152812		
00					16.5
		AI823969	Hs.132678		3.3
		AW972227		Homo sapiens cDNA: FLJ22765 fis, clone K	5
		AW993522	Hs.292934		10.4
	324631	AA937116	Hs.293683	ESTs, Weakly similar to 154374 gene NF2	3.3
65		BE169746	Hs.12504	likely ortholog of mouse Arkadia	3.2
-		AW974941		ESTs, Weakly similar to 178885 serine/th	3
		AA631739	Hs.335440		3

		AI031771 AW516704	Hs.132586 Hs.208726		4.2 3.4	
	324824	AI826999	Hs.224624	EST\$	3.1	
•		AA704806	Hs.143842	ESTs, Weakly similar to 2004399A chromos	4.4	
5		AA613792		gb:no97h03.s1 NCI_CGAP_Pr2 Homo saplens	3.9	
		Al375572	Hs.172634		18.8	
		AI805416 AI064690	Hs.213897		3.3	
	325372	Alubabad	Hs.171176		4.2 4.4	
10	325544			Phase 2 & 3 Exons Phase 2 & 3 Exons	5.7	
10	327075			Phase 2 & 3 Exons	3.8	
	332798			C22000007;gi[12314195]emb[CAB99338.1] (A	4.3	
	334223			NM_005080°:Homo sapiens X-box binding pr	26.2	
	334447			NM_012429*:Homo saplens SEC14 (S. cerevi	3.9	
15	335809			NM_014509*:Homo sapiens kraken-like (BK1	10.1	
	335824			ENSP00000249072*:DJ222E13.1 (N-TERMINAL	20	
	338255			NM_014323*:Homo saplens zinc finger prot	9	
	409430	R21945	Hs.166975	splicing factor, arginine/sedne-rich 5	4	
	428046	AW812795	Hs.155381	ESTs, Moderately similar to I38022 hypot	4.6	
20	432558		Hs.177269	ESTs	3.2	
		AA731602	Hs.120266		3.9	
		BE382657		signal transducer and activator of trans	4.1	
		AW836724	Hs.339660	Homo sapiens mRNA expressed only in plac	3.7	
25		M97935		AFFX control: STAT1	3.2	
25		M97935		AFFX control: STAT1	3	
		M55150		fumarylacetoacetate	3	
		M13755		interferon stimulated protein; 15 kDa	4.5	
		AI052047 AA252033		ESTs	6.7	
30		AA401739		ESTs; Weakly similar to !!!! ALU SUBFAMILY J	3.2 3.3	
50		H18459		ESTs hepatocellular carcinoma associated protein;	3.3	
		R48744		ESTs	4.2	
		M31682		inhibin; beta B (activin AB beta polypeptide)	3	
		AA416873		ESTs	3	
35		D80240		HUM5G11A Human fetal brain (TFujiwara) Homo	4	
		R49590		ESTs	3.2	
				CH22_FGENES.678_5	16.8	
				CH22_FGENES.619_7	12.9	
40				CH22_FGENES.619_12	11.3	
40				CH22_EM:AC005500.GENSCAN.127 9	9.2	
				CH22_EM:AC005500.GENSCAN.304 2	8.5	
				CH22_FGENES.271_8	8.4	
				CH22_FGENES.619_13	8	
45				CH22_FGENES.271_7	7.3	
40				CH22_FGENES.617_7	7.2	
				CH.07_hs gi 6004473 CH22_FGENES.264_1	7.1 6.8	
		X03363		HER2 receptor tyrosine kinase (c erbB 2; ERBB2;		
		***************************************		CH22_FGENES.617_9	6.5	
50				CH.07_hs gi 5868264	5.8	
				CH.19_hs gi 5867439	5.7	
				CH22_FGENES.63	5.3	
				CH.17_hs gl 5867230	5.1	
				CH.20_hs gi[6552458	5.1	
55				CH22_EM:AC005500.GENSCAN.148 22	4.7	
				CH22_FGENES.669_10	4.6	
		AA034918		KIAA1028 protein	4.6	
				CH22_FGENES.48_12	4.5	
<b>C</b> 0				CH22_FGENES.118_2	4.5	
60		AF049569		ESTs	4.4	
		M13955		multiple UniGene matches	4.3	
				CH22_FGENES.619_8 CH22_FGENES.13.7	4.3 4.3	
		HG4126 HT43	96	CH22_FGENES.13 7	4.3 Zinc Finger Protein Hzf4	4.3
65				CH22_FGENES.360_3	4.3	4.3
00				CH22_FGENES.706_9	4.3	
				CH.21_hs gi[6531965	4.2	

		CH.17_hs gi 5867215	4.1	
		CH22_FGENES.669_8	4.1	
	HG2614 HT2710		Collagen, Type Viii, Alpha 1 4.1	
_		CH22_FGENES.48_18	4.1	
5	X83535	matrix metalloproteinase 14 (membrane Inserted)	4	
		CH22_FGENES.271_6	3.9	
		CH22_FGENES.617_3	3.9	
		CH22_FGENES.290_8	3.8	
	HG4716 HT5158		Guanosine 5' Monophosphate Synthase	3.8
10		CH22_FGENES.13 5	3.8	0.0
		CH22_FGENES.13 2	3.8	
		CH.14_hs gi 6682474	3.8	
		CH.02_hs gi[5867750	3.8	
		CH22_FGENES.617_8	3.7	
15	HG4677 HT5102	0122_1 0ENE0:017_0	Oncogene Ret/Ptc2, Fusion Activated	3.7
	1104077 1113/02	CH22_DJ32I10.GENSCAN.23 39	3.7	3.7
		CH22_FGENES.543_20	3.7	
		CH22_EM:AC005500.GENSCAN.96 1		
		CH22_FGENES.204_2	3.7	
20		CH22_FGENES.204_2 CH22_FGENES.619_4	3.5 3.5	
20		CH.16_hs gi[5867087		
	AA714311		3.5	
	W/ 14311	EST duster (not in UniGene)	3.4	
		CH22_EM:AC005500.GENSCAN.149 9	3.4	
25		CH22_EM:AC005500.GENSCAN.421 5 CH22_FGENES.13 4	3.4	
23		CH.07_hs gi/6004478	3.3	
		CH:07_IIS 9I 0004478 CH22_FGENES.360_1	3.3	
	HG2465 HT4871	CH22_FGENES.300_1	3.3	
	NG2400 H1407 1	OURS FORMER & A	Dna Binding Protein Ap 2, Alt. Splice 3	3.3
30		CH22_FGENES.6_2	3.3	
50		CH22_C20H12.GENSCAN.16 2	3.2	
	AA707750	CH22_C65E1.GENSCAN.8 1	3.2	
	AA707730	ESTs; Weakly similar to cis Golgi matrix	3.1	
		CH22_FGENES.307_4	3.1	
35		CH22_EM:AC005500.GENSCAN.248 14	3.1	
33		CH.06_hs gij5902482	3.1	
		CH22_FGENES.669_5	3.1	
		CH22_DJ32I10.GENSCAN.19 8	3.1	
		CH22_FGENES.527_6	3.1	
40		CH22_FGENES.330_10	3.1	
70	AA976074	CH22_FGENES.14 2	3.1	
	M310014	ESTS	3	
		CH22_FGENES.226 7	3	
		CH22_FGENES.13 3	3	
45		CH22_EM:AC005500.GENSCAN.209 12	3	
73	•	CH22_FGENES.271_3	3	

#### TABLE 17A

Table 17A shows the accession numbers for those pkeys lacking unigeneID's for Table 17. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Unique Eos probeset identifier number

CAT number: Accession:

314138 179960\_1

313591 103087 1

AA740616 AA654854 AA229923 AA046309 AI263500 AA046397

Gene duster number

Genbank accession numbers

```
15
        Pkev
                CAT number Accession
        116845 393481_1
                             AA649530 AA659316 H64973
20
        103207 30635_-4
                             X72790
        126257 182217_1
                             N99638 AW973750 AA328271 H90994 AA558020 AA234435 N59599 R94815
                             AF080229 AF080231 AF080230 AF080232 AF080233 AF080234 BE550633 AI636743 AW614951 BE467547 AI680833
        102791 37186_1
                             Al633818 N29986 U87592 U87593 U87590 U87591 $46404 U87587 AA463992 AW206802 Al970376 Al583718 Al672574
                             N25695 AW665466 Al818326 AA126128 Al480345 AW013827 AA248638 Al214968 AA204735 AA207155 AA206262 AA204833
25
                             AW003247 AW496808 Al080480 Al631703 Al651023 Al867418 AW818140 AA502500 Al206199 Al671282 Al352545 BE501030
                             Al652535 BE465762 AA206331 AW451866 AA471088 AA206342 AA204834 AA206100 AW021661 AA332922 N66048
AA703396 H92278 AW139734 H92683 U87589 U87595 H69001 U87594 BE466420 Al624817 BE466611 Al206344 AA574397
                             AA348354 AI493192
        126872 142696_1
                             AW450979 AA136653 AA136656 AW419381 AA984358 AA492073 BE168945 AA809054 AW238038 BE011212 BE011359
30
                             BE011367 BE011368 BE011362 BE011215 BE011365 BE011363
        112631 1746257 1
                             R82040 R70934
        120742 176835_1
                             AA225084 AA302713
                             Al311928 AA936030 T51931 AA609816 AA487195 AA664207
        106864 324239 1
        109700 genbank_F09609
                                       F09609
35
        111532 genbank_R08440
                                       RUSATU
        113938 genbank_W81598
                                       W81598
        113947 genbank_W84768
                                       W84768
        124357 genbank_N22401
                                       N22401
        108733 504187_1
                             AA121022 AA126422
40
        112303 genbank_R54797
                                       R54797
                             AF075083 H52291 H52528
        322136 46802_1
                             W76326 AF086341 W72300
        322296 47334_1
        321811 1527481_1
                             D80630 D80896 D80895
        314648 293660_1
                             AW979268 AA878419 AA431342 AA431628
45
        322520 38916_1
                             T55958 T57205 AF147346
        322521 38917_1
                             AF147347 T55426 T55503
        322675 86787_1
                             AA017656 AA017374 AA019761
        323332 179142_1
                             AI829520 AI791832 AA228414 AI791823 AA229211 AA229315
        316186 425440_1
                             Al433540 AA728984 AA804981
50
        322975 1510563_1
                             C16391 C16413
        324261 273265_1
                             BE069341 AW748403 AL044891 Al908240 AA393080
                             AA410943 AW948953 AA334202 AA332882
        323817 233566_1
        301976 128835_1
                             T97905 AA101672
        324961 376239_1
                             AA613792 AW182329 T05304 AW858385
        303642 284260_1
                             AW299459 AA417112
                             AW629759 AW749955 AA633408 AI651005
        303797 386364_1
        319551 357371_1
                             AA761668 AA573621 R92814 R09670
        311935 174129_1
                             AA216387 T63548 AA228676
                             AA071267 T65940 T64515 AA071334
        319834 112523_1
        319977 345248_1
                             AA534222 AA632632 T81234
```

308106 AI476803
338255 CH22\_6856FG\_\_LINK\_EM:AC00
335809 CH22\_3181FG\_617\_6\_LINK\_EM
335824 CH22\_3197FG\_619\_11\_LINK\_E

5 307010 AI140014
307041 AI144243
305917 AA876469
309574 AW168083

10 325372 c12\_hs
325544 c12\_hs
332798 CH22\_14FG\_6\_5\_LINK\_C4G1.G
334223 CH22\_1507FG\_360\_4\_LINK\_EM
327075 c21\_hs
15 334447 CH22\_1746FG\_387\_7\_LINK\_EM
304782 AA582081
313434 441798\_1 W92070 AW019952 W92053

#### **TABLE 17B**

Table 17B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 17. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication
	Strand: Nt_position:	entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

15	Pkey	Ref	Strand	Nt_position
20	335809 335824 332798	Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al.	Plus Plus Minus	14308764-14308824 26310772-26310909 26376860-26376942 232147-231974 12734365-12734269
25	325372 325544	Dunham, I. et.al. 5866920 6682452 6531965	Minus Minus Plus Plus	15242294-15242231 1117061-1117304 171228-171286 4041318-4041431

## TABLE 18: Table 2 from BRCA 014 P

Table 18 shows genes with atleast five times the expression in breast tumor tissue than is expressed in normal body tissues.

10	Pkey: ExAcon: UnigeneID: Unigene Title: R1:	Unique Eos probeset Identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of tumor to normal body tissue
----	---	--

5

15	Pkey	ExAcon	UnigeneID	Unigene Title	R1
	101378	BE563085	Hs.833	interferon-stimulated protein, 15 kDa	5.3
		M29874	Hs.1360	cytochrome P450, subfamily IIB (phenobar	9
		M81057	Hs.180884	carboxypeptidase 81 (tissue)	12
20		M97815	Hs.183650	cellular retinoic acid-binding protein 2	6.5
		X52509	Hs.161640	tyrosine aminotransferase	12.4
		AF183810		opposite strand to trichorhinophalangeal	7.6
			Hs.141883	ESTs	6.9
			Hs.155223	stanniocalcin 2	5.3
25			Hs.271627	ESTs	6.1
			Hs.334806	KIAA1238 protein	7.3
		AI791493	Hs.129873	ESTs, Weakly similar to A36036 cytochrom	8.2
		R82331	Hs.164599	ESTs	5.4
			Hs.241471	RNB6	6.2
30		W27249	Hs.8109	hypothetical protein FLJ21080	6.9
		AI733881	Hs.72472	BMP-R1B	10.1
		N92293	Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A	19.7
		AW449064		collagen, type III, alpha 1 (Ehlers-Dani	8.4
		M31669	Hs.1735	inhibin, beta B (activin AB beta polypep	5.6
35		AF182277		cytochrome P450, subfamily IIB (phenobar	6.2
		Al908165	Hs.169946	GATA-binding protein 3 (T-cell receptor	6.2
		D89377	Hs.89404	msh (Drosophila) homeo box homolog 2	5.8
		AW183618		solute carrier family 30 (zinc transport	9.9
		AA312082		GDNF family receptor alpha 1	5.7
40		AB020711		KIAA0904 protein	5. <i>1</i> 7.7
		BE542706		CEGP1 protein	7.3
		AW057736		HER2 receptor tyrosine kinase (c-erb-b2,	7.3 5.4
		AA179949		Homo sapiens mRNA; cDNA DKFZp564N0763 (	
		AL117406		ATP-binding cassette transporter MRP8	
45		AJ224172		Ipophilin B (uteroglobin family member)	6.7
		Al951118			13.8
		AW170035		Homo sapiens breast cancer antigen NY-BR Homo sapiens breast cancer antigen NY-BR	17.3
		Al380797	Hs.158992	ESTs	57.6
		AI821005	Hs.118599	ESTs	10.2
50		AA216387	113.110333	gb:nc16b02.s1 NCI_CGAP_Pr1 Homo sapiens	10.8
• •			Hs.118625	hexokinase 1	5.2
		AW449211			5.2
		C18863	Hs.163443	GDNF family receptor alpha 1	12.4
		AA648744		Homo sapiens cDNA FLJ11576 fis, clone HE ESTs	26.3
55		AA740616	113.203433		6.6
-		AA833655	He 206868	gb:ny97f11.s1 NCL_CGAP_GCB1 Homo sapiens Homo sapiens cDNA FLJ14056 fis, clone HE	
			Hs.190721	ESTs	8.5
		AW207206		ESTs	27.4
			Hs.298241		20.7
60		AA533447		Transmembrane protease, serine 3 ESTs	10.9
30		AW292425		ESTs	5.3
		AA551104			12.9
	313000	10101104	1 103040	ESTs, Moderately similar to ALUC_HUMAN!	5.8

		Al36/34/	Hs.44898	Homo sapiens clone TCCCTA00151 mRNA seq	u8.2	
		AW015415		ESTs	8.9	
		AA837085		ESTs	6.3	
-	316012	AA764950	Hs.119898	ESTs	7	
5		A1904982		ESTs, Moderately similar to ALU1_HUMAN A	30.7	
	316580	AA938198	Hs.146123	poly(A) polymerase gamma	9.4	
	317803	AW664964	Hs.128899	ESTs	6.1	
	317881	A1827248	Hs.224398	Homo sapiens cDNA FLJ11469 fis, clone HE	9.6	
	318740	NM_00254	3Hs.77729	oxidised low density lipoprotein (lectin	7.3	
10	318744	A1793124	Hs.144479	ESTs	17.8	
	320211	AL039402	Hs.125783	DEME-6 protein	9.2	
	321107	A1732643	Hs.144151	ESTs	12.3	
	321644	AW975944	Hs.237396	ESTs	11.7	
		N77342	Hs.21851	Homo sapiens cONA FLJ12900 fis, clone NT	5	
15	322035	AL137517	Hs.334473	hypothetical protein DKFZp564O1278	19	
	322766	AW068805	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.2	
		AW043782		ESTs	7.6	
	322975	C16391		gb:C16391 Clontech human aorta polyA mRN	16.5	
	323262	AL133990	Hs.190642	ESTs	10.5	
20	323332	AI829520		gb:wl19c06.x1 NCI_CGAP_Ut1 Homo sapiens	6.2	
	323817	AA410943		BMP-R1B	8.4	
	324261	BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	49.4	
	324432	AA464510	Hs.152812	ESTs	16.5	
	324598	AW972227	Hs.163986	Homo sapiens cDNA: FLJ22765 fis. clone K	5	
25	324603	AW993522	Hs.292934	ESTs	10.4	
	324987	AI375572	Hs.172634	ESTs	18.8	
	325544			Phase 2 & 3 Exons	5.7	
	330388		Hs.46	HER2 receptor tyrosine kinase (c-erb-b2.	6.6	
	334223			NM_005080*:Homo sapiens X-box binding pr	26.2	
30	335809			NM_014509*:Homo sapiens kraken-like (BK1	10.1	
	335824			ENSP00000249072*:DJ222E13.1 (N-TERMINAL		20
		A1052047		ESTs; Weakly similar to CYTOCHROME P450	6.7	
		R72427		CH22_EM:AC005500.GENSCAN.127 9	5.5	
				CH22_FGENES.619_13	9.2	
35			•	CH22_FGENES.617_9	8	
				CH22_FGENES.271_7	6.5	
					7.3	
				CH22_FGENES.271_8	12.9	
					8.4	
40				CH22_EM:AC005500.GENSCAN.304 2	11.3	
					8.5	
				CH22_FGENES.617_7	7.1	
				CH22_FGENES.678_5	7.2	
				CH22 FGENES 678 5	16.8	

#### TABLE 18A

Table 18A shows the accession numbers for those pkeys lacking unigeneID's for Table 18. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number

334223 CH22\_1507FG\_360\_4\_LINK\_EM

Accession:

Genbank accession numbers

15

#### Pkey CAT number Accession 323332 179142\_1 AI829520 AI791832 AA228414 AI791823 AA229211 AA229315 20 322975 1510563\_1 C16391 C16413 324261 273265\_1 BE069341 AW748403 AL044891 AI908240 AA393080 323817 233566\_1 AA410943 AW948953 AA334202 AA332882 311935 174129\_1 AA216387 T63548 AA228676 314138 179960\_1 AA740616 AA654854 AA229923 25 335809 CH22\_3181FG\_617\_6\_LINK\_EM 335824 CH22\_3197FG\_619\_11\_LINK\_E 325544 c12\_hs

#### **TABLE 18B**

Table 18B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 18. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Ref: Sequence er Strand: Indicate:		ice source. ntitled "The as DNA strar	per corresponding to an Eos probeset purce. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication of "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. A strand from which exons were predicted. Elections of predicted exons.			
15	ПСРОЗ	uoti. muicae	s nucleoude	positions of predicted exons.			
	Pkey	Ref	Strand	Nt_position			
20	335824 334223	Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al. 6682452	Plus	26310772-26310909 26376860-26376942 12734365-12734269 171228-171286			

# TABLE 19: 1045 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES

Table 19 shows 1045 genes up-regulated in breast cancer compared to normal adult tissues. These were selected from 59680 probesets on the Affymetrix/Eos-Hu03 GeneChip array such that the ratio of "average" breast cancer to "average" normal adult tissues was greater than or equal to 2.5. The "average" breast cancer level was set to the 90<sup>th</sup> percentile value. The "average" normal adult tissue level was set to the 90<sup>th</sup> percentile value amongst 144 non-malignant tissues. In order to remove gene-specific background levels of non-specific hybridization, the 15<sup>th</sup> percentile value amongst the 144 non-malignant tissues was subtracted from both the numerator and the denominator before the ratio was evaluated.

15	Pkev:	Unique Eos probeset identifier number
	ExAcon:	Exemplar Accession number, Genbank accession number
	UnigenelD:	Unigene number
	Unigene Title:	Unigene gene title

Ratio of tumor to normal body tissue

20

	•					
		Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
			AF015224	Hs.46452	mammaglobin 1	137.6
2	25	406964	M21305		gb:Human alpha satellite and satellite 3	71.0
		400291	AA401369	Hs.190721	ESTs	68.4
		407277	AW170035	Hs.326736	Homo saplens breast cancer antigen NY-BR	54.2
		449746	Al668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	46.4
	_	426878	BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	44.8
3	0	400292	AA250737	Hs.72472	BMP-R1B	37.4
		427585	D31152	Hs.179729	collagen, type X, alpha 1 (Schmid metaph	32.9
		408045	AW138959	Hs.245123	ESTs	31.9
		407178	AA195651	Hs.104106	ESTs	30.4
_	_	407377	C16391		gb:C16391 Clontech human aorta polyA mRN	27.7
3	15	450705	U90304	Hs.25351	iroquois homeobox protein 5	24.8
		407212	AA412108	Hs.269350	ESTs	22.0
		428848	NM_000230	Hs.194236	leptin (murine obesity homolog)	21.9
		404561			trichorhinophalangeal syndrome I (TRPS1)	21.8
		407980	AA046309		gb:zf12f01.s1 Soares_fetal_heart_NbHH19W	19.8
4	Ю	447350	Al375572	Hs.172634	ESTs	17.3
		450375	AA009647	Hs.8850	a disintegrin and metalloproteinase doma	16.6
		422109	S73265	Hs.1473	gastrin-releasing peptide	16.5
		435496	AW840171	Hs.265398	ESTs, Weakly similar to transformation-r	16.0
		453160	A1263307	Hs.239884	H2B histone family, member L	15.8
4	15	420813	X51501	Hs.99949	prolactin-induced protein	15.8
		415989	A1267700	Hs.317584	ESTs	15.5
		422505	AL120862	Hs.124165	programmed cell death 9 (PDCD9)	14.8
		424399	A1905687	Hs.2533	aldehyde dehydrogenase 9 family, member	14.5
			C18863		Homo sapiens cDNA FLJ11576 fis, clone HE	13.7
-	50	429441	AJ224172	Hs.204096		13.6
			AL133990	Hs.190642		13.5
		448595	AB014544	Hs.21572	KIAA0644 gene product	13.0
			AA399272	Hs.144341		12.8
		402578			C1001134:gij2117372 pir [65981 fatty ac	12.6
٥	55	422805	AA436989		H2A histone family, member A	12.2
		424634	NM_003613	Hs.151407	cartilage Intermediate layer protein, nu	12.0
			AA193450		0	11.9
		424086	Al351010	Hs.102267	lysyl oxidase	11.9
		459587	AA031956		gb:zk15e04.s1 Soares_pregnant_uterus_NbH	11.5

WO 02/059377

#### PCT/US02/02242

		AW291168	Hs.41295		11.5
		NM_001394	Hs.2359	dual specificity phosphatase 4	11.5
		Al951118		Homo sapiens breast cancer antigen NY-BR	11.4
5		AW137148 AL035414		Homo sapiens cDNA FLJ11382 fis, clone HE	11.3
		NM_007115	Hs.21068 Hs.29352	hypothetical protein	11.1
		A1684808		tumor necrosis factor, alpha-induced pro programmed cell death 9 (PDCD9)	11.0 10.9
		N78223		transcription factor	10.5
		AW873596		calmodulin 2 (phosphorylase kinase, delt	10.6
10		H87879		lysyl oxidase	10.5
	402606			NM_024626:Homo sapiens hypothetical prot	10.4
	409269	AA576953	Hs.22972	hypothetical protein FLJ13352	10.4
		Al370413	Hs.36563	hypothetical protein FLJ22418	10.3
	447033	Al357412	Hs.157601	ESTs	10.2
15		W72838	Hs.2533	aldehyde dehydrogenase 9 family, member	10.1
		NM_002497		NIMA (never in mitosis gene a)-related k	10.1
		AW292425	Hs.163484		9.9
		AI873274	Hs.190721		9.9
20		H23789	Hs.144530		9.8
20		BE218705 D90041		metallothionein-like 5, testis-specific	9.7
		W20027	Hs.23439	N-acetyttransferase 1 (arylamine N-acety ESTs	9.7
		AL360204		Homo sapiens mRNA full length insert cDN	9.6 9.6
		AI624342	Hs.170042		9.5
25		Al907673	110.170012	gb:iL-BT152-080399-004 BT152 Homo saplen	9.3
		AI267652	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434E082 (fr	
		AJ224741	Hs.278461		9.1
	400297	AI127076	Hs.334473	hypothetical protein DKFZp564O1278	9.1
••	449448	D60730	Hs.57471	ESTs	9.1
30		AA410943		gb:zt32h03.r1 Soares ovary tumor NbHOT H	9.1
	406348			Target Exon	9.0
		U31875		short-chain alcohol dehydrogenase family	9.0
		U23752	Hs.32964	SRY (sex determining region Y)-box 11	9.0
35	405654	AF026944	Hs.293797		8.8
75		AA279490	Hs.86368	C12001521:gi[7513934]pir[[T31081 cca3 pr calmegin	8.8
		A1955040		ESTs, Weakly similar to transformation-r	8.8 8.7
		AW732573	Hs.47584		8.5
		AB033025	Hs.50081		8.4
40		BE379594	Hs.49136	· · · · · · · · · · · · · · · · ·	8.3
		N52812	Hs.177403		8.2
	424001	W67883			8.2
	429859	NM_007050			8.1
4.5		AL080207	Hs.134585	DKFZP434G232 protein	8.1
45	405095				8.1
		AA236115	Hs.120785		8.0
		AF026941	Hs.17518		8.0
		BE242870	Hs.75379		8.0
50		AW876523 R17798	Hs.15929		0.8
50		AI811202	Hs.7535		7.9
		AF044197			7.9 7.9
		M31126			7.8 7.8
	400285		113.21 2020		7.7
55		T27503	Hs.15929		7.6
	427119	AW880562	Hs.114574		7.5
		AW976987			7.5
	433426	H69125	Hs.133525		7.5
<b>~</b> 0		A1222020			7.4
60	426214				7.4
		Al380797	Hs.158992	T111	7.3
		AA948033	Hs.130853		7.2
		AW602166			7.2
65		AW368397 AW242243			7.1 7.0
00		AW242243 AK001468			7.u 6.9
		AI734009			6.9
		, 0 1000			J.0

	420.42	A A 10700F0	11- 00007		
		2 Al678059 1 Al375672	Hs.165028	s synaptonemal complex protein 2	6.9
		8 Al732643	Hs.14415		6.9 6.9
_		3 AA808229	Hs.16777		6.8
5		B Al793124	Hs.144479		6.8
	404253			NM_021058*:Homo sapiens H2B histone fami	6.8
		3 Al015591	Hs.131004	ESTs. Weakly similar to T17227 hypotheti	6.7
		5 AW963419 7 AA321649	Hs. 155223 Hs. 2248	stanniocalcin 2	6.6
10		BE545072		small inducible cytokine subfamily B (CX hypothetical protein FLJ10461	6.6 6.6
		AW818127		gb:CM1-ST0277-061299-059-b07 ST0277 Hom	
		3 Al418055	Hs.161160	ESTs	6.6
		Al733682	Hs.130239		6.6
15		Al970394	Hs.197075		6.6
15		L11690 X78592	Hs.620	bullous pemphigoid antigen 1 (230/240kD)	6.5
		A76592 BE041395	Hs.99915		6.5
		X03635	Hs.1657	ESTs, Weakly similar to unknown protein estrogen receptor 1	6.5
		AW023482	Hs.97849	ESTs	6.5 6.5
20		U79293		Human clone 23948 mRNA sequence	6.4
		W29092	Hs.7678	cellular retinoic acid-binding protein 1	6.4
		NM_003866	Hs.153687	inositol polyphosphate-4-phosphatase, ty	6.4
		AW004854	Hs.228320	hypothetical protein FLJ23537	6.4
25		AL137517 NM_014398	Hs.10887	hypothetical protein DKFZp564O1278	6.2
23		AA586894		similar to lysosome-associated membrane S100 calcium-binding protein A7 (psorias	6.1 6.1
		Al240665	Hs.8895	ESTs CONTROL OF THE PROPERTY (DECIDES	6.1
		M13509	Hs.83169	matrix metalloproteinase 1 (MMP1; inters	6.0
20		AA972965	Hs.135568	ESTs	6.0
30		R45154	Hs. 106604		6.0
		AA464510 AA310693	Hs.152812		5.9
		AW975944	Hs.87329 Hs.237396	HSPC072 protein	5.9
		H39960		Homo sapiens cDNA FLJ12280 fis, clone MA	5.9 5.9
35		AF115402	Hs.11713	E74-like factor 5 (els domain transcript	5.9
		AW803341		gb:IL2-UM0079-090300-050-D03 UM0079 Home	
		AL049689		hypothetical protein similar to tenascin	5.9
		X72755	Hs.77367	monokine induced by gamma interferon	5.8
40		R20991 N28519	He 135101	gb:yg06h01.r1 Soares infant brain 1NIB H	5.8
		AL031224	Hs.33102	ESTs, Weakly similar to unnamed protein transcription factor AP-2 beta (activati	5.8 5.8
		W52854	Hs.27099	hypothetical protein FLJ23293 similar to	5.7
	430510	AW162916		hypothetical protein PRO2577	5.7
45		AI733881	Hs.72472	BMP-R18	5.6
45		AW016531	Hs.122147		5.6
		AW067903 AA463893	Hs.82772	collagen, type XI, alpha 1	5.5
		R41396	Hs.220933	hypothetical protein FLJ23045	5.5
		AW299598	Hs.50895	homeo box C4	5.5 5.4
50	434539	AW748078	Hs.214410	ESTs, Weakly similar to MUC2_HUMAN MUCIN	5.4
		AI742605	Hs.193696	ESTS	5.4
		AL121278	Hs.25144	ESTs	5.4
		BE246919		U5 snRNP-specific 40 kDa protein (hPrp8-	5.4
55		BE167434 Al879148	Hs.98471 Hs.26770	ESTs, Weakly similar to T18712 hypotheti	5.4
55		AW067800		fatty acid binding protein 7, brain stanniocalcin 2	5.4
		AA291553	Hs.190086	ESTs	5.3 5.3
		AW970060		gb:EST382140 MAGE resequences, MAGK Hom	05.3
<i>(</i> 0		AA421081	Hs.12388	ESTs	5.3
60	452838			preferentially expressed antigen in mela	5.3
		AB028945		cortactin SH3 domain-binding protein	5.3
	422867	X52509		tyrosine aminotransferase cartilage oligomeric matrix protein (COM	5.3
		R28363		ESTs	5.2 5.2
65		AW207084			5.2 5.2
	449765	N92293	Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A	5.2
	416276	U41060	Hs.79136		5.2

	400300	X03363		HER2 receptor tyrosine kinase (c-erb-b2,	5.2
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	5.2
	_	AW449211		GDNF family receptor alpha 1	5.2
5		AB028992	Hs.193143	KIAA1069 protein	5.2
)		AW852530	Un nennae	gb:PM1-CT0243-071099-001-g06 CT0243 Homo	
		AW851980		ESTs, Weakly similar to S72482 hypotheti	5.2
		AI916269 AA032279	Hs.61635	ESTs, Weakly similar to ALU5_HUMAN ALU S six transmembrane epithelial antigen of	5.1 5.1
		Al283133	Hs.297420		5.1
10		Al791495		calmodulin-like skin protein	5.1
		A1798680	Hs.25933		5.1
		AA642007	Hs.116369		5.1
	429220	AW207206	Hs.136319	ESTs	5.1
	405494	NA		C2001837*:gi 12697903 db  BAB21770.1  (A	5.1
15		AW195285	Hs.194097	ESTs, Weakly similar to I38022 hypotheti	5.1
		Al201849		gb:qs76g04.x1 NCI_CGAP_Pr28 Homo saplens	
		X70697	Hs.553	solute carrier family 6 (neurotransmitte	5.0
		BE387335		ESTs, Weakly similar to S64054 hypotheti	5.0
20		R43646 W02414	Hs.12422 Hs.38383	ESTs ESTs	5.0 5.0
20		AW665281	Hs.224625		5.0
		AA236776	Hs.79078		5.0
		AK000713		hypothetical protein FLJ20706	5.0
		AW512260	Hs.87767	ESTs	4.9
25	450480	X82125	Hs.25040	zinc finger protein 239	4.9
	437637	AJ003029	Hs.65792	syntrophin, gamma 2	4.9
		M30703		amphiregulin (schwannoma-derived growth	4.9
		Al655499	Hs.161712		4.8
20		A1820662	Hs.129598		4.8
30	430030	AF220050	MS.181385	uncharacterized hematopoletic stem/proge	4.8
		U71600		C16000922:gi 7499103 pir  T20903 hypothe gb:Human zinc finger protein zfp31 (zf31	4.8 4.8
		AI831190	Hs.166676		4.8
		BE218239	Hs.202656		4.8
35		Al217477	Hs.194591	ESTs	4.8
	412785	AW997556	Hs.78521	KIAA1717 protein	4.8
	428368	BE440042	Hs.83326	matrix metalloproteinase 3 (stromelysin	4.7
		Al349764	Hs.217081	- ·	4.7
40		AA191493	Hs.48778	niban protein	4.7
40	400284		11-070707	estrogen receptor 1	4.7
		AW248508		Homo saplens cDNA FLJ14035 fis, clone HE	4.7
		R42185 BE062109	Hs.274803		4.7 4.7
		AW961489	Hs.154116	chloride channel, calcium activated, fam	4.7
45		NM_003462	Hs.33846	dyneln, axonemal, light intermediate pol	4.7
		AF077345	Hs.177936		4.6
	421751	AW813731	Hs.159153	ESTs, Moderately similar to \$65657 alpha	4.6
	454074	R63503	Hs.28419	ESTs	4.6
50	405718			C4000799*:gi[6330365 db][BAA86508.1] (AB	4.6
50		AW207523	Hs.197628		4.6
		Z40313		Homo sapiens done IMAGE:23371, mRNA seq	4.6
		M81057		carboxypeptidase B1 (tissue)	4.6 4.6
		Al199268 AK000282	Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010 hypothetical protein FLJ20275	4.6
55		AW855717	113.233001	gb:RC1-CT0279-081299-013-b01 CT0279 Homo	
55		AA242758	Hs.79136	LIV-1 protein, estrogen regulated	4.6
		AA808189	Hs.272151		4.6
		AW936273		gb:QV0-DT0020-090200-107-g07 DT0020 Homo	
	458711	AL036877	Hs.282878		4.6
60		AA514660	Hs.128443		4.6
		H15261	Hs.21948	ESTs	4.6
		AW246333	Hs.17901	Homo sapiens, clone IMAGE:3937015, mRNA,	4.6
		AJ245671	Hs.12844	EGF-like-domain, multiple 6 (EGFL6)	4.5
65		AW966399 W68815	Hs.46821	hypothetical protein FLJ20086 Homo sapiens cDNA FLJ11346 fis, clone PL	4.5 4.5
0.5		AW503329	10.001000	gb:UI-HF-BN0-akx-e-02-0-UI.r1 NIH_MGC_50	4.5
		AI925153	Hs.217493	annexin A2	4.5

	412102	H56435		gb:yq98e09.r1 Soares fetal liver spleen	4.5
	431716	D89053	Hs.268012		4.5
	411050	AW814902		gb:MR1-ST0206-120400-022-f08 ST0206 Homo	4.5
	401418	NA			4.5
5	436194	AK001074	Hs.333435		4.5
	436211	AK001581			4.4
	414080	AA135257	Hs.47783		4.4
	424115	AA335497	Hs.293965	ESTs, Weakly similar to 138022 hypotheti	4.4
	415786	AW419196			4.4
10	442117	AW664964	Hs.128899	ESTs	4.4
		BE463857			4.4
		R31178	Hs.287820		4.4
		AW905138		gb:QV0-NN1071-280400-207-g07 NN1071 Homo	4.4
	405196	NA		C2000662*:gi 7512792 pir  T12482 hypothe	4.4
15	430217	N47863	Hs.336901	ribosomal protein S24	4.4
	401793			C17001545:gij5360127 gb AAD42882.1 AF155	4.4
		AA381209		gb:EST94257 Activated T-cells I Homo sap	4.4
	423679	AB007975	Hs.131454	KIAA0506 protein	4.4
••	400238				4.4
20		AF019612	Hs.297007		4.4
	400608				4.4
		AV657310	Hs.282898		4.3
		AL138272	Hs.62713		4.3
0.5	405906			•	4.3
25	405925				4.3
		BE247684	Hs.103070		4.3
		H57646	Hs.42586		4.3
		N63855	Hs.142634		4.3
20		AA603305			4.3
30		N71277	11 70705		4.3
		AA102670	Hs.70725		4.2
		A1266484	Hs.31570		4.2
		AA291377	Hs.50831		4.2
25		AA033714			4.2
35		NM_001898 BE158766	MS. 123114		4.2
				gb:IL2-HT0397-071299-024-F02 HT0397 Homo	
		BE144884 BE538082	Hs.8172	gb:CM0-HT0182-041099-065-e11 HT0182 Homo	4.2 4.2
		AF123050	Hs.44532		4.2 4.2
40		S82472	113.44332		4.2
40	404285			J	4.2
		NM_005940	He 155324		4.2
		AW812795			4.2
		AA026880	Hs.25252		4.2
45		AW592167	Hs.293299		4.2
		AI908165			4.2
		AW821113	Hs.72402	ESTs	4.2
		AA024538		=	4.2
		AW378065	Hs.8687		4.2
50		AI085198	Hs.164226		4.2
		AB007948			4.1
		J05070			4.1
	430009	AA894564	Hs.22242		4.1
		AA634806			4.1
55		BE241831	Hs.172330		4.1
		R18717	Hs.8929		4.1
	455700	BE068115		gb:CM1-BT0368-061299-060-g07 BT0368 Homo	4.1
		AK000850	Hs.272203	Homo sapiens cDNA FLJ20843 fis, clone AD	4.1
	438885	A1886558	Hs.184987	ESTs	4.1
60	401451				4.1
		A1685464			4.1
		AI735283	Hs.172608		4.1
		W60379	Hs.57773		4.1
		AI220547	Hs.135223		4.1
65		AW057736			4.1
		U85658	Hs.61796		4.1
	432912	BE007371	Hs.200313	ESIS	4.1

	402505			Tamal Evan	4.1
	403585	Al394151	Hs.37932	Target Exon ESTs	4.1
		AA640891	Hs.102406		4.1
		BE264901		carbonic anhydrase VIII	4.1
5		NM_004354	Hs.79069	cyclin G2	4.1
		AA296520	Hs.89546	selectin E (endothelial adhesion molecul	4.1
	400555			Target Exon	4.1
	410079		Hs.58589	glycogenin 2	4.0
10		NM_003528	Hs.2178	H2B histone family, member Q	4.0
10		AA448460	Hs.112017		4.0 4.0
		AL359055 AL117406	Hs.67709	Homo saplens mRNA full length insert cDN ATP-binding cassette transporter MRP8	4.0
		NM_002666	Hs.103253		4.0
		AA228776	Hs.191721		4.0
15		AW954552		zinc finger protein	4.0
		AW938484		gb:CM0-DT0057-290200-253-d06 DT0057 Homo	4.0
	404142	NA		Target Exon	4.0
		Al027604	Hs.159650		4.0
20		Al693927	Hs.265165		4.0
20		AA165232	Hs.222069		4.0 4.0
	452891		HS.2128/5	ESTs, Weakly similar to DYH9_HUMAN CILIA gb:601283601F1 NIH_MGC_44 Homo sapiens c	
	452281	BE390440	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	4.0
		AA417383	Hs.82582	Integrin, beta-like 1 (with EGF-like rep	4.0
25		Al281848		retinolc acid induced 3	4.0
		X77343		transcription factor AP-2 alpha (activat	4.0
	437854	AL119723		gb:DKFZp761A2124_r1 761 (synonym: hamy2)	4.0
	446140	AA356170	Hs.26750	hypothetical protein FLJ21908	4.0
20		AI591147	Hs.61232	ESTs	4.0
30		Al741122	H\$.101810	Homo sapiens cDNA FLJ14232 fis, clone NT	4.0 4.0
		N99626	He 209275	gb:za39d11.r1 Soares fetal liver spleen ESTs, Weakly similar to ALUA_HUMAN IIII	4.0
		A1199738 A1948607	Hs.264680		4.0
		AF153330	Hs.30246	solute carrier family 19 (thiamine trans	3.9
35		AA263143	Hs.24596	RAD51-interacting protein	3.9
	406554	NA		Target Exon	3.9
		AA573006	Hs.19173	ESTs	3.9
		Z42023	Hs.106576	alanine-glyoxylate aminotransferase 2-II	3.9
40		AA442176	11- 75040	gb:zw63b08.r1 Soares_total_fetus_Nb2HF8_	3.9 3.9
40	413930	M86153	Hs.75618	RAB11A, member RAS oncogene family Target Exon	3.9
		F05086	Hs.328142		3.9
		AA026777	110.000112	gb:ze93c11.r1 Soares_fetal_heart_NbHH19W	3.9
		AI819068	Hs.209122		3.9
45	419759	Z21336	Hs.135411	actin related protein	3.9
		AI472106	Hs.49303		3.9
		AF086534		ESTs, Moderately similar to ALU1_HUMAN A	3.9
		AA419529	Hs.76391		3.9 3.9
50		AB037791 BE537217	Hs.29716 Hs.30343	hypothetical protein FLJ10980 ESTs	3.9
50		BE568414		Homo sapiens cDNA: FLJ22097 fis, done H	3.9
		AI073512	Hs.133916		3.9
		BE152428		gb:CM0-HT0323-151299-126-b04 HT0323 Home	9.80
	401785			NM_002275*:Homo sapiens keratin 15 (KRT1	3.9
55		M86699		TTK protein kinase	3.9
		AI989885	Hs.231926		3.9
		H75391	Hs.255748	gb:MR0-HT0559-110300-005-h11 HT0559 Hom	3.9
		BE172186 AA236645	Hs.98274	ESTs	3.8
60		Al184268	Hs.339665		3.8
00		AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	3.8
	403593			Target Exon	3.8
		AW016669	Hs.29190		3.8
<i>(</i>		AW664873	Hs.87836		3.8
65		W02410	Hs.205555 Hs.144762		3.8 3.8
		AI217928 AA503020	Hs.36563	hypothetical protein FLJ22418	3.8
	403042	1000000	113.00003		٠.٠

	443162	T49951	Hs.9029	DKFZP434G032 protein	3.8
	458194	AW383618	Hs.265459	ESTs, Moderately similar to ALU2_HUMAN A	3.8
	422475	AL359938	Hs.117313	Meis (mouse) homolog 3	3.8
_	440705	AA904244	Hs.153205		3.8
5	447290	Al476732	Hs.263912	ESTs	3.8
	403426			Target Exon	3.8
	427821	AA470158	Hs.98202	ESTs	3.8
		BE222648		ESTs, Highly similar to c380A1.1b [H.sap	3.8
• •		AW206942	Hs.253594		3.8
10		AW105231	Hs.192035		3.8
		AW794600		gb:RC6-UM0014-170300-022-C05 UM0014 Hon	
		NM_005756		G protein-coupled receptor 64	3.8
		BE622641	Hs.38489	ESTs, Weakly similar to I38022 hypotheti	3.8
1.5		Al742618	Hs.181733	ESTs, Weakly similar to nitrilase homolo	3.7
15	401747	1114 044504		Homo saplens keratin 17 (KRT17)	3.7
		NM_014581		odorant-binding protein 2A	3.7
		AP000692		chromosome 21 open reading frame 5	3.7
		AB029496	Hs.59729	semaphorin sem2	3.7
20		BE005346	Hs.116410		3.7
20		AK001666		similar to SALL1 (sal (Drosophila)-like	3.7
	402696	AA018534	Hs.103334		3.7
		AV660737	Hs.135100	C3002523:gi 6686211 sp Q27533 YH2M_CAEEI	3.7 3.7
		AW816379	Hs.335018		3.7
25		U80736		trinucleotide repeat containing 9	3.7
20		AB020689	Hs.90419		3.7
		AA312082		GDNF family receptor alpha 1	3.7
		N62840	Hs.48648	ESTs	3.7
	401508			NM_024817:Homo sapiens hypothetical prot	3.7
30		AA324597	Hs.21851	Homo sapiens cONA FLJ12900 fis, clone NT	3.7
-	420362	U79734	Hs.97206	huntingtin interacting protein 1	3.7
	433384	AI021992	Hs.124244		3.7
	434302	AA629065	Hs.116301	ESTs	3.7
	443938	R55373	Hs.20864	ESTs	3.7
35	448420	BE623004		gb:601441282F1 NIH_MGC_72 Homo sapiens c	3.7
		Al347502		hypothetical protein FLJ20761	3.7
		T32982	Hs.102720		3.7
	405232			NM_015832:Homo sapiens methyl-CpG bindin	3.7
40		AL109791	Hs.241559	Homo sapiens mRNA full length insert cDN	3.7
40		BE011668		gb:CM3-BN0223-100500-177-a04 BN0223 Home	
		AI239923	Hs.30098	ESTs	3.7
		AI970797	Hs.64859	ESTs	3.7
		Al248584	MS.190/45	Homo sapiens cDNA: FLJ21326 fis, clone C	3.7
45	401049		11- 00404	Target Exon	3.6
45		D31771	Hs.89404	msh (Drosophila) homeo box homolog 2	3.6
		N74530 AV658444	Hs.21168	ESTs tankyrase, TRF1-interacting ankyrin-rela	3.6 3.6
		Al377755	Hs.120695		3.6
		M97815		cellular retinoic acid-binding protein 2	3.6
50		Al698839	110.100000	gb:wd31f02.x1 Soares_NFL_T_GBC_S1 Homo s	
-		AL120173	Hs.301663		3.6
		AW901456	. 10.00 1000	ab:RC0-NN1012-270300-031-c07 NN1012 Homo	
		AA352111		gb:EST60061 Activated T-cells XX Homo sa	3.6
		Al142095	Hs.143273		3.6
55		BE164500		gb:RC4-HT0469-230300-014-e10 HT0469 Homo	
	414869	AA157291	Hs.21479	ubinuclein 1	3.6
	409064	AA062954	Hs.141883	ESTs	3.6
	407721	Y12735	Hs.38018	dual-specificity tyrosine-(Y)-phosphoryl	3.6
		AK000054	Hs.12347	hypothetical protein FLJ20047	3.6
60	404091			Target Exon	3.6
		AA125985	Hs.56145	thymosin, beta, Identified in neuroblast	3.6
	405153			Target Exon	3.6
		AA380177	Hs.125845	ribulose-5-phosphate-3-epimerase	3.6
CE	403639	NA		ENSP00000233023*:CDNA FLJ12662 fis, clon	3.6
65	404360	A A 700000	11- 00000	C7001385:gi 12082809 gb AAG48618.1 AF315	3.6
		AA766296	Hs.99200	ESTs	3.6
	4/3338	AB007961	rts.127338	KIAA0492 protein	36

	424202	BE350295	Hs.15032		3.6
		AA514986	Hs.283705		3.6
		AA853978	Hs.124577		3.6
5		AA441838	Hs.62905		3.6 3.6
5	406446		He 105970		3.6 3.6
		AA315308 AW015415	Hs.127780		3.6
		W87707	Hs.82065		3.6
		AI697121			3.6
10		AW291095	Hs.21814		3.6
		AW297920	Hs.130054	ESTs	3.5
	407647	AW860158		gb:RC0-CT0379-290100-032-b04 CT0379 Homo	3.5
		AW968226	Hs.60798	<del></del>	3.5
	402820				3.5
15		AA191719	Hs.314714		3.5
		AW393080			3.5 3.5
		A1806335 AA420683	Hs.98321		3.5
		NM_015368	Hs.30985		3.5
20	400610	_	110.0000		3.5
		W07361	Hs.22545		3.5
	419335	AW960146	Hs.284137		3.5
	451592	AI805416	Hs.213897		3.5
0.5		NM_004272			3.5
25		AW392342			3.5
		AW448937 AW753967	Hs.197030	gb:RC2-CT0304-080100-011-h12 CT0304 Homo	3.5
		NM_000288	Hs.79993		3.5
		R20893			3.5
30		AL043002			3.5
	415778	H84847	Hs.49391		3.5
		AW316843	Hs.66309		3.5
		N32536	Hs.42645		3.5
25		AI917494	Hs.9812		3.5
35		A1057094 A1370876	Hs.96867 Hs.79090		3.5
		AW850178	113.13030	gb:lL3-CT0219-271099-022-H12 CT0219 Homo	
		AA314337	Hs.301547	ribosomal protein S7	3.5
		AA877124	Hs.172844	ESTs	3.5
40	431291	N25521	Hs.25275		3.5
		Al935016	Hs.216639		3.5
		BE145808		gb:MR0-HT0208-101299-103-f11 HT0208 Homo	
		AW295151	Hs.163612		3.5
45		AW167087 Z50158	Hs.131562	ESTS, Weakly similar to MMHUB1 laminin b	3.
43		AW474547	Hs.53565		3.5
•		BE614743		prostaglandin E synthase	3.5
		AW505021	Hs.88414	BTB and CNC homology 1, basic leucine zi	3.5
		AI908400	Hs.143789		3.5
50	439405	AF086224	Hs.55238	ESTs	3.
	405917			C17000675:gi[7290703 gb]AAF46150.1] (AE0	3.
		AW993582	Hs.176220		3.
		W47595		transforming growth factor, beta 2	3.4
55		AA283185 AW904466	Hs.19327	ESTs PDZ domain protein (Drosophila inaD-like	3.
J.)		BE252383		SBBI31 protein	3.
		BE064962		gb:RC1-BT0313-130400-016-c02 BT0313 Homo	
		U92649	Hs.64311	a disintegrin and metalloproteinase doma	3.
	447754	AW073310	Hs.163533	Homo saplens cDNA FLJ14142 fis, done MA	3.
60		AW749855		gb:QV4-BT0534-281299-053-c05 BT0534 Homo	
	404097		น. วอวกวา	C5000242*:gi 9369379 gb AAF87128.1 AC006	3.
		AF119861 AI215069	Hs.89113	hypothetical protein PRO2015 ESTs	3.
	402421		110.00110	C1001578*:gi[6759903]gb[AAF28099.1] (AF1	3.
65	405248			Target Exon	3.
	407638	AJ404672		hypothetical protein FLJ23571	3.
	403000	DE2/7275	Mc 451787	115 snRNP-specific omtein 116 kD	3

		AF038564	Hs.98074	itchy (mouse homolog) E3 ubiquitin prote	3.
		X81334	Hs.2936	matrix metalloproteinase 13 (collagenase	3.
		BE618395		hypothetical protein DKFZp761J1523	3.
5		R41823	Hs.7413	ESTs; calsyntenin-2	3.
5		AA210765		gb:zr90c06.r1 NCI_CGAP_GCB1 Homo saplens	_
		AI346468	Hs.145789	_	3.
		AJ613276	Hs.5662	guanine nucleotide binding protein (G pr	3.4
		Al247716	Hs.232168		3.4
10		AA164366	HS.1519/3	hypothetical protein FLJ23511	3.4
10		AI971313		KIAA0551 protein	3.4
		AF102546	Hs.63931	dachshund (Drosophila) homolog	3.
	405460		11- 40004F	Target Exon	3.5
		AW503603	rts.129915	phosphotriesterase related	3.3
15		AL037925 AW885727	U= 201570	gb:DKFZp564M037_r1 564 (synonym: hfbr2)	3.5
13		R81733	Hs.301570 Hs.33106	ESTs	3.3
		AA814043	Hs.88045	ESTs	3.3
		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	3.3
		BE296227		serine/threonine kinase 15	3.3
20		Al160386	Hs.125087		3.3
		AF055575	Hs.23838	calcium channel, voltage-dependent, L ty	3.3
		NM_000685	Hs.89472	angiotensin receptor 1	3.3
		AA160079		Homo sapiens mRNA for partial 3'UTR, seq	3.3
		AW503857	Hs.4007	Sarcolemmal-associated protein	3.3
25		NM_005982	Hs.54416	sine oculis homeobox (Drosophila) homolo	3.3
		AW138872	Hs.135288		3.3
		AA280627	Hs.57846	ESTs	3.3
		AA296961		gb:EST112514 Adrenal gland tumor Horno sa	3.3
		A1936450	Hs.147482		3.3
30	402892	NA		Target Exon	3.3
	426681	AA994896	Hs.22514	ESTs	3.3
	458722	AA741545	Hs.282832	ESTs, Weakly similar to T24961 hypotheti	3.3
	409430	R21945	Hs.166975	splicing factor, arginine/serine-rich 5	3.3
~ ~		AI954968	Hs.279009		3.3
35		AV653771			3.3
		AA121686	Hs.10592		3.3
	406151				3.3
		AW511956	Hs.293261		3.3
40		AW820260		gb:QV2-ST0296-150200-040-c10 ST0296 Homo	
40		T16971			3.3
		AF086120	Hs.102793		3.3
	401575		ti- 44000		3.3
		AL045633 Al344166	Hs.44269		3.3
45			Hs.155743		3.3
7.7		AW369771 AW204610	Hs.52620 Hs.22270		3.3
		AA976718	Hs.202242		3.3 3.3
		AA206186	Hs.79889		3.3
		AW043921	Hs.130526		3.3
50		T70874	Hs.207636		3.2
-		T10213			3.2
		AI824009	Hs.44577		3.2
		R60336	Hs.52792	Homo sapiens mRNA; cDNA DKFZp586I1823 (f	
		W88774	Hs.118370		3.2
55		BE336654	Hs.70937		3.2
		AA863360	Hs.26040		3.2
	410153	BE311926	Hs.15830		3.2
	403637				3.2
	405547				3.2
60		C05766	Hs.181022		3.2
	451871	AI821005	Hs.118599	ESTs	3.2
		R10305	Hs.185683	ESTs :	3.2
		N27833		ESTs, Weakly similar to 138022 hypotheti	3.2
CF		AI652777	Hs.197069		3.2
65		NM_004460	Hs.418	fibroblast activation protein, alpha	3.2
		AI253123	Hs.127356	ESTs, Highly similar to S21424 nestin [H	3.2
	459055	N23235	Hs.30567	ESTs, Weakly similar to B34087 hypotheti	3.2

	452190	M26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	3.2
		AA489732	Hs.154918	•	3.2
	405394	77403732	113.101310		3.2
		BE169810	Hs.47557		3.2
5	454265			= · ·	3.2
•		AA765917	Hs.122840	· ·	3.2
		AK000684			3.2
	414083	AL121282	Hs.257786	ESTs	3.2
	411670	AW856552		gb:RC1-CT0294-080100-012-a04 CT0294 Homo	
10	416283	NM_005429	Hs.79141	The state of the s	3.2
	437488	AA758239	Hs.180330	==:-	3.2
		AI249368	Hs.98558		3.2
	452042				3.2
15		AI904743			3.2 3.2
15		AI016377 AB033052	Hs.131693 Hs.22151		3,2
		AI198719	Hs.176376		3.2
	404580	74 1501 15	115.1100.0		3.2
		AA326187	Hs.17170		3.2
20		AW974903	Hs.291231		3.1
	429838	AW904907	Hs.30732		3.1
	459702	A1204995		3	3.1
	400195				3.1
25		AW408557	Hs.235498		3.1
25		AW974175		ESTs, Weakly similar to MAPB_HUMAN MICRO	3.1
		AA312735 AA701327	Hs.30512 Hs.17949		3.1
		AA906366	Hs.190535		3.1
		D38122	Hs.2007	==	3,1
30		AW891294	Hs.132136		3.1
	439677	R82331	Hs.164599		3.1
		A1638627			3.1
		AA503653			3.1
25		AA339449	Hs.82285	F	3.1
35		AA470519	H- 47400	•	3.1
		BE327311	Hs.47166	HT021 gb:QV4-ST0023-160400-172-d12 ST0023 Homo	3.1
		AW806906 H15302	He 168050	Homo sapiens mRNA; cDNA DKFZp566A1046 (f	
	405336		113.100000		3.1
40		AI683150	Hs.201550		3.1
		A1583052	Hs.270058	ESTs	3.1
	455945	BE160636		gb:PM1-HT0422-291299-002-c08 HT0422 Homo	
	430437	A1768801	Hs.169943	Homo sapiens cDNA FLJ13569 fis, clone PL	3.1
15	405848			Target Exon	3.1
45		BE066976		gb:PM0-BT0340-211299-003-c12 BT0340 Homo	
		M29994	Hs.256972	gb:Human alpha-I spectrin gene, exon 12.	3.1
		W26713 D45027		R3H domain (binds single-stranded nuclei	3.1
		AI065104		ESTs, Weakly similar to A46010 X-linked	3.1
50		BE165753		Homo sapiens, clone IMAGE:4098694, mRNA,	3.1
		AA706910	Hs.112742		3.1
		AL050027		gb:Homo saplens mRNA; cDNA DKFZp566C032	43.1
	448602	AI541305	Hs.48778	niban protein	3.1
~ ~		AW407181	Hs.218377	Homo sapiens cDNA FLJ11927 fis, clone HE	3.1
55		AF026942		gb:Homo saplens cig33 mRNA, partial sequ gb:MR4-ST0062-180200-001-e10 ST0062 Homo	3.1
		AW807227	He 420226	replication factor C (activator 1) 2 (40	3.1
		NM_002914 R83066	Hs.7043	succinate-CoA ligase, GDP-forming, alpha	3.1
		BE295866	Hs.94382	adenosine kinase	3.1
60		W94997	Hs.189917		3.1
		U07616		amphiphysin (Stiff-Mann syndrome with br	3.1
		AL117431		Homo sapiens cDNA FLJ12198 fis, clone MA	3.1
		BE466639	Hs.61779	Homo sapiens cDNA FLJ13591 fis, clone PL	3.1
65	-	AW138413	Hs.139336	ATP-binding cassette, sub-family C (CFTR	3.1
65		AA382814	Ne tuceso	gb:EST96097 Testis I Homo sapiens cDNA 5	3.1
		Al248013 AW135274	Hs. 12433	ESTs, Weakly similar to 138588 reverse t ESTs	3.1 3.1
	40/333	A11100614	110, 12700		J. 1

	AACACC	Linnan	11- 000		2.4
		H38026 BE219794	Hs.308	arrestin 3, retinal (X-arrestin)	3.1 3.1
		AK001423	Hs.293471 Hs.94694		3.0
		AB033035	Hs.51965	Homo saplens cDNA FLJ10561 fis, clone NT KIAA1209 protein	3.0
5		BE153855	Hs.61460	lg superfamily receptor LNIR	3.0
•		AA232658		UDP-glucose:glycoprotein glucosyttransfe	3.0
		AI830417	Hs.44143	polybromo 1	3.0
		N93266	Hs.40747	ESTs	3.0
		AL133731	Hs.4774	Homo sapiens mRNA; cDNA DKFZp761C1712 (i	
10	420139	NM_005357	Hs.95351	lipase, hormone-sensitive	3.0
	405609	NA		ENSP00000241065*:CDNA	3.0
	404274			NM_002944*:Homo sapiens v-ros avian UR2	3.0
		Al971362	Hs.231945		3.0
1.5		H07118	Hs.6099	ESTs	3.0
15		N59650	Hs.27252	ESTs	3.0
	406291	NA BE383592		Target Exon	3.0
		AW972359	Hs.293334	gb:601297871F1 NIH_MGC_19 Homo sapiens c	3.0
		A1791988	Hs.129115		3.0
20		N21043	Hs.42932	ESTs	3.0
		Al969716	Hs.13034	ESTs	3.0
	418026	BE379727	Hs.83213	fatty acid binding protein 4, adipocyte	3.0
	401326	NA	•	C10000447*:gi 1168375 sp P43467 AGA1_PED	3.0
0.5		BE169746	Hs.12504	likely ortholog of mouse Arkadia	3.0
25		AI926047	Hs.162859		3.0
		AF245505	Hs.72157	DKFZP564I1922 protein	3.0
	401045	A A E Q A O C O	Un 272700	C11001883*:gij6753278 ref NP_033938.1  c	3.0 3.0
		AA584062 AI221894	Hs.39311	hypothetical protein FLJ20413 ESTs	3.0
30		BE077155		hypothetical protein DKFZp761B1514	3.0
50		AW958879	Hs.270535		3.0
		H91882		Dvl-binding protein IDAX (inhibition of	3.0
	433014	NM_014711	Hs.279912	KIAA0419 gene product	3.0
2.5		R13474	Hs.290263	ESTs, Weakly similar to I38022 hypotheti	3.0
35		R52782		gb:yg99d09.r1 Soares Infant brain 1NIB H	3.0
		AB014528	Hs.43133	KIAA0628 gene product	3.0
		AW004683	Hs.78934	mutS (E. coli) homolog 2 (colon cancer,	3.0
		AI754212 AW021173	Hs.21951 Hs.18612	Homo sapiens Xq pseudoautosomal region; Homo sapiens cDNA: FLJ21909 fis, clone H	3.0
40		AW901879	Hs.314453		3.0
		D31118		hypothetical protein MGC10520	3.0
		AW294795	Hs.198529		3.0
		AA878939	Hs.125406		3.0
	443608	A1375957	Hs.289074	F-box only protein 22	3.0
45	414140	AA281279	Hs.23317	hypothetical protein FLJ14681	3.0
		NM_014400	Hs.11950	GPI-anchored metastasis-associated prote	3.0
		AA701259	Hs.189299		3.0
		AI041793	Hs.42502	ESTS	3.0
50		BE175605 AW295923	He 255472	gb:RC5-HT0580-100500-022-H07 HT0580 Home KIAA1843 protein	3.0
50		M31659		solute carrier family 25 (mitochondrial	3.0
		AA397658	Hs.60257	Homo sapiens cDNA FLJ13598 fis, done PL	3.0
		W01938		ESTs, Weakly similar to ALU7_HUMAN ALU S	2.9
	433043	W57554		lymphoid nuclear protein (LAF-4) mRNA	2.9
55	420802	U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	2.9
		BE246743	Hs.288529	hypothetical protein FLJ22635	2.9
	403677			C4001462:gi 4887715 gb AAA79329.2  (L088	2.9
		BE067650	H- 40004F	gb:MR4-BT0358-090300-003-e01 BT0358 Homo	
60		W87434 BE568102		ESTs, Moderately similar to ALU1_HUMAN A mitochondrial ribosomal protein S16	2.9 2.9
00		A1674818		Homo sapiens cDNA FLJ11375 fis, clone HE	2.9
		AA179949		Homo sapiens mRNA; cDNA DKFZp564N0763 (	
		AW365665	Hs.120388		2.9
	423600	A1633559	Hs.310359		2.9
65		N34128	Hs.145268		2.9
	402109		U- ancas	Target Exon	2.9
	425029	BE501732	Hs.30622	Homo sapiens cDNA FLJ13010 fis, done NT	2.9

			11 001000	11	•
		A1827248			2.9
		AA249573	HS.152618		2.9
	404721	41000404	11. 447040		2.9
5		AI208121	MS.14/313		2.9 2.9
3	401987	AA481282	Un 100110		2.9 2.9
			Hs.190149 Hs.146883		2.9
		A1939339	Hs.149006		2.9
		AW873606 AW194426	Hs.20726		2.9
10		AI868634			2.9
10	401458	A10000034	113.240000		2.9
		NM_003478	Hs.101299		2.9
		BE514127	113.101233	gb:601315974F1 NIH_MGC_8 Homo sapiens cD	
		NM_012288	He 153954		2.9
15		BE003760	Hs.55209	Homo sapiens mRNA; cDNA DKFZp434K0514 (f	
13		D45371	Hs.80485		2.9
		BE161151	710100100	gb:PM0-HT0425-141299-001-F08 HT0425 Homo.	
		NM_016122	Hs.56148		2.9
		AA743991		gb:ny57g01.s1 NCI_CGAP_Pr18 Homo sapiens	2.9
20		Al193043	Hs.128685	ESTs, Weakly similar to T17226 hypotheti	2.9
		Z45439	Hs.270425		2.9
		Y15221			2.9
		AF015592	Hs.28853	CDC7 (cell division cycle 7, S. cerevisi	2.9
	457402	AW452648	Hs.149342	activation-induced cytidine deaminase	2.9
25	449051	AW961400	Hs.333526	HER2 receptor tyrosine kinase (c-erb-b2,	2.9
	408761	AA057264	Hs.238936	ESTs, Wealdy similar to (defline not ava	2.9
	401093			C12000586*:gij6330167 dbj BAA86477.1  (A	2.9
	435061	AI651474	Hs.163944		2.9
	447985	Al681475	Hs.200949		2.9
30	449340	AW235786	Hs.195359		2.9
		AI472078	Hs.303662		2.9
		BE265067		gb:601193893F1 NIH_MGC_7 Homo sapiens cD	
	405953			, g	2.8
2.5		AW296927		32.0,11.2.10.0,0	2.8
35		AA846811			2.8
		AA295331		Homo sapiens cDNA FLJ20042 fis, clone CO	2.8
		AA243837	Hs.57787		2.8 2.8
		AW206453	Hs.3782		2.8
40		AW452434	Hs.58006	ESTs, Weakly similar to ALUS_HUMAN ALU S	
40		BE176480	Un 40425	gb:RC3-HT0585-160300-022-c02 HT0585 Homo	2.8
		AL039852	Hs.49136		2.8
		A1038997 T97490	Hs.132921		2.8
		AW806899	Hs.50002	gb:QV4-ST0023-160400-172-c12 ST0023 Homo	
45		AI910896	Hs.132413		2.8
43		Y00272		cell division cycle 2, G1 to S and G2 to	2.8
		AL035588		MyoD family Inhibitor	2.8
		BE070800	. 10. 100200	qb:RC3-BT0502-251199-011-c07 BT0502 Homo	2.8
	400250			Eos Control	2.8
50		NM_016206	Hs.23142	colon carcinoma related protein	2.8
		AA485224		gb:aa41b12.s1 NCI_CGAP_GCB1 Homo sapiens	2.8
		AA502490	Hs.336695		2.8
	431854	AA383550	Hs.271699	polymerase (DNA directed) lota	2.8
	405873			Target Exon	2.8
55	440400	AA994364	Hs.125594	ESTs, Weakly similar to T25472 hypotheti	2.8
	458265	AI075375	Hs.128193	ESTs, Weakly similar to IRX2_HUMAN IROQU	2.8
	413708	BE158791		gb:lL2-HT0397-091299-025-D02 HT0397 Homo	2.8
	423739	AA398155	Hs.97600	ESTs	2.8
	424408	A1754813	Hs.146428	collagen, type V, alpha 1	2.8
60	453096	AW294631	Hs.11325	ESTs	2.8
		AA298758	Hs.183747	ESTs, Moderately similar to CALB_HUMAN C	2.8
		R64719		gb:EST22d11 WATM1 Homo sapiens cDNA clon	
	402765		11 /0-0-	C1003621*:gi]12407405 gb AAG53491.1 AF22	2.8
65		R41339	Hs.12569	ESTs	2.8
65		AW338625	Hs.22120	ESTs Tamet Even	2.8
	401497			Target Exon C19000763*:gil1363912 pirl JC4296 ring f	2.8
	402376			Crooper of Sulfaces (Sulfaces on 197)	۵.0

	405041	NA		C3001706*:gi[1345652 sp[P15989]CA36_CHIC	2.8
	408758	NM_003686	Hs.47504	exonuclease 1	2.8
	431917	D16181	Hs.2868	peripheral myelin protein 2	2.8
_	437583	AA761190	Hs.244627	ESTs	2.8
5	453737	AA744862	Hs.194293	ESTs, Weakly similar to I54374 gene NF2	2.8
	458094	AF086325		gb:Homo sapiens full length insert cDNA	2.8
	401283	NA		Target Exon	2.8
	410784	AW803201		gb:IL2-UM0077-070500-080-E06 UM0077 Hom	
	417601	NM_014735	Hs.82292	KIAA0215 gene product	2.8
10	418236	AW994005	Hs.337534	ESTs	2.8
	435532	AW291488	Hs.117305	Homo sapiens, done IMAGE:3682908, mRNA	2.8
	454714	AW815098		gb:QV4-ST0212-091199-023-f10 ST0212 Homo	
	418629	BE247550	Hs.86859	growth factor receptor-bound protein 7	2.8
	442101	Al651930	Hs.135684		2.8
15	405080	AK000375	Hs.88820	HDCMC28P protein	2.8
	414661	T97401	Hs.21929	ESTs	2.8
	425589	AI650633	Hs.143688	Homo sapiens cDNA: FLJ23031 fis, clone L	2.8
	429638	Al916662		kinectin 1 (kinesin receptor)	2,7
• •	428824	W23624	Hs.173059	ESTs	2.7
20	421566	NM_000399	Hs.1395	early growth response 2 (Krox-20 (Drosop	2.7
	414596	BE386870		gb:601275271F1 NIH_MGC_20 Homo sapiens of	2.7
	440868	R79707	Hs.263339	ESTs, Moderately similar to 138022 hypot	2.7
	452943	BE247449	Hs.31082	hypothetical protein FLJ10525	2.7
	443772	AV646449	Hs.282872		2.7
25	432361	A1378562	Hs.159585	ESTs	2.7
	430375	AW371048	Hs.93758	H4 histone family, member H	2.7
	406504	NA		C5000558:gi]4504675[ref]NP_002175.1] int	2.7
	423279	AW959861	Hs.290943		2.7
	424871	NM_004525	Hs.153595	low density lipoprotein-related protein	2.7
30	453619	H87648	Hs.33922		2.7
	423961	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	2.7
	422156	N34524		gb:yy56d10.s1 Soares_multiple_sclerosis_	2.7
	415752	BE314524	Hs.78776	putative transmembrane protein	2.7
	419987	NM_005014	Hs.94070	osteomodulin	2.7
35	406182	NA		Target Exon	2.7
	416495	X69970	Hs.79350	RYK receptor-like tyrosine kinase	2.7
	444701	AI916512	Hs.198394		2.7
	408171	AA301228	Hs.43299	hypothetical protein FLJ12890	2.7
	430153	AW968128	Hs.336679		2.7
40	413383	AA128978	Hs.154706	hypothetical protein FLJ14917	2.7
	414831	M31158	Hs.77439	protein kinase, cAMP-dependent, regulato	2.7
	413278	BE563085	Hs.833	interferon-stimulated protein, 15 kDa	2.7
	433132	AB026264	Hs.284245	hypothetical protein IMPACT	2.7
	437030	AA742577	Hs.303781		2.7
45		AF075079		gb:Homo sapiens full length insert cDNA	2.7
		W74653	Hs.271593	ESTs, Moderately similar to A47582 B-cel	2.7
	406153			Target Exon	2.7
	406625	Y13647	Hs.119597	stearoyl-CoA desaturase (delta-9-desatur	2.7
	444698	Al188139	Hs.147050		2.7
50	432328	Al572739	Hs.195471	6-phosphofructo-2-kinase/fructose-2,6-bi	2.7
		H09604	Hs.13268	ESTs	2.7
	420149	AA255920	Hs.88095	ESTs	2.7
	431207	AA495925	Hs.9394	ESTs	2.7
	438394	BE379623	Hs.27693	peptidylprolyl isomerase (cyclophilin)-l	2,7
55		A1050073	Hs.135338		2.7
		Al741320		Homo sapiens cDNA: FLJ23228 fis, clone C	2.7
		AA054726	Hs.285574		2.7
	416515			ESTs, Weakly similar to 138022 hypotheti	2.7
	429922			H1 histone family, member 0	2.7
60	418203		Hs.83758	CDC28 protein kinase 2	2.7
		AF086332	Hs.58314	ESTs	2.7
	402184			ENSP00000245238*:CDNA FLJ10922 fis, clon	2.7
	450496		Hs.257131		2.7
		AI825440	Hs.224952		2.7
65		Al373638	Hs.133900		2.7
-		AA938663	Hs.199828		2.7
		AI806867	Hs.126594		27

	402020	4.4303000	11- 4000		
		AA383092	Hs.1608	replication protein A3 (14kD)	2.7
		AV653485	Hs.6390	Homo sapiens clone FLB3344 PRO0845 mRNA,	
		AW293165 X91662	Hs.143134		2.7 2.7
5		AW137636	Hs.66744 Hs.146059	twist (Orosophila) homolog (acrocephalos	2.7
,		AA496493	Hs.23136	ESTs	2.7
	406069		113.23100	Target Exon	2.7
		AI470235	Hs.172698		2.7
	401256		110.11 2000	NM_024089*:Homo sapiens hypothetical pro	2.7
10		AW975942	Hs.48524	ESTs	2.7
		AW958037	Hs.286	ribosomal protein L4	2.7
		BE144762		gb:CM0-HT0180-041099-065-b04 HT0180 Homo	
	438825	BE327427	Hs.79953	ESTs	2.6
	409564	AA045857	Hs.54943	fracture callus 1 (rat) homolog	2.6
15	452837	AL121053	Hs.5534	Homo saplens cONA FLJ12961 fis, clone NT	2.6
		AF160477	Hs.61460	lg superfamily receptor LNIR	2.6
		AK001122		hypothetical protein FLJ10260	2.6
		AW893940	Hs.59698	ESTs	2.6
20		Z30201		gb:HHEA22G Atrium cDNA library Human hea	2.6
20		D38299		prostaglandin E receptor 3 (subtype EP3)	2.6
		NM_006456		sialyltransferase	2.6
		AA300900	Hs.98849	ESTs, Moderately similar to AF161511 1 H	2.6
		AA447990	Hs.190478		2.6 2.6
25		AW975920 AI346487	Hs.283361 Hs.28739	ESTS	2.6
43		Al123555	Hs.81796	ESTs	2.6
		AW451645		Homo sapiens cDNA FLJ11973 fis, clone HE	2.6
		AW754311	1.0.101001	gb:CM1-CT0337-141299-068-07 CT0337 Homo	
		AI675944	Hs.188691	Homo sapiens cDNA FLJ12033 fis, clone HE	2.6
30	410530	M25809	Hs.64173	ATPase, H transporting, lysosomal (vacuo	2.6
	456672	AK002016	Hs.114727	Homo sapiens, clone MGC:16327, mRNA, com	2.6
	425071	NM_013989	Hs.154424	deiodinase, lodothyronine, type II	2.6
		AW292286	Hs.255058		2.6
26		AA018311	Hs.114762		2.6
35	405822			Target Exon	2.6
		AW976201	Hs.53913	hypothetical protein FLJ10252	2.6
		A1080042		ribosomal protein S24	2.6 2.6
		AA643687 AW205878	Hs.29643	Homo sapiens cDNA FLJ11980 fis, clone HE	2.6
40	405638	AVV203070	NS.25043	Homo sapiens cDNA FLJ13103 fis, clone NT Target Exon	2.6
40		AW812256		gb:RC0-ST0174-191099-031-a07 ST0174 Homo	
	403943	7111012200		C5000355:gi]4503225[ref]NP_000765.1] cyt	2.6
		Z25884	Hs.121483	chloride channel 1, skeletal muscle (Th	2.6
	402800			Target Exon	2.6
45		Al989503	Hs.233405		2.6
	454934	AW846080	Hs.314324	ESTs	2.6
		H03754	Hs.152213	wingless-type MMTV integration site fami	2.6
		AW974476		regulator of G-protein signalling 16	2.6
		AA418187	Hs.330515		2.6
50		AK001826	Hs.25245	hypothetical protein FLJ11269	2.6
		BE246010	Hs.271468	Homo sapiens mRNA for FLJ00038 protein,	2.6
		AW855802	11. 475700	gb:RC1-CT0279-170200-023-d08 CT0279 Homo	
		AB028955		KIAA1032 protein	2.6
55		NM_015434 Z47542	Hs.48604	DKFZP434B168 protein small nuclear RNA activating complex, po	2.6 2.6
55		NM_000163		growth hormone receptor	2.6
	406271	1414_000103	113.123100	Target Exon	2.6
		BE566962	Hs.7063	Homo sapiens cDNA: FLJ20913 fls, done A	2.6
		AW016892	Hs.100855		2.6
60		AI928513	Hs.59203	ESTs	2.6
	434398	AA121098	Hs.3838	serum-inducible kinase	2.6
		BE069326		gb:QV3-BT0381-170100-060-g03 BT0381 Homo	
		W24320	Hs.102941	Homo sapiens cDNA: FLJ21531 fis, done C	2.6
65		X64984		gb:H.saplens mRNA HTPCRX10 for olfactory	2.6
65	425101	AA830431	Hs.180811	ESIS	2.6
		AACCOZCO	U- 004000	COT-	
	435153	AA668763 Al681917	Hs.291939 Hs.3321	ESTs ESTs, Highly similar to IRX1_HUMAN IROQU	2.6 2.6

	455400	DE400400		-L-OVA 1370440 040000 050 L004370440 II	••
		BE160198	11- 70570	gb:QV1-HT0413-010200-059-h03 HT0413 Homo	
		BE274552	Hs.76578	protein inhibitor of activated STAT3	2.6
		A1732892 AA831267	Hs.190489 Hs.12244		2.6
5		AA825686		hypothetical protein FLJ20097 ESTs Wookh similar to S65824 square t	2.6 2.6
,	404440	~~023000	113.321170	ESTs, Weakly similar to S65824 reverse t NM_021048:Homo saplens melanoma antigen,	2.6
	403388	NA		C3001398*:gi[12248917]dbj[BAB20375.1] (A	2.6
	403775			Target Exon	2.6
	405037			NM_021628*:Homo sapiens arachidonate lip	2.6
10		AF290544		gb:Homo sapiens aminopeptidase mRNA, par	2.6
		AA282067	Hs.88972		2.6
		AI872932		gb:wm72e03.x1 NCI_CGAP_Ut2 Homo sapiens	
		AW516211	Hs.125300	ring finger protein 21, Interferon-respo	2.6
	445854	AI702885	Hs. 145568		2.6
15	421247	BE391727	Hs.102910	general transcription factor IIH, polype	2.6
	414870	N72264	Hs.300670	KIAA1204 protein	2.6
	457411	AW085961	Hs.130093	ESTs	2.6
		Y08565	Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:polyp	2.6
20	404443			C8001428*:gi[6572242 emb CAB62951.1  (Z9	2.6
20		NM_003512	Hs.28777	H2A histone family, member L	2.6
		A1073913		ESTs, Weakly similar to JE0350 Anterior	2.6
		Al192105	Hs.147170		2.6
		AW963372	Hs.46677		2.6
25	459089	R36075	NS.21313	Homo sapiens mRNA; cDNA DKFZp564O1763 (I	
23		AW081681	H= 260064	gb:yh88b01.s1 Soares placenta Nb2HP Homo ESTs, Weakly similar to T42689 hypotheti	2.6 2.6
		NM_000169	Hs.69089	galactosidase, alpha	2.6
		S70284	113.03003	gb:stearoyl-CoA desaturase [human, adipo	2.6
		H62943	Hs.154188		2.6
30		BE065837	110.101100	gb:RC2-BT0318-110100-012-g12 BT0318 Homo	
• •		NM_012247	Hs.124027	SELENOPHOSPHATE SYNTHETASE; Human:	
		Al538613		Transmembrane protease, serine 3	2.5
		AF012023		integrin cytoplasmic domain-associated p	2.5
	445417	AK001058	Hs.12680	Homo sapiens cDNA FLJ10196 fis, clone HE	2.5
35	422225	BE245652	Hs.118281	zinc finger protein 266	2.5
	428330		Hs.2256	matrix metalloproteinase 7 (MMP7; uterin	2.5
		AB020641	Hs.57856		2.5
		NM_000909		neuropeptide Y receptor Y1	2.5
40		AW973708		Homo sapiens cDNA FLJ13446 fis, clone PL	2.5
40		AA767881	Hs.122897		2.5
		AK001741	Hs.8739	hypothetical protein FLJ10879	2.5
		AL042306 AW628666	Hs.97689		2.5 2.5
		AK002032		ESTs, Weakly similar to 138022 hypotheti Homo sapiens cDNA FLJ11170 fis, clone PL	2.5
45		BE080908	113.212243	gb:QV1-BT0631-280200-084-h07 BT0631 Homo	
7.5		Al362790	He 278630	KIAA1684 protein; likely homolog of mous	2.5
		BE394723		S100 calcium-binding protein A6 (calcycl	2.5
		NM_002318	Hs.83354	lysyl oxidase-like 2	2.5
		AW375610		hypothetical protein FLJ13046 similar to	2.5
50	458012	Al424899	Hs.188211		2.5
	422996	BE091089		gb:PM4-BT0724-130400-006-c07 BT0724 Homo	2.5
	410804	U64820	Hs.66521	Machado-Joseph disease (spinocerebellar	2.5
		AW972565	Hs.32399		2.5
c c		AW089705		ESTs, Weakly similar to S64329 probable	2.5
55		AI471598	Hs.197531		2.5
		AA065081	11- 44000	gb:zm13a03.s1 Stratagene pancreas (93720	2.5
		BE178536	Hs.11090	membrane-spanning 4-domains, subfamily A	2.5
		AF109298	Hs.118258		2.5
60		AW247529	Hs.6793	platelet-activating factor acetylhydrola	2.5
00		BE158687	Hs.12407	gb:CM0-HT0395-280100-169-b09 HT0395 Homo ESTs	2.5 2.5
		AW953168 AA652687	Hs.96151	Human DNA sequence from clone RP5-1103G7	
	404826	L0/10/2001	. 10.00101	Target Exon	2.5 2.5
		NM_001809	Hs.1594	centromere protein A (17kD)	2.5
65		NM_014918		KIAA0990 protein	2.5
		NM_007350	Hs.82101	pleckstrin homology-like domain, family	2.5
		AW898595		gb:RC1-NN0073-260400-011-g09 NN0073 Homo	2.5

	403356	NA		ENSP00000251525*:Hypothetical protein KI	2.5
	404983			ENSP00000252242*:Keratin, type II cytosk	2.5
		AA215535	Hs.98133	ESTs	2.5
_		AW467143		actin related protein	2.5
5		AF186114		tumor necrosis factor (figand) superfami	2.5
		AW071349	Hs.215937		2.5
	421246	AW582962		CGI-47 protein	2.5
	439217	AF086041	Hs.42975	ESTs .	2.5
	400925			Target Exon	2.5
10	404552	NA		ENSP00000220888*:ZINC FINGER TRANSCRI	
	417168	AL133117	Hs.81376	Homo sapiens mRNA; cDNA DKFZp586L1121 (I	
	418841	NM_002332	Hs.89137	low density ilpoprotein-related protein	2.5
	426853	U32974		baculoviral IAP repeat-containing 4	2.5
		NM_000318		peroxisomal membrane protein 3 (35kD, Ze	2.5
15	457384	AA501760	Hs.15806	Homo sapiens mRNA; cDNA DKFZp434H2019 (	
	447128	AI271898	Hs.164866		2.5
	454693	AW813428		gb:MR3-ST0192-010200-210-c05 ST0192 Homo	
	434657	AA641876	Hs.191840		2.5
	402077	NA		Target Exon	2.5
20	400289	X07820	Hs.2258	matrix metalloproteinase 10 (MMP10; str	2.5
	. 409723	AW885757	Hs.257862		2.5
		T27308	Hs.16986	hypothetical protein FLJ11046	2.5
	455068	AI807894	Hs.47274	Homo sapiens mRNA; cDNA DKFZp564B176 (fr	2.5
	431232	A1024353	Hs.131755	hypothetical protein FLJ14298	2.5
25		AA059013	Hs.22607	ESTs	2.5
	411571	AA122393	Hs.70811	hypothetical protein FLJ20516	2.5
		AW162919		RAB2, member RAS oncogene family-like	2.5
	428248	Al126772	Hs.40479		2.5
		A1580090	Hs.48295	RNA helicase family	2.5
30		N80077	Hs.24792	chromosome 12 open reading frame 5	2.5
		AA449644		Homo sapiens cDNA FLJ14201 fis, clone NT	2.5
		AW297921	Hs.255703		2.5
		AA256769	Hs.94949		2.5
~ ~		AW086180	Hs.37636	ESTs, Weakly similar to KIAA1392 protein	2.5
35		U29344	Hs.83190	fatty acid synthase	2.5
		AA356923		nuclear cap binding protein subunit 2, 2	2.5
		AL039402		DEME-6 protein	2.5
		N52639	Hs.32683	ESTs	2.5
4.0		A1743977	Hs.205144		2.5
40		AA740875	Hs.44307		2.5
		AW500507		KIAA1600 protein	2.5
		A1920783	Hs.191435		2.5
		AA479033		ESTs, Weakly similar to A47582 B-cell gr	2.5
4.0		A1446747		olfactory receptor, family 7, subfamily	2.5
45		AA116021	Hs.38260		2.5
		NM_007069	Hs.37189		2.5
		H00820	Hs.30977		2.5
		AA236255	Hs.298419		2.5
50		H20669	Hs.35406		2.5
50		AL046412	Hs.202151		2.5
		AI640355	Hs.312691		2.5
		AW298631	Hs.27721		2.5
		A1937547	Hs.124915	hypothetical protein MGC2601	2.5
		AW837349	41- 400044	gb:QV2-LT0038-270300-108-d12 LT0038 Home	2.5
55		AA843719	Hs.122341	CCOOCCCC - 140 40 441 - 104 CC 441 TA 4 CAT 1	
	406414		11- 440077	C5000506*:gi[124941 spiP18614 ITA1_RAT	2.5
		AB033043		hypothetical protein DKFZp761L0424	2.5
		BE548446	Hs.5167	Homo sapiens mRNA; cDNA DKFZp434F152 (f	2.5
60		AA347746	Hs.9521	ESTs, Weakly similar to ZN43_HUMAN ZINC	
60		BE159984	Hs.125395	Hemp popiese - Phile - Phile BI/E7-42400545	2.5
		AA635062	Hs.50094	Homo sapiens mRNA; cDNA DKFZp434O0515	2.5
		D86983		Melanoma associated gene	2.5
		AL135623		KIAA0575 gene product	2.5
65		AA442324	Hs.795	H2A histone family, member O	2.5
65		D13752		cytochrome P450, subfamily XIB (steroid	2.5
		AA081395	Hs.42173	Homo sapiens cDNA FLJ10366 fis, clone NT Target Exon	2.5
	403133	)		I alder evall	2.0

#### WO 02/059377

5

#### PCT/US02/02242

400346 435509	Al458679	Hs.272263 Hs.181915		2.5 2.5
458145	A1239457	Hs.130794	ESTs	2.5

#### TABLE 19A

Table 19A shows the accession numbers for those pkeys lacking unigeneID's for Table 19. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10
----

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene duster number
Accession:	Genbank accession numbers

15			
	Pkey	CAT number	Accessions
20	407647 407980 408254	1007366_1 103087_1 1049346_1	AW860158 AW862385 AW860159 AW862386 AW862341 AW821869 AW821893 AW062660 AW062656 AA046309 Al263500 AA046397 AW807227 AW807576 AW807137 AW807157 AW807495 AW807494 AW807417 AW807083 AW845786 AW845801
	10025		AW807130 AW807335 AW807081 AW807349 AW807339 AW807164 AW807341 AW807224 AW845903 AW177424 AW807159 AW807123 BE141576 AW807340 AW807334 AW807520 AW807205 AW807505 BE141574 AW807390 AW807395 AW807395 AW807589 AW807101 AW807089 AW807519 AW807239 AW807509 AW807356 AW807526 AW807098
25			AW807307 AW807153 AW807295 AW807313 AW807322 AW807265 AW807513 AW807516 AW807166 AW807501 AW807120 AW807168 AW807121 AW807527 AW807151 AW807203 AW807489 AW807511 AW807518 AW845800 AW807507 AW845793 AW845796 AW807296 AW845781 AW807444 AW845871 AW807512 AW807242 AW807141
30			AW807522 AW807487 AW807514 AW807142 AW807232 AW807379 AW807114 AW807518 AW807199 AW807211 AW807498 AW807086 AW807492 AW807218 AW807082 AW807525 AW807493 AW807523 AW807087 AW845784 AW807037 AW807128 AW807080 AW807118 AW845807 AW807524 AW845803 AW807249 AW845795 AW807160
			AW807343 AW807515 AW807233 AW807289 AW177102 AW807352 AW807394 AW177105 AW807176 AW177103 AW845870 AW177099 AW177101 AW807528 AW807336 AW807038 AW177100 AW807411 AW807088 AW845865 AW807226 AW807517 AW807397 AW807303 AW807177 AW807154 AW807136 AW807146 AW807085 AW807521
35	409163	110418_1	AW807488 AW807385 AW807355 AW807223 AW807155  AA065081 AA075017 AA084791 AA071015 AA081560 AA071459 AA545727 AA083100 AA085366 AA115845 AA075457  AA064704 AA082878 AA075742 AA069162
	409695	114876_1	AA296961 AA296889 AA076945 AA077528 AA077497
	410534	1207247_1	AW905138 AW753008 R13818 Z43519
40	410672 410784	1214882_1 1221005_1	AW794600 AW794730
40	410785	1221005_1	AW803201 BE079700 BE062940 AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355
	410735	1223785_1	AW806906 AW806915 AW866460 AW866475 AW866462 AW866448 AW866372 AW866604
	411050	1230330_1	AW814902 BE156656 BE156667 BE156590 BE156441 BE156447
	411086	1231500_1	BE070800 AW875226 BE149115
45	411093	1231970_1	BE067650 AW817053
	411111	1232669_1	AW818127 AW818161 R09719
	411171	1234393_1	AW820260 AW820332 R94406
	411337	1239217_1	AW837349 AW837355 AW882717
50	411514 411670	1248638_1 1253680_1	AW850178 AW850233 AW850445 AW850446 AW856552 AW861101 AW856574 AW861099 AW861100 AW856573 AW856576 AW856562
50	411905	1265181_1	BE265067 BE264978 AW875420
	412102	1277395_1	H56435 H56572 AW892929
	412209	1283610_1	AW901456 AW901450 AW901441
	412248	1285000_1	BE176480 AW903298 AW903313
55	413043	1346556_1	BE158766 BE061699 BE147360 BE147362 BE061666 BE061697 BE061647 BE061678
	413111	1349546_1	BE065837 BE065805 BE065799 BE065818 BE065839 BE065831 BE065894 BE065789 BE065792
	413189	1352723_1	BE070231 BE070229 BE070255
	413221 413499	1353887_1 1373910_1	BE161151 BE162495 BE161002 BE072205 BE160989 BE162482 BE144884 H97942
60	413708	1384140_1	BE158791 BE158806 BE158748 BE158744 BE158740 BE158739 BE158811 BE158700 BE158741 BE158683 BE158685
00	414210	1426051_1	BE383592 BE261671
	414596	1465004_1	BE386870 Z41986 H08501

	414605	14657901	BE390440
	415747	155189_1	AA381209 AA381245 AA167683
	416173	1574973_1	R52782 R17313 H24192 R19876
_	417742	1696282_1	R64719 Z44680 R12451
5	417974	171237_1	AA210765 T95700 H94407
	418636	177402_1	AW749855 AA225995 AW750208 AW750206
	419536	185688_1	AA603305 AA244095 AA244183
	420854	197072_1	AW296927 AI684514 AI263168 AA281079
	422156	212379_1	N34524 AA305071 AW954803 AA502335 Al433430 Al203597 AW026670 AW265323 AW850787 AA317554 AW993643
10			AW835572 AW385512 Al334966 W32951 H62656 H53902 R88904 AW835732
	422996	223666_1	BE091089 BE091123 AA319959
	423833	232451_1	AW503329 N46610 AA331571
	423841	232507_1	AW753967 AA370795 AA331630 AW962550
	423945	233566_1	AA410943 AW948953 AA334202 AA332882
15	425201	247933_1	AA352111 AW962247 AA429695
	426650	270283_1	AA382814 AA402411 AA412355
	426878	273265_1	BE069341 AW748403 AL044891 Al908240 AA393080
	430264	315008_1	AA470519 BE303010 BE302954 BE384120
00	430785	323486_1	Z30201 AA486132 T72025
20	431676	336411_1	AI685464 AW971336 AA513587 AA525142
	433687	373061_1	AA743991 AA604852 AW272737
	434338	383982_1	AW754311 AA630185 AW803285
	434469	387447_1	AA634806 C18732 AA729161 AA729860
25	435447	406400_1	Al872932 AA682306 BE220163 W88695 T81307 H91447
25	437152	43386_1	AL050027 BE089051
	437854	44418_1	AL119723 AL119874 Al909018 U50537
	439031	46798_1	AF075079 H48601 H48795
	439255	470321_1	BE164500 AA832198 BE164502
30	444910	624951_1	A1201849 BE069007 AV/946544
30	445432 446922	63943_1	AV653771 BE089370
	440922	69865_1 711623_1	BE175605 Z43529 F06610 BE175602 AV661027
	448420	76273_1	R36075 Al366546 R36167 BE623004 AA380669 BE263627 BE246433
	448516	766241_1	AW898595 AW898588 AW898590 AW898663 AW898592 AI525093
35	450522	837264_1	A1698839 A1909260 A1909259
33	450736	844652_1	AW970060 AI732366 AI792313 AW839644
	451024	85565_1	AA442176 AA259181
	451067	85759_1	BE172186 AA059279 AA020815 AA013437
	451340	86640_1	AW936273 AW340350 AA017208
40	452542	921410_1	AW812256 AW812257 AI906423 AI906422
	452564	92227_1	AA026777 N50065 R09961 N54721
	453472	968371_1	AL037925 AL037931 AL037957
	454307	1106070_1	AW855717 AW362452 AW362443
	454359	1130674_1	N71277 AW390764
45	454545	1223779_1	AW806899 AW866451 AW866393 AW866297 AW817869
	454693	1229132_1	AW813428 AW813444 AW813367 AW813368 AW813429 AW813424
	454714	1230493_1	AW815098 BE154843 BE154831
	455047	1250536_1	AW852530 AW852527 AW852526
	455092	1252971_1	BE152428 AW855572 AW855607
50	455097	1253130_1	AW855802 AW855794 AW855797 AW855806 AW855796 AW855808 AW855793 AW855807
	455100	1253334_1	BE160198 AW935898 T11520 AW935930 AW856073 AW861034
	455431	1289854_1	AW938484 BE001245 BE001190
	455511	1321229_1	BE144762 AW979091
55	455609	1337548_1	BE011668 BE011689 BE011627 BE011679 BE011699 BE011678 BE011696 BE011675 BE011622 BE011635
22	455651	1348732_1	BE064952 BE064979 BE064853 BE064857 BE064856 BE064977 BE064960 BE064860 BE064815 BE064957 BE064804
	ACECOE	1250202 4	BE064816 BE064850 BE064806 BE064796 BE064818 BE064975 BE064819 BE064810 BE064668 BE065059
	455685	1350393_1	BE066976 BE066928 BE066927
	455700 455708	1351264_1 1352232_1	BE068115 BE068104 BE068102 BE068096 BE068103 BE068154 BE068198 BE069326 BE069290 BE069352
60	455732	1353874_1	BE080908 BE072258 BE072190 BE072236
00	455838	1374605_1	BE145808 BE145807 BE181883
	455935	1384144_1	BE158687 BE158688
	455945	1385588_1	BE160636 BE160606 BE160703
	456207	1650781	AA193450
65	456482	192289_1	AA485224 AA287308 AA258121
	458094 .	47311_1	AF086325 W72956 W73221 AA219112
	458673	679507_1	N99626 Al302701

#### **TABLE 19B**

Table 19B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 19. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10 15	Pkey: Ref: Strand: Nt_position:		Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.					
	Pkey	Ref	Strand	Nt_position				

	Pkey	Ref	Strand	Nt_position
	400555	9801191	Minus	134694-134817
20	400608	9887666	Minus	96756-97558
	400610	9887671	Minus	117606-117928,124040-124147
	400925	7651921	Plus	38183-38391,43900-44086
	401045	8117619	Plus	90044-90184,91111-91345
	401049	7232177	Plus	149157-150692
25	401093	8516137	Minus	22335-23166
	401256	9796573	Minus	45482-45620
	401283	9800093	Minus	47256-47456 ·
	401326	9212516	Minus	226246-227505
	401418	7452889	Minus	124865-125075
30	401451	6634068	Minus	119926-121272
	401458	9187886	Plus	76485-77597
	401497	7381770	Plus	92607-92813
	401508	7534110	Minus ·	110779-110983
		7229804	Minus	76253-76364
35	401747	9789672	Minus	118596-118816,119119-119244,119609-119761,120422-120990,130161-130381,130468-130593,131097-
				131258,131866-131932,132451-132575,133580-134011
		7249190	Minus	83215-83435,83531-83656,83740-83901,84237-84393,84955-85037,86290-86814
		7249190	Minus	165776-165996,166189-166314,166408-166569,167112-167268,167387-167469,168634-168942
40		7263888	Minus	102945-103083
40		4406829	Minus	72893-73021,76938-77049
		8117414	Plus	65014-65195
		8131678	Minus	171722-171859,173197-173303
		8576001	Minus	112844-112986,113505-113636
4.5		9625329	Minus	21753-22385
45		9796341	Minus	46609-46662,46758-46811,86293-86346,89776-89829,90048-90101,102817-102924
		9884928	Plus	66350-66496
		9909429	Minus	81747-82094
		7328818	Minus	23600-23731
50		9367757	Plus	109588-109726
30		6010175	Plus	43921-44049,46181-46273
		6456853	Minus	82274-82443
		8086844	Minus	194384-194645
		7331427	Plus	38314-38634
55		8569930	Plus	92839-93036
33		9438331	Plus	112733-113001,114599-114735
		9719529 8101208	Minus	157156-158183 .
		6862650	Minus Minus	131266-131769 62554-62712,69449-69602
		8671936	Minus	142647-142771,145531-145762
60		8671948	Plus .	113234-113326,115186-115287,119649-119786
JU		7331517	Minus	55008-55083.62860-63051
		7770580	Minus	102247-102326,103095-103148
		7711864	Plus	100742-100904,101322-101503
	400040	77 11004	1.102	100176-1003071101046-101000

```
404091 7684554
                          Minus
                                    82121-83229
         404097 7770701
                                    55512-55781
                          Plus
         404142 9856692
                          Minus
                                    80316-80459
         404253 9367202
                          Minus
                                    55675-56055
  5
         404274 9885189
                          Plus
                                    104127-104318
         404285 2326514
                          Plus
                                    32282-32416
         404360 9858450
                                    122873-122966,151324-151469,153093-153253
                          Minus
         404440 7528051
                                    80430-81581
                          Plus
         404443 7579073
                                    87198-87441
                          Minus
10
        404552 7243881
                                    19854-20010
                          Plus
         404561 9795980
                          Minus
                                    69039-70100
        404580 6539738
                          Minus
                                    240588-241589
         404721 9856648
                                    173763-174294
                          Minus
         404826 6572184
                          Pius
                                    47726-48046
15
         404983 4432779
                                    51178-51374,52000-52173
                          Minus
         405037 7543748
                                    127374-127578
                          Minus
         405041 7547195
                                    121230-121714
                          Plus
         405095 8072599
                          Plus
                                    138877-139066
         405153 9965565
                                    175317-175500
                          Minus
20
         405196 7230083
                          Minus
                                    135716-135851
         405232 7249042
                          Plus
                                    125904-126063
         405248 7259728
                                    637-777
                          Plus
        405336 6094635
                                    33267-33563
                          Plus
         405394 6624123
                                    31900-32373
                          Minus
25
         405460 7684569
                                    52223-52389
                          Minus
         405494 8050952
                          Minus
                                    70284-70518
         405547 1054740
                          Plus
                                    124361-124520,124914-125050
        405609 5757553
                                    42814-43010,43583-43783,44863-45033,46429-46554,47815-48018,49961-50153,51624-51727,51823-51959,52702-
                          Minus
                                    52918,55469-55601,57111-57307,58169-58296,60215-60332,61482-61727
30
        405638 6289229
                          Plus
                                    199260-199372,199826-199929
        405654 4895155
                                    53624-53759
                          Minus
         405718 9795467
                                    113080-113266
                          Plus
         405822 6273498
                                    154660-154974.155203-155379
                          Minus
         405848 7651809
                                    28135-28244
                          Minus
35
         405873 6758747
                                    32129-32764
                          Minus
         405906 7705124
                          Minus
                                    10835-11059
        405917 7712162
                                    106829-107213
                          Minus
         405925 6758795
                          Plus
                                    129935-130282
         405953 7960374
                          Minus
                                    65101-65574
40
         406069 9117732
                                    68880-69374
                          Plus
         406151 7144806
                                    94087-94285
                          Minus
        406153 9929734
                                    12902-13069
                          Minus
        406182 5923650
                                    28256-28935
                          Minus
         406271 7534217
                                    36179-36692
                          Plus
45
        406291 5686274
                          Plus
                                    9562-9867
        406348 9255985
                                    71754-71944
                          Minus
         406414 9256407
                          Plus
                                    49593-49850
        406446 9454509
                          Minus
                                    116424-116527,118721-118859,121187-121364
        406504 7711360
                                    107068-107277
                          Minus
50
        406554 7711566
                                    106956-107121
                          Plus
```

# TABLE 20: 544 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES THAT ARE LIKELY TO ENCODE EXTRACELLULAR OR CELL-SURFACE PROTEINS

Table 20 shows 544 genes up-regulated in breast cancer compared to normal adult tissues that are likely to encode extracellular or cell-surface proteins. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the "average" normal adult tissue level was set to the 85<sup>th</sup> percentile value amongst 144 non-malignant tissues, and the 96<sup>th</sup> percentile value amongst the 73 breast cancer specimens was greater than or equal 100 units, and the predicted protein contained a structural domain that is indicative of extracellular localization (e.g. ig, fn3, egf, 7tm domains, signal sequences, transmembrane domains). The predicted protein domains are noted.

15

5

Pkey: Unique Eos probeset Identifier number

ExAccn: Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number

20 Pred.Prot.Domains: Predicted Protein Domains

Unigene Title: Unigene gene title

R1: Ratio of 93rd percentile of tumor to 85th percentile of normal body tissue

25	Pkey	ExAccn	UnigenelD	Pred.Prot.Domains	UnigeneTitle	R1
	408591	AF015224	Hs.46452	SS,Uteroglobin,SS,Uteroglobin	mammaglobin 1	168.6
	400291	AA401369	Hs.190721	TM	ESTs	73.2
	449746	AI668594	Hs.176588	,SS,p450	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	65.7
30	407277	AW170035	Hs.326736	TM .	Homo sapiens breast cancer antigen NY-BR	57.6
•	400292	AA250737	Hs.72472	death, ZU5, TM, Activin_recp, pkinase,	BMP-R1B .	55.9
		U31875	Hs.272499	,SS,TM	short-chain alcohol dehydrogenase family	53.8
	426878	BE069341		TM	gb:QV3-BT0381-270100-073-c08 BT0381 Homo	50.3
			0Hs.194236	SS, Leptin, SS, Leptin,	leptin (murine obesity homolog)	40.8
35	407178	AA195651	Hs.104106	SS,Dihydroorotase,	ESTs	39.3
	408000	L11690	Hs.620	Plectin_repeat,SH3,spectrin,SS,Plectin_r	bullous pemphigoid antigen 1 (230/240kD)	37.3
	427585	D31152	Hs.179729	SS,C1q,Collagen,SS,C1q,Collagen,	collagen, type X, alpha 1 (Schmid metaph	35.2
	429441	AJ224172	Hs.204096	SS,Uteroglobin,	lipophilin B (uteroglobin family member)	30.0
	450375	AA009647	Hs.8850	,SS,TM,disintegrin,Pep_M12B_propep,Repro	a disintegrin and metalloproteinase doma	25.7
40	420931	AF044197	Hs.100431	SS,ILB,SS	small inducible cytokine B subfamily (Cy	25.2
	422109	S73265	Hs.1473	SS,Bombesin,SS	gastrin-releasing peptide	24.8
	445730	A1624342	Hs.170042	.SS.TM.Cation_efflux	ESTs	24.1
	451110	AI955040	Hs.265398	SS	ESTs, Weakly similar to transformation-r	24.0
	400297	Al127076	Hs.334473	TM	hypothetical protein DKFZp564O1278	23.8
45	420813	X51501	Hs.99949	SS,SS	prolactin-induced protein	22.8
	452744	A1267652	Hs.30504	,SS,TM,GNS1_SUR4,cNMP_binding,Rlla	Homo sapiens mRNA; cDNA DKFZp434E082 (fr	22.6
	424634	NM_00361	3Hs.151407	ig,tsp_1,SS,AAA	cartilage intermediate layer protein, nu	21.7
	420757	X78592	Hs.99915	hormone_rec,Androgen_recep,zf-C4,	androgen receptor (dihydrotestosterone r	21.7
	424399	AI905687	Hs.2533	SS	aldehyde dehydrogenase 9 family, member	20.3
50	447350	AI375572	Hs.172634	,pkinase,	ESTs	19.2
-	456207	AA193450		,SS,TM,p450,p450	gb:zr40e07.rl Soares_NhHMPu_S1 Homo sapi	18.3
	431448	AL137517	Hs.334473	TM	hypothetical protein DKFZp564O1278	18.2
	427217	AA399272	Hs.144341	SS	ESTs	18.2
	456938	X52509	Hs.161640	,SS,TM,aminotran_1_2,Cadherin_C_term,cac	I tyrosine aminotransferase	18.1
55	435496	AW840171	Hs.265398	SS	ESTs, Weakly similar to transformation-r	17.9
	402578			SS,p450,SS,TM,p450	C1001134:gi[2117372 pir [165981 fatty ac	17.8
	453160	A1263307	Hs.239884	SS	H2B histone family, member L	17.8
•	422505	AL120862	Hs.124165	SS	programmed cell death 9 (PDCD9)	17.7
	444342	NM_01439	8Hs.10887	Lamp,SS,TM,Lamp,	similar to lysosome-associated membrane	17.5

		N92293	Hs.206832	SS	ESTs, Moderately similar to ALU8_HUMAN A	17.3
		AA321649		SS,ILB,	small inducible cytokine subfamily B (CX	17.0
		D90041	Hs.155956	,SS,Acetyltransf2,	N-acetyltransferase 1 (arylamine N-acety	16.7
5		W67883	Hs.137476	,pkinase,	paternally expressed 10	16.5
5		AB014544		LRRCT,LRR,SS,LRRCT,serine_carbpept	KIAA0644 gene product	16.3
		D60730	Hs.57471	SS	ESTs	16.2
		M13509	Hs.83169	SS,hemopexin,Peptidase_M10,SS,Peptidase_		15.7
		AA296520 AA441838		SS,lectin_c,sushl,EGF,SS,EGF,lectin_c,su	selectin E (endothelial adhesion molecul	15.5
10				SS SCIED VIEW	hypothetical protein FLJ14834	15.5 15.0
10		NM_00711: H44186	Hs.15456	,SS,CUB,Xlink,	tumor necrosis factor, alpha-induced pro	14.9
			Hs.120785	PDZ,SS SS	PDZ domain containing 1 ESTs	14.8
		U65011	Hs.30743	SS,SS	preferentially expressed antigen in mela	14.7
			Hs.121017	histone, SS, histone, histone	H2A histone family, member A	14.3
15		AL035414		SS	hypothetical protein	14.2
10		Al199268		"SS,lipocalin	Homo sapiens, Similar to RIKEN cDNA 2010	14.2
		W20027	Hs.23439	,SS,Peptidase_M1,	ESTs	13.9
			Hs.134662	.SS.TM.SNF	ESTs	13.7
		AA031956	***************************************	,SS,LIM,	gb:zk15e04.s1 Soares_pregnant_uterus_NbH	13.7
20			Hs.130239	SS	ESTs	13.5
		X07820	Hs.2258	hemopexin,Peptidase_M10,SS,Peptidase_M1		13.5
		BE336654		histone, SS, histone, histone	H3 histone family, member A	13.3
			Hs.130853	.SS,histone,histone,linker_histone	ESTs	13.2
			Hs.112742	,SS,Ribosomal_L7Ae,	ESTs	13.1
25			Hs.326736	TM	Homo sapiens breast cancer antigen NY-BR	13.1
			Hs.182278	SS,DENN	calmodulin 2 (phosphorylase kinase, delt	13.0
			Hs.197653	SS	programmed cell death 9 (PDCD9)	12.9
			Hs.102267	,SS,Lysyl_oxidase	lysyl oxidase	12.8
		W72838	Hs.2533	SS	aldehyde dehydrogenase 9 family, member	12.7
30	452461	N78223	Hs.108106	,SS,G9a,PHD,	transcription factor	12.5
	427365	A1873274	Hs.190721	TM	ESTs	12.4
	433365	AF026944	Hs.293797	,SS,TPR	ESTs	12.3
		AA576953		SS,TM,UPF0016,SS,TM,UPF0016	hypothetical protein FLJ13352	12.0
			Hs.278461	SS,EGF,vwa,SS,TM,vwa,	matrilin 3	11.9
35		AW732573		TM,K_tetra,lon_trans,SS,TM,K_tetra,ion_t	potassium voltage-gated channel, delayed	11.9
			Hs.200313	,SS,TM,Folate_carrier	ESTs	11.9
			Hs.157601	SS	ESTs	11.8
		H87879	Hs.102267	SS,Lysyl_oxidase,Aldose_epim,Epimerase,S		11.8
40		NM_002497		pkinase,SS,TM,pkinase,polyprenyl_synt,	NIMA (never in mitosis gene a)-related k	11.7
40		AL049689		SS	hypothetical protein similar to tenascin	11.6
		R28363	Hs.24286	,SS,TM,7tm_1,p450,rrm	ESTs	11.5
		AI907673		,pkinase,	gb:IL-BT152-080399-004 BT152 Homo sapien	11.5
		AA410943	11- 000050	death,ZU5,TM,Activin_recp,pkinase,	gb:zt32h03.r1 Soares ovary tumor NbHOT H	11.4
45		AL360204	Hs.283853	SS	Homo sapiens mRNA full length insert cDN	11.4
43	402606	1167040	11- 40500	SS	NM_024626:Homo sapiens hypothetical prot	11.3
	445263		Hs.42586	,SS,Acyltransferase,	KIAA1560 protein	11.2
	430217		Hs.336901	,SS,RNA_pol_A,RNA_pol_A2,Ribosomal_S24		11.1
		AF026941 BE178536		,TM,IBR	Homo sapiens cig5 mRNA, partial sequence membrane-spanning 4-domains, subfamily A	11.1 11.1
50		AL080207		,SS,TM		10.9
50		R17798	Hs.7535	,SS,TM,BRCT,ank,ABC_tran,ABC_tran	DKFZP434G232 protein COBW-like protein	10.9
	425704		Hs.159264	,SS,Fork_head, SS	Human done 23948 mRNA sequence	10.5
		NM_007050		,SS,TM,Y_phosphatase,MAM,fn3,	protein tyrosine phosphatase, receptor t	10.7
		AB007948		,SS,taminin_B,taminin_EGF,taminin_Nterm	KIAA0479 protein	10.3
55		BE440042		SS,Peptidase_M10,hemopexin,SS,Peptidase		10.3
33		NM 00068		SS,TM,7tm_1,SS,TM,7tm_1,	angiotensin receptor 1	10.3
		U80736	Hs.110826	\$S	trinucleotide repeat containing 9	10.3
		AL120173		,SS,pkinase,	ESTs	10.3
		AW016531		,SS,ArfGap,	ESTs	10.2
60	400608			SS,TM,SS,TM	C10001899:gi[7508633[plr]]T25392 hypothe	10.1
		BE242870	Hs.75379	SS	solute carrier family 1 (glial high affi	10.0
		W68815	Hs.301885	SS	Homo sapiens cDNA FLJ11346 fis, clone PL	9.9
	402408			,SS,carb_anhydrase	NM_030920*:Homo saplens hypothetical pro	9.8
	445537	AJ245671	Hs.12844	,SS,TM,ras	EGF-like-domain, multiple 6 (EGFL6)	9.7
65	451621	A1879148	Hs.26770	SS, lipocalin, lipocalin,	fatty acid binding protein 7, brain	9.6
	405654			BTB,SS	C12001521:gi[7513934[ptr]]T31081 cca3 pr	9.6
	434988	AI418055	Hs.161160	SS	ESTs	9.6

	416220	N49776	Hs.170994	,SS,TM	hypothetical protein MGC10946	9.5
				SS,TM,EGF,SS	amphiregulin (schwannoma-derived growth	9.5
		AW368397			Homo saplens cDNA FLJ14438 fis, clone HE	9.4
		AA032279		TM	six transmembrane epithelial antigen of	9.4
5	418601	AA279490 1	Hs.86368	SS,TM,calreticulin,SS,TM,calreticulin,	calmegin	9.4
	415539	Al733881	Hs.72472	death, ZU5, TM, Activin_recp, pkinase,	BMP-R18	9.4
	421451	AA291377	Hs.50831	TM	ESTs	9.3
	429432	AI678059	Hs.202676	SS	synaptonemal complex protein 2	9.3
_	442441	AI820662	Hs.129598	SS	ESTs	9.1
10	426429	X73114	Hs.169849	,SS,TM,fn3,ig,	myosin-binding protein C, slow-type	9.1
	406687	M31126	Hs.272620	SS,Peptidase_M10,hemopexin,SS,Peptidase_		9.1
	448693	AW004854	Hs.228320	SS	hypothetical protein FLJ23537	9.1
		AB041035	Hs.93847	Ferric_reduct,TM,Ferric_reduct,	NM_016931:Homo saplens NADPH oxidase 4 (	9.1
					ESTs, Moderately similar to ALU7_HUMAN A	9.0
15		A1798680		,SS,TM,histone,Sec1,histone,sugar_tr	ESTs	8.9
			Hs.77367	SS,IL8,SS,IL8	monokine induced by gamma interferon	8.8
	400285			,TM,ABC_tran,ABC_membrane,	Eos Control	8.8
				SS,TM,EGF,SS,TM	epiregulin	8.8
20		NM_004354		cyclin,SS	cyclin G2	8.8
20		AW512260	Hs.87767	SS	ESTS	8.7
				,SS,TGF-beta,TGFb_propeptide,	Homo sapiens cDNA FLJ11041 fis, clone PL	8.7
		AA642007		SS	ESTs	8.6
		AF123050		,SS,TM,ubiquitin,7tm_3,ANF_receptor,sush	diubiquitin	8.6 8.6
25		AI732643		TM	ESTs	8.5
25		A1222020	Hs.182364	SS,SS	CocoaCrisp	8.5
		BE622641			nis_reESTs, Weakly similar to I38022 hypotheti	8.5
			Hs.133525	,SS,TM	ESTs	8.4
		NM_004525	HS.153595	SS,EGF,ldl_recept_a,ldl_recept_b,SS,TM,E	low density lipoprotein-related protein	8.4
30		AW963419		SS	stanniocalcin 2	8.4
30		AA635062 Al831297		TM TM	Homo sapiens mRNA; cDNA DKFZp434O0515 (f ESTs	8.3
		AA780473		SS,p450,SS,p450	cytochrome P450, subfamily IVB, polypept	8.3
		NM_003866		SS,SS	inositol polyphosphate-4-phosphatase, ty	8.3
				SS,Cys_knot,SS	Nome disease (pseudoglioma)	8.3
35			Hs.106604	death,ZU5,pkinase,Activin_recp,	ESTs	8.3
))		AW449211		SS	GDNF family receptor alpha 1	8.2
		M81057	He 180884	SS,Zn_carbOpept,Propep_M14,SS,Propep_N	114carboxypeptidase B1 (tissue)	8.2
		AA280627		SS,cpn10	ESTs	8.2
				SS,TGF-beta,TGFb_propeptide,SS	transforming growth factor, beta 2	8.2
40		AW885727		SS,kazal,	ESTs	8.1
		AW419196		SS ·	hypothetical protein FLJ13782	8.1
		AW248508		SS	Homo saplens cDNA FLJ14035 fis, clone HE	8.0
	404347			SS	Target Exon	8.0
		AA743991		TM	gb:ny57g01.s1 NCI_CGAP_Pr18 Homo sapiens	8.0
45	421373	AA808229	Hs.167771	,SS,IMPDH_C,IMPDH_N,CBS	ESTs	8.0
		NM_016010		SS	CGI-62 protein	7.9
	453310	X70697	Hs.553	TM,SNF,SS,TM,SNF.	solute carrier family 6 (neurotransmitte	7.9
			Hs.190368	,SS,TM	ESTs	7.8
	407771	AL138272	Hs.62713	,TM,cpn60_TCP1,Sema,	ESTs	7.8
50	443646	AI085198	Hs.164226	,TSPN,vwc,tsp_1,EGF,thiored,	ESTs	7.8
	446142	AI754693	Hs.145968	,TM,cadherin,Cadherin_C_term,	ESTs -	7.7
	444649	AW207523	Hs.197628	,SS,rm,	ESTs	7.6
	435147	AL133731	Hs.4774	,TM,SDF,UPAR_LY6,	Homo sapiens mRNA; cDNA DKFZp761C1712 (f	7.6
	439138	A1742605	Hs.193696	TM	ESTs	7.6
55		AW207206		SS	ESTs	7.6
	428804	AK000713	Hs.193736	,SS,UDPGT	hypothetical protein FLJ20706	7.5
		AL031224		SS,SS	transcription factor AP-2 beta (activati	7.5
		R41396	Hs.101774	SS .	hypothetical protein FLJ23045	7.5
		AA157291		SS	ubinuclein 1	7.5
60			Hs.79136	SS,TM,TM	LIV-1 protein, estrogen regulated	7.5
		AW378065		,SS,Pep_M12B_propep,Reprolysin,tsp_1,	ESTs	7.4
			Hs.31297	,SS,TM	duodenal cytochrome b	7.4
			Hs.8895	SS_TM,disintegrin,Pep_M12B_propep,Repro		7.3
<i>c</i> =		U22376	Hs.1334	SS,NA,myb_DNA-binding	v-myb avian myeloblastosis viral oncogen	7.3
65		R43646	Hs.12422	SS	ESTs	7.2
		L32137	Hs.1584	SS,EGF,tsp_3,SS,E2F_TDP,	cartilage oligomeric matrix protein (COM	7.2
	418004	U37519	Hs.87539	SS,aldedh,SS,aldedh,	aldehyde dehydrogenase 3 family, member	7.2

	426451	Al908165	He 160046	SS,GATA,	GATA-binding protein 3 (T-cell receptor	7,1
		H39960	Hs.288467	,SS,LRR	Homo sapiens cDNA FLJ12280 fis, clone MA	7.1
		Al198719		SS	ESTs	7.1
			Hs.64311	,TM,disIntegrin,Reprotysin,	a disintegrin and metalloproteinase doma	7.1
5	433138	AB029496	Hs.59729	SS,ig,Sema,SS,Sema,efhand	semaphorin sem2	7.0
		AA102670	Hs.70725	SS,TM,SS,TM	gamma-aminobutyric acid (GABA) A recepto	7.0
	409079	W87707	Hs.82065	,TM,fn3,	Interleukin 6 signal transducer (gp130,	7.0
		X63578	Hs.295449	SS,efhand,SS,efhand,ras	parvalbumin	7.0
10			Hs.287820	,SS,fn3,fn1,fn2,fn2,fn1	fibronectin 1	6.9
10		AK001741	Hs.8739	WD40,SS	hypothetical protein FLJ10879	6.9
		AF026942	11 4	,TM,IBR	gb:Homo sapiens dg33 mRNA, partial sequ	6.8
		AF077345	Hs.177936	SS,lectin_c,SS	ESTS	6.8
		AW803341		SS -20.00 IOE -40.10E -20.10E -40.10E	gb:IL2-UM0079-090300-050-D03 UM0079 Homo	6.7
15	401045	C11001993		ICE_p20,SS,ICE_p10,ICE_p20,ICE_p10,ICE    INP_033938.1  c	6.7	
13	418986	Al123555		,SS,Reprolysin,Isp_1,	ESTs	6.7
		R41823	Hs.7413	,TM,EPH_lbd,pkinase,SAM,fn3,	ESTs; calsyntenin-2	6.7
		AA243837		SS SS	ESTs	6.6
		A1655499		,TM,Activin_recp,pkinase,death,ZU5,	ESTs	6.6
20			Hs.325823	SS,TM,CD36	ESTs, Moderately similar to ALU5_HUMAN A	6.6
		BE387335		,SS,mito_carr	ESTs, Weakly similar to S64054 hypotheti	6.6
	404091	NA		,TM,7tm_3,ANF_receptor,	Target Exon	6.6
		AW067903		SS,Collagen,COLFI,TSPN,SS,TSPN	collagen, type XI, alpha 1	6.6
25		AL135623		SS,SS	KIAA0575 gene product	6.5
25				,SS,Ribosomal_S4e	transcription factor AP-2 gamma (activat	6.4
		AW067800	11. 30000	SS	stanniocalcin 2	6.2
		NM_005025	HS.78589	,SS,serpin, SS,TM,ig,SS,TM ,SS,kinestin, ,SS,lg,Sema,pkinase, SS TM 62	serine (or cysteine) proteinase inhibito	6.2
		AI815601 AA219691	HS./919/	SS, IM,IG,SS, IM	CD83 antigen (activated B lymphocytes, i	6.2 6.2
30		AW167087	He 131563	,30,kulesui, CS in Sama nkinasa	RAB6 interacting, kinesin-like (rabkines ESTs	6.2
50		AA026880	Hs 25252	,SS,TM,fn3,	protactin receptor	6.1
					DKFZP434G032 protein	6.1
			Hs.256972		ESTs	6.1
			Hs.184572		cell division cycle 2, G1 to S and G2 to	6.1
35	400300			,SS,TM,pkinase,Recep_L_domain,SH2,PH,Fu		6.1
	433404	T32982	Hs.102720	SS	ESTs	6.1
		U94362	Hs.58589	Glyco_transf_8,SS	glycogenin 2	6.1
	401781			,SS,filament,Pribosyltran,filament,Armad	Target Exon	6.1
40		NM_012093	3Hs.18268	SS,adenylatekinase,	adenylate kinase 5	6.1
40	402230		VII- 0470	,SS,TM,p450,	Target Exon	6.1
		NM_003528		histone, SS, histone,	H2B histone family, member Q	6.1
		AI249368 BE550224		,SS,TM SS	ESTs - metallothionein 1E (functional)	6.0 6.0
				SS,IL6,IL6,	interleukin 6 (interferon, beta 2)	6.0
45				,SS,TM	solute carrier family 16 (monocarboxylic	6.0
.5		AI793257		,SS,zf-C2H2,	ESTs	5.8
	424687			SS,Peptidase_M10,fn2,hemopexin,SS,TM,Pe		5.8
		AI823951		SS	tollold-like 1	5.8
	421296	NM_002666	Hs.103253	SS	perilipin	5.8
50		AW664964		,SS,TM	ESTs	5.7
		AA242758		,SS,TM	LIV-1 protein, estrogen regulated	5.7
		AB020689			KIAA0882 protein	5.7
		AI199738	Hs.208275	SS	ESTs, Weakly similar to ALUA_HUMAN !!!!	5.7
55				SS,Peptidase_M10,hemopexin,SS,Peptidase		5.6
23		AA904244	HS.153205	TM	ESTs	5.6
	400286 446466			SS,TM,ABC_tran,ABC_membrane,SS arrestin,SS	C16000922:gij7499103 pir jT20903 hypothe arrestin 3, retinal (X-arrestin)	5.6 5.5
		NM_000163		SS,TM,fn3,SS	growth hormone receptor	5.5
				SS	lymphold nuclear protein (LAF-4) mRNA	5.5
60		AF086332		,SS,TM,Syntaxin	ESTs	5.4
		NM_005940		SS,Peptidase_M10,hemopexin,SS	matrix metalloproteinase 11 (MMP11; stro	5.4
		NM_001898		,SS,cystatin,	cystatin SN	5.4
	425292	NM_005824	Hs.155545	SS	37 kDa leucine-rich repeat (LRR) protein	5.4
	448045	AJ297436	Hs.20166	,SS,TM	prostate stem cell antigen	5.4
65		AF153330		,SS,TM	solute carrier family 19 (thiamine trans	5.3
		AL355715		SS	programmed cell death 9	5.3
	439310	AF086120	Hs.102793	,SS,TM,UDPGT,casein_kappa	ESTs	5.2
				307	•	
				307		

		A1806867	Hs.126594	,SS,TM,Phosphodiest,	ESTs	5.2
		N54926	Hs.29202	TM,7tm_1,TM	G protein-coupled receptor 34	5.2
		M31659	Hs.180408	SS	solute carrier family 25 (mitochondrial	5.2
_		AW749855		,SS,TM,HECT	gb:QV4-BT0534-281299-053-c05 BT0534 Homo	5.2
5	429353	AL117406	Hs.200102	,SS,TM,ABC_tran,ABC_membrane,	ATP-binding cassette transporter MRP8	5.1
	441690	R81733	Hs.33106	,SS,HECT, zf-UBR1,PABP,14-3-3,	ESTs	5.1
	430447	W17064	Hs.332848	SS	SWI/SNF related, matrix associated, acti	5.1
	429698	A1685086	Hs.26339	,SS,ras,	ESTs, Weakly similar to S21348 probable	5.1
	425325	X52730	Hs.1892	SS,NNMT_PNMT_TEMT,SS,NNMT_PNMT_		
10		phenylethar	notamine N-met		5.1	
	423600			ŚS	ESTs	5.1
	414737	Al160386		SS	ESTs	5.1
	403593			,CIDE-N,pkinase	Target Exon	5.1
		D50915	Hs.38365	SS,SS	KIAA0125 gene product	5.0
15		AW137636		,SS,TM	ESTs	5.0
		NM_000169		SS,Melibiase,BTK,PH,pkinase,SH2,SH3,Ribo		4.9
		NM_01458		SS, lipocalin, SS, lipocalin	odorant-binding protein 2A	4.9
		W88559	Hs.1787	,TM,ion_trans,K_tetra,	proteolipid protein 1 (Pelizaeus-Merzbac	4.9
		AA206186		SS,TM,TM	monocyte to macrophage differentiation-a	4.9
20	401093	741200100	113.1 3003	TMLRRCT,TM,LRRCT,	C12000586*:gi]6330167 db  BAA86477.1  (A	4.9
20		U80034	Hs.68583	Peptidase_M3,	mitochondrial intermediate peptidase	4.9
		AW085961		SS	ESTs .	4.9
		AI247716			ESTs .	4.9
				,SS,adh_zinc, SS,DPPIV_N_term,Peptidase_S9,SS,DPPIV_		
25		NM_004460		· · · ·		4.9
25		AA641836		,SS,trypsin	hypothetical protein FLJ23186	4.9
		AI215069		SS	ESTs	4.8
		AF012023		,SS,14-3-3	integrin cytoplasmic domain-associated p	4.8
			Hs.105938	SS,transferrin,7tm_1,transferrin,	lactotransferrin	4.8
20	403199			SS,TM,Folate_carrier,SS,TM,Folate_carrie	NM_025243*:Homo saplens solute carrier f	4.8
30		AW057736		,SS,TM,pkinase,Recep_L_domain,SH2,PH,F		4.8
		AF070526		,SS,Ca_channel_B,	Homo sapiens clone 24787 mRNA sequence	4.7
		M93221	Hs.75182	SS,TM,lectin_c,fn2,Ricin_B_lectin,SS,TM	mannose receptor, C type 1	4.7
		AA526235		SS	Homo saplens cDNA FLJ11983 fis, clone HE	4.7
25		BE093589		SS	hypothetical protein FLJ23468	4.6
35		AA447453		,SS,TM,7tm_1,	Homo sapiens mRNA; cDNA DKFZp586M0723 (I	4.6
		AW016669		,SS,TM,CBS,voltage_CLC	ESTs	4.6
		A1668605		,TM,Glyco_hydro_1	ESTs, Moderately similar to ALU6_HUMAN A	4.6
		AA687376		,SS,pkinase,RhoGEF,lg,PH,SH3,	ESTs	4.6
40		AA339449		AIRS,formyl_transf,GARS,SS,GARS,AIRS,for		4.6
40		AI860021		,pkinase	ESTs, Moderately similar to A47582 B-cel	4.6
		AA151342		SS,UPF0099,SS,UPF0099,	CGI-147 protein	4.6
		BE614743		,SS,TM,MAPEG,	prostaglandin E synthase	4.5
		A1493046	Hs.146133	,SS,TM,UDPGT	ESTs	4.5
		H26735	Hs.91668	,SS,TM,PH,SH2,Furin-like,pkinase,Recep_L	Homo sapiens done PP1498 unknown mRNA	4.5
45	434674	AA831879	Hs.136985	,SS,Hist_deacetyl,	ESTs ·	4.5
	419986	A1345455	Hs.78915	pkinase,OPR,	GA-binding protein transcription factor,	4.5
	421582	Al910275	Hs.1406	SS,trefoil,SS,TM,Idl_recept_a,SRCR,tryps	trefoil factor 1 (pS2)	4.5
•	410361	BE391804	Hs.62661	SS,TM,GBP,TM,GBP	guanylate binding protein 1, Interferon-	4.5
	426327	W03242	Hs.44898	SS	Homo sapiens clone TCCCTA00151 mRNA sequ	4.5
50	406639	M97711		SS,SS,ig,	gb:Human T-cell receptor (V beta 18.1, J	4.5
	452834	AI638627	Hs.105685	,SS,DEAD,Fork_head	KIAA1688 protein	4.5
	427315	AA179949	Hs.175563	SS	Homo sapiens mRNA; cDNA DKFZp564N0763 (f	4.4
	446733	AA863360	Hs.26040	,SS,TM,p450,	ESTs, Weakly similar to fatty acid omega	4.4
	442118	AA976718	Hs.202242	,ig,Sema,	ESTs	4.4
55	421524	AA312082	Hs.105445	SS	GDNF family receptor alpha 1	4.4
	453060	AW294092	Hs.21594	,SS,ras,Y_phosphatase,ras	hypothetical protein MGC15754	4.4
		BE466639		,SS,HMG_box,filament,	Homo sapiens cDNA FLJ13591 fis, clone PL	4.4
		AK000136		SS,LRR,SS	asportn (LRR class 1)	4.4
		H87648	Hs.33922	SS	Homo saplens, clone MGC:9084, mRNA, comp	4.3
60		NM_000248		SS,LRR,	MHC class II transactivator	4.3
		A1472078		"SS,ArfGap,	ESTs	4.3
		AW935490		,SS,BIR	Human chromosome 5q13.1 clone 5G8 mRNA	4.3
		D45371	Hs.80485	SS,C1q,Collagen,SS,C1q,	adipose most abundant gene transcript 1	4.3
		AW296927		,SS,TM,Peptidase_M1,	gb:UI-H-BW0-aic-c-07-0-UI.s1 NCI_CGAP_Su	4.3
65	418867		Hs.89404	SS,homeobox,homeobox,	msh (Drosophila) homeo box homolog 2	4.3
		BE464288		,SS,TM,MIP,	ESTS	4.3
		AW262580		,SS,TM,cadherin,cadherin	protocadherin beta 16	4.3
	111, 700	,		,	protoculation total 19	7.0

	441560 F13386 Hs.7888	,pkinase,	Homo saplens done 23736 mRNA sequence	4.3
	409064 AA062954 Hs.141883	,SS,CUB,	ESTs	4.3
	422667 H25642 Hs.133471	,SS,TM,FMO-like	ESTs	4.3
	454032 W31790 Hs.194293	,SS,TM	ESTs, Wealdy similar to 154374 gene NF2	4.3
5	432663 Al984317 Hs.122589	TM	ESTs	4.3
	401747	,SS,filament,filament	Homo sapiens keratin 17 (KRT17)	4.3
	432882 NM_013257Hs.279696	pkinase,pkinase_C,	serum/glucocorticoid regulated kinase-li	4.2
	437036 Al571514 Hs.133022	SS,TM	ESTs	4.2
	447754 AW073310 Hs.163533	pkinase,	Homo saplens cDNA FLJ14142 fis, done MA	4.2
10	443194 AI954968 Hs.279009	,SS,TM	matrix Gla protein	4.2
	451871 AI821005 Hs.118599	,SS,GDNF,	ESTs	4.2
	457211 AW972565 Hs.32399	WH1,WH1	ESTs, Weakly similar to S51797 vasodilat	4.2
	421566 NM_000399Hs.1395	zf-C2H2,SS	early growth response 2 (Krox-20 (Drosop	4.2
	431657 Al345227 Hs.105448	SS,TM,pkinase	ESTs, Weakly similar to B34087 hypotheti	4.1
15	427899 AA829286 Hs.332053	,SS,SAA_proteins,ABC_membrane,ABC_tran		4.1
13	444779 Al192105 Hs.147170	SS	ESTs	4.1
	442295 A1827248 Hs.224398	,COLFI,vwc,Collagen,	Homo sapiens cDNA FLJ11469 fis, clone HE	4.1
			wingless-type MMTV integration site fami	4.1
	436396 Al683487 Hs.152213	,wnt,	ESTs	4.1
20	446039 Al150491 Hs.90756	,TM,Glyco_hydro_1		4.1
20	422938 NM_001809Hs.1594	,SS,TM,thiolase, SS,TM,Desaturase,SS	centromere protein A (17kD) gb:stearoyl-CoA desaturase [human, adlpo	4.1
	406922 \$70284			4.1
	439285 AL133916 Hs.172572	,SS,ig,pklnase,LRRNT,LRRCT,	hypothetical protein FLJ20093	4.1
	424800 AL035588 Hs.153203	HLH,SS	MyoD family inhibitor	
25	429922 Z97630 Hs.226117	,SS,TM,linker_histone,7tm_1	H1 histone family, member 0	4.1
25	447178 AW594641 Hs.192417	,SS,TM	ESTs	4.0
	409038 T97490 Hs.50002	SS,IL8,SS,IL8	small Inducible cytokine subfamily A (Cy	4.0
	452747 BE153855 Hs.61460	,SS,HLH	ig superfamily receptor LNIR	4.0
	420139 NM_005357Hs.95351	,SS,TM,p450,	lipase, hormone-sensitive	4.0
0.0	408877 AA479033 Hs.130315	,SS,TM	ESTs, Weakly similar to A47582 B-cell gr	4.0
30	403329 NA	SS,SS	Target Exon	4.0
	439926 AW014875 Hs.137007	SS	ESTs	4.0
	430832 Al073913 Hs.100686	SS	ESTs, Weakly similar to JE0350 Anterior	4.0
	432481 AW451645 Hs.151504	,SS,Collagen,COLFI,TSPN,	Homo sapiens cDNA FLJ11973 fis, clone HE	4.0
	452410 AL133619 Hs.29383	,SS,TM,ras	Homo sapiens mRNA; cDNA DKFZp434E2321 (f	4.0
35	418661 NM_001949Hs.1189	SS	E2F transcription factor 3	4.0
	431958 X63629 Hs.2877	SS,TM,Cadherin_C_term,cadherin,SS,TM,cad	dcadherin 3, type 1, P-cadherin (placenta	4.0
	425071 NM_013989Hs.154424	SS,T4_delodinase,T4_deiodinase,	deiodinase, iodothyronine, type II	4.0
	447197 R36075	,TM,SDF,	gb:yh88b01.s1 Soares placenta Nb2HP Homo	4.0
	428722 U76456 Hs.190787	,SS,TIMP,	tissue inhibitor of metalloproteinase 4	3.9
40	428330 L22524 Hs.2256	SS,Peptidase_M10,SS,Peptidase_M10,hemo	pematrix metalloproteinase 7 (MMP7; uterin	3.9
	423242 AL039402 Hs.125783	SS	DEME-6 protein	3.9
•	449048 Z45051 Hs.22920	SS,SS,TM	similar to \$68401 (cattle) glucose induc	3.9
	414831 M31158 Hs.77439	,SS,cNMP_binding,Rlla,HMG_box	protein kinase, cAMP-dependent, regulato	3.9
	413589 AW452631 Hs.313803	,SS,abhydrolase	ESTs, Highly similar to AF157833 1 noncl	3.8
45	408875 NM_015434Hs.48604	SS	DKFZP434B168 protein	3.8
	418629 BE247550 Hs.86859	SS,SH2,PH,SS,TM,PH,SH2,Furin-like,pkinas		3.8
	450787 AB006190 Hs.25475	SS,TM,MIP,SS,TM,MIP,	aquaporin 7	3.8
	414870 N72264 Hs.300670	SS	KIAA1204 protein	3.8
	450325 Al935962 Hs.26289	SS	ESTs	3.8
50	407633 NM_007069Hs.37189	TM,TM	similar to rat HREV107	3.8
• •	426172 AA371307 Hs.125056	,SS,DENN	ESTs	3.8
	442262 BE170651 Hs.8700	,SS,START,	deleted in liver cancer 1	3.8
	427961 AW293165 Hs.143134	SS	ESTs	3.8
	445563 AW873606 Hs.149006	,SS,WH1,WH1	ESTs	3.8
55	403943	p450,SS,p450	C5000355:gi 4503225 ref NP_000765.1  cyt	3.8
55	408761 AA057264 Hs.238936	,SS,TM,7tm_1,	ESTs, Weakly similar to (defline not ava	3.8
	-423279 AW959861 Hs.290943	SS S	ESTs	· 3.8
	420440 NM_002407Hs.97644	,SS,SRCR,Uteroglobin	mammaglobin 2 (MGB2; mammaglobin B; lip	3.8
	445107 Al208121 Hs.147313	,SS,TM	ESTs, Weakly similar to 138022 hypotheti	3.7
60			regulator of G-protein signalling 16	3.7
UU	428303 AW974476 Hs.183601	SS,RGS,RGS,RGS TM	gb:QV1-HT0413-010200-059-h03 HT0413 Homo	3.7
	411667 BE160198 427809 M26380 Hs.180878			3.7 3.7
	427809 M26380 Hs.180878 418203 X54942 Hs.83758	,SS,lipase,PLAT,Sec7,PH, CKS,SS,CKS.	lipoprotein lipase CDC28 protein kinase 2	3.7 3.7
	430376 AW292053 Hs.12532	SS	chromosome 1 open reading frame 21	3.7
65	444190 Al878918 Hs.10526	SS	cysteine and glycine-rich protein 2	3.7 3.7
05				3.7 3.7
	433495 AW373784 Hs.71	SS,lg,MHC_I,connexin,SCAN,SS,TM	alpha-2-glycoprotein 1, zinc	3.7
	429638 AI916662 Hs.211577	SS,TM,SS	kinectin 1 (kinesin receptor)	3.1

	454071 Al041793 Hs.42502	,TM,7tm_1,	ESTS	3.7
	451859 H44491 Hs.252938		ESTs, Weakly similar to ALU1_HUMAN ALU S	3.7
	420281 Al623693 Hs.191533	,SS,AAA,	ESTs	3.7
_	427691 AW194426 Hs.20726	,SS,Glycos_transt_2,	ESTs	3.7
5	428824 W23624 Hs.173059	SS	ESTs	3.7
	424676 Y08565 Hs.151678	Glycos_transf_2,Ricin_B_lectin,SS,Glycos	UDP-N-acetyl-alpha-D-galactosamine:polyp	3.7
	418026 BE379727 Hs.83213	lipocalin, SS, lipocalin, lipocalin, ferriti	fatty acld binding protein 4, adipocyte	3.7
	457465 AW301344 Hs.122908	,SS,Pribosyltran,Sulfatase	DNA replication factor	3.7
	417601 NM_014735Hs.82292	PHD,pkinase,SS	KIAA0215 gene product	3.7
10	407999 Al126271 Hs.49433	SS	ESTs, Wealdy similar to YZ28_HUMAN HYPOT	3.7
	425548 AA890023 Hs.1906	SS,TM,fn3,SS,TM,fn3,	prolactin receptor	3.7
	446619 AU076643 Hs.313	,SS,TM,elhand,ion_trans	secreted phosphoprotein 1 (osteopontin,	3.7
	411213 AA676939 Hs.69285	SS,TM,CUB,F5_F8_type_C,MAM,SS,TM,CU		3.6
	406625 Y13647 Hs.119597	SS,TM,Desaturase,SS	stearoyi-CoA desaturase (delta-9-desatur	3.6
15	417511 AL049176 Hs.82223	SS	chordin-like	3.6
13			ESTs	3.6
	428769 AW207175 Hs.106771	,SS,7tm_1,SPRY,		
	407137 T97307	,SS,TM,GDA1_CD39	gb:ye53h05.s1 Soares fetal liver spleen	3.6
	401866	,SS,filament,	Target Exon	3.6
••	451195 U10492 Hs.438	SS,homeobox,Ets,SS,homeobox,	mesenchyme homeo box 1	3.6
20	426044 AA502490 Hs.336695	SS	ESTs	3.6
	426310 NM_000909Hs.169266	SS,TM,7tm_1,	neuropeptide Y receptor Y1	3.6
	440029 AW089705 Hs.293711	SS	ESTs, Weakly similar to S64329 probable	3.6
	408573 AA284775 Hs.43148	,SS,TM,PMP22_Claudin,	ESTs	3.6
	431830 Y16645 Hs.271387	,SS,TM,IL8	small inducible cytokine subfamily A (Cy	3.6
25	444781 NM_014400Hs.11950	,SS,PH,lactamase_B	GPI-anchored metastasis-associated prote	3.6
	431493 AI791493 Hs.129873	,SS,p450,p450	ESTs, Weakly similar to A36036 cytochrom	3.6
	414175 Al308876 Hs.103849	,TM,hemopexin,Peptidase_M10,hemopexin,I		3.6
	411789 AF245505 Hs.72157	ig,LRRCT,	DKFZP56411922 protein	3.6
	418851 Al417828 Hs.192435	SS,TM	ESTs	3.5
30	453968 AA847843 Hs.62711	SS,HMG_box,	Homo sapiens, clone IMAGE:3351295, mRNA	3.5
50	407104 S57296 Hs.323910	SS,TM,SH2,PH,pkinase,Recep_L_domain,F	Funcarb.h2 avian and hmhlastic loukemia v	3.5
	449051 AW961400 Hs.333526	SS	HER2 receptor tyrosine kinase (c-erb-b2,	3.5
				3.5
	434398 AA121098 Hs.3838	pkinase,POLO_box,SS,pkinase,POLO_box,		3.5
25	454042 H22570 Hs.172572	,SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	
35	459496 AA808940 Hs.274450	,SS,TM,KRAB,SCAN,zf-C2H2,ig	EST	3.5
	414998 NM_002543Hs.77729	,SS,TM	oxidised low density lipoprotein (lectin	3.5
	407756 AA116021 Hs.38260	SS,UCH-1,UCH-2,SS,TM,G_glu_transpept	ubiquitin specific protease 18	3.5
	442101 Al651930 Hs.135684	\$S	ESTs	3.5
4.0	449722 BE280074 Hs.23960	cyclin,SS,TM,cyclin,	cyclin B1	3.5
40	452554 AW452434 Hs.58006	SS	ESTs, Weakly similar to ALU5_HUMAN ALU S	3.5
	421991 NM_014918Hs.110488	SS ·	KIAA0990 protein	3.4
	420058 AK001423 Hs.94694	SS	Homo sapiens cDNA FLJ10561 (is, clone NT	3.4
	425776 U25128 Hs.159499	SS,TM,7tm_2,SS,TM,7tm_2	parathyroid hormone receptor 2	3.4
	407846 AA426202 Hs.40403	,TM,ABC_membrane,ABC_tran,Ribosomal_	S4eCbp/p300-interacting transactivator, wit	3.4
45	406925 L34041 Hs.9739		PEglycerol-3-phosphate dehydrogenase 1 (so	3.4
	445873 AA250970 Hs.251946	SS,rrm,PABP,pkinase,14-3-3,rrm	poly(A)-binding protein, cytoplasmic 1-1	3.4
	418054 NM_002318Hs.83354	,SS,TM,mito_carr,Lysyl_oxidase	lysyl oxidase-like 2	3.4
	414921 BE390551 Hs.77628	SS,START,SS,START,NNMT_PNMT_TEMT	stemidonenic acute regulatory protein r	3.4
	452268 NM_003512Hs.28777	SS,histone,Calc_CGRP_IAPP,lg,MHC_I,SPI		3.4
50	428862 NM_000346Hs.2316	SS,HMG_box,	SRY (sex determining region Y)-box 9 (ca	3.4
50		histone,SS,histone,BolA	H2A histone family, member O	3.4
	412520 AA442324 Hs.795			3.4
	410530 M25809 Hs.64173	ATP-synt_ab,SS,7tm_1,ATP-synt_ab	ATPase, H transporting, lysosomal (vacuo NM_005557*:Homo sapiens keratin 16 (foca	3.4
	401780	filament,SS,filament,filament		
~~	447131 NM_004585Hs.17466	TM	retinoic acid receptor responder (tazaro	3.4
55	418334 AA319233 Hs.5521	,SS,TM,Ribosomal_L27e,	ESTs	3.4
	415138 C18356 Hs.295944	,Kunltz_BPTI,	tissue factor pathway inhibitor 2	3.4
	421168 AF182277 Hs.330780	SS,p450,SS	cytochrome P450, subfamily IIB (phenobar	3.4
	431473 AA825686 Hs.321176	SS	ESTs, Weakly similar to S65824 reverse t	3.4
_	421379 Y15221 Hs.103982	SS,IL8,	small inducible cytokine subfamily B (Cy	3.4
60	411984 NM_005419Hs.72988	SH2,STAT,SS,STAT	signal transducer and activator of trans	3.4
	408101 AW968504 Hs.123073	,pkinase,	CDC2-related protein kinase 7	3.4
	405366	RhoGEF,PH,SS,RhoGEF,PH,	NM_003371*:Homo sapiens vav 2 oncogene (	3.4
	414612 BE274552 Hs.76578	SAP,SS,FG-GAP,vwa	protein inhibitor of activated STAT3	3.4
	411393 AW797437 Hs.69771	SS,sushi,trypsin,vwa,rrm,fibrinogen_C,fn	B-factor, properdin	3.3
65	435767 H73505 Hs.117874	SS,Peptidase_S8,P,Peptidase_S8,P	ESTs	.3.3
-	416406 D86961 Hs.79299	SS,TM	lipoma HMGIC fusion partner-like 2	3.3
	433068 NM_006456Hs.288215	,SS,Pribosyltran,	sialyltransferase	3.3
	10000 14M_000400113.200213	tack uppalment		0.0

44562 AA37676 hz.286549 SS.SS hypothesical protein MSC3077 3 3 3 4 52077 AP (103027 hz.27455 SS profiled protein MSC3077 h					
452017 AF (108027 145-27495   SS   prostable cancer associated problem 7   33.3   33.3   33.4   34.7599   Mol 140528   Ha. 33.955   SS   47590   Mol 26258   Ha. 33555   SS   AFRICAN   Mol 270   Ha. 172914   43825   BEST   Mol 270   Ha. 172914   43825   BEST   Mol 270   Ha. 17293   SS. S. J. Maleshing		445462 AA378776 Hs.288649	SS,SS		3.3
409999 AV000725   1-50579   SS				B-cell CLL/lymphoma 11B (zinc finger pro	3.3
5 452106 Al141031 Hs.21342 47519 U46259 Hs.37236 47519 U46259 Hs.372365 Hs.37236 Hs.				prostate cancer associated protein 7	3.3
## 447519 U46258 H-339655   SS   SS   SS   A62959 A0709026   H-172294   SS   A62959 A0709026   H-172294   SS   A62959 A0709026   H-172294   SS   A611-A611-A709029   H-172294   SS   A611-A611-A709029   H-172294   SS   A611-A611-A709029   H-172294   SS   SS   M-172294   SS   A611-A611-A709029   H-172294   H-172294   SS   SS   SS   SS   SS   SS   SS	_			hypothetical protein FLJ20718	3.3
486926 BE37472 H-57995 SS,TM-SIND-RAMF_Drosphetics of Februal Geryllogensas 5 (11-cls and 9-d 3.3 414575 H11257 H-52968 SS,TM-SISHOR_AMF_Drosphetics of Februal Geryllogensas 5 (11-cls and 9-d 3.3 414575 H11257 H-52968 SS,Diprasselly, 1-10 S	)				
43825 BE337427 h5-79953   4147537 h11275 h 129529   525 Ministone,ANF peoploriguarylate, oy   417837 AL079905 hs.1103   42728 AV8981145   42826 AV8981145   42826 AV8981145   42826 AV8981145   42826 AV8981145   42826 AV82371 hs.164590   53.SS,SE,Dipopeptide,TGF-bela,SS   42826 AV82371 hs.164590   53.SS,SE,Dipopeptide,TGF-bela,SS   42826 AV82373 hs.164590   53.SS,SE,Dipopeptide,TGF-bela,SS   42826 AV82373 hs.164590   53.SS,SE,Dipopeptide,TGF-bela,SS   53.SS,SE,Dipopeptide,TGF-bela,SS   42826 AV82373 hs.164590   43226 AV82373 hs.164590   43226 AV82372 hs.159412   428501 AV82382 hs.159413   428501 AV82382 hs.159513   428501 AV82382 hs.159					
444575 H11257				retinol dehydrogenase 5 (11-cis and 9-ci	
47737 AUGUSTO H.S.1703 42728 AUR881145 S. S				ESTs	
42997   AV2317   Hs.172635   S.S.S. Jpoxygenase.PLAT   S.T.	10			Homo saplens clone IMAGE:451939, mRNA se	
44994   A26737   Hs.172636   SS,SS,Dovygenase,PLAT   EST   SS   A4995   A161239   Hs.280380   SS,SS,Pepidase_M1,EGF.lg.Jectin_c,sush   A4997   A16796152   Hs.19491   SS,SS,Pepidase_M1,EGF.lg.Jectin_c,sush   A4997   A16796152   Hs.19491   SS,SS,TM,Tm_1   Horno saplers and cone 24628 mRNA sequence   A4922   A2674   A167252   Hs.19412   SS,TM,Tm_1   Horno saplers and cone 24628 mRNA sequence   A4922   A2674   A167428   Hs.17876   SS,ST,M,Tm_1   Horno saplers and cone 24628 mRNA sequence   A4998   A4998   A16742   Hs.17876   A199983   Hs.57664   A2886   A.197286   Hs.13339   SS,TM,Tm,Tm,TeMT,TeMT,TeMT,TeMT,TeMT,TeMT,	10				
44954   Alfe 1334   Alfe 1346   Alfe 134			* -	gb:QV0-OT0033-010400-182-a07 OT0033 Homo	
44454   Alfici23   https://doi.org/10.1009/1					
15   45956   Als94736   Hs.134981   SS			• • • • • • • • • • • • • • • • • • • •		
425741   AF052152   1s.159412   "pkinase,   Homo saplens clone 24628 mRNA sequence   33	1.5				
455501 AW043762 Hs.293616 SS ESTS, Weakly similar to AF208855 BM-01 33 4528 Z42047 Hs.283978 SS, TM, Tm, 1 Homo sapiens PROZ751 mRNA, complete cds yas yas youthly be transmembrane protein 33 yudalive transmembrane protein 33 43750 AL39003 Hs.27664 Hs.13448 SS, TM, TM, TM, TM, TM, TM, TM, TM, TM, TM	13				
485698 AA502764 Ist.123469 SS ESTS, Weakly similar to AF208655 BNA-01 33 34242 242047 Hz.23378 SS,TM,Tm.1 Homo saplens PROZ751 mRNA, complete ods 419752 BE314524 Ist.37876 Hs.78776 TM public description of the complete ods 419750 AL359053 Hs.78767 SS, Pepidase_M1, Target 133 32 1439750 AL359053 Hs.78767 SS, Pepidase_M1, Target 1439750 AL359053 Hs.133483 SS,TM Homo saplens mRNA full length insert cDN 33 42888 AA82777 Hs.334833 SS,TMT Hm. Homo saplens mRNA full length insert cDN 33 42888 AA82777 Hs.334833 SS,TART.NIMIT_PNMT_TEMT, ESTS 42888 AA82777 Hs.334833 SS,TMT MS 147433 BE270265 Hs.812128 SS,TMT,Tm.33NF_receptor,sushi 24988 AA82777 Hs.324930 SS,TMT,Tm.33NF_receptor,sushi 249841 AB49413 Hs.126274 SS,TM_TRRT_TMLRRT,TMLRRT_TMLRRT_TMLRRT_TMLRRT_TMLRT_TM					
434228 242047 H. 233376 434767 BE345324 H. 57876 H. S. 776764 A. 19750 BE34532 H. 57664 A. 19750 BE34532 H. 57664 A. 19750 BE34532 H. 57664 A. 19750 BE3453 H. 57664 A. 19750 BE3553 BE. 3766 A. 19750 BE. 197					
41752 BE314524 ks.78776 TM putative transmembrane protein 33 and 4014 APG84545 SS.Pepidase, M1, 23858 AL13286 ks.133483 SS.TM Homo saplens mRNA full length insert cDN 33 are specified to the specific protein specified to the specific protein specified protein specified specified protein specified specified protein specifie					
400419 AF084545 43975 AL39053 H.57664 43288 AL37328 H.513348 42861 AW22865 H.5133483 42861 AW22865 H.5133483 5S.TM 42861 AW22865 H.5133483 5S.TM 43883 AL37378 H.52785 42888 AA52777 H.5334383 5S.TM 43883 AL37278 H.529109 5Sena.ig. 41743 BEZ70265 H.5.82128 452194 Al89417 J.529109 44061 M.8373 H.510247 42004 AW015140 H.516723 42004 AW015140 H.516724 42004 AW01540 H.516724 4	20			Homo sapiens PRO2751 mRNA, complete cds	
439750 AL399505 Hs.57664 . T.M.Integrin g.Ricin_B.Jectin,rm	20			putative transmembrane protein	
42368 AL137326 Hs.132438   SS,TM   Homo sapiens mRNA; cDNA DKFZPA34B0660 (f   3.3   42868   AW23661 Hs.193139   SS,START,NNMT_PNMT_TEMT,   ESTS   STS   428688   AA852773   Hs.334838   SS,TM,TM   Sema,ig,   Sema,ig,   SSTM_TRANSMT_PNMT_TEMT,   SST   START,NNMT_PNMT_TEMT,   STS   STS   A4888   Y0976   Hs.22762   SS,TM_TRANSMT_PNMT_TEMT,   SST   STS   START,NNMT_PNMT_TEMT,   SST   A4888   Y0976   Hs.22762   SS,TM_TRANSMT_PNMT_TEMT,   SST   STS   STS					
428514 AW29761 Hs.193139   SS,STARTANNT_PNMT_TEMT,			,TM,integrin_B,Ricin_B_lectin,rrm	Homo sapiens mRNA full length insert cDN	
Add			,SS,TM	Homo sapiens mRNA; cDNA DKFZp434B0650 (f	
Has	25		,SS,START,NNMT_PNMT_TEMT,	ESTs	3.3
432072 NG2937	25				
417433 BEZ70266					
432194   Al894413   Hs. 312649   SS,TM,Trm_3,ANF_receptor,sushi   Additional Network   SS, Si, Si, Si, Si, Si, Si, Si, Si, Si,					
30					
420042 AW015140 Hs.161723   SS_CIB_R   FST   Sypothetical protein FLJ14251   32   457292   A1921270 Hs.334882   SS_TM_SS_TM_G-patch   SS_CIB_R   SS_TM_SS_TM_G-patch   SS_CIB_R   SS_TM_SS_TM_G-patch   SS_CIB_R   SS_TM_SS_TM_G-patch   SS_CIB_R   SS_TM_ST_TM_G-patch   SS_TM_ST_TM_G-patch   SS_TM_ST_TM_G-patch   SS_TM_ST_TM_G-patch   SS_TM_ST_TM_G-patch   SS_TM_ST_TM_G-patch   SS_TM_ST_TM_G-patch   SS_TM_ST_TM_G-patch   SS_TM_ST_TM_G-patch   SS_TM_ST_TM_G-patc	20				
457292 Algorithms	30				
421458   MM_003654 Hs, 104576   Schma, ig,   Schmopbox,   A49767   BE562136   Hs, 9736   Hs, 9737   Hs, 9736   Hs, 9737				— T 1	
41104 AW970859 Hs. 313503   Sema jg   ESTs   S2					
43767   BE562138   Hs.9736   Hs.201925   F.GF.   F.GF.   Homo saplens (DNA FLJ13446 fis, chone PL   3.2   Homo saplens GNA FLJ13446 fis, chone PL   413278   BE563085   Hs.833   Hs.201925   Hs.75517   Hs.75					
419589 AW973708 Hs.201925	25				
415447 Z97171	33				
43464 BE548446 Hs.5167 SS,TM,SSF,SS,TM Homo saplens mRNA; cDNA DKFZp434F152 (fr dystal) 43278 BE563085 Hs.833					
404 413278 BE563085 Hs.833					
40 413278 BE563085 Hs.833					
458451 AW297181 Hs.195922	40				
440449 AA885430 Hs.201925 413763 U17760 Hs.75517 A38876 AF160477 Hs.61460 438876 AF160477 Hs.61460 A38876 AF213457 Hs.44234 A15773 R21651 Hs.324725 A45404 AV658411 Hs.24234 ASS, Ig., SS, TM A58876 AF213457 Hs.44234 ASS, Ig., SS, TM A58877 R21651 Hs.324725 A45404 AV658411 Hs.242656 A50847 NM_003155Hs.25590 A50847 NM_003155Hs.25005 A50847 NM_003155Hs.25590 A50847 NM_0031	40				
413753 U17760 Hs.75517 434876 AF160477 Hs.61460 435575 AF213457 Hs.61460 435575 AF213457 Hs.61460 415773 R21651 Hs.324725 446440 AV658411 Hs.42656 450847 NM_003155Hs.25590 SS, Im.Ribosomal_S3Ae,G-gamma ESTs, Moderately similar to A47582 B-cel 3.2 426075 AW513891 Hs.270149 45210 T47667 Hs.28005 439963 AW247529 Hs.6793 TM,p450,Ets platelet-activating factor acetylhydrola 3.2 439963 AW247529 Hs.6793 TM,p450,Ets platelet-activating factor acetylhydrola 3.2 439451 AF086270 Hs.278554 413011 AW06811 Hs.9739 413011 AW06811 Hs.2930 413011 AW06811 Hs.2930 413011 AW06811 Hs.2930 429197 H24471 Hs.26930 43903 N30714 Hs.325960 407604 AW191962 Hs.29301 419092 J05581 Hs.89603 419092 J05581 Hs.89603 419092 J05581 Hs.89603 419092 J05581 Hs.114727 443171 BE281128 Hs.9030 45226 AK002016 Hs.114727 443171 BE281128 Hs.9030 45226 AK002016 Hs.114727 443171 BE281128 Hs.9030 45226 AK002016 Hs.114727 443171 BE281128 Hs.9030 55 M32201 Al538613 Hs.298241					
434876 AF160477 Hs.51460 ,SS,HLH				Homo saplens cDNA FLJ13446 fls, clone PL	
45					
415773 R21651 Hs.324725	15				
446440 AV658411 Hs.42656 450847 NM_003155Hs.25590 SS_homeobox, stanniocalcin 1 3.2 426075 AW513691 Hs.270149 SS_fn3, ESTs, Weakly similar to 2109260A B cell 3.2 426075 AW513691 Hs.270149 SS_fn3, ESTs, Weakly similar to 2109260A B cell 3.2 439963 AW247529 Hs.6793 TM_p450_Ets platelet-activating factor acetylhydrola 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 402837 NA SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 40284 NA STAN STAN STAN STAN SS_fn3, ESTS, Weakly similar to 2109260A B cell 3.2 40284 NA STAN STAN STAN STAN STAN STAN STAN S	43				
450847 NM_003155Hs_25590					
426075 AW513891 Hs.270149					
452110         T47667         Hs.28005         ,SS,TM,Activin_recp,pklnase         Homo sapiens cDNA FLJ11309 fls, clone PL         3.2           439963         AW247529         Hs.6793         ,TM,p450,Ets         platelet-activating factor acetylhydrola         3.2           439451         AF085270         Hs.278554         ,SS,Chromo_shadow,chromo,         ENSP00000241312*:DJ947L8.1.8 (novel Sush         3.2           40664         L34041         Hs.9739         ,SS,Chormo_shadow,chromo,         heterochromatin-like protein 1         3.1           55         417315         Al080042         Hs.336901         ,SS,RNA_pol_ARNA_pol_A2Ribosomal_S24e,ribosomal protein S24         3.1           413011         AW068115         Hs.821         SS,Connexin,hormone_rec_zf-C4,connexin         blglycan         3.1           414987         AA524394         Hs.294022         ,SS,connexin,hormone_rec_zf-C4,connexin         hypothetical protein FLJ14950         3.1           48030         N30714         Hs.325960         ,SS,TM,C1q,         ESTs, Weakly similar to T20272 hypotheti         3.1           407604         AW191962         Hs.249239         SS,TM,SEA,         mucin 1, tansmembrane         3.1           456672         AK002016         Hs.114727         ,SS,PK,PK         Homo sapiens cDNA FLJ10071 fis, clone HE         3.1<					
439963 AW247529 Hs.6793 ,TM,p450,Ets platelet-activating factor acetylhydrola 3.2 Av2837 NA	50				
402837 NA 439451 AF086270 Hs.278554 439451 AF086270 Hs.278554 406664 L34041 Hs.9739 417315 Al080042 Hs.336901 413011 AW068115 Hs.821 414987 AA524394 Hs.294022 429197 H24471 Hs.26930 448030 N30714 Hs.294022 429197 H24471 Hs.26930 407604 AW191962 Hs.249239 419092 J05581 Hs.89603 456672 AK002016 Hs.114727 443171 BEZ81128 Hs.9930 452256 AK000933 Hs.28661 452256 AK000931 Hs.28661 452256 AK000931 Hs.28661 452256 AK000931 Hs.298241 452250 AK002016 Hs.298241 452256 AK000931 Hs.28661 452256 AK000931 Hs.286613 452256 AK000931 Hs.28661 452256 AK000931 Hs.286613 452256 AK00	30				
439451 AF086270 Hs.278554 406668 L34041 Hs.9739 SS,Chromo_shadow,chromo, heterochromatin-like protein 1 3.1 406668 L34041 Hs.9739 SS,TM,transport_prot,SWIB,RhoGAP,DAG_PEglycerol-3-phosphate dehydrogenase 1 (so 3.1 413011 AW068115 Hs.821 SS,TRAL_RRNT,SS,LRRNT,LRR, 414987 AA524394 Hs.294022 429197 H24471 Hs.26930 SS,Connexin,hormone_rec_zt-C4,connexin hypothetical protein FLJ14950 3.1 48030 N30714 Hs.26930 SS,Connexin,hormone_rec_zt-C4,connexin hypothetical protein FLJ14950 3.1 ESTs, Weakly similar to T20272 hypotheti 3.1 48030 N30714 Hs.249239 SS,TM,C1q, collagen, type VIII, alpha 2 3.1 4159672 AK002016 Hs.114727 SS,TM,C1q, mucin 1, transmembrane 3.1 456672 AK002016 Hs.114727 SS,TM,C1q, Hs.243171 BE281128 Hs.9030 SS,TM,C1q, Hs.243171 BE281128 Hs.9030 SS,TM,C1q, Hs.243171 BE281128 Hs.9030 SS,TM,C1q, Hs.243171 Hs.28661 TM,GDI,Ttm_1, rrm,SS TONDU 3.1 452256 AK000933 Hs.28661 TM,GDI,Ttm_1, rrm,SS TONDU 3.1 452826 AK002016 Hs.245210 SS,TM,C1q, Transmembrane protease, serine 3 3.1 406642 AJ245210 SS				platelet-activating factor acetylhydrola	
406664   L34041   Hs.9739   SS,TM,transport_prot,SWIB,RhoGAP,DAG_PEgtycerol-3-phosphate dehydrogenase 1 (so   3.1				ENSP00000241312*:DJ947L8.1.8 (novel Sush	3.2
A17315 A1080042   Hs.336901   SS.RNA_pol_ARNA_pol_A2,Ribosomal_S24e,ribosomal protein S24				heterochromatin-like protein 1	
413011 AW068115 Hs.821 SS_LRR_LRRNT_SS_LRRNT_LRR, 14/4987 AA524394 Hs.294022 SS_connexin,hormone_rec_zf_C4,connexin	<i>E E</i>				3.1
414987   A4524394   Hs.294022   SS.connextin,hormone_rec,zf-C4,connextin   hypothetical protein FLJ14950   3.1     429197   H24471   Hs.26930   SS.Gelsolin,   SS.Gelsolin,   SS.TM, C1q,   collagen, type VIII, alpha 2   3.1     407604   AW191962   Hs.249239   SS.TM,C1q,   collagen, type VIII, alpha 2   3.1     419092   J05581   Hs.89603   SS.TM,SEA,   mucin 1, transmembrane   3.1     456672   AK002016   Hs.114727   SS.PK,PK   Horno saplens, clone MGC:16327, mRNA, com   3.1     443171   BE281128   Hs.9930   SS.TM,ftm_1,rm,SS   TONDU   3.1     452256   AK000933   Hs.28661   TM,GDI,7tm_1,   Horno saplens cDNA FLJ10071 fis, clone HE   3.1     406642   AJ245210   SS.TM,trypsin,SS,TM,trefoil,trypsin,tref   Transmembrane profease, serine 3   3.1	23		,SS,RNA_pot_A,RNA_pot_A2,Ribosomal_S24	4e,ribosomal protein S24	
429197 H24471 Hs.26930 ,SS,Gelsolin, 448030 N30714 Hs.325960 ,SS,TM membrane-spanning 4-domains, subfamily A 3.1 407604 AW191962 Hs.249239 ,SS,TM,C1q, collagen, type VIII, alpha 2 3.1 419092 J05581 Hs.89603 SS,TM,SEA, mucin 1, transmembrane 3.1 456672 AK002016 Hs.114727 ,SS,PK,PK Homo saplens, clone MGC:16327, mRNA, com 3.1 43171 BE281128 Hs.9030 SS,TM,Tm_1,rrm,SS TONDU 3.1 452256 AK000933 Hs.28661 ,TM,GDI,Ttm_1, Homo saplens cDNA FL/10071 fis, clone HE 3.1 406642 AJ245210 SS,TM,Typsin,SS,TM,trefoil,trypsin,tref 5 Transmembrane protease, serine 3 gb:Homo saplens mRNA for immunoglobulin 3.1			SS,LRR,LRRNT,SS,LRRNT,LRR,		3.1
448030 N30714 Hs.325960 SS,TM membrane-spanning 4-domains, subfamily A 3.1 (collagen, type VIII, alpha 2 3.1 (419092 J05581 Hs.89603 SS,TM,C1q, collagen, type VIII, alpha 2 3.1 (456672 AK002016 Hs.14727 K43171 BE281128 Hs.9030 SS,TM,SEA, Horno saplens, clone MGC:16327, mRNA, com 3.1 (452256 AK002033 Hs.28661 TM,GDI,7tm_1,rm,SS TM,U1,1 Horno saplens cDNA FLJ10071 fis, clone HE 3.1 (406642 AJ245210 SS,TM,trefoil,trypsin,tref SS,TM,trefoil,trypsin,tref SS SS,TM,trefoil,trypsin,tref SS SS GbHomo saplens mRNA for immunoglobulin 3.1					3.1
60       407604 AW191962 Hs.249239 Hs.249239 419092 J05581 Hs.89603 456072 AK000216 Hs.114727 ,SS,TM,SEA, 43171 BE281128 Hs.99030 SS,TM,SEA, 43171 BE281128 Hs.99030 Hs.28661 452256 AK000933 Hs.28661 TM,GDI,7tm_1,rrm,SS TONDU 3.1 452256 AK000933 Hs.28661 TM,GDI,7tm_1, Tm,SS TONDU 3.1 432201 Al538613 Hs.298241 SS,TM,trefoll,trypsin,tref 432201 Al538613 Hs.298241 SS,TM,trefoll,trypsin,tref 432201 Al538613 Hs.298241 SS       TM,GDI,7tm_1,rrm,SS TONDU 3.1 Transmembrane protease, serine 3 3.1 Transmembrane protease, serine 3 gb:Homo saplens mRNA for immunoglobulin 3.1				ESTs, Weakly similar to T20272 hypotheti	3.1
419092 J05581 Hs.89603 SS,TM,SEA, mucin 1, transmembrane 3.1 456672 AK002016 Hs.114727 SS,PK,PK Homo saplens, clone MGC:16327, mRNA, com 3.1 443171 BE281128 Hs.9030 SS,TM,ftm_1,mm,SS TONDU 3.1 452256 AK000933 Hs.28661 TM,GDI,7tm_1, mm,SS TONDU 3.1 452256 AK000931 Hs.28661 TM,GDI,7tm_1, mm,SS TONDU 3.1 406642 AJ245210 SS,TM,trefoil,trypsin,tref 5S,TM,trefoil,trypsin,tref	60				3.1
456672 AK002016 Hs.114727	οU			collagen, type VIII, alpha 2	3.1
443171 BE281128 Hs.9030 SS,TM,7tm_1,rrm,SS TONDU 3.1 452256 AK000933 Hs.28661 TM,GDI,7tm_1, Homo sapiens cDNA FLJ10071 fis, clone HE 3.1 43221 Al538613 Hs.298241 SS,TM,trefoil,trypsin,tref Transmembrane protease, serine 3 3.1 406642 AJ245210 SS SS SS,TM,trefoil,trypsin,tref SS SS SS,TM,trefoil,trypsin,tref SS SS SS,TM,trefoil,trypsin,tref SS SS SS,TM,trefoil,trypsin,tref SS SS,TM,Trm_1,rrm,SS TONDU 3.1					3.1
443171 BE281128 Hs.9030 SS,TM,7tm_1,rrm,SS TONDU 3.1 452256 AK000933 Hs.28661 ,TM,GDI,7tm_1, Homo sapiens cDNA FLJ10071 fis, clone HE 3.1 432201 Al538613 Hs.298241 SS,TM,trefoil,trypsin,tref Transmembrane protease, serine 3 3.1 406642 AJ245210 SS SS SS,TM,trefoil,trypsin,tref SS SS SS,TM,trefoil,trypsin,tref SS SS SS,TM,trefoil,trypsin,tref SS SS SS,TM,trefoil,trypsin,tref Transmembrane protease, serine 3 3.1					3.1
432201 Al538613 Hs.298241 SS,TM,tefoil,trypsin,tref Transmembrane protease, serine 3 3.1 406642 AJ245210 SS Transmembrane protease, serine 3 gb:Homo saplens mRNA for immunoglobulin 3.1				TONDU	
432201 Al538613 Hs.298241 SS,TM,tefoil,trypsin,tref Transmembrane protease, serine 3 3.1 406642 AJ245210 SS Transmembrane protease, serine 3 gb:Homo saplens mRNA for immunoglobulin 3.1	~~			Homo sapiens cDNA FLJ10071 fis, clone HE	
406642 AJ245210 SS gb.Homo sapiens mRNA for immunoglobulin 3.1	65		SS,TM,trypsin,SS,TM,trefoil,trypsin,tref	Transmembrane protease, serine 3	
		406642 AJ245210		gb:Homo sapiens mRNA for immunoglobulin	
		400903 NA	SS		3.1

	434400	A1031771	Hs.132586	,SS,Glyco_hydro_2	ESTs	3.1
		AW962597			KIAA1547 protein	3.1
					class I cytokine receptor	3.1
			Hs.201189		ESTs, Weakly similar to G01763 atrophin-	3.1
5		A1936442	He 50838	UBACT_repeat,SS,UBACT_repeat,ThiF_famil		3.1
,		T29618	Hs.89640	,TM,pkinase,fn3,	TEK tyrosine kinase, endothelial (venous	3.1
		AA587773		,SS,SRCR,	Homo saplens, Similar to RIKEN cDNA 5830	3.1
			Hs.104211	,Sema,ig,	ESTs	3.1
		BE568452		,SS,abhydrolase,	protein regulator of cytokinesis 1	3.1
10				SS	ESTs, Weakly similar to S38383 SEB4B pro	3.1
10		AA196241			troponin T1, skeletal, slow	3.1
			Hs.241493	"SS, pro_isomerase,	natural killer-tumor recognition sequenc	3.1
				,55,pro_sonterase, ,TM,histone,Sec1,histone,sugar_tr	ESTs	3.1
		AA809875			ESTs	3.1
1.5			Hs.199754	,SS,TM,7tm_2,GPS	putative ankyrin-repeat containing prote	3.1
15		AJ278120		,SS,WD40	Homo sapiens, done MGC:9381, mRNA, comp	3.1
		AW630534	HS./62//	,SS,TM,rrm,oxidored_q6,oxidored_q6	gb:ye79c02.s1 Soares fetal liver spleen	3.0
		R00866		SS	Transmembrane protease, serine 3	3.0
			Hs.298241	,SS,TM,trefoil,trypsln,trefoil	ESTs. Weakly similar to KIAA1214 protein	3.0
20			Hs.126730	,тм,рн,		3.0
20			Hs.325823	,SS,TM,CD36	ESTs, Moderately similar to ALU5_HUMAN A	3.0
		R91600		,SS,Ran_BP1,LIM,Ran_BP1,GRIP,TPR,LIM	gb:yq10c02.r1 Soares fetal liver spleen	3.0
			Hs.162209	SS,TM,SS,TM,PMP22_Claudin,PMP22_Claudin	unclaudin o	3.0
		H58373	Hs.332938	,SS,TM	hypothetical protein MGC5370	3.0
0.5	401197			arf,arf,	ENSP00000229263*:HSPC213.	3.0
25			Hs.291887	,wnt,	ESTs	3.0
			Hs.336432	,SS,mm,zf-RanBP,pkinase,C2,pkinase_C,DA	ESIS	3.0
		AA381807		SS,SS	hypoxia-inducible protein 2	3.0
		W27249	Hs.8109	SS	hypothetical protein FLJ21080	3.0
••	404826			,SS,TM	Target Exon	3.0
30		H70284	Hs.160152	,SS,RA	ESTs, Weakly similar to FPHU alpha-fetop	3.0
			Hs.43627	HMG_box,pkinase,zf-CCHC,SS,TM,HMG_bo	x,SRY (sex determining region Y)-box 22	
		AW977653		,SS,ribonuc_red_sm,	ribonucleotide reductase M2 polypeptide	3.0
			Hs.193465	,death,ZU5,pkinase,Activin_recp,	ESTs	3.0
			Hs.282804	SS,Cu-oxidase,SS,Cu-oxidase,Cu-oxidase	hypothetical protein FLJ22704	3.0
35		C05837	Hs.145807	,SS,TM	hypothetical protein FLJ13593	· 3.0
			Hs.179808	SS	ESTs	3.0
	409956	AW103364	Hs.727	SS,TGF-beta,TGFb_propeptide,SS,TGF-beta	, inhibin, beta A (activin A, activin AB a	3.0
	419667	AU077005	Hs.92208	SS, disintegrin, Reprotysin, Pep_M12B_prope	a disintegrin and metalloproteinase doma	3.0
	450946	AA374569	Hs.127698	SS	ESTs, Moderately similar to 2109260A B c	3.0
40	447770	AB032417	Hs.19545	Frizzled,Fz,SS,TM,Frizzled,Fz,	frizzled (Drosophila) homolog 4	3.0
		U20325	Hs.1707	SS,SS	cocaine- and amphetamine-regulated trans	3.0
	418838	AW385224	Hs.35198	,SS,TM,Phosphodiest,	ectonucleotide pyrophosphatase/phosphodi	3.0
	442804	AW300118	Hs.131257	,SS,TM,G-gamma	ESTs	3.0
	432284	AA532807	Hs.105822	,SS,TM,pkinase,	ESTs	3.0

#### TABLE 20A

Table 20A shows the accession numbers for those pkeys lacking unigeneID's for Table 20.

For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1	Λ	
1	v	

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number
ONI HUHBUG.	Oche diales nation

Accession:

Genbank accession numbers

	Pkey	CAT number	Accessions
20	410785 411667 418636	1221055_1 1253334_1 177402_1	AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355 BE160198 AW935898 T11520 AW935930 AW856073 AW861034 AW749855 AA225995 AW750208 AW750206
	420854	197072_1	AW295927 AI684514 AI263168 AA281079
	422128	211994_1	AW881145 AA490718 M85637 AA304575 T06067 AA331991
25	423431	228162_1	AA326062 AA325758 AW962182
	423945	233566_1	AA410943 AW948953 AA334202 AA332882
	426878	273265_1	BE069341 AW748403 AL044891 Al908240 AA393080
30	433687	373061_1	AA743991 AA604852 AW272737
	447197	711623_1	R36075 AJ366546 R36167
	451631	878098_1	R00866 R01523 Al806815
	456207	165078 -1	AA193450
5.5	456592	202684_1	R91600 T87079 AA291455

#### TABLE 20B

Table 20B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 20. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: ) Ref:		Sequence:	nber corresponding to an Eos probeset source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication ed "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_posit	ion:	Indicates D	NA strand from which exons were predicted. ucleotide positions of predicted exons.
15	Pkey	Ref	Strand	Nt_position
	400608	9887666	Minus	96756-97558
	400903	2911732	Plus	59112-59228
20	401045	8117619	Plus	90044-90184,91111-91345
	401093	8516137	Minus	22335-23166
	401197	9719705	Plus	176341-176452
	401747	9789672	Minus	118596-118816,119119-119244,119609-119761,120422-120990,130161-130381,130468-130593,131097-131258,131866-131932,132451-132575,133580-134011
25	401780	7249190	Minus	28397-28617,28920-29045,29135-29296,29411-29567,29705-29787,30224-30573
	401781	7249190	Minus	83215-83435,83531-83656,83740-83901,84237-84393,84955-85037,86290-86814
		8018108		73126-73623
		9966312		29782-29932
		9796239		110326-110491
30		9884928		66350-66496
		9909429		81747-82094
		9369121		2013-2186,9570-9758,11136-11309,19429-19677,21210-21455,23368-23562,24342-24527,29132-29320
		9958183		58895-59036,66618-66789
25		8516120		96450-96598
35		6862650		62554-62712,69449-69602
		7711864		100742-100904,101322-101503
		7684554		82121-83229
		9838195		74493-74829
40		6572184		47726-48046
40		2182280		22478-22632
	405654	4895155	Minus	53624-53759

# TABLE 21: 210 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES THAT ARE LIKELY TO ENCODE EITHER ENZYMES OR PROTEINS AMENABLE TO MODULATION BY SMALL MOLECULES

Table 21 shows 210 genes up-regulated in breast cancer compared to normal adult tissues that are likely to encode either enzymes or proteins amenable to modulation by small molecules. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the "average" normal adult tissue level was set to the 85<sup>th</sup> percentile value amongst 144 non-malignant tissues, and the 96<sup>th</sup> percentile value amongst 73 breast cancers was greater than or equal 80 units, and the predicted protein contained a structural domain that is indicative of enzymatic function or of being modulatable by small molecules (e.g. pkinase, peptidase, phosphatase, ATPase, or ion\_transporter domains). The predicted protein domains are noted.

•	Pkey:	Unique Eos probeset identifier number
20	ExAccn:	Exemplar Accession number. Genhank

ExAcon: Exemplar Accession number, Genbank accession number

Unigene Title: Unigene number Unigene gene title

5

10

15

R1: Ratio of 93rd percentile turnor to 85th percentile of normal body tissue

25						
	Pkey	ExAccn	UnigenelD	Predicted Protein Domains	UnigeneTitle	R1
		AI668594		SS,p450	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	65.7
•		AA250737	Hs.72472	death,ZU5,TM,Activin_recp,pkinase,	BMP-R1B	55.9
30		U31875	Hs.272499	ŞS,TM	short-chain alcohol dehydrogenase family	53.8
		AA195651		SS,Dihydroorotase,	ESTs	39.3
		AW138959		Phosphodiest,Somatomedin_B,	ESTs	34.9
		AA009647		SS,TM,disintegrin,Pep_M12B_propep,Reprol	a disintegrin and metalloproteinase doma	25.7
25		NM_00139		DSPc,Rhodanese,	dual specificity phosphatase 4	24.9
35		A1624342		SS,TM,Cation_efflux	ESTs	24.1
		NM_00361	3Hs.151407	ig,tsp_1,SS,AAA	cartilage intermediate layer protein, nu	21.7
			Hs.99915	hormone_rec,Androgen_recep,zf-C4,	androgen receptor (dihydrotestosterone r	21.7
		AI905687		SS	aldehyde dehydrogenase 9 family, member	20.3
40		AI375572	Hs.172634	pkinase,	ESTs	19.2
40		AA193450		SS,TM,p450,p450	gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sapi	18.3
		X52509	Hs.161640	SS,TM,aminotran_1_2,Cadherin_C_term,cadi	htyrosine aminotransferase	18.1
	402578			SS,p450,SS,TM,p450	C1001134:gi 2117372 pir  165981 fatty ac	17.8
			Hs.155956	SS,Acetyltransf2,	N-acetyltransferase 1 (arylamine N-acety	16.7
4.5			Hs.137476	pkinase,	paternally expressed 10	16.5
45			Hs.83169	SS,hemopexin,Peptidase_M10,SS,Peptidase_	matrix metalloproteinase 1 (MMP1; Inters	15.7
			Hs.107318		kynurenine 3-monooxygenase (kynurenine 3	15.3
			Hs.23439	SS,Peptidase_M1,	ESTs	13.9
			Hs.2258	hemopexin,Peptidase_M10,SS,Peptidase_M1	Omatrix metalloprotelnase 10 (MMP10; str	13.5
<b>C</b> O		AW873596			calmodulin 2 (phosphorylase kinase, delt	13.0
50		Al351010			lysyl oxidase	12.8
			Hs.2533	SS	aldehyde dehydrogenase 9 family, member	12.7
		AW732573		TM,K_tetra,ion_trans,SS,TM,K_tetra,ion_t	potassium voltage-gated channel, delayed	11.9
	421155		Hs.102267	SS,Lysyl_oxidase,Aldose_epim,Epimerase,S	fysyl oxidase	11.8
		NM_002497			NIMA (never in mitosis gene a)-related k	11.7
55			Hs.24286		ESTs	11.5
		AI907673		pkinase,	gb:IL-BT152-080399-004 BT152 Homo sapien	11.5
		AA410943		death,ZU5,TM,Activin_recp,pkinase,	gb:zt32h03.r1 Soares ovary tumor NbHOT H	11.4
	445263	H57646	Hs.42586	SS,Acyltransferase,	KIAA1560 protein	11.2

		AL080207		SS,TM,BRCT,ank,ABC_tran,ABC_tran	DXFZP434G232 protein	10.9
		NM_007050		SS,TM,Y_phosphatase,MAM,fn3,	protein tyrosine phosphatase, receptor t	10.4 10.3
		BE440042 NM_000685		SS,Peptidase_M10,hemopexin,SS,Peptidase_SS,TM,7tm_1,SS,TM,7tm_1,	angiotensin receptor 1	10.3
5		AL120173		SS,pkinase,	ESTs	10.3
	402408		1.0.001000	SS,carb_anhydrase	NM_030920*:Homo sapiens hypothetical pro	9.8
			Hs.72472	death,ZU5,TM,Activin_recp,pkinase,	BMP-R1B	9.4
	406687	M31126	Hs.272620	SS,Peptidase_M10,hemopexin,SS,Peptidase_	_matrix metalloproteinase 11 (MMP11; stro	9.1
	419948	AB041035	Hs.93847	Ferric_reduct,TM,Ferric_reduct,	NM_016931:Homo sapiens NADPH oxidase 4 (	9.1
10	400285			TM,ABC_tran,ABC_membrane,	Eos Control	8.8
		AF123050		SS,TM,ubiquitin,7tm_3,ANF_receptor,sushi	diubiquitin	8.6
		AA780473		SS,p450,SS,p450	cytochrome P450, subfamily IVB, polypept	8.3 8.3
		NM_003866		SS,SS SS Con Ingl SS	inositol polyphosphate-4-phosphatase, ty Norrie disease (pseudoglioma)	8.3
15	431725 418092		Hs.2839 Hs.106604	SS,Cys_knot,SS death,ZU5,pkinase,Activin_recp,	ESTs	8.3
13	427811		Hs.180884	SS,Zn_carbOpept,Propep_M14,SS,Propep_N		8.2
	423554		Hs.1674	GATase_2,SIS,	glutamine-fructose-6-phosphate transamin	8.1
		AW242243		SS,TM,WD40,ubiquitin,E1-E2_ATPase,Cation		7.8
		NM_001034		SS	ribonucleotide reductase M2 polypeptide	7.6
20	432677	NM_004482	2Hs.278611	SS,TM,Glycos_transf_2,Ricin_B_lectin,DPP	UDP-N-acetyl-alpha-D-galactosamine:polyp	7.6
	456986		Hs.170917	SS,TM,7tm_1,	prostaglandin E receptor 3 (subtype EP3)	7.5
		A1240665		SS,TM,disintegrin,Pep_M12B_propep,Reprol		7.3
	407721		Hs.38018	pkinase,	dual-specificity tyrosine-(Y)-phosphoryl	7.2 7.2
25	418004		Hs.87539	SS,aldedh,SS,aldedh,	aldehyde dehydrogenase 3 family, member a disIntegrin and metalloproteinase doma	7.2 7.1
25	410555		Hs.64311	TM, disintegrin, Reprolysin,	ESTs. Weakly similar to AF126780 1 retin	6.9
		AW204099 AP000692		GAF,PDEase	chromosome 21 open reading frame 5	6.8
	401045	AP000032	HS. 123701	ICE_p20,SS,ICE_p10,ICE_p20,ICE_p10,ICE_		
		C11001883	*:ail6753278lre	f[NP_033938.1] c	6.7	
30	442082		Hs.7413	TM,EPH_lbd,pkinase,SAM,fn3,	ESTs; calsyntenin-2	6.7
		A1655499		TM,Activin_recp,pkinase,death,ZU5,	ESTs	6.6
	404091	NA		TM,7tm_3,ANF_receptor,	Target Exon .	6.6
		A1248013		zf-C2H2	ESTs, Weakly similar to I38588 reverse t	6.5
25		NM_002914		SS,AAA,Viral_helicase1,rm,	replication factor C (activator 1) 2 (40	6.5 6.4
35		AF055575		TM.ion_trans,SS,TM.ion_trans,	calcium channel, voltage-dependent, L ty ESTs	6.2
		AA932186		TM,7tm_1,	serine (or cysteine) proteinase inhibito	6.2
		NM_005025 AW167087		SS,serpin, SS,ig,Sema,pkinase,	ESTs	6.2
		R45503	Hs.97469	SS,TM	ESTs, Highly similar to A39769 N-acetyll	6.1
40		Y00272	Hs.184572	SS,pkinase,pkinase	cell division cycle 2, G1 to S and G2 to	6.1
	400300			SS,TM,pkinase,Recep_L_domain,SH2,PH,Fu		6.1
		NM_012093	3Hs.18268	SS,adenylatekinase,	adenylate kinase 5	6.1
	402230			SS,TM,p450,	Target Exon	6.1
	424687	J05070	Hs.151738	SS,Peptidase_M10,fn2,hemopexin,SS,TM,Pe	prinatrix metalloproteinase 9 (gelatinase B	5.8
45		Al572739	Hs.195471	6PF2K,PGAM,	6-phosphofructo-2-kinase/fructose-2,6-bi	5.8
	432239		Hs.2936	SS,Peptidase_M10,hemopexin,SS,Peptidase	mathx metalloproteinase 13 (collagellase	5.6 5.6
	400286		01 L 455304	SS,TM,ABC_tran,ABC_membrane,SS SS,Peptidase_M10,hemopexin,SS	C16000922:gi[7499103 pir][T20903 hypothe matrix metalloproteinase 11 (MMP11; stro	5.4
		NM_005946 AA828246		UCH-1,pkinase,OPR,Rhodanese,AMP-bindin		5.4
50		AF086120		SS.TM,UDPGT,casein_kappa	ESTs	5.2
30			Hs.126594	SS,TM,Phosphodiest,	ESTs	5.2
		N54926	Hs.29202	TM,7tm_1,TM	G protein-coupled receptor 34	5.2
		M31659	Hs.180408	SS	solute carrier family 25 (mitochondrial	5.2
	429353	AL117406	Hs.200102	SS,TM,ABC_tran,ABC_membrane,	ATP-binding cassette transporter MRP8	5.1
55	425325		Hs.1892	SS,NNMT_PNMT_TEMT,SS,NNMT_PNMT_	TEMT,STAR	
			notamine N-me	thyltransferase	5.1	- 4
		AW291095	Hs.21814	SS,TM,pkinase,	interleukin 20 receptor, alpha	5.1
	403593		LI- 000 4377	CIDE-N,pkinase	Target Exon	5.1 5.0
<b>6</b> 0			Hs.269477	alpha-amylase,	ESTs retinolc acid induced 3	4.9
60			Hs.194691	SS,TM,7tm_3,Ribosomal_L13 SS,Melibiase,BTK,PH,pkinase,SH2,SH3,Ribo		4.9
		NM_00016 W88559	Hs.1787	TM,lon_trans,K_tetra,	proteolipid protein 1 (Pelizaeus-Merzbac	4.9
	411096	U80034	Hs.68583	Peptidase_M3,	mitochondrial intermediate peptidase	4.9
		NM_00446		SS,DPPIV_N_term,Peptidase_S9,SS,DPPIV		4.9
65		AA641836		SS,trypsin	hypothetical protein FLJ23186	4.9
	447752	M73700	Hs.105938	SS,transferrin,7tm_1,transferrin,	lactotransferrin	4.8
	427122	AW057736	Hs.323910	SS,TM,pkinase,Recep_L_domain,SH2,PH,Ft	uriHER2 receptor tyrosine kinase (c-erb-b2,	4.8

	400404					
	400181			SS,TM,3Beta_HSD,	ENSP00000171555:CDNA FLJ10727 fis, clone	4.6
		AA447453		SS,TM,7tm_1,	Homo sapiens mRNA; cDNA DKFZp586M0723 (f	4.6
			Hs.269533	SS.pkinase,RhoGEF,ig,PH,SH3,	ESTs	4.6
-	41/5/6	AA339449	Hs.82285	AIRS,formyl_transf,GARS,SS,GARS,AIRS,for	r phosphoribosylglycinamide formyltransfer	4.6
5	446089	AI860021	Hs.270651	pkinase	ESTs, Moderately similar to A47582 B-cel	4.6
			Hs.146688	SS,TM,MAPEG,	prostaglandin E synthase	4.5
		H26735	Hs.91668	SS,TM,PH,SH2,Furin-like,pkinase,Recep_L_	Homo sapiens clone PP1498 unknown mRNA	4.5
		Al345455		pkinase,OPR,	GA-binding protein transcription factor,	4.5
10		Al910275		SS,trefoil,SS,TM,tdl_recept_a,SRCR,tryps	trefoil factor 1 (pS2)	4.5
10		AA863360		SS,TM,p450,	ESTs, Weakly similar to fatty acid omega	4.4
		AW294092	Hs.21594	SS,ras,Y_phosphatase,ras	hypothetical protein MGC15754	4.4
	400205				NM_006265*:Homo sapiens RAD21 (S. pombe)	4.4
		AW296927		SS,TM,Peptidase_M1,	gb:UI-H-BW0-ajc-c-07-0-UI.s1 NCI_CGAP_Su	4.3
1 ~			Hs.278627	SS,pyr_redox,SS,Ribosomal_L39	prenylcysteine lyase	4.3
15		F13386	Hs.7888	pkinase,	Homo sapiens clone 23736 mRNA sequence	4.3
	416445	AL043004	Hs.79337	SS,pkinase,	KIAA0135 protein	4.3
	439024	R96696	Hs.35598	SS,TM,trypsin,vwd,ig	ESTs	4.3
	432882	NM_01325	7Hs.279696	pkinase,pkinase_C,	serum/glucocorticold regulated kinase-li	4.2
	447754	AW073310	Hs.163533	pkinase,	Homo sapiens cDNA FLJ14142 fis. clone MA	4.2
20	453775	NM_00291	6Hs.35120	SS,AAA,PI3_PI4_kinase,PI3Ka,PI3K_rbd,PI3	replication factor C (activator 1) 4 (37	4.2
	431657	Al345227	Hs.105448	SS,TM,pkinase	ESTs, Weakly similar to B34087 hypotheti	4.1
	427899	AA829286	Hs.332053	SS,SAA_proteins,ABC_membrane,ABC_tran,	serum amyloid A1	4.1
		NM_00180		SS,TM,thiolase,	centromere protein A (17kD)	4.1
		U38945	Hs.1174	ank,ank	cyclin-dependent kinase inhibitor 2A (me	4.1
25	406922	S70284		· · · · · · · · · · · · · · · ·	gb:stearoyl-CoA desaturase [human, adipo	4.1
	439285	AL133916	Hs.172572	SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	4.1
		Z97630	Hs.226117		H1 histone family, member 0	4.1
	420139	NM_00535		SS,TM,p450,	lipase, hormone-sensitive	4.0
			9Hs.154424		delodinase, lodothyronine, type II	4.0
30	424511	BE300512	Hs.193557	SS,Y_phosphatase,Band_41	ESTs, Moderately similar to ALU7_HUMAN A	4.0
		U76456	Hs.190787		tissue inhibitor of metalloproteinase 4	3.9
	428330		Hs.2256	SS,Peptidase_M10,SS,Peptidase_M10,hemor		3.9
		M31158	Hs.77439		protein kinase, cAMP-dependent, regulato	3.9
			Hs.313803		ESTs, Highly similar to AF157833 1 noncl	3.8
35		BE247550		SS,SH2,PH,SS,TM,PH,SH2,Furin-like,pkinas	amuth factor recentor hound postain 7	3.8
			Hs.128065		ESTs	3.8
	403943		110.120000		C5000355:gi 4503225[ref]NP_000765.1] cyt	3.8
		AV653785	Hs.173334	•		3.8
			Hs.238936		ELL-RELATED RNA POLYMERASE II, ELONGATIO ESTs, Weakly similar to (defline not ava	3.8
40		M26380	Hs.180878		lipoprotein lipase	3.7
		X54942	Hs.83758			3.7
		AI041793			CDC28 protein kinase 2 ESTs	
	424676		Hs.151678	- T		3.7
			Hs.122908		UDP-N-acetyl-alpha-D-galactosamine:polyp DNA replication factor	3.7
45		NM_01473				3.7
13		AU076643			KIAA0215 gene product	3.7
	406625		Hs.119597		secreted phosphoprotein 1 (osteopontin,	3.7
			Hs.106771		stearoyl-CoA desaturase (delta-9-desatur	3.6
			Hs.169266		ESTs	3.6
50		NM_003157			neuropeptide Y receptor Y1	3.6
50		NM_014400			serine/threonine kinase 2	3.6
			Hs.129873		GPI-anchored metastasis-associated prote	3.6
		AF059214			ESTs, Weakly similar to A36036 cytochrom	3.6
		Al308876	He 102240	The homosovia Doubless - \$440 homosovia Do	cholesterol 25-hydroxylase	3.6
55		AW895719	FIS. 103043	TM,hemopexin,PeptIdase_M10,hemopexin,Pe	propouneucal protein DKFZp761D112	3.6
55			Un 2442	TM,ion_trans,K_tetra,	gb:QV4-NN0039-290300-154-f06 NN0039 Homo	3.6
		NM_003816	105.244Z	And the state of t	a disIntegrin and metalloproteinase doma	3.6
	425320	AA383550	Hs.83190	Acy_transf,adh_zinc,ketoacyl-synt,pp-bi	fatty acid synthase	3.5
	407104			IMS,SS	polymerase (DNA directed) lota	3.5
60		AW961400	Hs.323910	SS,TM,SH2,PH,pkinase,Recep_L_domain,Fur	iv-ero-bz avian erythroblastic leukemia v	3.5
UU				SS	HER2 receptor tyrosine kinase (c-erb-b2,	3.5
		AA121098			serum-inducible kinase	3.5
	454042		Hs.172572	SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	3.5
		AA116021		SS,UCH-1,UCH-2,SS,TM,G_glu_transpept	ubiquitin specific protease 18	3.5
65		AF039241		Peptidase_M24,	histone deacetylase 5	3.5
0.5	412040	AB026436		DSPc,Myosin_tail,	dual specificity phosphatase 10	3.5
	412049 425776	いしひみろど L1つにもつり		SS,adenylatekinase,	adenylate kinase 5	3.5
	123/10	U23120	113.133433	SS,TM,7tm_2,SS,TM,7tm_2	parathyroid hormone receptor 2	3.4
				0.4 5		

406925   134041   Hs.9739   SS,TM,Tarasport_prot_SWIB_RhbOAP_DAG_PE_gricernt3-phosphale dehydrogenase 1 (so			AA426202 Hs.40403	TM,ABC_membrane,ABC_tran,Rlbosomal_S		3.4
418054 NM. 00348Hs. 83345 SS,TM.milo.carr.Lysyl_coidase   hysyl oxidase-lika 2   3.4   406815 AA833390 Hs. 288036 SS,PFT,						
5         406815 AA833330 HS 289305 AUS 289305 AUS 289305 AUS 28930 HS 289305 AUS 28930 HS 289305 AUS 28930 HS 289305 AUS 28930 AUS 28930 HS 289305 AUS 28930 AUS 2						
410530 Md25809 Hs.54173 ATP-synt_ab, 407021 U52077 421168 AF182277 Hs.330780 Sp.p450,SS U5p.p450,SS U5	_					
407021 US2077 42168 AF182277 Hs. 330780 SS.p450,SS cytochrome P450, subfamily Ills (phenobar 34 cytochrome P450	5					
421168 AF182277 Hs.330780				ATP-synt_ab,SS,7tm_1,ATP-synt_ab		
431472   AA25666   H-3 21176   SS				•		
August   A		421168	AF182277 Hs.330780	SS,p450,SS		
422083 NM_00144Hs_111256		431473	AA825686 Hs.321176	SS	ESTs, Weakly similar to S65824 reverse t	
411393 AW797437 Hs. 69771	10	408101	AW968504 Hs.123073	pkinase,	CDC2-related protein kinase 7	3.4
411393 AW797437 Hs.69771   SS.sushliypsin,war.mr,fibrinogen_C.fn   435767 H73505 Hs.17874   SS.s.Peptidase_S8.P.Peptidase_S8.P   ESTs   S3.3     43508 NM_006456Hs.288215   SS.Peptidase_S8.P.Peptidase_S8.P   SS.Peptidase_S8.P   SS.Peptidase_S9.P		422083	NM_001141Hs.111256	lipoxygenase PLAT.	arachidonate 15-lipoxygenase, second typ	3.3
433767 H73505					B-factor, properdin	3.3
43068 NM, 006456Hs.288215   SS, Pribosyltran,   siahtransferase   3.3     426928 AF037062 Hs.172914   st.22968   SS, phinase.lg,   SS, SS, physicale,   SS, SS, SS, physicale,   SS, SS, SS, SS, SS, SS, SS, SS, SS,					ESTs	3.3
15					sialvitransferase	
44574   A1267371	15					
445941 Al267371						
444542 Al161293 Hs. 280380   SS,SS,Peptidase_M1,EGF,ig.lectin_c,sushi aminopeptidase   Homo saplens clone 24628 mRNA sequence   3.3						
425741   AF052152   Hs.159412   Pikhase,   Hormo saplens clone 24628 mRNA sequence   3.3						
20						
433284   D85782   Hs.3229   Hs.3229   Cysteine dioxygenase, type I   3.3     400419   AF084545   Hs.325053   Hs.57664   TM,Integrin_B,Ricln_B_lectin,rmm   Homo sapiens mRNA full length insert cDN   3.3     417757   R19897   Hs.106604   death_ZU5,pkinase,Activin_recp,   ESTs   SST	20					
400419 AF084545 439750 AL359053 Hs.57664 417757 R19897 Hs.106604 417757 R19897 Hs.106604 421458 NM_003654Hs.104576 443767 BE562136 Hs.9736 422648 D86983 Hs.118893 422431 AA326062 30 451284 Al768235 452110 T47667 Hs.28005 453961 U39817 Hs.36820 453941 U39817 Hs.36820 453941 U39817 Hs.36820 45284 R31770 Hs.23540 420911 U77413 Hs.10293 443171 BE281128 Hs.9030 452266 AK000933 Hs.28661 40 432201 Al533613 Hs.298241 40 432201 Al533613 Hs.298241 40 432201 Al533613 Hs.28661 40 43220 Al533613 Hs.28661 40 43220 Al533613 Hs.28661 40 43220 A	20			55,114,7011_1		
A39750 AL359053 Hs.57664   Hs.106004   H				CC Dontidose M4		
417757 R19897 Hs.106604 Hs.332649 421458 NM_003654Hs.104576 443767 BE562136 Hs.9736 SS,TM,7tm_3,ANF_receptor,sushi 422648 D86983 Hs.118893 422431 AA326062 SS,PCI,RasGEF,hormone_rec,zf-C4, peroxidase,LRRCT, Melanoma associated gene 3.2 423431 AA326062 SS,TM,Activin_recp,pkinase gb:wg82g08.x1 Soares_NSF_r8_9W_OT_PA_PS 452110 T47667 Hs.28005 SS,TM,Activin_recp,pkinase Hs.3931 U39817 Hs.36820 SS,TM,Activin_recp,pkinase Hs.3931 U39817 Hs.36820 SS,TM,Activin_recp,pkinase Phosphate dehydrogenase 1 (so 453487 R31770 Hs.23540 Hs.10293 Hs.20661 U77413 Hs.100293 Hs.20661 U77413 Hs.2061 TM,Fot_n_t, SS,TM,Tm_1,Tm,SS TONDU 432201 Al538613 Hs.298241 Hs.8930 V426263 AW03937Hs.1691139 SS,TM,trefoil,typsin,tref 142623 NM_003937Hs.169139 V426263 NM_003937Hs.169139 V426263 NM_003937Hs.169139 V426263 AW137691 Hs.19575 V4360 SS,TM,Ttrefoil,typsin,trefoil V44015 AW1591433 Hs.298241 V5,TM,Tm_2,GPS SS,TM,trefoil,typsin,trefoil Transmembrane protease, serine 3 3.1 Value 144015 AW1591433 Hs.298241 V5,TM,Tm_2,GPS SS,TM,trefoil,typsin,trefoil Transmembrane protease, serine 3 3.0 value 2.5 valu						
25 452194 Al694413 Hs.332649 421458 NM_003654Hs.104576 443767 BE562136 Hs.9736 SS_PCI_RasGEF_hormone_rec_zi_C4, proteasome (prosome, macropain) 26S subu 3.2 422648 D86983 Hs.118893 423431 AA326062 SS_PCI_RasGEF_hormone_rec_zi_C4, proteasome (prosome, macropain) 26S subu 3.2 423431 AA326062 SS_PCI_RasGEF_hormone_rec_zi_C4, proteasome (prosome, macropain) 26S subu 3.2 423431 AA326062 SS_PCI_RasGEF_hormone_rec_zi_C4, proteasome (prosome, macropain) 26S subu 3.2 423431 AA326062 SS_PCI_RasGEF_hormone_rec_zi_C4, proteasome (prosome, macropain) 26S subu 3.2 423431 AA326062 SS_PCI_RasGEF_hormone_rec_zi_C4, proteasome (prosome, macropain) 26S subu 3.2 423431 AA326062 SS_PCI_RasGEF_hormone_rec_zi_C4, proteasome (prosome, macropain) 26S subu 3.2 423431 AA326062 SS_PCI_RasGEF_hormone_rec_zi_C4, proteasome (prosome, macropain) 26S subu 3.2 425101 T47667 Hs.28005 SS_PCI_RasGEF_hormone_rec_zi_C4, proteasome (prosome, macropain) 26S subu 3.2 425101 T47667 Hs.28005 SS_PCI_RasGEF_hormone_rec_zi_C4, proteasome (prosome, macropain) 26S subu 3.2 425171 Cerebellum II Horno saplens c 3.2 9b; mg82g08.x1 Soares_NSF_F8_9W_OT_PA_P_S 3.2 45311 T47667 Hs.28005 SS_TM_Atcivin_recp.pkinase Horno saplens c CNA FLJ11309 fis, clone PL 3.2 453941 U39817 Hs.36820 SS_PCAD_HRDC_helicase_C, Bloom syndrome 3.1 T47171 Hs.281128 Hs.9030 SS_TM_transport_prot_SWIB_RhoGAP_DAG_PE- glycerol-3-444171 BE281128 Hs.9030 SS_TM_transport_prot_SWIB_RhoGAP_DAG_PE- glycerol-3-444171 BE281128 Hs.9030 SS_TM_Ttm_1,rrm_SS TONDU 3.1 T47171 Horno saplens cDNA FLJ10071 fis, clone HE 3.1 T47171 Horno saplens cDNA FLJ10071 fis, clone HE 3.1 T47171 Horno saplens cDNA FLJ10071 fis, clone HE 3.1 T47171 T47171 Horno saplens cDNA FLJ10071 fis, clone HE 3.1 T47171 T4717 Horno saplens cDNA FLJ10071 fis, clone HE 3.1 T47171 T4717 Horno saplens cDNA FLJ10071 fis, clone HE 3.1 T47171 T4717 Horno saplens cDNA FLJ10071 fis, clone HE 3.1 T47171 T4717 Horno saplens cDNA FLJ10071 fis, clone HE 3.1 T47171 T4717 Horno saplens cDNA FLJ10071 fis, clone HE 3.1 T47171 T4717 Horno saplens cDNA FLJ						
421458 NM_003654Hs.104576 SS Carbohydrate (keratan sulfate Gal-6) sul 3.2 43767 BE552136 Hs.9736 SS,PCI,RasGEF,hormone_rec,zi-C4, proteasome (prosome, macropain) 26S subu 3.2 422648 D86983 Hs.118893 peroxidase,LRRCT, Melanoma associated gene 3.2 423431 AA326062 SS,p450,p450 gb:EST29171 Cerebeillum II Horno sapiens c 3.2 452110 T47667 Hs.28005 SS,Trehalase gb:wg82g08.x1 Soares_NSF_F8_9W_OT_PA_P_S 3.2 452110 T47667 Hs.28005 SS,Trehalase gb:wg82g08.x1 Soares_NSF_F8_9W_OT_PA_P_S 3.2 453941 U39817 Hs.36820 SS,DEAD,HRDC,helicase_C, Bloom syndrome 3.1 453487 R31770 Hs.23540 TM,p450_Ets glatelet-activating factor acetylhydrola 3.2 453487 R31770 Hs.23540 TM,7tm_1, ESST0 453487 R31770 Hs.23540 TM,7tm_1, Tm,SS TONDU 3.1 443171 BE281128 Hs.9930 SS,TM,transport_prot,SWIB.RhoGAP,DAG_PE-3 443171 BE281128 Hs.9930 SS,TM,Ttm_1,rm,SS TONDU 3.1 452256 AK000933 Hs.28661 TM,GDI,7tm_1, Horno sapiens cDNA FLJ10071 fis, clone HE 3.1 443171 BE281128 Hs.9930 SS,TM,trefoil,trypsin,tref Transmembrane protease, serine 3 3.1 452256 AK000937 Hs.169139 SS,TM,trefoil,trypsin,tref Tarkenembrane protease, serine 3 3.1 443628 NM_003937Hs.169139 SS,abhydrolase, protein regulator of cytokinesis 1 3.1 450223 AA418204 Hs.241493 SS,pro_isomerase, anatural killer-tumor recognition sequenc 3.1 448105 AW591433 Hs.298241 SS,TM,trefoil,trypsin,trefoil Transmembrane protease, serine 3 3.0	25					
A43767 BE562136 Hs.9736   SS,PCI,RasGEF,hormone_rec,zf-C4,   proteasome (prosome, macropain) 26S subu   3.2	25					
422648 D86983 Hs.118893 peroxidase,LRRCT, Melanoma associated gene 3.2 423431 AA326062 SS,p450,p450 gb:EST29171 Cerebellum II Homo saplens c 3.2 451210 T47667 Hs.28005 SS,TmActivin_recp,pkinase gb:wg82g08.xt Soares_NSF_F8_9W_OT_PA_P_S 3.2 459963 AW247529 Hs.6793 TM,p450,Ets platelet-activating factor acetylhydrola 3.2 453941 U39817 Hs.36820 SS,DEAD,HRDC,helicase_C, Bloom syndrome 3.1 453941 U39817 Hs.36820 SS,DEAD,HRDC,helicase_C, Bloom syndrome 3.1 453941 U39817 Hs.36820 SS,DEAD,HRDC,helicase_C, Bloom syndrome 3.1 453487 R31770 Hs.23540 TM,7tm_1, ESTs 453487 R31770 Hs.23540 TM,7tm_1, ESTs 443171 BE281128 Hs.9030 SS,TM,7tm_1,rrm,SS TONDU 3.1 443171 BE281128 Hs.9030 SS,TM,7tm_1,rrm,SS TONDU 3.1 452256 AK000933 Hs.28661 TM,GDI,7tm_1, Homo saplens cDNA FLJ10071 fis, clone HE 3.1 419150 T29618 Hs.89640 TM,pkinase,fn3, Transmembrane protease, serine 3 3.1 426283 NM_003937Hs.169139 Kynurenlnase (L-kynurenlne hydrolase) 3.1 436291 BE568452 Hs.5101 SS,abhydrolase, protein regulator of cytokinesis 1 3.1 426283 AW137691 Hs.199754 SS,TM,trefoil,trypsin,trefoil 448105 AW591433 Hs.298241 SS,TM,trefoil,trypsin,trefoil 55,TM,trefoil,trypsin,trefoil 76,Tm,2,GPS Transmembrane protease, serine 3 3.0						
423431 AA326062 SS,p450,p450 gb:EST29171 Cerebellum II Homo saplens c 3.2 452110 T47667 Hs.28005 SS,Trehalase gb:wg82g08.x1 Soares_NSF_F8_9W_OT_PA_P_S 3.2 452110 T47667 Hs.28005 SS,TmActivin_recp.pkinase Homo saplens c CDNA FLJ11309 fis, clone PL 3.2 453941 U39817 Hs.36820 SS,DEAD.HRDC.helicase_C, Bloom syndrome 3.1 406664 L34041 Hs.9739 SS,TM,transport_prot,SWIB.RhoGAP,DAG_PE- glycerol-3-  35 phosphate dehydrogenase 1 [so 453487 R31770 Hs.23540 TM,7tm_1, EST3 O-linked N-acetylglucosamine (GlcNAc) tr 3.1 420911 U77413 Hs.100293 SS,TM,7tm_1,rm,SS TONDU 3.1 43171 BE281128 Hs.9030 SS,TM,7tm_1,rm,SS TONDU 3.1 452256 AK000933 Hs.28661 TM,GDI,7tm_1, Homo saplens cDNA FLJ10071 fis, clone HE 3.1 419150 T29618 Hs.89640 TM,pkinase,fn3, TEX tyrosine kinase, endothelial (venous 3.1 444443 Al149286 Hs.55099 SS rab GTPase activating protein (GAP and 3.1 456283 NM_003937Hs.169139 SS,molecular to the complex of the complex						
30						
452110 T47667 Hs.28005 SS,TM,Activin_recp.pkinase Homo saplens cDNA FLJ11309 fis, clone PL 439963 AW247529 Hs.6793 TM,p450,Ets platelet-activating factor acetylhydrola 3.2 453941 U39817 Hs.36820 SS,DEAD,HRDC,helicase_C, Bloom syndrome 3.1 406664 L34041 Hs.9739 SS,TM,transport_prot,SWIB,RhoGAP,DAG_PE- glycerol-3-2540 TM,7tm_1, ESTs 3.1 453487 R31770 Hs.23540 TM,7tm_1, ESTs O-linked N-acetylglucosamine (GlcNAc) tr 3.1 420911 U77413 Hs.100293 SS,TM,trm_1,rrm,SS TONDU 3.1 443171 BE281128 Hs.9030 SS,TM,7tm_1,rrm,SS TONDU 3.1 452256 AK000933 Hs.28661 TM,GDI,7tm_1, Homo saplens cDNA FLJ10071 fis, clone HE 3.1 419150 T29518 Hs.89640 TM,pkinase,fin3, TEK tyrosine kinase, endothelial (venous 3.1 444443 Al149286 Hs.55099 SS TM,trypsin,SS,TM,trefoil,trypsin,tref 446283 NM_003937Hs.169139 436291 BE568452 Hs.5101 SS,abhydrolase, protein regulator of cytokinesis 1 3.1 436291 BE568452 Hs.5101 SS,abhydrolase, protein regulator of cytokinesis 1 3.1 448105 AW591433 Hs.298241 SS,TM,trefoil,trypsin,trefoil Transmembrane protease, serine 3 3.1 448105 AW591433 Hs.298241 SS,TM,trefoil,trypsin,trefoil Transmembrane protease, serine 3 3.0				SS,p450,p450		
439963 AW247529 Hs.6793	30					
439963 AW247529 Hs.6793 TM,p450,Ets platelet-activating factor acetylhydrola 3.2 453941 U39817 Hs.36820 SS,DEAD,HRDC,helicase_C, Bloom syndrome 3.1 4006664 L34041 Hs.9739 SS,TM,transport_prot,SWIB,RhoGAP,DAG_PE- glycerol-3- 453487 R31770 Hs.23540 TM,7tm_1, ESTs 3.1 420911 U77413 Hs.100293 OS,TM,Tm_1,rrm,SS TONDU 3.1 443171 BE281128 Hs.9030 SS,TM,Tm_1,rrm,SS TONDU 3.1 423201 Al538613 Hs.28661 TM,GDI,7tm_1, Homo sapiens cDNA FLJ10071 fis, clone HE 3.1 419150 T29518 Hs.89640 TM,pkinase,fin3, TEK tyrosine kinase, endothelial (venous 3.1 444443 Al149286 Hs.55099 SS rabbet Hs.55099 SS rabbet GTPase activating protein (GAP and 3.1 426283 NM_003937Hs.169139 436291 BE568452 Hs.5101 SS,abhydrolase, protein regulator of cytokinesis 1 3.1 45 450223 AA418204 Hs.241493 SS,pro_Isomerase, anatural killer-tumor recognition sequenc 3.1 448105 AW591433 Hs.298241 SS,TM,trefoil,trypsin,trefoil Transmembrane protease, serine 3 3.0				SS,TM,Activin_recp,pkinase		
35				TM,p450,Ets		
Phosphate dehydrogenase 1 (so 453487 R31770 Hs.23540 TM,7tm_1,		453941	U39817 Hs.36820			
Phosphate dehydrogenase 1 (so 453487 R31770 Hs.23540 TM,7tm_1,		406664	L34041 Hs.9739	SS,TM,transport_prot,SWIB,RhoGAP,DAG_F	PE-	glycerol-3-
420911 U77413 Hs.100293 O-linked N-acetylglucosamine (GlcNAc) tr 3.1 443171 BE281128 Hs.9030 SS,TM,7tm_1,rm,SS TONDU 3.1 452256 AK000933 Hs.28661 TM,GDI,7tm_1, Homo sapiens cDNA FLJ10071 fis, clone HE 3.1 40 432201 Al538613 Hs.298241 SS,TM,trypsin,SS,TM,trefoil,trypsin,tref 1419150 T29618 Hs.89640 TM,pkinase,fin3, TEK tyrosine kinase, endothelial (venous 3.1 444443 Al149286 Hs.55099 SS rab6 GTPase activating protein (GAP and 3.1 426283 NM_003937Hs.169139 kynureninase (L-kynurenine hydrolase) 3.1 436291 BE568452 Hs.5101 SS,abhydrolase, protein regulator of cytokinesis 1 3.1 45 450223 AA418204 Hs.241493 SS,pro_isomerase, anatural killer-tumor recognition sequenc 3.1 424269 AW137691 Hs.199754 SS,TM,trefoil,trypsin,trefoil Transmembrane protease, serine 3 3.0	35	phospha	ite dehydrogenase 1 (so		•	
420911 U77413		453487	R31770 Hs.23540	TM,7tm_1,	ESTs	3.1
443171 BE281128 Hs.9030   SS,TM,7tm_1,rm,SS   TONDU   3.1		420911	U77413 Hs.100293	· -	O-linked N-acetylglucosamine (GlcNAc) tr	3.1
452256 AK000933 Hs.28661 TM,GDI,7tm_1, Homo saplens cDNA FLJ10071 fis, clone HE 3.1 432201 AJ536613 Hs.298241 SS,TM,tryosin,SS,TM,trefoil,tryosin,trefoil Transmembrane protease, serine 3 3.1 432201 AJ536613 Hs.298241 SS,TM,tryosin,SS,TM,trefoil,tryosin,trefoil Transmembrane protease, serine 3 3.1 TEK tyrosine kinase, endothelial (venous 3.1 AJ5221 AJ5221 AJ5222 AV5222 AV				SS.TM.7tm 1.rm.SS		3.1
40 432201 Al538613 Hs.298241 SS,TM,trypsin,SS,TM,trefoil,trypsin,tref 149150 T29618 Hs.89640 TM,pkinase,fn3, SS TM,trypsin,tref 144443 Al149286 Hs.55099 SS rab6 GTPase activating protein (GAP and 426283 NM_003937Hs.169139 Kynureninase (L-kynurenine hydrolase) 3.1 Ad5291 BE568452 Hs.5101 SS,abhydrolase, protein regulator of cytokinesis 1 3.1 Ad5293 AA418204 Hs.241493 SS,pro_isomerase, anatural killer-tumor recognition sequenc 3.1 Ad48205 AW137691 Hs.199754 SS,TM,Tm_2,GPS ESTs 3.1 Ad8105 AW591433 Hs.298241 SS,TM,trefoil,trypsin,trefoil Transmembrane protease, serine 3 3.0						
419150 T29618 Hs.89640 TM,pkinase,fn3, TEK tyrosine kinase, endothelial (venous 3.1 444443 Al149286 Hs.55099 SS rab6 GTPase activating protein (GAP and 426283 NM_003937Hs.169139 kynureninase (L-kynurenine hydrolase) 3.1 436291 BE56824 Hs.5101 SS,abhydrolase, protein regulator of cytokinesis 1 3.1 436293 AA418204 Hs.241493 SS,pro_isomerase, natural killer-tumor recognition sequenc 3.1 424269 AW137691 Hs.199754 SS,TM,7tm_2,GPS ESTs 3.1 448105 AW591433 Hs.298241 SS,TM,trefoil,trypsin,trefoil Transmembrane protease, sertine 3 3.0	40					3.1
444443 A1149286 Hs.55099 SS rab6 GTPase activating protein (GAP and 3.1 426283 NM_003937Hs.169139 kynureninase (L-kynurenine hydrolase) 3.1 436291 BE568452 Hs.5101 SS,abhydrolase, protein regulator of cytokinesis 1 3.1 450223 AA418204 Hs.241493 SS,pro_isomerase, protein regulator of cytokinesis 1 3.1 424269 AW137691 Hs.199754 SS,TM,Tm_2,GPS ESTs ESTs 3.1 448105 AW591433 Hs.298241 SS,TM,trefoil,trypsin,trefoil Transmembrane protease, serine 3 3.0						
426283 NM_003937Hs.169139 kynureninase (L-kynurenine hydrolase) 3.1 436291 BE568452 Hs.5101 SS,abhydrolase, protein regulator of cytokinesis 1 3.1 45 450223 AA418204 Hs.241493 SS,pro_isomerase, anatural killer-tumor recognition sequenc 3.1 424269 AW137691 Hs.199754 SS,TM,Tm_2,GPS ESTs 448105 AW591433 Hs.298241 SS,TM,trefoil,trypsin,trefoil Transmembrane protease, serine 3 3.0						
436291 BE568452 Hs.5101 SS,abhydrolase, protein regulator of cytokinesis 1 3.1 45 450223 AA418204 Hs.241493 SS,pro_isomerase, natural killer-tumor recognition sequenc 3.1 424269 AW137691 Hs.199754 SS,TM,7tm_2,GPS ESTs 3.1 448105 AW591433 Hs.298241 SS,TM,trefoil,trypsin,trefoil Transmembrane protease, serine 3 3.0				33		
45 45023 AA418204 Hs.241493 SS,pro_isomerase, natural killer-tumor recognition sequenc 3.1 424269 AW137691 Hs.199754 SS,TM,7tm_2,GPS ESTs 3.1 448105 AW591433 Hs.298241 SS,TM,trefoil,trypsin,trefoil Transmembrane protease, serine 3 3.0				CC abburdening		
424269 AW137691 Hs.199754 SS,TM,7tm_2,GPS ESTs 3.1 448105 AW591433 Hs.298241 SS,TM,trefoil,trypsin,trefoil Transmembrane protease, serine 3 3.0	45					
448105 AW591433 Hs.298241 SS,TM,trefoil,trypsin,trefoil Transmembrane protease, sertine 3 3.0	70					
40200U BEU1/1004 HS.330432						
		452500	BEU1/U04 MS.330432	55,mm,zr-Kanbr,pkinase,cz,pkinase_C,DAC	2018	3.0

#### TABLE 21A

Table 21 A shows the accession numbers for those pkeys lacking unigeneID's for Table 21. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

1	Λ	
1	v	

Pkey:	Unique Eos probeset Identifier number
CAT number:	Gene cluster number

Accession:

Genbank accession numbers

15

	Pkey	CAT number	Accessions
20	420854	197072_1	AW296927 AI684514 AI263168 AA281079
	423431	228162_1	AA326062 AA325758 AW962182
	423945	233566_1	AA410943 AW948953 AA334202 AA332882
	451264	863988_1	AI768235 R31400 H29082 H23107
	455325	1279475_1	AW895719 N31451 N41451
	456207	1650781	AA193450

### TABLE 21B

Table 21B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 21. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref;	Unique number corresponding to an Eos probeset  Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

10				
13	Pkey	Ref	Strand	Nt_position
	401045	8117619	Plus	90044-90184,91111-91345
	402230	9966312	Minus	29782-29932
20	402408	9796239	Minus	110326-110491
	402578	9884928	Plus	66350-66496
	403593		Minus	62554-62712,69449-69602
		7711864	Plus	100742-100904,101322-101503
	404091		Minus	82121-83229

### TABLE 22: 739 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT BREAST

**Table 22** shows 739 genes up-regulated in breast cancer compared to normal adult breast. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the denominator was the 85<sup>th</sup> percentile value for 12 non-malignant breast specimens, and the 96<sup>th</sup> percentile value amongst the 73 breast cancers was greater than or equal 100 units.

10

5

15	Pkey: ExAccn: UnigeneID: Unigene Title: R1;	Unique Eos probeset Identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of 90th percentile tumor to 85th percentile normal breast tissu			
20	Pkey ExAcc	n UnigenelD UnigeneTitle	R1		

20	· ncy	LANCOI	ungenen	Ottigeneritie	KI
~0	400292	AA250737	Hs.72472	BMP-R1B	51.5
		U31875	Hs.272499		38.3
		Al127076	Hs.334473		29.9
		AL137517	Hs.334473	.,,	26.9
25		AI955040	Hs.265398		25.8
		M86849	Hs.323733		23.2
		X54942	Hs.83758	CDC28 protein kinase 2	22.6
		AA046309	113.03730	gb:zf12f01.s1 Soares_fetal_heart_NbHH19W	
		AA353776	Hs.901	CD48 antigen (B-cell membrane protein)	18.9
30		AB012113	Hs.16530	small inducible cytokine subfamily A (Cy	18.0
-		AB033025		KIAA1199 protein	17.6
		AA219691	Hs.73625	RAB6 Interacting, kinesin-like (rabkines	17.6
		AA147884	Hs.9812	Homo sapiens cDNA FLJ14388 fis, clone HE	17.1
		AI263307		H2B histone family, member L	17.0
35		T97307	113.255004	gb:ye53h05.s1 Soares fetal liver spleen	16.1
-		D90041	He 155956	N-acetyltransferase 1 (arylamine N-acety	16.1
		AJ440266	Hs.170673	ESTs, Weakly similar to T24832 hypotheti	16.0
		AA321649		small inducible cytokine subfamily B (CX	15.5
		NM_01439		similar to lysosome-associated membrane	15.1
40		AL120862	Hs.124165	programmed cell death 9 (PDCD9)	14.9
		AA746503	Hs.283313		14.7
		H60720	Hs.81892	KIAA0101 gene product	14.4
		AI267652	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434E082	
		AI768015	Hs.92127	ESTs	14.2
45		Al733881	Hs.72472	BMP-R1B	14.1
				ESTs, Weakly similar to transformation-r	13.8
		AL120659	Hs.6111	aryl-hydrocarbon receptor nuclear transl	13.8
	400205			NM_006265*:Homo sapiens RAD21 (S. pomb	
		AA489732	Hs.154918		13.4
50		AA948033	Hs.130853		13.3
		AL120173	Hs.301663		13.2
		BE280074	Hs.23960	cyclin B1	13.2
		M18728		gb:Human nonspecific crossreacting antig	13.0
		M29540	Hs.220529	carcinoembryonic antigen-related cell ad	12.8
55		NM_000788			12.8
		U33632	Hs.79351	potassium channel, subfamily K, member 1	12.7
	432378	AI493046	Hs.146133		12.5
		BE218239	Hs.202656		12.5
		AA193450		gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sa	
60		AA436989	Hs.121017	H2A histone family, member A	12.2
	407811			cysteine knot superfamily 1, BMP antagon	12.2
		AA195651	Hs.104106		12.2

	420931	AF044197	Hs.100431	small inducible cytokine B subfamily (Cy	12.1
			Hs.107318	kynurenine 3-monooxygenase (kynurenine 3	12.0
			Hs.132586		12.0
					11.9
5		BE178536			11.8
3					11.7
		NM_006159		nel (chicken)-like 2	11.7
					11.6
		AF026944			
10		AA156781			11.5
10		AW975398			11.4
			Hs.21948		11.3
		AW600291			11.3
	420757	X78592	Hs.99915		11.3
		BE336654	Hs.70937		11.2
15			Hs.310359		11.2
	430770	AA765694	Hs.123296		11.0
	421037	AI684808	Hs.197653	programmed cell death 9 (PDCD9)	10.9
	452461	N78223	Hs.108106	transcription factor	10.7
		AA576953	Hs.22972	hypothetical protein FLJ13352	10.6
20		AW965339			10.6
		Al370413	Hs.36563	hypothetical protein FLJ22418	10.4
		W67883		paternally expressed 10	10.4
		Al199268	Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010	
				NIMA (never in mitosis gene a)-related k	10.1
25				Homo sapiens, clone MGC:9084, mRNA, com	
25		H87648	Hs.33922		10.1
	442942	AW167087	HS.131302	Home assiste all IA EL 144292 for plane ME	
				Homo sapiens cDNA FLJ11382 fis, clone HE	
		AA399272			10.1
20		AI624342	Hs.170042		10.0
30		A1926047	Hs.162859		10.0
		AL355715		programmed cell death 9	9.9
		AW966399		hypothetical protein FLJ20086	9.9
		Y00971	Hs.2910	phosphoribosyl pyrophosphate synthetase	9.9
		H23789	Hs.144530		9.9
35	418836	Al655499	Hs.161712	ESTs	9.8
	430291	AV660345	Hs.238126	CGI-49 protein	9.8
	444665	BE613126	Hs.47783	B aggressive lymphoma gene	9.7
	407377	C16391		gb:C16391 Clontech human aorta polyA mRN	9.7
		AA151342	Hs.12677	CGI-147 protein	9.7
40		AI064690	Hs.171176		9.7
•		AI022650	Hs.8117	erbb2-Interacting protein ERBIN	9.7
				uncharacterized bone marrow protein BM04	9.7
		AL360204	Hs.283853	Homo sapiens mRNA full length insert cDN	9.6
				cholesterol 25-hydroxylase	9.6
45		D60730	Hs.57471	ESTs	9.6
43		Al375499	Hs.27379	ESTs .	9.5
		R31178		fibronectin 1	9.3
				leucine-rich repeat-containing 2	9.3
			Hs.7535	COBW-like protein	9.3
50		R17798			9.2
50		U80736		trinucleotide repeat containing 9	9.2
,		AJ224741			9.2
			HS.2/8004	heterochromatin-like protein 1	
		AA410943		gb:zt32h03.r1 Soares ovary tumor NbHOT H	0.1
c c		BE093589	Hs.38178	hypothetical protein FLJ23468	9.1
55		Al337735		ESTs, Moderately similar to ZN91_HUMAN Z	9.0
		AW732573		potassium voltage-gated channel, delayed	9.0
	437021	AI076089	Hs.292239		9.0
	428479	Y00272	Hs.184572	cell division cycle 2, G1 to S and G2 to	8.9
	428839	AI767756	Hs.82302	Homo saplens cDNA FLJ14814 fis, clone NT	8.9
60	402408	NA		NM_030920°:Homo sapiens hypothetical pro	
		AA279490	Hs.86368	calmegin	8.8
		W03242	Hs.44898	Homo sapiens clone TCCCTA00151 mRNA s	
		Al198719	Hs.176376	ESTs	8.8
	440621		Hs.150434		8.8
65		A1754693	Hs.145968		8.8
		A1745649	Hs.26549	KIAA1708 protein	8.7
		AW594641			8.7

	427585	D31152	Hs.179729	collagen, type X, alpha 1 (Schmid metaph	8.6
	415857	AA866115		Homo sapiens cDNA FLJ11381 fis, clone HE	8.6
		Al651474	Hs.163944		8.6
5				CTP synthase	8.4
)		AW067903		collagen, type XI, alpha 1	8.4
		AA382207		ecotropic viral integration site 2B	8.3
		AA767373		ESTs, Moderately similar to ALU1_HUMAN A DKFZP434G232 protein	
		BE268362		COBW-like protein	8.2 8.2
10				protein tyrosine phosphatase, receptor t	8.2
	410193	AJ132592	Hs.59757	zinc finger protein 281	8.2
		X65724	Hs.2839	Norrie disease (pseudoglioma)	8.1
	446258	AI283476	Hs.263478		8.1
	416747	AW876523	Hs.15929	hypothetical protein FLJ12910	8.1
15		Al811202		Homo sapiens cONA: FLJ23523 fis, clone L.	8.1
		AA781795			8.0
	429534	AW976987	Hs.163327	ESTs, Weakly similar to 2109260A B cell	8.0
				DNA replication factor	8.0
20		AW293165			8.0
20		AA379597		HSPC150 protein similar to ubiquitin-con AF15q14 protein	8.0 8.0
		U29926	Hs.83918	adenosine monophosphate deaminase (isofo	
	400285		110.00010	Eos Control	7.9 7.9
		AF039241	Hs.9028	histone deacetylase 5	7.9
25		M18728		gb:Human nonspecific crossreacting antig	7.8
	422232			transcription factor EC	7.8
				hypothetical protein FLJ23403	7.8
		AI161293			7.8
20		A1683487		wingless-type MMTV integration site fami	7.7
30	408805	AL110216			7.6
	437207		Hs.48269 Hs.15929		7.6
		AK001741			7.6 7.6
					7.5 7.5
35	424687				7.5
		NM_016293			7.5
	433426	H69125	Hs.133525		7.5
	406639			gb:Human T-cell receptor (V beta 18.1, J	7.5
40		AW512260			7.4
40					7.4
		NM_001809			7.4
		AI391662 AV653785	He 173334	Homo sapiens, done MGC:12318, mRNA, cor ELL-RELATED RNA POLYMERASE II, ELON	R/.4 CATIO7 2
	410361	BE391804	Hs 62661		7.3
45	400268			NM_003292:Homo sapiens translocated prom	
		AF086332	Hs.58314		7.3
	407771	AL138272	Hs.62713		7.3
	407202		Hs.109370		7.3
<b>5</b> 0	433096	AU076803	Hs.282975	carboxylesterase 2 (intestine, liver)	7.2
50	422094				7.1
		A1073913	HS. 100000	ESTs, Weakly similar to JE0350 Anterior	7.1 57.0
	430207	AA398155	He 07600	ESTs, Weakly similar to LEU5_HUMAN LEUKI ESTs	7.0 7.0
		AJ475858	113.37 000	gb:tc87d07.x1 NCI_CGAP_CLL1 Homo sapier	
55			Hs.326736	Homo sapiens breast cancer antigen NY-BR	
	454440	BE062906	Hs.28338	KIAA1546 protein	7.0
	444783	AK001468	Hs.62180	anillin (Drosophila Scraps homolog), act	7.0
	421373	AA808229	Hs.167771	ESTs	6.9
<b>C</b> D		AW241821			6.9
60					6.8
		AW440211		serine/threonine protein kinase MASK	6.8
		AW449211 AA135257			6.8 6.8
			Hs.193002		6.7
65		AF123050			6.7
					6.7
	446651	AA393907	Hs.97179		6.7

	419839		Hs.93304	phospholipase A2, group VII (platelet-ac	6.7
		AA810265			6.7
		AI910275	Hs.1406	trefoli factor 1 (pS2)	6.7
_		AW023482		ESTs	6.6
5		NM_003816		a disintegrin and metalloproteinase doma	6.6
				CGI-62 protein	6.6
		Al215069	Hs.89113	ESTs	6.5
		A1798680	Hs.25933	ESTs	6.5
10		N40449			6.5
10		Al151418		protein phosphalase 3 (formerly 2B), cat	6.4
		NM_001898			6.4
		AF026941		Homo sapiens cig5 mRNA, partial sequence	6.4
	456938			tyrosine aminotransferase	6.4
		AI820961	Hs.193465		6.4
15				inositol polyphosphate-4-phosphatase, ty	6.4
	452838		Hs.30743	preferentially expressed antigen in mela	6.4
		AA918317	Hs.57987	B-cell CLL/lymphoma 11B (zinc finger pro	6.4
		AJ235664		gb:Homo sapiens mRNA for immunoglobulin	6.3
00		AI222020		CocoaCrisp .	6.3
20		AF217513		done HQ0310 PRO0310p1	6.3
		Al193043		ESTs, Weakly similar to T17226 hypotheti ,	6.2
		AA394183	Hs.26873	ESTs	6.2
	402578	•		C1001134:gi 2117372 plr  165981 fatty ac	6.2
~-		AW161391		deoxycytidine kinase	6.1
25		W17064		SWI/SNF related, matrix associated, acti	6.1
	432415			ESTs, Weakly similar to A43932 mucin 2 p	6.1
	443709	A1082692	Hs. 134662		6.1
		Al694143		programmed cell death 4	6.1
• •		BE440042		matrix metalloprotelnase 3 (stromelysin	6.1
30		AI126772	Hs.40479	ESTs	6.0
	420344	BE463721	Hs.97101	putative G protein-coupled receptor	6.0
	453392	U23752	Hs.32964	SRY (sex determining region Y)-box 11	6.0
		J04088		topoisomerase (DNA) II alpha (170kD)	6.0
		M13509	Hs.83169	matrix metalloprotelnase 1 (MMP1; inters	6.0
35				KIAA0403 protein	6.0
		AA761605		ESTs, Weakly similar to ALU1_HUMAN ALU	
		AA583206		RAR-related orphan receptor A	6.0
		M31126		matrix metalloproteinase 11 (MMP11; stro	6.0
io		R45154	Hs.106604		6.0
40				ESTs, Weakly similar to Con1 [H.sapiens]	6.0
		AA972965			6.0
		X81334	Hs.2936	matrix metalloproteinase 13 (collagenase	6.0
		AA100847		ESTs, Highly similar to AF174600 1 F-box	5.9
4.0		Al831297	Hs.123310		5.9
45		AW972512	Hs.20985	sin3-associated polypeptide, 30kD	5.9
		AW803341		gb:IL2-UM0079-090300-050-D03 UM0079 Ho	
				CGI-83 protein	5.9
		AI793124	Hs.144479		5.9
50				hypothetical protein FLJ22624	5.8
50		AI005043	Hs.24143	Wiskott-Aldrich syndrome protein interac	5.8
		N32536	Hs.42645	solute carrier family 16 (monocarboxylic	5.8
		Al375572	Hs.172634		5.8
				hypothetical protein PRO2013	5.8
		AA306105		SEC22, veside trafficking protein (S. c	5.8
55		Al571940	Hs.7549	ESTs	5.8
		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, done PL	5.8
		Al299139	Hs.17517	ESTs	5.8
		Al033965		sterol-C4-methyl oxidase-like	5.8
<b>CO</b>	400289	X07820	Hs.2258	matrix metalloproteinase 10 (MMP10; str	5.7
60				ESTs, Moderately similar to S65657 alpha	5.7
		AA831879			5.7
		W47595		transforming growth factor, beta 2	5.7
		NM_00711		tumor necrosis factor, alpha-induced pro	5.7
				hypothetical protein MGC14797	5.7
65		AW016531		ESTS	5.7
	446203	Z47553	Hs. 14286	flavin containing monooxygenase 5	5.7
	428336	AA503115	HS.183752	microseminoprotein, beta-	5.6

	43037	AF134149	Hs.24039	5 potassium channel, subfamily K, member 6	5.6
	42283	5 BE21870	5 Hs.12137	8 metallothioneln-like 5, testis-specific	5.6
	44475	3 ALO44878	3 Hs.11899	3-hydroxy-3-methylglutaryl-Coenzyme A re	5.6
_	443426	AF098158	Hs.9329	chromosome 20 open reading frame 1	5.6
5	400301	X03635	Hs.1657	estrogen receptor 1	5.6
	447078	3 AW88572	7 Hs.301570	DESTS	56
	432015	AL157504	Hs.15911	Homo sapiens mRNA; cDNA DKFZp586O07	24 (65 5
	438691	AA906288	Hs.212184	4 ESTs	5.5
	439809	R41396	Hs.101774	hypothetical protein FL123045	5.5
10	415786	AW41919	6 Hs.257924	hypothetical protein FLJ13782	5.5
	456373	BE247706	Hs.89751	membrane-spanning 4-domains, subfamily A	5.5
	401645	NA .		C16001440*:gi]12330704 gb]AAG52890.1 A	F35.5
		BE277414		mel transforming oncogene (derived from	5.5
		AI734009		KIAA1603 protein	5.4
15	439138	A1742605	Hs. 193698		5.4
	440270	NM_01598	36Hs.7120	cytokine receptor-like molecule 9	5.4
		X91221	Hs.144465		5.4
		R28363	Hs.24286	ESTs	5.4
••	452741	BE392914	Hs.30503	Homo sapiens cDNA FLJ11344 fis, clone PL	5.4
20	426214	H59846	Hs.128355	ESTs, Moderately similar to ALU7, HUMAN A	5.4
		AA319146	Hs.75426	secretogranin II (chromogranin C)	5.4
	422867	L32137	Hs.1584	cartilage oligomeric matrix protein (COM	5.4
		N34895	Hs.44648	ESTs	5.4
0.5	446382	AW205168	3 Hs.150823	ESTs	5.4
25	422406	AF025441	Hs.116206	Opa-interacting protein 5	5.3
	438321	AA576635	Hs.6153	CGI-48 protein	5.3
		AA814100			5.3
		U91616	Hs.91640		5.3
20		H39960	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.3
30	445900	AF070526	Hs.13429	Homo sapiens clone 24787 mRNA sequence	5.2
	449051	AW961400	Hs.333526	HER2 receptor tyrosine kinase (c-erb-b2,	5.2
	418758	AW959311	Hs.172012	hypothetical protein DKFZp434J037	5.2
	4310/0	AW408164	Hs.249184	transcription factor 19 (SC1)	5.2
35		U65590	Hs.81134		5.2
33		AF013758	Hs.109643	polyadenylate binding protein-interactin	5.2
	428804	AKUUU713	Hs.193736	hypothetical protein FLJ20706	5.2
		AF077345	Hs.177936		5.2
	403485	* * E00004	11- 440400	C3001813*:gi 12737279 ref XP_012163.1  k	
40	424 100	AA300694	MS.112408	S100 calcium-binding protein A7 (psorias	5.1
40		A1878857	MS. 109/06	hematological and neurological expressed	5.1
		X69490 X70697	Hs.172004		5.1
		M81933	Hs.553	solute carrier family 6 (neurotransmitte	5.1
		Al810054	Hs.1634	cell division cycle 25A	5.1
45			Hs.14119	ESTs	5.1
73	447313 453031	AL121278	Ha 25144	ESTs, Moderately similar to ALU7_HUMAN A	
	404347	AL121210	NS.23144	ESTS	5.1
		M30703	He 270922	Target Exon amphiregulin (schwannoma-derived growth	5.1
		D28235	He 106394		5.1
50	436291	BE568452	He 5101		5.1
-	450603	R43646	Hs.12422	protein regulator of cytokinesis 1 ESTs	5.1
		AK000796			5.1
	435981		Hs.188620		5.0
			He 142287		5.0
55	431689	AA305688	Hs 267695		5.0 5.0
	405348	NA		C7001664:0il126980611dbilBAB24940 41/AB	EΛ
	436196	AK001084	Hs 333498	Homo sapiens cDNA FLJ10222 fis, clone HE	5.U 5.N
	437065	AL036450	Hs 103238		
		AI936442	Hs.59838	1	5.0 5.0
60		NM_006235	Hs.2407		5.0 5.0
_		AU076643	Hs.313		3.U 4.9
	403329	NA			4.9 4.9
	442875	BE623003	Hs.23625	Homo sapiens clone TCCCTA00142 mRNA se	r.J O Mina
	442441		Hs.129598		4.9
65		AW371048	Hs.93758	H4 histone family, member H	4 Q
	424128	AW966163		ab:EST378236 MAGE reservences MAGI He	mo4.9
	408873	AL046017	Hs.182278		4.9

	407040		11- 44000	Character lands of the transport man	4.0
		AA650274 NM_002104		fibronectin leucine rich transmembrane p granzyme K (serine protease, granzyme 3;	4.9 4.9
	453204		Hs.191990		4.8
				ESTs, Weakly similar to AT2A_HUMAN POTE	
5		Z45051	Hs.22920	similar to S68401 (cattle) glucose induc	4.8
	408369	R38438	Hs.182575	solute carrier family 15 (H??? transport	4.8
	431645	AF078849	Hs.266483	dyneln light chaln-A	4.8
				Homo sapiens cDNA FLJ11576 fis, clone HE	4.8
10		H93281	Hs.10710	hypothetical protein FLJ20417	4.8
10				GDNF family receptor alpha 1	4.8 4.8
		AI571835 AL135173	Hs.55468 Hs.878	ESTs sorbitol dehydrogenase	4.8
		AL161999		eukaryotic translation termination facto	4.8
		M93119	Hs.89584	insulinoma-associated 1	4.8
15			Hs.191518		4.8
		Al357412			4.8
	451621	AJ879148	Hs.26770	fatty acid binding protein 7, brain	4.7
		X04430	Hs.93913	Interleukin 6 (Interferon, beta 2)	4.7
20				disintegrin protease	4.7
20				hypothetical protein FLJ10326	4.7 4.7
		AAU95971 AW192307		Homo sapiens cDNA: FLJ22463 fis, clone H dolichyl-P-Glc:Man9GlcNAc2-PP-dolichylgl	4.7
		NM_015310		KIAA0942 protein	4.7
		AI675749		nucleoporin 153kD	4.7
25	,			glutathione reductase	4.7
	405801			NM_000390:Homo sapiens choroideremia (R	a4.6
			Hs.282070		4.6
		W26354		hypothetical protein FLJ11360; artemis p	4.6
20		U62027		complement component 3a receptor 1	4.6 4.6
30		A1864053	Hs.39972 Hs.337404	ESTs, Weakly similar to 138588 reverse t	4.6
	424623		NS.33/404	Target Exon	4.6
	402542	IVA		Target Exon	4.6
		AI916071	Hs.15607	Homo sapiens Fanconi anemia complementa	t 4.6
35		Al907114	Hs.71465	squalene epoxidase	4.6
	456844	Al264155		CDP-diacylglycerol synthase (phosphatida	4.6
		A1459306	Hs.24908	ESTs	4.5
			Hs.245123		4.5 4.5
40		A1472209	Hs.323117 Hs.76277		
40		AF146761		BCM-like membrane protein precursor	4.5
		Al692181	Hs.49169	KIAA1634 protein	4.5
		AW962128		gb:EST374201 MAGE resequences, MAGG I	Homo4.5
	428801	AW277121	Hs.254881		4.5
45		Al815395		fatty acid desaturase 2	4.5
				ESTs, Weakly similar to 2109260A B cell	4.4 4.4
		A1377755			4.4
		AA121673		Homo sapiens winged helix/forkhead trans zinc linger protein 281	4.4
50		AI815206		ESTs	4.4
•	401866		.,	Target Exon	4.4
			Hs.191721	ESTs	4.4
	406348			Target Exon	4.4
	_	AW895387		gb:QV4-NN0038-300300-157-c10 NN0038 H	
55		AW297880		ESTs gb:QV4-CT0361-301299-074-b05 CT0361 H	4.4
	411/43	AW862214	He 283037	HSPC039 protein	4.4
	423300	NM 00412	9Hs 126590	guanylate cyclase 1, soluble, beta 2	4.4
	423456	AL110151	Hs.128797	DKFZP586D0824 protein	4.4
60	452190	H26735	Hs.91668	Homo sapiens done PP1498 unknown mRN	
_	424871	NM_00452	5Hs.153595	low density lipoprotein-related protein	4.3
		AA706003		ESTs	4.3
		Z97630		H1 histone family, member 0	4.3
65		Y15221	HS.103982	small inducible cytokine subfamily B (Cy HER2 receptor tyrosine kinase (c-erb-b2,	4.3 4.3
05		X03363 AL041243	Hs.174104		4.3
		T57448	Hs.15467	hypothetical protein FLJ20725	4.3
	7 10000	101 110	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	•• • • • • • • • • • • • • • • • • • • •	_

	403011		ENSP00000215330*:Probable serine/threoni	4.3
		Al365384 Hs.11571	Homo sapiens cDNA FLJ11570 fis, clone HE	4.3
	418661	NM_001949Hs.1189	E2F transcription factor 3	4.3
-		AA687538 Hs.38972	tetraspan 1	4.3
5	429183	AB014604 Hs.19795		4.3
		AW188551 Hs.99519	hypothetical protein FLJ14007	4.3
		Al091795 Hs.17924		4.3
			olfactory receptor, family 2, subfamily	4.3
10		M63835 Hs.77424		4.2
10			7 Homo sapiens cONA FLJ14035 fis, clone HE	4.2
	432110	T47667 Hs.28005	Homo sapiens cDNA FLJ11309 fis, done PL	
	#420U/	AMDE2027 Ha 42004	3 nucleolar phosphoprotein Nopp34	4.2
		AW953937 Hs.12891	ESTS	4.2
15	421010	Al085198 Hs.16422	5 ESTs, Weakly similar to T47184 hypotheti	4.2
13			ESTs, Weakly similar to S72482 hypotheti	4.2
	446830	BE091926 Hs.16244	mitotic spindle coiled-coil related prot	4.2 4.2
		AL039402 Hs.12578		4.2
		AA902953 Hs.308538		4.2
20		T97490 Hs.50002	small inducible cytokine subfamily A (Cy	4.2
			hypothetical protein FLJ22635	4.2
	425139	AW630488 Hs.325826	) protease, serine, 23	4.2
	447397	BE247676 Hs.18442	E-1 enzyme	4.2
		AK001376 Hs.59346	hypothetical protein FLJ10514	4.1
25		AW779318 Hs.88417	ESTs	4.1
	430486	BE062109 Hs.241551	chloride channel, calcium activated, fam	4.1
		AW294909 Hs.132208	B ESTs	4.1
		BE244074 Hs.58831	regulator of Fas-induced apoptosis	4.1
20		AW973352 Hs.290585		4.1
30			matrix metalloproteinase 11 (MMP11; stro	4.1
		AF041163 Hs.74647	Human T-cell receptor active alpha-chain	4.1
		BE562826	gb:601336534F1 NIH_MGC_44 Homo saplen	
		AK000136 Hs.10760	asporin (LRR class 1)	4.1
35	405850		conserved gene amplified in osteosarcoma  Target Exon	4.1 4.1
55		Al732892 Hs.190489		4.0
		AW292425 Hs.163484		4.0
	400284		estrogen receptor 1	4.0
		N91453 Hs.102987		4.0
40	429732	U20158 Hs.2488	lymphocyte cytosolic protein 2 (SH2 doma	4.0
	411393	AW797437 Hs.69771	B-factor, properdin	4.0
			Human clone 23948 mRNA sequence	4.0
		AA013051 Hs.91417	topoisomerase (DNA) II binding protein	4.0
4=		J05581 Hs.89603	mucin 1, transmembrane	4.0
45		Al034351 Hs.19030	ESTs	4.0
		AW963372 Hs.46677	PRO2000 protein	4.0
		T32982 Hs. 102720		4.0
			thymidine kinase 1, soluble	4.0
50		BE250127 Hs.82906 AW630088 Hs.76550	CDC20 (cell division cycle 20, S. cerevi	3.9
50		AW411479 Hs.848	Homo sapiens mRNA; cDNA DKFZp564B126	
	404580	AW411475 113.040	FK506-binding protein 4 (59kD) NM_014112*:Homo saplens trichorhinophala	3.9
		AB018345 Hs.27657	KIAA0802 protein	3.9
		AA031956	gb:zk15e04.s1 Soares_pregnant_uterus_NbH	
55		U03272 Hs.79432	fibrillin 2 (congenital contractural ara	3.9
			pre-B-cell leukemia transcription factor	3.9
	429353	AL117406 Hs.200102	ATP-binding cassette transporter MRP8	3.9
	419038	AW134924 Hs.190325	ESTs	3.9
	418918	X07871 Hs.89476	CD2 antigen (p50), sheep red blood cell	3.9
60			ribosomal protein L26 homolog	3.9
		At201183 Hs.130251	ESTs	3.9
			cytochrome P450, subfamily IIB (phenobar	3.9
		AW935490 Hs.14658	Human chromosome 5q13.1 clone 5G8 mRNA	3.9
<i>c</i>		BE019020 Hs.85838	solute carrier family 16 (monocarboxylic	3.9
65		NM_002543Hs.77729	oxidised low density lipoprotein (lectin	3.9
		AA809875 Hs.25933		3.9
	413/41	NM_007019Hs.93002	ubiquitin carrier protein E2-C	3.9

PCT/US02/02242

## WO 02/059377

	430017	AA263172	Hs.35	protein tyrosine phosphatase, non-recept	3.9	
				ESTs, Weakly similar to Z195_HUMAN ZINC		
		AW236861			3.8	
					3.8	
5		NM_002267				
)	409425				3.8	
		BE565647			3.8	
	424028	AF055084	Hs.153692		3.8	
	400021			AFFX control - HUMISGF3A/M97935_MA	3.8	
	453403	BE466639	Hs.61779	Homo sapiens cDNA FLJ13591 fis, clone PL	3.8	
10			Hs.172636		3.8	
		AA631739			3.8	
		AW207206			3.8	
		A1446444			3.8	
	401045				3.8	
15		AW449612			3.8	
	423397	NM_001838	Hs.1652	chemokine (C-C motif) receptor 7	3.8	
	447630	Al660149	Hs.44865	lymphoid enhancer-binding factor 1	3.8	
	436391	AJ227892	Hs.146274	ESTs	3.8	
		AW068115			3.8	
20			Hs.179833		3.8	
20					3.8	
		NM_003512				
					3.8	
		AA165232			3.8	
			Hs.50115	Homo sapiens mRNA; cDNA DKFZp761J1112		3.8
25	427122	AW057736	Hs.323910	HER2 receptor tyrosine kinase (c-erb-b2,	3.7	
	400286	NA		C16000922:gi[7499103 pir][T20903 hypothe	3.7	
		A1623693	Hs.191533		3.7	
		AW900992			3.7	
				hypothetical protein FLJ22439	3.7	
30			Hs.125056		3.7	
50				kinectin 1 (kinesln receptor)	3.7	
		Al916662			3.7	
	457001		Hs.2062	vitamin D (1,25- dihydroxyvitamin D3) re		
		AW406878		gb:UI-HF-BL0-adg-g-06-0-UI.r1 NIH_MGC_37		
		NM_014737		Ras association (RalGDS/AF-6) domain fam	3.7	
35		A1208737			3.7	
	430448	A1633553	Hs.13303	Homo sapiens cDNA: FLJ21784 fis, clone H	3.7	
	432729	AK000292	Hs.278732	hypothetical protein FLJ20285	3.7	
	413916	N49813	Hs.75615	apolipoprotein C-II	3.7	
			Hs.106552	cell recognition molecule Caspr2	3.7	
40				normal mucosa of esophagus specific 1	3.7	
				ESTs, Weakly similar to (defline not ava	3.7	
		AA001204	113.230330		3.7	
	406153	4141070000	11- 440000	Target Exon	3.7	
		AW873606				
40		AI884911	Hs.32989	receptor (calcitonin) activity modifying	3.7	
45	448918	AB011152		KIAA0580 protein	3.7	
	413936	AF113676	Hs.297681		3.6	
	448069	U76248	Hs.20191	seven in absentia (Drosophila) homolog 2	3.6	
	453313	BE005771	Hs.153746	hypothetical protein FLJ22490	3.6	
	425234	AW152225	Hs.165909	ESTs, Weakly similar to 138022 hypotheti	3.6	
50		X98654	Hs.93837	phosphatidylinositol transfer protein, m	3.6	
-		AF188625	Hs.189507	phospholipase A2, group IID	3.6	
		Z29572	Hs.2556	tumor necrosis factor receptor superfami	3.6	
					3.6	
		A1800470	Hs.171941		3.6	
				transcription factor 2, hepatic; LF-83;		
55			Hs.183526	ESTs, Weakly similar to 138022 hypotheti	3.6	
	426878	BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Ho		j
	434061	AW024973	Hs.283675	NPD009 protein	3.6	
		AV653264		Homo sapiens cDNA FLJ14666 fls, clone NT	3.6	
		T60298	Hs.10844	Homo sapiens cDNA FLJ14476 fis, clone MA	3.6	
60	427581	NIM OLATRI	RHs 179703	KIAA0129 gene product	3.6	
50		AW961434		ESTs	3.6	
				glucose-6-phosphate dehydrogenase	3.6	
		NM_00040		Homo sapiens cDNA: FLJ22219 fis, clone H		
		W26187	Hs.3327		3.6	
6		S42303	Hs.161	cadherin 2, type 1, N-cadherin (neuronal	3.6	
65	434360	AW015415	HS.12/780	ESTs	3.6	
	428970	BE276891	Hs.194691	retinoic acid induced 3	3.6	
	415079	R43179	Hs.22895	hypothetical protein FLJ23548	3.6	

	409619	AK001015	Hs.55220	BCL2-associated athanogene 2	3.6	
	430044	AA464510	Hs.152812		3.6	
			Hs.194024	ESTs	3.6	
_		AA380731		Interleukin 2 receptor, gamma (severe co	3.6	
5		AF088020		EST	3.6	
		H63010	Hs.5740	ESTs	3.5	
		AA351647		eukaryotic translation elongation factor	3.5	
		AI418055	Hs.161160		3.5	
10		AF234882 AA284166		suppression of tumorigenicity 7	3.5	
10				cyclin-dependent kinase inhibitor 3 (CDK CEGP1 protein	3.5 3.5	
		AI907673	110.20000	gb:IL-BT152-080399-004 BT152 Homo saple		
	403212			NM_019595:Homo sapiens intersectin 2 (IT	3.5	
		AK000725	Hs.50579	hypothetical protein FLJ20718	3.5	
15		AA847843		Homo sapiens, clone IMAGE:3351295, mRN/		
	436338	W92147	Hs.118394		3.5	
		Z43784	Hs.75893	ankyrin 3, node of Ranvier (ankyrin G)	3.5	
		A1827248		Homo sapiens cONA FLJ11469 fis, clone HE	3.5	
20		AA641836		hypothetical protein FLJ23186	3.5	
20		AK002135		hypothetical protein FLJ11273	3.5	
			Hs.137007		3.5	
•				poly(A)-binding protein, cytoplasmic 1-1	3.4	
		BE311926 AW881145	ns. 13630	hypothetical protein FLJ12691	3.4	2.4
25		BE390551	He 77628	gb:QV0-OT0033-010400-182-a07 OT0033 Ho steroidogenic acute regulatory protein r	3.4	3.4
20		W29092	Hs.7678	cellular retinoic acid-binding protein 1	3.4	
		AI167877	Hs.143716		3.4	
	402470			Target Exon	3.4	
	418120	AA213437	Hs.192249		3.4	
30	422414	AW875237	Hs.13701	ESTs	3.4	
		AI681545	Hs.152982	hypothetical protein FLJ13117	3.4	
		U61412	Hs.51133	PTK6 protein tyrosine kinase 6	3.4	
				fucosyltransferase 8 (alpha (1,6) fucosy	3.4	
35		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	3.4	
33		AA447492	HS.20183	ESTs, Weakly similar to AF164793 1 prote	3.4	
	402359		Hs.221504	C19001991*:gi 12656111 gb AAK00751.1 AF		
		F01020	Hs.172004		3.4 3.4	
		AA812633		ESTs	3.4	
40		R11141		hypothetical protein	3.4	
				dipeptidylpeptidase III	3.4	
	412115	AK001763	Hs.73239	hypothetical protein FLJ10901	3.4	
		Y18418		RuvB (E coli homolog)-like 1	3.4	
10			Hs.194698		3.4	
45		U58766		tissue specific transplantation antigen	3.4	
				Homo sapiens, done IMAGE:3616574, mRNA		
		AF037335		carbonic anhydrase XII (tumor antigen H	3.4	
		AW392550	Hs.184339	proteasome (prosome, macropain) subunit,	3.4	
50			Hs.200266		3.3 3.3	
<b>J U</b>		AI335773	Hs.270123		3.3	
		NM_000505		coagulation factor XII (Hageman factor)	3.3	
		AW160375		amyloid beta (A4) precursor-like protein	3.3	
	418327	U70370	Hs.84136	paired-like homeodomain transcription fa	3.3	
55	449065	A1627393	Hs.258998	ESTs, Weakly similar to high mobility gr	3.3	
	425999	AW513051	Hs.332981	ESTs, Weakly similar to I38022 hypotheti	3.3	
				Interleukin 7 receptor	3.3	
		AA161071		squalene epoxidase	3.3	
60			Hs.170197 Hs.204044	glutamic-oxaloacetic transaminase 2, mit	3.3	
<del>UU</del>		A1086138		ras-related C3 botulinum toxin substrate	3.3	
	426429			myosin-binding protein C, slow-type	3.3 3.3	
•		AA026880	Hs.25252	prolactin receptor	3.3	
		U41763	Hs.184916	clathrin, heavy polypeptide-like 1	3.3	
65		BE243136			3.3	
		AI601188	Hs.120910	ESTs	3.3	
	411257	AA628967	Hs.115274	ESTs, Highly similar to IHH_HUMAN INDIAN	3.3	

	430253	AK001514	Hs.236844	hypothetical protein FLJ10652	3.3
	430066	A1929659	Hs.237825	signal recognition particle 72kD	3.3
			Hs.5198	Down syndrome critical region gene 2	3.3
_				polymerase (DNA directed), eta	3.3 3.3
5		H09048		ESTs	3.3
	457183	H91882	Hs.118569	DVI-binding protein IDAX (inhibition of	
	431215	AA496078	HS.121004	Human DNA sequence from clone RP11-2180	3.3
				ret finger protein 2	3.3
10		R43409	Hs.193804 Hs.6829	Homo sapiens mRNA for KIAA1644 protein,	3.3
10		AW978484	He 03842	Homo sapiens cDNA: FLJ22554 fis, clone H	3.3
		AI015709	Hs 172089	Homo sapiens mRNA; cDNA DKFZp586l2022	(13.3
	439237	AW408158	Hs 318893	ESTs. Weakly similar to A47582 B-cell gr	3.3
		BE300330	Hs.118725	selenophosphate synthetase 2	3.3
15		BE614387		c-Myc target JPO1	3.3
		U24683	Hs.302063	Immunoglobulin heavy constant mu	3.3
	434137	AA907734	Hs.124895	ESTs	3.3
	408877	AA479033	Hs.130315	ESTs, Weakly similar to A47582 B-cell gr	3.3
		C01765	Hs.38750	hypothetical protein FLJ11526	3.3
20 ⋅		AA912183		ESTs	3.3 3.3
		U46258	Hs.339665		3.3
	404755		11- 440000	Target Exon	3.2
		AI821005	Hs.118599		3.2
25	420319	AW406289	Un 200607	hypothetical protein immunoglobulin heavy constant gamma 3 (G	
25			HS.300037	NM_002795*:Homo sapiens proteasome (pro	s3.2
	400202 400222			NM_002082*:Homo sapiens G protein-couple	3.2
		BE045897	Hs 274454	ESTs, Weakly similar to 138022 hypotheti	3.2
		BE550224	Hs.74170	metallothionein 1E (functional)	3.2
30		AJ002744	Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polyp	3.2
•		A1027643	Hs.120912	ESTs	3.2
	442353	BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	3.2
		U79745		solute carrier family 16 (monocarboxylic	3.2
		Al793257	Hs.128151		3.2 3.2
35		AA640891			3.2
		H04588	Hs.30469	ESTs \text{ trinucleotide repeat containing 9}	3.2
		AI244459	HS. 1 10820	gb:nt78f05.x5 NCI_CGAP_Pr3 Homo sapien	
		AI821926	Hs.110857		3.2
40		NM_01515		KIAA0071 protein	3.2
40		Al472078	Hs.303662		3.2
		N30714	Hs.325960	membrane-spanning 4-domains, subfamily A	3.2
	418739	AA310964	Hs.88012	SHP2 interacting transmembrane adaptor	3.2
	442053	R35343	Hs.24968	Human DNA sequence from clone RP1-233	G163.
45	A3A7A7	A 4837085	Hs.220585	FSTs	3.2
	427297	AW29259	3 Hs.334907	<ul> <li>Homo sapiens, clone MGC:17333, mRNA, c</li> </ul>	om3.2
	412228	3 AW50378	5 Hs.73792	complement component (3d/Epstein Barr VI	3.2 3.2
		AA025386		ESTs, Weakly similar to \$10590 cysteine	3.2
<b>c</b> 0			7 Hs.36972	CD7 antigen (p41)	3.2
50		3 D50915	Hs.38365	KIAA0125 gene product	3.2
		AL047586	5 Hs.10283 9 Hs.112157	RNA binding motif protein 8B 7 ESTs	3.2
		3 W20128	Hs.296039		3.2
		AA31923		ESTs	3.2
55	45022	3 AA41820	4 Hs.24149	3 natural killer-tumor recognition sequenc	3.2
55			8 Hs.54642	methionine adenosyltransferase II, beta	3.2
		8 AL11866		gb:DKFZp761l0310_r1 761 (synonym: ham	y2)3.2
	41779	3 AW40543	4 Hs.82575	small nuclear ribonucleoprotein polypept	3.2
	42802	7 U22029	Hs.33434	5 cytochrome P450, subfamily IIA (phenobar	3.2
60	44119	7 BE24463	8 Hs.166	sterol regulatory element binding transc	3.2
	42463	4 NM_0036	13Hs.15140	7 cartilage Intermediate layer protein, nu	3.2 3.2
	41998	6 Al345455	Hs.78915		
	41671	4 AF28377	0 Hs.79630	CD79A antigen (immumoglobulin-associate CREB binding protein (Rubinstein-Taybi s	3.2
65	44946	5 NM_UU43	80Hs.23598	5 S100 calcium-binding protein A9 (calgran	3.2
65	42210	6 W72424 9 W87707	Hs.82065		3.2
•	40907	3 AA32759	113.02003 18 Hs.23378		3.2

	450000				
			Hs.61829	· · · · · · · · · · · · · · ·	
		AI733682 AI796870	Hs.130239		3.2
		AF076292	Hs.54277	DNA segment on chromosome X (unique) 99: forkhead box H1	23.2 3.2
5		BE122762		ESTs	3.2
-		S57296		v-erb-b2 avian erythroblastic leukemia v	3.2
		AI703172		ESTs, Weakly similar to 2109260A B cell	3.1
		T06199	Hs.237506	DnaJ (Hsp40) homolog, subfamily B, membe	3.1
10				Interleukin 21 receptor	3.1
10		A1278023	Hs.89986	ESTS	3.1
		BE388898 AL137589		hypothetical protein FLJ11307 hypothetical protein DKFZp434K0410	3.1 3.1
				proteasome (prosome, macropain) 26S subu	3.1
	432715	AA247152	Hs.200483	ESTs, Weakly similar to KIAA1074 protein	3.1
15	431574	AW572659	Hs.261373	hypothetical protein dJ434O14.3	3.1
	436876	Al124756	Hs.5337	isocitrate dehydrogenase 2 (NADP), mitoc	3.1
	405017			Target Exon	3.1
			Hs.112742		3.1
20		AL353957 X70297	Hs.2540	hypothetical protein DKFZp434P0531	3.1 3.1
20			1Hs.111256	cholinergic receptor, nicotinic, alpha p arachidonate 15-lipoxygenase, second typ	3.1
	413507			ESTs, Weakly similar to 138022 hypotheti	3.1
		Al267700	Hs.317584		3.1
25		AI879263	Hs.6986	Human glucose transporter pseudogene	3.1
25		AA890023		prolactin receptor	3.1
		AW247529		non-metastatic cells 1, protein (NM23A)	3.1 3.1
		A1638516	Hs.22630	platelet-activating factor acetylhydrola cofactor required for Sp1 transcriptiona	3.1
		AI885190	Hs.156089		3.1
30	418478	U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	3.1
	400814	NA		Target Exon	3.1
	402327	44400740		Target Exon	3.1
		AA190712	He 106975	gb:zp87f09.r1 Stratagene HeLa cell s3 93 Homo sapiens EST from clone 35214, full	3.1 3.1
35		AL571514	Hs.133022		3.1
	449523	NM_00057		chemokine (C-C motif) receptor 5	3.1
		AJ245210		gb:Homo sapiens mRNA for immunoglobulin	3.1
		AF052762	11 400000		3.1
40		AU076633		coronin, actin-binding protein, 1A	3.1
70		N38857	Hs.203933	serine (or cysteine) proteinase inhibito	3.1 3.1
		D89974	Hs.121102		3.1
		Al399956	Hs.208956		3.1
. ~				hypothetical protein FLJ20035	3.1
45			Hs.339315		3.1
					3.1
	405381	AB012124 NA	ns.30090	and the second s	3.1 3.1
			Hs.192861		3.1
50		AL133731		Homo sapiens mRNA; cDNA DKFZp761C171;	
	425782		Hs.159525		3.1
		W88562	Hs.108198		3.1
		AA234276			3.1
55	417105		Hs.81226	ESTs, Moderately similar to 178885 serin CD6 antigen	3.1 3.0
•					3.0
		BE241595			3.0
	402606				3.0
60	401451	A A 2000CCC	11- 444400	NM_004496*:Homo saplens hepatocyte nucle	
60		BE384836		Homo sapiens cDNA FLJ11643 fis, clone HE	3.0 3.0
		BE561850	Hs.80506		3.0 3.0
	414324		Hs.890		3.0
		X74794		minichromosome maintenance deficient (S.	3.0
65	401519				3.0
		Al499220	Hs.71573		3.0
	420013	AL 100020	115. 1333 14	KIAA0575 gene product	3.0

### WO 02/059377

	428423	AUU/651/	MS. 1042/0	Solute Carrier lanny 5 (Socium Mydrogen	J.U	
	413835	AJ272727	Hs.249163	fatty acid hydroxylase	3.0	
	412600	L28824	Hs.74101	spleen tyrosine kinase	3.0	
	410491	AA465131	Hs.64001	Homo sapiens done 25218 mRNA sequence		
5	433658	L03678	Hs.156110	Immunoglobulin kappa constant	3.0	
	427666	AI791495	Hs.180142	calmodulin-like skin protein	3.0	
	452514	AI904898		gb:RC-BT068-130399-085 BT068 Homo sapi	en3.0	
	429500	X78565	Hs.289114	hexabrachion (tenascin C, cytotactin)	3.0	
	432485	N90866	Hs.276770	CDW52 antigen (CAMPATH-1 antigen)	3.0	
10	437400	AB011542	Hs.5599	EGF-like-domain, multiple 5	3.0	
	452234	AW084176	Hs.223296	ESTs, Weakly similar to I38022 hypotheti	3.0	
	413269	BE167526		gb:CM4-HT0509-080300-107-g07 HT0509 H	omo	3.0
	453216	AL137566	Hs.32405	Homo sapiens mRNA; cDNA DKFZp586G03;	21 (f	3.0
	400929			ENSP00000252232*:Sterol regulatory eleme		
15	445145	Al961702	Hs.147434	ESTs	3.0	
	432615	AA557191	Hs.55028	ESTs, Weakly similar to I54374 gene NF2	3.0	
	423279	AW959861	Hs.290943	ESTs	3.0	
	429392	AL109712	Hs.296506	Homo saptens mRNA full length insert cDN	3.0	
	408548	AA055449	Hs.63187	ESTs, Weakly similar to ALUC_HUMAN IIII	3.0	
20	451346	NM_00633	8Hs.26312	glioma amplified on chromosome 1 protein	3.0	
	413109	AW389845	Hs.110855	ESTs	3.0	
	401714	NA		ENSP00000241802*:CDNA FLJ11007 FIS, C	CLON	3.0
	421462	AF016495	Hs.104624		3.0	
	421750	AK000768	Hs.107872	hypothetical protein FLJ20761	3.0	
25	453293	AA382267	Hs.10653	ESTs	3.0	
	457085	AA412446	Hs.98138	ESTs	3.0	
				hynothetical protein AL110115	3.0	

## TABLE 22A

Table 22A shows the accession numbers for those pkeys lacking unigeneID's for Table 22.

For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey:	Unique Eos probeset Identifier number
CAT number:	Gene cluster number
Accession:	Genbank accession numbers

AA193450

35

456207 165078\_-1

15			
13	Pkey	CAT number	Accessions
			AA046309 Al263500 AA046397
20		1221055_1	AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355
20	411743		AW862214 AW859811 AW862215
	412138	1279172_1	AW895387 AW895547 AW895564 AW895323 AW895405 AW895539 AW895538
	413269	1356961_1	BE167526 BE167651 BE076401 R24654
	416935	163179_1	AA190712 AA190665 AA252564
	422128	211994_1	AW881145 AA490718 M85637 AA304575 T06067 AA331991
25	423945	233566_1	AA410943 AW948953 AA334202 AA332882
	424109	235506_1	AW406878 AW966560 AW966151 AW966496 AA336174 AA335376 AA335537
	424128	235728_1	AW966163 AA335983 AA336011 AA335668 AA335973
	425331	250199_1	AW962128 AA355353 AA427363
	426878	273265_1	BE069341 AW748403 AL044891 Al908240 AA393080
30	432745	353673_1	AI821926 AA658826 AA564492 AA635129 AI791191
	441153	51084_2	BE562826 BE378727
	448212	755099_1	Al475858 AW969013
	451128	859865_1	AL118668 D78823 AI762176
	452514	920172 1	ΔΙΡΑΝΕΙΑ ΡΕΝΑΝΕΙΑ ΕΡΝΑΝΕΙΑ ΕΡΝΑΝΕΙΑ ΕΡΝΑΝΕΙΑ ΕΡΝΑΝΕΙΑ ΕΡΝΑΝΕΙΑ ΕΡΝΑΝΕΙΑ ΕΡΝΑΝΕΙΑ ΕΝΝΑΝΕΙΑ ΕΝΝΑΝΕΙ

# TABLE 22B

Table 22B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 22. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset  Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

1.0				•
15	Pkey	Ref	Strand	Nt_position
	400814	8569925	Minus	72840-72924,74761-74849
	400929	7651921	Minus	122033-122241,123483-124028
20	401045	8117619	Plus	90044-90184,91111-91345
	401451	6634068	Minus	119926-121272
	401519	6649315	Plus	157315-157950
	401645	7657839	Minus	34986-35133
	401714	6715702	Plus	96484-96681
25	401866	8018106	Plus	73126-73623
	402327	7656695	Minus	108675-108770,109801-109910
	402359	9211204	Minus	40403-41961
	402408	9796239	Minus	110326-110491
	402470	9797107	Plus	195129-195776
30	402542	9801558	Minus	67076-67594 ·
	402578	9884928	Plus	66350-66496
	402606	9909429	Minus	81747-82094
	403011	6693597	Minus	3468-3623
		7630897	Minus	156037-156210
35		8516120	Plus	96450-96598
		8783692	Minus	49323-49652
	403485	9966528	Plus	2888-3001,3198-3532,3655-4117
	404347		Plus	74493-74829
		6539738	Minus	240588-241589
40		7706327	Minus	53729-53846
	405017		Plus	35551-35690
	405348		Minus	43310-43462
	405381		Minus	7636-8054
	405801		Plus	63469-63694
45		6164995	Plus	13871-14110
		9929734	Minus	12902-13069
	406348	9255985	Minus	71754-71944

# TABLE 23: 320 GENES DOWN-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT BREAST

Table 23 shows 320 genes down-regulated in breast cancer compared to normal adult breast. These were selected as for Table 22, except that the numerator was set to the median value for 12 non-malignant breast specimens, the denominator was set to the median value amongst the 73 breast cancers, the 90<sup>th</sup> percentile value amongst the 12 non-malignant breast specimens was greater than or equal 80 units, and the ratio was greater than or equal to 4.0

(i.e. 4-fold down-regulated in tumor vs. normal breast).

Pkey:	Unique Eos probeset identifier number
-------	---------------------------------------

ExAccn: Exemplar Accession number, Genbank accession number

15 UnigeneID: Unigene number

Unigene Title: Unigene gene title
R1: Ratio of 50<sup>th</sup> percentile normal body tissue to 75<sup>th</sup> percentile tumor

20	Pkey	ExAccn	UnigeneID	UnigeneTitle	Ratio
•	428722	U76456	Hs.190787	tissue Inhibitor of metalloproteinase 4	22.4
	428848	NM_000230	Hs.194236	leptin (murine obesity homolog)	17.4
	445263	H57646	Hs.42586	KIAA1560 protein	15.4
25	418935	T28499	Hs.89485	carbonic anhydrase IV	15.0
	407228	M25079	Hs.155376	hemoglobin, beta	14.6
		AL049176	Hs.82223	chordin-like	14.6
	439285	AL133916	Hs.172572	hypothetical protein FLJ20093	14.3
	412442	A1983730	Hs.26530	serum deprivation response (phosphatidyl	13.6
30		A1446543	Hs.95511	ESTs	12.6
		AA934589	Hs.49696	ESTs	12.2
		H25642	Hs.133471	ESTs	12.0
		L34041	Hs.9739	glycerol-3-phosphate dehydrogenase 1 (so	12.0
		NM_000163	Hs.125180	growth hormone receptor	11.7
35		AF027208	Hs.112360	prominin (mouse)-like 1	10.8
	428769	AW207175	Hs.106771	ESTs	10.6
		X72632		NM_021724*:Homo sapiens nuclear receptor	10.1
		AW088826	Hs.117176	poly(A)-binding protein, nuclear 1	9.8
		N32759	Hs.172944	chorionic gonadotropin, beta polypeptide	9.8
40		A1220684	Hs.272572	hemoglobin, alpha 2	9.5
		AF039843	Hs.18676	sprouty (Drosophila) homolog 2	9.5
		NM_004657	Hs.26530	serum deprivation response (phosphatidyl	9.4
		AW410377	Hs.41502	hypothetical protein FLJ21276	9.0
		AI365585	Hs.146246	ESTs	9.0
45		T53088	Hs.155376	hemoglobin, beta	8.9
		AF115402	Hs.11713	E74-like factor 5 (ets domain transcript	8.8
		X54162	Hs.79386	leiomodin 1 (smooth muscle)	8.7
		D78874	Hs.8944	procollagen C-endopeptidase enhancer 2	8.6
		AA779958	Hs.185932	ESTs	8.5
50		AU076442	Hs.117938	∞llagen, type XVII, alpha 1	8.4
	433138	AB029496	Hs.59729	semaphorin sem2	8.3
	402195			NM_004497*:Homo sapiens hepatocyte nucle	8.1
		A1754634	Hs.131987	ESTs	8.1
		Al208121	Hs.147313	ESTs, Weakly similar to I38022 hypotheti	8.1
55		N77976	Hs.272572	hemoglobin, alpha 2	8.0
		AW377424	Hs.205126	Homo saplens cDNA: FLJ22667 fis, clone H	8.0
		AA815048	Hs.24078	hypothetical protein FLJ12649	7.8
		AA760849	Hs.294052	ESTs	7.5
<b>CO</b>		AK000027	Hs.98633	ESTs	7.5
60		NM_002599	Hs.154437	phosphodiesterase 2A, cGMP-stimulated	7.5
	430327	AW973636	Hs.55931	ESTs	7.4

PCT/US02/02242

# WO 02/059377

		Al393693	Hs.183297	DKFZP566F2124 protein	7.4
		Al150491	Hs.90756	ESTs	7.2
		R20893	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	7.2
e		AA452006	Hs.333199	ESTs	7.1
5		AW956360	Hs.4748	adenylate cyclase activating polypeptide	7.1
		AI352340	Hs.131194	ESTs	7.0 6.9
		Al219304 Al446183	Hs.283108 Hs.9572	hemoglobin, gamma G	6.8
		AA346839	Hs.209100	ESTs, Highly similar to CYA5_HUMAN ADENY DKFZP434C171 protein	6.7
10		A1478427	Hs.43125	esophageal cancer related gene 4 protein	6.7
10		AB002058	Hs.113275	purinergic receptor P2X-like 1, orphan r	6.7
		AA256395	Hs.88156	ESTs	6.6
	404368			ENSP00000241075*:TRRAP PROTEIN.	6.6
	447261	NM_006691	Hs.17917	extracellular link domain-containing 1	6.5
15		AA193282	Hs.85863	ESTs, Weakly similar to B34612 zinc fing	6.5
	410677	NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	6.5
	427283	AL119796	Hs.174185	ectonucleotide pyrophosphatase/phosphodi	6.5
		AW963085		gb:EST375158 MAGE resequences, MAGH Hom	
20		S72043	Hs.73133	metallothionein 3 (growth inhibitory fac	6.4
20		BE250659	Hs.15463	Homo sapiens, clone IMAGE:2959994, mRNA	6.4
		AA701483	Hs.36341	ESTs	6.3
	402779		U- 42C004	Target Exon	6.3
		AA213626	Hs.136204	EST	6.3 6.3
25		AA742697 AA001732	Hs.62492 Hs.173233	ESTs, Weakly similar to B39066 proline-r	6.2
23		BE143068	113.173233	gb:MR0-HT0158-030200-003-b09 HT0158 Homo	
		BE004783		gb:MR2-BN0114-270400-004-e11 BN0114 Homo	6.1
		NM_012093	Hs.18268	adenylate kinase 5	6.1
		NM_014759	Hs.334688	KIAA0273 gene product	6.1
30		H15968	Hs.293845	Homo saplens, clone IMAGE:3502329, mRNA,	6.1
	417011	F08212	Hs.234898	ESTs, Weakly similar to 2109260A B cell	6.0
	400089	NA		Eos Control	6.0
	433614	W07475	Hs.277101	cytochrome c oxidase subunit IV isoform	5.9
25		N92818	Hs.64754	ESTs, Weakly similar to potential CDS [H	5.9
35		BE067414		gb:MR4-BT0355-200100-201-e05 BT0355 Homo	
		AA062610	Hs.148050	EST	5.9
	406563		11- 05040	Target Exon	5.9 5.9
		AW451023	Hs.65848	hypothetical protein DKFZp761O132	5.9
40		AA843387 NM_001874	Hs.87279 Hs.334873	ESTs carboxypeptidase M	5.8
40		AW809163	H3.3340/3	gb:MR4-ST0118-261099-012-a03 ST0118 Homo	
		AB014533	Hs.33010	KIAA0633 protein	5.8
		Al372588	Hs.8022	TU3A protein	5.8
		AA372052	Hs.334559	Homo sapiens cDNA FLJ14458 fis, clone HE	5.8
45		BE063555		gb:CM1-BT0283-081199-033-d09 BT0283 Homo	
	454192	AW876813	Hs.3343	phosphoglycerate dehydrogenase	5.7
		AW014486	Hs.22509	ESTs	5.7
		AW452355	Hs.256037	ESTs	5.7
50		AL036557	Hs.95910	putative lymphocyte G0/G1 switch gene	5.7
50		AI695473	Hs.298006	ESTs	5.7
		AA181641	Hs.184907	G protein-coupled receptor 1	5.6
	404689		11-005400	Target Exon	5.6
		R68857	Hs.265499	ESTS	5.6 5.6
55		S47833 H23963	Hs.82927 Hs.32043	adenosine monophosphate deaminase 2 (iso ESTs	5.6
JJ		R50253	Hs.249129	cell death-inducing DFFA-like effector a	5.5
		C15819	130,243 123	gb:C15819 Clontech human aorta polyA mRN	5.5
		AW444613	Hs.288809	hypothetical protein FLJ20159	5.5
		AB020629	Hs.38095	ATP-binding cassette, sub-family A (ABC1	5.5
60		A1668605	Hs.60380	ESTs, Moderately similar to ALU6_HUMAN A	5.5
		AA345824	Hs.76688	carboxylesterase 1 (monocyte/macrophage	5.5
	401665			C11000703:gi[10048448]ref[NP_065258.1[g	5.5
		T99079	Hs.191194	ESTs	5.5
15		A1161428	Hs.75916	splicing factor 3b, subunit 2, 145kD	5.5
65		BE005346	Hs.116410	ESTs	5.5
		BE617015	Hs.11006 Hs.42824	ESTs, Moderately similar to T17372 plasm hypothetical protein FLJ10718	5.5
	400122	AI432652	1 13.44044	וויטעטובעעמו עויטבווו ר ש ועי ויט	5.5

	454016	AW016806	Hs.233108	ESTs	5.5
	414913	R25621			5.4
	459033	AA017590	Hs.129907		5.4
_		BE172240	Hs.126379		5.4
5		N49826	Hs.18602		5.4
		AA994520		gb:ou42g09.s1 Soares_NFL_T_GBC_S1 Homo s	
	403612			· 3 · · · · · · ·	5.3
		AA007629	Hs.9739	3	5.3
10		R66634	Hs.268107		5.3
10		BE272452	Hs.183109		5.3
		AA620814	Hs.144959		5.3
		R99530	Hs.272572		5.3
		AF012023	Hs.173274		5.3
15		BE261320	Hs.158196		5.3 5.3
IJ		AW613948	Hs.194915		5.3
	402054	AI809481	Hs.131227		5.3
			He 272406		5.3
		AF212829 R59638	Hs.272406 Hs.6181		5.2
20		AI904646	115.0101		5.2
20		AB037721	Hs.173871		5.2
		BE467930	Hs.170381		5.2
		Al285901	Hs.181297		5.2
	402698		110.101201		5.2
25	401810			Target Exon	5.2
		AA827674	Hs.189073	· • · • · • · · · · · · · · · · · · · ·	5.2
		AA424074	Hs.76780		5.2
		M26380	Hs.180878		5.1
		NM_006744	Hs.76461		5.1
30	451186	AW023469	Hs.65256		5.1
		AI821324	Hs.100445		5.1
	402583	NA		NM_021620:Homo sapiens PR domain contain	5.1
	431130	NM_006103	Hs.2719	HE4; WFDC2; putative ovarian carcinoma m	5.1
	458218	Al435179	Hs.126820	ESTs	5.1
35	416083	R53467	Hs.269122	ESTs, Weakly similar to ALU1_HUMAN ALU S	5.1
		BE143867		gb:MR0-HT0164-070100-013-h02 HT0164 Homo	
		X03350	Hs.4	alcohol dehydrogenase 18 (class I), beta	5.1
		BE244537	Hs.167382	natriuretic peptide receptor A/guanylale	5.1
40		AA486620	Hs.41135		5.0
40		AW026692	Hs.224829		5.0
		D59597	Hs.118821		5.0
		AI524307	Hs.162870		5.0
		A1076012	Hs.121388	ESTs, Weakly similar to MDHC_HUMAN MALAT	
45		BE160229	11- 54470	gb:QV1-HT0413-090200-062-a12 HT0413 Homo	5.0
43		AF012626 AW502327	Hs.54472		5.0
	405062	AVV302321		gb:UI-HF-BR0p-aka-a-07-0-UI.r1 NIH_MGC_5 Target Exon	5.0
		AK000706	Hs.15125	hypothetical protein FLJ20699	5.0
		AW298163	Hs.82318	WAS protein family, member 3	5.0
50		AJ243662	Hs.110196	NICE-1 protein	5.0
50		R62431	Hs.12758	ESTs	5.0
		R35009	Hs.24903	ESTs	5.0
		R00348		gb:ye69e06.r1 Soares fetal liver spleen	5.0
		AJ243191	Hs.56874	heat shock 27kD protein family, member 7	5.0
55		AI768289	Hs.304389	ESTs	4.9
		BE550889	Hs.158491	ESTs	4.9
	443074	AW341470	Hs.144907	ESTs	4.9
	451324	A1783600	Hs.208052	ESTs	4.9
		AW014734	Hs.157969	ESTs	4.9
60		AI989812	Hs.199850	ESTs	4.9
		N94587	Hs.55063	ESTs	4.9
		AW973716	Hs.13913	KIAA1577 protein	4.9
		AA682722	Hs.192725	ESTs	4.9
ce		AF026263	Hs.247920	cholinergic receptor, muscarinic 5	4.8
65		AW137094	Hs.97990	ESTS	4.8
		AA868510	Hs.112496	ESTS	4.8 4.8
	420334	AI349351	Hs.118944	hypothetical protein FLJ22477	4.0

	421795	X63094	Hs.283822	Rhesus blood group, D antigen	4.8
	427138	N77624	Hs.173717	phosphatidic acid phosphatase type 2B	4.8
	413072	BE063965		gb:QV3-BT0296-140200-085-h01 BT0296 Homo	4.8
_	443721	AW450451	Hs.266355	ESTs	4.8
5	408053	AW139474	Hs.246862	ESTs	4.8
	427067	AA843716	Hs.177927	ESTs	4.7
	442969	AI025499	Hs.132238	ESTs	4.7
	426220	Al383475	Hs.171697	ESTs, Weakly similar to T13924 sdk prote	4.7
	414593	BE386764		gb:601273249F1 NIH_MGC_20 Homo sapiens c	4.7
10	426893	AA398716	Hs.97418		4.7
	434046	AW292618	Hs.113011	ESTs	4.7
	401590	NA		Target Exon	4.7
	457971	AW134679	Hs.242849	ESTs	4.7
	427722	AK000123	Hs.180479	hypothetical protein FLJ20116	4.6
15		AA045290	Hs.25930		4.6
	407737	R49187	Hs.6659	ESTs	4.6
	441955	AA972327	Hs.142903	ESTs	4.6
		AW298235	Hs.101689	ESTs	4.6
		Al382726	Hs.182434		4.6
20	403017			Target Exon	4.6
		N40087	Hs.15248	ESTs	4.6
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	4.6
		M31158	Hs.77439	protein kinase, cAMP-dependent, regulato	4.6
		NM_001546	Hs.34853		4.6
25		Al142027	Hs.146650	ESTs	4.6
	408614	AL137698	Hs.46531	Homo sapiens mRNA; cDNA DKFZp434C1915 (f	4.6
	449638	AW204277	Hs.250723	hypothetical protein MGC2747	4.6
	434418	AF134707	Hs.278679	a disintegrin and metalloproteinase doma	4.6
	447360	Al375984	Hs.167216	ESTs	4.6
30	419583	F00312		gb:HSBB0D101 STRATAGENE Human skeletal i	n4.6
	440698	Al348455	Hs.147492	Homo sapiens cONA FLJ11777 fis, clone HE	4.6
	451199	AI290653	Hs.124758	ESTs	4.6
	438338	NM_014861	Hs.6168		4.6
0.5		AW015933	Hs.112654		4.5
35		S67580 `	Hs.1645	cytochrome P450, subfamily IVA, polypept	4.5
		H86385	Hs.81737	palmitoyl-protein thioesterase 2	4.5
		AL389981	Hs.149219	Homo sapiens mRNA full length insert cDN	4.5
		AA335769	Hs.16262	ESTs	4.5
40		H73444	Hs.394	adrenomedullin	4.5
40		N94835	Hs.283828		4.5
		AF035303	11 0500	gb:Homo sapiens clone 23943 mRNA sequenc	4.5
		NM_012190	Hs.9520	formyltetrahydrofolate dehydrogenase	4.5
		AA169114	Hs.12247	hypothetical protein FLJ11413	4.5
15		Z43619	Un COCEA	gb:HSC1GE121 normalized Infant brain cDN	4.5
45		BE142052	Hs.62654	kringle-containing transmembrane protein	4.5
		BE387287	Hs.83384	S100 calcium-binding protein, beta (neur	4.4
		AI356125	Hs.157767	ESTs, Weakly similar to HXA2_HUMAN HOMEO eukaryotic translation initiation factor	4.4
	401093	AA156998	Hs.211568		4.4
50		AW206494	Hs.253560	C12000586*:gi 6330167 dbj BAA86477.1  (A ESTs	4.4
50		AW842353	Hs.321717	ESTs, Weakly similar to S22765 heterogen	4.4
		AL133112	Hs.183085	Homo sapiens mRNA; cDNA DKFZp434K098 (fr	
		Al264634	Hs.131127	ESTs	4.4
		AL359599	Hs.283850	Homo sapiens mRNA; cDNA DKFZp547C126 (fr	
55		AI380906	Hs.158436	ESTs	4.4
33		H03589	113.150455	gb:yj42d08.r1 Soares placenta Nb2HP Homo	4.4
		R37101	Hs.20982	ESTs	4.4
		AA807958	Hs.314232	ESTs	4.4
		AI499723	Hs.135089	ESTs	4.4
60		H87407	Hs.172944	chorionic ganadotropin, beta polypeptide	4.4
		AF147401	Hs.23917	ESTs	4.3
	400870			C11000905:gi[11692565]gb[AAG39879.1]AF28	4.3
		AA933590	Hs.28937	homeobox protein from AL590526	4.3
		H45384		gb:yn99c10.r1 Soares adult brain N2b5HB5	4.3
65		M12873		gb:Human Ig rearranged H-chain mRNA VDJ4	4.3
	444567	AV654020	Hs.184261	ESTs, Weakly similar to T26686 hypotheti	4.3
	403263	NA		Target Exon	4.3

	44000				
		BE067414	LI- 420054	gb:MR4-BT0355-200100-201-e05 BT0355 Hom	
		AI421645 BE395260	Hs.139851 Hs.309438	caveolin 2 EST	4.3
		D45371	Hs.80485	adipose most abundant gene transcript 1	4.3 4.3
5		NM_002666	Hs.103253	perlipin	4.3
	400973			ENSP00000236667*:Mucin 5B (Fragment).	4.3
	452602	AW366194	Hs.55962	ESTs	4.3
		NM_005100	Hs.788	A kinase (PRKA) anchor protein (gravin)	4.3
10	405016			CY000171*:gij9280405 gb AAF86402.1 AF245	4.3
10		AJ475671	Hs.88607	ESTs, Highly similar to F-box protein FB	4.3
	406118			ENSP00000246632:CDNA FLJ20261 fis, done	4.3
		T02850	LI- 004700	gb:FB12A9 Fetal brain, Stratagene Homo s	4.3
		AA480818 AW451206	Hs.221736 Hs.115899	ESTs ESTs	4.3
15		AA342329	Hs.115920		4.3
10		AI803166	Hs.28462	Homo sapiens cDNA: FLJ22816 fis, clone K ESTs, Weakly similar to I38022 hypotheti	4.3 4.3
		Al377221	Hs.40528	ESTs	4.2
		BE293116	Hs.76392	aldehyde dehydrogenase 1 family, member	4.2
	444975	AV652165	Hs.182482	ESTs, Weakly similar to T00362 hypotheti	4.2
20	403921			C5000212*:gi 10047237[dbj BAB13407.1] (A	4.2
		AI798425	Hs.42710	ESTs	4.2
	406344	44404004	11. 05004	C5001660:gi 11611537 db  BAB18935.1  (AB	4.2
		AA191201 BE155866	Hs.35861	DKFZP586E1621 protein	4.2
25		AW070634	Hs.25522 Hs.144794	KIAA1808 protein ESTs	4.2
	404682		(15.144/54	C9001188*:gi[12738842 refjNP_073725.1  p	4.2 4.2
		N69913	Hs.6858	ESTs, Weakly similar to 178885 serine/th	4.2
	403433		110.000	NM_001622:Homo sapiens alpha-2-HS-glycop	4.2
	446532	AW975460	Hs.143563	ESTs	4.2
30		A1309298	Hs.279898	Homo sapiens cDNA: FLJ23165 fis, done L	4.2
		A1871247	Hs.6262	hypothetical protein MGC8407	4.2
		AW973708	Hs.201925	Homo sapiens cDNA FLJ13446 fis, clone PL	4.2
		AA397789 AF193807	Hs.161803	ESTs Standard Salaranti	4.2
35		Y09763	Hs.131835 Hs.22785	Rhesus blood group, B glycoprotein	4.2
55		AI733098	Hs.130800	gamma-aminobutyric acid (GABA) A recepto ESTs	4.2 4.2
		AF086410	113.100000	gb:Homo sapiens full length insert cDNA	4.2
		AA399975	Hs.274151	ligatin	4.2
	408932	AW594172	Hs.278513	TP53TG3 protein	4.2
40		T77545	Hs.187559	ESTs	4.2
		Al144152	Hs.58246	ESTs	4.2
		AA318060	Hs. 135121	hypothetical protein FLJ22415	4.2
		NM_015977	Hs.285681	Williams-Beuren syndrome chromosome regi	4.2
45	410036	R57171	Hs.57975	calsequestrin 2 (cardiac muscle)	4.1
43	403051			Target Exon Target Exon	4.1
		NM_005357	Hs.95351	lipase, hormone-sensitive	4.1 4.1
		AA007534	Hs.125062	ESTs	4.1
	453261	AA034116	Hs.118494	ESTs	4.1
50		W52010	Hs.191379	ESTs	4.1
		Al307802	Hs.135560	ESTs, Weakly similar to T43458 hypotheti	4.1
		AI150595	Hs.122226	ESTs	4.1
		AA082947	11- 00400	gb:zn10g07.s1 Stratagene hNT neuron (937	4.1
55		BE270758 Al306150	Hs.69428 Hs.153450	hypothetical protein MGC3020	4.1
55		AK000708	Hs.169764	ESTs, Weakly similar to 1909123A Na gluc hypothetical protein FLJ20701	4.1
		AL110416	113.103704	gb:DKFZp434K0431_r1 434 (synonym: htes3)	4.1 4.1
		AW817177	Hs.102558	Homo sapiens, clone MGC:5352, mRNA, comp	4.1
		AA203281	Hs.21798	ESTs	4.1
60	412912	AW118878	Hs.110835	ESTs	4.1
		AW807116		gb:MR4-ST0062-040100-024-b12 ST0062 Homo	4.1
		AW631296		gb:hh83c09.y1 NCL_CGAP_GU1 Homo sapiens	4.1
	435942		Hs.191215	ESTS	4.1
65	417629 403593				4.1
33	402690	nv.		Target Exon Target Exon	4.0
	418190	R49591	Hs.270425	ESTs	4.0 4.0
					7.0

	408641	AW245207	Hs.5555	hypothetical protein MGC5347	4.0
	427899	AA829286	Hs.332053	serum amyloid A1	4.0
	445975	AI811536	Hs.145734	ESTs	4.0
	438831	BE263273	Hs.6439	synapsin II	4.0
5	455578	BE006350	Hs.14355	Homo sapiens dDNA FLJ13207 fis, clone NT	4.0
	401840	NA		Target Exon	4.0
	413753	U17760	Hs.75517	laminin, beta 3 (niceln (125kD), kalinin	4.0
	445030	Al205925	Hs.147238	ESTs, Highly similar to AAC3_HUMAN ALPHA	4.0
	433873	AW156913	Hs.150478	ESTs, Weakly similar to A Chain A, Cryst	4.0
10	456736	AW248217	Hs.1619	achaete-scute complex (Drosophila) homol	4.0
	450112	BE047734	Hs.5473	ESTs, Moderately similar to ALU5_HUMAN A	4.0
	448906	A1589567	Hs 309719	ESTs	40

### TABLE 23A

Table 23A shows the accession numbers for those pkeys lacking unigeneID's for Table 23. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number
Accession: Genbank accession numbers

15

55

454404 1170594\_1

454775 1234106\_1

455282 1273020\_1

459159 919998\_1

#### Pkey CAT number Accessions AW502327 AW502488 AW501829 AW502625 AW502687 409853 1156226\_1 20 BE067414 BE067958 BE067419 BE067963 AW577127 AW601412 410034 1170594\_1 410233 118656\_1 AA082947 AA083036 H03589 AW750687 AW750688 410490 1205347\_1 AW809163 AW809247 AW809177 AW809190 AW809225 410882 1225686\_1 BE143068 AW849143 AW848705 AW848569 AW848071 AW848475 AW848092 AW848005 411478 1247073\_1 25 BE063555 BE151321 BE151319 BE151657 BE151655 BE063556 BE151322 413065 1347960\_1 BE063965 BE063968 BE064034 BE064028 BE063874 BE063966 BE063869 BE064043 BE064033 BE063884 413072 1348163\_1 414593 1464909\_1 BE386764 BE387560 414913 1506721\_1 R25621 C03959 C04010 415011 151328\_1 AW963085 AA159005 AW963073 30 415986 1564410\_1 Z43619 R61274 H12206 R12883 416267 1583547\_1 H45384 H49125 H41699 417574 1687770\_1 R00348 R09593 417629 1690392\_1 T76945 R20210 R05755 T02850 418556 1767866\_-1 35 419583 186198\_1 F00312 AA247490 F31427 AA383663 F22045 426328 264901\_1 AW631296 AA375484 439590 47413\_1 AF086410 W94386 W74609 442398 541271\_1 AA994520 AW393574 452205 90415\_1 C15819 AA024741 AA024742 40 452654 925931\_1 BE004783 BE004947 AI911790 453692 977825\_1 AL110416 AW876759 AW807116 AW807569 AW807415 AW807338 AW807288 AW807263 AW807316 AW177402 AW807413 AW807068 BE141561 454183 1049636\_1 BE141569 AW807401 AW807310 BE141565 AW807318 AW807119 AW807299 AW807241 AW807225 AW807204 AW807345 AW807103 BE141615 AW807431 AW807393 AW807337 AW807406 AW807259 AW807375 AW845890 AW807220 AW807399 45 AW807064 AW807376 AW807024 BE141595 AW807236 AW807027 AW807112 AW807378 AW807202 BE141593 AW807216 AW807138 AW807244 AW807221 AW807297 AW807050 AW807248 AW807404 AW807075 AW807237 AW807212 AW807308 AW807110 AW807104 BE140912 AW807301 AW807382 AW807294 AW807026 AW807020 AW807108 AW807025 AW807433 AW807124 AW807419 AW807031 AW807264 AW807032 AW807029 AW807052 AW807391 AW807207 AW807215 AW807019 AW807238 AW807201 BE141590 AW807302 AW807323 AW807380 AW807109 BE141588 AW845877 AW807418 AW807407 50 AW807309 BE141614 AW845861 AW807396 AW807300 AW807348 AW807311 AW807214 AW807132 AW807402 AW807350 AW807028 AW807298 AW807291 AW807305 AW807217 AW807312 AW807261 AW807268 AW807260 AW807266 AW807198 AW807346 AW807315 BE140940 AW807351 AW807122 AW807235 AW807076 AW807314 AW807213 AW807143 AW807131 AW800079 AW807066 AW807077 AW845923 AW807421 BE141619 BE140943 AW807420 AW807381 BE141621 AW845921 BE141629 BE141625 BE141624 BE141636 BE141630 AW807405 AW807290 AW807353

BE067414 BE067958 BE067419 BE067963 AW577127 AW601412

BE143867 AW935060 AW886684

Al904646 BE179494 BE179421

BE160229 AW819879 AW820179 AW819882 AW819876 AW820169 BE153201 AW993736 BE152911

# TABLE 23B.

Table 23B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 23. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

·10	Pkey: Ref:	Unique number corresponding to an Eos probeset  Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I, et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I, et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.
15		

15	Pkey	Ref	Strand	Nt_position
	400545	9800107	Minus	124618-124881
	400870	9838306	Minus	34081-35027
20	400973	7960452	Minus	98119-98253
	401093	8516137	Minus	22335-23166
	401590	9966320	Minus	33547-33649
	401665	7145001	Plus	121591-122537
	401810	7342191	Plus	129063-129476
25	401840	7684597	Plus	56283-56439
	402054	8083691	Minus	8288-8806
	402195	7689778	Minus	147901-148884
	402583	7684486	Plus	94883-95003
	402690	8348058	Plus	13368-13998
30	402698	8570304	Minus	108641-108903
	402779	9588555	Minus	38173-39210
	403017	6693623	Plus	78630-79367
	403051	4827080	Minus	5269-5411
	403263	7770677	Plus	52431-52737
35	403433	9719611	Minus	72225-72437
	403593	6862650	Minus	62554-62712,69449-69602
	403612	8469060	Minus	94723-94859
	403921	7711590	Minus	3297-3536
	404368	7630956	Minus	102053-102199
40	404682	9797231	Minus	40977-41150
	404689	7534100	Plus	119461-119717
	405016	6524300	Plus	51997-53308
	405062	7657730	Plus	101283-101432
	406118	9143818	Plus	53997-54629
45	406344	9255974	Plus	20254-20374,20526-20659,20835-21097
	406563	7711604	Plus	34401-34538

## **TABLE 24:**

Table 24 depicts Seq ID No., UnigeneID, UnigeneTitle, Pkey, Pred.Cell.Loc., and ExAcon for all of the sequences in Table 25. The information in Table 24 is linked by Seq ID No. to Table 25.

10		n: nelD: ne Title:	Unique Eos pro Exemplar Acce Unigene numbe Unigene gene ti Predicted Cellui	ile		
15	Seq.iD			e Identification Number found in Table 25		
	Pkey	ExAccn	UnigeneID	Unigene Title	Pred.Cell.Loc.	Seq. ID. No.
20	407276 415539 400297 450378	6 Al668594 6 Al951118 9 Al733881 7 Al127076 6 AA00964 7 NM_0013	Hs.326736 Hs.72472 Hs.334473 7 Hs.8850	ESTs, Weakly similar to CP4Y_HUMAN CYT Homo saplens breast cancer antigen NY-BR BMP-R1B hypothetical protein DKFZp564O1278 a dishtegrin and metalloproteinase doma		Seq ID 1 & 2 Seq ID 3 & 4 Seq ID 5 & 6 Seq ID 7 & 8 Seq ID 9 & 10
25	429170 424399 422505 449765	NM_0013 AJ905687	94Hs.2359	dual specificity phosphatase 4 dual specificity phosphatase 4 aldehyde dehydrogenase 9 family, member ESTs ESTs, Moderately similar to ALU8_HUMAN A	nuclear nuclear cytoplasm	Seq ID 11 & 12 Seq ID 11 & 12 Seq ID 13 & 14 Seq ID 15 & 16 Seq ID 17 & 18
30	426215 439840 410102	AW96341 AW44921 AW24850	9 Hs.155223 1 Hs.105445 8 Hs.279727 6 Hs.136319	N-acetyttransferase 1 (arytamine N-acety stanniocalcin 2 GDNF family receptor alpha 1 Homo sapiens cDNA FLJ14035 fis, clone HE ESTs		Seq ID 19 & 20 Seq ID 21 & 22 Seq ID 23 & 24 Seq ID 25 & 26
35	416276 409079 442818 442082	U41060 W87707 AK001741 R41823	Hs.79136 Hs.82065	LIV-1 protein, estrogen regulated interleukin 6 signal transducer (gp130, hypothetical protein FLJ10879 ESTs		Seq ID 27 & 28 Seq ID 29 & 30 Seq ID 31 & 32 Seq ID 33 & 34 Seq ID 35 & 36
40	446163 416636 442117 433043	AA026880 N32536 AW664964 W57554	Hs.25252 Hs.42645 Hs.128899 Hs.125019 Hs.200102	ESTs, Weakly similar to S64054 hypotheti Homo sapiens cDNA FLJ13603 fis, done PL solute carrier family 16 (monocarboxylic ESTs lymphoid nuclear protein (LAF-4) mRNA ATP-binding cassette transporter MRP8		Seq ID 37 & 38 Seq ID 39 & 40 Seq ID 41 & 42 Seq ID 43 & 44 Seq ID 45 & 46
45	452190 446733 452747 423242 417433	H26735 AA863360 BE153855 AL039402 BE270266	Hs.91668 Hs.26040 Hs.61460 Hs.125783 Hs.82128	Homo sapiens done PP1498 unknown mRNA ESTs, Weakly similar to fatty acid omega Ig superfamily receptor LNIR DEME-6 protein 5T4 oncofetal trophoblast glycoprotein		Seq ID 47 & 48 Seq ID 49 & 50 Seq ID 51 & 52 Seq ID 53 & 54 Seq ID 55 & 56 Seq ID 57 & 58
50	423961 439569	D13666 AW602166 BE066778	Hs.298241 Hs.136348 Hs.222399 Hs.151678	Transmembrane protease, serine 3 osteoblast specific factor 2 (fascicfin CEGP1 protein UDP-N-acetyl-atpha-D-galactosamine:potyp NM_014112*:Homo sapiens trichorhinophala		Seq ID 59 & 60 Seq ID 61 & 62 Seq ID 63 & 64 Seq ID 65 & 66 Seq ID 67 & 68
55	112287 335824 424735 400289 427585	AB033064 NA U31875 X07820 D31152	Hs.334806 Hs.272499 Hs.2258 Hs.179729	KIAA1238 protein ENSP00000249072*:DJ222E13.1 (N-TERMIN, short-chain alcohol dehydrogenase family matrix metalloproteinase 10 (stromelysin collagen, type X, atpha 1 (Schmid metaph	nuclear Al.	Seq ID 69 & 70 Seq ID 71 & 72 Seq ID 73 & 74 Seq ID 75 & 76 Seq ID 77 & 78 Seq ID 79 & 80
60	429441 421155 420931 420813	AJ224172 H87879 AF044197	6Hs.226213 Hs.204096 Hs.102267 Hs.100431 Hs.99949 Hs.30504	lipophilin B (uteroglobin family member) lysyl oxidase small inducible cytokine B subfamily (Cy	ER extracellular nuclear fr	Seq ID 81 & 82 Seq ID 83 & 84 Seq ID 85 & 86 Seq ID 87 & 88 Seq ID 89 & 90 Seq ID 91 & 92

	420757	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	cytoplasm	Seq ID 93 & 94
	424905	NM_00249	7Hs.153704	NIMA (never in mitosls gene a)-related k	nuclear	Seq ID 95 & 96
	429859	NM 007050	OHs.225952	protein tyrosine phosphatase, receptor t		Seq ID 97 & 98
	446921	AB012113	Hs.16530	small inducible cytokine subfamily A (Cy	extracellular	Seq ID 99 & 100
5	445537	AJ245671	Hs.12844	EGF-like-domain, multiple 6		Seq ID 101 & 102
•			Hs.2248	small inducible cytokine subfamily B (Cy	extracellular	Seq ID 103 & 104
	424001	W67883	Hs.137476	paternally expressed 10		Seq ID 105 & 106
		Y13153	Hs.107318	kynurenine 3-monooxygenase (kynurenine 3		Seq ID 107 & 108
		U65011	Hs.30743	preferentially expressed antigen in mela	nuclear	Seq ID 109 & 110
10	419667	AU077005	Hs.92208	a disintegrin and metalloproteinase doma		Seq ID 111 & 112
	414812	X72755	Hs.77367	monokine induced by gamma Interferon	extracellular	Seq ID 113 & 114
	426320	W47595	Hs.169300	transforming growth factor, beta 2	extracellular	Seg ID 115 & 116
	422867	L32137	Hs.1584	cartilage oligomeric matrix protein (pse	extracellular	Seq ID 117 & 118
	411558	AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto		Seq ID 119 & 120
15	417866	AW067903	Hs.82772	collagen, type XI, alpha 1		Seq ID 121 & 122
	428398	AI249368	Hs.98558	ESTs		Seq ID 123 & 124
	431958	X63629	Hs.2877	cadherin 3, type 1, P-cadherin (placenta	plasma membrane	Seq ID 125 & 126
	428722	U76456	Hs.190787	tissue inhibitor of metalloproteinase 4	•	Seq ID 127 & 128
	412970	AB026436	Hs.177534	dual specificity phosphatase 10		Seq ID 129 & 130
20	421379	Y15221	Hs.103982	small inducible cytokine subfamily B (Cy	extracellular	Seq ID 131 & 132
	415752	BE314524	Hs.78776	putative transmembrane protein		Seq ID 133 & 134
	444051	N48373	Hs.10247	activated teucocyte cell adhesion molecu		Seq ID 135 & 136
	451110	A1955040	Hs.265398	ESTs, Weakly similar to transformation-r		Seq ID 137 & 138

## **TABLE 24A**

Table 24A shows the accession numbers for those pkeys lacking unigeneID's for Table 24. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10 Pkey: CAT number: Unique Eos probeset identifier number Gene cluster number Accession: Genbank accession numbers

15 Pkey CAT number Accession 335824 CH22\_3197FG\_619\_11\_LINK\_E 325372 c12\_hs

### TABLE 24B

Table 24B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 24. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand:	Indicates DNA strand from which exons were predicted.
	Nt_position:	Indicates nucleotide positions of predicted exons.

 Pkey
 Ref
 Strand
 Nt\_position

 404561
 9795980
 Minus
 69039-70100

### Table 25

75

Seq ID NO: 1 DNA sequence

The 69 gene sequences identified to be overexpressed in breast cancer may be used to identify coding regions from the public DNA databases (nr and htgs in Genbank). The sequences may be used to either identify genes that encode known proteins, or they may be used to predict the coding regions from genomic DNA using exon prediction algorithms, such as FGENESH (Salamov and Solovyev, 2000, Genome Res. 10:516-522) 5

Nucleic Acid Accession #: FGENESH predicted ORF 1-1518 (underlined sequences correspond to start and stop codons) Coding sequence: 10 ATGCAGTAA AGGAGTTTGA GGTGATCAT AAGCTGATGG AAAAATACCC ATGTGCTGTT 240 15 CCCTTGTGGG TTGGACCCTT TACGATGTTC TTCAGTGTCC ATGACCCAGA CTATGCCAAG 300 ATTCTCCTGA AAAGACAAGA TCCCAAAAGT GCTGTTAGCC ACAAAATCCT TGAATCCTGG 360 GTTGGTCGAG GACTTGTGAC CCTGGATGGT TCTAAATGGA AAAAGCACCG CCAGATTGTG 420 ANACCTIGGET TCAACATCAG CATTCTGAAA ATATTCATCA CCATGATGTC TGAGAGTGTT 480
CGGATGATGC TGAACAACATG GGAGGAACGC ATTGCCCAAA ACTCACGTCT GGAGCTCTTT 540
CAACATGTCT CCCTGATGAC CCTGGACAGC ATCATGAAGT GTGCCTTCAG CCACCAGGGC 600
AGCATCACGT TGGACAGTAC CCTGGACTCA TACCTGAAAG CAGTGTTCAA CCTTAGCAAA 660
ATCTCCAACC AGCGCATGAA CAATTTTCTA CATCACAACG ACCTGGTTTT CAAATTCAGC 720 20 25 TCTCAAGGCC AAATCTTTTC TAAATTTAAC CAAGAACTTC ATCAGTTCAC AGAGAAAGTA 780 ATCCAGGACC GGAAGGAGTC TCTTAAGGAT AAGCTAAAAC AAGATACTAC TCAGAAAAAGG 840 CGCTGGGATT TTCTGGACAT ACTTTTGAGT GCCAAAAGCG AAAACACCAA AGATTTCTCT 900
GAAGCAGATC TCCAGGCTGA AGTGAAAACG TTCATGTTTG CAGGACATGA CACCACATCC 960
AGTGCTATCT CCTGGATCCT TTACTGCTTG GCAAAGTACC CTGAGCATCA GCAGAGATGC 1020 AGTGCTATCT CCTGGATCCT TTACTGCTTG GCAAAGTACC CTGAGCATCA GCAGAGATGC 1020
CGAGATGAAA TCAGGGAACT CCTAGGGGAT GGGTCTTCTA TTACCTGGGA ACACCTGAGC 1080
CAGATGCCTT ACACCACGAT GTGCATCAAG GAATGCCTCC GCCTCTACGC ACCGGTAGTA 1140
AACATATCCC GGTTACTCGA CAAACCCATC ACCTTTCCAG ATGGACGCTC CTTACCTGCA 1200
GGAATAACTG TGTTTATCAA TATTTGGGCT CTTCACCACA ACCCCTATTT CTGGGAAGAC 1260
CCTCAGGTCT TTAACCCCTT GAGATTCTCC AGGGAAAATT CTGAAAAAAAT ACATCCCTAT 1320
GCCTTCATAC CATTCTCAGC TGGATTAAGG AACTGCATTG GGCAGCATTT TGCCATAATT 1380
GAGTGTAAAG TGGCAGTGGC ATTAACTCTG CTCCGCTTCA AGCTGGCTCC AGACCACTCA 1440
AGGCCTCCCC AGCCTGTTCG TCAAGTTGTC CTCAAGTCCA AGAATGGAAT CCATGTGTTT 1500 30 35 GCAAAAAAAG TITIGCTAATT TTAAGTCCTT TCGTATAAGA ATTAATGAGA CAATTTTCCT 1560 ACCAAAGGAA GAACAAAAGG ATAAATATAA TACAAAATAT ATGTATATGG TTGTTTGACA 1620 AATTATATAA CITAGGATAC TTCTGACTGG TTTTGACATC CATTAACAGT AATTTTAATT 1680 40 TCTTTGCTGT ATCTGGTGAA ACCCACAAAA ACACCTGAAA AAACTCAAGC TGACTTCCAC 1740 TGCGAAGGGA AATTATTGGT TTGTGTAACT AGTGGTAGAG TGGCTTTCAA GCATAGTTTG 1800 ATCAAAACTC CACTCAGTAT CTGCATTACT TTTATCTCTG CAAATATCTG CATGATAGCT 1860 TTATTCTCAG TTATCTTTCC CCAATAATAA AAAA 45 Seq ID NO: 2 <u>Protein sequence:</u>
Protein Accession #: FGENESH predicted 50 31 21 41 MEPSWLQELM AHPFILLILL CMSLLLFQVI RLYQRRRWMI RALHLFPAPP AHWFYGHKEF 60 YPVKEFEVYH KLMEKYPCAV PLWVGPFTMF FSVHDPDYAK ILLKRQDPKS AVSHKILESW 120 VGRGLVTLDG SKWKKHRQIV KPGFNISILK IFITMMSESV RMMLNKWEER IAQNSRLELF 180 55 QHVSLMTLDS IMKCAFSHQG SIQLDSTLDS YLKAVFNLSK ISNQRMNNFL HHNDLVFKFS 240 SQGQIFSKFN QELHQFTEKV IQDRKESLKD KLKQDTTQKR RWDFLDILLS AKSENTKDFS 300 EADLQAEVKT FMFAGHDTTS SAISWILYCL AKYPEHQQRC RDEIRELLGD GSSITWEHLS 360 QMPYTTMCIK ECLRLYAPVV NISRLLDKPI TFPDGRSLPA GITVFINIWA LHHNPYFWED 420 PQVFNPLRFS RENSEKIHPY AFIPFSAGLR NCIGQHFAII ECKVAVALTL LRFKLAPDHS 480 60 RPPQPVRQVV LKSKNGIHVF AKKVC Seq ID NO: 3 DNA sequence Nucleic Acid Accession #: NM 052997 100-4125 (underlined sequences correspond to start and stop codons) Coding sequence: 65 31 21 CTAGTCTATA CCAGCAACGA CTCCTACATC GTCCACTCTG GGGATCTTAG AAAGATCCAT 60 70 AAAGCTGCCT CCCGGGGACA AGTCCGGAAG CTGGAGAAGA TGACAAAAGAG GAAGAAGACC 120
ATCAACCTTA ATATACAAGA CGCCCAGAAG AGGACTGCTC TACACTGGGC CTGTGTCAAT 180
GGCCATGAGG AAGTAGTAAC ATTTCTGGTA GACAGAAAGT GCCAGCTTGA CGTCCTTGAT 240 GGCGAACACA GGACACCTCT GATGAAGGCT CTACAATGCC ATCAGGAGGC TTGTGCAAAT 300
ATTCTGATAG ATTCTGGTGC CGATATAAAT CTCGTAGATG TGTATGGCAA CATGGCTCTC 360
CATTATGCTG TTTATAGTGA GATTTTGTCA GTGGTGGCAA AACTGCTGTC CCATGGTGCA 420

GTCATCGAAG TGCACAACAA GGCTAGCCTC ACACCACTTT TACTATCCAT AACGAAAAGA 480

AGTGAGCAAA TTGTGGAATT TTTGCTGATA AAAAATGCAA ATGCGAATGC AGTTAATAAG 540
TATAAATGCA CAGCCCTCAT GCTTGCTGTA TGTCATGGAT CATCAGAGAT AGTTGGCATG 600 CTTCTTCAGC AAAATGTTGA CGTCTTTGCT GCAGATATAT GTGGAGTAAC TGCAGAACAT 660
TATGCTGTTA CTTGTGGATT TCATCACATT CATGAACAAA TTATGGAATA TATACGAAAA 720
TTATCTAAAA ATCATCAAAA TACCAATCCA GAAGGAACAT CTGCAGGAAC ACCTGATGAG 78 GCTGCACCCT TGGCGGAAG AACACCTGAC ACAGCTGAAA GCTTGGTGGAA AAAAACACCT 840
GATGAGGCTG CACCCTTGGT GGAAAGAACA CCTGACACGG CTGAAAGCTTGGTGGAAAAAA 900
ACACCTGATG AGGCTGCATC CTTGGTTGGAG GGAACATCTG ACAAAATTCA ATGTTTGGAG 960
ACACCTGATG AGGCTGCATC CTTGGTTGGAG GGAACATCTG ACAAAATTCA ATGTTTTGGAG 960
ACACCTGATAG AGACTCTGGAAAGTT CGAACAGTCA GCAGAAGAAA CACCTAGGGA AATTACGAGT 1020
CCTGCAAAAG AAACATCTGA GAAATTTACG TGGCCAGCAA AAGGAAGACC TAGGAAGATC 1080
GCATGGGAGA AAAAAGAAGA CACACCTAGG GAAATTTATG GTCCCCCAAA AGAAACATCT 1140 10 GAGAAATTTA CGTGGGCAGC AAAAGGAAGA CCTAGGAAGA TCGCATGGGA GAAAAAAGAA 1200 ACACCTGTAA AGACTGGATG CGTGGCAAGA GTAACATCTA ATAAAACTAA AGTTTTGGAÅ 1260 AAAGGAAGAT CTAAGATGAT TGCATGTCCT ACAAAAGAAT CATCTACAAA AGCAAGTGCC 1320 AATGATCAGA GGTTCCCATC AGAATCCAAA CAAGAGGAAG ATGAAGAAT ATCTTGTGAT 1380
TCTCGGAGTC TCTTTGAGAG TCTCGCAAAG ATTCAAGTGT GTATACCTGA GTCTATATAT 1440
CAAAAAGTAA TGGAGATAAA TAGAGAAGTA GAAGAGCCTC CTAAGAAGCC ATCTGCCTTC 1500
AAGCCTGCCA TTGAAATGCA AAAACTCTGTT CCAAATAAAAG CCTTTGAATT GAAGAATGAA 1560
CAAACATTGA GAGCAGATCC GATGTTCCCA CCAGAATCCA AACAAAAGGA CTATGAAGAA 1620
AATTCTTGGG ATTCAGAAGGA AATGCAA AATAAATAAA ATCAATAAATGCAA AATTAGAAGA CTTTCCCTAAT 1700 15 20 AAGGCTACAC ATCAAAAAGA AATAGATAAA ATAAATGGAA AATTAGAAGA GTCTCCTAAT 1740 AAAGATGGTC TTCTGAAGGC TACCTGCGGA ATGAAAGTTT CTATTCCAAC TAAAGCCTTA 1800 GAATTGAAGG ACATGCAAAC TTTCAAAGCG GAGCCTCCGG GGAAGCCATC TGCCTTCGAG 1860 CCTGCCACTG AAATGCAAAA GTCTGTCCCA AATAAAGCCT TGGAATTGAA AAATGAACAA 1920 ACATGGAGAG CAGATGAGAT ACTCCCATCA GAATCCAAAC AAAAGGACTA TGAAGAAAAT 1980 TCTTGGGATA CTGAGAGTCT CTGTGAGACT GTTTCACAGA AGGATGTGTG TTTACCCAAG 2040 25 GCTGCGCATC AAAAAGAAAT AGATAAAATA AATGGAAAAT TAGAAGGGTC TCCTGTTAAA 2100 GATGGTCTTC TGAAGGCTAA CTGCGGAATG AAAGTTTCTA TTCCAACTAA AGCCTTAGAA 2160 TTGATGGACA TGCAAACTTT CAAAGCAGAG CCTCCCGAGA AGCCATCTGC CTTCGAGCCT 2220 30 GCCATTGAAA TGCAAAAGTC TGTTCCAAAT AAAGCCTTGG AATTGAAGAA TGAACAAACA 2280 TTGAGAGCAG ATGAGATACT CCCATCAGAA TCCAAACAAA AGGACTATGA AGAAAGTTCT 2340 TGGGATTCTG AGAGTCTCTG TGAGACTGTT TCACAGAAGG ATGTGTGTTT ACCCAAGGCT 2400 ACACATCAAA AAGAAATAGA TAAAATAAAT GGAAAATTAG AAGAGTCTCC TGATAATGAT 2460 GGTTTCTGA AGGCTCCCTG CAGAATGAAA GTTTCTATTC CAACTAAAGC CTTAGAATTG 2520 35 ATGGACATGC AAACTTTCAA AGCAGAGCCT CCCGAGAAGC CATCTGCCTT CGAGCCTGCC 2580
ATTGAAATGC AAAAGTCTGT TCCAAATAAA GCCTTGGAAT TGAAGAATGA ACAAACATTG 2640
AGAGCAGATC AGATGTTCCC TTCAGAATCA AAACAAAAGA AGGTTGAAGA AAATTCTTGG 2700 GATTCTGAGA GTCTCCGTGA GACTGTTTCA CAGAAGGATG TGTGTGTACC CAAGGCTACA 2760 CATCAAAAAG AAATGGATAA AATAAGTGGA AAATTAGAAG ATTCAACTAG CCTATCAAAA 2820 ATCTTGGATA CAGTTCATTC TTGTGAAAGA GCAAGGGAAC TTCAAAAAGA TCACTGTGAA 2880 40 CAACGTACAG GAAAAATGGA ACAAATGAAA AAGAAGTTTT GTGTACTGAA AAAGAAACTG 2940 TCAGAAGCAA AAGAAATAAA ATCACAGTTA GAGAACCAAA AAGTTAAATG GGAACAAGAG 3000 CTCTGCAGTG TGAGATTGAC TTTAAACCAA GAAGAAGAA AGGAAGAAA TGCCGATATA 3060 TTAAATGAAA AAATTAGGGA AGAATTAGGA AGAATCGAAG AGCAGCATAG GAAAGAGTTA 3120 GAAGTGAAAC AACAACTTGA ACAGGCTCTC AGAATACAAG ATATAGAATT GAAGAGTGTA 3180 45 · GAAAGTAATT TGAATCAGGT TTCTCACACT CATGAAAATG AAAATTATCT CTTACATGAA. 3240
AATTGCATGT TGAAAAAAGGA AATTGCCATG CTAAAAACTGG AAAATTACCCAC ACTGAAACAC 3300
CAATACCAGG AAAAGGAAAA TAAATACTTT GAGGACATTA AGATTTTAAA AGAAAAGAAT 3360 GCTGAACTTC AGATGACCCT AAAACTGAAA GAGGAATCAT TAACTAAAAG GGCATCTCAA 3420 TATAGTGGGC AGCTTAAAGT TCTGATAGCT GAGAACACAA TGCTCACTTC TAAATTGAAG 3480 GAAAAACAAG ACAAAGAAAT ACTAGAGGCA GAAATTGAAT CACACCATCC TAGACTGGCT 3540 50 TCTGCTGTAC AAGACCATGA TCAAATTGTG ACATCAAGAA AAAGTCAAGA ACCTGCTTTC 3600 CACATTGCAG GAGATGCTTG TTTGCAAAGA AAAATGAATG TTGATGTGAG TAGTACGATA 3660 TATAACAATG AGGTGCTCCA TCAACCACTT TCTGAAGCTC AAAGGAAATC CAAAAGCCTA 3720 AAAATTAATC TCAATTATGC AGGAGATGCT CTAAGAGAAA ATACATTGGT TTCAGAACAT 3780 GCACAAAGAG ACCAACGTGA AACACAGTGT CAAATGAAGG AAGCTGAACA CATGTATCAA 3840 AACGAACAAG ATAATGTGAA CAAACACACT GAACAGCAGG AGTCTCTAGA TCAGAAATTA 3900 55 TTTCAACTAC AAAGCAAAAA TATGTGGCTT CAACAGCAAT TAGTTCATGC ACATAAGAAA 3960 CCTGACAACA AAAGCAAGAT AACAATTGAT ATTCATTTTC TTGAGAGGAA AATGCAACAT 4020
CATCTCCTAA AAGAGAAAAA TGAGGAGATA TTTAATTACA ATAACCATTT AAAAAACCGT 4080
ATATATCAAT ATGAAAAAG GAAAGCAGAA ACAGAAAAACT CATGAGAGAC AAGCAGAAGAAAACTCATTT TGGAGAGACA AACACTAAGAAAACTCATTTAATTACAA ATAACCATTT AAAAAACCGT 4080
AAACTTCTTT TGGAGAAACA ACAGACCAGA TCTTTACTCA CAACTCATGC TAGGAGGCCA 4200
GTCCTAGCAT CACCTTATGT TGAAAATCTT ACCAATAGTC TGTGTCAACA GAATACTTAT 4260 60 TTTAGAAGAA AAATTCATGA TTTCTTCCTG AAGCCTACAG ACATAAAATA ACAGTGTGAA 4320 GAATTACTTG TTCACGAATT GCATAAAGCT GCACAGGATT CCCATCTACC CTGATGATGC 4380 65 AGCAGACATC ATTCAATCCA ACCAGAATCT CGCTCTGCAC TCCAGCCTAG GTGACAGAGT 4440 GAGACTCCAC CTCGGAAA

Seq ID NO: 4 Protein sequence:
Protein Accession #: NP\_443723.1 21

41

31

70

MTKRKKTINL NIQDAQKRTA LHWACVNGHE EVVTFLVDRK CQLDVLDGEH RTPLMKALQC 60 HQEACANILI DSGADINLVD VYGNMALHYA VYSEILSVVA KLLSHGAVIE VHNKASLTPL 120 75 LLSITKRSEQ IVEFLLIKNA NANAVNKYKC TALMLAVCHG SSEIVGMLLQ QNVDVFAADI 180

CGVTAEHYAV TCGFHHIHEQ IMEYIRKLSK NHQNTNPEGT SAGTPDEAAP LAERTPDTAE 240
SLVEKTPDEA APLVERTPDT AESLVEKTPD EAASLVEGTS DKIQCLEKAT SGKFEQSAEE 300
TPREITSPAK ETSEKFTWPA KGRPRKIAWE KKEDTPREIM SPAKETSEKF TWAAKGRPRK 360
IAWEKKETPV KTGCVARVTS NKTKVLEKGR SKMIACPTKE SSTKASANDQ RFPSESKQEE 420
DEFYSCDSRS LFESSAKIQV CIPESIYQKV MEINREVEEP PKKPSAFKPA IEMQNSVPNK 480
AFELKNEQTL RADPMFPPES KQKDYEENSW DSESLCETVS QKDVCLPKAT HQKEIDKING 540
KLEESPNKDG LLKATCGMKV SIPTKALELK DMQTFKAEPP GKPSAFEPAT EMQKSVPNKA 600
LELKNEQTWR ADEILPSESK QKDVEENSWD TESLCETVSQ KDVCLPKAAH QKEIDKINGK 660
LEGSPVKDGL LKANCGMKVS IPTKALELMD MQTFKAEPPE KPSAFEPAIE MQKSVPNKAL 720
ELKNEQTLRA DEILPSESKQ KDYEESSWDS ESLCETVSQK DVCLPKATHQ KEIDKINGKL 780
ESSPDNDGFL KAPCRMKVSI PTKALELMD MQTFKAEPPE KPSAFEPAIEM QKSVPNKALE 840
LKNEQTLRAD DMFPSESKQK KVEENSWDSE SLCETVSQKD VCVPKATHQ KEIDKINGKL 780
DSTSLSKILD TVHSCERARE LQKDHCEQRT GKMEQMKKKF CVLKKKLSEA KEIKSQLENQ 960
KVKWEQELCS VRLTLNQEEE KRRNADILNE KIREELGRIE EQHRKELEVK QQLEQALRIQ 1020
DSTSLSKILD TVHSCERARE LQKDHCEQRT GKMEQMKKKF CVLKKKLSEA KEIKSQLENQ 960
KVKWEQELCS VRLTLNQEEE KRRNADILNE KIREELGRIE EQHRKELEVK QQLEQALRIQ 1020
DELKSVESN LNQVSHTHEN ENYLLHENCM LKKEIAMIKL EIATLKHQYQ EENKYFEDI 1080
KILKENNAEL QMTLKLKEES LTKRASQYSG QLKVLIAENT MLTSKLKEKQ DKEILEAEIE 1140
SHEPRLASAV QDHDQIVTSR KSQEPAFHIA GDACLQRKMN VDVSSTTYNN EVLHQPLSEA 1200
QRKSKSLKIN LNYAGDALRE NTLVSEHAQR DQRETQCOMK EAEHMYQNEQ DNVNKHTEQQ 1260
ESLDQKLFQL QSKNMWLQQQ LVHAHKKADN KSKITIDIHF LERKMQHHLL KEKNEEIFNY 1320
NNHLKNRTYQ YEKEKAETEN S

Seq ID NO: 5 DNA sequence

25

Nucleic Acid Accession #: none found

Coding sequence: 273-1785 (underlined sequences correspond to start and stop codons)

1 11 21 31 41 51


CGCGGGGCGC GGAGTCGGCG GGGCCTCGCG GGACGCGGGC AGTGCGGAGA CCGCGGCGCT 60 30 GAGGACGCGG GAGCCGGGAG CGCACGCGCG GGGTGGAGTT CAGCCTACTC TTTCTTAGAT 120 GTGAAAGGAA AGGAAGATCA TTTCATGCCT TGTTGATAAA GGTTCAGACT TCTGCTGATT 180 CATAACCATT TGGCTCTGAG CTATGACAAG AGAGGAAACA AAAAGTTAAA CTTACAAGCC 240 TGCCATAAGT GAGAAGCAAA CTTCCTTGAT AACATGCTTT TGCGAAGTGC AGGAAAATTA 300 AATGTGGGCA CCAAGAAAGA GGATGGTGAG AGTACAGCCC CCACCCCCG TCCAAAGGTC 360
TTGCGTTGTA AATGCCACCA CCATTGTCCA GAAGACTCAG TCAACAATAT TTGCAGCACA 420
GACGGATATT GTTTCACGAT GATAGAAGAG GATGACTCTG GGTTGCCTGT GGTCACTTCT 480 35 GGTTGCCTAG GACTAGAAGG CTCAGATTT CAGTGTCGGG ACACTCCCAT TCCTCATCAA 540
AGAAGATCAA TTGAATGCTG CACAGAAAGG AACGAATGTA ATAAAGACCT ACACCCTACCA 600
CTGCCTCCAT TGAAAAACAG AGATTTTGTT GATGGACCTA TACACACAG GGCTTTACTT 660
ATATCTGTGA CTGTCTGTAG TTTGCTCTTG GTCCTTATCA TATTATTTTTG TTACTTCCGG 720
TATAAAAGAC AAGAAACCAG ACCTCGATAC AGCATTGGGT TAGAACAGGA TGAAACTTAC 780 40 ATTCCTCCTG GAGAATCCCT GAGAGACTTA ATTGAGCAGT CTCAGAGCTC AGGAAGTGGA 840
TCAGGCCTCC CTCTGCTGGT CCAAAGGACT ATAGCTAAGC AGATTCAGAT GGTGAAACAG 900
ATTGGAAAAG GTCGCTATGG GGAAGTTTGG ATGGGAAAGT GGCGTGGCGA AAAGGTAGCT 960 45 GTGAAAGTGT TCTTCACCAC AGAGGAAGCC AGCTGGTTCA GAGAGACAGA AATATATCAG 1020 ACAGTGTTGA TGAGGCATGA AAACATTTTG GGTTTCATTG CTGCAGATAT CAAAGGGACA 1080 GGGTCCTGGA CCCAGTTGTA CCTAATCACA GACTATCATG AAAATGGTTC CCTTTATGAT 1140 TATCTGAAGT CCACCACCCT AGACGCTAAA TCAATGCTGA AGTTAGCCTA CTCTTCTGTC 1200 AGTGGCTTAT GTCATTTACA CACAGAAATC TTTAGTACTC AAGGCAAACC AGCAATTGCC 1260 50 CATCGAGATC TGAAAAGTAA AAACATTCTG GTGAAGAAAA ATGGAACTTG CTGTATTGCT 1320 GACCTGGCC TGGCTGTTAA ATTTATTAGT GATACAAATG AAGTTGACAT ACCACCTAAC 1380 ACTCGAGTTG GCACCAAACG CTATATGCCT CCAGAAGTGT TGGACGAGAG CTTGAACAGA 1440 ACTOMOTICS CAACAGG CITATGCCI CEAGAAGIGI I IGGACGAG CITAACAGA 1440
AATCACTTCC AGTCTTACAT CATGGCTGAC ATGTATAGTT TTGGCCTCAT CCTTTGGGAG 1500
GTTGCTAGGA GATGTGTACA CAGGAGGTATA GTGGAAGAAT ACCAGCTTCC TTATCATGAC 1560
CTAGTGCCCA GTGACCCCTC TTATGAGGAC ATGAGGGAGA TTGTGTGCAT CAAGAAGTTA 1620
CGCCCCTCAT TCCCAAACCG GTGGAGCAGT GATGAGTGTC TAAGGCAGGAT GGGAAAACTC 1680
ATGACAGAAT GCTGGGCTCA CAATCCTGCA TCAAGGCTGA CAGCCCTGCG GGTTAAGAAA 1740
ACACTTGCCA AAATGTCAGA GTCCCAGGAC ATTAAACTCT GATAGGAGAG GAAAAGTAAA 1860 55 CATCTCTGCA GAAAGCCAAC AGGTACTCTT CTGTTTGTGG GCAGAGCAAA AGACATCAAA 1860 TAAGCATCCA CAGTACAAGC CTTGAACATC GTCCTGCTTC CCAGTGGGTT CAGACCTCAC 1920 60 CTTTCAGGGA GCGACCTGGG CAAAGACAGA GAAGCTCCCA GAAGGAGAGA TTGATCCGTG 1980

65 Seq ID NO: 6 Protein sequence:
Protein Accession #: none found

TCTGTTTGTA GGCGGAGAAA CCGTTGGGTA ACTTGTTCAA GATATGATGC AT

EEYQLPYHDL VPSDPSYEDM REIVCIKKLR PSPPNRWSSD ECLRQMGKLM TECWAHNPAS 480 RLTALRVKKT LAKMSESODI KL

Seq ID NO: 7 DNA sequence
Nucleic Acid Accession #: none found
Coding sequence: 482-3007(underlined sequences correspond to start and stop codons)



Seq ID NO: 8 Protein sequence:
Protein Accession #: none found

70

1 11 21 31 41 51

MKLWIHLFYS SLLACISLHS QTPVLSSRGS CDSLCNCEEK DGTMLINCEA KGIKMVSEIS 60

VPPSRPFQLS LLNNGLTMLH TNDFSGLTNA ISIHLGFNNI ADIEIGAFNG LGLLKQLHIN 120

HNSLEILKED TFHGLENLEF LQADNNFITV IEPSAFSKLN RLKVLILNDN AIESLPPNIF 180

RFVPLTHLDL RGNQLQTLPY VGFLEHIGRI LDLQLEDNKW ACNCDLLQLK TWLENMPPQS 240

IIGDVVCNSP PFFKGSILSR LKKESICPTP PVYEEHEDPS GSLHLAATSS INDSRMSTKT 300

TSILKLPTKA PGLIPYITKP STQLPGPYCP IPCNCKVLSP SGLLIHCQER MIESLSDLRP 360

350

NHLTKLSKGM FLGLHNLEYL YLEYNAIKEI LPGTFNPMPK LKVLYLNNNL LQVLPHIFS 480 GVPLTKVNLK TNQFTHLPVS NILDDLDLLT QIDLEDNPWD CSCDLVGLQQ WIQKLSKNTV 540 TDDILCTSPG HLDKKELKAL NSEILCPGLV NNPSMPTQTS YLMVTTPATT TNTADTILRS 600 LTDAVPLSVI. II.GLLIMFIT IVFCAAGIVV LVLHRRRRYK KKQVDEQMRD NSPVHLQYSM 660
YGHKTIHHTT ERPSASLYEQ HMVSFMYHVY RSPSFOPKHL EEEEERNEKE GSDAKHLQRS 720
LLEQENHSPL TGSNMKYKTT NQSTEFLSFQ DASSLYRNIL EKERELQQLG ITEYLRKNIA 780
QLQPDMEAHY PGAHEELKLM ETLMYSRPRK VLVEQTKNEY FELKANLHAE PDYLEVLEQQ 840 5 10 Seq ID NO: 9 DNA sequence Nucleic Acid Accession #: NM\_003474 Coding sequence: 307-3036 (underlined sequences correspond to start and stop codons) 15 11 21 31 41 51 CACTAACGCT CTTCCTAGTC CCCGGGCCAA CTCGGACAGT TTGCTCATTT ATTGCAACGG 60 TCAAGGCTGG CTTGTGCCAG AACGGCGCGCGCGCGACGCA CGCACACACA CGGGGGGAAA 120 CTITITTAAA AATGAAAGGC TAGAAGAGCT CAGCGGCGGG CGGGGCCTG CGCGAGGGCT 180
CCGGAGCTGA CTGCCCGAGG CAGGAAATCC CTCCGGTGG GAGGCCCGGC CCGCTGGC 240
GCCCGCGTGG GATGGTGCAG CGCTCGCCG CGGGCCCCGAG AGGTCTGCA CTGAAGGCCG 300
GCGACGATGG CAGCGCCCCC GCTGCCCGT TCCCCGCCC GCGCCTCTGCT GCCCGCCT GTCGCCCTG 360
GCCGGTGCTC TGCTCGCCCC CTGCGAGGCC CGAGGGGTGA GCTTATGGAA CGAAGGAAGA 420 20 GCTGATGAAG TIGTCAGTGC CIGCGAGGCC CLAGGGGTAC GCTIATUGAA CGAAGGAAGA 420
TTCGACTCCA AGAATCATCC AGAAGTGCTG AATATTCGAC TACAACGGGA AAGCAAAGAA 540
CTGATCATAA ATCTGGAAAG AAATGAAGGT CTCATTGCCA GCAGTTTCAC GGAAACCCAC 600
TATCTGCAAG ACGGTACTGA TGTCTCCCTC GCTCGAAATT ACACGGTAAT TCTGGGTCAC 660
TGTTACTACC ATGGACATGT ACGGGGATAT TCTGATTCAG CAGTCAGTCT CAGCACGTGT 720 25 30 TCTGGTCTCA GGGGACTTAT TGTGTTTGAA AATGAAAGCT ATGTCTTAGA ACCAATGAAA 780
AGTGCAACCA ACAGATACAA ACTCTTCCCA GCGAAGAAGC TGAAAAGCGT CCGGGGATCA 840
TGTGGATCAC ATCACAACAC ACCAAACCTC GCTGCAAAGA ATGTGTTTCC ACCACCCTCT 900 CAGACATGGG CAAGAAGGCA TAAAAGAGAG ACCCTCAAGG CAACTAAGTA TOTGGAGCTG 960
GTGATCGTGG CAGACAACCG AGAGTTTCAG AGGCAAGGAA AAGATCTGGA AAAAGTTAAG 1020
CAGCGATTAA TAGAGATTGC TAATCACGTT GACAAGTTTT ACAGACCACT GAACATTCGG 1080 35 40 AATCATGACA CACTGGACAG GGGCTGTAGC TGTCAAATGG CGGTTGAGAA AGGAGGCTGC 1440
ATCATGAACG CTTCCACCGG GTACCCATTT CCCATGGTGT TCAGCAGTTG CAGCAGGAAG 1500
GACTTGGAGA CCAGCCTGGA GAAAGGAATG GGGGTGTGCC TGTTTAACCT GCCGGAAGTC 1560 AGGGAGTCTT TCGGGGGCCA GAAGTGTGGG AACAGATTTG TGGAAGAAGG AGAGGAGTGT 1620 GACTGTGGGG AGCCAGAGGA ATGTATGAAT CGCTGCTGCA ATGCCACCAC CTGTACCCTG 1680 45 AAGCCGGACG CTGTGTGCGC ACATGGGCTG TGCTGTGAAG ACTGCCAGCT GAAGCCTGCA 1740 GGAACAGCGT GCAGGGACTC CAGCAACTCC TOTGACCTCC CAGAGTTCTG CACAGGGGCC 1800
AGCCCTCACT GCCCAGCCAA CGTGTACCTG CACGATGGGC ACTCATGTCA GGATGTGGAC 1860
GGCTACTGCT ACAATGGCAT CTGCCAGACT CACGAGCAGC AGTGTGTCAC ACTCTGGGGA 1920 50 CCAGGTGCTA AACCTGCCCC TGGGATCTGC TTTGAGAGAG TCAATTCTGC AGGTGATCCT 1980
TATGGCAACT GTGGCAAAGT CTCGAAGAGT TCCTTTGCCA AATGCGAGAT GAGAGATGCT 2040
AAATGTGGAA AAATCCAGTG TCAAGGAGGT GCCAGCCGGC CAGTCATTGG TACCAATGCC 2100 GTTTCCATAG AAACAAACAT CCCCCTGCAG CAAGGAGGCC GGATTCTGTG CCGGGGGACC 2160 CACGTGTACT TGGGCGATGA CATGCCGGAC CCAGGGCTTG TGCTTGCAGG CACAAAGTGT 2220 55 GCAGATGGAA AAATCTGCCT GAATCGTCAA TGTCAAAATA TTAGTGTCTT TGGGGTTCAC 2280 GAGTGTGCAA TGCAGTGCCA CGGCAGAGGG GTGTGCAACA ACAGGAAGAA CTGCCACTGC 2340 GAGGCCCACT GGGCACCTCC CTTCTGTGAC AAGTTTGGCT TTGGAGGAAG CACAGACAGC 2400 GGCCCCATCC GGCAAGCAGA TAACCAAGGT TTAACCATAG GAATTCTGGT GACCATCCTG 2460
TGTCTTCTTG CTGCCGGATT TGTGGTTTAT CTCAAAAGGA AGACCTTGAT ACGACTGCTG 2520
TTTACAAATA AGAAGACCAC CATTGAAAAA CTAAGGTGTG TGCGCCCTTC CCGGCCACCC 2580 60 CGTGGCTTCC AACCCTGTCA GGCTCACCTC GGCCACCTTG GAAAAGGCCTT GATGAGGAAG 2640 CCGCCAGATT CCTACCCACC GAAGGACAAT CCCAGGAGAT TGCTGCAGTG TCAGAATGTT 2700 GACATCAGCA GACCCCTCAA CGGCCTGAAT GTCCCTCAGC CCCAGTCAAC TCAGCGAGTG 2760 CTTCCTCCCC TCCACCGGGC CCCAGTGCA CCTAGCTCAGC CCTGCCAGCC CTGCCAGCC CCTGCCAGCC 2820 AAGCCTGCAC TTAGGCAGCC CCAGGGGACC TGTAAGCCAA ACCCCCCTCA GAAGCCTCTG 2880 65 AAGCCTGCAC HAGGCAGGC CCAGGGGACC TGTAAGCCAA ACCCCCCTCA GAAGCCTCTG 2880
CCTGCAGATC CTCTGGCCAG AACAACTCGG CTCACTCATG CCTTGGCCAG GACCCCAGGA 2940
CAATGGAGATC CTCTGGCCAG AACAACTCGG CTCACTCATG CTTGGCCAG GACCCCAGGA 2940
CAATGGAACAGA CTGGGCTCCC CCCAGACCTG CTCCACAATA TCCACACCAA 3000
GTGCCCAGAT CCACCCACAC CGCCTATATT AAGTGAGAAG CCGACACCTT TTTTCAACAG 3060
TGAAGACAGA AGTTTGCACT ATCTTTCAGC TCCAGTTGGA GTTTTTTTTA CCAACTTTTTA 3120
GCTGTGCTGT GCTATGGTGC TCTGTCTACT TGCACAGGTA CTTGTAAATT ATTAATTTAT 3240
GCAGAATGTT GATTACAGTG CAGTGCGCTG TAGTAGGCAT TTTTACCATC ACTGAGTTTT 3300
CCATGGCAGG AAGGCTTGTT GTGCTTTTAG TATTTTAGTG AACTTGAAATA ATCCTGCTTG 3360
ATGGGATTCT GGACAGGATTGT GTTTTGCTTT TTGATCAAGG CCTTATTGGAAAT ATCCTCTTG 3360
ATGGGATTCT GGACAGGATTG TGTTTTCTTTTTAGT AACTTATTTGAATA AACCAGTCCC 4200 70 ATGGGATTCT GGACAGGATG TGTTTGCTTT CTGATCAAGG CCTTATTGGA AAGCAGTCCC 3420
CCAACTACCC CCAGCTGTGC TTATGGTACC AGATGCAGC CAAGAGATCC CAAGTAGAAT 3480
CTCAGTTGAT TTTCTGGATT CCCCATCTCA GGCCAGAGCC AAGGGGCTTC AGGTCCAGGC 3540 75

PPQNPRKLIL AGNIHSLMK SDLVEYFTLE MLHLGNNRIE VLEEGSFMNL TRLOKLYLNG 420

ACACCTGGGA GAAATCTGGC TTCTGGCCAG GAAGCTTTGG TGAGAACCTG GGTTGCAGAC 3660 AGGAATCTTA AGGTGTAGCC ACACCAGGAT AGAGACTGGA ACACTAGACA AGCCAGAACT 3720 TGACCCTGAG CTGACCAGCC GTGAGCATGT TTGGAAGGGG TCTGTAGTGT CACTCAAGGC 3780 GGTGCTTGAT AGAAATGCCA AGCACTTCTT TTTCTCGCTG TCCTTTCTAG AGCACTGCCA 3840 CCAGTAGGTT ATTTAGCTTG GGAAAGGTGG TGTTTCTGTA AGAAACCTAC TGCCCAGGCA 3900 CTGCAAACCG CCACCTCCCT ATACTGCTTG GAGCTGAGCA AATCACCACA AACTGTAATA 3960 5 CAATGATCCT GTATTCAGAC AGATGAGGAC TITTCCATGGG ACCACAACTA TITTCAGATG 4020
TGAACCATTA ACCAGATCTA GTCAATCAAG TCTGTTTACT GCAAGGTTCA ACTTATTAAC 4080
AATTAGGCAG ACTCTTTATG CTTGCAAAAA CTACAACCAA TGGAATGTGA TGTTCATGGG 4140 10 TATAGTTCAT GTCTGCTATC ATTATTCGTA GATATTGGAC AAAGAACCTT CTCTATGGGG 4200 CATCCTCTTT TTCCAACTTG GCTGCAGGAA TCTTTAAAAAG ATGCTTTTAA CAGAGTCTGA 4260 ACCTATTTCT TAAACACTTG CAACCTACCT GTTGAGCATC ACAGAATGTG ATAAGGAAAT 4320 CAACTTGCTT ATCAACTTCC TAAATATTAT GAGATGTGGC TTGGGCAGCA TCCCCTTGAA 4380 CTCTTCACTC TTCAAATGCC TGACTAGGGA GCCATGTTTC ACAAGGTCTT TAAAGTGACT 4440 15 AATGGCATGA-GAAATACAAA AATACTCAGA TAAGGTAAAA TGCCATGATG CCTCTGTCTT 4500 CTGGACTGGT TTTCACATTA GAAGACAATT GACAACAGTT ACATAATTCA CTCTGAGTGT 4560 TTTATGAGAA AGCCTTCTTT TGGGGTCAAC AGTTTTCCTA TGCTTTGAAA CAGAAAAATA 4620 TGTACCAAGA ATCTTGGTTT GCCTTCCAGA AAACAAAACT GCATTTCACT TTCCCGGTGT 4680 TCCCCACTGT ATCTAGGCAA CATAGTATTIC ATGACTATGG ATAAACTAAA CACGTGACAC 4740 AAACACACAC AAAAGGGAAC CCAGCTCTAA TACATTCCAA CTCGTATAGC ATGCATCTGT 4800 20 TTATTCTATA GTTATTAAGT TCTTTAAAAT GTAAAGCCAT GCTGGAAAAT AATACTGCTG 4860 AGATACATAC AGAATTACTG TAACTGATTA CACTTGGTAA TTGTACTAAA GCCAAACATA 4920 TATATACTAT TAAAAAGGTT TACAGAATTT TATGGTGCAT TACGTGGGCA TTGTCTTTTT 4980 AGATGCCCAA ATCCTTAGAT CTGGCATGTT AGCCCTTCCT CCAATTATAA GAGGATATGA 5040 25 АССАЛАЛАЛА АЛЛАЛАЛАЛА ЛА

30

MAARPLPYSP ARALLLALAG ALLAPCEARG VSLWNEGRAD EVVSASVRSG DLWIPVKSFD 60
SKNHPEVLNI RLQRESKELI INLERNEGLI ASSFTETHYL QDGTDVSLAR NYTVILGHCY 120
YHGHVRGYSD SAVSLSTCSG LRGLIVFENE SYVLEPMKSA TNRYKLFPAK KLKSVRGSCG 180
SHINTPNLAA KNVFPPPSQT WARRIKRETL KATKYVELVI VADNREFQRQ GKDLEKVKQR 240
LIEIANHVDK FYRPLNIRIV LVGVEVWNDM DKCSVSQDPF TSLHEFLDWR KMKLLPRKSH 300
DNAQLVSGVY FQGTTIGMAP IMSMCTADQS GGIVMDHSDN PLGAAVTLAH ELGHNFGMNH 360
DTLDRGCSCQ MAVEKGGCIM NASTGYPFPM VFSSCSRKDL ETSLEKGMGV CLFNLPEVRE 420
SFGGQKCGNR FVEEGEECDC GEPEECMNRC CNATTCTLKP DAVCAHGLCC EDCQLKPAGT 480
ACRDSSNSCD LPEFCTGASP HCPANVYLHD GHSCQDVDGY CYNGICQTHE QQCVTLWGPG 540
AKPAPGICFE RVNSAGDPYG NGGKVSKSSF AKCEMRDAKC GKIQCQGGAS RPVIGTNAVS 600
IETNIPLQQG GRILCRGTHY YLGDDMPDPG LVLAGTKCAD GKICLNRQCQ NISVFGVEEC 660
AMQCHGRGVC NNRKNCHCEA HWAPPFCDKF GFGGSTDSGP IRQADNQGLT IGILVTILCL 720
LAAGFVVYLK RKTLIRLLFT NKKTTIEKLR CVRPSRPPRG FOPCOAHLGH LGKGLMRKPP 780

LAAGFVVYLK RKTLIRLLFT NKKTTIEKLR CVRPSRPPRG FQPCQAHLGH LGKGLMRRPP 780
DSYPPKDNPR RLLQCQNVDI SRPLNGLNVP QPQSTQRVLP PLHRAPRAPS VPARPLPAKP 840
ALRQAQGTCK PNPPQKPLPA DPLARTTRLT HALARTPGQW ETGLRLAPLR PAPQYPHQVP 900
RSTHTAYIK

50 Scq ID NO: 11 DNA sequence
Nucleic Acid Accession #: NM\_001394
Coding sequence: 400-1584(underlined sequences correspond to start and stop codons)

WO 02/059377

PCT/US02/02242

5	GAGTTCGTTA AGCAGCGCCG CAGCATCATC TCGCCCAACT TCAGCTTCAT GGGGCAGCTG 1380 CTGCAGTTCG AGTCCCAGGT GCTGGCCACG TCCTGTGCTG CGGAGGCTGC TAGCCCCTCG 1440 GGACCCCTGC GGGAGCGGGG CAAGACCCCC GCCACCCCCA CCTCGCAGGTT CGTCTTCAGC 1500 TTTCCGGTCT CCGTGGGCGCT GCACTCGGCC CCCAGCAGCC TGCCCTACCT GCACAGCCCC 1560 ATCACCACCT CTCCCAGCTG TTAGAGCCGC CCTGGGGGCC CCAGAACCAG AGCTGGCTCC 1620 CAGCAAGGGT AGGACGGGCC GCATGCGGCA GAAAGTTGGG ACTGAGCAGC TGGGAGCAGG 1680 CGACCGAGCT CCTTCCCCAT CATTTCTCCT TGGCCAACGA CGAGGCCAGC CAGAATGGCA 1740
10	ATAAGGACTC CGAATACATA ATAAAAGCAA ACAGAACACT CCAACTTAGA GCAATAACCG 1800 GTGCCGCAGC AGCCAGGGAA GACCTTGGTT TGGTTTATGT GTCAGTTTCA CTTTTCCGAT 1860 AGAAATTTCT TACCTCATTT TTTTAAGCAG TAAGGCTTGA AGTGATGAA CCCACAGATC 1920 CTAGCAAATG TGCCCAACCA GCTTTACTAA AGGGGGGGAGGA AGGGAGGGCA AAGGGATGAG 1980 AAGCAAGTT TCCCAGAAGT GCCTGGTTCT GGGTACTTGT CCCTTTGTTG TCGTTGTTGT 2040 AGTTAAAGGA ATTICATTT TAAAAAGAAAT CTTCGAAGGT GTGGTTTTCA TTTCTCAGTC 2100
15	ACCAACAGAT GAATAATTAT GCTTAATAAT AAAGTATTTA TTAAGACTTT CTTCAGAGTA 2160 TGAAAGTACA AAAAGTCTAG TTACAGTGGA TTTAGAATAT ATTTATGTTG ATGTCAAACA 2220 GCTGAGCACC GTAGCATGCA GATGTCAAGG CAGTTAGGAA GTAAATGGTG TCTTGTAGAT 2280 ATGTGCAAGG TAGCATGATG AGCAACTTGA GTTTGTTGCC ACTGAGAAGC AGGCGGGTTG 2340 GGTGGGAGGA GGAAGAAAGG GAAGAATTAG GTTTTGAATTG CTTTTTAAAA AAAAAAGAA 2400
20	AGAAAAAGAC AGCATCTCAC TATGTTGCCA AGGCTCATCT TGAGAAGCAG GCGGGTTGGG 2460 TGGGAGGAGG AAGAAAGGGA AGAATTAGGT TTGAATTGCT TTTTTAAAAA AAAA Seq ID NO: 12 Protein sequence:
	Protein Accession #: NP_001385
25	t 11 21 31 41 51
30	60 MVTMEELREM DCSVLKRLMN RDENGGGAGG SGSHGTLGLP SGGKCLLLDC RPFLAHSAGY 60 LIGSVNVRCN TIVRRRAKGS VSLEQILPAE EEVRARLRSG LYSAVIVYDE RSPRAESLRE 120 DSTVSLVVQA LRRNAERTDI CLLKGGYERF SSEYPEFCSK TKALAAIPPP VPPSATEPLD 180
30	LGCSSCGTPL HDQGGPVEIL PFLYLGSAYH AARRDMLDAL GITALLNVSS DCPNHFEGHY 240 QYKCEPVEDN HKADISSWFM EAIEYIDAVK DCRGRVLVHC QAGISRSATI CLAYLMMKKR 300 VRLEEAFEFV KQRRSLISPN FSFMGQLLQF ESQVLATSCA AEAASPSGPL RERGKTPATP 360 TSQFVFSFPV SVGVHSAPSS LPYLHSPITT SPSC
35	Seq ID NO: 13 DNA sequence Nucleic Acid Accession #: none found Coding sequence: 68-340(underlined sequences correspond to start and stop codons)
40	1 11 21 31 41 51 1 1 AGCGCCTTGC CTTCTCTTAG GCTTTGAAGC ATTTTTGTCT GTGCTCCCTG ATCTTCAGGT 60
45	CACCACCATG AAGTTCTTAG CAGTCCTGGT ACTCTTGGGA GTTTCCATCT TTCTGGTCTC 120 TGCCCAGAAT CCGACAACAG CTGCTCCAGC TGACACGTAT CCAGCTACTG GTCCTGGTGA 180 TGATGAAGCC CCTGATGCTG AAACCACTGC TGCTGCAACC ACTGCGACCA CTGCTGGTCC 240 TACCACTGCA ACCACCGCTG CTTCTACCAC TGCTCGTAAA GACATTCCAG TTTTACCCAA 300 ATGGGTTGGG GATCTCCCGA ATGGTAGAGT GTGTCCCTGA GATGGAATCA GCTTGAGTCT 360
50	TCTGCAATTG GGTCACAACT ATTCATGCTT CCTGTGATTT CATCCAACTA CTTACCTTGC 420 CTACGATATC CCCTTTATCT CTAATCAGTT TATTTTCTTT CAAATAAAAA ATAACTATGA 480 GCGAGCTAAC AT
55	Seq ID NO: 14 Protein sequence: Protein Accession #: none found
	1 11 21 31 41 51
60	MKFLAVLVLL GVSIFLVSAQ NPTTAAPADT YPATGPADDE APDAETTAAA TTATTAAPTT 60 ATTAASTTAR KDIPVLPKWV GDLPNGRVCP
65	Seq ID NO: 15 DNA sequence Nucleic Acid Accession #: NM_016640.2 Coding sequence: 39-1358(underlined sequences correspond to start and stop codons)
70	1 11 21 31 41 51
75	CGACGGTGCA CGCTGCGGAG TCGGTAGACG AGAAGCTGCG AATCCTCACC AAGATGCAGT 300 TTATGAAGTA CATGGTTTAC CCGCAGACCT TCGCACTGAA TGCCGACCGC TGGTACCAGT 360 ACTTCACCAA GACCGTGTTC CTGTCGGGTCTGCCCGCCGC CCCAGCGGAG CCCGAGCCCG 420 AGCCCGAACC CGAACCTGAA CCTGCGCTGG ACCTCGCGGC GCTGCGTGCG GTCGCCTGCG 480 ACTGCCTGCT GCAGGAGCAC TTCTACCTGC GGCGCAGGCG GCGCTGCAC CGTTACGAGG 540

Seq ID NO: 16 <u>Protein sequence:</u>
Protein Accession #: NP\_057724.1

30 MAARCWRPL LRGPRLSLHT AANAAATATE TTSQDVAATP VARYPPIVAS MTADSKAARL 60 RRIERWQATV HAAESVOEKL RILTKMQFMK YMVYPQTFAL NADRWYQYFT KTVFLSGLPP 120 PPAEPEPEPE PEPEPALDLA ALRAVACDCL LQEHFYLRRR RRVHRYEESE VISLPFLDQL 180 VSTLVGLLSP HNPALAAAAL DYRCPVHFYW VRGEEIIPRG HRRGRIDDLR YQIDDKPNNQ 240 IRISKQLAEF VPLDYSVPIE IPTIKCKPDK LPLFKRQYEN HIFVGSKTAD PCCYGHTQFH 300 LLPDKLRRER LLRQNCADQI EVVFRANAIA SLFAWTGAQA MYQGFWSEAD VTRPFYSQAV 360 ITDGKYFSFF CYQLNTLALT TQADQNNPRK NICWGTQSKP LYETIEDNDV KGFNDDVLLQ 420 IVHFLLNRPK EEKSQLLEN

Seq ID NO: 17 DNA sequence
Nucleic Acid Accession #: NM\_025059.1
Coding sequence: 3-2150 (underlined sequences correspond to start and stop codons)

AAAGATTGGT CCATTCACAT CAGCATCACT TTGTTACCTG TGCCTGCCTC AAAGATGTGA 2100 CTACTGGGCA AGAGAGGCAC CCACAAGGCC ATTTACAGCT TCTTCATTGA ACACTGTATC 2160 TCTTGAGAGA GGTGGCCATA AGACATGGCA CACAATTCCC AATTTCACAA ATTCCTCATG 2220 TCTTTGAGAT TTGATCAGTT TGTGAATATT TTATGCTTTG ATGATATAGT GAGAATGCAT 2280 CACTTGCAAA AACGATCTCA AAAGTGTCAG CCTTAGATAA ACGTCAGCAT TAAAAAACGC 2340 CAAAAAAAAA AAAAAAAAGC ATTTTAGGAT CCAGAAGAAT TCCACCAGAT TGCATGAGTT 2400 AGATTGGGAA ATGGGAGTGG GAGATAATAT TGGGAGGTAT CTATTTTAAG TCAGGGGCTT 2460 TACTAGCCGA TITAGTTCTC ACAATAACCA TGTGGAGAAG CTGTGACAAT TITAATTTAC 2520
AACCTTTCTG GGGCTCAGAC ATAAAGTTAC CTATCCAAAGC TTGCAGTTGG GTAGTGGTGG 2580
GACCAGGATG GACAACTCAT TGGCCCTGCC TCAAAAGCCA TACCTCTTCT CCTGCTATACC 2640
AGAATCTGTT TCTCCTGAAT CTCTGTGATG CTGGTGGGGAA TTGTTTGCAT AGAGGAAGGA 2700
CAATAACCCT GCCATCGTGA GTTAATGTCC GGGCTGGTCA CAGTGGTTCA TGCCTGTAAT 2760 10 CCCAGCACTT TGGGAGTCCA AGGCAGGCAT ATCATTTGAG GTCAGGAGTT TAAGACCAGC 2820 CTGGCTAACA TAGTGAGACC CTGTTTCTAC TAAAAATACA AAAATAAGCC AGGTGTGGTG 2880 GTGCATGACT GTAATCCCAA CTACTCAGCA GGAGAAGCAC TTGAACCCAG GAGACGGAGG 2940 15 CGGCAGTGAG CCAAGATTGT GCCACTGCAC TCCAGCCTGG GCGACAGAGT GAAACTACAT 3000 20 AGCTTTATTT GGAGCCCAAC CCTATAAGAT GAAGAAATCC TATATAGTCT TATTCACCAA 3300 TATATCCAAT ACACCCACAG CAATGGTACC TITTTAAGAT CAGGATTITA TTATGAATTC 3360 CTGTCACTTT CTGTTTTCCA TTTAAATTTC TATTTTACAA ATTTTTCAGG GAATCATATT 3420 CITAACTICA CIGAGAAAAA TGTGTTACTC TTTTGGACAA TTTATCTTAT TTCTATCATA 3480 TAAGATGTAT TTTTTTATTG TCCTTAAAAG AAGCTCTAGC ATGAAATTAA AGGAAAGGGA 3540 AAGAAATAGA TCTGGTGCAC CCGAACATTA GGAGAAAATG AAAAATATAC AACCAACCGT 3600 25 TOGTOAGTCA TCAAAAAGTC AAAGTCAGCC TGGCCAAACAT GAAAAATATAC AACCAACCGT 3660
AAAAATACAA AAAATGAGCC GGTATGTTGG CATATGCCTG TAATCCCAGC TACTCGAGAG 3720
GCTGAGACAC GAAAATTGCT TGAACCTGGG AGGCGGAGGT TGCAATGAGC CGAGATCGCG 3780
CTACTGCACT CCAGCCTGGG CAACAGAGAG AGACCTTGTC TCAAAAACA ACAACAACAA 3840
AAAGTCAAAG TCATAATAAG CAAATTATTG GCTTCTTTCT TCTAGACYAA AAGAAATTAA 3900
AGAGATGAAA AATATTGTTGC AATAGTTGTA AAAATTGAA TGAGCTTGTT TGAATGAAA 3960 30 AAAGCATAAA ATATTCTTGC AATAATTGTA AAAATTTGAA TGTGGACTAA GTCCTAGATT 4020 ATATTAAAAT ATTTTTAATT TTTTAAGCTT GACAAATGCA CTGATTGTTA TACTTTAAAT 4080 35 AACTAAAAAT CTGAGAATCC ACAGTGCTAC AGACAATAAA TGATAAAATG GGAAAAAAA 4140 AAAAAAAAA A

Seq ID NO: 18 Protein sequence: 40 NP\_079335.1 Protein Accession #:

31

MSLDCTSHIA LGAASPAPEE TYDHLSEVPV TREOLNHYRN VAONARSELA ATLVKFECAO 60 45 SELQDLRSKM LSKEVSCQEL KAEMESYKEN NARKSSLLTS LRDRVQELEE ESAALSTSKI 120 RTEITAHAAI KENQELKKKV VELNEKLQKC SKENEENKKQ VSKNCRKHEE FLTQLRDCLD 180 PDERNDKASD EDLILKLRDL RKENEFVKGQ IVILEETINV HEMEAKASRE TIMRLASEVN 240 REQKKAASCT EEKEKLNQDL LSAVEAKEAL EREVKIFQER LLAGQQVWDA SKQEVSLLKK 300 SSSELEKSLK ASQDAVTTSQ SQYSSFREKI AALLIGRILBM TÖSTEDTILE KIREMÖSRE 360
SRDRMVSQLE AQISELVEQI GKESGFHQKA LQRAQKAENM LETILQQQLTH LEAELVSGGV 420
LRDNLNFEKQ KYLKFLDQLS QKMKLDQMAA ELGFDTRLDV VLARTEQLVR LESNAVIENK 480
TIAHNLQRKL KTQKERLESK ELHMSLLRQK IAQLEEEKQA RTALVVERDN AHLTIRNLQK 540
KVERLQKELN TCRDLHTELK AKLADTNELK IKTLEQTKAI EDLNKSRDQL EKMKEKAEKK 600 50

LMSVKSELDT TEHEAKENKE RARNMIEVVT SEMKTLKKSL EEAEKREKQL ADFREVVSQM 660 LGLNVTSLAL PDYEIIKCLE RLVHSHQHHF VTCACLKDVT TGQERHPQGH LQLLH 55

Seq ID NO: 19 DNA sequence

AF071552, NM\_000662 Nucleic Acid Accession #: 60 Coding sequence: 441-1313 (underlined sequences correspond to start and stop codons)

11 21 51 31 41 65 CTTTGTATAA GGCTCAGCTA AAAGGGAAAT TGAGTGGGTC AGGTACCACG GATACTATAC 60 CITITICATIA GGCTCAGCTA AAAGGGAAAT TGAGTGGGTC AGGTACCACG GATACTATAC 60
ACTCTATTIGC ATGATTCTCC TGCCTACATC AGAAGACGTT TATAAGCCTA ATTTTAAAGGA 120
TACCAGTTGG AATCTCTCT TTATTAAATCA CCAAGAGAAC CATGAACAAG CTGTTTATCA 180
TTTGACTCAT CATITAATCT TGATTTCCAG CTTCTCACAC TTGAAAAGAAG ACATAATACA 240
TTTCTCACAG GATTCTGGGA CTATTAACTG AACTTATGTG TGTAAAAAGGA ATTCATACAA 300
TGAAAGCACT AGAAATAATT ATTATACTTA TAACCATTGT ATTTTTACAT GTTTAAAATA 360
TAGCCATAAT FAGCCTACTC AAATCCAAGT GTAAAAAGTAA AATGATTTGC TTTCGTTTTG 420
TTTTCCTTGC TTAGGGGATC ATGGAACAT TAACTGACAT TCTTCAACAC CAGATCCGAG 540
CTGTTCCCTT TGAGAACCTT AACATCCATT GTGGGGATCC CATGGACTTA GGCTAAGAG 600
CCATTTTTTTA TCAAGGTTGTG AGAAGAAATC GGGGTTGGATCATCCAG GTCAATCATC 660 70 75 CCATTTTTGA TCAAGITGTG AGAAGAAATC GGGGTGGATG GTGTCTCCAG GTCAATCATC 660
TTCTGTACTG GGCTCTGACC ACTATTGGTT TTGAGACCAC GATGTTGGGA GGGTATGTTT 720 ACAGCACTCC AGCCAAAAAA TACAGCACTG GCATGATTCA CCTTCTCCTG CAGGTGACCA 780

TIGATGGCAG GAACTACATI GTCGATGCTG GGTTTGGACG CTCATACCAG ATGTGGCAGC 840 CTCTGGAGTT AATTTCTGGG AAGGATCAGC CTCAGGTGCC TTGTGTCTTC CGTTTGACGG 900 AAGAGAATGG ATTCTGGTAT CTAGACCAAA TCAGAAGGGA ACAGTACATT CCAAATGAAG 960 AATTTCTTCA TTCTGATCTC CTAGAAGACA GCAAATACCG AAAAATCTAC TCCTTTACTC 1020 TTAAGCCTCG AACAATTGAA GATTTTGAGT CTATGAATAC ATACCTGCAG ACATCTCCAT 1080 5 CATCTGTGTT TACTAGTAAA TCATTTTGTT CCTTGCAGAC CCCAGATGGG GTTCACTGTT 1140
TGGTGGGCTT CACCCTCACC CATAGGAGAT TCAATTATAA GGACAATACA GATCTAATAG 1200
AGTTCAAGAC TCTGAGTGAG GAAGAAATAG AAAAAGTGCT GAAAAATATA TTTAATATTT 1260 CCTTGCAGAG AAAGCTTGTG CCCAAACATG GTGATAGATT TTTTACTATT <u>TAG</u>AATAAGG 1320 AGTAAAACAA TCTTGTCTAT TTGTCATCCA GCTCACCAGT TATCAACTGA CGACCTATCA 1380 TGTATCTTCT GTACCCTTAC CTTATTTTGA AGAAAATCCT AGACATCAAA TCATTTCACC 1440 10 TATAAAAATG TCATCATATA TAATTAAACA GCTTTTTAAA GAAACATAAC CACAAACCTT 1500 TTCAAATAAT AATAATAATA ATAATAATAA ATGTATTTTA AAGATGGCCT GTGGTTATCT 1560 TGGAAATTGG TGATTTATGC TAGAAAGCTT TTAATGTTGG TTTATTGTTG AATTC 15 Seq ID NO: 20 <u>Protein sequence:</u>
Protein Accession #: NP\_000653.1 20 11 21 31 41 MDIEAYLERI GYKKSRNKLD LETLTDILOH OIRAVPFENL NIHCGDAMDL GLEAIFDOVV 60 RRNRGGWCLQ VNHLLYWALT TIGFETTMLG GYVYSTPAKK YSTGMIHLLL QVTIDGRNYI 120 VDAGFGRSYQ MWQPLELISG KDQPQVPCVF RLTEENGFWY LDQIRREQYI PNEEFLHSDL 180 LEDSKYRKIY SFTLKPRTIE DFESMNTYLQ TSPSSVFTSK SFCSLQTPDG VHCLVGFTLT 240 HRRFNYKDNT DLIEFKTLSE EEIEKVLKNI FNISLQRKLV PKHGDRFFTI 25 Sea ID NO: 21 DNA sequence Nucleic Acid Accession #: NM\_003714 30 Coding sequence: 123-1031 (underlined sequences correspond to start and stop codons) 31 41 51 35 CGGCACGAGC AAAAAGGAAG AGTGGGAGGA GGAGGGGAAG CGGCGAAGGA GGAAGAGGAG 60 GAGGAGGAAG AGGGGAGCAC AAAGGATCCA GGTCTCCCGA CGGGAGGTTA ATACCAAGAA 120 CC<u>ATG</u>TGTGC CGAGCGGCTG GGCCAGTTCA TGACCCTGGC TTTGGTGTTTG GCCACCTTTG 180 ACCCGGCGCG GGGGACCGAC GCCACCAACC CACCCGAGGG TCCCCAAGAC AGGAGCTCCC 240
AGCAGAAAGG CCGCCTGTCC CTGCAGAATA CAGCGGAGAT CCAGCACTGT TTGGTCAACG 300
CTGGCGATGT GGGGTGTGGC GTGTTTGAAT GTTTCGAGAA CAACTCTTGT GAGATTCGGG 360 40 GCTTACATG GATTTGCATG ACTITTCTGC ACAACGCTGG AAAATTGAT GCCAAGGGCA 420
AGTCATTCAT CAAAGACGCC TTGAAATGTA AGGCCCACGC TCTGCGGCAC AGGTTCGGCT 480
GCATAAGCCG GAAGTGCCCG GCCATCAGGG AAATGGTGTC CCAGTTGCAG CGGGAATGCT 540
ACCTCAAGACA CGACCCTGTGC GCGGCTGCCC AGGAGAACAC CCGGGTGATA GTGGAGATGG 600
TCCATTTCAA GGACTTGCTG CTGCACGAAC CCTACGTGGA CCTCGTGAAC TTGCTGCTGA 660
CCTGTGGGGA GGAGGTGAAG GAGGCCATCA CCCCACGCGT GCAGGTTCAG TGTGAGCAGA 720 45 ACTGGGGAAG CCTGTGCTCC ATCTTGAGCT TCTGCACCTC GGCCATCCAG AAGCCTCCCA 780 CGGCGCCCCC CGAGCGCCAG CCCCAGGTGG ACAGAACCAA GCTCTCCAGG GCCCACCACG 840 GGGAAGCAGG ACATCACCTC CCAGAGCCCA GCAGTAGGGA GACTGGCCGA GGTGCCAAGG 900
GTGAGCGAGG TAGCAAGAGC CACCCAAACG CCCATGCCCG AGGCAGAGTC GGGGGCCTTG 960
GGGCTCAGGG ACCTTCCGGA AGCAGCGAGT GGGAAGACGA ACAGTCTGAG TATTCTGATA 1020 50 GGGETCAGGG ACCTTCCGGA AGCAGCGAGT GGGAAGACGA ACAGTCTGAG TATTCTGATA 1020
TCCGGAGGTG AAATGAAAGG CCTGGCCACG AAATCTTTCC TCCACGCCGT CCATTTTCTT 1080
ATCTATGGAC ATTCCAAAAC ATTTACCATT AGAGAGGGG GATGTCACAC GCAGGATTCT 1140
GTGGGGACTG TGGACTTCAT CGAGGTGTGT GTTCGCGGAA CGGACAGGTG AGATGGAGAC 1200
CCCTGGGGCC GTGGGGTCTC AGGGGTGCCT GGTGAATTCT GCACTTACAC GTACTCAAGG 1260 55 GAGCGCCC GCGTTATCCT CGTACCTTTG TCTTCTTTCC ATCTGTGGAG TCAGTGGGTG 1320
TCGGCCGCTC TGTTGTGGGG GAGGTGAACC AGGGAGGGC AGGGCAAGGC AGGGCCCCCA 1380
GAGCTGGGCC ACACAGTGGG TGCTGGGCCT CGCCCCGAAG CTTCTGGTGC AGCAGCCTCT 1440 GGTGCTGTCT CCGCGGAAGT CAGGGCGGCT GGATTCCAGG ACAGGAGTGA ATGTAAAAAT 1500 AAATATCGCT TAGAATGCAG GAGAAGGGTG GAGAGGAGGC AGGGGCCGAG GGGGTGCTTG 1560 60 GTGCCAAACT GAAATTCAGT TICTTGTGTG GGGCCTTGCG GTTCAGAGCT CTTGGCGAGG 1620 GTGGAGGGAG GAGTGTCATT TCTATGTGTA ATTTCTGAGC CATTGTACTG TCTGGGCTGG 1680 GGGGGACACT GTCCAAGGGA GTGGCCCCTA TGAGTTTATA TTTTAACCAC TGCTTCAAAT 1740 CTCGATTTCA CTTTTTTAT TTATCCAGTT ATATCTACAT ATCTGTCATC TAAATAAATG 1800 65 GCTTTCAAAC AAAAAAAAAA AAAAAAAAAA AAAAAAA Seq ID NO: 22 Protein sequence: Protein Accession #: NP\_003705

70

75


21 31

11

41

Seg ID NO: 23 DNA sequence

RR



GGCCTTGAGG GCCAAGACCA ACACCTACAT CAAGACACCG GTGAGGGGGCG AGGAACCAGT 540 GTTCATGGTG ACAGGGCGAC GGGAGGACGT GGCCACAGCC CGGCGGGAAA TCATCTCAGC 600 AGCGGAGCAC TTCTCCATGA TCCGTGCCTC CCGCAACAAG TCAGGCGCCG CCTTTGGTGT 660 AGGGAGCAC TICTCCATGA TCCGTGCCTC CCGCAACAAG TCAGGCGCCG CCTTTGGTGT 660
GGCTCCTGCT CTGCCCGGCC AGGTGACCAT CCGTGTGTGG T20
GCTGGTGGTG GGCCCCAAAG GGGCAACAAT CAAGCGCATC CAGCAGCATAA 780
CATTATCACA CCAAGCCGTG ACCGCGACCC CGTGTTCGAG ATCACGGGTG CCCCAGGCAA 840
CGTGGAGCGT GCGCGCGAGG AGATCCAGAG GCACATCGCG GTGCGCACTG GCAAGATCCT 900
CGAGTACAAC AATGAAAACG ACTTCCTGGC GGGGAGCCCC GACGCACTA TCGATAGCCG 960
CTACTCCGAC GCCTGGCGG TGCACCAGCC CGGCTGCAAG CCCCTCTCCA CCTTCCGGCA 1020
GAACAGCCTG GGCTGCATCG GCAGTGCGG AGTGCACTT GGCTTTGAGG CCCCACGCCT 1080
GGGTGAGCAG GGCGGGACT TTGGCTACGG CGGGTACCTT CTTCCCGGCA 1020
CAAGCAGGAT GTGTACTACG GCGTGCCCA GACTAGCCCC CCGCTGTGGG CGGGCCAGGA 1200
GAACGCCCG CCCACCTCCG TGCTCTTCTC CTCTGCCTC TCCTCCTCCT CCTCTCCCC 1260
CAAGGCCCGC GCTGGGCCCC CGGGCGCACA CCGCTCCCCT CCCACTTCCG CGGGACCCGA 1320
GAACGCCCGC CCCCCGGGGCCCCCCGGG AGACCCCCC CAGGCTTTCCG CGGGACCCGA 1320
GCTGGCCGGA CTCCCGAGGC CCCCCCGGG AGACCCCC CAGGCTTCCT CTAACTTGG 1380
TGGGGGCCGCC CTCCGGAGCC CCGGCGGCGG AGACCCCTC CAGGCTTTCT TTAAAACTGG 1380 10 15 20 TGGGGGCGGC CTGCGGAGCC CCGGCGGCGG GCGGGATTGC ATGGTCTGCT TTGAGAGCGA 1440
AGTGACTGCC GCCCTTGTGC CCTGCGGACA CAACCTGTTC TGCATGGAGT GTGCAGTACG 1500 CATCTGCGAG AGGACGGACC CAGAGTGTCC CGTCTGCCAC ATCACAGCCA CGCAAGCCAT 1560 CCGAATATTC TCCTAA 25 Seq 1D NO: 26 <u>Protein sequence</u>:

Protein Accession #: FGENESH predicted 30 11 21 31 41 FCFAMPSLVV SGIMERNGGF GELGCFGGSA KDRGLLEDER ALQLALDQLC LLGLGEPPAP 60 RAGEDGGGG GGAPAQPTAP PQPAPPPPPA APPAAPTTAP AAQTPQPPTA PKGASDAKLC 120 ALYKEAELRL KGSSNTTECV PVPTSEHVAE IVGRQGCKIK ALRAKTNTYI KTPVRGEEPV 180 35 FMVTGRREDV ATARREIISA AEHFSMIRAS RNKSGAAFGV APALPGQVTI RVRVPYRVVG 240 LVVGPKGATI KRIQQQTNTY IITPSRDRDP VFEITGAPGN VERAREEIET HIAVRTGKIL 300 EYNNENDFLA GSPDAAIDSR YSDAWRVHQP GCKPLSTFRQ NSLGCIGECG VDSGFEAPRL 360 GEQGGDFGYG GYLFPGYGVG KQDVYYGVAE TSPPLWAGQE NATPTSVLFS SASSSSSSSA 420 KARAGPPGAH RSPATSAGPE LAGLPRRPPG EPLQGFSKLG GGGLRSPGGG RDCMVCFESE 480 40 VTAALVPCGH NLFCMECAVR ICERTDPECP VCHITATQAI RIFS Sea ID NO: 27 DNA sequence Nucleic Acid Accession #: FGENESH predicted Coding sequence: 1-2070 (underlined sequences correspond to start and stop codons) 45 51 ATGAGGGTG CGGGGTGGG GGCTGGGACG CGCCCCA GCTCGCCGAC CCCGGGCTCT 60
CGGCGCCGGC GCCAGCGCCC CTCTGTGGGC GTCCACTCCT TGAGGCCGCA GAGCCCGCAG 120
CTCAGGCAGA GCGACCCGCA GAAACGGAAC CTGGACCTGG AGAAAAGCCT GCAGTTCCTG 180
CAGCAGCAGC ACTCGGAGAT GCTGGCCAAG CTCCATGAGG AGATCGAGCA TCTGAAGCGG 240 50 GAAAACAAGG GTGAGCCGGC GCGGGGCCCT AGGCCGGCCC TGCCTCCCCA GGCACACTCA 300 ACACTGCCGC TCCCGCAGCA CAGAAACACA GCCATCAACT CCAGCACACG CCTGGGCTCA 360 ACACTGCCGC TCCCGCAGCA CAGAAACAC GCCATCAACT CCAGCACACG CCTGGCTCA 360
GGGGGAACAC AGGACGGGGA GCCCCTCCAG ACTGTCCTTG CCCACCTGGC TGCACTGGC 420
CCTGTATGCC AACCCAGTGG GTACAGGTTC TGGGGGACCT GGACAGATGC CGCTACCTCT 480
AGCCGTGGCT GGACGATGTT ATGCAGCCAA GCACAGCACG TGCTCCTCC GGGAAGCCCA 340
GGGCCTGAGG TCATTGCAGG GCGCAGGTG GCCACAGGGT GCTCCCCAGA CCTCCCTCCT 660
CCAAGTAGAG CTGAAATGGG AAGGAACCCC TGGGACAGCC CCTGCCTGC TAGGATCTTTG 660
CCTCAGATTG CTGCTGTGGC CAGGCCCAGG ATTTCCAGCC CTATGGCTCT GAGTCCTCAC 720
ATGCTGGGGG CCCAGGGGAT ATGGACACAC TCCATCCAGG GATCCCTTCC TGCCATCTGG 780
GCAGCAACCA TGGGGACAAA GGGAGGAAGC AGAGTCCTGT TTCCTTGCCA CTTGTCCAAG 840
GCACTTCACTCC ATCCTGACAG CGGCCCCCAC CCAGCCCAGG ATCCTGGCT GTGGTCTCAA 960 55 60 65 70 CCCCTACTTC ACAACAGCAA GCTGGACAAA GTTCCTGGGG TACAAGGGCA GGCCAGAAAG 1620
GAGAAAGCAG AGGCCTCTAA TGCAGGAGCT GCCTGTATGG GGAACAGCA GCACCAGGGC 1680
AGGCAGATGG GGGCGGGGGC ACACCCCCCA ATGATCCTGC CCCTTCCCCT GCGAAAGCCC 1740 75

CAGGGCGGGC GAGGACGGGG GAGGTGGGGG GGGCGGCGCC CCCGCGCAGC CGACAGCCCC 240

ACCACACTTA GGCAGTGCGA AGTGCTCATC CGCGAGCTGT GGAATACCAA CCTCCTGCAG 1800

ACCCAAGAGC TGCGGCACCT CAAGTCCCTC CTGGAAGGGA GCCAGAGGCC CCAGGCAGCC 1860 CCGGAGGAAG CTAGCTTTCC CAGGACCAA GAAGCCACGC ATTTCCCCAA GGTCTCCACC 1920 AAGACCATC CCAAGAAAAAATG CCTGAGCCCA CCTGTGGCGG AGCGTGCCAT CCTGCCCGCA 1980 CTGAAGCAGA CCCCGAAGAA CAACTTTGCC GAGAGGCAGA AGAGGCTGCA GGCAATGCAG 2040 AAACGGCGCC TGCATCGCTC AGTGCTT<u>TGA</u>

Seq ID NO: 28 <u>Protein sequence:</u>
Protein Accession #: FGENESH predicted

5

25

30

35

40

45

50

55

60

65

70

75

1 11 21 31 41 51

| MSGAGVAAGT RPPSSPTPGS RRRRQRPSVG VQSLRPQSPQ LRQSDPQKRN LDLEKSLQFL 60
QQQHSEMLAK LHEEIEHLKR ENKGEPARGP RPALPPQAHS TLPLPQHRNT AINSSTRLGS 120
GGTQDGEPLQ TVLAHLAALA PVCQPSGYRF WGTWTDAATS SRGWTMLCSQ AQHVLLSGSP 180
GPEVIAGRQV ATGCSPDLPP PSRAEMGRNP WDSPCPARSL PQIAAVARPR ISSPMALSPH 240
MLGAQGIWTH SIQGSLPAIW AATMGTKGGS RVLFFCHLSK ALPHEPDSGPH PAQDPGLWSQ 300
AHEPLSLGLG LTSGGHLTGG WSQPGNIAAG AVPRALPSQG DMEKGVEGGP FPSRCGNSSE 360
LFWAKCGPSR QPQPCSAGDA DRTREEAMLS LGTCCSMCPK PSCFPDGPSG NHLSRASAFL 420
GRAWVCINGV WVEPGGPSPA RLKEGSSRTH RPGGKRGRLA GGSADTVRSP ADSLSMSSFQ 480
SVKSISNSAN SQGKARPQPG SFNKQDSKAD VSQKADLEEE PLLHNSKLDK VPGVQGQARK 540
EKAEASNAGA ACMGNSQHQG RQMGAGAHPP MILPLPLRKP TTLRQCEVIL RELWNTNILQ 600
TQELRHLKSL LEGSQRPQAA PEEASFPRDQ EATHFPKVST KSLSKKCLSP PVAERALIPA 660
LKQTFKNNFA ERQKRLQAMQ KRRLHRSVL

Seq ID NO: 29 DNA sequence
Nucleic Acid Accession #: NM\_012319.2
Coding sequence: 138-2405 (underlined sequences correspond to start and stop codons)

41 11 21 31 51 GTAAAGATCC TAGAAACAGC CAGGGGAAAG GAGCTCACCG ACCAGAACAT GCCAGTGGTA 660 GAAGGAATGT CAAGGACAGT GTTAGTGCTA GTGAAGTGAC CTCAACTGTG TACAACACTG 720 TCTCTGAAGG AACTCACTTT CTAGAGACAA TAGAGACTCC AAGACCTGGA AAACTCTTCC 780 CCAAAGATGT AAGCAGCTCC ACTCCACCCA GTGTCACATC AAAGAGCCGG GTGAGCCGGC 840 TGGCTGGTAG GAAAACAAAT GAATCTGTGA GTGAGCCCCG AAAAGGCTTT ATGTATTCCA 900 GAAACACAAA TGAAAATCCT CAGGAGTGTT TCAATGCATC AAAGCTACTG ACATCTCATG 960 GCATGGGCAT CCAGGTTCCG CTGAATGCAA CAGAGTTCAA CTATCTCTGT CCAGCCATCA 1020 TCAACCAAAT TGATGCTAGA TCTTGTCTGA TTCATACAAG TGAAAAGAAG GCTGAAATCC 1080 CTCCAAAGAC CTATTCATTA CAAATAGCCT GGGTTGGTGG TTTTATAGCC ATTTCCATCA 1140 TCAGTTICCT GICTCTGCTG GGGGTTATCT TAGTGCCTCT CATGAATCGG GTGTTTTTCA 1200
AATTTCTCCT GAGTTTCCTT GTGGCACTGG CCGTTGGGAC TTTGAGTGGT GATGCTTTT 1260
TACACCTTCT TCCACATTCT CATGCAAGTC ACCACCATGA TCATAGCCAT GAAGAACCAG 1320
CAATGGAAAT GAAAAGAGGA CCACTTTTCA GTCATCTGTC TTCTCAAAAC ATAGAAGAAA 1330
GTGCCTATTT TGATTCCACG TGGAAGGGTC TAACAGCTCT AGGAGGCCTG TATTTCATGT 1440 TTCTTGTTGA ACATGTCCTC ACATTGATCA AACAATTTAA AGATAAGAAG AAAAAGAATC 1500 AGAAGAAACC TGAAAATGAT GATGATGTGG AGATTAAGAA GCAGTTGTCC AAGTATGAAT 1560 CTCAACTTTC AACAAATGAG GAGAAAGTAG ATACAGATGA TCGAACTGAA GGCTATTTAC 1620 GAGCAGACTC ACAAGAGCCC TCCCACTTTG ATTCTCAGCA GCCTGCAGTC TTGGAAGAAG 1680
AAGAGGTCAT GATAGCTCAT GCTCATCCAC AGGAAGTCTA CAATGAATAT GTACCCAGAG 1740
GGTGCAAGAA TAAATGCCAT TCACATTTCC ACGATACACT CGGCCAGTCA GACGATCTCA 1800 TTCACCACCA TCATGACTAC CATCATATTC TCCATCATCA CCACCACCAA AACCACCATC 1860
CTCACAGTCA CAGCCAGCGC TACTCTCGGG AGGAGCTGAA AGATGCCGGC GTCGCCACTT 1920
TGGCCTGGAT GGTGATAATG GGTGATGGCC TGCACAATTT CAGCGATGGC CTAGCAATTG 1980 TGGCCTGGAT GGTGATAATG GGTGATGGCC TGCACAATTT CAGCGATGGC CTAGCAATTG 1980
GTGCTGCTTT TACTGAAGGC TTATCAAGTG GTTTAAGTAC TTCTGTTGCT GTGTTCTGTC 2040
ATGAGTTGCC TCATGAATTA GGTGACTTTG CTGTTCTACT AAAGGCTGGC ATGACCGTTA 2100
AGCAGGCTGT CCTTTATAAT GCATTGTCAG CCATGCTGGC GTATCTTGGA ATGGCAACAG 2160
GAATTTTCAT TGGTCATTAT GCTGAAAATG TTTCTATGTG GATATTTGCA CTTACTGCTG 2220
GCTTATCAT GATGTTGCT CTGGTTGATA TGGTACCTGA AATGCTGCAC CAATGATGCTA 2280
GTGACCATGG ATGTAGCCGC TGGGGGTATT TCTTTTTACA GAATGCTGGG ATGCTTTTTGG 2340
GTTTTGGAAT TATGTTACTT ATTTCCATAT TTGAACATAA AATGGTGTTT CGTATAAATT 2400 TCTAGTTAAG GTTTAAATGC TAGAGTAGCT TAAAAAGTTG TCATAGTTTC AGTAGGTCAT. 2460
AGGGAGATGA GTTTGTATGC TGTACTATGC AGCGTTTAAA GTTAGTGGGT TTTGTGATTT 2520
TTGTATTGAA TATTGCTGTC TGTTACAAAG TCAGTTAAAG GTACGTTTTA ATATTTAAGT 2580 TATTCTATCT TGGAGATAAA ATCTGTATGT GCAATTCACC GGTATTACCA GTTTATTATG 2640 TAAACAAGAG ATTTGGCATG ACATGTTCTG TATGTTTCAG GGAAAAATGT CTTTAATGCT 2700

TTTTCAAGAA CTAACACAGT TATTCCTATA CTGGATTTTA GGTCTCTGAA GAACTGCTGG 2760 TGTTTAGGAA TAAGAATGTG CATGAAGCCT AAAATACCAA GAAAGCTTAT ACTGAATTTA 2820 AGCAAAGAAA TAAAGGAGAA AAGAGAAGAA TCTGAGAATT GGGGAGGCAT AGATTCTTAT 2880 AAAAATCACA AAATTTGTTG TAAATTAGAG GGGAGAAATT TAGAATTAAG TATAAAAAAGG 2940 CAGAATTAGT ATAGAGTACA TTCATTAAAC ATTTTTGTCA GGATTATTTC CCGTAAAAAC 3000 GTAGTGAGCA CTCTCATATA CTAATTAGTG TACATTTAAC TTTGTATAAT ACAGAAATCT 3060 5 AAATATATTI AATGAATTCA AGCAATATAC ACTTGACCAA GAAATTGGAA TITCAAAATG 3120 TTCGTGCGGG TTATATACCA GATGAGTACA GTGAGTAGTT TATGTATCAC CAGACTGGGT 3180 TATTGCCAAG TTATATATCA CCAAAAGCTG TATGACTGGA TGTTCTGGTT ACCTGGTTTA 3240 10 CAAAATTATC AGAGTAGTAA AACTTTGATA TATATGAGGA TATTAAAACT ACACTAAGTA 3300 TCATTTGATT CGATTCAGAA AGTACTTTGA TATCTCTCAG TGCTTCAGTG CTATCATTGT 3360 GAGCAATTGT CTTTATATAC GGTACTGTAG CCATACTAGG CCTGTCTGTG GCATTCTCTA 3420 GATGTTTCTT TTTTACACAA TAAATTCCTT ATATCAGCTT G

15 Seq 1D NO: 30 <u>Protein sequence:</u>
Protein Accession #: NP\_036451.2

20 FYRYGENNSL SVEGFRKLLQ NIGIDKIKRI HIHHDHDHHS DHEHHSDHER HSDHEHHSDH 120 EHHSDHDHHS HHNHAASGKN KRKALCPDHD SDSSGKDPRN SQGKGAHRPE HASGRRNVKD 180 SVSASEVTST VYNTVSEGTH FLETIETPRP GKLFPKDVSS STPPSVTSKS RVSRLAGRKT 240

NESVSEPRKG FMYSRNTNEN PQECFNASKL LTSHGMGIQV PLNATEFNYL CPAINQIDA 300 RSCLIHTSEK KAEIPPKTYS LQIAWVGGFI AISIISFLSL LGVILVPLMN RVFFKFLLSF 360 LVALAVGTLS GDAFLHLLPH SHASHHHSHS HEEPAMEMKR GPLFSHLSSQ NIEESAYFDS 420 25 TWKGLTALGG LYFMFLVEHV LTLIKQFKDK KKKNQKKPEN DDDVEIKKQL SKYESQLSTN 480 EEKVDTDDRT EGYLRADSQE PSHFDSQQPA VLEEEEVMIA HAHPQEVYNE YVPRGCKNKC 540 HSHFHDTLGQ SDDLIHHIHD YHHILHHHHH QNHIPHSHSQ RYSREELKDA GVATLAWMVI 600 30 MGDGLHNFSD GLAIGAAFTE GLSSGLSTSV AVFCHELPHE LGDFAVLLKA GMTVKQAVLY 660 NALSAMLAYL GMATGIFIGH YAENVSMWIF ALTAGLFMYV ALVDMVPEML HNDASDHGCS 720

Sea ID NO: 31 DNA sequence 35 Nucleic Acid Accession # NM\_002184.1 Coding sequence: 256-3012(underlined sequences correspond to start and stop codons)

RWGYFFLQNA GMLLGFGIML LISIFEHKIV FRINF

40 GAGCAGCCAA AAGGCCCGCG GAGTCGCGCT GGGCCGCCCC GGCGCAGCTG AACCGGGGGC 60 CGCGCCTGCC AGGCCGACGG GTCTGGCCCA GCCTGGCGCC AAGGGGTTCG TGCGCTGTGG 120
AGACGCGGAG GGTCGAGGCG GCGCGGCCTG AGTGAAACCC AATGGAAAAA GCATGACATT 180
TAGAAGTAGA AGACTTAGCT TCAAATCCCT ACTCCTTCAC TTACTAATTT TGTGATTTTGG 240

AAATATCCGC GCAAGATGTT GACGTTGCAG ACTTGGGTAG TGCAAGCCTT GTTTATTTTC 300
CTCACCACTG AATCTACAGG TGAACTTCTA GATCCATGTG GTTATATCAG TCCTGAATCT 360
CCAGTTGTAC AACTTCATTC TAATTTCACT GCAGTTTGTG TGCTAAAGGA AAAATGTATG 420 45 GATTATTTTC ATGTAAATGC TAATTACATT GTCTGGAAAA CAAACCATTT TACTATTCCT 480 AAGGAGCAAT ATACTATCAT AAACAGAACA GCATCCAGTG TCACCTTTAC AGATATAGCT 540

TCATTAAATA TTCAGCTCAC TTGCAACATT CTTACATTCG GACAGCTTGA ACAGAATGTT 600
TATGGAATCA CAATAATTTC AGGCTTGCCT CCAGAAAAAC CTAAAAATTT GAGTTGCAT 660
GTGAACGAGG GGAAGAAAAT GAGGTGTGAG TGGGATGGTG GAAGGGAAAC ACACTTGGAG 720 50 ACAACCTICACT TO GAATGGCA ACACAAGT TTGCTGATTG CAAAGCAAAA 780
CGTGACACC CCACCTCATG CACTGTGAT TATTCTACTG TGTATTTTGT CAACATTGAA 840
GTCTGGGTAG AAGCAGAGA TGCCCTTTGGA AAGTTACAT CAGATCATA CAATTTTGAT 900
CCTGTATATA AAGTGAAGCC CAATCCGCCA CATAATTTAT CAGTGATCAA CTCAGAGGAA 960
CTGTCTAGTA TCTTAAAATT GACATGGACC AACCCAAGTA TTAAGAGTGT TATAATACTA 1020
AAATATAACA TTCAATATAG GACCAAAGAT GCCTCAACTT GGAGCCAGAT TCCTCCTGAA 1080 55

GACACAGCAT CCACCCGATC TTCATTCACT GTCCAAGACC TTAAACCTTT TACAGAATAT 1140 GTGTTTAGGA TTCGCTGTAT GAAGGAAGAT GGTAAGGGAT ACTGGAGTGA CTGGAGTGAA 1200 GAAGCAAGTG GGATCACCTA TGAAGATAGA CCATCTAAAG CACCAAGTTT CTGGTATAAA 1260 60

ATAGATICAT CCCATACTCA AGGCTACAGA ACTGTACAAC TCGTGTGGAA GACATTGCCT 1320 CCTTTTGAAG CCAATGGAAA AATCTTGGAT TATGAAGTGA CTCTCACAAG ATGGAAATCA 1380 CATTTACAAA ATTACACAGT TAATGCCACA AAACTGACAG TAAATCTCAC AAATGATCGC 1440

CATTTACAAA ATTACACAGT TAATGCCACA AAACTGACAG TAAATCTCAC AAATGATCGC 1440
TATCTAGCAA CCCTAACAGT AAGAAATCTT GTTGGCAAAAT CAGAATGCAGC TGTTTTAACT 1500
ATCCCTGCCT GTGACTTTCA AGCACACTCAC CCTGTAATGG ATCTTAAAGC ATTCCCCAAA 1560
GATAACATGC TTTGGGTGGA ATGGACTACT CCAAGGGAAT CTGTAAAGAA ATATATACTT 1620
GAGTGGTGTG TGTTATCAGA TAAAGCACCC TGTATCACAG ACTGGCAACA AGAAGTGGT 1680
ACCGTGCATC GCACCTATTT AAGAGGGAAC TTAGCAGAGA GCAAATGCTA TTTGATAACA 1740
GTTACTCCAG TATATGCTGA TGGACCAGGA AGCCCTGAAT CCATAAAGGC ATACCTTAAA 1800
CAAGCTCCAC CTTCCAAAGG ACCTACTGTT GGACAAAAA AAGTAGGGAA AAACGAAGCT 1860
GTCTTAGAGT GGGACCAACT TCCTGTTGAT GTTCAGAATG GATTTATCAG AAATTATACT 1920 65

70 ATATTITATA GAACCATCAT TGGAAATGAA ACTGCTGTGA ATGTGGATTC TTCCCACACA 1980 GAATATACAT TGTCCTCTTT GACTAGTGAC ACATTGTACA TGGTACGAAT GGCAGCATAC 2040 ACAGATGAAG GTGGGAAGGA TGGTCCAGAA TTCACTTTTA CTACCCCAAA GTTTGCTCAA 2100

GGAGAAATTG AAGCCATAGT COTGCCTGTT TGCTTAGCAT TCCTATTGAC AACTCTTCTG 2160 GGAGTGCTGT TCTGCTTTAA TAAGCGAGAC CTAATTAAAA AACACATCTG GCCTAATGTT 2220 CCAGATCCTT CAAAGAGTCA TATTGCCCAG TGGTCACCTC ACACTCCTCC AAGGCACAAT 2280 75

TTTAATTCAA AAGATCAAAT GTATTCAGAT GGCAATTTCA CTGATGTAAG TGTTGTGGAA 2340 TTTAATTCAA AAGATCAAAT GTATTCAGAT GGCAATTTCA CTGATGTAAG TGTTGTGGAA 2340
ATAGAAGCAA ATGACAAAAA GCCTTTTCCA GAAGATCTGA AATCATTGGA CCTGTTTCAAA 2400
AAGGAAAAAA TTAATACTGA AGGACACAGC AGTGGTATTG GGGGGTCTTC ATGCATGTCA 2460
TCTTCTAGGC CAAGCATTTC TAGCAGTGAT GAAAATGAAT CTTCACAAAA CACTTCGAGC 2520
ACTGTCCAGT ATTCTACCGT GGTACACAGT GGCTACCAGAC ACCAAGTTCC GTCAGTCCAA 2580
GCTTTCTCAA GATCCAGTC TACCCAGCCC TTGTTAGATT CAGAGGAGCG GCCAGAAGAT 2640
CTACAATTAG TAGATCATGT AGATGGCGGT GATGGTATTT TGCCCAGGCA ACAGTACTTC 2700
AAACAGAACT GCAGTCAGCA TGAATCCAGT CCCAGATATTT CACATTTTGA AAGGTCAAAG 2760
CAAGTTTCAT CAGTCAATGA GGAAGATTTT GTTAGACTTA AACAGCAGAT TTCAGATCAT 2820
ATTTCACAAT CCTGTGGATC TGGGCAAAATG AAAATGTTTC AGGAAGTTTT GCAGACGAT 2880
GCTTTTGGTC CAGGTACTGA GGGACAAGTA GAAAGATTTT AAACAGTTAG CATGGAGGCT 2940
GCGACTGATG AAGGCATGCC TAAAAGTTAC TTACCACAGA CTGTACGGCA AGGCGGCTAC 3000
ATGCCTCAGT GAAGGACTAG TAGTTCCTGT TACAACTTCA GCAGATACTTA AAAAGTAAAT 5 10 CTAAAATGAT TTTATCTGTG AATTC 15 Seq ID NO: 32 <u>Protein sequence:</u> Protein Accession #: NP\_002175.1 21 31 41 20 MLTLQTWVVQ ALFIFLTTES TGELLDPCGY ISPESPVVQL HSNFTAVCVL KEKCMDYFHV 60 NANYIVWKTN HETIPKEQYT IINRTASSVT FTDIASINIQ LTCNILTEQ LEQNVYGITI 120 ISGLPPEKPK NLSCIVNEGK KMRCEWDGGR ETHLETNFTL KSEWATHKFA DCKAKRDTPT 180 SCTYDYSTYY FYNIEVWYEA ENALGKYTSD HINFDPYYKV KPNPPHNLSV INSEELSSIL 240
KLTWTNPSIK SYIILKYNIQ YRTKDASTWS QIPPEDTAST RSSFTYQDLK PFTEYYFRIR 300
CMKEDGKGYW SDWSEEASGI TYEDRPSKAP SFWYKIDPSH TQGYRTVQLV WKTLPPFEAN 360
GKILDYEVTL TRWKSHLQNY TYNATKLTYN LTNDRYLATL TYRNLVGKSD AAVLTIPACD 420 25 FQATHPYMDL KAPKDNMLW VEWTTPRESV KKYILEWCVL SDKAPCITDW QQEDGTVHRT 480
YLRGNLAESK CYLITVTPVY ADGPGSPESI KAYLKQAPPS KGPTVRTKKV GKNEAVLEWD 540
QLPVDVQNGF IRNYTIFYRT IIGNETAVNV DSSHTEYTLS SLTSDTLYMV RMAAYTDEGG 600 30 KDGPEFTETT PKFAQGEIEA IVVPVCLAFL LTTLLGVLFC FNKRDLIKKH IWPNYPDPSK 660
SHLAQWSPHT PPRINFNSKD QMYSDGNFTD VSVVEIEAND KKPFPEDLKS LDLFKKEKIN 720 TEGHSSGIGG SSCMSSSRPS ISSSDENESS QNTSSTVQYS TVVHSGYRHQ VPSVQVFSRS 780 TEUTISSUIUS SCAMSSANTA ISSSUENTESS QNI ISSI VQ IS I VYTISUI IKIŲ VI SVŲVITSKS /6U ESTOPLLIDSE ERPEDLQLVD HVDGGDGILP RQQYFKQNCS QIESSPDISH FERSKQVSSV 840 NEEDFVRLKQ QISDHISQSC GSGQMKMFQE VSAADAFGPG TEGQVERFET VGMEAATDEG 900 35 MPKSYLPOTV ROGGYMPO Seq ID NO: 33 DNA sequence Nucleic Acid Accession #: NM\_018255.1 40 Coding sequence: 11-2491 (underlined sequences correspond to start and stop codons) 31 45 50 55 60 65 70 75

GAGTCCTGAC AGCAAGTATT TCTTCACTGG GAGTCGAGAC AAAAAGGTGG TTGTCTGGGG 2100 TGAGTGCGAC TCCACTGATG ACTGTATTGA GCACAACATT GGCCCCTGCT CCTCAGTCCT 2160 GGACGTGGGT GGGGCTGTGA CAGCTGTCAG CGTCTGCCCA GTGCTCCACC CTTCTCAACG 2220 TCATACAGTA GGTCTGAGA TAGTGGG AAAGATTIGC TTATATACCT GGAAAAAAGAC 2280
TGATCAAGTT CCAGAAATAA ATGACTGGAC CCACTGTGTA GAAACAAGTC AAAGCCAAAG 2340
TCATACACTG GCTATCAGAA AATTATGCTG GAAGAATTGC AGTGGAAAAA CTGAACAAGA 2400
GGAAGCAGAA GGTGCTGAGT GGTTACACTT TGCAAGCTGT GGTGAAAGATC ACACTGTGAA 2460 GATACACAGA GTCAATAAAT GTGCACTG<u>TA A</u>TGG

Seq ID NO: 34 <u>Protein sequence:</u>
Portein Accession #: NP\_060725.1 10

5

30

35

40

45

50

55

60

65

15 MVAPVLETSH VFCCPNRVRG VLNWSSGPRG LLAFGTSCSV VLYDPLKRVV VTNLNGHTAR 60 VNCIQWICKQ DGSPSTELVS GGSDNQVIHW EIEDNQLIKA VHLQGHEGPV YAVHAVYQRR 120 TSDPALCTLI VSAAADSAVR LWSKKGPEVM CLQTLNFGNG FALALCLSFL PNTDVPILAC 180 GNDDCRIHIF AQQNDQFQKV LSLCGHEDWI RGVEWAAFGR DLFLASCSQD CLIRIWKLYI 240 KSTSLETQDD DNIRLKENTF TIENESVKIA FAVTLETVLA GHENWYNAVH WQPVFYKDOV 300 LQQPVRLLSA SMDKTMILWA PDEESGVWLE QVRVGEVGGN TLGFYDCQFN EDGSMIAHA 360 PHGALHLWKQ NTVNPREWTP EIVISGHFDG VQDLVWDPEG EFIITVGTDQ TTRLFAPWKR 420 20 KDQSQVTWHE IARPQIHGYD LKCLAMINRF QFVSGADEKV LRVFSAPRNF VENFCAITGQ 480 SLNHVLCNQD SDLPEGATVP ALGLSNKAVF QGDIASQPSD EEELLTSTGF EYQQVAFQPS 540 ILTEPPTEDH LLQNTLWPEV QKLYGHGYEI FCVTCNSSKT LLASACKAAK KEHAAIILWN 600 25

TTSWKQVQNL VFHSLTVTQM AFSPNEKFLL AVSRDRTWSL WKKQDTISPE FEPVFSLFAF 660 TNKITSVHSR IIWSCDWSPD SKYFFTGSRD KKVVVWGECD STDDCIEHNI GPCSSVLDVG 720 GAVTAVSVCP VLHPSQRYVV AVGLECGKIC LYTWKKTDQV PEINDWTHCV ETSQSQSHTL 780 AIRKLOWKNO SOKTEQKEAE GAEWLHFASO GEDHTVKIHR VNKCAL

Seq ID NO: 35 DNA sequence Nucleic Acid Accession #: NM 022131 Coding sequence: 11-2878 (underlined sequences correspond to start and stop codons)

31 41 TGCTGCGAGG ATGCTGCCTG GGCGGCTGTG CTGGGTGCCG CTCCTGCTGG CGCTGGGCGT 60 GGGGAGCGGC AGCGGCGGTG GCGGGGACAG CCGGCAGCGC CGCCTCCTCG CGGCTAAAGT 120 CAATAAGCAC AAGCCATGGA TCGAGACTTC ATATCATGGA GTCATAACTG AGAACAATGA 180 CACAGTCATT TTGGACCCAC CACTGGTAGC CCTGGATAAA GATGCACCGG TTCCTTTTGC 240
AGGGGAAATC TGTGCGTTCA AGATCCATGG CCAGGAGCTG CCCTTTGAGG CTGTGGTGCT 300
CAACAAGACA TCAGGAGAGG GCCGGCTCCG TGCCAAGAGC CCCATTGACT GTGAGTTGCA 360 GAAGGAGTAC ACATTCATCA TCCAGGCCTA TGACTGTGGT GCTGGGCCCC ACGAGACAGC 420
CTGGAAAAAG TCACACAAGG CCGTGGTCCA TATACAGGTG AAGGATGTCA ACGAGTTTGC 480
TCCCACCTTC AAAGAGCCAG CCTACAAGGC TGTTGTGACG GAGGGCAAGA TCTATGACAG 540 CATTCTGCAG GTGGAGGCCA TTGACGAGGA CTGCTCCCCA CAGTACAGCA GAGATTGCAA 600
CTATGCAGG GTCGCCACAG ATGTGCCTTT TGCCATCGAC AGAAATGGCA ACATCAGGAA 600
CATGAGAAG CTGAGCTATG ACAAACAACA CCAGTATGAG ATCCTGGTGA CCGCCTACGA 720
CTGTGGACAG AAGCCCGCTG CTCAGGACAC CCTGGTGCAG GTGGATGTGA AGCCAGTTTTG 780
CAAGCCTGGC TGGCAAGACT GGACCAAGAG GATTGAGTAC CAGCCTGGCT CCGGAGCAT 840 GCCCCTGTTC CCCAGCATCC ACCTGGAGAC GTGCGATGGA GCCGTGTCTT CCCTCCAGAT 900 CGTCACAGAG CTGCAGACTA ATTACATTGG GAAGGGTTGT GACCGGGAGA CCTACTCTGA 960
GAAATCCCTT CAGAAGTTAT GTGGAGCCTC CTCTGGCATC ATTGACCTCT TGCCATCCCC 1020 TAGCGCTGCC ACCAACTGGA CTGCAGGACT GCTGGTGGAC AGCAGTGAGA TGATCTTCAA 1080 GTTTGACGGC AGGCAGGGTG CCAAAATCCC CGATGGGATT GTGCCCAAGA ACCTGACCGA 1140
TCAGTTCACC ATCACCATGT GGATGAAACA CGGCCCCAGC CCTGGTGTGA GAGCCGAGAA 1200 GGAAACCATC CTCTGCAACT CAGACAAAAC CGAAATGAAC CGGCATCACT ATGCCCTGTA, 1260
TGTGCACAAC TGCCGCCTCG TCTTTCTCTT GCGGAAGGAC TTCGACCAGG CTGACACCTT, 1320
TCGCCCCGCG GAGTTCCACT GGAAGCTGGA TCAGATTTGT GACAAAGAGT GGCACTACTA, 1380 TGTCATCAAT GTGGAGTTTC CTGTGGTAAC CTTATACATG GATGGAGCAA CATATGAACC 1440 ATACCTGGTG ACCAACGACT GGCCCATTCA TCCATCTCAC ATAGCCATGC AACTCACAGT 1500 CGGCGCTTGT TGGCAAGGAG GAGAAGTCAC CAAACCACAG TTTGCTCAGT TCTTTCATGG 1560

AGCCTGGCC AGTCTCACCA TCCGCCCTGG CAAAATGGAA AGCCAGAAGG TGATCTCTTG 1620
CCTGCAGGCC TGCAAAGGAAG GGCTGGACAT TAATTCCTTG GAAAGCCTTG GCCAAGGAAT 1680
AAAGTATCAC TTCAACCCCT CGCAGTCCAT CCTGGTGATG GAAGGGTGACG ACATTGGGAA 1780
CATTAACCGT GCTCTCCAGA AAGTCTCCTA CATCAACTCC AGGCAGTTCC CAACGGCGGG 1800
TGTGCGGCGC CTCAAAGTAT CCTCCAAAGT CCAGTGGTTT GGGGAACG TATGCATCAG 1860

TATCCCTGAG GTAGATGCCT ATGTGATGGT CCTCCAGGCC ATGGAGCCC GGATCACCAT 1920
CCGGGGCACA GACCACTTCT GGAGACCTGC TGCCCAGTTT GAAAGTGCCA GGGGAGTGAC 1980
CCTCTTCCCT GATATCAAGA TTGTGAGCAC CTTCGCCAAA ACCGAAGCCC CCGGGGACGT 2040
GAAAACCACA GACCCCAAAT CAGAAGTCTT AGAGGAAATG CTTCATAACT TAGATTTCTG 2100
TGACATTTTG GTGATCGGAG GGGACTTGGA CCCAAGGCAG GAGTGCTTGG AGCTCAACCA 2160
CAGTGAGCTC CACCAACGAC ACCTGGATGC CACTAATTCT ACTGCAGGCT ACTCCATCTA 2220 70 CGGTGTGGGC TCCATGAGCC GCTATGAGCA GGTGCTACAT CACATCCGCT ACCGCAACTG 2280
GCGTCCGGCT TCCCTTGAGG CCCGGCGTTT CCGGATTAAG TGCTCAGAAC TCAATGGGCG 2340
CTACACTAGC AATGAGTTCA ACTTGGAGGT CAGCATCCTT CATGAAGACC AAGTCTCAGA 2400 75

TAAGGAGCAT GTCAATCATC TGATTGTGCA GCCTCCCTTC CTCCAGTCTG TCCATCATCC 2460
TGAGTCCCGG AGTAGCATCC AGCACAGTTC AGTGGTCCCA AGCATTGCCA CAGTGGTCAT 2520

CATCATCTCC GTGTGCATGC TTGTGTTTGT CGTGGCCATG GGTGTGTACC GGGTCCGGAT 2580 CGCCCACCAG CACTTCATCC AGGAGACTGA GGCTGCCAAG GAATCTGAGA TGGACTGGGA 2640 CGATTCTGCG CTGACTATCA CAGTCAACCC CATGGAGAAA CATGAAGGAC CAGGGCATGG 2700 GGAAGATGAG ACTGAGGGAG AGAGAGGAGA AGAAGCCCAGAGGATGA 2760
GGAAGATGAG ACTGAGGGAG AGAAGACCAGAGGATGA GCTCCAGCCAG 2760
TGGCTCTGAC GACAGCGAAG AGGAGGAGGA GGAGGATGAG ATGGGCAGAG GCAGACATGG 2820
GCAGAATGGA GCCAGGCAAG CCCACCTGCA GTGGGATGAC TCCACCCTCC CCTACTAGTG 2880
CCCAGGGGTC TGCTGCCTGG CCCACATGTC CCTTTTGTAA ACCCTGACCC AGTGTATGCC 2940
CATGTCTATC ATACCTCACC TCTGATGTCT GTGACATGTC TGGGAAGGCC TTCTCCAGCT 3000
TCCTGGAGCC ACCCTTTAA GCCTTGGGCA CTCCCTGTGT TTCATCCATG GGGAAGTTCC 3060
AGAAGCCCA GCATGCCAGCACAGTCA CACTGACGCTACACTTCACCTCCACCT 5 AGAAGCCCA GCATGGCCAT CAGTGAGGCA CITCCIGIGIT TICATCCATG GGGAAGTTCC 3060
AGAAGCCCA GCATGGCCAT CAGTGAGGAC TTCAGGGTAG ACTITGTCCT GTAGCCTCCA 3120
CTTCTGCCCT AAGTTCCCCA GCATCCTGAC TACCTGTCTG CAGAGTTTGC CTTTGTTTTT 3180
TCCTGCAGGG AAGAAGGCC ACCTTTGTGT CACTCACCTC CCCAGGCTCA GAGTCCCCAA 3240
GGCCCTGGGG TTCCAACTCA CTGTGCGTCT CCTCCACACA GACCAGTAGG TTCTCCTATG 3300
TGCTTAACAG TTTAAAGGAA AGTCCTTGTT GAGGCAGAAC TAAGTTTACA GGGAAAGGTA 3420
CACACATTCT CTCTCTCTCT CTCTCTCTGT CTATCTAGTT CCCCAGCTTG GAGAGCCTTT 3480
CCCCTTGCTT CTTTCTGAGG CCATATAAGC TTATAAGGAAA AGTCCCCAAAC CAAGAAATAGG 3540
TCCTTGGCCA CAAGCAGGGT CTGATCCCCC ATCAGAGCTA TCTGAGCCTG CTGTCTTGGG 3600 10 15 TCCTTGGCCA CAAGCAGGGT CTGATCCCCC ATCAGAGCTA TCTGAGCCTG CCTGTCTGGG 3600
CACCTGCTGC AACCATGCAG CTACCCTGCC AGGGGCACTC AGCAAACAG ACCACAGGGC 3660
CCAGGAGGCA TTCCACACAG GCACTGCCCC AGGACAACAC AACAAGGACA GTCACAACAA 3720 20 GGACAACAAG GACACAACAC AACACACAAC AAGGACAGTC ACAACAAGCC TAGAGCCAGA 3780 AAGCAGATGG AAATGCTAAT GAGGTCAAAC GTAGGCTTCA TGGTGGGTGG AGTGGGGGTG 3840 GCTGGGCTCC CCCAGGACAG AGGGGACCCT GAGGTTGGCA AGGCTCTCAC CACTCAGCCT 3900 TATGGTCCCT TATCTCCTAT CTTCCCTCTT GAGAAAATAC ACGCTTTCTG CATGTATTAG 3960 AAACGCACGA GCTCCACCAA GTCTACAATG AAAGTTTGAA ATTTAACTGC AAGGAATTAG 4020 AAGCATATTT GCAATCATTG CAGCTTCTTC TTTCTTCTGC TCATAAAAGG AGGAACACTT 4080 25 TAGATAGAGG GCAAATATAT CTGAAAACCT AATTICTTTC TITTITTGAT AAGGAAATCT 4140
TTTCCATCTC CATCCTAACA TGCACAACCT GTGAAGAGAA TTGTTTCTAT AGTAACTGGT 4200
CTGTGATCTT TTGTGGCCAA GAGAATAGCA GGCAAGAATT AGGGCCTTGA CAGAATTTCC 4260
ACGAAGCTCT GGGAACATGT TTGTTTCGAA TGCTCATCTTTTGTCA TCAATGTTCC 4250
TGCTCTGTCC CCATCCTTCA CTCCTCCAA AGCTCACACC AATTIGGTTTG GCACAGGCAC 4380
AGAGCTGGTC CCTAGTTAAG TGGCATTTAT GTTAAAAAAAA AATAGTTCAG AATCTCAGCC 4440 30 TTTTCTTTGT GTCATCAAAA CAGCTTAAGA AGGGGACTAC TGCCAATGTC CTCTAGTCTG 4500 ACCTCCACCC AGGGAGGACC CATGGCAGGT CTTTTCAACT TTCTGATTCA TGAGAACAAC 4560 CTTGTGAAGC TTTTCCCACC TCCTAAAGTG TTTTCTGCAT CTGTTCCTTC CTTTGGACCT 4620 35 CACAACAAAT CCTGTGAAGT AACTGAGACA TCTGTTGTTA GATACATTTT TGTGATGAGT 4680 AAACTGAGGC TTCG Seq ID NO: 36 <u>Protein sequence:</u>
Protein Accession #: NP\_071414.1

40

65

70

75

31 21 41

MLPGRLCWVP LLLALGVGSG SGGGGDSRQR RLLAAKVNKH KPWIETSYHG VITENNDTVI 60 LDPPLVALDK DAPVPFAGEI CAFKIHGQEL PFEAVVLNKT SGEGRLRAKS PIDCELQKEY 120 45 TFIIQAYDCG AGPHETAWKK SHKAVVHIQV KDVNEFAPTF KEPAYKAVVT EGKIYDSILQ 180 VEAIDEDCSP QYSQICNYEI VTTDVPFAID RNGNIRNTEK LSYDKQHQYE ILVTAYDCGQ 240 KPAAQDTLVQ VDYKPVCKPG WQDWTKRIEY QPGSGSMPLF PSIHLETCDG AVSSLQIVTE 300 LQTNYIGKGC DRETYSEKSL QKLCGASSGI IDLLPSPSAA TNWTAGLLVD SSEMIFKFDG 360 RQGAKIPDGI VPKNLTDQFT ITMWMKHGPS PGVRAEKETI LCNSDKTEMN RHHYALYYHN 420 CRLVFLLRKD FDQADTFRPA EFHWKLDQIC DKEWHYYVIN VEFPVVTLYM DGATYEPYLV 480 50 TNDWPIHPSH IAMQLTVGAC WQGGEVTKPQ FAQFFHGSLA SLTIRPGKME SQKVISCLQA 540 CKEGLDINSL ESLGQGIKYH FNPSQSILVM EGDDIGNINR ALQKVSYINS RQFPTAGVRR 600 LKVSSKVQCF GEDVCISIPE VDAYVMVLQA IEPRITLRGT DHFWRPAAQF ESARGVTLFP 660 55

DIKIVSTFAK TEAPGDVKTT DPKSEVLEEM LHNLDFCDIL VIGGDLDPRQ ECLELNHSEL 720
HQRHLDATNS TAGYSIYGVG SMSRYEQVLH HIRYRNWRPA SLEARRFRIK CSELNGRYTS 780
NEFNLEVSIL HEDQVSDKEH VNHLIVQPPF LQSVHHPESR SSIQHSSVVP SLATVVIIIS 840
VCMLVFVVAM GVYRVRIAHQ HFIQETEAAK ESEMDWDDSA LTITVNPMEK HEGPGHGEDE 900
TEGEEEEEAE EEMSSSSGSD DSEEEEEEEG MGRGRHGQNG ARQAQLEWDD STLPY

60

Seq ID NO: 37 DNA sequence Nucleic Acid Accession #: none found Coding sequence: 143-874 (underlined sequences correspond to start and stop codons) 31 41

GGGAGGAGA GAGGCGCGCG GGTGAAAGGC GCATTGATGC AGCCTGCGGC GGCCTCGGAG 60
CGCGGCGGAG CAGACGCTG ACCACGTTCC TCTCCTCGGT CTCCTCCGCC TCCAGCTCCG 120
CGCTGCCCGG CAGCCGGAAG CCATGCGACC CCAGGGCCCC GCCACCTCCC CGCAGCGGCT 180
CCGCCGGCCTC CTGCTGCTCC TGCTGCTTGCA GCTGCCCGGC CCTCTCAGAGA 240
CCCCAAGGGG AAGCAAAAGG CGCAGCTCCG GCAGAGGGAG GTGGTGGACC TGTATAATGG 300 AATGTGCTTA CAAGGGCCAG CAGGAGTGCC TGGTCGAGAC GGGAGCCCTG GGGCCAATGG 360
CATTCCGGGT ACACCTGGGA TCCCAGGTGG GGATGGATC AAAGGAGAAA AGGGGGAATG 420
TCTGAGGGAA AGCTTTGAGG AGTCCTGGAC ACCCAACTAC AAGCAGTGTT CATGGAGTTC 480
AATGAATTAT GGCATAGAT TTGGGAAAAT TGCGGAGTGT ACATTACCAA AGATGCGTTC 540
AAATAGTGCT CTAAGAGTTT TGTTCAGTGG CTCACTTCCG CTAAAATGCA GAAATGCATG 600 CTGTCAGCGT TGGTATTTCA CATTCAATGG AGCTGAATGT TCAGGACCTC TTCCCATTGA 660

AGCTATAATT TATTTGGACC AAGGAAGCCC TGAAATGAAT TCAACAATTA ATATTCATCG 720 CACTTCTTCT GTGGAAGGAC TTTGTGAAGG AATTGGTGCT GGATTAGTGG ATGTTGCTAT 780 CTGGGTTGGC ACTTGTTCAG ATTACCCAAA AGGAGATGCT TCTACTGGAT GGAATTCAGT 840 TTCTCGCATC ATTATTGAAG AACTACCAAA A<u>TAA</u>ATGCTT TAATTTTCAT TTGCTACCTC 900
TTTTTTTATT ATGCCTTGGA ATGGTTCACT TAAATGACAT TTTAAATAAG TTTATGTATA 960 5 CATCTGAATG AAAAGCAAAG CTAAATATGT TTACAGACCA AAGTGTGATT TCACACTGTT 1020 TTTAAATCTA GCATTATTCA TTTTGCTTCA ATCAAAAGTG GTTTCAATAT TTTTTTTAGT 1080 TGGTTAGAAT ACTTTCTTCA TAGTCACATT CTCTCAACCT ATAATTTGGA ATATTGTTGT 1140 GGTCTTTTGT TTTTTCTCTT AGTATAGCAT TTTTAAAAAA ATATAAAAGC TACCAATCTT 1200 10 TGTACAATTT GTAAATGTTA AGAATTTTTT TTATATCTGT TAAATAAAAA TTATTTCCAA 1260 **CAACCTTAAA AAAAAAAAAA AAAA** 

Seq ID NO: 38 Protein sequence:

21 31

Protein Accession #: 15

31 41 21 MRPOGPAASP ORLRGILLLL LLQLPAPSSA SEIPKGKOKA QLRQREVVDL YNGMCLQGPA 60 GVPGRDGSPG ANGIPGTPGI PGRDGFKGEK GECLRESFEE SWTPNYKQCS WSSLNYGIDL 120 GKIAECTFTK MRSNSALRVL FSGSLRLKCR NACCQRWYFT FNGAECSGPL PIEAIIYLDQ 180 20 GSPEMNSTIN IHRTSSVEGL CEGIGAGLVD VAIWVGTCSD YPKGDASTGW NSVSRIIIEE 240

Seg ID NO: 39 DNA sequence 25 Nucleic Acid Accession #: NM 000949 285-2153 (underlined sequences correspond to start and stop codons) Coding sequence:

30 

ATGICTICGI GLAGGAGIA CILCUALI MATGIGGA ACTITICACIA ACTITICACACA TATALA ACTITICACACA GAGCCCTGAA 240
GTGAACTICT GATACATTICA TGGAGGAGAAC ACTGAGGAGT GCTTTCCACACA GAACCCCTGAA 240
GTGAACTICT GATACATTIC CTGCAGCAAG AGAAGGCAGC CAACATGAAG GAAAAATGTGG 300
CATCTGCAAC CGTTTTCACACT CTGCTACTTIT TTCTCAACAC CTGCCTTCTG AATGGACAGT 360
GCTGGTGGAG GCCTGGGACA GATGGAGGAC TTCCTACCAA TTATTCACTG ACTTACCACA 480
GCTGGTGGAG GCCTGGGACA GATGGAGGAC TTCCTACCAA TTATTCACTG ACTTACCACA 480 35 GGGAAGGAGA GACACTCATG CATGAATGTC CAGACTACAT AACCGGTGGC CCCAACTCCT 540
GCCACTTTGG CAAGCAGTAC ACCTCCATGT GGAGGACATA CATCATGATG GTCAATGCCA 600
CTAACCAGAT GGGAAGCAGT TTCTCGGATG AACTTTATGT GGACGTGACT TACATAGTTC 660 40

AGCCAGACCC TCCTTTIGGAG CTGGCTGTGG AAGTAAAACA GCCAGAAGAC AGAAAACCCT 720
ACCTGTGGAT TAAATGGTCT CCACCTACCC TGATTGACTT AAAAACTGGT TGGTTCACGC 780
TCCTGTATGA AATTCGATTA AAACCCGAGA AAGCAGCTGA GTGGGAGATC CATTTTGCTG 840
GGCAGCAAC AGAGTTTAAG ATTCTCAGCCC TACATCCAGG ACAGAAATAC CTTGTCCAGG 900
TTCGCTGCAA ACCAGACCAT GGATACTGAG TGCATTGAG TCCAGGACC TTCATTCAGA 960
TACCTAGTGA CTTCACCATG AATGATACCAA CCGTGTGGAT CTCTGTGGGT GTCCTTTCTG 1020 45

CTGTCATCTG TTTGATTATT GTCTGGGCAG TGGCTTTGAA GGGCTATAGC ATGGTGACCT 1080 GCATCTTTCC GCCAGTTCCT GGGCCAAAAA TAAAAGGATT TGATGCTCAT CTGTTGGAGA 1140 AGGGCAAGTC TGAAGAACTA CTGAGTGCCT TGGGATGCCA AGACTTTCCT CCCACTTCTG 1200 50

AGGGCAAGTC TGAAGAACTA CTGAGTGCCT TGGGATGCCA AGACTTTCCT CCCACTTCTG 1200
ACTATGAGGA CTTGCTGGTG GAGTATTTAG AAGTAGATGA TAGTGAGGAC CAGCATCTAA 1260
TGTCAGTCCA TTCAAAAGAA CACCCAAGTC AAGTAGTAGAA ACCCACATAC CTGGATCCTG 1320
ACACTGACTC AGGCCGGGGG AGCTGTGACA GCCCTTCCCT TTTGTCTGAA AAGTGTGAGG 1380
AACCCCAGGC CAATCCCTCC ACATTCTATG ATCCTGAGGT CATTGAGAAG CCACACACAC CACACCCTGG GACCCCCAGT GCATAAGCAT GGAAGGCAAA ATCCCCTATT 1500
TCATGCTGG TGGATCCAAA TGTTCAACAT GGCCCTTACC ACAGCCCAGC CAGCACAACC 1560
CCAGATCCTCTTACCACAAT ATTACTGATG TGTGTGAGCT GGCTGTGGGC CCTGCAGGTG 1620
CACCGGCCAC TCTGTTGAAT GAAGCAGGTA AAGATGCTTT AAAATCCTC CAAACCATTA 1680
AGTCTAGAGA ACAGGGAAAG GCAACACCACACACACACACAAT 1680 55

AGTCTAGAGA AGAGGGAAAG GCAACCCAGC AGAGGGAGGT AGAAAGCTTC CATTCTGAGA 1740
CTGACCAGGA TACGCCCTGG CTGCTGCCCC AGGAGAAAAC CCCCTTTGGC TCCGCTAAAC 1800
CCTTGGATTA TGTGGAGATT CACAAGGTCA ACAAAGATGG TGCATTATCA TTGCTACCAA 1860

60 AACAGAGAG GAACAGCGGC AAGCCCAAGA AGCCCGGGACTCCTGAGAAC AATAAGGAGT 1920 ATGCCAAGGT GTCCGGGGTC ATGGATAACA ACATCCTGGT GTTGGTGCCA GATCCACATG 1980 CTAAAAACGT GGCTTGCTTT GAAGAATCAG CCAAAGAGGC CCCACCATCA CTTGAACAGA 2040

CIAAAAACGI GCTIGCTTI GAAAAACGI CARAGAAGTAA GAGAAGTAA GAGAAGTAA AGCAAGTAA AGCAAGTAA AGCAAGTAA AGCAAGTAA AGCAAGTAA AGCAAGTAA CAGCTCCAGC 2100
TGGGTGGTTT GGATTACCTG GATCCCGCAT GTTTACACA CTCCTTTCAC TGATAGCTTG 2160
ACTAATGGAA TGATTGGTTA AAATGTGATT TTTCTTCAGG TAACACTACA GAGTACGTGA 2220 65

ACTICAGO ANTOLOGITA AAATGIGATI TILLICAGO TAACACTACA GAGTACATGA 2220

AATGCTCAAG AATGTAGTCA GACTGACACT ACTAAAGCTC CCAGCTCCTT TCATGCTCCA 2280

TITTITAACCA CTIGCCTCTT TCTCCAGCAG CTGATTCCAG AACAAATCAT TATGTTTCCT 2340

AACTGTGATT TGTAGATTTA CTTTTTGCTG TTAGTTATAA AACTATGTG TCAATGAAAT 2400


AAAAGCACAC TGCTTAGTAT TCTTGAGGGG CAATGCCAAT AGGTATATCC TCTGGAAAAG 2460

GCTTTCATGA TTTGGCATGG GACAGACGGA AATGAAATTGT TCAAAATTGT TTACCATAGA 2520 70 AAGATGACAA AAGAAAATTT TCCACATAGG AAAATGCCAT GAAAATTGCT TTTGAAAAAC 2580
AACTGCATAAA CCTTTACACT CCTCGTCCAT TTTATTAGGA TTACCCAAAT ATAACCATTT 2640
AAAGAAAGAA TGCATTCCAG AACAAATTGT TTACATAAGT TCCTATACCT TACTGACACA 2700 75 TTGCTGATAT GCAAGTAAGA AAT

PCT/US02/02242


WO 02/059377

Protein Accession #: NP 000940.1



PCT/US02/02242

WO 02/059377



Seq ID NO: 44 <u>Protein sequence:</u>
Protein Accession #: FGENESH predicted


31

60

65 70

Seq ID NO: 45 DNA sequence 75 Nucleic Acid Accession # NM 002285 Coding sequence: 55-3738 (underlined sequences correspond to start and stop codons)

HDSVPMTAVP PFMDGLQPGY RQIQSPFPHT NSEQKMYPAV TV



QDQAPDESPK LKSSSETSVH CTSYRGVPAS KPEPARAKAK LSKFSIPKQG EESRSGETNS 300
CVEEIIREMT WLPPLSAIQA PGKVEPTKFP FPNKDSQLVS SGHNNPKKGD AEPESPDNGT 360
SNTSMLEDDL KLSSDEEENE QQAAQRTALR ALSDSAVVQQ PNCRTSVPSS KGSSSSSSSG 420
TSSSSSDSES SSGSDESTES SSSESEGSKP PHFSSPBAEP ASSNKWQLDK WLNKVNPHKP 480
PILIQNESHG SESNQYYNPV KEDVQDCGKV PDVCQPSLRE KEIKSTCKEE QRPRTANKAP 540
GSKGVKQKSP PAAVAVAVSA AAPPPAVPCA PAENAPAPAR RSAGKKPTRR TERTSAGDGA 600
NCHRPEEPAA ADALGTSVVV PPEPTKTRPC GNNRASHRKE LRSSVTCEKR RTRGLSRIVP 660
KSKEFIETES SSSSSSSDSD LESEQEEYPL SKAQTVAASA SSGNDQRLKE AAANGGSGFR 720
APVGSINART TSDIAKELEE QFYTLVPFGR NELLSPLKDS DEIRSLWVKI DLTLLSRIPE 780
HLPQEFGVUS APATKDSESA PPSHTISDTPA EKALPKSKRK RKCDNEDDYR EIKKSQEKD 840
SSSRLATSTS NTLSANHCNM NINSVAIPIN KNEKMLRSPI SPLSDASKHK YTSEDLTSSS 900
RPNGNSLFTS ASSSKKPKAD SQLQPHGGDL TKAAHNNSEN IPLHKSRPQT KPWSPGSNGH 960
RDCKRQKLVF DDMPRSADVF MQEAKRMKHK ADAMVEKFGK ALNYAEAALS FIECGNAMEQ 1020
GPMESKSPYY LMYSETVELI RYAMRLKTHS GPNATPEDKQ LAALCYRCLA LLYWMFRIK 1080
RDHAVKYSKA LIDYFKNSSK AAQAPSPWGA SGKSTGTISS ISRNFFFGSS VGSQGSLSNA 1140
SALSPSTIVS IPQRHQMAA NHVSITNSIL HSYDYWEMAD NLAKENREFF NDLDLLMGPV 1200

Seq ID NO: 47 DNA sequence
Nucleic Acid Accession #: NM\_033151
Coding sequence: 351-4499(underlined sequences correspond to start and stop codons)

TLHSSMEHLV QYSQQGLHWL RNSAHLS

10

15

21 31 25 ACTGGGATAA AGCAAGAAGA CTGATTTTAT GAGCAGGGGT TTGATACATC AAAGGAGATT 60 GCCCAGGATC AAGGGTGCGG TGTTGGGGGT GGGTTGGGGA GGGTGGTTAG AGAAGGTTTC 120 ACTAAGTGAT TTGGGCCTGA GGCCTGAGAA GATGTTTAAA AAGAGGGATC AAGCACAGGC 180 TAAGGAGAGG AAAGAGCAGG CACCCAAACC TCTGCATGGC CCCAATATGC TCCCTGCAGG 240
GTAGTGCCCC CTCTTCTGGC TGCTCAAGGC GAGATCTAAG CTTCTTCTAA CTCCTGCTGT 300
CTTTTCATAT TCTCTGATTC TGGGAAACGA AGAATTGGCA GGAACTGAAA ATGACTAGGA 360 30 AGAGGACATA CTGGGTGCCC AACTCTTCTG GTGGCCTCCT GAATCGTGGC ATCGACATAG 420 GCGATGACAT GGTTTCAGGA CTTATTTATA AAACCTATAC TCTCCAAGAT GGCCCCTGGA 480 GTCAGCAAGA GAGAAATCCT GAGGCTCCAG GGAGGGCAGC TGTCCCACCG TGGGGGAAGT 540 GTCAGCAAGA GAGAAATCCT GAGGCTCCAG GGAGGGCAGC TGTCCCACCG TGGGGGAAGT 54
ATGATGCTGC CTTGAGAACC ATGATTCCCT TCCGTCCCAA GCCGAGGTTT CCTGCCCCC 600
AGCCCCTGGA CAATGCTGGC CTGTTCTCCT ACCTCACCGT GTCATGGCTC ACCCCGCTCA 660
TGATCCAAAG CTTACGGAGT CGCTTAGATG AGAACACCAT CCCTCCACTG TCAGTCCATG 720
ATGCCTCAGA CAAAAATGTC CAAAGGCTTC ACCGCCTTTG GGAAGAAGAA GTCTCAAGGC 780
GAGGGATTGA AAAAGCTTCA GTGCTTCTGG TGATGCTGAG GTTCCAGAGA ACAAGGTTGA 840
TTTTCGATGC ACTTCTGGGC ATCTGCTTCT GCATTGCCAG TGTACTCGGG CCAATATTGA 900
TTATACCAAA GATCCTGGAA TATTCAGAAG AGCAGTTGGG GAATGTTGTC CATGGAGTGG 960
GACTCTGCTT TGCCCTTTTT CTCTCCGAAT GTGTAAGTC TCTGAGTTTC TCCTCCAGTT 1020
GGATCATCAA CCAACGACAA GCCATCAGGT TCCGAGCAGC TGTTTCCTCC TTTGCCTTTIG 1080 35 40 GACTETGETT TGCCCTTTTT CTCTCCGAAT GTGTGAAGTC TCTGAGTTTC TCCTCCAGTT 1020
GGATCATCAA CCAAACGCACA GCCATCAGGT TCCGAGCAGCAG TGTTTCCTCC TTTGCCTTTG 1080
AGAAGCTCAT CCAATTTAAG TCTGTAATAC ACATCACCTC AGGAGAGGCC ATCAGCTTCT 1140
TCACCGGTGA TGTAAACTAC CTGTTTGAAG GGGTGTGCTA TGGACCCCTA GTACTGATCA 1200
CCTGCGCATC GCTGGTCATC TGCAGCACTT CTTCCTACTT CATTAATTGGA TACACCTGCAT 1260
TTATTGCCAT CTTATGCTAT CTCCTGGTTT TCCCACTGGC GGTATTCATG ACAAGAATGG 1320
CTGTGAAGGC TCAGCATCAC ACATCTGAGG TCAGCCACCA GCGCATCCGT GTGACCAGTG 1380 45 AGITICTICAC TIGCATTAAG CTGATTAAAA TOTACACATG GGAGAAACCA TITIGCAAAAA 1440
TCATTGAAGA CCTAAGAAGG AAGGAAAGGA AACTATTGGA GAAGTGCGGG CTTGTCCAGA 1500
GCCTGACAAG TATAACCTTG TTCATCATCC CCACAGTGGC CACAGCGGTC TGGGTTCTCA 1560 50 GCCTGACAAG TATAACCTTG TICATCATCACACAGTIGGC CACAGGGGT TGGGTTCAC TO TCCACACAGT CTTAAAGCTTG AAACTCACAG CGCAATGGC CTTCAGCATG CTGGCCTCCT 1620
TGAATCTCCT TCGGCTGTCA GTGTTCTTTG TGCCTATTGC AGTCAAAGGT CTCACGAATT 1680
CCAAGTCTGC AGTGATGAGG TTCAAGAAGT TTTTCCTCA GGAGAGCCCT GTTTTCTATG 1740
TCCAGACATT ACAAGACCCC AGCAAAGCTC TGGTCTTTTGA GGAGGCCACC TTGTCATGGG 1800
AACAGACCTG TCCCGGGATC GTCAATGGGG CACTGGAGCT GGAGAGAAC GGGCATGCTT 1860
CTGAGGGGGAT GACCAGGCCT AGAGATGCCC TCGGGCCAGA GGAAAGAAGG AACAAGCCTGG 1920 55 CTGAGGGGAT GACCAGGCCT AGAGATGCCC TCGGGCCAGA GGAAGAAGGG AACAGCCTGG 1920
GCCCAGAGTT GCACAAGATC AACCTGGTG TGTCCAAAGG GATGATGTTA GGGGTCTGCG 1980
GCACACACGGG GAGTGGTAAG AGCAGCCTGT TGTCAAGGG GATGATGTTA GGGGTCTGCG 1980
TCGAGGGCTC GGTGGGGGTG CAGGGAAGCC TGGCCTATGT CCCCCAGCAG GCCTGGATCG 2100
TCAGCGGGAA CATCAGGGAG AACATCCTCA TGGGAGGGCGC ATATGACAAG GCCCGGATACC 2160
TCCAGGTGCT CCACTGCTGC TCCCTGAATC GGGACCTGGA ACTTCTGCCC TTTGGAGACA 2220
TGACAGAGAT TGGAGAGCGG GGCCTCAACC TCTCTGGGGG GCAGAAACAG AGGATCAGCC 2280
TGGCCGCC CGTCTATTCC GACCGTCAGA TCTACCTGCT GGACGACCCC CTGTCTGGCTG 2140
TGGACGCCCA CGTGGGGAAG CACATTTTTG AGGAGTGCAT TAAGAAGACA CTCAGGGGGA 2400
AGACGGTCGT CCTGGTGACC CACCACCTGC AGTACTTAGA ATTTTTGTGGC CAGATCATT 2460
TGTTGGAAAA TGGGAAAATC TGTGAAAATG GAACTCACAG TGAGTTAATG CAGAAAAAGG 2590
GGAAATATGC CCAACTTATC CAGAAGATGC ACAAGGAAGC CACTTCGGAC ATTTTGCAGG 2580
ACACAGCAAA GATAGCCAAAG AACCCAAAGG TAGAAAGTCA GCCTCTGGCC ACTCCCTGG 2640
AAGAGCTCT CAACGGAAAT GCTGTGCCG AGCACTCACT CACACAGGAG AGGACTCCTCGG 2640
AAGAGCCTC CTGAGTTG AGGGTCTACC ACCACTACACT CACACAGGAG GAGGACTACA 2700
AAGAAGGCTC CTCAATTTTC TTCTTCTGGT TGCTACCT CTTCTTAACG ATCTTCAACG 60 65 70 AAGAAGGC CTTGAGTIGG AGGCTACC CEACHARCT CTCTTAACG ATCTTCAGCT 2820
TCTGGTCTCTT CATAATTTTC TTCTTCGTGG TGCTGATCGT CTTCTTAACG ATCTTCAGCT 2820
TCTGGTGGCT GAGCTACTGG TTGGAGCAGG CCTCGGGGAC CAATAGCAGC CGAGAGAGCA 2880
ATGGAACCAT GGCAGACCTTG GGCAACATTG CAGACAATCC TCAACTGTCC TTCTACCAGC 2940
TGGTGTTACGG CCTCAACGCC CTGCTCCTCA TCTGTGTGGG GGTCTGCTCC TCAAGGGATTT 3000
TCACCAAAGT CACGAGGAAG GCATCCACGG CCTGCACAA CAAGCTCTTC AACAAGGTTT 3060 75 TCCGCTGCCC CATGAGTTTC TTTGACACCA TCCCAATAGG CCGGCTTTTG AACTGCTTCG 3120

CAGGGGACTT GGAACAGCTG GACCAGCTCT TGCCCATCTT TTCAGAGCAG TTCCTGGTCC 3180
TGTCCTTAAT GGTGATCGCC GTCCTGTTGA TTGTCAGTGT GCTGTCTCCA TATATCCTGT 3240
TAATGGGAGGC CATAATCATG GTTATTTGCT TCATTTATTA TATGATGTTC AAGAAGGCCA 3200
TCGGTGTGTT CAGAGAGCTG GAGAACTATA GCCGGTCTCC TTTATTCTC CACATCCTCA 3360
ATTCTCTGCA AGGCCTGAGC TCCATCCATG TCTATGGAAA AACTGAAGAC TTCATCAGCC 3420
AGTTTAAGAG GCTGAGTG GCGCAGAATA ACTACCTGCT GTTGTTTTCTA TCTTCACACA 3480
GATGGATGGC ATTGAGGCTG GAGATCATGA CCAACCTTGT GACCTTGGCT GTTGCCCTGT 3540
TCGTGGCTTT TGGCATTTCC TCCACCCCCT ACTCCTTTAA AGTCATGGCT GTTGACCATC3 3600
TGCTGCAGCT GGCGTCCAGC TTCCACGCCCC ACTCCCTTTAA AGTCATGGCT GTCACAATCG 3600
TGCTGCAGCT GGCGTCCAGC TTCCACGCCCC ACTCCCTTTAA AGTCATGGCT GTCACACTCG 3600
TGCTGCAGCT GGCGTCCAGC TTCCACGCCCC ACTCCCTTTAA AGTCATGGCT GACACAGCGCA 3660
AGTTCACGGC TGTAGAGAGG ATACTGCAGGT ACAACAAGAAT GTGTGTCTCG GAAGCTCCTT 3720
TACACATGGA AGGCACAAGT TGTCCCCAGG GGTGGCCACA GCATGGGGAA ATCATTATTTC 3780
AGGATTATCA CATGAAATAC AGAGACAACA CACCCACCGT GCTTCAGGC ATCAACCTGA 3840
CCATCCGCGG CCACGAAGTG GTGGGCAACA CACCCACCGT GCTTCAGGC ATCAACCTGA 3840
CCATCCGCGG CCACGAAGTG GTGGGGAACCA CACCCACCGT GCTTCAGGC ATCAACCTGA 3840
CCATCCGCGG CCACGAAGTG GTGGGGAACC CCATGGCAGC GCGGATTCTC ATTGACGCG 3960
TGGGCATGCT CTCTTCCGC CTGGTGGAGC CCATGGCAGC CGGATTCTC ATTGACGCG 3960
ACCACCAGCTC CTCTTCCGC CTGGTGGAGC CCATGGCAGC CGGATTCTC ATTGACCACTG 4020
ATCCAGTGCT GCTCTCAGGA ACCATCAGAT TCAACCTAGA TCCCTCAAG 4020
ATCCAGTGCT GCTTCAGGA ACCATCAGAT TCAACCTAGA TCCCTTCAGTG AACCCTCAAG
ACCAGCAGAT CTGGGATGCC TTGGAGAGGA CATTCCTGAC CAAGGCCATC TCAAAAGTTC 4140
CCAAAAAGCT GCATTACAGAT TGGGTGGAAA CCGTGACAC CACGCCACAATC CGTGAAGACC 4320
ACCAGCCTC CATTGCCAGG CCTGTGTCTC GCAACTCCAA GATCATCCTT ATCGATGAAC 4260
CCACAGCCTC CATTGCCAGG CCTGTGCTTC GCAACTCCAA GATCATCCTT ATCGATGAAC 4260
CCACAGCCTC CATTGCCAG CCTTGTTCTC GCAACTCCAA GATCATCCTT ATCGATGAAC 4260
CCACAGCCTC CATTGCCAGC CCTTTTTCTC GCAACTCCAA GATCATCCTT ATCGATAAGAC 4380
ACATCCTGGT TATTGCCC GCCCTCA TGGCCACAGC CACTTCTTCA CTGAGATAAG 4500
CCACAGCCC CAGTCTGCGC CCTCTTTTGTT TGGAGATAGA AACTCTTCCT CAAGGCCTA 4560
TCCAA

Seq ID NO: 48 <u>Protein sequence:</u>
Protein Accession #: NP\_149163.2


55

35 MTRKRTYWVPNSSGGLVNRGIDIGDDMVSGLIYKTYTLQDGPWSQQERNPEAPGRAAVPPWGKYDAALRT
MIPFRPKPRPPAPQPLDNAGLFSYLTVSWLTPLMIQSLRSRLDENTIPPLSVHDASDKNVQRLHRLWEEE
VSRRGIEKASVLLVMLRFQRTRLIFDALLGICFCIASVLGPILIIPKILEYSEQLGNVVHGVGLCFALF
LSECVKSLSFSSSWIINQRTAIRFRAAVSSFAFEKLIQFKSVIHITSGEAISFFTGDVNYLFEGVCYGPL
VLITCASLVICSISSYFIIGYTAFIAILCYLLVFPLAVFMTRMAVKAQHHTSEVSDQRIRVTSEVLTCIK
LIKMYTWEKPPKALIEDLRRKERKLLEKCGLVQSLTSTITLFIIPTVATAVWVLIHTSLKLKLTASMAFSM
LASINLIRLSVFFVPIAVKGLTNSKSAVMRFKKFFLQESPVFYVQTLQDPSKALVFEEATLSWQQTCPGI
VNGALELERNGHASEGMTRPRDALGPEEEGNSLGPELHKINLVVSKGMMLGVCGNTGSGKSSLLSAILEE
MHLLEGSVGVQGSLAYVPQQAWIVSGNIRENILMGGAYDKARYLQVLHCCSLNRDLELLPFGDMTEIGER
GLNLSGGGVQRISLARAVYSDRQIYLLDDPLSAVDAHVGKHFEECIKKTLRGKTVVLVTHQLQYLEFGG
QIILLENGKICENGTHSELMQKKGKYAQLIQKMHKEATSDMLQDTAKIAEKPKVESQALATSLEESINGN
AVPEHQLTQEEEMEGSLSWRVYHHYIQAAGGYMVSCIIFFFVVLIVFLTIFSFWWLSYWLEQGSGTINSS
RESNGTMADLGNIADNPQLSFYQLVYGLNALLLICVGVCSSGIFTKVTRKASTALHNKLFNKVFRCPMSF
FDTIPIGRLINCFAGDLEQLDQLLPIFSEGFLVLSLMVIAVLLIVSVLSPYILLMGAIMVICFTYYMMF
KKAIGVFKRLENYSRSPLFSHILNSLQGLSSIHVYGKTEDFISQFKRLTDAQNNYLLLFLSSTRWMALRL
EIMTNLVTLAVALFVAFGISSTPYSFKVMAVNIVLQLASSFQATARIGLETEAQFTAVERILQYMKMCVS
EAPLHMEGTSCPQGWPQHGEIIFQDYHMKYRDNTPTVLHGINLTRGHEVVGIVGRTGSGKSSLGMALFR
LVEPMAGRILDGGVDICSIGLEDLRSKLSVIPQDPVLLSGTIRFNLDPFDRHTDQQWDALERTFLTKAI

SKFPKKLHTDVVENGGNFSVGERQLLCIARAVLRNSKIILIDEATASIDMETDTLIQRTIREAFQGCTVL

Seq ID NO: 49 DNA sequence
Nucleic Acid Accession #: NM\_033419
Coding sequence: 18-980 (underlined sequences correspond to start and stop codons)

VIAHRVTTVLNCDHILVMGNGKVVEFDRPEVLRKKPGSLFAALMATATSSLR



KVFDPLRFSQ ENSDQRHPYA YLPFSAGSRN CIGQEFAMIE LKVTIALILL HFRVTPDPTR 120 PLTFPNHFIL KPKNGMYLHL KKLSEC

Seq ID NO: 53 DNA sequence Nucleic Acid Accession #: NM 030916 Coding sequence: 1-1533 (underlined sequences correspond to start and stop codons) 5 41 ATGCCCCTGT CCCTGGGAGC CGAGATGTGG GGGCCTGAGG CCTGGCTGCT GCTGCTGCTA 60 CTGCTGGCAT CATTTACAGG CCGGTGCCCC GCGGGTGAGC TGGAGACCTC AGACGTGGTA 120 ACTGTGGTGC TGGGCCAGGA CGCAAAACTG CCCTGCTTCT ACCGAGGGGA CTCCGGCGAG 180 CAAGTIGGGC AAGTIGGCATIG GGCTCGGGTG GACGGGGGG AAGGCGCCA GGAACTAGGG 240
CTACTIGCACT CCAAATACGG GCTTCATGTG AGCCGGGGTT ACGAGGGCCCA GGAACTAGGC 240
CCGCCGCCCC CACGCAACCC CCTGGACGGC TCAGTGCTCC TGCGCAACGC ATGTGCAGGC 360
CATGAGGGC AGTACGAGTG CCGGGTCAGC ACCTTCCCCG CCGCACGTT CCAGGGCGCGG 420
CTGCGGCTCC GAGTGCTGGT GCCTCCCCTG CCCTCACTGA ATCCTGGTCC AGCACTAGAA 480 10 15 GAGGGCCAGG GCCTGACCCT GGCAGCCTCC TGCACAGCTG AGGGCAGCCC AGCCCCCAGC 540
GTGACCTGGG ACACGGAGGT CAAAGGCACA ACGTCCAGCC GTTCCTTCAA GCACTCCCGC 600
TCTGCTGCCG TCACCTCAGA GTTCCACTTG GTGCCTAGCC GCAGCATGAA TGGGCAGCCA 660 CTGACTTGTG TGGTGTCCCA TCCTGGCCTG CTCCAGGACC AAAGGATCAC CCACATCCTC 720
CACGTGTCCT TCCTTGCTGA GGCCTCTGTG AGGGGCCTTG AAGACCAAAA TCTGTGGCAC 780
ATTGGCAGAG AAGGAGCTAT GCTCAAGTGC CTGAGTGAAG GGCAGCCCCC TCCCTCATAC 840 20 AACTGGACAC GGCTGGATGG GCCTCTGCCC AGTGGGGTAC GAGTGGATGG GGACACTTTG 900
GGCTTTCCCC CACTGACCAC TGAGCACAGC GGCATCTACG TCTGCCATGT CAGCAATGAG 960
TTCTCCTCAA GGGATTCTCA GGTCACTGTG GATGTTCTTG ACCCCAGGA AGACTCTGGG 1020 TICTCCTCAA GGGATTCTCA GGTCACTGTG GATGTTCTTG ACCCCAGGA AGACTCTGGG 1020
AAGCAGGTGG ACCTAGTGTC AGCCTCGGTG GTGGTGGTGGTGGTGATCGC CGCACTCTTG 1080
TICTGCCTTC TGGTGGTGGT GGTGGTGCTC ATGTCCCGAT ACCATCGGCG CAAGGCCCAG 1140
CAGATGACCC AGAAATATGA GGAGGAGCTG ACCCTGACCA GGGAGAACTC CATCCGGAGG 1200
CTGCATTCCC ATCACACGGA CCCCAGGAGC CAGCCGGAGG AGAGTGTAAGG GCTGAGAGCC 1260
GAGGGCCACC CTGATAGTCT CAAGGACAAC AGTAGCTTGCTTGATGAG TGAAGAGCCC 1320
GAGGGCCGCA GTTACTCCAC GCTGACCACG GTGAGGGAGA TAGAAACACA GACTGAACTG 1380
CTGTCTCCAG GCTCTGGCCG GGCCGAGGAG GAGGAAGATC AGGATGAAGG CATCAAACAG 1440
GCCATGAACC ATTTTGTTCA GGAGAATCGG ACCCTACGGG CCAAGCCCAC GGGCAATGGC 1500
ATCTACATCA ATGGGCCGGG ACACCTGGTC TGA 25 30 ATCTACATCA ATGGGCGGGG ACACCTGGTC TGA Seq ID NO: 54 Protein sequence:
Protein Accession #: NP\_112178.1 35 31 41 MPLSIGAEMW GPEAWLLLL LLASFTGRCP AGELETSDVV TVVLGQDAKL PCFYRGDSGE 60
QVGQVAWARV DAGEGAQELA LLHSKYGLHV SPAYEGRVEQ PPPPRNPLDG SVLLRNAVQA 120
DEGEYECRVS TFPAGSFQAR LRLRVLVPPL PSLNFGPALE EGGGLTLAAS CTAEGSPAPS 180
VTWDTEVKGT TSSRSFKHSR SAAVTSEFHL VPSRSMNGQP LTCVVSHPGL LQDQRITHIL 240
HVSFLAEASV RGLEDQNLWH IGREGAMLKC LSEGQPPPSY NWTRLDGPLP SGVRVDGDTL 300
GFPPLTTEHS GTYVCHVSNE FSSRDSQVTV DVLDPQEDSG KQVDLVSASV VVVGVIAALL 360 40 45 FCLLVVVVVL MSRYHRRKAQ OMTOKYEEEL TLTRENSIRR LHSHHTDPRS QPEESYGLRA 420 EGHPDSLKDN SSCSVMSEEP EGRSYSTLTT VREIETQTEL LSPGSGRAEE EEDQDEGIKQ 480 AMNHFVQENG TLRAKPTGNG IYINGRGHLV Seg ID NO: 55 DNA sequence 50 Nucleic Acid Accession #: AF007170.1 Coding sequence: 73-1725 (underlined sequences correspond to start and stop codons) 55 AAGGAGGCGG CCTCCGGGAA AAGCGACCGC AGGACTCCTG AGAGCAGCCT CCATGAGGCC 60 CTGGACCAGT GCATGACCGC CCTGGACCTC TTCCTCACCA ACCAGTTCTC AGAAGCACTC 120
AGCTACCTCA AGCCCAGAAC CAAGGAAAGC ATGTACCACT CACTGACATA TGCCACCATC 180
CTGGAGATGC AGGCCATGAT GACCTTTGAC CCTCAGGACA TCCTGCTTGC CGGCAACATG 240 CTGGAGATGC AGGCCATGAT GACCTTTGAC CCTCAGGACA TCCTGCTTGC CGGCAACATG 240
ATGAAGGAGG CACAGATGCT GTGTCAGAGG CACCGGAGGA AGTCTTCTGT AACAGATTCC 300
TTCAGCAGCC TGGTGAACCG CCCCACGCTG GGCCAATTCA CTGAAGGAGA AATCCACGCT 360
AGGTCTGCT ATGCAGAGTG CCTGCTGCAG CGAGCAGCCC TGACCTTCCT GCAGGACGAG 420
AACATGGTGA GCTTCATCAA AGGCGGCATC AAAGTTCGAA ACAGCTACCA GACCTACAAG 480
GAGCTGGACA GCCTTGTTCA GTCCTCACAA TACTGCAAGG GTGAGAACCA CCCGCACTTT 540
GAAGGAGGA GGAAGCTTGG TGTAGGGGCC TTCAACCTGA CACTGTCCAT GTCTCTACT 600
AGGATCCTGA GGCTGTTGGA GTTTGTGGGGC TTCTACCTG TCCTTCTACT 600
CAGCTGGAGG AGGGAGCGTC AGGGCACAGC TTCCGCTCTG TGCTCTGTGT CATGCTCCTG
CCGCAGAAGC TCTTGAAGCC CTACCTTGAAC CGGTACCTA ACACTGTCAA CATCGCAGGAG
GCCGAGAAGC TCTTGAAGCC CTACCTGAAC CGGTACCTA AGGGTGCCAT CTTCCTGTTC 840
TTTGCAGGGA GGATTGAAGC CACTGGAAC CAGTTCCAC ACACTTCCAGC 900
GAGTGCTGTG AGGCCCAGCA GCACTGGAAC CAGTTCCAC CACATGTGCAC CGGCATTCCAG
ATGTGGTGCT CACCTACAA GGGCCAGTGG AACATTTCACC ACATGTGCTA CTGCGAGCTG 960
AAGGTGCTGTG AGGCCCAGCA GCACTGGAAG CAGTTTCACC ACATGTGCTA CTGCGAGCTG 960
AAGGTGCTGT AGGCCCAGCA GCACTGGAAG CAGTTTCACC ACATGTGCTA CTGCGAGCTG 960
ATGTTGTGGA AGGACCACTACAA GGGCCAGTTC GAGGCCAGCTC 1020
AGCAAGGAGA ACTGCTGGTC CAAGGCCACC TACATTTACA TGAAGGCCGC CTACCTCAGC 1080
ATGTTTTGGGA AGGACCAC AAGCCGTTC GGGGAACACA CATCTCAGC 1080
ATGTTTTGGGA AGGACCAC AAGCCGTTC GGGGAACACATCTCACC CACATGTTCCTCTCCACC
CGGAAGTCCC GGCGCTACTT CTCCTCCCAAC CCTACTCTCACC CACAGGAAA GTTTTCCACCT
CACAGAGGAAA ACTTCCTGGGAAAC CTTACTTCACC CACAGGAAA GTTTTCCACCT
CACAGAGGACAACCTCATCTCCTCCCACC TACCTTCACC CACAGGAAA GTTTTCCCACC
CGGAAGTCCC GGCCCTACTT CTCCTCCCAAC CCTACTCCCC TGCCTCTGGAA 1250
CCGGAAGTCCC GGCGCTACTT CTCCTCCCAAC CCTACTCTCCC TGCCTCTGGAA 1250 60 65 70 75 CGGAAGTCCC GGCGCTACTT CTCCTCCAAC CCTATCTCGC TGCCAGTGCC TGCTCTGGAA 1260 ATGATGTACA TCTGGAACGG CTACGCCGTG ATTGGGAAGC AGCCGAAACT CACGGATGGG 1320 ATACTTGAGA TTATCACTAA GGCTGAAGAG ATGCTGGAGA AAGGCCCAGA GAACGAGTAC 1380

TCAGTGGATG ACGAGTGCTT GGTGAAATTG TTGAAAGGCC TGTGTCTGAA ATACCTGGGC 1440 CGTGTCCAGG AGGCCGAGGA GAATTTTAGG AGCATCTCTG CCAATGAAAA GAAGATTAAA 1500 TATGACCACT ACTTGATCCC AAACGCCCTG CTGGAGCTGG CCCTGCTGCT TATGGAGCAA 1560
GACAGAAACG AAGAGGCCAT CAAACTTTTG GAATCTGCCA AGCAAAACTA CAAGAATTAC 1620
TCCATGGAGT CAAGGACACA CTTTCGAATC CAGGCAGCCA CACTCCAAGC CAAGTCTTCC 1680 CTAGAGAACA GCAGCAGATC CATGGTCTCA TCAGTGTCCT TGTAGCTTTG TGCAGCAGTT 1740
CCGGGCTGGA AGACAGAGAC AGCTGGACAG AGCTCCTGAA AACATTTCAA AATACCCCCT 1800
CCCCTGCC TGCCCTGCCT TTGGGGTCCA CCGGCACTCC AGTTGGATGG CACAACATAG 1860 TGTATCCGTG CAGAAGCCGA GCTGGCATTT TCACCAGTGT AGCCAAGGGC CTTTGCCAAG 1920 GGCAGAGCAG GTGGAGCCCT CTGCCTGCCC TATCACACAT ACGGGTACTT GCTTTTCACT 1980 10 GTGATGTTTA AGAGAATGTA TGAACAGTTT ACATTTTCCT TAGAAATACA TTGATGGGAT 2040 CACAGTTGGC TTTAAAAACC AACAACAATC AACCACCTGT AAGTCTTTGT CTTCACCTAT 2100
TATCATCTGG AGGTAAATCT CTTTATATGA TGATGCCAAA GGGCAAATTG CTTTTCAAAT 2160 TCAGCAAGTT CTCAGCTTGT GTGACGGAAG GTCCTTCAGA GGACCTGAGG AATGCCTGGG 2220 15 AGAGGCTAAG CCTCAGGCTT CAATGCTTCT GGGGTTGGGC ATGAGGATGT ACACAGACAC 2280
CCACTACCTT ACTACTCACA CTTCATTTCA CTCCTTTTGT AAATTTCCAA TTTAAAAATC 2340 AAGCACGTCT TTTTAGTGAG ATAAAATCTG AGCTCTTCTG TAGAAAAATC AATCTCTACC 2400 AGTAGAAAAT GCCAGGGCTT GATGGAAGAG CTGTGTAGCC CTTTCTATGC CAAAGCCAGG 2460 AAATTTGGGG GGCAGGAGGA GGTTCTCAGA ATCCAGTCTG TATCTTTGCT GTATGCCAAA 2520 CTGAAACCAC TGGGAATAAT TTATGAAACA TAAAAATCTT CTGTACTTCA CTCCAAGGTA 2580 20 Seq ID NO: 56 <u>Protein sequence:</u>
Protein Accession #: AAC39582.1 25 41 MTALDLFITN OFSEALSYLK PRIKESMYHS LTYATILEMQ AMMTFDPQDI LLAGNMMKEA 60 QMLCQRHRRK SSVTDSFSSL VNRPTLGQFT EEEIHAEVCY AECLLQRAAL TFLQDENMVS 120 FIKGGIKVRN SYQTYKELDS LVQSSQYCKG ENHPHFEGGV KLGVGAFNLT LSMLPTRILR 180 30 LLEFYGFSGN KDYGLLQLEE GASGHSFRSV LCVMLLLCYH TFLITFVLGTG NVNIEEAEKL 240 LKPYLNRYPK GAIFLFFAGR IEVIKGNIDA AIRRFEECCE AQQHWKQFHH MCYWELMWCF 300 TYKGQWKMSY FYADLLSKEN CWSKATYIYM KAAYLSMFGK EDHKPFGDDE VELFRAVPGL 360 35 KLKIAGKSLP TEKFAIRKSR RYFSSNPISL PVPALEMMYI WNGYAVIGKQ PKLTDGILEI 420 ITKAEEMLEK GPENEYSVDD ECLVKLLKGL CLKYLGRVQE AEENFRSISA NEKKIKYDHY 480 LIPNALLELA LLLMEQDRNE EAIKLLESAK QNYKNYSMES RTHFRIQAAT LQAKSSLENS 540 40 Seq ID NO: 57 DNA sequence Nucleic Acid Accession #: NM\_006670.1 Coding sequence: 1-927 (underlined sequences correspond to start and stop codons) 45 ATGCTGGGG GGTGCTCCCG GGGCCCCGCC GCCGGGGACG GGCGTCTGCG GCTGGCGCGA 60
CTAGCGCTGG TACTCCTGGG CTGGGTCTCC TCGTCTTCTC CCACCTCCTC GGCATCCTCC 120
TTCTCCTCCT CGGCGCCGTT CCTGGCTTCC GCCGTGTCCG CCCAGCCCCC GCTGCCGGAC 180 CAGTGCCCCG CGCTGTGCGA GTGCTCCGAG GCAGCGCGCA CAGTCAAGTG CGTTAACCGC 240
AATCTGACCG AGGTGCCCAC GGACCTGCCC GCCTACGTGC GCAACCTCTT CCTTACCGGC 300
AACCAGCTGG CCAGCAACCA CTTCCTTTAC CTGCCGCGGG ATGTGCTGGC CCAACTGCCC 360 50 AGCCTCAGGC ACCTGGACTT AAGTAATAAT TCGCTGGTGA GCCTGACCTA CGTGTCCTTC 420 CGCAACCTGA CACATCTAGA AAGCCTCCAC CTGGAGGACA ATGCCCTCAA GGTCCTTCAC 480 AATGGCACCC TGGCTGAGTT GCAAGGTCTA CCCCACATTA GGGTTTTCCT GGACAACAAT 540 55 CCCTGGGTCT GCGACTGCCA CATGGCAGAC ATGGTGACCT GGCTCAAGGA AACAGAGGTA 600 GTGCAGGGCA AAGACCGGCT CACCTGTGCA TATCCGGAAA AAATGAGGAA TCGGGTCCTC 660 TTGGAACTCA ACAGTGCTGA CCTGGACTGT GACCCGATTC TTCCCCCATC CCTGCAAACC TCTTATGTCT TCCTGGGTAT TGTTTTAGCC CTGATAGGCG CTATTTTCCT CCTGGTTTTG 780
TATTTGAACC GCAAGGGGAT AAAAAAGTGG ATGCATAACA TCAGAGATGC CTGCAGGGAT 840
CACATGGAAG GGTATCATTA CAGATATGAA ATCAATGCGG ACCCCAGATT AACAAACCTC 900 60 AGTTCTAACT CGGATGTCCT CGAGTGA Seq ID NO: 58 <u>Protein sequence</u>

Protein Accession #: NP\_006661.1 65 31 41 51 21 MPGGCSRGPA AGDGRLRLAR LALVLLGWVS SSSPTSSASS FSSSAPFLAS AVSAQPPLPD 60 QCPALCECSE AARTVKCVNR NLTEVPTDLP AYVRNLFLTG NQLASNHFLY LPRDVLAQLP 120 SLRHLDLSNN SLVSLTYVSF RNLTHLESLH LEDNALKVLH NGTLAELQGL PHIRVFLDNN 180 70 PWVCDCHMAD MYTWLKETEV VQGKDRLTCA YPEKMRNRVL LELNSADLDC DPILPPSLQT 240 SYVFLGIVLA LIGAIFLLVL YLNRKGIKKW MHNIRDACRD HMEGYHYRYE INADPRLTNL 300


75

Sea ID NO: 59 DNA sequence

Nucleic Acid Accession #:

NM\_024022

Coding sequence: 1-1362(underlined sequences correspond to start and stop codons)



MGENDPPAVE APFSFTSLFG LDDLKISPVA PDADAVAAQI LSLLPLKFFP IIVIGIIALI 60 LALAIGLGIH FDCSGKYRCR SSFKCIELIA RCDGVSDCKD GEDEYRCVRV GGQNAVLQVF 120 35 TAASWKTMCS DDWKGHYANV ACAQLGFPSY VSSDNLRVSS LEGQFREEFV SIDHLLPDDK 180 VTALHHSVYV REGCASGHVV TLQCTACGHR RGYSSRIVGG NMSLLSQWPW QASLQFQGYH 240 LCGGSVITPL WIITAAHCVY DLYLPKSWTI QVGLVSLLDN PAPSHLVEKI VYHSKYKPKR 300 LGNDIALMKL AGPLTFNEMI QPVCLPNSEE NFPDGKVCWT SGWGATEDGG DASPVLNTIAA 360 VPLISNKICN HRDVYGGIIS PSMLCAGYLT GGVDSCQGDS GGPLVCQERR LWKLVGATSF 420 40

GIGCAEVNKP GVYTRVTSFL DWIHEQMERD LKT

Sea ID NO: 61 DNA sequence

65

70

Nucleic Acid Accession #: NM\_006475

45 Coding sequence: 28-2538 (underlined sequences correspond to start and stop codons)

ACAGAACTG CAACGGAGAG ACTCAAGATG ATTCCCTTTT TACCCATGTT TTCTCTACTA 60
TTGCTGCTTA TTGTTAACCC TATAAACGC AACAATCATT ATGACAAGAT CTTGGCTCAT 120
AGTCGTATCA GGGGTCGGGA CCAAGGCCCA AATGTCTGTG CCCTTCAACA GATTTTGGGC 180
ACCAAAAAGA AATACTTCAG CACTTGTAAG AACTGGTATA AAAAGTCCAT CTGTGGACAG 240
AAAACGACTG TTTTATATGA ATGTTGCCCT GGTTATATGA GAATGGAAGG AATGAAAGGC
300
TGCCCAGCAG TTTTGCCCAT TGACCATGTT TATGGACTC TGGGCATCGT GGGAGCACC 360
ACAACGCAGC GCTATTCTGA CGCCTCAAAA CTGAGGGAG AGATCGAGGG AAAGGGATCC 420
TTCACTTACT TTGCACCGAG TAATGAGGCT TGGACACACT TGGATTCTGA TATCCGTAGA 480
GGTTTGGAGA GCAACGTGAA TGTTGAATACTT TGCATGATTCTTATACTATTCTATACTATTCAAAACGAAAGGAATGT TAGCCAAAGGACACT TGGATGCTT TACATAGTCA CATGATTAAT 540
AGAGGAATGT TGACCAAGGA CTTAAAAAAT GGCATGATTAA TCATTATACTAT CATTATAACAAT 600 50 55 AAGAGAATGT TGACCAAGGA CTTAAAAAAT GGCATGATTA TTCCTTCAAT GTATAACAAT 600 TTGGGGCTTT TCATTAACCA TTATCCTAAT GGGGTTGTCA CTGTTAATTG TGCTCGAATC 660 ATCCATGGGA ACCAGATTGC AACAAATGGT GTTGTCCATG TCATTGACCG TGTGCTTACA 720 60

CAAATTIGGTA CCTCAATTCA AGACTTCATT GAAGCAGAAG ATGACCTTTC ATCTTTTAGA 780 GCAGCTGCCA TCACATCGGA CATATTIGGAG GCCCTTGGAA GAGACGGTCA CTTCACACTC 840 TTTGCTCCCA CCAATGAGGC TTTTGAGAAA CTTCCACGAG GTGTCCTAGA AAGGTTCATG 900 TITIGUECCCA CEANTGAGGC TITTIGAGAAA CITICACGAG GIGTICCTAGA AAGGTTCATG 900
GGAGACAAAG TGGCTTCCGA AGCTCTTATG AAGTACCACA TCTTAAATAC TCTCCAGTGT 960
TCTGAGTCTA TTATGGGAGG AGCAGTCTTT GAGACGCTGG AAGGAAATAC AATTGAGATA 1020
GGATGTGACG GTGACAGTAT AACAGTAAAT GGAATCAAAA TGGTGAACAA AAAGGATATT 1080
GTGACAAATA ATGGTGTGAT CCATTTGATT GATCAGGTCC TAAITTCTGA TTCTTGCCAAA 1140
CAAGTTATTG AGCTGGCTGG AAAACAGCAA ACCACCTTCA CGGATCTTGT GGCCCAATTA 1200
GGCTTGGCAT CTGCTCTGAG GCCAGATGGA GAATACACTT TGCTGGCACC TGTGAATAAT 1260
GCATTTTCTG ATGATACTCT CAGCATGGTT CAGCGCCCTC TTAAATTAAT TCTGCAGAAAT 1320 CACATATTGA AAGTAAAAGT TGGCCTTAAT GAGCTTTACA ACGGGCAAAT ACTGGAAACC 1380

ATCGGAGGCA AACAGCTCAG AGTCTTCGTA TATCGTACAG CTGTCTGCAT TGAAAATTCA 1440 TGCATGGAGA AAGGGAGTAA GCAAGGGAGA AACGGTGCGA TTCACATATT CCGCGAGATC 1500 ATCAAGCCAG CAGAGAAATC CCTCCATGAA AAGTTAAAAC AAGATAAGCG CTTTAGCACC 1560 TTCCTCAGCC TACTTGAAGC TGCAGACTTG AAAGAGCTCC TGACACAACC TGGAGACTGG 1620 ACATTATTTG TGCCAACCAA TGATGCTTTT AAGGGAATGA CTAGTGAAGA AAAAGAAATT 1680 75 CTGATACGGG ACAAAAATGC TCTTCAAAAC ATCATTCTTT ATCACCTGAC ACCAGGAGTT 1740

TTCATTGGAA AAGGATTTGA ACCTGGTGTT ACTAACATTT TAAAGACCAC ACAAGGAAGC 1800 AAAATCTTTC TGAAAGAAGT AAATGATACA CTTCTGGTGA ATGAATTGAA ATCAAAAGAA 1860 TCTGACATCA TGACAACAAA TGGTGTAATT CATGTTGTAG ATAAACTCCT CTATCCAGCA 1920 GACACACCTG TTGGAAATGA TCAACTGCTG GAAATACTTA ATAAATTAAT CAAATACATC 1980 5 CAAATTAAGT TTGTTCGTGG TAGCACCTTC AAAGAAATCC CCGTGACTGT CTATACAACT 2040 AAAATTATAA CCAAAGTTGT GGAACCAAAA ATTAAAGTGA TTGAAGGCAG TCTTCAGCCT 2100 ATTATCAAAA CTGAAGGACC CACACTAACA AAAGTCAAAA TTGAAGGTGA ACCTGAATTC 2160 AGACTGATTA AGGACC CALCITACA AAAGICAAAA HIGAAGIGA ACCIGAATIC 2160
AGACTGATTA AAGAAGCTGA AACAATAACT GAAGTGATCC ATGGAGAGCC AATTATTAAA 2220
AAATACACCA AAATCATTGA TGGAGTGCCT GTGGAAATAA CTGAAAAAGA GACACGAGAA 2280
GAACGAATCA TTACAGGTCC TGAAATAAAA TACACTAGGA TTTCTACTGG AGGTGGAGAA 2340
ACAGAAGAAA CTCTGAAGAA ATTGTTACAA GAAGAGGTCA CCAAGGTCAC CAAATTCATT 2400
GAAGGTGGTG ATGGTCATTT ATTTGAAGAT GAAGAAATTA AAAGACTGCT TCAGGGAGAC 2460 10 ACACCCGTGA GGAAGTTGCA AGCCAACAAA AAAGTTCAAG GTTCTAGAAG ACGATTAAGG 2520
GAAGGTCGTT CTCAG<u>TGA</u>AA ATCCAAAAAC CAGAAAAAAA TGTTTATACA ACCCTAAGTC 2580
AATAACCTGA CCTTAGAAAA TTGTGAGAGC CAAGTTGACT TCAGGAACTG AAACATCAGC 2640 15 ACAAAGAAGC AATCATCAAA TAATTCTGAA CACAAATTTA ATATTTTTTT TTCTGAATGA 2700 GAAACATGAG GGAAATTGTG GAGTTAGCCT CCTGTGGTAA AGGAATTGAA GAAAATATAA 2760 CACCTTACAC CCTTTTTCAT CTTGACATTA AAAGTTCTGG CTAACTTTGG AATCCATTAG 2820 CACCTIACAC CETTITICAT CTIGACATTA AAADTICTIGG CHACTTIGG ATTCCATAC 2820
AGAAAAAATCC TTGTCACCAG ATTCATTACA ATTCAAATCG AAGAGTTGTG AACTGTTATC 2880
CCATTGAAAA GACCGAGCCT TGTATGTATG TTATGGATAC ATAAAATGCA CGCAAGCCAT 2940
TATCTCTCCA TGGGAAGCTA AGTTATAAAA ATAGGTGCTT GGTGTACAAA ACTTTTTATA 3000
TCAAAAGGCT TTGCACATTT CTATATGAGT GGGTTTACTG GTAAATTATG TTATTTTTTA 3060 20 CAACTAATTI TGTACTCTCA GAATGTTTGT CATATGCTTC TTGCAATGCA TATTTTTTAA 3120
TCTCAAACGT TTCAATAAAA CCATTTTTCA GATATAAAGA GAATTACTTC AAATTGAGTA 3180 25 ATTCAGAAAA ACTCAAGATT TAAGTTAAAA AGTGGTTTGG ACTTGGGAA Seq ID NO: 62 Protein sequence:
Protein Accession #: NP\_006466 30 21 31 MIPFLPMFSL LLLLIVNPIN ANNHYDKILA HSRIRGRDQG PNVCALQQIL GTKKKYFSTC 60
KNWYKKSICG QKTTVLYECC PGYMRMEGMK GCPAVLPIDH VYGTLGIVGA TTTQRYSDAS 120
KLREEIEGKG SFTYFAPSNE AWDNLDSDIR RGLESNVYNVE ILNALHSHMI NKRMLTKDLK 180
NGMIPSMYN NLGLFINHYP NGVVTVNCAR IJHGNQIATN GVVHVIDRVL TQIGTSIQDF 240
IEAEDDLSSF RAAAITSDIL EALGRDGHFT LFAPTNEAFE KLPRGVLERF MGDKVASEAL 300
MKYHILNTLQ CSESIMGGAV FETLEGNTIE IGCDGDSITV NGIKMVNKKD IVTNNGVIHL 360
IDQVLIPDSA KQVIELAGKQ QTTFTDLVAQ LGLASALRPD GEYTLLAPVN NAFSDDTLSM 420
VQRLLKLILQ NHILKVKVGL NELYNGGILE TIGGKQLRVF VYRTAVCIEN SCMEKGSKQG 480
RNGAIHIFRE IIRPAEKSLH EKLKQDKRFS TFLSLLEAAD LKELLTQPGD WTLFVPTNDA 540
FKGMTSEEKE ILIRDKNALQ NIILYHLTPG VFIGKGFEPG VTNILKTTYG SKEFLKEVND 600
TLLVNELKSK ESDIMTTNGV IHVVDKLLYP ADTPVGNDQL LEILNKLIKY IQIKFVRGST 660
FKEIPVTVYT TKITKVVEP KIKVIEGSLQ PIKTTEGPTL TKVKIEGEPE FRLIKEGETI 720
TEVIHGEPII KKYTKIIDGV PVEITEKETR EERIITGPEI KYTRISTGGG ETEETLKKLL 780
QEEVTKVTKF IEGGDGHLFE DEEIKRLLQG DTPVPKLQAN KKVQGSRRRL REGRSQ 35 40 45 QEEVTKVTKF IEGGDGHLFE DEEIKRLLQG DTPVRKLQAN KKVQGSRRRL REGRSQ Seq ID NO: 63 DNA sequence Nucleic Acid Accession #: NM\_020974 Coding sequence: 81-3080 (underlined sequences correspond to start and stop codons) 50 GGCGTCCGCG CÁCACCTCCC CGCGCCGCCG CCGCCACCGC CCGCACTCCG CCGCCTCTGC 60 CCGCAACCGC TGAGCCATCC ATGGGGGTCG CGGGCCGCAA CCGTCCCGGG GCGGCCTGGG 120 CGGTGCTGCT GCTGCTGCTG CTGCTGCCGC CACTGCTGCT GCTGGCGGGG GCCGTCCCGC 180 CGGGTCGGGG CCGTGCCGCG GGGCCGCAGG AGGATGTAGA TGAGTGTGCC CAAGGGCTAG 240 55 ATGACTGCCA TGCCGACGCC CTGTGTCAGA ACACACCCAC CTCCTACAAG TGCTCCTGCA 300 AGCCTGGCTA CCAAGGGGAA GGCAGGCAGT GTGAGGACAT CGATGAATGT GGAAATGAGC 3 TCAATGGAGG CTGTGTCCAT GACTGTTTGA ATATTCCAGG CAATTATCGT TGCACTTGTT 420
TTGATGGCTT CATGTTGGCT CATGACGGTC ATAATTGTCT TGATGTGGAC GAGTGCCTGG 480
AGAACAATGG CGGCTGCCAG CATACCTGTG TCAACGTCAT GGGGAGCTAT GAGTGCTGCT 540 60 GCAGGAGGG GTTTTCCTG AGTGACATC AGCACACTG CATTCACCGC TCGGAAGAGG 660
GCCTGAGCTG CATGAATAAG GATCACGGCT GTAGTCACAT CTGCAAGGAG GCCCCAAGGG 660
GCAGCGTCGC CTGTGAGTGC AGGCCTGGTT TTGAGCTGGC CAAGAACCAG AGAGACTGCA 720 TCTTGACCTG TAACCATGGG AACGGTGGGT GCCAGCACTC CTGTGACGAT ACAGCCGATG 780
GCCCAGAGTG CAGCTGCCAT CCACAGTACA AGATGCACAC AGATGGGAGG AGCTGCCTTG 840
AGCGAGAGGA CACTGTCCTG GAGGTGACAG AGAGCAACAC CACATCAGTG GTGGATGGGG 900 65 AGGGGAGGA CACTGTCCTG GAGGTGACAG AGAGCACAC CACATCAGTG GTGGATGGG 900
ATAAACGGGT GAAACGGCGG CTGCTCATGG AAACGTGTGC TGTCAACAAT GGAGGCTGTG 960
ACCGCACCTG TAAGGATACT TCGACAGGTG TCCACTGCAG TTGTCCTGTT GGATTCACTC 1020
TCCAGTTGGA TGGGAGACA TGTAAAGATA TTGATGAGTG CCAGACCCGC AATGGAGGTT 1080
GTGATCATTT CTGCAAAAAC ATCGTGGGCA GTTTTGACTG CGCCTGCAAG AAAGGATTTA 1140
AATTATTAAC AGATGAGAAG TCTTGCCAAG ATGTGGATGA GTGCTCTTTG GATAGGACCT 1200
GTGACCACAG CTGCATCAAC CACCCTGGCA CATTTGCTTG TGCTTGCAAC CAAGGGTACA 1260
CCCTGTATGG CTTCACCCAC TGTGGAGACA CCAATGAGTG CAGCATCAAC AACGGAGGT
CTGTGTGGACA CAAGTGGGCA GCTATGAATG CCAGTGCCAC CCTGGGTACA 1380
AGCTCCACTG GAATAAAAAA GACTGTGTGG AAGTGAAGGG GCTCCTGCCC ACAAGTGTG 1440
CACCCCGTGT GTCCCTGCAC TGCGGTAAGA GTGGTGGAGG AGACGGGTGC TTCCTCCAGAT 1500

70

GTCACTCTGG CATTCACCTC TCTTCAGATG TCACCACCAT CAGGACAAGT GTAACCTTTA 1560 GICACTCTGG CATTCACCTC TCTTCAGATG TCACCACCAT CAGGACAAGT GTAACCTTTA 1560
AGCTAAATGA AGGCAAGTGT AGTTTGAAAA ATGCTGAGCT GTTTCCCGAG GGTCTGCGAC 1620
CAGCACTACC AGAGAAGCAC AGCTCAGTAA AAGAGAGCTT CCGCTACGTA AACCTTACAT 1680
GCAGCTCTGG CAAGCAAGTC CCAGGAGCCC CTGGCCGACC CAGCACCCCT AAGGAAATGT 1740
ITATCACTGT TGAGTTTGAG CTTGAAACTA ACCAAAAGGA GGTGACAGCT TCTTGTGACC 1880
GGAGCTGCAT CCTAAAAGCGA ACCGAGAAGC GGCTCCGTAA AGCCATCCGC ACGCTCAGAA 1860
AGGCCGTCCA CAGGGAGCAG TTTCACCTCC AGCTCTCAGG CATGAACCTC GACGTGGCTA 1920
AAAAGCCTCC CAGAACATCT GAACGCCAGG CAGAGTCCTG TGGAGTGGGC CAGGGTCATG 1980 5 CAGAAAACCA ATGTGTCAGT TGCAGGGCTG GGACCTATTA TGATGGAGCA CGAGAACGCT 2040 GCATTTTATG TCCAAATGGA ACCTTCCAAA ATGAGGAAGG ACAAATGACT TGTGAACCAT 2100 10 GCCCAAGACC AGGAAATTCT GGGGCCCTGA AGACCCCAGA AGCTTGGAAT ATGTCTGAAT 2160
GTGGAGGTCT GTGTCAACCT GGTGAATATT CTGCAGATGG CTTTGCACCT TGCCAGCTCT 2220
GTGCCCTGGG CACGTTCCAG CCTGAAGCTG GTCGAACTTC CTGCTTCCCC TGTGGAGGAG 2280 GIGECCIGGG CACGITICCAG CCIGAAGCTG GTCGAACTTC CTGCTICCCC TGTGGAGGAG 2280
GCCTTGCCAC CAAACATCAG GGAGCTACTT CCTTTCAGGA CTGTGAAACC AGAGTTCAAT 2340
GTTCACCTGG ACATTTCTAC AACACCACCA CTCACCGATG TATTCGTTGC CCAGTGGGAA 2400
CATACCAGCC TGAATTTGGA AAAAATAATT GTGTTTCTTG CCCAGGAAAT ACTACGACTG 2460
ACTTTGATGG CTCCACAAAC ATAAACCAGT GTAAAAAACAG AAGATGTGGA GGGGAGCTGG 2520
GAGATTTCAC TGGGTACATT GAATCCCCCAA ACTACCCAGG CAATTACCCA GCCAACACCG 2580
AGTGTACGTG GACCATCAAC CCACCCCCCA AGCGCCGCAT CCTGATCGTG GTCCCTGAGA 2640
TCTTCCTGCC CATAGAGGAC GACTGTGGGGG ACTATCTGGT GATCGCGCACACCT 2700
CCAATTCTGT GACAACATAT GAAACCTGCC AGACCTACCGA ACGCCCATC GCCTTCACCT 2760
CCAGGTCAAA GAAAGCTGTGG ATTCAGTTCA AGTCCAATGA AGGCGCAACAGCGCTACAGAGGCT 2820 15 20 CCAGGTCAAA GAAGCTGTGG ATTCAGTTCA AGTCCAATGA AGGGAACAGC GCTAGAGGGT 2820
TCCAGGTCCC ATACGTGACA TATGATGAGG ACTACCAGGA ACTCATTGAA GACATAGTTC 2880
GAGATGGCAG GCTCTATGCA TCTGAGAACC ATCAGGAAAT ACTTAAGGAT AAGAAACTTA 2940 GAGATGGCAG GCTCTATGCA TCTGAGAACC ATCAGGAAAT ACTTAAGGAT AAGAAACTTA 2940
TCAAGGCTCT GTTTGATGTC CTGGCCCATC CCCAGAACTA TTTCAAGTAC ACAGCCCAGG 3000
AGTCCCGAGA GATGTTTCCA AGATCGTTCA TCCGATTGCT ACGTTCCAAAG TGTCCCAGGT 3060
TTTTGAGACC TTACAAATGA CTCAGCCCAC GTGCCACTCA ATACAAATGT TCTGCTATAG 3120
GGTTGGTGGG ACAGAGCTGT CTTCCTTCTG CATGTCAGCA CAGTCGGGTA TTGCTGCCTC 3180
CCGTATCAGT GACTCATTAG AGTTCAATTT TTATAGATAA TACAGATATT TTGGTTAAATT 3240
GAACTTGGTT TTTCTTTCCC AGCATCGTGG ATGTAGACTG AGAATGGCTT TGAGTGGCAT 3300
CAGCTTCTCA CTGCTTGGG CGGATGTCTT GGATAGATCA CGGGCTGGCT GAGCTGGACT 3360
TTGGTCAGCC TAGGTGAGAC TCACCTGTCC TTCTTGGGTC TTACTCCTC TCAAGGAGTC 3420
TGTAGTGGAA AGGAGGCCAC AGAATAAGCT GCTTATTCTG AAACTTCAGC TTCCTCTCAG 3480
CCGGCCCTCT CTAAGGGAGC CCCTTCCACCT GCTGTGCCAG CCACCTTTGAG ACCTGGGAGG 3500
CAAGAGGGGA GGGAAGGAG CCCCTTCCAGCT CTCCTCCAC CCACCTTTGAG ACCTGGGAGG 3600
ACTCAGTTTC TCCACAGCCT TCTCCCAGCCT TGTGGATAACA AGTTTGATCC CAGGAACTTG 3660 25 30 35 ACTCAGTTTC TCCACAGCCT TETCCAGCCT GTGTGATACA AGTTTGATCC CAGGAACTTG 3660
AGTTCTAAGC AGTGCTCGTG AAAAAAAAA GCAGAAAGAA TTAGAAATAA ATAAAAACTA 3720 AGCACTTCTG GAGACAT

Seq ID NO: 64 <u>Protein sequence</u>; Protein Accession #: NP\_066025.1 40

| | | | | | | MGVAGRNRPG AAWAVLLLLL LLPPLLLLAG AVPPGRGRAA GPQEDVDECA QGLDDCHADA 60 45 LCQNTPTSYK CSCKPGYQGE GRQCEDIDEC GNELNGGCVH DCLNIPGNYR CTCFDGFMLA 120 HOGHNCLDVD ECLENNGGCQ HTCVNVMGSY ECCKEGFFL SDNQHTCHR SEEGLSCMNK 180
DHGCSHICKE APRGSVACEC RPGFELAKNQ RDCILTCNHG NGGCQHSCDD TADGPECSCH 240
PQYKMHTDGR SCLEREDTVL EVTESNTTSV VDGDKRVKRR LLMETCAVNN GGCDRTCKDT 300
STGVHCSCPV GFTLQLDGKT CKDIDECQTR NGGCDHFCKN IVGSFDCGCK KGFKLLTDEK 360
SCQDVDECSL DRTCDHSCN HPGTFACACN RGYTLYGFTH CGDTNECSIN NGGCQVCVN 420 50 SCQDVDECSL DRTCDHSCIN HPGTFACACN RGYTLYGFTH CGDTNECSIN NGGCQQVCVN 420
TVGSYECQCH PGYKLHWNKK DCVEVKGLLP TSVSPRVSLH CGKSGGGDGC FLRCHSGIHL 480
SSDVTIIRTS VTFKLNEGKC SLKNAELFPE GLRPALPEKH SSVKESFRYV NLTCSSGKQV 540
PGAPGRPSTP KEMFITVEFE LETNQKEVTA SCDLSCIVKR TEKRLRKAIR TLRKAVHREQ 600
FHLQLSGMNL DVAKKPPRTS ERQAESCGVG QGHAENQCVS CRAGTYYDGA RERCILCPNG 660
TFQNEEGQMT CEPCPPPGNS GALKTPEAWN MSECGGLCQP GEYSADGFAP CQLCALGTFQ 720
PEAGRTSCFP CGGGLATKHQ GATSFQDCET RVQCSPGHFY NTTTHRCIRC PVGTYQPEFG 780
KNNCVSCPGN TTTDFDGSTN ITQCKNRRCG GELGDFTGYI ESPNYPGNYP ANTECTWTIN 840
PPPKRRILLV VPEIFLPIED DCGDYLVMRK TSSSNSVTTY ETCQTYERPI AFTSRSKKLW 900
IQFKSNEGNS ARGFQVPYVT YDEDYQELIE DIVRDGRLYA SENHQEILKD KKLIKALFDV 960
LAHPONYFKY TAOESREMFP RSFIRLLRSK VSRFI RPYK 55 60

Seq ID NO: 65 DNA sequence Nucleic Acid Accession #: NM\_007210 65 Coding sequence: 1-1869 (underlined sequences correspond to start and stop codons)

LAHPONYFKY TAQESREMFP RSFIRLLRSK VSRFLRPYK

| 1 | 1 | 1 | 60 |
ATGAGGETCC TCCGCAGACG CCACATGCCC CTGCGCCTGG CCATGGTGGG CTGCGCCTTT 60
GTGCTCTTCC TCCTCCCC GCACAGGACG TGCAGCAGCAGAGAGGC CACAGAGAAG 120 |
CCGTGGCTGA AGTCCCTGGT GAGCCGGAAG GATCACGTCC TGGACCTCAT GCTGGAGGCC 180
ATGAACAACC TTAGAGATTC AATGCCCAAG CTCCAAATCA GGGCTCCAGA AGCCCAGCAG 240
ACTCTGTTTCT CCATAAACCA GTCCTGCAGTCTC ATACCCCAGC TGAACTGAAG 300
CCCTTCTGGG AACGGCCAC ACAGGACCCC AATGCCCCTG GGGCAGATGG AAAAGCATTT 360
CAGAAGAGCA AGTGGACCCC CCTGGAGACC CAGGAAAAGG AAGAAGGCTA TAAGAAGCAC 420
TGTTTCAATG CCTTTGCCAG CGACCGGATC TCCCTGCAGA GGTCCCTGGG GCCAGACACC 480
CGACCACCTG AGTGTGTGGA CCAGAAGTTC CGGCGCTGCC CCCCACTGGC CACCACCAGC 540 70 75 CGACCACCTG AGTGTGTGGA CCAGAAGTTC CGGCGCTGCC CCCCACTGGC CACCACCAGC 540

GTGATCATTG TGTTCCACAA CGAAGCCTGG TCCACACTGC TGCGAACAGT GTACAGCGTC 600 CTACACACCA CCCCTGCCAT CTTGCTCAAG GAGATCATAC TGGTGGATGA TGCCAGCACA 660 GAGGAGCACC TAAAGGAGAA GCTGGAGCAG TACGTGAAGC AGCTGCAGGT GGTGAGGGTG 720 GTGCGGCAGG AGGAGCGGAA GGGGTTGATC ACCGCCCGGC TGCTGGGGGC CAGCGTGGCA 780 CAGGCGGAGG TGCTCACGTT CCTGGATGCC CACTGTGAGT GCTTCCACGG CTGGCTGGAG 840 5 CCCCTCCTGG CTCGAATCGC TGAGGACAAG ACAGTGGTGG TGAGCCCAGA CATCGTCACC 900
ATCGACCTTA ATACTTTTGA GTTCGCCAAG CCCGTCCAGA GGGGCAGAGT CCATAGCCGA 960
GGCAACTTTG ACTGGAGCCT GACCTTCGGC TGGGAAACAC TTCCTCCACA TGAGAAGCAG 1020 AGGCGCAAGG ATGAAACATA CCCCATCAAA TCCCCGACGT TTGCTGGTGG CCTCTTCTCC 1080 ATCCCCAAGT CCTACTTTGA GCACATCGGT ACCTATGATA ATCAGATGGA GATCTGGGGA 1140 GGGGAGAACG TGGAAATGTC CTTCCGGGTG TGGCAGTGTG GGGGCCAGCT GGAGATCATC 1200 10 CCCTGCTCTG TCGTAGGCCA TGTGTTCCGG ACCAAGAGCC CCCACACCTT CCCCAAGGGC 1260 ACTAGTGTCA TTGCTCGCAA TCAAGTGCGC CTGGCAGAGG TCTGGATGGA CAGCTACAAG 1320 AAGATTTTCT ATAGGAGAAA TCTGCAGGCA GCAAAGATGG CCCAAGAGAA ATCCTTCGGT 1380 15 ATCAAGAACC TCGGCACCAA CCAATGCCTG GATGTGGGTG AGAACAACCG CGGGGGGAAG 1560 CCCCTCATCA TGTACTCCTG CCACGGCCTT GGCGGCAACC AGTACTTTGA GTACACAACT 1620 CAGAGGGACC TTCGCCACAA CATCGCAAAG CAGCTGTGTC TACATGTCAG CAAGGGTGCT 1680 20 CTGGGCCTTG GGAGCTGTCA CTTCACTGGC AAGAATAGCC AGGTCCCCAA GGACGAGGAA 1740 TGGGAATTGG CCCAGGATCA GCTCATCAGG AACTCAGGAT CTGGTACCTG CCTGACATCC 1800 CAGGACAAAA AGCCAGCCAT GGCCCCTGC AATCCCAGTG ACCCCCATCA GTTGTGGCTC 1860 TTTGTTAGG ACCCAGATCA TCCCCAGAGA GAGCCCCCAC AAGCTCCTCA GGAAACAGGA 1920
TTGCTGATGT CTGGGAACCT GATCACCAGC TTCTCTGGAG GCCGTAAAGA TGGATTTCTA 1980
AACCCACTGG GTGGCAAGGC AGGACCTTCC TAATCCTTGC AACAACATTG GGCCCATTTT 2040 25 CTTTCCTTCA CACCGATGGA AGAGACCATT AGGACATATA TTTAGCCTAG CGTTTTCCTG 2100
TTCTAGAAAT AGAGGCTCCC AAAGTAGGGA AGGCAGCTGG GGGAGGGTTC AGGGCAGCAA 2160
TGCTGAGTTC AAGAAAAGTA CTTCAGGCTG GGCACAGTGG CTCATGCCTG AAATCCTAGC 2220 ACTTTGGGAA GACAATGTGG GAGAATGGCT TGAGCCCAGG AGTTCAAGAC CGGCCTGAGC 2280 AACATAGTGA GGATCCCATC TCTACGCCCA CCCTCCCCCC GGCAAAAAAA AAAGCTGGGT 2340 30 ATGGTGGCTT ATGCCTGTAG TCGCAGCTAC TCAGAAGGCT GAGGTGGGAG GATTGCTTGT 2400 TCCCCGGAGG TTGAAGCTAC AGTGAGCCTT GATTGTGTCA CTGCACTCCA GCCTGGGCAA 2460 CAGGTAAGAC TCTGTCTCAA AAAAAAAACA AAAAAGAAGA AGAAAAGTAC TTCTACAGCC 2520 ATGTCCTATT CCTTGATCAT CCAAAGCACC TGCAGAGTCC AGTGAAATGA TATATTCTGG 2580 35 CTGGGCACAG TGGCTCACAC CTGTAATCCT AGCACTTTGG GAGGCCAAGG CAGGTGGATC 2640 ACCTGAGGTC AGAAGTTTGA AACCAGCCTG GACTACATGG TGAAACTCCA TCTCTACTAA 2700 AAGTACAAAA ATTAGCTGGG CATGATGGCA CGCACCTGCA GTCCCAGCTA CTTGGGAGGC 2760 TGAGGCAGGA GAATCACTCG AACCCAGGAG GCAGAGGTTG CAGTGAGCCA AGACAGCACC 2820 ATTGCACCCC AGCCTGAGCA ACAAGAGCGA AACTCCATCT CAGGAAAAAA AAAAAAAAA 2880 40 Seq ID NO: 66 Protein sequence:
Protein Accession #: NP\_009141

45

50

55

65

70

75

MRLLRRRHMP LRLAMVGCAF VLFLFLLHRD VSSREEATEK PWLKSLVSRK DHVLDLMLEA 60 MKLLKRKHMF KRLAMVOCAF VLFLFELHRO VSSREBATEK FWLKSLVSKK DHVLDLMEA MNNLRDSMPK LQIRAPEAQQ TLFSINQSCL PGFYTPAELK PFWERPPQDP NAPGADGKAF 120 QKSKWTPLET QEKEEGYKKH CFNAFASDRI SLQRSLGPDT RPPECVDQKF RRCPPLATTS 180 VIIVFHNEAW STLLRTVYSV LHTTPAILLK EIILVDDAST EEHLKEKLEQ YVKQLQVVRV 240 VRQEERKGLI TARLLGASVA QAEVLTFLDA HCECFHGWLE PLLARIAEDK TVVVSPDIVT 300 IDLNTFEFAK PVQRGRVHSR GNFDWSLTFG WETLPPHEKQ RRKDETYPIK SPTFAGGLFS 360 PKSYFEHIG TYDNQMEIWG GENVEMSFRV WQCGGQLEII PCSVVGHVFR TKSPHTFPKG 420 TSVIARNQVR LAEVWMDSYK KIFYRRNLQA AKMAQEKSFG DISERLQLRE QLHCHNFSWY 480 LHNVYPEMFV PDLTPTFYGA IKNLGTNQCL DVGENNRGGK PLIMYSCHGL GGNQYFEYTT 540 QRDLRHNIAK QLCLHVSKGA LGLGSCHFTG KNSQVPKDEE WELAQDQLIR NSGSGTCLTS 600 QDKKPAMAPC NPSDPHQLWL FV

Seq ID NO: 67 DNA sequence 60 Nucleic Acid Accession # NM\_014112 Coding sequence: 600-4484 (underlined sequences correspond to start and stop codons)

TTCCTCCGCG AAGGCTCCTT TGATATTAAT AGTGTTGGTG TCTTGAAACT GACGTAATGC 60 GCGGAGACTG AGGTCCTGAC AAGCGATAAC ATTTCTGATA AAGACCCGAT CTTACTGCAA 120
TCTCTAGCGT CCTCTTTTTT GGTGCTGCTG GTTTCTCCAG ACCTCGCGTC CTCTCGATTG 180 TTAGGCTCCT GCTAGTTGAC TAATAGAATT AATAATTGTA AAAAGCACTC TAAAGCCACA 600
TGCCTTATGA AGTCAATGCT GGGTATGATT TTACAAATAT GGTCCGGAAA AAGAACCCCC 660
CTCTGAGAAA CGTTGCAAGT GAAGGCGAGG GCCAGATCCT GGAGCCTATA GGTACAGAAA 77 GCAAGGTATC TGGAAAGAAC AAAGAATTCT CTGCAGATCA GATGTCAGAA AATACGGATC 780

CTTCTAGCAG TAAGAAGGAC TTGAAAAGCG CAGTTCTGAG TGAGAAGGCT GGCTTCAATT 900 ATGAAAGCCC CAGTAAGGGA GGAAACTTTC CCTCCTTTCC GCATGATGAG GTGACAGACA 960 GAAATATGTT GGCTTTCTCA TTTCCAGCTG CTGGGGGAGT CTGTGAGCCC TTGAAGTCTC 1020 5 CGCAAAGAGC AGAGGCAGAT GACCCTCAAG ATATGGCCTG CACCCCTCA GGGGACTCAC 1080 TGGAGACAAA GGAAGATCAG AAGATGTCAC CAAAGGCTAC AGAGGAAACA GGGCAAGCAC 1140 AGAGTGGTCA AGCCAATTGT CAAGGTTTGA GCCCAGTTTC AGTGGCCTCA AAAAACCCAC 1200 AAGTGCCTTC AGATGGGGGT GTAAGACTGA ATAAATCCAA AACTGACTTA CTGGTGAATG 1260
ACAACCCAGA CCCGGCACCT CTGTCTCCAG AGCTTCAGGA CTTTAAATGC AATATCTGTG 1320
GATATGGTTA CTACGGCAAC GACCCCACAG ATCTGATTAA GCACTTCCGA AAGTATCACT 1380 10 TAGGACTGCA TAACCGCACC AGGCAAGATG CTGAGCTGGA CAGCAAAATC TTGGCCCTTC 1440 ATAACATGGT GCAGTTCAGC CATTCCAAAG ACTTCCAGAA GGTCAACCGT TCTGTGTTTT 1500 CTGGTGTGCT GCAGGACATC AATTCTTCAA GGCCTGTTTT ACTAAATGGG ACCTATGATG 1560 TGCAGGTGAC TTCAGGTGGA ACATTCATTG GCATTGGACG GAAAACACCA GATTGCCAAG 1620 GGAACACCAA GTATTTCCGC TGTAAATTCT GCAATTTCAC TTATATGGGC AACTCATCCA 1680 15 CCGAATTAGA ACAACATTTT CTTCAGACTC ACCCAAACAA AATAAAAGCT TCTCTCCCCT 1740 CCTCTGAGGT TGCAAAACCT TCAGAGAAAA ACTCTAACAA GTCCATCCCT GCACTTCAAT 1800 CCAGTGATTC TGGAGACTTG GGAAAATGGC AGGACAAGAT AACAGTCAAA GCAGGAGATG 1860 CAGIGATIC IGGGAACTIG GGAAATIGGC AOGACAGOAT AACAGICATAA GCAGGAGAGT 1880
CAGAGGCCAC CAGTTACTAC TGGTGTAAAT TTTGTAGTTT CAGCTGTAGA CAAAATGGTA 1920
CAGAGGCCAC CAGTTACTAC TGGTGTAAAT TTTGTAGTTT CAGCTGTGAG TCATCTAGCT 1980
CACTTAAACT GCTAGAACAT TATGGCAAGC AGCACAGGAGC AGTGCAGTCA GGCGGCCTTA 2040
ATCCAGAGTT AAATGATAAG CTTTCCAGGG GCTCTGTCAT TAATCAGAAT GATCTAGCCA 2100
AAAGTTCAGA AGGAGAGACA ATGACCAAGA CAGACAAGAG CTCGAGTGGG GCTAAAAAGA 2160 20 AGGACTTCTC CAGCAAGGGA GCCGAGGATA ATATGGTAAC GAGCTATAAT TGTCAGTTCT 2220 25 GTGACTTCCG ATATTCCAAA AGCCATGGCC CTGATGTAAT TGTAGTGGGG CCACTTCTCC 2280
GTCATTATCA ACAGCTCCAT AACATTCACA AGTGTACCAT TAAACACTGT CCATTCTGTC 2340
CCAGAGGACT TTGCAGCCCA GAAAAGCACC TTGGAGAAAT TACTTATCCG TTTGCTTGTA 2400 GAAAAAGTAA TTGTTCCCAC TGTGCACTCT TGCTTCTGCA CTTGTCTCCT GGGGCGGCTG 2460 GAAGCTCGCG AGTCAAACAT CAGTGCCATC AGTGTTCATT CACCACCCCT GACGTAGATG 2520 TACTICCTICTT TCACTATGAA AGTGTGCATG AGTCCCAAGC ATCGGATGTC AAACAAGAAG 2580
CAAATCACCT GCAAGGATCG GATGGGCAGC AGTCTGTCAA GGAAAGCAAA GAACACTCAT 2640
GTACCAAATG TGATTTTATT ACCCAAGTGG AAGAAGAGAT TTCCCGACAC TACAGGAGAG 2700 30 GACACAGCTG CTACAAATGC CGTCAGTGCA GATTTTACAGC TGCCGATACT CAGTCACTAC 2760
TGGAGCACTT CAACACTGTT CACTGCCAGG AACAGGACAT CACTACAGCC AACGGCGAAG 2820
AGGACGGTCCA TGCCATATACC ACCATCAAAG AGGACCCAA AATTGACTTC AGGGTCTACA 2880
ATCTGCTAAC TCCAGACTCT AAAATGGCGAG AGCCAGTTTC TGAGAGTGTG GTGAAGAGAG 2940
AGAAGCTGGA AGAGAAGGAC GGGCTCAAAG AGAAAGTTTG GACCGAGGT TCCAGTGATG 3000 35 ACCTTCGCAA TOTGACTTGG AGAGGGGCAG ACATCCTGCG GGGGAGTCCG TCATACACCC 3060
AAGCAAGCCT GGGGCTGCTG ACGCCTGTGT CTGGCACCCA AGAGCAGACA AAGACTCTAA 3120
GGGATAGTCC CAATGTGGAG GCCGCCCATC TGGCGCGACC TATTTATGGC TTGGCTGTGG 3180 40 AAACCAAGGG ATTCCTGCAG GGGGCGCCAG CTGGCGGAGA GAAGTCTGGG GCCCTCCCCC 3240 AGCAGTATCC TGCATCGGGA GAAAACAAGT CCAAGGATGA ATCCCAGTCC CTGTTACGGA 3300 GGCGTAGAGG CTCCGGTGTT TTTTGTGCCA ATTGCCTGAC CACAAAGACC TCTCTCTGGC 3360 GAAAGAATGC AAATGGCGGA TATGTATGCA ACGCGTGTGG CCTCTACCAG AAGCTTCACT 3420 CGACTCCCAG GCCTTTAAAC ATCATTAAAC AAAACAACGG TGAGCAGATT ATTAGGAGGA 3480 45 GAACAAGAAA GCGCCTTAAC CCAGAGGCAC TTCAGGCTGA GCAGCTCAAC AAACAGCAGA 3540 GGGGCAGCAA TGAGGAGCAA GTCAATGGAA GCCCGTTAGA GAGGAGGTCA GAAGATCATC 3600 TAACTGAAAG TCACCAGAGA GAAATTCCAC TCCCCAGCCT AAGTAAATAC GAAGCCCAGG 3660 GTTCATTGAC TAAAAGCCAT TCTGCTCAGC AGCCAGTCCT GGTCAGCCAA ACTCTGGATA 3720 50 TTCACAAAAG GATGCAACCT TTGCACATTC AGATAAAAAG TCCTCAGGAA AGTACTGGAG 3780 ATCCAGGAAA TAGTTCATCC GTATCTGAAG GGAAAGGAAG TTCTGAGAGA GGCAGTCCTA 3840 ANALAGTA CATGAGACCT GCGAAACACC CAAATTATTC ACCACCAGGC AGCCCTATTG 3900
AAAAGTACCA GTACCCACTT TTTGGACTTC CCTTTGTACA TAATGACTTC CAGAGTGAAG 3960
CTGATTGGCT GCGGTTCTGG AGTAAATATA AGCTCTCCGT TCCTGGGAAT CCGCACTACT 4020 55 TGAGTCACGT GCCTGGCCTA CCAAATCCTT GCCAAAACTA TGTGCCTTAT CCCACCTTCA 4080 ATCTGCCTCC TCATTTTTCA GCTGTTGGAT CAGACAATGA CATTCCTCTA GATTTGGCGA 4140 TCAAGCATTC CAGACCTGGG CCAACTGCAA ACGGTGCCTC CAAGGAGAAA ACGAAGGCAC 4200 CACCAAATOT AAAAAATGAA GGTCCCTTGA ATGTAGTAAA AACAGAGAAA GTTGATAGAA 4260 GTACTCAAGA TGAACTTTCA ACAAAATGTG TGCACTGTGG CATTGTCTTT CTGGATGAAG 4320 TGATGTATGC TTTGCATATG AGTTGCCATG GTGACAGTGG ACCTTTCCAG TGCAGCATAT 4380 60 GCCAGCATCT TTGCACGGAC AAATATGACT TCACAACACA TATCCAGAGG GGCCTGCATA 4440
GGAACAATGC ACAAGTGGAA AAAATGGAA AACCTAAAGA GTAAAACCTT AGCACTTAGC 4500
ACAATTAAAT AGAAATAGGT TTTCTTGATG GGAATTCAAT AGCTTGTAAT GTCTTTATGAA 4560
GACCTATTAA AAAATACTT CATAGAGCCT GCCTTATCCA ACATGAAATT CCTTCTTTT 4620
GTTATTCTTT CTTTTGATGA GTAGGTTACC AAGATTAAAA AGGGAGATTA ATGGTCAATG 4680 65 GTTATTCTTT CTTTTGATGA GTAGGTTACC AAGATTAAAA AGTGAGATAA ATGGTCAATG 4680
AGAAAGAATG GAAGATGGTA AACAATCACT TTTTAAAACC TGTTAAGTCA AAACCATCTT 4740
GGCTAATATG TACTGGGGAA ATAATCCATA AGAGATATCA CCAGACTAGA ATTAATATAT 4800
TTATAAAGAA AGAGACCAAA ACTGTCTAGA ATTTGAAAGG GTTTACATAT TATTATACTA 4860
AAGCAGTACT GGACTGGCCA TTGGACACCT TGTTCCAAAA CCCATAAAATT GTTGCCTAAA 4920
TTTATAATATGA TCATGAAACC CTTAGGCAGAG GAGGAGAAAT TGAAGGTCCA GGGCAATGAA 4980
AGAAAAATGG CGCCCTCTCA ATTTAGTCTT CTCTCATTGG CCATGTTTCA GATTTTGACC 5040
TAGAAATGCG AGCTGTGGTT AGGCTTGGTT AGAGTGCAGC AAGCAACATG ACAGATGTT 5160
GCACGCTGTT TTTACCCAGC CCTGCCTGTA CATACACATG CACACCCTCT CTGATATTTT 5160
TGTCCTTTAG ATGTTCAAAT ACTCAGTAGT CCTTTTGTTT GCGGTTTAGA TTCATTTTT 5220
CCACACATGT ACCCATTTTA AAAAACAATG TCCTCGATGC TCTGTAGTGT ATTTCTTTG TSCTGATAGTCTTTT 5280 70 75 AGCCAGGTAT TTCTTTCTTG TGTGTGATGA ACCAGTATGG ATTTGCTTTT CTAAGCCTCC 5340 TGTTGGTTAC TAATCTCACT TGGCACATTA TAACTAAAGG AATCCCCTCA ATTCAAAAGC 5400

AGAGTGATGC TGCAGAACTA AATCATAAGG AGGAACATAG CTTGCATGTT CAAGATCCAT 840

ATAGATGGAT ACAAATGTCA GACCGTGGGT TTAATTTGTT TAGAACACAT GGCATTTCTT 5460 CACAAGGTAA CCTGCTGTAT TTATTTATTT TCTTTTGGTT AAATATAATT TCCAAACTTT 5520 GTGGTCAGGC AGCGTCTAAG GTTACGTTAC CACAGACTGA CAGTTGGTAT ATGTACCAGC 5580 CAATCCCTTC ATTAAATGTA TACAGATTTA GTTAAGTAGC ATTAAATAGG ATTCTTAGAA 5640 GTATGTCCTC ATAGAACTTT TAATACTTAA GGCTTTGTAA AAACTATCCA TGAAGGGAAA 5700 GCTCCTCAGC ATAACTGCTC AGGGAAATAG GGCTAAATAA CTGAACATTA AATAATTGGT 5760 TAAAGGTGCT GTTAGTCGAG CCTCAATGCT TGCTACAAGG ATGTATGTAC AAGGACTGAC 5820
TTTAATAATT TGCATTATAT TGTCCCAACC AGTAGTTTAT TTTTTGCCAC GGAGATGTAG 5880 AAGATATTAC AAGCTACTGG ATGCACTGTC AGATTAACTT ATTTCATTAA AGAAGTTGGG 5940 10 AGAACAAATA GGAAAAAAA AACTTATTTT TCTAGTAAAT ATTAATGTAT TACATTTCAA 6000 ATAATGGTGC CTGACATATT GAATAATTAT TTTCTACAGT GTACGTATGC AACAAAGATA 6060 TTCCATCATG CATTAGAGTC AGTTCTGGCT CTGCCTAGCT GTTTACATTT GCAAATGTAG 6120 CAAACAAGGT AATGAAGCAA CTATTTCTAT TGCAGTAGGAT ATCCTTTTGT GTGTGTGTGT 6180
GTGCATTAAA GTTGTAAACG GTAACATGAA ACAATGAAA GTTCTTGCTA TAATGGTATG 6240
GAAAACAAGA AGGAAATGAAAATGATTATTA TGCCTACTTA GGAAAAAAA GGTTAGCACTT 6300
ATTCATTCCA AGTACTTTTT TTTTTTTAAT TTTTTAAGCTC TTAACTCACA TTGTTATGCT 6360
TAAGATGATA AACATATATC CTCTTTTTAT TGCTTGTTTTCATA TGAAAACATTT 6420 15 CAGAAATTAT TITGATAAGT GTIGCTGGAA TCTGCAACGC TGATTTTTT TTGCATTCTG 6480 TAGTCGCATT TGCACTCCAT TITTACATTA ATTCGCAGTT GCTTTGTATC ATTGTTTTGT 6540 TTGGGTTTTG TTTCTTTTC ACAGTGCCGG GTCTTCGTTT CTTAAAGTTG GATGGCAGGT 6600 20 AGAGTTCAAC CAGTTCGTGA CTGTTGTAGC GAATGAAGTT AAAAAAATGT CTTTCTGATG 6660 TTGTGTTGTC ATTTTCATTT TTGCATTTTT TTGTTTGCAT ATTAAAAAAA GAGAAAAGAG 6720 AAAGCAAGAG ACAGAAATCA GGACTAAGTC CTCTGCTTCA GTTTCATTGT TAACGGGCCT 6780 AAAGAAGAG ACADAAATCA GAGATAAGTC LETIGUTURA HTITTAAGTATATT TAACGAGCT 6840
AATGAGGAGC TITTGACATTC AAATTATTGTG ATGTAATTTA TCTTCCTTAG GAATTTTGAT 6900
GGATGCATCT CAAAAATGTAT AGCCAGACTT GAGAGGTGAC AATTAAAGAATAT CTAAAAAAAGA 6960
GAGGAGATTC CCCCAAACAA CAATATTTAA TTTTCTTAGT AAAAAAGAATAA CAGAATGCA 7020
TCGTGGCAAT CCTTAAGCAA CATTATTAT TTTTCTTAGT AAAAAGAATAA CAGAATGCA 7020
AGTTTGGTTA ACTTGGGCAA TATGACAAGT ATTACTTTTT GGGCAAAATAAT ACTCATTAAG 7140 25 30 CAATTTCTCT AGTGTGTCGG ACACAAATAG GTTCTTTATT TTTGGCATGT ATGCCTTTTT 7200 ATTTTCATTC AATTTTTTT TTTTCTCAGA CAGACATAGT AGTATCAACT AGCATTGGAA 7260 AATACATATC ACTATTCTTG GAATATTTAT GGTCAGTCTA CTTTTTAGTA AAATATTTTT 7320 35 GAGACAAAAA TTTATTATAA CACTAAACAC TCCTTTTTTG ACATATTAAA GCCTTTATTC 7500 CATCTCTCAA GATATATTAT AAAATTATT TITTTAATTT AAGATTTCTG AATTATTTTA 7560 TCTTAAATTG TGATTTTAAA CGAGCTATTA TGGTACGGAA CTTTTTTTAA TGAGGAATTT 7620 CATGATGATT TAGGAATTTT CTCTCTTGGA AAAGGCTTCC CCTGTGATGA AAATGATGTG 7680 CCAGCTAAAA TIGTGTGCCA TITAAAAACT GAAAATATTT TAAAATTATT TGTCTATATT 7740 CTAAATTGAG CTTTGGATCA AACTTTAGGC CAGGACCAGC TCATGCGTTC TCATTCTTCC 7800 40 TTTTCTCACT CTTTCTCTCA TCACTCACCT CTGTATTCAT TCTGTTGTTT GGGATAGAA 7860 AATCATAAAG AGCCAACCCA TCTCAGAACG TTGTGGATTG AGAGAGACAC TACATGACTC 7920 CAAGTATATG AGAAAAGGAC AGAGCTCTAA TTGATAACTC TGTAGTTCAA AAGGAAAAGA 7980 CAAGTATATO AGAANAGGAC AGAGCTCTAA TTGATAACTC TGTAGTTCAA AAGGAANAGA 7986
GTATGCCCAA TICTCTCTAC ATGACATATT GAGATTTTTT TTAATCAACT TTTAAGATAG 8040
TGATGTTCTG TICTAAACTG TTCTGTTTTA GTGAAGGTAG ATTTTTATAA AACAGCATG 8100
GGGATTCTTT TCTAAGGTAA TATTAATGAG AAGGGAAAAA AGTACTTTA ACAGCTCTTT 8160
GTTGAAGCCT GTGGTAGCAC ATTATGTTTA TAATTGCACA TGTGCACATA ATCTATTATG 8220
ATCCAATGCA AATACAGCTC CAAAAAATATT AAATGTATAT ATATTTTAAA ATGCCTTGAGG 8280
AATACATTT TTCTTAATAA ACTGAAGAGT CTCAGTATGG CTATTAAAAT AAATTATTAGC 8340
CTCCTGTTGT GTGGCTGCAA AACATCACAA AGTGACCGGT CTTGAGACCT GTGAACTGCT 8400
GCCCTGTTTA GTAAATAAAA TTAATGCATT TCTAGAGGGG GAATATCTGC CATCCAGTGG 8460
TGGAAATGTG GAGTAAAGAA GCTGGTGTC TGCTTTTGGT CTGTATGCCA GCCTTTTGCC 8520 45 50 TTAAGTTGAG AGGAGGTCAA CTTTAGCTAC TGTCTTTGGT TTGAGAGCCA TGGCAAAAAA 8580 AAAAAAAGAA AAAAAGATCA AGTCGTCTTT GGTGAGCCAG TAAGGTGAAA GCTTGCTGAC 8640 55 TOTCCAAGGC ACAAGAGAAA ATTGAGGAAT TGAAATGCAA CCTGAGTATC AAACTAAATA 8700 TTCTAATCAA AGGTAGGTAC TGTTAGGTGG AATTCTATCA GCAGGCAACT GCAAATGAGA 8760 AGAAGATAGA AGGACGCCCG TCGGGACTTT GGAGGGCATT GTTATTTTCC CAAAGAAAGA 8820 AGAAGATAGA AGGACGCCCG TCGGGACTTT GGAGGGCATT GTTATTTTC. CAAAGAAAAA 8820
CGGCCAAGGG CAGAGGCATG GATTCTTTGC AGAGGACTTC CTTTTTGGTTT TTCAGTACTG 8880
TTTCATAGAC AGTGGGCTCA CATGTTCCTG ATAGTGCTGC AGTTGCTTAG AAAGCATCCC 8940
AGTTAATTGC AGTAATTAGA ACTTCTGGAA TATGGTAGGG CAGAAGTATG TCAAGTATGT 9000
CACATGAAGA AAATGTGAAA TTCAAGAGTA ATCCACACGT AGAAAACTAG ACAATGTACA 9060
TTCATGTGTT CTCTTGAAAG GAAAAGGGAGA GCTGTAAGCT TCACTCTGTC CTACACCGGA 9120
GAAAAGCAGG AATAACTTTA CCGTGGAAAT AATGTTTAGC TTTTATCAGA GAAAATTGTC 9180 60 GAAAAGCAGG AATAACTTTA CCGTGGAAAT AATGTTTACC TITTATCAGA GAAAATTTTC 9180
CTTCTAGAGC ATAGAGTCCC AAAACTCAAT TCTGGTTTTC CCCTGTTTTT TTTTTTTT 9240
TTTTTCCCAA CATATGAACT GCAGCATATC ACTTTTTCTT TTTGTGCCTC AGGTTCCTCA 9300
CCTGTAAAAT TGAAAAATAT ATGTATTAAT AATATTATTA ATAATAATAA TGGTAATGTA 9360
GTACTTGTTT GTAAAGCACT TTGAGATCCT TGGTTGAAAG GCACCATAGG AGTGCCAAGGTTG 9420
ATTATTATGT GGCCAAGGGG GTTATTTAAA CTGTCAGTTC CCAAAGGCCA GGAAAGGTTG 9480
GGGTCATTTT TCTTAAAGAC GAGCTGTAAA TATCAACTAG GCAGCCAATA GTGTTGACTA 9540
TGAAGATGCA AAACTATTAC TAGGCTGATA AAATCATAGT TTCTTAATGG CTACCAATAA 9600
GGCAAATATC ACAATAATAA ACGCCAAATT CCTTAGGGCG GACTATTTGA CAACCACATG 9660 -65 70 GAAAACTITIG GGGAGGCAT GAGGGGGGAA CATCTCAAAA TGCCAATGTA AAATTTAACT 9720 TACAGCAATA TTCACCAGCA GAAAATGTCT TTCATATGGA ATGATTTCAT GTTGCTAAGA 9780 AAAAGAATTC AATTTGTAGT CCTGATTTGA ATACTAGAAT GTTGGCTATA ATAGTTCTGT 9840 75 TCTTACAACA CATGAAATTI TITCGTTTTA TTTTATTTTG TTTTCATAGT GCATGTTCAT 9900 TTCTACTCAC AAACATGTTC TTGGTGTATT TCTTATGCAA ACAATCTTCA GGCAGCAAAG 9960 ATGTCTGTTA CATCTAAACT TGAATAATAA AGTTTTACCA CCAGTTACAC A

Seq ID NO: 68 <u>Protein sequence:</u>
Protein Accession #: NP\_054831 5 11 21 31 MPYEVNAGYD FTNMVRKKNP PLRNVASEGE GQILEPIGTE SKVSGKNKEF SADQMSENTD 60 QSQANCQGL SPVSVASKNP QVPSDGGVRL NKSKTDLLVN DNPDPAPLSP ELQDFKCNIC 240
GYGYYGNDPT DLIKHFRKYH LGLHNRTRQD AELDSKILAL HNMVQFSHSK DFQKVNRSVF 300
SGVLQDINSS RPVLLNGTYD VQVTSGGTFI GIGRKTPDCQ GYTKYPRCKF CNFTYMGNSS 360 10 SOVLQDINSS RPVLLNGTYD VQVTSGGTFI GIGRKTPDCQ GNTKYFRCKF CNFTYMGNSS 360
TELEQHFLQT HPNXIKASLP SSEVAKPSEK NSNKSPALQ SSDSGDLGKW QDKITVKAGD 420
DTPVGYSVPI KPLDSSRQNG TEATSYYWCK FCSFSCESS SLKLLEHYGK QHGAVQSGGL 480
NPELNDKLSR GSVINQNDLA KSSEGETMTK TDKSSSGAKK KDFSSKGAED NMVTSYNCQF 540
CDFRYSKSHG PDVIVVGPLL RHYQQLHNIH KCTIKHCPFC PRGLCSPEKH LGEITYPFAC 600
RKSNCSHCAL LLLHLSPGAA GSSRVKHQCH QCSFTTPDVD VLLFHYESVH ESQASDVKQE 660
ANHLQGSDGQ QSVKESKEHS CTKCDFITQV EEEISRHYRR AHSCYKCRQC SFTAADTQSL 720
LEHFNTVHCQ EQDITTANGE EDGHAISTIK EEPKIDFRVY NLLTPDSKMG EPVSESVVKR 780
EKLEEKDGLK EKVWTESSSD DLRNVTWRGA DILRGSSPYT QASLGLLTPV SGTQEOTKTL 840
RDSPNVEAAH LARPIYGLAV ETKGFLQGAP AGGEKSGALP QQYPASGENK SKDESQSLLR 900
RRRGSGVFCA NCLTTKTSLW RKNANGGYVC NACGLYQKLH STPRPLNIIK QNNGEQIBR 960
RTRKRLINFEA LQAEQLNKQQ RGSNEEQVNG SPLERRSEDH LTESHQREIP LPSLSKYFAQ 1020
GSLTKSHSAQ QPVLVSQTLD IHKRMQPLHI QIKSPQESTG DPGNSSSVSE GKGSSERGSP 1080
IEKYMRPAKH PNYSPPGSPI EKYQYPLFGL PFVHNDFQSE ADWLRFWSKY KLSVPGNPHY 1140
LSHVPGLPNP CQNYVPYPTF NLPPHFSAVG SDNDIPLDLA IKHSRPGPTA NGASKEKTKA 1200
PPNYKNEGPL NVVKTEKVDR STQDELSTKC VHCGIVFLDE VMYALHMSCH GDSGPFQCS1 1260 15 20 25 PPNVKNEGPL NVVKTEKVDR STQDELSTKC VHCGIVFLDE VMYALHMSCH GDSGPFQCSI 1260 CQHLCTDKYD FTTHIQRGLH RNNAQVEKNG KPKE 30 Seq ID NO: 69 DNA sequence Nucleic Acid Accession #: XM\_073879 Coding sequence: 1-387(underlined sequences correspond to start and stop codons) 35 ATGOGGTTTG GAGACCAGGG AACGGTGGAA GGGAGCCTAG GAACGTCGAA AAAACCACCT 60 GAAGTGAAAA TGTTTGGAGC CAGTCAAGGT TTGCTGACAA TGGAAACAAA CCAGTCCCTG 120
GCACAAGGCA CAGGCTGCTC AGTAGTAAAG GTAGACACTG TTCTCTTCGA GAGTTTATAC 180
CACTGCGGCT TTGAACACGG GAGCGTGATG CACTGCCTTG GGGATGATCA CCCCCAGGAA 240 40 GACAGGAAGG CTCACTTCTC TGCCCCAGTT GCAGCCATCG CCTCTCCAGC ACCGACTCCT 300 GTCTGTCCTG CACACCACTC AACACAGAGC ATCTGCCAGT TTCTACAGCA CTGCAGGCAG 360 AACACTCACT TGCAGGCTGC TAACTAA Seq ID NO: 70 <u>Protein sequence:</u>
Protein Accession #: XP\_073879 45 21 31 41 MGFGDQGTVE GSLGTSKKPP EVKMFGASQG LLTMETNQSL AQGTGCSVVK VDTVLFESLY 60 HCGFEHGSVM HCLGDDHPQE DRKAHFSAPV AAIASPAPTP VCPAHHSTQS ICQFLQHCRQ 120 50 NTHLOAAN Seq ID NO: 71 DNA sequence Nucleic Acid Accession #: AB033064 55 Coding sequence: 826-1986 (underlined sequences correspond to start and stop codons) 51 21 31 GGGGAACAGC AAATTCAGTC ACAGACAATC CTCCACTCGG TCAAGAGCCA CTTTTCTCTT 60 CCTGCCTTGC CCCCCGCAG GGGGTAAGGA ACTGAGCGTT TAATCTTTAG CCGGTTGGCT 120 ACCAGCTAAA ATTCTACTTA TCTTAGTTTC TAGTGGATAG CTTTCTTATT TTGCCCATGT 180 60 ACCAGCIAMA ATICTACITA TCTTAGTTTC TAGTGGATAG CTTTCTTATT TTGCCCATGT 180
TTTCTTAGAA TCCCTGTTTA ATATACTTTT GTCAGTAGTA GTATCTAGGA GTAGCAGGA 240
GAGTGACAAT AAATTAGCCC CTTCTTTTTT CCCTTGTCAT TCAGGCCCCT TTTCCTCCC 300
AGAGGGAAAT TACCAGTAAA CTCTTCTAAA TCTTCCACCC CTTCTCAGTC ATACTGTGAA 360
GAAACACACT AAAGTGGACA TTATTTGACC AGTGAACACG AACCCAGCTT CAGGCATTGG 420
TTTGTTGTGG CACATGGAGA AACATCTCTT TTAAAATATC TCCCAAATTAC CCTTTTCAAA 480
ATTTGTATCC ACCTAGGATT TGCTGCTGGG GTAAGTCACT AGATTTATTT CTCAAAAGCTC 540
CCCTCTCTAT GAGCTGAAAG ACTGACCAAC CATGAACACT AGTAGGGGAT GGGGAAAGGG 600
GACAGACCAG AGCCAGTTGT TCCACACTTT GGGAACCAGG AGTAGCTTTT ATCATCTTCC 660
TCTGGGGGAGC AGGCATAGAG ACATAAAACTG AGTGAAAAATG GGTGGAAGGAA GAACTTCTCAT 770
TCTGGGGGAGC AGGCATAGAG ACATAAAACTG AGTGAAAAATG GGTGGAAGGAA GAACTTCTAT 770 65 70 TCTGGGGAGC AGGCATAGAG ACATAAACTG AGTGAAAATG GGTGGAGGAA GAACTTCTAT 720 ACCCACGAAC AACATGTGAA GAGAGAGAAC CAAACATAAA GTAAGGAGGG TAGACGTTAC 780 ATCCAAGAGG AAATAATCCA GGCAAGGAAG CACAAGCTGA TCAAGA<u>TG</u>TG TAGTTCTGTG 840
GCTGCCAAGT TGTGGTTTTT GACAGATCGT CGCATCAGGG AAGACTATCC TCAAAAAGAG 900
ATTTTACGAG CATTGAAGGC CAAATGTTGT GAGGAGGAAC TGGACTTTAG GGCTGTGGTG 960 75 ATTGATGAGG TGGTGCTGAC AATCGAGGAA GGAAACCTGG GTGTGCGGAT CAATGGAGAG 1020 CTAATCACTG CCTACCCACA AGTGGTGGTA GTCAGAGTAC CAACCCCTTG GGTGCAAAGT 1080

GATAGTGACA TCACTGTTTT GCGCCATCTA GAGAAGATGG GATGTCGGTT AATGAACCGA 1140

CCTCAAGCCA TCCTGAACTG CGTTAATAAG TTCTGGACAT TTCAAGAGTT GGCTGGCCAT 1200 GGTGTTCCTC TGCCGGATAC TTTCTCTTAT GGTGGCCACG AAAATTTTGC TAAAATGATT 1260
GATGAGGCTG AAGTTCTGGA GTTCCCAATG GTAGTAAAAGA ATACGCGGGG TCACAGAGGT 1320
AAAGCTGTTT TCTTGGCTCG AGATAAGCAC CATTTGGCTG ATCTAAGCAC TCTTATTCGC
CATGAAGCGC CATACCTGTT CCAGAAGTAT GTTAAAGAGT CTCATGGACG GGATGTACGT 1440
GTCATTGTCG TGGGAGGCCG TGTGGTTGGC ACCATGTTAC GTTGTCACA AGATGGGAAA 1500
ATGCAAAGCA ACTGCTCATT AGGTGGTGTG GGGATGATGT GCTCATTGAG TGAACAAGGG 1540 5 AAGCAGCTAG CTATCCAGGT GTCTAATATC CTGGGGATGG ATGTGTGTGG CATTGACCTG 1620
CTGATGAAAG ATGACGGCTC CTTCTGCGTC TGTGAGGCCA ATGCAAATGT AGGTTTCATC 1680
GCCTTTGATA AGGCTTGTAA TCTAGATGTA GCTGGTATCA TAGCAGACTA TGCCGCCTCC 1740 10 CTTCTACCCT CTGGCCGGCT CACCCGGCGT ATGTCCCTGC TCTCCGTGGT GTCCACTGCC 1800 AGTGAGACTA GTGAGCCGGA GCTGGGTCCC CCAGCCAGCA CTGCTGTTGA CAACATGAGT 1860 GCAAGTTCCA GCTCTGTTGA CAGCGACCCT GAAAGCACGG AGCGAGAGCT GCTCACCAAG 1920 CTCCCAGGGG GCCTGTTCAA CATGAACCAG CTGCTAGCCA ATGAAATCAA ACTACTGGTG 1980 GACTGACTCC ACTGGTAATT AACCAACAAA ACCCTTGTAA AACTTTCTTT CTTCTTTTCT 2040 ATTTTTAAAA CCAACTTGCA ATGCTGTTCA TGGAGGATGC TCAGGAAGAT GAGAGAAAAT 2100 15 TAGTAGGATT AGTTGGAGAG AGTGGGAGAT AGATGAGACC TCTGCTAGTA AGATGTTACT 2160 TTCATTTACA AATCCTACAA ATAGAGAGGC AGAATAGGTG GGGTATAGAA AAATGTCAGG 2220 CTCTCATAGT TACCCTTTTA AATTGCTAAA AAATGTGTAT GCTCATAGGC CATGAGGAAC 2280 AAATACTITI TITTITICAT GGTCCCTTGC TITTGTTTTT GTACAAAAAA AAATGGTTTT 2340 GCTACAAATA TCCAAGTAGC ATAACTICAC ATTGTGTTGG AAGATTTGTC ATCAGTGAGG 2400 AAAACATCTG CTTAAATTAC AGGAATTTTT GTATTATACA GCTCTGAAAA TTCTGCCATT 2460 20 GGATITCITA CTAGGAGGCT TAGTITCIAG TITATGAAAT CTTGAGGGGC TCTTTTACTG 2520
GGATITCITA TITTTTGTT TATTCCCGCT TAATTTGGTG GGAGGTCAAA TTGAATATAA 2580
CCCAATAAAG GCTTCITAAT GAGAAAATTG GCATGTTTGC ATGATGAAAT GGAAATGAAC 2640
AGTATTGCAA TGTCCGGTAT ACAAAATAAC ATTAATTCAA TGATGAATAAA 370ACATTGA 2700
TTTAAAATAT GTGCATTCAC TTGTATTTGT TAGTGTTTTA GTCTTTTTTTT AAAGATGTCC 2760
TCTGTTAATG TTGCTTTTTT TTTTTTTTTTTTTTTAACAATGC TAGTCTAACAA TTTCCTGCTC 2820 25 TATGCCTGCA TCTTTAACAA TGGCCAAAGT GAAGAAAATG CTACCTTTTT TGTTAACAAG 2880 ACACTGACTT GAAACATGTA CATITAAAGC CTTTTATTTT TTCCCTTTTT GTTTTGGTAG 2940 30 TTGGGCATTT AAATAAGGAC AAGGAAAAAT ATTTTTGGGG GCAAATCAAG AGCCTATGAG 3000 TTCTAAGTAT AAAGCTGAAG TGATTTCGAA TGCCAGCGTT ATATATTTGC ATTTTTCACA 3060 TTTTACGAGG GAGTATATGT GTATGTGTGT GCACGCATGC ATGTGTATGT GTTTTGCTTT 3120 TTGTTTCCAT CAACTAATCA AAAAGGATAA TTTAGAAAAT GGAGCATGAT GGGAAACAGA 3180 GTTTTTGACT TTAAAAAACA GATGAGTTGT TTTCATAAGT AGACTCCACT GGGGTAGAGG 3240 TATTCACCTT AAAACATAGG GTGAGTAGAT GCTTTTTTAG GCCTTTTTGT GTATATGTAC 3300 35 GTTGTTTGTT TTTTTCCTTT TGTTTCTAGC CTGTTCAGTG TACAGTTTAT TCAAGGCTAC 3360
ATGCTTTTCT TTAATGCTTC TGGCTATGCA TTTTCTCTTT TTACATATAG GATTTGGGAT 3420
TGGGGGTGGG TTGGATGTTT TTGTTTGGGG ACTTATTTAG TAGTATTGAG TCTCTTATAG 3480 CCCTACTCTT AAGCCTTCAA TACTGTCCAC TCTTTATATT CCTTTACTTG CAGAATTTAT 3540

AAAAGCCCC AAACTGCATA TAATATGAGC CTTTAAAACA TAGGGTAAAAC TAATCCCATT 3660

GATGGGTTTG GATGGTATGT TAAGAAATGG AGATGCTGCA GAGCCCACC TAATTTTTTA 3660

AACAGCAAGT TTTCCATCTC CCTACGAATC CTCTGAAGCT TATCCCAAG CCCTTTCTTG 3720

CCTCTCCAGT GCTATTTTCC TTCAGATGGA CCTTAAACAT AATTTCTTGG ACACTACTAG 3780

AGAGACTTCG AGGCAATAAT AAAAGATCAG TATTAACCAG CTATAACAGA GGTTTTGATCA 3840 40 45 TGCTTACTTG TACAGTTTTT CCCCCGTTTT AAAAAGGAAT GTAATAAAAT TTGTTTTTTC 3900 CATAGAATTA AATAATATTA AAATTGAGTG AAAGGTTGAT TGTTGATGAA TAGAATAGTA 3960 CCTCTCATCT GTGCAGTGTC TCATTTCACC TCAGAGAAAA GGATACATAA GAGGAGTTTG 4020 TAATTTATCT TAGGATATTC TAATTGCATT TAAAAGAACT TATCTTGCGC AGGGTAAATG 4080 GGGGACTCAC ATACATATAT TAATACCTCT GACTCATTAA CAGAAAGAAA TACTTGGTAC 4140 50-TTCTTTCGCT GAATGACCAT ACTGTGGAGG ATGCATACTA TTTGGTATAG AGAAATAAAT 4200 GAGGAAGAAA GAACTGCTTA ATTAAATTAT CATTCATATG TTCATATAGA GACCATCTGG 4260 TTGCCATGTG TATTATGACA CATACACTTT GAATAGTTAC ATATCACAAG TATGTAGTTC 4320 TTGCCATGTG TATTATGACA CATACACTIT GAATAGTTAC ATALCACAAG TAGTAGTIC 4320
ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380
ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440
TATTATGCAT TCACATGATA TTAAAACCATA CACTCACATG TTAGAATGAA AACAGCAGTA 4500
GTTATCITAG ATTTTTAAAAA CATGGATATC TTCTTAGAATT CCTTCAAGAT TAGGGTAGAG 4560
AATAAGAGCA AATCATTCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620
TAAACTTATT TTCATAAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680 55 60 65 70 TTTGTTGTAC TAGGATTTTA AAAAATGTAA TATATTGCAG GATTTATAAC CAG

Seq ID NO: 72 Protein sequence; Protein Accession #: BAA86552

75

1 11 21 31 41 51

MCSSVAAKLW FLTDRRIRED YPQKEILRAL KAKCCEEELD FRAVVMDEVV LTIEQGNLGL 60 RINGELITAY PQVVVVRVPT PWVQSDSDIT VLRHLEKMGC RLMNRPQAIL NCVNKFWTFQ 120 ELAGHGVPLP DTFSYGGHEN FAKMIDEAEV LEFPMVVKNT RGHRGKAVFL ARDKHHLADL 180 SHLIRHEAPY LFQKYVKESH GRDVRVIVVG GRVVGTMLRC STDGRMQSNC SLGGVGMMCS 240 LSEQGKQLAI QVSNILGMDV CGIDLLMKDD GSFCVCEANA NVGFIAFDKA CNLDVAGIIA 300 DYAASLLPSG RLTRRMSLLS VVSTASETSE PELGPPASTA VDNMSASSSS VDSDPESTER 360 **ELLTKLPGGL FNMNQLLANE IKLLVD** Seq ID NO: 73 DNA sequence 10 Nucleic Acid Accession #: XM\_040080.2 Coding sequence: 159-1104 (underlined sequences correspond to start and stop codons)

41 15 CTGAGTGGGG GCGGGGACTG CTGGAGTTGC GGGGCCTGCC TGGGGTAGGG CGGGGCAGGA 60 CAGCTTGGAG ATAGGGCCCG GAATTGCGGG CGTCACTCTG CTCCTGCGAC CTAGCCAGGC 120
GTGAGGGAGT GACAGCAGC CATTCGCGGG ACGAGCAGA TGAGTGAGAA CGCCGCACCA 180
GGTCTGATCT CAGAGCTGAA GCTGGCTGTG CCCTGGGGCC ACATCGCAGC CAAAGCCTTGG 240
GGCTCCCTGC AGGGCCTCC AGTTCTCTGC CTGCACGGCT GGCTGGACAA TGCCAGGCTC 300
TTCGACAGAC TCATCCCTCT TCTCCCGCAA GACTTTTATT ACGTTGCCAT GGATTTCGGA 360 20 GGTCATGGGC TCTCGTCCCA TACAGCCCA GGTGTCCCAT ATTACCTCCA GACTITTIGTG 420
AGTGAGATCC GAAGAGTTGT GGCAGCCTTG AAATGGAATC GATTCTCCAT TCTGGGCCAC 480
AGCTTCGGTG GCGTCGTGGG CGGAATGTTT TTCTGTACCT TCCCCGAGAT GGTGGATAAA 540 CTTATCTTGC TGGACACGCC GCTCTTTCTC CTGGAATCAG ATGAAATGGA GAACTTGCTG 600 ACCTACAAGC GGAGAGCCAT AGAGCACGTG CTGCAGGTAG AGGCCTCCCA GGAGCCCTCG 660 25 CACGTGTTCA GCCTGAAGCA GCTGCTGCAG AGGTTACTGA GAGCCATACA GCACTTGAGT 720

GAGGAGTGCG GGGAGCTTCT CCTGCAAAGA GGGACCACGA AGGTGGCCAC AGGTCTGGTT 780

CTGAACAGAG ACCAGAGGGCT CGCCTGGGCA GAGAACAGCA TTGACTTCAT CAGCAGGGAG 840

CTGTGTGCGC ATTCCATCAC GAAGCTGCAG GCCCATGTCC TGTTGATCAA AGCAGTCCAC 900

GGATATTTTG ATTCAAGACA GAATTACTCT GAGAAGGAGT CCCTGTCGTT CATGATAGAC 960

ACGATGAAAT CCACCCTCAA AGAGCAGTTC CAGTTTGTGG AAGTCCCAGG CAATTACACTGT 1020 30 ACCATGA GGGAACCCCA GCACGTGGCC AGTATTCAGG AGTCCLAGG CATCACTG 1080
CACATGA GGGAACCCCA GCACGTGGCC AGTATTCATCA GCTCCTCTTT ACAGTGCACA 1080
CACATGCTCC CAGCCCAGCT GTAGCTCTGGG CCCTGGAACT ATGAAGACCT AGTGCTCCCA 1140
GACTCAACAC TGGGACTCTG AGTTCCTGAG CCCCACAACA AGGCCAGGGA TGGTGGGGAC 1200
AGGCCTCACACT AGTCTTGAGG CCCAGCCTAG GATGGTAGTC AGGGGAAGGA GCGAGATTCC 1260
AACTTCAACA TCTGTGACCT CAAGGGGGAG ACAGAGTCTG GGTTCCAGGG CTGCTTTCTC 1320 35 CTGGCTAATA ATAAATATCC AGCCAGCTGG AGGAAGGAAG GGCAGGCTGG GCCCACCTAG 1380

40 Seq ID NO: 74 Protein sequence:
Protein Accession #: XP\_040080.1

55

60

65

70

75

21 31 41 51

45 MSENAAPGLI SELKLAYPWG HIAAKAWGSL QGPPVLCLHG WLDNASSFDR LIPLLPQDFY 60 YVAMDFGGHG LSSHYSPGVP YYLQTFVSEI RRVVAALKWN RFSILGHSFG GVVGGMFFCT 120 FPEMVDKLIL LDTPLFILES DEMENLLTYK RRAIEHVLQV EASQEPSHVF SLKQLLQRLL 180 KSNSHLSEEC GELLLQRGTT KVATGLVLNR DQRLAWAENS IDFISRELCA HSIRKLQAHV 240 LLIKAVHGYF DSRQNYSEKE SLSFMIDTMK STLKEQFQFV EVPGNHCVHM SEPQHVASII 300 50 SSFLQCTHML PAQL

CCTTTCCCTG CTGCCCAACT GGATGGAAAA TAAAAGGTTC TTGTATTCTC A

Seq ID NO: 75 DNA sequence Nucleic Acid Accession #: NM 005794 Coding sequence: 434-1276 (underlined sequences correspond to start and stop codons)

GGTTCCCTTC CACGCTGTGA AGCTTTGTTC TTTTGGTCTT CATGATAAAT CTTGCTGCTG 60 CTCACTCGTT GGGTCCGTGC CACCTTTAAG AGCTGTAACA CTCACCGCGA AGGTCTGCAA 120 CTTCACTCCT GGGGCCAGCA AGACCACGAA TGCACCGAGA GGAATGAACA ACTCTGGACA 180 CACCATCTTT AAGAACCGTA ATACTCACCG CAAGGGTCTG CAACTTCATT CTTGAAGTCA 240
GTGAGGCCAA GAACCCATCA ATTCCGTACA CATTTTGGTG ACTTTGAAGA GACTGTCACC 300
TATCACCAAG TGGTGAGACT ATTGCCAAGC AGTGAGACTA TTGCCAAGTG GTGAGACCAT 360 CACCAAGCGG TGAGACTATC ACCTATCGCC AAGTGGCCTG ATTCAGCAGG AAGCATCTCA 420
GACACCAACC ACT<u>ATG</u>CTGT CAGCAGTTGC CCGGGGCTAC CAGGGCTGGT TTCATCCCTG 480
TGCTAGGCTT TCTGTGAGGA TGAGCAGCAC CGGGATAGAC AGGAAGGGCG TCCTGGCTAA 540 TGCTAGGCTT TCTGTGAGGA TGAGCAGCAC CGGGATAGAC AGGAAGGGCG TCCTGGCTAA 540
CCGGGTAGCC GTGGTCACGG GGTCCACCAG TGGGATCGGC TTTGCCATCG CCCGACCGTCT 600
GGCCCGGGAC GGGGCCCACG TGGTCACACA TGGGATCGGC TTTGCCATCG CCGACCGGGG 660
CATGGCCAG CTGCAGGGGG AGGGGCTGAG TGTGGCGGAG CACTGTGGGC ACCTGGGGAA 720
GGCTGAGGAC CGGAGCAAC TGGTGGCCAA GGCCCTGGAG CACTGTGGGG CGCTCCACTT 780
CCTGGTGTGC AGGCCAGGGG TCAACCCTCT GGTAGGGAC ACTCTGGGGA CCAGTGAGCA 840
GATCTGGGAC AAGATCCTAA GTGTGAACGT GAAGTCCCCA GCCCTGCTGC TGAGCCAGTT 900
GCTGCCCTAC ATGGAGAACA GGAGGGGTGC TGTCATCCTG GTCTCTTCCA TTGCAGCTTA 960
TAATCCAGTA GTGGCCTGG GTGTCTACAA TGTCAGCAAG ACAGCGCTGC TGGGTCTCAC 1020
TAGAACACTG GCATTGGAGC TGGCCCCCCAA GGACATCCGG GTAAACTCGC TGGTTCCACG 1080
AATTATAAAA ACTGACTTCA GCAAAAGTGTT TCATGGGAAT GAGTCTCCT GGAAGAACTT 1140
CAAGGAACAT CATCAGCTGC AGAGGATTGG GGAGTCAGAG GAATCGTGTC 1200

5	CTCCACTOGG CTCTGAGAGG AGTGGGGGGG GCTGCGTAGC TGGTGGCCAG GCCCAGGAGC 1320 CTGAGGGGGT GTCTAGGTGA TCATTTGGAT CTGGAGCAGA GTCTGCCATT CTGCCAGAGC 1380 AGCAATTTGG GGGCTTACTC ATGCTAGGCT TGAGGAAGAA GAAAAACGCT TCGCCATTCT 1440 CC
	Seq ID NO: 76 Protein sequence: Protein Accession #: NP_005785
10	I II 21 31 41 51 
15	AHVVISSRKQ QNVDRAMAKL QGEGLSVAGI VCHVGKAEDR EQLVAKALEH CGGVDFLVCS 120 AGVNPLVGST LGTSEQIWDK ILSVNVKSPA LLLSQLLPYM ENRRGAVILV SSIAAYNPVV 180 ALGVYNVSKT ALLGLTRLA LELAPKDIRV NCVVPGIIKT DFSKVFHGNE SLWKNFKEHH 240 QLQRIGESED CAGIVSFLCS PDASYVNGEN IAVAGYSTRL
20	Seq ID NO: 77 DNA sequence Nucleic Acid Accession #: NM_002425 Coding sequence: 26-1453 (underlined sequences correspond to start and stop codons)
	1 11 21 31 41 51
25	AAAGAAGGTA AGGGCAGTGA GAATGATGCA TCTTGCATTC CTTGTGCTGT TGTGTCTGCC 60 AGTCTGCTCT GCCTATCCTC TGAGTGGGGC AGCAAAAGAG GAGGACTCCA ACAAGGATCT 120 TGCCCAGCAA TACCTAGAAA AGTACTACAA CCTCGAAAAG GATGTGAAAC AGTTTAGAAG 180 AAAGGACAGT AATCTCATTG TTAAAAAAAT CCAAAGGAATG CAGAAGTCC TTGGGTTGGA 240 GGTGACAGGG AAGCTCA GGTGTAGACA CTGACACTCT GGAGGTGATG CGCAAGCCCA GGTGTGGAGT 300
30	TCCTGACGTT GGTCACTTCA GCTCCTTTCC TGGCATGCCG AAGTGGAGGA AAACCCACCT 360 TACATACAGG ATTGTGAATT ATACACCAGA TTTGCCAAGA GATGCTGTTG ATTCTGCCAT 420 TGAGAAAGCT CTGAAAGTCT GGGAAGAGGT GACTCCACTC ACATTCTCCA GGCTGATATGA 480 AGGAGAGGCT GATATAATGA TCTCTTTCGC AGTTAAAAGAA CATGGAGACT TTTACTCTTT 540 TGATGGCCCA GGACACAGTT TGGCTCATGC CTACCCACCT GGACCTGGGC TTTATGGAGA 600
35	TATICACTIT GATGATGATG AAAAATGGAC AGAAGATGCA TCAGGCACCA ATTTATTCCT 660 CGTTGCTGCT CATGAACTTG GCCACTCCCT GGGGCTCTTT CACTCAGGCA ACACTGAAGC 720 TTTGATGTAC CCACTCTACA ACTCATTCAC AGAGCTCGCC CAGTTCCGCC TTTCGCAAGA 780 TGATGTGAAT GGCATTCAGT CTCTCTACGG ACCTCCCCCT GCCTCTACTG AGGAACCCCT 840
40	GGTGCCCACA AAATCTGTTC CTTCGGGATC TGAGATGCCA GCCAAGTGTG ATCCTGCTTT 900 GTCCTTCGAT GCCATCAGCA CTCTGAGGGG AGAATATCTG TTCTTTAAAG ACAGATATTT 960 TTGGCGAAGA TCCCACTGGA ACCCTGAACC TGAATTTCAT TTGATTTCTG CATTTTGGCC 1020 CTCTCTTCCA TCATATTTGG ATGCTGCATA TGAAGTTAAC AGCAGGGACA CCGTTTTTAT 1080 TTTTAAAGGA AATGAGTTCT GGGCCATCAG AGGAAATGAG GTACAAGCAG GTTATCCAAG 1140 AGGCATCCAT ACCCTGGGTT TTCCTCCAAC CATAAGGAAA ATTGATGCAG CTGTTTCTGA 1200
45	CAAGGAAAAG AAGAAAACAT ACTICTITIGC AGCGGACAAA TACTIGAGAT TITGATGAAAA 1260 TAGCCAGTCC ATIGAAGGCAAG GCTTCCCTAG ACTAATAGCT GATGACTTTC CAGGAGTTGA 1320 GCCTAAGGTT GATGCTGTAT TACAGGCATT TGGATTITTC TACTTCTTCA GTGGATCATC 1380 ACAGTTTGAG TTTGACCCCA ATGCCAGGAT GGTGACACAC ATATTAAAGA GTAACAGCTG 1440
50	OTTACATTGC TAGGCGAGAT AGGGGGAAGA CAGATATGGG TGTTTTTAAT AAATCTAATA 1500 ATTATTCATC TAATGTATTA TGAGGCCAAAA TGGTTAATTT TTCCTGCATG TTCTGTGAGACT 1560 GAAGAAGATG AGCCTTGCAG ATATCTGCAT GTGTCATGAA GAATGTTCT GGAATTCTTC 1620 ACTTGCTTTT GAATTGCACT GAACAGAATT AAGAAATACT CATGTGCAAT AGGTGAGAGA 1680 ATGTATTTTC ATAGATGTGT TATTACTTCC TCAATAAAAA GTTTTATTTT GGGCCTGTTC 1740
55	Seq ID NO: 78 Protein sequence: Protein Accession #: NP_002416
60	I 11 21 31 41 51
65	HAYPPGPGLY GDIHFDDDEK WTEDASGTNL FLVAAHELGH SLGLFHSANT EALMYPLYNS 240 FFELAQFRLS QDDVNGIQSL YGPPPASTEE PLVPTKSVPS GSEMPAKCDP ALSFDAISTL 300 RGEYLFFKDR YFWRRSHWNP EPEFHLISAF WPSLPSYLDA AYEVNSRDTV FIFKDEFWA 360 IRGNEVQAGY PRGIHTLGFP PTIRKIDAAV SDKEKKKTYF FAADXYWRFD ENSQSMEQGF 420 PRLIADDFPG VEPKVDAVLQ AFGFFYFFSG SSQFEFDPNA RMVTHILKSN SWLHC
70	Seq ID NO: 79 DNA sequence Nucleic Acid Accession #: NM_000493.1 Coding sequence: 1-2043 (underlined sequences correspond to start and stop codons)
75	1 11 21 31 41 51 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

CAGTTCTTCA TTCCCTACAC CATAAAGAGT AAAGGTATAG CAGTAAGAGG AGAGCAAGGT 180 ACTCCTGGTC CACCAGGCCC TGCTGGACCT CGAGGGCACC CAGGTCCTTC TGGACCACCA 240
GGAAAACCAG GCTACGGAAG TCCTGGACTC CAAGGAGAGC CAGGGTTGCC AGGACCACCG 300 GGACCATCAG CTGTAGGGAA ACCAGGTGTG CCAGGACTCC CAGGAAAACC AGGAGAGAGA 360
GGACCATATG GACCAAAAGG AGATGTTGGA CCAGCTGGCC TACCAGGACC CCGGGGCCCA 420
CCAGGACCAC CTGGAATCCC TGGACCGGCT GGAATTTCTG TGCCAGGAAA ACCTGGACAA 480 5 CAGGGACCCA CAGGAGCCCC AGGACCCAGG GGCTTTCCTG GAGAAAAGGG TGCACCAGGA 540 GTCCCTGGTA TGAATGGACA GAAAGGGGAA ATGGGATATG GTGCTCCTGG TCGTCCAGGT 600 GAGAGGGGTC TTCCAGGCCC TCAGGGTCCC ACAGGACCAT CTGGCCCTCC TGGAGTGGGA 660 GAGAGGGGTC TTCCAGGCCC TCAGGGTCCC ACAGGACCAT CTGGCCCTCC TGGAGTGGGA 660

AAAAGAGGTG AAAATGGGGT TCCAGGACAG CCAGGCATCA AAGGTGATAG AGGTTTTCCG 720

GGAGAAATGG GACCAATTGG CCCACCAGGT CCCCAAGGCC CTCCTGGGGA ACGAGGGCCA 780

GAAGGCATTG GAAAGCCAGG AGCTGCTGGA GCCCCAGGCC AGCCAGGGAT TCCAGGAACA 840

AAAGGTCTCC CTGGGGCTCC AGGAATAGCT GGGCCCCCAG GGCCTCCTGG CTTTGGGAAA 900

CCCAGGCTTGC CAGGCCTGAA GGGAGAAGA GGACCTGCTG GCCTTCCTGG GGGTCCAGGT 960

GCCAAAGGGG AACAAGGGCC AGCAGGTCTT CCTGGGAAGC CAGGTCTGAC TGGACCCCCT 1020

GGGAATATGG GACCCCAAGG ACCAAAAGGC ATCCCGGGTA GCCATGGTCT CCCAGGCCCT 1080

AAAGGTGAGA CAGGGCCAGC TGGGCCTGCA GGATACCCTG GGGCTAAAGGG TGAAAGGGGT 1140 10 15 TCCCCTGGGT CAGATGGAAA ACCAGGGTAC CCAGGAAAAC CAGGTCTCGA TGGTCCTAAG 1200 GGTAACCCAG GGTTACCAGG TCCAAAAGGT GATCCTGGAG TTGGAGGACC TCCTGGTCTC 1260 CCAGGCCCTG TGGGCCCAGC AGGAGCAAAG GGAATGCCCG GACACAATGG AGAGGCTGGC 1320 20 CCAAGAGGTG CCCCTGGAAT ACCAGGTACT AGAGGCCCTA TTGGGCCACC AGGCATTCCA 1380
GGATTCCCTG GGTCTAAAGG GGATCCAGGA AGTCCCGGTC CTCCTGGCCC AGCTGGCATA 1440
GCAACTAAGG GCCTCAATGG ACCCACCGGG CCACCAGGGC CTCCAGGTCC AAGAGGCCCC 1500 TCTGGAGAGC CTGGTCTTCC AGGGCCCCCT GGGCCTCCAG GCCCACCAGG TCAAGCAGTC 1560 ATGCCTGAGG GTTTTATAAA GGCAGGCCAA AGGCCCAGTC TTTCTGGGAC CCCTCTTGTT 1620 AGTGCCAACC AGGGGGTAAC AGGAATGCCT GTGTCTGCTT TTACTGTTAT TCTCTCCAAA 1680 25 GCTTACCCAG CAATAGGAAC TCCCATACCA TTTGATAAAA TTTTGTATAA CAGGCAACAG 1740 CATTATGACC CAAGGACTGG AATCTTTACT TGTCAGATAC CAGGAATATA CTATTTTTCA 1800 TACCACGTGC ATGTGAAAGG GACTCATGTT TGGGTAGGCC TGTATAAGAA TGGCACCCCT 1860
GTAATGTACA CCTATGATGA ATACACCAAA GGCTACCTGG ATCAGGCTTC AGGGAGTGCC 1920
ATCATCGATC TCACAGAAAA TGACCAGGTG TGGCTCCAGC TTCCCAATGC CGAGTCAAAT 1980 30 GGCCTATACT CCTCTGAGTA TGTCCACTCC TCTTTCAG GATTCCAGT GGCTCCAATG 2040

IGAGTACACC CCACAGAGCT AATCTAAATC TTGTGCTAGA AAAAGCATTC TCTAACTCTA 2100

CCCCACCCTA CAAAATGCAT ATGGAGGTAG GCTGAAAAGA ATGTAATTTT TATTTTCTGA 2160

AATACAGATT TGGCTATCA GACCAACAAA CCTTCCCCT GAAAAGTGAG CAGCAACGTA 2220

AAAACGTATG TGAAGCCTCT CTTGAATTTC TAGTTAGCAA TCTTAAGGCT CTTTAAGGTT 2280 35 TTCTCCAATA TTAAAAAATA TCACCAAAGA AGTCCTGCTA TGTTAAAAAC AAACAACAAA 2340 AAACAAAGCA ACAAAAAAAA AAATTAAAAA AAAAAAACAGA AATAGAGCTC TAAGTTATGT 2400 GAAATTTGAT ITGAGAAACT CGGCATTTCC TTTTTAAAAA AGCCTGTTTC TAACTATGAA 2460 40 TATGAGAACT TCTAGGAAAC ATCCAGGAGG TATCATATAA CTTTGTAGAA CTTAAATACT 2520 TGAATATTCA AATTTAAAAG ACACTGTATC CCCTAAAATA TTTCTGATGG TGCACTACTC 2580 TGAGGCCTGT ATGGCCCCTT TCATCAATAT CTATTCAAAT ATACAGGTGC ATATATACTT 2640 GTTAAAGCTC TTATATAAAA AAGCCCCAAA ATATTGAAGT TCATCTGAAA TGCAAGGTGC 2700 TTTCATCAAT GAACCTTTTC AAAACTTTTC TATGATTGCA GAGAAGCTTT TTATATACCC 2760 45 AGCATAACTT GGAAACAGGT ATCTGACCTA TTCTTATTTA GTTAACACAA GTGTGATTAA 2820 TTTGATTTCT TTAATTCCTT ATTGAATCTT ATGTGATATG ATTTTCTGGA TTTACAGAAC 2880 ATTAGCACAT GTACCTTGTG CCTCCCATTC AAGTGAAGTT ATAATTTACA CTGAGGGTTT 2940 CAAAATTCGA CTAGAAGTGG AGATATATTA TITATTTATG CACTGTACTG TATTITTATA 3000 TTGCTGTTTA AAACTTTTAA GCTGTGCCTC ACTTATTAAA GCACAAAATG TTTTACCTAC 3060 TCCTTATTTA CGACACAATA AAATAACATC AATAGATTTT TAGGCTGAAT TAATTTGAAA 3120 50 **CATCAATAGA TITTTAGG** 

Seq ID NO: 80 <u>Protein sequence:</u>
Protein Accession #: NP\_000484.1

1 11 21 31 41 51

Seq ID NO: 81 DNA sequence

Nucleic Acid Accession #: NM\_000786

75 Coding sequence: 332-1861 (underlined sequences correspond to start and stop codons)

CGCGATTCTC AGGGATTGAT CCGCCTCTTC AGGTAAGTTA TCTTCCGGCC CCGTACCACT 60 GTGCCACAGG CGCAGCCCGC TTCCTCAGGT GCCCTATCCC GCGCAGAAGA CCACGGCTTC 120
ACAGAGTGTT ATTTAAGGGC GTGGCCAGCG GAACATCCCG CCCCATTCTG TGACGCACGG 180 GGTGGGCGCG GTGGGACCCG AGGGGTGGGG CTGGGTTTAG TAGGAGACCT GGGGCAAGGC 240
CCCCTGTGGA CGACCATCTG CCAGCTTCTC TCGTTCCGTC GATTGGGAGG AGCGGTGGCG 300
ACCTCGGCCT TCAGTGTTTC CGACGGAGTG AATGGCGGC GCGGCTGGGA TGCTGCTGCT 360
GGGCTTGCTG CAGGCGGGTG GGTCGGTGGC GGGCCAGGCG ATGGAGAAGG TGACAGGCGG 420
CAACCTCTTG TCCATGCTGC TGATCGCCTG CGCCTTCACC CTCAGCCTGG TCTACCTGAT 480
CCGTCTGGCC GCCGGCCACC TGGTCCAGCT GCCCCCAGGGG GTGAAAAGTC CTCCATACAT 540 10 TTTCTCCCCA ATTCCATTCC TTGGGCATGC CATAGCATTT GGGAAAAGTC CAATTGAATT 600
TCTAGAAAAT GCATATGAGA AGTATGGACC TGTATTTAGT TTTACCATGG TAGGCAAGAC 660
ATTTACTTAC CTTCTGGGGA GTGATGCTGC TGCACTGCTT TTTAATAGTA AAAATGAAGA 720 15 20 GCTGCCTTTG CCTAGTTTCA GACGCAGGGA CAGAGCTCAT CGGGAAATCA AGGATATTTT 1140 CTATAAGGCA ATCCAGAAAC GCAGACAGTC TCAAGAAAAA ATTGATGACA TTCTCCAAAC 1200 TTTACTAGAT GCTACATACA AGGATGGGCG TCCTTTGACT GATGATGAAG TAGCAGGGAT 1260 GCTTATTGGA TTACTCTTGG CAGGGCAGCA TACATCCTCA ACTACTAGTG CTTGGATGGG 1320 CTTCTTTTTG GCCAGAGACA AAACACTTCA AAAAAAATGT TATTTAGAAC AGAAAACAGT 1380 CTGTGGAGAG AATCTGCCTC CTTTAACTTA TGACCAGCTC AAGGATCTAA ATTTACTTGA 1440 25 TCGCTGTATA AAAGAAACAT TAAGACTTAG ACCTCCTATA ATGATCATGA TGAGAATGGC 1500 CAGAACTCCT CAGACTGTGG CAGGGTATAC CATTCCTCCA GGACATCAGG TGTGTGTTTC 1560 TOCCACTGTC AGACTGTIG CAGGGTATAC CATTCTICCA GGACATCAGG IGIGIGATIC 1800
TCCCACTGTC AATCAAAGAC TTAAAGACTC ATGGGTAGAA CGCCTGGACT TTAATCCTGA 1620
TCGCTACTTA CAGGATAACC CAGCATCAGG GGAAAAGTTT GCCTATGTIG CATTTTGGAGC 1680
TGGGCGTCAT CGTTGTATTG GGGAAAAATTT TGCCTATGTT CAAATTAAGA CAATTTGGTC 1740
CACTATGCTT CGTTTATATG AATTTGATCT CATTGATGGA ACTTTCCCA CTGTGAATTA 1800 30 TACAACTATG ATTCACACCC CTGAGAACCC AGTTATCCGT TACAAACGAA GATCAAAA<u>TG</u> 1860 AAAAAGGTTG CAAGGAACGA ATATATGTGA TTATCACTGT AAGCCACAAA GGCATTCGAA 1920 GAGAATGAAG TGTACAAAAC AACTCTTGTA GTTTACTGTT TTTTTAAGTG TGTAATTCTA 1980 35 AAAGCCAGTT TATGATTTAG GATTTTGTTA ACTGAATGGT TCTATCAAAT ATAATAGCAT 2040 TTGACACATT TTCTAATAGT TATGATACTT ATACATGTGC TTTCAGGAAG TTCCTTGGTG 2100 AAACAATTGT TGAGGGGGGA TCTAGGTAAT TGGCAGATTC TAAATAATA AATTTCCAGA 2160 TAGTAATTTT AAGAGTACTC ATCGCTCTTG CCAAATAAGT TCAGGGTATT CAAATCTTGG 2220 ACTAGTCCTG CAAGGTATAA AGAATAAAAA TCCCAGTGAG ATACTTGGAA ACCACAGTTT 2280 ACTACTAME CAAGGITAA AGATAAAA ITACATGIGA ATACTITUGAA ACACAGTIT 2240
ACATCTAMAG CCTTGAATAA GAGAATACTA ATTGTTTTGG TATGATGATA CTCAGAAATG 2400
GAGATATTAT AGGAAAAAGA AATCCTTTGG AATTTTAACT AAAATCACTG CATATGGGAA 2460
ATTAAGGGAT CCAGGACCAT ATTTGGTAAA GAGTTCCTAAA AATAATGTAA TATTAATAATGC 2520
TAAAGACTGC TCATGTATCT TGATCTAATT ACTAAAAAAA TTACATATTT ATTTACCTGA 2580
TAAATATGTA TCTAGTTCTA CAAGGTCACA TTTATGTGGA AGTCCAAAGT CAAGTCCCTTA 2640 40 45 GGGGATAATT TTGTTTTGGG CTCAGTTGTT CCCTGCTTCC TTTTTTTTT TTTTTTTT 2700 TTGAGATGGA GTCTCGCTCT GTTGCCCAGG CTGGAGTGCA GTGGTGCGAT CTCAGCTCAC 2760 TGCATCCTCT GCCTCCCGGG TTCAAGCAAT TCTCTGCCTC AGCCTCCCAA GTAGTTGGGA 2820 TGCATCCTCT GCCTCCCGGG TTCAAGCAAT TCTCTGCCTC AGCCTCCCAA GTAGTTGGGA 2820
TTACAGGCAC CTGCCACCAT GCCTGGCTAA TTTTTTGTAT TTTTAGTAGA GACGGGGGTT 2880
TCACTATGTT GGCTAGGCTG GTCTTGAACT CCTGAGCCTC GTGAGTCCAC CCGCCTTGGC 2940
CTCCCAAAGT GCTGGGATTA CAGGCATGAG CCACCGCACC TGGCCTTCCC TGCTTCCTCT 3000
CTAGAATCCA ATTAGGGATG TTTGTTACTA CTCATATTGA TTAAAAACAGT TAACAAACTT 3060
CTTGGGAGTA ATAAAATTGGAG ATCAGTGAAC TCTGGTTTTA AGATAATCTG AAACAAGGTC 3120
CTTGGGAGTA ATAAAATTGG TCACATTCTG TAAAGCACAT TCTGTTTAGG AATCAACTTA 3180
TCTCAAATTG TAACTCGGGG CCTAACTATA TGAGATGGCT GAAAAAATAC CACATCGTCT 3240
GTTTTCACTA GGTGATGCCA AAATATTTTG CTTTATGTAT ATTACAGTT TTTTTAAAAC 3300
ACTGGAAGAC TCATGTTAAA CTCTAATTGT GAAAGCAGAA TCTCTGCTAA 50 55 ACTGGAAGAC TCATGTTAAA CTCTAATTGT GAAGGCAGAA TCTCTGCTAA TTTTTCAGAT 3360 TAAAATTCTC TTTGAAAAAA T Seq ID NO: 82 <u>Protein sequence:</u>
NP\_000777 60 41 MAAAAGMLLL GLLQAGGSVL GQAMEKVTGG NLLSMLLIAC AFTLSLVYLI RLAAGHLVQL 60

75 Seq ID NO: 83 DNA sequence Nucleic Acid Accession #: NM\_006551.2 Coding sequence: 64-336 (underlined sequences correspond to start and stop codons)

	1 11 21 31 41 51
5	AATICTAGAA GTCAAATCA CTCATTGTTT GTGAAAGCTG AGCTCACAGC AAAACAAGCC 60 ACCATGAAGC TGTCGGTGTG TCTCCTGCTG GTCACGCTGG CCCTCTGCTG CTACCAGGCC 120 AATGCCGAGT TCTGCCCAGC TCTTGTTTCT GAGCTGTTAG ACTTCTTCTT CATTAGTGAA 180 CCTCTGTTCA AGTTAAGTCT TGCCAAATTT GATGCCCCTC CGGAAGCTGT TGCAGCCAAG 240 TTAGGAGTGA AGAGATGCAC GGATCAGATG TCCCTTCAGA AACGAAGCCT CATTGCGGAA 300
10	GTCCTGGTGA AAATATTGAA GAAATGTAGT GTG <u>TGA</u> CATG TAAAAACTTT CATCCTGGTT 360 TCCACTGTCT TTCAATGACA CCCTGATCTT CACTGCAGAA TGTAAAGGTT TCAACGTCTT 420 GCTTTAATAA ATCACTTGCT CTAC
15	Seq ID NO: 84 Protein sequence:   Protein Accession #: NP_006542.1
20	GVKRCTDQMS LQKRSLIAEV LVKILKKCSV  Seq ID NO: 85 DNA sequence Nucleic Acid Accession #: NM_002317.1  Coding sequence: 231-1484 (underlined sequences correspond to start and stop codons)
25	1 11 21 31 41 51   GGCCAGGAC TGAGAAAGGG GAAAGGGAAG GGTGCCACGT CCGAGCAGC GCCTTGACTG 60 GGGAAGGGT TGAATCCCAC CCTTGGCATT GCTTGGTGGA GACTGAGATA CCCGTGCTCC 120 GCTCGCCTCC TTGGTTGAA ATTTCTCCTT CCCTCACGTG ATTTGAGCCC CCTTTTATT 180
30	TTCTGTGAGC CACGTCCTCC TCGAGCGGGG TCAATCTGGC AAAAGGAGTG ATGCGCTTCG 240 CCTGGACCGT GCTCCTGCTC GGGCCCTTTGC AGCTCTGGC GCTAGTGCAC TGCGCCCCTC 300 CCGCCGCCGG CCAACAGCAG CCCCCGCGC AGCCCCCGGC GGCTCCCGGGC GCTCCTGGCGCC 360 ACGCAGATCCA ATGGGAGAAC AACGGGCAGG TGTTCAGCTT GCTGAGCCTG GGCTCACAGT 420 ACCAGCCTCA GCGCCGCCGCGG GACCCCGGGC CCCCGTCCC TGGTGCAGCC AACGCCTCCG 480
35	CCCAGCAGCC CCGCACTCCG ATCCTGCTGA TCCGCGACAA CCGCACCGCC GCGGGGCGAA 540 CGCGGACGGC CGGCTCACT GGAGTCACCG CTGGCCGCC CAGGCCCACC GCCCGTCACT 600 GGTTCCAAGC TGGCTACTCG ACATCTAGAG CCCGCGAGA 6ACAGACAGC GCCGGGAGA 6ACAGACAGC GCCGGGAGA GACAGCAGACAGC GCCGGGAGA GACAGCAGACAGC GCCGCGAGA GACAGCAGACAGC GCCGAGAA GTTCCTGCTC TCAGTAACCT GCGGCCGCC AGCCGCTGG 720 ACGGCATGGT GGGGAACACCTTACAACC CCTACAAGTA CTCTGACGAC AACCCTTATT 780
40	ACAACTACTA CGATACTTAT GAAAGGCCCA GACCTGGGGG CAGGTACCGG CCCGGATACG 840 GCACTGGCTA CTTCCAGTAC GGTCTCCCAG ACCTGGTGGC CGACCCCTAC TACATCCAGG 900 CGTCCACGTA CGTGCAGAAG ATGTCCATGT ACAACCTGAG ATGCCGGCG GAGGAAAACT 960 GTCTGGCCAG TACAGCATAC AGGGCAGATG TCAGAGATTA TGATCACAGG GTGCTGCTCA 1020 GATTTCCCCA AAGAGTGAAA AACCAAGGGA CATCAGATTT CTTACCCAGC CGACCAAGAT 1080
45	ATTCCTGGGA ATGGCACAGT TGTCATCAAC ATTACCACAG TATGGATGAG TTTAGCCACT 1140 TGTACCTGCT TGATGCCAAC ACCCAGAGGA GATGGGCTGA AGGCCACAAA GCAAGTTTCT 1200 GTCTTGAAGA CACATCCTGT GACTATGGCT ACCACAGGCG ATTTGCATGT ACTGCACACA 1260 CACAGGGATT GAGTCCTGGC TGTTATGATA CCTATGGTGC AGACATAGAC TGCCAGTGGA 1320 TTGATATTAC AGATGTAAAA CCTGGAAACT ATATCCTAAA GGTCAGTGTA AACCCCAGCT 1380
50	ACCTGGTTCC TGAATCTGAC TATACCAACA ATGTTGTGCG CTGTGACATT CGCTACACAG 1440 GACATCATGC GTATGCCTCA GGCTGCACAA TTTCACCGTA T <u>TAG</u> AAGGCA AAGCAAAACT 1500 CCCAATGGAT AAATCAGTGC CTGGTGTTCT GAAGTGGGAA AAAATAGACT AACTTCAGTA 1560 GGATTTATGT ATTTTGAAAA AGAGAACAGA AAACAACAAA AGAATTTTTG TTTGGACTGT 1620
55	TITICAATAAC AAAGCACATA ACTGGATTIT GAACGCTIAA GTCATCATTA CTTGGGAAAT 1680 TITITAATGTT TATTATTIAC ATCACTITGT GAATTAACAC AGTGTTTCAA TICTGTAATT 1740 ACATATTITGA CTCTTTCAAA AAAAAAAAAAAAAAAAAAAAAAAAA
60	Seq ID NO: 86   Protein sequence:   Protein Accession #: NP_002308.1   11   21   31   41   51   1   1   1   1   1   1   1   1
65 70	MRFAWTVLLL GPLQLCALVH CAPPAAGQQQ PPREPPAAFG AWRQQIQWEN NGQVFSLLSL 60 GSQYQPQRRR DPGAAVPGAA NASAQQPRTP ILLIRDNRTA AGRIRTAGSS GVTAGRPRPT 120 ARHWFQAGYS TSRAREAGPS RAENQTAPGE VPALSNLRPP SRVDGMVGDD PYNPYKYSDD 180 NPYYNYYDTY ERPRPGGRYR PGYGTGYFQY GLPDLVADPY YIQASTYVQK MSMYNLRCAA 240 EENCLASTAY RADVRDYDHR VLLRFPQRVK NQGTSDFLPS RPRYSWEWHS CHQHYHSMDE 300 FSHLYLLDAN TQRRWAEGHK ASFCLEDTSC DYGYHRRFAC TAHTQGLSPG CYDTYGADID 360 CQWIDITDVK PGNYILKVSV NPSYLVPESD YTNNVVRCDI RYTGHHAYAS GCTISPY
, ,	Seq ID NO: 87 DNA sequence Nucleic Acid Accession #: NM_006419.1 Coding sequence: 91-420 (underlined sequences correspond to start and stop codons)
75	1 11 21 31 41 51 

	ATGCTGCTGG TCAGCAGCCT CTCTCCAGTC CAAGGTGTTC TGGAGGTCTA TTACACAAGC 180
	TTGAGGTGTA GATGTGTCCA AGAGAGCTCA GTCTTTATCC CTAGACGCTT CATTGATCGA 240
•	ATTCAAATCT TGCCCCGTGG GAATGGTTGT CCAAGAAAAG AAATCATAGT CTGGAAGAAG 300
5	AACAAGTCAA TTGTGTGTGT GGACCCTCAA GCTGAATGGA TACAAAGAAT GATGGAAGTA 360 TTGAQAAAAA GAAGTTCTTC AACTCTACCA GTTCCAGTGT TTAAGAGAAA GATTCCC <u>TGA</u> 420
	TGCTGATATT TCCACTAAGA ACACCTGCAT TCTTCCCTTA TCCCTGCTCT GGATTTTAGT 480
	TTTGTGCTTA GTTAAATCTT TTCCAGGGAG AAAGAACTTC CCCATACAAA TAAGGCATGA 540
10	GGACTATGTG AAAAATAACC TTGCAGGAGC TGATGGGGCA AACTCAAGCT TCTTCACTCA 600
10	CAGCACCCTA TATACACTTG GAGTTTGCAT TCTTATTCAT CAGGGAGGAA AGTTTCTTTG 660
	AAAATAGTTA TICAGTTATA AGTAATACAG GATTATTTTG ATTATATACT TGTTGTTTAA 720 TGTTTAAAAT TICTTAGAAA ACAATGGAAT GAGAATTTAA GCCTCAAATT TGAACATGTG 780
	GCTTGAATTA AGAAGAAAAT TATGGCATAT ATTAAAAGCA GGCTTCTATG AAAGACTCAA 840
	AAAGCTGCCT GGGAGGCAGA TGGAACTTGA GCCTGTCAAG AGGCAAAGGA ATCCATGTAG 900
15	TAGATATCCT CTGCTTAAAA ACTCACTACG GAGGAGAATT AAGTCCTACT TTTAAAGAAT 960
	TTCTTTATAA AATTTACTGT CTAAGATTAA TAGCATTCGA AGATCCCCAG ACTTCATAGA 1020
	ATACTCAGGG AAAGCATTTA AAGGGTGATG TACACATGTA TCCTTTCACA CATTTGCCTT 1080 GACAAACTTC TTTCACTCAC ATCTTTTTCA CTGACTTTTT TTGTGGGGGC GGGGCCGGGG 1140
	GGACTCTGGT ATCTAATTCT TTAATGATTC CTATAAATCT AATGACATTC AATAAAGTTG 1200
20	AGCAAACATT TTACTT
	A . ID. 10 . 10 . 10 . 10 . 10 . 10 . 10 . 10
	Seq ID NO: 88 Protein sequence: Protein Accession #: NP_006410.1
	Tioletii Accession #. 141 _000410.1
25	1 11 21 31 41 51
	MKFISTSLLL MLLVSSLSPV QGVLEVYYTS LRCRCVQESS VFIPRRFIDR IQILPRGNGC 60 PRKEIIVWKK NKSIVCVDPQ AEWIQRMMEV LRKRSSSTLP VPVFKRKIP
	PROCESS WAS TRUSTED BY ADMINISTRATION OF THE STATE OF THE
30	Seq ID NO: 89 DNA sequence
	Nucleic Acid Accession #: NM_002652
	Coding sequence: 37-477 (underlined sequences correspond to start and stop codons)
	1 11 21 31 41 51
35	1 1 1 1 1
	CTTCTCTGGG ACACATTGCC TTCTGTTTTC TCCAGCATGC GCTTGCTCCA GCTCCTGTTC 60
	AGGGCCAGCC CTGCCACCCT GCTCCTGGTT CTCTGCCTGC AGTTGGGGGC CAACAAAGCT 120 CAGGACAACA CTCGGAAGAT CATAATAAAG AATTTTGACA TTCCCAAGTC AGTACGTCCA 180
	A ATGACGA AG TCACTGCAGT GCTTGCAGTT CAAACAGAAT TGAAAGAATG CATGGTGGTT 240
40	AAAACTTACC TCATTAGCAG CATCCCTCTA CAAGGTGCAT TTAACTATAA GTATACTGCC 300
	TGCCTATGTG ACGACAATCC AAAAACCTTC TACTGGGACT TTTACACCAA CAGAACTGTG 360
	CAAATTGCAG CCGTCGTTGA TGTTATTCGG GAATTAGGCA TCTGCCCTGA TGATGCTGCT 420 GTAATCCCCA TCAAAAACAA CCGGTTTTAT ACTATTGAAA TCCTAAAGGT AGAA <u>TAA</u> TGG 480
	AAGCCCTGTC TGTTTGCCAC ACCCAGGTGA TTTCCTCTAA AGAAACTTGG CTGGAATTTC 540
45	TGCTGTGGTC TATAAAATAA ACTTCTTAAC ATGCTT
	g rp NO 00 Ptris
	Seq ID NO: 90 Protein sequence: Protein Accession #: NP_002643.1
	Truckii Accession Tra _seas to
50	1 11 21 31 41 51
	MRLLQLLFRA SPATLLLVLC LQLGANKAQD NTRKIIIKNF DIPKSVRPND EVTAVLAVQT 60
	ELKECMVVKT YLISSIPLQG AFNYKYTACL CDDNPKTFYW DFYTNRTVQI AAVVDVIREL 120
	GICPDDAAVI PIKNNRFYTI EILKV
55	
	Seq ID NO: 91 DNA sequence
	Nucleic Acid Accession #: AK000341  Coding sequence: 85-975 (underlined sequences correspond to start and stop codons)
	Coming acquerice. 63-973 (mineriment acquaintees contraspond to start and step security)
60	1 11 21 31 41 51
	GATAGCGCCG GGCAGAGGGA CCCGGCTACC CTGGACAGCG CATCGCCGCC CGCCCGGGTC 60
	GCCCCCCAC ACCCCCTGCG GATCATGGAA CATCTAAAGG CCTTTGATGA TGAAATCAAT 120
	COTTESTEG ACANTATGET TGGACCGCGA GATTCTCGAG TCAGAGGGTG GTTCACGTTG 180
65	GACTCTTACC TTCCTACCTT TTTTCTTACT GTCATGTATC TGCTCTCAAT ATGGCTGGGT 240
	AACAAGTATA TGAAGAACAG ACCTGCTCTT TCTCTCAGGG GTATCCTCAC CTTGTATAAT 300 CTTGGAATCA CACTTCTCTC CGCGTACATG CTGGCAGAGC TCATTCTCTC CACTTGGGAA 360
	GGAGGCTACA ACTTACAGTG TCAAGATCTT ACCAGCGCAG GGGAAGCTGA CATCCGGGTA 420
	GCCAAGGTGC TTTGGTGGTA CTATTTCTCC AAATCAGTAG AGTTCCTGGA CACAATTTTC 480
·70	TTCGTTTTGC GGAAAAAAA GAGTCAGATT ACTTTTCTTC ATGTATATCA TCATGCTTCT 540
	ATGTTTAACA TCTGGTGGTG TGTCTTGAAC TGGATACCTT GTGGACAAAG TTTCTTTGGA 600 CCAACACTGA ACAGTTTTGT CCACATTCTT ATGTACTCCT ACTATGGACT TTCTGTGTTT 660
	CCATCTATGC ACAAGTATCT TTGGTGGAAG AAATATCTCA CACAGGCTCA GCTGGTGCAG 720
	TTCGTGCTCA CCATCACGCA CACCATGAGC GCCGTCGTGA AACCGTGTGG CITCCCCTTC 780
75	COTTOTOTO TOTTOCAGTO ATOTTATATG CTAACGTTAG TOATCCTCTT CITAAATTTT 840
	TATGTTCAGA CATACCGAAA AAAGCCAATG AAGAAAGATA TGCAAGAGCC ACCTGCAGGG 90 AAAGAAGTGA AGAATGGTTT TTCCAAAGCC TACTTCACTG CAGCAAATGG AGTGATGAAC 960
	386
	300

AAGAAAGCAC AA<u>TAA</u>AAATG AGTAACAGAA AAAGCACATA TACTAGCCTA ACAGATTGGC 1020 TTGTTTTAAA GCAAAGACTG AATTGAAGGT TACATGTTTT AGGATAAACT AATTTCTTTT 1080 GAGTTCATAA ATCATTTGTA CCCAGAATGT ATTAATATAT TGCTATTAGG TTAATCTGTT 1140 AACTGAATGC TTTGATCAGC ATTGAGGTGA TGCTCACCTC CGAGGACCTC AGAACTGGTG 1200 CAGCTTCTCT CTCCCTCCCT CCCACAGACT GAACCTTTCG CCAGAAGCTG TCCTTATAAC 1260
GCCTTATACG CATACACAGC CAGGAAACGT GGAGCATTGT TTCTCACAGA GAGTCTCCAA 1320
ATAAAAAGGG TTTTGTTCAG ATTAAAATGT TTACAACAAA ATGTTAATTA TATTCTAAAT 1380 5 ACAGGATATG TICTAATCTA TATTAAGCAA TAATGCCAGT GCATAATCAT TCCATTTGTT 1440
CCTTTAGCAA TCAACCCCAG AAAATATTAA AATGGGATCA TACACAGAAG ATAGAAAAAT 1500
CTAGCAAAAC TTCTCTTTCT GTAAGCCAGA GTCTTGTCTA TCAGATTCCC ACAACCACTC 1560 10 CTGATTCTAA ATTTAGTGAT ATGGTAATGA AATTGGTATT TATTTTAAAT ATTAGTTATT 1620 CTAAGGAGAA AAAAATGCTT CTGCAAGATT TTCATAATTC AGGGGCTGTG GATAGGATTG 1680 TTCCTCTGTT TCCCTAATCA TTCATCTGTT CATGTCTCCC TCTTGTGCCA GTCAGCCTAG 1740 GTTATACAGA TGCCATGCTC CACACCACGA GCAGTGTACA AATCTGGCTG CCCGTTTACT 1800 TTCTGAGCAA GCACTGGAGT CCACTCCGAC CTTTTTCTTT GAACATGCAT GCTGCTGGAA 1860 15 TATGTATAAA TCAGAACTAG CAGAAGTAGC AGAGTGATGG GAGCAAAATA GGCACTGAAT 1920
TCGTCAACTC TTTTTTGTGA GCCTACTTGT GAATATTACC TCAGATACCT GTTGTCACTC 1980
TTCACAGGTT ATTTAAGTTC TTGAAGCTGG GAGGAAAAAG ATGGAGTAGC TTGGAAAGAT 2040 TICCAGGAT ATTIAAGTIC TIGAAGATU AND AND ANAMACA ATGAMACAT TICCAGCACTG AGCCGTGAGC CGGTCATGAG CCACGATAAA AAATGCCAGT TTGGCAAACT 2100 CAGCACTCCT GTTCCCTGCT CAGGTATATG CGATCTCTAC TGAGAAGCAA GCACAAAAGT 2160 AGACCAAAAGT ATTAATGAGT ATTTCCTTTC TCCATAAGTG CAGGACTGTT ACTCACTACT 2220 AAACTCTACC AAGAATGGAA ACCAAGAATA TTTTCTGAAG ATTTTTTTGA AGATTAATTT 2280 20 Seq ID NO: 92 Protein sequence: 25 BAA91096.1 Protein Accession #: 21 31 MEHLKAFDDE INAFLDNMFG PRDSRVRGWF TLDSYLPTFF LTVMYLLSIW LGNKYMKNRP 60 30 ALSLRGILTL YNLGITLLSA YMLAELILST WEGGYNLQCQ DLTSAGEADI RVAKVLWWYY 120 FSKSVEFLDT IFFVLRKKTS QITFLHVYHH ASMFNIWWCV LNWIPCGQSF FGPTLNSFVH 180 ILMYSYYGLS VFPSMHKYLW WKKYLTQAQL VQFVLTITHT MSAVVKPCGF PFGCLIFQSS 240 YMLTLVILFL NFYVQTYRKK PMKKDMQEPP AGKEVKNGFS KAYFTAANGV MNKKAQ 35 Sea ID NO: 93 DNA sequence NM 000044 Nucleic Acid Accession #: Coding sequence: 1115-3874 (underlined sequences correspond to start and stop codons) 40 51 41 CGAGATCCCG GGGAGCCAGC TTGCTGGGAG AGCGGGACGG TCCGGAGCAA GCCCACAGGC 60 CGAGATICCO GGAGCAGCAGC TIOTOGAA AAGGGCCGA GCTAGCCGCT CCAGTGCTGT ACAGGAGCCG 120
AAGGGAGCGA CCACGCCAGC CCCAGCCCGG CTCCAGCGAC AGCCAACGCC TCTTGCAGCG 180 AAGGGACGCA CCACGCCAGC CCCAGCCCGG CTCCAGCGAC AGCCAACGCC TCTTGCAGCG 180
CGGCGGCTTC GAAGCCGCCG CCCGGAGCTG CCCTTTCCT TCCGGTGAAG TTTTTAAAAA 240
CTGCTAAAGA CTCGGAGGAA GAAGGGAAAG TGCCTGCTC TCCGGTGAAG TTTTTTAAAAAC 240
CTCCTCCTCT CCACCCGCC TCCCCCCACC CTGCCTTCCC CCCCCCCCC GTCTTCTC 300
CCGCAGCTGC CTCAGCCGGC TACTCTCAGC CAACCCCCCT CACCACCCTT CTCCCCCACCC 420
GCCCCCCCGC CCCCGTCGGC CCAGCGCTGC CAGCCCGAGT TTGCAGAGAAG GTAACTCCCT 480
TTGGCTGCGA GCGGGCGAGC TAGCTGCACA TTGCAAAGAA GGCTCTTAGG AGCCAGGCGA 540
CTGGGGAGCG GCTTCAGCAC TGCAGCCACG ACCCGCCTGG TTAGAATTCC GGCGGAAGAA 600
ACCCTCTGTT TTCCCCCACT CTCTCTCAC CTCCTCCTC CTTCCCCACC CCAGCTGCGG 660
ACCCTCTGTT TTCCCCCACT CTCTTCAC AGTCTCTCCAC CCCACC CCAGTTCCGG
AAAAACAAAA AAGCCGAAAT AAAAGAAAAA GATAATAACT CAGTTCTTAT TTGCACCTAC 780
TTCAGTGGAC ACTGAATTTG GAAGGTGAG GATTTTGTTT TTTTTTTA AGATCTGGC 840
ATCTTTTGAA TCTACCCTTC AAGTATTAAG AGACAAGATG TGAGCCTAGC AGGGCAGATC 900 45 50 55 TICAGTGGAC ACTGAATTTG GAAGGTGGAG GATTTTGTTT TTTTCTTTTA AGATCTGGGC 840
ATCTTTTGAA TCTACCCTTC AAGTATTAAG AGACAGACTG TGAGCCTAGC AGGGCAGATC 900
TTGTCCACCG TGTGTCTTCT TCTGCACGAG ACTTTGAGGC TGTCAGAGCG CTTTTTGCGT 960
GGTTGCTCCC GCAAGTTTCC TTCTCTGGAG CTTCCCGCAG GTGGGCAGCT AGCTGCAGCG 1020
ACTACCGCAT CATCACAGCC TGTTGAACTC TTCTGAGCAA GAGAAGGGGA GGCGGGGTAA 1080
GGGAAGTAGG TGGAAGATTC AGCCAAGCTC AAGGATGGAA GTGCAGTTAG GGCTGGGAAG 1140
GGTCTACCCT CGGCCGCCGT CCAAGACCTA CCCAGGAGCT TTCCAGAATC TGTTCAGAGC 60 CGTGCGCGAA GTGATCCAGA ACCCGGGCCC CAGGCACCCA GAGGCCGCGA GCGCAGCACC 1260
TCCCGGCGCC AGTTTGCTGC TGCTGCAGCA GCAGCAGCAG CAGCAGCAGC AGCAGCAGCA 1320
GCAGCAGCAG CAGCAGCAGC AGCAGCAGCA GACCAGCAGCA 1380 65 70 AGGRAGGCGTTG GAGCATCTGA GTCCAGGGGA ACAGCTTCGG GGGGATTGCA TGTACGCCCC 1920
ACTTTTGGGA GTTCCACCCG CTGTGCGTCC CACTCCTTGT GCCCCATTGG CCGAATGCAA 1980
AGGTTCTCTG CTAGACGACA GCGCAGGCAA GAGCACTGAA GATACTGCTG AGTATTCCCC 2040

75

TTTCAAGGGA GGTTACACCA AAGGGCTAGA AGGCGAGAGC CTAGGCTGCT CTGGCAGCGC 2100

AGCACTGGAC GAGGCAGCTG CGTACCAGAG TCGCGACTAC TACAACTTTC CACTGGCTCT 2220 GGCCGGACCG CCGCCCCTC CGCCGCCTCC CCATCCCCAC GCTCGCATCA AGCTGGAGAA 2280 CCCGCTGGAC TACGGCAGCG CCTGGGCGGC TGCGGCGGCG CAGTGCCGCT ATGGGGACCT 2340
GGCGAGCCTG CATGGCGCGG GTGCAGCGGG ACCCGGTTCT GGGTCACCCT CAGCCGCCGC 2400
TTCCTCATCC TGGCACACTC TCTTCACAGC CGAAGAAGGC CAGTTGTATG GACCGTGTGG 2460 5 CAGAGTGCCC TATCCCAGTC CCACTTGTGT CAAAAGCGAA ATGGGCCCCT GGATGGATAG 2700 CTACTCCGGA CCTTACGGGG ACATGCGTTT GGAGACTGCC AGGGACCATG TTTTGCCCAT 2760 TGACTATTAC TTTCCACCCC AGAAGACCTG CCTGATCTGT GGAGATGAAG CTTCTGGGTG 2820 10 TCACTATGGA GCTCTCACAT GTGGAAGCTG CAAGGTCTTC TTCAAAAGAG CCGCTGAAGG 2880 GAAACAGAAG TACCTGTGCG CCAGCAGAAA TGATTGCACT ATTGATAAAT TCCGAAGGAA 2940 AAATTGTCCA TCTTGTCGTC TTCGGAAATG TTATGAAGCA GGGATGACTC TGGGAGCCCG 3000 15 GAAGCTGAAG AAACTTGGTA ATCTGAAACT ACAGGAGGAA GGAGAGGCTT CCAGCACCAC 3060 CAGCCCCACT GAGGAGACAA CCCAGAAGCT GACAGTGTCA CACATTGAAG GCTATGAATG 3120 TCAGCCCATC TTTCTGAATG TCCTGGAAGC CATTGAGCCA GGTGTAGTGT GTGCTGGACA 3180 GGACAACAAC CAGCCCGACT CCTTTGCAGC CTTGCTCTCT AGCCTCAATG AACTGGGAGA 3240
GAGACAGCT GTACACGTGG TCAATGAGC CAAGGCCTTG CCTGGCTTCC GCAACTTACA 3300
CGTGGACGAC CAGATGGCTG TCATTCAGTA CTCCTGGATG GGGCTCATG TGTTTGCCAT 3360
GGGCTGGCGA TCCTTCACCA ATGTCAACTC CAGGATGCTC TACTTCGCC CTGATCTGGT 3420
TTTCAATGAG TACCGCATGC ACAAGTCCCG GATGTACAGC CAGTGTGTCC GAATGAGGCA 3480
CCTCTCTCAA GAGTTTGGAT GGCTCCAAAT CACCCCCCAG GAATTCCTGT GCATGAAAGC 3540 20 CCITICICAA GAGITIGGAT GGCTICCAAAT CACCCCCCAG GAATICCTGT GCATGAAAGC 3540
ACTGCTACTC TTCAGCATTA TTCCAGTGGA TGGGCTGAAA AATCAAAAAT TCTTTGATGA 3600
ACTTCGAATG AACTACAATCA AGGAACTCGA TCGTATCATT GCATGCAAAA GAAAAAATCC 3660
CACATCCTGC TCAAGACGCT TCTACCAGCT CACCAAGCTC CTGGACTCCG TGCAGCCTAT 3720
TGCGAGAGAG CTGCATCAGT TCACTTTTGA CCTGCTAATC AAGTCACACA TGGTGAGCGT 3780
GGACTTTCCG GAAATGATGG CAGGAGATCAT CTCTGTGCAA GTGCCCAAGA TCCTTCTTGG 3840
GAAAGTCAAG CCCATCTATT TCCACACCCA GTGAAGCATT GGAAACCCTA TTTCCCCACC 3960
CCAGCTCATG CCCCCTTTCA GATGTCTTCT GCCTGTTATA ACTCTGCACT ACTCCTCTGC 3960
AGTGCCTTGG GGAATTTCCT CTATTGATGT ACAGTCTGTC ATGAACATGT TCCTGCAATTC 4020 25 30 AACCCTCCCA TGGCACCTTC AGACTTTGCT TCCCATTGTG GCTCCTATCT GTGTTTTGAA 4140 TGGTGTTGTA TGCCTTTAAA TCTGTGATGA TCCTCATATG GCCCAGTGTC AAGTTGTGCT 4200 35 

Seq ID NO: 94 <u>Protein sequence:</u>
Protein Accession #: NP\_000035.1 40

60

31 21

MEVOLGLGRV YPRPPSKTYR GAFONLFQSV REVIONPGPR HPEAASAAPP GASLLLLQQQ 60 QQQQQQQQQ QQQQQQET SPRQQQQQG EDGSPQAHRR GFTGYLVLDE EQQPSQPQSA 120 LECHPERGCV PEPGAAVAAS KGLPQQLPAP PDEDDSAAPS TLSLLGPTFP GLSSCSADLK 180 45 DILSEASTMQ LLQQQQEAV SEGSSSGRAR EASGAPTSSK DNYLGGTSTI SDNAKELCKA 240 VSVSMGLGVE ALEHLSPGEQ LRGDCMYAPL LGVPPAVRPT PCAPLAECKG SLLDDSAGKS 300 TEDTAEYSPF KGGYTKGLEG ESLGCSGSAA AGSSGTLELP STLSLYKSGA LDEAAAYQSR 360 DYYNFPLALA GPPPPPPPH PHARIKLENP LDYGSAWAAA AAQCRYGDLA SLHGAGAAGP 420 GSGSPSAAAS SSWHTLFTAE EGQLYGPCGG GGGGGGGGGGGGGGGGGGGGGGGGGGGAGAVAPY 480 50 GSGSPSAAAS SSWHTLFTAE EGQLYGPCGG GGGGGGGGGGGGGGGGGGGGGGGGAVAPY 480
GYTRPPQGLA GQESDFTAPD VWYPGGMVSR VPYPSPTCVK SEMGPWMDSY SGPYGDMRLE 540
TARDHVLPID YYFPPQKTCL ICGDEASGCH YGALTCGSCK VFFKRAAEGK QKYLCASRND 600
CTIDKFRKKN CPSCRLRKCY EAGMTLGARK LKKLGNLKLQ EEGEASSTTS PTEETTQKLT 660
VSHLEGYECQ PIFLNVLEAI EPGVVCAGHD NNQPDSFAAL LSSLNELGER QLVHVVKWAK 720
ALPGFRNLHV DDQMAVIQYS WMGLMVFAMG WRSFTNVNSR MLYFAPDLVF NEYRMHKSRM 780
YSQCVRMRHL SQEFGWLQIT PQEFLCMKAL LLFSIDPVDG LKNQKFFDEL RMNYIKELDR 840
HACVBVNDT SCSDBFVLQIT PLO SVQPIJA BELLMCTERUL ILKSLMVSVD EPSMAAERS 600 55 IIACKRKNPT SCSRRFYQLT KLLDSVQPIA RELHQFTFDL LIKSHMVSVD FPEMMAEIIS 900 VQVPKILSGK VKPIYFHTQ

Seq ID NO: 95 DNA sequence NM 002497 Nucleic Acid Accession #: Coding sequence: 135-1472 (underlined sequences correspond to start and stop codons)

65 51 11 21 31 41 GGACGACTA GGGTGGCGG GTCAGTGCTG CTCGGGGGGCT TCTCCATCCA GGTCCCTGGA 6 GTTCCTGGTA GGGTGGCGG GTCACTTGGC GCGCAACCTG CGTGAGGCAG GCGACCTCT 120 GCGACTGGC GGCCACTTGGC AGGACTATGA AGTGTTGTAC ACCATTGGCA 180 CAGGCTCCTA CGGCCGCTGC CAGAAGATCC GGAGGAAGAG TGATGGCAAG ATATTAGTTT 240 GGAAAGAACT TGACTATGGC TCCATGACAG AAGCTGAGAA ACAGATGCTT GTTTCTGAAG 300 TGAATTTGCT TCGTGAACTG AAACATCCAA ACATCGTTCG TTACTAATGAT CGGATTATTG 360 ACCGGACCAA TACAACACTG TACATTGTAA TGGAATATTG TGAAGGAGG GATCTGGCTA 420 GTGAATTAC AAAGGGAACC AAGGAAAGGC AATACTTAGA TGAAGAGTTT GTTCTTCGAG 430 TGATGACTCA GTTGACTCAG ATGATATCA AAAGGGAACC AAGGAAAGGC AATACTTAGA TGAAGAGTTT GTTCTTCGAG 430 CGATTATTGC ACCGGATCTT AAACCACCCA ATGTTTTCCT GGATGACTA GTTGGTCATA 540 CCGTATTGCA TCGGGTACTT AAACCAGCCA ATGTTTTCCT GGATGGCAAG CAAAACGTCA 600 AGCTTGGAGA CTTTGGGCTA GCTAGAATAT TAAACCATGA CACCAGTTTT GCAAAAACAT 660 70 75

PCT/US02/02242

WO 02/059377

TAAAAGAATT CTTCAGTTA Seq ID NO: 96 Protein sequence:

Protein Accession #: NP\_002488

LSDIEKNYOL KSRQILGMR

Seq ID NO: 97 DNA sequence NM\_007050.2 Nucleic Acid Accession #: Coding sequence: 185-4576 (underlined sequences correspond to start and stop codons)

CCTCCCGCCT CAGTTCGCGC CGCGCCTCGG CTTGGAACGC AGGAGCGCCG GCTCCGGGAG 60 

GGGGAAAGTG TTCAAGCTCC GGAATGAAAC CCACCACCTC TTTGTGGGTC TGTACCCAGG 1860
GACCACCTAT TCCTTCACCA TCAAGGCCAG CACAGCAAAG GGCTTTGGGC CCCCTGTCAC 1920
CACTCGGATT GCCACCAAAA TTTCAGCTCC ATCCATGCCT GAGTACGACA CAGACACCCC 1980
ATTGAATGAG ACAGACACGA CCATCACAGT GATGCTGAAA CCCGCTCAGT CCCGGGGAGC 2040
TCCTGTCAGT GTTTATCAGC TGGTTGTCAA GGAGGAGCGA CTTCAGAAGT CACGGAGGGC 2100 AGCTGACATT ATTGAGTGCT TTTTCGGTGCC CGTGAGCTAT CGGAATGCCT CCAGCCTCGA 2160
TTCTCTACAC TACTTTGCTG CTGAGTTGAA GCCTGCCAAC CTGCCTGTCA CCCAGCCATT 2220
TACAGTGGGT GACAATAAGA CATACAATGG CTACTGGAAC CCTCCTCTCT CTCCCCTGAA 2280 AAGCTACAGC ATCTACTTCC AGGCACTCAG CAAAGCCAAT GGAGAGACCA AAATCAACTG 2340
TGTTCGTCTG GCTACAAAAG CACCAATGGG CAGCGCCCAG GTGACCCCGG GGACTCCACT 2400
CTGCCTCCTC ACCACAGGTG CCTCCACCCA GAATTCTAAC ACTGTGGAGC CAGAGAAGCA 2460 10 GGTGGACAAC ACCGTGAAGA TGGCTGGCGT GATCGCTGGC CTCCTCATGT TCATCATCAT 2520
TCTCCTGGGC GTGATGCTCA CCATCAAAAG GAGAAGAAAT GCTTATTCCT ACTCCTATTA 2580
CTTGTCCCAA AGGAAGCTGG CCAAGAAGCA GAAGGAGACC CAGAGTGGAG CCCAGAGGGA 2640 GATGGGGCCT GTGGCCTCTG CCGACAAACC CACCACCAAG CTCAGCGCCA GCCGCAATGA 2700
TGAAGGCTTC TCTTCTAGTT CTCAGGACGT CAACGGATTC ACAGATGGCA GCCGCGGGGA 2760
GCTTTCCCAG CCCACCCTCA CGATCCAGAC TCATCCCTAC CGCACCTGTG ACCCTGTGGA 2820 15 GCTTTCCCAG CCACCCTCA CGATCCAGAC TCATCCCTAC CGCACCTGTG ACCCTGTGGA 2820
GATGAGCTAC CCCCGGGACC AGTTCCAACT CGCCATCCGG GTGGCTGACT TGCTGCAGCA 2880
CATCACGCAG ATGAAGAGAG GCCAGGGCTA CCGGTTCCAAG GAGGAATACG AGGCCTTACC 2940
AGAGGGGCAG ACACCTTCGT GGGACACAGC CAAGGAGGAT GAAAACCGCA ATAAGAATCG 3000
ATATGGGAAC ATCATATCCT ACGACCATTC CCCGGTGAGG CTGCTGGTGC TGGATGGAGA 3060
CCCGCACTCT GACTACATCA ATGCCAACTA CATTGACGGA TACCATCGAC CTCGGCACTA 3120
CATTGCGACT CAAGGTCCGA TGCAGGAGAC TGTAAAGGAC TTTTTGGAGAA TGATCTGGCA 3180
GGAGAACTCC GCCAGCATCG TCATGGTCAC AAACCTGGTG GAAGTGGGCA GGGTGAAAT 3240
TGTGCGATC TGGCCAGATA ACCTCATACG CACCTTCACA GAAGAAGCAC CTCGACTTGAC
AAACGAGCCC CTGGCAGAAT ACCTCATACG CACCTTCACA GTCCAGAAGA AAGGCTACCA 3360
TGGAGATCCGG GAGCTCCGCC TCTTCCACTT CACCAGCTGG CCTGACCACAG GCGTTCCCTG 3420 20 25 TGAGATCCGG GAGCTCCGCC TCTTCCACTT CACCAGCTGG CCTGACCACG GCGTTCCCTG 3420 CTATGCCACT GGCCTTCTGG GCTTCGTCCG CCAGGTCAAG TTCCTCAACC CCCCGGAAGC 3480 TGGGCCCATA GTGGTCCACT GCAGTGCTGG GGCTGGGCGG ACTGGCTGCT TCATTGCCAT 3540 30 TGACACCATG CTTGACATGG CCGAGAATGA AGGGGTGGTG GACATCTTCA ACTGCGTGCG 3600
TGAGCTCCGG GCCCAAAGGG TCAACCTGGT ACAGACAGAG GAGCAATATG TGTTTGTGCA 3660 CGATGCCATC CTGGAAGCGT GCCTCTGTGG CAACACTGCC ATCCCTGTGT GTGAGTTCCG 3720 TTCTCTCTAC TACAATATCA GCAGGCTGGA CCCCCAGACA AACTCCAGCC AAATCAAAGA 3780 TGAATTTCAG ACCCTCAACA TTGTGACACC CCGTGTGCGG CCCGAGGACT GCAGCATTGG 3840 35 GCTCCTGCCC CGGAACCATG ATAAGAATCG AAGTATGGAC GTGCTGCCTC TGGACCGCTG 3900 CCTGCCCTTC CTTATCTCAG TGGACGGAGA ATCCAGCAAT TACATCAACG CAGCACTGAT 3960
GGATAGCCAC AAGCAGCTG CCGCCTTCGT GGTCACCCAG CACCCTCTAC CCAACACCGT 4020
GGCAGACTTC TGGAGGCTG TGTTCGATTA CAACTGCTCC TCTGTGGTGA TGCTGAATGA 4080
GATGGACACT GCCCAGTTCT GTATGCAGTA CTGGCCTGAG AAGACCTCCC GGTGCTATGG 4140
GCCCATCCAG GTGGAGTTCT CTCCCGCAGA CATCGACGAG GACATCATCC ACAGAATATT 4200 40 CCGCATCTOT AACATGGCCC GGCCACAGGA TGGTTATCGT ATAGTCCAGC ACCTCCAGTA 4260 CATTGGCTGG CCTGCCTACC GGGACACGCC CCCCTCCAAG CGCTCTCTGC TCAAAGTGGT 4320 CCGACGACTG GAGAAGTGGC AGGAGCAGTA TGACGGGAGG GAGGGACGTA CTGTGGTCCA 4380 CTGCCTAAAT GGGGGAGGCC GTAGTGGAAC CTTCTGTGCC ATCTGCAGTG TGTGTGAGAT 4440
GATCCAGCAG CAAAACATCA TTGACGTGTT CCACATCGTG AAAACACTGC GTAACAACAA 4500
ATCCAACATG GTGGAGACCC TGGAACAGTA TAAATTTTGTA TACCAGGTGG CACTGGAATA 4560
TTTAAACTCC TTTTAGCTCA ATGGGATGGG GAACTGCCGG AGTCCAGAGG CTGCTGTGAC 4620
CAAGCCCCT TTTGTGTGAA TGGCAGTGGCCT GTGTTCCAG AGGTCCAGAGG TGGCACCCTG 4680
CCTGACTCCA AGGAGAAGAC TGGTGGCCCT GTGTTCCACG GGGGGCTCTG CACCTTCTGA 4740
CCCCCTCTTCTCTCTCTCCACCTCCACAACCCCCCC CACCTCTCCTCTCTACACCT 4800 45 CCTGACTCCA AGGAGAAGAC TGGTGGCCCT GTGTTCCACG GGGGGCTCTG CACCTTCTGA 4740
GGGGTCTCCT GTTGCCGTGG GAGATGCTGC TCCAAAAAGGC CCAGGCTTCC TTTTCAACCT 4800
AACCAGCCAC AGCCAAGGGC CCAAGCAGAA GTACACCAC AAGCAAGGCC TTGGATTTCT 4860
GGCTCCCAGA CCACCTGCTT TTGTTCTGAG TTTGTGGATC TCTTGGCAAG CCAACTGTGC 4920
AGGTGCTGGG GAGTGGGAGG CTCCCCTGCC CTCCTTCTCC TTAGGAGTGG AGGAGATGTG 4980
TGTTCTGCTC CTCTACGTCA TGGAAAAGAT TGAGGCTCTT GGGGGTCACT GCTCTGCTGC 5040
CCCCTGCAAC CTCCTTCAGG GGCCTCTGGC ACCAGACATT TGCAGTCTGG ACCAGTGTGA 5100 50 55 CCTTACGATG TICCCTAGGC CACAAGAGAG GCCCCCCATC CTCACACCTA ACCTGCATGG 5160
GGCTTCGCCC ACAACCATTC TGTACCCCTT CCCCAGCCTG GGCCTTGACC GTCCAGCATT
5220 CACTGGCCGG CCAGCTGTGT CCACAGCAGT TTTTGATAAA GGTGTTCTTT GCTTTTTTGT 5280
GTGGTCAGTG GGAGGGGGTG GAACTGCAGG GAACTTCTCT GCTCCTCCTT GTCTTTGTAA 5340
AAAGGGACCA CCTCCCTGGG GCAGGGCTTG GGCTGACCTG TAGGATGTAA CCCCTGTGTT 5400 60 TCTTTGGTGG TAGCTTTCTT TGGAAGAGAC AAACAAGATA AGATTTGATT ATTTTCCAAA \$460 GTGTATGTGA AAAGAAACTT TCTTTTGGAG GGTGTAAAAT CTTAGTCTCT TATGTCAAAA \$520 AGAAGGGGGC GGGGGAGTTT GAGTATGTAC CTCTAAGACA AATCTCTCGG GCCTTTTATT \$580 TTTTCCTGGC AATGTCCTTA AAAGCTCCCA CCCTGGGACA GCATGCCACT GAGCAAGGAG 5640
AGATGGGTGA GCCTGAAGAT GGTCCCTTTG GTTTCTGGGG CAAATAGAGC ACCAGCTTTG 5700
TGCATAATTT GGATGTCCAA ATTTGAACTC CTTCCTAAAG AAACCCAGCA GCCACCTTGA 5760 65 AAAAGGCCAT TGTGGAGCCC ATTATACTTT GATTTAAAAT AGGCCAAGAG AATCAGGCCT 5820
GGAGATCTAG GGTCTTGTCC AAAGTGTGAG TGAGTCAATG AGAGGGAACC AACATTTGCT 5880
AAGTCTCTAC TGTATGCCAG GGATCATGCT TGGCACTTTC CATAGGACAT TTCACACAGT 5940 AAGTCTCTAC TGTATGCCAG GGATCATGCT TGGCACTTTC CATAGGACAT TTCACACAG 1940
CCTTAGAACC CCCAGGAGAG AGCTACTGAC TTGTATCAT CTCATTTGA TCATCTCCTC 6000
CAATGAGGAA ACCCACGCAC CTTCCTTAGT AATGAAATCC TGGGTTCCAA AGGGGCAGGT 6060
AATGGCAATG AGACTTCTCC GTGCTGTTTT CTTCATCTTC TCTAAGCCAA GCAATTATTT 6120
TATGGAGGGA AAATAAGGCC AGAAACTTCT GAGCAGATAA CTCCACAAAT GGAAATTTAG 6180
TACTTTCTTC CTGATGCCAG TTCTTCTGGG AAGCGCAGAA TTTCAGATAT ATTTTAGTAA 6240
CACATTCCCA GCTCCCCAGG AAAGCCAGTC TCATCTAATT TCTTAGTCAG TAAAAACAAT 6300
TCCCTGTTCC TTCAGGCTAT GAATGGACCA GCCAGGGAAA CTCTCGACCT TGATCTCTAG 6360
CCAGTGCTTA GGCCCAATAT CTGACAGCCT CAGGTGGGCT GGGACCTAGG AAGCTCCATC 6420 70 75

TTGAAGGCTG GTCTAGCCCC AGACAGGGCA TGAGGGGCAG AGAATTCAAG AAGGTACAGC 6480 TTTGGCCCTC AAGAGCCCAC TGTATGCTGG GGAAATGGAA CCATGGTGCA GTAGTGTGGA 6540 GTGGATGAGT GTTCCATGAG CCTAGGAGCA AGAAAGTCTC TTCGGCCTCG GGCTTCCTGG 6600 AGAAGGGAC GTCCATTCCT GCTGGGTCTT AACAGCATA AAAAGGAAAA AAAGGAAACT 6660 CAGGCAAAGG GATCCATATG TGCAATGGCA AAGAAATGTG AAAAGGCATT GGGAGAAGCA 6720 GTCTGGGGGA GGCCAGCCCA GTGCGGGCAC AGCACAACAC GGGGAGCAGC AAGAGATGAG 6780 5 CCAGGGTCCA GGAGACAGAT GCCCATCGCG AGTACAGACT TTGTCCTATT GGCAACAAGG 6840 AGTCCATGGA GCTTTAGAGA GATGCACTCA GCTTCGTGTT GGCCAAGACT CCTTCTGGGC 6900 CAATGGGGCT GCCTCTTTTC CTTTCATCAG ACACTGTGAA AACATTCCCT TAAGCGTGCA 6960 10 15 AGCAGACCCC GGGGACCCAC CCCCACTGGG CCTGCTGGCC TCCCTCGGCT CCAGCCCAAT 7380
GCCCCAGCTG GCCTTCCCCA GCCTGCAAGG AGCCTGTAGC ATGGCAAATC TGCCTGCTGT 7440 ATGCTATTTT CTTAGATCTT GGTACATCCA GACAGGATGA GGGTGGAGGG AGAGCTATTT 7500 AACACAAATC CTAAGATTIT TITCTGCTCA GGAAGGGGTG AAATAGCTGG CAGATACAAA 7560
AGACAGTGGC TITTATCATT TTAAATGGTA GGAATTTAAG GTGTGACTTC AGGGAGAAAC 7620
AAACTIGCAA AAAAAAAAAA TCTCAGGCCA TGTTGGGGTA ACCCAGCAAG GGCCAGTGAT 7680
GATTITCCCC AGCTCCATCCC CTTATTTTCC CACAACCCAA CCATTCTCTA AAGCAGGACA 7740
GTGAATAGGT CTTAGGCCAG TGCACACAGG AAGAAATTGA GGCTTATGGA TGGGGATGAC 7800
TICCCTAAGA TCCCATGGGA CAAGGAATGT GCAAGCCTTG GATGAGATGG GGCCCAGTG 7860 20 25 CCCAGGAATT TGAACATTTT CCTTTACCCA GGAAATCTCC GGAGCCAACA CCACCACCCC 7920 CAGGGGGTCT CCCCACCCCA CCCCATTTAC AGGGTGAGCT CAGCCTGTCA TGAGCAGAGG 7980 AAAATATTAT TAATGCTCTC TGAGTCTTTA CAACAGGAGC TCTTACCTCA TAGATGTGGG 8840
CTCTGTTTGG GGAAGATGCA AGGAAGTAAT GAGAAGCCCA GGAAATTTCT CCACCTGTGT 8100
TTATGGCCTA AATAGCTTCA GGATGTATCT TAGCTGCACT CCAACATTGC ATCCTTTCTG 8160 30 GGGTGAAGAA TCTGGGCCAA CCAGGGGTCC TTGGGCCTCT AGAAGGCCAC AGTAGGCCTC 8220 TCTTTGTGGG AATGGAAGGG GACAGTTTGC TTTTAGTGCT GGCCCTCTCT GTGGGTGTGG 8280 CCTGCAAAGG AACCAACAGA CCCTATGCTG GGGACTCTAA CATGTGAGCT CATTAAATTC 8340 TICCAGCATT CTAAAGGAGG GTITGTGATT GTCACCATTT ACTGATGAGG AAACTAAGGC 8400 TCCTAGGGGA GAAATCACTT GCCCACAGTT CCACAGCTAG TGAGTGAATG AACCAGGATT 8460 TAAACCGGTT TTTTCTCACT ACAGAGACAA TATTTTTCCA CCATTGTATC TCACATTTTT 8520 35 CCCAGGAGGT TACCCATAAC AGAAGAGACT AGAGTGGAAC AGATACGTCA GTGGATAAAG 8580 CTCAAAGCAA ACAACAGTAA GCTTAAAATT CCTTCATAGT CTCATGTTTT ACGTTCACAA 8640 TTCATGCAAA ATTTGCATTC CACTITCTGA TTTAGCCTTG TTGGTTTTAA TATGACTCTA 8700 40 CTAGGCAGCT CCTTTGGTGT GTGGGTGCTC TGACCTCACT GTTCATGAGG GGACCTCAAC 8940 TAAGGCATCT TCCAGTTGGG TGCTGGAAGG AACCCATTAA CTCACACTAG AATGATGAGG 9000 ATTTGCTCAT CTGGCGTGGA GAAGGATGAG CCCACAAAAC CCTAAAGGGA AAAGAGAAGC 9060 45 TGGACACAGC TGTACTCAGC AGATTCCTGA ATGCTAGGCT GGAAAGTGGT GCCTGTTGTC 9120 CAAGTGGAGT CACATGGTTG CTAATGTGGG CAAGTCTGAG GACACACTTC ATGAGCAGCT 9180 GGGGTCTGGA AGGCTCCTCA CTTTACCCTA GCCACACATA ATTACTGGGT GCCTACAGCA 9240 CCTAGCACCT TGGAGGGGGC ACTATTAGGA AATCGAGATT ACTATGGCAC AATTAATTCC 9300 TGGGTAAGGC ATGGGGTTGT GGTGGACAGA GCTCAGTCTT TAGTTTGAAC GAAAACATAC 9360 50 ATACATGAAA AACATACATG AAAAAAGGAC CCTCATCAAC ATTAGAAGGG GTAGATTTGG 9420 AGCACTTTAG GCAGGAAAAC AGGAACGCAA GGCCAGGAAA CTGGAACCCA GTGAATACTC 9480 AGAACCGAGG ATGCAGATGA CTTATTTAGC AAAATGGTCA CTTCTGTGAC ATAGCTGGAG 9540 AAAGGATGGG TAACAGCTTG CCAGAGCCAC TTGGAACAAG GGCAAATCTC AGTGTCTGGG 9600 GCAAAAGATG ATGCATTTCC CTCTGACCCA TCATGTTTAT TCATCCTCCA CTCCCCATTG 9660 CCACACTAGC TCTTGCTGTA AGTCCTCACC AGGATCTACA TTTCCTCGTC GCTGGTGGGA 9720 55 ACCCCTTAGA GTACATAGAG GTATCAGTCC AGTAAGACTG CTCTACACAA CAGAAGTGAG 9780 GCCCAGGGAG TAGCAGCCAG GCCCTTATCC TGTTACCTCT GCAGGAGTGA CTGCCCAACC 9840 CAGATCCAGA GACATTGAAG GAAATGATAA TTCCTTGGTA CCTCACTGCC TTGGGACAAA 9900 ATGAAGAAG CCACCCTTCC TTAGGCTGCA GCTTGCCACT CCTGGGCTGG GTAAACAGGT 9960 CATCAGCACC AGGCTCAACC AGGAGTAACA TTCTGGAAGA CATGGGTGAG CCCAAGAGGA 10020 AGCATGAACA GGACGCTGTT CCTAAGTCAT GTCAACAGGT TGTGCTGGGC CAGGATCCCC 10080 60 AGGGAAAAAA ATGGTCAACC CAACTGGAGG GTAGGTTAGA AGAAAAAAA CATAAACGTG 10140 GATAGTCATG TCATCTCAAA TCCCTGACTT GGCTTCCCCA TTACTTGACA GTCTGAGCTC 10200 GATAGICATO ICATICACA TECCTORCH TO GET TECCATAGE TAGET TAGET TO A TECCTOR TAGET TO TECCTOR TAGET TO TECCATAGE TO THE TECCTOR AGAINST THE TECCATAGE AGAINST THE TECCTOR AGAINST THE TECCTOR AGAINST THE TECCATAGE AGAIN 65 TGGATCTGAT CCTCCGAAGC ACAGCAGAGA TATCTAAGCC ATATT TGG CACTGAGCAG 10560
ACTCTTCTAG TTTTTTAGTA ACCAGGATG GGCTTTTGCA TGGCACTGC TATAGAGATG 10620
TCTTGTAGAG ATCAAGCCAG TCTTTTGCAT CCCACCTGCC CACCTCCAGA AGAGATGGGA 10680
AAAGGTCATC AAAGGCCATT CACCAACTGA AATCCACTCA TGAATGTTAG GTCTCTAAAA 10740
GGAGGCATCA ACACTCACAA TGGTAGCCTC CAAACCTAGC ATCCCACCTA TCTAAGAGCT 10800
CAGGGGTGGT CCACTGGGGC AGATACAAGG GAAGTGCAAG GGCTCAGGAT GAAAGAAAAT 10860 70 75 CTATTGGGAA GAGTTTTAGG GGCTTGATCA TTATGGGGCT TCCTTCTATA TCTGAGAACT 10920
GCTCTGGGTG GTGAGATGTG GACTCTGATC CTTAATTGGA ATGTTCGGAG AATGAGTGTC 10980
TGGTGGCCTT GAAGTGTTGG ACAGAAAAGT ATCAGTATAA AAGCCTGGAG CTCAGGGTAA 11040

PCT/US02/02242

WO 02/059377

70

75

TTAATGTAGT TCATGGTTCC TTAGTGAGCA GGACTCTTGG ATGTGGAGGA GAAAGGGTCA 11100 TAGGAAGTAA ACCACAAAA TTACAAAATT GAGTCTCTGT ACAATTACTT CAGTGCCTTT 11160
GGGCTTATGA ATACAAATCA GTGGGCCTTC TCTATGATGG TCCAACAAAC TCTCAGTGTC 11220
CACCCTGTCC CTGTATCTCC CATGGAAGAT GAATAATGTC AGGTGTTCTT TGGGTCAAAG 11280 GCCCCAGGGC AGTCTGGAGG CTTAGAGGGC AGAGTGGTGT CATTCCATGT AAAGTTAGGC 11340
TTCTGAGGGG TCAGGCAGAA TATGGTGTCC ATATCTTCCA TAGCTCTGCA GATTCTTGGA 11400
TGAAGTCAAG CACAGTTTGC TAGACCCAGG TCACTCCTCT GAGTATAACT AGGACCCATG 11460 TGAAGTCAAG CACAGTTTGC TAGACCCAGG TCACTCCTCT GAGTATAACT AGGACCCATG 11460
AGTGAAACTT AATAGCTGTA AGGAAGAACC TGCTGTCTGC CAGAAGAGGAT AAGCTGCCCA 11520
TCTCAGCAGC TGTCTAAAAG AAGGCAGGTG TCTCTTTAAA GGGAAGAGAA AGCATTGGTGA 11580
AATGGATTTC AGGTCACTTC CATTCCAGAT GGGTGAGATC TTGTGGAGCT GGGATCATGT 11640
TTGAACTCAT TCATACCTGT AGAGCACGAA TCCAAGTAGA TTGTGTTTGG TCTGTACAGG 11700
CTGAAGCCCC CTGCTCTCCC ACCCAAGTGC CCCACTGAG CAGGCCAACA TGCTGTTTGTG 11760
GCCACATATA CTGGGCTGAT CCAGGCTGGT TATCACCAAA CAGCAAACCA TAGGGAACAG 11820
CTGCTTTGCC ATAGACCCAA TACCCATGTA GATCTCTCAT GAGAGCAGCC ATAACTCAGA 11880
CCCACTGACC AACAGGGCCA TGAGTGACAG CCAGAACCAG TGAAGGTCCA AGTAGGCACAC 11940
AGAGCAGGGC TTTTCTTACC ATACACATTA TCTCCAGAGG TTATTTCTAC CCCACTCCCT 12000 10 15 AGAGCAGGGC TTTTCTTACC ATACACATIA ICTICAGAGG TIATTTCAC CUCACTCC 1240
ATTCAAGGCC TGTTGGAGCA CACACATITA ICTICAGAGG TIATTTCAC CATG 12060
ATTATAATCA TTTCCAGTGC ACACATTTCA TCACCAGGTG GATCCTGAGC TAGCCCATGT 12120
AAATCCGGGT TAACCCATAT TGGTAATCAT ACTCAAAAGC ACTTTTCACC CTACATTCTA 12180
CTAGCCAATC AAAGACAAAG AGTTGTGGCC TCTACCCATTG CCTTGGCTTC TGGACACCCT 12240
CACAAGCTAT CCCAAGGTTC CCGCTCAACT CCAGGGAGGC TGACATCTTC ACATCCACTG 12300
GGCATATAAT ATTGCATGAG ACCAAAGTCT CCACACTCTT TGCAGCCTCC TCCATGAATC 12360 20 CCAATGGCCT GCACTTGTAC AGTTTGGGTG TTTGATAGAT AAAGCACGTA TGAGAAAGA 12420
AAACAAAATA AATCAACTTT TTAAAAAAGC CAGCACTGTG CTGTCAATGT TTTTTTTTTC 12480
TTTTCAATTC TAGCTCAGAA AAGCAGAAGG TAAATAATGT CAGGTCAATG AATATCAGAT 12540
ATATTTTTTTT GACTGTACATT ACAGTGAAGT GTAATCTTTT TACACCTGCA AGTCCATCTT 12600
ATTTATTCTT GTAAATGTTC CCTGACAATG TTTGTAATAT GGCTGTGTTA AAAAATCTAT 12660 25 ACAATAAAGC TGTGACCCTG Seq ID NO: 98 <u>Protein sequence:</u>
Protein Accession #: NP\_008981.1 30 31 35 40 RPGEGGTGPP GAPLTTRTKC ADPVHGPQNV EIVDIRARQL TLQWEPFGYA VTRCHSYNLT 480 VQYQYVFNQQ QYEAEEVIQT SSHYTLRGLR PFMTIRLRLL LSNPEGRMES EELVVQTEED 540 VPGAVPLESI QGGPFEEKLY IQWKPPNETN GVITLYEINY KAVGSLDPSA DLSSQRGKVF 600 VPGAVPLESI QGOPFEEKIY IQWKPPNETN GVITLYEINY KAVGSLDPSA DLSSQRGKVF 600
KLRNETHHLF VGLYPGTTYS FTIKASTAKG FGPPVTTRIA TKISAPSMPE YDTDTPLNET 660
DTTITVMLKP AQSRGAPVSV YQLVKEERL QKSRRAADII ECFSVPVSVR NASSLDSLHY 720
FAAELKPANL PVTQPFTVGD NKTYNGYWNP PLSPLKSYSI YFQALSKANG ETKINCVRLA 780
TKAPMGSAQV TPGTPLCLLT TGASTQNSNT VEPEKQVDNT VKMAGVIAGL LMFIILLGV 840
MLTIKRRRNA YSYSYYLSQR KLAKKQKETQ SGAQREMGPV ASADKPTTKL SASRNDEGFS 900
SSSQDVNGFT DGSRGELSQP TLTIQTHPYR TCDPVEMSYP RDQFQLAIRV ADLLQHITQM 960
KRGQGYGFKE EYEALPEGQT ASWDTAKEDE NRNKNRYGNI ISYDHSRVRL LVLJGDPHSD 1020
YINANYIDGY HRPRHYIATQ GPMQETVKDF WRMIWQENSA SIVMVTINLVE VGRVKCVRYW 1080
PDDTEVYGDI KVTLIETEPL AEPVIRTFTV QKKGYHEIRE LRLFHFTSWP DHGVPCYATG 1140
LLGFVRQVKF LNPPEAGPIV VHCSAGAGRT GCFIAIDTML DMAENEGVVD IFNCVRELRA 1200
QRVNLVQTEE QYVFVHDAIL EACLCGNTAI PVCEFRSLYY NISRLDPQTIN SSQIKDEFGT 1260
LNIVTPRVRP EDCSIGLLPR NHDKNRSMOV LPLDRCLPFL ISVDGESSNY INAALMDSHK 1320
OPAAFVVTQH PLPNTVADFW RLVFDYNCSS VVMLNEMDTA QFCMQYWPEK TSGCYGPIQV 1380 50 55 QPAAFVYTQH PLPNTVADFW RLVFDYNCSS VYMLNEMDTA QFCMQYWPEK TSGCYGPIQV 1380 EFVSADIDED IHRIFRICN MARPQDGYRI VQHLQYIGWP AYRDTPPSKR SLLKVVRRLE 1440 KWQEQYDGRE GRTVYHCLNG GGRSGTFCAI CSVCEMIQQQ NIIDVFHIVK TLRNNKSNMV 1500 60 ETLEQYKFVY EVALEYLSSF Seq ID NO: 99 DNA sequence Nucleic Acid Accession #: NM\_002988.1 Coding sequence: 71-340 (underlined sequences correspond to start and stop codons). 65 

TTCCCTTCAA CTCTTCGTAC ATTCAATGCA TGGATCAATC AGTGTGATTA GCTTTCTCAG 660 CAGACATTGT GCCATATGTA TCAAATGACA AATCTTTATT GAATGGTTTT GCTCAGCACC 720 ACCITITAAT ATATIGGCAG TACITATIAT ATAAAAGGTA AACCAGCATI CICACIGIGA 780 ΑΑΑ ΑΑΑΑΑΑΑΑ ΑΑΑΑΑΑΑΑΑΑ 5 Seq ID NO: 100 <u>Protein sequence:</u>
Protein Accession #: NP\_002979.1 10 LLTKRGRQIC ADPNKKWVQK YISDLKLNA Seq ID NO: 101 DNA sequence 15 Nucleic Acid Accession #: NM 015507.2 Coding sequence: 241-1902 (underlined sequences correspond to start and stop codons) 31 20 CCGCAGAGGA GCCTCGGCCA GGCTAGCCAG GGCGCCCCCA GCCCCTCCCC AGGCCGCGAG 60 CGCCCCTGCC GCGGTGCCTG GCCTCCCCTC CCAGACTGCA GGGACAGCAC CCGGTAACTG 120 CGAGTGGAGC GGAGGACCCG AGCGGCTGAG GAGAGAGGAG GCGGCGGCTT AGCTGCTACG 180 GGGTCCGGCC GGCGCCCTCC CGAGGGGGGC TCAGGAGGAG GAAGGAGGAC CCGTGCGAGA 240

ATGCCTCTGC CCTGGAGCCT TGCGCTCCCG CTGCTGCTCT CCTGGGTGGC AGGTGGTTTC 300

GGGAACGCGG CCAGTGCAAG GCATCACGGG TTGTTAGCAT CGGCACGTCA GCCTGGGGTC 360 25 TGTCACTATG GAACTAAACT GGCCTGCTGC TACGGCTGGA GGAAGAACAG CAAGGGAGTC 420
TGTGAAGCTA CATGCGAACC TGGATGTAAG TTTGGTGAGT GCCTGGGACC AAACAAATGC 480
AGATGCTTC CAGGATACAC CGGGAAAACC TGCAGTCAAG ATGTGAATGA GTGTGGAATG 4AAACCCGGC CATGCCAACA CAGATGTGTG AATACACACC GAAGCTACACA GTGCTTTTGC 600
CTCAGTGGCC ACATGCTCAT GCCAGATGCT ACGTGTGTGA ACTCTAGGAC ATGTCCATC 660
ATAAACTGTC AGTACAGCTG TGAAGACACA GAAGAAGGGC CACAGTGCCT GTGTCCATCC 720 30 TCAGGACTCC GCCTGGCCCC AAATGGAAGA GACTGTCTAG ATATTGATGA ATGTGCCTCT 780
GGTAAAGTCA TCTGTCCCTA CAATCGAAGA TGTGTGAACA CATTTGGAAG CTACTACTGC 840 AAATGTCACA TIGGTTTCGA ACTGCAATAT ATCAGTGGAC GATATGACTG TATAGATATA 900
AATGAATGTA CTATGGATAG CCATACGTGC AGCCACCATG CCAATTGCTT CAATACCCAA 960
GGGTCCTTCA AGTGTAAATG CAAGCAGGGA TATAAAGGCA ATGGACTTCG GTGTTCTGCT 1020 35 ATCCCTGAAA ATTCTGTGAA GGAAGTCCTC AGAGCACCTG GTACCATCAA AGACAGAATC 1080 AAGAAGTTGC TTGCTCACAA AAACAGCATG AAAAAGAAGG CAAAAATTAA AAATGTTACC 1140 CCAGAACCCA CCAGGACTCC TACCCCTAAG GTGAACTTGC AGCCCTTCAA CTATGAAGAG 1200 40 ATAGTTTCCA GAGGCGGGAA CTCTCATGGA GGTAAAAAAG GGAATGAAGA GAAAATGAAA 1260 GAGGGGCTTG AGGATGAGAA AAGAGAAGAG AAAGCCCTGA AGAATGACAT AGAGGAGCGA 1320 AGCCTGCGAG GAGATGTGTT TTTCCCTAAG GTGAATGAAG CAGGTGAATT CGGCCTGATT 1380 CTGGTCCAAA GGAAAGCGCT AACTTCCAAA CTGGAACATA AAGATTTAAA TATCTCGGTT 1440 GACTGCAGCT TCAATCATGG GATCTGTGAC TGGAAACAGG ATAGAGAAGA TGATTTTGAC 1500 TGGAATCCTG CTGATCGAGA TAATGCTATT GGCTTCTATA TGGCAGTTCC GGCCTTGGCA 1560 45 GGTCACAAGA AAGACATTGG CCGATTGAAA CTTCTCCTAC CTGACCTGCA ACCCCAAAGC 1620 AACTTCTGTT TGCTCTTTGA TTACCGGCTG GCCGGAGACA AAGTCGGGAA ACTTCGAGTG 1680 TTTGTGAAAA ACAGTAACAA TGCCCTGGCA TGGGAGAAGA CCACGAGTGA GGATGAAAAG 1740 TGGAAGACAG GGAAAATTCA GTTGTATCAA GGAACTGATG CTACCAAAAG CATCATTTTT 1800 GAAGCAGAAC GTGGCAAGGG CAAAACCGGC GAAATCGCAG TGGATGGCGT CTTGCTTGTT 1860 50 TCAGGCTTAT GTCCAGATAG CCTTTTATCT GTGGATGACT GAATGTTACT ATCTTTATAT 1920
TTGACTTTGT ATGTCAGTTC CCTGGTTTTT TTGATATTTGC ATCATAGGAC CTCTGGCATT 1980
TTAGAATTAC TAGCTGAAAA ATTGTAATGT ACCAACAGAA ATATTATTGT AAGATGCCTT 2040 TCTTGTATAA GATATGCCAA TATTTGCTTT AAATATCATA TCACTGTATC TTCTCAGTCA 2100
TTTCTGAATC TTTCCACATT ATATTATAAA ATATGGAAAT GTCAGTTTAT CTCCCCTCCT 2160
CAGTATATCT GATTTGTATA AGTAAGTTGA TGAGCTTCT CTACAACAT TTCTAGAAAA 2220 55 TAGAAAAAA AGCACAGAGA AATGTTTAAC TGTTTGACTC TTATGATACT TCTTGGAAAC 2280 TATGACATCA AAGATAGACT TTTGCCTAAG TGGCTTAGCT GGGTCTTTCA TAGCCAAACT 2340 60 Seq ID NO: 102 <u>Protein sequence:</u> Protein Accession #: NP\_056322.2

MPLPWSLALP LLLSWVAGGF GNAASARHHG LLASARQPGV CHYGTKLACC YGWRRNSKGV 60
CEATCEPGCK FGECVGPNKC RCFPGYTGKT CSQDVNECGM KPRPCQHRCV NTHGSYKCFC 120
LSGHMLMPDA TCVNSRTCAM INCQYSCEDT EEGPQCLCPS SGLRLAPNGR DCLDIDECAS 180
GKVICPYNRR CVNTFGSYYC KCHIGFELQY ISGRYDCIDI NECTMDSHTC SHHANCFNTQ 240
GSFKCKCKQG YKGNGLRCSA PPENSVKEVL RAPGTIKDRI KKLLAHKNSM KKKAKIKNVT 300

GSFKCKCKQG YKUNGLICCSA IPENSYNEYL NAFOTIKUBI KALLAHKNISM KKKAKURIYI 300
PEPTRIPTPK VNLQPFNYEE IVSRGGNSHG GKKGNEEKMK EGLEDEKREE KALKNDIEER 360
SLRGDVFFFK VNEAGEFGLI LVQRKALTSK LEHKDLINISV DCSFNHGICD WKQDREDDFD 420
WNPADRDNAI GFYMAVPALA GHKKDIGRLK LLLPDLQPQS NFCLLFDYRL AGDKVGKLRV 480
FVKNSNNALA WEKTTSEDEK WKTGKIQLYQ GTDATKSIIF EAERGKGKTG EIAVDGVLLV 540

Seq ID NO: 103 DNA sequence

SGLCPDSLLS VDD

21 31 41

65

70

PCT/US02/02242

WO 02/059377

Nucleic Acid Accession #:

75

51 31 41 GAGACCATCC TCAATTGCTT AGACATATTC TGAGCCTACA GCAGAGGAAC CTCCAGTCTC 60
AGCACCATGA ATCAAACTGC GATTCTGATT TGCTGCCTTA TCTTTCTGAC TCTAAGTGGC 120
ATTCAAGGAG TACCTCTCTC TAGAACCCGTA CGCTGTACCT GCATCAGCAT TAGTAATCAA 180
CCTGTTAATC CAAGGTCTTT AGAAAAACTT GAAATTATTC CTGCAAGCCA ATTTTGTCCA 240
CGTGTTGAGA TCATTGCTAC AATGAAAAAG AAGGGTGAGA AGAGATGTCT GAATCCAGAA 300 10 TCGAAGGCCA TCAAGAATTT ACTGAAAGCA GTTAGCAAGG AAATGTCTAA AAGATCTCCT 360 TAAAACCAGA GGGGAGCAAA ATCGATGCAG TGCTTCCAAG GATGGACCAC ACAGAGGCTG 420 CCTCTCCCAT CACTTCCCTA CATGGAGTAT ATGTCAAGCC ATAATTGTTC TTAGTTTGCA 480 GTTACACTA AAGGTGACCA ATGATGGTCA CCAAATCAGC TGCTACTACT CCTGTAGGAA 540
GGTTAATGTT CATCATCCTA AGCTATTCAG TAAATCAGC TGCTACTACT CCTGTAGGAA 540
GCTCTACTGA GGTGCTATGT TCTTAGTGGA TGTTCTGACC CTGCTTCAAA AATTCTCCCTC 660
ACCTTTCCCA TCTTCCAAGG GTACTAAGGA ATCTTTCTGC TTTTGGGTTT ATCAGAATTC 720
TCAGGAATCTC AAATAACTAA AAGGTATGCA ATCAAATCTG CTTTTTAAAG AATGCTCTTT 780
ACTTCATGGA CTTCCACTGC CATCCTCCCA AGGGGCCCAA ATTCTTTCAG TGGCTACCTA 840 15 CATACAATTC CAAACACATA CAGGAAGGTA GAAATATCTG AAAATGTATCTG TAGAATTT 900
CITATITAAAT GAAAGACTGT ACAAAGTATA GTTTAAGTATTT 960
TITCAGTGTA CATGGAATAA CATGTAATTA AGTCTTAGAT GTATATATTT CCTATATTGT 960
TITCAGTGTA CATGGAATAA CATGTAATTA AGTACTATGT ATCAATGAGT AACAGGAAAA 1020
TITTAAAAAT ACAGATAGAT ATATGCTCTG CATGTTACAT AAGATAAATG TGCTGAATGG 1080 20 TTTTCAAATA AAAATGAGGT ACTCTCCTGG AAATATTAAG 25 Seq ID NO: 104 Protein sequence:
Protein Accession #: NP\_001556.1 30 MNQTAILICC LIFLTLSGIQ GVPLSRTVRC TCISISNQPV NPRSLEKLEI IPASQFCPRV 60 EIIATMKKKG EKRCLNPESK AIKNLLKAVS KEMSKRSP Seq ID NO: 105 DNA sequence 35 NM 015068.1 Nucleic Acid Accession #: Coding sequence: 1170-2243 (underlined sequences correspond to start and stop codons) 31 51 GCGGGGGTGCTG CAGCAGCTGC CCACCCCCCCC TTTTATGGC CCAGTGCCAG 420 40 45 50 55 60 65 70

NM 001565.1

Coding sequence: 67-363 (underlined sequences correspond to start and stop codons)

TTTATTCCTG TTCAGCTTCT CAATCAGTGA CTGTGTGCTA AATTITAGGC TACTGTATCT 2340 TCAGGCCACC TGAGGCACAT CCTCTCTGAA ACGCTATGG AAGGTTAGGG CCACTCTGGA 2400 CTGGCACACA TCCTAAAGCA CCAAAAGACC TTCAACATTT TCTGAGAGCA ACAGAGTATT 2460 TGCCAATAAA TGATCTCTCA TTTTTCCACC TTGACTGCCA ATCTAACTAA AATAATTAAT 2520 AAGTTTACTT TCCAGCCAGT CCTGGAAGTC TGGGTTTTAC CTGCCAAAAC CTCCATCACC 2580 ATCTAAATTA TAGGCTGCCA AATTTGCTGT TTAACATTTA CAGAGAAGCT GATACAAACG 2640 CAGGAAATGC TGATTTCTTT ATGGAGGGGG AGACGAGGAG AGGGAGGACA TGACTTTTCT 2700
TGCGGTTTCG GTACCCTCTT TTTAAATCAC TGGAGGACTG AGGCCTTATT AAGGAAGCCA 2760
AAATTATCGG TGCAGTGTGG AAAGGCTTCC GTGATCCTCT CGCTGCACCC TTAGAAACTT 2820 CACCOTCTTC AAACTCCATT TCCATGGTTC TGTTAATTCT CAAGGAGCAG CAACTCGACT 2880
GGTTCTCCCA GGAGCAGGAA AAACCCTTGT GACATGAAAC ATCTCAGGCC TGAAAAGAAA 2940
GTGCTCTCTC AGATGGACTC TTGCAATGTTA AGACTATGTC TCCACTCAT GGTGCAAATC 3000
ACATGTTACCC AATGACTCC GCTTTGACAC AACACCTTAC CATCATCATG CCATGATGCC 3060
TTCCACAAAG CATTAAACCT GGTAACCAGA GATTACTGGT GGCTCCAGCG TTGTTAGATG 3120 10 15 TTCATGAAAT GTGACCACCT CTCAATCACC TTTGAGGGCT AAAGAGTAGC ACATCAAAAG 3180
GACTCCAAAA TCCCATACCC AACTCTTAAG AGATTTGTCC TGGTACTTCA GAAAGAATTT 3240
TCATGAGTGT TCTTAATTGG CTGGAAAAGC ACCAGCTGAC GTTTTGGAAG AATCTATCCA 3300 TGTGTCTGCC TCCATATGCA TCTGGGCATT TCATCTTCAG TCCCCTCATT AGACTGTAGC 3360 ATTAGGATGT GTGGAGAGAG GAGAAATGAT TTAGCACCCA GATTCACACT CCTATGCCTG 3420 GAAGGGGGAC ATCTTTGAAG AAGAGGAATT AGGGCTGTGG ACACTGTCTT GAGGATGTGG 3480 20 ACTTCCTTAG TGAGCTCCAC ATTACTTGAT GGTAACCACT TCAAAAGGAT CAGAATCCAC 3540 GTAATGAAAA AGGTCCCTCT AGAGGATGGA GCTGATGTGA AGCTGCCAAT GGATGAAAAG 3600 CCTCAGAAAG CAACTCAAAG GACTCAAAGC AACGGACAAC ACAAGAGTTG TCTTCAGCCC 3660 AGTGACACCT CTGATGTCCC CTGGAAGCTT TGTGCTAACC TGGGACTGCC TGACTTCCTT 3720
TAGCCTGGTC CCTTGCTACT ACCTTGAACT GTTTTATCTA ACCTCTCTTT TTCTGTTTAA 3780
TTCTTTGCTA CTGCCATTGA CCCTGCTGCA GGATTTGTGT CATTTTCCTG CCTGGTTGCT 3840 25 GAGACTCCAT TTTGCTGCCA CACACAGAGA TGTAAGAGGC AGGCTTTAAT TGCCAAAGCA 3900 CAGTTTGAGC AGTAGAAAAC AACATGGTGT ATATCTCAAA TTGCCTGACA TGAAGAGGGA 3960 TCTAACGGTG AAGTTTCACT TTTCATCAGC ATCATCTTTC ACATGTTCAT TATCATCCGC 4020 TCTTATTCTT GCATGTTTAA ACACTTAAAA TTTTTAGTAT AATTTTTAGT GTGTTTTGAA 4080 GTGGTGACTA GGCTTTCAAA AACTTCCATT GAATTACAAA GCACTATCCA GTTCTTATTG 4140 30 TTAAACTAAG TAAAAATGAT AAGTAACATA GTGTAAAATA TTCCTTTACT GTGAACTTCT 4200 TACAATGCTG TGAATGAGAG GCTCCTCAGA ACTGGAGCAT TTGTATAATA ATTCATCCTG 4260 TTCATCTTCA ATTITAACAT CATATATAAT TTCAATTCTA TCAATTGGGC CITTAAAAAT 4320 35 CATATAAAAG GATATAAAAT ITGAAAAGAG AAACCTAATT GGCTATTTAA TCCAAAACAA 4380 CTTTTTTTTT TCCTTCAATG GAATCAGAAA GCTTGTCAAT CACTCATGTG TTTTAGAGTA 4440 40 GGCATGTGCA CACGGACATT TGCCACCACT GCAAGCAAAA GTCTGGAGAA GTTCACCAAC 4680 GACAAGAACG ATTAGGGAAA ATATGCTGCT GTGGGTTAAC AACTCAGAAA GTCCCTGATC. 4740 CACATTTGGC TGTTTACTAA AGCTTGTGAT TAACTTTTTG GCAGTGTGTA CTATGCTCTA 4800 TIGCTATATA TGCTATCTAT AAATGTAGAT GTTAAGGATA AGTAATTCTA AAATTTATTAT 4860
TCTATAGTIT TGAAGTTTGG TTAAGTTTCC TITCACTCAA TTGATTATTAT TGTTGTTAA 4920
TCAAATTTAT GTTAATTGGA TCCTTTAAAT TTTTTTTTGC ATTTCCAAC AAAAATGGCT 4980
TTATTCATAA GAAAGGAAAA AAATCAATGG AATTTGATAT CTAAAGAAGT TAGAAAGGGA 5040
GCAAAATAAA AAACATAAAG GAGATAGATG AATTAGTAAG CAAATCAGTA GTCGAGTTTT 5100 45 TCAAACTGGC AAAATTAATT AATTGACTTT TAGCCCAAAT TTACATTGTT AATTAAATCA 5160 AGAAGGAAGA AGATCTAAGA GCTCCCATTG ATAGGCAAGC CTAGAGAGAA CTAGCTAAAT 5220 TTATCATGCT AGGATATTGA AACACAGAAA GTTTACATAC ATTTATGAAG GGTCAATTTA 5280 50 GTTTGGACAG TGAGGTATTT GTCTTAGTGG AAAAAAGGAG AATTAGTCTG ATCAAATCGT 5340 GAAGTAATAC AGTGAACTTG CAGGTGCACA AAATAAGAGG GCCACATCTA TATGGTGCAG 5400 TCTGGAATTC TGTTTAAGTT TGTAGGTACC TCTTGGACTT CTGAATTGAT CAGTTGTCA \$460
TCCACCACAG ACATCTCACA TCAGATACAG ACAGTTCCAA GATTGACAAC AGAGAACAAC 5520
CTGCTGGAAA GACCTGGGCA GAAATGGAGA GCCCTGCGGG AACCATGCTA CATTTTCATC 5580 55 TAAAGAGAGA ATGCACATCT GATGAGACTG AAAGTTCTTT GTTGTTTTAG ATTGTAGAAT 5640 GGTATTGAAT TGGTCTGTGG AAAATTGCAT TGCTTTTATT TCTTTTGTGTA ATCAAGTTTA 5700 AGTAATAGGG GATATATAAT CATAAGCATT TTAGGGTGGG AGGGACTATT AAGTAATTTT 5760 AGGGGGGGGGTTATTTAG AATGTTAGAA TAATATTATG TATTAGATAT CCCTATAAAT 520
GGACATGCGT ACTIACTTGT AACCCTTTAC CCTATAATTG CTATCCTTAA AGATTTCAAA 5880
TAAACTCGGA GGGAACTGCA GGGAGACCAA CTTATTTAGA GCGAATTGGA CATGGATAAAA 5940
AACCCCAGTG GGAGAAAGTT CAAAGGTGAT TAGATTAATAA ATTTAATAGA GGATGAGTGA 6000
CCTCTGATAA ATTACTGCTA GAATGAACTT GTCAATGATG GATGGTAAAT TTTCATGGAA 6060 60 GTTATAAAAG TGATAAATAA AAACCCTTGC TTTTACCCCT GTCAGTAGCC CTCCTCCTAC 6120 65 CACTGAACCC CATTGCCCCT ACCCCTCCTT CTAACTTTAT TGCTGTATTC TCTTCACTCT 6180 ATATTTCTCT CTATTTGCTA ATATTGCATT GCTGTTACAA TAAAAAATTCA ATAAAGATTT 6240 AGTGGTTAAG TGC

Seq ID NO: 106 <u>Protein sequence:</u>
Protein Accession #: NP\_055883.1

70

I II 21 · 31 41 51

<sup>75</sup> MTERRIDELS EEINLIREKV MKQSEENNNL QSQVQKLTEE NTTLREQVEP TPEDEDDDIE 60
LRGAAAAAAP PPPIEEECPE DLPEKFDGNP DMLAPFMAQC QIFMEKSTRD FSVDRVRVCF 120
VTSMMTGRAA RWASAKLERS HYLMHNYPAF MMEMKHVFED PQRREVAKRK IRRLRQGMGS 180
VIDYSNAFQM IAQDLDWNEP ALIDQYHEGL SDHIQEELSH LEVAKSLSAL IQQCHHERR 240

LARAAAARKP RSPPRALVLP HIASHHQVDP TEPVGGARMR LTQEEKERRR KLNLCLYCGT 300 GGHYADNCPA KASKSSPAGN SPAPL

NM 003679.1

Seq ID NO: 107 DNA sequence

Nucleic Acid Accession #

5

55

60

65

70

Coding sequence: 47-1507(underlined sequences correspond to start and stop codons) 31 GGCACGAGCA GAAGCAACAA TAATTGTGAA AAATACTTCA GCAGTT<u>ATG</u>G ACTCATCTGT 60 CATTCAAAGG AAAAAAGTAG CTGTCATTGG TGGTGGCTTG GTTGGCTCAT TACAAGCATG 120 10 CTTTCTTGCA AAGAGGAATT TCCAGATTGA TGTATATGAA GCTAGGGAAG ATACTCGAGT 180
GGCTACCTTC ACACGTGGAA GAAGCATTAA CTTAGCCCTT TCTCATAGAG GACGACAAGC 240
CTTGAAAGCT GTTGGCCTGG AAGATCAGAT TGTATCCCAA GGTATTCCCA TGAGAGCAAG 300 .15 20 CAGTCAGCAG TACATTCCTC ATGGGTACAT GGAGTTGACT ATTCCACCTA AGAACGGAGA 660 TTATGCCATG GAACCTAATT ATCTGCATAT TTGGCCTAGA AATACCTTTA TGATGATTGC 720
ACTTCCTAAC ATGAACAAAT CATTCACATG TACTTTGTTC ATGCCCTTTG AAGAGTTTGA 780 AAAACTTCTA ACCAGTAATG ATGTGGTAGA TTTCTTCCAG AAATACTTTC CGGATGCCAT 840
CCCTCTAATT GGAGAGAAAC TCCTAGTGCA AGATTTCTTC CTGTTGCCTG CCCAGCCCAT 900
GATATCTGTA AAGTGCTCTT CATTTCACTT TAAATCTCAC TGTGTACTGC TGGGAGATGC 960 25 AGCTCATGCT ATAGTGCCGT TTTTTGGGCA AGGAATGAAT GCGGGCTTTG AAGACTGCTT 1020
GGTATTTGAT GAGTTAATGG ATAAATTCAG TAACGACCTT AGTTTGTTC TTCCTGTGTT 1080
CTCAAGATTG AGAATCCCAG ATGATCACGC GATTTCAGAC CTATCCATGT ACAATTACAT 1140 AGAGATGCGA GCACATGTCA ACTCAAGCTG GTTCATTTTT CAGAAGAACA TGGAGAGATT 1200
TCTTCATGCG ATTATGCCAT CGACCTTTAT CCCTCTCTAT ACAATGGTCA CTTTTTCCAG 1260
AATAAGATAC CATGAGGCTG TGCAGCGTTG GCATTGGCAA AAAAAGGTGA TAAACAAAGG 1320 30 ACTORITHTIC TIGGGATCAC TGATAGCCAT CAGCAGTACC TACCTACTAT ATCACTACTA 1380
GTCACCACGA TCTTTCCTCT GCTTGAGAAG ACCATGGAAC TGGATAGCT ACCTACTAT ATCACTACAT 1380
GTCACCACGA TCTTTCCTCT GCTTGAGAAG ACCATGGAAC TGGATAGCT ACCTTCCGGAA 1440
TACAACATGT TTCCCCGCAA AGGCCGTGGA CTCCCTTAGAA CAAATTTCCA ATCTCATTAG 1500
CAGGTGATAG AAAGGTTTTG TGGTAGCAAA TGCATGATTTCTCTGTGACC AAAATTAAGC 1560
ATGAAAAAAA TGTTTCCATT GCCATATTTG ATTCACTAGT GGAAGATAGT GTTCTGCTTA 1620
TAATTAAAACT GAATGTAGAG TATCTCTGTT TGTTAATTGC AATTACTGGT TGGGGGGTGC 1680 35 ATTITAAAAG ATGAAACATG CAGCTTCCCT ACATTACACA CACTCAGGTT GAGTCATTCT 1740 AACTATAAAA GTGCAATGAC TAAGATCCTT CACTTCTCTG AAAGTAAGGC CCTAGATGCC 1800 TCAGGGAAGA CAGTAATCAT GCCTTTTCTT TAAAAGACAC AATAGGACTC GCAACAGCAT 1860 40 45 50 TGTCTACATG TGCCAGAATG GAAAGGAAAC AAGGGGAGAC AACTTTTATA GAAATACAAA 2580 GCCATTACTT TATTCAATTT CAGACCCTCA GAAGCAATTT ACTAATTTAT TCTTCGACTA 2640 CATACTGCAG CAGAACCAGC AATACACTTG ATTTTTAAAA GCACATTTAG TGAAATGTTT 2700

GGAGTTTGCC TTGTAGATTC CTCTGGTGGT GGTCTCCAGG CTGACAAGGA TTCAAAGTTG 3240 TCTCTGAAAC TCCTCTTTGT CATACTGCAC ATATAAAACG TCTTTTGTTT CCAACAAGAG 3300 GATTTCTTTT TCATTCTAGA ATTATCTCCT TGATAACTTG ATCAGATATA GGACATGACA 3360 CTGAATAGAG TCCAACAGTA CAAAAAAAAT TCAGTATGTT CTAGCTACTT CACACATGTG 3420

TACGCGACAG TTATTTTTAC AGTAAGGTAT TTTCGAGAAA AATGCATTAC GTGTTTTGGA 3480 AAATAGAGTA ATTTAAAAAA TATATTTGAA ATGAAAATCT CCAACACATT AGAAGATGAT 3540 GATGTTAGAT GCCCATCGTG TGCCACAAGT GGTTTTTTCA TTATGTAAAG CACCCGTTGA 3600 ATTAAAAGAA TTTGTTTTTG TTCAACCTCT TCCTGAGGCC CAAGAGCATA TGGGCAATTC 3660 GGATTTCCTG CTGGACCACA AGGTTCTGTT GATATTACAT AGAAACGGGT ATTCCAGACA 3720

GGATTICCIG CIGGACCACA AGGTICTGIT GATATIACAI AGAAACGGGT ATTCCAGACA 3/20
CTICTTATGA TGAAAAGTCCA AAAGTGGCAT CCAATTTAAG GCCCCATCTT TCGTTTGCCAT 3/80
TCTTCATTCC TACAAAGGAC GAACTTGGAT TACATCAACT TTGGACCCAT TGGTTTTTGT 3840
GCTGTCGTCA ACTGACAGTG ATTCACCACT GGTGATGATA AAAATGATGG AAGAAGAGTT 3960
CTGCATTTCA CTTCCTTTTGTTG GCCTGTCCCC ATCTTTCTGT GACACTACACAA TGGGTCTGAT 3960
CTGCATTTCA CTTCCAGCTG CTGGTAGGTC TTTAGCAGGC CTCTGGCACC TCAGCAGTCG 4020
GAGGCACAGA AGCTGCAAAA GGGATCTTCG AAACTGGGCA GAGAAAAAT AAAGTGGAAT 4080 75

ATTAAGTAAA AGTTGGGCAC TAATCTGGAT TAACATTCGA GGAAATCAGT TGAGCTGATT 4140 TAAGTTGTTT TITGTTTGTT AGCAGGTGTG GATGTGGGGT TATGTGGTCA TGCTCAGATC 4200 TACCTAAATC ACCCCAGAGC TITATGTCTT TTATTCATTC TAAATCTTAT TAACCGGAAT 4260 ATGTAGGACC ATTTCAATAC CTTGTAATCC TCCAAGCTTC AATCTGCACA CACTTTCTAT 4320 GAGGGCAGGT ACAACTATTA AGAGATTTTG AACATTAAGT TAGTCCACAA ATATTCAGTG 4380
GGCATCTACT AGGTGACAGC CACTGTGCTA TAATTAGAGA CTTTTTACTA TAAGCATCAA 4440
AAACAGATAA GGCTCTTCCT GGCAGAGTTT ACAGCCTGGT GTACTTGCTA ATGTCTCTTT 4500 AATTAGGTGA AGAATTTTTT TTTTCTATCG AAATTACTAA TCAGTTGGGG AAAAAAATAC 4560 TATAGCAGAC AGCACTAATG TCATCAACAA ACATTGTTCT TCTCCGTGTC CTGGGTACAA 4620 CATCGAATAA TATTTCTTGG CCTCCTTTCC GCTTCTCCTC TCTGCTGTTC CTCTCTACAA 4680 10 GAACCTGGGA GGCCAACGCC TAAAGATCAT AATATCACAA TGGAAGGAAC CTAGATTCCT 4740
AAATGACTGC ATAGGACAGA TCCCATCTCC TCCACCCAAT ACATTATTAG ACTGAACTGT 4800
GACCTGAAAT GAGCAATAAA CTCTGTATTA ATTCACTGAA ATGTTGGGGT TGCTTGTTAT 4860 AGTAGTCGGT CCATCATGAC CAGTAAAACA TAAATCAAAA GTTAATGTAA TTGTTATCCC 4920 ATTATTTAGA GCGAAATAAA TGTTGAATAT ATGGACTTTC TCAGATTAGG AAATACCAAT 4980 15 TAAAAATATA ATAAATAGCT Seq ID NO: 108 Protein sequence: Protein Accession #: NP\_003670.1 20 31 41 MDSSVIQRKK VAVIGGGLVG SLQACFLAKR NFQIDVYEAR EDTRVATFTR GRSINLALSH 60 RGRQALKAVG LEDQIVSQGI PMRARMIHSL SGKKSAIPYG TKSQYILSVS RENLNKDLLT 120 AAEKYPNYKM HENHRLLKCN PEEGMITVLG SDKVPKDVTC DLIVGCDGAY STVRSHLMKK 180
PRPDYSQQYI PHGYMELTIP PKNGDYAMEP NYLHIWPRNT FMMIALPNMN KSFTCTLFMP 240
FEEFEKLLTS NDVVDFFQKY FPDAIPLIGE KLLVQDFFLL PAQPMISVKC SSFHFKSHCV 300 25 LLGDAAHAIV PFFGQGMNAG FEDCLVFDEL MDKFSNDLSL CLPVFSRLRI PDDHAISDLS 360 MYNYIEMRAH VNSSWFIFQK NMERFLHAIM PSTFIPLYTM VTFSRIRYHE AVQRWHWQKK 420 VINKGLFFLG SLIAISSTYL LIHYMSPRSF LCLRRPWNWI AHFRNTTCFP AKAVDSLEQI 480 30 SNLISR Seq ID NO: 109 DNA sequence Nucleic Acid Accession # NM 006115.1 35 Coding sequence: 236-1765 (underlined sequences correspond to start and stop codons) 21 31 41 GCTTCAGGGT ACAGCTCCCC CGCAGCCAGA AGCCGGGCCT GCAGCCCCTC AGCACCGCTC GCGGACACCC CACCCGCTTC CCAGGCGTGA CCTGTCAACA GCAACTTCGC GGTGTGGTGA 120 40 ACTCTCTGAG GAAAAACCAT TTTGATTATT ACTCTCAGAC GTGCGTGGCA ACAAGTGACT 180 AGGAAGCCTAGA AATCCAAGCG TTGGAGGTCC TGAGGCCAGC CTAAGTCGCT TCAAAATTGGA 240
ACGAAGGCGT TTGTGGGGTT CCATTCAGAG CCGATACATC AGCATGAGTG TGTGGACAAG 300 CCCACGGAGA CTTGTGGAGC TGGCAGGGCA GAGCCTGCTG AAGGATGAGG CCCTGGCCAT 360
TGCCGCCCTG GAGTTGCTGC CCAGGGAGCT CTTCCCGCCA CTCTTCATGG CAGCCTTTGA 420
CGGGAGACAC AGCCAGACCC TGAAGGCAAT GGTGCAGGCC TGGCCCTTCA CCTGCCTCCC 480 45 TCTGGGAGTG CTGATGAAGG GACAACATCT TCACCTGGAG ACCTTCAAAG CTGTGCTTGA 540 TGGACTTGAT GTGCTCCTTG CCCAGGAGGT TCGCCCCAGG AGGTGGAAAC TTCAAGTGCT 600
GGATTTACGG AAGAACTCTC ATCAGGACTT CTGGACTGTA TGGTCTGGAA ACAGGGCCAG 660
TCTGTACTCA TTTCCAGGACGCAGAAGCAGC TCAGCCCATG ACAAAGAAGCAGC GAAAAGTAGA 720
TGGTTTGAGC ACAGAGGGCAG AGCAGCCCTT CATTCCAGTA GAGGTGCTCG TAGACCTGTT 780
CCTCAAGGAA GGTGCCTGTG ATGAATTGTT CTCCTACCTC ATTGAGAAAG TGAAGCGAAA 840 50 GAAAATGTA CTACGCCTGT GCTGTAAGAA GCTGAAGATT TTTGCAATGC CCATGCAGGA 900
TATCAAGATG ATCCTGAAAA TGGTGCAGCT GGACTCTATT GAAGATTTGG AAGTGACTTG 960
TACCTGGAAG CTACCCACCT TGGCGAAATT TTCTCCTTAC CTGGGCCAGA TGATTAATCT 1020 55 GCGTAGACTC CTCCTCTCCC ACATCCATGC ATCTTCCTAC ATTTCCCCGG AGAAGGAAGA 1080
GCAGTATATC GCCCAGTTCA CCTCTCAGTT CCTCAGTCTG CAGTGCCTGC AGGCTCTCTA 1140
TGTGGACTCT TTATTTTTCC TTAGAGGCCG CCTGGATCAG TTGCTCAGGC ACGTGATGAA 1200

COCCTIGGAA ACCCTCTCAA TAACTAACTG CCGCCTTTCG GAAGGGGATG TGATGCATCT 1260
GTCCAGAGT CCCAGCGTCA GTCAGCTAAG TGTCCTGAGAGAG ACCTCTCAGA 1300
CGATGTAAGT CCCGAGCCTCCAAGCTCT GCTGAGAGAG GCCTCTGCCAC CCCTCCAGGA 1380
CCTGGTCTTT GATGAGTGTG GGATCACGGA TGATCAGCTC CTTGCCCTCC TGCCTTCCCT 1440
GAGCCACTGC TCCCAGCTTA CAACCTTAAG CTTCTACGGG AATTCCATCT CCATATCTGC 1500

CTTGCAGAGT CTCCTGCAGC ACCTCATCGG GCTGAGCAAT CTGACCCACG TGCTGTATCC 1560
TGTCCCCCTG GAGAGTTATG AGGACATCCA TGGTACCCTC CACCTGGAGA GGCTTGCCTA 1620
TCTGCATGCC AGGCTCAGGG AGTTGCTGTG TGAGTTGGGG CGGCCCAGCA TGGTCTGGCT 1680

TCTGCATGCC AGGETCAGGG AGTIGCTOTG TOATHGGGG COGCAGACATAGCT TGAGGGGAGAGCTC TATGGCCCGG AGCCCATCCT 1740
TAGTGCCAAC CCCTGTCTCCTC ACTGTGGGGGA CAGAACCTTC TATGACCCGG AGCCCATCCT 1740
GTGCCCCTGT TTCATGCCTA ACTAGCTGGG TGCACATATC AAATGCTTCA TTCTGCATAC 1800
TTGGACACTTA AAGCCAGGAAT GTGCATGCAT CTTGAAGCAA CAAAGCAGCC ACAGTTTCAG 1860
ACAAATGTTC AGTGTGAGTG AGGAAAACAT GTTCAGTGAG GAAAAAACAT TCAGACAAAT 1920
GTTCAGTGAG GAAAAAAAGG GGAAGTTGGG GATAGGCAGA TGTTGACTTG AGGAGTTAAT 1920

GRATICTIG GGGAGATACA TCTTATAGAG TTAGAAATAG AATCGAATT GTAAAGGGA 2040 GATTCTGGCT TGGGAAGTAC ATGTAGGAGT TAATCCCTGT GTAGACTGTT GTAAAGGAAAC 2100

TGTTGAAAAT AAAGAGAAGC AATGTGAAGC AAAAAAAAA AAAAAAAA

Seq ID NO: 110 Protein sequence:
Protein Accession #: NP\_006106.1

60

65

70

75

MERRILWGSI QSRYISMSVW TSPRRLVELA GQSLLKDEAL AIAALELLPR ELFPPLFMAA 5 FDGRHSQTLK AMVQAWPFTC LPLGVLMKGQ HLHLETFKAV LDGLDVLLAQ EVRPRRWKLQ 120 VLDLRKNSHQ DFWTVWSGNR ASLYSFPEPE AAQPMTKKRK VDGLSTEAEQ PFIPVEVLVD 180 LFLKEGACDE LFSYLIEKVK RKKNVLRLCC KKLKIFAMPM QDIKMILKMV QLDSIEDLEV 240 TCTWKLPTLA KFSPYLGQMI NLRRLLLSHI HASSYISPEK EEQYIAQFTS QFLSLQCLQA 300 LYVDSLFFLR GRLDQLLRHV MNPLETLSIT NCRLSEGDVM HLSQSPSVSQ LSVLSLSGVM 360 10 LTDVSPEPLQ ALLERASATL QDLVFDECGI TDDQLLALLP SLSHCSQLTT LSFYGNSISI 420 SALQSLLQHL IGLSNLTHVL YPVPLESYED IHGTLHLERL AYLHARLREL LCELGRPSMV 480 WLSANPCPHC GDRTFYDPEP ILCPCFMPN 15 Seq ID NO: 111 DNA sequence Nucleic Acid Accession NM 003815 Coding sequence: 8-2452 (underlined sequences correspond to start and stop codons) 41 51 20 CGCTGCCATG CGCCTGCCCC TGCTCTGGGC CCTGGGGCTC CTGGGCGCGG GCAGCCCTCT 60 GCCTTCCTGG CCGCTCCCAA ATATAGGTGG CACTGAGGAG CAGCAGGCAG AGTCAGAGAA 120 GGCCCCGAGG GAGCCCTTGG AGCCCCAGGT CCTTCAGGAC GATCTCCCAA TTAGCCTCAA 180 AAAGGTGCTT CAGACCAGTC TGCCTGAGCC CCTGAGGATC AAGTTGGAGC TGGACGGTGA 25 CAGTCATATC CTGGAGCTGC TACAGAATAG GGAGTTGGTC CCAGGCCGCC CAACCCTGGT 300
GTGGTACCAG CCCGATGGCA CTCGGGTGGT CAGTGAGGGA CACACTTTGG AGAACTGCTG 360
CTACCAGGGA AGAGTGCGGG GATATGCAGG CTCCTGGGTG TCCATCTGCA CCTGCTCTGG 420 GCTCAGAGGC TTGGTGGTCC TGACCCCAGA GAGAAGCTAT ACCCTGGAGC AGGGGCCTGG 480
GGACCTTCAG GGTCCTCCCA TTATTTCGCG AATCCAAGAT CTCCACCTGC CAGGCCACAC 540 30 CTGTGCCCTG AGCTGGCGGG AATCTGTACA CACTCAGACG CCACCAGAGC ACCCCCTGGG 600 ACAGCGCCAC ATTCGCCGGA GGCGGGATGT GGTAACAGAG ACCAAGACTG TGGAGTTGGT 660
GATTGTGGCT GATCACTCGG AGGCCCAGAA ATACCGGGAC TTCCAGCACC TGCTAAACCG 720 CACACTGGAA GTGGCCCTCT TGCTGGACAC ATTCTTCCGG CCCCTGAATG TACGAGTGGC 780 ACTAGTGGGC CTGGAGGCCT GGACCCAGCG TGACCTGGTG GAGATCAGCC CAAACCCAGC 840
TGTCACCCTC GAAAACTTCC TCCACTGGCG CAGGGCACAT TTGCTGCCTC GATTGCCCCA 900
TGACAGTGCC CAGCTGGTGA CTGGTACTTC ATTCTCTGGG CCTACGGTGG GCATGGCCAT 960 35 TGACAGTGCC CAGCTGGTGA CTGGTACTTC ATTCTCTGGG CCTACGGTGG GCATGGCCAT 960
TCAGAACTCC ATCTGTTCTC CTGACTTCTC AGGAGGTGTG AACATGGACC ACTCCACCAG 1020
CATCCTGGGA GTCGCCTCCT CCATAGCCCA TGAGTTGGGC CACAGCCTGG GCCTGGACCA 1080
TGATTTGCCT GGGAATAGCT GCCCCTGTCC AGGTCCAGCC CCAGCCAAGA CCTGCATCAT 1140
GGAGGCCTCC ACAGACTTCC TACCAGGCCT GAACTTCAGC AACTGCAGCC GACGGGCCCT 1200
GGAGAAAGCC CTCCTGGATG GAATGGGCAG CTGCCTCTTC GAACGGCTGC CTAGCCTACC 1260
CCCTATGGCT GCTTTCTGCG GAAATATGTT TGTGGAGCCG GGCGAGCAGT GTGACTGTGG 1320
CTTCCTGGAT GACTGCGTCG ATCCCTGCTG TGATTCTTTG ACCTGCCAGC TGAGGCCAGG 1380 40 TGCACAGTGT GCATCTGACG GACCCTGTTG.TCAAAATTGC CAGCTGCGCC CGTCTGGCTG 1440 45 GCAGTGTCCT CCTACCAGAG GGGATTGTGA CTTGCCTGAA TTCTGCCCAG GAGACAGCTC 1500 CCAGTGTCCC CCTGATGTCA GCCTAGGGGA TGGCGAGCCC TGCGCTGGCG GGCAAGCTGT 1560 GTGCATGCAC GGGCGTTGTG CCTCCTATGC CCAGCAGTGC CAGTCACTTT GGGGACCTGG 1620 AGCCCAGCCC GCTGCGCCAC TTTGCCTCCA GACAGCTAAT ACTCGGGGAA ATGCTTTTGG 1680
GAGCTGTGGG CGCAACCCCA GTGGCAGTTA TGTGTCCTGC ACCCCTAGAG ATGCCATTTG 1740 50 TGGGCAGCTC CAGTGCCAGA CAGGTAGGAC CCAGCCTCTG CTGGGCTCCA TCCGGGATCT 1800
ACTCTGGGAG ACAATAGATG TGAATGGGAC TGAGCTGAAC TGCAGCTGGG TGCACCTGGA 1860
CCTGGGCAGT GATGTGGCCC AGCCCCTCCT GACTCTGCCT GGCACAGCCT GTGGCCCTGG 1920 CCTGGTGTGT ATAGACCATC GATGCCAGCG TGTGGATCTC CTGGGGGCAC AGGAATGTCG 1980
AAGCAAATGC CATGGACATG GGGTCTGTGA CAGCAACAGG CACTGCTACT GTGAGGAGGG 2040
CTGGGCACCC CCTGACTGCA CCACTCAGCT CAAAGCAACC AGCTCCCTGA CCACAGGGCT 2100 55 GCTCCTCAGC CTCCTGGTCT TATTGGTCCT GGTGATGCTT GGTGCCGGCT ACTGGTACCG 2160
TGCCCGCCTG CACCAGCGAC TCTGCCAGCT CAAGGGACCC ACCTGCCAGT ACAGGGCAGC 2220
CCAATCTGGT CCCTCTGAAC GGCCAGGACC TCCGCAGAGG GCCCTGCTGG CACGAGGCAC 2280 TAAGTCTCAG GGGCCAGCCA AGCCCCCACC CCCAAGGAAG CCACTGCCTG CCCACCCCCA 2340
GGGCCGGTGC CCATCGGGTG ACCTGCCCGG CCCAGGGGCT GGAATCCCGC CCCTAGTGGT 2400
ACCCTCCAGA CCAGCGCCAC CGCCTCCGAC AGTGTCCTCG CTCTACCTC<u>T GA</u>CCTCTCCG 2460 60 GAGGTTCCGC TGCCTCCAAG CCGGACTTAG GGCTTCAAGA GGCGGGCGTG CCCTCTGGAG 2520
TCCCCTACCA TGACTGAAGG CGCCAGAGAC TGGCGGTGTC TTAAGACTCC GGGCACCGCC 2580
ACGCGCTGTC AAGCAACACT CTGCGGACCT GCCGGCGTAG TTGCAGCGGG GGCTTGGGGA 2640 65 GGGGCTGGGG GTTGGACGGG ATTGAGGAAG GTCCGCACAG CCTGTCTCTG CTCAGTTGCA 2700 ATAAACGTGA CATCTTGGGA GCGTTAAAAA AAAAAAAAA Seq ID NO: 112 Protein sequence:
Protein Accession #: NP\_003806.2 Protein Accession #: 70 MRIALLWALG LIGAGSPLPS WPLPNIGGTE EQQAESEKAP REPLEPQVLQ DDLPISLKKV 60 LQTSLPEPLR IKLELDGDSH ILELLQNREL VPGRPTLVWY QPDGTRVVSE GHTLENCCYQ 120 GRVRGYAGSW VSICTCSGLR GLVVLTPERS YTLEQGPGDL QGPPIISRIQ DLHLPGHTCA 180 75 LSWRESVHTQ TPPEHPLGQR HIRRRRDVVT ETKTVELVIV ADHSEAQKYR DFQHLLNRTL 240 EVALLLDTFF RPLNVRVALV GLEAWTQRDL VEISPNPAVT LENFLHWRRA HLLPRLPHDS 300

11 21 31

51

PCT/US02/02242

AQLVTGTSFS GPTVGMAIQN SICSPDFSGG VNMDHSTSIL GVASSIAHEL GHSLGLDHDL 360 PGNSCPCPGP APAKTCIMEA STDFLPGLNF SNCSRRALEK ALLDGMGSCL FERLPSLPPM 420 AAFCGNMFVE PGEQCDCGFL DDCVDPCCDS LTCQLRPGAQ CASDGPCCQN CQLRPSGWQC 480
RPTRGDCDLP EFCPGDSSQC PPDVSLGDGE PCAGGQAVCM HGRCASYAQQ CQSLWGPGAQ 540
PAAPLCLQTA NTRGNAFGSC GRNPSGSYVS CTPRDAICGQ LQCCTGRTQP LLGSIRDLLW 600 PAAPLLQIA NIKUNAPUSE UKNYSUSY YS CIPKDAICOQ LQCQIGRIQP ELUSIKULLW 600
ETIDVNGTEL NCSWVHLDLG SDVAQPLLTL PGTACGPGLV CIDHRCQRVD LLGAQECRSK 660
CHGHGVCDSN RHCYCEEGWA PPDCTTQLKA TSSLTTGLLL SLLVLLVLVI LGAGYWYRAR 720
LHQRLCQLKG PTCQYRAAQS GPSERPGPPQ RALLARGTKS QGPAKPPPPR KPLPADPQGR 780
CPSGDLPGPG AGIPPLVVPS RPAPPPPTVS SLYL 10 Seg ID NO: 113 DNA sequence Nucleic Acid Accession #: NM\_002416 Coding sequence: 40-417 (underlined sequences correspond to start and stop codons) 15 41 31 51 ATCCAATACA GGAGTGACTT GGAACTCCAT TCTATCACT<u>A TG</u>AAGAAAAG TGGTGTTCTT 60 TTCCTCTTGG GCATCATCTT GCTGGTTCTG ATTGGAGTGC AAGGAACCCC AGTAGTGAGA 120 AAGGGTCGCT GTTCCTGCAT CAGCACCAAC CAAGGGACTA TCCACCTACA ATCCTTGAAA 180 20 25 TICCAAAGGA GGATGGCATA TAATACAAAG GCTTATTAAT TIGACTAGAA AATTTAAAAC 540
ATTACTCTGA AATTGTAACT AAAGTTAGAA AGTTGATTIT AAGAATCCAA ACGTTAAGAA
TIGATTAAAGG CTAGTATTG CTTTGTTCTT CTACCACCCA CCAGTTGAAT TITCATCATGC 660
TTAAGGCCAT GATTTTAGCA ATACCCATGT CTACAACAGAT GTTCACCACA CCACACCCCA 720
CTCACAACAG CTGCCTGGAA GAGCAGCCCT AGGCTTCCAC GTACTGCAGC CTCCAGAGAG 780
TATCTGAGGC ACATGTCAGC AAGTCCTAAG CCTGTTAGCA TGCTGGTGAG CCAGACAGTT 840
TGAAATTGAG CTGGACCTCA CCAAGCTGCT GTGGCCATCA ACCTCTGTAT TIGAATCAGC 900
CTACAGGCCT CACACACAAT GTGTCTGAGA GATTCATGCT GATTGTTATT GGGTATCACC 960
ACTGGAGATC ACCAGTGTGT GGCTTTCAGA GCCCTCTTTC TGGCTTTGGA AGCCATTGA 1020
TTCCATCTTG CCCGCTCAGG CTGACCACTT TATTTCTTTT TGTTCCCCTT TGCTTCATTC 1080 30 ACTGGAGATC ACCAGTGTG GGCTTTCAGA GCCTCCTTTC TGGCTTGGA AGCLATGIA 1020
TTCCAATCTTG CCCGCTCAGG CTGACCACTT TATTTCTTTT TGTTCCCCTT TGCTTCATC 1080
AAGTCAGCTC TTCTCCATCC TACCACAATG CAGTGCCTTT CTTCTCTCA GTGCACCTGT 1140
CATATGCTCT GATTTATCTG AGTCAACTCC TTTCTCATCT TGTCCCCAAC ACCCCCACAGA 1200
AGTGCTTTCT TCTCCCAATT CATCCTCACT CAGTCCAGCT TAGTTCAAGT CCTGCCTCTT 1250
AAATAAACCT TTTTGGACAC ACAAATTATC TTAAAACTCC TGTTTCACTT GGTTCAGTAC 1320
CACATGGGTG AACACTCAAT GGTTAACTAA TTCTTGGGTG TTTATCCTAT CTCTCCAACC 1380 35 AGATTGTCAG CTCCTTGAGG GCAAGAGCA CAGTATATTT CCCTGTTTCT TCCACAGTGC 1440
CTAATAATAC TGTGGAACTA GGTTTTAATA ATTTTTTAAT TGATGTTGTT ATGGGCAGGA 1500
TGGCAACCAG ACCATTGTCT CAGAGCAGGT GCTGGCTCTT TCCTGGCTAC TCCATGTTGG 1560 40 CTAGCCTCTG GTAACCTCTT ACTTATTATC TTCAGGACAC TCACTACAGG GACCAGGGAT 1620
GATGCAACAT CCTTGTCTTT TTATGACAGG ATGTTTGCTC AGCTTCTCCA ACAATAAGAA 1680
GCACGTGGTA AAACACTTGC GGATATTCTG GACTGTTTTT AAAAAATATA CAGTTTACCG 1740 45 AAAATCATAT AATCTTACAA TGAAAAGGAC TTTATAGATC AGCCAGTGAC CAACCTTTTC 1800
CCAACCATAC AAAAATTCCT TTTCCCGAAG GAAAAGGGCT TTCTCAATAA GCCTCAGCTT 1860
TCTAAGATCT AACAAGATAG CCACCGAGAT CCTTATCGAA ACTCATTTTA GGCAAATATG 1920 50 55 AAACAGTATT GACTTGTATA CCTTGTAATT TGAAATATTT TCTTTGTTAA AATAGAATGG 2520 TATCAATAAA TAGACCATTA ATCAG 60 Seq ID NO: 114 Protein sequence:
Protein Accession #: NP\_002407 41 21 31 65 70 Seq ID NO: 115 DNA sequence NM\_003238.1 Nucleic Acid Accession #: Coding sequence: 182-1426 (underlined sequences correspond to start and stop codons) 21 31 75 CAAGCAGGAT ACGTTTTCT GTTGGGCATT GACTAGATTG TTTGCAAAAG TTTCGCATCA 60 AAAACAAACA ACAACAACAA AAAACCAAAC AACTCTCCTT GATCTATACT TTGAGAATTG 120

WO 02/059377

TTGATTTCTT TTTTTTATT CTGACTTTTA AAAACAACTT TTTTTTCCAC TTTTTTAAAA 180 CACTITICTAC AGACCCTACT TCAGAATTGT TCGATTTGAC GTCTCAGCAA TGGAGAAGAA 600
TGCTTCCAAT TTGGTGAAAG CAGAGTTCAG AGTCTTTCGT TTGCAGAACC CAAAAGCCAG 660
AGTGCCTGAA CAACGGATTG AGCTATATCA GATTCTCAAG TCCAAAGATT TAACATCTCC 720 10 AACCCAGCGC TACATCGACA GCAAAGTTGT GAAAACAAGA GCAGAAGGCG AATGGCTCTC 780 CTTCGATGTA ACTGATGCTG TTCATGAATG GCTTCACCAT AAAGACAGGA ACCTGGGATT 840
TAAAATAAGC TTACACTGTC CCTGCTGCAC TTTTGTACCA TCTAATAATT ACATCATCCC 900 AAATAAAAGT GAAGAACTAG AAGCAAGATT TGCAGGTATT GATGGCACCT CCACATATAC 960 15 CAGTGGTGAT CAGAAAACTA TAAAGTCCAC TAGGAAAAAA AACAGTGGGA AGACCCCACA 1020 TCTCCTGCTA ATGTTATTGC CCTCCTACAG ACTTGAGTCA CAACAGACCA ACCGGCGGAA 1080 GAAGCGTGCT TTGGATGCGG CCTATTGCTT TAGAAATGTG CAGGATAATT GCTGCCTACG 1140 TCCACTITAC ATTGATTICA AGAGGGATCT AGGGTGGAAA TGGATACACG AACCCAAAGG 1200 GTACAATGCC AACTTCTGTG CTGGAGCATG CCCGTATTTA TGGAGTTCAG ACACTCAGCA 1260 GRACARGCE AACH ICHGIG CHGAAGCATG CCCUTATHA IGAGATHCAG ACACLAGCA 1200
CAGCAGGGGTC CTGAGCTTAT ATAATACCAT AAATCCAGAA GCATCTGCTT CTCCTTGCTG 1320
CGTGTCCCAA GATTTAGAAC CTCTAACCAT TCTCTACTAC ATTGGCAAAA CACCCAAGAT 1380
TGAACAGCTT TCTAATATGA TTGTAAAGTC TTGCAAATGC AGCTAAAATT CTTGGAAAAG 1440
TGGCAAGACC AAAATGACAA TGATGATGAT AATGATGATG ACGACGACAA CGATGATGCT 1500
TGTAACAAGA AAACATAAGA GAGCCTTGGT TCATCAGTGT TAAAAAATTT TTGAAAAGGC 1560
GGTACTAGTT CAGACACTTT GGAAGTTTGT GTTCTGTTTG TTAAAACTGG CATCTGACAC 1620 20 25 AAAAAAAGTT GAAGGCCTTA TTCTACATTT CACCTACTTT GTAAGTGAGA GAGACAAGAA 1680 GCAAATTTTT TTAAA Seq ID NO: 116 <u>Protein sequence:</u>
Protein Accession #: NP\_003229.1 30 31 MHYCVLSAFL ILHLVTVALS LSTCSTLDMD QFMRKRIEAI RGQILSKLKL TSPPEDYPEP 60 35 EEVPPEVISI YNSTROLLOE KASRRAAACE RERSDEEYYA KEVYKIDMPP FFPSENAIPP 120 TFYRPYFRIV RFDVSAMEKN ASNLVKAEFR VFRLONPKAR VPEQRIELYQ ILKSKDLTSP 180 TORYIDSKVV KTRAEGEWLS FOVTDAVHEW LHHKDRNLGF KISLHCPCCT FVPSNNYIIP 240
NKSEELEARF AGIDGTSTYT SGDQKTIKST RKKNSGKTPH LLLMLLPSYR LESQQTNRRK 300
KRALDAAYCF RNVQDNCCLR PLYIDFKRDL GWKWIHEPKG YNANFCAGAC PYLWSSDTQH 360 40 SRVLSLYNTI NPEASASPCC VSQDLEPLTI LYYIGKTPKI EQLSNMIVKS CKCS Seg ID NO: 117 DNA sequence Nucleic Acid Accession # NM\_000095.1 Coding sequence: 26-2299 (underlined sequences correspond to start and stop codons) 45 CAGCACCCAG CTCCCCGCCA CCGCCATGGT CCCCGACACC GCCTGCGTTC TTCTGCTCAC 60 CCTGGCTGCC CTCGGCQCGT CCGGACAGGG CCAGAGCCCG TTGGGCTCAG ACCTGGGCCC 120
GCAGATGCTT CGGGAACTGC AGGAAACCAA CGCGGCGCTG CAGGACGTGC GGGACTGGCT 180
GCGGCAGCAG GTCAGGGAGA TCACGTTCCT GAAAAACACG GTGATGGAGT GTGACGCGTG 240 50 GCGGCAGCAG GTCAGGGAGA TCACGTTCCT GAAAAACACG GTGATGGAGT GTGACGCGTG 240
CGGGATGCAG CAGTCAGTAC GCACCGGCCT ACCCAGCGTG CGGCCCCTGC TCCACTGGCC 300
GCCCGGCTTC TGCTTCCCCG GCGTGGCCTG CATCCAGACG GAGAGCGGCG GCCGCTGGCG 360
CCCTGCCCC GCGGGCTTCA CGGGCAACGG CTCGCACGCA ACGACGGCG GCCGCTGCGG 360
CCCTGCCCC GCGGGGTTCA CGGGCAACGG CTCGCACTGC ACCGACGTCA ACGAGTGCAA 420
GGCCAACCCC TGCTTCCCCCC GAGTCCGCTG TATCAACACC AGCCCGGGGT TCCGCTGCGA 480
GGCCAACAAG CAGGTTTGCA CGGACATCAA CGAGTGTGAG ACCGGGCTTTCGCCAA 540
GCCAACTCC GTGTGCATCA ACACCCGGGG CTCCTTCCAG TGCGGCCCGT GCCAGCCCGG 660
CTTCGTGGGC GACCAGGCGT CCGGCTGCCA GCGCGCGCA CAGGCCTTC GCCAGCCCGACGG 720
CTCGCCCAGCG GAGTGCCACG AGCATGCAGA CTGCGTCTTA GAGCGCGATG GCTCGCCGACGG 720
GTGCGTTGT CCCGACGGA AGCTGCCACA CGGGATCCTC TGTGGTCGCG ACACTGACCT 840
AGACGGCTTC CCGGACGAGA AGCTGCCGTC CCCGGACGC CAGTGCCGTA AGGACACTG 900
CGTGACTTC CCCGACGGG ACGCGGCAGAGGA TGTGGACCGC GATGGCATCA AGGACACTG 960
CGATCCGGAT GCCAACTCAG GGCCAGGAGGA TGTGGACCGC GATGGCATCA GAGACCCT 960
CGATCCGGAT GCCAACTCAG GGCCAGGAGGA CAGGGCCG CAGTGCCATA AGGAACCTG 960
CGATCCGGAT GCCGACGGGG ACGGGGTCCC CAATGAAAAAG GACAACTGCC CGCTGGTGGC 1020
GAACCAGAC CAGCGCAACA CGGACGAGACA CAGACCAGGAC GACGGCGA ACGACCGCG ATGCCCAACTGCCG 1080
GTCCCAGAAC AACGACCA CAGACGACA CAGACCAGGAC GACCGGACTGCCG ATGCGTCCG ATGCGTCCGA 1140 55 60 65 70 TAACAGTGCC CAGGAGGACT CAGACCACGA TGGCCAGGGT GATGCCTGCG ACGACGACGA 1440
CGACAATGAC GGAGTCCCTG ACAGTCGGGA CAACTGCCGC CTGGTGCCTA ACCCCGGCCA 1500
GGAGGACGCG GACAGGGACG GCGTGGGCCA CGTGTGCCAG GACGACTTTG ATGCAGACAA 1560 GGTGGTAGAC AAGATCGACG TGTGTCCGGA GAACGCTGAA GTCACGCTCA CCGACTTCAG 1620
GGCCTTCCAG ACAGTCGTGC TGGACCCGGA GGGTGACGCG CAGATTGACC CCAACTGGGT 1680
GGTGCTCAAC CAGGGAAGGG AGATCGTGCA GACAATGAAC AGCGACCCAG GCCTGGCTGT 1740 75

PCT/US02/02242 WO 02/059377

GGATGACGAC TATGCGGGCT TCATCTTTGG CTACCAGGAC AGCTCCAGCT TCTACGTGGT 1860 CATGTGGAAG CAGATGGAGC AAACGTATTG GCAGGCGAAC CCCTTCCGTG CTGTGGCCGA 1920
GCCTGGCATC CAACTCAAGG CTGTGAAGTC TTCCACAGGC CCCGGGGAAC AGCTGCGGAA 1980
CGCTCTGTGG CATACAGGAG ACACAGAGTC CCAGGTGCGG CTGCTGTGA AGGACCCGCG 2040 AAACCTGGGT TGGAAGGACA AGAAGTCCTA TCGTTGGTTC CTGCAGCACC GGCCCCAAGT 2100
GGGCTACATC AGGGTGCGAT TCTATGAGGG CCCTGAGCTG GTGGCCGACA GCAACGTGGT 2160
CTTGGACACA ACCATGCGGG GTGGCCGCCT GGGGGTCTTC TGCTTCTCCC AGGAGAACAT 2220 CATCTGGGCC AACCTGCGTT ACCGCTGCAA TGACACCATC CCAGAGGACT ATGAGACCCA 2280
TCAGCTGCGG CAAGCCTAGG GACCAGGGTG AGGACCCGCC GGATGACAGC CACCCTCACC 2340
GCGGCTGGAT GGGGGCTCTG CACCCAGCCC AAGGGGTGGC CGTCCTGAGG GGGAAGTGAG 2400 AAGGGCTCAG AGAGGACAAA ATAAAGTGTG TGTGCAGGG

Seq ID NO: 118 Protein sequence:
Protein Accession #: NP\_000086.1

5

10

15

35

40

45

50

55

60

65

70

75

31 41

MVPDTACVLL LTLAALGASG QGQSPLGSDL GPQMLRELQE TNAALQDVRD WLRQQVREIT 60 MYPDTACVIL ITLAALDASG QGGPLUSDLEGYERINAKEUS INAALDAVE WEEGVALET 120

NGSHCTDVNE CNAHPCFPRV RCINTSPGFR CEACPPGYSG PTHQGVGLAF AKANKQVCTD 180

NECETGQEN CVPNSVCINT RGSFQCGPCQ PGFVGDQASG CQRGAQRFCP DGSPSECEEHE 240

ADCVLERDGS RSCVCRVGWA GNGILCGRDT DLDGFPDEKL RCPPPQCRKD NCVTVPNSGQ 300

EDVDRDGIGD ACDPDADGDG VPNEKDNCPL VRNPDQRNTD EDKWGDACDN CRSQKNDDQK 360

DTDQDGRGDA CDDDIDGDRI RNQADNCPRV PNSDQKDSDG DGIGDACDNC PQKSNPDQAD 420 20 DTDQDGRGDA CDDDIDGDRI RNQADNCPRV PNSDQKDSDG DGIGDACDNC PQKSNPDQAD 420 VDHDFVGDAC DSDQDQDGDG HQDSRDNCPT VPNSAQEDSD HDGQGDACDD DDDDNDGVPDS 480 RDNCRLVPNP GQEDADRDGV GDVCQDDFDA DKVVDKIDVC PENAEVTLTD FRAFQTVVLD 540 PEGDAQIDPN WVVLNQGREI VQTMNSDPGL AVGYTAFNGV DFEGTFHVNT YTDDDYAGFI 660 FGYQDSSSFY VVMWKQMEQT YWQANPFRAV AEPGIQLKAV KSSTGPGEQL RNALWHTGDT 660 ESQVRLLWKD PRNVGWKDKK SYRWFLQHRP QVGYTRVRFY EGPELVADSN VVLDTTMRGG 720 RLGVFCFSQE NIIWANLRYR CNDTIPEDYE THQLRQA 25 30

Seg ID NO: 119 DNA sequence NM\_014211 Nucleic Acid Accession #: Coding sequence: 157-1479 (underlined sequences correspond to start and stop codons)

31 21

GGGACAGGGC TGAGGATGAG GAGAACCCTG GGGACCCAGA AGACCGTGCC TTGCCCGGAA 60
GTCCTGCCTG TAGGCCTGAA GGACTTGCCC TAACAGAGCC TCAACAACTA CCTGGTGATT 120
CCTACTTCAG CCCCTTGGTG TGAGCAGGTT CTCAACATGA ACTACAGCCC CCACTTGGCC 180
TTCGTGTGTC TGAGTCTCTT CACTGAGAGG ATGTGCATCC AGGGGAGTCA GTTCAACGTC 240
GAGGTCGGCA GAAGTGACAA GCTTTCCCTG CCTGGCTTTG AGAACCTCAC AGCAGGATAT 300
AACAAATTTC TCAGGCCCAA TTTTGGTGGA GAACCCGTAC AGATAGCGCT GACTCTGGAC 360
ATTGCAAGTA TCTCTAGGAT TTCAGAGAGT AACATGGACT ACACAGCCAC CATATACCTC 420
CGACAGCGCT GGATGGACCA GCGCTGGTG TTTGAAGGCA ACAAGACGT CACTCTGGAT 480
GCCCGCCTCG TGGAGTTCCT CTGGGTGCCA GATACTTACA TTGTGGAGTC CAAGAAGTCC 540 TTCCTCCATG AAGTCACTGT GGGAAACAGG CTCATCCGCC TCTTCTCCAA TGGCACGGTC 600 CTGTATGCCC TCAGAATCAC GACAACTGTT GCATGTAACA TGGATCTGTC TAAATACCCC 660 ATGGACACAC AGACATGCAA GTTGCAGCTG GAAAGCTGGG GCTATGATGG AAATGATGTG 720 GAGTTCACCT GGCTGAGAGG GAACGACTCT GTGCGTGGAC TGGAACACCT GCGGCTTGCT 780
CAGTACACCA TAGAGCGGTA TTTCACCTTA GTCACCAGAT CGCAGCAGGA GACAGGAAAT 840
TACACTAGAT TGGTCTTACA GTTTGAGCTT CGGAGGAATG TTCTGTATTT CATTTTGGAA 900 TACACTAGAT TGGTCTTACA GTTTGAGCTT CGGAGGAATG TTCTGTATT CATTTGGAA 900
ACCTACGTTC CTTCCACTTT CCTGGTGGTG TTGTCCTGGG TTTCATTTTG GATCTTCTC 960
GATTCAGTCC CTGCAAGAAC CTGCATTGGA GTGAACGACCG TGTTACAATTTG GATCTCTCTC 960
ATGATCGGGT CCCGCACTTC TCTTCCCAAC ACCAACTGCT TCATCAAGGC CATCGATGGG 1080
TACCTGGGGA TCTGCTTTAG CTTTGTGTTT GGGGCCTTGC TAGAATATGC AGTTGCTCAC 1140
TACAGTTCCT TACAGCAGAT GGCAGCCAAA GATAGGGGA CAACAAAGGA AGTAGAAGAA 1200
GTCAGTTATTA CTAATATCAT CAACAGCTCC ATCTCCAGCT TTAAACGGAA GATAGCCTT 1260
GCCAGCATTG AAATTTCCAG CGACAACGTT GACTACAGTG ACTTGACAAT GAAAACCAGC 1320
GACAAGTTCA AGTTTGTCTT CCGAGGAAAG ATGGGCAGGA TTGTTCAATT 1380
CAAAACCCCA GTAATGTTGA TCACTATTCC AAACTACTGT TTCCTTTGAT TTTTACACATT 1380
GCCAATGTAT TTTACTGGGC ATACTACATG TATTTTTGAG TCAATGTTAA ATTTCTTGCA 1500
TGCCATAGGT CTTCAACAGG ACAAGATAAT GATGTAAATG GTATTTTAGG CCAAAGGTGC 1560
ACCCACACCC AATGGTGCTA CAAGTGACTG AAATAATATT TGAGTCTTTC GCTCAAAGA 1620 ACCACATCC AATGGTGCTA CAAGTGACTG AAATAATATT TGAGTCTTTC TGCTCAAAGA 1620
ATGAAGCTCC AACCATTGTT CTAAGCTGTG TAGAAGTCCT AGCATTATAG GATCTTGTAA 1680
TAGAAACATC AGTCCATTCC TCTTTCATCT TAATCAAGGA CATTCCCATG GAGCCCAAGA 1740 TAGAAACATC AGTCCATTCC TCTTTCATCT TAATCAAGGA CATTCCCATG GAGCCCAAGA 1740
TTACAAATGT ACTCAGGGCT GTTTATTCGG TGGCTCCCTG GTTTGCATTT ACCTCATATA 1800
AAGAATGGGA AGGAGACCAT TGGGTAACCC TCAAGTGTCA GAAGTTGTTT CTAAAACTAAC 1860
TATACATGTT TTTTACTAAA TCTCTGCAGT GCTTATAAAA TACATTGTTG CCTATTTAGG 1920
GAGTAACATT TTCTAGTTTTT TGTTTCTGGT TAAAATGAAA TATGGGCTTA TGTCAATTCA 1980
TTGGAAGTCA ATGCACTAAC TCAATACCAA GATGAGTTTT TAAAATAATGA ATATTATTTA 2040
AATACCACAAC AGAATTATCC CCAATTTCCA ATAAGTCCTA TCATTGAAAA TTCAAATATA 2100
AGTGAAGAAA AAATTAGTAG ATCAACAATC TAAACAAATC CCTCGGTTCT AAGATACAAT 2160
GGATTCCCCA TACTGGAAGG ACTCTGAGGC TITATTCCC CCACTATTGCAT ATCTTATACAT 2220
TTTATTATTA TACACACCATC CATCCTAAAC TATACTAAAG CCCTTTTCCC ATGCATGAT 2220
GGAAATGGAA GATTTTTTTG TAACTTGTTC TAGAAGTCTT AATATGGGCT GTTGCCATGA 2340
AGGCTTGCAG AATTGAGTCC ATTTTCTAGC TGCCTTTATT CACATAGTGTA TGGGGTACTA 2400

GGGACAGGGC TGAGGATGAG GAGAACCCTG GGGACCCAGA AGACCGTGCC TTGCCCGGAA 60

PCT/US02/02242 WO 02/059377

AAAGTACTGG GTTGACTCAG AGAGTCGCTG TCATTCTGTC ATTGCTGCTA CTCTAACACT 2460 GAGCAACACT CTCCCAGTGG CAGATCCCCT GTATCATTCC AAGAGGAGCA TTCATCCCTT 2520 TGCTCTAATG ATCAGGAATG ATGCTTATTA GAAAACAAAC TGCTTGACCC AGGAACAAGT 2580
GGCTTAGCTT AAGTAAACTT GGCTTTGCTC AGATCCCTGA TCCTTCCAGC TGGTCTGCTC 2640
TGAGTGGCTT ATCCCGCATG AGCAGGAGCG TGCTGGCCCT GAGTACTGAA CTTTCTGAGT 2700 5 AACAATGAGA CACGTTACAG AACCTATGTT CAGGTTGCGG GTGAGCTGCC CTCTCCAAAT 2760 CCAGCCAGAG ATGCACATTC CTCGGCCAGT CTCAGCCAAC AGTACCAAAA GTGATTTTTG 2820 AGTGTGCCAG GGTAAAGGCT TCCAGTTCAG CCTCAGTTAT TTTAGACAAT CTCGCCATCT 2880 TTAATTICIT AGCTTCCTGT TCTAATAAAT GCACGGCTTT ACCTTTCCTG TCAGAAATAA 2940 ACCAAGGCTC TAAAAGATGA TTTCCCTTCT GTAACTCCCT AGAGCCACAG GTTCTCATTC 3000 CTTTTCCCAT TATACTTCTC ACAATTCAGT TTCTATGAGT TTGATCACCT GATTTTTTTA 3060 10 ACAAAATATT TCTAACGGGA ATGGGTGGGA GTGCTGGTGA AAAGAGATGA AATGTGGTTG 3120
TATGAGCCAA TCATATTTGT GATTTTTAA AAAAAGTTTA AAAGGAAATA TCTGTTCTGA 3180
AACCCCACTT AAGCATTGTT TTTATATAAA AACAATGATA AAGATGTGAA CTGTGAAATA 3240 15 AATATACCAT ATTAGCTACC CACC Seq ID NO: 120 Protein sequence:
Protein Accession #: NP\_055026.1

20 31 11 21 MNYSLHLAFV CLSLFTERMC IQGSQFNVEV GRSDKLSLPG FENLTAGYNK FLRPNFGGEP 60 VQIALTLDIA SISSISESNM DYTATIYLRQ RWMDQRLVFE GNKSFTLDAR LVEFLWVPDT 120 VQIALILDIA SISSISESIMM DYTATITLEQ KWINDQLVFE GINSFILDAR EVEREWYPT 120
YIVESKKSFL HEVTVGNRLI RLFSNGTVLY ALRITTIVAC NMDLSKYPMD TQTCKLQLES 180
WGYDGNDVEF TWLRCNDSVR GLEHLRLAQY TIERYFTLVT RSQQETGNYT RLVLQFELRR 240
NVLYFILETY VPSTFLVVLS WVSFWISLDS VPARTCIGVT TVLSMTTLMI GSRTSLPNTN 300
CFIKAIDVYL GICFSFVFGA LLEYAVAHYS SLQQMAAKDR GTTKEVEEVS ITNIINSSIS 360
SFKRKISFAS IEISSDNVDY SDLTMKTSDK FKFVFREKMG RIVDYFTIQN PSNVDHYSKL 420 25 LFPLIFMLAN VFYWAYYMYF

Seq ID NO: 121 DNA sequence Nucleic Acid Accession # NM\_001854 Coding sequence: 163-5582 (underlined sequences correspond to start and stop codons)

30

35

AACCATCAAA TTTAGAAGAA AAAGCCCTTT GACTTTTTCC CCCTCTCCCT CCCCAATGGC 60 TGTGTAGCAA ACATCCCTGG CGATACCTTG GAAAGGACGA AGTTGGTCTG CAGTCGCAAT 120
TTCGTGGGGTT GAGTTCACAG TTGTGAGTGC GGGGCTCGGA GATGGAGCCG TGGTCCTCTA 180 45 50 55 GGACAAATGA GCCAAATCCA GTTGAAGAAA TATTTACIGA ADAATATIA ACGGGAGAGAGGA 1200
ATTATGATTC CCAGAGGAAA AATTCTGAGG ATACACTATA TGAAACCAAA GAAATAGACG 1200
GCAGGGATTC TGATCTTCTG GTAGATGGAG ATTAGACTATA TGAAACCAAA GAAATAGACG 1200
AAGAATATGA AGATAAACCA ACAAGCCCCC CTAATGAGAG ATTTGGTCCA GGTGTACCAG 1380
CAGAAACTGA TATTACAGAA ACAAGCATAA ATGGCCATGG TGCAATAGGA GAGAAAGGAC 1440
AGAAAGGAGA ACCAGCAGTG GTTGAGCCTG GTATGCTTGT CGAAGGACCA CCAGGACCAG 1500
CAGGACCTGC AGGTATTATG GGTCCTCCAG GTCTACCAG GCCCCACTGGA CCCCTGGTG 1560
ACCCTGGCGA TAGGGGCCC CCAGGACGTC CTGGCTTACC AGGGGCTGAT GGTCTACCTG 1620
GTCCTCCTGG TACTATGTTG ATGTTACCGT TCCGTTATGC TGGTGATGGT TCCAAAAGGAC 1680
CAACCATCTC TGCTCAGGAA GCTCAGGCCC AAGCTATTCT TCAGCAGGCC CGGATTGCTC 1740
TGAGAGGCCC ACCTGGCCCA ATGGGTCTAA CTGGAAGACC AGGTCCTGTG GGGGGGCCT 1800
ATTCATCTGG GGCCAAAGGT GAGAGTGGTG ATCCAGGTC TCAGGGCCCT CGAGTGGCT 1800
AGGGTCCCCC TGGTCCAACG GGAAAACCTG GAAAAAGGGG TCGTCCAGGT GCAGATGGAG 1920
GAACAGGAAT GCCAGGAGAA CCTGGGGCCAA AGGGAAACCA GGGTTTGAT GAGAGGCCC ACCAGGACGAA CCTGGGGCCAA AGGGAAAACCTG GAAAAAGGGG TCGTCCAGGT GCAGATGGAG 1920
GAACAGGAAT GCCAGGAGAA CCTGGGGCCAA AGGGAAACCA AGGGTTTGAT GACATCCCG 1980
GTCTGCCAGG TGAAAAGGT CACAGGGGTG AACGAAGGTC TCAAGGTCCT CCAGGTCCTC 2040
CTGGTGATGA TGGAATGAGG GGAAAAGTG AGGAAATTGA ACGAAGGTT CTCCAGGTG 2100
AAGCTGGCCC ACGAGGTTTG CTGGGTCCAA GGGGAAAATTGA ACGAAGCTCC CAAGGGCCCT 2040
CTGGTGATGA TGGAATGGC CCCCCAGGAC CAAAAAGGGAA CATGGGTCCCC AGGGCACCTC 2160
GTATGGCAGG TGTAAAAAGGGAAACCAGAACACAAAGGGAA CATGGGTCCCC AGGGCACCTC 2160
CTATGGCCCC AGGTCAAAAGGGAAACCAAAGGGAA CATGGGTCCCC AGGGCACCTC 2160
CTATGGCCCC CAGGTCAACAA GGGAAATCCAA GGGAACTCCAGGG TCTTCCAGGTC 2280
CAATTGGTCC TCCTGGTGAA AAAGGACCAA GAAAAGGAAA CATGGGTCCCC CAGGGGACCCCCACGGGCACCTC 2160
GTGCTGATGG GCCTCCTGGT CATCCTGGGA AAAAAGGAAA CATGGGTCCCC AGGGCACCTC 2160
GTGCTGATGG CCCCCAGGG AAAAAGGACAA GGGAACTCCAGGG TCTTCCTGGT CCACAAGGCCACCTA 2160
GTGCTGATGG CCCCCAGGAC CAAAAGGAAACC AGGAACTCCAC GGGCACCTCC 2160
GTGCTGATGG CCCCCAGGGACACAAAGGAAACC AGGAACTCCCCCAGGG CCCCCAGGGAAAAAGGAAACC AGGAACTTCCTG 2140
GTGCTGATGG CCCCCAGGGA AAAAGGACAC AAGG 60 65 70 75

PCT/US02/02242 WO 02/059377


CAGATGGTGT CAGAGGTCTC AAGGGATCTA AAGGTGAAAA GGGTGAAGAT GGTTTTCCAG 2520 GATTCAAAGG TGACATGGGT CTAAAAGGTG ACAGAGGAGA AGTTGGTCAA ATTGGCCCAA 2580 GAGGGNAAGA TGGCCCTGAA GGACCCAAAG GTCGAGCAGG CCCAACTGGA GACCCAGGTC 2640 CTTCAGGTCA AGCAGGAGAA AAGGGAAAAC TTGGAGTTCC AGGATTACCA GGATATCCAG 2700 GAAGACAAGG TCCAAAGGGT TCCACTGGAT TCCCTGGGTT TCCAGGTGCC AATGGAGAGA 2760 AAGGTGCACG GGGAGTAGCT GGCAAACCAG GCCCTCGGGG TCAGCGTGGT CCAACGGGTC 2820 CTCGAGGTTC AAGAGGTGCA AGAGGTCCCA CTGGGAAACC TGGGCCAAAG GGCACTTCAG 2880 5 GTGGCGATGG CCCTCCTGGC CCTCCAGGTG AAAGAGGTCC TCAAGGACCT CAGGGTCCAG 2940
TTGGATTCCC TGGACCAAAA GGCCCTCCTG GACCACCAGG AAGGATGGGC TGCCCAGGAC 3000
ACCCTGGGCA ACGTGGGGAG ACTGGATTC AAGGCAAGAC CGGCCCTCCT GGGCCAGGGG 3060 10 GAGTGGTTGG ACCACAGGGA CCAACCGGTG AGACTGGTCC AATAGGGGAA CGTGGGTATC 3120 CTGGTCCTCC TGGCCCTCCT GGTGAGCAAG GTCTTCCTGG TGCTGCAGGA AAAGAAGGTG 3180 CAAAGGGTGA TCCAGGTCCT CAAGGTATCT CAGGGAAAGA TGGACCAGCA GGATTACGTG 3240 GTTTCCCAGG GGAAAGAGGT CTTCCTGGAG CTCAGGGTGC ACCTGGACTG AAAGGAGGGG 3300 AAGGTCCCCA GGGCCCACCA GGTCCAGTTG GCTCACCAGG AGAACGTGGG TCAGCAGGTA 3360 CAGCTGGCCC AATTGGTTTA CGAGGGCGCC CGGGACCTCA GGGTCCTCCT GGTCCAGCTG 3420 15 GAGAGAAAGG TGCTCCTGGA GAAAAAGGTC CCCAAGGGCC TGCAGGGAGA GATGGAGTTC 3480 AAGGTCCTGT TGGTCTCCCA GGGCCAGCTG GTCCTGCCGG CTCCCCTGGG GAAGACGGAG 3540 ACAAGGGTGA AATTGGTGAG CCGGGACAAA AAGGCAGCAA GGGTGGCAAG GGAGAAAATG 3600 GCCCTCCCGG TCCCCCAGGT CTTCAAGGAC CAGTTGGTGC CCCTGGAATT GCTGGAGGTG 3660 ATGGTGAACC AGGTCCTAGA GGACAGCAGG GGATGTTTGG GCAAAAAGGT GATGAGGGTG 3720 CCAGAGGCTT CCCTGGACCT CCTGGTCCAA TAGGTCTTCA GGGTCTGCCA GGCCCACCTG 3780 20 CCAGAGGCTT CCCTGGACCT CCTGGTCCAA TAGGTCTTCA GGGTCTGCCA GGCCCACCTG 3780
GTGAAAAAGG TGAAAATGG GATGTTGGTC CATGGGGGCC ACCTGGTCCT CCAGGCCCAA 3840
GAGGCCCTCA AGGTCCCAAT GGAGCTGATG GACCACAAGG ACCCCCAGGT TCTGTTGGTT 3900
CAGTTGGTGG TGTTGGAGAA AAGGGTGAAC CTGGAGAAGC AGGAAACCCA GGGCCTCCTG 3960
GGGAAGCAGG TGTAGGCGGT CCCAAAGGAG AAAGAGGAGA GAAAGGGGAA GCTGGTCCAC 4020
CTGGAGCTGC TGGACCTCCA GGTGCCAAGG GGCCGCCAGG TGATGATGGC CCTAAGGGTA 4080
ACCCGGGTCC TGTTGGTTTT CCTGGAGATC CTGGTCCTCC TGGGGAACTT GGCCCTGCAG 4140
GTCAAGATGG TGTTGGTGGT GACAAGGGTG AAGATGGAGA TCCTGGTCAA CCGGGTCCTC 4200
CTGGCCCATC TGGTGAGGCT GGCCCACCAG GTCCTCCTGG AAAAGCAGGT CCTCCTGGAG
4260
CTGCAGGTGC AGAGGGAAGA CAAGGTGAAA AAGGTGCTAA GGGGGAAGCA GGTGCAGAAG 4320 25 30 CTGCAGGTGC AGAGGGAAGA CAAGGTGAAA AAGGTGCTAA GGGGGAAGCA GGTGCAGAAG 4320 GTCCTCCTGG AAAAACCGGC CCAGTCGGTC CTCAGGGACC TGCAGGAAAG CCTGGTCCAG 4380 AAGGTCTTCG GGGCATCCCT GGTCCTGTGG GAGAACAAGG TCTCCCTGGA GCTGCAGGCC 4440 AAGATGGACC ACCTGGTCCT ATGGGACCTC CTGGCTTACC TGGTCTCAAA GGTGACCCTG 4500
GCTCCAAGGG TGAAAAGGGA CATCCTGGTT TAATTGGCCT GATTGGTCCT CCAGGAGAAC 4560 35 AAGGGGAAAA AGGTGACCGA GGGCTCCCTG GAACTCAAGG ATCTCCAGGA GCAAAAGGGG 4620 ATGGGGGAAT TCCTGGTCCT GCTGGTCCCT TAGGTCCACC TGGTCCTCCA GGCTTACCAG 4680 GTCCTCAAGG CCCAAAGGGT AACAAAGGCT CTACTGGACC CGCTGGCCAG AAAGGTGACA 4740 GTGGTCTTCC AGGGCCTCCT GGGCCTCCAG GTCCACCTGG TGAAGTCATT CAGCCTTTAC 4800 CAATCTTGTC CTCCAAAAAA ACGAGAAGAC ATACTGAAGG CATGCAAGCA GATGCAGATG 4860 ATAATATTCT TGATTACTCG GATGGAATGG AAGAAATATT TGGTTCCCTC AATTCCCTGA 4920 40 AACAAGACAT CGAGCATATG AAATTTCCAA TGGGTACTCA GACCAATCCA GCCCGAACTT 4980 GTAAAGACCT GCAACTCAGC CATCCTGACT TCCCAGATGG TGAATATTGG ATTGATCCTA 5040 ACCAAGGTTG CTCAGGAGAT TCCTTCAAAG TTTACTGTAA TTTCACATCT GGTGGTGAGA 5100 45 CTTGCATTTA TCCAGACAAA AAATCTGAGG GAGTAAGAAT TTCATCATGG CCAAAGGAGA 5160 AACCAGGAAG TTGGTTTAGT GAATTTAAGA GGGGAAAACT GCTTTCATAC TTAGATGTTG 5220 AAGGAAATTC CATCAATATG GTGCAAATGA CATTCCTGAA ACTTCTGACT GCCTCTGCTC 5280 AAGGAAATTC CATCAATATG GTGCAAATGA CATTCCTGAA ACTTCTGACT GCCTCTGCTC 5280
GGCAAAATTT CACCTACCAC TGTCATCAGT CAGCAGCCTG GTATGATGTG TCATCAGGAA 5340
GTTATGACAA AGCACTTCGC TTCCTGGGAT CAAATGATGA GGAGATGTCC TATGACAATA 5400
ATCCTTTTAT CAAAACACTG TATGATGGTT GTACGTCCAG AAAAGGCTAT GAAAAAACTG 5460
TCATTGAAAT CAATACACCA AAAATTGATC AAGTACCTAT TGTTGATGTC ATGATCAGTG 5520
ACTTTGGTGA TCAGAATCAG AAGTTCGGAT TTGAAGTTGG TCCTGTTTGT TTTCTTGGCT 5580
AAGATTAAGA CAAAGAACAT ATCAAATCAA CAGAAAATGT ACCTTGGTGC CACCAACCCA 5640
TTTTGTGCCA CATGCAAGTT TTGAATAAGG ATGTATGGAA AACAACCGTG CATATACAGC 5700 50 TTTTGTGCCA CATGCAAGTT TTGAATAAGG ATGTATGGAA AACAACGCTG CATATACAGG 5700
TACCATTTAG GAAATACCGA TGCCTTTGTG GGGGCAGAAT CACAGACAAA AGCTTTGAAA 5760
ATCATAAAGA TATAAGTTGG TGTGGCTAAG ATGGAAACAG GGCTGATTCT TGATTCCCAA 5820 55 ATCATANAGA TATAAGTITG TOTOGLAND ATGATACA GASTACTA AAAAAAAAA 5880
AATATATAT CATAAAAAAA ATGGTGCTCA TTCTCATCCA TCCAGGATGT ACTAAAAAAA 5880
AATATATAT CATAAAAAAA ATGGTGCTCA TTCTCATCCA TCCAGGATGT ACTAAAAAAA 5890
TGTGTTTAAT AAAATTATAT TATTTTGTGT ACAGTTCTAT ACTGTTATCT GTGTCCATTT 6000
GATGGCAATA ATATATGTAT TATGAAAATG AAGTTATGAT TTCCGATGAC CCTAAGTCCC 6120 60 TTICTITGGT TAATGATGAA ATTCCTTTGT GTGTGTTT

Seq ID NO: 122 Protein sequence: 65 Protein Accession #: NP 001845

<sup>70</sup> 75

PCT/US02/02242

WO 02/059377



CAGCTCTGTT TAGCACTGAT AATGATGACT TCACTGTGCG GAATGGCGAG ACAGTCCAGG 300 AAAGAAGGTC ACTGAAGGAA AATGATGACT TCACTGTGCG GAATGGCGAG ACAGTCCAG 360
AAAGAAGGTC ACTGAAGGAA AGGAATCCAT TGAAGATCTT CCCATCCAAA CGTATCTTAC 360
GAAGACACAA GAGAATTGG GTGGTTGCTC CAATATCTGT CCCTGAAAAT GGCAAGGGTC 420
CCTTCCCCCA GAGACTGAAT CAGCTCAAGT CTAATAAAGA TAGAGACACC AAGATTTTCT 480
ACAGCATCAC GGGGCCGGGG GCAGACAGC CCCCTGAGGG TGTCTTCGCT GTAGAGAAGG 540 5 AGACAGGCTG GTTGTTGTTG AATAAGCCAC TGGACCGGGA GGAGATTGCC AAGTATGAGC 600
TCTTTGGCCA CGCTGTGTCA GAGAATGGTG CCTCAGTGGA GGACCCCATG AACATCTCCA 660
TCATCGTGAC CGACCAGAAT GACCACAAGC CCAAGTTTAC CCAGGACACC TTCCGAGGGA 720 GTGTCTTAGA GGGAGTCCTA CCAGGTACTT CTGTGATGCA GGTGACAGCC ACAGATGAGG 780
ATGATGCCAT CTACACCTAC AATGGGGTGG TTGCTTACTC CATCCATAGC CAAGAACCAA 840
AGGACCCACA CGACCTCATG TTCACAATTC ACCGGAGCAC AGGCACCATC AGCGTCATCT 900 10 15 CTGAGAGCAA CCAGGGCATC CTGACAACCA GGAAGGGTTT GGATTTTGAG GCCAAAAACC 1260 AGCACACCCT GTACGTTGAA GTGACCAACG AGGCCCCTTT TGTGCTGAAG CTCCCAACCT 1320 CCACAGCCAC CATAGTGGTC CACGTGGAGG ATGTGAATGA GGCACCTGTG TTTGTCCCAC 1380 20 CCTCCAAAGT CGTTGAGGTC CAGGAGGGCA TCCCCACTGG GGAGCCTGTG TGTGTCTACA 1440 CTGCAGAAGA CCCTGACAAG GAGAATCAAA AGATCAGCTA CCGCATCCTG AGAGACCCAG 1500 CAGGGTGGCT AGCCATGGAC CCAGACAGTG GGCAGGTCAC AGCTGTGGGC ACCCTCGACC 1560 ATGGAGGCC AGTCCCTGAG CCCGTCAGA TCACCATCT CAACCAAAGC CCTGTGGCC 1740 25 ACGTGCTGAA CATCACGGAC AAGGACCTGT CTCCCCACAC CTCCCCTTTC CAGGCCCAGC 1800
TCACAGATGA CTCAGACATC TACTGGACGG CAGAGGTCAA CGAGGAAGGT GACACAGTGG 1860
TCTTGTCCCT GAAGAAGTTC CTGAAGCAGG ATACATATGA CGTGCACCTT TCTCTGTCTG 1920 ACCATGGCAA CAAAGAGCAG CTGACGGTGA TCAGGGCCAC TGTGTGCGAC TGCCATGGCC 1980 ATGTCGAAAC CTGCCCTGGA CCCTGGAAAG GAGGTTTCAT CCTCCCTGTG CTGGGGGCTG 2040 TCCTGGCTCT GCTGTTCCTC CTGCTGGTGC TGCTTTTGTT GGTGAGAAAG AAGCGGAAGA 2100 30 TCAAGGAGCC CCTCCTACTC CCAGAAGATG ACACCCGTGA CAACGTCTTC TACTATGGCG 2160
AAGAGGGGGG TGGCGAAGAG GACCAGGACT ATGACATCAC CCAGCTCCAC CGAGGTCTGG 2220
AGGCCAGGCC GGAGGTGGTT CTCCGCAATG ACGTGGCACC AACCATCATC CCGACACCCA 2280 35 TGTACCGTCC TAGGCCAGCC AACCCAGATG AAATCGGCAA CTTTATAATT GAGAACCTGA 2340 AGGCGGCTAA CACAGACCCC ACAGCCCCGC CCTACGACAC CCTCTTGGTG TTCGACTATG 2400 AGGGCAGCGG CTCCGACGCC GCGTCCCTGA GCTCCCTCAC CTCCTCCGCC TCCGACCAAG 2460 AGGGCAGGGC CICCGAGCC GCCICCCTOA GETCCTOA CICCCTOCAGC 2680
ACCAAGATTA CCATTATCTG AACGAGTGGG GCAGCCGCTT CAAGAAGCTG GCAGACATGT 2520
ACGGTGGCGG GGAGGACGAC TAGGCGGCCT GCCTGCAGGG CTGGGGACCA AACGTCAGGC 2580
CACAGAGCAT CTCCAAGGG TCTCAGTTCC CCCTTCAGCT GAGGACTTCG GAGCTTGCA 2640
GGAAGTGGCC GTAGCAACTT GGCGGAGACA GGCTATGAGT CTGACGTTAG AGTGGTTGCT 2700
TCCTTAGCCT TTCAGGATGG AGGAATGTGG GCAGTTTGAC TTCAGCACTG AAAACCTCTC 2760 40 CACCTGGGCC AGGGTTGCCT CAGAGGCCAA GTTTCCAGAA GCCTCTTACC TGCCGTAAAA 2820 TGCTCAACCC TGTGTCCTGG GCCTGGGCCT GCTGTGACTG ACCTACAGTG GACTTTCTCT 2880 CTGGAATGGA ACCTTCTTAG GCCTCCTGGT GCAACTTAAT TTTTTTTTT AATGCTATCT 2940 45 TCAAAACGTT AGAGAAAGTT CTTCAAAAGT GCAGCCCAGA GCTGCTGGGC CCACTGGCCG 3000
TCCTGCATTT CTGGTTTCCA GACCCCAATG CCTCCCATTC GGATGGATCT CTGCGTTTTT 3060
ATACTGAGTG TGCCTAGGTT GCCCCTTATT TTTTATTTTC CCTGTTGCGT TGCTATAGAT 3120 GAAGGGTGAG GACAATCGTG TATATGTACT AGAACTTTTT TATTAAAGAA A 50 Seq ID NO: 126 <u>Protein sequence:</u>
Protein Accession #: NP\_001784 55 60 65 TVVLSLKKFL KQDTYDVHLS LSDHGNKEQL TVIRATVCDC HGHVETCPGP WKGGFLIPVL 660
GAVLALLFLL LVLLLLVRKK RKIKEPLLLP EDDTRDNVFY YGEEGGGEED QDYDITQLHR 720
GLEARPEVVL RNDVAPTIIP TPMYRPRPAN PDEIGNFIIE NLKAANTDPT APPYDTLLVF 780 DYEGSGSDAA SLSSLTSSAS DQDQDYDYLN EWGSRFKKLA DMYGGGEDD 70 Seq ID NO: 127 DNA sequence Nucleic Acid Accession #: NM\_003256.1 Coding sequence: 60-734 (underlined sequences correspond to start and stop codons) 75 31 CCTGCTGGGG CCGTCCAGTC CCCCAGACCT CACAGGCTCA GTCGCGGATC TGCAGTGTCA 60

PCT/US02/02242

WO 02/059377

TGCCTGGGAG CCCTCGGCCC GCGCCAAGCT GGGTGCTGTT GCTGCGGCTG CTGGCGTTGC 120
TGCGGCCCCC GGGGCTGGGT GAGGCATGCA GCTGCGCCCC GGCGCACCCT CAGCAGCACA 180 TCTGCCACTC GGCACTTGTG ATTCGGGCCA AAATCTCCAG TGAGAAGGTA GTTCCGGCCA 240 GTGCAGACCC TGCTGACACT GAAAAAATGC TCCGGTATGA AATCAAACAG ATAAAGATGT 300
TCAAAGGGTT TGAGAAAGTC AAGGATGTTC AGTATATCTA TACGCCTTTT GACTCTTCCC 360
TCTGTGGTGT GAAACTAGAA GCCAACAGCC AGAAGCAGTA TCTCTTGACT GGTCAGGTCC 420 5 TCTGTGGTGT GAAACTAGAA GCCAACAGCC AGAAGCAGTA TCTCTTGACT GGTCAGGTCC
1CAGTGATGG AAAAGTCTTC ATCCATCTGT GCAACTACAT CGAGCCCTGG GAGGACCTGT
480
CCTTGGTGCA GAGGGAAAGT CTGAAATCATC ACTACCATCT GAACTGTGGC TGCCAATCA
540
CCACCTGCTA CACAGTACCC TGTACCATCT CGGCCCCTAA CGAGTGCCTC TGGACAGACT
600
GGCTGTTGGA ACGAAAGCTC TATGGTTACC AGGCCCTAA CGAGTGCCTC TGGACAGACT
1TGACGGCAC CTGCAGCTGG TACCGGGGCC ACCTGCCCTT CAGGAAGGAG TTTGTTGACA
720
TCGTTCAGCC CTAGTAGGGA CCAGTGACCA TCACATCCCT TCAAGAGTCC TGAAATCAA
780
GCCAGTTCTC CTTCCCTGCA GAGCTTTGGC TACAATCCCT TCAAGAGTCC TGAAACTCAA
780
ATAAGAAGTG CCAAGTGGAC AGTCTTGGCCA CTGTCAAGGC AGGGAAGGGG CCATGACTTT
900
TCTGCCCTGC CCTCAGCCTG TTGCCCTGC TCCCAAACCC CATTAGTCTA GCCTTGTAGC
960
TGTTACTGCA AGTGTTTCTT CTGGCTTAGT CTGTTTTCTA AAGCCAGGAC TATTCCCTTT
1020
CCTCCCAGGA AATATGTGTT TTCCTTTTGTC TTAATCGATC TGGTAAGGGA GAAATGGCGA
1800
ATGTCATACA CATGAGATGG TATATCCTTG CGATGTACAA AATCAGAAGG TGGTTTGACA
1140 10 15 ATGTCATACA CATGAGATGG TATATCCTTG CGATGTACAG AATCAGAAGG TGGTTTGACA 1140 20 Seq ID NO: 128 <u>Protein sequence:</u>
Protein Accession #: NP\_003247.1 25 SADPADTEKM LRYEIKQIKM FKGFEKVKDV QYIYTFFDSS LCGYKLEANS QKQYLLTGQV 120
LSDGKYFIHL CNYIEFWEDL SLVQRESLNH HYHLNCGCQI TTCYTVPCTI SAPNECLWTD 180
WLLERKLYGY QAQHYVCMKH VDGTCSWYRG HLPLRKEFVD IVQP 30 Seq ID NO: 129 DNA sequence NM\_007207.2 Nucleic Acid Accession #: Coding sequence: 143-1591 (underlined sequences correspond to start and stop codons) 35 31 CCACGCGTCC GCAATGAAGC CGAGTGAATG GGGGCTGAAT GTGCGAGTCC ATAGCTGAAG 60 AGGAGCGCCA GATGGTGGAG GAATACACTT ATTTATGAAA CTGTCTTGAG TTCTTCTTGA 120
ATTGCCAGTT TTCAGCCTCC TCATGCCTCC GTCTCCTTTA GACGACAGGG TAGTAGTGGC 180
ACTATCTAGG CCCGTCCGAC CTCAGGATCT CAACCTTTGT TTAGACTCTA GTTACCTTGG 240 40 ACTATCTAGG CCCGTCCGAC CTCAGGATCT CAACCTTTGT TTAGACTCTA GTTACCTTGG 240
CTCTGCCAAC CCAGGCAGTA ACAGCCACCC TCCTGTCATC GCCACCACCG TTGTGTCCCT 300
CAAGGCTGCG AATCTGACGT ATATGCCCCT ATCCAGCGGC TCTGCCCGCT CGCTGAATTG 360
TGGATGCAGC AGTGCCAGCT GCTGCACTGT GGCAACCTAC GACAAGGACA ATCAGGCCCA 420
AACCCAAGCC ATTGCCGCTG GCACCACCAC CACTGCCCATC GGAACCTTCTA CCACCTGCCC 480
GGCAGCCCT GTGTCAGCGA CCCCCAAGCA GCTAGCCAGC ATCAAAATAA TCTACCCCAA 600
TGACTTGGCA AAGAAAGATGA CCCAAAGCA GCTAGCCAGC ATCAAAATAA TCTACCCCAA 600
CATCACTGGCA AAGAAAGATGA CCAAATGCAG CAACAAGAGT CACATCCAAG GAGCTGTCCC 720
CATTAACTGT GCCGGTAAAGA TCAGCCGGC GAGACTGCCAG CAGGGCAAGA TCACTGTCCT 780
AGACTTGATT TCCTGTAGGG AAGGCAAGGA CTCTTTCAAG AGGATCTTTT CCAAAGAAAT 840
TATAGTTTAT GATGAGAATA CCAAATGAACC AAGCCGAGTG ATGCCCTCC AGCCACTTCA 900
CATGACTTCG AGGCCCTTCA AGAGAGAAGAG CAAAGAACCT CTGGTGTGTTG AAGGTGGACT 960 45 50 CATAGTCCTC GAGTCCCTGA AGAGAGAGG CAAAGAACT CTGGTGTTGA AAGGTGACT 960
TAGTAGTTTT AAGCAGAACC ATGAAAACCT CTGTGACAAC TCCCTCCAGC TCCAAGAGTG 1020
CCGGGAGGTG GGGGGGGGC CATCCGCGGC CTCGAGCTTG CTACCTCAGC CCATCCCCAC 1080 CACCCCTGAC ATCGAGAACG CTGAGCTCAC CCCCATCTTG CCCTTCCTGT TCCTTGGCAA 1140
TGAGCAGGAT GCTCAGGACC TGGACACCAT GCAGCGGCTG AACATCGGCT ACGTCATCAA 1200
CGTCACCACT CATCTTCCCC TCTACCACTA TGAGAAAGGC CTGTTCAACT ACAAGCGGCT 1260 55 CGTCACCACT CATCTTCCCC TCTACCACTA TGAGAAAGGC CTGTTCAACT ACAAGGGGCT 1260
GCCAGCCACT GACAGCAACA AGCAGAACCT GCGGCAGTAC TTTGAAGAGG CTTTTGAGTT 1320
CCATTGAGGAA GCTCACCAGT GTGGGAAGGG GCTTCTCATC CACTGCCAGG CTGGGGGTGTC 1380
CCGCTCCGCC ACCATCGTCA TCGCTTACTT GATGAAGCAC ACTCGGATGA CCATGACTGA 1440
TGCTTATAAA TTTGTCAAAG GCAAACGACC AATTATCTCC CCAAACCTTA ACTTCATGGG 1500
GCAGTTGCTA GAGTTCGAGG AAGACCTAAA CAACGGTGTG ACACCGAGAA TCCTTACACC 1560
AAGCTGATG GGCGTGGAGA CGGTTGTGTGACAATGGTCT GGATGGAAAG GATTGCTGCT 1620
CTCCATTAGG AGACAATGAG GAAGAGGAGT GGATTCTGGT TTTTTTTTT 1680
TTGTAGTTGG GAGTAAAGTT TGTGAATGGA AACAAACTTG GTTAAACACT TATTTTTAA 1740
CAAGTGTAAG AAGACTATAC TTTTGATGCC ATTGAGATTC ACCTTCCACA AACTGGCCAA 1800
ATTAAGGAGG TTAAAGAAGT AATTTTTTTT AAGCCCCACC ATTAAAAATT TAATACAACT 1860
TGGTTTCTCC CCCTTTTTCC TTTAAAGCTA NTTTGTAAAA GTTTATTGAG 60 65 Seq ID NO: 130 Protein sequence:
Accession #: NP\_009138.1 70 41 51 31 MPSSEGSARS LNCGCSSASC CTVATYDKDN QAQTQAIAAG TTTTAIGTST TCPANQMVNN 120 NENTGSLSPS SGVGSPVSGT PKQLASIKII YPNDLAKKMT KCSKSHLPSQ GPVIIDCRPF 180 75

MEYNKSHIQG AVHINCADKI SRRRLQQGKI TVLDLISCRE GKDSFKRIFS KEIIVYDENT 240
NEPSRVMPSQ PLHIVLESLK REGKEPLVLK GGLSFKQNH ENLCDNSLQL QECREVGGGA 300
SAASSLLPQP IPTTPDIENA ELTPILPFLF LGNEQDAQDL DTMQRLNIGY VINVTTHLPL 360
YHYEKGLFNY KRLPATDSNK QNLRQYFEEA FEFIEEAHQC GKGLLIHCQA GVSRSATIVI 420
AYLMKHTRMT MTDAYKFVKG KRPIISPNLN FMGQLLEFEE DLNNGVTPRI LTPKLMGVET 480

5

55

60

65

70

75

Seq ID NO: 131 DNA sequence Nucleic Acid Accession #: NM\_005409.3 10 Coding sequence: 94-378 (underlined sequences correspond to start and stop codons) TTCCTTTCAT GTTCAGCATT TCTACTCCTT CCAAGAAGAG CAGCAAAGCT GAAGTAGCAG 60 CAACAGCACC AGCAGCAACA GCAAAAAACA AACATGAGTG TGAAGGGCAT GGCTATAGCC 120
TTGGCTGTGA TATTGTGTGC TACAGTTGTT CAAGGCTTCC CCATGTTCAA AAGAGGACGC 180
TGTCTTTGCA TAGGCCCTGG GGTAAAAGCA GTGAAAGTGG CAGATATTGA GAAAGCCTCC 240 15 ATAATGTACC CAAGTAACAA CTGTGACAAA ATAGAAGTGA TTATTACCCT GAAAGAAAAT 300 AAAGGACAAC GATGCCTAAA TCCCAAATCG AAGCAAGCAA GGCTTATAAT CAAAAAAGTT 360 GAAAGAAAGA ATTTT<u>TAA</u>AA ATATCAAAAC ATÄTGAAGTC CTGGAAAAGG GCATCTGAAA 420 20 GAAGAAAGA ATTTITAAAA ATATCAAAAC ATATGAAGIC CIGGAAAAGG GCAICIGAAA 42.0
AACCTAGAAC AAGTTTAACT GIGACTACTG AAATGACAAG AATTCTACAG TAAGGAAACTG 480
AGACTTTCTA TGGTTTTGT GACTTTCAAC TITTIGTACAG TATTGTGAAG GATGAAAGGT 540
GGGTGAAAGG ACCAAAAACA GAAATACAGT CTTCCTGAAT GAATGACAAT CAGAATTCCA 660
CTGCCCAAAG GAGTCCAGCA ATTAAATGGA TTTCTAGGAA AAGCTACCTT AAGAAAGGCT 660
GGTTACCATC GGAGTTTACA AAGTGCTTTC ACGTTCTTAC TTGTTGTATT ATACATTCAT 720
GCATTTCTAG GCTAGAGAAC CTTCTAGATT TGATGCTTAC AACTATTCT TTGTGACTAT 780
GAGAACATT CTGTCTCTAG AAGTTATCTG TCTGTATTGA TCTTTATGCT ATATTACTAT 840
CTGTGGTTAC AGTGGAGACA TTGACATTAT TACTGGAGTC AAGCCCTTAT AAGTCAAAAG 900
CATCTATGTG TCGTAAAAGCA TTCCTCAAAAC ATTTTTCAT GCAAAATACAC ACCTCTTTCC 960 25 CATCTATOTG TCGTAAAGCA TTCCTCAAAC ATTTTTCAT GCAAATACAC ACTTCTTTCC 960 CCAAATATCA TGTAGCACAT CAATATGTAG GGAAACATTC TTATGCATCA TTTGGTTTGT 1020 TTTATAACCA ATTCATTAAA TGTAATTCAT AAAATGTACT ATGAAAAAAA TTATACGCTA 1080 30 TGGGATACTG GCAACAGTGC ACATATTTCA TAACCAAATT AGCAGCACCG GTCTTAATTT 1140 GATGTTTTTC AACTTTTATT CATTGAGATG TTTTGAAGCA ATTAGGATAT GTGTGTTTAC 1200 TGTACTTTTT GTTTTGATCC GTTTGTATAA ATGATAGCAA TATCTTGGAC ACATTTGAAA 1260 TACAAAATGT TITTTOTCTAC CAAAGAAAAA TGTTGAAAAA TAAGCAAATG TATACCTAGC 1320 AATCACTITT ACTITTTGTA ATTCTGTCTC TTAGAAAAAT ACATAATCTA ATCAATTTCT 1380 TTGTTCATGC CTATATACTG TAAAATTTAG GTATACTCAA GACTAGTTTA AAGAATCAAA 1440 35 40 Seq ID NO: 132 Protein sequence: NP\_005400.1 Protein Accession #: 45 MSVKGMAIAL AVILCATVVQ GFPMFKRGRC LCIGPGVKAV KVADIEKASI MYPSNNCDKI 60 EVIITLKENK GORCLNPKSK QARLIIKKVE RKNF See ID NO: 133 DNA sequence Nucleic Acid Accession # NM\_012342 Coding sequence: 373-1155 (underlined sequences correspond to start and stop codons) 50 41 CTGGCGCGGG CGGGAGCTGC GGCGGATACC CTTGCGTGCT GTGGAGACCC TACTCTCTTC 60 GCTGAGAACG GCCGCTAGCG GGGACTGAAG GCCGGGAGCC CACTCCCGAC CCGGGGCTAG 120 CGTGCGTCCC TAGAGTCGAG CGGGGCAAGG GAGCCAGTGG CCGCCGACGG GGGACCGGGA 180

AACTTTTCTG GGCTCCTGGA GAGCCCTGTA GCCGCGCTCC ATGCTCCGGC AGCGGCCCGA 240
AACCCAGCCC CGCCGCTGAC GGAGCCCGCC GCTCCGGGCA GGGCCCATGC CCTGCGCGCT 300
CCGGGGGTCG TAGCTGCCGC CGAGCCGGGG CTCCGGAAGC CGCGGGGGC GCCGCGGCCG 360 

TAAACAAAAA TGTGCCCTAT GTAAGCTTCT ACATCTTGAT TTATTGTAAA GATTTAAAAG 1500 AAATATATAT ATTTTGTCTG A

Seq ID NO: 134 Protein sequence:
Protein Accession #: NP\_036474.1 41 21 31 MDRISSYIFI WLQLELCAMA VLLTKGEIRC YCDAAHCVAT GYMCKSELSA CFSRLLDPQN 60 SNSPLTHGCL DSLASTTDIC QAKQARNHSG TTIPTLECCH EDMCNYRGLH DVLSPPRGEA 120 SGQGNRYQHD GSRNLITKVQ ELTSSKELWF RAAVIAVPIA GGLILVLLIM LALRMLRSEN 180 10 KRLODOROOM LSRLHYSFHG HHSKKGQVAK LDLECMVPVS GHENCCLTCD KMRQADLSND 240 KILSLVHWGM YSGHGKLEFV 15 Seq ID NO: 135 DNA sequence NM 001627.1 Nucleic Acid Accession # Coding sequence: 64-1815 (underlined sequences correspond to start and stop codons) 41 20 AATATGGAAT CCAAGGGGGC CAGTTCCTGC CGTCTGCTCT TCTGCCTCTT GATCTCCGCC 120 ACCOTETTCA GGCCAGGCCT TGGATGGTAT ACTGTAAATT CAGCATATGG AGATACCATT 180
ATCATACCTT GCCGACTTGA CGTACCTCAG AATCTCATGT TTGGCAAATG GAAATATGAA 240
AAGCCCGATG GCTCCCCAGT ATTTATTGCC TTCAGATCCT CTACAAAGAA AAGTGTGCAG 300 25 TACGACGATG TACCAGAATA CAAAGACAGA TTGAACCTCT CAGAAAACTA CACTTTGTCT 360
ATCAGTAATG CAAGGATCAG TGATGAAAAG AGATTTGTGT GCATGCTAGT AACTGAGGAC 420
AACGTGTTTG AGGCACCTAC AATAGTCAAG GTGTTCAAGC AACCATCTAA ACCTGAAATT 480 GTAAGCAAAG CACTGTTTCT CGAAACAGAG CAGCTAAAAA AGTTGGGTGA CTGCATTTCA 540
GAAGACAGTT ATCCAGATGG CAATATCACA TGGTACAGGA ATGGAAAAGT GCTACATCCC 600 30 CTTGAAGGAG CGGTGGTCAT AATTTTTAAA AAGGAAATGG ACCCAGTGAC TCAGCTCTAT 660
ACCATGACTT CCACCCTGGA GTACAAGACA ACCAAGGCTG ACATACAAAT GCCATTCACC 720
TGCTCGGTGA CATATTATGG ACCATCTGGC CAGAAAACAA TTCATTCTGA ACAGGCAGTA 780 TTTGATATTT ACTATCCTAC AGAGCAGGTG ACAATACAAG TGCTGCCACC AAAAAATGCC 840 ATCAAAGAAG GGGATAACAT CACTCTTAAA TGCTTAGGGA ATGGCAACCC TCCCCCAGAG 900 GAATTTTTGT TTTACTTACC AGGACAGCCC GAAGGAATAA GAAGCTCAAA TACTTACACA 960 35 GAATITITGT TITACTTACC AGGACAGCCC GAAGGAATAA GAAGCTCAAA TACTTACACA 960
CTGATGGATG TGAGGCGCAA TGCAACAGGA GACTACAAGT GTTCCCTGAT AGACCAAAAAA 1020
AGCATGATTG CTTCAACAGC CATCACAGTT CACTATTTGG ATTTGTCCTT AAACCCAAGT 1080
GGAGAAGTGA CTAGACAGAT TGGTGATGCC CTACCCGTGT CATGCACAAT ATCTGCTAGC 1140
AGGAATGCAA CTGTGGTATG GATGAAAGAT AACATCAGGC TTCGATCTAG CCCGTCATTT 1200
TCTAGTCTTC ATTATCAGGA TGCTGGAAAC TATGTCTGCG AAACTGCTCT GCAGGAGGTT 1260
GAAGGACTAA AGAAAGAGA GTCATTGACT CTCATTGTAG AAGCCAAACC TCAAATAAAA 1320
ATGACAAAGA AAACTGATCC CAGTGGACTA TCTAAAACAA TAATCTGCCA TGTGGAAGGT 1380
TTTCCAAAGC CAGCCATTCA GTGGACAATT ACTGGCAGTG GAAGCGTCAT AAACCAAACA 1440
GAGGAATCT CTTATATTAA TGGCAGGTAT TATAGTAAAA TTATCATTTC CCCTGAAAGA 1500
AATGTTACAT TAACTTGCAC AGCAGAAAAC CAACTGGAGA GAACAGTAAA CTCCTTTGAAT 1560 40 45 AATGITACAT TAACTTGCAC AGCAGAAAAC CAACTGGAGA GAACAGTAAA CTCCTTGAAT 1560 GTCTCTGCTA TAAGTATTCC AGAACACGAT GAGGCAGACG AGATAAGTGA TGAAAACAGA 1620 GAAAAGGTGA ATGACCAGGC AAAACTAATT GTGGGAATCG TTGTTGGTCT CCTCCTTGCT 1680 50 55 60 AAAGACATAA AACAGAATT Seq ID NO: 136 Protein sequence:
Protein Accession #: NP\_001618.1 65 21 31 70 MESKGASSCR LLFCLLISAT VFRPGLGWYT VNSAYGDTII IPCRLDVPQN LMFGKWKYEK 60 MESKGASSCR LLFCLLISAT VFRPGLGWYT VNSAYGDTII IPCRLDVPQN EMFGKWYFER 60
PDGSPVFIAF RSSTKKSVQY DDVPEYKDRI NLSENYTILSI SNARISDEKR FVCMLVTEDN 120
VFEAPTIVKV FKQPSKPEIV SKALFLETEQ LKKLGDCISE DSYPDGNITW YRNGKVLHPL 180
EGAVVIEKK EMDPVTQLYT MTSTLEYKTT KADIQMPFTC SYTYYGPSGQ KTIHISEQAVF 240
DIYYPTEQVT IQVLPPKNAI KEGDNITLKC LGNGNPPPEE FLFYLPGQPE GIRSSNTYTL 300
MDVRRNATGD YKCSLIDKKS MIASTAITVH YLDLSLMPSG EVTRQIGDAL PVSCTISASR 360
NATVVWMKDN IRLRSSPSFS SLHYQDAGNY VCETALQEVE GLKKRESLTL IVEGKPQIKM 420
TKKTDPSGLS KTIICHVEGF PKPAIQWTIT GSGSVINQTE ESPYINGRYY SKIIISPEEN 480 75

WO 02/059377

PCT/US02/02242

VTLTCTAENQ LERTVNSLNV SAISIPEHDE ADEISDENRE KVNDQAKLIV GIVVGLLLAA 540 LVAGVVYWLY MKKSKTASKH VNKDLGNMEE NKKLEENNHK TEA

5 Seq ID NO: 137 DNA sequence XM\_030559 Nucleic Acid Accession #: Coding sequence: 1-119 (underlined sequences correspond to start and stop codons) 21 10 ATGAACCGCA GCCACCGGCA CGGGGCGGGC AGCGGCTGCC TGGGCACTAT GGAGGTGAAG 60
AGCAAGTTTG GAGCTGAATT TCGTCGGTTT TCGCTGGAAA GATCAAAACC TGGAAAATTT 120
AGGAGTTTG GAGCTGAATT TCGTCGGTTT TCGCTGGAAA GATCAAAACC TGGAAAATTT 120
AGGAGTTTT ATGGATTACT ACAACATGTT CATAAGATCC CCAATGTTGA CGTTTTGGTA 180
GGCTATGCAG ACATCCATGG AGACTTACTA CCTATAAAATA ATGATGATAA TTATCACAAA 240
GCTGTTTCAA CGGCCAATCC ACCTGCTTAGG ATATTTATAC AAAAGAAGAA AGAAGCAGAC 300
TACAGTGCCT TTGGTACAGA CACGCTAATA AAGAAGAAGA ATGTTTTAAC CAACGTATTG 360
CGTCCTGACA ACCATAGAAA AAAGCCACAT ATAGTCATTA GTATGCCCA AGACTTTAGA 420
CCTGTGTCTT CTATTATAGA CGTGGATATT CTCCCAGAAA CGCATCGTAG GGTACGTCTT 480
TACAAATACG GCACGGAGAA ACCCCTAGGA TTCTACATCC GGGATGGCTC CAGTGTCAGG 540
GTACACCAC ATGGCTTAGA AAAGGTTCCA GGGATCTTTTA TATCCAGGCT TGTCCCAGGA 600
GGTCTGGCTC AAAGTACAGG ACTATTAGCT GTTAATGATG AAGTTTAGAA GGTTAATGGC 660
ATAGAAAGTTT CAGGGAAGAG CCTTGATCAA GTAACAGACA TGATGATTGC AAATAACGCGT 720
AACCTCATCA TAACAGTGAG ACCGCCAAAC CAGAGGAATA ATGTTGTGAG GAACAGTCCG 780
ACTTCTGGCA GTTCCGGTCA GTCTACTGAT AACAGCCTTC TTGGCTACCA CACAGCAGTT 840
GAACCAAGCT TTGAGCCAGA GGATGAAGAC AGCCGTAAATA ATGTTGTGAG GAACCAGCATT 840
GAACCAAGCT TTGAGCCAGA GGATGAAGAC AGCGAAGAAG ATGACATTAT CATTGAAGAC 900
AATGGAAGTG CACAGCAGAT TCCAAAAAGCT GTTCCTTAATA CTGAGAGCCT GGAGTCATTA 960
ACACGAATAG AGCTTAAGCAT TCAGATCAGAC AGCAGATTAT CATTGAAGAGT 1020
AACCTCATCA TAACAGTAGA GAGATGAAGAC AGCGAAATAA ACACATTAT CATTGAAGAGT 1020
AACCTCATCA TAACAGTAGAAGAC AGCGAATTAT ACAGACTT TCAATGAAGTG 1020
AACCTCATCA TAACAGTAGAAGAC AGCGAATTAT AACAGCCTT TAATGAAGTG 1020
AACCTCATCA GAGAAGATGA AACAATCATA ACATTA<u>TGA</u> ATGAACCGCA GCCACCGGCA CGGGGCGGCC AGCGGCTGCC TGGGCACTAT GGAGGTGAAG 60 15 20 25 30 Seq ID NO: 138 Protein sequence:
Protein Accession #: XP\_030559 41 31 35 40

45

409

It is understood that the examples described above in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All publications, sequences of accession numbers, and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

## WHAT IS CLAIMED IS:

1

12.

1 1. A method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a 2 polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence 3 as shown in Tables 1-25. 4 2. The method of claim 1, wherein the biological sample comprises 1 2 isolated nucleic acids. The method of claim 2, wherein the nucleic acids are mRNA. 1 3. 4. The method of claim 2, further comprising the step of amplifying 1 nucleic acids before the step of contacting the biological sample with the polynucleotide. 2 The method of claim 1, wherein the polynucleotide comprises a 5. 1 sequence as shown in Tables 1-25. 2 6. The method of claim 1, wherein the polynucleotide is immobilized on 1 2 a solid surface. 7. The method of claim 1, wherein the patient is undergoing a therapeutic 1 2 regimen to treat breast cancer. 8. The method of claim 1, wherein the patient is suspected of having 1 2 breast cancer. 1 9. An isolated nucleic acid molecule consisting of a polynucleotide 2 sequence as shown in Tables 1-25. The nucleic acid molecule of claim 9, which is labeled. 10. 1 An expression vector comprising the nucleic acid of claim 9. 11. 1

A host cell comprising the expression vector of claim 11.

1	1:	3.	An isolated polypeptide which is encoded by a nucleic acid molecule	
2	having polynucleotide sequence as shown in Tables 1-25.			
1	14	4.	An antibody that specifically binds a polypeptide of claim 13.	
1	1:	5.	The antibody of claim 14, further conjugated to an effector component.	
1 2	10 fluorescent label		The antibody of claim 15, wherein the effector component is a	
-	madication mode	•		
1	1	7.	The antibody of claim 15, wherein the effector component is a	
2	radioisotope or a	cytot	oxic chemical.	
1	18	8.	The antibody of claim 15, which is an antibody fragment.	
1	_ 19	9.	The antibody of claim 15, which is a humanized antibody	
1	20	0.	A method of detecting a breast cancer cell in a biological sample from	
2	a patient, the me	thod c	comprising contacting the biological sample with an antibody of claim	
3	14.			
1	2	1.	The method of claim 20, wherein the antibody is further conjugated to	
2	an effector component.			
1	22	2.	The method of claim 21, wherein the effector component is a	
2	fluorescent label			
1	23	3.	A method for identifying a compound that modulates a breast cancer-	
2	associated polyp	eptide	e, the method comprising the steps of:	
3	(i	) cont	acting the compound with a breast cancer-associated polypeptide, the	
4	polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least			
5	80% identical to a sequence as shown in Tables 1-25; and			
6	(i	i) dete	ermining the functional effect of the compound upon the polypeptide.	
1	24	4.	A drug screening assay comprising the steps of	

2	(i) administering a test compound to a mammal having breast cancer or a cell		
3	isolated therefrom;		
4	(ii) comparing the level of gene expression of a polynucleotide that selectively		
5	hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25 in a		
6	treated cell or mammal with the level of gene expression of the polynucleotide in a control		
7	cell or mammal, wherein a test compound that modulates the level of expression of the		
8	polynucleotide is a candidate for the treatment of breast cancer.		

## This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
COLOR OR BLACK AND WHITE PHOTOGRAPHS
GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER:

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)